PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mattapallil, JJ; Douek, DC; Hill, B; Nishimura, Y; Martin, M; Roederer, M				Mattapallil, JJ; Douek, DC; Hill, B; Nishimura, Y; Martin, M; Roederer, M			Massive infection and loss of memory CD4(+) T cells in multiple tissues during acute SIV infection	NATURE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; GASTROINTESTINAL-TRACT; HIV-1 INFECTION; RHESUS-MONKEYS; EXPRESSION; DEPLETION; DYNAMICS; TRANSMISSION; REPLICATION; LYMPHOCYTES	It has recently been established that both acute human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infections are accompanied by a dramatic and selective loss of memory CD4(+) T cells predominantly from the mucosal surfaces. The mechanism underlying this depletion of memory CD4(+) T cells (that is, T-helper cells specific to previously encountered pathogens) has not been defined. Using highly sensitive, quantitative polymerase chain reaction together with precise sorting of different subsets of CD4(+) T cells in various tissues, we show that this loss is explained by a massive infection of memory CD4(+) T cells by the virus. Specifically, 30-60% of CD4(+) memory T cells throughout the body are infected by SIV at the peak of infection, and most of these infected cells disappear within four days. Furthermore, our data demonstrate that the depletion of memory CD4(+) T cells occurs to a similar extent in all tissues. As a consequence, over one-half of all memory CD4(+) T cells in SIV-infected macaques are destroyed directly by viral infection during the acute phase-an insult that certainly heralds subsequent immunodeficiency. Our findings point to the importance of reducing the cell-associated viral load during acute infection through therapeutic or vaccination strategies.	NIAID, Immunotechnol Sect, NIH, Bethesda, MD 20892 USA; NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Roederer, M (corresponding author), NIAID, Immunotechnol Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	Roederer@nih.gov	Roederer, Mario/G-1887-2011	Mattapallil, Joseph/0000-0002-7412-9507	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000415, ZIAAI005019, ZIAAI000190, ZIAAI005034, Z01AI005019, Z01AI005034, Z01AI000415, Z01AI000190] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Chen ZW, 1997, J VIROL, V71, P2705, DOI 10.1128/JVI.71.4.2705-2714.1997; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Endo Y, 2000, J VIROL, V74, P6935, DOI 10.1128/JVI.74.15.6935-6945.2000; FOLKS T, 1985, P NATL ACAD SCI USA, V82, P4539, DOI 10.1073/pnas.82.13.4539; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; Gratton S, 2000, P NATL ACAD SCI USA, V97, P14566, DOI 10.1073/pnas.97.26.14566; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Jung A, 2002, NATURE, V418, P144, DOI 10.1038/418144a; Lassen K, 2004, TRENDS MOL MED, V10, P525, DOI 10.1016/j.molmed.2004.09.006; Lifson JD, 2001, J VIROL, V75, P10187, DOI 10.1128/JVI.75.21.10187-10199.2001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marcon L, 1997, J VIROL, V71, P2522, DOI 10.1128/JVI.71.3.2522-2527.1997; Mattapallil JJ, 2004, AIDS, V18, P13, DOI 10.1097/00002030-200401020-00002; Mattapallil JJ, 1998, J VIROL, V72, P6421, DOI 10.1128/JVI.72.8.6421-6429.1998; Mengozzi M, 2001, P NATL ACAD SCI USA, V98, P11644, DOI 10.1073/pnas.211205098; MORI K, 1992, J VIROL, V66, P2067, DOI 10.1128/JVI.66.4.2067-2075.1992; Nishimura Y, 2004, P NATL ACAD SCI USA, V101, P12324, DOI 10.1073/pnas.0404620101; Pitcher CJ, 2002, J IMMUNOL, V168, P29, DOI 10.4049/jimmunol.168.1.29; Veazey RS, 2000, J VIROL, V74, P57, DOI 10.1128/JVI.74.1.57-64.2000; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Veazey RS, 2000, J VIROL, V74, P11001, DOI 10.1128/JVI.74.23.11001-11007.2000; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zhang ZQ, 2004, P NATL ACAD SCI USA, V101, P5640, DOI 10.1073/pnas.0308425101	25	1002	1041	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 28	2005	434	7037					1093	1097		10.1038/nature03501	http://dx.doi.org/10.1038/nature03501			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	920MD	15793563				2022-12-28	WOS:000228693300033
J	Khimich, D; Nouvian, R; Pujol, R; Dieck, ST; Egner, A; Gundelfinger, ED; Moser, T				Khimich, D; Nouvian, R; Pujol, R; Dieck, ST; Egner, A; Gundelfinger, ED; Moser, T			Hair cell synaptic ribbons are essential for synchronous auditory signalling	NATURE			English	Article							ZONE PROTEIN BASSOON; AFFERENT SYNAPSE; TRANSMITTER RELEASE; CALCIUM-DEPENDENCE; ACTIVE ZONES; EXOCYTOSIS; VESICLES; ENDOCYTOSIS; MICROSCOPE; MEMBRANE	Hearing relies on faithful synaptic transmission at the ribbon synapse of cochlear inner hair cells (IHCs)(1-3). At present, the function of presynaptic ribbons at these synapses is still largely unknown(1,4). Here we show that anchoring of IHC ribbons is impaired in mouse mutants for the presynaptic scaffolding protein Bassoon. The lack of active-zone-anchored synaptic ribbons reduced the presynaptic readily releasable vesicle pool, and impaired synchronous auditory signalling as revealed by recordings of exocytic IHC capacitance changes and sound-evoked activation of spiral ganglion neurons. Both exocytosis of the hair cell releasable vesicle pool and the number of synchronously activated spiral ganglion neurons co-varied with the number of anchored ribbons during development. Interestingly, ribbon-deficient IHCs were still capable of sustained exocytosis with normal Ca2+-dependence. Endocytic membrane retrieval was intact, but an accumulation of tubular and cisternal membrane profiles was observed in ribbon-deficient IHCs. We conclude that ribbon-dependent synchronous release of multiple vesicles at the hair cell afferent synapse is essential for normal hearing.	Univ Goettingen, Dept Otolaryngol, D-37099 Gottingen, Germany; Univ Goettingen, Ctr Mol Physiol Brain, D-37099 Gottingen, Germany; Univ Montpellier, INSERM, U583, INM, F-34091 Montpellier, France; Univ Montpellier, CRIC, F-34091 Montpellier, France; Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; Max Planck Inst Biophys Chem, Dept Nanobiophoton, D-37077 Gottingen, Germany	University of Gottingen; University of Gottingen; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Leibniz Institut fur Neurobiologie (LIN); Max Planck Society	Moser, T (corresponding author), Univ Goettingen, Dept Otolaryngol, D-37099 Gottingen, Germany.	tmoser@gwdg.de	Nouvian, Regis/AAW-4207-2021; Nouvian, Regis/AFQ-8065-2022; Moser, Tobias/L-5068-2014	Nouvian, Regis/0000-0002-0901-4666; Nouvian, Regis/0000-0002-0901-4666; Moser, Tobias/0000-0001-7145-0533; Egner, Alexander/0000-0001-5248-3858; Pujol, Remy/0000-0002-7837-7129				Altrock WD, 2003, NEURON, V37, P787, DOI 10.1016/S0896-6273(03)00088-6; Beutner D, 2001, NEURON, V29, P681, DOI 10.1016/S0896-6273(01)00243-4; Dick O, 2003, NEURON, V37, P775, DOI 10.1016/S0896-6273(03)00086-2; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Edmonds BW, 2004, J PHYSIOL-LONDON, V560, P439, DOI 10.1113/jphysiol.2004.066035; Egner A, 2002, P NATL ACAD SCI USA, V99, P3370, DOI 10.1073/pnas.052545099; Fuchs PA, 2003, CURR OPIN NEUROBIOL, V13, P452, DOI 10.1016/S0959-4388(03)00098-9; Glowatzki E, 2002, NAT NEUROSCI, V5, P147, DOI 10.1038/nn796; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HELL S, 1992, J OPT SOC AM A, V9, P2159, DOI 10.1364/JOSAA.9.002159; Holt M, 2003, J NEUROSCI, V23, P1329, DOI 10.1523/JNEUROSCI.23-04-01329.2003; KEMP DT, 1978, J ACOUST SOC AM, V64, P1386, DOI 10.1121/1.382104; Lagnado L, 2003, CURR BIOL, V13, pR631, DOI 10.1016/S0960-9822(03)00566-9; Lenzi D, 2002, NEURON, V36, P649, DOI 10.1016/S0896-6273(02)01025-5; LIBERMAN MC, 1982, SCIENCE, V216, P1239, DOI 10.1126/science.7079757; Moser T, 2000, P NATL ACAD SCI USA, V97, P883, DOI 10.1073/pnas.97.2.883; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Paillart C, 2003, J NEUROSCI, V23, P4092; Schmitz F, 2000, NEURON, V28, P857, DOI 10.1016/S0896-6273(00)00159-8; Shnerson A, 1981, Brain Res, V254, P77; SMITH CA, 1961, J ULTRA MOL STRUCT R, V5, P184, DOI 10.1016/S0022-5320(61)90013-2; SMITH JE, 1980, J EXP BIOL, V89, P19; Spassova MA, 2004, JARO-J ASSOC RES OTO, V5, P376, DOI 10.1007/s10162-004-5003-8; Starr A, 1996, BRAIN, V119, P741, DOI 10.1093/brain/119.3.741; Sterling P, 2005, TRENDS NEUROSCI, V28, P20, DOI 10.1016/j.tins.2004.11.009; TOMDIECK S, IN PRESS J CELL 0222, DOI DOI 10.1083/JCB.2001.200408157; Trussell LO, 1999, ANNU REV PHYSIOL, V61, P477, DOI 10.1146/annurev.physiol.61.1.477; vonGersdorff H, 1996, NEURON, V16, P1221, DOI 10.1016/S0896-6273(00)80148-8; Zenisek D, 2000, NATURE, V406, P849, DOI 10.1038/35022500	30	360	382	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					889	894		10.1038/nature03418	http://dx.doi.org/10.1038/nature03418			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829963	Green Published			2022-12-28	WOS:000228327600039
J	Heymann, DL; Sutter, RW; Aylward, RB				Heymann, DL; Sutter, RW; Aylward, RB			A global call for new polio vaccines	NATURE			English	Editorial Material									WHO, Global Polio Eradicat Initiat, CH-1211 Geneva, Switzerland	World Health Organization	Heymann, DL (corresponding author), WHO, Global Polio Eradicat Initiat, 20 Ave Appia, CH-1211 Geneva, Switzerland.							Fine P E, 2001, Dev Biol (Basel), V105, P129; Heymann DL, 2004, LANCET, V363, P1566, DOI 10.1016/S0140-6736(04)16234-X; Heymann DL, 2004, NEW ENGL J MED, V351, P1275, DOI 10.1056/NEJMp048204; Mulders MN, 1997, J INFECT DIS, V176, P617, DOI 10.1086/514081; Savolainen C, 2003, LANCET, V361, P1145, DOI 10.1016/S0140-6736(03)12965-0; *WHO, 2002, GLOB ACT PLAN LAB CO; *WHO, IN PRESS REP WHO CON	7	48	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					699	700		10.1038/434699a	http://dx.doi.org/10.1038/434699a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815604	Bronze, Green Published			2022-12-28	WOS:000228160700017
J	James, WD				James, WD			Acne	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; ADAPALENE GEL 0.1-PERCENT; ORAL-CONTRACEPTIVES; TOPICAL TREATMENT; BENZOYL PEROXIDE; MODERATE ACNE; RESISTANT PROPIONIBACTERIA; ETHINYL ESTRADIOL; ISOTRETINOIN USE; CLINDAMYCIN GEL	A 17- year- old boy with a six- month history of acne presents for initial evaluation and treatment. Physical examination reveals closed and open comedones and a large number of erythematous papules and pustules ( 50 or more) of the face and upper trunk. How should he be treated?	Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA	University of Pennsylvania	James, WD (corresponding author), Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.							*AG HEALTHC RES QU, 2001, AHRQ PUBL; BOTTOMLEY WW, 1993, DERMATOLOGY, V187, P193, DOI 10.1159/000247241; Braathen L R, 1984, Scand J Infect Dis Suppl, V43, P71; CHIVOT M, 1990, DERMATOLOGICA, V180, P240, DOI 10.1159/000248038; Coates P, 2002, BRIT J DERMATOL, V146, P840, DOI 10.1046/j.1365-2133.2002.04690.x; Cooper AJ, 1998, MED J AUSTRALIA, V169, P259, DOI 10.5694/j.1326-5377.1998.tb140250.x; Cunliffe WJ, 2003, J AM ACAD DERMATOL, V49, pS218, DOI 10.1067/S0190-9622(03)01153-8; Cunliffe WJ, 2002, CLIN THER, V24, P1117, DOI 10.1016/S0149-2918(02)80023-6; CUNLIFFE WJ, 1986, BRIT J DERMATOL, V115, P386, DOI 10.1111/j.1365-2133.1986.tb05757.x; Cunliffe WJ, 1998, BRIT J DERMATOL, V139, P48; Dickinson BD, 2001, OBSTET GYNECOL, V98, P853, DOI 10.1016/S0029-7844(01)01532-0; EADY EA, 1989, BRIT J DERMATOL, V121, P51, DOI 10.1111/j.1365-2133.1989.tb01399.x; FYRAND O, 1986, DERMATOLOGICA, V172, P263, DOI 10.1159/000249352; Goldsmith LA, 2004, J AM ACAD DERMATOL, V50, P900, DOI 10.1016/j.jaad.2004.02.012; Gollnick H, 1998, DERMATOLOGY, V196, P119, DOI 10.1159/000017844; Gollnick H, 2003, J AM ACAD DERMATOL, V49, pS1, DOI 10.1067/mjd.2003.618; GOODFELLOW A, 1984, BRIT J DERMATOL, V111, P206; HARCUP JW, 1980, PRACTITIONER, V224, P747; HARRISON PV, 1988, CLIN EXP DERMATOL, V13, P242, DOI 10.1111/j.1365-2230.1988.tb00689.x; Hull PR, 2003, AM J CLIN DERMATOL, V4, P493, DOI 10.2165/00128071-200304070-00005; Jacobs DG, 2001, J AM ACAD DERMATOL, V45, pS168, DOI 10.1067/mjd.2001.118233; Jacyk W K, 2001, Cutis, V68, P48; JAMES WD, 1985, J AM ACAD DERMATOL, V12, P319, DOI 10.1016/S0190-9622(85)80043-8; KOO J, 1995, J AM ACAD DERMATOL, V32, pS25; KRANING KK, 1979, J INVEST DERMATOL, V73, P395; LAYTON AM, 1993, BRIT J DERMATOL, V129, P292, DOI 10.1111/j.1365-2133.1993.tb11849.x; LEHUCHERCEYRAC D, 1993, DERMATOLOGY, V186, P123, DOI 10.1159/000247322; Levy RM, 2003, ARCH DERMATOL, V139, P467, DOI 10.1001/archderm.139.4.467; Leyden J, 2002, J AM ACAD DERMATOL, V47, P399, DOI 10.1067/mjd.2002.122192; Leyden James J, 2002, Cutis, V69, P12; LEYDEN JJ, 1987, ARCH DERMATOL, V123, P606, DOI 10.1001/archderm.123.5.606; Leyden JJ, 2001, J CUTAN MED SURG, V5, P37, DOI 10.1007/s102270000008; LEYDEN JJ, 1975, J INVEST DERMATOL, V65, P382, DOI 10.1111/1523-1747.ep12607634; Leyden JJ, 1997, DERMATOLOGY, V195, P29, DOI 10.1159/000246017; Lookingbill DP, 1997, J AM ACAD DERMATOL, V37, P590, DOI 10.1016/S0190-9622(97)70177-4; Lucky AW, 1997, J AM ACAD DERMATOL, V37, P746, DOI 10.1016/S0190-9622(97)70112-9; Mallon E, 1999, BRIT J DERMATOL, V140, P672; McConnell RC, 1998, J AM ACAD DERMATOL, V38, P221, DOI 10.1016/S0190-9622(98)70598-5; MILLS OH, 1992, ADV THER, V9, P14; Ng CH, 2003, AUST NZ J PSYCHIAT, V37, P78; NORRIS JFB, 1988, BRIT J DERMATOL, V118, P651, DOI 10.1111/j.1365-2133.1988.tb02566.x; Ozolins M, 2004, LANCET, V364, P2188, DOI 10.1016/S0140-6736(04)17591-0; PECK GL, 1982, J AM ACAD DERMATOL, V6, P735, DOI 10.1016/S0190-9622(82)70063-5; PEPALL LM, 1991, BRIT J DERMATOL, V125, P256, DOI 10.1111/j.1365-2133.1991.tb14751.x; Rosen MP, 2003, AM J OBSTET GYNECOL, V188, P1158, DOI 10.1067/mob.2003.294; Ross JI, 2001, BRIT J DERMATOL, V144, P339, DOI 10.1046/j.1365-2133.2001.03956.x; SAMUELSON JS, 1985, J AM ACAD DERMATOL, V12, P461, DOI 10.1016/S0190-9622(85)70064-3; Shalita A, 1996, J AM ACAD DERMATOL, V34, P482, DOI 10.1016/S0190-9622(96)90443-0; Shaw JC, 2000, J AM ACAD DERMATOL, V43, P498, DOI 10.1067/mjd.2000.105557; Shaw JC, 2002, J CUTAN MED SURG, V6, P541, DOI 10.1007/s10227-001-0152-4; Skidmore R, 2003, ARCH DERMATOL, V139, P459, DOI 10.1001/archderm.139.4.459; STAINFORTH JM, 1993, BRIT J DERMATOL, V129, P297, DOI 10.1111/j.1365-2133.1993.tb11850.x; Thiboutot D, 1998, DERMATOLOGY, V196, P38, DOI 10.1159/000017863; THIBOUTOT D, 1995, J INVEST DERMATOL, V105, P209, DOI 10.1111/1523-1747.ep12317162; Thiboutot DM, 2001, J EUR ACAD DERMATOL, V15, P57, DOI 10.1046/j.0926-9959.2001.00014.x; Thorneycroft IH, 1999, CONTRACEPTION, V60, P255, DOI 10.1016/S0010-7824(99)00093-1; van Vloten Willem A, 2002, Cutis, V69, P2; Vega B, 2002, J EUR ACAD DERMATOL, V16, P123; Webster Guy F, 2002, Cutis, V69, P4; White G M, 1999, Adv Dermatol, V14, P29; Wolf JE, 2003, J AM ACAD DERMATOL, V49, pS211, DOI 10.1067/S0190-9622(03)01152-6; Wysowski DK, 2001, J AM ACAD DERMATOL, V45, P515, DOI 10.1067/mjd.2001.117730; Zouboulis CC, 2000, BRIT J DERMATOL, V143, P498, DOI 10.1111/j.1365-2133.2000.03701.x	63	184	194	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1463	1472		10.1056/NEJMcp033487	http://dx.doi.org/10.1056/NEJMcp033487			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814882				2022-12-28	WOS:000228145200010
J	Saadoun, S; Papadopoulos, MC; Hara-Chikuma, M; Verkman, AS				Saadoun, S; Papadopoulos, MC; Hara-Chikuma, M; Verkman, AS			Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption	NATURE			English	Article							WATER CHANNELS; EXPRESSION; RECEPTOR; GROWTH; MICE; PERMEABILITY; PROTEIN	Aquaporin-1 (AQP1) is a water channel protein expressed widely in vascular endothelia, where it increases cell membrane water permeability(1-3). The role of AQP1 in endothelial cell function is unknown. Here we show remarkably impaired tumour growth in AQP1-null mice after subcutaneous or intracranial tumour cell implantation, with reduced tumour vascularity and extensive necrosis. A new mechanism for the impaired angiogenesis was established from cell culture studies. Although adhesion and proliferation were similar in primary cultures of aortic endothelia from wild-type and from AQP1-null mice, cell migration was greatly impaired in AQP1-deficient cells, with abnormal vessel formation in vitro. Stable transfection of non-endothelial cells with AQP1 or with a structurally different water-selective transletters porter (AQP4) accelerated cell migration and wound healing in vitro. Motile AQP1-expressing cells had prominent membrane ruffles at the leading edge with polarization of AQP1 protein to lamellipodia, where rapid water fluxes occur. Our findings support a fundamental role of water channels in cell migration, which is central to diverse biological phenomena including angiogenesis, wound healing, tumour spread and organ regeneration.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Papadopoulos, Marios/0000-0001-9174-4176; Saadoun, Samira/0000-0002-5480-5678				Carter EP, 1998, BIOPHYS J, V74, P2121, DOI 10.1016/S0006-3495(98)77919-6; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; Egami K, 2003, J CLIN INVEST, V112, P67, DOI 10.1172/JCI200316645; Endo M, 1999, MICROVASC RES, V58, P89, DOI 10.1006/mvre.1999.2158; HASEGAWA H, 1994, AM J PHYSIOL, V266, pC893, DOI 10.1152/ajpcell.1994.266.4.C893; Ishida T, 2003, J BIOL CHEM, V278, P34598, DOI 10.1074/jbc.M304890200; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Miao WM, 2001, CANCER RES, V61, P7830; Moon C, 2003, ONCOGENE, V22, P6699, DOI 10.1038/sj.onc.1206762; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Ribatti D, 2002, ANAT REC, V268, P85, DOI 10.1002/ar.10123; ROSENGREN S, 1994, AM J PHYSIOL-CELL PH, V267, pC1623, DOI 10.1152/ajpcell.1994.267.6.C1623; Saadoun S, 2002, BRIT J CANCER, V87, P621, DOI 10.1038/sj.bjc.6600512; Schwab A, 1999, PFLUG ARCH EUR J PHY, V438, P330, DOI 10.1007/s004240050917; Schwab A, 2001, AM J PHYSIOL-RENAL, V280, pF739, DOI 10.1152/ajprenal.2001.280.5.F739; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Vacca A, 2001, BRIT J HAEMATOL, V113, P415, DOI 10.1046/j.1365-2141.2001.02738.x; Yang BX, 1996, J BIOL CHEM, V271, P4577; Yao L, 1999, BLOOD, V93, P1612, DOI 10.1182/blood.V93.5.1612.405a13_1612_1621	28	579	674	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					786	792		10.1038/nature03460	http://dx.doi.org/10.1038/nature03460			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815633				2022-12-28	WOS:000228160700046
J	Taylor, WR				Taylor, WR			Stirring the primordial soup	NATURE			English	Article									Natl Inst Med Res, Div Math Biol, London NW7 1AA, England	MRC National Institute for Medical Research	Taylor, WR (corresponding author), Natl Inst Med Res, Div Math Biol, Mill Hill, London NW7 1AA, England.				Medical Research Council [MC_U117581331] Funding Source: Medline; MRC [MC_U117581331] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Atkins J.F, 1999, RNA WORLD; Dyson F., 1985, ORIGINS LIFE; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; Szathmary E, 1995, MAJOR TRANSITIONS EV; Taylor WR, 2004, COMPUT BIOL CHEM, V28, P313, DOI 10.1016/j.compbiolchem.2004.09.008	5	8	8	9	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 7	2005	434	7034					705	705		10.1038/434705a	http://dx.doi.org/10.1038/434705a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815609				2022-12-28	WOS:000228160700020
J	Garbutt, JC; Kranzler, HR; O'Malley, SS; Gastfriend, DR; Pettinati, HM; Silverman, BL; Loewy, JW; Ehrich, EW				Garbutt, JC; Kranzler, HR; O'Malley, SS; Gastfriend, DR; Pettinati, HM; Silverman, BL; Loewy, JW; Ehrich, EW		Vivitrex Study Grp	Efficacy and tolerability of long-acting injectable for alcohol dependence - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE; NALTREXONE; METAANALYSIS; VIVITREX(R); MULTICENTER; OUTCOMES; THERAPY	Context Alcohol dependence is a common disorder associated with significant morbidity and mortality. Naltrexone, an opioid antagonist, has been shown to be effective for treatment of alcohol dependence. However, adherence to daily oral pharmacotherapy can be problematic, and clinical acceptance and utility of oral naltrexone have been limited. Objective To determine efficacy and tolerability of a long-acting intramuscular formulation of naltrexone for treatment of alcohol-dependent patients. Design, Setting, and Participants A 6-month, randomized, double-blind, placebo-controlled trial conducted between February 2002 and September 2003 at 24 US public hospitals, private and Veterans Administration clinics, and tertiary care medical centers. Of the 899 individuals screened, 627 who were diagnosed as being actively drinking alcohol-dependent adults were randomized to receive treatment and 624 received at least 1 injection. Intervention An intramuscular injection of 380 mg of long-acting naltrexone (n = 205) or 190 mg of long-acting naltrexone (n = 210) or a matching volume of placebo (n = 209) each administered monthly and combined with 12 sessions of low-intensity psychosocial intervention. Main Outcome Measure The event rate of heavy drinking days in the intent-to-treat population. Results Compared with placebo, 380 mg of long-acting naltrexone resulted in a 25% decrease in the event rate of heavy drinking days (P = .03) and 190 mg of naltrexone resulted in a 17% decrease (P = .07). Sex and pretreatment abstinence each showed significant interaction with the medication group on treatment outcome, with men and those with lead-in abstinence both exhibiting greater treatment effects. Discontinuation due to adverse events occurred in 14.1% in the 380-mg and 6.7% in the 190-mg group and 6.7% in the placebo group. Overall, rate and time to treatment discontinuation were similar among treatment groups. Conclusions Long-acting naltrexone was well tolerated and resulted in reductions in heavy drinking among treatment-seeking alcohol-dependent patients during 6 months of therapy. These data indicate that long-acting naltrexone can be of benefit in the treatment of alcohol dependence.	Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA; Univ Connecticut, Sch Med, Dept Psychiat, Farmington, CT USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA; Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; Alkermes Inc, Cambridge, MA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Connecticut; Yale University; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Pennsylvania; Alkermes	Garbutt, JC (corresponding author), Univ N Carolina, Sch Med, Dept Psychiat, CB 7160, Chapel Hill, NC 27599 USA.	jc_garbutt@med.unc.edu	kranzler, henry/AAS-1113-2020	kranzler, henry/0000-0002-1018-0450	NIAAA NIH HHS [K24-AA13736, N43AA01002] Funding Source: Medline; NIDA NIH HHS [K24-DA00427] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [N43AA001002, K24AA013736] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K24DA000427] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1999, SAS STAT USERS GUIDE; Anton RF, 1999, AM J PSYCHIAT, V156, P1758; Bartus RT, 2003, NEUROPSYCHOPHARMACOL, V28, P1973, DOI 10.1038/sj.npp.1300274; BOUZA C, 2001, ADDICTION, V99, P811; CHIANG CN, 1985, DRUG ALCOHOL DEPEN, V16, P1, DOI 10.1016/0376-8716(85)90076-6; Chick J, 2000, ALCOHOL ALCOHOLISM, V35, P587, DOI 10.1093/alcalc/35.6.587; Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027; Davidson D, 1999, ALCOHOL CLIN EXP RES, V23, P195, DOI 10.1097/00000374-199902000-00001; Dawson DA, 2000, J SUBST ABUSE, V12, P79, DOI 10.1016/S0899-3289(00)00041-9; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Grant BF, 2004, DRUG ALCOHOL DEPEN, V74, P223, DOI 10.1016/j.drugalcdep.2004.02.004; Hogan JW, 2004, STAT MED, V23, P1455, DOI 10.1002/sim.1728; Johnson BA, 2004, ALCOHOL CLIN EXP RES, V28, P1356, DOI 10.1097/01.ALC.0000139823.30096.52; Koob GF, 2003, ALCOHOL CLIN EXP RES, V27, P232, DOI 10.1097/01.ALC.0000057122.36127.C2; Kranzler HR, 2000, NEUROPSYCHOPHARMACOL, V22, P493, DOI 10.1016/S0893-133X(99)00135-9; Kranzler HR, 2004, ALCOHOL CLIN EXP RES, V28, P1051, DOI 10.1097/01.ALC.0000130804.08397.29; Kranzler HR, 2001, ALCOHOL CLIN EXP RES, V25, P1335, DOI 10.1097/00000374-200109000-00014; Kranzler HR, 1998, ALCOHOL CLIN EXP RES, V22, P1074; Krystal JH, 2001, NEW ENGL J MED, V345, P1734, DOI 10.1056/NEJMoa011127; Lin DY, 2000, J ROY STAT SOC B, V62, P711, DOI 10.1111/1467-9868.00259; Littleton J, 2003, AM J ADDICTION, V12, pS3, DOI 10.1111/j.1521-0391.2003.tb00492.x; Mark TL, 2003, DRUG ALCOHOL DEPEN, V71, P219, DOI 10.1016/S0376-8716(03)00134-0; McCaul ME, 2001, NEUROPSYCHOPHARMACOL, V25, P537, DOI 10.1016/S0893-133X(01)00241-X; McGinnis JM, 1999, P ASSOC AM PHYSICIAN, V111, P109, DOI 10.1046/j.1525-1381.1999.09256.x; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Monti PM, 2001, ALCOHOL CLIN EXP RES, V25, P1634, DOI 10.1111/j.1530-0277.2001.tb02170.x; Murray C. J. L., 1996, GLOBAL BURDEN DIS; *NORTHR GRUNM CORP, 2005, MED DICT REG ACT SUB; O'Connor PG, 1998, NEW ENGL J MED, V338, P592, DOI 10.1056/NEJM199802263380907; O'Malley SS, 2003, ARCH INTERN MED, V163, P1695, DOI 10.1001/archinte.163.14.1695; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; Pettinati HM, 2000, J ADDICT DIS, V19, P71, DOI 10.1300/J069v19n01_06; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Raytek H, 1993, WOMEN SUBSTANCE ABUS, P314; Rinn W, 2002, J NEUROPSYCH CLIN N, V14, P52, DOI 10.1176/appi.neuropsych.14.1.52; SANCHEZCRAIG M, 1989, BRIT J ADDICT, V84, P395; SCHNEIDER KM, 1995, ADDICT BEHAV, V20, P1, DOI 10.1016/0306-4603(94)00037-Y; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41, DOI 10.1007/978-1-4612-0357-5_3; Srisurapanont M, 2002, Cochrane Database Syst Rev, pCD001867, DOI 10.1002/14651858.CD001867; Streeton C, 2001, ALCOHOL ALCOHOLISM, V36, P544, DOI 10.1093/alcalc/36.6.544; Swift RM, 1999, ALCOHOL RES HEALTH, V23, P207; *USDA, 1990, HOME GARDEN B, V232; VEREBEY K, 1976, CLIN PHARMACOL THER, V20, P315; Volpicelli JR, 1997, ARCH GEN PSYCHIAT, V54, P737; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 2000, COMBINING MEDICATION; Wang SJ, 2002, ALCOHOL CLIN EXP RES, V26, P1803, DOI 10.1097/01.ALC.0000042009.07691.12	48	428	459	1	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2005	293	13					1617	1625		10.1001/jama.293.13.1617	http://dx.doi.org/10.1001/jama.293.13.1617			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913EV	15811981	Bronze			2022-12-28	WOS:000228135300024
J	Demoly, P; Daures, JP				Demoly, P; Daures, JP			Managing asthma during pregnancy	LANCET			English	Editorial Material							RHINITIS		Univ Hosp Montpellier, Hop Arnaud Villeneuve, INSERM, U454, F-34295 Montpellier, France; Univ Montpellier I, Inst Univ Rech Clin Montpellier, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier	Demoly, P (corresponding author), Univ Hosp Montpellier, Hop Arnaud Villeneuve, INSERM, U454, F-34295 Montpellier, France.	dernoly@rnontp.inserm.fr	Demoly, Pascal/Y-9938-2019	Demoly, Pascal/0000-0001-7827-7964				Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Bousquet J, 2003, ALLERGY, V58, P691, DOI 10.1034/j.1398-9995.2003.00105.x; Demoly P, 2003, DRUGS, V63, P1813, DOI 10.2165/00003495-200363170-00004; Demoly P, 2003, EXPERT OPIN PHARMACO, V4, P1019, DOI 10.1517/14656566.4.7.1019; Dombrowski MP, 2004, OBSTET GYNECOL, V103, P5, DOI 10.1097/01.AOG.0000103994.75162.16; Global Initiative for Asthma, 2004, GLOB STRAT ASTHM MAN; Martel MJ, 2005, BMJ-BRIT MED J, V330, P230, DOI 10.1136/bmj.38313.624352.8F; Wedzicha JA, 2003, THORAX, V58, P1, DOI 10.1136/thorax.58.1.1	8	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2005	365	9466					1212	1213		10.1016/S0140-6736(05)74791-7	http://dx.doi.org/10.1016/S0140-6736(05)74791-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811441				2022-12-28	WOS:000228107600008
J	Gainford, MC; Dranitsaris, G; Clemons, M				Gainford, MC; Dranitsaris, G; Clemons, M			Recent developments in bisphosphonates for patients with metastatic breast cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BONE METASTASES; SKELETAL COMPLICATIONS; DOUBLE-BLIND; ORAL IBANDRONATE; PAMIDRONATE; PLACEBO; EFFICACY; CLODRONATE; WOMEN; MANAGEMENT		Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Clemons, M (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Med Oncol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	Mark.Clemons@sw.ca						ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663; Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367; Brown JE, 2005, JNCI-J NATL CANCER I, V97, P59, DOI 10.1093/jnci/dji002; Brown JE, 2003, BRIT J CANCER, V89, P2031, DOI 10.1038/sj.bjc.6601437; Clamp A, 2004, LANCET ONCOL, V5, P607, DOI 10.1016/S1470-2045(04)01596-7; CLEMONS M, IN PRESS BREAST CANC; Clemons Mark, 2004, Can J Clin Pharmacol, V11, pe168; Conte PF, 1996, J CLIN ONCOL, V14, P2552, DOI 10.1200/JCO.1996.14.9.2552; Hillner BE, 2000, J CLIN ONCOL, V18, P72, DOI 10.1200/JCO.2000.18.1.72; Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; Hultborn R, 1999, ANTICANCER RES, V19, P3383; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Kristensen B, 1999, J INTERN MED, V246, P67, DOI 10.1046/j.1365-2796.1999.00507.x; Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z; LoRusso P, 2001, SEMIN ONCOL, V28, P22, DOI 10.1016/S0093-7754(01)90228-3; Major PP, 2002, AM J CLIN ONCOL-CANC, V25, pS10, DOI 10.1097/00000421-200212001-00003; PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59; PAVLAKIS N, 2004, COCHRANE DATABASE SY, V4, P2521; Plunkett TA, 2000, EUR J CANCER, V36, P476, DOI 10.1016/S0959-8049(99)00331-7; Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892; Ross JR, 2003, BMJ-BRIT MED J, V327, P469, DOI 10.1136/bmj.327.7413.469; Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846; Tripathy D, 2004, ANN ONCOL, V15, P743, DOI 10.1093/annonc/mdh173; Tubiana-Hulin M, 2001, B CANCER, V88, P701; VANHOLTENVERZANTVOORT ATM, 1993, J CLIN ONCOL, V11, P491, DOI 10.1200/JCO.1993.11.3.491; Verma S, 2004, SUPPORT CARE CANCER, V12, P852, DOI 10.1007/s00520-004-0671-9; WONG R, 2004, COCHRANE DB SYST REV, V3	29	41	43	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					769	773		10.1136/bmj.330.7494.769	http://dx.doi.org/10.1136/bmj.330.7494.769			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15802719	Green Published			2022-12-28	WOS:000228222900024
J	Griffiths, PD; Paley, MNJ; Whitby, EH				Griffiths, PD; Paley, MNJ; Whitby, EH			Post-mortern MRI as an adjunct to fetal or neonatal autopsy	LANCET			English	Review							PERINATAL PATHOLOGY; CLINICAL-TRIAL; ATTITUDES; CONTEXT	Context Understanding what was wrong with a dead fetus or why a newborn child died can help the parents to grieve, while any findings can be used to inform the parents if there is a risk to future pregnancies and the level of risk. This information is mainly obtained from autopsies, but the number of parents agreeing to autopsy has dropped, which has prompted the search for adjuncts to autopsy. Starting point The UK's Chief Medical Officer outlined the rationale for exploring alternatives to autopsy in 2000 and 2001. After wide consultation, MRI was deemed to offer the most realistic chance of making a contribution. Results so far are promising, but of insufficient depth and quality to make firm recommendations about providing a service in the future. In 2004, the UK Department of Health therefore tendered for this research to be done in fetal and neonatal (and adult) cases, and this work is due to start in 2005. Where next? High-quality anatomical information about the brain and spine of fetuses and neonates can be easily obtained with standard MRI scanners. Most developmental and acquired abnormalities can be seen on postmortem MRI. More work needs to be done on organs not in the central nervous system, and heart malformations, in particular, might present diagnostic problems. A possible outcome could be whole-body MRI plus targeted biopsies of abnormalities taken under image guidance as an adjunct to formal autopsy.	Univ Sheffield, Sect Acad Radiol, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield	Griffiths, PD (corresponding author), Univ Sheffield, Sect Acad Radiol, Sheffield S10 2JF, S Yorkshire, England.	p.griffiths@sheffield.ac.uk	Whitby, Elspeth/G-5517-2010	Whitby, Elspeth/0000-0002-8912-8013				Alderliesten ME, 2003, BJOG-INT J OBSTET GY, V110, P378, DOI 10.1016/S1470-0328(02)02076-1; Brookes JAS, 1996, LANCET, V348, P1139, DOI 10.1016/S0140-6736(96)02287-8; Chief Medical Officer, 2001, REM RET US HUM ORG T; Griffiths PD, 2003, AM J NEURORADIOL, V24, P22; Huisman TAGM, 2002, FETAL DIAGN THER, V17, P58, DOI 10.1159/000048008; Larroche, 1987, DEV CERVEAU FOETAL H; Parker A, 2004, LESS INVASIVE AUTOPS; Snowdon C, 2004, ARCH DIS CHILD-FETAL, V89, pF208, DOI 10.1136/adc.2003.041392; Snowdon C, 2004, ARCH DIS CHILD-FETAL, V89, pF204, DOI 10.1136/adc.2002.012732; The Chief Medical Officer, 2000, REP CENS ORG TISS RE; Whitby EH, 2004, BJOG-INT J OBSTET GY, V111, P784, DOI 10.1111/j.1471-0528.2004.00149.x; Woodward PJ, 1997, AM J ROENTGENOL, V168, P41, DOI 10.2214/ajr.168.1.8976917	12	87	91	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1271	1273		10.1016/S0140-6736(05)74816-9	http://dx.doi.org/10.1016/S0140-6736(05)74816-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811461				2022-12-28	WOS:000228107600031
J	Jabbour, S				Jabbour, S			Healing and peace making in the middle east: challenges for doctors	LANCET			English	Editorial Material							HEALTH				Jabbour, S (corresponding author), POB 9633, Aleppo, Syria.	sjabbour@post.harvard.edu	Jabbour, Samer/Y-6860-2018	Jabbour, Samer/0000-0002-7150-6856				Barnea T, 2000, ISRAELI PALESTINIAN; Payne D, 1999, BRIT MED J, V319, P870, DOI 10.1136/bmj.319.7214.870; Santa Barbara J, 2004, LANCET, V364, P384; SCHAM P, 2000, MIDDLE E REV INT AFF, V4, P1; Vass A, 2001, BRIT MED J, V323, P1020, DOI 10.1136/bmj.323.7320.1020	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1211	1212		10.1016/S0140-6736(05)74790-5	http://dx.doi.org/10.1016/S0140-6736(05)74790-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	912VI	15811440				2022-12-28	WOS:000228107600007
J	Wexler, ID; Branski, D; Kerem, E				Wexler, ID; Branski, D; Kerem, E			Treatment of sick children during low-intensity conflict	LANCET			English	Editorial Material							WAR		Hadassah Univ Hosp, Dept Pediat, IL-91240 Jerusalem, Israel	Hebrew University of Jerusalem	Wexler, ID (corresponding author), Hadassah Univ Hosp, Dept Pediat, IL-91240 Jerusalem, Israel.	shwexler@hadassah.org.il						CARTER J, NOBEL LECT; Goldson E, 1996, CHILD ABUSE NEGLECT, V20, P809, DOI 10.1016/0145-2134(96)00069-5; Leppaniemi AK, 1998, WORLD J SURG, V22, P1197, DOI 10.1007/s002689900544; Ofran Yishai, 2004, Ann Intern Med, V140, P307; Pearn J, 2003, J PAEDIATR CHILD H, V39, P166, DOI 10.1046/j.1440-1754.2003.00124.x; Pedersen D, 2002, SOC SCI MED, V55, P175, DOI 10.1016/S0277-9536(01)00261-1; Perez-Stable EJ, 2000, AM J MED, V108, P509, DOI 10.1016/S0002-9343(00)00317-X; van Creveld Martin, 1991, TRANSFORMATION WAR	8	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1278	1279		10.1016/S0140-6736(05)74818-2	http://dx.doi.org/10.1016/S0140-6736(05)74818-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811463				2022-12-28	WOS:000228107600033
J	Bailis, R; Ezzati, M; Kammen, DM				Bailis, R; Ezzati, M; Kammen, DM			Mortality and greenhouse gas impacts of biomass and petroleum energy futures in Africa	SCIENCE			English	Article							BIRTH-WEIGHT; EXPOSURE; SMOKE	We analyzed the mortality impacts and greenhouse gas (GHG) emissions produced by household energy use in Africa. Under a business-as-usual (BAU) scenario, household indoor air pollution will cause an estimated 9.8 million premature deaths by the year 2030. Gradual and rapid transitions to charcoal would delay 1.0 million and 2.8 million deaths, respectively; similar transitions to petroleum fuels would delay 1.3 million and 3.7 million deaths. Cumulative BAU GHG emissions will be 6.7 billion tons of carbon by 2050, which is 5.6% of Africa's total emissions. Large shifts to the use of fossil fuels would reduce GHG emissions by 1 to 10%. Charcoal-intensive future scenarios using current practices increase emissions by 140 to 190%; the increase can be reduced to 5 to 36% using currently available technologies for sustainable production or potentially reduced even more with investment in technological innovation.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA; Univ Calif Berkeley, Goldman Sch Publ Policy, Berkeley, CA 94720 USA	Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Ezzati, M (corresponding author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	mezzati@hsph.harvard.edu; kammen@berkeley.edu	Bailis, Robert/O-6643-2019; Bailis, Rob/B-9779-2015	Bailis, Robert/0000-0002-4111-3760; Bailis, Rob/0000-0002-4111-3760	NIA NIH HHS [P01-AG17625] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG017625] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1996, GLOBAL BURDEN DIS; [Anonymous], 2004, WORLD POP PROSP 2002; Bailis R, 2003, ENVIRON SCI TECHNOL, V37, P2051, DOI 10.1021/es026058q; Bond T. C., 2004, ENERGY SUSTAIN DEV, V3, P20, DOI DOI 10.1016/S0973-0826(08)60464-0; Boy E, 2002, ENVIRON HEALTH PERSP, V110, P109, DOI 10.1289/ehp.02110109; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Ezzati M, 2000, ENVIRON SCI TECHNOL, V34, P578, DOI 10.1021/es9905795; FERREIRA OC, 2000, EC ENERGY        MAY, P20; *GOV IND, 2001, CENS IND 2001; Houghton JT, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P1; IEA, 2002, WORLD EN OUTL, P365; *IEA, 2004, EN STAT NONOECD COUN; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Karekezi S, 2002, ENERG POLICY, V30, P915, DOI 10.1016/S0301-4215(02)00047-2; Ministry of Energy, 2002, STUD KEN EN DEM SUPP; Mishra V, 2004, ANN EPIDEMIOL, V14, P740, DOI 10.1016/j.annepidem.2004.01.009; Smith K.R., 2004, COMP QUANTIFICATION, V18, P1435; Smith KR, 2002, SCIENCE, V298, P1847, DOI 10.1126/science.298.5600.1847; SMITH KR, 2000, GREENHOUSE GASES SMA; SMITH KR, 1999, EPA600R99109 US EPA; *UN FAO, 2004, FAOSTAT DAT; WHO, 2002, RED RISKS PROM HLTH; *WORLD BANK, 2000, AFR DEV IND SER	23	207	215	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					98	103		10.1126/science.1106881	http://dx.doi.org/10.1126/science.1106881			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802601				2022-12-28	WOS:000228221500041
J	Brown, RH				Brown, RH			Amyotrophic lateral sclerosis - A new role for old drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Brown, RH (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180	1	7	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1376	1378		10.1056/NEJMcibr050274	http://dx.doi.org/10.1056/NEJMcibr050274			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800236				2022-12-28	WOS:000227998300019
J	Isaacs, FJ; Blake, WJ; Collins, JJ				Isaacs, FJ; Blake, WJ; Collins, JJ			Signal processing in single cells	SCIENCE			English	Editorial Material							EUKARYOTIC GENE-EXPRESSION; NETWORKS; NOISE; AUTOREGULATION		Harvard Univ, Sch Med, Lipper Ctr Computat Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Boston Univ, Ctr Biodynam, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Boston University; Boston University	Isaacs, FJ (corresponding author), Harvard Univ, Sch Med, Lipper Ctr Computat Genet, Boston, MA 02115 USA.	jcollins@bu.edu						Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; Hooshangi S, 2005, P NATL ACAD SCI USA, V102, P3581, DOI 10.1073/pnas.0408507102; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Pedraza JM, 2005, SCIENCE, V307, P1965, DOI 10.1126/science.1109090; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4	13	13	13	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1886	1888		10.1126/science.1110797	http://dx.doi.org/10.1126/science.1110797			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790834				2022-12-28	WOS:000227957300036
J	Sauerwald, A; Zhu, WH; Major, TA; Roy, H; Palioura, S; Jahn, D; Whitman, WB; Yates, JR; Ibba, M; Soll, D				Sauerwald, A; Zhu, WH; Major, TA; Roy, H; Palioura, S; Jahn, D; Whitman, WB; Yates, JR; Ibba, M; Soll, D			RNA-Dependent cysteine biosynthesis in archaea	SCIENCE			English	Article							GENETIC-CODE ORIGIN; METHANOCOCCUS-JANNASCHII; IN-VIVO; SYNTHETASE; CYSTEINYL-TRNA(CYS); PYRROLYSINE; ACID	Several methanogenic archaea lack cysteinyl-transfer RNA (tRNA) synthetase (CysRS), the essential enzyme that provides Cys-tRNA(Cys) for translation in most organisms. Partial purification of the corresponding activity from Methanocaldococcus jannaschii indicated that tRNA(Cys) becomes acylated with O-phosphoserine (Sep) but not with cysteine. Further analyses identified a class II-type O-phosphoseryl-tRNA synthetase (SepRS) and Sep-tRNA:Cys-tRNA synthase (SepCysS). SepRS specifically forms Sep-tRNA(Cys), which is then converted to Cys-tRNA(Cys) by SepCysS. Comparative genomic analyses suggest that this pathway, encoded in all organisms lacking CysRS, can also act as the sole route for cysteine biosynthesis. This was proven for Methanococcus maripaludis, where deletion of the SepRS-encoding gene resulted in cysteine auxotrophy. As the conversions of Sep-tRNA to Cys-tRNA or to selenocysteinyl-tRNA are chemically analogous, the catalytic activity of SepCysS provides a means by which both cysteine and selenocysteine may have originally been added to the genetic code.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Georgia, Dept Microbiol, Athens, GA 30602 USA; Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA; Tech Univ Carolo Wilhelmina Braunschweig, Dept Microbiol, D-38106 Braunschweig, Germany	Yale University; Yale University; Scripps Research Institute; University System of Georgia; University of Georgia; University System of Ohio; Ohio State University; Braunschweig University of Technology	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu	Whitman, William/AAC-5896-2020	Whitman, William/0000-0003-1229-0423; Jahn, Dieter/0000-0002-4064-9205				Ambrogelly A, 2004, CELL MOL LIFE SCI, V61, P2437, DOI 10.1007/s00018-004-4194-9; AVALOS J, 1991, FEBS LETT, V286, P176, DOI 10.1016/0014-5793(91)80968-9; BALCH WE, 1979, J BACTERIOL, V137, P264, DOI 10.1128/JB.137.1.264-273.1979; Basurko MJ, 1999, IUBMB LIFE, V48, P525, DOI 10.1080/713803557; Blight SK, 2004, NATURE, V431, P333, DOI 10.1038/nature02895; BOCK A, 2004, AMINOACYL TRNA SYNTH, P320; Brooks DJ, 2002, MOL CELL PROTEOMICS, V1, P125, DOI 10.1074/mcp.M100001-MCP200; CALENDAR R, 1966, PROG NUCL ACID RES M, V1, P375; Carlson BA, 2004, P NATL ACAD SCI USA, V101, P12848, DOI 10.1073/pnas.0402636101; Das R, 1999, BIOCHIMIE, V81, P1037, DOI 10.1016/S0300-9084(99)00332-6; Di Giulio M, 1999, J MOL EVOL, V49, P1, DOI 10.1007/PL00006522; Di Giulio M, 2002, J MOL EVOL, V55, P616, DOI 10.1007/s00239-002-2357-6; Fabrega C, 2001, NATURE, V411, P110, DOI 10.1038/35075121; Farahi K, 2004, J MOL EVOL, V58, P615, DOI 10.1007/s00239-004-2582-2; Giometti CS, 2002, J CHROMATOGR B, V782, P227, DOI 10.1016/S1570-0232(02)00568-8; Ibba M, 2000, TRENDS BIOCHEM SCI, V25, P311, DOI 10.1016/S0968-0004(00)01600-5; Jeffares DC, 1998, J MOL EVOL, V46, P18, DOI 10.1007/PL00006280; Kim HS, 1998, J BACTERIOL, V180, P6446, DOI 10.1128/JB.180.24.6446-6449.1998; Li T, 1999, FEBS LETT, V462, P302, DOI 10.1016/S0014-5793(99)01550-1; Lipman RSA, 2000, BIOCHEMISTRY-US, V39, P7792, DOI 10.1021/bi0004955; Min B, 2002, P NATL ACAD SCI USA, V99, P2678, DOI 10.1073/pnas.012027399; Mino K, 2003, FEBS LETT, V551, P133, DOI 10.1016/S0014-5793(03)00913-X; Polycarpo C, 2004, P NATL ACAD SCI USA, V101, P12450, DOI 10.1073/pnas.0405362101; Ruan BF, 2004, J BACTERIOL, V186, P8, DOI 10.1128/JB.186.1.8-14.2004; SAUERWALD A, UNPUB; Sethi A, 2005, P NATL ACAD SCI USA, V102, P4045, DOI 10.1073/pnas.0409715102; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Stathopoulos C, 2001, P NATL ACAD SCI USA, V98, P14292, DOI 10.1073/pnas.201540498; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; White RH, 2003, BBA-GEN SUBJECTS, V1624, P46, DOI 10.1016/j.bbagen.2003.09.005; WONG JTF, 1975, P NATL ACAD SCI USA, V72, P1909, DOI 10.1073/pnas.72.5.1909; Zhang Chun-Mei, 2004, RNA Biol, V1, P35	32	185	195	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1969	1972		10.1126/science.1108329	http://dx.doi.org/10.1126/science.1108329			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790858				2022-12-28	WOS:000227957300059
J	Byass, P; Ghebreyesus, TA				Byass, P; Ghebreyesus, TA			Making the world's children count	LANCET			English	Editorial Material							SURVIVAL		Umea Univ, Umea Int Sch Publ Hlth Epidemiol & Publ Hlth Sci, S-90187 Umea, Sweden; Fed Minist Hlth, Addis Ababa, Ethiopia	Umea University; Federal Ministry of Health - Ethiopia (FMOH)	Byass, P (corresponding author), Umea Univ, Umea Int Sch Publ Hlth Epidemiol & Publ Hlth Sci, S-90187 Umea, Sweden.	peter.byass@epiph.umu.se		Byass, Peter/0000-0001-5474-4361				Ali M, 2005, B WORLD HEALTH ORGAN, V83, P27; Byass P, 2001, SCAND J PUBLIC HEALT, V29, P84, DOI 10.1080/14034940152393336; Commission for Africa, 2005, OUR COMMON INTEREST; Horton R, 2005, LANCET, V365, P821, DOI 10.1016/S0140-6736(05)71015-1; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; *UN GEN ASS, 2004, A59282 UN; UNICEF, 2004, STAT WORLDS CHILDR 2; United Nations Development Programme, 2004, HUM DEV REP 2004 CUL; Wall S, 2002, SCAND J PUBLIC HEALT, V30, P162, DOI 10.1080/140349402320290872; *WHO, IN PRESS WORLD HLTH; 2005, MAKE POVERTY HIST	11	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR-APR	2005	365	9465					1114	1116		10.1016/S0140-6736(05)71854-7	http://dx.doi.org/10.1016/S0140-6736(05)71854-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794952				2022-12-28	WOS:000227909500005
J	Audibert, F				Audibert, F			Screening for pre-eclampsia: the quest for the Holy Grail?	LANCET			English	Editorial Material							DOPPLER VELOCIMETRY; EARLY PREDICTION; PREVENTION; ULTRASOUND; RISK		Univ Montreal, Hop St Justine, Dept Obstet & Gynecol, Montreal, PQ H3T 1C5, Canada	Universite de Montreal	Audibert, F (corresponding author), Univ Montreal, Hop St Justine, Dept Obstet & Gynecol, Montreal, PQ H3T 1C5, Canada.	francois.audibert@umontreal.ca	Audibert, François/AAL-1265-2020	Audibert, Francois/0000-0002-2697-3826				Audibert F, 2005, FETAL DIAGN THER, V20, P48, DOI 10.1159/000081369; Audibert F, 2001, ULTRASOUND OBST GYN, V18, P26, DOI 10.1046/j.1469-0705.2001.00457.x; Chappell LC, 1999, LANCET, V354, P810, DOI 10.1016/S0140-6736(99)80010-5; Conde-Agudelo A, 2004, OBSTET GYNECOL, V104, P1367, DOI 10.1097/01.AOG.0000147599.47713.5d; Dekker G, 2001, LANCET, V357, P209, DOI 10.1016/S0140-6736(00)03599-6; Florio P, 2003, ULTRASOUND OBST GYN, V21, P165, DOI 10.1002/uog.29; Harrington K, 1997, BRIT J OBSTET GYNAEC, V104, P674, DOI 10.1111/j.1471-0528.1997.tb11977.x; Roberts JM, 2001, LANCET, V357, P53, DOI 10.1016/S0140-6736(00)03577-7; Salomon LJ, 2003, AM J OBSTET GYNECOL, V189, P1517, DOI 10.1016/S0002-9378(03)00902-5; Sibai BM, 1998, AM J OBSTET GYNECOL, V179, P1275, DOI 10.1016/S0002-9378(98)70146-2	10	12	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 16	2005	365	9468					1367	1369		10.1016/S0140-6736(05)66350-7	http://dx.doi.org/10.1016/S0140-6736(05)66350-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836870				2022-12-28	WOS:000228401900006
J	Routledge, T; Jenkins, D				Routledge, T; Jenkins, D			An unusual case of pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Papworth Hosp, Cambridge CB3 8RE, England	Papworth Hospital	Routledge, T (corresponding author), Papworth Hosp, Cambridge CB3 8RE, England.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1578	1578		10.1056/NEJMicm040637	http://dx.doi.org/10.1056/NEJMicm040637			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829538				2022-12-28	WOS:000228324200010
J	De Luca, G; Suryapranata, H; Stone, GW; Antoniucci, D; Tcheng, JE; Neumann, FJ; Van de Werf, F; Antman, EM; Topol, EJ				De Luca, G; Suryapranata, H; Stone, GW; Antoniucci, D; Tcheng, JE; Neumann, FJ; Van de Werf, F; Antman, EM; Topol, EJ			Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction - A meta-analysis of randomized trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GLYCOPROTEIN IIB/IIIA INHIBITION; TISSUE-PLASMINOGEN-ACTIVATOR; PRIMARY ANGIOPLASTY; RECEPTOR BLOCKADE; CORONARY ANGIOPLASTY; THROMBOLYTIC THERAPY; ARTERY; IMPROVES; PLACEBO; EPTIFIBATIDE	Context The benefits of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) are still a matter of debate. Objective To combine data from all randomized trials conducted with abciximab in STEMI. Data Sources Formal searches of electronic databases (MEDLINE, PubMed) from from January 1990 to December 2004. Study Selection We examined all completed, published, randomized trials of abciximab in STEM. The following key words were used for study selection: randomized trial, myocardial infarction, reperfusion, primary angioplasty, facilitated angioplasty, stenting, fibrinolysis, IIb-IIIa inhibitors, and abciximab. Data Extraction Information on study design, type and dosage of drugs, inclusion and exclusion criteria, number of patients, and clinical outcome was extracted by 2 investigators. Disagreements were resolved by consensus. Data Synthesis Eleven trials were analyzed, involving 27115 patients (12 602 [46.5%] in the abciximab group, 14513 [53.5%] in the control group). When compared with the control group, abciximab was associated with a significant reduction in short-term (30 days) mortality (2.4% vs 3.4%, P=.047) and long-term (6-12 months) mortality (4.4% vs 6.2%, P=.01) in patients undergoing primary angioplasty but not in those treated with fibrinolysis or in all trials combined. Abciximab was associated with a significant reduction in 30-day reinfarction, both in all trials combined (2.1% vs 3.3%, P<.001), in primary angioplasty (1.0% vs 1.9%, P=.03), and in fibrinolysis trials (2.3% vs 3.6%, P<.001). Abciximab did not result in an increased risk of intracranial bleeding(0.61% vs 0.62%, P=.62) but was associated with an increased risk of major bleedIng complications when combined with fibrinolysis (5.2% vs 3.1 %, P<.001) but not with primary angioplasty (4.7% vs 4.1 %, P=36). Conclusions This meta-analysis shows that, when compared with the control group, adjunctive abciximab for STEMI is associated with a significant reduction in 30-day and long-term mortality in patients treated with primary angioplasty but not in those receiving fibrinolysis. The 30-day reinfarction rate is significantly reduced in patients treated with either fibrinolysis or primary angioplasty. A higher risk of major bleeding complications is observed with abciximab in association with fibrinolysis.	Hosp Weezenlanden, Isala Klinieken, NL-8011 JW Zwolle, Netherlands; Cardiovasc Res Fdn, Lenox Hill Hosp, New York, NY USA; Vasc Inst, New York, NY USA; Careggi Hosp, Div Cardiol, Florence, Italy; Duke Clin Res Inst, Durham, NC USA; Tech Univ Munich, Med Klin, D-8000 Munich, Germany; Univ Hosp Gasthuisberg, Dept Cardiol, B-3000 Louvain, Belgium; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cardiovascular Research Foundation (CRF); Northwell Health; University of Florence; Azienda Ospedaliero Universitaria Careggi; Duke University; Technical University of Munich; KU Leuven; University Hospital Leuven; Harvard University; Brigham & Women's Hospital; Cleveland Clinic Foundation	Suryapranata, H (corresponding author), Hosp Weezenlanden, Isala Klinieken, Groot Wezenland 20, NL-8011 JW Zwolle, Netherlands.	h.suryapranata@diagram-zwolle.nl	Suryapranata, H./H-8095-2014	Topol, Eric/0000-0002-1478-4729; Van de Werf, Frans/0000-0001-9479-7767				Antman EM, 2000, EUR HEART J, V21, P1944, DOI 10.1053/euhj.2000.2243; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Antman EM, 2002, CIRCULATION, V105, P1642, DOI 10.1161/01.CIR.0000013402.34759.46; Antoniucci D, 2003, J AM COLL CARDIOL, V42, P1879, DOI 10.1016/j.jacc.2003.07.017; Antoniucci D, 2002, AM J CARDIOL, V90, P353, DOI 10.1016/S0002-9149(02)02487-6; Araujo JODF, 2004, AM HEART J, V148, P937, DOI 10.1016/j.ahj/2004.05.047; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; Brener SJ, 2002, J AM COLL CARDIOL, V39, P377, DOI 10.1016/S0735-1097(01)01758-2; Coller BS, 1999, AM HEART J, V138, pS1, DOI 10.1053/hj.1999.v138.99078; de Lemos JA, 2000, CIRCULATION, V101, P239, DOI 10.1161/01.CIR.101.3.239; De Luca G, 2004, J AM COLL CARDIOL, V43, P1363, DOI 10.1016/j.jacc.2003.11.042; De Luca G, 2003, EUR HEART J, V24, P270, DOI 10.1016/S0195-668X(03)94646-X; De Luca G, 2003, J AM COLL CARDIOL, V42, P991, DOI 10.1016/S0735-1097(03)00919-7; Di Mario C, 2004, AM HEART J, V148, P378, DOI 10.1016/j.ahj.2004.03.038; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Eisenberg MJ, 2003, J AM COLL CARDIOL, V42, P1, DOI 10.1016/S0735-1097(03)00566-7; EISENBERG PR, 1992, J AM COLL CARDIOL, V19, P1065, DOI 10.1016/0735-1097(92)90296-Y; Ellis SG, 2004, AM HEART J, V147, DOI 10.1016/j.ahj.2003.07.025; Giugliano RP, 2003, J AM COLL CARDIOL, V41, P1251, DOI 10.1016/S0735-1097(03)00123-2; Gyongyosi M, 2004, EUR HEART J, V25, P2125, DOI 10.1016/j.ehj.2004.09.018; Harrington RA, 1998, J AM COLL CARDIOL, V32, P2003; Henriques JPS, 2002, EUR HEART J, V23, P1112, DOI 10.1053/euhj.2001.3035; Kandzari DE, 2004, AM HEART J, V147, P457, DOI 10.1016/j.ahj.2003.08.011; Kleiman NS, 1993, J AM COLL CARDIOL, V22, P381, DOI 10.1016/0735-1097(93)90041-X; Lee CW, 2002, AM J CARDIOL, V90, P1243, DOI 10.1016/S0002-9149(02)02843-6; Lee DP, 2003, CIRCULATION, V107, P1497, DOI 10.1161/01.CIR.0000056120.00513.7A; Lefkovits J, 1996, AM J CARDIOL, V77, P1045, DOI 10.1016/S0002-9149(96)00128-2; Lincoff AM, 2002, JAMA-J AM MED ASSOC, V288, P2130, DOI 10.1001/jama.288.17.2130; Montalescot G, 2004, JAMA-J AM MED ASSOC, V292, P362, DOI 10.1001/jama.292.3.362; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Ndrepepa G, 2004, EUR HEART J, V25, P1635, DOI 10.1016/j.ehj.2004.04.031; Neumann FJ, 2000, J AM COLL CARDIOL, V35, P915, DOI 10.1016/S0735-1097(99)00635-X; Neumann FJ, 1998, CIRCULATION, V98, P2695, DOI 10.1161/01.CIR.98.24.2695; Ohman EM, 1997, CIRCULATION, V95, P846; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; Peters S, 2002, Z KARDIOL, V91, P233, DOI 10.1007/s003920200016; Petronio AS, 2003, EUR HEART J, V24, P67, DOI 10.1016/S0195-668X(02)00324-1; Petronio AS, 2002, AM HEART J, V143, P334, DOI 10.1067/mhj.2002.119762; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; Ronner E, 2000, EUR HEART J, V21, P1530, DOI 10.1053/euhj.1999.2035; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; Savonitto S, 2003, EUR HEART J, V24, P1807, DOI 10.1016/j.ehj.2003.07.004; Schwarz M, 2002, THROMB RES, V107, P121, DOI 10.1016/S0049-3848(02)00207-4; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 2003, J AM COLL CARDIOL, V42, P1886, DOI 10.1016/j.jacc.2003.09.010; Van de Werf F, 2001, LANCET, V358, P605; van't Hof AWJ, 2004, EUR HEART J, V25, P837, DOI 10.1016/j.ehj.2004.04.003; van't Hof AWJ, 1998, CIRCULATION, V97, P2302, DOI 10.1161/01.CIR.97.23.2302; Wohrle J, 2003, CIRCULATION, V107, P1840, DOI 10.1161/01.CIR.0000066852.98038.D1; ZIJLSTRA F, 1909, NEW ENGL J MED, V341, P1413; Zorman S, 2002, AM J CARDIOL, V90, P533, DOI 10.1016/S0002-9149(02)02530-4	53	455	471	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1759	1765		10.1001/jama.293.14.1759	http://dx.doi.org/10.1001/jama.293.14.1759			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827315				2022-12-28	WOS:000228301100030
J	Frost, KR				Frost, KR			Ensuring the safety of HIV/AIDS generics	LANCET			English	Editorial Material									Amer Fdn AIDS Res, Global Initiat, New York, NY 10005 USA		Frost, KR (corresponding author), Amer Fdn AIDS Res, Global Initiat, New York, NY 10005 USA.	kevin.frost@amfar.org						ADELMAN C, 2004, WALL STREET J E 1209; *AM FDN AIDS RES, 2004, EXP AV HIV AIDS DRUG; BROWN D, 2004, WASHINGTON POST 0327, P3; BUCKLEY S, 2000, WASHINGTON POST 0917, P22; DSILVA J, 2004, EC TIMES NEW DE 1030; MASON A, 2004, SAN FRANCISCO C 1201, pB11; MCNEIL DG, 2005, NY TIMES        0126, pA9; SOLOMON J, 2004, OFFICIALS KNEW AIDS; VERJEE N, 2004, TIMES LOND      1120, P66; WHALEN J, 2004, WALL STREET J   1110, pB1	10	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1290	1291		10.1016/S0140-6736(05)61007-0	http://dx.doi.org/10.1016/S0140-6736(05)61007-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823366				2022-12-28	WOS:000228219600008
J	Brunet, M; Guy, F; Pilbeam, D; Lieberman, DE; Likius, A; Mackaye, HT; de Leon, MSP; Zollikofer, CPE; Vignaud, P				Brunet, M; Guy, F; Pilbeam, D; Lieberman, DE; Likius, A; Mackaye, HT; de Leon, MSP; Zollikofer, CPE; Vignaud, P			New material of the earliest hominid from the Upper Miocene of Chad	NATURE			English	Article							PALEOANTHROPOLOGY; SAHELANTHROPUS; SAHELPITHECUS; ETHIOPIA; LUKEINO; KENYA	Discoveries in Chad by the Mission Paleoanthropologique Franco-Tchadienne have substantially changed our understanding of early human evolution in Africa(1-3). In particular, the TM 266 locality in the Toros-Menalla fossiliferous area yielded a nearly complete cranium (TM 266-01-60-1), a mandible, and several isolated teeth assigned to Sahelanthropus tchadensis(3) and biochronologically dated to the late Miocene epoch ( about 7 million years ago). Despite the relative completeness of the TM 266 cranium, there has been some controversy about its morphology and its status in the hominid clade(4,5). Here we describe new dental and mandibular specimens from three Toros-Menalla ( Chad) fossiliferous localities ( TM 247, TM 266 and TM 292) of the same age(6). This new material, including a lower canine consistent with a non-honing C/P-3 complex, post-canine teeth with primitive root morphology and intermediate radial enamel thickness, is attributed to S. tchadensis. It expands the hypodigm of the species and provides additional anatomical characters that confirm the morphological differences between S. tchadensis and African apes. S. tchadensis presents several key derived features consistent with its position in the hominid clade close to the last common ancestor of chimpanzees and humans.	Univ Poitiers, Fac Sci, CNRS,UMR 6046, Lab Geobiol Biochronol & Paleontol Humaine, F-86022 Poitiers, France; Harvard Univ, Peabody Museum, Cambridge, MA 02138 USA; Univ Ndjamena, Ndjamena, Chad; Univ Zurich Irchel, MultiMedia Lab, Inst Anthropol, CH-8057 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; Harvard University; University of Zurich	Brunet, M (corresponding author), Univ Poitiers, Fac Sci, CNRS,UMR 6046, Lab Geobiol Biochronol & Paleontol Humaine, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	michel.brunet@univ-poitiers.fr	Lund, Laura/H-7335-2012	GUY, Franck/0000-0001-7032-7963				Brunet M, 1997, CR ACAD SCI II A, V324, P341; Brunet M, 2002, NATURE, V419, P582, DOI 10.1038/419582a; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Brunet M, 1996, CR ACAD SCI II A, V322, P907; Deino AL, 2002, J HUM EVOL, V42, P117, DOI 10.1006/jhev.2001.0521; Haile-Selassie Y, 2004, SCIENCE, V303, P1503, DOI 10.1126/science.1092978; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; MACDOUGALL I, 2003, LOTHAGAM DAWN HUMANI, P43; Senut B, 2001, CR ACAD SCI II A, V332, P137, DOI 10.1016/S1251-8050(01)01529-4; Vignaud P, 2002, NATURE, V418, P152, DOI 10.1038/nature00880; WHITE TD, 1994, NATURE, V371, P306, DOI 10.1038/371306a0; Wolpoff MH, 2002, NATURE, V419, P581, DOI 10.1038/419581a; WOOD BA, 1988, J ANAT, V156, P107	14	160	171	0	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 7	2005	434	7034					752	755		10.1038/nature03392	http://dx.doi.org/10.1038/nature03392			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815627	Green Published			2022-12-28	WOS:000228160700038
J	Rasmann, S; Kollner, TG; Degenhardt, J; Hiltpold, I; Toepfer, S; Kuhlmann, U; Gershenzon, J; Turlings, TCJ				Rasmann, S; Kollner, TG; Degenhardt, J; Hiltpold, I; Toepfer, S; Kuhlmann, U; Gershenzon, J; Turlings, TCJ			Recruitment of entomopathogenic nematodes by insect-damaged maize roots	NATURE			English	Article							CORN-ROOTWORM COLEOPTERA; SESQUITERPENE HYDROCARBONS; VOLATILE EMISSIONS; BIOLOGICAL-CONTROL; PLANTS; STEINERNEMATIDAE; CARPOCAPSAE; VARIABILITY; PARASITISM; EFFICACY	Plants under attack by arthropod herbivores often emit volatile compounds from their leaves that attract natural enemies of the herbivores. Here we report the first identification of an insect-induced belowground plant signal, (E)-beta-caryophyllene, which strongly attracts an entomopathogenic nematode. Maize roots release this sesquiterpene in response to feeding by larvae of the beetle Diabrotica virgifera virgifera, a maize pest that is currently invading Europe. Most North American maize lines do not release (E)-beta-caryophyllene, whereas European lines and the wild maize ancestor, teosinte, readily do so in response to D. v. virgifera attack. This difference was consistent with striking differences in the attractiveness of representative lines in the laboratory. Field experiments showed a fivefold higher nematode infection rate of D. v. virgifera larvae on a maize variety that produces the signal than on a variety that does not, whereas spiking the soil near the latter variety with authentic (E)-beta-caryophyllene decreased the emergence of adult D. v. virgifera to less than half. North American maize lines must have lost the signal during the breeding process. Development of new varieties that release the attractant in adequate amounts should help enhance the efficacy of nematodes as biological control agents against root pests like D. v. virgifera.	Univ Neuchatel, Inst Zool, Lab Anim Ecol & Entomol, CH-2007 Neuchatel, Switzerland; Max Planck Inst Chem Ecol, D-07745 Jena, Germany; CABI Biosci Switzerland Ctr, CH-2800 Delemont, Switzerland	University of Neuchatel; Max Planck Society	Turlings, TCJ (corresponding author), Univ Neuchatel, Inst Zool, Lab Anim Ecol & Entomol, CP 2, CH-2007 Neuchatel, Switzerland.	ted.turlings@unine.ch	Köllner, Tobias G/H-3375-2014; Gershenzon, Jonathan/K-1331-2013; Hiltpold, Ivan/D-1666-2016; Turlings, Ted CJ/E-8671-2012; Hiltpold, Ivan/AAH-6805-2021; Rasmann, Sergio/T-5376-2017	Köllner, Tobias G/0000-0002-7037-904X; Gershenzon, Jonathan/0000-0002-1812-1551; Hiltpold, Ivan/0000-0001-6374-6684; Turlings, Ted CJ/0000-0002-8315-785X; Hiltpold, Ivan/0000-0001-6374-6684; Rasmann, Sergio/0000-0002-3120-6226				Agrawal AA, 1999, INDUCED PLANT DEFENSES AGAINST PATHOGENS AND HERBIVORES, P251; [Anonymous], 1986, METHODS STUDY PEST D; Baufeld P, 2005, WESTERN CORN ROOTWORM: ECOLOGY AND MANAGEMENT, P285, DOI 10.1079/9780851998176.0285; Boff MIC, 2001, ENTOMOL EXP APPL, V98, P329, DOI 10.1023/A:1018907812376; CURRAN J, 1992, J NEMATOL, V24, P631; De Moraes CM, 1998, NATURE, V393, P570, DOI 10.1038/31219; Degen T, 2004, PLANT PHYSIOL, V135, P1928, DOI 10.1104/pp.104.039891; DICKE M, 1988, NETH J ZOOL, V38, P148, DOI 10.1163/156854288X00111; Ellsbury MM, 1996, J ECON ENTOMOL, V89, P74, DOI 10.1093/jee/89.1.74; Fedoroff NV, 2003, SCIENCE, V302, P1158, DOI 10.1126/science.1092042; GAUGLER R, 1988, AGR ECOSYST ENVIRON, V24, P351, DOI 10.1016/0167-8809(88)90078-3; Gouinguene S, 2001, CHEMOECOLOGY, V11, P9, DOI 10.1007/PL00001832; GREWAL PS, 1994, PARASITOLOGY, V108, P207, DOI 10.1017/S003118200006830X; Grewal PS, 1997, J CHEM ECOL, V23, P503, DOI 10.1023/B:JOEC.0000006374.95624.7e; Hammack L, 2001, J CHEM ECOL, V27, P1373, DOI 10.1023/A:1010365225957; Hass B, 1999, J NEMATOL, V31, P508; Jackson JJ, 1996, J ECON ENTOMOL, V89, P366, DOI 10.1093/jee/89.2.366; Jaenicke-Despres V, 2003, SCIENCE, V302, P1206, DOI 10.1126/science.1089056; Journey AM, 2000, ENVIRON ENTOMOL, V29, P822, DOI 10.1603/0046-225X-29.4.822; Karban R., 1997, INDUCED RESPONSES HE, DOI 10.7208/chicago/9780226424972.001.0001; KAYA HK, 1993, ANNU REV ENTOMOL, V38, P181, DOI 10.1146/annurev.en.38.010193.001145; Kessler A, 2001, SCIENCE, V291, P2141, DOI 10.1126/science.291.5511.2141; Khan ZR, 1997, NATURE, V388, P631, DOI 10.1038/41681; Kollner TG, 2004, PHYTOCHEMISTRY, V65, P1895, DOI 10.1016/j.phytochem.2004.05.021; Konig WA, 1999, FLAVOUR FRAG J, V14, P367, DOI 10.1002/(SICI)1099-1026(199911/12)14:6&lt;367::AID-FFJ856&gt;3.0.CO;2-4; Kuhlmann Ulrich, 1998, Biocontrol News and Information, V19, p59N; LEVINE E, 1991, ANNU REV ENTOMOL, V36, P229, DOI 10.1146/annurev.en.36.010191.001305; LEWIS EE, 1995, PARASITOLOGY, V110, P207, DOI 10.1017/S0031182000063976; LEWIS EE, 1993, CAN J ZOOL, V71, P765, DOI 10.1139/z93-101; O'Halloran DM, 2003, PARASITOLOGY, V127, P375, DOI 10.1017/S0031182003003688; OSTEEN C, 2003, AGR RESOURCES ENV IN, P1; POINAR GO, 1983, PROT ECOL, V5, P337; Sotelo A., 1997, FUNCTIONALITY FOOD P, P89; Thaler JS, 1999, NATURE, V399, P686, DOI 10.1038/21420; Turlings TCJ, 1998, PLANTA, V207, P146, DOI 10.1007/s004250050466; TURLINGS TCJ, 1990, SCIENCE, V250, P1251, DOI 10.1126/science.250.4985.1251; Turlings TCJ, 2004, PHYSIOL ENTOMOL, V29, P45, DOI 10.1111/j.1365-3032.2004.0362.x; Van der Putten WH, 2001, TRENDS ECOL EVOL, V16, P547, DOI 10.1016/S0169-5347(01)02265-0; van Tol RWHM, 2001, ECOL LETT, V4, P292, DOI 10.1046/j.1461-0248.2001.00227.x; Wardle DA, 2004, SCIENCE, V304, P1629, DOI 10.1126/science.1094875	40	868	927	9	473	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					732	737		10.1038/nature03451	http://dx.doi.org/10.1038/nature03451			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815622	Green Submitted			2022-12-28	WOS:000228160700032
J	Pincock, S				Pincock, S			Peter James Henry Solomon Benenson	LANCET			English	Biographical-Item												stephenpincock@blueyonder.co.uk		Pincock, Stephen/0000-0003-1655-2902					0	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1224	1224		10.1016/S0140-6736(05)74800-5	http://dx.doi.org/10.1016/S0140-6736(05)74800-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15828079				2022-12-28	WOS:000228107600015
J	Lee, KY; D'Acquisto, F; Hayden, MS; Shim, JH; Ghosh, S				Lee, KY; D'Acquisto, F; Hayden, MS; Shim, JH; Ghosh, S			PDK1 nucleates T cell receptor-induced signaling complex for NF-kappa B activation	SCIENCE			English	Article							KINASE-C-THETA; COSTIMULATION; UBIQUITINATION; INHIBITION; PATHWAY; CARMA1; BCL10	Activation of the transcription factor NF-kappa B after engagement of the T cell receptor (TCR) is important for T cell proliferation and activation during the adaptive immune response. Recent reports have elucidated a signaling pathway that involves the protein kinase C theta (PKC theta), the scaffold protein CARD11 (also called CARMA-1), the caspase recruitment domain (CARD)-containing protein Bcl10, and the paracaspase (protease related to caspases) MALT1 as critical intermediates linking the TCR to the I kappa B kinase (IKK) complex. However, the events proximal to the TCR that initiate the activation of this signaling pathway remain poorly defined. We demonstrate that 3-phosphoinositide-dependent kinase 1 (PDK1) has an essential role in this pathway by regulating the activation of PKC theta and through signal-dependent recruiting of both PKC theta and CARD11 to lipid rafts. PDK1-associated PKC theta recruits the IKK complex, whereas PDK1-associated CARD11 recruits the Bcl10-MALT1 complex, thereby allowing activation of the IKK complex through Bcl10-MALT1-dependent ubiquitination of the IKK complex subunit known as NEMO (NF-kappa B essential modifier). Hence, PDK1 plays a critical role by nucleating the TCR-induced NF-kappa B activation pathway in T cells.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.	Sankar.ghosh@yale.edu	D'Acquisto, Fulvio/E-7204-2018; Hayden, Matthew/C-1263-2008	D'Acquisto, Fulvio/0000-0002-4513-1608; Shim, Jae-Hyuck/0000-0002-4947-3293	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI033443, R37-AI33443] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Costello PS, 2002, NAT IMMUNOL, V3, P1082, DOI 10.1038/ni848; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harriague J, 2002, NAT IMMUNOL, V3, P1090, DOI 10.1038/ni847; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hinton HJ, 2004, NAT IMMUNOL, V5, P539, DOI 10.1038/ni1062; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee K. T., UNPUB; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Sparatore B, 2003, FEBS LETT, V554, P35, DOI 10.1016/S0014-5793(03)01073-1; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	23	198	210	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					114	118		10.1126/science.1107107	http://dx.doi.org/10.1126/science.1107107			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802604				2022-12-28	WOS:000228221500045
J	Xie, SC; Pancost, RD; Yin, HF; Wang, HM; Evershed, RP				Xie, SC; Pancost, RD; Yin, HF; Wang, HM; Evershed, RP			Two episodes of microbial change coupled with Permo/Triassic faunal mass extinction	NATURE			English	Article							PERMIAN-TRIASSIC BOUNDARY; SOUTH CHINA; DIVERSITY; AUSTRALIA; PATTERNS; BASIN	Microbial expansion following faunal mass extinctions in Earth history can be studied by petrographic examination of microbialites ( microbial crusts)(1,2) or well-preserved organic-walled microbes(3). However, where preservation is poor, quantification of microbial communities can be problematic. We have circumvented this problem by adopting a lipid biomarker-based approach to evaluate microbial community changes across the Permo/Triassic (P/Tr) boundary at Meishan in South China. We present here a biomarker stratigraphic record showing episodic microbial changes coupled with a high-resolution record of invertebrate mass extinction. Variation in the microbial community structure is characterized by the 2-methylhopane (2-MHP) index ( a ratio of the abundance of cyanobacterial biomarkers to more general bacterial biomarkers). Two episodes of faunal mass extinction were each preceded by minima in the 2-MHP index, followed by strong maxima, likely reflecting microbial responses to the catastrophic events that caused the extinction and initiated ecosystem changes. Hence, both cyanobacterial biomarker and invertebrate fossil records provide evidence for two episodes of biotic crisis across the P/Tr boundary.	Univ Bristol, Sch Chem, Organ Geochem Unit, Bristol Biogeochem Ctr, Bristol BS8 1TS, Avon, England; China Univ Geosci, Fac Earth Sci, Wuhan 430074, Peoples R China; China Univ Geosci, State Key Lab Geol Proc & Mineral Resources, Wuhan 430074, Peoples R China; China Univ Geosci, Sch Environm Studies, Wuhan 430074, Peoples R China	University of Bristol; China University of Geosciences; China University of Geosciences; China University of Geosciences	Pancost, RD (corresponding author), Univ Bristol, Sch Chem, Organ Geochem Unit, Bristol Biogeochem Ctr, Cantocks Close, Bristol BS8 1TS, Avon, England.	r.d.pancost@bristol.ac.uk	Xie, Shucheng/E-6713-2011	Pancost, Richard/0000-0003-0298-4026				Brocks JJ, 2003, GEOCHIM COSMOCHIM AC, V67, P4321, DOI 10.1016/S0016-7037(03)00209-6; DIONISIOPIRES LM, 2004, FRESHWATER BIOL, V49, P116; Erwin DH, 2002, GEOL SOC AM SPEC PAP, V356, P363; Erwin DH, 2001, P NATL ACAD SCI USA, V98, P5399, DOI 10.1073/pnas.091092698; ERWIN DH, 1990, ANNU REV ECOL SYST, V21, P495; HALLAM A, 1997, MASS EXTINCTIONS THE; Jin YG, 2000, SCIENCE, V289, P432, DOI 10.1126/science.289.5478.432; Keeling MJ, 2000, SCIENCE, V290, P1758, DOI 10.1126/science.290.5497.1758; KNOLL AH, 1992, NATURE, V356, P673, DOI 10.1038/356673a0; Lai XL, 2001, PALAEOGEOGR PALAEOCL, V171, P63, DOI 10.1016/S0031-0182(01)00269-3; Lehrmann DJ, 2003, PALAIOS, V18, P138, DOI 10.1669/0883-1351(2003)18<138:PBSFSC>2.0.CO;2; Mastin Brian J., 2002, Journal of Aquatic Ecosystem Stress and Recovery, V9, P103, DOI 10.1023/A:1014406930450; Racki G, 1999, PALAEOGEOGR PALAEOCL, V154, P107, DOI 10.1016/S0031-0182(99)00089-9; Rampino MR, 1998, GEOLOGY, V26, P415, DOI 10.1130/0091-7613(1998)026<0415:EFALPM>2.3.CO;2; Retallack GJ, 1998, GEOLOGY, V26, P979, DOI 10.1130/0091-7613(1998)026<0979:SFEOIA>2.3.CO;2; ROHMER M, 1992, BIOLOGICAL MARKERS IN SEDIMENTS AND PETROLEUM, P1; ROHMER M, 1984, J GEN MICROBIOL, V130, P1137; Sheehan PM, 2004, NATURE, V430, P75, DOI 10.1038/nature02654; Simonin P, 1996, EUR J BIOCHEM, V241, P865, DOI 10.1111/j.1432-1033.1996.00865.x; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; TONG J., 1993, PERMO TRIASSIC EVENT, P90; VALENTINE JW, 1986, P NATL ACAD SCI USA, V83, P6912, DOI 10.1073/pnas.83.18.6912; Vecoli M, 2004, EARTH-SCI REV, V67, P267, DOI 10.1016/j.earscirev.2004.03.002; Ward PD, 2000, SCIENCE, V289, P1740, DOI 10.1126/science.289.5485.1740; WIGNALL PB, 1993, PALAEOGEOGR PALAEOCL, V102, P215, DOI 10.1016/0031-0182(93)90068-T; YIN H., 1996, PALAEOZOIC MESOZOIC; Yin HF, 1998, PALAEOGEOGR PALAEOCL, V143, P199, DOI 10.1016/S0031-0182(98)00111-4; Yin HF, 2001, EPISODES, V24, P102	28	256	328	23	198	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 24	2005	434	7032					494	497		10.1038/nature03396	http://dx.doi.org/10.1038/nature03396			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791253				2022-12-28	WOS:000227836000039
J	Ting, SB; Caddy, J; Hislop, N; Wilanowski, T; Auden, A; Zhao, LL; Ellis, S; Kaur, P; Uchida, Y; Holleran, WM; Elias, PM; Cunningham, JM; Jane, SM				Ting, SB; Caddy, J; Hislop, N; Wilanowski, T; Auden, A; Zhao, LL; Ellis, S; Kaur, P; Uchida, Y; Holleran, WM; Elias, PM; Cunningham, JM; Jane, SM			A homolog of Drosophila grainy head is essential for epidermal integrity in mice	SCIENCE			English	Article							DEVELOPMENTAL TRANSCRIPTION FACTORS; SKIN BARRIER FUNCTION; GENETIC-CONTROL; FAMILY; LACKING; TRANSGLUTAMINASE-1; IDENTIFICATION; MELANOGASTER; PROTEINS; FEATURES	The Drosophila cuticle is essential for maintaining the surface barrier defenses of the fly. Integral to cuticle resilience is the transcription factor grainy head, which regulates production of the enzyme required for covalent cross-linking of the cuticular structural components. We report that formation and maintenance of the epidermal barrier in mice are dependent on a mammalian homolog of grainy head, Grainy head-like 3. Mice tacking this factor display defective skin barrier function and deficient wound repair, accompanied by reduced expression of transglutaminase 1, the key enzyme involved in cross-linking the structural components of the superficial epidermis. These findings suggest that the functional mechanisms involving protein cross-linking that maintain the epidermal barrier and induce tissue repair are conserved across 700 million years of evolution.	Royal Melbourne Hosp PO, Rotary Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Peter MacCallum Res Inst, Epithelial Stem cell Biol Lab, Microscopy Imaging Facil, Melbourne, Vic 3001, Australia; Univ Calif San Francisco, Dept Vet Affairs Med Ctr, Res Unit, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dermatol Serv, San Francisco, CA 94121 USA; Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA 94121 USA; St Jude Childrens Res Hosp, Div Expt Hematol, Memphis, TN 38101 USA	Royal Melbourne Hospital; Peter Maccallum Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; St Jude Children's Research Hospital	Jane, SM (corresponding author), Royal Melbourne Hosp PO, Rotary Bone Marrow Res Labs, Grattan St, Parkville, Vic 3050, Australia.	jane@wehi.edu.au	Wilanowski, Tomasz/R-4077-2016; Jane, Stephen/D-6659-2011; Kaur, Pritinder/I-2605-2013	Ellis, Sarah/0000-0002-5772-6051; Uchida, Yoshikazu/0000-0002-4980-3416; Kelly, Nikki/0000-0003-1517-3249; Kaur, Pritinder/0000-0002-4994-2782; Wilanowski, Tomasz/0000-0003-4447-8164; Jane, Stephen Marsden/0000-0002-1045-0481	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039448] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765] Funding Source: Medline; NHLBI NIH HHS [P01 HL53749-03] Funding Source: Medline; NIAMS NIH HHS [P01-AR39448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; Harden N, 2002, DIFFERENTIATION, V70, P181, DOI 10.1046/j.1432-0436.2002.700408.x; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Hemphala J, 2003, DEVELOPMENT, V130, P249, DOI 10.1242/dev.00218; Herrmann T, 2003, J CELL BIOL, V161, P1105, DOI 10.1083/jcb.200207080; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Inada R, 2000, AM J PATHOL, V157, P1875, DOI 10.1016/S0002-9440(10)64826-2; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; Kuramoto N, 2002, J CLIN INVEST, V109, P243, DOI 10.1172/JCI200213563; Lee HY, 2004, MECH DEVELOP, V121, P37, DOI 10.1016/j.mod.2003.11.002; Mace KA, 2005, SCIENCE, V308, P381, DOI 10.1126/science.1107573; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Martin P, 2004, DEVELOPMENT, V131, P3021, DOI 10.1242/dev.01253; Matsuki M, 1998, P NATL ACAD SCI USA, V95, P1044, DOI 10.1073/pnas.95.3.1044; MCCLUSKEY J, 1995, DEV BIOL, V170, P102, DOI 10.1006/dbio.1995.1199; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Ostrowski S, 2002, GENETICS, V161, P171; Payre F, 2004, INT J DEV BIOL, V48, P207, DOI 10.1387/ijdb.15272387; Phillips Marjorie A, 2004, BMC Dermatol, V4, P2, DOI 10.1186/1471-5945-4-2; SCHAEFER J, 1987, SCIENCE, V235, P1200, DOI 10.1126/science.3823880; SCHOLNICK SB, 1986, SCIENCE, V234, P998, DOI 10.1126/science.3095924; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Takagi S, 2003, J CLIN INVEST, V112, P1372, DOI 10.1172/JCI200318513; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Ting SB, 2003, NAT MED, V9, P1513, DOI 10.1038/nm961; Ting SB, 2003, BIOCHEM J, V370, P953, DOI 10.1042/BJ20021476; Venkatesan K, 2003, NUCLEIC ACIDS RES, V31, P4304, DOI 10.1093/nar/gkg644; Wilanowski T, 2002, MECH DEVELOP, V114, P37, DOI 10.1016/S0925-4773(02)00046-1; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104	31	228	229	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 15	2005	308	5720					411	413		10.1126/science.1107511	http://dx.doi.org/10.1126/science.1107511			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831758				2022-12-28	WOS:000228492000052
J	Wei, L; Ebrahim, S; Bartlett, C; Davey, PG; Sullivan, FM; MacDonald, TM				Wei, L; Ebrahim, S; Bartlett, C; Davey, PG; Sullivan, FM; MacDonald, TM			Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; HIGH-RISK; PRAVASTATIN; DRUGS	Objective To compare the social mid demographic profiles of patients who receive statin treatment after myocardial infarction mid patients included in randomised trials. To estimate the effect of statin use in community based patients on subsequent all cause mortality and cardiovascular recurrence, contrasting effects with trial patients. Design Observational cohort study using a record linkage database. Setting Tayside, Scotland (population size mid characteristics: about 400 000, mixed urban and rural). Subjects 4892 patients were discharged from hospital after their first myocardial infarction between January 1993 and December 2001. 2463 (50.3%) were taking statins during an average follow-up of 3.7 years (3.1% in 1993 and 62.9% in 2001). Main outcome maeasures All cause mortality and recurrence of cardiovascular events. Results 319 deaths occur-red in the statin treated group (age adjusted rate 4.1 per 100 person years, 95% confidence interval 3.2 to 4.9), and 1200 in the statin untreated group (12.7 per 100 person years, 11.1 to 14.3). More older people and women were represented in the population of patients treated with statins than among those recruited into clinical trials (mean age 67.8 v 59.8; women 39.6% v 16.9%, respectively). The effects of statins in routine clinical practice were consistent with, and similar to, those reported in clinical trials (adjusted hazard ratio for all cause mortality 0.69, 95% confidence interval 0.59 to 0.80; adjusted hazard ratio for cardiovascular recurrence 0.82, 0.71 to 0.95). Conclusions The community effectiveness of statins in those groups that were not well represented in clinical trials was similar to the efficacy of statins in these trials.	Univ Dundee, Ninewells Hosp & Med Sch, Div Med & Therapeut, Hlth Informat Ctr,Med Monitoring Unit, Dundee DD1 9SY, Scotland; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; Univ Dundee, Div Community Hlth Sci, Tayside Ctr Gen Practice, Dundee DD2 4BF, Scotland	University of Dundee; University of Bristol; University of Dundee	MacDonald, TM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Div Med & Therapeut, Hlth Informat Ctr,Med Monitoring Unit, Dundee DD1 9SY, Scotland.	t.m.macdonald@dundee.ac.uk	Sullivan, Frank/L-8286-2019; Sullivan, Frank m/A-7767-2009	Sullivan, Frank/0000-0002-6623-4964; MacDonald, Thomas/0000-0001-5189-6669				Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; BARTLETT C, IN PRESS HLTH TECHNO; BARTLETT G, IN PRESS HLTH TECHNO; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Donnan PT, 2003, FAM PRACT, V20, P706, DOI 10.1093/fampra/cmg614; EVANS JMM, 2000, PHARMACOEPIDEM DR S, P361; GISSI Prevenzione Investigators, 2000, ITAL HEART J, V1, P810; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; Hippisley-Cox J, 2003, BMJ-BRIT MED J, V326, P689, DOI 10.1136/bmj.326.7391.689; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; MacDonald TM, 1997, BMJ-BRIT MED J, V315, P1333, DOI 10.1136/bmj.315.7119.1333; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SCOTT INT GUID NE, 2000, SIGN PUBL, V41; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SMEETH L, 2000, BMJ-BRIT MED J, V321, P950; Sullivan Frank M, 2003, Inform Prim Care, V11, P215; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Walker AM, 1996, EPIDEMIOLOGY, V7, P335; Wei L, 2002, HEART, V88, P229, DOI 10.1136/heart.88.3.229; 1997, SCOTTISH HLTH SURVEY, V1, P140	24	70	73	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 9	2005	330	7495					821	824A		10.1136/bmj.38398.408032.8F	http://dx.doi.org/10.1136/bmj.38398.408032.8F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915BZ	15790616	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000228273900018
J	Hajduk, M; Zijlstra, AA; Herwig, F; van Hoof, PAM; Kerber, F; Kimeswenger, S; Pollacco, DL; Evans, A; Lopez, JA; Bryce, M; Eyres, SPS; Matsuura, M				Hajduk, M; Zijlstra, AA; Herwig, F; van Hoof, PAM; Kerber, F; Kimeswenger, S; Pollacco, DL; Evans, A; Lopez, JA; Bryce, M; Eyres, SPS; Matsuura, M			The real-time stellar evolution of Sakurai's object	SCIENCE			English	Article							FINAL HELIUM FLASH; V4334 SGR; STARS; EMISSION; SHELL	After a hot white dwarf ceases its nuclear burning, its helium may briefly and explosively reignite. This causes the star to evolve back into a cool giant, whereupon it experiences renewed mass ejection before reheating. A reignition event of this kind was observed in 1996 in V4334 Sgr (Sakurai's object). Its temperature decrease was 100 times the predicted rate. To understand its unexpectedly fast evolution, we have developed a model in which convective mixing is strongly suppressed under the influence of flash burning. The model predicts equally rapid reheating of the star. Radio emission from freshly ionized matter now shows that this reheating has begun. Such events may be an important source of carbon and carbonaceous dust in the Galaxy.	Univ Manchester, Sch Phys & Astron, Manchester M60 1QD, Lancs, England; Ctr Astron UMK, PL-87100 Torun, Poland; Los Alamos Natl Lab, Theoret Astrophys Grp T6, Los Alamos, NM 87545 USA; Queens Univ Belfast, Dept Phys & Astron, APS Div, Belfast BT7 1NN, Antrim, North Ireland; Royal Observ Belgium, Brussels, Belgium; European So Observ, Space Telescope European Coordinating Facil, D-85748 Garching, Germany; Univ Innsbruck, Inst Astrophys, A-6020 Innsbruck, Austria; Univ Keele, Sch Chem & Phys, Dept Phys, Keele ST5 5BG, Staffs, England; Univ Nacl Autonoma Mexico, Inst Astron, Ensenada 22800, Baja California, Mexico; Univ Manchester, Sch Phys & Astron, Jodrell Bank Observ, Macclesfield SK11 9DL, Cheshire, England; Univ Cent Lancashire, Ctr Astrophys, Preston PR1 2HE, Lancs, England	University of Manchester; Nicolaus Copernicus University; United States Department of Energy (DOE); Los Alamos National Laboratory; Queens University Belfast; European Southern Observatory; University of Innsbruck; Keele University; Universidad Nacional Autonoma de Mexico; University of Manchester; Jodrell Bank Centre for Astrophysics; University of Central Lancashire	Zijlstra, AA (corresponding author), Univ Manchester, Sch Phys & Astron, POB 88, Manchester M60 1QD, Lancs, England.	a.zijlstra@manchester.ac.uk	Hajduk, Marcin/C-9693-2014; Eyres, Stewart/AAF-1660-2020; Eyres, Stewart/AAF-6931-2020; Kimeswenger, of/K-7393-2013	Hajduk, Marcin/0000-0001-6028-9932; Eyres, Stewart/0000-0002-6663-7675; Lopez, Jose Alberto/0000-0002-3149-8599; Zijlstra, Albert/0000-0002-3171-5469; Matsuura, Mikako/0000-0002-5529-5593; Kimeswenger, Stefan/0000-0003-2379-0474				Amari S, 2001, ASTROPHYS J, V559, P463, DOI 10.1086/322397; Asplund M, 1997, ASTRON ASTROPHYS, V321, pL17; Asplund M, 1999, ASTRON ASTROPHYS, V343, P507; BLOECKER T, 1997, ASTRON ASTROPHYS, V324, P991; Clayton GC, 1996, PUBL ASTRON SOC PAC, V108, P225, DOI 10.1086/133715; Duerbeck HW, 1996, ASTROPHYS J, V468, pL111, DOI 10.1086/310241; Evans A, 2002, ASTRON ASTROPHYS, V394, P971, DOI 10.1051/0004-6361:20021229; Evans A, 2002, MON NOT R ASTRON SOC, V332, pL35, DOI 10.1046/j.1365-8711.2002.05476.x; Eyres SPS, 1999, MON NOT R ASTRON SOC, V307, pL11, DOI 10.1046/j.1365-8711.1999.02791.x; Eyres SPS, 2002, ASTROPHYS SPACE SCI, V279, P69, DOI 10.1023/A:1014652108087; FUJIMOTO MY, 1977, PUBL ASTRON SOC JPN, V29, P331; Herwig F, 1999, ASTRON ASTROPHYS, V349, pL5; Herwig F, 2001, ASTROPHYS J, V554, pL71, DOI 10.1086/320911; HERWIG F, 2003, IAU S, V209, P111; Hinkle K, 2002, ASTR SOC P, V279, P187; Iben Jr I., 1995, LECT NOTE PHYS, V443, P48; Kerber F, 1999, ASTRON ASTROPHYS, V344, pL79; Kerber F, 2002, ASTROPHYS J, V581, pL39, DOI 10.1086/345773; Kimeswenger S, 2002, ASTROPHYS SPACE SCI, V279, P79, DOI 10.1023/A:1014656224926; Koller J, 2001, ASTROPHYS J, V559, P419, DOI 10.1086/322407; Lawlor TM, 2003, ASTROPHYS J, V583, P913, DOI 10.1086/345411; Lechner MFM, 2004, ASTRON ASTROPHYS, V426, P145, DOI 10.1051/0004-6361:20040387; Meaburn J, 1998, ASTRON ASTROPHYS, V334, P670; Pavlenko YV, 2004, ASTRON ASTROPHYS, V417, pL39, DOI 10.1051/0004-6361:20040078; Romano D, 2003, MON NOT R ASTRON SOC, V342, P185, DOI 10.1046/j.1365-8711.2003.06526.x; SEITTER WC, 1987, ESO MESSENGER, P14; Tyne VH, 2002, MON NOT R ASTRON SOC, V334, P875, DOI 10.1046/j.1365-8711.2002.05561.x; Zijlstra AA, 2002, ASTROPHYS SPACE SCI, V279, P171, DOI 10.1023/A:1014633014448	28	50	50	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					231	233		10.1126/science.1108953	http://dx.doi.org/10.1126/science.1108953			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821085				2022-12-28	WOS:000228273700046
J	Tanaka, M; Chien, P; Yonekura, K; Weissman, JS				Tanaka, M; Chien, P; Yonekura, K; Weissman, JS			Mechanism of cross-species prion transmission: An infectious conformation compatible with two highly divergent yeast prion proteins	CELL			English	Article							PROTEASE-RESISTANT FORMS; SINGLE AMINO-ACID; SACCHAROMYCES-CEREVISIAE; SUP35 PROTEIN; MOLECULAR-BASIS; IN-VITRO; MAMMALIAN PRIONS; STRUCTURAL BASIS; INCUBATION-TIME; PSI+ PRIONS	Efficiency of interspecies prion transmission decreases as the primary structures of the infectious proteins diverge. Yet, a single prion protein can misfold into multiple infectious conformations, and such differences in "strain conformation" also alter infection specificity. Here, we explored the relationship between prion strains and species barriers by creating distinct synthetic prion forms of the yeast prion protein Sup35. We identified a strain conformation of Sup35 that allows transmission from the S. cerevisiae (Sc) Sup35 to the highly divergent C. albicans (Ca) Sup35 both in vivo and in vitro. Remarkably, cross-species transmission leads to a novel Ca strain that in turn can infect the Sc protein. Structural studies reveal strain-specific conformational differences in regions of the prion domain that are involved in intermolecular contacts. Our findings support a model whereby strain conformation is the critical determinant of cross-species prion transmission while primary structure affects transmission specificity by altering the spectrum of preferred amyloid conformations.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, WM Keck Adv Microscopy Lab, San Francisco, CA 94158 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weissman, JS (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	weissman@cmp.ucsf.edu	YONEKURA, Koji/N-5060-2015; Tanaka, Motomasa/N-5064-2015	Tanaka, Motomasa/0000-0002-2994-7703; Yonekura, Koji/0000-0001-5520-4391; Weissman, Jonathan/0000-0003-2445-670X				Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; Barron RM, 2001, EMBO J, V20, P5070, DOI 10.1093/emboj/20.18.5070; Baylis M, 2004, NATURE, V432, P810, DOI 10.1038/432810a; Bossers A, 1997, P NATL ACAD SCI USA, V94, P4931, DOI 10.1073/pnas.94.10.4931; Bradley ME, 2004, MOL MICROBIOL, V51, P1649, DOI 10.1111/j.1365-2958.2003.03955.x; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Chernoff YO, 2000, MOL MICROBIOL, V35, P865, DOI 10.1046/j.1365-2958.2000.01761.x; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 2004, P NATL ACAD SCI USA, V101, P12934, DOI 10.1073/pnas.0404968101; Derkatch IL, 1996, GENETICS, V144, P1375; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; King CY, 2001, J MOL BIOL, V307, P1247, DOI 10.1006/jmbi.2001.4542; Kochneva-Pervukhova NV, 2001, YEAST, V18, P489, DOI 10.1002/yea.700; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; Kushnirov VV, 2000, EMBO J, V19, P324, DOI 10.1093/emboj/19.3.324; Kushnirov VV, 2000, CURR BIOL, V10, P1443, DOI 10.1016/S0960-9822(00)00802-2; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Liu JJ, 2002, P NATL ACAD SCI USA, V99, P16446, DOI 10.1073/pnas.252652099; Maddelein ML, 2002, P NATL ACAD SCI USA, V99, P7402, DOI 10.1073/pnas.072199199; Manson JC, 1999, EMBO J, V18, P6855, DOI 10.1093/emboj/18.23.6855; Nakayashiki T, 2001, MOL CELL, V7, P1121, DOI 10.1016/S1097-2765(01)00259-3; Osherovich LZ, 2004, PLOS BIOL, V2, P442, DOI 10.1371/journal.pbio.0020086; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Santoso A, 2000, CELL, V100, P277, DOI 10.1016/S0092-8674(00)81565-2; Serag AA, 2002, NAT STRUCT BIOL, V9, P734, DOI 10.1038/nsb838; Soto C, 2004, NAT MED, V10, pS63, DOI 10.1038/nm1069; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; TERAVANESYAN MD, 1994, GENETICS, V137, P671; Tuite MF, 2003, NAT REV MOL CELL BIO, V4, P878, DOI 10.1038/nrm1247; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; Vanik DL, 2004, MOL CELL, V14, P139, DOI 10.1016/S1097-2765(04)00155-8; Wadsworth JDF, 2004, SCIENCE, V306, P1793, DOI 10.1126/science.1103932; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wille H, 1999, BIOPHYS J, V76, P1048, DOI 10.1016/S0006-3495(99)77270-X; Zhou P, 1999, EMBO J, V18, P1182, DOI 10.1093/emboj/18.5.1182	52	150	154	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					49	62		10.1016/j.cell.2005.03.008	http://dx.doi.org/10.1016/j.cell.2005.03.008			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820678	Bronze			2022-12-28	WOS:000228348500009
J	Buck, WR; Lavier, LL; Poliakov, ANB				Buck, WR; Lavier, LL; Poliakov, ANB			Modes of faulting at mid-ocean ridges	NATURE			English	Article							EAST PACIFIC RISE; MID-ATLANTIC RIDGE; SEISMIC STRUCTURE; OCEANIC-CRUST; SEAMARC-II; LITHOSPHERE; SEGMENTATION; GENERATION; EVOLUTION; DIRECTION	Abyssal-hill-bounding faults that pervade the oceanic crust are the most common tectonic feature on the surface of the Earth. The recognition that these faults form at plate spreading centres came with the plate tectonic revolution. Recent observations reveal a large range of fault sizes and orientations; numerical models of plate separation, dyke intrusion and faulting require at least two distinct mechanisms of fault formation at ridges to explain these observations. Plate unbending with distance from the top of an axial high reproduces the observed dip directions and offsets of faults formed at fast-spreading centres. Conversely, plate stretching, with differing amounts of constant-rate magmatic dyke intrusion, can explain the great variety of fault offset seen at slow-spreading ridges. Very-large-offset normal faults only form when about half the plate separation at a ridge is accommodated by dyke intrusion.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; CALTECH, Seismol Lab, Pasadena, CA 91125 USA; Royal Bank Canada, London EC4V 4DE, England	Columbia University; California Institute of Technology; Bank of Canada	Buck, WR (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	buck@ldeo.columbia.edu	Lavier, Luc/G-6141-2010					Alexander RT, 1996, MAR GEOPHYS RES, V18, P557, DOI 10.1007/BF00310069; Barclay AH, 2001, J GEOPHYS RES-SOL EA, V106, P2017, DOI 10.1029/2000JB900371; Blackman DK, 2002, MAR GEOPHYS RES, V23, P443, DOI 10.1023/B:MARI.0000018232.14085.75; BUCK WR, 1993, GEOLOGY, V21, P933, DOI 10.1130/0091-7613(1993)021<0933:EOLTOT>2.3.CO;2; Buck WR, 2001, J GEOPHYS RES-SOL EA, V106, P3953, DOI 10.1029/2000JB900360; Buck WR, 1998, NATURE, V392, P272, DOI 10.1038/32636; Cann JR, 1997, NATURE, V385, P329, DOI 10.1038/385329a0; CARBOTTE SM, 1990, GEOLOGY, V18, P749, DOI 10.1130/0091-7613(1990)018<0749:COVIFF>2.3.CO;2; Cochran JR, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001830; Cochran JR, 1997, J GEOPHYS RES-SOL EA, V102, P15463, DOI 10.1029/97JB00511; Crawford WC, 1998, J GEOPHYS RES-SOL EA, V103, P9895, DOI 10.1029/97JB03532; DETRICK RS, 1987, NATURE, V326, P35, DOI 10.1038/326035a0; Dick HJB, 2003, NATURE, V426, P405, DOI 10.1038/nature02128; Dunn RA, 2000, J GEOPHYS RES-SOL EA, V105, P23537, DOI 10.1029/2000JB900210; Eberle MA, 1998, J GEOPHYS RES-SOL EA, V103, P12309, DOI 10.1029/98JB00437; EINARSSON P, 1980, J GEOPHYS-Z GEOPHYS, V47, P160; GENTE P, 1995, EARTH PLANET SC LETT, V129, P55, DOI 10.1016/0012-821X(94)00233-O; Hannington M. D., 1995, SEAFLOOR HYDROTHERMA, P115, DOI [DOI 10.1029/GM091P0115), DOI 10.1029/GM091P0115]; HAXBY W, 2004, GEOMAPAPP VERSION 1; HEEZEN BC, 1960, SCI AM, V203, P98, DOI 10.1038/scientificamerican1060-98; Hooft EEE, 1997, J GEOPHYS RES-SOL EA, V102, P27319, DOI 10.1029/97JB02349; KARSON JA, 1987, NATURE, V328, P681, DOI 10.1038/328681a0; Karson JA, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000155; KUO BY, 1986, GEOPHYS RES LETT, V13, P681, DOI 10.1029/GL013i007p00681; Lavier LL, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000513; Lavier LL, 2000, J GEOPHYS RES-SOL EA, V105, P23431, DOI 10.1029/2000JB900108; LIN J, 1990, J GEOPHYS RES-SOLID, V95, P4909, DOI 10.1029/JB095iB04p04909; Macdonald KC, 1996, NATURE, V380, P125, DOI 10.1038/380125a0; MACDONALD KC, 1992, MAR GEOPHYS RES, V14, P299, DOI 10.1007/BF01203621; Magde LS, 1997, J GEOPHYS RES-SOL EA, V102, P20571, DOI 10.1029/97JB01278; Michael PJ, 2003, NATURE, V423, P956, DOI 10.1038/nature01704; PHIPPSMORGAN J, 1993, J GEOPHYS RES, V98, P6283; Poliakov ANB, 1998, GEOPH MONOG SERIES, V106, P305; Price NJ, 1990, ANAL GEOLOGICAL STRU, P1; PURDY GM, 1992, NATURE, V355, P815, DOI 10.1038/355815a0; Shah AK, 2001, J GEOPHYS RES-SOL EA, V106, P30865, DOI 10.1029/2000JB000079; TAPPONNIER P, 1978, J GEOPHYS RES, V83, P3955, DOI 10.1029/JB083iB08p03955; THATCHER W, 1995, J GEOPHYS RES-SOL EA, V100, P561, DOI 10.1029/94JB02593; Tucholke BE, 1998, J GEOPHYS RES-SOL EA, V103, P9857, DOI 10.1029/98JB00167; TUCHOLKE BE, 1994, J GEOPHYS RES-SOL EA, V99, P11937, DOI 10.1029/94JB00338; Van Dover CL, 2002, SCIENCE, V295, P1253, DOI 10.1126/science.1067361; VERA EE, 1990, J GEOPHYS RES-SOLID, V95, P15529, DOI 10.1029/JB095iB10p15529	42	271	285	4	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					719	723		10.1038/nature03358	http://dx.doi.org/10.1038/nature03358			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815620				2022-12-28	WOS:000228160700030
J	Chapman, T				Chapman, T			Pure but not simple	NATURE			English	Article																			0	23	25	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 7	2005	434	7034					795	800		10.1038/434795a	http://dx.doi.org/10.1038/434795a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815637	Bronze			2022-12-28	WOS:000228160700049
J	Jaenicke, R				Jaenicke, R			Abundance of cellular material and proteins in the atmosphere	SCIENCE			English	Article							AEROSOLS		Univ Mainz, Inst Phys Atmosphare, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Jaenicke, R (corresponding author), Univ Mainz, Inst Phys Atmosphare, D-55099 Mainz, Germany.	jaenicke@uni-mainz.de	Jaenicke, Ruprecht/G-2296-2010					Andrews E, 2000, J AIR WASTE MANAGE, V50, P648, DOI 10.1080/10473289.2000.10464116; ARTAXO P, 1988, J GEOPHYS RES-ATMOS, V93, P1605, DOI 10.1029/JD093iD02p01605; BORODULIN AI, 2003, J AEROSOLS CI, V34, pS681; Graedel T. E., 1993, ATMOSPHERIC CHANGE E; Graham B, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD004049; Kenny C. M., 1998, J AEROSOL SCI, V29, pS779, DOI [DOI 10.1016/S0021-8502(98)90572-9, 10.1016/S0021-8502(98)90572-9]; O'Dowd CD, 2004, NATURE, V431, P676, DOI 10.1038/nature02959; Penner JE, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P289	8	373	400	6	163	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					73	73		10.1126/science.1106335	http://dx.doi.org/10.1126/science.1106335			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802596				2022-12-28	WOS:000228221500034
J	Brixner, T; Stenger, J; Vaswani, HM; Cho, M; Blankenship, RE; Fleming, GR				Brixner, T; Stenger, J; Vaswani, HM; Cho, M; Blankenship, RE; Fleming, GR			Two-dimensional spectroscopy of electronic couplings in photosynthesis	NATURE			English	Article							PHOTON-ECHOES; FEMTOSECOND SPECTROSCOPY; INFRARED-SPECTROSCOPY; CHLOROBIUM-TEPIDUM; DIFFRACTIVE OPTICS; ANTENNA COMPLEXES; LINE-SHAPES; FMO COMPLEX; DYNAMICS; PROTEIN	Time-resolved optical spectroscopy is widely used to study vibrational and electronic dynamics by monitoring transient changes in excited state populations on a femtosecond timescale(1). Yet the fundamental cause of electronic and vibrational dynamics-the coupling between the different energy levels involved-is usually inferred only indirectly. Two-dimensional femtosecond infrared spectroscopy based on the heterodyne detection of three-pulse photon echoes(2-7) has recently allowed the direct mapping of vibrational couplings, yielding transient structural information. Here we extend the approach to the visible range(3,8) and directly measure electronic couplings in a molecular complex, the Fenna-Matthews-Olson photosynthetic light-harvesting protein(9,10). As in all photosynthetic systems, the conversion of light into chemical energy is driven by electronic couplings that ensure the efficient transport of energy from light-capturing antenna pigments to the reaction centre(11). We monitor this process as a function of time and frequency and show that excitation energy does not simply cascade stepwise down the energy ladder. We find instead distinct energy transport pathways that depend sensitively on the detailed spatial properties of the delocalized excited-state wavefunctions of the whole pigment-protein complex.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Inst Quantitat Biomed Res QB3, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA; Korea Univ, Dept Chem, Seoul 136701, South Korea; Korea Univ, Div Chem & Mol Engn, Ctr Multidimens Spect, Seoul 136701, South Korea; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Korea University; Korea University; Arizona State University; Arizona State University-Tempe	Fleming, GR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	grfleming@lbl.gov	Brixner, Tobias/S-1451-2016; Cho, Minhaeng/C-9983-2011	Brixner, Tobias/0000-0002-6529-704X; Cho, Minhaeng/0000-0003-1618-1056				[Anonymous], 2002, PHOTOSYNTHETICA; Asbury JB, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.237402; Asplund MC, 2000, P NATL ACAD SCI USA, V97, P8219, DOI 10.1073/pnas.140227997; BLANKENSHIP RE, 2003, LIGHT HARVESTING ANT, P195; Brixner T, 2004, J CHEM PHYS, V121, P4221, DOI 10.1063/1.1776112; Brixner T, 2004, OPT LETT, V29, P884, DOI 10.1364/OL.29.000884; Cervetto V, 2004, J CHEM PHYS, V121, P5935, DOI 10.1063/1.1778163; Cho MH, 2001, J CHEM PHYS, V115, P4424, DOI 10.1063/1.1389844; Cowan ML, 2004, CHEM PHYS LETT, V386, P184, DOI 10.1016/j.cplett.2004.01.027; FENNA RE, 1975, NATURE, V258, P573, DOI 10.1038/258573a0; Goodno GD, 1998, J OPT SOC AM B, V15, P1791, DOI 10.1364/JOSAB.15.001791; Jonas DM, 2003, ANNU REV PHYS CHEM, V54, P425, DOI 10.1146/annurev.physchem.54.011002.103907; Khalil M, 2003, J PHYS CHEM A, V107, P5258, DOI 10.1021/jp0219247; Kwac K, 2003, J PHYS CHEM A, V107, P5903, DOI 10.1021/jp034727w; Lepetit L, 1996, OPT LETT, V21, P564, DOI 10.1364/OL.21.000564; Li YF, 1997, J MOL BIOL, V271, P456, DOI 10.1006/jmbi.1997.1189; Maznev AA, 1998, OPT LETT, V23, P1319, DOI 10.1364/OL.23.001319; Mukamel S, 2000, ANNU REV PHYS CHEM, V51, P691, DOI 10.1146/annurev.physchem.51.1.691; Prall BS, 2004, J CHEM PHYS, V120, P2537, DOI 10.1063/1.1644794; Savikhin S, 1998, J PHYS CHEM B, V102, P5556, DOI 10.1021/jp981186f; Tian PF, 2003, SCIENCE, V300, P1553, DOI 10.1126/science.1083433; Tokmakoff A, 2000, J PHYS CHEM A, V104, P4247, DOI 10.1021/jp993207r; van Amerongen H., 2000, PHOTOSYNTHETIC EXCIT; Vulto SIE, 1998, J PHYS CHEM B, V102, P9577, DOI 10.1021/jp982095l; Vulto SIE, 1999, J PHYS CHEM B, V103, P8153, DOI 10.1021/jp984702a; Wendling M, 2002, PHOTOSYNTH RES, V71, P99, DOI 10.1023/A:1014947732165; Wright JC, 2002, INT REV PHYS CHEM, V21, P185, DOI 10.1080/01442350210124506; Yang M, 2003, BIOPHYS J, V85, P140, DOI 10.1016/S0006-3495(03)74461-0; ZEWAIL AH, 1994, FEMTOCHEMISTRY; Zhang WM, 1998, J CHEM PHYS, V108, P7763, DOI 10.1063/1.476212	30	978	994	9	391	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					625	628		10.1038/nature03429	http://dx.doi.org/10.1038/nature03429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800619				2022-12-28	WOS:000228011000040
J	Bryce, J; Boschi-Pinto, C; Shibuya, K; Black, RE				Bryce, J; Boschi-Pinto, C; Shibuya, K; Black, RE		WHO Child Hlth Epidemiology Refer	WHO estimates of the causes of death in children	LANCET			English	Article							RESPIRATORY-INFECTIONS; GLOBAL BURDEN; PNEUMONIA; COUNTRIES; SURVIVAL; MEASLES; MALARIA; DISEASE; AGE	Background Child survival efforts can be effective only if they are based on accurate information about causes of deaths. Here, we report on a 4-year effort by WHO to improve the accuracy of this information. Methods WHO established the external Child Health Epidemiology Reference Group (CHERG) in 2001 to develop estimates of the proportion of deaths in children younger than age 5 years attributable to pneumonia, diarrhoea, malaria, measles, and the major causes of death in the first 28 days of life. Various methods, including single-cause and multi-cause proportionate mortality models, were used. The role of undemutrition as an underlying cause of death was estimated in collaboration with CHERG. Findings In 2000-03, six causes accounted for 73% of the 10.6 million yearly deaths in children younger than age 5 years: pneumonia (19%), diarrhoea (18%), malaria (8%), neonatal pneumonia or sepsis (10%), preterm, delivery (10%), and asphyxia at birth (8%). The four communicable disease categories account for more than half (54%) of all child deaths. The greatest communicable disease killers are similar in all WHO regions with the exception of malaria; 94% of global deaths attributable to this disease occur in the Africa region. Undernutrition is an underlying cause of 53% of all deaths in children younger than age 5 years. Interpretation Achievement of the millennium development goal of reducing child mortality by two-thirds from the 1990 rate will depend on renewed efforts to prevent and control pneumonia, diarrhoea, and undernutrition in all WHO regions, and malaria in the Africa region. In all regions, deaths in the neonatal period, primarily due to preterm delivery, sepsis or pneumonia, and birth asphyxia should also be addressed. These estimates of the causes of child deaths should be used to guide public-health policies and programmes.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; WHO, CH-1211 Geneva, Switzerland	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; World Health Organization	Black, RE (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	rblack@jhsph.edu	Pinto, Cynthia Boschi/AAA-6990-2020; Campbell, Harry/E-2959-2010	Pinto, Cynthia Boschi/0000-0002-0069-7974; Campbell, Harry/0000-0002-6169-6262; Shibuya, Kenji/0000-0003-2528-7530; Black, Robert/0000-0001-9926-7984				[Anonymous], 2003, WORLD POP PROSP 2002; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; BOSCHIPINTO C, CHERG DIARRHOEA MORT; CARNEIRO I, CHERG MALARIA MORBID; Caulfield LE, 2004, AM J TROP MED HYG, V71, P55, DOI 10.4269/ajtmh.2004.71.55; Caulfield LE, 2004, AM J CLIN NUTR, V80, P193; DARMSTADT GL, 2005, LANCET          0305; FENN B, IN PRESS INT J EPIDE; *JOINT UN PROGR HI, 2004, REP GLOB AIDS EP 200; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; KNIPPENBERG R, 2005, LANCET          0303; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; Lanata CF, 2004, INT J EPIDEMIOL, V33, P1362, DOI 10.1093/ije/dyh229; LANATA CF, CHERG IMPROVING DIAR; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Mathers CD, 2003, GLOBAL BURDEN DIS 20; Morris SS, 2003, INT J EPIDEMIOL, V32, P1041, DOI 10.1093/ije/dyg241; Murray CJL, 2004, BMJ-BRIT MED J, V329, P1096, DOI 10.1136/bmj.329.7474.1096; Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562; ROWE AK, CHERG MALARIA MORTAL; Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895; RUDAN I, IN PRESS LANCET; Salomon JA, 2002, POPUL DEV REV, V28, P205, DOI 10.1111/j.1728-4457.2002.00205.x; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; Stein CE, 2003, J INFECT DIS, V187, pS8, DOI 10.1086/368114; THUMM M, CHILD HLTH EPIDEMIOL; UNICEF, 2004, STAT WORLDS CHILDR 2; Walker N, 2002, LANCET, V360, P284, DOI 10.1016/S0140-6736(02)09550-8; WALKER N, IN PRESS B WHO; *WHO, 2005, NEON PER MORT YEAR 2; *WHO, IN PRESS WORLD HLTH; *WHO, 2004, MEASL MORT REV M REP; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0; World Bank, 2004, WORLD DEV IND 2004; World Health Organization, 2004, WORLD HLTH REP 2004	35	1321	1410	3	114	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1147	1152		10.1016/S0140-6736(05)71877-8	http://dx.doi.org/10.1016/S0140-6736(05)71877-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794969				2022-12-28	WOS:000227909500027
J	Wahrenberg, H; Hertel, K; Leijonhufvud, BM; Persson, LG; Toft, E; Arner, P				Wahrenberg, H; Hertel, K; Leijonhufvud, BM; Persson, LG; Toft, E; Arner, P			Use of waist circumference to predict insulin resistance: retrospective study	BRITISH MEDICAL JOURNAL			English	Article								Insulin resistance is an important pathogenic factor in common metabolic disorders. No easy clinical test exists for predicting the insulin resistance of an individual. We assessed how effectively different anthropometric measurements and biochemical markers used in clinical practice can predict insulin sensitivity.	Karolinska Univ Hosp, Dept Med M61, Karolinska Inst, SE-14186 Stockholm, Sweden; Karolinska Univ Hosp, Dept Clin Physiol, Karolinska Inst, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Wahrenberg, H (corresponding author), Karolinska Univ Hosp, Dept Med M61, Karolinska Inst, SE-14186 Stockholm, Sweden.	hans.wahrenherg@medhs.ki.se		Arner, Peter/0000-0002-6208-6220; Toft, Eva/0000-0003-1087-445X				Ascaso Juan F, 2003, Eur J Intern Med, V14, P101, DOI 10.1016/S0953-6205(03)00022-0; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; HAN TS, 1995, BRIT MED J, V311, P1401, DOI 10.1136/bmj.311.7017.1401; McLaughlin T, 2003, ANN INTERN MED, V139, P802, DOI 10.7326/0003-4819-139-10-200311180-00007; Wallace TM, 2002, DIABETIC MED, V19, P527, DOI 10.1046/j.1464-5491.2002.00745.x	5	162	179	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 11	2005	330	7504					1363	1364		10.1136/bmj.38429.473310.AE	http://dx.doi.org/10.1136/bmj.38429.473310.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936FE	15833749	Green Published			2022-12-28	WOS:000229840100019
J	Cao, AM; Romanowicz, B; Takeuchi, N				Cao, AM; Romanowicz, B; Takeuchi, N			An observation of PKJKP: Inferences on inner core shear properties	SCIENCE			English	Article								The seismic phase PKJKP, which traverses the inner core as a shear wave and would provide direct evidence for its solidity, has been difficult to detect. Using stacked broadband records from the Gafenberg array in Germany, we documented a high signal-to-noise phase, the arrival time and slowness of which agree with theoretical predictions for PKJKP. The back azimuth of this arrival is also consistent with predictions for PKJKP, as is the comparison with a pseudoliquid inner core model. Envelope modeling of the PKJKP waveform implies a shear velocity gradient with depth in the inner core that is slightly larger than that in the preliminary reference Earth model.	Univ Calif Berkeley, Seismol Lab, Berkeley, CA 94720 USA; Univ Tokyo, Earthquake Res Inst, Tokyo 113, Japan	University of California System; University of California Berkeley; University of Tokyo	Cao, AM (corresponding author), Univ Calif Berkeley, Seismol Lab, Berkeley, CA 94720 USA.	acao@seismo.berkeley.edu	Romanowicz, barbara A/H-6726-2017; Takeuchi, Nozomu/AAJ-3031-2020	Romanowicz, barbara A/0000-0002-6208-6044; Takeuchi, Nozomu/0000-0003-3636-7800				Birch F, 1940, AM J SCI, V238, P192; Cao A, 2004, EARTH PLANET SC LETT, V228, P243, DOI 10.1016/j.epsl.2004.09.032; Deuss A, 2000, GEOPHYS J INT, V142, P67, DOI 10.1046/j.1365-246x.2000.00147.x; DZIEWONSKI AM, 1971, NATURE, V234, P465, DOI 10.1038/234465a0; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Engdahl ER, 1998, B SEISMOL SOC AM, V88, P722; JULIAN BR, 1972, NATURE, V235, P317, DOI 10.1038/235317a0; Lehmann I., 1936, BUR CENTR SEISMOL A, V14, P87; Okal EA, 1998, EARTH PLANET SC LETT, V164, P23, DOI 10.1016/S0012-821X(98)00210-6; Schimmel M, 1997, GEOPHYS J INT, V130, P497, DOI 10.1111/j.1365-246X.1997.tb05664.x; Takeuchi N, 1996, GEOPHYS RES LETT, V23, P1175, DOI 10.1029/96GL00973	11	43	43	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 3	2005	308	5727					1453	1455		10.1126/science.1109134	http://dx.doi.org/10.1126/science.1109134			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15831719				2022-12-28	WOS:000229619300049
J	Nimmerjahn, A; Kirchhoff, F; Helmchen, F				Nimmerjahn, A; Kirchhoff, F; Helmchen, F			Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo	SCIENCE			English	Article							ADULT CORTEX; ACTIVATION; CNS; NEOCORTEX; MOTILITY; PROTEIN; ACTIN	Microglial cells represent the immune system of the mammalian brain and therefore are critically involved in various injuries and diseases. Little is known about their role in the healthy brain and their immediate reaction to brain damage. By using in vivo two-photon imaging in neocortex, we found that microglial cells are highly active in their presumed resting state, continually surveying their microenvironment with extremely motile processes and protrusions. Furthermore, blood-brain barrier disruption provoked immediate and focal activation of microglia, switching their behavior from patroling to shielding of the injured site. Microglia thus are busy and vigilant housekeepers in the adult brain.	Max Planck Inst Med Res, Zellphysiol Abt, D-69120 Heidelberg, Germany; Max Planck Inst Expt Med, Abt Neurogenet, D-37075 Gottingen, Germany	Max Planck Society; Max Planck Society	Helmchen, F (corresponding author), Max Planck Inst Med Res, Zellphysiol Abt, Jahnstr 29, D-69120 Heidelberg, Germany.	fritjof@mpimf-heidelberg.mpg.de	Kirchhoff, Frank/B-9335-2008; Helmchen, Fritjof/A-6255-2008	Kirchhoff, Frank/0000-0002-2324-2761; Helmchen, Fritjof/0000-0002-8867-9569				Capani F, 2001, BRAIN RES, V923, P1, DOI 10.1016/S0006-8993(01)03189-4; Denk W, 1997, NEURON, V18, P351, DOI 10.1016/S0896-6273(00)81237-4; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Hirrlinger J, 2004, EUR J NEUROSCI, V20, P2235, DOI 10.1111/j.1460-9568.2004.03689.x; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEHMENKUHLER A, 1993, NEUROSCIENCE, V55, P339, DOI 10.1016/0306-4522(93)90503-8; Nimmerjahn A, 2004, NAT METHODS, V1, P31, DOI 10.1038/nmeth706; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.3.CO;2-A; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Vilhardt F, 2005, INT J BIOCHEM CELL B, V37, P17, DOI 10.1016/j.biocel.2004.06.010	17	3671	3783	14	306	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1314	1318		10.1126/science.1110647	http://dx.doi.org/10.1126/science.1110647			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15831717				2022-12-28	WOS:000229482300049
J	Cabinum-Foeller, E; Frasier, L				Cabinum-Foeller, E; Frasier, L			Bruising in children	LANCET			English	Editorial Material									E Carolina Univ, Brody Sch Med, Greenville, NC 27834 USA; TEDI BEAR Childrens Advocacy Ctr, Greenville, NC USA; Univ Utah, Sch Med, Primary Childrens Med Ctr, Ctr Safe & Healthy Families, Salt Lake City, UT USA	University of North Carolina; East Carolina University; Utah System of Higher Education; University of Utah	Cabinum-Foeller, E (corresponding author), E Carolina Univ, Brody Sch Med, Greenville, NC 27834 USA.	cabinumfoellere@mail.ecu.edu						Bariciak ED, 2003, PEDIATRICS, V112, P804, DOI 10.1542/peds.112.4.804; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Jenny C., 2001, CHILD ABUSE MED DIAG, P23; Maguire S, 2005, ARCH DIS CHILD, V90, P182, DOI 10.1136/adc.2003.044065; Maguire S, 2005, ARCH DIS CHILD, V90, P187, DOI 10.1136/adc.2003.044073; Schwartz AJ, 1996, PEDIATRICS, V97, P254; Sirotnak AP, 2004, PEDIATR REV, V25, P264, DOI 10.1542/pir.25-8-264; Sugar NF, 1999, ARCH PEDIAT ADOL MED, V153, P399, DOI 10.1001/archpedi.153.4.399	8	3	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 16	2005	365	9468					1369	1370		10.1016/S0140-6736(05)66351-9	http://dx.doi.org/10.1016/S0140-6736(05)66351-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836871				2022-12-28	WOS:000228401900007
J	Koniaris, LG; Zimmers, TA; Lubarsky, DA; Sheldon, JP				Koniaris, LG; Zimmers, TA; Lubarsky, DA; Sheldon, JP			Inadequate anaesthesia in lethal injection for execution	LANCET			English	Article								Anaesthesia. during lethal injection is essential to minimise suffering and to maintain public acceptance of the practice. Lethal injection is usually done by sequential administration of thiopental, pancuronium, and potassium chloride. Protocol information from Texas and Virginia showed that executioners had no anaesthesia training, drugs were administered remotely with no monitoring for anaesthesia, data were not recorded and no peer-review was done. Toxicology reports from Arizona, Georgia, North Carolina, and South Carolina showed that post-mortem concentrations of thiopental in the blood were lower than that required for surgery in 43 of 49 executed inmates (88%); 21 (43%) inmates had concentrations consistent with awareness. Methods of lethal injection anaesthesia are flawed and some inmates might experience awareness and suffering during execution.	Univ Miami, Dewitt Daughtry Family Dept Surg, Miami, FL 33152 USA; Univ Miami, Dept Anaesthesiol Perioperat Med & Pain Managemen, Miami, FL 33152 USA; Univ Miami, Sch Business, Dept Management, Miami, FL 33152 USA; Law Off Jonathan P Sheldon, Arlington, VA USA	University of Miami; University of Miami; University of Miami	Koniaris, LG (corresponding author), Sylvester Comprehens Canc Ctr 3550 310T, 1475 NW 12th Ave, Miami, FL 33136 USA.	LKoniaris@med.miami.edu	Zimmers, Teresa/AAD-5461-2019	Zimmers, Teresa/0000-0001-7872-0540				Beaver BV, 2001, J AM VET MED ASSOC, V218, P669, DOI 10.2460/javma.2001.218.669; Denno, 2002, OHIO ST LJ, V63, P63; HUNG OR, 1992, ANESTHESIOLOGY, V77, P237, DOI 10.1097/00000542-199208000-00003; Khan A, 2002, J FORENSIC SCI, V47, P847; Martens-Lobenhoffer J, 1999, PHARMAZIE, V54, P597	5	47	47	1	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2005	365	9468					1412	1414		10.1016/S0140-6736(05)66377-5	http://dx.doi.org/10.1016/S0140-6736(05)66377-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836890				2022-12-28	WOS:000228401900030
J	Sommer, C; Weishaupt, A; Brinkhoff, J; Biko, L; Wessig, C; Gold, R; Toyka, KV				Sommer, C; Weishaupt, A; Brinkhoff, J; Biko, L; Wessig, C; Gold, R; Toyka, KV			Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin	LANCET			English	Article							MOTOR-NERVE TERMINALS; MUSCLE HYPERALGESIA; MYASTHENIC SYNDROME; MOUSE; AUTOANTIBODIES; ENCEPHALOMYELITIS; ENDOCYTOSIS; THERAPY; NEURONS; GRAVIS	Background Stiff-person syndrome (SPS) with antibodies to amphiphysin is a paraneoplastic disorder of the central nervous system with a putative autoimmune pathogenesis. Proof of a causal role of the antibodies is still lacking for this and all other antibody-associated paraneoplastic syndromes of the central nervous system. Methods We obtained the plasma filtrate of a patient with breast cancer and SPS that responded to therapeutic plasmapheresis. The purified IgG fraction included high-titre antibodies to the synaptic protein amphiphysin. In a cotransfer design, this IgG fraction was injected intraperitoneally into female Lewis rats that had received encephalitogenic T-helper (Th) lymphocytes specific for myelin basic protein, to induce an immune-mediated leaky blood-brain barrier. The rats were followed up with behavioural tests, video photography, and electromyography. Findings The injection of the IgG fraction including antibodies to amphiphysin resulted in a dose-dependent stiffness with spasms resembling human SPS. Control IgG injected into rats that had received the same encephalitogenic Th cells had no effect. IgG binding was demonstrated in the central nervous system of rats that Showed signs of the disorder. Interpretation These experiments support the hypothesis of a pathogenetic role of antibodies to amphiphysin, thus adding paraneoplastic SPS to the group of antibody-mediated autoimmune disorders. Relevance to practice These findings provide a strong argument for a direct pathogenetic role of anti-amphiphysin in this type of SPS and support therapeutic attempts to eliminate these autoantibodies by plasmapheresis. The experimental approach used could help to elucidate the role of autoantibodies in other paraneoplastic syndromes, such as SPS with antibodies to glutamic acid decarboxylase, and others including anti-Hu-associated subacute cerebellar degeneration and limbic encephalitis.	Univ Wurzburg, Neurol Klin, Dept Neurol, D-97080 Wurzburg, Germany; Univ Gottingen, Inst MS Forsch, Bereich Humanmed, D-3400 Gottingen, Germany; Gemeinnutzige Hertie Stiftung, Gottingen, Germany	University of Wurzburg; University of Gottingen	Sommer, C (corresponding author), Univ Wurzburg, Neurol Klin, Dept Neurol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.	sommer@mail.uni-wuemburg.de	Sommer, Claudia/A-9820-2010	Sommer, Claudia/0000-0002-7064-5002				BRASHEAR HR, 1991, NEUROLOGY, V41, P1588, DOI 10.1212/WNL.41.10.1588; Buchwald B, 1998, EUR J NEUROSCI, V10, P281, DOI 10.1046/j.1460-9568.1998.00053.x; Dropcho EJ, 1998, J NEUROL SCI, V153, P264, DOI 10.1016/S0022-510X(97)00296-7; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; FUKUNAGA H, 1983, P NATL ACAD SCI-BIOL, V80, P7636, DOI 10.1073/pnas.80.24.7636; Kehl LJ, 2000, PAIN, V85, P333, DOI 10.1016/S0304-3959(99)00282-1; Kittler JT, 2000, J NEUROSCI, V20, P7972; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; LANG B, 1983, J PHYSIOL-LONDON, V344, P335, DOI 10.1113/jphysiol.1983.sp014943; LININGTON C, 1988, AM J PATHOL, V130, P443; Meinck HM, 2002, MOVEMENT DISORD, V17, P853, DOI 10.1002/mds.10279; Meinck HM, 2001, CNS DRUGS, V15, P515, DOI 10.2165/00023210-200115070-00002; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; Saiz A, 1999, J NEUROL NEUROSUR PS, V66, P214, DOI 10.1136/jnnp.66.2.214; Schafers M, 2003, PAIN, V104, P579, DOI 10.1016/S0304-3959(03)00115-5; Schmidt J, 2000, BRAIN, V123, P1431, DOI 10.1093/brain/123.7.1431; Schmierer K, 1998, NEUROLOGY, V51, P250, DOI 10.1212/WNL.51.1.250; TORO C, 1994, SEMIN NEUROL, V14, P154, DOI 10.1055/s-2008-1041073; TOYKA KV, 1980, J NEUROL NEUROSUR PS, V43, P836, DOI 10.1136/jnnp.43.9.836; TOYKA KV, 1975, SCIENCE, V190, P397, DOI 10.1126/science.1179220; Vasconcelos Olavo M., 2003, Curr Treat Options Neurol, V5, P79, DOI 10.1007/s11940-003-0024-x; Voltz R, 2002, LANCET NEUROL, V1, P294, DOI 10.1016/S1474-4422(02)00135-7; Wessig C, 2003, NEUROLOGY, V61, P195, DOI 10.1212/01.WNL.0000073143.53337.DD; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8	24	146	154	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 16	2005	365	9468					1406	1411		10.1016/S0140-6736(05)66376-3	http://dx.doi.org/10.1016/S0140-6736(05)66376-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836889				2022-12-28	WOS:000228401900029
J	Khosla, C; Tang, Y				Khosla, C; Tang, Y			A new route to designer antibiotics	SCIENCE			English	Editorial Material									Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90095 USA	Stanford University; Stanford University; Stanford University; University of California System; University of California Los Angeles	Khosla, C (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.	khosta@stanford.edu; yitang@ucta.edu		Khosla, Chaitan/0000-0001-6529-495X				Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Charest MG, 2005, SCIENCE, V308, P395, DOI 10.1126/science.1109755; Dantley KA, 1998, J BACTERIOL, V180, P4089, DOI 10.1128/JB.180.16.4089-4092.1998; McConnell J, 2004, LANCET INFECT DIS, V4, P717, DOI 10.1016/S1473-3099(04)01219-8; Petkovic H, 1999, J BIOL CHEM, V274, P32829; Tamura N, 2003, CURR OPIN CHEM BIOL, V7, P570, DOI 10.1016/j.cbpa.2003.08.014	6	15	21	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 15	2005	308	5720					367	368		10.1126/science.1111415	http://dx.doi.org/10.1126/science.1111415			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831747				2022-12-28	WOS:000228492000039
J	Holmes, LB; Gargiulo, AR; Nadel, AS; Racowsky, C				Holmes, LB; Gargiulo, AR; Nadel, AS; Racowsky, C			A 32-year-old pregnant woman with an abnormal fetal karyotype - Balanced maternal chromosomal translocation 46,XX,t(1;18)(q42.1;p11.2) resulting in an unbalanced fetal translocation 46,XY,der(18)t(1;18)(q42.1;p11.2)mat.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PREIMPLANTATION GENETIC DIAGNOSIS; EMBRYOS; PGD		Massachusetts Gen Hosp, MassGen Hosp Children, Genet & Teratol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Cambridge, MA 02138 USA; Brigham & Womens Hosp, Ctr Reprod Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Brigham & Women's Hospital	Holmes, LB (corresponding author), Massachusetts Gen Hosp, MassGen Hosp Children, Genet & Teratol Unit, Boston, MA 02114 USA.							[Anonymous], 11 14 WEEK SCAN DIAG; Antczak M, 1999, HUM REPROD, V14, P429, DOI 10.1093/humrep/14.2.429; Ciotti PM, 2000, MOL CELL ENDOCRINOL, V169, P63, DOI 10.1016/S0303-7207(00)00353-1; Iwarsson E, 2000, PRENATAL DIAG, V20, P1038, DOI 10.1002/1097-0223(200012)20:13<1038::AID-PD976>3.3.CO;2-#; LIBERFARB RM, 1979, AM J MED GENET, V4, P27, DOI 10.1002/ajmg.1320040105; Munne S, 2000, FERTIL STERIL, V73, P1209, DOI 10.1016/S0015-0282(00)00495-7; Sermon K, 2005, HUM REPROD, V20, P19, DOI 10.1093/humrep/deh552; Strom CM, 2000, PEDIATRICS, V106, P650, DOI 10.1542/peds.106.4.650; TARKOWSKI AK, 1966, CYTOGENETICS, V5, P394, DOI 10.1159/000129914; Van de Velde H, 2000, PRENATAL DIAG, V20, P1030, DOI 10.1002/1097-0223(200012)20:13<1030::AID-PD977>3.0.CO;2-D; Wilson RD, 1998, LANCET, V351, P242	11	1	1	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1579	1587		10.1056/NEJMcpc059005	http://dx.doi.org/10.1056/NEJMcpc059005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829539				2022-12-28	WOS:000228324200012
J	Lendlein, A; Jiang, HY; Junger, O; Langer, R				Lendlein, A; Jiang, HY; Junger, O; Langer, R			Light-induced shape-memory polymers	NATURE			English	Article							GELS; DERIVATIVES; ELASTOMERS; ACTUATORS; FILM	Materials are said to show a shape-memory effect if they can be deformed and fixed into a temporary shape, and recover their original, permanent shape only on exposure to an external stimulus(1-3). Shape-memory polymers have received increasing attention because of their scientific and technological significance(4,5). In principle, a thermally induced shape-memory effect can be activated by an increase in temperature ( also obtained by heating on exposure to an electrical current(6) or light illumination(6,7)). Several papers have described light-induced changes in the shape of polymers(8-12) and gels(13-15), such as contraction(8-10), bending(11-13) or volume changes(14,15). Here we report that polymers containing cinnamic groups can be deformed and fixed into predetermined shapes - such as ( but not exclusively) elongated films and tubes, arches or spirals - by ultraviolet light illumination. These new shapes are stable for long time periods, even when heated to 50 degrees C, and they can recover their original shape at ambient temperatures when exposed to ultraviolet light of a different wavelength. The ability of polymers to form different pre-determined temporary shapes and subsequently recover their original shape at ambient temperatures by remote light activation could lead to a variety of potential medical and other applications.	GKSS Res Ctr Geesthacht GmbH, Inst Chem, D-14513 Teltow, Germany; mnemoSci GmbH, D-52074 Aachen, Germany; Rhein Westfal TH Aachen, Inst Technol & Dev Med Devices, D-52074 Aachen, Germany; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung; RWTH Aachen University; Massachusetts Institute of Technology (MIT)	Lendlein, A (corresponding author), GKSS Res Ctr Geesthacht GmbH, Inst Chem, Kantstr 55, D-14513 Teltow, Germany.	Lendlein@gkss.de	Lendlein, Andreas/K-9553-2013	Lendlein, Andreas/0000-0003-4126-4670				AKABORI S, 1987, B CHEM SOC JPN, V60, P3453, DOI 10.1246/bcsj.60.3453; Camacho-Lopez M, 2004, NAT MATER, V3, P307, DOI 10.1038/nmat1118; EISENBACH CD, 1980, POLYMER, V21, P1175, DOI 10.1016/0032-3861(80)90083-X; Finkelmann H, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.015501; HADDLETON DM, 1989, MAKROMOL CHEM-RAPID, V10, P391; Ikeda T, 2003, ADV MATER, V15, P201, DOI 10.1002/adma.200390045; Juodkazis S, 2000, NATURE, V408, P178, DOI 10.1038/35041522; Kim BK, 1996, POLYMER, V37, P5781, DOI 10.1016/S0032-3861(96)00442-9; Koerner H, 2004, NAT MATER, V3, P115, DOI 10.1038/nmat1059; Lendlein A, 2002, ANGEW CHEM INT EDIT, V41, P2034, DOI 10.1002/1521-3773(20020617)41:12<2034::AID-ANIE2034>3.0.CO;2-M; Li MH, 2003, ADV MATER, V15, P569, DOI 10.1002/adma.200304552; Liu DL, 2002, CHINESE SCI BULL, V47, P52, DOI 10.1360/02tb9010; Maitland DJ, 2002, LASER SURG MED, V30, P1, DOI 10.1002/lsm.10007; OSADA Y, 1995, NATURE, V376, P219, DOI 10.1038/376219a0; Rousseau IA, 2003, J AM CHEM SOC, V125, P15300, DOI 10.1021/ja039001s; SUZUKI A, 1990, NATURE, V346, P345, DOI 10.1038/346345a0; TANAKA H, 1977, J POLYM SCI POL CHEM, V15, P2685, DOI 10.1002/pol.1977.170151113; Tobushi H, 1996, SMART MATER STRUCT, V5, P483, DOI 10.1088/0964-1726/5/4/012; Wei ZG, 1998, J MATER SCI, V33, P3743, DOI 10.1023/A:1004692329247; Yu YL, 2003, NATURE, V425, P145, DOI 10.1038/425145a	20	1531	1600	33	1228	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	2005	434	7035					879	882		10.1038/nature03496	http://dx.doi.org/10.1038/nature03496			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829960				2022-12-28	WOS:000228327600036
J	Reya, T; Clevers, H				Reya, T; Clevers, H			Wnt signalling in stem cells and cancer	NATURE			English	Article							HAIR FOLLICLE MORPHOGENESIS; BETA-CATENIN; PROGENITOR CELLS; HEMATOPOIETIC-CELLS; COLORECTAL-CANCER; MOUSE EPIDERMIS; SMALL-INTESTINE; SELF-RENEWAL; SPORADIC MEDULLOBLASTOMAS; TRANSLOCATION PRODUCTS	The canonical Wnt cascade has emerged as a critical regulator of stem cells. In many tissues, activation of Wnt signalling has also been associated with cancer. This has raised the possibility that the tightly regulated self-renewal mediated by Wnt signalling in stem and progenitor cells is subverted in cancer cells to allow malignant proliferation. Insights gained from understanding how the Wnt pathway is integrally involved in both stem cell and cancer cell maintenance and growth in the intestinal, epidermal and haematopoietic systems may serve as a paradigm for understanding the dual nature of self-renewal signals.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Duke University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Reya, T (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	t.reya@duke.edu; clevers@niob.knaw.nl						Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Baeza N, 2003, ONCOGENE, V22, P632, DOI 10.1038/sj.onc.1206156; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141; Braun KM, 2003, DEVELOPMENT, V130, P5241, DOI 10.1242/dev.00703; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615; COWIN P, 1985, J CELL BIOL, V101, P1442, DOI 10.1083/jcb.101.4.1442; Dahmen RP, 2001, CANCER RES, V61, P7039; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Galceran J, 2004, GENE DEV, V18, P2718, DOI 10.1101/gad.1249504; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hackney JA, 2002, P NATL ACAD SCI USA, V99, P13061, DOI 10.1073/pnas.192124499; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Heath JP, 1996, CELL BIOL INT, V20, P139, DOI 10.1006/cbir.1996.0018; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lee HY, 2004, SCIENCE, V303, P1020, DOI 10.1126/science.1091611; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lo Celso C, 2004, DEVELOPMENT, V131, P1787, DOI 10.1242/dev.01052; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004; Mulroy T, 2002, EUR J IMMUNOL, V32, P967, DOI 10.1002/1521-4141(200204)32:4<967::AID-IMMU967>3.0.CO;2-6; Murdoch B, 2003, P NATL ACAD SCI USA, V100, P3422, DOI 10.1073/pnas.0130233100; Muroyama Y, 2004, BIOCHEM BIOPH RES CO, V313, P915, DOI 10.1016/j.bbrc.2003.12.023; Niemann C, 2002, TRENDS CELL BIOL, V12, P185, DOI 10.1016/S0962-8924(02)02263-8; Niemann C, 2002, DEVELOPMENT, V129, P95; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z; Potten CS, 2002, J CELL SCI, V115, P2381; Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246; RANHEIM E, 2004, BLOOD           1130, DOI DOI 10.1182/BLOOD-2004-06-2334; Rattis FM, 2004, CURR OPIN HEMATOL, V11, P88, DOI 10.1097/01.moh.0000133649.61121.ec; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; Smit L, 2004, J BIOL CHEM, V279, P17232, DOI 10.1074/jbc.M307801200; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Turksen K, 2004, DEV CELL, V6, P454, DOI 10.1016/S1534-5807(04)00105-4; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Viti J, 2003, J NEUROSCI, V23, P5919; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Xu YY, 2003, NAT IMMUNOL, V4, P1177, DOI 10.1038/ni1008; Yamane T, 2001, J IMMUNOL, V167, P765, DOI 10.4049/jimmunol.167.2.765; Zechner D, 2003, DEV BIOL, V258, P406, DOI 10.1016/S0012-1606(03)00123-4; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700; Zhu AJ, 1999, DEVELOPMENT, V126, P2285; Zurawel RH, 1998, CANCER RES, V58, P896	90	2823	3109	7	432	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					843	850		10.1038/nature03319	http://dx.doi.org/10.1038/nature03319			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829953				2022-12-28	WOS:000228327600029
J	Robinson, C				Robinson, C			Flight of fancy	NATURE			English	Editorial Material									Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Cambridge	Robinson, C (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.								0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	2005	434	7035					827	827		10.1038/434827a	http://dx.doi.org/10.1038/434827a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829942	Bronze			2022-12-28	WOS:000228327600020
J	Li, ZP; Maglione, M; Tu, WL; Mojica, W; Arterburn, D; Shugarman, LR; Hilton, L; Suttorp, M; Solomon, V; Shekelle, PG; Morton, SC				Li, ZP; Maglione, M; Tu, WL; Mojica, W; Arterburn, D; Shugarman, LR; Hilton, L; Suttorp, M; Solomon, V; Shekelle, PG; Morton, SC			Meta-analysis: Pharmacologic treatment of obesity	ANNALS OF INTERNAL MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; CORONARY-HEART-DISEASE; TYPE-2 DIABETIC-PATIENTS; LONG-TERM MAINTENANCE; WEIGHT-LOSS; DOUBLE-BLIND; BODY-WEIGHT; CLINICAL-TRIALS; US ADULTS	Background: in response to the increase in obesity, pharmacologic treatments for weight loss have become more numerous and more commonly used. Purpose: To assess the efficacy and safety of weight loss medications approved by the U.S. Food and Drug Administration and other medications that have been used for weight loss. Data Sources: Electronic databases, experts in the field, and unpublished information. Study Selection: Up-to-date meta-analyses of sibutramine, phentermine, and diethylpropion were identified. The authors assessed in detail 50 studies of orlistat, 13 studies of fluoxetine, 5 studies of bupropion, 9 studies of topiramate, and 1 study each of sertraline and zonisamide. Meta-analysis was performed for all medications except sertraline, zonisamide, and fluoxetine, which are summarized narratively. Data Extraction: The authors abstracted information about study design, intervention, co-interventions, population, outcomes, and methodologic quality, as well as weight loss and adverse events from controlled trials of medication. Data Synthesis: All pooled weight loss values are reported relative to placebo. A meta-analysis of sibutramine reported a mean difference in weight loss of 4.45 kg (95% Cl, 3.62 to 5.29 kg) at 12 months. In the meta-analysis of orlistat, the estimate of the mean weight loss for orlistat-treated patients was 2.89 kg (Cl, 2.27 to 3.51 kg) at 12 months. A recent meta-analysis of phentermine and diethylpropion reported pooled mean differences in weight loss at 6 months of 3.6 kg (Cl, 0.6 to 6.0 kg) for phentermine-treated patients and 3.0 kg (Cl, -1.6 to 11.5 kg) for diethyl propion -treated patients. Weight loss in fluoxetine studies ranged from 14.5 kg of weight lost to 0.4 kg of weight gained at 12 or more months. For bupropion, 2.77 kg (Cl, 1.1 to 4.5 kg) of weight was lost at 6 to 12 months. Weight loss due to topiramate at 6 months was 6.5% (Cl, 4.8% to 8.3%) of pretreatment weight. With one exception, long-term studies of health outcomes were lacking. Significant side effects that varied by drug were reported. Limitations: Publication bias may exist despite a comprehensive search and despite the lack of statistical evidence for the existence of bias. Evidence of heterogeneity was observed for all metaanalyses. Conclusions: Sibutramine, orlistat, phentermine, probably diethylpropion, bupropion, probably fluoxetine, and topiramate promote modest weight loss when given along with recommendations for diet. Sibutramine and orlistat are the 2 most-studied drugs.	So Calif Evidence Based Practice Ctr, RAND Hlth Div, Santa Monica, CA USA; Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA; Dept Vet Affairs, Cincinnati, OH USA	RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Li, ZP (corresponding author), LA Vet Affairs Med Ctr, W111A,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.							Allison D B, 1995, Endocr Pract, V1, P353; Anderson JW, 2002, OBES RES, V10, P633, DOI 10.1038/oby.2002.86; Anderson KJ, 2001, J AM COLL HEALTH, V50, P21, DOI 10.1080/07448480109595707; Apfelbaum M, 1999, AM J MED, V106, P179, DOI 10.1016/S0002-9343(98)00411-2; Arterburn DE, 2004, ARCH INTERN MED, V164, P994, DOI 10.1001/archinte.164.9.994; Bakris G, 2002, J HYPERTENS, V20, P2257, DOI 10.1097/00004872-200211000-00026; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BRAY G, 2002, 62 SCI SESS AM DIAB; Bray GA, 1999, ENDOCR REV, V20, P805, DOI 10.1210/er.20.6.805; Bray GA, 2003, OBES RES, V11, P722, DOI 10.1038/oby.2003.102; Breum L, 1995, METABOLISM, V44, P1570, DOI 10.1016/0026-0495(95)90077-2; Broom I., 2001, International Journal of Obesity, V25, pS106; Broom I, 2002, INT J CLIN PRACT, V56, P494; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; CATERSON I, 2003, 18 INT DIAB FED C PA; *CDCP, 2002, OB EP INCR DRAM US; Clinical Guidelines on the Identification, 1998, OBES RES S2, V6, p51S; CONNOLLY VM, 1995, DIABETIC MED, V12, P416, DOI 10.1111/j.1464-5491.1995.tb00505.x; Croft H, 2002, CLIN THER, V24, P662, DOI 10.1016/S0149-2918(02)85141-4; DARGA LL, 1991, AM J CLIN NUTR, V54, P321, DOI 10.1093/ajcn/54.2.321; Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235; Deerochanawong C, 2001, DIABETES, V50, pA433; Derosa G, 2003, CLIN THER, V25, P1107, DOI 10.1016/S0149-2918(03)80070-X; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Eckel RH, 1998, CIRCULATION, V97, P2099, DOI 10.1161/01.CIR.97.21.2099; ESPEJO RM, 1995, ATEN PRIM, V16, P364; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Friedrich MJ, 2002, JAMA-J AM MED ASSOC, V287, P1382, DOI 10.1001/jama.287.11.1382; Gadde KM, 2003, JAMA-J AM MED ASSOC, V289, P1820, DOI 10.1001/jama.289.14.1820; Gilliam FG, 2003, NEUROLOGY, V60, P196, DOI 10.1212/01.WNL.0000048200.12663.BC; Gokcel A, 2002, DIABETES OBES METAB, V4, P49, DOI 10.1046/j.1463-1326.2002.00181.x; GOLDSTEIN DJ, 1994, INT J OBESITY, V18, P129; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; Gotfredsen A, 2001, INT J OBESITY, V25, P1154, DOI 10.1038/sj.ijo.0801639; GRAY DS, 1992, INT J OBESITY, V16, P193; Haddock CK, 2002, INT J OBESITY, V26, P262, DOI 10.1038/sj.ijo.0801889; Halpern A, 2003, DIABETES OBES METAB, V5, P180, DOI 10.1046/j.1463-1326.2003.00262.x; Hanefeld M, 2002, DIABETES OBES METAB, V4, P415, DOI 10.1046/j.1463-1326.2002.00237.x; Hauner H., 2000, International Journal of Obesity, V24, pS100; Hauptman J, 2000, ARCH FAM MED, V9, P160, DOI 10.1001/archfami.9.2.160; Hedges LV, 2014, STAT METHODS META AN; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hill JO, 1999, AM J CLIN NUTR, V69, P1108; Hollander PA, 1998, DIABETES CARE, V21, P1288, DOI 10.2337/diacare.21.8.1288; Huang ZP, 1997, JAMA-J AM MED ASSOC, V278, P1407, DOI 10.1001/jama.278.17.1407; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jain AK, 2002, OBES RES, V10, P1049, DOI 10.1038/oby.2002.142; Jeffery RW, 2004, ANN BEHAV MED, V27, P100, DOI 10.1207/s15324796abm2702_4; Karhunen L, 2000, INT J OBESITY, V24, P1567, DOI 10.1038/sj.ijo.0801443; Katzmarzyk PT, 2002, CAN MED ASSOC J, V166, P1039; Kelley DE, 2002, DIABETES CARE, V25, P1033, DOI 10.2337/diacare.25.6.1033; Kim I, 1988, J Okla State Med Assoc, V81, P395; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KOKKINOS J, 1993, STROKE, V24, P310, DOI 10.1161/01.STR.24.2.310; Krempf M, 2003, INT J OBESITY, V27, P591, DOI 10.1038/sj.ijo.0802281; KTZMARZYK PT, 2001, CMAJ, V164, P1563; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Lindgarde F, 2000, J INTERN MED, V248, P245, DOI 10.1046/j.1365-2796.2000.00720.x; Lucas CP, 2003, AM J CARDIOL, V91, P961, DOI 10.1016/S0002-9149(03)00112-7; MARCUS MD, 1990, AM J PSYCHIAT, V147, P876; McNulty SJ, 2003, DIABETES CARE, V26, P125, DOI 10.2337/diacare.26.1.125; MICHELSON D, 1999, 152 ANN M AM PSYCH A; Micic D, 1999, Med Pregl, V52, P323; Miles JM, 2002, DIABETES CARE, V25, P1123, DOI 10.2337/diacare.25.7.1123; Mokdad AH, 2000, JAMA-J AM MED ASSOC, V284, P1650, DOI 10.1001/jama.284.13.1650; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Muls E, 2001, INT J OBESITY, V25, P1713, DOI 10.1038/sj.ijo.0801814; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Naumov VG, 2002, TERAPEVT ARKH, V74, P47; NIELSEN JA, 1992, AM J CLIN NUTR, V55, P185, DOI 10.1093/ajcn/55.1.185s; OKANE M, 1994, DIABETIC MED, V11, P105, DOI 10.1111/j.1464-5491.1994.tb00238.x; PiSunyer FX, 1996, CLIN THER, V18, P1006, DOI 10.1016/S0149-2918(96)80057-9; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; PUDHOMME D, 2003, N AM ASS STUD OB 200; Reaven G, 2001, AM J CARDIOL, V87, P827, DOI 10.1016/S0002-9149(00)01521-6; RISSANEN A, 2003, 18 INT DIAB FED C PA; Rissanen P, 2001, INT J OBESITY, V25, P212, DOI 10.1038/sj.ijo.0801540; Rosenfalck AM, 2002, DIABETES OBES METAB, V4, P19, DOI 10.1046/j.1463-1326.2002.00161.x; Rossner S, 2000, OBES RES, V8, P49, DOI 10.1038/oby.2000.8; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; Smith IG, 2001, J FAM PRACTICE, V50, P505; STENLOF K, 2003, N AM ASS STUD OB 200; STENLOF K, 2003, 18 INT DIAB FED C PA; *THOMPS CENTERWATC, 2004, DRUGS APPR FDA DRUG; TONSTAD S, 2003, N AM ASS STUD OB 200; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Vidgren HM, 1999, CLIN PHARMACOL THER, V66, P315, DOI 10.1016/S0009-9236(99)70040-8; Wadden T A, 1995, Obes Res, V3, P549; Wadden TA, 2000, OBES RES, V8, P431, DOI 10.1038/oby.2000.53; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; Wirth A, 2001, JAMA-J AM MED ASSOC, V286, P1331, DOI 10.1001/jama.286.11.1331; Woods TM, 2004, ANN PHARMACOTHER, V38, P887, DOI 10.1345/aph.1D219; World Health Organization, 2002, CONTR GLOB OB EP; YI FS, 2001, DIABETES, V50, pA101	95	514	547	1	54	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 5	2005	142	7					532	546		10.7326/0003-4819-142-7-200504050-00012	http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00012			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913QL	15809465				2022-12-28	WOS:000228167800007
J	Baughman, RH				Baughman, RH			Playing nature's game with artificial muscles	SCIENCE			English	Editorial Material							TECHNOLOGY; ACTUATORS; STRAIN		Univ Texas, NanoTech Inst, Richardson, TX 75083 USA; Univ Texas, Dept Chem, Richardson, TX 75083 USA	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas	Baughman, RH (corresponding author), Univ Texas, NanoTech Inst, Richardson, TX 75083 USA.	ray.baughman@utdallas.edu	Baughman, Ray/A-8628-2018	Baughman, Ray/0000-0001-5845-5137				Baughman RH, 1996, SYNTHETIC MET, V78, P339, DOI 10.1016/0379-6779(96)80158-5; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; BAUGHMAN RH, 2003, Patent No. 6555945; EBRON VH, UNPUB; Hara S, 2004, J MATER CHEM, V14, P1516, DOI 10.1039/b404232h; HARA S, IN PRESS SYNTH METAL; Kaneko D, 2002, J MATER CHEM, V12, P2169, DOI 10.1039/b109981g; Lu W, 2002, SCIENCE, V297, P983, DOI 10.1126/science.1072651; Madden JDW, 2004, IEEE J OCEANIC ENG, V29, P706, DOI 10.1109/JOE.2004.833135; Nemat-Nasser S, 2003, J APPL PHYS, V93, P5255, DOI 10.1063/1.1563300; Pelrine R, 2000, SCIENCE, V287, P836, DOI 10.1126/science.287.5454.836; Schreyer HB, 2000, BIOMACROMOLECULES, V1, P642, DOI 10.1021/bm005557l; Smela E, 2003, ADV MATER, V15, P481, DOI 10.1002/adma.200390113; SMELA E, 1995, SCIENCE, V268, P1735, DOI 10.1126/science.268.5218.1735; Spinks GM, 2002, ADV MATER, V14, P1728, DOI 10.1002/1521-4095(20021203)14:23<1728::AID-ADMA1728>3.0.CO;2-8; Zhang M, 2004, SCIENCE, V306, P1358, DOI 10.1126/science.1104276; Zhang QM, 1998, SCIENCE, V280, P2101, DOI 10.1126/science.280.5372.2101	17	202	208	6	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					63	65		10.1126/science.1099010	http://dx.doi.org/10.1126/science.1099010			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802593				2022-12-28	WOS:000228221500031
J	Panksepp, J				Panksepp, J			Beyond a joke: From animal laughter to human joy?	SCIENCE			English	Editorial Material							ULTRASONIC VOCALIZATIONS; RATS; HUMOR		Bowling Green State Univ, Dept Psychol, JP Scott Ctr Neurosci Mind & Behav, Bowling Green, OH 43403 USA; Northwestern Univ, Dept Biomed Engn, Falk Ctr Mol Therapeut, Evanston, IL 60201 USA	University System of Ohio; Bowling Green State University; Northwestern University	Panksepp, J (corresponding author), Bowling Green State Univ, Dept Psychol, JP Scott Ctr Neurosci Mind & Behav, Bowling Green, OH 43403 USA.	jpankse@bgnet.bgsu.edu						Bachorowski JA, 2001, J ACOUST SOC AM, V110, P1581, DOI 10.1121/1.1391244; Burgdorf J, 2005, BEHAV GENET, V35, P67, DOI 10.1007/s10519-004-0856-5; Burgdorf J, 2001, BEHAV NEUROSCI, V115, P940, DOI 10.1037/0735-7044.115.4.940; Burghardt GM, 2005, GENESIS OF ANIMAL PLAY: TESTING THE LIMITS, P1; Darwin Charles, 1998, EXPRESS EMOT MAN, V3rd, DOI [10.1037/h0076058, DOI 10.1037/10001-000]; Grandin T., 2005, ANIMALS TRANSLATION; Harro J., 2004, TXB BIOL PSYCHIAT, P661; JOUBERT L, 1579, TREATISE LAUGHTER; Knutson B, 2002, PSYCHOL BULL, V128, P961, DOI 10.1037//0033-2909.128.6.961; Matsusaka T, 2004, PRIMATES, V45, P221, DOI 10.1007/s10329-004-0090-z; McMillan FD, 2005, MENTAL HEALTH AND WELL-BEING IN ANIMALS, P1; Mobbs D, 2003, NEURON, V40, P1041, DOI 10.1016/S0896-6273(03)00751-7; Panksepp J, 2005, CONSCIOUS COGN, V14, P22, DOI 10.1016/j.concog.2004.10.002; Panksepp J, 2003, PHYSIOL BEHAV, V79, P533, DOI 10.1016/S0031-9384(03)00159-8; Panksepp J, 2002, ADDICTION, V97, P459, DOI 10.1046/j.1360-0443.2002.00025.x; Panksepp J., 1998, AFFECTIVE NEUROSCIEN; PANKSEPP J, 2003, CONSCIOUSNESS EMOTIO, V4, P197; Panksepp Jaak, 2002, Neuro Endocrinol Lett, V23 Suppl 4, P105; Poeck K., 1969, HDB CLIN NEUROLOGY, V3; Provine R., 2000, LAUGHTER; Wild B, 2003, BRAIN, V126, P2121, DOI 10.1093/brain/awg226	21	91	94	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					62	63		10.1126/science.1112066	http://dx.doi.org/10.1126/science.1112066			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802592				2022-12-28	WOS:000228221500030
J	Backhed, F; Ley, RE; Sonnenburg, JL; Peterson, DA; Gordon, JI				Backhed, F; Ley, RE; Sonnenburg, JL; Peterson, DA; Gordon, JI			Host-bacterial mutualism in the human intestine	SCIENCE			English	Review							EXTENSIVE DNA INVERSIONS; BACTEROIDES-THETAIOTAOMICRON; ANAEROBIC-BACTERIA; GENE-EXPRESSION; CELL-SURFACE; HUMAN FECES; COMMUNITIES; DIVERSITY; GUT; ENVIRONMENTS	The distal human intestine represents an anaerobic bioreactor programmed with an enormous population of bacteria, dominated by relatively few divisions that are highly diverse at the strain/subspecies level. This microbiota and its collective genomes (microbiome) provide us with genetic and metabolic attributes we have not been required to evolve on our own, including the ability to harvest otherwise inaccessible nutrients. New studies are revealing how the gut microbiota has co-evolved with us and how it manipulates and complements our biology in ways that are mutually beneficial. We are also starting to understand how certain keystone members of the microbiota operate to maintain the stability and functional adaptability of this microbial organ.	Washington Univ, Sch Med, Ctr Genome Sci, St Louis, MO 63108 USA	Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Sch Med, Ctr Genome Sci, St Louis, MO 63108 USA.	jgordon@molecool.wustl.edu	Backhed, Fredrik/ABE-6613-2020; Ley, Ruth E/M-8542-2014	Backhed, Fredrik/0000-0002-4871-8818; Ley, Ruth E/0000-0002-9087-1672				Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Breitbart M, 2003, J BACTERIOL, V185, P6220, DOI 10.1128/JB.185.20.6220-6223.2003; Brune A, 2000, CURR OPIN MICROBIOL, V3, P263, DOI 10.1016/S1369-5274(00)00087-4; Cerdeno-Tarraga AM, 2005, SCIENCE, V307, P1463, DOI 10.1126/science.1107008; Chacon O, 2004, ANNU REV MICROBIOL, V58, P329, DOI 10.1146/annurev.micro.58.030603.123726; Dunbar J, 2002, APPL ENVIRON MICROB, V68, P3035, DOI 10.1128/AEM.68.6.3035-3045.2002; Fernandez AS, 2000, APPL ENVIRON MICROB, V66, P4058, DOI 10.1128/AEM.66.9.4058-4067.2000; Flegal KM, 2000, INT J OBESITY, V24, P807, DOI 10.1038/sj.ijo.0801232; Fuhrman JA, 1999, NATURE, V399, P541, DOI 10.1038/21119; Galperin MY, 2004, NUCLEIC ACIDS RES, V32, pD3, DOI 10.1093/nar/gkh143; GOEBEL BM, 1994, APPL ENVIRON MICROB, V60, P1614, DOI 10.1128/AEM.60.5.1614-1621.1994; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Kuwahara T, 2004, P NATL ACAD SCI USA, V101, P14919, DOI 10.1073/pnas.0404172101; LEY RE, UNPUB; McCann KS, 2000, NATURE, V405, P228, DOI 10.1038/35012234; MCNEIL NI, 1984, AM J CLIN NUTR, V39, P338, DOI 10.1093/ajcn/39.2.338; MILLER TL, 1982, ARCH MICROBIOL, V131, P14, DOI 10.1007/BF00451492; MOORE WEC, 1974, APPL MICROBIOL, V27, P961, DOI 10.1128/AEM.27.5.961-979.1974; Rainey PB, 2003, NATURE, V425, P72, DOI 10.1038/nature01906; ROLANDELLI RH, 1989, J NUTR, V119, P89, DOI 10.1093/jn/119.1.89; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; Seksik P, 2003, GUT, V52, P237, DOI 10.1136/gut.52.2.237; Shipman JA, 2000, J BACTERIOL, V182, P5365, DOI 10.1128/JB.182.19.5365-5372.2000; Sonnenburg JL, 2004, NAT IMMUNOL, V5, P569, DOI 10.1038/ni1079; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; STAMS AJM, 1994, ANTON LEEUW INT J G, V66, P271, DOI 10.1007/BF00871644; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; Taddei F, 1997, TRENDS MICROBIOL, V5, P427, DOI 10.1016/S0966-842X(97)01157-8; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; Towle HC, 2001, P NATL ACAD SCI USA, V98, P13476, DOI 10.1073/pnas.251530798; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Winter C, 2004, APPL ENVIRON MICROB, V70, P804, DOI 10.1128/AEM.70.2.804-813.2004; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029; Yachi S, 1999, P NATL ACAD SCI USA, V96, P1463, DOI 10.1073/pnas.96.4.1463; YAMANAKA M, 1977, J NUTR SCI VITAMINOL, V23, P221, DOI 10.3177/jnsv.23.221; Zoetendal EG, 1998, APPL ENVIRON MICROB, V64, P3854; Zoetendal Erwin G., 2001, Microbial Ecology in Health and Disease, V13, P129, DOI 10.1080/089106001750462669	38	3283	3584	83	1476	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1915	1920		10.1126/science.1104816	http://dx.doi.org/10.1126/science.1104816			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790844	Green Published			2022-12-28	WOS:000227957300045
J	Javanainen, J				Javanainen, J			Bose-Einstein condensates interfere and survive	SCIENCE			English	Editorial Material							QUANTUM PHASE; ATOMS		Univ Connecticut, Dept Phys, Storrs, CT 06269 USA	University of Connecticut	Javanainen, J (corresponding author), Univ Connecticut, Dept Phys, Storrs, CT 06269 USA.	jj@phys.uconn.edu	Javanainen, Juha/B-7350-2008					Andrews MR, 1997, SCIENCE, V275, P637, DOI 10.1126/science.275.5300.637; Geremia JM, 2004, SCIENCE, V304, P270, DOI 10.1126/science.1095374; Gustavson TL, 2000, CLASSICAL QUANT GRAV, V17, P2385, DOI 10.1088/0264-9381/17/12/311; Javanainen J, 1996, PHYS REV LETT, V76, P161, DOI 10.1103/PhysRevLett.76.161; Orzel C, 2001, SCIENCE, V291, P2386, DOI 10.1126/science.1058149; Saba M, 2005, SCIENCE, V307, P1945, DOI 10.1126/science.1108801	7	4	4	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1883	+		10.1126/science.1110247	http://dx.doi.org/10.1126/science.1110247			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790832				2022-12-28	WOS:000227957300034
J	Sommer, T; Hirsch, C				Sommer, T; Hirsch, C			San1p, checking up on nuclear proteins	CELL			English	Editorial Material							DEGRADATION	Cellular quality control mechanisms perform vital tasks by ensuring that the proteome reflects precisely the information encoded by the genome. In this issue of Cell, Gardner et al. (2005) report the discovery of a novel protein quality control system that resides in the nucleus. Central to this system is the E3 ligase San1p, which monitors nuclear proteins and targets aberrant species for destruction.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sommer, T (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.							Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Hirsch C, 2004, BBA-MOL CELL RES, V1695, P215, DOI 10.1016/j.bbamcr.2004.10.006; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264	5	4	4	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 25	2005	120	6					734	736		10.1016/j.cell.2005.03.003	http://dx.doi.org/10.1016/j.cell.2005.03.003			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797374	Bronze			2022-12-28	WOS:000228067500003
J	Pluta, RM; Dejam, A; Grimes, G; Gladwin, MT; Oldfield, EH				Pluta, RM; Dejam, A; Grimes, G; Gladwin, MT; Oldfield, EH			Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENTRICULAR SODIUM-NITROPRUSSIDE; OXIDE SYNTHASE ACTIVITY; CEREBROSPINAL-FLUID; BLOOD-FLOW; INTRAVENOUS NITROGLYCERIN; ENDOTHELIAL DYSFUNCTION; S-NITROSOHEMOGLOBIN; HYPOXIC CONDITIONS; GUANYLATE-CYCLASE; ANEURYSM-SURGERY	Context Delayed cerebral vasospasm causes permanent neurological deficits or death in at least 15% of patients following otherwise successful treatment for ruptured intracranial aneurysm. Decreased bioavailability of nitric oxide has been associated with the development of cerebral vasospasm. Objective To determine whether infusions of nitrite will prevent delayed cerebral vasospasm. Design, Setting, and Subjects A total of 14 anesthetized cynomolgus monkeys had an autologous blood clot placed around the right middle cerebral artery. Cerebral arteriography was performed before clot placement and on days 7 and 14 to assess vasospasm. The study was conducted from August 2003 to February 2004. Interventions A 90-mg sodium nitrite intravenous solution infused over 24 hours plus a 45-mg sodium nitrite bolus daily (n=31); a 180-mg sodium nitrite intravenous solution infused over 24 hours (n=3); or a control saline solution infusion (n=8). Each was infused continuously for 14 days. Main Outcome Measures Nitrite, S-nitrosothiol, and methemoglobin levels in blood and cerebrospinal fluid and degree of arteriographic vasospasm. Results In control monkeys, mean (SD) cerebrospinal fluid nitrite levels decreased from 3.1 (1.5) mu mol/L to 0.4 (0.1) mu mol/L at day 7 and to 0.4 (0.4) mu mol/L at day 14 (P=.03). All 8 control monkeys developed significant vasospasm of the right middle cerebral artery which was complicated by stroke and death in I animal. Sodium nitrite infusions increased the nitrite and methemoglobin levels (<2.1% of total hemoglobin) in the blood and cerebrospinal fluid without evoking systemic hypotension. Nitrite infusion prevented development of vasospasm (no animals developed significant vasospasm; mean [SD] reduction in right middle cerebral artery area on day 7 after subarachnoid hemorrhage of 8% [9%] in nitrite-treated monkeys vs 47% [5%] in saline-treated controls; P<.001). There was a negative correlation between the concentration of nitrite in cerebrospinal fluid and the degree of cerebral vasospasm (P<.001). Pharmacological effects of nitrite infusion were also associated with the formation of S-nitrosothiol in cerebrospinal fluid. There was no clinical or pathological evidence of nitrite toxicity. Conclusion Subacute sodium nitrite infusions prevented delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage.	NINDS, Surg Neurol Branch, Bethesda, MD 20892 USA; NIDDKD, Biol Chem Lab, Bethesda, MD 20892 USA; NHLBI, Dept Pharm, Ctr Clin, Vasc Therapeut Sect,Cardiovasc Branch, Bethesda, MD 20892 USA; NIH, Dept Crit Care Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA	Pluta, RM (corresponding author), NINDS, Surg Neurol Branch, 10 Ctr Dr,Room 5D37, Bethesda, MD 20892 USA.	rysiek@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002854] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AFSHAR JKB, 1995, J NEUROSURG, V83, P118, DOI 10.3171/jns.1995.83.1.0118; Asano T, 1999, CRIT REV NEUROSURG, V9, P303, DOI 10.1007/s003290050147; BAETMANN A, 1985, CEREBRAL VASCULAR SP, P209; BARKOVICH AJ, 1988, RADIOL CLIN N AM, V26, P801; BROWN FD, 1977, SURG NEUROL, V7, P67; Bryan NS, 2004, P NATL ACAD SCI USA, V101, P4308, DOI 10.1073/pnas.0306706101; BURNETT M, 2004, MANAGEMENT CEREBRAL, P127; Clark JF, 2002, J CEREBR BLOOD F MET, V22, P472, DOI 10.1097/00004647-200204000-00011; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Dejam A, 2004, BLOOD CELL MOL DIS, V32, P423, DOI 10.1016/j.bcmd.2004.02.002; Dietrich HH, 2000, NEUROSURGERY, V46, P517, DOI 10.1097/00006123-200003000-00001; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; EGEMEN N, 1993, NEUROL RES, V15, P310; ESPINOSA F, 1984, J NEUROSURG, V60, P1167, DOI 10.3171/jns.1984.60.6.1167; FRAZEE JG, 1981, J NEUROSURG, V55, P865, DOI 10.3171/jns.1981.55.6.0865; Gabikian P, 2002, STROKE, V33, P2681, DOI 10.1161/01.STR.0000033931.62992.B1; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2004, FREE RADICAL BIO MED, V36, P707, DOI 10.1016/j.freeradbiomed.2003.11.032; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; HASHI K, 1972, J NEUROL SCI, V17, P1, DOI 10.1016/0022-510X(72)90016-0; Heros R C, 1976, Surg Neurol, V6, P227; HEROS RC, 1983, ANN NEUROL, V14, P599, DOI 10.1002/ana.410140602; Hino A, 1996, NEUROSURGERY, V39, P562, DOI 10.1097/00006123-199609000-00026; Hunter CJ, 2004, NAT MED, V10, P1122, DOI 10.1038/nm1109; IGNARRO LJ, 1980, BIOCHIM BIOPHYS ACTA, V631, P221, DOI 10.1016/0304-4165(80)90297-4; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Ito Y, 2000, J CARDIOVASC PHARM, V35, P45, DOI 10.1097/00005344-200001000-00006; Iuliano BA, 2004, J NEUROSURG, V100, P287, DOI 10.3171/jns.2004.100.2.0287; Jung CS, 2004, J NEUROSURG, V101, P836, DOI 10.3171/jns.2004.101.5.0836; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KASSELL NF, 1984, STROKE, V15, P566, DOI 10.1161/01.STR.15.3.566; KASUYA H, 1995, J NEUROSURG, V82, P250, DOI 10.3171/jns.1995.82.2.0250; Khaldi A, 2001, NEUROSURGERY, V49, P33; KIM P, 1990, CEREBRAL VASOSPASM, P83; KISTLER JP, 1979, STROKE, V10, P26, DOI 10.1161/01.STR.10.1.26; Kranc KR, 2000, EUR J BIOCHEM, V267, P7094, DOI 10.1046/j.1432-1327.2000.01812.x; Lauer T, 2001, P NATL ACAD SCI USA, V98, P12814, DOI 10.1073/pnas.221381098; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; Macdonald RL, 2001, CEREBRAL VASOSPASM; Meyer F B, 1990, Neurosurg Clin N Am, V1, P367; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Nakao K, 1996, STROKE, V27, P1882, DOI 10.1161/01.STR.27.10.1882; Ng WH, 2001, NEUROSURGERY, V49, P622, DOI 10.1097/00006123-200109000-00016; NISHIZAWA S, 1995, STROKE, V26, P1916, DOI 10.1161/01.STR.26.10.1916; PAKARINEN S, 1967, ACTA NEUROL SCAND  S, V29, P1; Park KW, 2001, ANESTH ANALG, V92, P990; PAULSON OB, 1970, NEUROLOGY, V20, P63, DOI 10.1212/WNL.20.1.63; PLUTA R, 2004, VAS P 8 INT C NEW YO, P71; Pluta RM, 1998, J NEUROSURG, V88, P557, DOI 10.3171/jns.1998.88.3.0557; PLUTA RM, 1992, J NEUROSURG, V77, P740, DOI 10.3171/jns.1992.77.5.0740; Pluta RM, 1996, J NEUROSURG, V84, P648, DOI 10.3171/jns.1996.84.4.0648; Pluta RM, 2001, ACT NEUR S, V77, P67; Pluta RM, 1997, J NEUROSURG, V87, P746, DOI 10.3171/jns.1997.87.5.0746; Pluta RM, 2005, PHARMACOL THERAPEUT, V105, P23, DOI 10.1016/j.pharmthera.2004.10.002; Polin RS, 1998, NEUROSURGERY, V42, P1256, DOI 10.1097/00006123-199806000-00031; Raabe A, 2002, NEUROSURGERY, V50, P1006, DOI 10.1097/00006123-200205000-00013; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Sadamitsu D, 2001, CRIT CARE MED, V29, P77, DOI 10.1097/00003246-200101000-00018; Sakowitz OW, 2001, J CEREBR BLOOD F MET, V21, P1067, DOI 10.1097/00004647-200109000-00004; SAMBROOK MA, 1973, BRAIN, V96, P171, DOI 10.1093/brain/96.1.171; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; SHIMODA M, 1993, J NEUROSURG, V78, P423, DOI 10.3171/jns.1993.78.3.0423; Suzuki M, 1999, NEUROSURG REV, V22, P96, DOI 10.1007/s101430050038; Thomas JE, 1999, NEUROSURGERY, V44, P48, DOI 10.1097/00006123-199901000-00026; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TODA N, 1993, CIRC RES, V72, P206, DOI 10.1161/01.RES.72.1.206; Treggiari-Venzi MM, 2001, NEUROSURGERY, V48, P249, DOI 10.1097/00006123-200102000-00001; Wang XY, 2002, STROKE, V33, P1882, DOI 10.1161/01.STR.0000020121.41527.5D; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; Weyerbrock A, 2003, J NEUROSURG, V99, P728, DOI 10.3171/jns.2003.99.4.0728; Woszczyk A, 2003, ACTA NEUROCHIR, V145, P257, DOI 10.1007/s00701-003-0004-7; Yamamoto S, 1997, BRAIN RES, V757, P1, DOI 10.1016/S0006-8993(96)01433-3; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	79	211	219	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2005	293	12					1477	1484		10.1001/jama.293.12.1477	http://dx.doi.org/10.1001/jama.293.12.1477			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908KA	15784871	Bronze			2022-12-28	WOS:000227784700027
J	Grimes, DA; Schulz, KF				Grimes, DA; Schulz, KF			Epidemiology 2 - Compared to what? Finding controls for case-control studies	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RISK-FACTORS; NEIGHBORHOOD CONTROLS; POPULATION-CONTROLS; HOSPITAL CONTROLS; SELECTION BIAS; DISEASE; CANCER; ABUSE	Use of control (comparison) groups is a powerful research tool. In case-control studies, controls estimate the frequency of an exposure in the population under study. Controls can be taken from known or unknown study populations. A known group consists of a defined population observed over a period, such as passengers on a cruise ship. When the study group is known, a sample of the population can be used as controls. If no population roster exists, then techniques such as random-digit dialling can be used. Sometimes, however, the study group is unknown, for example, motor-vehicle crash victims brought to an emergency department, who may come from far away. In this situation, hospital controls, neighbourhood controls, and friend, associate, or relative controls can be used. In general, one well-selected control group is better than two or more. When the number of cases is small, the ratio of controls to cases can be raised to improve the ability to find important differences. Although no ideal control group exists, readers need to think carefully about how representative the controls are. Poor choice of controls can lead to both wrong results and possible medical harm.	Family Hlth Int, Res Triangle Pk, NC 27709 USA		Grimes, DA (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	dgrimes@fhi.org						Baron JA, 2003, PROG EXP TUMOR RES, V37, P1; Chan AT, 2003, CANCER CAUSE CONTROL, V14, P413, DOI 10.1023/A:1024986220526; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; Funkhouser E, 2000, ANN EPIDEMIOL, V10, P59, DOI 10.1016/S1047-2797(99)00046-0; GOLDSTEIN AM, 1989, INT J EPIDEMIOL, V18, P985, DOI 10.1093/ije/18.4.985; GRIMES DA, 1987, CONTRACEPTION, V36, P97, DOI 10.1016/0010-7824(87)90063-1; GRIMES DA, 1995, OBSTET GYNECOL, V86, P1031, DOI 10.1016/0029-7844(95)00276-W; GRIMES DA, 1985, AM J OBSTET GYNECOL, V153, P179, DOI 10.1016/0002-9378(85)90108-5; Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2; Grimes DA, 2002, LANCET, V359, P341, DOI 10.1016/S0140-6736(02)07500-1; HARTGE P, 1984, AM J EPIDEMIOL, V120, P825, DOI 10.1093/oxfordjournals.aje.a113955; HENDERSON BE, 1983, BRIT J CANCER, V48, P437, DOI 10.1038/bjc.1983.210; HULKA BS, 1980, AM J OBSTET GYNECOL, V137, P92, DOI 10.1016/0002-9378(80)90391-9; IBRAHIM MA, 1979, J CHRON DIS, V32, P139, DOI 10.1016/0021-9681(79)90026-2; Infante-Rivard C, 2003, AM J EPIDEMIOL, V157, P176, DOI 10.1093/aje/kwf174; Kearney DJ, 2003, GASTROINTEST ENDOSC, V57, P823, DOI 10.1016/S0016-5107(03)70015-7; LEVENTHAL JM, 1981, PEDIATRICS, V68, P684; Lopes CS, 1996, INT J EPIDEMIOL, V25, P1267, DOI 10.1093/ije/25.6.1267; MARBACH JJ, 1992, CLIN J PAIN, V8, P39, DOI 10.1097/00002508-199203000-00008; Moritz DJ, 1997, AM J EPIDEMIOL, V145, P653; MOSS AR, 1987, AM J EPIDEMIOL, V125, P1035, DOI 10.1093/oxfordjournals.aje.a114619; OLSON SH, 1994, AM J EPIDEMIOL, V139, P302, DOI 10.1093/oxfordjournals.aje.a116998; OLSON SH, 1992, AM J EPIDEMIOL, V135, P210, DOI 10.1093/oxfordjournals.aje.a116273; PERILLO MG, 1993, J MANIP PHYSIOL THER, V16, P578; ROOKS JB, 1979, JAMA-J AM MED ASSOC, V242, P644, DOI 10.1001/jama.242.7.644; Rossouw JE, 1996, CIRCULATION, V94, P2982, DOI 10.1161/01.CIR.94.11.2982; Rothman K, 1986, MODERN EPIDEMIOLOGY; RYU JE, 1989, AM J EPIDEMIOL, V129, P407; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Schulz KF, 2002, LANCET, V359, P431, DOI 10.1016/S0140-6736(02)07605-5; Schulz KF, 2002, LANCET, V359, P966, DOI 10.1016/S0140-6736(02)08029-7; VERNICK LJ, 1984, J CHRON DIS, V37, P177, DOI 10.1016/0021-9681(84)90145-0; Voigt LF, 2003, AM J EPIDEMIOL, V157, P66, DOI 10.1093/aje/kwf185; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397; WEST DW, 1984, INT J EPIDEMIOL, V13, P235, DOI 10.1093/ije/13.2.235; Wiebe DJ, 2003, ACCIDENT ANAL PREV, V35, P711, DOI 10.1016/S0001-4575(02)00049-0; Zondervan KT, 2002, HUM REPROD, V17, P1415, DOI 10.1093/humrep/17.6.1415	39	280	286	2	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 16	2005	365	9468					1429	1433		10.1016/S0140-6736(05)66379-9	http://dx.doi.org/10.1016/S0140-6736(05)66379-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836892				2022-12-28	WOS:000228401900032
J	Sonder, GJB; Regez, RM; Brinkman, K; Prins, JM; Mulder, JW; Spaargaren, J; Coutinho, RA; van den Hoek, A				Sonder, GJB; Regez, RM; Brinkman, K; Prins, JM; Mulder, JW; Spaargaren, J; Coutinho, RA; van den Hoek, A			Prophylaxis and follow-up after possible exposure to HIV, hepatitis B virus, and hepatitis C virus outside hospital: evaluation of policy 2000-3	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INJECTION-DRUG USE; POSTEXPOSURE PROPHYLAXIS	Problem Prophylactic treatment and follow-up after exposure to HIV, hepatitis B, and hepatitis C outside hospital needs to be improved. Background and setting Until January 2000, people in Amsterdam Could report exposure outside hospital to either a hospital or the municipal health service. If they reported to the municipal health service, they were then referred to hospitals for HIV prophylaxis, whereas the municipal health service handled treatment and follow-up related to hepatitis B and hepatitis C and traced sources. For cases reported to a hospital, hospital staff often did not trace HIV sources or follow up patients for hepatitis B and hepatitis C. Key measures for improvement Providing adequate treatment for HIV, hepatitis B and hepatitis C after exposure for all reported exposures outside hospital. Strategies for change On 1 January 2000, a new protocol was introduced in which three Amsterdam hospitals and the municipal health service collaborated in the treatment and follow-up of exposures outside hospital. Both municipal health service and hospitals can decide whether HIV prophylaxis is necessary and prescribe accordingly. All people exposed in the community who report to hospitals are subsequently referred to the municipal health service for further treatment and follow-up. Effects of change The protocol is effective in that most people comply with treatment and follow-up. When indicated, HIV prophylaxis is started soon after exposure. In nearly two thirds of cases the municipal health service traced and tested tire source. Lessons learnt Provision of treatment and follow-up in one place enables treatment, tracing and testing sources, and follow-tip, including counselling and registration of all reported exposures in Amsterdam, which allows for swift identification of emerging epidemiological trends. Since May 2004 all Amsterdam hospitals have participated in the protocol.	Dept Infect Dis, NL-1018 WT Amsterdam, Netherlands; Onze Lieve Vrouw Hosp, Dept Internal Med, Dept Clin Res, NL-1091 HA Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands; Slotervaart Hosp, Dept Internal Med, NL-1066 EC Amsterdam, Netherlands; Municipal Hlth Lab, Amsterdam, Netherlands; Municipal Hlth Serv Amsterdam, Amsterdam, Netherlands	Onze Lieve Vrouwe Gasthuis Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital	Sonder, GJB (corresponding author), Dept Infect Dis, Nieuwe Achtergracht 100, NL-1018 WT Amsterdam, Netherlands.	gsonder@gggd.amsterdam.nl	Prins, Jan M./AAF-4945-2020					Almeda J, 2004, Euro Surveill, V9, P35; COLOMBO C, 2004, EUROSURVEILLANCE, V9, P40; Giele CM, 2002, SEX TRANSM INFECT, V78, P130, DOI 10.1136/sti.78.2.130; Kahn JO, 2001, J INFECT DIS, V183, P707, DOI 10.1086/318829; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; Laporte A, 2002, AIDS, V16, P397, DOI 10.1097/00002030-200202150-00011; Tubiana Roland, 2004, Euro Surveill, V9, P3; van der Ende ME, 2002, INT J STD AIDS, V13, P30, DOI 10.1258/095646202762226137; VANSTEENBERGEN JE, 1999, LANDELIJKE COORDINAT	9	12	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 9	2005	330	7495					825	829		10.1136/bmj.330.7495.825	http://dx.doi.org/10.1136/bmj.330.7495.825			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915BZ	15817550	Green Published			2022-12-28	WOS:000228273900019
J	Bino, A; Ardon, M; Shirman, E				Bino, A; Ardon, M; Shirman, E			Formation of a carbon-carbon triple bond by coupling reactions in aqueous solution	SCIENCE			English	Article							CLUSTER COMPOUNDS; ALKYNE LIGAND; COMPLEXES	Formation of a carbon-carbon triple bond by coupling reactions usually takes place at high temperatures, in anhydrous media and anaerobic conditions. We describe the formation of a carbon-carbon triple bond at room temperature in an aqueous solution exposed to the atmosphere. Two ethylidyne ligands of a trimolybdenum cluster coupled spontaneously to form 2-butyne. This unexpected result demonstrates the plausibility of alkylidyne chain lengthening and metathesis processes under ambient, environmentally friendly conditions.	Hebrew Univ Jerusalem, Dept Inorgan & Analyt Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Bino, A (corresponding author), Hebrew Univ Jerusalem, Dept Inorgan & Analyt Chem, IL-91904 Jerusalem, Israel.	bino@vms.huji.ac.it						ALLISON NT, 1983, J AM CHEM SOC, V105, P1384, DOI 10.1021/ja00343a060; ARDON M, 1981, INORG CHEM, V20, P4083, DOI 10.1021/ic50226a010; ARDON M, 1982, INORG CHEM, V21, P1912, DOI 10.1021/ic00135a041; BINO A, 1981, J AM CHEM SOC, V103, P6741, DOI 10.1021/ja00412a035; BLOUNT JF, 1966, J AM CHEM SOC, V88, P292, DOI 10.1021/ja00954a021; CHI Y, 1985, ORGANOMETALLICS, V4, P1900, DOI 10.1021/om00129a040; Connon SJ, 2003, ANGEW CHEM INT EDIT, V42, P1900, DOI 10.1002/anie.200200556; DELLACA RJ, 1970, INORG CHEM, V9, P2204, DOI 10.1021/ic50092a002; Filippou AC, 1999, EUR J INORG CHEM, P1905; FISCHER EO, 1977, ANGEW CHEM INT EDIT, V16, P465, DOI 10.1002/anie.197704651; FURSTNER A, 2003, HDB METATHESIS, V2, P432, DOI DOI 10.1002/9783527619481.CH27; HOFFMANN R, 1982, J AM CHEM SOC, V104, P632, DOI 10.1021/ja00366a052; KHAND IU, 1974, J ORGANOMET CHEM, V73, P383, DOI 10.1016/S0022-328X(00)83838-3; LENTZ D, 1988, ANGEW CHEM INT EDIT, V27, P845, DOI 10.1002/anie.198808451; NAKATA K, 1991, INORG CHEM, V30, P1575, DOI 10.1021/ic00007a028; Zaera F, 1995, CHEM REV, V95, P2651, DOI 10.1021/cr00040a003	16	48	49	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					234	235		10.1126/science.1109965	http://dx.doi.org/10.1126/science.1109965			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	915BX	15821086				2022-12-28	WOS:000228273700047
J	Alexander, RM				Alexander, RM			Walking made simple	SCIENCE			English	Editorial Material							PASSIVE DYNAMIC WALKING		Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Alexander, RM (corresponding author), Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England.	r.m.alexander@leeds.ac.uk						Alexander R., 1983, ANIMAL MECH; ALEXANDER R. M., 1995, APPL MECH REV, V48, P461, DOI [10.1115/1.3005107, DOI 10.1115/1.3005107]; Collins S, 2005, SCIENCE, V307, P1082, DOI 10.1126/science.1107799; Kuo AD, 1999, INT J ROBOT RES, V18, P917, DOI 10.1177/02783649922066655; Kuo AD, 2002, J BIOMECH ENG-T ASME, V124, P113, DOI 10.1115/1.1427703; Margaria R., 1976, BIOMECHANICS ENERGET; MCGEER T, 1990, INT J ROBOT RES, V9, P62, DOI 10.1177/027836499000900206; PUGH LGCE, 1970, J PHYSIOL-LONDON, V207, P823, DOI 10.1113/jphysiol.1970.sp009097	8	36	40	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					58	59		10.1126/science.1111110	http://dx.doi.org/10.1126/science.1111110			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802589				2022-12-28	WOS:000228221500027
J	Goddard, MR; Godfray, HCJ; Burt, A				Goddard, MR; Godfray, HCJ; Burt, A			Sex increases the efficacy of natural selection in experimental yeast populations	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MEIOSIS-I; RECOMBINATION; FITNESS; EVOLUTION; GENE; CHLAMYDOMONAS; PERSPECTIVE; ADAPTATION; MUTATIONS	Why sex evolved and persists is a problem for evolutionary biology, because sex disrupts favourable gene combinations and requires an expenditure of time and energy(1). Further, in organisms with unequal-sized gametes, the female transmits her genes at only half the rate of an asexual equivalent ( the twofold cost of sex)(2). Many modern theories that provide an explanation for the advantage of sex incorporate an idea originally proposed by Weismann more than 100 years ago: sex allows natural selection to proceed more effectively because it increases genetic variation(3-5). Here we test this hypothesis, which still lacks robust empirical support, with the use of experiments on yeast populations. Capitalizing on recent advances in the molecular biology of recombination in yeast, we produced by genetic manipulation strains that differed only in their capacity for sexual reproduction. We show that, as predicted by the theory, sex increases the rate of adaptation to a new harsh environment but has no measurable effect on fitness in a new benign environment where there is little selection.	Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ascot SL5 7PY, Berks, England	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); Imperial College London	Goddard, MR (corresponding author), Univ Auckland, Sch Biol Sci, Private Bag 92019, Auckland 1, New Zealand.	m.goddard@auckland.ac.nz	Goddard, Matthew/C-7462-2014	Burt, Austin/0000-0001-5146-9640; Goddard, Matthew/0000-0002-7482-4438				BAGANZ F, 1997, YEAST, V13, P1536; BARTON NH, 1995, GENET RES, V65, P123, DOI 10.1017/S0016672300033140; Barton NH, 1998, SCIENCE, V281, P1986, DOI 10.1126/science.281.5385.1986; Bell G., 1982, MASTERPIECE NATURE; BERRY DR, 1982, BIOL YEASTS; Birdsell J, 1996, P NATL ACAD SCI USA, V93, P908, DOI 10.1073/pnas.93.2.908; Bruggeman J, 2003, GENETICS, V164, P479; Burke D., 2000, METHODS YEAST GENETI; Burt A, 2000, EVOLUTION, V54, P337; BURT A, 1995, EVOLUTION, V49, P1, DOI 10.1111/j.1558-5646.1995.tb05954.x; Colegrave N, 2002, NATURE, V420, P664, DOI 10.1038/nature01191; Goho S, 2000, P ROY SOC B-BIOL SCI, V267, P123, DOI 10.1098/rspb.2000.0976; Greig D, 1998, P ROY SOC B-BIOL SCI, V265, P1017, DOI 10.1098/rspb.1998.0393; GREWAL NS, 1972, CAN J MICROBIOL, V18, P1897, DOI 10.1139/m72-295; Kaltz O, 2002, EVOLUTION, V56, P1743; KLAPHOLZ S, 1985, GENETICS, V110, P187; Marini A, 1999, CURR GENET, V35, P77, DOI 10.1007/s002940050435; MICHOD RE, 1988, EVOLUTION SEX EXAMIN; Muller HJ, 1932, AM NAT, V66, P118, DOI 10.1086/280418; Otto SP, 2002, NAT REV GENET, V3, P252, DOI 10.1038/nrg761; Pinheiro J, 2001, MIXED EFFECTS MODELS; Rice WR, 2001, SCIENCE, V294, P555, DOI 10.1126/science.1061380; Rice WR, 2002, NAT REV GENET, V3, P241, DOI 10.1038/nrg760; Shonn MA, 2002, GENE DEV, V16, P1659, DOI 10.1101/gad.975802; STEELE DF, 1991, GENETICS, V127, P53; Wach A, 1998, METHOD MICROBIOL, V26, P67; WANG HT, 1987, MOL CELL BIOL, V7, P1425, DOI 10.1128/MCB.7.4.1425; WEISMANN A, 1904, EVOLUTION THEORY, V2; Zeyl C, 2001, GENETICS, V157, P53	29	312	320	0	271	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 31	2005	434	7033					636	640		10.1038/nature03405	http://dx.doi.org/10.1038/nature03405			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800622				2022-12-28	WOS:000228011000043
J	Saba, M; Pasquini, TA; Sanner, C; Shin, Y; Ketterle, W; Pritchard, DE				Saba, M; Pasquini, TA; Sanner, C; Shin, Y; Ketterle, W; Pritchard, DE			Light scattering to determine the relative phase of two Bose-Einstein condensates	SCIENCE			English	Article							QUANTUM PHASE; ATOMS; INTERFERENCE; TRANSITION; DIFFUSION; ARRAYS; GAS	We demonstrated an experimental technique based on stimulated light scattering to continuously sample the relative phase of two spatially separated Bose-Einstein condensates of atoms. The phase measurement process created a relative phase between two condensates with no initial phase relation, read out the phase, and monitored the phase, evolution. This technique was used to realize interferometry between two trapped Bose-Einstein condensates without need for splitting or recombining the atom cloud.	MIT, Dept Phys, MIT Harvard Ctr Ultracold Atoms, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Saba, M (corresponding author), MIT, Dept Phys, MIT Harvard Ctr Ultracold Atoms, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	msaba@mit.edu	Shin, Yong-il/B-1955-2008; Saba, Michele/M-4239-2013	Shin, Yong-il/0000-0003-0481-9841; Saba, Michele/0000-0001-6416-3122				Anderson BP, 1998, SCIENCE, V282, P1686, DOI 10.1126/science.282.5394.1686; Andrews MR, 1997, SCIENCE, V275, P637, DOI 10.1126/science.275.5300.637; Bloch I, 2000, NATURE, V403, P166, DOI 10.1038/35003132; Castin Y, 1997, PHYS REV A, V55, P4330, DOI 10.1103/PhysRevA.55.4330; Cataliotti FS, 2001, SCIENCE, V293, P843, DOI 10.1126/science.1062612; Chikkatur AP, 2002, SCIENCE, V296, P2193, DOI 10.1126/science.296.5576.2193; Cirac JI, 1996, PHYS REV A, V54, pR3714, DOI 10.1103/PhysRevA.54.R3714; COHENTANNOUDJI C, 1992, LASER SPECTROSCOPY, P3; Dubetsky B, 2002, J MOD OPTIC, V49, P55, DOI 10.1080/09500340110090800; Geremia JM, 2004, SCIENCE, V304, P270, DOI 10.1126/science.1095374; Gupta S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.140401; Hall DS, 1998, PHYS REV LETT, V81, P1543, DOI 10.1103/PhysRevLett.81.1543; IMAMOGLU A, 1997, PHYS REV A, V55, P849; Javanainen J, 1997, PHYS REV LETT, V78, P4675, DOI 10.1103/PhysRevLett.78.4675; Javanainen J, 1996, PHYS REV LETT, V76, P161, DOI 10.1103/PhysRevLett.76.161; Javanainen J, 1996, PHYS REV A, V54, pR4629, DOI 10.1103/PhysRevA.54.R4629; Kasevich MA, 2001, CR ACAD SCI IV-PHYS, V2, P497, DOI 10.1016/S1296-2147(01)01181-7; Kozuma M, 1999, PHYS REV LETT, V82, P871, DOI 10.1103/PhysRevLett.82.871; Naraschewski M, 1996, PHYS REV A, V54, P2185, DOI 10.1103/PhysRevA.54.2185; Orzel C, 2001, SCIENCE, V291, P2386, DOI 10.1126/science.1058149; Pitaevskii L, 1999, PHYS REV LETT, V83, P4237, DOI 10.1103/PhysRevLett.83.4237; RAZEWSKI K, 1992, J PHYS B ATOM MOL PH, V25, pL319; Ruostekoski J, 1997, PHYS REV A, V56, P2996, DOI 10.1103/PhysRevA.56.2996; Shin Y, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.050405; Smerzi A, 1997, PHYS REV LETT, V79, P4950, DOI 10.1103/PhysRevLett.79.4950; Stenger J, 1999, PHYS REV LETT, V82, P4569, DOI 10.1103/PhysRevLett.82.4569; Wheeler J. A., 1983, QUANTUM THEORY MEASU	29	89	90	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 25	2005	307	5717					1945	1948		10.1126/science.1108801	http://dx.doi.org/10.1126/science.1108801			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790851				2022-12-28	WOS:000227957300052
J	Schweitzer, MH; Wittmeyer, JL; Horner, JR; Toporski, JK				Schweitzer, MH; Wittmeyer, JL; Horner, JR; Toporski, JK			Soft-tissue vessels and cellular preservation in Tyrannosaurus rex	SCIENCE			English	Article							DINOSAUR	Soft tissues are preserved within hindlimb elements of Tyrannosaurus rex (Museum of the Rockies specimen 1125). Removal of the mineral phase reveals transparent, flexible, hollow blood vessels containing small round microstructures that can be expressed from the vessels into solution. Some regions of the demineralized bone matrix are highly fibrous, and the matrix possesses elasticity and resilience. Three populations of microstructures have cell-like morphology. Thus, some dinosaurian soft tissues may retain some of their original flexibility, elasticity, and resilience.	N Carolina State Univ, Dept Marine Earth Atmospher Sci, Raleigh, NC 27695 USA; N Carolina State Museum Nat Sci, Raleigh, NC 27601 USA; Montana State Univ, Museum Rockies, Bozeman, MT 59717 USA; Carnegie Inst Sci, Geophys Lab, Washington, DC 20018 USA	University of North Carolina; North Carolina State University; Montana State University System; Montana State University Bozeman; Carnegie Institution for Science	Schweitzer, MH (corresponding author), N Carolina State Univ, Dept Marine Earth Atmospher Sci, Raleigh, NC 27695 USA.	schweitzer@ncsu.edu	schweitzer, mary h/A-6756-2010; Schweitzer, Mary/V-8143-2019	schweitzer, mary h/0000-0002-0427-3829; 				Briggs DEG, 1997, J GEOL SOC LONDON, V154, P587, DOI 10.1144/gsjgs.154.4.0587; Chiappe LM, 1998, NATURE, V396, P258, DOI 10.1038/24370; Dal Sasso C, 1998, NATURE, V392, P383; Hedges REM, 2002, ARCHAEOMETRY, V44, P319, DOI 10.1111/1475-4754.00064; Higby Schweitzer Mary, 1999, Annales de Paleontologie, V85, P179, DOI 10.1016/S0753-3969(99)80013-5; Horner JR, 2004, P ROY SOC B-BIOL SCI, V271, P1875, DOI 10.1098/rspb.2004.2829; Ji Q, 1998, NATURE, V393, P753, DOI 10.1038/31635; Kellner AWA, 1996, NATURE, V379, P32, DOI 10.1038/379032a0; Martill David M., 1995, Neues Jahrbuch fuer Geologie und Palaeontologie Monatshefte, V2, P118; MURPHY NL, 2002, J VERTEBR PALEONTOL, V33, pA91; MUYZER G, 1992, GEOLOGY, V20, P871, DOI 10.1130/0091-7613(1992)020<0871:POTBPO>2.3.CO;2; Pawlicki R, 1998, ANN ANAT, V180, P73, DOI 10.1016/S0940-9602(98)80140-4; PAWLICKI R, 1966, NATURE, V211, P655, DOI 10.1038/211655a0; SCHWEITZER M, UNPUB; Schweitzer MH, 1999, J EXP ZOOL, V285, P146; Schweitzer MH, 1997, P NATL ACAD SCI USA, V94, P6291, DOI 10.1073/pnas.94.12.6291; Sykes GA, 1995, ORG GEOCHEM, V23, P1059, DOI 10.1016/0146-6380(95)00086-0; WEINER S, 1989, APPL GEOCHEM, V4, P231; Wuttke M., 1988, Senckenberg-Buch, V64, P265; Xu X, 1999, NATURE, V401, P262, DOI 10.1038/45769	20	106	128	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1952	1955		10.1126/science.1108397	http://dx.doi.org/10.1126/science.1108397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790853				2022-12-28	WOS:000227957300054
J	Shaywitz, DA; Melton, DA				Shaywitz, DA; Melton, DA			The molecular biography of the cell	CELL			English	Editorial Material							EMBRYONIC STEM-CELLS; DIFFERENTIATION		Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Howard Hughes Medical Institute	Shaywitz, DA (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457,55 Fruit St, Boston, MA 02114 USA.	dshaywitz@mcb.harvard.edu; dmelton@harvard.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Gilbert Scott F, 1994, CONCEPTUAL HIST MODE; GURDON JB, 1962, DEV BIOL, V4, P256, DOI 10.1016/0012-1606(62)90043-X; Herrera PL, 2000, DEVELOPMENT, V127, P2317; Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397; Latham KE, 2004, DIFFERENTIATION, V72, P11, DOI 10.1111/j.1432-0436.2004.07201003.x; Lee KJ, 1999, ANNU REV NEUROSCI, V22, P261, DOI 10.1146/annurev.neuro.22.1.261; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8	11	8	8	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 25	2005	120	6					729	731		10.1016/j.cell.2005.03.002	http://dx.doi.org/10.1016/j.cell.2005.03.002			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797372	Bronze			2022-12-28	WOS:000228067500001
J	Sonnenburg, JL; Xu, J; Leip, DD; Chen, CH; Westover, BP; Weatherford, J; Buhler, JD; Gordon, JI				Sonnenburg, JL; Xu, J; Leip, DD; Chen, CH; Westover, BP; Weatherford, J; Buhler, JD; Gordon, JI			Glycan foraging in vivo by an intestine-adapted bacterial symbiont	SCIENCE			English	Article							HOST-MICROBIAL INTERACTIONS; BACTEROIDES-THETAIOTAOMICRON; ECOSYSTEM; ENVIRONMENT; COMMENSAL; STARCH	Germ-free mice were maintained on polysaccharide-rich or simple-sugar diets and colonized for 10 days with an organism also found in human guts, Bacteroides thetaiotaomicron, followed by whole-genome transcriptional profiling of bacteria and mass spectrometry of cecal glycans. We found that these bacteria assembled on food particles and mucus, selectively induced outer-membrane polysaccharide-binding proteins and glycoside hydrolases, prioritized the consumption of liberated hexose sugars, and revealed a capacity to turn to host mucus glycans when polysaccharides were absent from the diet. This flexible foraging behavior should contribute to ecosystem stability and functional diversity.	Washington Univ, Ctr Genome Sci, St Louis, MO 63108 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63108 USA; Washington Univ, Dept Comp Sci & Engn, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gordon, JI (corresponding author), Washington Univ, Ctr Genome Sci, St Louis, MO 63108 USA.	jgordon@molecool.wustl.edu	Xu, Jian/A-6831-2008; Xu, Jian/G-8430-2012	Xu, Jian/0000-0002-0548-8477	NIDDK NIH HHS [DK052574, DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; Chang DE, 2004, P NATL ACAD SCI USA, V101, P7427, DOI 10.1073/pnas.0307888101; Cho KH, 2001, J BACTERIOL, V183, P7198, DOI 10.1128/JB.183.24.7198-7205.2001; Hooper LV, 1999, P NATL ACAD SCI USA, V96, P9833, DOI 10.1073/pnas.96.17.9833; Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; MOORE WEC, 1974, APPL MICROBIOL, V27, P961, DOI 10.1128/AEM.27.5.961-979.1974; SALYERS AA, 1979, AM J CLIN NUTR, V32, P158, DOI 10.1093/ajcn/32.1.158; SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543; Shipman JA, 2000, J BACTERIOL, V182, P5365, DOI 10.1128/JB.182.19.5365-5372.2000; Sonnenburg JL, 2004, NAT IMMUNOL, V5, P569, DOI 10.1038/ni1079; WESTOVER BP, 2004, BIOINFORMATICS  1111; Xu J, 2003, P NATL ACAD SCI USA, V100, P10452, DOI 10.1073/pnas.1734063100; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029; Yachi S, 1999, P NATL ACAD SCI USA, V96, P1463, DOI 10.1073/pnas.96.4.1463	16	778	815	8	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1955	1959		10.1126/science.1109051	http://dx.doi.org/10.1126/science.1109051			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790854				2022-12-28	WOS:000227957300055
J	Chan, AW; Altman, DG				Chan, AW; Altman, DG			Epidemiology and reporting of randomised trials published in PubMed journals	LANCET			English	Article							CLINICAL-TRIALS; SAMPLE-SIZE; QUALITY	Although randomised trials are important for evidence-based medicine, little is known about their overall characteristics. We assessed the epidemiology and reporting of methodological details for all 519 PubMed-indexed randomised trials published in December, 2000 (383 [74%] parallel-group, 116 [22%] crossover). 482 (93%) were published in specialty journals. A median of 80 participants (10th-90th percentile 25-369) were recruited for parallel-group trials. 309 (60%) were blinded. Power calculation, primary outcomes, random sequence generation, allocation concealment, and handling of attrition were each adequately described in less than half of publications. The small sample sizes are worrying, and poor reporting of methodological characteristics will prevent reliable quality assessment of many published trials.	Canc Res UK NHS, Ctr Stat Med, Oxford, England; Univ Hlth Network, Dept Med, Toronto, ON, Canada	Cancer Research UK; University of Oxford; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Chan, AW (corresponding author), Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada.	anwen.chan@utoronto.ca						DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; Devereaux PJ, 2001, JAMA-J AM MED ASSOC, V285, P2000, DOI 10.1001/jama.285.15.2000; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; MEINERT CL, 1984, CONTROL CLIN TRIALS, V5, P328, DOI 10.1016/S0197-2456(84)80013-6; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Mulward S, 1996, DAN MED BULL, V43, P96; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150	10	343	355	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1159	1162		10.1016/S0140-6736(05)71879-1	http://dx.doi.org/10.1016/S0140-6736(05)71879-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794971				2022-12-28	WOS:000227909500029
J	Lucero, MG; Williams, G				Lucero, MG; Williams, G			Vaccine trial as "probe"" to define the burden of pneumococcal pneumonia disease	LANCET			English	Editorial Material							CONJUGATE VACCINE; CHILDREN; EFFICACY; SAFETY		Res Inst Trop Med, Alabang 1770, Metromanila, Philippines; Univ Queensland, Mayne Med Sch, Sch Populat Hlth, St Lucia, Qld 4006, Australia	Research Institute for Tropical Medicine - Philippines; University of Queensland	Lucero, MG (corresponding author), Res Inst Trop Med, Alabang 1770, Metromanila, Philippines.	mglucero@pldtdsl.net		Williams, Gail/0000-0002-4822-5263				Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/00006454-200209000-00005; CHERIAN T, IN PRESS B WHO; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; LUCERO MG, 2004, COCHRANE LIB; O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6; *WHO DEP VACC BIOL, 2000, VACC TRIAL REG DIR; WHO Pneumonia Vaccine Trial Investigators' Group, 2001, STAND INT CHEST RAD	8	6	6	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR-APR	2005	365	9465					1113	1114		10.1016/S0140-6736(05)71853-5	http://dx.doi.org/10.1016/S0140-6736(05)71853-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794951				2022-12-28	WOS:000227909500004
J	DasGupta, R; Kaykas, A; Moon, RT; Perrimon, N				DasGupta, R; Kaykas, A; Moon, RT; Perrimon, N			Functional genomic analysis of the Wnt-Wingless signaling pathway	SCIENCE			English	Article							BETA-CATENIN; MORPHOGEN GRADIENT; WNT/BETA-CATENIN; DROSOPHILA; PROTEIN; CELL; TRANSDUCTION; REPRESSION; ARMADILLO; FAMILY	The Wnt-Wingless (Wg) pathway is one of a core set of evolutionarily conserved signaling pathways that regulates many aspects of metazoan development. Aberrant Writ signaling has been linked to human disease. In the present study, we used a genomewide RNA interference (RNAi) screen in Drosophila cells to screen for regulators of the Writ pathway. We identified 238 potential regulators, which include known pathway components, genes with functions not previously linked to this pathway, and genes with no previously assigned functions. Reciprocal-Best-Blast analyses reveal that 50% of the genes identified in the screen have human orthologs, of which similar to 18% are associated with human disease. Functional assays of selected genes from the cell-based screen in Drosophila, mammalian cells, and zebrafish embryos demonstrated that these genes have evolutionarily conserved functions in Writ signaling. High-throughput RNAi screens in cultured cells, followed by functional analyses in model organisms, prove to be a rapid means of identifying regulators of signaling pathways implicated in development and disease.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol,Ctr Dev Biol, Seattle, WA 98195 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	DasGupta, R (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, New Res Bldg 339,77 Ave Louis Pasteur, Boston, MA 02115 USA.	rdasgupt@genetics.med.harvard.edu; rtmoon@u.washington.edu; perrimon@receptor.med.harvard.edu	Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Dasgupta, Ramanuj/0000-0001-9015-3729; Perrimon, Norbert/0000-0001-7542-472X				Adams MD, 2002, NAT REV GENET, V3, P189, DOI 10.1038/nrg752; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Baeg GH, 2004, DEV BIOL, V276, P89, DOI 10.1016/j.ydbio.2004.08.023; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Benmerah A, 2004, CURR BIOL, V14, pR314, DOI 10.1016/j.cub.2004.03.053; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Dasgupta R, 2004, ONCOGENE, V23, P8359, DOI 10.1038/sj.onc.1208028; DASGUPTA R, UNPUB; Eggert US, 2004, PLOS BIOL, V2, P2135, DOI 10.1371/journal.pbio.0020379; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Greaves S, 1999, GENETICS, V153, P1753; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Jung CY, 2004, CANCER RES, V64, P3046, DOI 10.1158/0008-5472.CAN-03-2614; KELLY GM, 1995, DEVELOPMENT, V121, P1787; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; LOGAN CY, 2004, ANN REV CELL DEV BIO; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Matsubayashi H, 2004, MOL CELL BIOL, V24, P2012, DOI 10.1128/MCB.24.5.2012-2024.2004; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Miller AS, 2000, IN VITRO CELL DEV-AN, V36, P180; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; MOON RT, UNPUB; MOON RT, 2005, SCI STKE         APR; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nusse R, 1999, TRENDS GENET, V15, P1, DOI 10.1016/S0168-9525(98)01634-5; PEEL DJ, 1990, TISSUE CELL, V22, P749, DOI 10.1016/0040-8166(90)90069-L; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PERRIMON N, 2005, SCI STKE         APR; Polakis P, 2000, GENE DEV, V14, P1837; Ramel MC, 2004, DEVELOPMENT, V131, P3991, DOI 10.1242/dev.01277; Rosenfeld JL, 2002, RECEPTOR CHANNEL, V8, P87, DOI 10.1080/10606820212398; Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201; Schlesinger A, 2004, DEV CELL, V7, P535, DOI 10.1016/j.devcel.2004.09.001; Schweizer L, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-4; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Sinner D, 2004, DEVELOPMENT, V131, P3069, DOI 10.1242/dev.01176; Su MA, 2001, GENETICS, V157, P717; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tang AH, 2001, DEVELOPMENT, V128, P801; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; Wharton KA, 2001, DEV BIOL, V234, P93, DOI 10.1006/dbio.2001.0238; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yanagawa S, 1998, J BIOL CHEM, V273, P32353, DOI 10.1074/jbc.273.48.32353; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087	52	267	288	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 6	2005	308	5723					826	833		10.1126/science.1109374	http://dx.doi.org/10.1126/science.1109374			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924NW	15817814	Green Submitted			2022-12-28	WOS:000228986500041
J	Frebel, A; Aoki, W; Christlieb, N; Ando, H; Asplund, M; Barklem, PS; Beers, TC; Eriksson, K; Fechner, C; Fujimoto, MY; Honda, S; Kajino, T; Minezaki, T; Nomoto, K; Norris, JE; Ryan, SG; Takada-Hidal, MT; Tsangarides, S; Yoshii, Y				Frebel, A; Aoki, W; Christlieb, N; Ando, H; Asplund, M; Barklem, PS; Beers, TC; Eriksson, K; Fechner, C; Fujimoto, MY; Honda, S; Kajino, T; Minezaki, T; Nomoto, K; Norris, JE; Ryan, SG; Takada-Hidal, MT; Tsangarides, S; Yoshii, Y			Nucleosynthetic signatures of the first stars	NATURE			English	Article							METAL-POOR STARS; CARBON-RICH; ABUNDANCE; HE-0107-5240; SUPERNOVAE	The chemically most primitive stars provide constraints on the nature of the first stellar objects that formed in the Universe; elements other than hydrogen, helium and traces of lithium present within these objects were generated by nucleosynthesis in the very first stars. The relative abundances of elements in the surviving primitive stars reflect the masses of the first stars, because the pathways of nucleosynthesis are quite sensitive to stellar masses. Several models(1-5) have been suggested to explain the origin of the abundance pattern of the giant star HE0107 - 5240, which hitherto exhibited the highest deficiency of heavy elements known(1,6). Here we report the discovery of HE1327 - 2326, a subgiant or main-sequence star with an iron abundance about a factor of two lower than that of HE0107 - 5240. Both stars show extreme overabundances of carbon and nitrogen with respect to iron, suggesting a similar origin of the abundance patterns. The unexpectedly low Li and high Sr abundances of HE1327 - 2326, however, challenge existing theoretical understanding: no model predicts the high Sr abundance or provides a Li depletion mechanism consistent with data available for the most metal-poor stars.	Australian Natl Univ, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia; Natl Astron Observ Japan, Tokyo 1818588, Japan; Hamburger Sternwarte, D-21029 Hamburg, Germany; Uppsala Astron Observ, Dept Phys & Space Sci, SE-75120 Uppsala, Sweden; Michigan State Univ, Dept Phys & Astron, E Lansing, MI 48824 USA; Michigan State Univ, JINA, E Lansing, MI 48824 USA; Hokkaido Univ, Dept Phys, Sapporo, Hokkaido 0600810, Japan; Univ Tokyo, Sch Sci, Inst Astron, Tokyo 1810015, Japan; Univ Tokyo, Sch Sci, Dept Astron, Tokyo 1130033, Japan; Open Univ, Dept Phys & Astron, Milton Keynes MK7 6AA, Bucks, England; Tokai Univ, Liberal Arts Educ Ctr, Hiratsuka, Kanagawa 2591292, Japan	Australian National University; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); University of Hamburg; Uppsala University; Michigan State University; Michigan State University; Hokkaido University; University of Tokyo; University of Tokyo; Open University - UK; Tokai University	Frebel, A (corresponding author), Australian Natl Univ, Res Sch Astron & Astrophys, Cotter Rd, Weston, ACT 2611, Australia.	anna@mso.anu.edu.au	Beers, Timothy/D-1193-2019	Ryan, Sean/0000-0001-9069-5122; Christlieb, Norbert/0000-0002-4043-2727; Asplund, Martin/0000-0002-5804-3682				Alonso A, 1996, ASTRON ASTROPHYS, V313, P873; Aoki W, 2000, ASTROPHYS J, V536, pL97, DOI 10.1086/312740; ASPLUND M, 2004, IN PRESS ASP C SER; ASPLUND M, IN PREV ANN REV ASTR; Beers TC, 1999, ASTRON J, V117, P981, DOI 10.1086/300727; BEERS TC, IN PRESS ANN REV AST; Bessmertnyi VS, 2004, GLASS CERAM+, V61, P63, DOI 10.1023/B:GLAC.0000026777.25013.59; Christlieb N, 2004, ASTRON ASTROPHYS, V428, P1027, DOI 10.1051/0004-6361:20041536; Coc A, 2004, ASTROPHYS J, V600, P544, DOI 10.1086/380121; Cutri R. M., 2003, 2MASS ALL SKY CATALO; Fryer CL, 2001, ASTROPHYS J, V550, P372, DOI 10.1086/319719; Girard TM, 2004, ASTRON J, V127, P3060, DOI 10.1086/383545; Kim YC, 2002, ASTROPHYS J SUPPL S, V143, P499, DOI 10.1086/343041; Kurucz R. L., 1993, ATLAS9 STELLAR ATMOS; Limongi M, 2003, ASTROPHYS J, V594, pL123, DOI 10.1086/378734; Noguchi K, 2002, PUBL ASTRON SOC JPN, V54, P855, DOI 10.1093/pasj/54.6.855; Norris JE, 1997, ASTROPHYS J, V485, P370, DOI 10.1086/304390; Pinsonneault MH, 1999, ASTROPHYS J, V527, P180, DOI 10.1086/308048; Richard O, 2002, ASTROPHYS J, V580, P1100, DOI 10.1086/343733; Ryan SG, 1999, ASTROPHYS J, V523, P654, DOI 10.1086/307769; Ryan SG, 2002, ASTROPHYS J, V571, P501, DOI 10.1086/339939; Shigeyama T, 2003, ASTROPHYS J, V586, pL57, DOI 10.1086/374635; Suda T, 2004, ASTROPHYS J, V611, P476, DOI 10.1086/422135; Travaglio C, 2004, ASTROPHYS J, V601, P864, DOI 10.1086/380507; Umeda H, 2003, NATURE, V422, P871, DOI 10.1038/nature01571; Wisotzki L, 2000, ASTRON ASTROPHYS, V358, P77; YOSHII Y, 1981, ASTRON ASTROPHYS, V97, P280; YOSHII Y, 2002, NEW TRENDS THEORETIC, P235	30	490	495	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					871	873		10.1038/nature03455	http://dx.doi.org/10.1038/nature03455			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829957	Green Submitted			2022-12-28	WOS:000228327600033
J	Freitas-Junior, LH; Hernandez-Rivas, R; Ralph, SA; Montiel-Condado, D; Ruvalcaba-Salazar, OK; Rojas-Meza, AP; Mancio-Silva, L; Leal-Silvestre, RJ; Gontijo, AM; Shorte, S; Scherf, A				Freitas-Junior, LH; Hernandez-Rivas, R; Ralph, SA; Montiel-Condado, D; Ruvalcaba-Salazar, OK; Rojas-Meza, AP; Mancio-Silva, L; Leal-Silvestre, RJ; Gontijo, AM; Shorte, S; Scherf, A			Telomeric heterochromatin propagation and histone acetylation control mutually exclusive expression of antigenic variation genes in malaria parasites	CELL			English	Article							PLASMODIUM-FALCIPARUM; GENOME SEQUENCE; VARIANT ANTIGEN; TRANSCRIPTION; RECOMBINATION; ERYTHROCYTES; PROTEINS; ORGANIZATION; COMPARTMENT; PHENOTYPES	Malaria parasites use antigenic variation to avoid immune clearance and increase the duration of infection in the human host. Variation at the surface of P. falciparurn-infected erythrocytes is mediated by the differential control of a family of surface antigens encoded by var genes. Switching of var gene expression occurs in situ, mostly from telomere-associated loci, without detectable DNA alterations, suggesting that it is controlled by chromatin structure. We have identified chromatin modifications at telomeres that spread far into telomere-proximal regions, including var gene loci (> 50 kb). One type of modification is mediated by a protein homologous to yeast Sir2 called PfSir2, which forms a chromosomal gradient of heterochromatin structure and histone hypoacetylation. Upon activation of a specific telomere-associated var gene, PfSir2 is removed from the promoter region and acetylation of histone occurs. Our data demonstrate that mutually exclusive transcription of var genes is linked to the dynamic remodeling of chromatin.	Inst Pasteur, Biol Host Parasite Interact Unit, CNRS, URA2581, F-75724 Paris, France; Dynam Imaging Platform, F-75724 Paris, France; IPN, Dept Mol Biomed, Ctr Invest & Estudios Avanzados, Mexico City 07360, DF, Mexico	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Scherf, A (corresponding author), Inst Pasteur, Biol Host Parasite Interact Unit, CNRS, URA2581, 25 Rue Dr Roux, F-75724 Paris, France.	ascherf@pasteur.fr	Silvestre, Ricardo/C-7243-2011; Mancio-Silva, Liliana/F-9905-2013; Scherf, Artur/A-9674-2014; Freitas-Junior, Lucio H/C-8677-2011; Silva, Liliana Mancio/AAB-2192-2020; Gontijo, Alisson/G-6719-2011; Ralph, Stuart/C-8590-2014	Silvestre, Ricardo/0000-0002-9270-2717; Mancio-Silva, Liliana/0000-0002-5585-018X; Freitas-Junior, Lucio H/0000-0002-8904-7897; Silva, Liliana Mancio/0000-0002-5585-018X; Gontijo, Alisson/0000-0002-2530-3708; Scherf, Artur/0000-0003-2411-3328; Shorte, Spencer/0000-0002-2125-8663; MONTIEL CONDADO, DVORAK/0000-0003-0338-2764; Ralph, Stuart/0000-0003-0114-7808				Al-Khedery B, 1999, MOL CELL, V3, P131, DOI 10.1016/S1097-2765(00)80304-4; Andrews KT, 2003, MOL MICROBIOL, V49, P655, DOI 10.1046/j.1365-2958.2003.03595.x; Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; BOZDECH Z, 2003, PLOS BIOL, V109; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Deitsch KW, 1999, MOL BIOCHEM PARASIT, V101, P107, DOI 10.1016/S0166-6851(99)00062-6; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118; Duraisingh MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036; Fan Q, 2004, EUKARYOT CELL, V3, P264, DOI 10.1128/EC.3.2.264-276.2004; Figueiredo LM, 2000, MOL BIOCHEM PARASIT, V106, P169, DOI 10.1016/S0166-6851(99)00199-1; Figueiredo LM, 2005, NUCLEIC ACIDS RES, V33, P1111, DOI 10.1093/nar/gki260; Figueiredo LM, 2002, EMBO J, V21, P815, DOI 10.1093/emboj/21.4.815; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Healer J, 2002, INFECT IMMUN, V70, P5751, DOI 10.1128/IAI.70.10.5751-5758.2002; Hediger F, 2002, NAT CELL BIOL, V4, pE53, DOI 10.1038/ncb0302-e53; Horrocks P, 2004, MOL BIOCHEM PARASIT, V134, P193, DOI 10.1016/j.molbiopara.2003.11.016; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaviratne Mallika, 2003, P291, DOI 10.1016/B978-012194851-1/50039-1; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673; LANZER M, 1992, NUCLEIC ACIDS RES, V20, P3051, DOI 10.1093/nar/20.12.3051; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Navarro M, 2001, NATURE, V414, P759, DOI 10.1038/414759a; PRENSIER G, 1986, J PARASITOL, V72, P731, DOI 10.2307/3281465; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; Sambrook J, 1988, MOL CLONING LAB MANU; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Scherf A, 2001, CURR OPIN MICROBIOL, V4, P409, DOI 10.1016/S1369-5274(00)00227-7; Shankaranarayana GD, 2003, CURR BIOL, V13, P1240, DOI 10.1016/S0960-9822(03)00489-5; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Taylor HM, 2000, MOL BIOCHEM PARASIT, V110, P391, DOI 10.1016/S0166-6851(00)00286-3; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Voss TS, 2003, MOL MICROBIOL, V48, P1593, DOI 10.1046/j.1365-2958.2003.03528.x; Voss TS, 2000, MOL BIOCHEM PARASIT, V107, P103, DOI 10.1016/S0166-6851(00)00176-6; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045	47	376	387	0	30	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 8	2005	121	1					25	36		10.1016/j.cell.2005.01.037	http://dx.doi.org/10.1016/j.cell.2005.01.037			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820676	Bronze			2022-12-28	WOS:000228348500007
J	Pinter, N				Pinter, N			Environment - One step forward, two steps back on US floodplains	SCIENCE			English	Editorial Material							UNITED-STATES; FLOOD; PRECIPITATION; TRENDS; RIVER		So Illinois Univ, Dept Geol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University	Pinter, N (corresponding author), So Illinois Univ, Dept Geol, Carbondale, IL 62901 USA.	npinter@geo.siu.edu						BELT CB, 1975, SCIENCE, V189, P681, DOI 10.1126/science.189.4204.681; BRADLEY SE, COMMUNICATION; Criss RE, 2001, GEOLOGY, V29, P875, DOI 10.1130/0091-7613(2001)029<0875:FETFC>2.0.CO;2; DYHOUSE GR, 1995, US ARMY CORPS ENG NE, V32, P6; *GEN ACC OFF, 1995, GAORCED95125; Groisman PY, 2001, B AM METEOROL SOC, V82, P219, DOI 10.1175/1520-0477(2001)082&lt;0219:HPAHSI&gt;2.3.CO;2; HIPPLE JD, IN PRESS LANDSC URBA; Humphreys Benjamin G., 1914, FLOODS LEVEES MISSIS; *INT FLOODPL MAN R, 1994, SCI FLOODPL MAN 21 C; Interagency Floodplain Management Review Committee, 1994, SHAR CHALL FLOODPL M; LARSON L, 2001, NAT HAZARDS REV, V2, P171; LEAVENWORTH S, 2004, SACRAMENTO BEE  0412, pA1; Milly PCD, 2002, NATURE, V415, P514, DOI 10.1038/415514a; Mount J.F., 1995, CALIFORNIA RIVERS ST; MYERS MF, 1993, ENVIRONMENT, V35, P6, DOI 10.1080/00139157.1993.9929131; *NAT RES COUNC COM, 1982, LEV POL NAT FLOOD IN; Pielke RA, 2000, J CLIMATE, V13, P3625, DOI 10.1175/1520-0442(2000)013<3625:PADFTI>2.0.CO;2; Pinter N, 2005, J HYDROL, V302, P70, DOI 10.1016/j.jhydrol.2004.06.039; Pinter N, 2001, NATO ASI 2, V78, P113; Pinter N.R., 2001, EOS T AM GEOPHYS UN, V82, P333, DOI [DOI 10.1029/01EO00199, 10.1029/01EO00199]; Plate EJ, 2001, WATER INT, V26, P51; SHIPLEY S, 2003, ST LOUIS POST D 0427, pA1; SILVA W, 2001, ROOM RHINE BRANCHES; SUTER CR, 1995, EFFECTS RECENT LEVEE; TOBIN GA, 1995, WATER RESOUR BULL, V31, P359, DOI 10.1111/j.1752-1688.1995.tb04025.x; TOWSEND CM, 1914, FLOODS LEVEES MISSIS; van Leussen W, 2000, NEW APPROACHES TO RIVER MANAGEMENT, P287; Van Stokkom H.T.C., 2002, FLOOD DEFENCE 2002, V1, P34	28	104	104	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					207	208		10.1126/science.1108411	http://dx.doi.org/10.1126/science.1108411			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821076				2022-12-28	WOS:000228273700035
J	Gould, MS; Marrocco, FA; Kleinman, M; Thomas, JG; Mostkoff, K; Cote, J; Davies, M				Gould, MS; Marrocco, FA; Kleinman, M; Thomas, JG; Mostkoff, K; Cote, J; Davies, M			Evaluating iatrogenic risk of youth suicide screening programs - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIAGNOSTIC INTERVIEW SCHEDULE; MEXICAN-AMERICAN ADOLESCENTS; BECK DEPRESSION INVENTORY; HIGH-SCHOOL-STUDENTS; PREVENTION PROGRAMS; IDEATION QUESTIONNAIRE; DRUG-USE; AWARENESS CURRICULUM; TREATING DEPRESSION; MAJOR DEPRESSION	Context Universal screening for mental health problems and suicide risk is at the forefront of the national agenda for youth suicide prevention, yet no study has directly addressed the potential harm of suicide screening. Objective To examine whether asking about suicidal ideation or behavior during a screening program creates distress or increases suicidal ideation among high school students generally or among high-risk students reporting depressive symptoms, substance use problems, or suicide attempts. Design, Setting, and Participants A randomized controlled study conducted within the context of a 2-day screening strategy. Participants were 2342 students in 6 high schools in New York State in 2002-2004. Classes were randomized to an experimental group (n = 1172), which received the first survey with suicide questions, or to a control group (n = 1170), which did not receive suicide questions. Main Outcome Measures Distress measured at the end of the first survey and at the beginning of the second survey 2 days after the first measured on the Profile of Mood States adolescent version (POMS-A) instrument. Suicidal ideation assessed in the second survey. Results Experimental and control groups did not differ on distress levels immediately after the first survey (mean [SD] POMS-A score, 5.5 [9.7] in the experimental group and 5.1 [10.0] in the control group; P = .66) or 2 days later (mean [SD] POMS-A score, 4.3 [9.0] in the experimental group and 3.9 [9.4] in the control group; P = .41), nor did rates of depressive feelings differ (13.3% and 11.0%, respectively; P = .19). Students exposed to suicide questions were no more likely to report suicidal ideation after the survey than unexposed students (4.7% and 3.9%, respectively; P = .49). High-risk students (defined as those with depression symptoms, substance use problems, or any previous suicide attempt) in the experimental group were neither more suicidal nor distressed than high-risk youth in the control group; on the contrary, depressed students and previous suicide attempters in the experimental group appeared less distressed (P = .01) and suicidal (P = .02), respectively, than high-risk control students. Conclusions No evidence of iatrogenic effects of suicide screening emerged. Screening in high schools is a safe component of youth suicide prevention efforts.	New York State Psychiat Inst & Hosp, New York, NY 10032 USA; Columbia Univ, Div Child & Adolescent Psychiat, New York, NY USA; Columbia Univ, Dept Epidemiol, New York, NY USA	New York State Psychiatry Institute; Columbia University; Columbia University	Gould, MS (corresponding author), New York State Psychiat Inst & Hosp, 1051 Riverside Dr, New York, NY 10032 USA.	gouldm@childpsych.columbia.edu		Gould, Madelyn/0000-0002-2881-9152	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH064632] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH64632] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABBEY KJ, 1989, SUICIDE LIFE-THREAT, V19, P216; Altman DG, 1998, ENCY BIOSTATISTICS, P1000; Aseltine R., 2003, ADOLESCENT FAMILY HL, V3, P81; Aseltine RH, 2004, AM J PUBLIC HEALTH, V94, P446, DOI 10.2105/AJPH.94.3.446; Beck A, 1993, MANUAL BECK DEPRESSI; Berg AO, 2004, ANN INTERN MED, V140, P820, DOI 10.7326/0003-4819-140-10-200405180-00014; Berger BG, 1997, PERCEPT MOTOR SKILL, V84, P1199, DOI 10.2466/pms.1997.84.3c.1199; Brent DA, 2004, NEW ENGL J MED, V351, P1598; Brent DA, 1999, J AM ACAD CHILD PSY, V38, P1497, DOI 10.1097/00004583-199912000-00010; CIFFONE J, 1993, SOC WORK, V38, P197; *COL U, TEENSCREEN; COSTELLO EJ, 1993, J AM ACAD CHILD PSY, V32, P1106, DOI 10.1097/00004583-199311000-00002; Doron A, 1998, SUICIDE LIFE-THREAT, V28, P309; FABRE LF, 1995, BIOL PSYCHIAT, V38, P592, DOI 10.1016/0006-3223(95)00178-8; Fekete S., 1995, IMPACT SUICIDE, P142; FERGUSON E, HOUSE EXPECTED PASS; Gaynes BN, 2004, ANN INTERN MED, V140, P822, DOI 10.7326/0003-4819-140-10-200405180-00015; Gould MS, 2003, J AM ACAD CHILD PSY, V42, P386, DOI 10.1097/01.CHI.0000046821.95464.CF; Gould MS, 2004, J AM ACAD CHILD PSY, V43, P1124, DOI 10.1097/01.chi.0000132811.06547.31; Gould MS, 2001, ANN NY ACAD SCI, V932, P200; Gould MS, 1998, J AM ACAD CHILD PSY, V37, P915, DOI 10.1097/00004583-199809000-00011; Groholt B, 1998, J AM ACAD CHILD PSY, V37, P473, DOI 10.1097/00004583-199805000-00008; Hazell P, 1996, AUST NZ J PSYCHIAT, V30, P633, DOI 10.3109/00048679609062659; Hovey JD, 1998, PSYCHOL REP, V83, P249, DOI 10.2466/PR0.83.5.249-250; ITIL TM, 1983, BR J CLIN PHARM, V15, P4335; KALAFAT J, 1995, SUICIDE LIFE-THREAT, V25, P123; KALAFAT J, 1994, SUICIDE LIFE-THREAT, V24, P224; KASHANI JH, 1989, J AM ACAD CHILD PSY, V28, P912, DOI 10.1097/00004583-198911000-00016; Keane EM, 1996, J ABNORM CHILD PSYCH, V24, P735, DOI 10.1007/BF01664737; King CA, 1996, J AM ACAD CHILD PSY, V35, P743, DOI 10.1097/00004583-199606000-00014; KING CA, 1993, J AM ACAD CHILD PSY, V32, P82, DOI 10.1097/00004583-199301000-00012; King CA, 1997, J ABNORM CHILD PSYCH, V25, P173, DOI 10.1023/A:1025739730823; KIRISCI L, 1995, ADDICT BEHAV, V20, P149, DOI 10.1016/0306-4603(94)00058-1; KIRISCI L, 1994, ALCOHOL CLIN EXP RES, V18, P1335, DOI 10.1111/j.1530-0277.1994.tb01433.x; KRAEMER RR, 1990, J SPORT MED PHYS FIT, V30, P241; Lucas CP, 1999, J ABNORM CHILD PSYCH, V27, P429, DOI 10.1023/A:1021975824957; Lydiard RB, 1997, J CLIN PSYCHIAT, V58, P484, DOI 10.4088/JCP.v58n1104; Mazza JJ, 1999, J ABNORM CHILD PSYCH, V27, P203, DOI 10.1023/A:1021900423004; Mazza JJ, 2000, SUICIDE LIFE-THREAT, V30, P91; McNair D.M., 1992, POMS MANUAL PROFILE; McNair D.M., 1971, MANUAL PROFILES MOOD; MEEHAN PJ, 1992, AM J PSYCHIAT, V149, P41; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; NEWCOMBE PA, 1995, INT J SPORT PSYCHOL, V26, P277; Newman TB, 2004, NEW ENGL J MED, V351, P1595; NORCROSS JC, 1984, J CLIN PSYCHOL, V40, P1270, DOI 10.1002/1097-4679(198409)40:5<1270::AID-JCLP2270400526>3.0.CO;2-7; OVERHOLSER JC, 1989, J AM ACAD CHILD PSY, V28, P925, DOI 10.1097/00004583-198911000-00018; President's New Freedom Commission on Mental Health, 2003, ACH PROM TRANSF MENT; Rasmussen KM, 1997, J EARLY ADOLESCENCE, V17, P390, DOI 10.1177/0272431697017004003; Reynolds W., 1988, SIQ PROFESSIONAL MAN; Reynolds WM, 1999, SCHOOL PSYCHOL REV, V28, P17; REYNOLDS WM, 1990, PSYCHOL ASSESSMENT J, V2, P382, DOI DOI 10.1037/1040-3590.2.4.382; REYNOLDS WM, 1991, FAM COMMUNITY HEALTH, V14, P64; RHOADES HM, 1993, PSYCHOPHARMACOL BULL, V29, P263; ROBERTS RE, 1991, J AM ACAD CHILD PSY, V30, P58, DOI 10.1097/00004583-199101000-00009; Schmidtke A, 2000, INT HDB SUICIDE ATTE, P675; *SCREEN MENT HLTH, SIGNS SUIC; SHAFFER D, 1990, JAMA-J AM MED ASSOC, V264, P3151, DOI 10.1001/jama.264.24.3151; SHAFFER D, 1991, J AM ACAD CHILD PSY, V30, P588, DOI 10.1097/00004583-199107000-00010; Shaffer D, 1996, ARCH GEN PSYCHIAT, V53, P339; Shaffer D, 2000, J AM ACAD CHILD PSY, V39, P28, DOI 10.1097/00004583-200001000-00014; Shaffer D, 1999, J CLIN PSYCHIAT, V60, P70; Shaffer D, 2004, J AM ACAD CHILD PSY, V43, P71, DOI 10.1097/00004583-200401000-00016; SIBTHORPE B, 1995, AUST NZ J PSYCHIAT, V29, P248, DOI 10.3109/00048679509075917; SIEMEN JR, 1994, PSYCHOL REP, V75, P947, DOI 10.2466/pr0.1994.75.2.947; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9; SPIRITO A, 1988, J AM ACAD CHILD PSY, V27, P705, DOI 10.1097/00004583-198811000-00007; Stack S, 2000, SOC SCI QUART, V81, P957; STEPTOE A, 1988, HEALTH PSYCHOL, V7, P329, DOI 10.1037/0278-6133.7.4.329; STROBER M, 1981, J CONSULT CLIN PSYCH, V49, P482, DOI 10.1037/0022-006X.49.3.482; TARTER R, 1992, PSYCHOL ADDICT BEHAV, V6, P233, DOI DOI 10.1037/H0080632; Tarter R.E., 1991, ALCOHOL HEALTH RES W, V15, P65; Tarter R. E., 1994, J CHILD ADOLES SUBST, V3, P25; TARTER RE, 1995, DRUG ALCOHOL DEPEN, V39, P15, DOI 10.1016/0376-8716(95)01129-M; TARTER RE, 1990, AM J DRUG ALCOHOL AB, V16, P1, DOI 10.3109/00952999009001570; Tarter RE, 1997, AM J ADDICTION, V6, P150; TERI L, 1982, J ABNORM CHILD PSYCH, V10, P277, DOI 10.1007/BF00915946; Terry PC, 1999, J SPORT SCI, V17, P861, DOI 10.1080/026404199365425; Thompson EA, 1999, J AM ACAD CHILD PSY, V38, P1506, DOI 10.1097/00004583-199912000-00011; USALA PD, 1989, RES AGING, V11, P403, DOI 10.1177/0164027589114001; VELEZ CN, 1988, J AM ACAD CHILD PSY, V27, P349, DOI 10.1097/00004583-198805000-00014; VIELAND V, 1991, J AM ACAD CHILD PSY, V30, P811, DOI 10.1016/S0890-8567(10)80021-8	82	313	314	0	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2005	293	13					1635	1643		10.1001/jama.293.13.1635	http://dx.doi.org/10.1001/jama.293.13.1635			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913EV	15811983	Bronze			2022-12-28	WOS:000228135300026
J	Friedrich, JO; Adhikari, N; Herridge, MS; Beyene, J				Friedrich, JO; Adhikari, N; Herridge, MS; Beyene, J			Meta-analysis: Low-dose dopamine increases urine output but does not prevent renal dysfunction or death	ANNALS OF INTERNAL MEDICINE			English	Review							CONGESTIVE-HEART-FAILURE; PATENT DUCTUS-ARTERIOSUS; CRITICALLY-ILL PATIENTS; RESPIRATORY-DISTRESS-SYNDROME; GLOMERULAR-FILTRATION-RATE; RISK SURGICAL-PATIENTS; SPLANCHNIC BLOOD-FLOW; INTENSIVE-CARE-UNIT; DOUBLE-BLIND TRIAL; CARDIOPULMONARY BYPASS	Background: Surveys have documented the continued popularity of low-dose dopamine to influence renal dysfunction even though few data support it and editorials and reviews have discouraged its use. Purpose: To evaluate the effects of low-dose dopamine (<= 5 mu g/kg of body weight per minute) compared with placebo or no therapy in patients with or at risk for acute renal failure. Data Sources: MEDLINE (1966-January 2005), EMBASE (1980week 5, 2005), CANCERLIT (1975-2002), CINAHL (1982-January 2005), and CENTRAL (The Cochrane Library, fourth quarter, 2004); bibliographies of retrieved publications; and additional information from 50 trials. Study Selection: Two reviewers independently selected parallel group randomized and quasi -randomized controlled trials of lowdose dopamine versus control. Data Extraction: Study methods, clinical and renal physiologic outcomes, and adverse events (arrhythmias and myocardial, limb, and cutaneous ischemia) were extracted. Data Synthesis: 61 trials that randomly assigned 3359 patients were identified. Meta-analyses using random-effects models showed no effect of low-dose dopamine on mortality (relative risk, 0.96 [95% Cl, 0.78 to 1.191), need for renal replacement therapy (relative risk, 0.93 [Cl, 0.76 to 1.151), or adverse events (relative risk, 1.13 [Cl, 0.90 to 1.41]). Low-dose dopamine increased urine output by 24% (Cl, 14% to 35%) on day 1. Improvements in serum creatinine level (4% relative decrease [CI, 1% to 7%]) and measured creatinine clearance (6% relative increase [Cl, 1% to 11%]) on day 1 were clinically insignificant. There were no significant changes on days 2 and 3 of therapy. Limitations: Statistically significant between-study heterogeneity in physiologic but not clinical outcomes was unexplained by prespecified hypotheses. Conclusion: Low-dose dopamine offers transient improvements in renal physiology, but no good evidence shows that it offers important clinical benefits to patients with or at risk for acute renal failure.	Univ Toronto, St Michaels Hosp, Toronto Gen Hosp,Hosp Sick Children, Univ Hlth Network,Sunnybrook & Womens Coll Hlth S, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Saint Michaels Hospital Toronto; Sunnybrook Health Science Center; University Health Network Toronto; Toronto General Hospital	Friedrich, JO (corresponding author), Univ Toronto, St Michaels Hosp, Toronto Gen Hosp,Hosp Sick Children, Univ Hlth Network,Sunnybrook & Womens Coll Hlth S, 30 Bond St,Bond Wing 4-011, Toronto, ON M5B 1W8, Canada.	j.friedrich@utoronto.ca		Friedrich, Jan/0000-0001-7248-2350; Herridge, Margaret/0000-0002-2903-1631				Abizaid AS, 1999, AM J CARDIOL, V83, P260, DOI 10.1016/S0002-9149(98)00833-9; Antonucci F, 1996, NEPHRON, V74, P668, DOI 10.1159/000189472; Armitage P, 2002, STAT METHODS MED RES, P147; Baenziger O, 1999, KLIN PADIATR, V211, P438, DOI 10.1055/s-2008-1043829; BALDWIN L, 1994, ANN INTERN MED, V120, P744, DOI 10.7326/0003-4819-120-9-199405010-00004; Barrington K, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.Cd003213, DOI 10.1002/14651858.CD003213]; Bellomo R, 2000, LANCET, V356, P2139; BennettGuerrero E, 1996, JAMA-J AM MED ASSOC, V275, P687, DOI 10.1001/jama.275.9.687; Berlin JA, 2002, STAT MED, V21, P371, DOI 10.1002/sim.1023; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; Biancofiore G, 2004, LIVER TRANSPLANT, V10, P986, DOI 10.1002/lt.20145; BICIK Z, 2000, 37 C EUR REN ASS EUR, P107; BIRNBAUM DE, 1991, Z KARDIOL, V80, P47; BIRNBAUM DE, 1990, CARDIOLOGY, V77, P34, DOI 10.1159/000174669; Brause M., 2001, Intensivmedizin und Notfallmedizin, V38, P451, DOI 10.1007/s003900170042; CAGLIKULEKCI M, 1998, TURKISH J SURG, V14, P230; Camp MJ, 1998, ANTIMICROB AGENTS CH, V42, P3103, DOI 10.1128/AAC.42.12.3103; Carcoana OV, 2003, ANESTH ANALG, V97, P1222, DOI 10.1213/01.ANE.0000086727.42573.A8; CARMELLINI M, 1994, TRANSPLANT P, V26, P2626; Cason DL, 1999, J INVEST MED, V47, p119A; CHAIYAROJ S, 1999, ASIAN CARDIOVASC THO, V7, P9; Chazot C, 1987, NEPHROL DIAL TRANSPL, V2, P460; Chertow GM, 1996, AM J MED, V101, P49, DOI 10.1016/S0002-9343(96)00075-7; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; Cochrane H, 2001, PROSTHET ORTHOT INT, V25, P21, DOI 10.1080/03093640108726564; Cormier JN, 1997, J IMMUNOTHER, V20, P292, DOI 10.1097/00002371-199707000-00006; Corwin HL, 2000, CRIT CARE MED, V28, P1657, DOI 10.1097/00003246-200005000-00072; Costa P, 1990, J Cardiothorac Anesth, V4, P469, DOI 10.1016/0888-6296(90)90293-O; Cotter G, 1997, CLIN PHARMACOL THER, V62, P187, DOI 10.1016/S0009-9236(97)90067-9; Cregg N, 1999, PAEDIATR ANAESTH, V9, P505, DOI 10.1046/j.1460-9592.1999.00043.x; CUEVAS L, 1991, AM J DIS CHILD, V145, P799; DAVIS RF, 1982, CRIT CARE MED, V10, P852, DOI 10.1097/00003246-198212000-00009; Debaveye YA, 2004, ANESTH ANALG, V98, P461, DOI 10.1213/01.ANE.0000096188.35789.37; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; DELASSON L, 1995, EUR J VASC ENDOVASC, V10, P82, DOI 10.1016/S1078-5884(05)80202-3; DELOSANGELES A, 1985, KIDNEY INT, V27, P339; Denton MD, 1996, KIDNEY INT, V50, P4, DOI 10.1038/ki.1996.280; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diez T, 1999, MEDICINA-BUENOS AIRE, V59, P55; DISESSA TG, 1981, J PEDIATR-US, V99, P772, DOI 10.1016/S0022-3476(81)80409-X; Dive A, 2000, INTENS CARE MED, V26, P901, DOI 10.1007/s001340051279; Donmez A, 1999, TRANSPLANT P, V31, P3305, DOI 10.1016/S0041-1345(99)00736-8; DUKE GJ, 1994, CRIT CARE MED, V22, P1919; Dunning Joel, 2004, Interact Cardiovasc Thorac Surg, V3, P114, DOI 10.1016/S1569-9293(03)00230-5; Dural O, 2000, TURK J MED SCI, V30, P453; FAJARDO CA, 1992, J PEDIATR-US, V121, P771, DOI 10.1016/S0022-3476(05)81914-6; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; Galley HF, 2000, LANCET, V356, P2112, DOI 10.1016/S0140-6736(00)03484-X; Garcia MS, 2001, LANCET, V357, P1707, DOI 10.1016/S0140-6736(00)04839-X; GARCIA MS, 2004, EFFECT TORSEMIDE DOP; GARDEBACK M, 1995, ACTA ANAESTH SCAND, V39, P1066, DOI 10.1111/j.1399-6576.1995.tb04231.x; Gare M, 1999, J AM COLL CARDIOL, V34, P1682, DOI 10.1016/S0735-1097(99)00422-2; Gatot I, 2004, J CARDIAC SURG, V19, P128, DOI 10.1111/j.0886-0440.2004.04044.x; GOLDBERG LI, 1963, NEW ENGL J MED, V269, P1060, DOI 10.1056/NEJM196311142692003; GRAY PA, 1991, ANAESTHESIA, V46, P638, DOI 10.1111/j.1365-2044.1991.tb09711.x; GRUNDMANN R, 1982, KLIN WOCHENSCHR, V60, P193, DOI 10.1007/BF01715586; HALL KA, 1992, J SURG RES, V53, P317, DOI 10.1016/0022-4804(92)90054-4; HANS B, 1990, RADIOLOGY, V176, P651, DOI 10.1148/radiology.176.3.2202010; Hans SS, 1998, AM SURGEON, V64, P432; Hansen JM, 1996, SCAND J CLIN LAB INV, V56, P367, DOI 10.3109/00365519609090589; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Holmes CL, 2003, CHEST, V123, P1266, DOI 10.1378/chest.123.4.1266; HUNT R, COCHRANE DATABASE SY; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; JONES TJJ, 2004, 98672577 ISRCTN; Juste RN, 1998, INTENS CARE MED, V24, P1217, DOI 10.1007/s001340050747; KADIEVA VS, 1993, ANESTH ANALG, V76, P362; Kapoor A, 1996, INT J CARDIOL, V53, P233, DOI 10.1016/0167-5273(95)02547-2; Kasaba T, 2000, CAN J ANAESTH, V47, P237, DOI 10.1007/BF03018919; Katz Denise Varella, 2003, Rev. Assoc. Med. Bras., V49, P317, DOI 10.1590/S0104-42302003000300038; Kawano Tetsuro, 1993, Japanese Journal of Fertility and Sterility, V38, P55; Keiseb J, 2002, HYPERTENS PREGNANCY, V21, P225, DOI 10.1081/PRG-120016787; Kellum JA, 2001, CRIT CARE MED, V29, P1526, DOI 10.1097/00003246-200108000-00005; Kimura Takashi, 2002, Masui, V51, P286; Lassnigg A, 2000, J AM SOC NEPHROL, V11, P97, DOI 10.1681/ASN.V11197; LAUSCHKE A, 2001, NEPHROL DIAL TRANSPL, V12, pA173; LAUWERS JB, 1994, J CARDIOTHOR VASC AN, V8, P105; Lee Raymond Wai Chuen, 2004, Best Pract Res Clin Anaesthesiol, V18, P53, DOI 10.1016/j.bpa.2003.09.005; LEITNER MJ, 1980, PEDIATR RES, V14, P622; Lema G, 1998, ANESTH ANALG, V86, P3, DOI 10.1097/00000539-199801000-00002; Lherm T, 1996, INTENS CARE MED, V22, P213, DOI 10.1007/BF01712239; Liet JM, 2002, J PEDIATR-US, V140, P373, DOI 10.1067/mpd.2002.123100; Lisbon A, 2003, CHEST, V123, p460S, DOI 10.1378/chest.123.5_suppl.460S; LUMLERTGUL D, 1989, NEPHRON, V52, P40, DOI 10.1159/000185580; Lundstrom K, 2000, EARLY HUM DEV, V57, P157, DOI 10.1016/S0378-3782(00)00048-7; Lynch SK, 2003, PEDIATR NEPHROL, V18, P649, DOI 10.1007/s00467-003-1148-7; MacGregor DA, 2000, ANESTHESIOLOGY, V92, P338, DOI 10.1097/00000542-200002000-00013; Maleck WH, 2003, CAN J ANAESTH, V50, P93, DOI 10.1007/BF03020198; Maleck WH, 2002, CRIT CARE MED, V30, P1934, DOI 10.1097/00003246-200208000-00062; Mantel GD, 1997, BRIT J OBSTET GYNAEC, V104, P1180, DOI 10.1111/j.1471-0528.1997.tb10943.x; MARIK PE, 1993, HEART LUNG, V22, P171; Marik PE, 2002, INTENS CARE MED, V28, P877, DOI 10.1007/s00134-002-1346-y; Marik PE, 1999, AM J MED, V107, P387; MAYNARD ND, 1995, CHEST, V108, P1648, DOI 10.1378/chest.108.6.1648; McHugh GJ, 2001, ANAESTH INTENS CARE, V29, P623, DOI 10.1177/0310057X0102900612; McNicol L, 1999, J CARDIOTHOR VASC AN, V13, P292, DOI 10.1016/S1053-0770(99)90266-5; MEMOLI B, 1995, AM J KIDNEY DIS, V26, P27, DOI 10.1016/0272-6386(95)90149-3; Modi G K, 2001, Natl Med J India, V14, P88; MONTORI V, 2002, GUIDES MED LIT MANUA, P539; MYLES PS, 1993, ANAESTH INTENS CARE, V21, P56, DOI 10.1177/0310057X9302100114; Nadjmadadi M H, 1975, Med Welt, V26, P554; NAKAZAWA M, 1987, JPN CIRC J, V51, P1010, DOI 10.1253/jcj.51.1010; Niiya Sadayo, 2001, Japanese Journal of Anesthesiology, V50, P122; O'Hara JF, 2002, J UROLOGY, V167, P24, DOI 10.1016/S0022-5347(05)65374-8; OHATA M, 1994, ANESTHESIA RESUSCITA, V30, P299; Olson D, 1996, AM J RESP CRIT CARE, V154, P1664, DOI 10.1164/ajrccm.154.6.8970352; PALMIERI G, 1993, EUR J CANCER, V29A, P1119, DOI 10.1016/S0959-8049(05)80300-4; PAPE HC, 1992, UNFALLCHIRURG, V95, P419; PARKER S, 1981, CRIT CARE MED, V9, P630, DOI 10.1097/00003246-198109000-00002; PARKS RW, 1994, BRIT J SURG, V81, P437, DOI 10.1002/bjs.1800810338; PAUL MD, 1986, AM J NEPHROL, V6, P427, DOI 10.1159/000167248; Perez J, 2002, SURG ENDOSC, V16, P1297, DOI 10.1007/s00464-001-9201-8; PHILLIPOS EZ, 1996, PEDIATR RES, V39, pA425; PHILLIPOS EZ, 2000, PEDIATR RES, V47, pA238; Piepenbrock S, 1975, Med Welt, V26, P551; Piepenbrock S, 1980, Anasth Intensivther Notfallmed, V15, P460, DOI 10.1055/s-2007-1005177; Piper SN, 2003, CAN J ANAESTH, V50, P285, DOI 10.1007/BF03017799; POLSON RJ, 1987, ANAESTHESIA, V42, P15, DOI 10.1111/j.1365-2044.1987.tb02938.x; Prins I, 2001, INTENS CARE MED, V27, P206, DOI 10.1007/s001340000775; RAFTERY AT, 1979, BRIT MED J, V1, P522, DOI 10.1136/bmj.1.6162.522; RATGE D, 1990, CLIN EXP PHARMACOL P, V17, P361, DOI 10.1111/j.1440-1681.1990.tb01332.x; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; ROBINSON T, 1994, BRIT J CLIN PHARMACO, V37, P261, DOI 10.1111/j.1365-2125.1994.tb04273.x; Rudis MI, 2001, CRIT CARE MED, V29, P1638, DOI 10.1097/00003246-200108000-00026; Rudis MI, 1997, AM J MED, V102, P320; SALEM MG, 1988, ANN ROY COLL SURG, V70, P9; Sanchez M, 2003, J AM SOC NEPHROL, V14, p44A; Sanchez Miguel, 2001, Journal of the American Society of Nephrology, V12, p180A; SANDBERG J, 1992, TRANSPLANT P, V24, P357; Saxena AK, 2002, DIALYSIS TRANSPLANT, V31, P615; Schilling T, 2004, INTENS CARE MED, V30, P1127, DOI 10.1007/s00134-004-2279-4; Schilling T, 2001, INTENS CARE MED, V27, P1908, DOI 10.1007/s00134-001-1144-y; Schneider M, 1999, ANAESTH INTENS CARE, V27, P13, DOI 10.1177/0310057X9902700103; Schnuelle P, 2004, AM J TRANSPLANT, V4, P419, DOI 10.1111/j.1600-6143.2004.00331.x; SCHULZE K, 1999, CRIT CARE, V3, P79; SERI I, 1984, INT J PED NEPHROL, V5, P209; Sharpe DAC, 1999, PERFUSION-UK, V14, P29, DOI 10.1177/026765919901400105; Shimoda M, 1989, Neurol Med Chir (Tokyo), V29, P890, DOI 10.2176/nmc.29.890; Sirivella S, 2000, ANN THORAC SURG, V69, P501, DOI 10.1016/S0003-4975(99)01298-9; SOMLO G, 1995, J CLIN ONCOL, V13, P1231, DOI 10.1200/JCO.1995.13.5.1231; SOONG CV, 1995, BRIT J SURG, V82, P912, DOI 10.1002/bjs.1800820718; Spoto S, 2000, Clin Ter, V151, P323; Sprung J, 2000, ANESTH ANALG, V90, P388, DOI 10.1097/00000539-200002000-00028; Stevens NA, 1999, J AM COLL CARDIOL, V33, P403; SUBHEDAR NV, COCHRANE DATABASE SY; Sumeray M, 2001, J NEPHROL, V14, P397; Suominen S, 2004, ANN PLAS SURG, V53, P425, DOI 10.1097/01.sap.0000137133.08105.73; SWYGERT TH, 1991, ANESTHESIOLOGY, V75, P571, DOI 10.1097/00000542-199110000-00005; Tanaka N, 1997, ANESTH ANALG, V85, P286, DOI 10.1097/00000539-199708000-00008; Tang ATM, 1999, EUR J CARDIO-THORAC, V15, P717, DOI 10.1016/S1010-7940(99)00081-0; Teplan V., 2000, Nephrology Dialysis Transplantation, V15, pA259; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; THORELIUS J, 1994, SCAND J THORAC CARD, V28, P135, DOI 10.3109/14017439409099118; Ungar A, 2004, CRIT CARE MED, V32, P1125, DOI 10.1097/01.CCM.0000124871.58281.D1; VANDENBERGHE G, 1994, CRIT CARE MED, V22, P1747, DOI 10.1097/00003246-199422110-00008; VANDENBERGHE G, 1994, J CLIN ENDOCR METAB, V79, P1141, DOI 10.1210/jc.79.4.1141; VANDENBERGHE G, 1994, CLIN ENDOCRINOL, V41, P731; VANDENBERGHE G, 1994, CLIN ENDOCRINOL, V41, P563; Vargo DL, 1996, J AM SOC NEPHROL, V7, P1032; Varriale P, 1997, CLIN CARDIOL, V20, P627, DOI 10.1002/clc.4960200709; VINCENT JL, 1994, CRIT CARE MED, V22, P5, DOI 10.1097/00003246-199401000-00004; Wahbah AM, 2000, HEPATO-GASTROENTEROL, V47, P1691; WALASZEWSKI J, 1988, TRANSPLANT P, V20, P913; Watanabe K, 1995, Masui, V44, P950; WEISBERG LS, 1993, RENAL FAILURE, V15, P61, DOI 10.3109/08860229309065574; WEISBERG LS, 1994, KIDNEY INT, V45, P259, DOI 10.1038/ki.1994.32; WENSTONE R, 1991, BRIT J ANAESTH, V67, P591, DOI 10.1093/bja/67.5.591; Whelan Thomas V., 1993, Journal of the American Society of Nephrology, V4, P966; WIERDA JMKH, 1990, CLIN PHARMACOKINET, V19, P491, DOI 10.2165/00003088-199019060-00005; Woo EBC, 2002, EUR J CARDIO-THORAC, V22, P106, DOI 10.1016/S1010-7940(02)00246-4; Yavuz S, 2002, J CARDIOVASC SURG, V43, P25; Yavuz S, 2002, MED SCI MONITOR, V8, pPI45; ZARITSKY A, 1988, CRIT CARE MED, V16, P217, DOI 10.1097/00003246-198803000-00002	176	275	295	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 5	2005	142	7					510	524		10.7326/0003-4819-142-7-200504050-00010	http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00010			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913QL	15809463				2022-12-28	WOS:000228167800005
J	Espinal, MA; Dye, C				Espinal, MA; Dye, C			Can DOTS control multidrug-resistant tuberculosis?	LANCET			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; DRUG-RESISTANCE; SOUTHERN MEXICO; COMMUNITY; COHORT; PERU		WHO, Stop TB Partnership, CH-1211 Geneva, Switzerland; WHO, Stop TB Dept, CH-1211 Geneva, Switzerland	World Health Organization; World Health Organization	Espinal, MA (corresponding author), WHO, Stop TB Partnership, CH-1211 Geneva, Switzerland.	espinalm@who.int	Dye, Christopher/AIC-4659-2022	Dye, Christopher/0000-0002-2957-1793				Blower SM, 2004, NAT MED, V10, P1111, DOI 10.1038/nm1102; Cohen T, 2004, NAT MED, V10, P1117, DOI 10.1038/nm1110; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Espinal MA, 2001, NEW ENGL J MED, V344, P1294, DOI 10.1056/NEJM200104263441706; Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630; Garcia-Garcia MD, 1999, INT J EPIDEMIOL, V28, P135, DOI 10.1093/ije/28.1.135; Garcia-Garcia MD, 2000, INT J TUBERC LUNG D, V4, P12; Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x; Hong YP, 2000, INT J TUBERC LUNG D, V4, P911; Kam KM, 2001, INT J TUBERC LUNG D, V5, P815; Leimane V, 2005, LANCET, V365, P318, DOI 10.1016/S0140-6736(05)17786-1; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; *SCI PAN WORK GROU, 2000, GUID EST DOTS PLUS P; Styblo K, 1991, TUBERCULOSIS SURVEIL, V2, P60; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; Tahaoglu K, 2001, NEW ENGL J MED, V345, P170, DOI 10.1056/NEJM200107193450303; Van Deun A, 2004, INT J TUBERC LUNG D, V8, P560; *WHO, 2004, GLOB TUB CONTR SURV	19	25	25	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1206	1209		10.1016/S0140-6736(05)74788-7	http://dx.doi.org/10.1016/S0140-6736(05)74788-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811438				2022-12-28	WOS:000228107600005
J	Esashi, F; Christ, N; Gannon, J; Liu, YL; Hunt, T; Jasin, M; West, SC				Esashi, F; Christ, N; Gannon, J; Liu, YL; Hunt, T; Jasin, M; West, SC			CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair	NATURE			English	Article							HOMOLOGY-DIRECTED REPAIR; DOUBLE-STRAND BREAKS; CANCER SUSCEPTIBILITY; DNA-DAMAGE; RADIATION HYPERSENSITIVITY; CELL-CYCLE; RAD51; REPEATS; GENE; BINDING	Inherited mutations in BRCA2 are associated with a predisposition to early-onset breast cancers. The underlying basis of tumorigenesis is thought to be linked to defects in DNA double-strand break repair by homologous recombination. Here we show that the carboxy-terminal region of BRCA2, which interacts directly with the essential recombination protein RAD51, contains a site (serine 3291; S3291) that is phosphorylated by cyclin-dependent kinases. Phosphorylation of S3291 is low in S phase when recombination is active, but increases as cells progress towards mitosis. This modification blocks C-terminal interactions between BRCA2 and RAD51. However, DNA damage overcomes cell cycle regulation by decreasing S3291 phosphorylation and stimulating interactions with RAD51. These results indicate that S3291 phosphorylation might provide a molecular switch to regulate RAD51 recombination activity, providing new insight into why BRCA2 C-terminal deletions lead to radiation sensitivity and cancer predisposition.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Cancer Research UK; Memorial Sloan Kettering Cancer Center	West, SC (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk		Esashi, Fumiko/0000-0003-0902-2364; West, Stephen/0000-0001-8848-9418	Wellcome Trust [101009] Funding Source: Medline; Breast Cancer Now [2002:445] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission); Breast Cancer Now		Aylon Y, 2004, EMBO J, V23, P4868, DOI 10.1038/sj.emboj.7600469; Baumann P, 1997, MUTAT RES-DNA REPAIR, V384, P65, DOI 10.1016/S0921-8777(97)00028-1; Bertwistle D, 1997, CANCER RES, V57, P5485; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Godthelp BC, 2002, ONCOGENE, V21, P5002, DOI 10.1038/sj.onc.1205656; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Tarsounas M, 2004, PHILOS T R SOC B, V359, P87, DOI 10.1098/rstb.2003.1368; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2003, ONCOGENE, V22, P2926, DOI 10.1038/sj.onc.1206522; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; WEST SC, 2003, NATURE REV MOL CELL, V4, P1, DOI DOI 10.1038/NRM1127; Wohlschlegel JA, 2001, MOL CELL BIOL, V21, P4868, DOI 10.1128/MCB.21.15.4868-4874.2001; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547	48	336	346	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					598	604		10.1038/nature03404	http://dx.doi.org/10.1038/nature03404			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800615				2022-12-28	WOS:000228011000035
J	Rappas, M; Schumacher, J; Beuron, F; Niwa, H; Bordes, P; Wigneshweraraj, S; Keetch, CA; Robinson, CV; Buck, M; Zhang, XD				Rappas, M; Schumacher, J; Beuron, F; Niwa, H; Bordes, P; Wigneshweraraj, S; Keetch, CA; Robinson, CV; Buck, M; Zhang, XD			Structural insights into the activity of enhancer-binding proteins	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; ANGSTROM RESOLUTION; MOLECULAR MACHINE; ESCHERICHIA-COLI; CENTRAL DOMAIN; SIGMA(54); ATPASES; AAA(+); SIGMA-54; NTRC	Activators of bacterial sigma(54)-RNA polymerase holoenzyme are mechanochemical proteins that use adenosine triphosphate (ATP) hydrolysis to activate transcription. We have determined by cryogenic electron microscopy (cryo-EM) a 20 angstrom resolution structure of an activator, phage shock protein IF [PspF((1-275))], which is bound to an ATP transition state analog in complex with its basal factor, sigma(54). By fitting the crystal structure of PspF((1-275)) at 1.75 angstroms into the EM map, we identified two loops involved in binding sigma(54). Comparing enhancer-binding structures in different nucleotide states and mutational analysis led us to propose nucleotide-dependent conformational changes that free the loops for association with sigma(54)..	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, London SW7 2AZ, England; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	Imperial College London; Imperial College London; University of London; Institute of Cancer Research - UK; University of Cambridge	Zhang, XD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England.	xiaodong.zhang@imperial.ac.uk		Bordes, Patricia/0000-0002-5746-0556; robinson, carol/0000-0001-7829-5505; Zhang, Xiaodong/0000-0001-9786-7038; Wigneshweraraj, Sivaramesh/0000-0002-1418-4029	Biotechnology and Biological Sciences Research Council [B17129] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Bordes P, 2004, BIOCHEM J, V378, P735, DOI 10.1042/BJ20031464; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; Burrows PC, 2003, J BIOL CHEM, V278, P29728, DOI 10.1074/jbc.M303596200; Cannon W, 2003, J BIOL CHEM, V278, P19815, DOI 10.1074/jbc.M301296200; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Furst J, 2003, EMBO J, V22, P4365, DOI 10.1093/emboj/cdg420; Gonzalez V, 1998, MOL MICROBIOL, V28, P55, DOI 10.1046/j.1365-2958.1998.00772.x; Lee DerNan, 1997, Journal of the Chinese Society of Animal Science, V26, P373; Lee SY, 2003, GENE DEV, V17, P2552, DOI 10.1101/gad.1125603; Li JL, 1999, J BACTERIOL, V181, P5443, DOI 10.1128/JB.181.17.5443-5454.1999; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; MORETT E, 1993, J BACTERIOL, V175, P6067, DOI 10.1128/JB.175.19.6067-6074.1993; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Neuwald AF, 1999, GENOME RES, V9, P27; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; Studholme DJ, 2003, J BACTERIOL, V185, P1757, DOI 10.1128/JB.185.6.1757-1767.2003; Svergun DI, 2000, J BIOL CHEM, V275, P4210, DOI 10.1074/jbc.275.6.4210; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Wang YK, 1997, J BACTERIOL, V179, P5812, DOI 10.1128/jb.179.18.5812-5819.1997; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; Xu H, 2001, CURR OPIN MICROBIOL, V4, P138, DOI 10.1016/S1369-5274(00)00179-X; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	27	135	139	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1972	1975		10.1126/science.1105932	http://dx.doi.org/10.1126/science.1105932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790859	Green Accepted			2022-12-28	WOS:000227957300060
J	Isobe, H; Miyagoshi, T; Shibata, K; Yokoyama, T				Isobe, H; Miyagoshi, T; Shibata, K; Yokoyama, T			Filamentary structure on the Sun from the magnetic Rayleigh-Taylor instability	NATURE			English	Article							X-RAY JETS; FAST RECONNECTION MECHANISM; COMPUTER; FLUX	Magnetic flux emerges from the solar surface as dark filaments connecting small sunspots with opposite polarities(1-3). The regions around the dark filaments are often bright in X-rays and are associated with jets(4-6). This implies plasma heating and acceleration, which are important for coronal heating. Previous two-dimensional simulations of such regions showed that magnetic reconnection between the coronal magnetic field and the emerging flux produced X-ray jets and flares, but left unresolved the origin of filamentary structure and the intermittent nature of the heating. Here we report three-dimensional simulations of emerging flux showing that the filamentary structure arises spontaneously from the magnetic Rayleigh - Taylor instability(7,8), contrary to the previous view that the dark filaments are isolated bundles of magnetic field that rise from the photosphere carrying the dense gas(9-11). As a result of the magnetic Rayleigh - Taylor instability, thin current sheets are formed in the emerging flux, and magnetic reconnection occurs between emerging flux and the pre-existing coronal field in a spatially intermittent way. This explains naturally the intermittent nature of coronal heating and the patchy brightenings in solar flares.	Kyoto Univ, Kwasan Observ, Kyoto 6078471, Japan; Kyoto Univ, Hida Observ, Kyoto 6078471, Japan; Univ Tokyo, Dept Earth & Planetary Sci, Bunkyo Ku, Tokyo 1130033, Japan	Kyoto University; Kyoto University; University of Tokyo	Isobe, H (corresponding author), Kyoto Univ, Kwasan Observ, Kyoto 6078471, Japan.	isobe@kwasan.kyoto-u.ac.jp	Yokoyama, Takaaki/B-9315-2008	Yokoyama, Takaaki/0000-0001-5457-4999; Isobe, Hiroaki/0000-0002-7744-3219; Miyagoshi, Takehiro/0000-0002-8908-9990				Asai A, 2004, ASTROPHYS J, V605, pL77, DOI 10.1086/420768; Bruzek A., 1967, SOL PHYS, V2, P451; CATTANEO F, 1988, J FLUID MECH, V196, P323, DOI 10.1017/S0022112088002721; FRAZIER EN, 1972, SOL PHYS, V26, P130, DOI 10.1007/BF00155113; Galsgaard K, 1996, J GEOPHYS RES-SPACE, V101, P13445, DOI 10.1029/96JA00428; GOLUB L, 1981, ASTROPHYS J, V243, P309, DOI 10.1086/158599; HACHISU I, 1990, ASTROPHYS J, V358, pL57, DOI 10.1086/185779; Innes DE, 2003, SOL PHYS, V217, P247, DOI 10.1023/B:SOLA.0000006899.12788.22; Karpen JT, 1996, ASTROPHYS J, V460, pL73, DOI 10.1086/309965; KITAHARA T, 1990, SOL PHYS, V125, P321, DOI 10.1007/BF00158409; MATSUMOTO R, 1993, ASTROPHYS J, V414, P357, DOI 10.1086/173082; Miyagoshi T, 2003, ASTROPHYS J, V593, pL133, DOI 10.1086/378215; PARKER EN, 1988, ASTROPHYS J, V330, P474, DOI 10.1086/166485; SHARP DH, 1984, PHYSICA D, V12, P3, DOI 10.1016/0167-2789(84)90510-4; SHIBATA K, 1992, PUBL ASTRON SOC JPN, V44, pL173; SHIBATA K, 1989, ASTROPHYS J, V338, P471, DOI 10.1086/167212; Solanki SK, 2003, NATURE, V425, P692, DOI 10.1038/nature02035; Ugai M, 1996, PHYS PLASMAS, V3, P853, DOI 10.1063/1.871789; UGAI M, 1992, PHYS FLUIDS B-PLASMA, V4, P2953, DOI 10.1063/1.860458; Yokoyama T, 1996, PUBL ASTRON SOC JPN, V48, P353, DOI 10.1093/pasj/48.2.353; YOKOYAMA T, 1995, NATURE, V375, P42, DOI 10.1038/375042a0; YOKOYAMA T, 1994, ASTROPHYS J, V436, pL197, DOI 10.1086/187666; Yoshimura K, 1999, ASTROPHYS J, V517, P964, DOI 10.1086/307213; ZIRIN H, 1972, SOL PHYS, V22, P34, DOI 10.1007/BF00145459; ZWAAN C, 1985, SOL PHYS, V100, P397, DOI 10.1007/BF00158438	25	141	142	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					478	481		10.1038/nature03399	http://dx.doi.org/10.1038/nature03399			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791248				2022-12-28	WOS:000227836000034
J	Chandran, K; Sullivan, NJ; Felbor, U; Whelan, SP; Cunningham, JM				Chandran, K; Sullivan, NJ; Felbor, U; Whelan, SP; Cunningham, JM			Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection	SCIENCE			English	Article							ENVELOPE GLYCOPROTEIN; CATHEPSIN-B; INFLUENZA HEMAGGLUTININ; MEMBRANE-FUSION; INHIBITORS; CYSTEINE; ENTRY; PROTEINASES; CELLS; MICE	Ebola virus (EboV) causes rapidly fatal hemorrhagic fever in humans and there is currently no effective treatment. We found that the infection of African green monkey kidney (Vero) cells by vesicular stornatitis viruses bearing the EboV gtycoprotein (GP) requires the activity of endosomal cysteine proteases. Using selective protease inhibitors and protease-deficient cell lines, we identified an essential role for cathepsin B (CatB) and an accessory role for cathepsin L (CatL) in EboV GP-dependent entry. Biochemical studies demonstrate that CatB and CatL mediate entry by carrying out proteolysis of the EboV GP subunit GP1 and support a multistep mechanism that explains the relative contributions of these enzymes to infection. CatB and CatB/CatL inhibitors diminish the multiplication of infectious EboV-Zaire in cultured cells and may merit investigation as anti-EboV drugs.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Biozentrum, Inst Human Genet, D-97074 Wurzburg, Germany; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Wurzburg; Harvard University; Harvard Medical School	Cunningham, JM (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	jcunningham@rics.bwh.harvard.edu		Whelan, Sean/0000-0003-1564-8590	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059371, Z01AI005079, Z01AI005081, Z01AI005082] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI059371, R01 AI059371-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOULAY F, 1987, EMBO J, V6, P2643, DOI 10.1002/j.1460-2075.1987.tb02555.x; Chandran K, 2003, TRENDS MICROBIOL, V11, P374, DOI 10.1016/S0966-842X(03)00178-1; Deussing J, 1998, P NATL ACAD SCI USA, V95, P4516, DOI 10.1073/pnas.95.8.4516; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200; Felbor U, 2002, P NATL ACAD SCI USA, V99, P7883, DOI 10.1073/pnas.112632299; Geisbert TW, 2004, NAT MED, V10, pS110, DOI 10.1038/nm1142; Ito H, 1999, J VIROL, V73, P8907, DOI 10.1128/JVI.73.10.8907-8912.1999; Jeffers SA, 2002, J VIROL, V76, P12463, DOI 10.1128/JVI.76.24.12463-12472.2002; Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662; Mothes W, 2000, CELL, V103, P679, DOI 10.1016/S0092-8674(00)00170-7; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; NIBERT ML, 1993, THESIS HARVARD U; Otto HH, 1997, CHEM REV, V97, P133, DOI 10.1021/cr950025u; Sanchez A, 1998, J VIROL, V72, P6442, DOI 10.1128/JVI.72.8.6442-6447.1998; SHAW E, 1994, METHOD ENZYMOL, V244, P649; Simmons G, 2003, J VIROL, V77, P13433, DOI 10.1128/JVI.77.24.13433-13438.2003; Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Takada A, 1997, P NATL ACAD SCI USA, V94, P14764, DOI 10.1073/pnas.94.26.14764; Turk B, 1997, BIOL CHEM, V378, P141; Volchkov VE, 1999, CURR TOP MICROBIOL, V235, P35; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; Wool-Lewis RJ, 1998, J VIROL, V72, P3155, DOI 10.1128/JVI.72.4.3155-3160.1998; Zhang T, 2000, IMMUNOLOGY, V100, P13, DOI 10.1046/j.1365-2567.2000.00000.x	25	629	670	1	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1643	1645		10.1126/science.1110656	http://dx.doi.org/10.1126/science.1110656			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15831716	Green Accepted			2022-12-28	WOS:000229827000062
J	Mack, TM				Mack, TM			The ghost of pandemics past	LANCET			English	Editorial Material							ACUTE RESPIRATORY SYNDROME; TRANSMISSION; SMALLPOX; AGENT; SARS		Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California	Mack, TM (corresponding author), Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA.	tmack@usc.edu						Arness MK, 2004, AM J EPIDEMIOL, V160, P642, DOI 10.1093/aje/kwh269; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P278; de Rugy V., 2002, POLICY ANAL, V434, P1; DESOPO M, 2005, EXERCISE ILLUMINATES; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; Greenberg RN, 2005, LANCET, V365, P398, DOI 10.1016/S0140-6736(05)70234-8; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Lane JM, 2003, ANN INTERN MED, V138, P488, DOI 10.7326/0003-4819-138-6-200303180-00014; Mack T, 2003, NEW ENGL J MED, V348, P460, DOI 10.1056/NEJMsb022994; Monto AS, 2005, NEW ENGL J MED, V352, P323, DOI 10.1056/NEJMp048343; O'Toole T, 2002, CLIN INFECT DIS, V34, P972, DOI 10.1086/339909; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; Seto WH, 2003, LANCET, V361, P1519, DOI 10.1016/S0140-6736(03)13168-6; STEVENSON RW, 2002, NY TIMES        1126, pA1; Stohr K, 2005, NEW ENGL J MED, V352, P405, DOI 10.1056/NEJMe048344; Tomlinson B, 2003, LANCET, V361, P1486, DOI 10.1016/S0140-6736(03)13218-7; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; World Health Organization, 2003, SARS BREAK CHAINS TR; Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102	20	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2005	365	9468					1370	1372		10.1016/S0140-6736(05)66352-0	http://dx.doi.org/10.1016/S0140-6736(05)66352-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836872	Green Published, Bronze			2022-12-28	WOS:000228401900008
J	Van Gaal, LF; Rissanen, AM; Scheen, AJ; Ziegler, O; Rossner, S				Van Gaal, LF; Rissanen, AM; Scheen, AJ; Ziegler, O; Rossner, S		RIO-Europe Study Grp	Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study	LANCET			English	Article							METABOLIC SYNDROME; WAIST CIRCUMFERENCE; INSULIN-RESISTANCE; HEART-DISEASE; SR 141716; OBESITY; ANTAGONIST; ENDOCANNABINOIDS; SYSTEM; HEALTH	Background In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We assessed the effect of rimonabant, a selective CB1 blocker, on bodyweight and cardiovascular risk factors in overweight or obese patients. Methods 1507 patients with body-mass index 30 kg/m(2) or greater, or body-mass index greater than 27 kg/m(2) with treated or untreated dyslipidaemia, hypertension, or both, were randomised to receive double-blind treatment with placebo, 5 mg rimonabant, or 20 mg rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day deficit). The primary efficacy endpoint was weight change from baseline after 1 year of treatment in the intention-to-treat population. Findings Weight loss at 1 year was significantly greater in patients treated with rimonabant 5 mg (mean -3.4 kg [SD 5.7]; p=0.002 vs placebo) and 20 mg (-6.6 kg [7.2]; p<0.001 vs placebo) compared with placebo (-1.8 kg [6.4]). Significantly more patients treated with rimonabant 20 mg than placebo achieved weight loss of 5% or greater (p<0.001) and 10% or greater (p<0.001). Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, HDL-cholesterol, triglycerides, and insulin resistance, and prevalence of the metabolic syndrome. The effects of rimonabant 5 mg were of less clinical significance. Rimonabant was generally well tolerated with mild and transient side effects. Interpretation CB, blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 year, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.	Univ Antwerp Hosp, Dept Diabetol Metab & Clin Nutr, B-2650 Edegem, Belgium; Univ Helsinki, Cent Hosp, Dept Psychiat, Obes Res Unit, Helsinki, Finland; Univ Liege, Div Diabet Nutr & Metab Disorders, Liege, Belgium; CHU Nancy, Hop Jeanne Arc, Serv Diabetol, Toul, France; Huddinge Univ Hosp, Obes Unit, S-14186 Huddinge, Sweden	University of Antwerp; University of Helsinki; Helsinki University Central Hospital; University of Liege; CHU de Nancy; Karolinska Institutet	Van Gaal, LF (corresponding author), Univ Antwerp Hosp, Dept Diabetol Metab & Clin Nutr, Wilrijkstr 10, B-2650 Edegem, Belgium.	luc.van.gaal@uza.be						Alexander CM, 2003, DIABETES, V52, P1210, DOI 10.2337/diabetes.52.5.1210; Arnone M, 1997, PSYCHOPHARMACOLOGY, V132, P104, DOI 10.1007/s002130050326; Bensaid M, 2003, MOL PHARMACOL, V63, P908, DOI 10.1124/mol.63.4.908; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Cota D, 2003, INT J OBESITY, V27, P289, DOI 10.1038/sj.ijo.0802250; Croci T, 1998, BRIT J PHARMACOL, V125, P1393, DOI 10.1038/sj.bjp.0702190; Despres JP, 2001, BMJ-BRIT MED J, V322, P716, DOI 10.1136/bmj.322.7288.716; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; Gomez R, 2002, J NEUROSCI, V22, P9612; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Horvath TL, 2003, J CLIN INVEST, V112, P323, DOI [10.1172/JCI19376, 10.1172/JCI200319376]; Howlett AC, 2004, NEUROPHARMACOLOGY, V47, P345, DOI 10.1016/j.neuropharm.2004.07.030; Howlett AC, 2002, PROSTAG OTH LIPID M, V68-9, P619, DOI 10.1016/S0090-6980(02)00060-6; James PT, 2004, EUR J CARDIOV PREV R, V11, P3, DOI 10.1097/01.hjr.0000114707.27531.48; Janssen I, 2004, AM J CLIN NUTR, V79, P379; Kirkham TC, 2003, AM J PHYSIOL-REG I, V284, pR343, DOI 10.1152/ajpregu.00706.2002; Kunos G, 2001, NEUROCHEM RES, V26, P1015, DOI 10.1023/A:1012301021419; *LEX COMP, 1996, LAB TEST HDB; Liu YL, 2005, INT J OBESITY, V29, P183, DOI 10.1038/sj.ijo.0802847; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Meigs JB, 2003, DIABETES, V52, P2160, DOI 10.2337/diabetes.52.8.2160; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; PETROCELLIS LD, 2004, BRIT J PHARMACOL, V141, P765; Simiand J, 1998, BEHAV PHARMACOL, V9, P179; Trillou CR, 2003, AM J PHYSIOL-REG I, V284, pR345, DOI 10.1152/ajpregu.00545.2002; VanGaal LF, 1997, INT J OBESITY, V21, pS5; *WHO, 2002, INT MAN CARD RISK RE; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; York DA, 2004, CIRCULATION, V110, pE463, DOI 10.1161/01.CIR.0000140125.26161.49; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zhu SK, 2002, AM J CLIN NUTR, V76, P743, DOI 10.1093/ajcn/76.4.743; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	1146	1220	0	46	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2005	365	9468					1389	1397		10.1016/S0140-6736(05)66374-X	http://dx.doi.org/10.1016/S0140-6736(05)66374-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836887	Green Submitted			2022-12-28	WOS:000228401900027
J	Harden, N				Harden, N			Of grainy heads and broken skins	SCIENCE			English	Editorial Material							TRANSCRIPTION FACTOR; DROSOPHILA; EMBRYO		Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada	Simon Fraser University	Harden, N (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.	nharden@sfu.ca						ATTARDI LD, 1993, P NATL ACAD SCI USA, V90, P10563, DOI 10.1073/pnas.90.22.10563; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; Mace KA, 2005, SCIENCE, V308, P381, DOI 10.1126/science.1107573; Martin P, 2004, DEVELOPMENT, V131, P3021, DOI 10.1242/dev.01253; Martin P, 2002, CURR OPIN CELL BIOL, V14, P569, DOI 10.1016/S0955-0674(02)00369-1; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Ting SB, 2003, NAT MED, V9, P1513, DOI 10.1038/nm961; Venkatesan K, 2003, NUCLEIC ACIDS RES, V31, P4304, DOI 10.1093/nar/gkg644; Wright TRF, 1996, J HERED, V87, P175, DOI 10.1093/oxfordjournals.jhered.a022983	10	12	12	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 15	2005	308	5720					364	365		10.1126/science.1112050	http://dx.doi.org/10.1126/science.1112050			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831745				2022-12-28	WOS:000228492000037
J	Huey, RB; Ward, PD				Huey, RB; Ward, PD			Hypoxia, global warming, and terrestrial Late Permian extinctions	SCIENCE			English	Article							TRIASSIC BOUNDARY; KAROO BASIN; OXYGEN; VERTEBRATES; DIVERSITY; CYCLE; MODEL	A catastrophic extinction occurred at the end of the Permian Period. However, baseline extinction rates appear to have been elevated even before the final catastrophe, suggesting sustained environmental degradation. For terrestrial vertebrates during the Late Permian, the combination of a drop in atmospheric oxygen plus climate warming would have induced hypoxic stress and consequently compressed altitudinal ranges to near sea level. Our simulations suggest that the magnitude of altitudinal compression would have forced extinctions by reducing habitat diversity, fragmenting and isolating populations, and inducing a species-area effect. It also might have delayed ecosystem recovery after the mass extinction.	Univ Washington, Dept Biol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Huey, RB (corresponding author), Univ Washington, Dept Biol, Box 351800, Seattle, WA 98195 USA.	hueyrb@u.washington.edu	Huey, Raymond/F-1597-2010	Huey, Raymond/0000-0002-4962-8670				ANGIELCZYK K, COMMUNICATION; BATTISTI D, COMMUNICATION; Benton MJ, 2004, NATURE, V432, P97, DOI 10.1038/nature02950; Benton MJ, 2003, TRENDS ECOL EVOL, V18, P358, DOI 10.1016/S0169-5347(03)00093-4; Bergman NM, 2004, AM J SCI, V304, P397, DOI 10.2475/ajs.304.5.397; Berner R.A., 2004, PHANEROZOIC CARBON C; Berner RA, 2001, AM J SCI, V301, P182, DOI 10.2475/ajs.301.2.182; Berner RA, 2003, ANNU REV EARTH PL SC, V31, P105, DOI 10.1146/annurev.earth.31.100901.141329; Berner RA, 2002, P NATL ACAD SCI USA, V99, P4172, DOI 10.1073/pnas.032095199; Berner RA, 2001, GEOCHIM COSMOCHIM AC, V65, P685, DOI 10.1016/S0016-7037(00)00572-X; BERNER RA, IN PRESS GEOCHIM COS; Bouverot P., 1985, ADAPTATION ALTITUDE; Bowring SA, 1999, P NATL ACAD SCI USA, V96, P8827, DOI 10.1073/pnas.96.16.8827; Erwin D. H, 1993, GREAT PALEOZOIC CRIS; Frazier MR, 2001, PHYSIOL BIOCHEM ZOOL, V74, P641, DOI 10.1086/322172; GASTON KJ, 2003, STRUCTURE DYNAMICS; GRAHAM JB, 1995, NATURE, V375, P117, DOI 10.1038/375117a0; Greenlee KJ, 2004, J EXP BIOL, V207, P497, DOI 10.1242/jeb.00767; Hallam A, 1999, EARTH-SCI REV, V48, P217, DOI 10.1016/S0012-8252(99)00055-0; Hanski I., 1999, METAPOPULATION ECOLO; Hillenius WJ, 2004, PHYSIOL BIOCHEM ZOOL, V77, P1019, DOI 10.1086/425185; JANZEN DH, 1967, AM NAT, V101, P233, DOI 10.1086/282487; Kidder DL, 2004, PALAEOGEOGR PALAEOCL, V203, P207, DOI 10.1016/S0031-0182(03)00667-9; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; LABANDEIRA CC, 1993, SCIENCE, V261, P310, DOI 10.1126/science.11536548; Lasaga AC, 2002, GEOCHIM COSMOCHIM AC, V66, P361, DOI 10.1016/S0016-7037(01)00685-8; Rees PM, 2002, GEOLOGY, V30, P827; Retallack GJ, 2003, GEOL SOC AM BULL, V115, P1133, DOI 10.1130/B25215.1; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; Rowley DB, 2001, EARTH PLANET SC LETT, V188, P253, DOI 10.1016/S0012-821X(01)00324-7; Sheldon ND, 2002, GEOLOGY, V30, P919, DOI 10.1130/0091-7613(2002)030<0919:LOLIET>2.0.CO;2; SIDOR CA, IN PRESS NATURE; Ward PD, 2005, SCIENCE, V307, P709, DOI 10.1126/science.1107068; Wignall PB, 1999, J GEOL SOC LONDON, V156, P453, DOI 10.1144/gsjgs.156.3.0453	34	166	190	3	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					398	401		10.1126/science.1108019	http://dx.doi.org/10.1126/science.1108019			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831755				2022-12-28	WOS:000228492000048
J	Schultz, JM; Yang, Y; Caride, AJ; Filoteo, AG; Penheiter, AR; Lagziel, A; Morell, RJ; Mohiddin, SA; Fananapazir, L; Madeo, AC; Penniston, JT; Griffith, AJ				Schultz, JM; Yang, Y; Caride, AJ; Filoteo, AG; Penheiter, AR; Lagziel, A; Morell, RJ; Mohiddin, SA; Fananapazir, L; Madeo, AC; Penniston, JT; Griffith, AJ			Modification of human hearing loss by plasma-membrane calcium pump PMCA2	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEAFNESS; ASSOCIATION; CADHERIN-23; MUTATION; DFNB12; MUTANT; MICE	Five adult siblings presented with autosomal recessive sensorineural hearing loss: two had high-frequency loss, whereas the other three had severe-to-profound loss affecting all frequencies. Genetic evaluation revealed that a homozygous mutation in CDH23 (which encodes cadherin 23) caused the hearing loss in all five siblings and that a heterozygous, hypofunctional variant (V586M) in plasma-membrane calcium pump PMCA2, which is encoded by ATP2B2, was associated with increased loss in the three severely affected siblings. V586M was detected in two unrelated persons with increased sensorineural hearing loss, in the other caused by a mutation in MYO6 (which encodes myosin VI) in one and by noise exposure, suggesting that this variant may modify the severity of sensorineural hearing loss caused by a variety of factors.	NIDCD, Sect Gene Struct & Funct, NIH, Rockville, MD 20850 USA; NIDCD, Sect Human Genet, NIH, Rockville, MD 20850 USA; NIDCD, Hearing Sect, NIH, Rockville, MD 20850 USA; NHLBI, Cardiovasc Branch, NIH, Bethesda, MD 20892 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Anesthesiol, Rochester, MN 55905 USA; Massachusetts Gen Hosp, Ctr Neurosci, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Mayo Clinic; Mayo Clinic; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Griffith, AJ (corresponding author), NIDCD, Sect Gene Struct & Funct, NIH, 5 Res Ct,Rm 2A-01, Rockville, MD 20850 USA.	griffita@nidcd.nih.gov	Morell, Robert James/Q-2042-2019; Madeo, Anne C/AAA-6186-2022; Madeo, Anne/K-2880-2012	Mohiddin, Saidi/0000-0002-1031-4084; Morell, Robert/0000-0003-1537-7356	NIDCD NIH HHS [1 Z01 DC000060-02, 1 Z01 DC000064-02, DC04200, 1 Z01 DC000039-05] Funding Source: Medline; NIGMS NIH HHS [GM28825] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000039, Z01DC000064, R01DC004200, Z01DC000060] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Astuto LM, 2002, AM J HUM GENET, V71, P262, DOI 10.1086/341558; Bork JM, 2002, ADV OTO-RHINO-LARYNG, V61, P145; Bork JM, 2001, AM J HUM GENET, V68, P26, DOI 10.1086/316954; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; Caride AJ, 2001, CELL CALCIUM, V30, P49, DOI 10.1054/ceca.2001.0212; Di Palma F, 2001, GENE, V281, P31, DOI 10.1016/S0378-1119(01)00761-2; Dumont RA, 2001, J NEUROSCI, V21, P5066, DOI 10.1523/JNEUROSCI.21-14-05066.2001; Fortnum HM, 2001, BRIT MED J, V323, P536, DOI 10.1136/bmj.323.7312.536; Friedman TB, 2003, ANNU REV GENOM HUM G, V4, P341, DOI 10.1146/annurev.genom.4.070802.110347; Frolenkov GI, 2004, NAT REV GENET, V5, P489, DOI 10.1038/nrg1377; Gates GA, 1999, ARCH OTOLARYNGOL, V125, P1285; Gates GA, 1999, ARCH OTOLARYNGOL, V125, P654, DOI 10.1001/archotol.125.6.654; Huygen PL, 2003, AUDIOL MED, V1, P37, DOI DOI 10.1080/16513860310003049; *INT ORG STAND, 1984, ISO70291984; Kozel PJ, 2002, HEARING RES, V164, P231, DOI 10.1016/S0378-5955(01)00420-8; McCullough BJ, 2004, HEARING RES, V195, P90, DOI 10.1016/j.heares.2004.05.003; Mohiddin SA, 2004, J MED GENET, V41, P309, DOI 10.1136/jmg.2003.011973; Noben-Trauth K, 2003, NAT GENET, V35, P21, DOI 10.1038/ng1226; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Penheiter AR, 2001, HEARING RES, V162, P19, DOI 10.1016/S0378-5955(01)00356-2; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; Riazuddin S, 2000, NAT GENET, V26, P431, DOI 10.1038/82558; Wang Y, 2002, JARO, V3, P248, DOI 10.1007/s101620020028; Wood JD, 2004, JARO-J ASSOC RES OTO, V5, P99, DOI 10.1007/s10162-003-4022-1	24	139	146	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1557	1564		10.1056/NEJMoa043899	http://dx.doi.org/10.1056/NEJMoa043899			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829536				2022-12-28	WOS:000228324200008
J	Guber, C				Guber, C			Type 2 diabetes	LANCET			English	Editorial Material																		American Diabetes Association, 2003, AM DIAB ASS COMPL GU; [No title captured]	2	0	0	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1347	1347		10.1016/S0140-6736(05)61033-1	http://dx.doi.org/10.1016/S0140-6736(05)61033-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823386				2022-12-28	WOS:000228219600031
J	Kloer, DP; Ruch, S; Al-Babili, S; Beyer, P; Schulz, GE				Kloer, DP; Ruch, S; Al-Babili, S; Beyer, P; Schulz, GE			The structure of a retinal-forming carotenoid oxygenase	SCIENCE			English	Article							BETA-CAROTENE; OXIDATIVE CLEAVAGE; SUBSTRATE-SPECIFICITY; DIOXYGENASE; ENZYME; IDENTIFICATION; BIOSYNTHESIS; ARABIDOPSIS; PROTEIN; 15,15'-DIOXYGENASE	Enzymes that produce retinal and related apocarotenoids constitute a sequence- and thus structure-related family, a member of which was analyzed by x-ray diffraction. This member is an oxygenase and contains an Fe2+-4-His arrangement at the axis of a seven-bladed beta-propeller chain fold covered by a dome formed by six large loops. The Fe2+ is accessible through a long nonpolar tunnel that holds a carotenoid derivative in one of the crystals. on binding, three consecutive double bonds of this carotenoid changed from a straight all-trans to a cranked cis-trans-cis conformation. The remaining trans bond is located at the dioxygen-ligated Fe2+ and cleaved by oxygen.	Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Schulz, GE (corresponding author), Univ Freiburg, Inst Organ Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	georg.schulz@ocbc.uni-freiburg.de		Al-Babili, Salim/0000-0003-4823-2882	NATIONAL EYE INSTITUTE [R01EY020551] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Barua AB, 2000, J NUTR, V130, P1996, DOI 10.1093/jn/130.8.1996; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Booker J, 2004, CURR BIOL, V14, P1232, DOI 10.1016/j.cub.2004.06.061; Bouvier F, 2003, SCIENCE, V300, P2089, DOI 10.1126/science.1085162; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; Camara B, 2004, ARCH BIOCHEM BIOPHYS, V430, P16, DOI 10.1016/j.abb.2004.06.028; DellaPenna D, 1999, SCIENCE, V285, P375, DOI 10.1126/science.285.5426.375; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Gillmor SA, 1997, NAT STRUCT BIOL, V4, P1003, DOI 10.1038/nsb1297-1003; Giuliano G, 2003, TRENDS PLANT SCI, V8, P145, DOI 10.1016/S1360-1385(03)00053-0; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; Jung KH, 2003, MOL MICROBIOL, V47, P1513, DOI 10.1046/j.1365-2958.2003.03395.x; Kajander T, 2002, STRUCTURE, V10, P483, DOI 10.1016/S0969-2126(02)00744-X; Kato T, 2003, J SURFACTANTS DETERG, V6, P331, DOI 10.1007/s11743-003-0278-x; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Lancaster CRD, 1999, J MOL BIOL, V286, P883, DOI 10.1006/jmbi.1998.2532; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; MOLNAR P, 1997, J CHEM RES, V5, P120; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Ruch S, 2005, MOL MICROBIOL, V55, P1015, DOI 10.1111/j.1365-2958.2004.04460.x; Scharff EI, 2001, STRUCTURE, V9, P493, DOI 10.1016/S0969-2126(01)00610-4; Schwartz SH, 2004, J BIOL CHEM, V279, P46940, DOI 10.1074/jbc.M409004200; Schwartz SH, 2001, J BIOL CHEM, V276, P25208, DOI 10.1074/jbc.M102146200; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Tan BC, 2003, PLANT J, V35, P44, DOI 10.1046/j.1365-313X.2003.01786.x; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wendt KU, 1999, J MOL BIOL, V286, P175, DOI 10.1006/jmbi.1998.2470; Woggon WD, 2002, PURE APPL CHEM, V74, P1397, DOI 10.1351/pac200274081397; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619	32	208	217	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					267	269		10.1126/science.1108965	http://dx.doi.org/10.1126/science.1108965			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821095				2022-12-28	WOS:000228273700058
J	Chapman, T				Chapman, T			Small-scale separation	NATURE			English	Article																			0	23	25	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 7	2005	434	7034					795	795		10.1038/434795b	http://dx.doi.org/10.1038/434795b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815637	Bronze			2022-12-28	WOS:000228160700050
J	Bonomo, Y; Proimos, J				Bonomo, Y; Proimos, J			ABC of adolescence - Substance misuse: alcohol, tobacco, inhalants, and other drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Review							YOUNG ADULTHOOD; PATTERNS; RISK		Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	University of Melbourne	Bonomo, Y (corresponding author), Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.		Proimos, Jenny/M-4529-2019					Goldenring JM, 1988, CONT PEDIAT, V5, P75; HAWKINS JD, 1992, PSYCHOL BULL, V112, P64, DOI 10.1037/0033-2909.112.1.64; KANDEL DB, 1984, AM J PUBLIC HEALTH, V74, P660, DOI 10.2105/AJPH.74.7.660; PROCHASKA JO, 1991, CANCER-AM CANCER SOC, V67, P805, DOI 10.1002/1097-0142(19910201)67:3+<805::AID-CNCR2820671409>3.0.CO;2-4; *ROYAL COLL PHYS J, 1995, ALCOHOL YOUNG; YAMAGUCHI K, 1984, AM J PUBLIC HEALTH, V74, P668, DOI 10.2105/AJPH.74.7.668	6	17	21	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					777	780		10.1136/bmj.330.7494.777	http://dx.doi.org/10.1136/bmj.330.7494.777			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	914JE	15802722	Green Published			2022-12-28	WOS:000228222900027
J	Herget-Rosenthal, S				Herget-Rosenthal, S			One step forward in the early detection of acute renal failure	LANCET			English	Editorial Material							GELATINASE-ASSOCIATED LIPOCALIN; NEUTROPHIL GELATINASE; URINARY BIOMARKER; INJURY; PROTEIN; KIDNEY; MARKER; ARF		Univ Duisburg Essen, Univ Hosp, Div Nephrol, D-45122 Essen, Germany	University of Duisburg Essen	Herget-Rosenthal, S (corresponding author), Univ Duisburg Essen, Univ Hosp, Div Nephrol, D-45122 Essen, Germany.	stefan.herget-rosenthal@uni-essen.de						du Cheyron D, 2003, AM J KIDNEY DIS, V42, P497, DOI 10.1016/S0272-6386(03)00744-3; Gwira JA, 2005, J BIOL CHEM, V280, P7875, DOI 10.1074/jbc.M413192200; Herget-Rosenthal S, 2004, KIDNEY INT, V66, P1115, DOI 10.1111/j.1523-1755.2004.00861.x; Hewitt SM, 2004, J AM SOC NEPHROL, V15, P1677, DOI 10.1097/01.ASN.0000129114.92265.32; Ichimura T, 2004, AM J PHYSIOL-RENAL, V286, pF552, DOI 10.1152/ajprenal.00285.2002; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Kwon O, 2003, AM J KIDNEY DIS, V41, P1074, DOI 10.1016/S0272-6386(03)00206-3; Lameire N, 2005, LANCET, V365, P417; Liano F, 1996, KIDNEY INT, V50, P811, DOI 10.1038/ki.1996.380; Mehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.x; Mishra J, 2004, J AM SOC NEPHROL, V15, P3073, DOI 10.1097/01.ASN.0000145013.44578.45; Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6; Mori K, 2005, J CLIN INVEST, V115, P610, DOI 10.1172/JCI200523056; Parikh CR, 2004, AM J KIDNEY DIS, V43, P405, DOI 10.1053/j.ajkd.2003.10.040; Schrier RW, 2004, J CLIN INVEST, V114, P5, DOI 10.1172/JC1200422353; Thakar CV, 2005, KIDNEY INT, V67, P1112, DOI 10.1111/j.1523-1755.2005.00177.x	16	15	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1205	1206		10.1016/S0140-6736(05)74787-5	http://dx.doi.org/10.1016/S0140-6736(05)74787-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811437				2022-12-28	WOS:000228107600004
J	Kimball, AM; Thant, M				Kimball, AM; Thant, M			"What, me worry?" Businesses and AIDS at Davos	LANCET			English	Editorial Material									Univ Washington, Sch Publ Hlth, Hlth Serv, Seattle, WA 98195 USA; Asian Dev Bank, Manila, Philippines	University of Washington; University of Washington Seattle; Asian Development Bank	Kimball, AM (corresponding author), Univ Washington, Sch Publ Hlth, Hlth Serv, Seattle, WA 98195 USA.	akimball@u.washington.edu		Thant, Myo/0000-0002-3696-5977				Arora P, 2004, CAN MED ASSOC J, V171, P1337, DOI 10.1503/cmaj.045032; BLOOM D, 2005, WORLD EC FOR DAV; Brooks RA, 2004, AIDS CARE, V16, P756, DOI 10.1080/09540120412331269594; *GLOB BUS COAL HIV, 2005, MIN HLTH GLOB BUS CO; Kimball AM, 1996, LANCET, V347, P1670, DOI 10.1016/S0140-6736(96)91493-2; NAGELKERKE JD, 2002, B WORLD HEALTH ORGAN, V8, P89; Russell S, 2004, AM J TROP MED HYG, V71, P147, DOI 10.4269/ajtmh.2004.71.147; *UNAIDS, 2004, FACT SHEET AS; 2004, LANCET, V364, P909	9	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1213	1215		10.1016/S0140-6736(05)74792-9	http://dx.doi.org/10.1016/S0140-6736(05)74792-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811442	Green Published, Bronze			2022-12-28	WOS:000228107600009
J	Auslaender, OM; Steinberg, H; Yacoby, A; Tserkovnyak, Y; Halperin, BI; Baldwin, KW; Pfeiffer, LN; West, KW				Auslaender, OM; Steinberg, H; Yacoby, A; Tserkovnyak, Y; Halperin, BI; Baldwin, KW; Pfeiffer, LN; West, KW			Spin-charge separation and localization in one dimension	SCIENCE			English	Article								We report on measurements of quantum many-body modes in ballistic wires and their dependence on Coulomb interactions, obtained by tunneling between two parallel wires in an GaAs/AlGaAs heterostructure while varying electron density. We observed two spin modes and one charge mode of the coupled wires and mapped the dispersion velocities of the modes down to a critical density, at which spontaneous localization was observed. Theoretical calculations of the charge velocity agree well with the data, although they also predict an additional charge mode that was not observed. The measured spin velocity was smaller than theoretically predicted.	Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel; Harvard Univ, Lyman Lab Phys, Cambridge, MA 02138 USA; Lucent Technol, Bell Labs, Murray Hill, NJ 07974 USA	Weizmann Institute of Science; Harvard University; Alcatel-Lucent; Lucent Technologies; AT&T	Yacoby, A (corresponding author), Weizmann Inst Sci, Dept Condensed Matter Phys, IL-76100 Rehovot, Israel.	amir.yacoby@weizmann.ac.il	Steinberg, Hadar/R-7417-2018; Steinberg, Hadar/G-3821-2013; Steinberg, Hadar/Q-7504-2019	Steinberg, Hadar/0000-0002-7409-5087; Steinberg, Hadar/0000-0002-7409-5087				Altshuler B. L., 1985, Electron-electron interactions in disordered systems, P1; Auslaender OM, 2002, SCIENCE, V295, P825, DOI 10.1126/science.1066266; BEENAKKER CWJ, 1991, SOLID STATE PHYS, V44, P1; Boese D, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.085315; Carpentier D, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.153304; Cheianov VV, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.176401; COLL CF, 1974, PHYS REV B, V9, P2150, DOI 10.1103/PhysRevB.9.2150; Creffield CE, 2001, EUROPHYS LETT, V53, P221, DOI 10.1209/epl/i2001-00140-7; Cronenwett SM, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.226805; de Picciotto R, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.036805; de Picciotto R, 2001, NATURE, V411, P51, DOI 10.1038/35075009; Hausler W, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.085104; Hirose K, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.026804; KANE CL, 1992, PHYS REV B, V46, P15233, DOI 10.1103/PhysRevB.46.15233; Matveev KA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.106801; MATVEEV KA, 1993, PHYS REV LETT, V70, P990, DOI 10.1103/PhysRevLett.70.990; Meir Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.196802; Nozieres  P., 1999, THEORY QUANTUM LIQUI; Reilly DJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.246801; SCHULZ HJ, 1993, PHYS REV LETT, V71, P1864, DOI 10.1103/PhysRevLett.71.1864; Sushkov OP, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.195318; Thomas KJ, 2004, J PHYS-CONDENS MAT, V16, pL279, DOI 10.1088/0953-8984/16/23/L01; Thomas KJ, 1996, PHYS REV LETT, V77, P135, DOI 10.1103/PhysRevLett.77.135; Tserkovnyak Y, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.125312; Tserkovnyak Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.136805; Yacoby A, 1996, PHYS REV LETT, V77, P4612, DOI 10.1103/PhysRevLett.77.4612	28	317	320	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					88	92		10.1126/science.1107821	http://dx.doi.org/10.1126/science.1107821			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802599	Green Submitted			2022-12-28	WOS:000228221500038
J	van Oers, NSC; Chen, ZJJ				van Oers, NSC; Chen, ZJJ			Kinasing and upping down the NF-kappa B trail	SCIENCE			English	Editorial Material							T-CELL-RECEPTOR; ANTIGEN RECEPTOR; ACTIVATION; BCL10; CARMA1; LYMPHOCYTES; CASPASE-8; SYNAPSE; PATHWAY; MALT1		Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	van Oers, NSC (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA.	zhijian.chen@utsouthwestern.edu	Van+Oers, Nicolai/ABA-2437-2021; Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251; van Oers, Nicolai/0000-0002-6545-8405				Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Hara H, 2004, J EXP MED, V200, P1167, DOI 10.1084/jem.20032246; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; Lin X, 2004, SEMIN IMMUNOL, V16, P429, DOI 10.1016/j.smim.2004.08.022; Pitcher LA, 2003, TRENDS IMMUNOL, V24, P554, DOI 10.1016/j.it.2003.08.003; Sedwick CE, 2004, MOL IMMUNOL, V41, P675, DOI 10.1016/j.molimm.2004.01.007; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Weil R, 2004, CURR OPIN IMMUNOL, V16, P374, DOI 10.1016/j.coi.2004.03.003; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zhou R., COMMUNICATION	15	23	25	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					65	66		10.1126/science.1110902	http://dx.doi.org/10.1126/science.1110902			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802594				2022-12-28	WOS:000228221500032
J	Kang, HK; Hyams, KC				Kang, HK; Hyams, KC			Mental health care needs among recent war veterans	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Dept Vet Affairs, War Related Illness & Injury Study Ctr, Washington, DC USA; Dept Vet Affairs, Cent Off, Washington, DC USA		Kang, HK (corresponding author), Dept Vet Affairs, War Related Illness & Injury Study Ctr, Washington, DC USA.							Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kulka R.A., 1990, TRAUMA VIETNAM WAR G	3	78	81	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1289	1289		10.1056/NEJMp058024	http://dx.doi.org/10.1056/NEJMp058024			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JL	15800224				2022-12-28	WOS:000227998300004
J	Stanton, H; Rogerson, FM; East, CJ; Golub, SB; Lawlor, KE; Meeker, CT; Little, CB; Last, K; Farmer, PJ; Campbell, IK; Fourie, AM; Fosang, AJ				Stanton, H; Rogerson, FM; East, CJ; Golub, SB; Lawlor, KE; Meeker, CT; Little, CB; Last, K; Farmer, PJ; Campbell, IK; Fourie, AM; Fosang, AJ			ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro	NATURE			English	Article							ANTIGEN-INDUCED ARTHRITIS; EXPRESSION; GENE; METALLOPROTEINASE; INTERLEUKIN-1; CHONDROCYTES; PROTEIN; CLONING; FAMILY; MICE	Aggrecan is the major proteoglycan in cartilage, endowing this tissue with the unique capacity to bear load and resist compression. In arthritic cartilage, aggrecan is degraded by one or more 'aggrecanases' from the ADAMTS ( a disintegrin and metalloproteinase with thrombospondin motifs(1)) family of proteinases. ADAMTS1, 8 and 9 have weak aggrecan-degrading activity(2-5). However, they are not thought to be the primary aggrecanases because ADAMTS1 null mice are not protected from experimental arthritis(6), and cleavage by ADAMTS8 and 9 is highly inefficient. Although ADAMTS4 and 5 are expressed in joint tissues(7-13), and are known to be efficient aggrecanases in vitro, the exact contribution of these two enzymes to cartilage pathology is unknown. Here we show that ADAMTS5 is the major aggrecanase in mouse cartilage, both in vitro and in a mouse model of inflammatory arthritis. Our data suggest that ADAMTS5 may be a suitable target for the development of new drugs designed to inhibit cartilage destruction in arthritis, although further work will be required to determine whether ADAMTS5 is also the major aggrecanase in human arthritis.	Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Dept Surg, Parkville, Vic 3052, Australia; Univ Sydney, Royal N Shore Hosp, Raymond Purves Bone & Joint Res Labs, St Leonards, NSW 2065, Australia; Walter & Eliza Hall Inst Med Res, Reid Rheumatol Lab, Parkville, Vic 3052, Australia; Johnson & Johnson Pharmaceut Res & Dev, San Diego, CA 92121 USA	University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Royal North Shore Hospital; University of Sydney; Walter & Eliza Hall Institute; Johnson & Johnson; Johnson & Johnson USA	Fosang, AJ (corresponding author), Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia.	amanda.fosang@mcri.edu.au	Little, Christopher B/A-9280-2015	Little, Christopher B/0000-0002-0353-7634; STANTON, HEATHER/0000-0002-3427-5614; Last, Karena/0000-0002-4396-8404; Lawlor, Kate/0000-0003-0471-6842; Fosang, Amanda/0000-0002-5523-5427				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Bau B, 2002, ARTHRITIS RHEUM, V46, P2648, DOI 10.1002/art.10531; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; Glasson SS, 2004, ARTHRITIS RHEUM-US, V50, P2547, DOI 10.1002/art.20558; Ilic MZ, 2000, MATRIX BIOL, V19, P257, DOI 10.1016/S0945-053X(00)00069-X; Kevorkian L, 2004, ARTHRITIS RHEUM-US, V50, P131, DOI 10.1002/art.11433; Koshy PJT, 2002, ARTHRITIS RHEUM, V46, P961, DOI 10.1002/art.10212; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; LITTLE CB, IN PRESS ARTHRITIS R; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Mould AW, 2003, ARTHRITIS RHEUM-US, V48, P2660, DOI 10.1002/art.11232; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; RODRIGUEZMANZANEQU, 2002, BIOCHEM BIOPH RES CO, V293, P501; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; van Meurs JBJ, 1998, ARTHRITIS RHEUM, V41, P647, DOI 10.1002/1529-0131(199804)41:4<647::AID-ART11>3.0.CO;2-T; van Meurs JBJ, 1999, ANN RHEUM DIS, V58, P350, DOI 10.1136/ard.58.6.350; van Meurs JBJ, 1999, ARTHRITIS RHEUM, V42, P1128, DOI 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2; Vankemmelbeke MN, 2001, EUR J BIOCHEM, V268, P1259, DOI 10.1046/j.1432-1327.2001.01990.x; Yamanishi Y, 2002, J IMMUNOL, V168, P1405, DOI 10.4049/jimmunol.168.3.1405	24	703	741	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 31	2005	434	7033					648	652		10.1038/nature03417	http://dx.doi.org/10.1038/nature03417			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800625				2022-12-28	WOS:000228011000046
J	Stein, S; Okal, EA				Stein, S; Okal, EA			Speed and size of the Sumatra earthquake	NATURE			English	Editorial Material							MODES		Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA	Northwestern University	Stein, S (corresponding author), Northwestern Univ, Dept Geol Sci, Evanston, IL 60208 USA.	seth@earth.northwestern.edu						Bird P, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000252; Chamotrooke N, 1999, EARTH PLANET SC LETT, V173, P439, DOI 10.1016/S0012-821X(99)00239-3; CURRAY JR, 1979, GEOLOGICAL GEOPHYSIC, P189; Dahlen F. A, 1998, THEORETICAL GLOBAL S; DAHLEN FA, 1979, GEOPHYS J ROY ASTR S, V58, P609, DOI 10.1111/j.1365-246X.1979.tb04797.x; GELLER RJ, 1979, B SEISMOL SOC AM, V69, P1671; Okal EA, 2004, GEOPHYS J INT, V158, P899, DOI 10.1111/j.1365-246x.2004.02347.x; Sella GF, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000033; Stein S., 1977, Journal of Physics of the Earth, V25, P117, DOI 10.4294/jpe1952.25.117; STEIN S, 1981, B SEISMOL SOC AM, V71, P1031	10	381	410	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					581	582		10.1038/434581a	http://dx.doi.org/10.1038/434581a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800611				2022-12-28	WOS:000228011000031
J	Huffard, CL; Boneka, F; Full, RJ				Huffard, CL; Boneka, F; Full, RJ			Underwater bipedal locomotion by octopuses in disguise	SCIENCE			English	Article							PATTERNS		Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Sam Ratulangi, Dept Fisheries & Marine Sci, Manado, North Sulawesi, Indonesia	University of California System; University of California Berkeley; Universitas Sam Ratulangi	Huffard, CL (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.	chuffard@berkeley.edu						Gutfreund Y, 1998, J NEUROSCI, V18, P5976; Hanlon RT, 1999, BIOL J LINN SOC, V66, P1; KIER WM, 1985, ZOOL J LINN SOC-LOND, V83, P307, DOI 10.1111/j.1096-3642.1985.tb01178.x; Mather JA, 1998, J COMP PSYCHOL, V112, P306, DOI 10.1037/0735-7036.112.3.306; PACKARD A, 1971, ANIM BEHAV, V19, P780, DOI 10.1016/S0003-3472(71)80181-1; Steinbeck J, 2000, CANNERY ROW; Sumbre G, 2001, SCIENCE, V293, P1845, DOI 10.1126/science.1060976; Vaughan CL, 2003, J BIOMECH, V36, P513, DOI 10.1016/S0021-9290(02)00419-0	8	62	64	2	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 25	2005	307	5717					1927	1927		10.1126/science.1109616	http://dx.doi.org/10.1126/science.1109616			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790846				2022-12-28	WOS:000227957300047
J	Weissman, JS				Weissman, JS			The trouble with uncompensated hospital care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Partners Inst Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Weissman, JS (corresponding author), Massachusetts Gen Hosp, Partners Inst Hlth Policy, Boston, MA 02114 USA.							*AHRQ MEDPAC, 2002, OV UNC CAR AUD VIS C; Gabel J, 2003, HEALTH AFFAIR, V22, P117, DOI 10.1377/hlthaff.22.5.117; Hadley J, 2003, WHO PAYS MUCH COST C; TU H, 2004, RISING HLTH COSTS ME; Weissman JS, 2003, INQUIRY-J HEALTH CAR, V40, P84, DOI 10.5034/inquiryjrnl_40.1.84	5	14	14	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1171	1173		10.1056/NEJMp048280	http://dx.doi.org/10.1056/NEJMp048280			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788492				2022-12-28	WOS:000227832300001
J	Kim, JK; Gabel, HW; Kamath, RS; Tewari, M; Pasquinelli, A; Rual, JF; Kennedy, S; Dybbs, M; Bertin, N; Kaplan, JM; Vidal, M; Ruvkun, G				Kim, JK; Gabel, HW; Kamath, RS; Tewari, M; Pasquinelli, A; Rual, JF; Kennedy, S; Dybbs, M; Bertin, N; Kaplan, JM; Vidal, M; Ruvkun, G			Functional genomic analysis of RNA interference in C-elegans	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; GERMLINE; GENE; BETA; MAP	RNA interference (RNAi) of target genes is triggered by doubte-stranded RNAs (dsRNAs) processed by conserved nucleases and accessory factors. To identify the genetic components required for RNAi, we performed a genome-wide screen using an engineered RNAi sensor strain of Caenorhabditis elegans. The RNAi screen identified 90 genes. These included Piwi/PAZ proteins, DEAH helicases, RNA binding/processing factors, chromatin-associated factors, DNA recombination proteins, nuclear import/export factors, and 11 known components of the RNAi machinery. We demonstrate that some of these genes are also required for germline and somatic transgene silencing. Moreover, the physical interactions among these potential RNAi factors suggest links to other RNA-dependent gene regulatory pathways.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Ruvkun, G (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	ruvkun@molbio.mgh.harvard.edu	Bertin, Nicolas/O-9602-2019; Bertin, Nicolas/C-3025-2008	Bertin, Nicolas/0000-0002-9835-9606; Rual, Jean-Francois/0000-0003-4465-8819; Kennedy, Scott/0000-0002-7974-8155	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG021613] Funding Source: NIH RePORTER; NIA NIH HHS [K08-AG21613] Funding Source: Medline; NIGMS NIH HHS [GM44619] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Chen CCG, 2005, CURR BIOL, V15, P378, DOI 10.1016/j.cub.2005.01.009; Domeier ME, 2000, SCIENCE, V289, P1928, DOI 10.1126/science.289.5486.1928; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; Grishok A, 2002, ADV GENET, V46, P339; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kelly WG, 1997, GENETICS, V146, P227; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Kim DH, 2002, SCIENCE, V297, P623, DOI 10.1126/science.1073759; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; MELLO CC, COMMUNICATION; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; Pirrotta V, 2002, CELL, V110, P661, DOI 10.1016/S0092-8674(02)00967-4; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rual JF, 2004, GENOME RES, V14, P2162, DOI 10.1101/gr.2505604; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Tijsterman M, 2004, CURR BIOL, V14, P111, DOI 10.1016/j.cub.2003.12.029; Vastenhouw NL, 2004, TRENDS GENET, V20, P314, DOI 10.1016/j.tig.2004.04.011; Yochem J, 1998, GENETICS, V149, P1323	26	227	283	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1164	1167		10.1126/science.1109267	http://dx.doi.org/10.1126/science.1109267			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15790806				2022-12-28	WOS:000229293400042
J	Mulhall, BP; Veerappan, GR; Jackson, JL				Mulhall, BP; Veerappan, GR; Jackson, JL			Meta-analysis: Computed tomographic colonography	ANNALS OF INTERNAL MEDICINE			English	Review							MULTISLICE CT COLONOGRAPHY; CONTRAST BARIUM ENEMA; COLORECTAL-CANCER; VIRTUAL COLONOSCOPY; CONVENTIONAL COLONOSCOPY; AVERAGE-RISK; DETECTION RATES; POLYPS; COLON; EXPERIENCE	Background: Computed tomographic (CT) colonography, also called virtual colonoscopy, is an evolving technology under evaluation as a new method of screening for colorectal cancer. However, its performance as a test has varied widely across studies, and the reasons for these discrepancies are poorly defined. Purpose: To systematically review the test performance of CT colonography compared to colonoscopy or surgery and to assess variables that may affect test performance. Data Sources: The PubMed, MEDLINE, and EMBASE databases and the Cochrane Controlled Trials Register were searched for English-language articles published between January 1975 and February 2005. Study Selection: Prospective studies of adults undergoing CT colonography after full bowel preparation, with colonoscopy or surgery as the gold standard, were selected. Studies had to have used state-of-the-art technology, including at least a single-detector CT scanner with supine and prone positioning, insufflation of the colon with air or carbon dioxide, collimation smaller than 5 mm, and both 2-dimensional and 3-dimensional views during scan interpretation. The evaluators of the colonogram had to be unaware of the findings from use of the gold standard test. Data Abstraction: Data on sensitivity and specificity overall and for detection of polyps less than 6 mm, 6 to 9 mm, and greater than 9 mm in size were abstracted. Sensitivities and specificities weighted by sample size were calculated, and heterogeneity was explored by using stratified analyses and meta-regression. Data Synthesis: 33 studies provided data on 6393 patients. The sensitivity of CT colonography was heterogeneous but improved as polyp size increased (48% [95% Cl, 25% to 70%] for detection of polyps < 6 mm, 70% [Cl, 55% to 84%] for polyps 6 to 9 mm, and 85% [Cl, 79% to 91%] for polyps > 9 mm). Characteristics of the CT colonography scanner, including width of collimation, type of detector, and mode of imaging, explained some of this heterogeneity. In contrast, specificity was homogenous (92% [Cl, 89% to 96%] for detection of polyps < 6 mm, 93% [Cl, 91% to 95%] for polyps 6 to 9 mm, and 97% [Cl, 96% to 97%] for polyps > 9 mm). Limitations: The studies differed widely, and the extractable variables explained only a small amount of the heterogeneity. In addition, only a few studies examined the newest CT colonography technology. Conclusions: Computed tomographic colonography is highly specific, but the range of reported sensitivities is wide. Patient or scanner characteristics do not fully account for this variability, but collimation, type of scanner, and mode of imaging explain some of the discrepancy. This heterogeneity raises concerns about consistency of performance and about technical variability. These issues must be resolved before CT colonography can be advocated for generalized screening for colorectal cancer.	Walter Reed Army Med Ctr, Serv Gastroenterol, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Washington, DC USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Mulhall, BP (corresponding author), Walter Reed Army Med Ctr, Serv Gastroenterol, 6900 Georgia Ave NW,Bldg 2,7F18, Washington, DC 20307 USA.	brian.mulhall@na.amedd.army.mil	Jackson, Jeffrey/AAA-3519-2019	Jackson, Jeffrey/0000-0002-9820-5834				Akerkar GA, 2001, GASTROINTEST ENDOSC, V54, P310, DOI 10.1067/mge.2001.117595; Angtuaco TL, 2001, AM J GASTROENTEROL, V96, P887; Bielen D, 2003, EUR RADIOL, V13, P453, DOI 10.1007/s00330-002-1755-x; Bond J H, 2000, Semin Gastrointest Dis, V11, P176; Brenes GA, 2000, PREV MED, V31, P410, DOI 10.1006/pmed.2000.0729; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P193; Chung DJ, 2005, AM J ROENTGENOL, V184, P98, DOI 10.2214/ajr.184.1.01840098; Cotton PB, 2004, JAMA-J AM MED ASSOC, V291, P1713, DOI 10.1001/jama.291.14.1713; Dachman AH, 2003, RADIOL CLIN N AM, V41, P377, DOI 10.1016/S0033-8389(02)00124-0; Dachman AH, 1998, AM J ROENTGENOL, V171, P989, DOI 10.2214/ajr.171.4.9762982; de Leon MP, 2000, DIGEST LIVER DIS, V32, P312, DOI 10.1016/S1590-8658(00)80024-9; DiPalma AM, 1998, SOUTHERN MED J, V91, P342, DOI 10.1097/00007611-199804000-00005; Fenlon HM, 1999, NEW ENGL J MED, V341, P1496, DOI 10.1056/NEJM199911113412003; Fletcher JG, 2000, SEMIN ROENTGENOL, V35, P385, DOI 10.1053/sroe.2000.17756; Fletcher JG, 2000, RADIOLOGY, V216, P704, DOI 10.1148/radiology.216.3.r00au41704; Geenen Remy W F, 2004, Radiographics, V24, pe18; Gluecker T, 2002, GUT, V51, P207, DOI 10.1136/gut.51.2.207; Gluecker TM, 2003, RADIOLOGY, V227, P378, DOI 10.1148/radiol.2272020293; Hara AK, 1997, RADIOLOGY, V205, P59, DOI 10.1148/radiology.205.1.9314963; Hara AK, 2001, RADIOLOGY, V219, P461, DOI 10.1148/radiology.219.2.r01ma28461; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoppe H, 2004, AM J GASTROENTEROL, V99, P1924, DOI 10.1111/j.1572-0241.2004.40238.x; Iannaccone R, 2003, EUR RADIOL, V13, P1297, DOI 10.1007/s00330-002-1704-8; Ioannou GN, 2003, AM J GASTROENTEROL, V98, P2082, DOI 10.1016/S0002-9270(03)00423-4; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Johnson CD, 2000, RADIOLOGY, V216, P331, DOI 10.1148/radiology.216.2.r00au47331; Johnson CD, 2003, GASTROENTEROLOGY, V125, P311, DOI 10.1016/S0016-5085(03)00894-1; Ladabaum U, 2004, CLIN GASTROENTEROL H, V2, P554, DOI 10.1016/S1542-3565(04)00247-2; Laghi A, 2002, AM J SURG, V183, P124, DOI 10.1016/S0002-9610(01)00857-1; Laghi A, 2001, SEMIN ULTRASOUND CT, V22, P425, DOI 10.1016/S0887-2171(01)90035-6; Lefere PA, 2002, RADIOLOGY, V224, P393, DOI 10.1148/radiol.2241011222; Leslie A, 2002, BRIT J SURG, V89, P845, DOI 10.1046/j.1365-2168.2002.02120.x; Macari M, 2000, AM J ROENTGENOL, V174, P1543, DOI 10.2214/ajr.174.6.1741543; Macari M, 2004, RADIOLOGY, V230, P629, DOI 10.1148/radiol.2303021624; Macari M, 2004, AM J ROENTGENOL, V183, P127, DOI 10.2214/ajr.183.1.1830127; Macari M, 2002, RADIOLOGY, V224, P383, DOI 10.1148/radiol.2242011382; McFarland EG, 2002, RADIOLOGY, V225, P380, DOI 10.1148/radiol.2252011625; Mendelson RM, 2000, MED J AUSTRALIA, V173, P472, DOI 10.5694/j.1326-5377.2000.tb139298.x; Miao YM, 2000, GUT, V47, P832, DOI 10.1136/gut.47.6.832; Morrin MM, 2000, RADIOLOGY, V217, P765, DOI 10.1148/radiology.217.3.r00nv42765; Morrin MM, 2000, DIS COLON RECTUM, V43, P303, DOI 10.1007/BF02258293; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; Munikrishnan V, 2003, DIS COLON RECTUM, V46, P1384, DOI 10.1007/s10350-004-6755-2; Nicholson FB, 2005, CLIN RADIOL, V60, P1, DOI 10.1016/j.crad.2004.07.010; Pavone P, 2001, SEMIN ULTRASOUND CT, V22, P400, DOI 10.1016/S0887-2171(01)90030-7; Pedersen BG, 2003, ENDOSCOPY, V35, P736, DOI 10.1055/s-2003-41584; Pickhardt PJ, 2004, RADIOLOGY, V232, P784, DOI 10.1148/radiol.2323031614; Pickhardt PJ, 2004, JAMA-J AM MED ASSOC, V292, P431, DOI 10.1001/jama.292.4.431-a; Pickhardt PJ, 2003, NEW ENGL J MED, V349, P2191, DOI 10.1056/NEJMoa031618; Pignone M, 2002, ANN INTERN MED, V137, P132, DOI 10.7326/0003-4819-137-2-200207160-00015; Pineau BC, 2003, GASTROENTEROLOGY, V125, P304, DOI 10.1016/S0016-5085(03)00885-0; Rex DK, 1999, GASTROINTEST ENDOSC, V50, P309, DOI 10.1053/ge.1999.v50.97776; Rex DK, 1997, GASTROENTEROLOGY, V112, P24, DOI 10.1016/S0016-5085(97)70214-2; Rockey DC, 2005, LANCET, V365, P305; Rogalla P, 2000, EUR J RADIOL, V36, P81, DOI 10.1016/S0720-048X(00)00267-9; Roncucci L, 1996, EUR J CANCER, V32A, P295, DOI 10.1016/0959-8049(95)00532-3; Royster AP, 1997, AM J ROENTGENOL, V169, P1237, DOI 10.2214/ajr.169.5.9353434; Scott RG, 2004, AM J GASTROENTEROL, V99, P1145, DOI 10.1111/j.1572-0241.2004.30253.x; Seeff LC, 2002, J FAM PRACTICE, V51, P761; Sonnenberg A, 1999, AM J GASTROENTEROL, V94, P2268; Sosna J, 2003, AM J ROENTGENOL, V181, P1593, DOI 10.2214/ajr.181.6.1811593; Spinzi G, 2001, AM J GASTROENTEROL, V96, P394; Summers RM, 2005, AM J ROENTGENOL, V184, P105, DOI 10.2214/ajr.184.1.01840105; Taylor SA, 2004, EUR RADIOL, V14, P1025, DOI 10.1007/s00330-004-2262-z; Taylor SA, 2003, CLIN RADIOL, V58, P855, DOI 10.1016/S0009-9260(03)00273-3; Taylor SA, 2003, AM J ROENTGENOL, V181, P913, DOI 10.2214/ajr.181.4.1810913; Terdiman J P, 2000, Semin Gastrointest Dis, V11, P194; Thompson SG, 1999, STAT MED, V18, P2693, DOI 10.1002/(SICI)1097-0258(19991030)18:20<2693::AID-SIM235>3.0.CO;2-V; van Gelder RE, 2004, RADIOLOGY, V233, P328, DOI 10.1148/radiol.2331031208; Van Gelder RE, 2004, GASTROENTEROLOGY, V127, P41, DOI 10.1053/j.gastro.2004.03.055; Vining DJ., 1994, AM J ROENTGENOL, V162, pS104; Whiting P, 2004, ANN INTERN MED, V140, P189, DOI 10.7326/0003-4819-140-3-200402030-00010; Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044; Yee J, 2003, RADIOLOGY, V226, P653, DOI 10.1148/radiol.2263010701; Yee J, 2001, RADIOLOGY, V219, P685, DOI 10.1148/radiology.219.3.r01jn40685; Yoshida H, 2005, ABDOM IMAGING, V30, P26, DOI 10.1007/s00261-004-0244-x	76	261	274	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					635	650		10.7326/0003-4819-142-8-200504190-00013	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00013			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916TZ	15838071				2022-12-28	WOS:000228410400007
J	Schwartz, MD; Basco, WT; Grey, MR; Elmore, JG; Rubenstein, A				Schwartz, MD; Basco, WT; Grey, MR; Elmore, JG; Rubenstein, A			Rekindling student interest in generalist careers	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-RESEARCH ENTERPRISE; IMPROVING PRIMARY-CARE; MEDICAL-STUDENTS; INTERNAL-MEDICINE; SPECIALTY CHOICE; FAMILY MEDICINE; CHRONIC ILLNESS; NATIONAL-SURVEY; PHYSICIAN; SCHOOL	Despite changes in the structure of the U.S. health care system, patients continue to need and seek out generalist physicians. However, the proportion of U.S. graduates of medical schools who choose to enter generalist residency training decreased from 50% in 1998 to less than 40% in the 2004 match. Unless we act now to reverse this trend, we may face a shortage of primary care physicians to care for the complex medical needs of an aging population. This article reviews the history of and trends in career choice and proposes 4 evidence-based recommendations to rekindle student interest in generalist careers: 1) We must improve satisfaction and enthusiasm among generalist physician role models. 2) Schools of medicine should redouble their efforts to produce primary care physicians. 3) We must facilitate the pathway from medical school to generalist residency. 4) The U.S. government should increase funding for primary care research and research training. In the absence of a major overhaul of economic incentives in favor of generalist careers, we will need to work at these multiple levels to restore balance to the generalist physician workforce and align with the desires and expectations of patients for continuing healing relationships with generalist physicians.	NYU, Sch Med, Div Gen Internal Med,Med Serv 111, Vet Affairs New York Harbor Healthcare Syst, New York, NY 10010 USA; Med Univ S Carolina, Charleston, SC 29425 USA; High St Hlth Cre, Springfield, MA USA; Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Robert Wood Johnson Clin Scholars Program, Seattle, WA 98104 USA; Univ Penn, Philadelphia, PA 19104 USA	New York University; Medical University of South Carolina; Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Pennsylvania	Schwartz, MD (corresponding author), NYU, Sch Med, Div Gen Internal Med,Med Serv 111, Vet Affairs New York Harbor Healthcare Syst, 423 E 23rd St, New York, NY 10010 USA.	mark.schwartz@med.nyu.edu	Basco, William/K-3394-2019	Schwartz, Mark/0000-0002-7123-0060	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS011955] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS11955-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*ADV COMM TRAIN PR, 2003, 3 REP SEC US DEP HLT; Atasoylu AA, 2003, J GEN INTERN MED, V18, P711, DOI 10.1046/j.1525-1497.2003.10425.x; Basco WT, 1998, ACAD MED, V73, P1207, DOI 10.1097/00001888-199811000-00021; Basco WT, 2001, ACAD MED, V76, P380, DOI 10.1097/00001888-200104000-00017; Beasley BW, 2003, J GEN INTERN MED, V18, P705, DOI 10.1046/j.1525-1497.2003.20639.x; BLAND CJ, 1995, ACAD MED, V70, P620, DOI 10.1097/00001888-199507000-00013; Block SD, 1996, JAMA-J AM MED ASSOC, V276, P677, DOI 10.1001/jama.276.9.677; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; *BUR HLTH PROF, HLTH RES SERV ADM; Campos-Outcalt D, 1999, ACAD MED, V74, P1016, DOI 10.1097/00001888-199909000-00016; Cohen JJ, 2002, ACAD MED, V77, P475, DOI 10.1097/00001888-200206000-00002; Colquitt WL, 1996, ACAD MED, V71, P400, DOI 10.1097/00001888-199604000-00023; Colwill JM, 1997, ACAD MED, V72, P745, DOI 10.1097/00001888-199709000-00007; Connelly MT, 2003, J GEN INTERN MED, V18, P159, DOI 10.1046/j.1525-1497.2003.01208.x; Cooper RA, 2002, HEALTH AFFAIR, V21, P140, DOI 10.1377/hlthaff.21.1.140; Crowley WF, 2004, JAMA-J AM MED ASSOC, V291, P1120, DOI 10.1001/jama.291.9.1120; DONALDSON MS, 1996, PRIMARY CARE AM HLTH, P216; Dorsey ER, 2003, JAMA-J AM MED ASSOC, V290, P1173, DOI 10.1001/jama.290.9.1173; Fryer GE, 2002, FAM MED, V34, P436; FUCHS VR, 1981, NEW ENGL J MED, V304, P1487, DOI 10.1056/NEJM198106113042412; Funkenstein DH., 1978, MED STUDENTS MED SCH; Ginsburg PB, 2003, ANN INTERN MED, V138, P233, DOI 10.7326/0003-4819-138-3-200302040-00020; Gorey TM, 2004, ANN FAM MED, V2, pS3, DOI 10.1370/afm.130; Grumbach K, 1999, JAMA-J AM MED ASSOC, V282, P261, DOI 10.1001/jama.282.3.261; Henderson MC, 1996, AM J MED, V101, P648, DOI 10.1016/S0002-9343(96)00334-8; Hueston W J, 1999, J S C Med Assoc, V95, P72; JOLLY P, 2004, AAMC REPORTER    MAR; Jones RF, 1998, ACAD MED, V73, P212, DOI 10.1097/00001888-199802000-00023; Kahn N, 2001, ACAD MED, V76, pS9, DOI 10.1097/00001888-200104001-00004; Kalet A, 1998, J GEN INTERN MED, V13, P327, DOI 10.1046/j.1525-1497.1998.00099.x; Kane C, 2003, PHYS SOCIOECONOMIC S, P5; Kassebaum DG, 1996, ACAD MED, V71, P198, DOI 10.1097/00001888-199602000-00030; KINDIG DA, 1993, JAMA-J AM MED ASSOC, V270, P1069; Landon BE, 2003, JAMA-J AM MED ASSOC, V289, P442, DOI 10.1001/jama.289.4.442; Larson EB, 2004, ANN INTERN MED, V140, P639, DOI 10.7326/0003-4819-140-8-200404200-00011; Leigh JP, 2002, ARCH INTERN MED, V162, P1577, DOI 10.1001/archinte.162.14.1577; Lenfant C, 2003, NEW ENGL J MED, V349, P868, DOI 10.1056/NEJMsa035507; Levinson W, 1999, NEW ENGL J MED, V341, P840, DOI 10.1056/NEJM199909093411111; Lewin L O, 1999, Acad Med, V74, pS82, DOI 10.1097/00001888-199901000-00037; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; Lindbloom EJ, 2004, MED CARE, V42, P45, DOI 10.1097/01.mlr.0000119397.65643.d4; Linzer M, 2004, J GEN INTERN MED, V19, P163; Linzer M, 2000, J GEN INTERN MED, V15, P441, DOI 10.1046/j.1525-1497.2000.05239.x; LUDMERER KM, 1999, TIME HEAL AM MED ED, P288; Mechanic D, 2001, NEW ENGL J MED, V344, P198, DOI 10.1056/NEJM200101183440307; MEURER LN, 1995, ACAD MED, V70, P388, DOI 10.1097/00001888-199505000-00015; Miller JB, 2001, J RURAL HEALTH, V17, P160, DOI 10.1111/j.1748-0361.2001.tb00952.x; *NAT HLTH SERV COR, LOAN REP FUNDS EX GR; National Residency Match Program website, NATL RESIDENCY MATCH; Newton DA, 2003, JAMA-J AM MED ASSOC, V290, P1179, DOI 10.1001/jama.290.9.1179; *NIH, NIH CLIN LOAN REP PR; *NIH OFF EXTR RES, INF NIH CAR DEV AW; O'Brien-Gonzales A, 2001, ACAD MED, V76, pS49, DOI 10.1097/00001888-200104001-00010; Pathman DE, 1999, ACAD MED, V74, P810, DOI 10.1097/00001888-199907000-00016; PERKOFF GT, 1989, J FAM PRACTICE, V29, P185; Petrany SM, 2002, FAM MED, V34, P669; Pew Health Professions Commission, 1995, SHIFT SUPPL OUR HLTH; *PHYS PAYM REV COM, 1997, ANN REP C; Porterfield DS, 2003, J HEALTH CARE POOR U, V14, P256, DOI 10.1177/1049208903014002009; *R WOOD JOHNS FDN, NAT PROGR REP GEN PH; Rabinowitz HK, 2004, ANN INTERN MED, V140, P660, DOI 10.7326/0003-4819-140-8-200404200-00016; Rabinowitz HK, 2001, ACAD MED, V76, P587, DOI 10.1097/00001888-200106000-00007; Rabinowitz HK, 2000, J RURAL HEALTH, V16, P249, DOI 10.1111/j.1748-0361.2000.tb00468.x; Reinhardt UE, 2002, HEALTH AFFAIR, V21, P169, DOI 10.1377/hlthaff.21.3.169; Retchin SM, 2001, ACAD MED, V76, P316, DOI 10.1097/00001888-200104000-00005; Rosenberg LE, 1999, J CLIN INVEST, V103, P1621, DOI 10.1172/JCI7304; Safran DG, 2003, ANN INTERN MED, V138, P248, DOI 10.7326/0003-4819-138-3-200302040-00033; Schroeder S A, 1985, Health Aff (Millwood), V4, P22, DOI 10.1377/hlthaff.4.2.22; Schroeder SA, 2002, ACAD MED, V77, P767, DOI 10.1097/00001888-200208000-00003; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; *SOC GEN INT MED, CLIN TEACHER INITIAT; Starr Paul, 1982, SOCIAL TRANSFORMATIO, P335; Steele D, 2001, ACAD MED, V76, pS61, DOI 10.1097/00001888-200104001-00012; Steiner JF, 2002, ACAD MED, V77, P712, DOI 10.1097/00001888-200207000-00015; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; Thomas PA, 2004, ACAD MED, V79, P258, DOI 10.1097/00001888-200403000-00013; Urbina Christopher, 2003, Educ Health (Abingdon), V16, P279, DOI 10.1080/13576280310001607451; Veloski JJ, 1999, ACAD MED, V74, P539, DOI 10.1097/00001888-199905000-00022; Wartman S, 2001, ACAD MED, V76, pS140, DOI 10.1097/00001888-200104001-00028; Weinick R M, 1998, Stat Bull Metrop Insur Co, V79, P11; Wheatley Ben, 2002, State Coverage Initiat Issue Brief, V3, P1; Whitcomb ME, 2004, NEW ENGL J MED, V351, P710, DOI 10.1056/NEJMsb045003; Wilensky GR, 2004, ANN INTERN MED, V140, P662, DOI 10.7326/0003-4819-140-8-200404200-00018; ZISSON S, 2001, CENTERWATCH, V8, P1; 1969, WEBSTERS 7 NEW COLLE, P466	86	39	39	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					715	724		10.7326/0003-4819-142-8-200504190-00040	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00040			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916TZ	15838091				2022-12-28	WOS:000228410400030
J	Coggon, DIW; Martyn, CN				Coggon, DIW; Martyn, CN			Time and chance: the stochastic nature of disease causation	LANCET			English	Article									Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Martyn, CN (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.	cnm@mrc.soton.ac.uk						*BIBLE, KING JAMES, V11; Pepys Samuel, 1664, DIARY S PEPYS; WHEATLEY HB, PROJECT GUTENBERG RE	3	37	37	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2005	365	9468					1434	1437		10.1016/S0140-6736(05)66380-5	http://dx.doi.org/10.1016/S0140-6736(05)66380-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836893				2022-12-28	WOS:000228401900033
J	Hawton, K; James, A				Hawton, K; James, A			ABC of adolescence - Suicide and deliberate self harm in young people	BRITISH MEDICAL JOURNAL			English	Review									Univ Oxford, Ctr Suicide Res, Oxford OX1 2JD, England; Warneford Hosp, Oxfordshire Mental Healthcare Trust, Highfield Adolescent Unit, Oxford OX3 7JX, England	University of Oxford	Hawton, K (corresponding author), Univ Oxford, Ctr Suicide Res, Oxford OX1 2JD, England.							Fox C, 2004, DELIBERATE SELF HARM; Gould MS, 2003, J AM ACAD CHILD PSY, V42, P386, DOI 10.1097/01.CHI.0000046821.95464.CF; GRAHAM P, 1995, SO YOUNG SO SAD SO L; Hawton K, 2002, BMJ-BRIT MED J, V325, P1207, DOI 10.1136/bmj.325.7374.1207; Hawton K, 2003, J CHILD PSYCHOL PSYC, V44, P1191, DOI 10.1111/1469-7610.00200; HILL K, 1997, BEREAVEMENT INFORMAT; *RCPSYCH, SUIC SELF HARM PEOPL; *RCPSYCH, DEPR CHILDR YOUNG PE; Wertheimer A., 2001, SPECIAL SCAR EXPERIE, V2nd; Wood A, 2001, J AM ACAD CHILD PSY, V40, P1246, DOI 10.1097/00004583-200111000-00003	10	185	191	1	20	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 16	2005	330	7496					891	894		10.1136/bmj.330.7496.891	http://dx.doi.org/10.1136/bmj.330.7496.891			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	917UA	15831877	Green Published			2022-12-28	WOS:000228493500025
J	Mayer, AL; Kauppi, PE; Angelstam, PK; Zhang, Y; Tikka, PM				Mayer, AL; Kauppi, PE; Angelstam, PK; Zhang, Y; Tikka, PM			Importing timber, exporting ecological impact	SCIENCE			English	Article							FOREST POLICY; CONSERVATION; MANAGEMENT		US EPA, Off Res & Dev, Natl Risk Management Res Lab, Cincinnati, OH 45268 USA; Univ Helsinki, Dept Biol & Environm Sci, FIN-00014 Helsinki, Finland; Swedish Univ Agr Sci, Fac Forest Sci, Sch Forest Engineers, S-75007 Uppsala, Sweden	United States Environmental Protection Agency; University of Helsinki; Swedish University of Agricultural Sciences	Mayer, AL (corresponding author), US EPA, Off Res & Dev, Natl Risk Management Res Lab, Cincinnati, OH 45268 USA.	mayer.audrey@epa.gov	Mayer, AL/AAO-3225-2020	Mayer, AL/0000-0003-3278-1182				Angelstam P, 2003, AMBIO, V32, P527, DOI 10.1639/0044-7447(2003)032[0527:TGAATF]2.0.CO;2; ANGELSTAM P, 2004, ECOL B, V51; BARBIER EB, 1999, WORLD FORESTS SOC EN, P106; Bergeron Y, 2004, FOREST CHRON, V80, P458, DOI 10.5558/tfc80458-4; BERLIK MM, 2002, 26 HARV U; Burnett C, 2003, CONSERV ECOL, V7; Burton PJ, 2003, TOWARDS SUSTAINABLE MANAGEMENT OF THE BOREAL FOREST, P1; Carlson A, 2000, FOREST ECOL MANAG, V131, P215, DOI 10.1016/S0378-1127(99)00215-7; Dekker-Robertson DL, 1998, BIOSCIENCE, V48, P471, DOI 10.2307/1313245; DUDAREV G, 2002, ETLA SERIES B, V195; FILIPTCHOUK AN, 2001, 18 UN EC COMM EUR; Flagstad O, 2003, MOL ECOL, V12, P869, DOI 10.1046/j.1365-294X.2003.01784.x; Hammett AL, 2001, J FOREST, V99, P4; Hanski I, 2000, ANN ZOOL FENN, V37, P271; Lehtonen E, 2003, ENVIRON SCI POLICY, V6, P195, DOI 10.1016/S1462-9011(03)00035-2; Linden H, 2000, WILDLIFE BIOL, V6, P179, DOI 10.2981/wlb.2000.007; Liski J, 2003, CLIMATIC CHANGE, V61, P89, DOI 10.1023/A:1026365005696; LUND HG, 1998, P INT WORKSH JOENS F; Moiseyev A., 1999, World forests, society and environment, P351; Sedjo RA, 2001, FOREST CHRON, V77, P221, DOI 10.5558/tfc77221-2; SEDJO RA, 1995, J FOREST, V93, P25; Sohngen B, 1999, AM J AGR ECON, V81, P1, DOI 10.2307/1244446; *US EMB BEIJ, 2000, FOR PEOPL PRC NAT FO; VEIJOLA P, COMMUNICATION; Wang S, 2004, FOREST POLICY ECON, V6, P71, DOI 10.1016/S1389-9341(02)00078-3; Wernick IK, 2000, J FOREST, V98, P8; Zhang PC, 2000, SCIENCE, V288, P2135, DOI 10.1126/science.288.5474.2135; 2003, XINHUA NEWS AGE 1201	28	128	135	4	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					359	360		10.1126/science.1109476	http://dx.doi.org/10.1126/science.1109476			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831743	Green Submitted			2022-12-28	WOS:000228492000034
J	Farmer, H; McCabe, N; Lord, CJ; Tutt, ANJ; Johnson, DA; Richardson, TB; Santarosa, M; Dillon, KJ; Hickson, I; Knights, C; Martin, NMB; Jackson, SP; Smith, GCM; Ashworth, A				Farmer, H; McCabe, N; Lord, CJ; Tutt, ANJ; Johnson, DA; Richardson, TB; Santarosa, M; Dillon, KJ; Hickson, I; Knights, C; Martin, NMB; Jackson, SP; Smith, GCM; Ashworth, A			Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy	NATURE			English	Article							HOMOLOGY-DIRECTED REPAIR; POLY(ADP-RIBOSE) POLYMERASE; REPLICATION FORKS; PROTEIN; CANCER; BREAKS; RECOMBINATION; PHOSPHORYLATION; INHIBITORS; PARP-1	BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination(1), and mutations in these genes predispose to breast and other cancers(2). Poly(ADP-ribose) polymerase ( PARP) is an enzyme involved in base excision repair, a key pathway in the repair of DNA single-strand breaks(3). We show here that BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis. This seems to be because the inhibition of PARP leads to the persistence of DNA lesions normally repaired by homologous recombination. These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer.	Canc Res UK Gene Funct & Regulat Grp, London SW3 6JB, England; Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Guys Hosp, London SE1 9RT, England; KuDOS Pharmaceut Ltd, Cambridge CB4 0WG, England; Univ Cambridge, Gurdon Inst Canc & Dev Biol, Wellcome Trust & Canc REs UK, Cambridge CB2 1QN, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QN, England	Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Guy's & St Thomas' NHS Foundation Trust; AstraZeneca; Cancer Research UK; University of Cambridge; University of Cambridge	Ashworth, A (corresponding author), Canc Res UK Gene Funct & Regulat Grp, Fulham Rd, London SW3 6JB, England.	gcmsmith@kudospharma.co.uk; alan.ashworth@icr.ac.uk	Santarosa, Manuela/A-7300-2013; Lord, Christopher/AAX-7130-2021; Lord, Christopher J/B-3295-2012; Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Santarosa, Manuela/0000-0001-7682-2578; Lord, Christopher J/0000-0002-3226-0515; Jackson, Stephen Philip/0000-0001-9317-7937; Hickson, Ian/0000-0002-9167-0514; Tutt, Andrew/0000-0001-8715-2901	NCI NIH HHS [F31 CA260794] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Now		Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Boulton S, 1999, CARCINOGENESIS, V20, P199, DOI 10.1093/carcin/20.2.199; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; Dillon KJ, 2003, J BIOMOL SCREEN, V8, P347, DOI 10.1177/1087057103008003013; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; LOH VM, IN PRESS BIOINORG ME; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284	22	4332	4498	27	687	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	2005	434	7035					917	921		10.1038/nature03445	http://dx.doi.org/10.1038/nature03445			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829967				2022-12-28	WOS:000228327600045
J	Mehta, RH; Alexander, JH; Van de Werf, F; Armstrong, PW; Pieper, KS; Garg, J; Califf, RM; Granger, CB				Mehta, RH; Alexander, JH; Van de Werf, F; Armstrong, PW; Pieper, KS; Garg, J; Califf, RM; Granger, CB			Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; MEDICATION ERRORS; THROMBOLYSIS; TRIAL; PREDICTORS; MORTALITY; ALTEPLASE; BENEFITS; STROKE; AGENTS	Context Incorrect dosing of alteplase has been associated with worse clinical outcomes in patients. However, patients at high risk of adverse events are more prone to dosing errors, thus confounding this relationship. Objective To determine if the association between incorrect dosing of alteplase and adverse outcomes is related to cause and effect or to confounding. Design, Setting, and Patients Observational analysis in May 2004 of a double-blind, double-dummy trial of 16949 patients with ST-segment elevation myocardial infarction who were enrolled in the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) trial and were assigned to either a bolus of tenecteplase (with alteplase placebo bolus plus infusion) or a bolus of alteplase (with tenecteplase placebo plus infusion). Main Outcome Measures Thirty-day mortality, in-hospital stroke, and major bleeding associated with incorrect dosing of active alteplase compared with placebo alteplase. Results Incorrect dosing occurred in 4.9% of patients who received active alteplase and in 4.6% of patients who received alteplase placebo. Patients receiving incorrect doses of alteplase or alteplase placebo were more likely to be older, female, black, shorter, have lower body weight and systolic blood pressure, and have a higher Killip class at presentation. Thirty-day mortality was higher in patients who received an overdose (9.8%) or underdose (19.5%) of alteplase compared with those who received a correct dose (5.4%). The same pattern was present in patients who received an alteplase placebo (10.0% for overdose, 23.5% for underclose, and 5.4% for correct dose). Similar patterns were seen for in-hospital intracranial hemorrhage and major bleeding. The higher rates of adverse outcomes with incorrect dosing were largely accounted for by adjusting for baseline characteristics. Conclusions The relationship between incorrect dosing and patient outcome in ASSENT-2 is primarily due to confounding factors rather than incorrect dosing itself. These data highlight the need for caution when ascribing a causal relationship to associations between incorrect dosing and adverse outcomes.	Duke Univ, Med Ctr, Durham, NC 27710 USA; Duke Clin Res Inst, Durham, NC USA; Katholieke Univ Leuven Hosp, Dept Internal Med, Div Cardiol, Louvain, Belgium; Univ Alberta, Dept Internal Med, Div Cardiol, Edmonton, AB, Canada	Duke University; Duke University; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; University of Alberta	Granger, CB (corresponding author), Duke Univ, Med Ctr, Box 3409, Durham, NC 27710 USA.	grang001@mc.duke.edu	Alexander, John/GVS-7271-2022; Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Van de Werf, Frans/0000-0001-9479-7767; Armstrong, Paul/0000-0002-0460-3445; Alexander, John/0000-0002-1444-2462				Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; Cannon CP, 2000, AM HEART J, V140, pS154, DOI 10.1067/mhj.2000.111605; Cannon CP, 2000, AM J CARDIOL, V85, p17C; COULTER SA, 2000, CIRCULATION S2, V102, P1590; Freedman JE, 2002, CIRCULATION, V106, P2623, DOI 10.1161/01.CIR.0000037748.19282.7D; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; GRANGER CB, 1994, CIRCULATION S1, V90, P1324; Gurwitz JH, 1998, ANN INTERN MED, V129, P597, DOI 10.7326/0003-4819-129-8-199810150-00002; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; Phillips DP, 1998, LANCET, V351, P643, DOI 10.1016/S0140-6736(98)24009-8; SMALLING RW, 1995, CIRCULATION, V91, P2725, DOI 10.1161/01.CIR.91.11.2725; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; VORCHHEIMER DA, 1997, CIRCULATION S1, V96, P1535	13	13	14	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1746	1750		10.1001/jama.293.14.1746	http://dx.doi.org/10.1001/jama.293.14.1746			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827313	Bronze			2022-12-28	WOS:000228301100028
J	Crombie, C; Fraser, A				Crombie, C; Fraser, A			Treating genetic disease through RNA interference	LANCET			English	Editorial Material							CELLS		Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Fraser, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	agf@sanger.ac.uk		Fraser, Andrew/0000-0001-9939-6014				Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Reich S, 2003, MOL VIS, V9, P210; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121	7	4	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2005	365	9467					1288	1290		10.1016/S0140-6736(05)61006-9	http://dx.doi.org/10.1016/S0140-6736(05)61006-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823365				2022-12-28	WOS:000228219600007
J	Kouri, JG; Oldfield, EH				Kouri, JG; Oldfield, EH			A twin with Cushing's disease	LANCET			English	Editorial Material									NINDS, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Kouri, JG (corresponding author), NINDS, Surg Neurol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002855] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1332	1332		10.1016/S0140-6736(05)61031-8	http://dx.doi.org/10.1016/S0140-6736(05)61031-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823384				2022-12-28	WOS:000228219600029
J	Asplund, M				Asplund, M			A stellar swan-song	SCIENCE			English	Editorial Material							FINAL HELIUM FLASH; SAKURAIS OBJECT; EVOLUTION		Australian Natl Univ, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia	Australian National University	Asplund, M (corresponding author), Australian Natl Univ, Res Sch Astron & Astrophys, Weston, ACT 2611, Australia.	martin@mso.anu.edu.au						Amari S, 2001, ASTROPHYS J, V559, P463, DOI 10.1086/322397; Asplund M, 1997, ASTRON ASTROPHYS, V321, pL17; Asplund M, 1999, ASTRON ASTROPHYS, V343, P507; Clayton GC, 1997, ASTRON J, V114, P2679, DOI 10.1086/118678; Duerbeck HW, 1997, ASTRON J, V114, P1657, DOI 10.1086/118595; Duerbeck HW, 1996, ASTROPHYS J, V468, pL111, DOI 10.1086/310241; Eyres SPS, 1999, MON NOT R ASTRON SOC, V307, pL11, DOI 10.1046/j.1365-8711.1999.02791.x; FUJIMOTO MY, 1977, PUBL ASTRON SOC JPN, V29, P331; Hajduk M, 2005, SCIENCE, V308, P231, DOI 10.1126/science.1108953; Herwig F, 2001, ASTROPHYS J, V554, pL71, DOI 10.1086/320911; IBEN I, 1983, ASTROPHYS J, V264, P605, DOI 10.1086/160631; Kerber F, 1999, ASTRON ASTROPHYS, V350, pL27; Kerber F, 2002, ASTROPHYS J, V581, pL39, DOI 10.1086/345773; Lawlor TM, 2003, ASTROPHYS J, V583, P913, DOI 10.1086/345411	15	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					210	211		10.1126/science.1110366	http://dx.doi.org/10.1126/science.1110366			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821078				2022-12-28	WOS:000228273700037
J	Huber, D; Veinante, P; Stoop, R				Huber, D; Veinante, P; Stoop, R			Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala	SCIENCE			English	Article							EXTENDED AMYGDALA; BINDING SITES; IN-VITRO; RAT; BEHAVIOR; BRAIN; RELEASE; NUCLEUS; ANTAGONIST; EXPRESSION	Vasopressin and oxytocin strongly modulate autonomic fear responses, through mechanisms that are still unclear. We describe how these neuro-peptides excite distinct neuronal populations in the central amygdala, which provides the major output of the amygdaloid complex to the autonomic nervous system. We identified these two neuronal. populations as part of an inhibitory network, through which vasopressin and oxytocin modulate the integration of excitatory information from the basolateral amygdala and cerebral cortex in opposite manners. Through this network, the expression and endogenous activation of vasopressin and oxytocin receptors may regulate the autonomic expression of fear.	Univ Lausanne, Ctr Hosp Univ Vaudois, Dept Cellular Biol & Morphol, CH-1015 Lausanne, Switzerland; Univ Lausanne, Ctr Hosp Univ Vaudois, Dept Psychiat, Ctr Psychiat Neurosci, CH-1015 Lausanne, Switzerland; Univ Strasbourg 1, CNRS, UMR 7519, Strasbourg, France	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Stoop, R (corresponding author), Univ Lausanne, Ctr Hosp Univ Vaudois, Dept Cellular Biol & Morphol, CH-1015 Lausanne, Switzerland.	rstoop@unil.ch	Huber, Daniel/C-2932-2013	Huber, Daniel/0000-0002-0744-7679; Veinante, Pierre/0000-0002-6608-8960				Bale TL, 2001, J NEUROSCI, V21, P2546, DOI 10.1523/JNEUROSCI.21-07-02546.2001; Bielsky IF, 2004, NEUROPSYCHOPHARMACOL, V29, P483, DOI 10.1038/sj.npp.1300360; Cassell MD, 1999, ANN NY ACAD SCI, V877, P217, DOI 10.1111/j.1749-6632.1999.tb09270.x; Champagne F, 2001, P NATL ACAD SCI USA, V98, P12736, DOI 10.1073/pnas.221224598; CONDESLARA M, 1994, BRAIN RES, V637, P277, DOI 10.1016/0006-8993(94)91245-9; DEVRIES GJ, 1983, BRAIN RES, V273, P307, DOI 10.1016/0006-8993(83)90855-7; Ebner K, 2005, NEUROPSYCHOPHARMACOL, V30, P223, DOI 10.1038/sj.npp.1300607; Ferguson JN, 2000, NAT GENET, V25, P284, DOI 10.1038/77040; Francis DD, 2002, J NEUROENDOCRINOL, V14, P349, DOI 10.1046/j.0007-1331.2002.00776.x; Griebel G, 2002, P NATL ACAD SCI USA, V99, P6370, DOI 10.1073/pnas.092012099; Kang-Park MH, 2004, NEUROPHARMACOLOGY, V46, P1, DOI 10.1016/S0028-3908(03)00340-X; Koob GF, 2003, EUR NEUROPSYCHOPHARM, V13, P442, DOI 10.1016/j.euroneuro.2003.08.005; KOVACS GL, 1994, PHARMACOL REV, V46, P269; Landgraf R, 2004, FRONT NEUROENDOCRIN, V25, P150, DOI 10.1016/j.yfrne.2004.05.001; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Lu YF, 1997, BRAIN RES, V768, P266, DOI 10.1016/S0006-8993(97)00655-0; Lubin DA, 2003, BEHAV NEUROSCI, V117, P195, DOI 10.1037/0735-7044.117.2.195; McDonald AJ, 1999, ANN NY ACAD SCI, V877, P309, DOI 10.1111/j.1749-6632.1999.tb09275.x; Nie ZG, 2004, SCIENCE, V303, P1512, DOI 10.1126/science.1092550; Pare D, 2004, J NEUROPHYSIOL, V92, P1, DOI 10.1152/jn.00153.2004; Quirk GJ, 2003, J NEUROSCI, V23, P8800, DOI 10.1523/jneurosci.23-25-08800.2003; Raggenbass M, 2001, PROG NEUROBIOL, V64, P307, DOI 10.1016/S0301-0082(00)00064-2; Sah P, 2003, PHYSIOL REV, V83, P803, DOI 10.1152/physrev.00002.2003; Savander V, 1996, J COMP NEUROL, V374, P291, DOI 10.1002/(SICI)1096-9861(19961014)374:2<291::AID-CNE10>3.0.CO;2-Y; SOFRONIEW MV, 1983, TRENDS NEUROSCI, V6, P467, DOI 10.1016/0166-2236(83)90221-7; Veinante P, 1997, J COMP NEUROL, V383, P305; Windle RJ, 1997, ENDOCRINOLOGY, V138, P2829, DOI 10.1210/en.138.7.2829	27	602	624	1	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					245	248		10.1126/science.1105636	http://dx.doi.org/10.1126/science.1105636			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821089				2022-12-28	WOS:000228273700051
J	Alexander, DM; Smail, I; Bauer, FE; Chapman, SC; Blain, AW; Brandt, WN; Ivison, RJ				Alexander, DM; Smail, I; Bauer, FE; Chapman, SC; Blain, AW; Brandt, WN; Ivison, RJ			Rapid growth of black holes in massive star-forming galaxies	NATURE			English	Article							ACTIVE GALACTIC NUCLEI; FIELD NORTH SURVEY; REDSHIFT; EVOLUTION; BRIGHT; QSO	The tight relationship between the masses of black holes and galaxy spheroids in nearby galaxies(1) implies a causal connection between the growth of these two components. Optically luminous quasars host the most prodigious accreting black holes in the Universe, and can account for greater than or similar to 30 per cent of the total cosmological black-hole growth(2,3). As typical quasars are not, however, undergoing intense star formation and already host massive black holes (>10(8) M (circle dot), where M (circle dot) is the solar mass)(4,5), there must have been an earlier pre-quasar phase when these black holes grew (mass range similar to(10(6)-10(8))M((circle dot)). The likely signature of this earlier stage is simultaneous black-hole growth and star formation in distant (redshift z > 1; > 8 billion light years away) luminous galaxies. Here we report ultra-deep X-ray observations of distant star-forming galaxies that are bright at submillimetre wavelengths. We find that the black holes in these galaxies are growing almost continuously throughout periods of intense star formation. This activity appears to be more tightly associated with these galaxies than any other coeval galaxy populations. We show that the black-hole growth from these galaxies is consistent with that expected for the pre-quasar phase.	Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England; Univ Durham, Inst Computat Cosmol, Durham DH1 3LE, England; CALTECH, Pasadena, CA 91125 USA; Penn State Univ, Dept Astron & Astrophys, University Pk, PA 16802 USA; Royal Observ, Astron Technol Ctr, Edinburgh EH9 3HJ, Midlothian, Scotland; Univ Edinburgh, Inst Astron, Edinburgh EH9 3HJ, Midlothian, Scotland	University of Cambridge; Durham University; California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Edinburgh; University of Edinburgh	Alexander, DM (corresponding author), Univ Cambridge, Inst Astron, Madingley Rd, Cambridge CB3 0HA, England.	dma@ast.cam.ac.uk	Brandt, William N/N-2844-2015; Ivison, R. J./G-4450-2011; Alexander, David/K-5544-2019; Smail, Ian/M-5161-2013; Smail, Ian/AAL-9018-2020	Brandt, William N/0000-0002-0167-2453; Ivison, R. J./0000-0001-5118-1313; Alexander, David/0000-0002-5896-6313; Smail, Ian/0000-0003-3037-257X; Smail, Ian/0000-0003-3037-257X; Bauer, Franz Erik/0000-0002-8686-8737				Alexander DM, 2003, ASTRON J, V126, P539, DOI 10.1086/376473; Alexander DM, 2003, ASTRON J, V125, P383, DOI 10.1086/346088; ALEXANDER DM, UNPUB ASTROPHYS J; Archibald EN, 2002, MON NOT R ASTRON SOC, V336, P353, DOI 10.1046/j.1365-8711.2002.05725.x; Barger AJ, 2005, ASTRON J, V129, P578, DOI 10.1086/426915; Chapman SC, 2003, NATURE, V422, P695, DOI 10.1038/nature01540; Conselice CJ, 2003, ASTROPHYS J, V596, pL5, DOI 10.1086/379109; Croom SM, 2004, MON NOT R ASTRON SOC, V349, P1397, DOI 10.1111/j.1365-2966.2004.07619.x; Dunlop JS, 2003, MON NOT R ASTRON SOC, V340, P1095, DOI 10.1046/j.1365-8711.2003.06333.x; ELVIS M, 1994, ASTROPHYS J SUPPL S, V95, P1, DOI 10.1086/192093; Fabian AC, 1999, MON NOT R ASTRON SOC, V308, pL39, DOI 10.1046/j.1365-8711.1999.03017.x; Fadda D, 2002, ASTRON ASTROPHYS, V383, P838, DOI 10.1051/0004-6361:20011842; Granato GL, 2004, ASTROPHYS J, V600, P580, DOI 10.1086/379875; GREVE TR, 2005, IN PRESS MON NOT R A; Hughes DH, 1998, NATURE, V394, P241, DOI 10.1038/28328; Ivison RJ, 2004, ASTROPHYS J SUPPL S, V154, P124, DOI 10.1086/423249; Lewis GF, 2005, ASTROPHYS J, V621, P32, DOI 10.1086/427489; Marconi A, 2004, MON NOT R ASTRON SOC, V351, P169, DOI 10.1111/j.1365-2966.2004.07765.x; McLure RJ, 2004, MON NOT R ASTRON SOC, V352, P1390, DOI 10.1111/j.1365-2966.2004.08034.x; Page MJ, 2004, ASTROPHYS J, V611, pL85, DOI 10.1086/423892; Smail I, 2004, ASTROPHYS J, V616, P71, DOI 10.1086/424896; Smail I, 2002, MON NOT R ASTRON SOC, V331, P495, DOI 10.1046/j.1365-8711.2002.05203.x; Springel V, 2005, ASTROPHYS J, V620, pL79, DOI 10.1086/428772; Steidel CC, 2004, ASTROPHYS J, V604, P534, DOI 10.1086/381960; Stevens JA, 2004, ASTROPHYS J, V604, pL17, DOI 10.1086/383314; Swinbank AM, 2004, ASTROPHYS J, V617, P64, DOI 10.1086/425171; Tecza M, 2004, ASTROPHYS J, V605, P109; Tremaine S, 2002, ASTROPHYS J, V574, P740, DOI 10.1086/341002; Veilleux S, 1999, ASTROPHYS J, V522, P113, DOI 10.1086/307634; Yu QJ, 2002, MON NOT R ASTRON SOC, V335, P965, DOI 10.1046/j.1365-8711.2002.05532.x	30	199	199	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					738	740		10.1038/nature03473	http://dx.doi.org/10.1038/nature03473			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815623	Green Submitted, Green Accepted			2022-12-28	WOS:000228160700033
J	Bricelj, VM; Connell, L; Konoki, K; MacQuarrie, SP; Scheuer, T; Catterall, WA; Trainer, VL				Bricelj, VM; Connell, L; Konoki, K; MacQuarrie, SP; Scheuer, T; Catterall, WA; Trainer, VL			Sodium channel mutation leading to saxitoxin resistance in clams increases risk of PSP	NATURE			English	Article							SITE-DIRECTED MUTAGENESIS; TETRODOTOXIN; INSENSITIVITY; ADAPTATION; MECHANISMS; BINDING; TOXINS; REGION; GENE	Bivalve molluscs, the primary vectors of paralytic shellfish poisoning (PSP) in humans, show marked inter-species variation in their capacity to accumulate PSP toxins (PSTs)(1) which has a neural basis(2,3). PSTs cause human fatalities by blocking sodium conductance in nerve fibres(4,5). Here we identify a molecular basis for inter-population variation in PSP resistance within a species, consistent with genetic adaptation to PSTs. Softshell clams (Mya arenaria) from areas exposed to 'red tides' are more resistant to PSTs, as demonstrated by whole-nerve assays, and accumulate toxins at greater rates than sensitive clams from unexposed areas. PSTs lead to selective mortality of sensitive clams. Resistance is caused by natural mutation of a single amino acid residue, which causes a 1,000-fold decrease in affinity at the saxitoxin-binding site in the sodium channel pore of resistant, but not sensitive, clams. Thus PSTs might act as potent natural selection agents, leading to greater toxin resistance in clam populations and increased risk of PSP in humans. Furthermore, global expansion of PSP to previously unaffected coastal areas(6) might result in long-term changes to communities and ecosystems.	Natl Res Council Canada, Inst Marine Biosci, Halifax, NS B3H 3Z1, Canada; Univ Maine, Sch Marine Sci, Orono, ME 04469 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; NOAA Fisheries, NW Fisheries Sci Ctr, Seattle, WA 98112 USA	International Business Machines (IBM); National Research Council Canada; University of Maine System; University of Maine Orono; University of Washington; University of Washington Seattle; National Oceanic Atmospheric Admin (NOAA) - USA	Bricelj, VM (corresponding author), Natl Res Council Canada, Inst Marine Biosci, Halifax, NS B3H 3Z1, Canada.	monica.bricelj@nrc-cnrc.gc.ca	KONOKI, Keiichi/U-2249-2019; Trainer, Vera/AAE-9306-2022					AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; Bricelj V, 1996, HARMFUL TOXIC ALGAL, P405; Bricelj V. Monica, 1998, Reviews in Fisheries Science, V6, P315, DOI 10.1080/10641269891314294; BRICELJ VM, 1991, MAR ECOL PROG SER, V74, P33, DOI 10.3354/meps074033; Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; Geffeney S, 2002, SCIENCE, V297, P1336, DOI 10.1126/science.1074310; Hallegraeff G. M., 2003, MANUAL HARMFUL MARIN, P25; He HQ, 1999, BIOCHEM BIOPH RES CO, V261, P558, DOI 10.1006/bbrc.1999.1076; HILLE B, 1968, J GEN PHYSIOL, V51, P199, DOI 10.1085/jgp.51.2.199; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; KONTIS KJ, 1993, MOL PHARMACOL, V43, P635; KVITEK RG, 1991, MAR ECOL PROG SER, V69, P47, DOI 10.3354/meps069047; Linford NJ, 1998, P NATL ACAD SCI USA, V95, P13947, DOI 10.1073/pnas.95.23.13947; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; Liu MY, 1998, ARCH INSECT BIOCHEM, V37, P73, DOI 10.1002/(SICI)1520-6327(1998)37:1&lt;73::AID-ARCH9&gt;3.0.CO;2-W; MACQUARRIE S. P., 2002, THESIS DALHOUSIE U; Martin JL., 1996, HARMFUL TOXIC ALGAL, P3; NARAHASHI T, 1968, J GEN PHYSIOL, V51, pS93; Oshima Y, 1995, MANUAL HARMFUL MARIN, P81; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; Sivilotti L, 1997, FEBS LETT, V409, P49, DOI 10.1016/S0014-5793(97)00479-1; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TWAROG BM, 1972, TOXICON, V10, P273, DOI 10.1016/0041-0101(72)90012-8; Twarog BM, 1974, P 2 INT COR REEF S, P505; Yamane M, 2003, INST GLOB ENVIRONM S, V3, P3	27	238	252	5	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					763	767		10.1038/nature03415	http://dx.doi.org/10.1038/nature03415			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815630				2022-12-28	WOS:000228160700041
J	Markel, H				Markel, H			April 12, 1955 - Tommy Francis and the Salk vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan	Markel, H (corresponding author), Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48104 USA.							CARTER R, 1966, BREAKTHROUGH SAGA J, P15; Francis Thomas, 1957, EVALUATION 1954 FIEL; GOULD T, 1995, SUMMER PLAGUE POLIO, P150; PAUL JR, 1971, HIST POLIOMYELITIS, P252; SMITH JS, 1990, PATENTING SUN POLIO, P320	5	8	9	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1408	1410		10.1056/NEJMp048250	http://dx.doi.org/10.1056/NEJMp048250			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814876				2022-12-28	WOS:000228145200003
J	Strom, BL				Strom, BL			Statins and over-the counter availibility	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Strom, BL (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.								0	18	18	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1403	1405		10.1056/NEJMp058025	http://dx.doi.org/10.1056/NEJMp058025			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814874				2022-12-28	WOS:000228145200001
J	Jenner, L; Romby, P; Rees, B; Schulze-Briese, C; Springer, M; Ehresmann, C; Ehresmann, B; Moras, D; Yusupova, G; Yusupov, M				Jenner, L; Romby, P; Rees, B; Schulze-Briese, C; Springer, M; Ehresmann, C; Ehresmann, B; Moras, D; Yusupova, G; Yusupov, M			Translational operator of mRNA on the ribosome: How repressor proteins exclude ribosome binding	SCIENCE			English	Article							RAY CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; SYNTHETASE GENE; SUBUNIT; SITE; EXPRESSION; S1	The ribosome of Thermus thermophilus was cocrystallized with initiator transfer RNA (tRNA) and a structured messenger RNA (mRNA) carrying a translational operator. The path of the mRNA was defined at 5.5 angstroms resolution by comparing it with either the crystal structure of the same ribosomal complex lacking mRNA or with an unstructured mRNA. A precise ribosomal environment positions the operator stem-loop structure perpendicular to the surface of the ribosome on the platform of the 30S subunit. The binding of the operator and of the initiator tRNA occurs on the ribosome with an unoccupied tRNA exit site, which is expected for an initiation complex. The positioning of the regulatory domain of the operator relative to the ribosome elucidates the molecular mechanism by which the bound repressor switches off translation. Our data suggest a general way in which mRNA control elements must be placed on the ribosome to perform their regulatory task.	Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France; Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; Paul Scherrer Inst, Swiss Light Source, CH-8048 Zurich, Switzerland; Inst Biol Physicochim, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Yusupov, M (corresponding author), Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France.	marat@titus.u-strasbg.fr	ROMBY, Pascale/AGP-3328-2022; Yusupov, Marat/I-6126-2013; Yusupova, Gulnara/E-1877-2014; Jenner, Lasse/H-1584-2017	Yusupov, Marat/0000-0001-5544-0597; Jenner, Lasse/0000-0003-3917-8853				Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Blaha G, 2001, COLD SPRING HARB SYM, V66, P135, DOI 10.1101/sqb.2001.66.135; Caillet J, 2003, MOL MICROBIOL, V47, P961, DOI 10.1046/j.1365-2958.2003.03364.x; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; GRAFFE M, 1992, SCIENCE, V255, P994, DOI 10.1126/science.1372129; Gromadski KB, 2004, MOL CELL, V13, P191, DOI 10.1016/S1097-2765(04)00005-X; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; KEITH GM, UNPUB; Komarova AV, 2002, RNA, V8, P1137, DOI 10.1017/S1355838202029990; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; Nogueira T, 2001, J MOL BIOL, V310, P709, DOI 10.1006/jmbi.2001.4796; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Romby P, 2003, TRENDS GENET, V19, P155, DOI 10.1016/S0168-9525(03)00020-9; Sacerdot C, 1998, MOL MICROBIOL, V29, P1077, DOI 10.1046/j.1365-2958.1998.00995.x; Sankaranarayanan R, 1999, CELL, V97, P371, DOI 10.1016/S0092-8674(00)80746-1; Schlax PJ, 2003, MOL MICROBIOL, V48, P1157, DOI 10.1046/j.1365-2958.2003.03517.x; Sengupta J, 2001, P NATL ACAD SCI USA, V98, P11991, DOI 10.1073/pnas.211266898; SPIRIN A, 1998, METHOD ENZYMOL, V164, P631; Torres-Larios A, 2002, NAT STRUCT BIOL, V9, P343, DOI 10.1038/nsb789; Vila-Sanjurjo A, 2003, P NATL ACAD SCI USA, V100, P8682, DOI 10.1073/pnas.1133380100; Winkler W, 2002, NATURE, V419, P952, DOI 10.1038/nature01145; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	25	76	83	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					120	123		10.1126/science.1105639	http://dx.doi.org/10.1126/science.1105639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802605				2022-12-28	WOS:000228221500047
J	DePalma, RG; Burris, DG; Champion, HR; Hodgson, MJ				DePalma, RG; Burris, DG; Champion, HR; Hodgson, MJ			Current concepts: Blast injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							COMPARTMENT SYNDROME; UNITED-STATES; BIOTERRORISM; EXPLOSION; RESUSCITATION; CONSEQUENCES; TERRORISM; SURVIVORS; BOMBINGS; RUPTURE		Vet Hlth Adm, Off Patient Care Serv, Med Surg Grp, Washington, DC 20420 USA; Vet Hlth Adm, Off Publ Hlth & Environm Hazards, Washington, DC 20420 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Uniformed Services University of the Health Sciences - USA	DePalma, RG (corresponding author), Vet Hlth Adm, Off Patient Care Serv, Med Surg Grp, 810 Vermont Ave NW,111B, Washington, DC 20420 USA.	rgdepalma@mail.va.gov						Abarbanell NR, 2001, AM J EMERG MED, V19, P137, DOI 10.1053/ajem.2001.21302; Abassi ZA, 1998, SEMIN NEPHROL, V18, P558; Aharonson-Daniel L, 2003, PEDIATRICS, V112, pE280, DOI 10.1542/peds.112.4.e280; Arnold JL, 2004, ANN EMERG MED, V43, P263, DOI 10.1016/S0196-0644(03)00723-6; Boholm A., 1998, J RISK RES, V1, P135, DOI [10.1080/136698798377231, DOI 10.1080/136698798377231]; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; BRUMBACK RJ, 1990, J BONE JOINT SURG AM, V72A, P134, DOI 10.2106/00004623-199072010-00023; Burris D, 1999, J TRAUMA, V46, P216, DOI 10.1097/00005373-199902000-00003; Bush LM, 2001, NEW ENGL J MED, V345, P1607, DOI 10.1056/NEJMoa012948; CHAMPION HR, 2004, TRAUMA, P1161; Clark MA, 1998, CLIN LAB MED, V18, P99; COPPEL DL, 1976, BRIT J SURG, V63, P735, DOI 10.1002/bjs.1800631003; Covello VT, 2001, J URBAN HEALTH, V78, P382, DOI 10.1093/jurban/78.2.382; Crompton R, 1980, Med Leg J, V48, P51; Cullis I G, 2001, J R Army Med Corps, V147, P16; DE CANDOLE C. A., 1967, CAN MED ASS J, V96, P207; *DEP DEF, EMERGENCY WAR SURG N; *FED BUR INV, 2003, FBI BOMB DAT CTR PUB, V367; Gans Lucille, 1996, Emergency Medicine Clinics of North America, V14, P301, DOI 10.1016/S0733-8627(05)70253-4; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107, DOI 10.1097/01.CCM.0000151072.17826.72; Guy R J, 1998, J R Nav Med Serv, V84, P79; Guzzi L M, 1996, Eur J Emerg Med, V3, P252, DOI 10.1097/00063110-199612000-00007; HABERSTROH J, 2004, NEWSDAY         0329; Halpern Pinchas, 2003, Prehosp Disaster Med, V18, P235; Hessmann M, 1998, ACTA CHIR BELG, V98, P18; Hogan DE, 1999, ANN EMERG MED, V34, P160, DOI 10.1016/S0196-0644(99)70224-6; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; JENSEN JH, 1993, ACTA OTO-LARYNGOL, V113, P62, DOI 10.3109/00016489309135768; Jernigan DB, 2002, EMERG INFECT DIS, V8, P1019, DOI 10.3201/eid0810.020353; KARMYJONES R, 1994, MIL MED, V159, P536, DOI 10.1093/milmed/159.7.536; KATZ E, 1989, ANN SURG, V209, P484, DOI 10.1097/00000658-198904000-00016; Kuwagata Y, 1997, J TRAUMA, V43, P427, DOI 10.1097/00005373-199709000-00007; LAVANOAS E, BLAST INJURIES; Leibovici D, 1999, ANN EMERG MED, V34, P168, DOI 10.1016/S0196-0644(99)70225-8; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Leppaniemi A, 1996, J SURG RES, V63, P413, DOI 10.1006/jsre.1996.0285; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703, DOI 10.1289/ehp.02110703; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; Miller ISM, 2002, OTOLARYNG HEAD NECK, V126, P127, DOI 10.1067/mhn.2002.122186; Miller K, 2003, EMERG MED CLIN N AM, V21, P533, DOI 10.1016/S0733-8627(03)00011-7; O'Mara MS, 2003, AM SURGEON, V69, P975; Odhiambo WA, 2002, INT J ORAL MAX SURG, V31, P374, DOI 10.1054/ijom.2001.0199; Okumura T, 1996, ANN EMERG MED, V28, P129, DOI 10.1016/S0196-0644(96)70052-5; Quintana DA, 1997, J PEDIATR SURG, V32, P307, DOI 10.1016/S0022-3468(97)90199-8; Quintana DA, 1997, J PEDIATR SURG, V32, P932; Stein M, 1999, SURG CLIN N AM, V79, P1537, DOI 10.1016/S0039-6109(05)70091-8; Su WT, 2004, J VASC SURG, V39, P672, DOI 10.1016/j.jvs.2003.09.020; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Vassalos A, 2003, SCOT MED J, V48, P82, DOI 10.1177/003693300304800306; WIGHTMAN JM, EXPLOSIONS BLAST INJ; Wood Stephen P, 2003, Prehosp Emerg Care, V7, P241, DOI 10.1080/10903120390936860; Yang ZH, 1996, J TRAUMA, V40, pS81, DOI 10.1097/00005373-199603001-00019	53	522	548	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1335	1342		10.1056/NEJMra042083	http://dx.doi.org/10.1056/NEJMra042083			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800229				2022-12-28	WOS:000227998300010
J	Kinjo, Y; Wu, D; Kim, GS; Xing, GW; Poles, MA; Ho, DD; Tsuji, M; Kawahara, K; Wong, CH; Kronenberg, M				Kinjo, Y; Wu, D; Kim, GS; Xing, GW; Poles, MA; Ho, DD; Tsuji, M; Kawahara, K; Wong, CH; Kronenberg, M			Recognition of bacterial glycosphingolipids by natural killer T cells	NATURE			English	Article							NKT CELLS; ALPHA-GALACTOSYLCERAMIDE; CUTTING EDGE; ACTIVATION	Natural killer T (NKT) cells constitute a highly conserved T lymphocyte subpopulation that has the potential to regulate many types of immune responses through the rapid secretion of cytokines(1,2). NKT cells recognize glycolipids presented by CD1d, a class I-like antigen- presenting molecule. They have an invariant T-cell antigen receptor (TCR) alpha-chain, but whether this invariant TCR recognizes microbial antigens is still controversial. Here we show that most mouse and human NKT cells recognize glycosphingolipids from Sphingomonas, Gram-negative bacteria that do not contain lipopolysaccharide(3-5). NKT cells are activated in vivo after exposure to these bacterial antigens or bacteria, and mice that lack NKT cells have a marked defect in the clearance of Sphingomonas from the liver. These data suggest that NKT cells are T lymphocytes that provide an innate-type immune response to certain microorganisms through recognition by their antigen receptor, and that they might be useful in providing protection from bacteria that cannot be detected by pattern recognition receptors such as Toll-like receptor 4.	La Jolla Inst Allergy & Immunol, Div Dev Immunol, San Diego, CA 92121 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; NYU, Sch Med, Dept Med, Div Gastroenterol, New York, NY 10016 USA; Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA; Kitasato Inst, Minato Ku, Tokyo 1088642, Japan	La Jolla Institute for Immunology; Scripps Research Institute; Scripps Research Institute; New York University; Rockefeller University; New York University	Kronenberg, M (corresponding author), La Jolla Inst Allergy & Immunol, Div Dev Immunol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	mitch@liai.org	Tsuji, Moriya/B-1471-2008	Poles, Michael/0000-0002-7993-6156; Tsuji, Moriya/0000-0001-8587-277X				Amprey JL, 2004, J EXP MED, V200, P895, DOI 10.1084/jem.20040704; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; Brossay L, 1998, J EXP MED, V188, P1521, DOI 10.1084/jem.188.8.1521; Brossay L, 1998, J IMMUNOL, V161, P5124; Cheroutre H, 2004, ANNU REV IMMUNOL, V22, P217, DOI 10.1146/annurev.immunol.22.012703.104522; FISCHER B, 1985, FERTILITAT, V1, P101; Fujii S, 2002, NAT IMMUNOL, V3, P867, DOI 10.1038/ni827; Fujii S, 2003, J EXP MED, V198, P267, DOI 10.1084/jem.20030324; Gonzalez-Aseguinolaza G, 2002, J EXP MED, V195, P617, DOI 10.1084/jem.20011889; Kawahara K, 2002, FEMS MICROBIOL LETT, V214, P289; KAWAHARA K, 1991, FEBS LETT, V292, P107, DOI 10.1016/0014-5793(91)80845-T; Kawahara K, 2000, EUR J BIOCHEM, V267, P1837, DOI 10.1046/j.1432-1327.2000.01189.x; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kobayashi E, 1995, ONCOL RES, V7, P529; Lehuen A, 1998, J EXP MED, V188, P1831, DOI 10.1084/jem.188.10.1831; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Matsuda JL, 2003, P NATL ACAD SCI USA, V100, P8395, DOI 10.1073/pnas.1332805100; Matsuda JL, 2001, P NATL ACAD SCI USA, V98, P12636, DOI 10.1073/pnas.221445298; Mempel M, 2002, J IMMUNOL, V168, P365, DOI 10.4049/jimmunol.168.1.365; Neef A, 1999, J IND MICROBIOL BIOT, V23, P261, DOI 10.1038/sj.jim.2900768; Park SH, 2000, EUR J IMMUNOL, V30, P620, DOI 10.1002/1521-4141(200002)30:2<620::AID-IMMU620>3.0.CO;2-4; Schumann J, 2003, J IMMUNOL, V170, P5815, DOI 10.4049/jimmunol.170.12.5815; Shaw PX, 2003, J IMMUNOL, V170, P6151, DOI 10.4049/jimmunol.170.12.6151; Sidobre S, 2004, P NATL ACAD SCI USA, V101, P12254, DOI 10.1073/pnas.0404632101; Skold M, 2003, INFECT IMMUN, V71, P5447, DOI 10.1128/IAI.71.10.5447-5455.2003; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.immunol.21.120601.141057; Vincent MS, 2003, NAT IMMUNOL, V4, P517, DOI 10.1038/ni0603-517; Wu DY, 2003, J EXP MED, V198, P173, DOI 10.1084/jem.20030446; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	30	741	772	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					520	525		10.1038/nature03407	http://dx.doi.org/10.1038/nature03407			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791257				2022-12-28	WOS:000227836000045
J	Zack, SP; Penkrot, TA; Bloch, JI; Rose, KD				Zack, SP; Penkrot, TA; Bloch, JI; Rose, KD			Affinities of 'hyopsodontids' to elephant shrews and a Holarctic origin of Afrotheria	NATURE			English	Article							MAMMALIA; EOCENE; RADIATION	Macroscelideans ( elephant shrews or sengis) are small-bodied ( 25 - 540 g), cursorial ( running) and saltatorial ( jumping), insectivorous and omnivorous(1) placental mammals represented by at least 15 extant African species classified in four genera(2). Macroscelidea is one of several morphologically diverse but predominantly African placental orders classified in the superorder Afrotheria by molecular phylogeneticists(3,4). The distribution of modern afrotheres, in combination with a basal position for Afrotheria within Placentalia and molecular divergence-time estimates, has been used to link placental diversification with the mid-Cretaceous separation of South America and Africa(4). Morphological phylogenetic analyses do not support Afrotheria(5-7) and the fossil record favours a northern origin of Placentalia(8). Here we describe fossil postcrania that provide evidence for a close relationship between North American Palaeocene Eocene apheliscine 'hyopsodontid' ` condylarths' ( early ungulates or hoofed mammals) and extant Macroscelidea. Apheliscine postcranial morphology is consistent with a relationship to other ungulate-like afrotheres (Hyracoidea, Proboscidea) but does not provide support for a monophyletic Afrotheria. As the oldest record of an afrothere clade, identification of macroscelidean relatives in the North American Palaeocene argues against an African origin for Afrotheria, weakening support for linking placental diversification to the break-up of Gondwana.	Johns Hopkins Univ, Sch Med, Ctr Funct Anat & Evolut, Baltimore, MD 21205 USA; Univ Florida, Florida Museum Nat Hist, Gainesville, FL 32611 USA	Johns Hopkins University; State University System of Florida; University of Florida	Zack, SP (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Funct Anat & Evolut, 1830 E Monument St, Baltimore, MD 21205 USA.	szack1@jhem.jhmi.edu		Bloch, Jonathan/0000-0003-1484-6931; Zack, Shawn/0000-0003-3098-7494				Archibald J. David, 1998, P292; Archibald JD, 2003, MOL PHYLOGENET EVOL, V28, P350, DOI 10.1016/S1055-7903(03)00034-4; Asher RJ, 1999, CLADISTICS, V15, P231, DOI 10.1111/j.1096-0031.1999.tb00266.x; Asher Robert J., 2003, Journal of Mammalian Evolution, V10, P131, DOI 10.1023/A:1025504124129; BUTLER PM, 1995, MAMMAL REV, V25, P3, DOI 10.1111/j.1365-2907.1995.tb00432.x; CIFELLI RL, 1983, AM MUS NOVIT, P1; COURT N, 1994, ZOOL J LINN SOC-LOND, V111, P297, DOI 10.1111/j.1096-3642.1994.tb01487.x; Gazin C. L., 1968, Smithsonian Miscellaneous Collections, V153, P1; Ginsburg L, 1999, CR ACAD SCI II A, V328, P209, DOI 10.1016/S1251-8050(99)80098-6; Godinot Marc, 1996, Palaeovertebrata (Montpellier), V25, P225; HARTENBERGER JL, 1986, CR ACAD SCI II, V302, P247; Jennings Mark R., 2001, Mammalian Species, V682, P1, DOI 10.1644/1545-1410(2001)682<0001:PT>2.0.CO;2; KINGDON J, 1974, E AFRICAN MAMMALS A, V2; MACPHEE RDE, 1994, B AM MUS NAT HIST, P1; McKenna MC, 1997, CLASSIFICATION MAMMA; Meng J, 2003, B AM MUS NAT HIST, P1; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; NOVACEK M J, 1986, Cladistics, V2, P257, DOI 10.1111/j.1096-0031.1986.tb00463.x; NOVACEK MJ, 1986, B AM MUS NAT HIST, V183, P1; RATHBUN GB, 1979, Z TIERPSYCHOL S, V20, P1; Rose K.D., 1990, GEOLOGICAL SOC AM SP, V243, P107; Rosenblatt J. A., 1997, CYTOMETRY, V26, P1; SAVAGE RJG, 1994, J VERTEBR PALEONTOL, V14, P427, DOI 10.1080/02724634.1994.10011569; SIMONS EL, 1991, P NATL ACAD SCI USA, V88, P9734, DOI 10.1073/pnas.88.21.9734; Stanhope MJ, 1998, P NATL ACAD SCI USA, V95, P9967, DOI 10.1073/pnas.95.17.9967; Szalay F. S., 1994, EVOLUTIONARY HIST MA; Tabuce R, 2001, J VERTEBR PALEONTOL, V21, P535, DOI 10.1671/0272-4634(2001)021[0535:ANGOMM]2.0.CO;2; THEWISSEN JGM, 1985, MAMMALIA, V49, P257, DOI 10.1515/mamm.1985.49.2.257; Van Valen L., 1967, Bulletin of the American Museum of Natural History, V135, P217; Whidden Howard P., 2002, Journal of Mammalian Evolution, V9, P161, DOI 10.1023/A:1021340012925	30	80	86	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					497	501		10.1038/nature03351	http://dx.doi.org/10.1038/nature03351			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791254	Green Published			2022-12-28	WOS:000227836000040
J	Berkley, JA; Maitland, K; Mwangi, I; Ngetsa, C; Mwarumba, S; Lowe, BS; Newton, CRJC; Marsh, K; Scott, JAG; English, M				Berkley, JA; Maitland, K; Mwangi, I; Ngetsa, C; Mwarumba, S; Lowe, BS; Newton, CRJC; Marsh, K; Scott, JAG; English, M			Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE BACTERIAL-MENINGITIS; CEREBRAL MALARIA; PROGNOSTIC INDICATORS; GAMBIAN CHILDREN; MANAGEMENT; PNEUMONIA; OVERLAP; DIAGNOSIS; TANZANIA; FEATURES	Objectives To determine how well antibiotic treatment is targeted by simple clinical syndromes and to what extent drug resistance threatens affordable antibiotics. Design Observational study involving a priori definition of a hierarchy of syndromic indications for antibiotic therapy derived from World Health Organization integrated management of childhood illness and inpatient guidelines and application of these rules to a prospectively collected dataset. Setting Kilifi District Hospital, Kenya. Participants 11 847 acute paediatric admissions. Main outcome measures Presence of invasive bacterial infection (bacteraemia or meningitis) or Plasmodium falciparum parasitaemia; antimicrobial sensitivities of isolated bacteria. Results 6254 (53%) admissions met criteria for syndromes requiring antibiotics (sick young infants; meningitis/encephalopathy; severe malnutrition; very severe, severe, or mild pneumonia; skin or soft tissue infection): 672 (11%) had an invasive bacterial infection (80% of all invasive bacterial infections identified), and 753 (12%) (lied (93%) of all inpatient deaths). Among P falciparum infected children with a syndromic indication for parenteral antibiotics, an invasive bacterial infection was detected in 4.0-8.8%. For the syndrome of meningitis/encephalopathy, 96/123 (76%) isolates were fully sensitive in vitro to penicillin or chloramphenicol. Conclusions Simple clinical syndromes effectively target children admitted with invasive bacterial infection and those at risk of death. Malaria parasitaemia does not justify withholding empirical parenteral antibiotics. Lumbar puncture is critical to the rational use of antibiotics.	Ctr Geog Med Res Coast, Kilifi, Kenya		Berkley, JA (corresponding author), Ctr Geog Med Res Coast, POB 230, Kilifi, Kenya.	jberkley@kilifi.mimcom.net	Newton, Charles RJC/B-7578-2014; Newton, Charles/V-7872-2019	Newton, Charles RJC/0000-0002-6999-5507; Newton, Charles/0000-0002-6999-5507; English, Michael/0000-0002-7427-0826; Maitland, Kathryn/0000-0002-0007-0645; Berkley, James/0000-0002-1236-849X	Wellcome Trust [061089, 081835] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X; Berkley JA, 2004, PEDIATRICS, V114, pE713, DOI 10.1542/peds.2004-0007; Berkley JA, 2003, BRIT MED J, V326, P361, DOI 10.1136/bmj.326.7385.361; Berkley JA, 1999, QJM-INT J MED, V92, P151, DOI 10.1093/qjmed/92.3.151; Berkley JA, 2001, LANCET, V357, P1753, DOI 10.1016/S0140-6736(00)04897-2; BERKLEY JA, 2002, NEW ENGL J MED, V352, P39; Duke T, 2003, ARCH DIS CHILD, V88, P536, DOI 10.1136/adc.88.6.536; English M, 1996, T ROY SOC TROP MED H, V90, P658, DOI 10.1016/S0035-9203(96)90423-X; English M, 2003, B WORLD HEALTH ORGAN, V81, P166; Evans JA, 2004, QJM-INT J MED, V97, P591, DOI 10.1093/qjmed/hch093; Falade AG, 1997, ANN TROP PAEDIATR, V17, P315, DOI 10.1080/02724936.1997.11747904; Falade AG, 2001, ANN TROP PAEDIATR, V21, P293, DOI 10.1080/07430170120093472; Kallander K, 2004, ACTA TROP, V90, P211, DOI 10.1016/j.actatropica.2003.11.013; Makani J, 2003, QJM-INT J MED, V96, P355, DOI 10.1093/qjmed/hcg059; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; Mbogo CM, 2003, AM J TROP MED HYG, V68, P734; MOLYNEUX ME, 1989, Q J MED, V71, P441; *NAT COMM CLIN LAB, 1997, M100S7 NCCLS; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; Perkins BA, 1997, B WORLD HEALTH ORGAN, V75, P33; PRADA J, 1993, LANCET, V342, P1114, DOI 10.1016/0140-6736(93)92096-C; *REP KEN MIN HLTH, 2001, AIDS KEN; *REP KENY MINST HL, 2001, AIDS KEN; Reyburn H, 2004, BMJ-BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; Robertson MA, 2001, ARCH DIS CHILD, V85, P214, DOI 10.1136/adc.85.3.214; Tamburlini G, 1999, ARCH DIS CHILD, V81, P478, DOI 10.1136/adc.81.6.478; Tulloch J., 1999, Lancet (British edition), V354, P16, DOI 10.1016/S0140-6736(99)90252-0; *WHO, 2000, T ROYAL SOC TROP S1, V94; World Health Organization, 2000, MAN CHILD SER INF SE; 1993, ADV PAED LIFE SUPPOR	30	112	114	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 30	2005	330	7498					995	999		10.1136/bmj.38408.471991.8F	http://dx.doi.org/10.1136/bmj.38408.471991.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923UP	15797893	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000228935100019
J	Larson, EB; Grumbach, K; Roberts, KB				Larson, EB; Grumbach, K; Roberts, KB			The future of generalism in medicine	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PRIMARY-CARE MEDICINE; INTERNAL-MEDICINE; REGIONAL-VARIATIONS; TASK-FORCE; PHYSICIAN; SOCIETY; CROSSROADS; DISEASES; DOMAIN		Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA	Group Health Cooperative; University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Larson, EB (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	larson.e@ghc.org	Grumbach, Kevin/L-9222-2016					ABRAMOWITZ KS, 1993, FUTURE HLTH CARE DEL; Anderson GF, 2003, ARCH INTERN MED, V163, P437, DOI 10.1001/archinte.163.4.437; Colwill JM, 1997, ACAD MED, V72, P745, DOI 10.1097/00001888-199709000-00007; Ferrer RL, 2005, ANN INTERN MED, V142, P691, DOI 10.7326/0003-4819-142-8-200504190-00037; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Gorey TM, 2004, ANN FAM MED, V2, pS3, DOI 10.1370/afm.130; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Larson EB, 2004, ANN INTERN MED, V140, P639, DOI 10.7326/0003-4819-140-8-200404200-00011; Larson EB, 2004, J GEN INTERN MED, V19, P69, DOI 10.1111/j.1525-1497.2004.31337.x; Larson EB, 2003, AM J MED, V114, P168, DOI 10.1016/S0002-9343(02)01564-4; Larson EB, 2001, ANN INTERN MED, V134, P997, DOI 10.7326/0003-4819-134-10-200105150-00013; Moore G, 2003, ANN INTERN MED, V138, P244, DOI 10.7326/0003-4819-138-3-200302040-00032; *R WOOD JOHNS FDN, GEN PHYS IN NAT PROG; ROTHMAN AA, 2004, FUTURE PRIMARY CARE, P180; Safran DG, 2003, ANN INTERN MED, V138, P248, DOI 10.7326/0003-4819-138-3-200302040-00033; Sandy LG, 2003, ANN INTERN MED, V138, P262, DOI 10.7326/0003-4819-138-3-200302040-00035; Schroeder SA, 2002, ACAD MED, V77, P767, DOI 10.1097/00001888-200208000-00003; Schwartz MD, 2005, ANN INTERN MED, V142, P715, DOI 10.7326/0003-4819-142-8-200504190-00040; Showstack J, 2003, ANN INTERN MED, V138, P268, DOI 10.7326/0003-4819-138-3-200302040-00036; STARFIELD B, 1994, LANCET, V344, P1129, DOI 10.1016/S0140-6736(94)90634-3; Stille CJ, 2005, ANN INTERN MED, V142, P700, DOI 10.7326/0003-4819-142-8-200504190-00038; Weiner SJ, 2005, ANN INTERN MED, V142, P709, DOI 10.7326/0003-4819-142-8-200504190-00039; Whitcomb ME, 2002, ACAD MED, V77, P759, DOI 10.1097/00001888-200208000-00001	24	20	20	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					689	690		10.7326/0003-4819-142-8-200504190-00036	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00036			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916TZ	15838087				2022-12-28	WOS:000228410400026
J	El-Kadiki, A; Sutton, AJ				El-Kadiki, A; Sutton, AJ			Role of multivitamins and mineral supplements in preventing infections in elderly people: systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRACE-ELEMENT SUPPLEMENTATION; VITAMIN SUPPLEMENTATION; MICRONUTRIENT SUPPLEMENTATION; IMMUNE-RESPONSES; OLDER-PEOPLE; QUALITY; INDIVIDUALS; POPULATION; INDEXES	Objective To evaluate the effectiveness of multivitamins and mineral supplements in reducing infections in an elderly population. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Medline and other databases. Reference lists of identified articles were inspected for further relevant articles. Selection of studies Trials were included if they evaluated the effect of multivitamins and mineral supplements on infections in an elderly population. Review methods Studies were assessed for the methodological quality by using the Jadad instrument. If the data required for the analyses were not available from the published articles we requested them from the original study authors. Meta-analysis was undertaken on three outcomes: the mean difference in number of days spent with infection, the odds ratio of at least one infection in the study period, and the incidence rate ratio for the difference in infection rates. Data on adverse events were also extracted. Results Eight trials met our inclusion criteria. Because the outcomes reported were inconsistent, only a proportion of the trials could be included in each meta-analysis. Multivitamins and mineral supplements were found to reduce the mean annual number of days spent with infection (three studies) by 17.5 (95% confidence interval I I to 24, P < 0.001). The odds ratio for at least one infection in the study period (three studies) was 1.10 (0.81 to 1.50, P = 0.53). The infection rate ratio (four studies) was 0.89 (0.78 to 1.03, P = 0.11). Reporting of adverse events was poor. Conclusion The evidence for routine use of multivitamin and mineral supplements to reduce infections in elderly people is weak and conflicting. Study results are heterogeneous, and this is partially confounded by outcome measure.	Royal Hallamshire Hosp, Dept Chem Pathol, Sheffield S10 2JF, S Yorkshire, England; Univ Leicester, Dept Hlth Sci, Leicester LE1 6TP, Leics, England	University of Sheffield; University of Leicester	El-Kadiki, A (corresponding author), Royal Hallamshire Hosp, Dept Chem Pathol, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	alia@elkadiki.fsnet.co.uk		Sutton, Alexander/0000-0002-8934-9940				Barringer TA, 2003, ANN INTERN MED, V138, P365, DOI 10.7326/0003-4819-138-5-200303040-00005; Bender DA, 2002, BRIT MED J, V325, P173, DOI 10.1136/bmj.325.7357.173; Boardley D, 2000, J AM DIET ASSOC, V100, P356, DOI 10.1016/S0002-8223(00)00108-5; BOGDEN JD, 1994, AM J CLIN NUTR, V60, P437, DOI 10.1093/ajcn/60.3.437; CHANDRA RK, 1992, LANCET, V340, P1124, DOI 10.1016/0140-6736(92)93151-C; Chandra RK, 2002, NUTR RES, V22, P5, DOI 10.1016/S0271-5317(01)00366-9; CHANDRA RK, 1993, ACP J CLUB, V118, P34; CHAVANCE M, 1993, INT J VITAM NUTR RES, V63, P11; CONI N, 1998, LECT NOTES GERIATRIC; Department of Health, 1991, DIET REF VAL FOOD EN; Expert Group on Vitamins and Minerals, 2003, SAF UPP LEV VIT MIN; Fawzi W, 2003, ANN INTERN MED, V138, P430, DOI 10.7326/0003-4819-138-5-200303040-00014; Fortes C, 1998, J AM GERIATR SOC, V46, P19, DOI 10.1111/j.1532-5415.1998.tb01008.x; Galan P, 1997, INT J VITAM NUTR RES, V67, P450; GERSHWIN M E, 1987, Comprehensive Therapy, V13, P18; Girodon F, 1997, ANN NUTR METAB, V41, P98, DOI 10.1159/000177984; Girodon F, 1999, ARCH INTERN MED, V159, P748, DOI 10.1001/archinte.159.7.748; GOODWIN JS, 1983, CLIN EXP IMMUNOL, V51, P647; GRAAT JM, 2003, FOCUS ALTERNAT COMPL, V8, P37; GRAAT JM, 2002, JAMA-J AM MED ASSOC, V14, P715; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; High KP, 2001, CLIN INFECT DIS, V33, P1892, DOI 10.1086/324509; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jain AL, 2002, NUTR RES, V22, P85, DOI 10.1016/S0271-5317(01)00369-4; Kemp F, 2001, FASEB J, V15, pA293; McKay DL, 2000, J AM COLL NUTR, V19, P613, DOI 10.1080/07315724.2000.10718959; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; MUNRO H, 1989, NUTR AGING ELDERLY H, V6; PENN ND, 1991, AGE AGEING, V20, P169, DOI 10.1093/ageing/20.3.169; PIKE J, 1995, INT J VITAM NUTR RES, V65, P117; TALBOTT MC, 1987, AM J CLIN NUTR, V46, P559; WOOD RJ, 1999, INTEGRATIVE MED, V212, P85; Yoshikawa TT, 1997, J INFECT DIS, V176, P1053, DOI 10.1086/516547	33	37	40	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	2005	330	7496					871	874		10.1136/bmj.38399.495648.8F	http://dx.doi.org/10.1136/bmj.38399.495648.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	917UA	15805125	Green Published, Bronze			2022-12-28	WOS:000228493500015
J	Boushey, HA; Sorkness, CA; King, TS; Sullivan, SD; Fahy, JV; Lazarus, SC; Chinchilli, VM; Craig, TJ; Dimango, EA; Deykin, A; Fagan, JK; Fish, JE; Ford, JG; Kraft, M; Lemanske, RF; Leone, FT; Martin, RJ; Mauger, EA; Pesola, GR; Peters, SP; Rollings, NJ; Szefler, SJ; Wechsler, ME; Israel, E				Boushey, HA; Sorkness, CA; King, TS; Sullivan, SD; Fahy, JV; Lazarus, SC; Chinchilli, VM; Craig, TJ; Dimango, EA; Deykin, A; Fagan, JK; Fish, JE; Ford, JG; Kraft, M; Lemanske, RF; Leone, FT; Martin, RJ; Mauger, EA; Pesola, GR; Peters, SP; Rollings, NJ; Szefler, SJ; Wechsler, ME; Israel, E		Natl Heart Lung Blood Inst Asthma	Daily versus as-needed corticosteroids for mild persistent asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED CORTICOSTEROIDS; CLINICAL REMISSION; ATOPIC ASTHMA; BUDESONIDE; QUESTIONNAIRE; INTERVENTION; VALIDATION; CHILDREN; TRIAL	Background Although guidelines recommend daily therapy for patients with mild persistent asthma, prescription patterns suggest that most such patients use these so-called controller therapies intermittently. In patients with mild persistent asthma, we evaluated the efficacy of intermittent short-course corticosteroid treatment guided by a symptom-based action plan alone or in addition to daily treatment with either inhaled budesonide or oral zafirlukast over a one-year period. Methods In a double-blind trial, 225 adults underwent randomization. The primary outcome was morning peak expiratory flow (PEF). Other outcomes included the forced expiratory volume in one second (FEV(sub 1)) before and after bronchodilator treatment, the frequency of exacerbations, the degree of asthma control, the number of symptom-free days, and the quality of life. Results The three treatments produced similar increases in morning PEF (7.1 to 8.3 percent; approximately 32 liters per minute; P=0.90) and similar rates of asthma exacerbations (P=0.24), even though the intermittent-treatment group took budesonide, on average, for only 0.5 week of the year. As compared with intermittent therapy or daily zafirlukast therapy, daily budesonide therapy produced greater improvements in pre-bronchodilator FEV(sub 1) (P=0.005), bronchial reactivity (P<0.001), the percentage of eosinophils in sputum (P=0.007), exhaled nitric oxide levels (P=0.006), scores for asthma control (P<0.001), and the number of symptom-free days (P=0.03), but not in post-bronchodilator FEV(sub 1) (P=0.29) or in the quality of life (P=0.18). Daily zafirlukast therapy did not differ significantly from intermittent treatment in any outcome measured. Conclusions It may be possible to treat mild persistent asthma with short, intermittent courses of inhaled or oral corticosteroids taken when symptoms worsen. Further studies are required to determine whether this novel approach to treatment should be recommended.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Wisconsin, Madison, WI USA; Penn State Univ, Coll Med, Hershey, PA USA; Univ Washington, Seattle, WA 98195 USA; Harlem Lung Ctr, New York, NY USA; Columbia Univ, New York, NY USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Natl Jewish Med & Res Ctr, Denver, CO USA	University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Washington; University of Washington Seattle; Columbia University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Jefferson University; National Jewish Health	Boushey, HA (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.		Wechsler, Michael/AAC-5506-2019; Wechsler, Michael/B-3979-2013	Wechsler, Michael/0000-0003-3505-2946; Pesola, Gene/0000-0002-3909-8039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U10HL051831, U10HL051810, U10HL051843, U10HL051834, U10HL051823, U10HL056443, U10HL051845] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 U10 HL051831, 5 U10 HL051823, 5 U10 HL051834, 5 U10 HL051843, 5 U10 HL051845, 5 U10 HL056443, 5 U10 HL051810] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Allen David B, 2003, J Allergy Clin Immunol, V112, pS1, DOI 10.1016/S0091-6749(03)01859-1; BINDER DA, 1992, BIOMETRIKA, V79, P139, DOI 10.1093/biomet/79.1.139; Cote J, 1997, AM J RESP CRIT CARE, V155, P1509, DOI 10.1164/ajrccm.155.5.9154850; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V262, P1472; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; *NAT ASTHM ED PREV, 1997, NIH PUBL; National cholesterol education program National heart lung and blood institute National institutes of health, 2002, 3 REP NAT CHOL ED PR; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; *RES TRIANGL I, 2001, SUDAAN SOFTW STAT AN; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953, DOI 10.1164/ajrccm.162.3.9909033; van den Toorn LM, 2002, AM J RESP CRIT CARE, V166, P1143	26	306	323	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1519	1528		10.1056/NEJMoa042552	http://dx.doi.org/10.1056/NEJMoa042552			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829533				2022-12-28	WOS:000228324200004
J	Kim, JH; Kim, B; Cai, L; Choi, HJ; Ohgi, KA; Tran, C; Chen, C; Chung, CH; Huber, O; Rose, DW; Sawyers, CL; Rosenfeld, MG; Baek, SH				Kim, JH; Kim, B; Cai, L; Choi, HJ; Ohgi, KA; Tran, C; Chen, C; Chung, CH; Huber, O; Rose, DW; Sawyers, CL; Rosenfeld, MG; Baek, SH			Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes	NATURE			English	Article							NF-KAPPA-B; PROSTATE-CANCER; RNA INTERFERENCE; TARGET; CELLS; TRANSFORMATION; PONTIN52; PROTEIN; GROWTH; COLON	Defining the molecular strategies that integrate diverse signalling pathways in the expression of specific gene programmes that are critical in homeostasis and disease remains a central issue in biology. This is particularly pertinent in cancer biology because downregulation of tumour metastasis suppressor genes is a common occurrence(1,2), and the underlying molecular mechanisms are not well established. Here we report that the downregulation of a metastasis suppressor gene, KAI1, in prostate cancer cells involves the inhibitory actions of beta-catenin, along with a reptin chromatin remodelling complex. This inhibitory function of beta-catenin - reptin requires both increased beta-catenin expression and recruitment of histone deacetylase activity. The coordinated actions of beta- catenin - reptin components that mediate the repressive state serve to antagonize a Tip60 coactivator complex(3-8) that is required for activation; the balance of these opposing complexes controls the expression of KAI1 and metastatic potential. The molecular mechanisms underlying the antagonistic regulation of b- catenin - reptin and the Tip60 coactivator complexes for the metastasis suppressor gene, KAI1, are likely to be prototypic of a selective downregulation strategy for many genes, including a subset of NF-kappa B target genes.	Seoul Natl Univ, Coll Nat Sci, Dept Sci Biol, Seoul 151742, South Korea; Univ Calif San Diego, Howard Hughes Med Inst, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Med, Los Angeles, CA 90095 USA; Charite, Inst Clin Chem & Pathobiochem, D-12200 Berlin, Germany; Univ Calif San Diego, Sch Med, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA	Seoul National University (SNU); Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of California System; University of California San Diego	Baek, SH (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Sci Biol, Seoul 151742, South Korea.	mrosenfeld@ucsd.edu; sbaek@snu.ac.kr	Huber, Otmar/AAA-4548-2021; Tran, Canh-Dung/D-4442-2011; Sawyers, Charles/G-5327-2016	Huber, Otmar/0000-0003-4359-1747; Tran, Canh-Dung/0000-0002-1011-4226; 				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ALBINI A, 1987, CANCER RES, V47, P3239; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feng Y, 2003, CANCER RES, V63, P8726; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Li J, 2001, J BIOL CHEM, V276, P18579, DOI 10.1074/jbc.M100846200; Madrid Lee V, 2003, Methods Mol Biol, V223, P523; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PETRYLAK DP, 1995, NAT MED, V1, P739, DOI 10.1038/nm0895-739; Rottbauer W, 2002, CELL, V111, P661, DOI 10.1016/S0092-8674(02)01112-1; Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X	25	255	268	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	2005	434	7035					921	926		10.1038/nature03452	http://dx.doi.org/10.1038/nature03452			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829968				2022-12-28	WOS:000228327600046
J	Rose, A; Zhu, ZG; Madigan, CF; Swager, TM; Bulovic, V				Rose, A; Zhu, ZG; Madigan, CF; Swager, TM; Bulovic, V			Sensitivity gains in chemosensing by lasing action in organic polymers	NATURE			English	Article							CONJUGATED POLYMERS; STIMULATED-EMISSION; SENSORY MATERIALS; ENERGY MIGRATION; FILMS; MICROCAVITIES; AMPLIFICATION	Societal needs for greater security require dramatic improvements in the sensitivity of chemical and biological sensors. To meet this challenge, increasing emphasis in analytical science has been directed towards materials and devices having highly nonlinear characteristics; semiconducting organic polymers (SOPs), with their facile excited state ( exciton) transport, are prime examples of amplifying materials(1-3). SOPs have also been recognized as promising lasing materials(4), although the susceptibility of these materials to optical damage has thus far limited applications. Here we report that attenuated lasing in optically pumped SOP thin films displays a sensitivity to vapours of explosives more than 30 times higher than is observed from spontaneous emission. Critical to this achievement was the development of a transducing polymer with high thin-film quantum yield, a high optical damage threshold in ambient atmosphere and a record low lasing threshold. Trace vapours of the explosives 2,4,6-trinitrotoluene ( TNT) and 2,4-dinitrotoluene (DNT) introduce non-radiative deactivation pathways(5) that compete with stimulated emission. We demonstrate that the induced cessation of the lasing action, and associated sensitivity enhancement, is most pronounced when films are pumped at intensities near their lasing threshold. The combined gains from amplifying materials and lasing promise to deliver sensors that can detect explosives with unparalleled sensitivity.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Swager, TM (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	tswager@mit.edu; bulovic@mit.edu	Swager, Timothy M/H-7459-2012; Zhu, Zhengguo/A-7870-2011; Bulovic, Vladimir/U-5449-2019	Swager, Timothy M/0000-0002-3577-0510; 				Berggren M, 1997, NATURE, V389, P466; Bulovic V, 1998, SCIENCE, V279, P553, DOI 10.1126/science.279.5350.553; Cumming CJ, 2001, IEEE T GEOSCI REMOTE, V39, P1119, DOI 10.1109/36.927423; Halls JJM, 1996, APPL PHYS LETT, V68, P3120, DOI 10.1063/1.115797; Hamer PJ, 1996, PHILOS MAG B, V73, P367, DOI 10.1080/01418639609365831; Heliotis G, 2004, ADV FUNCT MATER, V14, P91, DOI 10.1002/adfm.200305504; KOGELNIK H, 1971, APPL PHYS LETT, V18, P152, DOI 10.1063/1.1653605; Kozlov VG, 1997, NATURE, V389, P362, DOI 10.1038/38693; Levitsky IA, 1999, J AM CHEM SOC, V121, P1466, DOI 10.1021/ja982610t; McQuade DT, 2000, CHEM REV, V100, P2537, DOI 10.1021/cr9801014; Rose A, 2001, J AM CHEM SOC, V123, P11298, DOI 10.1021/ja016662l; Scherf U, 2001, CURR OPIN SOLID ST M, V5, P143, DOI 10.1016/S1359-0286(01)00010-9; Swager TM, 1998, ACCOUNTS CHEM RES, V31, P201, DOI 10.1021/ar9600502; Tessler N, 1996, NATURE, V382, P695, DOI 10.1038/382695a0; Yang JS, 1998, J AM CHEM SOC, V120, P11864, DOI 10.1021/ja982293q; Yang JS, 1998, J AM CHEM SOC, V120, P5321, DOI 10.1021/ja9742996; Zahn S, 2002, ANGEW CHEM INT EDIT, V41, P4225, DOI 10.1002/1521-3773(20021115)41:22<4225::AID-ANIE4225>3.0.CO;2-3; ZHOU Q, 1995, J AM CHEM SOC, V117, P7017, DOI 10.1021/ja00131a031	18	664	689	8	216	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					876	879		10.1038/nature03438	http://dx.doi.org/10.1038/nature03438			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829959				2022-12-28	WOS:000228327600035
J	Dyson, F				Dyson, F			Hans A. Bethe (1906-2005)	SCIENCE			English	Biographical-Item									Inst Adv Study, Princeton, NJ 08540 USA	Institute for Advanced Study - USA	Dyson, F (corresponding author), Inst Adv Study, Olden Lane, Princeton, NJ 08540 USA.	dyson@ias.edu						BETHE H, PUBLICATION LIST; Brown GE, 2001, ANNU REV NUCL PART S, V51, P1, DOI 10.1146/annurev.nucl.51.101701.132401	2	1	1	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					219	219		10.1126/science.1112173	http://dx.doi.org/10.1126/science.1112173			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821082				2022-12-28	WOS:000228273700042
J	Sekijima, Y; Wiseman, RL; Matteson, J; Hammarstrom, P; Miller, SR; Sawkar, AR; Balch, WE; Kelly, JW				Sekijima, Y; Wiseman, RL; Matteson, J; Hammarstrom, P; Miller, SR; Sawkar, AR; Balch, WE; Kelly, JW			The biological and chemical basis for tissue-selective amyloid disease	CELL			English	Article							ENDOPLASMIC-RETICULUM; SECRETION EFFICIENCY; FIBRIL FORMATION; QUALITY-CONTROL; HUMAN LYSOZYME; HUNGARIAN-TYPE; TRANSTHYRETIN; PROTEIN; POLYNEUROPATHY; PLASMA	Factors controlling the onset and progression of extracellular amyloid diseases remain largely unknown. Central to disease etiology is the efficiency of the endoplasmic reticulum (ER) machinery that targets destabilized mutant proteins for degradation and the enhanced tendency of these variants to aggregate if secreted. We demonstrate that mammalian cells secrete numerous transthyretin (TTR) disease-assock ated variants with wild-type efficiency in spite of compromised folding energetics. Only the most highly destabilized TTR variants are subjected to ER-associated degradation (ERAD) and then only in certain tissues, providing insight into tissue selective amyloidosis. Rather than a "quality control" standard based on wild-type stability, we find that ER-assisted folding (ERAF), based on global protein energetics, determines the extent of export. We propose that ERAF (influenced by the energetics of the protein fold, chaperone enzyme distributions, and metabolite chaperones) in competition with ERAD defines the unique secretory aptitude of each tissue.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd,BCC506, La Jolla, CA 92037 USA.	webalch@scripps.edu; jkelly@scripps.edu		Hammarstrom, Per/0000-0001-5827-3587; Wiseman, Luke/0000-0001-9287-6840	NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NIGMS NIH HHS [GM 43226] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDO Y, 1995, BIOCHEM BIOPH RES CO, V211, P354, DOI 10.1006/bbrc.1995.1820; Benson MD, 1996, AM J PATHOL, V148, P351; Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DICKSON PW, 1987, J BIOL CHEM, V262, P13907; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; DWULET FE, 1983, BIOCHEM BIOPH RES CO, V114, P657, DOI 10.1016/0006-291X(83)90831-8; DWULET FE, 1984, P NATL ACAD SCI-BIOL, V81, P694, DOI 10.1073/pnas.81.3.694; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fan JQ, 2003, TRENDS PHARMACOL SCI, V24, P355, DOI 10.1016/S0165-6147(03)00158-5; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Garzuly F, 1996, NEUROLOGY, V47, P1562, DOI 10.1212/WNL.47.6.1562; Garzuly Ferenc, 1996, Orvosi Hetilap, V137, P2393; Gelman Marina S, 2003, Methods Mol Biol, V232, P27; Green NS, 2003, J AM CHEM SOC, V125, P13404, DOI 10.1021/ja030294z; Hamilton JA, 2001, CELL MOL LIFE SCI, V58, P1491, DOI 10.1007/PL00000791; Hammarstrom P, 2003, BIOCHEMISTRY-US, V42, P6656, DOI 10.1021/bi027319b; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; Harkany T, 2002, BRIT J DERMATOL, V146, P674, DOI 10.1046/j.1365-2133.2002.04594.x; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; Hurshman AR, 2004, BIOCHEMISTRY-US, V43, P7365, DOI 10.1021/bi049621l; Ikeda S, 2002, CLIN CHEM LAB MED, V40, P1257, DOI 10.1515/CCLM.2002.217; JACOBSON DR, 1992, HUM GENET, V89, P353; Jiang X, 2001, BIOCHEMISTRY-US, V40, P11442, DOI 10.1021/bi011194d; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Kowalski JM, 1998, J BIOL CHEM, V273, P19453, DOI 10.1074/jbc.273.31.19453; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; LaPointe P, 2004, MOL CELL, V14, P413, DOI 10.1016/S1097-2765(04)00267-9; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; OMURA F, 1991, EUR J BIOCHEM, V198, P477, DOI 10.1111/j.1432-1033.1991.tb16038.x; Plante-Bordeneuve V, 1998, NEUROLOGY, V51, P708, DOI 10.1212/WNL.51.3.708; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Sekijima Y, 2003, LAB INVEST, V83, P409, DOI 10.1097/01.LAB.0000059937.11023.1F; Shusta EV, 1999, J MOL BIOL, V292, P949, DOI 10.1006/jmbi.1999.3130; Spagnoli FM, 1998, J CELL BIOL, V143, P1101, DOI 10.1083/jcb.143.4.1101; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Suhr OB, 2002, LIVER TRANSPLANT, V8, P787, DOI 10.1053/jlts.2002.34386; TANIYAMA Y, 1992, J BIOL CHEM, V267, P4619; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; WALLACE MR, 1986, J CLIN INVEST, V78, P6, DOI 10.1172/JCI112573; Wang XD, 2004, J CELL BIOL, V167, P65, DOI 10.1083/jcb.200401035; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Zheng W, 2002, BRAIN RES, V958, P371, DOI 10.1016/S0006-8993(02)03683-1	54	347	353	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					73	85		10.1016/j.cell.2005.01.018	http://dx.doi.org/10.1016/j.cell.2005.01.018			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820680	Bronze			2022-12-28	WOS:000228348500011
J	Cram, P; Rosenthal, GE; Vaughan-Sarrazin, MS				Cram, P; Rosenthal, GE; Vaughan-Sarrazin, MS			Cardiac revascularization in specialty and general hospitals	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADMINISTRATIVE DATA; MEDICARE CLAIMS; CABG SURGERY; MORTALITY; QUALITY; EXPENDITURES; CERTIFICATE; MODELS; STATES; NEED	BACKGROUND: The emergence of specialty hospitals focusing on narrow procedural areas has generated controversy, although little is known about their quality. METHODS: We conducted a retrospective cohort study of 42,737 Medicare beneficiaries who underwent percutaneous coronary intervention (PCI) and 26,274 who underwent coronary-artery bypass grafting (CABG) during 2000 and 2001 in specialty cardiac hospitals (15 for PCI and 15 for CABG) and general hospitals (82 for PCI and 75 for CABG) in the same markets. Administrative data were used to compare patients' characteristics, hospital procedural volumes, and patient outcomes. RESULTS: Patients undergoing PCI or CABG in specialty hospitals were less likely to have coexisting conditions than those being treated at general hospitals and were less likely to have had an acute myocardial infarction (P<0.001). The better health of the patients at specialty hospitals than of those at general hospitals was reflected by the lower mean predicted risk of death (2.1 percent vs. 3.1 percent for PCI and 5.0 percent vs. 5.8 percent for CABG; P<0.001 for each comparison). Mean volumes of PCI and CABG procedures in 2000 and 2001 were higher in specialty hospitals than in general hospitals (799 vs. 375 PCI procedures, P<0.001; and 571 vs. 236 CABG procedures, P<0.001). The unadjusted rate of death during the index hospitalization or within 30 days after admission was lower in specialty hospitals than in general hospitals (2.1 percent vs. 3.2 percent for PCI and 4.7 percent vs. 6.0 percent for CABG; P<0.001 for both comparisons). In multivariate analyses adjusted for patients' characteristics, the odds ratio for death after PCI in specialty hospitals and general hospitals was similar (0.89; 95 percent confidence interval, 0.69 to 1.15; P=0.39), but the odds ratio for death after CABG was lower in specialty hospitals than in general hospitals (0.84; 95 percent confidence interval, 0.72 to 0.99; P=0.05). In stratified analyses comparing specialty and general hospitals with similar volumes, differences in mortality were not significant. CONCLUSIONS: The lower unadjusted mortality rate after cardiac revascularization in specialty cardiac hospitals is accounted for by their healthier patients and higher procedural volumes.	Univ Iowa, Carver Coll Med, Dept Internal Med, Div Gen Internal Med, Iowa City, IA USA; Iowa City Vet Affairs Med Ctr, Ctr Res Implementat Innovat Strategies Practice, Iowa City, IA USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Cram, P (corresponding author), Univ Iowa, Coll Med, Dept Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.	peter-cram@uiowa.edu	Ballard, David J/H-1062-2018; Cram, Peter/K-4472-2014	Cram, Peter/0000-0002-1910-346X; Vaughan Sarrazin, Mary/0000-0001-8717-1061				ASH AS, 1997, RISK ADJUSTMENT MEAS, P427; Birkmeyer JD, 1998, SURGERY, V124, P917, DOI 10.1067/msy.1998.90268; Birkmeyer JD, 2003, JAMA-J AM MED ASSOC, V290, P2703, DOI 10.1001/jama.290.20.2703; Casalino LP, 2003, HEALTH AFFAIR, V22, P56, DOI 10.1377/hlthaff.22.6.56; *DARTM MED SCH CTR, 2003, DARTM ATL HLTH CAR; Devers Kelly J, 2003, Issue Brief Cent Stud Health Syst Change, P1; DOBSON A, 2003, COMP STUDY PATIENT S; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fong Tony, 2003, Mod Healthc, V33, P20; Gaskin DJ, 2001, HEALTH SERV RES, V36, P25; *GEN ACC OFF, 2003, GAO04167, P1; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; Hannan EL, 1997, HEALTH SERV RES, V31, P659; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Milstein A, 2000, Eff Clin Pract, V3, P313; MILSTEIN A, 2001, EFF CLIN PRACT, V4, P94; MITCHELL JB, 1994, MED CARE, V32, pJS38; Piotrowski Julie, 2003, Mod Healthc, V33, P44; REILLY P, 2003, MOD HEALTHCARE, V33, P6; Robinson JL, 2001, AM J MED QUAL, V16, P155, DOI 10.1177/106286060101600502; Rosenthal GE, 1997, JAMA-J AM MED ASSOC, V278, P485, DOI 10.1001/jama.278.6.485; SLOAN FA, 1993, JAMA-J AM MED ASSOC, V269, P3155, DOI 10.1001/jama.269.24.3155; Swart K, 2004, MYCOTA, V2, P21; Vaughan-Sarrazin MS, 2002, JAMA-J AM MED ASSOC, V288, P1859, DOI 10.1001/jama.288.15.1859; Voelker R, 2003, JAMA-J AM MED ASSOC, V289, P409, DOI 10.1001/jama.289.4.409; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; 2000 US CENSUS DATA	32	105	107	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1454	1462		10.1056/NEJMsa042325	http://dx.doi.org/10.1056/NEJMsa042325			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814881				2022-12-28	WOS:000228145200009
J	Koster, DA; Croquette, V; Dekker, C; Shuman, S; Dekker, NH				Koster, DA; Croquette, V; Dekker, C; Shuman, S; Dekker, NH			Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB	NATURE			English	Article							VACCINIA TOPOISOMERASE; DUPLEX DNA; ESCHERICHIA-COLI; MECHANISM; MOLECULE; PROTEIN; ELASTICITY; COVALENT; ROTATION; GYRASE	Topoisomerases relieve the torsional strain in DNA that is built up during replication and transcription. They are vital for cell proliferation(1-3) and are a target for poisoning by anti-cancer drugs(4,5). Type IB topoisomerase (TopIB) forms a protein clamp around the DNA duplex(6-8) and creates a transient nick that permits removal of supercoils. Using real-time single-molecule observation, we show that TopIB releases supercoils by a swivel mechanism that involves friction between the rotating DNA and the enzyme cavity: that is, the DNA does not freely rotate. Unlike a nicking enzyme, TopIB does not release all the supercoils at once, but it typically does so in multiple steps. The number of supercoils removed per step follows an exponential distribution. The enzyme is found to be torque-sensitive, as the mean number of supercoils per step increases with the torque stored in the DNA. We propose a model for topoisomerization in which the torque drives the DNA rotation over a rugged periodic energy landscape in which the topoisomerase has a small but quantifiable probability to religate the DNA once per turn.	Delft Univ Technol, Fac Sci Appl, Kavli Inst Nanosci, NL-2628 CJ Delft, Netherlands; Ecole Normale Super, Lab Phys Stat, F-75005 Paris, France; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Delft University of Technology; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Universite Paris Cite; Memorial Sloan Kettering Cancer Center	Dekker, NH (corresponding author), Delft Univ Technol, Fac Sci Appl, Kavli Inst Nanosci, Lorentzweg 1, NL-2628 CJ Delft, Netherlands.	nynke.dekker@mb.tn.tudelft.nl		Dekker, Cees/0000-0001-6273-071X; Dekker, Nynke/0000-0003-4029-0973; Croquette, Vincent/0000-0003-1400-0039				BROWN PO, 1981, P NATL ACAD SCI-BIOL, V78, P843, DOI 10.1073/pnas.78.2.843; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Bustamante C, 2003, NATURE, V421, P423, DOI 10.1038/nature01405; Carey JF, 2003, P NATL ACAD SCI USA, V100, P5640, DOI 10.1073/pnas.1031537100; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; Krogh BO, 2000, BIOCHEMISTRY-US, V39, P6422, DOI 10.1021/bi000184u; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; MIZUUCHI K, 1980, P NATL ACAD SCI-BIOL, V77, P1847, DOI 10.1073/pnas.77.4.1847; Moroz JD, 1997, P NATL ACAD SCI USA, V94, P14418, DOI 10.1073/pnas.94.26.14418; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; RICE JA, 1988, MATH STAT DATA ANAL, P31; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Shuman S, 1997, EMBO J, V16, P6584, DOI 10.1093/emboj/16.21.6584; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; Strick TR, 2000, NATURE, V404, P901, DOI 10.1038/35009144; Strick TR, 1996, SCIENCE, V271, P1835, DOI 10.1126/science.271.5257.1835; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100	29	245	253	2	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 31	2005	434	7033					671	674		10.1038/nature03395	http://dx.doi.org/10.1038/nature03395			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800630				2022-12-28	WOS:000228011000051
J	Muratani, M; Kung, C; Shokat, KM; Tansey, WR				Muratani, M; Kung, C; Shokat, KM; Tansey, WR			The F box protein Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover and cotranscriptional mRNA processing	CELL			English	Article							UBIQUITIN-DEPENDENT PROTEOLYSIS; POLYMERASE-II TRANSCRIPTION; CARBOXY-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; ACTIVATE TRANSCRIPTION; PHOSPHORYLATED FORMS; CAPPING ENZYME; ELONGATION; KINASE; YEAST	We report here that the prototypical yeast transcription factor Gal4 undergoes two distinct modes of ubiquitin-mediated proteolysis: one that occurs independent of transcription and restricts Gal4 function, and another that is transcription coupled and essential for productive activation of Gal4 target genes. Destruction of transcriptionally active Gal4 depends on an F box protein called Dsgl/Mdm30. In the absence of Dsg1, Gal4 is stable, nonubiquitylated, and unable to productively stimulate transcription. Analysis of the phenotype of dsgl-nuil yeast reveals a striking disconnect between GAL gene RNA and protein levels; in the absence of Dsgl, Gal4 target genes are transcribed, but the resulting RNAs are not translated. The translational defects of these RNAs are related to defects in phosphorylation of the RNA polymerase 11 carboxy-terminal domain, which in turn affects recruitment of RNA processing machinery. We propose that Gal4 ubiquitylation and destruction are required for initiation-competent transcription complexes to transition to fully mature elongating complexes capable of appropriate mRNA processing.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	Cold Spring Harbor Laboratory; University of California System; University of California San Francisco	Tansey, WR (corresponding author), Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.	tansey@cshl.edu	Muratani, Masafumi/A-6379-2011		NCI NIH HHS [CA13106] Funding Source: Medline; NIAID NIH HHS [AI044009] Funding Source: Medline; NIGMS NIH HHS [GM067728] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; BAILEY RB, 1984, MOL GEN GENET, V193, P507, DOI 10.1007/BF00382091; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Dower K, 2002, RNA, V8, P686, DOI 10.1017/S1355838202024068; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Fritz S, 2003, MOL BIOL CELL, V14, P2303, DOI 10.1091/mbc.E02-12-0831; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Hirst M, 1999, MOL CELL, V3, P673, DOI 10.1016/S1097-2765(00)80360-3; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; Keogh MC, 2003, MOL CELL BIOL, V23, P7005, DOI 10.1128/MCB.23.19.7005-7018.2003; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Liu Y, 2004, MOL CELL BIOL, V24, P1721, DOI 10.1128/MCB.24.4.1721-1735.2004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Lutfiyya LL, 1998, GENETICS, V150, P1377; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; Mandal SS, 2004, P NATL ACAD SCI USA, V101, P7572, DOI 10.1073/pnas.0401493101; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Morillon A, 2003, CELL, V115, P425, DOI 10.1016/S0092-8674(03)00880-8; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; Ostendorff HP, 2002, NATURE, V416, P99, DOI 10.1038/416099a; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pei Y, 2003, J BIOL CHEM, V278, P7180, DOI 10.1074/jbc.M211713200; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; SADOWSKI I, 1991, P NATL ACAD SCI USA, V88, P10510, DOI 10.1073/pnas.88.23.10510; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Wu YB, 1996, EMBO J, V15, P3951, DOI 10.1002/j.1460-2075.1996.tb00769.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	45	139	142	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					887	899		10.1016/j.cell.2004.12.025	http://dx.doi.org/10.1016/j.cell.2004.12.025			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797387	Bronze			2022-12-28	WOS:000228067500016
J	Somerville, MA; Atlas, RM				Somerville, MA; Atlas, RM			Ethics: A weapon to counter bioterrorism	SCIENCE			English	Editorial Material									Univ Louisville, Ctr Deterrence Biowarfare & Bioterrorism, Louisville, KY 40205 USA; McGill Univ, McGill Ctr Med Eth & Law, Montreal, PQ H3A 1W9, Canada	University of Louisville; McGill University	Atlas, RM (corresponding author), Univ Louisville, Ctr Deterrence Biowarfare & Bioterrorism, Louisville, KY 40205 USA.	r.atlas@louisville.edu						AGRE P, 2003, STATEMENT REGARDING; Alibek K, 1999, BIOHAZARD CHILLING T; American Medical Association and the Council on Ethical and Judicial Affairs, 2004, COD MED ETH CURR OP; *APEC, 2003, LEAD STAT HLTH SEC; Atlas R, 2003, P NATL ACAD SCI USA, V100, P1464, DOI 10.1073/pnas.0630491100; Avery Donald H., 1998, SCI WAR CANADIAN SCI; Balmer B., 2001, BRITAIN BIOL WARFARE; British Medical Association, 1999, BIOT WEAP HUM; BURGESS S, 2001, 37 INSS US AIR FORC; Enserink M, 2003, SCIENCE, V302, P2054, DOI 10.1126/science.302.5653.2054; Harris SH, 2002, THEIRISHTIMES; Kadlec RF, 1998, JAMA-J AM MED ASSOC, V279, P273; Leitenberg M, 2001, CRIT REV MICROBIOL, V27, P267, DOI 10.1080/20014091096774; Lifton R.J., 2000, DESTROYING WORLD SAV; MALINAS G, 2004, STANFORD ENCY PHILOS; National Research Council, 2004, BIOT RES AG TERR, DOI [10.17226/10827, DOI 10.17226/10827]; NOWAK MA, 1995, SCI AM, V273, P58, DOI 10.1038/scientificamerican0895-58; Rappert B, 2004, BIOSECUR BIOTERROR, V2, P164, DOI 10.1089/15387130460759218; RAPPERT B, 2004, 13 U BRADF DEP PEAC; *SEL COMM SCI TECH, 2003, 8 SEL COMM SCI TECH; Somerville M., 2000, ETHICAL CANARY SCI S; *U EX, BIOL WEAP COD COND; Williams Peter, 1989, UNIT 731 JAPANS SECR; *WORLD MED ASS, 2002, 17400 WORLD MED ASS	24	40	40	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1881	1882		10.1126/science.1109279	http://dx.doi.org/10.1126/science.1109279			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	910UI	15790831				2022-12-28	WOS:000227957300033
J	Emanuel, EJ; Fuchs, VR				Emanuel, EJ; Fuchs, VR			Health care vouchers - A proposal for universal coverage	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROMOTE QUALITY; INSURANCE; ECONOMY; REFORM; 1990S; PLAN		Poster Project, Chicago, IL USA; Stanford Univ, Dept Econ, Stanford, CA 94305 USA	Stanford University	Emanuel, EJ (corresponding author), Poster Project, Chicago, IL USA.							Aaron H., 1991, SERIOUS UNSTABLE CON; CLINTON HR, 2004, NY TIMES MAGAZI 0428, P46; CLINTON HR, 2004, NY TIMES MAGAZINE, P26; CLINTON HR, 2004, NY TIMES MAGAZI 0428, P47; *CTR MED MED SERV, HLTH ACC; *CTR MED MED SERV, 2004 ANN RE BOARD TR; Danis M, 2002, J GEN INTERN MED, V17, P125, DOI 10.1046/j.1525-1497.2002.10609.x; Davis K, 2000, ARCH INTERN MED, V160, P3357, DOI 10.1001/archinte.160.22.3357; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P782, DOI 10.1001/jama.265.6.782; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P786; Emanuel E, 2002, HASTINGS CENT REP, V32, P32, DOI 10.2307/3528520; EMANUEL EJ, 1991, ENDS HUMAN LIFE MED, P155; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1979, HARVARD BUS REV, V57, P141; Fairbrother G, 2004, HEALTH AFFAIR, V23, P237, DOI 10.1377/hlthaff.23.1.237; FEDER J, 2001, COVERING AM REAL REM, P43; FEIN R, 1986, MED CARE MED COSTS; FUCHS VR, 1991, HEALTH AFFAIR, V10, P7, DOI 10.1377/hlthaff.10.4.7; FUCHS VR, 1994, JAMA-J AM MED ASSOC, V272, P560, DOI 10.1001/jama.272.7.560; FUCHS VR, 1969, MED ECON, P110; Gabel J, 2004, HEALTH AFFAIR, V23, P200, DOI 10.1377/hlthaff.23.5.200; GRUBER J, 2001, COVERING AM REAL REM, P57; Gruber Jonathan, 2004, HLTH POLICY UNINSURE, P98; Institute of Medicine, 2004, INS AM HLTH PRINC RE; Levit K, 2004, HEALTH AFFAIR, V23, P147, DOI 10.1377/hlthaff.23.1.147; MCLURE CE, 1987, VALUE ADDED TAX KEY; National Advisory Committee on Core Health and Disability Support Services, 1994, COR SERV 1995 96; PEAR R, 2004, NY TIMES        0207, pA7; Remler DK, 2003, AM J PUBLIC HEALTH, V93, P67, DOI 10.2105/AJPH.93.1.67; SHIELS J, 2004, HLTH AFFAIRS WE 0225; SINGER SJ, 2001, COVERING AM REAL REM, P153; THOMAS B, 2004, NAT PRESS CLUB FEBR; *US BUR CENS, 2002, HLTH INS COV US; WICKS EK, 2001, COVERING AM REAL REM, P193; 1984, TAX REFORM FAIRNESS, V3; [No title captured]	37	47	47	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1255	1260		10.1056/NEJMsb041704	http://dx.doi.org/10.1056/NEJMsb041704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	909AW	15788504				2022-12-28	WOS:000227832300016
J	Li, J; Laursen, TM; Precht, DH; Olsen, J; Mortensen, PB				Li, J; Laursen, TM; Precht, DH; Olsen, J; Mortensen, PB			Hospitalization for mental illness among parents after the death of a child	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE EVENTS; WOMEN; SCHIZOPHRENIA; BEREAVEMENT; DEPRESSION; SUICIDE; ONSET; RISK; PERSPECTIVE; DISORDERS	BACKGROUND: The loss of a child is considered one of the most stressful events in the life of a parent. We hypothesized that parental bereavement increases the risk of hospital admission for a psychiatric disorder, especially for affective disorders. METHODS: We studied a cohort of 1,082,503 persons identified from national registers in Denmark who were born between 1952 and 1999 and had at least one child under 18 years of age during the follow-up period, from 1970 to 1999. Parents who lost a child during follow-up were categorized as ``bereaved'' from the date of death of the child. RESULTS: As compared with parents who did not lose a child, parents who lost a child had an overall relative risk of a first psychiatric hospitalization for any disorder of 1.67 (95 percent confidence interval, 1.53 to 1.83). Bereaved mothers had a higher relative risk of being hospitalized for any psychiatric disorder than bereaved fathers (relative risks, 1.78 [95 percent confidence interval, 1.60 to 1.98] and 1.38 [95 percent confidence interval, 1.17 to 1.63], respectively; P value for interaction, 0.01). The relative risks of hospitalization specifically for affective disorders were 1.91 (95 percent confidence interval, 1.59 to 2.30) and 1.61 (95 percent confidence interval, 1.15 to 2.27) for bereaved mothers and fathers, respectively. Among mothers, the relative risk of being hospitalized for any psychiatric disorder was highest during the first year after the death of the child but remained significantly elevated five years or more after the death. CONCLUSIONS: The risk of psychiatric hospitalization was increased among parents, especially mothers, who lost a child.	Univ Aarhus, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, Aarhus, Denmark; Univ Aarhus, Natl Ctr Register Based Res, Aarhus, Denmark; Bispebjerg Hosp, Clin Unit Prevent Med & Hlth Promot, DK-2400 Copenhagen, Denmark	Aarhus University; Aarhus University; University of Copenhagen; Bispebjerg Hospital	Olsen, J (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Box 951772, Los Angeles, CA 90095 USA.	jo@ucla.edu	Mortensen, Preben B/D-2358-2015; Laursen, Thomas Munk/AFQ-8066-2022; li, jiong/L-6534-2014	Mortensen, Preben B/0000-0002-5230-9865; li, jiong/0000-0002-1716-8067; li, jiong/0000-0003-1125-026X; Laursen, Thomas Munk/0000-0001-6934-1784				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Andersen P. K., 2012, STAT MODELS BASED CO; Bennedsen BE, 2001, ARCH GEN PSYCHIAT, V58, P674, DOI 10.1001/archpsyc.58.7.674; Brown GW, 1989, LIFE EVENTS ILLNESS; Chen JH, 1999, PSYCHOL MED, V29, P367, DOI 10.1017/S0033291798008137; CLARKE M, 1979, LANCET, V1, P916; CLAYTON PJ, 1974, ARCH GEN PSYCHIAT, V30, P747; Cleiren M.P., 1993, BEREAVEMENT ADAPTATI; FINLAYJONES R, 1981, PSYCHOL MED, V11, P803, DOI 10.1017/S0033291700041301; FROST NR, 1977, ARCH GEN PSYCHIAT, V34, P1172; HOYER G, 1993, ARCH GEN PSYCHIAT, V50, P134; HUDGENS RW, 1967, ARCH GEN PSYCHIAT, V16, P134; Jablensky AV, 2003, AM J PSYCHIAT, V160, P425, DOI 10.1176/appi.ajp.160.3.425; Johnson L, 2000, J AFFECT DISORDERS, V59, P139, DOI 10.1016/S0165-0327(99)00146-9; KENDLER KS, 1992, ARCH GEN PSYCHIAT, V49, P109; Kivela SL, 1998, INT J GERIATR PSYCH, V13, P527, DOI 10.1002/(SICI)1099-1166(199808)13:8<527::AID-GPS814>3.3.CO;2-#; Krupnick J.L., 1984, BEREAVEMENT REACTION, P99; LAIRD N, 1981, J AM STAT ASSOC, V76, P231, DOI 10.2307/2287816; Lewis G, 1998, BMJ-BRIT MED J, V317, P1283, DOI 10.1136/bmj.317.7168.1283; Li J, 2003, LANCET, V361, P363, DOI 10.1016/S0140-6736(03)12387-2; MALIG C, 1996, 66 IIVRS; Malkinson R, 1999, DEATH STUD, V23, P413, DOI 10.1080/074811899200939; Mortensen PB, 1999, NEW ENGL J MED, V340, P603, DOI 10.1056/NEJM199902253400803; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; PARKES CM, 1965, BRIT J MED PSYCHOL, V38, P1, DOI 10.1111/j.2044-8341.1965.tb00956.x; PAYKEL ES, 1969, ARCH GEN PSYCHIAT, V21, P753; Qin P, 2003, ARCH GEN PSYCHIAT, V60, P797, DOI 10.1001/archpsyc.60.8.797; Rosenzweig A, 1997, ANNU REV MED, V48, P421; Rubin S.S., 2001, HDB BEREAVEMENT RES, P219, DOI DOI 10.1037/10436-009; VANCE JC, 1991, MED J AUSTRALIA, V155, P292, DOI 10.5694/j.1326-5377.1991.tb142283.x	30	225	228	1	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1190	1196		10.1056/NEJMoa033160	http://dx.doi.org/10.1056/NEJMoa033160			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	909AW	15788495				2022-12-28	WOS:000227832300005
J	Kyrle, PA; Eichinger, S				Kyrle, PA; Eichinger, S			Deep vein thrombosis	LANCET			English	Review							MOLECULAR-WEIGHT HEPARIN; RECURRENT VENOUS THROMBOEMBOLISM; ORAL ANTICOAGULANT-THERAPY; FACTOR-V-LEIDEN; INTENSITY WARFARIN THERAPY; PROTEIN-C DEFICIENCY; COAGULATION-FACTOR-V; TERM CLINICAL-COURSE; PULMONARY-EMBOLISM; D-DIMER	Deep vein thrombosis and its sequelae pulmonary embolism and post-thrombotic syndrome are some of the most common disorders. A thrombus either arises spontaneously or is caused by clinical conditions including surgery, trauma, or prolonged bed rest. In these instances, prophylaxis with low-dose anticoagulation is effective. Diagnosis of deep vein thrombosis relies on imaging techniques such as ultrasonography or venography. Only about 25% of symptomatic patients have a thrombus. Thus, clinical risk assessment and D-dimer measurement are used to rule out deep vein thrombosis. Thrombus progression and embolisation can be prevented by low-molecular-weight heparin followed by vitamin K antagonists. Use of these antagonists for 3-6 months is sufficient for many patients. Those with antithrombin deficiency, the lupus anticoagulant, homozygous or combined defects, or with previous deep vein thrombosis can benefit from indefinite anticoagulation. In cancer patients, low-molecular-weight heparin is more effective than and is at least as safe as vitamin K antagonists. Women seem to have a lower thrombosis risk than men, but pregnancy or use of oral contraceptives or hormone replacement therapy represent important risk factors.	Med Univ Vienna, Dept Internal Med 1, A-1090 Vienna, Austria	Medical University of Vienna	Kyrle, PA (corresponding author), Med Univ Vienna, Dept Internal Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	paul.kyrle@meduniwien.ac.at						Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; Alikhan R, 2004, ARCH INTERN MED, V164, P963, DOI 10.1001/archinte.164.9.963; Anderson DR, 2003, J THROMB HAEMOST, V1, P645, DOI 10.1046/j.1538-7836.2003.00131.x; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Baarslag HJ, 2004, EUR RADIOL, V14, P1263, DOI 10.1007/s00330-004-2252-1; Baron JA, 1998, LANCET, V351, P1077, DOI 10.1016/S0140-6736(97)10018-6; Bergqvist D, 2002, NEW ENGL J MED, V346, P975, DOI 10.1056/NEJMoa012385; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; Bernardi E, 2001, Semin Vasc Med, V1, P105, DOI 10.1055/s-2001-14547; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; Bloemenkamp KWM, 2000, ARCH INTERN MED, V160, P49, DOI 10.1001/archinte.160.1.49; Boccalon H, 2000, ARCH INTERN MED, V160, P1769, DOI 10.1001/archinte.160.12.1769; Bounameaux H, 2004, J THROMB HAEMOST, V2, P551, DOI 10.1111/j.1538-7933.2004.00648.x; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; Brill-Edwards P, 2000, NEW ENGL J MED, V343, P1439, DOI 10.1056/NEJM200011163432002; Buller HR, 2004, ANN INTERN MED, V140, P867, DOI 10.7326/0003-4819-140-11-200406010-00007; Cogo A, 1998, BRIT MED J, V316, P17, DOI 10.1136/bmj.316.7124.17; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; Couban S, 2002, BLOOD, V100, p703A; Cushman M, 2004, AM J MED, V117, P19, DOI 10.1016/j.amjmed.2004.01.018; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; den Heijer M, 1998, THROMB HAEMOSTASIS, V80, P874; DENHEIJER M, 2003, J THROMB HAEMOST S1, V1, pOC161; Dolovich LR, 2000, ARCH INTERN MED, V160, P181, DOI 10.1001/archinte.160.2.181; Douketis JD, 2002, ARCH INTERN MED, V162, P1465, DOI 10.1001/archinte.162.13.1465; Dryjski M, 2001, J VASC SURG, V34, P1010, DOI 10.1067/mva.2001.119889; Dykes AC, 2001, BRIT J HAEMATOL, V113, P636; Eichinger S, 2004, BLOOD, V103, P3773, DOI 10.1182/blood-2003-10-3422; Eichinger S, 1998, THROMB HAEMOSTASIS, V80, P566; Eichinger S, 2002, ARCH INTERN MED, V162, P2357, DOI 10.1001/archinte.162.20.2357; Eichinger S, 1999, THROMB HAEMOSTASIS, V82, P1232; Eikelboom JW, 2001, LANCET, V358, P9, DOI 10.1016/S0140-6736(00)05249-1; Eriksson B, 2002, LANCET, V360, P1441, DOI 10.1016/S0140-6736(02)11469-3; Eriksson BI, 2003, J THROMB HAEMOST, V1, P2490, DOI 10.1111/j.1538-7836.2003.00494.x; Eriksson BI, 2003, ARCH INTERN MED, V163, P1337, DOI 10.1001/archinte.163.11.1337; Eriksson BI, 2003, THROMB HAEMOSTASIS, V89, P288; Fowkes FJI, 2003, EUR J VASC ENDOVASC, V25, P1, DOI 10.1053/ejvs.2002.1778; Francis CW, 2003, BLOOD, V102, p6A; Francis CW, 2003, NEW ENGL J MED, V349, P1703, DOI 10.1056/NEJMoa035162; Francis CW, 2002, ANN INTERN MED, V137, P648, DOI 10.7326/0003-4819-137-8-200210150-00008; Friederich PW, 1996, ANN INTERN MED, V125, P955, DOI 10.7326/0003-4819-125-12-199612150-00003; Galli M, 2003, BLOOD, V101, P1827, DOI 10.1182/blood-2002-02-0441; Galli M, 2003, BLOOD, V102, P2717, DOI 10.1182/blood-2002-11-3334; GALLUS A, 1986, LANCET, V2, P1293; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GINSBERG JS, 1989, THROMB HAEMOSTASIS, V61, P189; GINSBERG JS, 1992, THROMB HAEMOSTASIS, V67, P519; Gould MK, 1999, ANN INTERN MED, V130, P800, DOI 10.7326/0003-4819-130-10-199905180-00003; Greer IA, 2003, BEST PRACT RES CL HA, V16, P261, DOI 10.1016/S1521-6926(02)00095-6; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9; Heim SW, 2004, CLIN CHEM, V50, P1136, DOI 10.1373/clinchem.2004.031765; Heit JA, 2000, ARCH INTERN MED, V160, P761, DOI 10.1001/archinte.160.6.761; Heit JA, 2002, ARCH INTERN MED, V162, P1245, DOI 10.1001/archinte.162.11.1245; Heit JA, 2001, THROMB HAEMOSTASIS, V86, P452, DOI 10.1161/ATVBAHA.108.162545; Hillarp A, 1997, THROMB HAEMOSTASIS, V78, P990; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; Hull RD, 2001, ARCH INTERN MED, V161, P1952, DOI 10.1001/archinte.161.16.1952; Joffe HV, 2004, CIRCULATION, V110, P1605, DOI 10.1161/01.CIR.0000142289.94369.D7; Kahn SR, 2004, ARCH INTERN MED, V164, P17, DOI 10.1001/archinte.164.1.17; Kearon C, 1998, ANN INTERN MED, V129, P1044, DOI 10.7326/0003-4819-129-12-199812150-00009; Kearon C, 2004, J THROMB HAEMOST, V2, P743, DOI 10.1046/j.1538-7836.2004.00698.x; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Kelly J, 2003, CHEST, V124, P1116, DOI 10.1378/chest.124.3.1116; Kelly J, 2003, J THROMB HAEMOST, V1, P1888, DOI 10.1046/j.1538-7836.2003.00382.x; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KILLEWICH LA, 1989, J VASC SURG, V9, P89, DOI 10.1067/mva.1989.vs0090089; Klatsky AL, 2000, AM J CARDIOL, V85, P1334, DOI 10.1016/S0002-9149(00)00766-9; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861, DOI 10.1001/archinte.154.8.861; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KOSTER T, 1995, LANCET, V345, P152, DOI 10.1016/S0140-6736(95)90166-3; Kyrle PA, 2000, NEW ENGL J MED, V343, P457, DOI 10.1056/NEJM200008173430702; Kyrle PA, 2004, NEW ENGL J MED, V350, P2558, DOI 10.1056/NEJMoa032959; Lassen MR, 2002, NEW ENGL J MED, V347, P726, DOI 10.1056/NEJMoa011327; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Martinelli I, 2004, CIRCULATION, V110, P566, DOI 10.1161/01.CIR.0000137123.55051.9B; Martinelli I, 1998, BLOOD, V92, P2353, DOI 10.1182/blood.V92.7.2353.2353_2353_2358; Martinelli I, 1999, ARTERIOSCL THROM VAS, V19, P700, DOI 10.1161/01.ATV.19.3.700; Mateo J, 1997, THROMB HAEMOSTASIS, V77, P444; McColl MD, 2004, CURR OPIN PULM MED, V10, P371, DOI 10.1097/01.mcp.0000136405.17204.5e; Meijers JCM, 2000, NEW ENGL J MED, V342, P696, DOI 10.1056/NEJM200003093421004; Mismetti P, 2001, BRIT J SURG, V88, P913, DOI 10.1046/j.0007-1323.2001.01800.x; Monreal M, 1996, THROMB HAEMOSTASIS, V75, P251; MONREAL M, 1994, THROMB HAEMOSTASIS, V71, P7; MONREAL M, 1991, CHEST, V99, P280, DOI 10.1378/chest.99.2.280; Monreal M, 1997, THROMB HAEMOSTASIS, V78, P1316; NICOLAIDES AN, 1971, BRIT J RADIOL, V44, P653, DOI 10.1259/0007-1285-44-525-653; Pabinger I, 2002, BLOOD, V100, P1060, DOI 10.1182/blood-2002-01-0149; Patel RK, 2004, ARCH INTERN MED, V164, P1348, DOI 10.1001/archinte.164.12.1348; Pinede L, 2001, CIRCULATION, V103, P2453; Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Prandoni P, 2002, BLOOD, V100, P3484, DOI 10.1182/blood-2002-01-0108; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Prandoni P, 2004, BMJ-BRIT MED J, V329, P484, DOI 10.1136/bmj.38167.684444.3A; Prandoni P, 2004, ANN INTERN MED, V141, P249, DOI 10.7326/0003-4819-141-4-200408170-00004; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; QUINTAVALLA R, 1992, EUR J RADIOL, V15, P32, DOI 10.1016/0720-048X(92)90199-J; Rathbun SW, 2004, ANN INTERN MED, V141, P839, DOI 10.7326/0003-4819-141-11-200412070-00007; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; REICHART P, 2002, P AN M AM SOC CLIN, V21, P1474; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; Rosendaal FR, 1999, THROMB HAEMOSTASIS, V82, P610; Rosendaal FR, 2003, J THROMB HAEMOST, V1, P1371, DOI 10.1046/j.1538-7836.2003.00264.x; Rosendaal FR, 1998, THROMB HAEMOSTASIS, V79, P706; ROSENDAAL FR, 1995, BLOOD, V85, P1504, DOI 10.1182/blood.V85.6.1504.bloodjournal8561504; Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103; Samama MM, 2000, ARCH INTERN MED, V160, P3415, DOI 10.1001/archinte.160.22.3415; Schulman S, 2003, NEW ENGL J MED, V349, P1713, DOI 10.1056/NEJMoa030104; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Segal JB, 2003, AM J MED, V115, P298, DOI 10.1016/S0002-9343(03)00326-7; Simioni P, 1999, THROMB HAEMOSTASIS, V81, P198, DOI 10.1055/s-0037-1614442; Simioni P, 2001, THROMB HAEMOSTASIS, V86, P929, DOI 10.1055/s-0037-1616153; Simioni P, 2000, BLOOD, V96, P3329; Sorensen HT, 1998, NEW ENGL J MED, V338, P1169, DOI 10.1056/NEJM199804233381701; Stein PD, 2004, ANN INTERN MED, V140, P589, DOI 10.7326/0003-4819-140-8-200404200-00005; Stein PD, 2002, CHEST, V122, P960, DOI 10.1378/chest.122.3.960; Strebel N, 2002, ARCH INTERN MED, V162, P1451, DOI 10.1001/archinte.162.13.1451; TAIT RC, 1995, THROMB HAEMOSTASIS, V73, P87; TAIT RC, 1994, BRIT J HAEMATOL, V87, P106, DOI 10.1111/j.1365-2141.1994.tb04878.x; THALER E, 1981, CLIN HAEMATOL, V10, P369; Tick LW, 2002, AM J MED, V113, P630, DOI 10.1016/S0002-9343(02)01347-5; Turpie AGG, 2003, CHEST, V124, p371S, DOI 10.1378/chest.124.6_suppl.371S; van Dongen CJJ, 2003, ARCH INTERN MED, V163, P1285, DOI 10.1001/archinte.163.11.1285; VANDENBELT AGM, 2004, COCHRANE DB SYST REV, V3; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VANDONGEN CJ, 2003, COCHRANE DB SYST REV, V1; Vlieg AV, 2000, BLOOD, V95, P3678; Wahl DG, 1998, LUPUS, V7, P15, DOI 10.1191/096120398678919688; Warkentin TE, 2004, CHEST, V126, p311S, DOI 10.1378/chest.126.3_suppl.311S; Watson L, 2010, COCHRANE DB SYST REV, V1, DOI [DOI 10.1002/14651858.CD002783.PUB2, 10.1002/14651858.CD002783.pub2]; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; Wells PS, 1999, THROMB HAEMOSTASIS, V81, P493; Weltermann A, 2003, J THROMB HAEMOST, V1, P28, DOI 10.1046/j.1538-7836.2003.00038.x; White RH, 2000, ARCH INTERN MED, V160, P2033, DOI 10.1001/archinte.160.13.2033; White RH, 2003, THROMB HAEMOSTASIS, V90, P446, DOI 10.1160/TH03-03-0152; White RH, 2000, NEW ENGL J MED, V343, P1758, DOI 10.1056/NEJM200012143432403	146	355	398	1	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1163	1174		10.1016/S0140-6736(05)71880-8	http://dx.doi.org/10.1016/S0140-6736(05)71880-8			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794972				2022-12-28	WOS:000227909500030
J	Eckburg, PB; Bik, EM; Bernstein, CN; Purdom, E; Dethlefsen, L; Sargent, M; Gill, SR; Nelson, KE; Relman, DA				Eckburg, PB; Bik, EM; Bernstein, CN; Purdom, E; Dethlefsen, L; Sargent, M; Gill, SR; Nelson, KE; Relman, DA			Diversity of the human intestinal microbial flora	SCIENCE			English	Article							GUT MICROBIOTA; COMMUNITIES; SEQUENCE; BACTERIA; MUCOSA	The human endogenous intestinal microflora is an essential "organ" in providing nourishment, regulating epithelial. development, and instructing innate immunity; yet, surprisingly, basic features remain poorly described. We examined 13,355 prokaryotic ribosomal RNA gene sequences from multiple colonic mucosal sites and feces of healthy subjects to improve our understanding of gut microbial diversity. A majority of the bacterial sequences corresponded to uncultivated species and novel microorganisms. We discovered significant intersubject variability and differences between stool and mucosa community composition. Characterization of this immensely diverse ecosystem is the first step in elucidating its role in health and disease.	Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Dept Microbiol & Immunol, Stanford, CA 94305 USA; Univ Manitoba, Dept Med, Gastroenterol Sect, Winnipeg, MB R3A 1R9, Canada; Stanford Univ, Dept Stat, Stanford, CA 94305 USA; Inst Genom Res, Rockville, MD 20850 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Stanford University; University of Manitoba; Stanford University; J. Craig Venter Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Eckburg, PB (corresponding author), Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Room S-169,300 Pasteur Dr, Stanford, CA 94305 USA.	eckburg1@stanford.edu; relman@stanford.edu	Bik, Elisabeth M/A-1204-2007; Dethlefsen, Les/R-2220-2018	Bik, Elisabeth M/0000-0001-5477-0324; Dethlefsen, Les/0000-0001-9622-1630; Relman, David A./0000-0001-8331-1354	NIAID NIH HHS [R01 AI051259, AI51259] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Barcenilla A, 2000, APPL ENVIRON MICROB, V66, P1654, DOI 10.1128/AEM.66.4.1654-1661.2000; COLWELL RK, 2004, ESTIMATES VERSION 7; Curtis TP, 2004, CURR OPIN MICROBIOL, V7, P221, DOI 10.1016/j.mib.2004.04.010; Fargione J, 2003, P NATL ACAD SCI USA, V100, P8916, DOI 10.1073/pnas.1033107100; Hayashi H, 2002, MICROBIOL IMMUNOL, V46, P535, DOI 10.1111/j.1348-0421.2002.tb02731.x; Hold GL, 2002, FEMS MICROBIOL ECOL, V39, P33, DOI 10.1111/j.1574-6941.2002.tb00904.x; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Horner-Devine MC, 2004, P ROY SOC B-BIOL SCI, V271, P113, DOI 10.1098/rspb.2003.2549; Martin AP, 2002, APPL ENVIRON MICROB, V68, P3673, DOI 10.1128/AEM.68.8.3673-3682.2002; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Pavoine S, 2004, J THEOR BIOL, V228, P523, DOI 10.1016/j.jtbi.2004.02.014; Pryde SE, 2002, FEMS MICROBIOL LETT, V217, P133, DOI 10.1016/S0378-1097(02)01106-0; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Relman DA, 2001, TRENDS MICROBIOL, V9, P206, DOI 10.1016/S0966-842X(01)02041-8; Schloss PD, 2004, APPL ENVIRON MICROB, V70, P5485, DOI 10.1128/AEM.70.9.5485-5492.2004; Sonnenburg JL, 2004, NAT IMMUNOL, V5, P569, DOI 10.1038/ni1079; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Suau A, 1999, APPL ENVIRON MICROB, V65, P4799; Wang X, 2003, J APPL MICROBIOL, V95, P508, DOI 10.1046/j.1365-2672.2003.02005.x; Zoetendal EG, 2002, APPL ENVIRON MICROB, V68, P3401, DOI 10.1128/AEM.68.7.3401-3407.2002	22	5077	5563	77	1757	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1635	1638		10.1126/science.1110591	http://dx.doi.org/10.1126/science.1110591			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15831718	Green Accepted, Green Submitted			2022-12-28	WOS:000229827000059
J	Wren, JD				Wren, JD			Open access and openly accessible: a study of scientific publications shared via the internet	BRITISH MEDICAL JOURNAL			English	Article							ONLINE; REFERENCES; WEB	Objectives To determine how often reprints of scientific publications are shared online, whether journal readership level is a predictor, how the amount of file sharing changes with the age of the article, and to what degree open access publications are shared on non-journal websites. Design The internet was searched using an application programming interface to Google, a popular and freely available search engine. Main outcome measures The proportion of reprints of journal articles published between 1994 and 2004 from within 13 subscription based and four open access journals that could be located online at non-journal websites. Results The probability that an article could be found online at a non-journal website correlated with the journal impact factor and the time since initial publication. Papers from higher impact journals and more recent articles were more likely to be located. On average, for the high impact journal articles published in 2003, over a third could be located at non-journal websites. Similar trends were observed for the delayed or full open access publications. Conclusions Decentralised sharing of scientific reprints through the internet creates a degree of de facto open access that, although highly incomplete in its coverage, is none the less biased towards publications of higher popular demand.	Univ Oklahoma, Adv Ctr Genome Technol, Dept Bot & Microbiol, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Wren, JD (corresponding author), Univ Oklahoma, Adv Ctr Genome Technol, Dept Bot & Microbiol, 101 David L Boren Blvd,Rm 2025, Norman, OK 73019 USA.	Jonathan.Wren@OU.edu	Wren, Jonathan D/E-5611-2011	Wren, Jonathan D/0000-0003-2776-3545				Dellavalle RP, 2003, SCIENCE, V302, P787, DOI 10.1126/science.1088234; Dufva M, 2003, NATURE, V426, P15, DOI 10.1038/426015c; Goto JJ, 2000, J BIOL CHEM, V275, P1007, DOI 10.1074/jbc.275.2.1007; Graczynski MR, 2004, MED SCI MONITOR, V10, pED1; GRACZYNSKI MR, 2004, MED SCI MONIT, V10; Harnad S, 2001, NATURE, V410, P1024, DOI 10.1038/35074210; Kaiser J, 2004, SCIENCE, V305, P764; Lawrence S, 2001, NATURE, V411, P521, DOI 10.1038/35079151; Lawrence S, 1998, SCIENCE, V280, P98, DOI 10.1126/science.280.5360.98; Mayor Susan, 2004, BMJ, V328, P1094, DOI 10.1136/bmj.328.7448.1094-d; Perneger TV, 2004, BRIT MED J, V329, P546, DOI 10.1136/bmj.329.7465.546; Plutchak TS, 2004, J MED LIBR ASSOC, V92, P1; ROEHR B, 2004, BRIT MED J, V329, P590; Shanon B, 2003, J CONSCIOUSNESS STUD, V10, P3; Shattil SJ, 2004, BLOOD, V103, P3257, DOI 10.1182/blood-2004-03-0879; Spinellis D, 2003, COMMUN ACM, V46, P71, DOI 10.1145/602421.602422; Suber Peter, 2004, SPARC OPEN ACCESS NE; Wellcome Trust, 2004, COSTS BUS MOD SCI RE; Wren JD, 2004, BIOINFORMATICS, V20, P668, DOI 10.1093/bioinformatics/btg465; ASBMB OPEN ACCESS PU; ISI J CITATION REPOR; STANDARD ROBOT EXCLU; ENHANCED PUBLIC ACCE	23	53	53	1	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 14	2005	330	7500					1128	1131		10.1136/bmj.38422.611736.E0	http://dx.doi.org/10.1136/bmj.38422.611736.E0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927BH	15827063	Green Published, Bronze			2022-12-28	WOS:000229166900022
J	Eckel, RH; Grundy, SM; Zimmet, PZ				Eckel, RH; Grundy, SM; Zimmet, PZ			The metabolic syndrome	LANCET			English	Review							CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; DENSITY-LIPOPROTEIN-CHOLESTEROL; TYPE-2 DIABETES-MELLITUS; FREE FATTY-ACIDS; SCANDINAVIAN SIMVASTATIN SURVIVAL; INSULIN-RESISTANCE SYNDROME; PLASMA ADIPONECTIN LEVELS; 3RD NATIONAL-HEALTH; BETA-CELL FUNCTION	The metabolic syndrome is a common metabolic disorder that results from the increasing prevalence of obesity. The disorder is defined in various ways, but in the near future a new definition(s) will be applicable worldwide. The pathophysiology seems to be largely attributable to insulin resistance with excessive flux of fatty acids implicated. A proinflammatory state probably contributes to the syndrome. The increased risk for type 2 diabetes and cardiovascular disease demands therapeutic attention for those at high risk. The fundamental approach is weight reduction and increased physical activity; however, drug treatment could be appropriate for diabetes and cardiovascular disease risk reduction.	Univ Colorado, Div Endocrinol Diabet & Metab, Aurora, CO 80045 USA; Hlth Sci Ctr, Aurora, CO 80045 USA; Univ Texas, SW Med Ctr Dallas, Dallas, TX 75235 USA; Int Diabet Inst, Melbourne, Vic, Australia	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Eckel, RH (corresponding author), Univ Colorado, Div Endocrinol Diabet & Metab, POB 6511,MS 8106, Aurora, CO 80045 USA.	Robert.Eckel@UCHSC.edu	Girelli, Domenico/B-1183-2008; Zimmet, Paul/O-8486-2019	Girelli, Domenico/0000-0001-9684-1899; Zimmet, Paul/0000-0003-0627-0776				Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS15; ANDERSON EA, 1991, J CLIN INVEST, V87, P2246, DOI 10.1172/JCI115260; Assmann G, 2002, CIRCULATION, V105, P310, DOI 10.1161/hc0302.102575; Aubert H, 2003, J THROMB HAEMOST, V1, P791, DOI 10.1046/j.1538-7836.2003.00147.x; Azizi F, 2003, DIABETES RES CLIN PR, V61, P29, DOI 10.1016/S0168-8227(03)00066-4; Bajaj Mandeep, 2004, Curr Diab Rep, V4, P213, DOI 10.1007/s11892-004-0026-4; Balkau B, 1999, DIABETIC MED, V16, P442; Ballantyne CM, 2001, CIRCULATION, V104, P3046, DOI 10.1161/hc5001.100624; Barbato A, 2004, DIABETOLOGIA, V47, P40, DOI 10.1007/s00125-003-1260-z; Bays Harold E, 2003, Prev Cardiol, V6, P179, DOI 10.1111/j.1520-037X.2003.03142.x; Bergman AJ, 2004, J CLIN PHARMACOL, V44, P1054, DOI 10.1177/0091270004268044; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Bonora E, 2004, DIABETIC MED, V21, P52, DOI 10.1046/j.1464-5491.2003.01068.x; Boucher A, 2004, J BIOL CHEM, V279, P27263, DOI 10.1074/jbc.M401167200; BRINTON EA, 1991, J CLIN INVEST, V87, P536, DOI 10.1172/JCI115028; Brolin RE, 2002, JAMA-J AM MED ASSOC, V288, P2793, DOI 10.1001/jama.288.22.2793; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796; Cameron AJ, 2004, ENDOCRIN METAB CLIN, V33, P351, DOI 10.1016/j.ecl.2004.03.005; Carr DB, 2004, DIABETES, V53, P2087, DOI 10.2337/diabetes.53.8.2087; Cases JA, 2001, DIABETES, V50, P348, DOI 10.2337/diabetes.50.2.348; Chambers JC, 2001, CIRCULATION, V104, P145, DOI 10.1161/01.CIR.104.2.145; Chang JT, 2004, PHARMACOEPIDEM DR S, V13, P417, DOI 10.1002/pds.977; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Choudhury Jayanta, 2004, Clin Liver Dis, V8, P575, DOI 10.1016/j.cld.2004.04.006; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Colwell John A, 2004, Am J Cardiovasc Drugs, V4, P87, DOI 10.2165/00129784-200404020-00003; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Conroy RM, 2003, EUR HEART J, V24, P987, DOI 10.1016/S0195-668X(03)00114-3; Cook S, 2003, ARCH PEDIAT ADOL MED, V157, P821, DOI 10.1001/archpedi.157.8.821; Dallongeville J, 2003, J CLIN ENDOCR METAB, V88, P4862, DOI 10.1210/jc.2003-030173; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; DEGRAAF J, 1993, ARTERIOSCLER THROMB, V13, P712, DOI 10.1161/01.ATV.13.5.712; Eckel R. H, 2003, OBESITY MECH CLIN MA; ECKEL RH, 1995, INT J OBESITY, V19, pS16; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; Egan BM, 2003, CURR HYPERTENS REP, V5, P247, DOI 10.1007/s11906-003-0028-7; EINHORN D, 2002, ENDOCR PRACT, V9, P236; ELIASSON B, 1994, ARTERIOSCLER THROMB, V14, P1946, DOI 10.1161/01.ATV.14.12.1946; FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008; Fernandez-Real JM, 2003, ENDOCR REV, V24, P278, DOI 10.1210/er.2002-0010; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; Ferreira AC, 2002, AM J CARDIOL, V90, p3H; Fonseca V, 2003, AM J MED, V115, P42, DOI 10.1016/j.amjmed.2003.09.005; Ford ES, 2003, DIABETES CARE, V26, P575, DOI 10.2337/diacare.26.3.575; FORD FS, 2002, JAMA-J AM MED ASSOC, V287, P356; Foufelle F, 2002, BIOCHEM J, V366, P377, DOI 10.1042/BJ20020430; Fumeron F, 2004, DIABETES, V53, P1150, DOI 10.2337/diabetes.53.4.1150; Garg A, 2004, ENDOCRIN METAB CLIN, V33, P305, DOI 10.1016/j.ecl.2004.03.003; Girman CJ, 2004, AM J CARDIOL, V93, P136, DOI 10.1016/j.amjcard.2003.09.028; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Grundy SM, 2002, AM J MED, V113, P25, DOI 10.1016/S0002-9343(01)00988-3; Grundy SM, 2002, ARCH INTERN MED, V162, P1568, DOI 10.1001/archinte.162.14.1568; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Guo ZK, 1999, DIABETES, V48, P1586, DOI 10.2337/diabetes.48.8.1586; Halle M, 1999, ATHEROSCLEROSIS, V143, P185, DOI 10.1016/S0021-9150(98)00278-0; Hanley AJG, 2002, DIABETES, V51, P2642, DOI 10.2337/diabetes.51.8.2642; Hanley AJG, 2003, DIABETES, V52, P2740, DOI 10.2337/diabetes.52.11.2740; Hanson RL, 2002, DIABETES, V51, P3120, DOI 10.2337/diabetes.51.10.3120; Hegele RA, 2003, TRENDS ENDOCRIN MET, V14, P371, DOI 10.1016/S1043-2760(03)00142-5; Hu G, 2004, ARCH INTERN MED, V164, P1066, DOI 10.1001/archinte.164.10.1066; Hunt KJ, 2004, CIRCULATION, V110, P1251, DOI 10.1161/01.CIR.0000140762.04598.F9; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; JENSEN MD, 1989, DIABETES, V38, P1595, DOI 10.2337/diabetes.38.12.1595; Jialal I, 2001, CIRCULATION, V103, P1933; Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200; Julius S, 2001, AM J HYPERTENS, V14, p310S, DOI 10.1016/S0895-7061(01)02237-3; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kim YB, 2002, J BIOL CHEM, V277, P32915, DOI 10.1074/jbc.M204710200; Klein S, 2004, AM J CLIN NUTR, V80, P257, DOI 10.1093/ajcn/80.2.257; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KRAUSS RM, 1995, AM J CARDIOL, V75, pB53, DOI 10.1016/0002-9149(95)80012-H; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kuroda S, 1999, J HUM HYPERTENS, V13, P257, DOI 10.1038/sj.jhh.1000800; KYLIN ES, 1923, ZENTRALBLATT INNERE, V44; Laaksonen DE, 2002, AM J EPIDEMIOL, V156, P1070, DOI 10.1093/aje/kwf145; Lada AT, 2004, CURR OPIN LIPIDOL, V15, P19, DOI 10.1097/00041433-200402000-00005; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Lakka TA, 2003, MED SCI SPORT EXER, V35, P1279, DOI 10.1249/01.MSS.0000079076.74931.9A; Lamarche B, 1998, JAMA-J AM MED ASSOC, V279, P1955, DOI 10.1001/jama.279.24.1955; LaMonte MJ, 2002, CIRCULATION, V106, P403, DOI 10.1161/01.CIR.0000025425.20606.69; Lee S, 2004, J APPL PHYSIOL, V97, P948, DOI 10.1152/japplphysiol.01200.2003; Lee WJ, 2004, ARCH SURG-CHICAGO, V139, P1088, DOI 10.1001/archsurg.139.10.1088; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; Lemieux I, 2000, CIRCULATION, V102, P179, DOI 10.1161/01.CIR.102.2.179; LEWIS GF, 1995, J CLIN INVEST, V95, P158, DOI 10.1172/JCI117633; Lewis GF, 1996, DIABETES CARE, V19, P390, DOI 10.2337/diacare.19.4.390; Liu J, 2004, JAMA-J AM MED ASSOC, V291, P2591, DOI 10.1001/jama.291.21.2591; Maahs DM, 2005, CIRCULATION, V111, P747, DOI 10.1161/01.CIR.0000155251.03724.A5; Malik S, 2004, CIRCULATION, V110, P1245, DOI 10.1161/01.CIR.0000140677.20606.0E; MANZATO E, 1993, CLIN CHIM ACTA, V219, P57, DOI 10.1016/0009-8981(93)90197-C; Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Medina J, 2004, DIABETES CARE, V27, P2057, DOI 10.2337/diacare.27.8.2057; Meigs JB, 2004, DIABETES CARE, V27, P1417, DOI 10.2337/diacare.27.6.1417; Minokoshi Y, 2003, BIOCHEM SOC T, V31, P196, DOI 10.1042/bst0310196; Mogensen CE, 2004, DIABETIC MED, V21, P4, DOI 10.1111/j.1464-5491.2004.01121.x; MURAKAMI T, 1995, ARTERIOSCL THROM VAS, V15, P1819, DOI 10.1161/01.ATV.15.11.1819; Nawrocki AR, 2004, CURR OPIN PHARMACOL, V4, P281, DOI 10.1016/j.coph.2004.03.003; Nesto R, 2004, DIABETIC MED, V21, P810, DOI 10.1111/j.1464-5491.2004.01296.x; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; *NIH, 1998, OBES RES S2, V6, pS51, DOI DOI 10.1001/JAMA.2012.39; Ninomiya JK, 2004, CIRCULATION, V109, P42, DOI 10.1161/01.CIR.0000108926.04022.0C; Onat A, 2003, ATHEROSCLEROSIS, V168, P81, DOI 10.1016/S0021-9150(03)00025-X; Organization WH, 2000, ASIA PACIFIC PERSPEC; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Packard CJ, 1996, CURR MED RES OPIN, V13, P379, DOI 10.1185/03007999609111557; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; PETERSEN KF, 2004, NEW ENGL J MED, V350, P664, DOI [10.1056/NEJMoa031314, DOI 10.1056/NEJMOA031314]; Pischon T, 2004, JAMA-J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730; Pyorala K, 2004, DIABETES CARE, V27, P1735, DOI 10.2337/diacare.27.7.1735; Reaven GM, 2004, DIABETES CARE, V27, P1011, DOI 10.2337/diacare.27.4.1011; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Rowley Kevin, 2003, Curr Diab Rep, V3, P80, DOI 10.1007/s11892-003-0058-1; Rubins HB, 2000, J CARDIOVASC RISK, V7, P339; Ruderman N, 1998, DIABETES, V47, P699, DOI 10.2337/diabetes.47.5.699; Rutter MK, 2004, CIRCULATION, V110, P380, DOI 10.1161/01.CIR.0000136581.59584.0E; Sacks FM, 2003, J CLIN ENDOCR METAB, V88, P4525, DOI 10.1210/jc.2003-030636; Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200; Scheen AJ, 2004, DRUGS, V64, P2537, DOI 10.2165/00003495-200464220-00004; Setter SM, 2003, CLIN THER, V25, P2991, DOI 10.1016/S0149-2918(03)90089-0; Seufert J, 2004, DIABETES, V53, pS152, DOI 10.2337/diabetes.53.2007.S152; Shen BJ, 2003, AM J EPIDEMIOL, V157, P701, DOI 10.1093/aje/kwg045; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; Stern MP, 2004, DIABETES CARE, V27, P2676, DOI 10.2337/diacare.27.11.2676; Sung RYT, 2003, DIABETES CARE, V26, P250, DOI 10.2337/diacare.26.1.250; Sutherland JP, 2004, METAB SYNDR RELAT D, V2, P82, DOI 10.1089/met.2004.2.82; Taghibiglou C, 2002, J BIOL CHEM, V277, P793, DOI 10.1074/jbc.M106737200; Tanaka S, 2003, ACTA DIABETOL, V40, pS302, DOI 10.1007/s00592-003-0093-z; Thompson PD, 2003, CIRCULATION, V107, P3109, DOI 10.1161/01.CIR.0000075572.40158.77; Tooke JE, 2000, J INTERN MED, V247, P425, DOI 10.1046/j.1365-2796.2000.00671.x; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; Tripathy D, 2003, DIABETES, V52, P2882, DOI 10.2337/diabetes.52.12.2882; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Unger RH, 2003, TRENDS ENDOCRIN MET, V14, P398, DOI 10.1016/j.tem.2003.09.008; VAGUE J, 1947, PRESSE MED, V55, P339; van den Hoogen PCW, 2000, NEW ENGL J MED, V342, P1, DOI 10.1056/NEJM200001063420101; van Dielen FMH, 2004, J CLIN ENDOCR METAB, V89, P4062, DOI 10.1210/jc.2003-032125; VanPuijenbroek EP, 1996, J INTERN MED, V240, P403, DOI 10.1046/j.1365-2796.1996.48879000.x; Wei JN, 2003, JAMA-J AM MED ASSOC, V290, P1345, DOI 10.1001/jama.290.10.1345; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weiss R, 2004, NEW ENGL J MED, V350, P2362, DOI 10.1056/NEJMoa031049; WHO, 2004, LANCET, V363, P902; Wilson PWF, 2004, ENDOCRIN METAB CLIN, V33, P467, DOI 10.1016/j.ecl.2004.03.012; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamauchi Toshimasa, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P243, DOI 10.2174/1568008033340090; Yaney GC, 2003, DIABETOLOGIA, V46, P1297, DOI 10.1007/s00125-003-1207-4; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zambon A, 1999, CIRCULATION, V99, P1959, DOI 10.1161/01.CIR.99.15.1959; Zimmet P, 2003, DIABETIC MED, V20, P693, DOI 10.1046/j.1464-5491.2003.01052.x; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	163	4788	5106	23	790	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2005	365	9468					1415	1428		10.1016/S0140-6736(05)66378-7	http://dx.doi.org/10.1016/S0140-6736(05)66378-7			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836891				2022-12-28	WOS:000228401900031
J	Abouchami, W; Hofmann, AW; Galer, SJG; Frey, FA; Eisele, J; Feigenson, M				Abouchami, W; Hofmann, AW; Galer, SJG; Frey, FA; Eisele, J; Feigenson, M			Lead isotopes reveal bilateral asymmetry and vertical continuity in the Hawaiian mantle plume	NATURE			English	Article							MAUNA-KEA VOLCANO; MAJOR-ELEMENT; HF; SYSTEMATICS; EVOLUTION; LAVAS; PB; BASALT; ORIGIN; ZONE	The two parallel chains of Hawaiian volcanoes ('Loa' and ` Kea') are known to have statistically different but overlapping radiogenic isotope characteristics. This has been explained by a model of a concentrically zoned mantle plume, where the Kea chain preferentially samples a more peripheral portion of the plume. Using high-precision lead isotope data for both centrally and peripherally located volcanoes, we show here that the two trends have very little compositional overlap and instead reveal bilateral, non-concentric plume zones, probably derived from the plume source in the mantle. On a smaller scale, along the Kea chain, there are isotopic differences between the youngest lavas from the Mauna Kea and Kilauea volcanoes, but the 550-thousand-year-old Mauna Kea lavas are isotopically identical to Kilauea lavas, consistent with Mauna Kea's position relative to the plume, which was then similar to that of present-day Kilauea. We therefore conclude that narrow ( less than 50 kilometres wide) compositional streaks, as well as the larger-scale bilateral zonation, are vertically continuous over tens to hundreds of kilometres within the plume.	Max Planck Inst Chem, D-55020 Mainz, Germany; MIT, Cambridge, MA 02139 USA; Rutgers State Univ, Dept Geol Sci, New Brunswick, NJ 08903 USA	Max Planck Society; Massachusetts Institute of Technology (MIT); Rutgers State University New Brunswick	Abouchami, W (corresponding author), Max Planck Inst Chem, Postfach 3060, D-55020 Mainz, Germany.	wafa@mpch-mainz.mpg.de		Frey, Frederick/0000-0002-5403-5677				Abouchami W, 2000, CHEM GEOL, V169, P187, DOI 10.1016/S0009-2541(00)00328-4; Blichert-Toft J, 1999, SCIENCE, V285, P879, DOI 10.1126/science.285.5429.879; Blichert-Toft J, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000340; BRYCE JG, 2000, EOS T AGU, V81; Clague D.A., 1989, GEOLOGY N AM VOLUME, P188; DALRYMPLE GB, 1973, AM SCI, V61, P294; DANA JD, 1849, GEOLOGY US EXPLORING, V10; DePaolo DJ, 1996, J GEOPHYS RES-SOL EA, V101, P11855, DOI 10.1029/95JB03494; DePaolo DJ, 2001, GEOCHEM GEOPHY GEOSY, V2; Easton R. M., 1987, 75 ANNIVERSARY VOLUM, V1, P243; Eisele J, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000339; Eisele J, 2002, EARTH PLANET SC LETT, V196, P197, DOI 10.1016/S0012-821X(01)00601-X; FARNETANI C, 2004, EOS T AGU, V85; Farnetani CG, 2002, EARTH PLANET SC LETT, V196, P1, DOI 10.1016/S0012-821X(01)00597-0; FEIKIACOVA Z, 2003, EOS T AGU, V84; Galer SJG, 1999, CHEM GEOL, V157, P255, DOI 10.1016/S0009-2541(98)00203-4; GALER SJG, 1985, NATURE, V316, P778, DOI 10.1038/316778a0; GARCIA MO, 1989, J GEOPHYS RES-SOLID, V94, P10525, DOI 10.1029/JB094iB08p10525; HAURI EH, 1994, J GEOPHYS RES-SOL EA, V99, P24275, DOI 10.1029/94JB01257; Hauri EH, 1996, J GEOPHYS RES-SOL EA, V101, P11793, DOI 10.1029/95JB03346; Hauri EH, 1996, NATURE, V382, P415, DOI 10.1038/382415a0; Hieronymus CF, 1999, NATURE, V397, P604, DOI 10.1038/17584; JACKSON ED, 1975, EARTH PLANET SC LETT, V26, P145, DOI 10.1016/0012-821X(75)90082-5; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; Kerr RC, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2004GC000749; Kurz MD, 1996, J GEOPHYS RES-SOL EA, V101, P11781, DOI 10.1029/95JB03345; Kurz MD, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2002GC000439; Lassiter JC, 1996, J GEOPHYS RES-SOL EA, V101, P11769, DOI 10.1029/96JB00181; Lipman PW, 2002, GEOPH MONOG SERIES, V128, P161; LOPER DE, 1983, PHYS EARTH PLANET IN, V33, P304, DOI 10.1016/0031-9201(83)90047-X; OLSON P, 1993, J GEOPHYS RES-SOL EA, V98, P6829, DOI 10.1029/92JB01013; Quane SL, 2000, J VOLCANOL GEOTH RES, V102, P319, DOI 10.1016/S0377-0273(00)00194-3; Ribe NM, 1999, EARTH PLANET SC LETT, V171, P517, DOI 10.1016/S0012-821X(99)00179-X; Schubert G, 2001, MANTLE CONVECTION EA; SHARP WA, IN PRESS GEOCHEM GEO; STILLE P, 1983, NATURE, V304, P25, DOI 10.1038/304025a0; STOLPER EM, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI DOI 10.1029/2003GC000553; Tanaka R, 2002, GEOPH MONOG SERIES, V128, P311; TATSUMOTO M, 1978, EARTH PLANET SC LETT, V38, P63, DOI 10.1016/0012-821X(78)90126-7; TENBRINK U, 1991, GEOLOGY, V19, P397, DOI 10.1130/0091-7613(1991)019<0397:VSAPR>2.3.CO;2; Wessel P, 1997, NATURE, V387, P365, DOI 10.1038/387365a0; YANG HJ, 1994, J GEOPHYS RES-SOL EA, V99, P15577, DOI 10.1029/94JB00895; ZINDLER A, 1986, ANNU REV EARTH PL SC, V14, P493, DOI 10.1146/annurev.ea.14.050186.002425	43	192	199	2	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					851	856		10.1038/nature03402	http://dx.doi.org/10.1038/nature03402			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829954				2022-12-28	WOS:000228327600030
J	Reynolds, EE				Reynolds, EE			A 60-year-old woman trying to discontinue hormone replacement therapy, 2 years later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; ESTROGEN											Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Grady D, 2002, JAMA-J AM MED ASSOC, V287, P2130, DOI 10.1001/jama.287.16.2130; LENFANT C, 2000, PRELIMINARY TRENDS W; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1780	1780		10.1001/jama.293.14.1780	http://dx.doi.org/10.1001/jama.293.14.1780			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827318				2022-12-28	WOS:000228301100033
J	Stein, REK; Stanton, B; Starfield, B				Stein, REK; Stanton, B; Starfield, B			How healthy are US children?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Albert Einstein Coll Med, Childrens Hosp Montefiore, Dept Pediat, Bronx, NY 10467 USA; Wayne State Univ, Sch Med, Childrens Hosp Michigan, Dept Pediat, Detroit, MI USA; Johns Hopkins Univ, Inst Med, Dept Pediat, Baltimore, MD USA; Johns Hopkins Univ, Inst Med, Dept Hlth Policy & Management, Baltimore, MD USA	Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; Children's Hospital of Michigan; Wayne State University; Johns Hopkins University; Johns Hopkins University	Stein, REK (corresponding author), Albert Einstein Coll Med, Childrens Hosp Montefiore, Dept Pediat, 111 E 210 St, Bronx, NY 10467 USA.	rstein@aecom.yu.edu						[Anonymous], 2005, STAT WORLDS CHILDR 2; Barker DJP, 1998, MOTHERS BABIES HLTH; de Quadros CA, 2000, INFECT DIS CLIN N AM, V14, P241, DOI 10.1016/S0891-5520(05)70226-9; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; Galobardes B, 2004, EPIDEMIOL REV, V26, P7, DOI 10.1093/epirev/mxh008; Hinman A, 1999, ANNU REV PUBL HEALTH, V20, P211, DOI 10.1146/annurev.publhealth.20.1.211; *I MED COMM EV CHI, 2004, CHILDR HLTH NAT WEAL; Institute of Medicine Committee on Integrating the Science of Early Childhood Development and Board on Children Youth and Families, 2000, NEUR NEIGHB SCI EARL; Institute of Medicine Committee on Prevention of Obesity in Children and Youth, 2005, PREV CHILDH OB HLTH; Krebs NF, 2003, PEDIATRICS, V112, P424, DOI 10.1542/peds.112.2.424; *NAT COMM VIT HLTH, 2001, INF HLTH STRAT BULD; *NAT CTR ED STAT, 1995, DROUP RAT US; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; *OTT CHART HLTH PR, 1986, 1 INT C HLTH PROM NO; Starfield B, 2004, HEALTH AFFAIR, V23, P165, DOI 10.1377/hlthaff.23.5.165; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; *US EPA, 2000, AM CHILDR ENV 1 VIEW; *US PHS, 2000, MENT HLTH REP SURG G; Wadsworth M. E. J., 1999, SOCIAL DETERMINANTS; WALLIS A, 2003, REPORT NATION TRENDS; 2000, MMWR MORB MORTAL WKL, V49, P135	21	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1781	1783		10.1001/jama.293.14.1781	http://dx.doi.org/10.1001/jama.293.14.1781			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827319				2022-12-28	WOS:000228301100034
J	Gilmore, AB; Radu-Loghin, C; Zatushevski, I; McKee, M				Gilmore, AB; Radu-Loghin, C; Zatushevski, I; McKee, M			Pushing up smoking incidence: plans for a privatised tobacco industry in Moldova	LANCET			English	Article							FORMER SOVIET-UNION; EMERGING MARKETS; GAINED ENTRY; MOVING EAST; IMPACT	Moldova, one of the former Soviet republics and Europe's poorest country, has so far resisted pressure to privatise its tobacco industry. This paper examines the policies pursued by the transnational tobacco companies in Moldova in order to inform the ongoing debate about tobacco industry privatisation. We analysed relevant internal industry documents made public through litigation. The documents suggest that although a competitive tender for the state owned monopoly was later announced, British American Tobacco (BAT) and the German manufacturer Reemtsma each initially sought to secure a dosed deal, with BAT accusing Reemtsma of underhand tactics. Imperial Tobacco, which now owns Reemstma, was unable to comment on these allegations as it only acquired Reemstma after the events in question. BAT sought to acquire a monopoly position, bolstered by excise rules developed by the company that would uniquely favour its products. Despite hoping to establish a monopoly, it planned intensive marketing, as if in a competitive market, aiming to target young urban dwellers, particularly opinion leaders. In so doing it predicted that smoking uptake would increase, especially among women. The documents also suggest that BAT was aware of the sensitive nature of its plans to cull the processing workforce and aimed to present "sanitised" information on future employment levels to the Moldovans. The potential for tobacco industry privatisation to undermine tobacco control and promote cigarette consumption is highlighted and is consistent with economic theory. Countries planning tobacco industry privatisation should ensure a transparent and competitive privatisation process, seek to prevent the predicted increase in consumption by implementing effective tobacco control policies and consider the impacts on employment. Multilateral financial organisations promoting tobacco industry privatisation. could ensure their loan conditions protect public health by making the implementation of tobacco control policies a pre-requisite for privatisation.	Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1E 7HT, England; Aer Pur Romania, Bucharest, Romania; Moldova State Univ, Dept Journalism, Kishinev, Moldova	University of London; London School of Hygiene & Tropical Medicine; Moldova State University	Gilmore, AB (corresponding author), Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, Keppel St, London WC1E 7HT, England.	anna.gilmore@lshtm.ac.uk	gilmore, anna B/I-7130-2012; McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	gilmore, anna B/0000-0003-0281-1248; McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683; RADU LOGHIN, Cornel/0000-0002-9922-4535	NATIONAL CANCER INSTITUTE [R01CA091021] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA91021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bettcher D, 2001, CONFRONTING TOBACCO; *CAMP TOB FREE KID, 2002, PUBL HLTH INT TRAD, V2; Chaloupka FJ, 2000, ADDICTION, V95, pS477, DOI 10.1080/09652140020013728; Chaloupka Frank J., 1996, 5543 NAT BUR EC RES; COSTAS N, 2003, J CHISINAU      0321, P3; COSTAS N, 2003, J CHISINAU      0228, P10; EAGLESHAM J, 2003, FINANCIAL TIMES 0307; Farrelly MC, 2002, AM J PUBLIC HEALTH, V92, P901, DOI 10.2105/AJPH.92.6.901; Gilmore A, 2004, AM J PUBLIC HEALTH, V94, P2177, DOI 10.2105/AJPH.94.12.2177; Gilmore AB, 2005, TOB CONTROL, V14, P13, DOI 10.1136/tc.2003.005082; Gilmore AB, 2004, TOB CONTROL, V13, P151, DOI 10.1136/tc.2003.005207; Gilmore AB, 2004, TOB CONTROL, V13, P143, DOI 10.1136/tc.2003.005108; Gilmore AB, 2004, TOB CONTROL, V13, P136, DOI 10.1136/tc.2002.002667; Gilmore ABC, 2001, PREV MED, V33, P453, DOI 10.1006/pmed.2001.0915; Mackay J, 1992, J Natl Cancer Inst Monogr, P25; NELLIS J, 1999, 38 INT FIN CORP; Pomerleau J, 2004, ADDICTION, V99, P1577, DOI 10.1111/j.1360-0443.2004.00885.x; RADZIWILL A, 2001, GDN COUNTRY GROWTH S; Stiglitz J, 2002, GLOBALISATION ITS DI; Vateesatokit P, 2000, TOB CONTROL, V9, P122, DOI 10.1136/tc.9.2.122; Weissman R, 2002, NEEDLESS HARM INT MO; *WHO REG OFF EUR, 2003, HLTH ALL DAT; World Bank, 1999, CURB EP GOV EC TOB C; *WORLD BANK, 2002, TRANS 1 10 YEARS AN; 1996, CHISINAU NEWS   0615; 2001, OBSERVATOR       APR; [No title captured]; 1997, TOBACCO J INT, V2, P6	28	23	23	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2005	365	9467					1354	1359		10.1016/S0140-6736(05)61035-5	http://dx.doi.org/10.1016/S0140-6736(05)61035-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823388				2022-12-28	WOS:000228219600033
J	Provoost, V; Cools, F; Mortier, F; Bilsen, J; Ramet, J; Vandenplas, Y; Deliens, L				Provoost, V; Cools, F; Mortier, F; Bilsen, J; Ramet, J; Vandenplas, Y; Deliens, L		Neonatal Intensive Care Consortium	Medical end-of-life decisions in neonates and infants in Flanders	LANCET			English	Article							SELF-REPORTED PRACTICES; INTENSIVE-CARE; ATTITUDES; EUTHANASIA; NEWBORNS	Background Paediatricians are increasingly confronted with end-of-life decisions in critically ill neonates and infants. little is known about the frequency and characteristics of end-of-life decisions in this population, nor about the relation with clinical and patients' characteristics. Methods A death-certificate study was done for all deaths of neonates and infants in the whole of Flanders over a 12-month period (August, 1999, to July, 2000). We sent an anonymous questionnaire by mail to the attending physician for each of the 292 children who died under the age of 1 year. Information on patients was obtained from national registers. An attitude study was done for all physicians who attended at least one death during the study period. Findings 253 (87%) of the 292 questionnaires were returned, and 121 (69%) of the 175 physicians involved completed the attitude questions. An end-of-life decision was possible in 194 (77%; 95% CI 70.4-82.4) of the 253 deaths studied, and such a decision was made in 143 cases (57%; 48.9-64.0). Lethal drugs were administered in 15 cases among 117 early neonatal deaths and in two cases among 77 later deaths (13% vs 3%; p=0.018). The attitude study showed that 95 (79%; 70.1-85.5) of the 121 physicians thought that their professional duty sometimes includes the prevention of unnecessary suffering by hastening death and 69 (58%; 48.1-66.5) of 120 supported legalisation of life termination in some cases. Interpretation Death of neonates and infants is commonly preceded by an end-of-life decision. The type of decision varied substantially according to the age of the child. Most physicians favour legalisation of the use of lethal drugs in some cases.	Free Univ Brussels, End Life Care Res Grp, B-1090 Brussels, Belgium; Free Univ Brussels, Univ Hosp, Dept Paediat, Brussels, Belgium; Univ Ghent, Ctr Bioeth, B-9000 Ghent, Belgium; Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Inst Res Extramural Med, Amsterdam, Netherlands	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Ghent University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Deliens, L (corresponding author), Free Univ Brussels, End Life Care Res Grp, Laarbeeklaan 103, B-1090 Brussels, Belgium.	luc.deliens@vub.ac.be	Provoost, Veerle/H-4214-2011	Mortier, Freddy/0000-0002-5390-3508; Cools, Filip/0000-0002-6581-7009; Deliens, Luc/0000-0002-8158-2422				*BRIT MED ASS, 1999, WITHH WITHDR LIF PRO; Cantagrel S, 2000, ARCH PEDIATRIE, V7, P725, DOI 10.1016/S0929-693X(00)80152-9; Cook L A, 1996, J Perinatol, V16, P133; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; de Leeuw R, 2000, J PEDIATR-US, V137, P608, DOI 10.1067/mpd.2000.109144; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; DILLMAN DA, 1991, ANNU REV SOCIOL, V17, P225, DOI 10.1146/annurev.so.17.080191.001301; Doron MW, 1998, PEDIATRICS, V102, P574, DOI 10.1542/peds.102.3.574; DUFF RS, 1973, NEW ENGL J MED, V289, P890, DOI 10.1056/NEJM197310252891705; *EUR WORK GROUP, 2001, 7 SCI PUBL HLTH EUR; Garel M, 1997, ARCH PEDIATRIE, V4, P662, DOI 10.1016/S0929-693X(97)83370-2; HARRIS J, 1985, VALUE LIFE INTRO MED, P34; Kollee LAA, 1999, SEMIN PERINATOL, V23, P234, DOI 10.1016/S0146-0005(99)80068-8; McCallum DE, 2000, J PAIN SYMPTOM MANAG, V20, P417, DOI 10.1016/S0885-3924(00)00212-8; McHaffie HE, 1999, J MED ETHICS, V25, P440, DOI 10.1136/jme.25.6.440; McHugh-Strong CM, 2000, AM J PERINAT, V17, P27, DOI 10.1055/s-2000-7291; Norup M, 1998, ACTA PAEDIATR, V87, P896, DOI 10.1080/080352598750013707; Norup M, 1999, ACTA PAEDIATR, V88, P438, DOI 10.1080/08035259950169846; POWDERLY KE, 1999, ETHICS CRITICAL CARE, P475; Rebagliato M, 2000, JAMA-J AM MED ASSOC, V284, P2451, DOI 10.1001/jama.284.19.2451; Sklansky M, 2001, J MED ETHICS, V27, P5, DOI 10.1136/jme.27.1.5; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; vanderHeide A, 1997, LANCET, V350, P251, DOI 10.1016/S0140-6736(97)02315-5	24	47	47	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2005	365	9467					1315	1320		10.1016/S0140-6736(05)61028-8	http://dx.doi.org/10.1016/S0140-6736(05)61028-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823381				2022-12-28	WOS:000228219600026
J	Davis, RL				Davis, RL			Remote control of fruit fly behavior	CELL			English	Editorial Material									Baylor Coll Med, Dept Mol & Cellular Biol, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA	Baylor College of Medicine	Davis, RL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Menninger Dept Psychiat & Behav Sci, 1 Baylor Plaza, Houston, TX 77030 USA.		Davis, Ronald/J-4998-2013	Davis, Ronald/0000-0002-5986-7608				Cohen MR, 2004, CURR OPIN NEUROBIOL, V14, P169, DOI 10.1016/j.conb.2004.03.016; Davis RL, 2005, ANNU REV NEUROSCI, V28, P275, DOI 10.1146/annurev.neuro.28.061604.135651; HUBER F, 1967, INVERTEBRATE NERVOUS, P333; Lima SQ, 2005, CELL, V121, P141, DOI 10.1016/j.cell.2005.02.004; Squire L. R., 1987, MEMORY BRAIN	5	2	2	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 8	2005	121	1					6	7		10.1016/j.cell.2005.03.010	http://dx.doi.org/10.1016/j.cell.2005.03.010			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820673	Bronze			2022-12-28	WOS:000228348500004
J	Snyder, L; Leffler, C				Snyder, L; Leffler, C		Eth Hu Ri Comm Amer Coll Physicans	Ethics manual - Fifth edition	ANNALS OF INTERNAL MEDICINE			English	Review							PHYSICIAN-INDUSTRY RELATIONS; COLLEGE-OF-PHYSICIANS; PALLIATIVE CARE; MANAGED CARE; PART 1; HEALTH; CONSULTATION; MEDICINE; GOALS; CODE	Medicine, law, and social values are not static. Reexamining the ethical tenets of medical practice and their application in new circumstances is a necessary exercise. The fifth edition of the College's Ethics Manual covers emerging issues in medical ethics and revisits old ones. It reflects on many of the ethical tensions faced by internists and their patients and attempts to shed light on how existing principles extend to emerging concerns. In addition, by reiterating ethical principles that have provided guidance in resolving past ethical problems, the Manual may help physicians avert future problems. The Manual is not a substitute for the experience and integrity of individual physicians, but it may serve as a reminder of the shared obligations and duties of the medical profession.	Amer Coll Physicians, Philadelphia, PA 19106 USA	American College of Physicians	Snyder, L (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.							*AM COLL PHYS, 2001, YOU HAV PAIN END LIF; *AM MED ASS, 1999, E509 AM MED ASS; *AM MED ASS, 1999, E1003 AM MED ASS; Amdur RJ, 2002, I REV BOARD MANAGEME; Amer College Physicians, 2004, ANN INTERN MED, V141, P226, DOI 10.7326/0003-4819-141-3-200408030-00015; American College of Legal Medicine, 2001, LEG MED; American College of Physicians Ethics Manual, 1989, ANN INTERN MED, V111, P327; American College of Physicians Ethics Manual, 1989, ANN INTERN MED, V111, P245; American Medical Association, 2011, GUID PHYS PAT EL COM, P28; ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; [Anonymous], 2003, Clin Med (Lond), V3, P249; World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; [Anonymous], 1990, Ann Intern Med, V113, P789; [Anonymous], 1990, NEW MED OLD ETHICS; [Anonymous], 2001, PAT ED CAR END OF LI; [Anonymous], 2003, NIH PUBL; [Anonymous], 2000, OEI019700196 DEP HLT; Aulisio MP, 2000, ANN INTERN MED, V133, P59, DOI 10.7326/0003-4819-133-1-200007040-00012; BEAUCHAMP TL, 2001, PRINICPLES BIOMEDICA; Berger JT, 2001, J CLIN ETHIC, V12, P375; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Boisaubin EV, 2001, AM J MED SCI, V322, P31, DOI 10.1097/00000441-200107000-00006; BRADDOCK CH, 2003, ETHICS TIME TIME PER; BUCHAN ML, 1995, J CLIN ETHIC, V6, P53; BURNUM JF, 1991, NEW ENGL J MED, V324, P1130, DOI 10.1056/NEJM199104183241611; CARROLL RJ, 1999, ACP ASIM OBERSVE JAN; Cassarett D., 2001, PHYS GUIDE END LIFE, P178; CASSARETT D, 2001, ACP OBSERVER     MAR; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; CONLEY FK, 1993, NEW ENGL J MED, V328, P351, DOI 10.1056/NEJM199302043280513; Coyle SL, 2002, ANN INTERN MED, V136, P396, DOI 10.7326/0003-4819-136-5-200203050-00014; Coyle SL, 2002, ANN INTERN MED, V136, P403, DOI 10.7326/0003-4819-136-5-200203050-00015; Crawley LM, 2001, PHYS GUIDE END LIFE, P35; Crook ED, 2005, ETHICAL CHOICES CASE, P148; *DEP HLTH HUM SERV, COMM RUL PROT HUM SU; Department of Health and Human Services, 1995, INT MISC RES REP COM; Drazen JM, 2000, NEW ENGL J MED, V343, P1643, DOI 10.1056/NEJM200011303432212; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Fletcher JC, 1996, J CLIN ETHIC, V7, P122; Gazelle G, 1998, NEW ENGL J MED, V338, P467, DOI 10.1056/NEJM199802123380712; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; Ginsburg J, 2001, ANN INTERN MED, V134, P787, DOI 10.7326/0003-4819-136-9-200205070-00023; Gostin LO, 2001, JAMA-J AM MED ASSOC, V285, P3015, DOI 10.1001/jama.285.23.3015; GOSTIN LO, 1989, JAMA-J AM MED ASSOC, V110, P930; *HAST CTR, 1987, GUID TERM LIF SUST T; Hedberg K, 2003, NEW ENGL J MED, V348, P961, DOI 10.1056/NEJM200303063481022; HENDEE WR, 1990, JAMA-J AM MED ASSOC, V263, P426; Herrin V, 2000, ACP ASIM OBSERVE FEB; *I MED, 1999, ERR HUM BUILD SAF HL; *I MED, 1997, APPR DEATH IMPR CAR; International Committee of Medical Journal Editors, 2004, UN REQ MAN SUBM BIOM; Joint Commission on Accreditation of Healthcare Organization, 2004, COMPR ACCR MAN HOSP; Jonsen A.R., 1998, BIRTH BIOETHICS; Karlawish JHT, 1999, ANN INTERN MED, V130, P835, DOI 10.7326/0003-4819-130-10-199905180-00018; KATZ J, 1997, SILENT WORLD DOCTOR; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LANKEN PN, 1991, AM REV RESPIR DIS, V144, P726, DOI 10.1164/ajrccm/144.3_Pt_1.726; LaPuma J, 1995, Trends Health Care Law Ethics, V10, P73; LIND SE, 1988, CLIN RES, V36, P546; LIND SE, 1990, NEW ENGL J MED, V323, P192, DOI 10.1056/NEJM199007193230310; Lo B, 1999, ANN INTERN MED, V130, P744, DOI 10.7326/0003-4819-130-9-199905040-00015; Lyckholm LJ, 1998, JAMA-J AM MED ASSOC, V280, P1944, DOI 10.1001/jama.280.22.1944; Mechanic D, 1996, JAMA-J AM MED ASSOC, V275, P1693, DOI 10.1001/jama.275.21.1693; *NAT COMM CORR HLT, 2005, CHARG INM FEE HLTH C; *NEW YORK STAT TAS, 1994, DEATH SOUGHT ASS SUI; *NIH NAT CTR COMPL, WHAT COMPL ALT MED C; ORENTLICHER D, 1992, JAMA-J AM MED ASSOC, V267, P2366; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; *PHYS PHARM IND, 1990, ANN INTERN MED, V112, P624; POVAR G, 1988, ANN INTERN MED, V109, P419, DOI 10.7326/0003-4819-109-5-419; Povar GJ, 1999, ANN INTERN MED, V131, P863, DOI 10.7326/0003-4819-131-11-199912070-00012; Povar GJ, 2004, ANN INTERN MED, V141, P131, DOI 10.7326/0003-4819-141-2-200407200-00012; *PRES COMM STUD ET, 1983, SEC ACC HLTH CAR REP; *PRES COMM STUD ET, 1982, SPL LIF REP SOC ETH; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, SCREEN COUNS GEN CON; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DEC FORG LIF SUST TR; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1982, MAK HLTH CAR DEC REP; QUILL TE, 1991, ARCH INTERN MED, V151, P463; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Reich W.T., 1995, ENCY BIOETHICS; Rich EC, 2004, J GEN INTERN MED, V19, P273, DOI 10.1111/j.1525-1497.2004.30401.x; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; Rothman D., 1991, STRANGERS BEDSIDE HI, DOI DOI 10.4324/9781315130286; Sabatino CP, 1999, J LAW MED ETHICS, V27, P297, DOI 10.1111/j.1748-720X.1999.tb01465.x; SNYDER L, 1989, ANN INTERN MED, V110, P930; SNYDER L, 1990, ANN INTERN MED, V112, P802, DOI 10.7326/0003-4819-112-11-802; Snyder L, 2001, ANN INTERN MED, V135, P209, DOI 10.7326/0003-4819-135-3-200108070-00015; Snyder L, 1998, J AM GERIATR SOC, V46, P378, DOI 10.1111/j.1532-5415.1998.tb01058.x; Snyder L, 1996, ETHICAL CHOICES CASE, P105; Snyder L, 2005, ETHICAL CHOICES CASE, P130; Snyder L, 2005, ETHICAL CHOICES CASE, P77; SNYDER L, 2001, PHYS GUID END CARE; Sulmasy DP, 1999, ARCH INTERN MED, V159, P545, DOI 10.1001/archinte.159.6.545; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Tobias BB, 1998, PRIMARY CARE, V25, P49, DOI 10.1016/S0095-4543(05)70325-0; Tulsky JA, 1997, ACP OBSERVER     MAR; *UN, 1995, 1 C PREV CRIM TREATM; *US DEP HHS, 2001, PRIV RUL STAND PRIV; Veatch R. M., 2000, TRANSPLANTATION ETHI; Veatch Robert M, 1981, THEORY MED ETHICS, V1; Weiner J, 2005, ETHICAL CHOICES CASE, P136; Weiner J, 2005, ETHICAL CHOICES CASE, P99; WHITE LJ, 1988, ANN INTERN MED, V108, P460, DOI 10.7326/0003-4819-108-3-460; WHITE LJ, 1989, ANN INTERN MED, V111, P843, DOI 10.7326/0003-4819-111-10-843; Williams MA, 2003, CRIT CARE MED, V31, P1568, DOI 10.1097/01.CCM.0000063090.21056.A6; WINER J, 1950, ETHICAL CHOICES CASE, P143; World Medical Association, DECL HELS ETH PRINC; 1986, J R COLL PHYS LOND, V20, P235	110	134	140	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 5	2005	142	7					560	582		10.7326/0003-4819-142-7-200504050-00014	http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00014			23	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913QL	15809467				2022-12-28	WOS:000228167800009
J	Dejardin, J; Rappailles, A; Cuvier, O; Grimaud, C; Decoville, M; Locker, D; Cavalli, G				Dejardin, J; Rappailles, A; Cuvier, O; Grimaud, C; Decoville, M; Locker, D; Cavalli, G			Recruitment of Drosophila Polycomb group proteins to chromatin by DSP1	NATURE			English	Article							HMG-LIKE PROTEIN; RESPONSE ELEMENT; HOMEOTIC GENE; BITHORAX COMPLEX; ENGRAILED GENE; DNA; MELANOGASTER; REPRESSION; REGION; GAGA	Polycomb and trithorax group (PcG and trxG) proteins maintain silent and active transcriptional states, respectively, throughout development(1). In Drosophila, PcG and trxG proteins associate with DNA regions named Polycomb and trithorax response elements (PRE and TRE), but the mechanisms of recruitment are unknown. We previously characterized a minimal element from the regulatory region of the Abdominal-B gene, termed Ab-Fab. Ab-Fab contains a PRE and a TRE and is able to maintain repressed or active chromatin states during development(2). Here we show that the Dorsal switch protein 1 (DSP1), a Drosophila HMGB2 homologue, binds to a sequence present within Ab-Fab and in other characterized PREs. Addition of this motif to an artificial sequence containing Pleiohomeotic and GAGA factor consensus sites is sufficient for PcG protein recruitment in vivo. Mutations that abolish DSP1 binding to Ab-Fab and to a PRE from the engrailed locus lead to loss of PcG protein binding, loss of silencing, and switching of these PREs into constitutive TREs. The binding of DSP1 to PREs is therefore important for the recruitment of PcG proteins.	CNRS, Inst Human Genet, F-34396 Montpellier, France; Univ Orleans, CNRS, Ctr Biophys Mol, F-45071 Orleans, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Orleans	Cavalli, G (corresponding author), CNRS, Inst Human Genet, 141 Rue Cardonille, F-34396 Montpellier, France.	giacomo.cavalli@igh.cnrs.fr	Cuvier, Olivier/ADO-0657-2022; cavalli, giacomo/Z-2754-2019; CUVIER, Olivier/AAC-4693-2019; Cavalli, Giacomo/A-7958-2008; grimaud, charlotte/Y-6689-2019	cavalli, giacomo/0000-0003-3709-3469; CUVIER, Olivier/0000-0003-0644-2734; Cavalli, Giacomo/0000-0003-3709-3469; grimaud, charlotte/0000-0001-7944-5931; DEJARDIN, Jerome/0000-0003-0151-1104				Americo J, 2002, GENETICS, V160, P1561; Brickman JM, 1999, P NATL ACAD SCI USA, V96, P10679, DOI 10.1073/pnas.96.19.10679; Brown JL, 2003, DEVELOPMENT, V130, P285, DOI 10.1242/dev.00204; BROWN KL, 1998, RRD INORG CHEM, V1, P1; Busturia A, 2001, DEVELOPMENT, V128, P2163; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; Decoville M, 2001, GENETICS, V157, P237; Dejardin J, 2004, EMBO J, V23, P857, DOI 10.1038/sj.emboj.7600108; Duncan IW, 2002, ANNU REV GENET, V36, P521, DOI 10.1146/annurev.genet.36.060402.100441; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Fritsch C, 1999, DEVELOPMENT, V126, P3905; Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7; Hagstrom K, 1997, GENETICS, V146, P1365; Kassis JA, 2002, ADV GENET, V46, P421; KASSIS JA, 1994, GENETICS, V136, P1025; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; MARTIN CH, 1995, P NATL ACAD SCI USA, V92, P8398, DOI 10.1073/pnas.92.18.8398; Mishra RK, 2001, MOL CELL BIOL, V21, P1311, DOI 10.1128/MCB.21.4.1311-1318.2001; Mohd-Sarip A, 2002, MOL CELL BIOL, V22, P7473, DOI 10.1128/MCB.22.21.7473-7483.2002; Mosrin-Huaman C, 1998, DEV GENET, V23, P324; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Ringrose L, 2003, DEV CELL, V5, P759, DOI 10.1016/S1534-5807(03)00337-X; Shimell MJ, 2000, DEV BIOL, V218, P38, DOI 10.1006/dbio.1999.9576; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	29	121	124	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					533	538		10.1038/nature03386	http://dx.doi.org/10.1038/nature03386			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791260				2022-12-28	WOS:000227836000048
J	Cutts, FT; Zaman, SMA; Enwere, G; Jaffar, S; Levine, OS; Okoko, JB; Oluwalana, C; Vaughan, A; Obaro, SK; Leach, A; McAdam, KP; Biney, E; Saaka, M; Onwuchekwa, U; Yallop, F; Pierce, NF; Greenwood, BM; Adegbola, RA				Cutts, FT; Zaman, SMA; Enwere, G; Jaffar, S; Levine, OS; Okoko, JB; Oluwalana, C; Vaughan, A; Obaro, SK; Leach, A; McAdam, KP; Biney, E; Saaka, M; Onwuchekwa, U; Yallop, F; Pierce, NF; Greenwood, BM; Adegbola, RA		Gambian Pneumococcal Vaccine Trial	Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial	LANCET			English	Article							INTEGRATED MANAGEMENT; CHILDHOOD ILLNESS; CHILDREN; SAFETY; IMMUNOGENICITY; PREVENTION; DIPHTHERIA; PERTUSSIS; TETANUS; AREA	Background Pneumonia is estimated to cause 2 million deaths every year in children. Streptococcus pneumoniae is the most important cause of severe pneumonia. We aimed to assess the efficacy of a nine-valent pneumococcal conjugate vaccine in children. Methods We undertook a randomised, placebo-controlled, double-blind trial in eastern Gambia. Children age 6-51 weeks were randomly allocated three doses of either pneumococcal conjugate vaccine (n=8718) or placebo (8719), with intervals of at least 25 days between doses. Our primary outcome was first episode of radiological pneumonia. Secondary endpoints were clinical or severe clinical pneumonia, invasive pneumococcal disease, and all-cause admissions. Analyses were per protocol and intention to treat. Findings 529 children assigned vaccine and 568 allocated placebo were not included in the per-protocol analysis. Results of per-protocol and intention-to-treat analyses were similar. By per-protocol analysis, 333 of 8189 children given vaccine had an episode of radiological pneumonia compared with 513 of 8151 who received placebo. Pneumococcal vaccine efficacy was 37% (95% CI 27-45) against first episode of radiological pneumonia. First episodes of clinical pneumonia were reduced overall by 7% (95% CI 1-12). Efficacy of the conjugate vaccine was 77% (51-90) against invasive pneumococcal disease caused by vaccine serotypes, 50% (21-69) against disease caused by all serotypes, and 15% (7-21) against all-cause admissions. We also found an efficacy of 16% (3-28) against mortality. 110 serious adverse events arose in children given the pneumococcal vaccine compared with 131 in those who received placebo. Interpretation In this rural African setting, pneumococcal conjugate vaccine has high efficacy against radiological pneumonia and invasive pneumococcal disease, and can substantially reduce admissions and improve child survival. Pneumococcal conjugate vaccines should be made available to African infants.	MRC Labs, Banjul, Gambia; London Sch Hyg & Trop Med, London WC1, England; NIAID, NIH, Bethesda, MD 20892 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	MRC Laboratory Molecular Biology; University of London; London School of Hygiene & Tropical Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Cutts, FT (corresponding author), WHO, Initiat Vaccine Res, CH-1211 Geneva, Switzerland.	cuttsf@who.int	Leach, Amanda/AAS-1120-2020	Leach, Amanda/0000-0002-7114-9967; Jaffar, Shabbar/0000-0002-9615-1588	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025477] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-25477] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEGBOLA RA, 1994, PEDIATR INFECT DIS J, V13, P975, DOI 10.1097/00006454-199411000-00008; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Black SB, 2002, PEDIATR INFECT DIS J, V21, P810, DOI 10.1097/00006454-200209000-00005; Campbell JD, 2004, PEDIATR INFECT DIS J, V23, P642, DOI 10.1097/01.inf.0000130951.85974.79; CHERIAN T, IN PRESS B WHO; Gove S, 1997, B WORLD HEALTH ORGAN, V75, P7; Greenwood B, 1999, PHILOS T R SOC B, V354, P777, DOI 10.1098/rstb.1999.0430; Jaffar S, 2003, INT J EPIDEMIOL, V32, P430, DOI 10.1093/ije/dyg082; Jaffar S, 1999, VACCINE, V18, P633, DOI 10.1016/S0264-410X(99)00277-7; Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077; O'Brien KL, 2003, LANCET, V362, P355, DOI 10.1016/S0140-6736(03)14022-6; Obaro SK, 2000, PEDIATR INFECT DIS J, V19, P463, DOI 10.1097/00006454-200005000-00014; Obaro SK, 2002, PEDIATR INFECT DIS J, V21, P940, DOI 10.1097/00006454-200210000-00011; Obaro SK, 1997, PEDIATR INFECT DIS J, V16, P1135, DOI 10.1097/00006454-199712000-00007; ODempsey TJD, 1996, PEDIATR INFECT DIS J, V15, P431, DOI 10.1097/00006454-199605000-00010; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; SALO P, 1995, J INFECT DIS, V171, P479, DOI 10.1093/infdis/171.2.479; Spratt BG, 2000, LANCET, V356, P1210, DOI 10.1016/S0140-6736(00)02779-3; Usen S, 2000, PEDIATR INFECT DIS J, V19, P444, DOI 10.1097/00006454-200005000-00010; van der Loeff MFS, 2003, AIDS, V17, P1841, DOI [10.1097/00002030-200308150-00014, 10.1097/01.aids.0000076303.76477.49]; Weber MW, 1997, B WORLD HEALTH ORGAN, V75, P25; Wernette CM, 2003, CLIN DIAGN LAB IMMUN, V10, P514, DOI 10.1128/CDLI.10.4.514-519.2003; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; *WHO PNEUM VACC TR, 2001, STAND CHEST RAD DIAG; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0; Williams G., 2004, COCHRANE DB SYST REV, V1, DOI [10.1002/14651858.CD004977, DOI 10.1002/14651858.CD004977]	29	683	735	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1139	1146		10.1016/S0140-6736(05)71876-6	http://dx.doi.org/10.1016/S0140-6736(05)71876-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794968				2022-12-28	WOS:000227909500026
J	Macleod, J; Salisbury, C; Low, N; McCarthy, A; Sterne, JAC; Holloway, A; Patel, R; Sanford, E; Morcom, A; Horner, P; Smith, GD; Skidmore, S; Herring, A; Caul, O; Hobbs, FDR; Egger, M				Macleod, J; Salisbury, C; Low, N; McCarthy, A; Sterne, JAC; Holloway, A; Patel, R; Sanford, E; Morcom, A; Horner, P; Smith, GD; Skidmore, S; Herring, A; Caul, O; Hobbs, FDR; Egger, M			Coverage and uptake of systematic postal screening for genital Chlamydia trachomatis and prevalence of infection in the United Kingdom general population: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article								Objective To measure the coverage and uptake of systematic postal screening for genital Chlamydia trachomatis and the prevalence of infection in the general population in the United Kingdom. To investigate factors associated with these measures. Design Cross sectional survey of people randomly selected from general practice registers. Invitation to provide a specimen collected at home. Setting England. Participants 19 773 men and women aged 16-39 years invited to participate in screening. Main outcome measures Coverage and uptake of screening; prevalence of chlamydia. Results Coverage of chlamydia screening was 73% and was lower in areas with a higher proportion of non-white residents. Uptake in 16-24 year olds was 31.5% and was lower in men, younger adults, and practices in disadvantaged areas. Overall prevalence of chlamydia was 2.8% (95% confidence interval 2.2% to 3.4%) in men and 3.6% (3. 1 % to 4.9%) in women, but it was higher in people younger than 25 years (men 5. 1 %; 4.0% to 6.3%; women 6.2%; 5.2% to 7.8%). Prevalence was higher in the subgroup of younger women who were harder to engage in screening. The strongest determinant of chlamydial infection was having one or more new sexual partners in the past year. Conclusions Postal chlamydia screening was feasible, but coverage was incomplete and uptake was modest. Lower coverage of postal screening in areas with more non-white residents along with poorer uptake in more deprived areas and among women at higher risk of infection could mean that screening leads to wider inequalities in sexual health.	Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England; Univ Bristol, Dept Community Based Med, Bristol BS6 6JL, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland; United Bristol Healthcare Trust, Milne Ctr, Bristol BS21 7LR, Avon, England; Publ Hlth Lab Serv, Birmingham B9 5SS, W Midlands, England; Publ Hlth Lab Serv, Genitourinary Infect Reference Lab, Bristol BS2 8EL, Avon, England	University of Birmingham; University of Bristol; University of Bristol; University of Bern	Macleod, J (corresponding author), Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England.	j.a.macleod@bham.ac.uk	Low, Nicola/H-4718-2019; Davey Smith, George/A-7407-2013; Sterne, Jonathan/Z-3106-2019; Salisbury, Chris/C-6724-2008; Fazli, Ghazal/AAE-8320-2022	Low, Nicola/0000-0003-4817-8986; Davey Smith, George/0000-0002-1407-8314; Sterne, Jonathan/0000-0001-8496-6053; Salisbury, Chris/0000-0002-4378-3960; Venkatasubramanian, Siddharth/0000-0002-5860-0768; s, hema/0000-0002-3440-9475; Horner, Paddy/0000-0003-0411-8332; Macleod, John/0000-0001-8202-1144; Holloway, Aisha/0000-0003-3070-3703; hobbs, richard/0000-0001-7976-7172; Egger, Matthias/0000-0001-7462-5132				Andersen B, 2002, J INFECT DIS, V185, P252, DOI 10.1086/338268; *DEP HLTH, 2001, CHOOS HLTH MAK HLTH; Fenton KA, 2001, LANCET, V358, P1851, DOI 10.1016/S0140-6736(01)06886-6; Low N, 2003, LANCET, V362, P1157, DOI 10.1016/S0140-6736(03)14480-7; Low N, 2002, INT J EPIDEMIOL, V31, P891, DOI 10.1093/ije/31.5.891; Low N, 2001, SEX TRANSM INFECT, V77, P15, DOI 10.1136/sti.77.1.15; Low N, 2004, SEX TRANSM INFECT, V80, P342, DOI 10.1136/sti.2003.006197; Macleod J, 1999, BRIT J GEN PRACT, V49, P455; OSTERGAARD L, 2002, SCREENING KLAMYDIA M; SALISBURY C, 2005, IN PRESS BRIT J GEN	10	97	98	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 23	2005	330	7497					940	942		10.1136/bmj.38413.663137.8F	http://dx.doi.org/10.1136/bmj.38413.663137.8F			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	920UP	15809231	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000228715900021
J	Janes, SEJ; Cowan, IA; Dijkstra, B				Janes, SEJ; Cowan, IA; Dijkstra, B			Lesson of the week - A life threatening complication after colonoscopy	BRITISH MEDICAL JOURNAL			English	Article							SPLENIC TRAUMA; MANAGEMENT		Christchurch Publ Hosp, Dept Gen Surg, Christchurch, New Zealand; Christchurch Publ Hosp, Dept Radiol, Christchurch, New Zealand	Christchurch Hospital New Zealand; Christchurch Hospital New Zealand	Janes, SEJ (corresponding author), New Cross Hosp, Dept Surg, Wolverhampton WV10 0QP, W Midlands, England.	janessimon@hotmail.com						Ahmed A, 1997, AM J GASTROENTEROL, V92, P1201; Barquist ES, 2004, J TRAUMA, V56, P334, DOI 10.1097/01.TA.0000052364.71392.70; Holzer K, 2004, Z GASTROENTEROL, V42, P509, DOI 10.1055/s-2004-813089; Reihner E, 1995, Eur J Emerg Med, V2, P47, DOI 10.1097/00063110-199503000-00010; Tsugawa K, 2002, HEPATO-GASTROENTEROL, V49, P1144; Velmahos GC, 2000, ARCH SURG-CHICAGO, V135, P674, DOI 10.1001/archsurg.135.6.674; Williams RA, 1997, AM J SURG, V174, P276, DOI 10.1016/S0002-9610(97)00135-9	7	43	44	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 16	2005	330	7496					889	890		10.1136/bmj.330.7496.889	http://dx.doi.org/10.1136/bmj.330.7496.889			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	917UA	15831876	Green Published			2022-12-28	WOS:000228493500022
J	Hernlund, JW; Thomas, C; Tackley, PJ				Hernlund, JW; Thomas, C; Tackley, PJ			A doubling of the post-perovskite phase boundary and structure of the Earth's lowermost mantle	NATURE			English	Article							MGSIO3 PEROVSKITE; TEMPERATURE; TRANSITION; PLATE	The thermal structure of the Earth's lowermost mantle - the D '' layer spanning depths of,2,600 - 2,900 kilometres(1) - is key to understanding the dynamical state and history of our planet. Earth's temperature profile ( the geotherm) is mostly constrained by phase transitions, such as freezing at the inner-core boundary or changes in crystal structure within the solid mantle, that are detected as discontinuities in seismic wave speed and for which the pressure and temperature conditions can be constrained by experiment and theory. A recently discovered phase transition at pressures of the D '' layer(2-4) is ideally situated to reveal the thermal structure of the lowermost mantle, where no phase transitions were previously known to exist. Here we show that a pair of seismic discontinuities observed in some regions of D '' can be explained by the same phase transition as the result of a double-crossing of the phase boundary by the geotherm at two different depths. This simple model can also explain why a seismic discontinuity is not observed in some other regions, and provides new constraints for the magnitude of temperature variations within D ''.	Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Univ Liverpool, Dept Earth & Ocean Sci, Liverpool L69 3GP, Merseyside, England	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Liverpool	Hernlund, JW (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.	hernlund@ess.ucla.edu	Hernlund, John/A-8931-2014; Tackley, Paul J/D-8155-2016	Hernlund, John/0000-0003-1008-0182; Tackley, Paul J/0000-0003-4878-621X; Thomas, Christine/0000-0002-7845-5385	Natural Environment Research Council [NE/B000095/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Aizawa Y, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018762; Alfe D, 2002, EARTH PLANET SC LETT, V195, P91, DOI 10.1016/S0012-821X(01)00568-4; Boehler R, 2000, REV GEOPHYS, V38, P221, DOI 10.1029/1998RG000053; Buffett BA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014649; Bullen K.E., 1949, MON NOT R ASTRON SOC, V5, P355, DOI [10.1111/j.1365-246x.1949.tb02952.x, DOI 10.1111/J.1365-246X.1949.TB02952.X, DOI 10.1111/J.1365-246X.1949.TB02951.X]; Christensen UR, 2004, NATURE, V429, P169, DOI 10.1038/nature02508; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; KENNETT BLN, 1995, GEOPHYS J INT, V122, P108, DOI 10.1111/j.1365-246X.1995.tb03540.x; LAY T, 1983, GEOPHYS RES LETT, V10, P63, DOI 10.1029/GL010i001p00063; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; MULLER G, 1985, J GEOPHYS-Z GEOPHYS, V58, P153; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; Nakagawa T, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020648; Oganov AR, 2004, NATURE, V430, P445, DOI 10.1038/nature02701; Sidorin I, 1998, EARTH PLANET SC LETT, V163, P31, DOI 10.1016/S0012-821X(98)00172-1; Stacey F. D., 1992, PHYS EARTH; Thomas C, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2004JB003013; Thomas C, 2004, EARTH PLANET SC LETT, V225, P105, DOI 10.1016/j.epsl.2004.05.038; Tsuchiya T, 2004, EARTH PLANET SC LETT, V224, P241, DOI 10.1016/j.epsl.2004.05.017; Wysession ME, 1998, GEODYNAMICS, V28, P273	20	284	291	1	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					882	886		10.1038/nature03472	http://dx.doi.org/10.1038/nature03472			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829961				2022-12-28	WOS:000228327600037
J	Shlipak, MG; Fried, LF; Cushman, M; Manolio, TA; Peterson, D; Stehman-Breen, C; Bleyer, A; Newman, A; Siscovick, D; Psaty, B				Shlipak, MG; Fried, LF; Cushman, M; Manolio, TA; Peterson, D; Stehman-Breen, C; Bleyer, A; Newman, A; Siscovick, D; Psaty, B			Cardiovascular mortality risk in chronic kidney disease - Comparison of traditional and novel risk factors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; ATHEROSCLEROSIS RISK; RENAL-INSUFFICIENCY; EVENTS; ASSOCIATION; DYSFUNCTION; POPULATION; CREATININE; OUTCOMES; ANEMIA	Context Elderly persons with chronic kidney disease have substantial risk for cardiovascular mortality, but the relative importance of traditional and novel risk factors is unknown. Objective To compare traditional and novel risk factors as predictors of cardiovascular mortality. Design, Setting, and Patients A total of 5808 community-dwelling persons aged 65 years or older living in 4 communities in the United States participated in the Cardiovascular Health Study cohort. Participants were initially recruited from 1989 to June 1990; an additional 687 black participants were recruited in 1992-1993. The average length of follow-up in this longitudinal study was 8.6 years. Main Outcome Measures Cardiovascular mortality among those with and without chronic kidney disease. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min per 1.73 m(2). Results Among the participants, 1249 (22%) had chronic kidney disease at baseline. The cardiovascular mortality risk rate was 32 deaths/1000 person-years among those with chronic kidney disease vs 16/1000 person-years among those without it. In multivariate analyses, diabetes, systolic hypertension, smoking, low physical activity, nonuse of alcohol, and left ventricular hypertrophy were predictors of cardiovascular mortality in persons with chronic kidney disease (all P values <.05). Among the novel risk factors, only log C-reactive protein (P=.05) and log interleukin 6 (P<.001) were associated with the outcome as linear predictors. Traditional risk factors were associated with the largest absolute increases in risks for cardiovascular deaths among persons with chronic kidney disease: for left ventricular hypertrophy, there were 25 deaths per 1000 person-years; current smoking, 20 per 1000 person-years; physical inactivity, 15 per 1000 person-years; systolic hypertension, 14 per 1000 person-years; diabetes, 14 per 1000 person-years; and nonuse of alcohol, 11 per 1000 person-years vs 5 deaths per 1000 person-years for those with increased C-reactive protein and 5 per 1000 person-years for those with increased interleukin 6 levels. A receiver operating characteristic analysis found that traditional risk factors had an area under the curve of 0.73 (95% confidence interval, 0.70-0.77) among those with chronic kidney disease. Adding novel risk factors only increased the area under the curve to 0.74 (95% confidence interval, 0.71-0.78; P for difference =. 15). Conclusions Traditional cardiovascular risk factors had larger associations with cardiovascular mortality than novel risk factors in elderly persons with chronic kidney disease. Future research should investigate whether aggressive lifestyle intervention in patients with chronic kidney disease can reduce their substantial cardiovascular risk.	Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Pittsburgh, PA USA; VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA; Univ Vermont, Coll Med, Dept Med, Colchester, VT USA; Univ Vermont, Coll Med, Dept Pathol, Colchester, VT USA; Univ Vermont, Coll Med, Dept Biochem, Colchester, VT USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Collaborat Hlth Studies Coordinating Ctr, Seattle, WA USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Wake Forest Univ, Bowman Gray Sch Med, Nephrol Sect, Winston Salem, NC USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA; Univ Pittsburgh, Div Geriatr Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; University of Vermont; University of Vermont; University of Vermont; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Amgen; Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Shlipak, MG (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.	shlip@itsa.ucsf.edu	Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150; Cushman, Mary/0000-0002-7871-6143	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085083, N01HC015103, N01HC035129, N01HC085082, N01HC085080, N01HC085085, N01HC085079, N01HC085084, N01HC085081, N01HC085086] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073208] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramson JL, 2003, KIDNEY INT, V64, P610, DOI 10.1046/j.1523-1755.2003.00109.x; Appel LJ, 2004, ANN INTERN MED, V140, P60, DOI 10.7326/0003-4819-140-1-200401060-00013; Ariyo AA, 2003, NEW ENGL J MED, V349, P2108, DOI 10.1056/NEJMoa001066; Astor BC, 2004, AM J KIDNEY DIS, V43, P836, DOI 10.1053/j.ajkd.2003.12.047; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Coresh J, 1998, AM J KIDNEY DIS, V32, P32, DOI 10.1053/ajkd.1998.v32.pm9669421; CUSHMAN M, 1995, CLIN CHEM, V41, P264; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Jurkovitz CT, 2003, J AM SOC NEPHROL, V14, P2919, DOI 10.1097/01.ASN.0000092138.65211.71; Knight EL, 2004, J AM SOC NEPHROL, V15, P1897, DOI 10.1097/01.asn.0000128966.55133.69; Levey AS, 1998, AM J KIDNEY DIS, V32, P853, DOI 10.1016/S0272-6386(98)70145-3; Manjunath G, 2003, KIDNEY INT, V63, P1121, DOI 10.1046/j.1523-1755.2003.00838.x; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Muntner P, 2005, J AM SOC NEPHROL, V16, P529, DOI 10.1681/ASN.2004080656; Muntner P, 2004, ANN INTERN MED, V140, P9, DOI 10.7326/0003-4819-140-1-200401060-00006; Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101; RAUTAHARJU PM, 1990, METHOD INFORM MED, V29, P362; Ritz E, 2004, J AM SOC NEPHROL, V15, P513, DOI 10.1097/01.ASN.0000115398.92270.30; Sarnak MJ, 2003, HYPERTENSION, V42, P1050, DOI 10.1161/01.HYP.0000102971.85504.7c; Shlipak MG, 2004, AM J KIDNEY DIS, V43, P861, DOI 10.1053/j.ajkd.2003.12.049; Shlipak MG, 2001, J AM COLL CARDIOL, V38, P705, DOI 10.1016/S0735-1097(01)01450-4; Shlipak Michael G, 2004, Am J Geriatr Cardiol, V13, P81, DOI 10.1111/j.1076-7460.2004.02125.x; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; Tracy RP, 1999, ARTERIOSCL THROM VAS, V19, P1776, DOI 10.1161/01.ATV.19.7.1776; Weiner DE, 2004, J AM SOC NEPHROL, V15, P1307, DOI 10.1097/01.ASN.0000123691.46138.E2; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865	29	516	543	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1737	1745		10.1001/jama.293.14.1737	http://dx.doi.org/10.1001/jama.293.14.1737			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827312	Bronze			2022-12-28	WOS:000228301100027
J	Altman, DG; Bland, JM				Altman, DG; Bland, JM			Treatment allocation by minimisation	BRITISH MEDICAL JOURNAL			English	Article							TRIALS		Ctr Stat Med, Canc Res UK Med Stat Grp, Oxford OX3 7LF, England; Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England	Cancer Research UK; University of Oxford; University of York - UK	Altman, DG (corresponding author), Ctr Stat Med, Canc Res UK Med Stat Grp, Oxford OX3 7LF, England.	doug.altman@cancer.org.uk						Altman DG, 1999, BRIT MED J, V319, P703, DOI 10.1136/bmj.319.7211.703; Buyse M., 2004, APPL CLIN TRIALS, V13, P36; Day S, 1999, BRIT MED J, V319, P947; Evans S, MINIM ALLOCATION MIN; Scott NW, 2002, CONTROL CLIN TRIALS, V23, P662, DOI 10.1016/S0197-2456(02)00242-8; Steptoe A, 2003, BRIT MED J, V326, P855, DOI 10.1136/bmj.326.7394.855; Treasure T, 1998, BRIT MED J, V317, P362	7	349	349	2	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	APR 9	2005	330	7495					843	843		10.1136/bmj.330.7495.843	http://dx.doi.org/10.1136/bmj.330.7495.843			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915BZ	15817555	Green Published, Bronze			2022-12-28	WOS:000228273900024
J	Hollifield, M				Hollifield, M			Taking measure of war trauma	LANCET			English	Editorial Material							TAMIL ASYLUM-SEEKERS; POSTTRAUMATIC STRESS; REFUGEES; IMMIGRANTS; SYMPTOMS; HEALTH		Univ Louisville, Dept Psychiat & Behav Sci, Louisville, KY 40202 USA	University of Louisville	Hollifield, M (corresponding author), Univ Louisville, Dept Psychiat & Behav Sci, Med Ctr 1, Louisville, KY 40202 USA.	m.hollifield@louisville.edu						[Anonymous], 1995, WORLD MENTAL HLTH PR; Antonovsky A., 1987, UNRAVELING MYSTERY H; BASOGLU M, 1994, JAMA-J AM MED ASSOC, V272, P357, DOI 10.1001/jama.272.5.357; DEGIROLAMO G, 1996, ETHNOCULTURAL ASPECT; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Fullilove MT, 1996, AM J PSYCHIAT, V153, P1516; Gavagan T, 1998, AM FAM PHYSICIAN, V57, P1061; Hollifield M, 2002, JAMA-J AM MED ASSOC, V288, P611, DOI 10.1001/jama.288.5.611; *NAT GEOGR NEWS, 2003, ANC IR SIT SHOW THEF; PALINKAS LA, 1995, SOC SCI MED, V40, P1643, DOI 10.1016/0277-9536(94)00344-S; Silove D, 1998, ACTA PSYCHIAT SCAND, V97, P175, DOI 10.1111/j.1600-0447.1998.tb09984.x; Steel Z, 1999, J TRAUMA STRESS, V12, P421, DOI 10.1023/A:1024710902534; Steel Z, 2002, LANCET, V360, P1056, DOI 10.1016/S0140-6736(02)11142-1; *USCR, 2002, WORLD REF SURV 2002	14	12	12	1	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1283	1284		10.1016/S0140-6736(05)61003-3	http://dx.doi.org/10.1016/S0140-6736(05)61003-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823362				2022-12-28	WOS:000228219600004
J	Stumvoll, M; Goldstein, BJ; van Haeften, TW				Stumvoll, M; Goldstein, BJ; van Haeften, TW			Type 2 diabetes: principles of pathogenesis and therapy	LANCET			English	Review							ACTIVATED PROTEIN-KINASE; INDUCED INSULIN-RESISTANCE; BETA-CELL FUNCTION; IMPAIRED GLUCOSE-TOLERANCE; FREE FATTY-ACIDS; KAPPA-B; MOLECULAR-MECHANISMS; GENETIC-VARIATION; MINIMAL-MODEL; PPAR-GAMMA	Type 2 diabetes mellitus has become an epidemic, and virtually no physician is without patients who have the disease. Whereas insulin insensitivity is an early phenomenon partly related to obesity, pancreas beta-cell function declines gradually over time already before the onset of clinical hyperglycaemia. Several mechanisms have been proposed, including increased non-esterified fatty acids, inflammatory cytokines, adipokines, and mitochondrial dysfunction for insulin resistance, and glucotoxicity, lipotoxicity, and amyloid formation for beta-cell dysfunction. Moreover, the disease has a strong genetic component, but only a handful of genes have been identified so far: genes for calpain 10, potassium inward-rectifier 6.2, peroxisome proliferator-activated receptor gamma, insulin receptor substrate-1, and others. Management includes not only diet and exercise, but also combinations of anti-hyperglycaemic drug treatment with lipid-lowering, antihypertensive, and anti platelet therapy.	Univ Med Ctr Utrecht, Dept Internal Med G02 228, NL-3508 GA Utrecht, Netherlands; Univ Leipzig, Dept Med 3, D-7010 Leipzig, Germany; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA 19107 USA	Utrecht University; Utrecht University Medical Center; Leipzig University; Jefferson University	van Haeften, TW (corresponding author), Univ Med Ctr Utrecht, Dept Internal Med G02 228, POB 85500, NL-3508 GA Utrecht, Netherlands.	T.W.vanHaeften@azu.nl	Stumvoll, Michael/ABE-1121-2021; Cerviño, Alejandro/L-5853-2014	Stumvoll, Michael/0000-0001-6225-8240; Cerviño, Alejandro/0000-0001-8014-3279	NIDDK NIH HHS [DK UO1-048468] Funding Source: Medline; PHS HHS [R01-063018, R01-43396] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK048468] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; [Anonymous], 2000, LANCET, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Baier LJ, 2000, J CLIN INVEST, V106, pR69, DOI 10.1172/JCI10665; Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906; Bajaj M, 2003, DIABETES, V52, P1364, DOI 10.2337/diabetes.52.6.1364; Beck-Nielsen H, 2003, BEST PRACT RES CL EN, V17, P445, DOI 10.1016/S1521-690X(03)00041-1; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Bergman RN, 2003, DIABETES, V52, P2168, DOI 10.2337/diabetes.52.8.2168; BERGMAN RN, 1989, DIABETES, V38, P1512, DOI 10.2337/diabetes.38.12.1512; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Bonadonna RC, 2003, DIABETES, V52, P470, DOI 10.2337/diabetes.52.2.470; Borch-Johnsen K, 1999, LANCET, V354, P617; BOSQUEPLATA L, 2004, MOL GENET METAB, V81, P122; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796; Chiasson JL, 1998, DIABETES CARE, V21, P1720, DOI 10.2337/diacare.21.10.1720; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Colwell John A, 2004, Diabetes Care, V27 Suppl 1, pS72; Cox NJ, 2001, HUM MOL GENET, V10, P2301, DOI 10.1093/hmg/10.20.2301; Cusi K, 1996, J CLIN ENDOCR METAB, V81, P4059, DOI 10.1210/jc.81.11.4059; Dandona Paresh, 2003, Clin Cornerstone, VSuppl 4, pS13; Danforth E, 2000, NAT GENET, V26, P13, DOI 10.1038/79111; Deacon CF, 2004, DIABETES, V53, P2181, DOI 10.2337/diabetes.53.9.2181; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Di Paola R, 2002, AM J HUM GENET, V70, P806, DOI 10.1086/339270; DINNEEN S, 1992, NEW ENGL J MED, V327, P707, DOI 10.1056/NEJM199209033271007; ECKEL RH, IN PRESS LANCET; Einhorn D, 2004, ENDOCRIN METAB CLIN, V33, P595, DOI 10.1016/j.ecl.2004.04.003; Ek J, 2001, DIABETOLOGIA, V44, P2220, DOI 10.1007/s001250100032; Ek J, 2001, DIABETOLOGIA, V44, P1170, DOI 10.1007/s001250100629; Elbein SC, 1999, J CLIN ENDOCR METAB, V84, P1398, DOI 10.1210/jc.84.4.1398; Evans JC, 2001, AM J HUM GENET, V69, P544, DOI 10.1086/323315; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Florez JC, 2004, DIABETES, V53, P1360, DOI 10.2337/diabetes.53.5.1360; Freeman MS, 2002, DIABETIC MED, V19, P994, DOI 10.1046/j.1464-5491.2002.00843.x; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Gerich JE, 1998, ENDOCR REV, V19, P491, DOI 10.1210/er.19.4.491; Gloyn AL, 2003, DIABETES, V52, P568, DOI 10.2337/diabetes.52.2.568; Goldstein BJ, 2004, J CLIN ENDOCR METAB, V89, P2563, DOI 10.1210/jc.2004-0518; Goldstein BJ, 2003, DIABETES MELLITUS FU, P255; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Grundy SM, 2002, ARCH INTERN MED, V162, P1568, DOI 10.1001/archinte.162.14.1568; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; Hanson RL, 2001, DIABETES-METAB RES, V17, P296, DOI 10.1002/dmrr.213; Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1; Havel PJ, 2002, CURR OPIN LIPIDOL, V13, P51, DOI 10.1097/00041433-200202000-00008; Henkin L, 2003, ANN EPIDEMIOL, V13, P211, DOI 10.1016/S1047-2797(02)00412-X; Hong Y, 2001, CLIN GENET, V60, P22, DOI 10.1034/j.1399-0004.2001.600104.x; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Horikawa Y, 2003, J CLIN ENDOCR METAB, V88, P244, DOI 10.1210/jc.2002-020847; Hotamisligil GS, 2000, INT J OBESITY, V24, pS23, DOI 10.1038/sj.ijo.0801497; Hsueh WC, 2000, DIABETES CARE, V23, P595, DOI 10.2337/diacare.23.5.595; Hull RL, 2004, J CLIN ENDOCR METAB, V89, P3629, DOI 10.1210/jc.2004-0405; Huxtable SJ, 2000, DIABETES, V49, P126, DOI 10.2337/diabetes.49.1.126; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Jenkins A B, 2000, Twin Res, V3, P148, DOI 10.1375/twin.3.3.148; KAPRIO J, 1992, DIABETOLOGIA, V35, P1060, DOI 10.1007/BF02221682; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972; Kim JK, 2001, J CLIN INVEST, V108, P437, DOI 10.1172/JCI11559; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Knowles NG, 2002, DIABETES CARE, V25, P292, DOI 10.2337/diacare.25.2.292; KREBS DL, 2003, SCI STKE, pE6; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lehtovirta M, 2000, DIABETOLOGIA, V43, P285, DOI 10.1007/s001250050046; Liu G, 2004, CURR OPIN MOL THER, V6, P331; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Ma H, 2001, J BIOL CHEM, V276, P28525, DOI 10.1074/jbc.M100603200; Maassen JA, 2004, DIABETES, V53, pS103, DOI 10.2337/diabetes.53.2007.S103; Machann J, 2004, DIABETES OBES METAB, V6, P239, DOI 10.1111/j.1462-8902.2004.00339.x; Mamputu JC, 2003, DIABETES METAB, V29, pS71; McCarthy Mark I, 2003, Curr Diab Rep, V3, P159, DOI 10.1007/s11892-003-0040-y; Memisoglu A, 2003, DIABETES CARE, V26, P2915, DOI 10.2337/diacare.26.10.2915; Meriden T, 2004, CLIN THER, V26, P177, DOI 10.1016/S0149-2918(04)90017-3; Meyer C, 1998, J CLIN INVEST, V102, P619, DOI 10.1172/JCI2415; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Mills GW, 2004, DIABETOLOGIA, V47, P732, DOI 10.1007/s00125-004-1338-2; Mogensen CE, 2000, BRIT MED J, V321, P1440, DOI 10.1136/bmj.321.7274.1440; Moller DE, 2000, TRENDS ENDOCRIN MET, V11, P212, DOI 10.1016/S1043-2760(00)00272-1; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muller YL, 2003, DIABETES, V52, P1864, DOI 10.2337/diabetes.52.7.1864; Nesto RW, 2003, CIRCULATION, V108, P2941, DOI 10.1161/01.CIR.0000103683.99399.7E; NEWMAN B, 1987, DIABETOLOGIA, V30, P763; Nichols GA, 2000, DIABETES CARE, V23, P1654, DOI 10.2337/diacare.23.11.1654; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Ong KKL, 1999, NAT GENET, V21, P262, DOI 10.1038/6775; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Parikh H, 2004, REV ENDOCR METAB DIS, V5, P151, DOI 10.1023/B:REMD.0000021437.46773.26; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; PETERSEN KF, 2004, NEW ENGL J MED, V350, P664, DOI [10.1056/NEJMoa031314, DOI 10.1056/NEJMOA031314]; PIERCE M, 1995, DIABETIC MED, V12, P6, DOI 10.1111/j.1464-5491.1995.tb02054.x; Porzio O, 1999, J CLIN INVEST, V104, P357, DOI 10.1172/JCI5870; Poulsen P, 1999, DIABETOLOGIA, V42, P139, DOI 10.1007/s001250051131; Pozzilli P, 2001, DIABETES CARE, V24, P1460, DOI 10.2337/diacare.24.8.1460; Rajala MW, 2003, ENDOCRINOLOGY, V144, P3765, DOI 10.1210/en.2003-0580; Rasmussen SK, 2002, DIABETES, V51, P3561, DOI 10.2337/diabetes.51.12.3561; Ravussin E, 2002, ANN NY ACAD SCI, V967, P363; Rendell M, 2004, DRUGS, V64, P1339, DOI 10.2165/00003495-200464120-00006; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; Robertson RP, 2003, DIABETES, V52, P581, DOI 10.2337/diabetes.52.3.581; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; Ruderman NB, 2003, BIOCHEM SOC T, V31, P202, DOI 10.1042/bst0310202; Rui LY, 2002, J BIOL CHEM, V277, P42394, DOI 10.1074/jbc.C200444200; Sakul H, 1997, AM J HUM GENET, V60, P651; Schernthaner G, 2004, EUR J CLIN INVEST, V34, P535, DOI 10.1111/j.1365-2362.2004.01381.x; Schoonjans K, 2000, LANCET, V355, P1008, DOI 10.1016/S0140-6736(00)90002-3; Senn JJ, 2003, J BIOL CHEM, V278, P13740, DOI 10.1074/jbc.M210689200; Seppala-Lindroos A, 2002, J CLIN ENDOCR METAB, V87, P3023, DOI 10.1210/jc.87.7.3023; Shoelson SE, 2003, INT J OBESITY, V27, pS49, DOI 10.1038/sj.ijo.0802501; SHULMAN GI, 2000, J CLIN INVEST, V106, P171, DOI DOI 10.1172/JCI10583; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Song YQ, 2004, AM J HUM GENET, V74, P208, DOI 10.1086/381400; Sreenan SK, 2001, DIABETES, V50, P2013, DOI 10.2337/diabetes.50.9.2013; Stumvoll M, 2003, DIABETES, V52, P903, DOI 10.2337/diabetes.52.4.903; Stumvoll M, 2001, DIABETES, V50, P882, DOI 10.2337/diabetes.50.4.882; Stumvoll M, 2002, DIABETES, V51, P2341, DOI 10.2337/diabetes.51.8.2341; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; TATTERSALL RB, 1975, DIABETES, V24, P452, DOI 10.2337/diabetes.24.5.452; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tripathy D, 2004, DIABETOLOGIA, V47, P782, DOI 10.1007/s00125-004-1393-8; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; van Haeften TW, 2002, DIABETES, V51, pS265, DOI 10.2337/diabetes.51.2007.S265; Wallace TM, 2002, DIABETIC MED, V19, P465; Watanabe RM, 1999, HUM HERED, V49, P159, DOI 10.1159/000022865; Weedon MN, 2003, AM J HUM GENET, V73, P1208, DOI 10.1086/379285; Wei M, 1998, DIABETES CARE, V21, P1167, DOI 10.2337/diacare.21.7.1167; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; Weyer C, 1999, J CLIN INVEST, V104, P787, DOI 10.1172/JCI7231; Weyer C, 1999, DIABETES, V48, P2197, DOI 10.2337/diabetes.48.11.2197; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; World Health Organization, 1999, DEF DIAGN CLASS DI 1; Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Ye JM, 2004, DIABETOLOGIA, V47, P1306, DOI 10.1007/s00125-004-1436-1; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yki-Jarvinen H, 2004, NEW ENGL J MED, V351, P1106, DOI 10.1056/NEJMra041001; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415, DOI 10.1210/er.13.3.415; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zhande R, 2002, MOL CELL BIOL, V22, P1016, DOI 10.1128/MCB.22.4.1016-1026.2002; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200	156	1564	1665	18	569	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2005	365	9467					1333	1346		10.1016/S0140-6736(05)61032-X	http://dx.doi.org/10.1016/S0140-6736(05)61032-X			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823385	Green Submitted			2022-12-28	WOS:000228219600030
J	Fridkin, SK; Hageman, JC; Morrison, M; Sanza, LT; Como-Sabetti, K; Jernigan, JA; Harriman, K; Harrison, LH; Lynfield, R; Farley, MM				Fridkin, SK; Hageman, JC; Morrison, M; Sanza, LT; Como-Sabetti, K; Jernigan, JA; Harriman, K; Harrison, LH; Lynfield, R; Farley, MM		Active Bacterial Core Surveillance	Methicillin-resistant staphylococcus aureus disease in three communities	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STREPTOCOCCUS-PNEUMONIAE; CLINDAMYCIN TREATMENT; UNITED-STATES; INFECTIONS; CHILDREN; SKIN; EPIDEMIOLOGY; BACTEREMIA; ADULTS	BACKGROUND: Methicillin-resistant Staphylococcus aureus (MRSA) infection has emerged in patients who do not have the established risk factors. The national burden and clinical effect of this novel presentation of MRSA disease are unclear. METHODS: We evaluated MRSA infections in patients identified from population-based surveillance in Baltimore and Atlanta and from hospital-laboratory-based sentinel surveillance of 12 hospitals in Minnesota. Information was obtained by interviewing patients and by reviewing their medical records. Infections were classified as community-acquired MRSA disease if no established risk factors were identified. RESULTS: From 2001 through 2002, 1647 cases of community-acquired MRSA infection were reported, representing between 8 and 20 percent of all MRSA isolates. The annual disease incidence varied according to site (25.7 cases per 100,000 population in Atlanta vs. 18.0 per 100,000 in Baltimore) and was significantly higher among persons less than two years old than among those who were two years of age or older (relative risk, 1.51; 95 percent confidence interval, 1.19 to 1.92) and among blacks than among whites in Atlanta (age-adjusted relative risk, 2.74; 95 percent confidence interval, 2.44 to 3.07). Six percent of cases were invasive, and 77 percent involved skin and soft tissue. The infecting strain of MRSA was often (73 percent) resistant to prescribed antimicrobial agents. Among patients with skin or soft-tissue infections, therapy to which the infecting strain was resistant did not appear to be associated with adverse patient-reported outcomes. Overall, 23 percent of patients were hospitalized for the MRSA infection. CONCLUSIONS: Community-associated MRSA infections are now a common and serious problem. These infections usually involve the skin, especially among children, and hospitalization is common.	Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Infect Dis, Atlanta, GA USA; Emory Univ, Sch Med, Atlanta, GA USA; Vet Affairs Med Ctr, Atlanta, GA 30033 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Minnesota Dept Hlth, Minneapolis, MN USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Minnesota Department of Health (MHD)	Fridkin, SK (corresponding author), CDC, NCID, DBMD, MDB, MS C-09,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	skf0@cdc.gov		Jernigan, John/0000-0001-8163-925X				Albanese BA, 2002, CLIN INFECT DIS, V34, P15, DOI 10.1086/323674; [Anonymous], 1999, JAMA, V282, P1123; Archer GL, 1998, CLIN INFECT DIS, V26, P1179, DOI 10.1086/520289; Baggett HC, 2003, INFECT CONT HOSP EP, V24, P397, DOI 10.1086/502221; BRUMFITT W, 1989, NEW ENGL J MED, V320, P1188, DOI 10.1056/NEJM198905043201806; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P919; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P88; Chambers HF, 2001, EMERG INFECT DIS, V7, P178, DOI 10.3201/eid0702.010204; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P53, DOI 10.1086/345476; Culpepper R, 2002, JAMA-J AM MED ASSOC, V287, P181; Daum RS, 2001, CRIT CARE MED, V29, pN92, DOI 10.1097/00003246-200104001-00007; Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184; Flannery B, 2004, JAMA-J AM MED ASSOC, V291, P2197, DOI 10.1001/jama.291.18.2197; Frank AL, 2002, PEDIATR INFECT DIS J, V21, P530, DOI 10.1097/00006454-200206000-00010; Fridkin SK, 2003, CLIN INFECT DIS, V36, P429, DOI 10.1086/346207; Gorak EJ, 1999, CLIN INFECT DIS, V29, P797, DOI 10.1086/520437; Groom AV, 2001, JAMA-J AM MED ASSOC, V286, P1201, DOI 10.1001/jama.286.10.1201; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; Iyer S, 2004, J AM ACAD DERMATOL, V50, P854, DOI 10.1016/j.jaad.2003.12.043; JORGENSEN JH, 1986, EUR J CLIN MICROBIOL, V5, P693, DOI 10.1007/BF02013307; Lee MC, 2004, PEDIATR INFECT DIS J, V23, P123, DOI 10.1097/01.inf.0000109288.06912.21; Lorenz E, 2000, INFECT IMMUN, V68, P6398, DOI 10.1128/IAI.68.11.6398-6401.2000; Lowy FD, 1998, NEW ENGL J MED, V339, P520, DOI 10.1056/NEJM199808203390806; Marcinak JF, 2003, CURR OPIN INFECT DIS, V16, P265, DOI 10.1097/00001432-200306000-00014; Martinez-Aguilar G, 2003, PEDIATR INFECT DIS J, V22, P593, DOI 10.1097/00006454-200307000-00006; Morin CA, 2001, J INFECT DIS, V184, P1029, DOI 10.1086/323459; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; NNIS System, 2002, AM J INFECT CONTROL, V30, P458, DOI 10.1067/mic.2002.130032; Raney PM, 2002, DIAGN MICR INFEC DIS, V43, P135, DOI 10.1016/S0732-8893(02)00378-4; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Sattler CA, 2002, PEDIATR INFECT DIS J, V21, P910, DOI 10.1097/00006454-200210000-00005; Taylor G, 1990, Can J Infect Dis, V1, P121; Watt JP, 2004, CLIN INFECT DIS, V38, P496, DOI 10.1086/381198; 2003, MMWR MORB MORTAL WKL, V52, P793; 2003, MMWR MORB MORTAL WKL, V52, P992; 2003, JAMA, V289, P1377; 2004, MMWR MORB MORTAL WKL, V53, P767	38	1114	1183	0	83	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1436	1444		10.1056/NEJMoa043252	http://dx.doi.org/10.1056/NEJMoa043252			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814879				2022-12-28	WOS:000228145200007
J	Bhimma, R; Robbs, J				Bhimma, R; Robbs, J			Nutcracker	LANCET			English	Editorial Material									Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Paediat & Child Hlth, Durban, South Africa; Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Surg, Durban, South Africa	University of Kwazulu Natal; University of Kwazulu Natal	Bhimma, R (corresponding author), Univ Kwazulu Natal, Nelson R Mandela Sch Med, Dept Paediat & Child Hlth, Durban, South Africa.	bhimma@nu.ac.za	Bhimma, Rajendra/N-5466-2013	Bhimma, Rajendra/0000-0003-3092-7790				Kaneko K, 2001, PEDIATR NEPHROL, V16, P745, DOI 10.1007/s004670100655; Oteki T, 2004, CLIN NEPHROL, V62, P62; Takahashi Y, 2000, CLIN NEPHROL, V53, P174; Takemura T, 2000, PEDIATR NEPHROL, V14, P1002, DOI 10.1007/s004670050062; Tanaka Hiroshi, 2004, Clin Exp Nephrol, V8, P68, DOI 10.1007/s10157-003-0267-6	5	5	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1280	1280		10.1016/S0140-6736(05)74819-4	http://dx.doi.org/10.1016/S0140-6736(05)74819-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811464				2022-12-28	WOS:000228107600034
J	DeRiemer, K; Garcia-Garcia, L; Bobadilla-del-Valle, M; Palacios-Martinez, M; Martinez-Gamboa, A; Small, PM; Sifuentes-Osornio, J; Ponce-de-Leon, A				DeRiemer, K; Garcia-Garcia, L; Bobadilla-del-Valle, M; Palacios-Martinez, M; Martinez-Gamboa, A; Small, PM; Sifuentes-Osornio, J; Ponce-de-Leon, A			Does DOTS work in populations with drug-resistant tuberculosis?	LANCET			English	Article							EPIDEMIOLOGY; STANDARD	Background Directly observed therapy (DOTS) is the main strategy for prevention and control of tuberculosis worldwide. However, its effect on tuberculosis transmission in populations with moderate rates of drug-resistant disease is not known. Methods This population-based prospective study in southern Mexico between March, 1995, and February, 2000, was based on passive case finding and detection of acid-fast bacilli in sputum samples to diagnose pulmonary tuberculosis. We also used cultures, drug-susceptibility testing, bacterial genotyping, and monitoring of treatment outcomes. Findings We enrolled 436 patients; the HIV seroprevalence rate was 2%. We used three indicators to monitor continuing tuberculosis transmission: the incidence rate of pulmonary tuberculosis, which decreased by 54.4% between 1995 and 2000, from 42.1 to 19.2 per 10(5) population (p=0.00048); the percentage of clustered pulmonary tuberculosis cases, which decreased by 62.6% from 22% to 8% (p=0.02); and the rate of primary drug resistance, which decreased by 84.0% from 9.4 to 1.5 per 10(5) population (p=0.004). Rates of multidrug-resistant (MDR) tuberculosis also decreased (p<0.0001). The case-fatality ratio was 12% for MDR tuberculosis (five of 41), 7% for strains resistant to at least one drug after exclusion of MDR (four of 55), and 3% for pansusceptible strains (nine of 272). There were 13 treatment failures (11%) in 1995 and one (2%) in 2000 (p=0.012). Interpretation Even in settings with moderate rates of MDR tuberculosis, DOTS can rapidly reduce the transmission and incidence of both drug-susceptible and drug-resistant tuberculosis. However, further interventions, such as drug-susceptibility testing and standardised or individualised treatment regimens, are needed to reduce mortality rates for MDR tuberculosis.	Inst Nacl Salud Publ, TB Unit, Cuernavaca 62508, Morelos, Mexico; Stanford Univ, Med Ctr, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Infect Dis, Mexico City, DF, Mexico; Bill & Melinda Gates Fdn, Seattle, WA USA; Univ Panamericana, Sch Med, Mexico City, DF, Mexico	Instituto Nacional de Salud Publica; Stanford University; Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Bill & Melinda Gates Foundation; Universidad Panamericana - Ciudad de Mexico	Garcia-Garcia, L (corresponding author), Inst Nacl Salud Publ, TB Unit, Ave Univ 655,Colonia Sta Maria Ahuacatitlan, Cuernavaca 62508, Morelos, Mexico.	garcigar@correo.insp.mx	García, Maria de Lourdes/I-2724-2019; Bobadilla-del-Valle, Miriam/AAD-6418-2020	García, Maria de Lourdes/0000-0001-5262-1157; Ponce-de-Leon, Alfredo/0000-0003-2640-2916; Sifuentes-Osornio, Jose/0000-0001-9584-1360; BOBADILLA-DEL VALLE, MIRIAM/0000-0003-1184-827X; DeRiemer, Kathryn/0000-0002-8375-7505	FOGARTY INTERNATIONAL CENTER [K01TW000001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035969] Funding Source: NIH RePORTER; FIC NIH HHS [K01 TW000001-06, K01 TW000001] Funding Source: Medline; NIAID NIH HHS [AI 35969] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Burgos M, 2003, J INFECT DIS, V188, P1878, DOI 10.1086/379895; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Elzinga G, 2004, LANCET, V363, P814, DOI 10.1016/S0140-6736(04)15698-5; Espinal MA, 2000, JAMA-J AM MED ASSOC, V283, P2537, DOI 10.1001/jama.283.19.2537; Garcia-Garcia MD, 2000, ARCH INTERN MED, V160, P630, DOI 10.1001/archinte.160.5.630; Garcia-Garcia MD, 1999, INT J EPIDEMIOL, V28, P135, DOI 10.1093/ije/28.1.135; Garcia-Garcia MD, 2000, INT J TUBERC LUNG D, V4, P12; Geng E, 2002, NEW ENGL J MED, V346, P1453, DOI 10.1056/NEJMoa012972; *I NAC EST GEOGR I, 1995, AN EST EST VER MEX T; Jasmer RM, 1999, ANN INTERN MED, V130, P971, DOI 10.7326/0003-4819-130-12-199906150-00004; Kim JY, 2003, TUBERCULOSIS, V83, P59, DOI 10.1016/S1472-9792(02)00078-1; Lie RK, 2004, J MED ETHICS, V30, P190, DOI 10.1136/jme.2003.006031; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Murray M, 2002, AM J EPIDEMIOL, V155, P565, DOI 10.1093/aje/155.6.565; Nachega JB, 2003, CLIN INFECT DIS, V36, pS24, DOI 10.1086/344657; Pablos-Mendez A, 2002, B WORLD HEALTH ORGAN, V80, P489; Pan AmericanHealthOrganization, 1998, B EPIDEMIOL, P1; Park SK, 2002, INT J TUBERC LUNG D, V6, P143; Pio A, 1997, B WORLD HEALTH ORGAN, V75, P569; Raviglione M, 2001, INT J TUBERC LUNG D, V5, P213; Richardson HS, 2004, HASTINGS CENT REP, V34, P25, DOI 10.2307/3528248; ROSNER B, 2000, FUNDAMENTALS BIOSTAT, P707; *SECR SAL, 2000, NOM006SSA2 NORM OF M; Secretaria de Salud, 1995, NOM006SSA2 SECR SAL, P20; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; *WHO IUATLD, 2000, WHOCDCTB2000278; World Health Organization, 2002, WHOCDSTB2002297; YANEZVELASCO LB, 1997, INT J TUBERC LUNG D, V1, pS68; Yang ZH, 2000, J CLIN MICROBIOL, V38, P3572, DOI 10.1128/JCM.38.10.3572-3576.2000	30	64	67	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2005	365	9466					1239	1245		10.1016/S0140-6736(05)74812-1	http://dx.doi.org/10.1016/S0140-6736(05)74812-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811457				2022-12-28	WOS:000228107600027
J	Schoffelen, JM; Oostenveld, R; Fries, P				Schoffelen, JM; Oostenveld, R; Fries, P			Neuronal coherence as a mechanism of effective corticospinal interaction	SCIENCE			English	Article							CAT VISUAL-CORTEX; CORTICAL-NEURONS; COINCIDENCE DETECTION; MOTOR CORTEX; HUMAN BRAIN; IN-VIVO; SYNCHRONIZATION; OSCILLATIONS; MODULATION; MUSCLE	Neuronal groups can interact with each other even if they are widely separated. One group might modulate its firing rate or its internal oscillatory synchronization to influence another group. We propose that coherence between two neuronal groups is a mechanism of efficient interaction, because it renders mutual input optimally timed and thereby maximally effective. Modulations of subjects' readiness to respond in a simple reaction-time task were closely correlated with the strength of gamma-band (40 to 70 hertz) coherence between motor cortex and spinal cord neurons. This coherence may contribute to an effective corticospinal interaction and shortened reaction times.	Radboud Univ Nijmegen, FC Donders Ctr Cognit Neuroimaging, NL-6525 EK Nijmegen, Netherlands; Radboud Univ Nijmegen, Dept Biophys, NL-6525 EZ Nijmegen, Netherlands; Aalborg Univ, Ctr Sensory Motor Interact, DK-9220 Aalborg, Denmark	Radboud University Nijmegen; Radboud University Nijmegen; Aalborg University	Schoffelen, JM (corresponding author), Radboud Univ Nijmegen, FC Donders Ctr Cognit Neuroimaging, NL-6525 EK Nijmegen, Netherlands.	jan.schoffelen@fcdonders.ru.nl	Fries, Pascal/E-3196-2010; Schoffelen, Jan-Mathijs/D-3716-2009; Oostenveld, Robert/D-3259-2009	Fries, Pascal/0000-0002-4270-1468; Schoffelen, Jan-Mathijs/0000-0003-0923-6610; Oostenveld, Robert/0000-0002-1974-1293				Andino SLG, 2005, HUM BRAIN MAPP, V24, P50, DOI 10.1002/hbm.20056; Azouz R, 2000, P NATL ACAD SCI USA, V97, P8110, DOI 10.1073/pnas.130200797; Azouz R, 2003, NEURON, V37, P513, DOI 10.1016/S0896-6273(02)01186-8; Baker SN, 1997, J PHYSIOL-LONDON, V501, P225, DOI 10.1111/j.1469-7793.1997.225bo.x; Brown P, 2000, PROG NEUROBIOL, V60, P97, DOI 10.1016/S0301-0082(99)00029-5; Conway BA, 1995, J PHYSIOL-LONDON, V489, P917, DOI 10.1113/jphysiol.1995.sp021104; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; FRIEN A, 1994, NEUROREPORT, V5, P2273, DOI 10.1097/00001756-199411000-00017; Fries P, 2002, J NEUROSCI, V22, P3739; Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465; Jarvis MR, 2001, NEURAL COMPUT, V13, P717, DOI 10.1162/089976601300014312; Kilner JM, 2000, J NEUROSCI, V20, P8838; KONIG P, 1995, P NATL ACAD SCI USA, V92, P290, DOI 10.1073/pnas.92.1.290; Livingstone MS, 1996, J NEUROPHYSIOL, V75, P2467, DOI 10.1152/jn.1996.75.6.2467; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; Pinto DJ, 2003, J COMPUT NEUROSCI, V15, P283, DOI 10.1023/A:1025825102620; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; Rodriguez E, 1999, NATURE, V397, P430, DOI 10.1038/17120; Salinas E, 2001, NAT REV NEUROSCI, V2, P539, DOI 10.1038/35086012; Salinas E, 2000, J NEUROSCI, V20, P6193, DOI 10.1523/JNEUROSCI.20-16-06193.2000; Schreiber S, 2004, J NEUROPHYSIOL, V91, P194, DOI 10.1152/jn.00556.2003; Tiesinga PHE, 2004, NEURAL COMPUT, V16, P251, DOI 10.1162/089976604322742029; Trillenberg P, 2000, CLIN NEUROPHYSIOL, V111, P1216, DOI 10.1016/S1388-2457(00)00274-1; van Rossum MCW, 2002, J NEUROSCI, V22, P1956, DOI 10.1523/JNEUROSCI.22-05-01956.2002; Volgushev M, 1998, NEUROSCIENCE, V83, P15, DOI 10.1016/S0306-4522(97)00380-1	26	371	377	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					111	113		10.1126/science.1107027	http://dx.doi.org/10.1126/science.1107027			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802603	Green Published			2022-12-28	WOS:000228221500044
J	Croll, DA; Maron, JL; Estes, JA; Danner, EM; Byrd, GV				Croll, DA; Maron, JL; Estes, JA; Danner, EM; Byrd, GV			Introduced predators transform subarctic islands from grassland to tundra	SCIENCE			English	Article							TROPHIC CASCADES; FOOD WEBS; COMMUNITIES; ECOLOGY; MARINE	Top predators often have powerful direct effects on prey populations, but whether these direct effects propagate to the base of terrestrial food webs is debated. There are few examples of trophic cascades strong enough to alter the abundance and composition of entire plant communities. We show that the introduction of arctic foxes (Alopex lagopus) to the Aleutian archipelago induced strong shifts in plant productivity and community structure via a previously unknown pathway. By preying on seabirds, foxes reduced nutrient transport from ocean to land, affecting soil fertility and transforming grasslands to dwarf shrub/forb-dominated ecosystems.	Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95060 USA; Univ Montana, Div Biol Sci, Missoula, MT 59812 USA; US Geol Survey, Western Ecol Res Ctr, Santa Cruz, CA 95060 USA; US Fish & Wildlife Serv, Homer, AK 99603 USA	University of California System; University of California Santa Cruz; University of Montana System; University of Montana; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; US Fish & Wildlife Service	Croll, DA (corresponding author), Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95060 USA.	croll@biology.ucsc.edu	Bond, Alexander L/A-3786-2010	Danner, Eric/0000-0003-0860-2869; Byrd, George Vernon/0000-0003-1108-541X				[Anonymous], 2004, FOOD WEBS LANDSCAPE; BYRD GV, 1994, T N AM WILDL NAT RES, P317; Carpenter S. R., 1993, Bulletin of the Ecological Society of America, V74, P186; CHAPIN FS, 1995, ECOLOGY, V76, P694, DOI 10.2307/1939337; COUNCIL NR, 1996, BERING SEA ECOSYSTEM; Dawson TE, 2002, ANNU REV ECOL SYST, V33, P507, DOI 10.1146/annurev.ecolsys.33.020602.095451; Erskine PD, 1998, OECOLOGIA, V117, P187, DOI 10.1007/s004420050647; FRETWELL SD, 1987, OIKOS, V50, P291, DOI 10.2307/3565489; HAIRSTON NG, 1960, AM NAT, V94, P421, DOI 10.1086/282146; Halaj J, 2002, ECOLOGY, V83, P3141, DOI 10.2307/3071849; Kitchell JF, 1999, LIMNOL OCEANOGR, V44, P828, DOI 10.4319/lo.1999.44.3_part_2.0828; Pace ML, 1999, TRENDS ECOL EVOL, V14, P483, DOI 10.1016/S0169-5347(99)01723-1; PAINE RT, 1980, J ANIM ECOL, V49, P667; Paine RT, 2000, J MAMMAL, V81, P637, DOI 10.1644/1545-1542(2000)081<0637:PFTMMR>2.3.CO;2; Polis GA, 2000, TRENDS ECOL EVOL, V15, P473, DOI 10.1016/S0169-5347(00)01971-6; Polis GA, 1996, AM NAT, V147, P396, DOI 10.1086/285858; Schmitz OJ, 2000, AM NAT, V155, P141, DOI 10.1086/303311; SCHNEIDER DE, 2004, FOOD WEBS LANDSCAPE, P12; SHAVER GR, 1986, ARCTIC ALPINE RES, V18, P261, DOI 10.2307/1550883; Terborgh J, 2001, SCIENCE, V294, P1923, DOI 10.1126/science.1064397; *US FISH WILDL SER, 2004, BER SEAB COL CAT COM; Williamson M. H., 1981, ISLAND POPULATIONS; [No title captured]	23	352	367	4	276	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 25	2005	307	5717					1959	1961		10.1126/science.1108485	http://dx.doi.org/10.1126/science.1108485			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790855				2022-12-28	WOS:000227957300056
J	Piotrowski, AM; Goldstein, SL; Hemming, SR; Fairbanks, RG				Piotrowski, AM; Goldstein, SL; Hemming, SR; Fairbanks, RG			Temporal relationships of carbon cycling and ocean circulation at glacial boundaries	SCIENCE			English	Article							LAST CLIMATIC CYCLE; DEEP-WATER FLUX; ICE CORE; ISOTOPIC COMPOSITION; SOUTH-ATLANTIC; LABRADOR SEA; ND; NEODYMIUM; VARIABILITY; CONSTRAINTS	Evidence from high-sedimentation-rate South Atlantic deep-sea cores indicates that global and Southern Ocean carbon budget shifts preceded thermohaline circulation changes during the last ice age initiation and termination and that these were preceded by ice-sheet growth and retreat, respectively. No consistent lead-lag relationships are observed during abrupt millennial. warming events during the last ice age, allowing for the possibility that ocean circulation triggered some millenial climate changes. At the major glacial-intergiacial transitions, the global carbon budget and thermohaline ocean circulation responded sequentially to the climate changes that forced the growth and decline of continental ice sheets.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Dept Earth & Environm Sci, Palisades, NY 10964 USA	Columbia University; Columbia University	Piotrowski, AM (corresponding author), Univ Cambridge, Dept Earth Sci, Downing St, Cambridge CB2 3EQ, England.	apio04@esc.cam.ac.uk		Hemming, Sidney/0000-0001-8117-2303				Abouchami W, 1997, GEOCHIM COSMOCHIM AC, V61, P3957, DOI 10.1016/S0016-7037(97)00218-4; Adams JM, 1999, GLOBAL PLANET CHANGE, V20, P243, DOI 10.1016/S0921-8181(99)00015-6; ADAMS JM, 1990, NATURE, V348, P711, DOI 10.1038/348711a0; ALBAREDE F, 1992, GEOLOGY, V20, P761, DOI 10.1130/0091-7613(1992)020<0761:WMONII>2.3.CO;2; Bayon G, 2004, EARTH PLANET SC LETT, V224, P477, DOI 10.1016/j.epsl.2004.05.033; Bayon G, 2002, CHEM GEOL, V187, P179, DOI 10.1016/S0009-2541(01)00416-8; BOYLE EA, 1992, ANNU REV EARTH PL SC, V20, P245, DOI 10.1146/annurev.ea.20.050192.001333; Broecker W.S., 2002, GLACIAL WORLD ACCORD; BROECKER WS, 1982, PROG OCEANOGR, V11, P151, DOI 10.1016/0079-6611(82)90007-6; Burton KW, 2000, EARTH PLANET SC LETT, V176, P425, DOI 10.1016/S0012-821X(00)00011-X; CHARLES CD, 1992, NATURE, V355, P416, DOI 10.1038/355416a0; Charles CD, 1996, EARTH PLANET SC LETT, V142, P19, DOI 10.1016/0012-821X(96)00083-0; CROWLEY TJ, 1995, GLOBAL BIOGEOCHEM CY, V9, P377, DOI 10.1029/95GB01107; Curry WB, 1988, PALEOCEANOGRAPHY, V3, P317, DOI 10.1029/PA003i003p00317; CURRY WB, 1982, QUATERNARY RES, V18, P218, DOI 10.1016/0033-5894(82)90071-0; Denton GH, 1999, GEOGR ANN A, V81A, P107, DOI 10.1111/j.0435-3676.1999.00055.x; Duplessy JC, 1988, PALEOCEANOGRAPHY, V3, P343, DOI 10.1029/PA003i003p00343; Fagel N, 1999, PALEOCEANOGRAPHY, V14, P777, DOI 10.1029/1999PA900041; Frank M, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000094; *G R I P MEMB, 1993, NATURE, V364, P203; Goldstein S.L., 2003, TREATISE GEOCHEMISTR, P453, DOI [10.1016/B0-08-043751-6/06179-X, DOI 10.1016/B0-08-043751-6/06179-X]; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; Hodell DA, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000367; Innocent C, 1997, EARTH PLANET SC LETT, V146, P607, DOI 10.1016/S0012-821X(96)00251-8; JACOBSEN SB, 1980, EARTH PLANET SC LETT, V50, P139, DOI 10.1016/0012-821X(80)90125-9; JEANDEL C, 1993, EARTH PLANET SC LETT, V117, P581, DOI 10.1016/0012-821X(93)90104-H; Johnsen SJ, 1997, J GEOPHYS RES-OCEANS, V102, P26397, DOI 10.1029/97JC00167; JOUZEL J, 1987, NATURE, V329, P403, DOI 10.1038/329403a0; LEVITUS S, 1994, NOAA ATLAS NESDROS I, V3; MACKENSEN A, 1993, PALEOCEANOGRAPHY, V8, P587, DOI 10.1029/93PA01291; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; Matsumoto K, 2002, QUATERNARY SCI REV, V21, P1693, DOI 10.1016/S0277-3791(01)00142-1; Matsumoto K, 1999, PALEOCEANOGRAPHY, V14, P149, DOI 10.1029/1998PA900028; Ninnemann US, 2002, EARTH PLANET SC LETT, V201, P383, DOI 10.1016/S0012-821X(02)00708-2; Ninnemann US, 1999, GEOPH MONOG SERIES, V112, P99; OPPO DW, 1987, EARTH PLANET SC LETT, V86, P1, DOI 10.1016/0012-821X(87)90183-X; PIEPGRAS DJ, 1987, GEOCHIM COSMOCHIM AC, V51, P1257, DOI 10.1016/0016-7037(87)90217-1; PIEPGRAS DJ, 1988, GEOCHIM COSMOCHIM AC, V52, P1373, DOI 10.1016/0016-7037(88)90208-6; Piotrowski AM, 2004, EARTH PLANET SC LETT, V225, P205, DOI 10.1016/j.epsl.2004.06.002; PIOTROWSKI AM, 2004, THESIS COLUMBIA U; Ruddiman WF, 2003, QUATERNARY SCI REV, V22, P1597, DOI 10.1016/S0277-3791(03)00087-8; Rutberg RL, 2000, NATURE, V405, P935, DOI 10.1038/35016049; RUTBERG RL, IN PRESS PALEOCEANOG; SIEGENTHALER U, 1991, GLOBAL CHANGES PAST, P245; Vance D, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2003PA000957; von Blanckenburg F, 1999, SCIENCE, V286, P1862; von Blanckenburg F, 2001, PALEOCEANOGRAPHY, V16, P424, DOI 10.1029/2000PA000550	47	235	246	1	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1933	1938		10.1126/science.1104883	http://dx.doi.org/10.1126/science.1104883			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790848				2022-12-28	WOS:000227957300049
J	Stainier, DYR				Stainier, DYR			No organ left behind: Tales of gut development and evolution	SCIENCE			English	Editorial Material							SONIC HEDGEHOG; GENES; REGIONALIZATION; ORGANOGENESIS; MORPHOGENESIS; EXPRESSION	The function of an organ is dependent on its cellular constituents as well as on their assembly into a cohesive unit. The developing gut faces unique challenges as one of the longest and largest organs in the body and also because it is constantly interfacing with external factors through the diet. Its location deep within the body has until recently hampered investigation into its formation. The patterning of the gut along its longitudinal, dorsoventral, left-right, and radial axes is one of the fascinating issues that pertain to the development, function, and homeostasis of this understudied organ.	Univ Calif San Francisco, Dept Biochem & Biophys, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Program Human Genet, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Stainier, DYR (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Program Dev Biol, San Francisco, CA 94143 USA.	didier_stainier@biochem.ucsf.edu		Stainier, Didier/0000-0002-0382-0026				Ao W, 2004, SCIENCE, V305, P1743, DOI 10.1126/science.1102216; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Barbara PD, 2002, AM J MED GENET, V115, P221, DOI 10.1002/ajmg.10978; Beck F, 2000, BIOESSAYS, V22, P431, DOI 10.1002/(SICI)1521-1878(200005)22:5<431::AID-BIES5>3.0.CO;2-X; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; Brittan M, 2004, CELL PROLIFERAT, V37, P35, DOI 10.1111/j.1365-2184.2004.00299.x; Clements D, 2001, INT REV CYTOL, V203, P383; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; Field HA, 2003, DEV BIOL, V253, P279, DOI 10.1016/S0012-1606(02)00017-9; Fukuda K, 2002, J GASTROENTEROL, V37, P239, DOI 10.1007/s005350200030; Grapin-Botton A, 2000, TRENDS GENET, V16, P124, DOI 10.1016/S0168-9525(99)01957-5; Horne-Badovinac S, 2003, SCIENCE, V302, P662, DOI 10.1126/science.1085397; Huang D, 1998, DEVELOPMENT, V125, P3235; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kiefer JC, 2003, DEV DYNAM, V228, P287, DOI 10.1002/dvdy.10382; Kondo T, 1996, DEVELOPMENT, V122, P2651; Madison BB, 2005, DEVELOPMENT, V132, P279, DOI 10.1242/dev.01576; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Matsumoto A, 2002, ANAT EMBRYOL, V205, P53, DOI 10.1007/s00429-001-0226-5; Pacha J, 2000, PHYSIOL REV, V80, P1633, DOI 10.1152/physrev.2000.80.4.1633; Parisi MA, 2000, CURR OPIN PEDIATR, V12, P610, DOI 10.1097/00008480-200012000-00017; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Roberts DJ, 1998, DEVELOPMENT, V125, P2791; ROBERTS DJ, 1995, DEVELOPMENT, V121, P3163; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Schubert M, 2005, DEVELOPMENT, V132, P61, DOI 10.1242/dev.01554; Stainier DYR, 2002, GENE DEV, V16, P893, DOI 10.1101/gad.974902; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; Yelon D, 2002, CURR BIOL, V12, pR707, DOI 10.1016/S0960-9822(02)01213-7; YOKOUCHI Y, 1995, DEV BIOL, V169, P76, DOI 10.1006/dbio.1995.1128	31	75	76	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1902	1904		10.1126/science.1108709	http://dx.doi.org/10.1126/science.1108709			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790841				2022-12-28	WOS:000227957300042
J	Izawa, D; Goto, M; Yamashita, A; Yamano, H; Yamamoto, M				Izawa, D; Goto, M; Yamashita, A; Yamano, H; Yamamoto, M			Fission yeast Mes1p ensures the onset of meiosis II by blocking degradation of cyclin Cdc13p	NATURE			English	Article							ANAPHASE-PROMOTING COMPLEX; CYTOSTATIC FACTOR ARREST; SCHIZOSACCHAROMYCES-POMBE; GENETICALLY INTERACTS; SPINDLE CHECKPOINT; PROTEIN-KINASE; DIRECT BINDING; CELL-CYCLE; MITOSIS; APC	Meiosis is a special form of nuclear division to generate eggs, spermand spores in eukaryotes. Meiosis consists of the first (MI) and the second (MII) meiotic divisions, which occur consecutively. MI is reductional, in which homologous chromosomes derived from parents segregate. MI is supported by an elaborate mechanism involving meiosis-specific cohesin and its protector(1). MII is equational, in which replicated sister-chromatids separate as in mitosis. MII is generally considered to mimic mitosis in mechanism. However, fission yeastMes1p is essential for MII but dispensable for mitosis. The mes1-B44 mutant arrests before MII2. Transcription of mes1 is low in vegetative cells and boosted in a narrow window between late MI and late MII3. The mes1 mRNA undergoes meiosis-specific splicing(4). Here we show that Mes1p is a factor that suppresses the degradation of cyclin Cdc13p at anaphase I. Mes1p binds to Slp1p, an activator of APC/C ( anaphase promoting complex/cyclosome), and counteracts its function to engage Cdc13p in proteolysis. Inhibition of APC/C-dependent degradation of Cdc13p by Mes1p was reproduced in a Xenopus egg extract. We therefore propose that Mes1p has a key function in saving a sufficient level of MPF ( M-phase-promoting factor) activity required for the execution of MII.	Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan; Univ Tokyo, Mol Genet Res Lab, Tokyo 1130033, Japan; Natl Inst Basic Biol, Dept Cell Proliferat, Okazaki, Aichi 4440867, Japan; Marie Curie Res Inst, Cell Cycle Control Grp, Surrey RH8 0TL, England	University of Tokyo; University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Yamamoto, M (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 1130033, Japan.	myamamot@ims.u-tokyo.ac.jp	Yamashita, Akira/A-5278-2015	Yamashita, Akira/0000-0002-1805-1434				Blanco MA, 2001, J CELL SCI, V114, P2135; Borgne A, 2002, MOL BIOL CELL, V13, P2080, DOI 10.1091/mbc.01-10-0507; BUENO A, 1993, MOL CELL BIOL, V13, P2286, DOI 10.1128/MCB.13.4.2286; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Decottignies A, 2001, J CELL SCI, V114, P2627; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; Iwabuchi M, 2000, EMBO J, V19, P4513, DOI 10.1093/emboj/19.17.4513; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KISHIDA M, 1994, CURR GENET, V25, P497, DOI 10.1007/BF00351668; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Nakajo N, 2000, GENE DEV, V14, P328; Ohsumi K, 2004, P NATL ACAD SCI USA, V101, P12531, DOI 10.1073/pnas.0405300101; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2002, NATURE, V416, P850, DOI 10.1038/416850a; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; SHIMODA C, 1985, MOL GEN GENET, V200, P252, DOI 10.1007/BF00425432; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Watanabe Y, 2004, J CELL SCI, V117, P4017, DOI 10.1242/jcs.01352; Yamada HY, 2000, J CELL SCI, V113, P3989; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Yamano H, 2000, MOL CELL, V6, P1377, DOI 10.1016/S1097-2765(00)00135-0	30	61	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					529	533		10.1038/nature03406	http://dx.doi.org/10.1038/nature03406			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791259				2022-12-28	WOS:000227836000047
J	Oransky, I				Oransky, I			H Jeremy C Swan - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						SWAN HJC, PUBLICATION LIST	1	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR-APR	2005	365	9465					1132	1132		10.1016/S0140-6736(05)71865-1	http://dx.doi.org/10.1016/S0140-6736(05)71865-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15822167				2022-12-28	WOS:000227909500015
J	Trichopoulou, A				Trichopoulou, A		EPIC-Elderly Prospective Study Grp	Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; CANCER; CALIBRATION; DISEASE; RISK; MEN; AGE	Objective To examine whether adherence to the modified Mediterranean diet, in which unsaturates were substituted for monounsaturates, is associated with longer life expectancy among elderly Europeans. Design Multicentre, prospective cohort study. Setting Nine European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, Spain, Sweden, United Kingdom). Participants 74 607 men and women, aged 60 or more, without coronary heart disease, stroke, or cancer at enrolment and with complete information about dietary intake and potentially confounding variables. Main outcome measures Extent of adherence to a modified Mediterranean diet using a scoring system on a 10 point scale, and death from any cause by time of occurrence, modelled through Cox regression. Results An increase in the modified Mediterranean diet score was associated with lower overall mortality, a two unit increment corresponding to a statistically significant reduction of 8% (95% confidence interval 3% to 12%). No statistically significant evidence of heterogeneity was found among countries in the association of the score with overall mortality even though the association was stronger in Greece and Spain. When dietary exposures were calibrated across countries, the reduction in mortality was 7% (1% to 12%). Conclusion The Mediterranean diet, modified so as to apply across Europe, was associated with increased survival among older people.	Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece	Athens Medical School; National & Kapodistrian University of Athens	Trichopoulou, A (corresponding author), Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece.	antonia@nut.uoa.gr	Krogh, Vittorio/K-2628-2016; van der Schouw, Yvonne T./F-8327-2014; Kesse-Guyot, Emmanuelle/K-4689-2012; M, RODRIGUEZ-BARRANCO/H-4541-2012; Nagel, Gabriele/C-3635-2012; Orfanos, Philippos/AAL-2606-2021; Clavel-Chapelon, Francoise/G-6733-2014; TRICHOPOULOU, ANTONIA/ABF-8727-2021	Krogh, Vittorio/0000-0003-0122-8624; van der Schouw, Yvonne T./0000-0002-4605-435X; M, RODRIGUEZ-BARRANCO/0000-0002-9972-9779; Nagel, Gabriele/0000-0001-6185-8535; TRICHOPOULOU, ANTONIA/0000-0002-7204-6396; Pera, Guillem/0000-0003-3188-7268; Orfanos, Philippos/0000-0002-9949-3137; Masala, Giovanna/0000-0002-5758-9069; tumino, rosario/0000-0003-2666-414X; Overvad, Kim/0000-0001-6429-7921; Benetou, Vassiliki/0000-0002-0415-0386; Riboli, Elio/0000-0001-6795-6080; Spencer, Elizabeth/0000-0002-9079-8006; Navarro, Carmen/0000-0001-8896-7483				BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; deGroot LCPGM, 1996, NUTR REV, V54, P211, DOI 10.1111/j.1753-4887.1996.tb03935.x; Deharveng G, 1999, EUR J CLIN NUTR, V53, P60, DOI 10.1038/sj.ejcn.1600677; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; *DEP HLTH, 2001, UK DEP HLTH REP HLTH, V41; *DEP HLTH, 1991, UK DEP HLTH REP HLTH, V41; Huijbregts P, 1997, BRIT MED J, V315, P13, DOI 10.1136/bmj.315.7099.13; Jacques PF, 2001, AM J CLIN NUTR, V73, P1, DOI 10.1093/ajcn/73.1.1; James W. P. T., 1990, HUMAN ENERGY REQUIRE; Kaaks R, 1997, INT J EPIDEMIOL, V26, pS15, DOI 10.1093/ije/26.suppl_1.S15; Keys A., 1980, MULTIVARIATE ANAL DE; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Kumagai S, 1999, J Nutr Health Aging, V3, P29; Lasheras C, 2000, AM J CLIN NUTR, V71, P987; Margetts BM, 1997, INT J EPIDEMIOL, V26, pS1, DOI 10.1093/ije/26.suppl_1.S1; Osler M, 1997, INT J EPIDEMIOL, V26, P155, DOI 10.1093/ije/26.1.155; Riboli E, 2002, PUBLIC HEALTH NUTR, V5, P1113, DOI 10.1079/PHN2002394; Singh RB, 2002, LANCET, V360, P1455, DOI 10.1016/S0140-6736(02)11472-3; Slimani N, 2002, PUBLIC HEALTH NUTR, V5, P1125, DOI 10.1079/PHN2002395; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; WILLETT W, 1998, NUTR EPIDEMIOLOGY, P414; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC	25	537	549	0	46	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 30	2005	330	7498					991	995		10.1136/bmj.38415.644155.8F	http://dx.doi.org/10.1136/bmj.38415.644155.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	923UP	15820966	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000228935100018
J	Lee, JH; Paull, TT				Lee, JH; Paull, TT			ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex	SCIENCE			English	Article							DAMAGE; NBS1; AUTOPHOSPHORYLATION; PHOSPHORYLATION; REQUIREMENT; MRE11/RAD50; CHECKPOINT; BINDING; REPAIR; SMC1	The ataxia-tetangiectasia mutated (ATM) kinase signals the presence of DNA double-strand breaks in mammalian cells by phosphorylating proteins that initiate cell-cycle arrest, apoptosis, and DNA repair. We show that the Mre11-Rad50-Nbs1 (MRN) complex acts as a double-strand break sensor for ATM and recruits ATM to broken DNA molecules. Inactive ATM dimers were activated in vitro with DNA in the presence of MRN, leading to phosphorylation of the downstream cellular targets p53 and Chk2. ATM autophosphorylation was not required for monomerization of ATM by MRN. The unwinding of DNA ends by MRN was essential for ATM stimulation, which is consistent with the central role of single-stranded DNA as an evolutionarily conserved signal for DNA damage.	Univ Texas, Inst Mol & Cellular Biol, Dept Mol Genet & Microbiol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Paull, TT (corresponding author), Univ Texas, Inst Mol & Cellular Biol, Dept Mol Genet & Microbiol, 1 Univ Stn,A4800, Austin, TX 78712 USA.	tpaull@icmb.utexas.edu	Lee, Jihoon/AAK-3497-2021	Lee, Jihoon/0000-0001-7387-935X; Paull, Tanya/0000-0002-2991-651X	NCI NIH HHS [CA094008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee JH, 2003, MOL CANCER RES, V1, P674; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Moncalian G, 2004, J MOL BIOL, V335, P937, DOI 10.1016/j.jmb.2003.11.026; Nakada D, 2003, GENE DEV, V17, P1957, DOI 10.1101/gad.1099003; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Stracker TH, 2004, DNA REPAIR, V3, P845, DOI 10.1016/j.dnarep.2004.03.014; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702	18	1021	1061	1	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 22	2005	308	5721					551	554		10.1126/science.1108297	http://dx.doi.org/10.1126/science.1108297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	922BK	15790808				2022-12-28	WOS:000228810500052
J	Stille, CJ; Jerant, A; Bell, D; Meltzer, D; Elmore, JG				Stille, CJ; Jerant, A; Bell, D; Meltzer, D; Elmore, JG			Coordinating care across diseases, settings, and clinicians: A key role for the generalist in practice	ANNALS OF INTERNAL MEDICINE			English	Article							ELECTRONIC MEDICAL-RECORDS; RANDOMIZED CONTROLLED TRIAL; HEALTH-CARE; COLLABORATIVE CARE; CHRONIC ILLNESS; INFORMATION-TECHNOLOGY; SPECIALTY CARE; HEART-DISEASE; CHILDREN; COMMUNICATION	Coordinated care is a defining principle of primary care, but it is becoming increasingly difficult to provide as the health care delivery system in the United States becomes more complex. To guide recommendations for research and practice, the evidence about implementation of coordinated care and its benefits must be considered. On the basis of review of the published literature this article makes recommendations concerning needs for a better-developed evidence base to substantiate the value of care coordination, generalist practices to be the hub of care coordination for most patients, improved communication among clinicians, a team approach to achieve coordination, integration of patients and families as partners, and incorporation of medical informatics. Although coordination of care is central to generalist practice, it requires far more effort than physicians alone can deliver. To make policy recommendations, further work is needed to identify essential elements of care coordination and prove its effectiveness at improving health outcomes.	Univ Massachusetts, Sch Med, Div Gen Pediat, Worcester, MA 01655 USA; Univ Calif Davis, Sacramento, CA 95817 USA; Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Univ Chicago, Chicago, IL 60637 USA; Univ Washington, Seattle, WA 98195 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Davis; University of California System; University of California Los Angeles; University of Chicago; University of Washington; University of Washington Seattle	Stille, CJ (corresponding author), Univ Massachusetts, Sch Med, Div Gen Pediat, Benedict A3-125,55 Lake Ave N, Worcester, MA 01655 USA.	stillec@ummhc.org	Bell, Douglas S/G-6702-2013; Bell, Douglas/HGE-6048-2022; Meltzer, David/C-2926-2009	Bell, Douglas S/0000-0002-5063-8294; Meltzer, David/0000-0003-2790-7393; Stille, Christopher/0000-0001-9192-6818	NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003026] Funding Source: NIH RePORTER; NCRR NIH HHS [G12 RR 03026-13] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; Antonelli R, 2002, PEDIATR RES, V51, p216A; Ayanian JZ, 2002, NEW ENGL J MED, V347, P1678, DOI 10.1056/NEJMsa020080; Bates DW, 2003, J AM MED INFORM ASSN, V10, P1, DOI 10.1197/jamia.M1097; Bell DS, 2003, J AM MED INFORM ASSN, V10, P484, DOI 10.1197/jamia.M1341; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; BRAILER D, USE ADOPTION COMPUTE; BYRD JC, 1987, J GEN INTERN MED, V2, P93, DOI 10.1007/BF02596304; Casebeer Linda, 2002, J Contin Educ Health Prof, V22, P33, DOI 10.1002/chp.1340220105; Christakis DA, 2001, AMBUL PEDIATR, V1, P99, DOI 10.1367/1539-4409(2001)001<0099:CAQOCF>2.0.CO;2; Coiera E, 2000, J AM MED INFORM ASSN, V7, P277, DOI 10.1136/jamia.2000.0070277; Cooley WC, 1999, AM J MED GENET, V89, P75; CUMMINS RO, 1980, JAMA-J AM MED ASSOC, V243, P1650, DOI 10.1001/jama.243.16.1650; Delbanco T, 2001, Health Expect, V4, P144, DOI 10.1046/j.1369-6513.2001.00145.x; Embi PJ, 2004, J AM MED INFORM ASSN, V11, P300, DOI 10.1197/jamia.M1525; Epstein R M, 1995, Arch Fam Med, V4, P403, DOI 10.1001/archfami.4.5.403; Forrest CB, 1999, PEDIATRICS, V104, P28, DOI 10.1542/peds.104.1.28; Forrest CB, 2000, ARCH PEDIAT ADOL MED, V154, P499, DOI 10.1001/archpedi.154.5.499; Gandhi TK, 2000, J GEN INTERN MED, V15, P626, DOI 10.1046/j.1525-1497.2000.91119.x; Goldsmith J, 2000, HEALTH AFFAIR, V19, P148, DOI 10.1377/hlthaff.19.1.148; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V270, P2487; GREENBERG MD, IN PRESS INQUIRY; Greenfield S, 1999, J GEN INTERN MED, V14, P516, DOI 10.1046/j.1525-1497.1999.05059.x; Grumbach K, 2004, JAMA-J AM MED ASSOC, V291, P1246, DOI 10.1001/jama.291.10.1246; Grumbach Kevin, 2003, Ann Fam Med, V1, P4, DOI 10.1370/afm.47; Harrold LR, 1999, J GEN INTERN MED, V14, P499, DOI 10.1046/j.1525-1497.1999.08168.x; *HLTH PRIV PROJ, HLTH PRIV POLL DAT; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Institute of Medicine, 2003, KEY CAP EL HLTH REC; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; Jerant AF, 2000, J FAM PRACTICE, V49, P349; KANTHOR H, 1974, PEDIATRICS, V54, P779; Katon W, 2002, J GEN INTERN MED, V17, P741, DOI 10.1046/j.1525-1497.2002.11051.x; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katz SJ, 2004, J GEN INTERN MED, V19, P978, DOI 10.1111/j.1525-1497.2004.30432.x; Kim MI, 2002, J AM MED INFORM ASSN, V9, P171, DOI 10.1197/jamia.M0978; Kisker CT, 1997, ARCH PEDIAT ADOL MED, V151, P1008, DOI 10.1001/archpedi.1997.02170470042008; KOLATA G, 2004, NY TIMES         AUG, V11; LEVY KK, 2002, NATION ONLINE AM EXP; MCINERNY T, 1984, PEDIATR CLIN N AM, V31, P199; MCPHEE SJ, 1984, ARCH INTERN MED, V144, P1265, DOI 10.1001/archinte.144.6.1265; Meltzer D, 2001, J LEGAL STUD, V30, P589, DOI 10.1086/339294; Miller MR, 2000, PEDIATRICS, V106, P264, DOI 10.1542/peds.106.2.264; Miller RH, 2004, HEALTH AFFAIR, V23, P116, DOI 10.1377/hlthaff.23.2.116; Mitchell E, 2001, BMJ-BRIT MED J, V322, P279, DOI 10.1136/bmj.322.7281.279; Nash DB, 1997, ANN INTERN MED, V127, P72, DOI 10.7326/0003-4819-127-1-199707010-00012; NEWTON J, 1992, BRIT MED J, V304, P821, DOI 10.1136/bmj.304.6830.821; Office of Civil Rights U. S. Departmrnt of Health and Human Services, 2000, FED REGISTER, V65, P82462; Overhage JM, 2002, ANN EMERG MED, V39, P14, DOI 10.1067/mem.2002.120794; Palfrey JS, 2004, PEDIATRICS, V113, P1507; PALFREY JS, 1980, PEDIATRICS, V65, P567; Parker J, 2000, J AM MED INFORM ASSN, V7, P453, DOI 10.1136/jamia.2000.0070453; Perrin EC, 2000, PEDIATRICS, V105, P277; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; REED MC, 2004, LIMITED INFORMATION; Rothman AA, 2003, ANN INTERN MED, V138, P256, DOI 10.7326/0003-4819-138-3-200302040-00034; Safran DG, 2003, ANN INTERN MED, V138, P248, DOI 10.7326/0003-4819-138-3-200302040-00033; Schillinger D, 2000, J GEN INTERN MED, V15, P329, DOI 10.1046/j.1525-1497.2000.07010.x; Shortliffe E H, 1995, JAMA, V273, P1064, DOI 10.1001/jama.273.13.1061; Sia CJ, 2002, PEDIATRICS, V110, P184; *SOC GEN INT MED, TASK FORC FUT GEN IN; Stange KC, 2002, INT J QUAL HEALTH C, V14, P267, DOI 10.1093/intqhc/14.4.267; STARFIELD B, 1994, DIABETES CARE, V17, P12; Starfield B, 1998, PRIMARY CARE BALANCI; Starfield Barbara, 2003, Ann Fam Med, V1, P8, DOI 10.1370/afm.1; Stein REK, 1999, ARCH PEDIAT ADOL MED, V153, P68; Stille CJ, 2003, PEDIATRICS, V112, P1314, DOI 10.1542/peds.112.6.1314; STOTT N, 1995, J INTERPROFESSIONAL, V9, P95; STOTT NCH, 1993, BRIT J GEN PRACT, V43, P254; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; *US DHHS OFF NAT C, DEC HLTH INF TECHN D; Wang SJ, 2003, AM J MED, V114, P397, DOI 10.1016/S0002-9343(03)00057-3; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227; Weiner M, 2003, ANN INTERN MED, V139, P430, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00010; WILSON GA, 1982, AM J PUBLIC HEALTH, V72, P698, DOI 10.2105/AJPH.72.7.698; YOUNG PC, 1994, PEDIATRICS, V94, P284; Ziring PR, 1999, PEDIATRICS, V104, P978; HYPERDICTIONARY; 2000, PEDIATRICS 2, V105, P157	80	133	134	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					700	708		10.7326/0003-4819-142-8-200504190-00038	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00038			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916TZ	15838089				2022-12-28	WOS:000228410400028
J	Ricci, L				Ricci, L			Dante's insight into galilean invariance	NATURE			English	Editorial Material									Univ Trent, Dipartimento Fis, I-38050 Trento, Italy	University of Trento	Ricci, L (corresponding author), Univ Trent, Dipartimento Fis, I-38050 Trento, Italy.	ricci@science.unitn.it	Ricci, Leonardo/P-4115-2019; Ricci, Leonardo/B-4207-2009	Ricci, Leonardo/0000-0001-9454-0988; Ricci, Leonardo/0000-0001-9454-0988				ALIGHIERI D, 1982, DIVINA COMMEDIA; Alighieri Dante, 2003, INFERNO; GALILEI G, 1968, DUE LEZIONI ALLACCAD; GALILEI G, 1970, DIALOGO SOPRA I DUE; Galilei Galileo, 1953, DIALOGUE 2 CHIEF WOR	5	2	2	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 7	2005	434	7034					717	717		10.1038/434717a	http://dx.doi.org/10.1038/434717a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815619	Green Published, Bronze			2022-12-28	WOS:000228160700028
J	Kearon, C; Ginsberg, JS; Douketis, J; Crowther, MA; Turpie, AG; Bates, SM; Lee, A; Brill-Edwards, P; Finch, T; Gent, M				Kearon, C; Ginsberg, JS; Douketis, J; Crowther, MA; Turpie, AG; Bates, SM; Lee, A; Brill-Edwards, P; Finch, T; Gent, M			A randomized trial of diagnostic strategies after normal proximal vein ultrasonography for suspected deep venous thrombosis: D-dimer testing compared with repeated ultrasonography	ANNALS OF INTERNAL MEDICINE			English	Article							WHOLE-BLOOD ASSAY; PULMONARY-EMBOLISM; NONINVASIVE DIAGNOSIS; THROMBOEMBOLISM; MANAGEMENT; SPECIFICITY; PROBABILITY; SENSITIVITY; OUTPATIENTS	Background: With suspected deep venous thrombosis and normal results on proximal vein ultrasonography, a negative (D)-climer result may exclude thrombosis and a positive (D)-dimer result may be an indication for venography. Objective: To evaluate and compare the safety of 2 diagnostic strategies for deep venous thrombosis. Design: Randomized, multicenter trial. Setting: Four university hospitals. Patients: 810 outpatients with suspected deep venous thrombosis and negative results on proximal vein ultrasonography. Interventions: Erythrocyte agglutination (D)-dimer testing followed by no further testing if the result was negative and venography if the result was positive (experimental) or ultrasonography repeated after 1 week in all patients (control). Measurements: Symptomatic deep venous thrombosis diagnosed initially and symptomatic venous thromboembolism during 6 months of follow-up. Results: Nineteen of 408 patients (4.7%) in the (D)-dimer group and 3 of 402 patients (0.7%) in the repeated ultrasonography group initially received a diagnosis of deep venous thrombosis (P < 0.001). During follow-up of patients without a diagnosis of deep venous thrombosis on initial testing, 8 patients (2.1% (95% Cl, 0.9% to 4.0%]) in the (D)-dimer group and 5 patients (1.3% [Cl, 0.4% to 2.9%1) in the repeated ultrasonography group developed symptomatic venous thromboembolism (difference, 0.8 percentage point [CI, -1.1 to 2.9 percentage points]; P > 0.2). Venous thromboembolism occurred in 1.0% (Cl, 0.2% to 2.8%) of those with a negative (D)-dimer result. Limitations: seventy patients (8.6%) deviated from the diagnostic protocols, and 9 patients (1.1 %) had inadequate follow-up. Conclusion: In outpatients with suspected deep venous thrombosis who initially had normal results on ultrasonography of the proximal veins, a strategy based on (D)-dimer testing followed by no further testing if the result was negative and venography if the result was positive had acceptable safety and did not differ from the safety of a strategy based on withholding anticoagulant therapy and routinely repeating ultrasonography after 1 week.	McMaster Univ, Hamilton, ON, Canada; Henderson Res Ctr, Hamilton, ON, Canada	McMaster University	Kearon, C (corresponding author), Hamilton Hlth Sci, Henderson Div, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Douketis, James/AAO-5659-2021; ginsberg, jeffrey s/ABC-1065-2020					Altman D., 2013, STAT CONFIDENCE CONF; Bernardi E, 1998, BRIT MED J, V317, P1037; Chunilal SD, 2002, ARCH INTERN MED, V162, P217, DOI 10.1001/archinte.162.2.217; Elias A, 2003, THROMB HAEMOSTASIS, V89, P221; Fancher TL, 2004, BMJ-BRIT MED J, V329, P821, DOI 10.1136/bmj.38226.719803.EB; Ginsberg JS, 1997, ARCH INTERN MED, V157, P1077, DOI 10.1001/archinte.157.10.1077; Ginsberg JS, 1998, ANN INTERN MED, V129, P1006, DOI 10.7326/0003-4819-129-12-199812150-00003; JOHN MA, 1990, THROMB RES, V58, P273, DOI 10.1016/0049-3848(90)90097-V; Kearon C, 1998, ANN INTERN MED, V129, P1044, DOI 10.7326/0003-4819-129-12-199812150-00009; Kearon C, 2003, CAN MED ASSOC J, V168, P183; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; Kearon C, 2001, ANN INTERN MED, V135, P108, DOI 10.7326/0003-4819-135-2-200107170-00011; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Kruip MJHA, 2003, ANN INTERN MED, V138, P941, DOI 10.7326/0003-4819-138-12-200306170-00005; Perrier A, 1999, LANCET, V353, P190, DOI 10.1016/S0140-6736(98)05248-9; Schellong SM, 2003, THROMB HAEMOSTASIS, V89, P228; Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153; WELLS PS, 1995, CIRCULATION, V91, P2184, DOI 10.1161/01.CIR.91.8.2184; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3	19	44	48	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 5	2005	142	7					490	496		10.7326/0003-4819-142-7-200504050-00007	http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913QL	15809460				2022-12-28	WOS:000228167800002
J	Schmittner, A				Schmittner, A			Decline of the marine ecosystem caused by a reduction in the Atlantic overturning circulation	NATURE			English	Article							NORTH-ATLANTIC; CLIMATE; PRODUCTIVITY; MODEL; SCALE; CO2	Reorganizations of the Atlantic meridional overturning circulation were associated with large and abrupt climatic changes in the North Atlantic region during the last glacial period(1-4). Projections with climate models suggest that similar reorganizations may also occur in response to anthropogenic global warming(5-7). Here I use ensemble simulations with a coupled climate-ecosytem model of intermediate complexity to investigate the possible consequences of such disturbances to the marine ecosystem. In the simulations, a disruption of the Atlantic meridional overturning circulation leads to a collapse of the North Atlantic plankton stocks to less than half of their initial biomass, owing to rapid shoaling of winter mixed layers and their associated separation from the deep ocean nutrient reservoir. Globally integrated export production declines by more than 20 per cent owing to reduced upwelling of nutrient-rich deep water and gradual depletion of upper ocean nutrient concentrations. These model results are consistent with the available high-resolution palaeorecord, and suggest that global ocean productivity is sensitive to changes in the Atlantic meridional overturning circulation.	Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA	Oregon State University	Schmittner, A (corresponding author), Oregon State Univ, Coll Ocean & Atmospher Sci, 104 COAS Adm Bldg, Corvallis, OR 97331 USA.	aschmittner@coas.oregonstae.edu	Schmittner, Andreas/A-3101-2008; Schmittner, Andreas/O-9647-2015	Schmittner, Andreas/0000-0002-8376-0843				Antoine D, 1996, GLOBAL BIOGEOCHEM CY, V10, P57, DOI 10.1029/95GB02832; Aumont O, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2001GB001745; Bopp L, 2001, GLOBAL BIOGEOCHEM CY, V15, P81, DOI 10.1029/1999GB001256; Clark PU, 2002, NATURE, V415, P863, DOI 10.1038/415863a; Conkright M., 2002, NOAA ATLAS NESDIS42; Cubasch U., 2001, PROJECTIONS FUTURE C, P525; Dokken TM, 1999, NATURE, V401, P458, DOI 10.1038/46753; Gregg WW, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL016889; Hendy IL, 2003, QUATERNARY SCI REV, V22, P673, DOI 10.1016/S0277-3791(02)00186-5; KIEFER T, 1998, 90 U KIEL GEOL PAL I; Lebreiro SM, 1997, PALEOCEANOGRAPHY, V12, P718, DOI 10.1029/97PA01748; MANABE S, 1993, NATURE, V364, P215, DOI 10.1038/364215a0; Ortiz JD, 2004, GEOLOGY, V32, P521, DOI 10.1130/G20234.1; Rasmussen TL, 2003, MAR MICROPALEONTOL, V47, P143, DOI 10.1016/S0377-8398(02)00115-9; Sarmiento JL, 2004, NATURE, V427, P56, DOI 10.1038/nature02127; SARTHEIN M, 2001, NO N ATLANTIC, P45; Schartau M, 2003, J MAR RES, V61, P765, DOI 10.1357/002224003322981147; Schmittner A, 2003, QUATERNARY SCI REV, V22, P659, DOI 10.1016/S0277-3791(02)00184-1; SCHMITTNER A, IN PRESS GLOB BIOGEO; Schulte S, 2001, GEO-MAR LETT, V21, P168, DOI 10.1007/s003670100080; Simmons HL, 2004, OCEAN MODEL, V6, P245, DOI 10.1016/S1463-5003(03)00011-8; Six KD, 1996, GLOBAL BIOGEOCHEM CY, V10, P559, DOI 10.1029/96GB02561; Stocker TF, 1997, NATURE, V388, P862, DOI 10.1038/42224; THOMAS E, 1995, PALEOCEANOGRAPHY, V10, P545, DOI 10.1029/94PA03056; Vink A, 2001, PALEOCEANOGRAPHY, V16, P479, DOI 10.1029/2000PA000582; Weaver AJ, 2001, ATMOS OCEAN, V39, P361, DOI 10.1080/07055900.2001.9649686; Weinelt M., 2003, Z DTSCH GEOL GES, V154, P47, DOI DOI 10.1127/ZDGG/154/2003/47; Willamowski C, 2000, PALEOCEANOGRAPHY, V15, P515, DOI 10.1029/1999PA000467	28	212	216	3	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					628	633		10.1038/nature03476	http://dx.doi.org/10.1038/nature03476			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800620				2022-12-28	WOS:000228011000041
J	Gluud, C; Gluud, LL				Gluud, C; Gluud, LL			Evidence based diagnostics	BRITISH MEDICAL JOURNAL			English	Article							VENTRICULAR SYSTOLIC DYSFUNCTION; BRAIN NATRIURETIC PEPTIDE; PLASMA	Diagnostic tests are often much less rigorously evaluated than new drugs. It is time to ensure that the harms and benefits of new tests are fully understood.	Univ Copenhagen Hosp, HS Rigshosp, Ctr Clin Intervent Res,Copenhagen Trial Unit, Cochrane Hepatobiliary Grp, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Gluud, C (corresponding author), Univ Copenhagen Hosp, HS Rigshosp, Ctr Clin Intervent Res,Copenhagen Trial Unit, Cochrane Hepatobiliary Grp, DK-2100 Copenhagen, Denmark.	cgluud@ctu.rh.dk	Gluud, Christian/AAY-1027-2021; Gluud, Christian/HGB-3191-2022; Gluud, Lise L/AAY-2120-2020	Gluud, Christian/0000-0002-8861-0799; Gluud, Lise L/0000-0002-9462-4468				ATIONU A, 1993, BRIT J BIOMED SCI, V50, P92; Bossuyt PM, COMPLETE ACCURATE RE; *COCHR COLL, 2003, COCHR LIB; DeKay ML, 1998, MED DECIS MAKING, V18, P19, DOI 10.1177/0272989X9801800105; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; Illes J, 2002, BRAIN COGNITION, V50, P358, DOI 10.1016/S0278-2626(02)00532-8; *INT C HARM STEER, ICH HARM TRIP GUID G; Jensen KT, 1997, SCAND J CLIN LAB INV, V57, P529, DOI 10.3109/00365519709084604; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; KNOTTNERUS JA, 2002, EVIDENCE BASE CLIN D, P209; Landray MJ, 2000, BRIT MED J, V320, P985, DOI 10.1136/bmj.320.7240.985; Sackett DL, 2002, BRIT MED J, V324, P539, DOI 10.1136/bmj.324.7336.539; Selvais PL, 1998, EUR J CLIN INVEST, V28, P636; Talwar S, 2000, HEART, V83, P278, DOI 10.1136/heart.83.3.278; THOUGHTON RW, 2000, LANCET, V355, P1126; Wang TJ, 2003, ANN INTERN MED, V138, P907, DOI 10.7326/0003-4819-138-11-200306030-00012; [No title captured]	17	111	113	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 26	2005	330	7493					724	726		10.1136/bmj.330.7493.724	http://dx.doi.org/10.1136/bmj.330.7493.724			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912IT	15790646	Green Published			2022-12-28	WOS:000228071900023
J	Colosimo, PF; Hosemann, KE; Balabhadra, S; Villarreal, G; Dickson, M; Grimwood, J; Schmutz, J; Myers, RM; Schluter, D; Kingsley, DM				Colosimo, PF; Hosemann, KE; Balabhadra, S; Villarreal, G; Dickson, M; Grimwood, J; Schmutz, J; Myers, RM; Schluter, D; Kingsley, DM			Widespread parallel evolution in sticklebacks by repeated fixation of ectodysplasin alleles	SCIENCE			English	Article							HYPOHIDROTIC ECTODERMAL DYSPLASIA; THREESPINE STICKLEBACKS; GASTEROSTEUS-ACULEATUS; GENETIC ARCHITECTURE; SELECTIVE PREDATION; MITOCHONDRIAL-DNA; LATERAL PLATES; REDUCTION; POPULATIONS; MUTATIONS	Major phenotypic changes evolve in parallel in nature by molecular mechanisms that are largely unknown. Here, we use positional cloning methods to identify the major chromosome locus controlling armor plate patterning in wild threespine sticklebacks. Mapping, sequencing, and transgenic studies show that the Ectodysplasin (EDA) signaling pathway plays a key role in evolutionary change in natural populations and that parallel evolution. of stickleback low-plated phenotypes at most freshwater locations around the world has occurred by repeated selection of Eda alleles derived from an ancestral low-plated haplotype that first appeared more than two million years ago. Members of this clade of tow-plated alleles are present at tow frequencies in marine fish, which suggests that standing genetic variation can provide a molecular basis for rapid, parallel evolution of dramatic phenotypic change in nature.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Stanford Human Genome Ctr, Stanford, CA 94305 USA; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Biodivers Res Ctr, Vancouver, BC V6T 1Z4, Canada	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University; Stanford University; University of British Columbia; University of British Columbia	Colosimo, PF (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.		Schmutz, Jeremy/N-3173-2013; Grimwood, Jane/ABD-5737-2021	Schmutz, Jeremy/0000-0001-8062-9172; Schluter, Dolph/0000-0003-1683-7836	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG002568] Funding Source: NIH RePORTER; NHGRI NIH HHS [1P50HG02568] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AVISE JC, 1976, GENET RES, V27, P33, DOI 10.1017/S0016672300016219; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Bell M.A., 1994, EVOLUTIONARY BIOL TH; Bergstrom CA, 2002, CAN J ZOOL, V80, P207, DOI 10.1139/Z01-226; Colosimo PF, 2004, PLOS BIOL, V2, P635, DOI 10.1371/journal.pbio.0020109; Cresko WA, 2004, P NATL ACAD SCI USA, V101, P6050, DOI 10.1073/pnas.0308479101; CUVIER G, 1829, HIST NATURELLE POISS; Deagle BE, 1996, CAN J ZOOL, V74, P1045, DOI 10.1139/z96-116; Futuyma D. J., 1998, EVOLUTIONARY BIOL; GILES N, 1983, J ZOOL, V199, P535; HAGEN DW, 1967, J FISH RES BOARD CAN, V24, P1637, DOI 10.1139/f67-138; HAGEN DW, 1972, EVOLUTION, V26, P32, DOI 10.1111/j.1558-5646.1972.tb00172.x; HAGEN DW, 1973, HEREDITY, V30, P273, DOI 10.1038/hdy.1973.38; HEUTS MJ, 1947, EVOLUTION, V1, P89, DOI 10.2307/2405407; Higuchi M, 1996, ENVIRON BIOL FISH, V47, P1, DOI 10.1007/BF00002375; Hosemann KE, 2004, BEHAVIOUR, V141, P1345, DOI 10.1163/1568539042948097; Kangas AT, 2004, NATURE, V432, P211, DOI 10.1038/nature02927; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kingsley DM, 2004, BEHAVIOUR, V141, P1331, DOI 10.1163/1568539042948150; Kondo S, 2001, CURR BIOL, V11, P1202, DOI 10.1016/S0960-9822(01)00324-4; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LINDSEY CC, 1962, CAN J ZOOLOG, V40, P271, DOI 10.1139/z62-028; MACLEAN J, 1980, CAN J ZOOL, V58, P2026, DOI 10.1139/z80-279; Mikkola ML, 1999, MECH DEVELOP, V88, P133, DOI 10.1016/S0925-4773(99)00180-X; MOODIE GEE, 1973, BEHAVIOUR, V47, P95, DOI 10.1163/156853973X00292; ORTI G, 1994, EVOLUTION, V48, P608, DOI 10.1111/j.1558-5646.1994.tb01348.x; Paakkonen K, 2001, Hum Mutat, V17, P349, DOI 10.1002/humu.33; Peichel CL, 2001, NATURE, V414, P901, DOI 10.1038/414901a; Ransom DG, 1999, METHOD CELL BIOL, V60, P195; Reimchen TE, 2000, BEHAVIOUR, V137, P1081, DOI 10.1163/156853900502448; REIMCHEN TE, 1992, EVOLUTION, V46, P1224, DOI 10.1111/j.1558-5646.1992.tb00631.x; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schluter D, 2004, AM NAT, V163, P809, DOI 10.1086/383621; Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415; Sire JY, 2003, BIOL REV, V78, P219, DOI 10.1017/S1464793102006073; Srivastava AK, 2001, HUM MOL GENET, V10, P2973, DOI 10.1093/hmg/10.26.2973; Taylor EB, 1999, BIOL J LINN SOC, V66, P271, DOI 10.1111/j.1095-8312.1999.tb01891.x; TAYLOR EB, 1986, CAN J ZOOL, V64, P416, DOI 10.1139/z86-064; THESLEFF I, 2002, SCI STKE, V131; Vincent MC, 2001, EUR J HUM GENET, V9, P355, DOI 10.1038/sj.ejhg.5200635; Wei CJ, 2004, ANNU REV CELL DEV BI, V20, P811, DOI 10.1146/annurev.cellbio.19.111301.144309; Williams-Blangero S, 2002, P NATL ACAD SCI USA, V99, P5533, DOI 10.1073/pnas.082115999; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	43	1069	1094	10	362	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 25	2005	307	5717					1928	1933		10.1126/science.1107239	http://dx.doi.org/10.1126/science.1107239			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790847				2022-12-28	WOS:000227957300048
J	Moja, LP; Telaro, E; D'Amico, R; Moschetti, I; Coe, L; Liberati, A				Moja, LP; Telaro, E; D'Amico, R; Moschetti, I; Coe, L; Liberati, A		Metaquality Study Grp	Assessment of methodological quality of primary studies by systematic reviews: results of the metaquality study cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIALS; PAPER-BASED JOURNALS; CLINICAL-TRIALS; COCHRANE REVIEWS; HEALTH-CARE; METAANALYSES; STATEMENT; THERAPY; ARTICLE; SCIENCE	Objectives To describe how the methodological quality of primary studies is assessed in systematic reviews and whether the quality assessment is taken into account in the interpretation of results. Data sources Cochrane systematic reviews and systmatic reviews in paper based journals. Study selection 965 systematic reviews (809 Cochrane reviews and 156 paper based reviews) published between 1995 and 2002. Data synthesis. The methodological quality of primary studies was assessed in 8 54 of the 965 systematic reviews (88.5%). This occurred more often in Cochrane reviews than in paper based reviews (93.9% v 60.3%, P < 0.0001). Overall, only 496 (51.4%) used the quality assessment in the analysis and interpretation of die results or in their discussion, with no significant differences between Cochrane reviews and paper based reviews (52% v 49%, P = 0.58). The tools and methods used for quality assessment varied widely. Conclusions Cochrane reviews fared better than systematic reviews published-in paper based journals in terms of assessment of methodological quality of primary studies, although they both largely failed to take it into account in the interpretation of results. Methods for assessment of methodological quality by systematic reviews are still in. their infancy and there is substantial room for improvement.	Univ Modena & Reggio Emilia, Modena, Italy; Ist Ric Farmacol Mario Negri, Ctr Cochrane Italiano, I-20157 Milan, Italy	Universita di Modena e Reggio Emilia; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Liberati, A (corresponding author), Univ Modena & Reggio Emilia, Modena, Italy.		D'Amico, Roberto/I-8106-2014; MOSCHETTI, IVAN/ABF-9728-2020; Moja, Pasquale Lorenzo/CAH-0318-2022	D'Amico, Roberto/0000-0002-3211-6687; MOSCHETTI, IVAN/0000-0003-4047-6655; Moja, Pasquale Lorenzo/0000-0001-6680-6507				Alderson P, 2004, COCHRANE LIB; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BROWN SA, 1991, NURS RES, V40, P352; BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; COUNSELL CE, 1994, BMJ-BRIT MED J, V309, P1677, DOI 10.1136/bmj.309.6970.1677; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; Egger M, 2003, Health Technol Assess, V7, P1; Greenland S, 2001, Biostatistics, V2, P463, DOI 10.1093/biostatistics/2.4.463; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248; Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; JUNI P, 2002, JAMA-J AM MED ASSOC, V287, P2408; JUNI P, 2001, SYSTEMATIC REV HLTH; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Lantz CA, 1996, J CLIN EPIDEMIOL, V49, P431, DOI 10.1016/0895-4356(95)00571-4; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; Linde K, 1999, J CLIN EPIDEMIOL, V52, P631, DOI 10.1016/S0895-4356(99)00048-7; McAlister FA, 1999, ANN INTERN MED, V131, P947, DOI 10.7326/0003-4819-131-12-199912210-00007; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Moher D, 1996, INT J TECHNOL ASSESS, V12, P195, DOI 10.1017/S0266462300009570; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Moher D., 1999, HEALTH TECHNOL ASSES, V3, pi, DOI [DOI 10.3310/HTA3120, 10.3310/hta3120]; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; Petticrew M, 1999, INT J TECHNOL ASSESS, V15, P671, DOI 10.1017/S0266462399015469; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Shea B, 2002, EVAL HEALTH PROF, V25, P116, DOI 10.1177/0163278702025001008; Tritchler D, 1999, STAT MED, V18, P2135, DOI 10.1002/(SICI)1097-0258(19990830)18:16<2135::AID-SIM183>3.3.CO;2-X; *U YORK CTR REV DI, 2004, DARE DAT HIGH QUAL R; Verhagen AP, 2001, J CLIN EPIDEMIOL, V54, P651, DOI 10.1016/S0895-4356(00)00360-7	40	156	155	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 7	2005	330	7499					1053	1055		10.1136/bmj.38414.515938.8F	http://dx.doi.org/10.1136/bmj.38414.515938.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	925YY	15817526	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000229090900017
J	Charest, MG; Lerner, CD; Brubaker, JD; Siege, DR; Myers, AG				Charest, MG; Lerner, CD; Brubaker, JD; Siege, DR; Myers, AG			A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics	SCIENCE			English	Article							RIBOSOMAL-SUBUNIT; BENZOIC-ACID; TETRACYCLINES; DERIVATIVES; CHEMISTRY; ALCOHOLS	Complex antibiotics based on natural products are almost invariably prepared by semisynthesis, or chemical transformation of the isolated natural products. This approach greatly limits the range of accessible structures that might be studied as new antibiotic candidates. Here we report a short and enantioselective synthetic route to a diverse range of 6-deoxytetracycline antibiotics. The common feature of this class is a scaffold of four linearly fused rings, labeled A through D. We targeted not a single compound but a group of structures with the D ring as a site of structural variability. A late-stage, diastereoselective C-ring construction was used to couple structurally varied D-ring precursors with an AB precursor containing much of the essential functionality for binding to the bacterial ribosome. Five derivatives were synthesized from benzoic acid in yields ranging from 5 to 7% over 14 to 15 steps, and a sixth, (-)-doxycycline, was synthesized in 8.3% yield over 18 steps.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Myers, AG (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	myers@chemistry.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048825] Funding Source: NIH RePORTER; NIAID NIH HHS [AI48825] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMYYES SGB, 2001, MAGIC BULLETS LOST H; BERK SC, 1990, ORGANOMETALLICS, V9, P3053, DOI 10.1021/om00162a016; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Bush K, 2004, CURR OPIN MICROBIOL, V7, P466, DOI 10.1016/j.mib.2004.08.013; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; COREY EJ, 1981, TETRAHEDRON LETT, V22, P3455, DOI 10.1016/S0040-4039(01)81930-4; DAVIS FA, 1992, J ORG CHEM, V57, P7274, DOI 10.1021/jo00052a050; Dodd J.H., 1979, TETRAHEDRON LETT, V20, P3593; FRIGERIO M, 1994, TETRAHEDRON LETT, V35, P8019, DOI 10.1016/0040-4039(94)80038-3; GUREVICH AI, 1967, TETRAHEDRON LETT, V8, P131; HAUSER FM, 1980, SYNTHESIS-STUTTGART, P72; HAUSER FM, 1978, J ORG CHEM, V43, P178, DOI 10.1021/jo00395a048; Ho T.L., 1992, TANDEM ORGANIC REACT; Katz L, 1997, CHEM REV, V97, P2557, DOI 10.1021/cr960025+; KORST JJ, 1968, J AM CHEM SOC, V90, P439, DOI 10.1021/ja01004a041; Leeb M, 2004, NATURE, V431, P892, DOI 10.1038/431892a; LEEPER FJ, 1978, J CHEM SOC CHEM COMM, P406, DOI 10.1039/c39780000406; MUXFELDT H, 1979, J AM CHEM SOC, V101, P689, DOI 10.1021/ja00497a035; Myers AG, 2001, ORG LETT, V3, P2923, DOI 10.1021/ol010151m; Myers AG, 1996, TETRAHEDRON LETT, V37, P4841, DOI 10.1016/0040-4039(96)00965-3; NELSON M, 2001, TETRACYCLINES BIOL C; PARHAM WE, 1976, J ORG CHEM, V41, P1184, DOI 10.1021/jo00869a022; PEVARELLO P, 1992, SYNTHETIC COMMUN, V22, P1939, DOI 10.1080/00397919208021324; Pine SH., 1970, ORG REACTIONS, V18, P403; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; Prilezhaeva E. N., 2001, RUSS CHEM REV, V70, P897; REINER AM, 1971, BIOCHEMISTRY-US, V10, P2530, DOI 10.1021/bi00789a017; ROGALSKI W, 1985, HDB EXPT PHARM, V78, pCH5; STEPHENS CR, 1963, J AM CHEM SOC, V85, P2643, DOI 10.1021/ja00900a027; Stork G, 1996, J AM CHEM SOC, V118, P5304, DOI 10.1021/ja960434n; STORK G, 1978, J AM CHEM SOC, V100, P3609, DOI 10.1021/ja00479a060; Strohl WR, 2001, METAB ENG, V3, P4, DOI 10.1006/mben.2000.0172; Sum PE, 1999, BIOORG MED CHEM LETT, V9, P1459, DOI 10.1016/S0960-894X(99)00216-4; Tatsuta K, 2000, CHEM LETT, P646, DOI 10.1246/cl.2000.646; VYAS DM, 1984, TETRAHEDRON LETT, V25, P487, DOI 10.1016/S0040-4039(00)99918-0; Walsh C., 2003, ANTIBIOTICS ACTIONS; WHITE JD, 1986, J ORG CHEM, V51, P1150, DOI 10.1021/jo00357a047	37	231	248	1	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					395	398		10.1126/science.1109755	http://dx.doi.org/10.1126/science.1109755			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	917TL	15831754				2022-12-28	WOS:000228492000047
J	Fazel, M; Wheeler, J; Danesh, J				Fazel, M; Wheeler, J; Danesh, J			Prevalence of serious mental disorder in 7000 refugees resettled in western countries: a systematic review	LANCET			English	Review							POSTTRAUMATIC-STRESS-DISORDER; III-R DISORDERS; VIETNAMESE REFUGEES; PSYCHIATRIC-DISORDERS; PSYCHOLOGICAL TRAUMA; ORGANIZED VIOLENCE; MAJOR DEPRESSION; BOSNIAN REFUGEES; 2 GENERATIONS; HEALTH-CARE	Background About 13 million people are classified as refugees worldwide, and many more former refugees have been granted citizenship in their new countries. However, the prevalence of post-traumatic stress disorder, major depression, or psychotic illnesses in these individuals is not known. We did a systematic review of surveys about these disorders in general refugee populations in western countries. Methods We searched for psychiatric surveys that were based on interviews of unselected refugee populations and that included current diagnoses of post-traumatic stress disorder, major depression, psychotic illnesses, or generalised anxiety disorder. We did computer-assisted searches, scanned reference lists, searched journals, and corresponded with authors to determine prevalence rates of these mental disorders and to explore potential sources of heterogeneity, such as diagnostic criteria, sampling methods, and other characteristics. Findings 20 eligible surveys provided results for 6743 adult refugees from seven countries, with substantial variation in assessment and sampling methods. In the larger studies, 9% (99% CI 8-10%) were diagnosed with post-traumatic stress disorder and 5% (4-6%) with major depression, with evidence of much psychiatric comorbidity. Five surveys of 260 refugee children from three countries yielded a prevalence of 11% (7-17%) for post-traumatic stress disorder. Larger and more rigorous surveys reported lower prevalence rates than did studies with less optimum designs, but heterogeneity persisted even in findings from the larger studies. Interpretation Refugees resettled in western countries could be about ten times more likely to have post-traumatic stress disorder than age-matched general populations in those countries. Worldwide, tens of thousands of refugees and former refugees resettled in western countries probably have post-traumatic stress disorder.	Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England; Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England	University of Oxford; University of Cambridge	Fazel, M (corresponding author), Univ Oxford, Dept Psychiat, Oxford OX3 7JX, England.	mina.fazel@psych.ox.ac.uk		Fazel, Mina/0000-0001-9342-2365				Ahmad A, 2000, EUR CHILD ADOLES PSY, V9, P285, DOI 10.1007/s007870070032; Almqvist K, 1997, CHILD ABUSE NEGLECT, V21, P351, DOI 10.1016/S0145-2134(96)00176-7; Altman D.G., 2000, STAT CONFIDENCE, Vsecond; Angel B, 2001, AM J ORTHOPSYCHIAT, V71, P4, DOI 10.1037/0002-9432.71.1.4; Armitage P., 2002, STAT METHODS MED RES; Blair RG, 2000, HEALTH SOC WORK, V25, P23, DOI 10.1093/hsw/25.1.23; BRACKEN PJ, 1995, SOC SCI MED, V40, P1073, DOI 10.1016/0277-9536(94)00181-R; Brady KT, 2000, J CLIN PSYCHIAT, V61, P22; CARLSON EB, 1991, AM J PSYCHIAT, V148, P1548; Cheung P, 1994, Int J Soc Psychiatry, V40, P17, DOI 10.1177/002076409404000102; CLARKE T, 1994, CAIR WORLD C POP DEV; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; de Girolamo G., 1996, ETHNOCULTURAL ASPECT, P33, DOI [DOI 10.1037/10555-002, 10.1037/10555-002]; de Jong JTVM, 2003, LANCET, V361, P2128, DOI 10.1016/S0140-6736(03)13692-6; de Jong JTVM, 2002, LANCET, V359, P1793, DOI 10.1016/S0140-6736(02)08729-9; EATON WW, 1992, INT MIGR REV, V26, P1395, DOI 10.2307/2546888; EHRENSAFT E, 2002, RELATIONSHIP RESILIE; Favaro A, 1999, J NERV MENT DIS, V187, P306, DOI 10.1097/00005053-199905000-00007; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; Fenta H, 2004, J NERV MENT DIS, V192, P363, DOI 10.1097/01.nmd.0000126729.08179.07; Fitzpatrick J., 2002, HUMAN RIGHTS PROTECT; GONGGUY E, 1987, CALIFORNIA SE ASIAN; HAUFF E, 1995, BRIT J PSYCHIAT, V166, P360, DOI 10.1192/bjp.166.3.360; HAUFF E, 1994, J NERV MENT DIS, V182, P85, DOI 10.1097/00005053-199402000-00004; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; HINTON WL, 1993, J NERV MENT DIS, V181, P113, DOI 10.1097/00005053-199302000-00007; HINTON WL, 1994, J GEN INTERN MED, V9, P202, DOI 10.1007/BF02600124; Hollifield M, 2002, JAMA-J AM MED ASSOC, V288, P611, DOI 10.1001/jama.288.5.611; *HOM OFF, 2003, AS STAT 4 Q 2002; HUBBARD J, 1995, J AM ACAD CHILD PSY, V34, P1167, DOI 10.1097/00004583-199509000-00014; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KINZIE JD, 1986, J AM ACAD CHILD PSY, V25, P370, DOI 10.1016/S0002-7138(09)60259-4; Kroll J, 2003, JAMA-J AM MED ASSOC, V290, P667, DOI 10.1001/jama.290.5.667; LAVIK NJ, 1996, J REFUG STUD, V9, P73, DOI DOI 10.1093/JRS/9.1.73; LEWINSOHN PM, 1993, J ABNORM PSYCHOL, V102, P133, DOI 10.1037/0021-843X.102.1.133; Locke CJ, 1996, ARCH PEDIAT ADOL MED, V150, P822, DOI 10.1001/archpedi.1996.02170330048008; Malekzai ASB, 1996, J TRAUMA STRESS, V9, P891, DOI 10.1007/BF02104111; MGHIR R, 1995, J NERV MENT DIS, V183, P24, DOI 10.1097/00005053-199501000-00005; Pirkis J, 2001, AUST NZ J PSYCHIAT, V35, P174, DOI 10.1046/j.1440-1614.2001.00882.x; PORTES A, 1992, J HEALTH SOC BEHAV, V33, P283, DOI 10.2307/2137309; Robins L.N., 1991, PSYCHIAT DISORDERS A; SACK WH, 1994, J NERV MENT DIS, V182, P387, DOI 10.1097/00005053-199407000-00004; SACK WH, 1993, J AM ACAD CHILD PSY, V32, P431, DOI 10.1097/00004583-199303000-00027; SACK WH, 1995, J AM ACAD CHILD PSY, V34, P1160, DOI 10.1097/00004583-199509000-00013; Silove D, 1997, BRIT J PSYCHIAT, V170, P351, DOI 10.1192/bjp.170.4.351; Steel Z, 2002, LANCET, V360, P1056, DOI 10.1016/S0140-6736(02)11142-1; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Summerfield D, 1999, SOC SCI MED, V48, P1449, DOI 10.1016/S0277-9536(98)00450-X; Tousignant M, 1999, J AM ACAD CHILD PSY, V38, P1426, DOI 10.1097/00004583-199911000-00018; Turner SW, 2003, BRIT J PSYCHIAT, V182, P444, DOI 10.1192/bjp.182.5.444; *US COMM REF, 2003, WORLD REF SURV 2003; *US IMM NAT SERV, 1997, STAT YB IMM NAT SERV; Veijola J, 2003, NORD J PSYCHIAT, V57, P119, DOI 10.1080/08039480310000941; Watters C, 2001, SOC SCI MED, V52, P1709, DOI 10.1016/S0277-9536(00)00284-7; Weine SM, 2000, J NERV MENT DIS, V188, P416, DOI 10.1097/00005053-200007000-00004; WESTERMEYER J, 1988, AM J PSYCHIAT, V145, P197; WESTERMEYER J, 1983, J OPER PSYCHIATR, V14, P36; Westermeyer J., 1997, TRANSCULT PSYCHIATRY, V34, P291, DOI [DOI 10.1177/136346159703400301, 10.1177/136346159703400301]	58	1199	1205	2	138	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2005	365	9467					1309	1314		10.1016/S0140-6736(05)61027-6	http://dx.doi.org/10.1016/S0140-6736(05)61027-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	914HY	15823380				2022-12-28	WOS:000228219600025
J	Siotia, AK; Chaudhuri, A; Muzulu, SI; Harling, D; Muthusamy, R				Siotia, AK; Chaudhuri, A; Muzulu, SI; Harling, D; Muthusamy, R			Interactive case report - Postoperative hypoxia in a woman with Down's syndrome: case presentation	BRITISH MEDICAL JOURNAL			English	Review									No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England; Ninewells Hosp, Dundee DD1 9SY, Scotland; Rotherham Dist Gen Hosp, Rotherham S60 2UD, S Yorkshire, England	Northern General Hospital; University of Dundee	Siotia, AK (corresponding author), No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England.	Anjan.Siotia@sth.nhs.uk							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 9	2005	330	7495					834	834		10.1136/bmj.330.7495.834	http://dx.doi.org/10.1136/bmj.330.7495.834			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915BZ	15817552	Green Published			2022-12-28	WOS:000228273900021
J	Bodiselitsch, B; Koeberl, C; Master, S; Reimold, WU				Bodiselitsch, B; Koeberl, C; Master, S; Reimold, WU			Estimating duration and intensity of Neoproterozoic snowball glaciations from Ir anomalies	SCIENCE			English	Article							EXTRATERRESTRIAL HE-3; ACCRETION RATE; EARTH; STRATIGRAPHY; DEGLACIATION; IRIDIUM; OCEAN	The Neoproterozoic glaciations supposedly ended in a supergreenhouse environment, Which led to rapid melting of the ice cover and precipitation of the so-called cap carbonates. If Earth was covered with ice, then extraterrestrial material would have accumulated on and within the ice and precipitated during rapid melting at the end of the glaciation. We found iridium (Ir) anomalies at the base of cap carbonates in three drill cores from the Eastern Congo craton. Our data confirm the presence of extended global Neoproterozoic glaciations and indicate that the duration of the Marinoan glacial episode was at least 3 million, and most likely 12 million, years.	Univ Vienna, Dept Geol Sci, A-1090 Vienna, Austria; Univ Witwatersrand, Sch Geosci, Impact Cratering Res Grp, ZA-2050 Johannesburg, South Africa	University of Vienna; University of Witwatersrand	Koeberl, C (corresponding author), Univ Vienna, Dept Geol Sci, Althanstr 14, A-1090 Vienna, Austria.	christian.koeberl@univie.ac.at	Reimold, Wolf Uwe/AAI-6226-2021	Hauser, Natalia/0000-0002-6975-6186; master, sharad/0000-0002-3343-4417				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Basaltic Volcanism Study Project, 1981, BASALTIC VOLCANISM T, P1286; CALDEIRA K, 1992, NATURE, V359, P226, DOI 10.1038/359226a0; CALDEIRA K, 1991, GEOLOGY, V19, P204, DOI 10.1130/0091-7613(1991)019<0204:CPCPAT>2.3.CO;2; CEPLECHA Z, 1992, ASTRON ASTROPHYS, V263, P361; Crowley TJ, 2001, GEOPHYS RES LETT, V28, P283, DOI 10.1029/2000GL011836; FAIRCHILD IJ, 1993, SEDIMENTOLOGY REV, P1; GROTZINGER JP, 1995, SCIENCE, V270, P598, DOI 10.1126/science.270.5236.598; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; Kennedy MJ, 1996, J SEDIMENT RES, V66, P1050, DOI 10.2110/jsr.66.1050; Key RM, 2001, J AFR EARTH SCI, V33, P503, DOI 10.1016/S0899-5362(01)00098-7; Kirschvink J. L., 1992, PROTEROZOIC BIOSPHER, P51; KNOLL AH, 1992, NATURE, V356, P673, DOI 10.1038/356673a0; Koeberl C, 2000, J RADIOANAL NUCL CH, V244, P655, DOI 10.1023/A:1006754409429; KYTE FT, 1986, SCIENCE, V232, P1225, DOI 10.1126/science.232.4755.1225; Marcantonio F, 1999, EARTH PLANET SC LETT, V170, P157, DOI 10.1016/S0012-821X(99)00100-4; Marcantonio F, 1996, NATURE, V383, P705, DOI 10.1038/383705a0; Marcantonio F, 1998, GEOCHIM COSMOCHIM AC, V62, P1535, DOI 10.1016/S0016-7037(98)00091-X; NOBLE DC, 1979, GEOL SOC AM SPEC PAP, V180, P77; PARLEY KA, 1995, NATURE, V378, P600; PEUCKEREHRENBRI.B, 1996, GEOCHIM COSMOCHIM AC, V60, P3192; PORADA H, 1989, PRECAMBRIAN RES, V44, P103, DOI 10.1016/0301-9268(89)90078-8; ROBERTS JD, 1974, J GEOL, V84, P47; Schmidt MH, 1997, EUR CHILD ADOLES PSY, V6, P88; Sohl LE, 1999, GEOL SOC AM BULL, V111, P1120, DOI 10.1130/0016-7606(1999)111<1120:PPRIMC>2.3.CO;2; Wasson J.T., 1985, METEORITES THEIR REC	29	87	96	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					239	242		10.1126/science.1104657	http://dx.doi.org/10.1126/science.1104657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821088				2022-12-28	WOS:000228273700049
J	Leeper, NJ; Wener, LS; Dhaliwal, G; Saint, S; Wachter, RM				Leeper, NJ; Wener, LS; Dhaliwal, G; Saint, S; Wachter, RM			One surprise after another	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDITIS		Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94143 USA; San Francisco VA Med Ctr, San Francisco, CA USA; Ann Arbor Vet Affairs Med Ctr, Ann Arbor Vet Affairs Hlth Serv Res & Dev Ctr Exc, Ann Arbor, MI USA; Ann Arbor Vet Affairs Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA; Univ Michigan Hlth Syst, Ann Arbor, MI USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Wachter, RM (corresponding author), Univ Calif San Francisco, Dept Med, Sch Med, Box 0120,Room M-994, San Francisco, CA 94143 USA.	bobw@medicine.ucsf.edu	Saint, Sanjay/AAF-5126-2019		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER; AHRQ HHS [P20-HS11540] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		D'Ambrosio A, 2001, HEART, V85, P499, DOI 10.1136/heart.85.5.499; MASON JW, 1995, NEW ENGL J MED, V333, P269, DOI 10.1056/NEJM199508033330501; Noutsias Michel, 2003, Heart Fail Monit, V3, P127; O'Connell J B, 1986, Curr Probl Cardiol, V11, P445; OCONNELL JB, 1994, CONGESTIVE HEART FAI, P223; PINNEY SP, 2004, HURSTS HEART, P1949; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; Smith SC, 1997, CIRCULATION, V95, P163, DOI 10.1161/01.CIR.95.1.163	8	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1474	1479		10.1056/NEJMcps040755	http://dx.doi.org/10.1056/NEJMcps040755			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814884				2022-12-28	WOS:000228145200012
J	Ross, MW; Fernandez-Esquer, ME				Ross, MW; Fernandez-Esquer, ME			Ethnicity in sexually transmitted infections and sexual behaviour research	LANCET			English	Editorial Material							HEALTH; RACE		Univ Texas, Sch Publ Hlth, WHO, Ctr Hlth Promot & Prevent Res, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; World Health Organization	Ross, MW (corresponding author), Univ Texas, Sch Publ Hlth, WHO, Ctr Hlth Promot & Prevent Res, Houston, TX 77225 USA.	Michael.W.Ross@uth.tmc.edu		Ross, Michael/0000-0002-5718-9989				Fernandez-Esquer ME, 2004, J SEX RES, V41, P390, DOI 10.1080/00224490409552246; Fernandez-Esquer ME, 2003, J STUD ALCOHOL, V64, P160, DOI 10.15288/jsa.2003.64.160; Klovdahl AS, 2001, SOC SCI MED, V52, P681, DOI 10.1016/S0277-9536(00)00170-2; Laumann EO, 1999, SEX TRANSM DIS, V26, P250, DOI 10.1097/00007435-199905000-00003; Probst JC, 2004, AM J PUBLIC HEALTH, V94, P1695, DOI 10.2105/AJPH.94.10.1695; Ross MW, 2004, INT J STD AIDS, V15, P778, DOI 10.1258/0956462042395168; Ross MW, 2003, SEX TRANSM DIS, V30, P110, DOI 10.1097/00007435-200302000-00003; Ross MW, 1998, SEX TRANSM INFECT, V74, P2; ROSS MW, 1990, J CLIN PSYCHOL, V46, P402, DOI 10.1002/1097-4679(199007)46:4<402::AID-JCLP2270460405>3.0.CO;2-Q; ROSS MW, 1999, SEXUALLY TRANSMITTED, P107; RUGGLES S, 1994, AM SOCIOL REV, V59, P136, DOI 10.2307/2096137	11	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1209	1210		10.1016/S0140-6736(05)74789-9	http://dx.doi.org/10.1016/S0140-6736(05)74789-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	912VI	15811439				2022-12-28	WOS:000228107600006
J	Kohfeld, KE; Le Quere, C; Harrison, SP; Anderson, RF				Kohfeld, KE; Le Quere, C; Harrison, SP; Anderson, RF			Role of marine biology in glacial-interglacial CO2 cycles	SCIENCE			English	Article							SOUTHERN-OCEAN; ATMOSPHERIC CO2; PHYTOPLANKTON BLOOM; IRON ENRICHMENT; CARBON-CYCLE; BOX MODELS; RECORDS; PACIFIC; PUMP; REPRESENTATION	It has been hypothesized that changes in the marine biological pump caused a major portion of the glacial reduction of atmospheric carbon dioxide by 80 to 100 parts per million through increased iron fertilization of marine plankton, increased ocean nutrient content or utilization, or shifts in dominant plankton types. We analyze sedimentary records of marine productivity at the peak and the middle of the last glacial cycle and show that neither changes in nutrient utilization in the Southern Ocean nor shifts in plankton dominance explain the CO2 drawdown. Iron fertilization and associated mechanisms can be responsible for no more than half the observed drawdown.	Max Planck Inst Biogeochem, Jena, Germany; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Dept Earth & Environm Sci, Palisades, NY 10964 USA	Max Planck Society; Columbia University; Columbia University	Kohfeld, KE (corresponding author), CUNY Queens Coll, Sch Earth & Environm Sci, Flushing, NY 11367 USA.	office@kohfeld.com	Le Quere, Corinne/C-2631-2017	Le Quere, Corinne/0000-0003-2319-0452; Anderson, Robert/0000-0002-8472-2494; Harrison, Sandy/0000-0001-5687-1903; Kohfeld, Karen/0000-0001-7241-1624				Anderson DM, 2002, NATURE, V416, P70, DOI 10.1038/416070a; Anderson RF, 2002, DEEP-SEA RES PT II, V49, P1909, DOI 10.1016/S0967-0645(02)00018-8; Archer D, 2000, REV GEOPHYS, V38, P159, DOI 10.1029/1999RG000066; ARCHER D, 1994, NATURE, V367, P260, DOI 10.1038/367260a0; Archer DE, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000760; BERGER AL, 1978, J ATMOS SCI, V35, P2362, DOI 10.1016/0033-5894(78)90064-9; Bijma J, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2002GC000388; Bopp L, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001445; Bopp L, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000810; Boyd PW, 2000, NATURE, V407, P695, DOI 10.1038/35037500; Broecker W, 1999, GLOBAL BIOGEOCHEM CY, V13, P817, DOI 10.1029/1999GB900050; BROECKER WS, 1982, GEOCHIM COSMOCHIM AC, V46, P1689, DOI 10.1016/0016-7037(82)90110-7; Brzezinski MA, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014349; Budziak D, 2000, PALEOCEANOGRAPHY, V15, P307, DOI 10.1029/1999PA000433; Calvo E, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2003PA000992; Catubig NR, 1998, PALEOCEANOGRAPHY, V13, P298, DOI 10.1029/98PA00609; Clemens SC, 1990, PALEOCEANOGRAPHY, V5, P109, DOI 10.1029/PA005i002p00109; Coale KH, 1996, NATURE, V383, P495, DOI 10.1038/383495a0; Coale KH, 2004, SCIENCE, V304, P408, DOI 10.1126/science.1089778; CONKRIGHT ME, 2002, 46 NOAA NESDIS, V5; De La Rocha CL, 1998, NATURE, V395, P680, DOI 10.1038/27174; Elderfield H, 2000, NATURE, V405, P305, DOI 10.1038/35012507; Francois R, 1997, NATURE, V389, P929, DOI 10.1038/40073; HESSE PP, 1994, QUATERNARY SCI REV, V13, P257, DOI 10.1016/0277-3791(94)90029-9; Hutchins DA, 1998, NATURE, V393, P561, DOI 10.1038/31203; Ikehara M, 2000, PALEOCEANOGRAPHY, V15, P170, DOI 10.1029/1999PA000425; Kaplan JO, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013366; Kawahata H, 2000, QUATERNARY SCI REV, V19, P1279, DOI 10.1016/S0277-3791(99)00096-7; Kawahata H., 1999, J OCEANOGR, V55, P747; Kohfeld KE, 2001, EARTH-SCI REV, V54, P81, DOI 10.1016/S0012-8252(01)00042-3; Levitus S, 2001, SCIENCE, V292, P267, DOI 10.1126/science.1058154; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; Martinez P, 1996, ORG GEOCHEM, V24, P411, DOI 10.1016/0146-6380(96)00044-7; Matsumoto K, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001442; MCELROY MB, 1983, NATURE, V302, P328, DOI 10.1038/302328a0; Muller PJ, 1997, PALAEOGEOGR PALAEOCL, V135, P71, DOI 10.1016/S0031-0182(97)00018-7; ORSI AH, 1995, DEEP-SEA RES PT I, V42, P641, DOI 10.1016/0967-0637(95)00021-W; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Robinson RS, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2003PA000996; Rosenthal Y, 2000, PALEOCEANOGRAPHY, V15, P65, DOI 10.1029/1999PA000369; SANYAL A, 1995, NATURE, V373, P234, DOI 10.1038/373234a0; SCHNEIDER S, 2002, BER FACHBER GEOWISS, V187, P134; Sicre MA, 2000, ORG GEOCHEM, V31, P577, DOI 10.1016/S0146-6380(00)00021-8; Sigman DM, 1999, PALEOCEANOGRAPHY, V14, P118, DOI 10.1029/1998PA900018; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; Stephens BB, 2000, NATURE, V404, P171, DOI 10.1038/35004556; TIEDEMANN R, 1994, PALEOCEANOGRAPHY, V9, P619, DOI 10.1029/94PA00208; Toggweiler JR, 1999, PALEOCEANOGRAPHY, V14, P571, DOI 10.1029/1999PA900033; Toggweiler JR, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2001GB001841; Toggweiler JR, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2001GB001401; Tsuda A, 2003, SCIENCE, V300, P958, DOI 10.1126/science.1082000; Watson AJ, 2000, NATURE, V407, P730, DOI 10.1038/35037561; XIE LS, 1995, FISH OCEANOGR, V4, P52, DOI 10.1111/j.1365-2419.1995.tb00060.x	53	289	297	3	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					74	78		10.1126/science.1105375	http://dx.doi.org/10.1126/science.1105375			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802597				2022-12-28	WOS:000228221500035
J	Okie, S				Okie, S			Perspective: Raising the safety bar - the FDA's coxib meeting.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Harris G., 2005, NY TIMES 0225, pA1; Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405	4	43	43	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1283	1285		10.1056/NEJMp058055	http://dx.doi.org/10.1056/NEJMp058055			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800221				2022-12-28	WOS:000227998300001
J	Steinbrook, R				Steinbrook, R			Standards of ethics at the National Institutes of Health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NIH											*DEP HLTH HUM SERV, 2005, NIH ASS SCI RESP SUP; Steinbrook R, 2004, NEW ENGL J MED, V351, P955, DOI 10.1056/NEJMp048235; Steinbrook R, 2004, NEW ENGL J MED, V350, P327, DOI 10.1056/NEJMp038247; WILLIMAN D, 2005, LOS ANGELES TIM 0303; 2005, FED REG, V70, P5543	5	6	6	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1290	1292		10.1056/NEJMp058049	http://dx.doi.org/10.1056/NEJMp058049			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JL	15800225				2022-12-28	WOS:000227998300005
J	Radtke, F; Clevers, H				Radtke, F; Clevers, H			Self-renewal and cancer of the gut: Two sides of a coin	SCIENCE			English	Review							TUMOR-SUPPRESSOR PROTEIN; INTESTINAL STEM-CELLS; POLYPOSIS-COLI GENE; BETA-CATENIN; COLORECTAL-CANCER; JUVENILE POLYPOSIS; MISMATCH REPAIR; APC GENE; ENTEROENDOCRINE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION	The intestinal epithelium follows the paradigms of stem cell biology established for other self-renewing tissues. With a unique topology, it constitutes a two-dimensional structure folded into valleys and hills: the proliferative crypts and the differentiated villi. Its unprecedented self-renewal rate appears reflected in a high susceptibility to malignant transformation. The molecular mechanisms that control homeostatic self-renewal and those that underlie colorectal cancer are remarkably symmetrical. Here, we discuss the biology of the intestinal epithelium, emphasizing the roles played by Wnt, bone morphogenic protein, and Notch signaling cascades in epithelial self-renewal and cancer.	Netherlands Inst Dev Biol, Hubrecht Inst, NL-3584 CT Utrecht, Netherlands; Univ Lausanne, Ludwig Inst Canc Res, Lausanne Branch, CH-1066 Epalinges, Switzerland	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Ludwig Institute for Cancer Research; University of Lausanne	Clevers, H (corresponding author), Netherlands Inst Dev Biol, Hubrecht Inst, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.	clevers@niob.knaw.nl	Radtke, Freddy/Q-3198-2017	Radtke, Freddy/0000-0003-4315-4045				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DE SB, 1999, NATURE, V398, P518; EVANS GS, 1988, VIRCHOWS ARCH B, V56, P191, DOI 10.1007/BF02890017; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GREGORIEFF A, UNPUB; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAGGITT RC, 1986, AM J SURG PATHOL, V10, P871, DOI 10.1097/00000478-198612000-00006; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Heath JP, 1996, CELL BIOL INT, V20, P139, DOI 10.1006/cbir.1996.0018; Heitzler P, 1996, DEVELOPMENT, V122, P161; Hocker M, 1998, ANN NY ACAD SCI, V859, P160, DOI 10.1111/j.1749-6632.1998.tb11120.x; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jenny M, 2002, EMBO J, V21, P6338, DOI 10.1093/emboj/cdf649; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kondo M, 2003, ANNU REV IMMUNOL, V21, P759, DOI 10.1146/annurev.immunol.21.120601.141007; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Madison BB, 2005, DEVELOPMENT, V132, P279, DOI 10.1242/dev.01576; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; Nucci MR, 1997, HUM PATHOL, V28, P1396, DOI 10.1016/S0046-8177(97)90230-6; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; PELTOMAKI P, 1993, CANCER RES, V53, P5853; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z; Potten CS, 2002, J CELL SCI, V115, P2381; Potten CS, 1998, PHILOS T R SOC B, V353, P821, DOI 10.1098/rstb.1998.0246; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC183, DOI 10.1152/ajpcell.1999.277.2.C183; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Preston SL, 2003, CANCER RES, V63, P3819; Rashid A, 2000, GASTROENTEROLOGY, V119, P323, DOI 10.1053/gast.2000.9361; ROTH KA, 1991, P NATL ACAD SCI USA, V88, P9407, DOI 10.1073/pnas.88.21.9407; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Stainier DYR, 2005, SCIENCE, V307, P1902, DOI 10.1126/science.1108709; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703	71	546	577	1	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1904	1909		10.1126/science.1104815	http://dx.doi.org/10.1126/science.1104815			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790842				2022-12-28	WOS:000227957300043
J	Rickaby, REM; Halloran, P				Rickaby, REM; Halloran, P			Cool La Nina during the warmth of the Pliocene?	SCIENCE			English	Article							EQUATORIAL PACIFIC; INDONESIAN THROUGHFLOW; WATER CIRCULATION; CLIMATE-CHANGE; OCEAN; TEMPERATURE; PALEOSALINITY; GREENHOUSE; SEAWATER; MG	The role of El Nino-Southern Oscillation (ENSO) in greenhouse warming and climate change remains controversial. During the warmth of the early-mid Pliocene, we find evidence for enhanced thermocline tilt and cold upwelling in the equatorial Pacific, consistent with the prevalence of a La Nina-like state, rather than the proposed persistent warm El Nino-like conditions. Our Pliocene paleothermometer supports the idea of a dynamic "ocean thermostat" in which heating of the tropical Pacific leads to a cooling of the east equatorial Pacific and a La Nina-like state, analogous to observations of a transient increasing east-west sea surface temperature gradient in the 20th-century tropical Pacific.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	University of Oxford	Rickaby, REM (corresponding author), Univ Oxford, Dept Earth Sci, Parks Rd, Oxford OX1 3PR, England.		Halloran, Paul R/G-3965-2012	Halloran, Paul R/0000-0002-9227-0678; Rickaby, Rosalind/0000-0002-6095-8419				Anand P, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000846; Billups K, 1998, PALEOCEANOGRAPHY, V13, P84, DOI 10.1029/97PA02995; Boccaletti G, 2004, J PHYS OCEANOGR, V34, P888, DOI 10.1175/1520-0485(2004)034<0888:TTSOTU>2.0.CO;2; Brown SJ, 1996, PALEOCEANOGRAPHY, V11, P543, DOI 10.1029/96PA01491; Budyko M. I., 1987, ANTHROPOGENIC CLIMAT; Cai WJ, 2000, GEOPHYS RES LETT, V27, P2577, DOI 10.1029/1999GL011253; Cane M. A., 2004, EARTH PLANET SC LETT, V164, P1; Cane MA, 2001, NATURE, V411, P157, DOI 10.1038/35075500; Cane MA, 1997, SCIENCE, V275, P957, DOI 10.1126/science.275.5302.957; Cannariato KG, 1997, PALEOCEANOGRAPHY, V12, P805, DOI 10.1029/97PA02514; Chaisson WP, 2000, PALEOCEANOGRAPHY, V15, P497, DOI 10.1029/1999PA000442; Clement AC, 1996, J CLIMATE, V9, P2190, DOI 10.1175/1520-0442(1996)009<2190:AODT>2.0.CO;2; CROWLEY TJ, 1991, QUATERNARY SCI REV, V10, P275, DOI 10.1016/0277-3791(91)90025-P; FARMER EC, 2000, THESIS COLUMBIA U; Fedorov AV, 2000, SCIENCE, V288, P1997, DOI 10.1126/science.288.5473.1997; Gu DF, 1997, SCIENCE, V275, P805, DOI 10.1126/science.275.5301.805; Hazeleger W, 2004, J PHYS OCEANOGR, V34, P320, DOI 10.1175/1520-0485(2004)034<0320:HCTPOH>2.0.CO;2; Hovan S., 1995, P OCEAN DRILLING PRO, P615, DOI DOI 10.2973/ODP.PROC.SR.138.132.1995; Huber M, 2003, SCIENCE, V299, P877, DOI 10.1126/science.1078766; Izumo T, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015073; King T, 1996, MAR MICROPALEONTOL, V27, P63, DOI 10.1016/0377-8398(95)00052-6; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; Lear CH, 2003, EARTH PLANET SC LETT, V208, P69, DOI 10.1016/S0012-821X(02)01156-1; Lear CH, 2003, EARTH PLANET SC LETT, V210, P425, DOI [10.1016/S0012-821X(03)00164-X, 10.1016/S0012-821X(03)-00164-X]; Levitus S., 1994, WORLD OCEAN ATLAS 19, V4; Maier-Reimer E, 1990, PALEOCEANOGRAPHY, V5, P349, DOI 10.1029/PA005i003p00349; Molnar P, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2001PA000663; Oort AH, 1996, J CLIMATE, V9, P2751, DOI 10.1175/1520-0442(1996)009<2751:OIVITH>2.0.CO;2; Philander SG, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000837; Raymo ME, 1996, MAR MICROPALEONTOL, V27, P313, DOI 10.1016/0377-8398(95)00048-8; Rodgers KB, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016003; Rodgers KB, 1999, J GEOPHYS RES-OCEANS, V104, P20551, DOI 10.1029/1998JC900094; Rodgers KB, 2000, GEOPHYS RES LETT, V27, P2941, DOI 10.1029/1999GL002372; Rohling EJ, 2000, MAR GEOL, V163, P1, DOI 10.1016/S0025-3227(99)00097-3; Rosenthal Y, 2000, PALEOCEANOGRAPHY, V15, P135, DOI 10.1029/1999PA000415; Schmidt GA, 1999, PALEOCEANOGRAPHY, V14, P422, DOI 10.1029/1999PA900008; Sloan LC, 1996, MAR MICROPALEONTOL, V27, P51, DOI 10.1016/0377-8398(95)00063-1; Spero HJ, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000814; Trenberth KE, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2000JD000297	39	68	72	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1948	1952		10.1126/science.1104666	http://dx.doi.org/10.1126/science.1104666			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790852				2022-12-28	WOS:000227957300053
J	Stanulla, M; Schaeffeler, E; Flohr, T; Cario, G; Schrauder, A; Zimmermann, M; Welte, K; Ludwig, WD; Bartram, CR; Zanger, UM; Eichelbaum, M; Schrappe, M; Schwab, M				Stanulla, M; Schaeffeler, E; Flohr, T; Cario, G; Schrauder, A; Zimmermann, M; Welte, K; Ludwig, WD; Bartram, CR; Zanger, UM; Eichelbaum, M; Schrappe, M; Schwab, M			Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMAL RESIDUAL DISEASE; S-METHYLTRANSFERASE; PROGNOSTIC VALUE; POPULATION; 6-MERCAPTOPURINE; QUANTIFICATION; IDENTIFICATION; POLYMORPHISM; PHENOTYPE; ALLELES	Context Early response to multiagent chemotherapy, including mercaptopurine, as measured by minimal residual disease is an important prognostic factor for children with acute lymphoblastic leukemia (ALL). Thiopurine m ethyltransfe rase (TPMT) is involved in the metabolism of mercaptopurine and subject to genetic polymorphism, with heterozygous individuals having intermediate and homozygous mutant individuals having very low TPMT activity. Objective To assess the association of TPMT genotype with minimal residual disease load before and after treatment with mercaptopurine in the early treatment course of childhood ALL. Design, Setting, and Patients TPMT genotyping of childhood ALL patients (n=814) in Germany consecutively enrolled in the ALL-BFM (Berlin-Frankfurt-MOnster) 2000 study from October 1999 to September 2002. Minimal residual disease was analyzed on treatment days 33 and 78 for risk-adapted treatment stratification. A 4-week cycle of mercaptopurine was administered between these 2 minimal residual disease measurements. Patients (n =4) homozygous for a mutant TPMT allele, and consequently deficient in TPMT activity, were treated with reduced doses of mercaptopurine and, therefore, not included in the analyses. Main Outcome Measures Minimal residual disease load before (day 33) and after (day 78) mercaptopurine treatment. Loads smaller than 10(-4) were defined as negative. Results Patients (n =55) heterozygous for allelic variants of TPMT conferring lower enzyme activity had a significantly lower rate of minimal residual disease positivity (9.1%) compared with patients (n=755) with homozygous wild-type alleles (22.8%) on day 78 (P=.02). This translated into a 2.9-fold reduction in risk for patients with wild-type heterozygous alleles (relative risk, 0.34; 95% confidence interval, 0.13-0.86). Conclusions TPMT genotype has a substantial impact on minimal residual disease after administration of mercaptopurine in the early course of childhood ALL, most likely through modulation of mercaptopurine dose intensity. Our findings support a role for minimal residual disease analyses in the assessment of genotype-phenotype associations in multiagent chemotherapeutic trials.	Hannover Med Sch, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany; Heidelberg Univ, Inst Human Genet, Heidelberg, Germany; Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-7000 Stuttgart, Germany; HELIOS Clin Berlin, Dept Hematol Oncol & Tumor Immunol, Robert Rossle Clin, Berlin, Germany; Univ Childrens Hosp, Kiel, Germany	Hannover Medical School; Ruprecht Karls University Heidelberg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Kiel; Schleswig Holstein University Hospital	Stanulla, M (corresponding author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Stanulla.Martin@MH-Hannover.de	Schrappe, Martin/ABA-6144-2020; Cario, Gunnar/D-2535-2010; Stanulla, Martin/N-4674-2017; Schrappe, Martin/A-8109-2010; Zanger, Ulrich M./A-9364-2012; Stanulla, Martin/D-2528-2010; Schwab, Matthias/ABH-7449-2020	Stanulla, Martin/0000-0002-3834-0727; Zanger, Ulrich M./0000-0002-5276-2002; 				BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; BURCHENAL JH, 1953, BLOOD, V8, P965, DOI 10.1182/blood.V8.11.965.965; Cave H, 1998, NEW ENGL J MED, V339, P591, DOI 10.1056/NEJM199808273390904; Ciudad J, 1998, J CLIN ONCOL, V16, P3774, DOI 10.1200/JCO.1998.16.12.3774; Coustan-Smith E, 2000, BLOOD, V96, P2691, DOI 10.1182/blood.V96.8.2691; Dworzak MN, 2002, BLOOD, V99, P1952, DOI 10.1182/blood.V99.6.1952; ELION GB, 1952, J AM CHEM SOC, V74, P411, DOI 10.1021/ja01122a037; Ganiere-Monteil C, 2004, EUR J CLIN PHARMACOL, V60, P89, DOI 10.1007/s00228-004-0732-5; Indjova D, 2003, THER DRUG MONIT, V25, P631, DOI 10.1097/00007691-200310000-00013; Kurzawski M, 2004, THER DRUG MONIT, V26, P541, DOI 10.1097/00007691-200410000-00013; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723; McLeod HL, 1999, BRIT J HAEMATOL, V105, P696, DOI 10.1046/j.1365-2141.1999.01416.x; *NAT CANC I, 1999, COMM TOX CRIT MAN VE; Nyvold C, 2002, BLOOD, V99, P1253, DOI 10.1182/blood.V99.4.1253; Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2; Relling MV, 1999, BLOOD, V93, P2817; Relling MV, 1999, JNCI-J NATL CANCER I, V91, P2001, DOI 10.1093/jnci/91.23.2001; Schaeffeler E, 2004, PHARMACOGENETICS, V14, P407, DOI 10.1097/01.fpc.0000114745.08559.db; Schaeffeler E, 2001, CLIN CHEM, V47, P548; Schrappe M, 2000, LEUKEMIA, V14, P2205, DOI 10.1038/sj.leu.2401973; Silverman LB, 2003, CURR OPIN HEMATOL, V10, P290, DOI 10.1097/00062752-200307000-00007; van der Velden VHJ, 2003, LEUKEMIA, V17, P1013, DOI 10.1038/sj.leu.2402922; van Dongen JJM, 1998, LANCET, V352, P1731, DOI 10.1016/S0140-6736(98)04058-6	24	214	237	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2005	293	12					1485	1489		10.1001/jama.293.12.1485	http://dx.doi.org/10.1001/jama.293.12.1485			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908KA	15784872				2022-12-28	WOS:000227784700028
J	Ali, Y				Ali, Y			Always trust your gut feeling	LANCET			English	Editorial Material									Brown Univ, Dept Med, Providence, RI 02906 USA	Brown University	Ali, Y (corresponding author), Brown Univ, Dept Med, 49 Seekonk St, Providence, RI 02906 USA.	yali@lifespan.org							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR-APR	2005	365	9465					1201	1201		10.1016/S0140-6736(05)71884-5	http://dx.doi.org/10.1016/S0140-6736(05)71884-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794976				2022-12-28	WOS:000227909500034
J	Martines, J; Paul, VK; Bhutta, ZA; Koblinsky, M; Soucat, A; Walker, N; Bahl, R; Fogstad, H; Costello, A				Martines, J; Paul, VK; Bhutta, ZA; Koblinsky, M; Soucat, A; Walker, N; Bahl, R; Fogstad, H; Costello, A		Lancet Neonatal Survival Steering	Neonatal Survival 4 - Neonatal survival: a call for action	LANCET			English	Review							MATERNAL MORTALITY; HUMAN-RESOURCES; HEALTH; MANAGEMENT	To achieve the Millennium Development Goal for child survival (MDG-4), neonatal deaths need to be prevented. Previous papers in this series have presented the size of the problem, discussed cost-effective interventions, and outlined a systematic approach to overcoming health-system constraints to scaling up. We address issues related to improving neonatal survival. Countries should not wait to initiate action. Success is possible in low-income countries and without highly developed technology. Effective, low-cost interventions exist, but are not present in programmes. Specific efforts are needed by safe motherhood and child survival programmes. Improved availability of skilled care during childbirth and family/community-based care through postnatal home visits will benefit mothers and their newborn babies. Incorporation of management of neonatal illness into the integrated management of childhood illness initiative (IMCI) will improve child survival. Engagement of the community and promotion of demand for care are crucial. To halve neonatal mortality between 2000 and 2015 should be one of the targets of MDG-4. Development, implementation, and monitoring of national action plans for neonatal survival is a priority. We estimate the running costs of the selected packages at 90% coverage in the 75 countries with the highest mortality rates to be US$4 center dot 1 billion a year, in addition to current expenditures of $2 center dot 0 billion. About 30% of this money would be for interventions that have specific benefit for the newborn child; the remaining 70% will also benefit mothers and older children, and substantially reduce rates of stillbirths. The cost per neonatal death averted is estimated at $2100 (range $1700-3100). Maternal, neonatal, and child health receive little funding relative to the large numbers of deaths. International donors and leaders of developing countries should be held accountable for meeting their commitments and increasing resources.	WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland; WHO, Dept Reprod Hlth & Res, CH-1211 Geneva, Switzerland; All India Inst Med Sci, WHO Collaborating Ctr Training & Res Newborn Care, Dept Pediat, New Delhi, India; Aga Khan Univ, Dept Paediat & Child Hlth, Karachi, Pakistan; Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; World Bank, Washington, DC 20433 USA; UNICEF, New York, NY USA; Inst Child Hlth, Int Perinatal Care Unit, London, England	University of Geneva; World Health Organization; World Health Organization; All India Institute of Medical Sciences (AIIMS) New Delhi; Aga Khan University; International Centre for Diarrhoeal Disease Research (ICDDR); The World Bank; UNICEF; University of London; University College London	Martines, J (corresponding author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland.	martinesj@who.int						Andersson T, 2000, INT J EPIDEMIOL, V29, P542, DOI 10.1093/ije/29.3.542; [Anonymous], 2004, LANCET, V364, P1555; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Bhandari N, 2003, LANCET, V361, P1418, DOI 10.1016/S0140-6736(03)13134-0; Bhutta ZA, 2002, BRIT MED J, V324, P358; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; Claeson M, 2000, B WORLD HEALTH ORGAN, V78, P1234; Claeson M, 2003, LANCET, V362, P323, DOI 10.1016/S0140-6736(03)13977-3; DADHICH J, 2004, STATE INDIAS NEWBORN; DARMSTADT GL, 2005, EVIDENCE BASED COST; Gwatkin DR, 2004, LANCET, V364, P1557, DOI 10.1016/S0140-6736(04)17324-8; Gwatkin DR, 2004, LANCET, V364, P1273, DOI 10.1016/S0140-6736(04)17145-6; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; Hogberg U, 2004, AM J PUBLIC HEALTH, V94, P1312, DOI 10.2105/AJPH.94.8.1312; Hongoro C, 2004, LANCET, V364, P1451, DOI 10.1016/S0140-6736(04)17229-2; *INT MON FUND, 2004, DEBT REL HEAV IND PO; Khadka N., 2003, SHAPING POLICY MATER, P47; KNIPPENBERG R, 2005, SYSTEMATIC SCALIN NE; LAWN J, 2005, DIS CONTROL PRIORITI; Lawn JE, 2004, LANCET, V364, P399, DOI 10.1016/S0140-6736(04)16783-4; LAWN JE, 2005, LANCET NEONATAL SURV; Macfarlane A, 1999, TUBERCULOSIS NONTUBE, P3; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; Martineau T, 2004, HEALTH POLICY, V70, P1, DOI 10.1016/j.healthpol.2004.01.006; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; *ORG EC COOP DEV, FIN ODA DAT 2003; Paul Vinod K, 2004, Semin Neonatol, V9, P117, DOI 10.1016/j.siny.2003.08.010; Reinikka R., 2002, ASSESSING FRONTLINE; ROSENFIELD A, 1985, LANCET, V2, P83; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; TINKER A, 2005, CONTINUUM CARE SAVE; *UNAIDS, 2002, REP GLOB HIV AIDS EP; Victora CG, 2004, LANCET, V364, P1541, DOI 10.1016/S0140-6736(04)17279-6; *WHO, 2004, IMPR HLTH INF SYST E; WHO, 2001, WORLD HLTH REPORT 20; *WHO, 2004, STRAT DIR IMPR NEWB; *WHO ICM FIGO, 2004, MAK PREGN SAF CRIT R; World Bank, 2004, MAK SERV WORK POOR W; INT MIGRATION HLTH P	39	194	197	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1189	1197		10.1016/S0140-6736(05)71882-1	http://dx.doi.org/10.1016/S0140-6736(05)71882-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794974				2022-12-28	WOS:000227909500032
J	Griesinger, CB; Richards, CD; Ashmore, JF				Griesinger, CB; Richards, CD; Ashmore, JF			Fast vesicle replenishment allows indefatigable signalling at the first auditory synapse	NATURE			English	Article							INNER HAIR-CELLS; RELEASABLE POOL; RIBBON SYNAPSE; EFFERENT SYNAPSES; AFFERENT SYNAPSE; ACTIVE ZONES; GUINEA-PIG; EXOCYTOSIS; ENDOCYTOSIS; COCHLEA	Ribbon-type synapses in inner hair cells of the mammalian cochlea encode the complexity of auditory signals by fast and tonic release through fusion of neurotransmitter-containing vesicles. At any instant, only about 100 vesicles are tethered to the synaptic ribbon, and about 14 of these are docked to the plasma membrane(1,2), constituting the readily releasable pool(3). Although this pool contains about the same number of vesicles as that of conventional synapses(4,5), ribbon release sites operate at rates of about two orders of magnitude higher(3,6,7) and with submillisecond precision(8-11). How these sites replenish their vesicles so efficiently remains unclear(3,12,13). We show here, using two-photon imaging of single release sites in the intact cochlea, that preformed vesicles derived from cytoplasmic vesicle-generating compartments(14) participate in fast release and replenishment. Vesicles were released at a maximal initial rate of 3 per millisecond during a depolarizing pulse, and were replenished at a rate of 1.9 per millisecond. We propose that such rapid resupply of vesicles enables temporally precise and sustained release rates. This may explain how the first auditory synapse can encode with indefatigable precision without having to rely on the slow, local endocytic vesicle cycle(7).	UCL, Dept Physiol, London WC1E 6BT, England; UCL, UCL Ear Inst, London WC1E 6BT, England; Univ Freiburg, Inst Physiol 2, D-79104 Freiburg, Germany	University of London; University College London; University of London; University College London; University of Freiburg	Griesinger, CB (corresponding author), UCL, Dept Physiol, Gower St, London WC1E 6BT, England.	claudius.griesinger@physiologie.uni-freiburg.de; j.ashmore@ucl.ac.uk						Beutner D, 2001, NEURON, V29, P681, DOI 10.1016/S0896-6273(01)00243-4; Edmonds BW, 2004, J PHYSIOL-LONDON, V560, P439, DOI 10.1113/jphysiol.2004.066035; Eisen MD, 2004, J NEUROPHYSIOL, V91, P2422, DOI 10.1152/jn.01130.2003; Fernandez-Alfonso T, 2004, NEURON, V41, P943, DOI 10.1016/S0896-6273(04)00113-8; Glowatzki E, 2002, NAT NEUROSCI, V5, P147, DOI 10.1038/nn796; Griesinger CB, 2002, J NEUROSCI, V22, P3939, DOI 10.1523/JNEUROSCI.22-10-03939.2002; Heidelberger R, 2002, J NEUROPHYSIOL, V88, P98, DOI 10.1152/jn.2002.88.1.98; Holt M, 2004, CURR BIOL, V14, P173, DOI 10.1016/j.cub.2003.12.053; JOHNSON DH, 1980, J ACOUST SOC AM, V68, P1115, DOI 10.1121/1.384982; KIANG NYS, 1965, ACTA OTOLARYNG STOCK, V59, P186, DOI DOI 10.3109/00016486509124552; Lenzi D, 2002, NEURON, V36, P649, DOI 10.1016/S0896-6273(02)01025-5; LIBERMAN MC, 1980, HEARING RES, V3, P189, DOI 10.1016/0378-5955(80)90046-5; MAMMANO F, 1993, NATURE, V365, P838, DOI 10.1038/365838a0; Moser T, 2000, P NATL ACAD SCI USA, V97, P883, DOI 10.1073/pnas.97.2.883; Neves G, 1999, J PHYSIOL-LONDON, V515, P181, DOI 10.1111/j.1469-7793.1999.181ad.x; PALMER AR, 1986, HEARING RES, V24, P1, DOI 10.1016/0378-5955(86)90002-X; Parsons TD, 2003, NEURON, V37, P379, DOI 10.1016/S0896-6273(03)00062-X; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; SAITO K, 1980, J ULTRA MOL STRUCT R, V71, P222, DOI 10.1016/S0022-5320(80)90108-2; Schikorski T, 1997, J NEUROSCI, V17, P5858; SEWELL WF, 1996, SPR HDB AUD, V8, P503; SIEGEL JH, 1981, BRAIN RES, V220, P188, DOI 10.1016/0006-8993(81)90224-9; Slepecky NB, 2000, HEARING RES, V144, P124, DOI 10.1016/S0378-5955(00)00055-1; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; Spicer SS, 1999, J COMP NEUROL, V409, P424; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; vonGersdorff H, 1996, NEURON, V16, P1221, DOI 10.1016/S0896-6273(00)80148-8; vonGersdorff H, 1997, J NEUROSCI, V17, P1919; Zenisek D, 2000, NATURE, V406, P849, DOI 10.1038/35022500	30	97	99	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 12	2005	435	7039					212	215		10.1038/nature03567	http://dx.doi.org/10.1038/nature03567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924ZO	15829919				2022-12-28	WOS:000229021100042
J	Sidor, CA; O'Keefe, FR; Damiani, R; Steyer, JS; Smith, RMH; Larsson, HCE; Sereno, PC; Ide, O; Maga, A				Sidor, CA; O'Keefe, FR; Damiani, R; Steyer, JS; Smith, RMH; Larsson, HCE; Sereno, PC; Ide, O; Maga, A			Permian tetrapods from the Sahara show climate-controlled endemism in Pangaea	NATURE			English	Article							PHYLOGENETIC ANALYSIS; TEMNOSPONDYL; STEREOSPONDYLI; PATTERNS	New fossils from the Upper Permian Moradi Formation of northern Niger(1-6) provide an insight into the faunas that inhabited low-latitude, xeric environments near the end of the Palaeozoic era (similar to 251 million years ago). We describe here two new temnospondyl amphibians, the cochleosaurid Nigerpeton ricqlesi gen. et sp. nov. and the stem edopoid Saharastega moradiensis gen. et sp. nov., as relicts of Carboniferous lineages that diverged 40 - 90 million years earlier(7-9). Coupled with a scarcity of therapsids, the new finds suggest that faunas from the poorly sampled xeric belt that straddled the Equator during the Permian period(10-12) differed markedly from well-sampled faunas that dominated tropical-to-temperate zones to the north and south(13-15). Our results show that long-standing theories of Late Permian faunal homogeneity are probably oversimplified as the result of uneven latitudinal sampling.	New York Coll Osteopath Med, Dept Anat, Old Westbury, NY 11568 USA; Univ Witwatersrand, Bernard Price Inst Palaeontol Res, ZA-2050 Johannesburg, South Africa; Museum Natl Hist Nat, Dept Hist Terre, CNRS, UMR 5143, F-75008 Paris, France; S African Museum, ZA-8000 Cape Town, South Africa; McGill Univ, Redpath Museum, Montreal, PQ H3A 2K6, Canada; Univ Chicago, Dept Organismal Biol & Anat, Chicago, IL 60637 USA; Inst Rech Sci Humaines, Niamey, Niger	New York Institute Technology; University of Witwatersrand; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); McGill University; University of Chicago	Sidor, CA (corresponding author), New York Coll Osteopath Med, Dept Anat, Old Westbury, NY 11568 USA.	casidor@nyit.edu	Larsson, Hans/AAD-4579-2019	Larsson, Hans/0000-0002-6377-4770; Steyer, J.-Sebastien/0000-0003-1835-7852; Maga, Abdoulaye/0000-0002-4684-217X				Angielczyk KD, 2003, ZOOL J LINN SOC-LOND, V139, P157, DOI 10.1046/j.1096-3642.2003.00081.x; BAKKER RT, 1972, NATURE, V238, P81, DOI 10.1038/238081a0; Battail B, 2000, J AFR EARTH SCI, V31, P165, DOI 10.1016/S0899-5362(00)00081-6; Damiani RJ, 2001, ZOOL J LINN SOC-LOND, V133, P379, DOI 10.1006/zjls.2001.0304; de Ricqles A., 1982, Annales de Paleontologie, V68, P33; Dias EV, 2001, AN ACAD BRAS CIENC, V73, P135, DOI 10.1590/S0001-37652001000100011; Gibbs MT, 2002, J GEOL, V110, P33, DOI 10.1086/324204; Jalil NE, 1999, J AFR EARTH SCI, V29, P219, DOI 10.1016/S0899-5362(99)00091-3; Lucas Spencer G., 2002, Canadian Society of Petroleum Geologists Memoir, V19, P479; Marsicano Claudia A., 1998, Bulletin of the Natural History Museum Geology Series, V54, P147; Milner A.R., 1993, P324; Milner AR, 1998, ZOOL J LINN SOC-LOND, V122, P261, DOI 10.1006/zjls.1997.0121; Modesto Sean P., 2000, P17; OKEEFE FR, IN PRESS J VERT PALE; Rees PM, 2002, J GEOL, V110, P1, DOI 10.1086/324203; Rubidge BS, 2001, ANNU REV ECOL SYST, V32, P449, DOI 10.1146/annurev.ecolsys.32.081501.114113; SCHOCH RR, 2000, HDB PALAOHERPETOLO B, V3, P1; Sequeira SEK, 2004, T ROY SOC EDIN-EARTH, V94, P21, DOI 10.1017/S0263593300000511; Sidor Christian A., 2003, Palaeontologia Africana, V39, P45; Taquet P., 1976, GEOLOGIE PALEONTOLOG, P1; Taquet P., 1972, BUREAU RECHERCHES G, V77, P407; Yates AM, 2000, ZOOL J LINN SOC-LOND, V128, P77, DOI 10.1111/j.1096-3642.2000.tb00650.x; Ziegler A.M., 1997, LATE GLACIAL POSTGLA, P111	23	77	82	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	2005	434	7035					886	889		10.1038/nature03393	http://dx.doi.org/10.1038/nature03393			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829962	Green Published			2022-12-28	WOS:000228327600038
J	Deitsch, KW				Deitsch, KW			Malada virulence genes: Controlling expression through chromatin modification	CELL			English	Editorial Material							ANTIGENIC VARIATION		Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Deitsch, KW (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, 1300 York Ave,Box 62, New York, NY 10021 USA.							Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Deitsch KW, 1999, MOL BIOCHEM PARASIT, V101, P107, DOI 10.1016/S0166-6851(99)00062-6; Duraisingh MT, 2005, CELL, V121, P13, DOI 10.1016/j.cell.2005.01.036; Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037; Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274; Kraemer SM, 2003, MOL MICROBIOL, V50, P1527, DOI 10.1046/j.1365-2958.2003.03814.x; Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673; Lavstsen T, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-27; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418	10	7	7	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					1	2		10.1016/j.cell.2005.03.019	http://dx.doi.org/10.1016/j.cell.2005.03.019			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820670	Bronze			2022-12-28	WOS:000228348500001
J	Garboczi, DN				Garboczi, DN			"D" is not for diversity	SCIENCE			English	Editorial Material							CELL ANTIGEN RECEPTOR; DELTA-T-CELLS		NIAID, Struct Biol Sect, Immunogenet Lab, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Garboczi, DN (corresponding author), NIAID, Struct Biol Sect, Immunogenet Lab, Rockville, MD 20852 USA.	dgarboczi@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000835] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams EJ, 2005, SCIENCE, V308, P227, DOI 10.1126/science.1106885; Allison TJ, 2001, NATURE, V411, P820, DOI 10.1038/35081115; Crowley MP, 2000, SCIENCE, V287, P314, DOI 10.1126/science.287.5451.314; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; Li HM, 1998, NATURE, V391, P502, DOI 10.1038/35172; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; Shin S, 2005, SCIENCE, V308, P252, DOI 10.1126/science.1106480; Wingren C, 2000, SCIENCE, V287, P310, DOI 10.1126/science.287.5451.310	9	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					209	210		10.1126/science.1111657	http://dx.doi.org/10.1126/science.1111657			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821077				2022-12-28	WOS:000228273700036
J	Onishi, KH; Baillargeon, R				Onishi, KH; Baillargeon, R			Do 15-month-old infants understand false beliefs?	SCIENCE			English	Article							CHILDRENS KNOWLEDGE; MIND; REPRESENTATION; 2-YEAR-OLD; DECEPTION	For more than two decades, researchers have argued that young children do not understand mental states such as beliefs. Part of the evidence for this claim comes from preschoolers' failure at verbal tasks that require the understanding that others may hold false beliefs. Here, we used a novel nonverbal task to examine 15-month-old infants' ability to predict an actor's behavior on the basis of her true or false belief about a toy's hiding place. Results were positive, supporting the view that, from a young age, children appeal to mental states-goals, perceptions, and beliefs-to explain the behavior of others.	McGill Univ, Dept Psychol, Montreal, PQ H3A 1B1, Canada; Univ Illinois, Dept Psychol, Champaign, IL 61820 USA	McGill University; University of Illinois System; University of Illinois Urbana-Champaign	Onishi, KH (corresponding author), McGill Univ, Dept Psychol, 1205 Dr Penfield Ave, Montreal, PQ H3A 1B1, Canada.	kris.onishi@mcgill.ca	slange, rimke/J-7457-2012		NICHD NIH HHS [R01 HD021104, HD-21104] Funding Source: Medline; NIMH NIH HHS [T32 MH019990, 1 T32MH19990] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD021104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019990] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASTINGTON JW, 1991, BRIT J DEV PSYCHOL, V9, P7, DOI 10.1111/j.2044-835X.1991.tb00859.x; BAILLARGEON R, 2004, MUN ENC COGN ACT M P; Baron-Cohen S., 1997, MINDBLINDNESS ESSAY; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bloom P, 2000, COGNITION, V77, pB25, DOI 10.1016/S0010-0277(00)00096-2; CHANDLER M, 1989, CHILD DEV, V60, P1263, DOI 10.2307/1130919; CLEMENTS WA, 1994, COGNITIVE DEV, V9, P377, DOI 10.1016/0885-2014(94)90012-4; Flavell JH, 1999, ANNU REV PSYCHOL, V50, P21, DOI 10.1146/annurev.psych.50.1.21; FLAVELL JH, 1990, COGNITIVE DEV, V5, P1, DOI 10.1016/0885-2014(90)90010-Q; FODOR JA, 1992, COGNITION, V44, P283, DOI 10.1016/0010-0277(92)90004-2; Garnham WA, 2001, DEVELOPMENTAL SCI, V4, P94, DOI 10.1111/1467-7687.00153; GERGELY G, 1995, COGNITION, V56, P165, DOI 10.1016/0010-0277(95)00661-H; GOPNIK A, 1993, BEHAV BRAIN SCI, V16, P1, DOI 10.1017/S0140525X00028636; Hare B, 2001, ANIM BEHAV, V61, P139, DOI 10.1006/anbe.2000.1518; Heyes CM, 1998, BEHAV BRAIN SCI, V21, P101, DOI 10.1017/S0140525X98000703; LESLIE AM, 1987, PSYCHOL REV, V94, P412, DOI 10.1037/0033-295X.94.4.412; MOSES LJ, 1990, CHILD DEV, V61, P929, DOI 10.2307/1130866; ONeill DK, 1996, CHILD DEV, V67, P659, DOI 10.2307/1131839; ONISHI KH, UNPUB; ONISHI KH, 2004, INT C INF STUD CHIC; Perner J, 1991, UNDERSTANDING REPRES; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Premack David, 1995, P205; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; WELLMAN HM, 1988, COGNITION, V30, P239, DOI 10.1016/0010-0277(88)90021-2; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Woodward AL, 1998, COGNITION, V69, P1, DOI 10.1016/S0010-0277(98)00058-4; ZAITCHIK D, 1990, COGNITION, V35, P41, DOI 10.1016/0010-0277(90)90036-J; [No title captured]	30	1171	1192	10	284	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					255	258		10.1126/science.1107621	http://dx.doi.org/10.1126/science.1107621			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	915BX	15821091	Green Accepted			2022-12-28	WOS:000228273700054
J	Zhou, FQ; Snider, WD				Zhou, FQ; Snider, WD			GSK-3 beta and microtubule assembly in axons	SCIENCE			English	Editorial Material							GSK3-BETA PHOSPHORYLATION; NEURONAL POLARITY; GROWTH; GUIDANCE; PROTEIN; KINASE; MULTITASKING; MECHANISMS; UPSTREAM; BINDING		Univ N Carolina, Sch Med, Ctr Neurosci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Zhou, FQ (corresponding author), Univ N Carolina, Sch Med, Ctr Neurosci, Chapel Hill, NC 27599 USA.	wsnider@med.unc.edu						Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001; Atwal JK, 2003, J NEUROSCI, V23, P7602; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Del Rio JA, 2004, CURR BIOL, V14, P840, DOI 10.1016/j.cub.2004.04.046; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Goold RG, 2005, MOL CELL NEUROSCI, V28, P524, DOI 10.1016/j.mcn.2004.11.005; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Krylova O, 2002, NEURON, V35, P1043, DOI 10.1016/S0896-6273(02)00860-7; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Salie R, 2005, NEURON, V45, P189, DOI 10.1016/j.neuron.2005.01.002; Trivedi N, 2005, J CELL SCI, V118, P993, DOI 10.1242/jcs.01697; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; ZHOU F, UNPUB; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	20	132	135	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					211	+		10.1126/science.1110301	http://dx.doi.org/10.1126/science.1110301			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15825222				2022-12-28	WOS:000228273700038
J	Gilron, I; Bailey, JM; Tu, DS; Holden, RR; Weaver, DF; Houlden, RL				Gilron, I; Bailey, JM; Tu, DS; Holden, RR; Weaver, DF; Houlden, RL			Morphine, gabapentin, or their combination for neuropathic pain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; POSTHERPETIC NEURALGIA; DIABETIC-NEUROPATHY; NEURONTIN	Background: The available drugs to treat neuropathic pain have incomplete efficacy and dose-limiting adverse effects. We compared the efficacy of a combination of gabapentin and morphine with that of each as a single agent in patients with painful diabetic neuropathy or postherpetic neuralgia. Methods: In this randomized, double-blind, active placebo-controlled, four-period crossover trial, patients received daily active placebo (lorazepam), sustained-release morphine, gabapentin, and a combination of gabapentin and morphine - each given orally for five weeks. The primary outcome measure was mean daily pain intensity in patients receiving a maximal tolerated dose; secondary outcomes included pain (rated according to the Short-Form McGill Pain Questionnaire), adverse effects, maximal tolerated doses, mood, and quality of life. Results: Of 57 patients who underwent randomization (35 with diabetic neuropathy and 22 with postherpetic neuralgia), 41 completed the trial. Mean daily pain (on a scale from 0 to 10, with higher numbers indicating more severe pain) at a maximal tolerated dose of the study drug was as follows: 5.72 at baseline, 4.49 with placebo, 4.15 with gabapentin, 3.70 with morphine, and 3.06 with the gabapentin-morphine combination (P<0.05 for the combination vs. placebo, gabapentin, and morphine). Total scores on the Short-Form McGill Pain Questionnaire (on a scale from 0 to 45, with higher numbers indicating more severe pain) at a maximal tolerated dose were 14.4 with placebo, 10.7 with gabapentin, 10.7 with morphine, and 7.5 with the gabapentin-morphine combination (P<0.05 for the combination vs. placebo, gabapentin, and morphine). The maximal tolerated doses of morphine and gabapentin were lower (P<0.05) with the combination than for each drug as single agent. At the maximal tolerated dose, the gabapentin-morphine combination resulted in a higher frequency of constipation than gabapentin alone (P<0.05) and a higher frequency of dry mouth than morphine alone (P<0.05). Conclusions: Gabapentin and morphine combined achieved better analgesia at lower doses of each drug than either as a single agent, with constipation, sedation, and dry mouth as the most frequent adverse effects.	Queens Univ, Dept Anesthesiol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Math & Stat, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Psychol, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Med, Div Endocrinol, Kingston, ON K7L 2V7, Canada; Dalhousie Univ, Dept Med, Div Neurol, Halifax, NS, Canada; Dalhousie Univ, Dept Chem, Halifax, NS, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; Dalhousie University; Dalhousie University	Gilron, I (corresponding author), Queens Univ, Dept Anesthesiol, 76 Stuart St, Kingston, ON K7L 2V7, Canada.	gilroni@post.queensu.ca		Holden, Ronald/0000-0002-9070-2510; Weaver, Donald/0000-0003-2042-6220				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; BECK AT, 1993, BECK DEPRESSION INEN; Carlton SM, 1998, PAIN, V76, P201, DOI 10.1016/S0304-3959(98)00043-8; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Dellemijn PLI, 1997, LANCET, V349, P753, DOI 10.1016/S0140-6736(96)09024-1; DICKENSON AH, 1994, PROGR PAIN RES MANAG, V2; Dworkin RH, 2003, ARCH NEUROL-CHICAGO, V60, P1524, DOI 10.1001/archneur.60.11.1524; Eckhardt K, 2000, ANESTH ANALG, V91, P185, DOI 10.1097/00000539-200007000-00035; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Field MJ, 1997, BRIT J PHARMACOL, V121, P1513, DOI 10.1038/sj.bjp.0701320; Fields HL, 1998, NEUROBIOL DIS, V5, P209, DOI 10.1006/nbdi.1998.0204; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gandek, 1997, SF 36 HLTH SURVEY MA; Gilron I, 2000, NEUROLOGY, V55, P964, DOI 10.1212/WNL.55.7.964; Gilron I, 2003, ANESTHESIOLOGY, V98, P1288, DOI 10.1097/00000542-200305000-00037; Hochberg Y, 1987, MULTIPLE COMPARISON; Jones B., 2003, DESIGN ANAL CROSS OV, V2nd; Luo ZD, 2002, J PHARMACOL EXP THER, V303, P1199, DOI 10.1124/jpet.102.041574; Marson AG, 1997, EPILEPSIA, V38, P859, DOI 10.1111/j.1528-1157.1997.tb01251.x; Matthews EA, 2002, ANESTHESIOLOGY, V96, P633, DOI 10.1097/00000542-200203000-00020; MAX MB, 1988, NEUROLOGY, V38, P1427, DOI 10.1212/WNL.38.9.1427; MAX MB, 1994, PROGR PAIN RES MANAG, V2; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Myoshi H, 2001, BONICAS MANAGEMENT P; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P116; Polydefkis M, 2003, JAMA-J AM MED ASSOC, V290, P1371, DOI 10.1001/jama.290.10.1371; Raja SN, 2002, NEUROLOGY, V59, P1015, DOI 10.1212/WNL.59.7.1015; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; Schmader KE, 2002, CLIN J PAIN, V18, P350, DOI 10.1097/00002508-200211000-00002; Shimoyama M, 1997, PAIN, V72, P375, DOI 10.1016/S0304-3959(97)00065-1; Singh L, 1996, PSYCHOPHARMACOLOGY, V127, P1, DOI 10.1007/BF02805968; Turner JA, 2002, PAIN, V99, P91, DOI 10.1016/S0304-3959(02)00060-X; Watson CPN, 2003, PAIN, V105, P71, DOI 10.1016/S0304-3959(03)00160-X	34	710	750	0	55	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1324	1334		10.1056/NEJMoa042580	http://dx.doi.org/10.1056/NEJMoa042580			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800228				2022-12-28	WOS:000227998300009
J	Jessen, JR; Solnica-Krezel, L				Jessen, JR; Solnica-Krezel, L			Axis formation - beta-catenin catches a Wnt	CELL			English	Editorial Material							CONVERGENT EXTENSION MOVEMENTS; GASTRULATION; INDUCTION	In this issue of Cell, the Heasman group implicates Wnt11 as a component of the canonical Wnt signaling pathway that specifies Xenopus laevis axis formation (Tao et al., 2005). This important work not only identifies a long-sougot-after dorsalizing factor but also highlights the pivotal role of extracellular cofactors in specifying the activation of either canonical or noncanonical Wnt pathways.	Vanderbilt Univ, Dept Sci Biol, Nashville, TN 37235 USA	Vanderbilt University	Jessen, JR (corresponding author), Vanderbilt Univ, Dept Sci Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.							FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; Hibi M, 2002, RES PRO CEL, V40, P48; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Ohkawara B, 2003, DEVELOPMENT, V130, P2129, DOI 10.1242/dev.00435; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; WEAVER C, 2004, J CELL BIOL, V162, P889	9	9	9	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 25	2005	120	6					736	737		10.1016/j.cell.2005.03.005	http://dx.doi.org/10.1016/j.cell.2005.03.005			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797375	Bronze			2022-12-28	WOS:000228067500004
J	Shimmi, O; Umulis, D; Othmer, H; O'Connor, MB				Shimmi, O; Umulis, D; Othmer, H; O'Connor, MB			Facilitated transport of a Dpp/Scw heterodimer by Sog/Tsg leads to robust patterning of the Drosophila blastoderm embryo	CELL			English	Article							SHORT GASTRULATION GENE; DORSAL-VENTRAL PATTERN; TWISTED GASTRULATION; ACTIVITY GRADIENT; GROWTH-FACTOR; BETA FAMILY; MORPHOGEN GRADIENT; I RECEPTORS; DPP; SOG	Patterning the dorsal surface of the Drosophila blastoderm embryo requires Decapentaplegic (Dpp) and Screw (Scw), two BMP family members. Signaling by these ligands is regulated at the extracellular level by the BMP binding proteins Sog and Tsg. We demonstrate that Tsg and Sog play essential roles in transporting Dpp to the dorsal-most cells. Furthermore, we provide biochemical and genetic evidence that a heterodimer of Dpp and Scw, but not the Dpp homodimer, is the primary transported ligand and that the heterodimer signals synergistically through the two type I BMP receptors Tkv and Sax. We propose that the use of broadly distributed Dpp homodimers and spatially restricted Dpp/Scw heterodimers produces the biphasic signal that is responsible for specifying the two dorsal tissue types. Finally, we demonstrate mathematically that heterodimer levels can be less sensitive to changes in gene dosage than homodimers, thereby providing further selective advantage for using heterodimers as morphogens.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Howard Hughes Med Inst, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Math, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; Howard Hughes Medical Institute; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	O'Connor, MB (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.	moconnor@mail.med.umn.edu	O'Connor, Michael B/C-9977-2014; Umulis, David/AAB-1312-2021; , 0000-0001-6341-9130/P-9094-2018	O'Connor, Michael B/0000-0002-3067-5506; , 0000-0001-6341-9130/0000-0001-6341-9130	NIGMS NIH HHS [GM29123, R01 GM029123] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029123] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; Ashe HL, 2000, DEVELOPMENT, V127, P3305; Biehs B, 1996, GENE DEV, V10, P2922, DOI 10.1101/gad.10.22.2922; Decotto E, 2001, DEVELOPMENT, V128, P3831; Dorfman R, 2001, DEVELOPMENT, V128, P965; Eldar A, 2002, NATURE, V419, P304, DOI 10.1038/nature01061; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANCOIS V, 1994, GENE DEV, V8, P2602, DOI 10.1101/gad.8.21.2602; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Holley SA, 1997, BIOESSAYS, V19, P281, DOI 10.1002/bies.950190404; Holley SA, 1996, CELL, V86, P607, DOI 10.1016/S0092-8674(00)80134-8; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MASON ED, 1994, GENE DEV, V8, P1489, DOI 10.1101/gad.8.13.1489; Massague J, 2000, GENE DEV, V14, P627; Neul JL, 1998, CELL, V95, P483, DOI 10.1016/S0092-8674(00)81616-5; Nguyen M, 1998, CELL, V95, P495, DOI 10.1016/S0092-8674(00)81617-7; Oelgeschlager M, 2000, NATURE, V405, P757, DOI 10.1038/35015500; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Raftery LA, 2003, TRENDS GENET, V19, P701, DOI 10.1016/j.tig.2003.10.009; RAY RP, 1991, DEVELOPMENT, V113, P35; Ross JJ, 2001, NATURE, V410, P479, DOI 10.1038/35068578; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; Rushlow C, 2001, GENE DEV, V15, P340, DOI 10.1101/gad.861401; Schier AF, 2001, CURR OPIN GENET DEV, V11, P393, DOI 10.1016/S0959-437X(00)00209-4; Schmid B, 2000, DEVELOPMENT, V127, P957; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Shimmi O, 2003, DEVELOPMENT, V130, P4673, DOI 10.1242/dev.00684; Srinivasan S, 2002, DEV CELL, V2, P91, DOI 10.1016/S1534-5807(01)00097-1; WHARTON KA, 1993, DEVELOPMENT, V117, P807	33	230	237	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					873	886		10.1016/j.cell.2005.02.009	http://dx.doi.org/10.1016/j.cell.2005.02.009			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797386	Bronze, Green Accepted			2022-12-28	WOS:000228067500015
J	Benabid, F; Couny, F; Knight, JC; Birks, TA; Russell, PS				Benabid, F; Couny, F; Knight, JC; Birks, TA; Russell, PS			Compact, stable and efficient all-fibre gas cells using hollow-core photonic crystal fibres	NATURE			English	Article							ACETYLENE; SHIFT; LASER; RB	Gas-phase materials are used in a variety of laser-based applications - for example, in high- precision frequency measurement(1,2), quantum optics and nonlinear optics(3,4). Their full potential has however not been realized because of the lack of a suitable technology for creating gas cells that can guide light over long lengths in a single transverse mode while still offering a high level of integration in a practical and compact set-up or device. As a result, solid-phase materials are still often favoured, even when their performance compares unfavourably with gas-phase systems. Here we report the development of all-fibre gas cells that meet these challenges. Our structures are based on gas-filled hollow-core photonic crystal fibres, in which we have recently demonstrated substantially enhanced stimulated Raman scattering(5,6), and which exhibit high performance, excellent long-term pressure stability and ease of use. To illustrate the practical potential of these structures, we report two different devices: a hydrogen-filled cell for efficient generation of rotational Raman scattering using only quasi-continuous-wave laser pulses; and acetylene-filled cells, which we use for absolute frequency-locking of diode lasers with very high signal-to-noise ratios. The stable performance of these compact gas-phase devices could permit, for example, gas-phase laser devices incorporated in a 'credit card' or even in a laser pointer.	Univ Bath, Dept Phys, Photon & Photon Mat Grp, Bath BA2 7AY, Avon, England	University of Bath	Benabid, F (corresponding author), Univ Bath, Dept Phys, Photon & Photon Mat Grp, Bath BA2 7AY, Avon, England.	pysab@bath.ac.uk	Birks, Tim A/GNW-3099-2022; Russell, Philip St.J./G-5132-2012; Knight, Jonathan C/D-3879-2011	Russell, Philip St.J./0000-0002-8972-2477; Knight, Jonathan C/0000-0002-0802-8804; Birks, Tim/0000-0001-7984-4932	Engineering and Physical Sciences Research Council [GR/S20178/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Benabid F, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.123903; Benabid F, 2002, SCIENCE, V298, P399, DOI 10.1126/science.1076408; Dushman S., 1962, SCI FDN VACUUM TECHN; Hall J., 1992, P SOC PHOTO-OPT INS, V1837, P2; Hansch T. W., 1989, HYDROGEN ATOM, P93; Hentschel M, 2001, NATURE, V414, P509, DOI 10.1038/35107000; Huber A, 1998, PHYS REV LETT, V80, P468, DOI 10.1103/PhysRevLett.80.468; Luiten A N, 2001, FREQUENCY MEASUREMEN; MACADAM KB, 1992, AM J PHYS, V60, P1098, DOI 10.1119/1.16955; MARCUSE D, 1977, AT&T TECH J, V56, P703, DOI 10.1002/j.1538-7305.1977.tb00534.x; Nakagawa K, 1996, J OPT SOC AM B, V13, P2708, DOI 10.1364/JOSAB.13.002708; Onae A, 2000, OPT COMMUN, V183, P181, DOI 10.1016/S0030-4018(00)00854-3; Quinn TJ, 2003, METROLOGIA, V40, P103, DOI 10.1088/0026-1394/40/2/316; Russell P, 2003, SCIENCE, V299, P358, DOI 10.1126/science.1079280; Steinmeyer G, 1999, SCIENCE, V286, P1507, DOI 10.1126/science.286.5444.1507; Swann WC, 2000, J OPT SOC AM B, V17, P1263, DOI 10.1364/JOSAB.17.001263; WIEMAN CE, 1991, REV SCI INSTRUM, V62, P1, DOI 10.1063/1.1142305	17	409	437	3	159	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					488	491		10.1038/nature03349	http://dx.doi.org/10.1038/nature03349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791251				2022-12-28	WOS:000227836000037
J	Hundley, HA; Walter, W; Bairstow, S; Craig, EA				Hundley, HA; Walter, W; Bairstow, S; Craig, EA			Human Mpp11 J protein: Ribosome-tethered molecular chaperones are ubiquitous	SCIENCE			English	Article							NEWLY SYNTHESIZED PROTEINS; SACCHAROMYCES-CEREVISIAE; ATPASE ACTIVITY; NASCENT CHAIN; HSP70; COMPLEX; DNAJ; SSB; TRANSLOCATION; BINDING	The existence of specialized molecular chaperones that interact directly with ribosomes is well established in microorganisms. Such proteins bind polypeptides exiting the ribosomal tunnel and provide a physical link between translation and protein folding. We report that ribosome-associated molecular chaperones have been maintained throughout eukaryotic evolution, as illustrated by Mpp11, the human ortholog of the yeast ribosome-associated J protein Zuo. When expressed in yeast, Mpp11 partially substituted for Zuo by partnering with the multipurpose Hsp70 Ssa, the homolog of mammalian Hsc70. We propose that in metazoans, ribosome-associated Mpp11 recruits the multifunctional soluble Hsc70 to nascent polypeptide chains as they exit the ribosome.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Grad Program Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Craig, EA (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	ecraig@wisc.edu	Hundley, Heather/AAV-2808-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031107] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM031107] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanese V, 2002, NAT STRUCT BIOL, V9, P716, DOI 10.1038/nsb1002-716; Barouch W, 1997, BIOCHEMISTRY-US, V36, P4303, DOI 10.1021/bi962727z; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Craig EA, 2003, CURR OPIN MICROBIOL, V6, P157, DOI 10.1016/S1369-5274(03)00030-4; D'Silva PD, 2003, P NATL ACAD SCI USA, V100, P13839, DOI 10.1073/pnas.1936150100; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Gautschi M, 2002, P NATL ACAD SCI USA, V99, P4209, DOI 10.1073/pnas.062048599; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Horwich A, 2004, NATURE, V431, P520, DOI 10.1038/431520a; Hundley H, 2002, P NATL ACAD SCI USA, V99, P4203, DOI 10.1073/pnas.062048399; Kim SY, 2005, EUKARYOT CELL, V4, P82, DOI 10.1128/EC.4.1.82-89.2005; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Pfund C, 2001, MOL BIOL CELL, V12, P3773, DOI 10.1091/mbc.12.12.3773; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; WALL D, 1994, J BIOL CHEM, V269, P5446; Walsh P, 2004, EMBO REP, V5, P567, DOI 10.1038/sj.embor.7400172; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Yan W, 1998, EMBO J, V17, P4809, DOI 10.1093/emboj/17.16.4809	24	85	89	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2005	308	5724					1032	1034		10.1126/science.1109247	http://dx.doi.org/10.1126/science.1109247			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927JR	15802566				2022-12-28	WOS:000229190700049
J	Ferrer, RL; Hambidge, SJ; Maly, RC				Ferrer, RL; Hambidge, SJ; Maly, RC			The essential role of generalists in health care systems	ANNALS OF INTERNAL MEDICINE			English	Article							CALIFORNIA KAISER-PERMANENTE; UNITED-STATES; MEDICAL-CARE; REGIONAL-VARIATIONS; FAMILY PHYSICIANS; AMBULATORY-CARE; COMMON SYMPTOMS; OUTCOMES; MORTALITY; SERVICES	Viewing primary care as merely one of the many niches in individual patient care fosters a narrow perspective that neither accounts for the full value of primary care nor offers proper guidance for reforming it. Instead, a systems view better articulates primary care's essential role in increasing the effectiveness and efficiency of other health care services. Primary care improves health care system functioning through such services as managing and triaging undifferentiated symptoms, matching patient needs to health care resources, and enhancing the system's ability to adapt to new circumstances. By acting as an appropriate filter for high-technology care, primary care helps ensure that it is appropriately applied, a major determinant of outcomes. Furthermore, because primary care is the most financially and geographically accessible arm of the health care system, it reduces socioeconomic and geographic disparities across the population. Even in the de facto health system that exists in the United States, these functions are necessary for the efficient, equitable, and sustainable delivery of health care and the adaptability and resilience of the system as a whole. As primary care reforms proceed, it will be important to explicitly consider how to support and strengthen its system-level benefits. Needed reforms include enabling universal access to primary care and providing the leadership, training, and infrastructure support to improve its performance as a central hub in the network of patients, clinicians, and communities. It is important that health systems realize the essential integrative function of primary care.	Univ Texas, Hlth Sci Ctr, Dept Family & Community Med, San Antonio, TX 78229 USA; Univ Colorado, Sch Med, Denver, CO 80202 USA; Denver Hlth Med Ctr, Denver, CO USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90024 USA	University of Texas System; University of Texas Health San Antonio; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ferrer, RL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Family & Community Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	ferrerr@uthscsa.edu	Ferrer, Robert/A-6854-2009	Hambidge, Simon/0000-0002-7535-0668				ABELSON R, 2004, NY TIMES        1101, pA1; Ackoff R., 1999, ACKOFFS BEST CLASSIC; [Anonymous], 1999, DEV FREEDOM; Arthur WB, 1999, SCIENCE, V284, P107, DOI 10.1126/science.284.5411.107; Baicker K, 2004, HEALTH AFFAIR, V23, pW4184, DOI 10.1377/hlthaff.W4.184; Bar-Yam Y, 2004, COMPLEXITY, V9, P15, DOI 10.1002/cplx.20029; Bar-Yam Y., 2005, MAKING THINGS WORK S; BECKER LA, 1993, J FAM PRACTICE, V37, P135; BLUMENTHAL D, 1995, HEALTH SERV RES, V30, P253; Bodenheimer T, 1999, JAMA-J AM MED ASSOC, V281, P2045, DOI 10.1001/jama.281.21.2045; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; BRODY H, 1981, J FAM PRACTICE, V12, P977; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSELL EJ, 1995, MILBANK Q, V73, P373, DOI 10.2307/3350372; Council on Graduate Medical Education, 1998, PHYS DISTR HLTH CAR; Culpepper L, 1999, LANCET, V353, P829, DOI 10.1016/S0140-6736(98)09101-6; Dea RA, 2000, PSYCHIAT QUART, V71, P17, DOI 10.1023/A:1004610616732; Donaldson M, 1996, PRIMARY CARE AM HLTH; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; Fiscella K, 2002, MED CARE, V40, P52, DOI 10.1097/00005650-200201000-00007; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher ES, 1999, JAMA-J AM MED ASSOC, V281, P446, DOI 10.1001/jama.281.5.446; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FRY J, 1994, PRIMARY HLHT CARE IN; Fryer GE, 2001, AM FAM PHYSICIAN, V63, P1669; Fullerton D, 1998, NATURE, V395, P433, DOI 10.1038/26606; Gabel J, 2003, HEALTH AFFAIR, V22, P117, DOI 10.1377/hlthaff.22.5.117; Green LA, 2001, NEW ENGL J MED, V344, P2021, DOI 10.1056/NEJM200106283442611; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; GRUMBACH K, 1993, NEW ENGL J MED, V328, P940, DOI 10.1056/NEJM199304013281308; Grumbach Kevin, 2003, Ann Fam Med, V1, P97, DOI 10.1370/afm.49; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Hueston WJ, 2004, FAM MED, V36, P359; Institute of Medicine, 2001, CROSSING QUALITY CHA; Jones R, 1996, NAT MED, V2, P959, DOI 10.1038/nm0996-959; Kleinke JD, 1998, BLEEDING EDGE BUSINE; KROENKE K, 1989, AM J MED, V86, P262, DOI 10.1016/0002-9343(89)90293-3; Larizgoitia I, 1997, HEALTH POLICY, V41, P121, DOI 10.1016/S0168-8510(97)00017-1; LEE PR, 1994, LANCET, V344, P1484, DOI 10.1016/S0140-6736(94)90295-X; Levin S., 1999, FRAGILE DOMINION; LEVIN SA, 1992, ECOLOGY, V73, P1943, DOI 10.2307/1941447; Maciejewski ML, 2002, MED CARE, V40, P587, DOI 10.1097/00005650-200207000-00005; Macinko J, 2003, HEALTH SERV RES, V38, P831, DOI 10.1111/1475-6773.00149; Madden CW, 1999, HEALTH SERV RES, V33, P1651; Mainous AG, 1998, AM J PUBLIC HEALTH, V88, P1539, DOI 10.2105/AJPH.88.10.1539; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; McMichael T., 2001, HUMAN FRONTIERS ENV; McWhinney I, 1997, TXB FAMILY MED; Meredith LS, 2001, MED CARE, V39, P349, DOI 10.1097/00005650-200104000-00006; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; Moore G, 2003, ANN INTERN MED, V138, P244, DOI 10.7326/0003-4819-138-3-200302040-00032; MOORE GT, 1992, MILBANK Q, V70, P361, DOI 10.2307/3350064; Murray M, 2003, JAMA-J AM MED ASSOC, V289, P1042, DOI 10.1001/jama.289.8.1042; Newhouse JP, 1993, FREE ALL LESSONS RAN; Nutting P, 1990, COMMUNITY ORIENTED P; Okkes IM, 2002, J FAM PRACTICE, V51, P31; ORTON P, 1994, LANCET, V344, P1413; PATCHMAN ML, 2004, FAM MED, V36, P22; PHILIBERT I, 2004, ACGME B, V10, P1; Pincus HA, 2001, GEN HOSP PSYCHIAT, V23, P311, DOI 10.1016/S0163-8343(01)00165-7; PLSEK PE, 2001, CROSSING QUALIT CHAS; Reich JM, 2002, CHEST, V121, P32, DOI 10.1378/chest.121.1.32; Roos N P, 1979, Inquiry, V16, P73; Rose G., 1992, STRATEGY PREVENTATIV; Rosser WW, 1996, J FAM PRACTICE, V42, P139; Rubenstein LV, 1996, ACAD MED, V71, P772, DOI 10.1097/00001888-199607000-00009; Safran DG, 2003, ANN INTERN MED, V138, P248, DOI 10.7326/0003-4819-138-3-200302040-00033; Sandy LG, 2003, ANN INTERN MED, V138, P262, DOI 10.7326/0003-4819-138-3-200302040-00035; SCHOEN CR, 2004, HLTH AFFAIRS; Schroeder SA, 2002, ACAD MED, V77, P767, DOI 10.1097/00001888-200208000-00003; Shi L, 2004, J EPIDEMIOL COMMUN H, V58, P374, DOI 10.1136/jech.2003.013078; Shi L, 2002, HEALTH SERV RES, V37, P529, DOI 10.1111/1475-6773.t01-1-00036; SHI LY, 1994, INT J HEALTH SERV, V24, P431, DOI 10.2190/BDUU-J0JD-BVEX-N90B; Showstack J, 2003, ANN INTERN MED, V138, P268, DOI 10.7326/0003-4819-138-3-200302040-00036; Smith J, 2004, REV EFFECTIVENESS PR; Sox HC, 1996, J FAM PRACTICE, V42, P155; Starfield B, 1996, AM J PUBLIC HEALTH, V86, P1365, DOI 10.2105/AJPH.86.10.1365; Starfield B, 2002, HEALTH POLICY, V60, P201, DOI 10.1016/S0168-8510(01)00208-1; Starfield B, 2002, EUR J PUBLIC HEALTH, V12, P51, DOI 10.1093/eurpub/12.1.51; Starfield B, 1998, PRIMARY CARE BALANCI; Starfield B., 1992, PRIMARY CARE CONCEPT; Stevens RA, 2001, FAM MED, V33, P232; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Tu JV, 1997, ANN INTERN MED, V126, P13, DOI 10.7326/0003-4819-126-1-199701010-00002; vanWeel C, 1996, LANCET, V348, P1431, DOI 10.1016/S0140-6736(96)08116-0; VANWEEL C, 1994, LANCET, V344, P1276, DOI 10.1016/S0140-6736(94)90756-0; Walshe K, 2004, BRIT MED J, V329, P871, DOI 10.1136/bmj.329.7471.871; WARE JE, 1993, BRIT MED J, V306, P1429, DOI 10.1136/bmj.306.6890.1429; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Weiss LJ, 1996, AM J PUBLIC HEALTH, V86, P1742, DOI 10.2105/AJPH.86.12.1742; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; Wennberg JE, 2002, BRIT MED J, V325, P961, DOI 10.1136/bmj.325.7370.961; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; Wong MD, 2001, AM J PUBLIC HEALTH, V91, P1889, DOI 10.2105/AJPH.91.11.1889	98	83	87	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					691	699		10.7326/0003-4819-142-8-200504190-00037	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00037			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916TZ	15838088				2022-12-28	WOS:000228410400027
J	Manheimer, E; White, A; Berman, B; Forys, K; Ernst, E				Manheimer, E; White, A; Berman, B; Forys, K; Ernst, E			Meta-analysis: Acupuncture for low back pain	ANNALS OF INTERNAL MEDICINE			English	Review							CHINESE MEDICINE ACUPUNCTURISTS; ELECTRICAL NERVE-STIMULATION; RANDOMIZED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; CHRONIC SPINAL PAIN; TERM-FOLLOW-UP; COMPARING ACUPUNCTURE; SYSTEMATIC REVIEWS; NECK PAIN; MANIPULATION	Background: Low back pain limits activity and is the second most frequent reason for physicians visits. Previous research shows widespread use of acupuncture for low back pain. Purpose: To assess acupuncture's effectiveness for treating low back pain. Data Sources: Randomized, controlled trials were identified through searches of MEDLINE, Cochrane Central, EMBASE, AMED, CINAHL, CISCOM, and GERA databases through August 2004. Additional data sources included previous reviews and personal contacts with colleagues. Study Selection: Randomized, controlled trials comparing needle acupuncture with sham acupuncture, other sham treatments, no additional treatment, or another active treatment for patients with low back pain. Data Extraction: Data were dually extracted for the outcomes of pain, functional status, overall improvement, return to work, and analgesic consumption. In addition, study quality was assessed. Data Synthesis: The 33 randomized, controlled trials that met inclusion criteria were subgrouped according to acute or chronic pain, style of acupuncture, and type of control group used. For the primary outcome of short-term relief of chronic pain, the meta-analyses showed that acupuncture is significantly more effective than sham treatment (standardized mean difference, 0.54 [95% CI, 0.35 to 0.73]; 7 trials) and no additional treatment (standardized mean difference, 0.69 [CI, 0.40 to 0.98]; 8 trials). For patients with acute low back pain, data are sparse and inconclusive. Data are also insufficient for drawing conclusions about acupuncture's short-term effectiveness compared with most other therapies. Limitations: The quantity and quality of the included trials varied. Conclusions: Acupuncture effectively relieves chronic low back pain. No evidence suggests that acupuncture is more effective than other active therapies.	Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21207 USA; Peninsula Med Sch, Plymouth, Devon, England	University System of Maryland; University of Maryland Baltimore; University of Plymouth	Manheimer, E (corresponding author), Univ Maryland, Sch Med, Ctr Integrat Med, 2200 Kernan Dr,Kernan Hosp Mans, Baltimore, MD 21207 USA.	emanheimer@compmed.umm.edu			National Center for Complementary & Integrative Health [R24AT001293] Funding Source: NIH RePORTER; NCCIH NIH HHS [R24 AT001293] Funding Source: Medline	National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ALDERSON P, 2003, REV HDB 5; ALDERSON P, 2004, COCHRANS REV HDB 4 2; Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; Birch S., 1997, COMPLEM THER MED, V5, P8; BIRCH S, 2001, CLIN ACUPUNCT ORIENT, V2, P17; Brinkhaus B, 2003, FORSCH KOMP KLAS NAT, V10, P185, DOI 10.1159/000073474; Carlsson CPO, 2001, CLIN J PAIN, V17, P296, DOI 10.1097/00002508-200112000-00003; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P463; Cherkin DC, 2003, ANN INTERN MED, V138, P898, DOI 10.7326/0003-4819-138-11-200306030-00011; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; COAN RM, 1980, AM J CHINESE MED, V8, P181, DOI 10.1142/S0192415X80000141; DASILVA GJB, 2004, ACUPUNCT MED, V22, P60; DUPLAN B, 1983, SEM HOP PARIS, V59, P3109; EDELIST G, 1976, CAN ANAESTH SOC J, V23, P303, DOI 10.1007/BF03005706; Ernst E, 1998, ARCH INTERN MED, V158, P2235, DOI 10.1001/archinte.158.20.2235; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; GALLACCHI G, 1981, SCHWEIZ MED WSCHR, V111, P1360; GARVEY TA, 1989, SPINE, V14, P962, DOI 10.1097/00007632-198909000-00008; GILES LG, 2003, SPINE, V502, P1502; Giles LGF, 2003, SPINE, V28, P1490, DOI 10.1097/00007632-200307150-00003; Giles LGF, 1999, J MANIP PHYSIOL THER, V22, P376, DOI 10.1016/S0161-4754(99)70082-5; Grant DJ, 1999, PAIN, V82, P9, DOI 10.1016/S0304-3959(99)00027-5; GUNN CC, 1980, SPINE, V5, P279, DOI 10.1097/00007632-198005000-00011; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hiroshi Tsukayama, 2002, CLIN ACUPUNCT ORIENT, V3, P105; Hogeboom CJ, 2001, COMPLEMENT THER MED, V9, P154, DOI 10.1054/ctim.2001.0457; ITO K, 2000, CONTROLLED COMP TRIA; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kalauokalani D, 2001, SPINE, V26, P1418, DOI 10.1097/00007632-200107010-00005; Kerr DP, 2003, CLIN J PAIN, V19, P364, DOI 10.1097/00002508-200311000-00004; Kittang G, 2001, Tidsskr Nor Laegeforen, V121, P1207; KUROSU Y, 1979, NIPPON GAN CHIRYO GA, V28, P31; Kvorning N, 2004, ACTA OBSTET GYN SCAN, V83, P246; LEBARS D, 1979, PAIN, V6, P283, DOI 10.1016/0304-3959(79)90049-6; LEHMANN TR, 1986, PAIN, V26, P277, DOI 10.1016/0304-3959(86)90057-6; Leibing E, 2002, PAIN, V96, P189, DOI 10.1016/S0304-3959(01)00444-4; Lewith G T, 1996, J Altern Complement Med, V2, P79, DOI 10.1089/acm.1996.2.79; Lopacz S, 1979, Neurol Neurochir Pol, V13, P405; MACDONALD AJR, 1983, ANN ROY COLL SURG, V65, P44; MAZIERES B, 1985, WORLD C RHEUM SYDN A, V100, pF53; MENDELSON G, 1983, AM J MED, V74, P49, DOI 10.1016/0002-9343(83)91117-8; Meng CF, 2003, RHEUMATOLOGY, V42, P1508, DOI 10.1093/rheumatology/keg405; Molsberger AF, 2002, PAIN, V99, P579, DOI 10.1016/S0304-3959(02)00269-5; NOBILI C, 1985, MINERVA RIFLESSOTERA, V2, P61; Sakai T., 2001, J JAPAN SOC ACUPUNCT, V51, P175; Sherman KJ, 2001, COMPLEMENT THER MED, V9, P146, DOI 10.1054/ctim.2001.0458; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; Thomas K J, 1999, Complement Ther Med, V7, P91, DOI 10.1016/S0965-2299(99)80087-9; THOMAS M, 1994, ACTA ANAESTH SCAND, V38, P63, DOI 10.1111/j.1399-6576.1994.tb03839.x; Tsukayama Hiroshi, 2002, Acupunct Med, V20, P175; Van Tulder M.W., 1999, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001351, 10.1002/14651858.CD001351]; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; Von Mencke M., 1989, AKUPUNKTUR, V5, P5; VONMENCKE M, 1988, AKUPUNKTUR, V4, P204; Wedenberg K, 2000, ACTA OBSTET GYN SCAN, V79, P331, DOI 10.1034/j.1600-0412.2000.079005331.x; Wolsko PM, 2003, SPINE, V28, P292, DOI 10.1097/00007632-200302010-00018; Yeung CKN, 2003, J ALTERN COMPLEM MED, V9, P479, DOI 10.1089/107555303322284767; Yokoyama M, 2004, ANESTH ANALG, V98, P1552, DOI 10.1213/01.ANE.0000112312.94043.DF; YUE SJ, 1978, ACUPUNCTURE ELECTRO, V3, P323; ZHANG DW, 2002, SHANGHAI J ACUPUCTUR, V21, P22; [张昭勇 Zhang Zhaoyong], 2002, [传感器技术, Sensor technology], V21, P15	63	281	292	3	58	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					651	663		10.7326/0003-4819-142-8-200504190-00014	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00014			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916TZ	15838072				2022-12-28	WOS:000228410400008
J	Syvitski, JPM; Vorosmarty, CJ; Kettner, AJ; Green, P				Syvitski, JPM; Vorosmarty, CJ; Kettner, AJ; Green, P			Impact of humans on the flux of terrestrial sediment to the global coastal ocean	SCIENCE			English	Article							CLIMATE-CHANGE; RIVERS; VARIABILITY; CALIFORNIA; DISCHARGE	Here we provide global estimates of the seasonal flux of sediment, on a river-by-river basis, under modern and prehuman conditions. Humans have simultaneously increased the sediment transport by global rivers through soil erosion (by 2.3 +/- 0.6 billion metric tons per year), yet reduced the flux of sediment reaching the world's coasts (by 1.4 +/- 0.3 billion metric tons per year) because of retention within reservoirs. Over 100 billion metric tons of sediment and 1 to 3 billion metric tons of carbon are now sequestered in reservoirs constructed largely within the past So years. African and Asian rivers carry a greatly reduced sediment load; Indonesian rivers deliver much more sediment to coastal areas.	Univ Colorado, Inst Arctic & Alpine Res, Environm Computat & Imaging Facil, Boulder, CO 80309 USA; Univ New Hampshire, Inst Study Earth Oceans & Space, Water Syst Anal Grp, Durham, NH 03824 USA; Delft Univ Technol, Delft, Netherlands	University of Colorado System; University of Colorado Boulder; University System Of New Hampshire; University of New Hampshire; Delft University of Technology	Syvitski, JPM (corresponding author), Univ Colorado, Inst Arctic & Alpine Res, Environm Computat & Imaging Facil, Boulder, CO 80309 USA.	james.syvitski@colorado.edu	Kettner, Albert/ABI-7635-2020; Syvitski, James P M/L-2008-2013	Kettner, Albert/0000-0002-7191-6521; Syvitski, Jaia/0000-0003-3116-6997				Dearing JA, 2003, GLOBAL PLANET CHANGE, V39, P147, DOI 10.1016/S0921-8181(03)00022-5; Douglas I., 1993, EARTH TRANSFORMED HU, P215; Fekete B M, 1999, 22 GRDC; Hagemann S, 1998, CLIM DYNAM, V14, P17, DOI 10.1007/s003820050205; Hu D, 2001, IGBP PUBLICATION SER, V3, P245; Inman DL, 1999, J GEOL, V107, P251, DOI 10.1086/314346; Liquete C., 2004, OCEANOGRAPHY, V17, P70, DOI [10.5670/oceanog.2004.05, DOI 10.5670/OCEANOG.2004.05]; Marmulla G., 2001, 419 FAO; McLaughlin CJ, 2003, GLOBAL PLANET CHANGE, V39, P191, DOI 10.1016/S0921-8181(03)00024-9; Milliman J.D., 1992, J GEOL, V100, P25; Morehead MD, 2003, GLOBAL PLANET CHANGE, V39, P95, DOI 10.1016/S0921-8181(03)00019-5; Morehead MK, 2001, GLOBAL PLANET CHANGE, V28, P107, DOI 10.1016/S0921-8181(00)00068-0; Pasternack GB, 2001, EARTH SURF PROC LAND, V26, P409, DOI 10.1002/esp.189; RESTROPO JD, IN PRESS GLOBAL PLAN; Smith SV, 2001, GLOBAL BIOGEOCHEM CY, V15, P697, DOI 10.1029/2000GB001341; Syvitski J.P.M., 1987, FJORDS PROCESSES PRO; Syvitski JP, 1999, MAR GEOL, V154, P13, DOI 10.1016/S0025-3227(98)00100-5; Syvitski JPM, 2004, SEDIMENT GEOL, V164, P345, DOI 10.1016/j.sedgeo.2003.11.001; Syvitski JPM, 2003, SEDIMENT GEOL, V162, P5, DOI 10.1016/S0037-0738(03)00232-X; Syvitski JPM, 2003, GLOBAL PLANET CHANGE, V39, P1, DOI 10.1016/S0921-8181(03)00008-0; Syvitski JPM, 2002, POLAR RES, V21, P323, DOI 10.1111/j.1751-8369.2002.tb00087.x; SYVITSKI JPM, IN PRESS J COASTAL R; SYVITSKI JPM, IN PRESS MAR GEOL; SYVITSKI JPM, IN PRESS LOICZ COAST; Vorosmarty CJ, 2000, GLOBAL BIOGEOCHEM CY, V14, P599, DOI 10.1029/1999GB900092; Vorosmarty CJ, 2003, GLOBAL PLANET CHANGE, V39, P169, DOI 10.1016/S0921-8181(03)00023-7; Vorosmarty CJ, 2000, BIOSCIENCE, V50, P753, DOI 10.1641/0006-3568(2000)050[0753:ADOTTW]2.0.CO;2; Walling DE, 2003, GLOBAL PLANET CHANGE, V39, P111, DOI 10.1016/S0921-8181(03)00020-1; Wolanski E, 2000, REG ENVIRON CHANGE, V1, P152, DOI 10.1007/s101130000014; [No title captured], DOI DOI 10.1126/SCIENCE.278.5341.1209C	30	1766	1888	40	688	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 15	2005	308	5720					376	380		10.1126/science.1109454	http://dx.doi.org/10.1126/science.1109454			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831750				2022-12-28	WOS:000228492000042
J	Bussey, DBJ; Fristad, KE; Schenk, PM; Robinson, MS; Spudis, PD				Bussey, DBJ; Fristad, KE; Schenk, PM; Robinson, MS; Spudis, PD			Planetary science - Constant illumination at the lunar north pole	NATURE			English	Editorial Material							MOON; DEPOSITS		Johns Hopkins Univ, Appl Phys Lab, Dept Space, Planetary Explorat Grp, Laurel, MD 20902 USA; Macalester Coll, St Paul, MN 55105 USA; Lunar & Planetary Inst, Houston, TX 77058 USA; Northwestern Univ, Ctr Planetary Sci, Evanston, IL 60208 USA	Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; Macalester College; Northwestern University	Bussey, DBJ (corresponding author), Johns Hopkins Univ, Appl Phys Lab, Dept Space, Planetary Explorat Grp, Laurel, MD 20902 USA.	ben.bussey@jhuapl.edu	Robinson, Mark/ABI-6841-2020					BURKE JD, 1985, LUNAR BASES SPACE AC, P77; Bussey DB, 1999, GEOPHYS RES LETT, V26, P1187, DOI 10.1029/1999GL900213; Bussey DBJ, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016180; BUSSEY DBJ, 2004, CLEMENTINE ATLAS MOO; Feldman WC, 2000, J GEOPHYS RES-PLANET, V105, P4175, DOI 10.1029/1999JE001129; Heiken GH., 1991, LUNAR SOURCEBOOK; NOZETTE S, 1994, SCIENCE, V266, P1835, DOI 10.1126/science.266.5192.1835; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495; Vasavada AR, 1999, ICARUS, V141, P179, DOI 10.1006/icar.1999.6175	9	45	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	2005	434	7035					842	842		10.1038/434842a	http://dx.doi.org/10.1038/434842a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829952	Bronze			2022-12-28	WOS:000228327600028
J	Perner, J; Ruffman, T				Perner, J; Ruffman, T			Infants' insight into the mind: How deep?	SCIENCE			English	Editorial Material							FALSE BELIEF; KNOWLEDGE		Salzburg Univ, Dept Psychol, A-5020 Salzburg, Austria; Univ Otago, Dept Psychol, Dunedin, New Zealand	Salzburg University; University of Otago	Perner, J (corresponding author), Salzburg Univ, Dept Psychol, A-5020 Salzburg, Austria.	josef.perner@sbg.ac.at; tedr@psy.otago.ac.nz						Carey S, 1996, PHILOS SCI, V63, P515, DOI 10.1086/289971; Carpenter M, 2002, BRIT J DEV PSYCHOL, V20, P393, DOI 10.1348/026151002320620316; CLEMENTS WA, 1994, COGNITIVE DEV, V9, P377, DOI 10.1016/0885-2014(94)90012-4; Morton JB, 2002, DEV PSYCHOBIOL, V40, P255, DOI 10.1002/dev.10033; ONeill DK, 1996, CHILD DEV, V67, P659, DOI 10.2307/1131839; Onishi KH, 2005, SCIENCE, V308, P255, DOI 10.1126/science.1107621; PERNER J, 1987, BRIT J DEV PSYCHOL, V5, P125, DOI 10.1111/j.2044-835X.1987.tb01048.x; Povinelli DJ, 2004, MIND LANG, V19, P1, DOI 10.1111/j.1468-0017.2004.00244.x; Ruffman T, 2001, J EXP CHILD PSYCHOL, V80, P201, DOI 10.1006/jecp.2001.2633; Wan HM, 1999, J NEUROSCI, V19, P1142; Wellman HM, 2001, CHILD DEV, V72, P655, DOI 10.1111/1467-8624.00304; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5	12	302	308	1	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					214	216		10.1126/science.1111656	http://dx.doi.org/10.1126/science.1111656			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	915BX	15821079				2022-12-28	WOS:000228273700039
J	Ryu, DY; Shin, K; Drockenmuller, E; Hawker, CJ; Russell, TP				Ryu, DY; Shin, K; Drockenmuller, E; Hawker, CJ; Russell, TP			A generalized approach to the modification of solid surfaces	SCIENCE			English	Article							COPOLYMER THIN-FILMS; DIBLOCK COPOLYMERS; TEMPLATES; ARRAYS	Interfacial interactions underpin phenomena ranging from adhesion to surface wetting. Here, we describe a simple, rapid, and robust approach to modifying solid surfaces, based on an ultrathin cross-linkable film of a random copolymer, which does not rely on specific surface chemistries. Specifically, thin films of benzocyclobutene-functionalized random copolymers of styrene and methyl methacrylate were spin coated or transferred, then thermally crosslinked on a wide variety of metal, metal oxide, semiconductor, and polymeric surfaces, producing a coating with a controlled thickness and well-defined surface energy. The process described can be easily implemented and adapted to other systems.	IBM Corp, Almaden Res Ctr, San Jose, CA 95120 USA; Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA	International Business Machines (IBM); University of Massachusetts System; University of Massachusetts Amherst	Hawker, CJ (corresponding author), IBM Corp, Almaden Res Ctr, 650 Harry Rd, San Jose, CA 95120 USA.	hawker@mrt.ucsb.edu; russell@mail.pse.umass.edu	Ryu, Du Yeol/G-8278-2012; Hawker, Craig J/G-4971-2011; Drockenmuller, Eric/AAJ-5571-2020; Russell, Thomas Paul/ADL-3689-2022	Hawker, Craig J/0000-0001-9951-851X; Russell, Thomas Paul/0000-0001-6384-5826; Drockenmuller, Eric/0000-0003-0575-279X				ANASTASIADIS SH, 1989, PHYS REV LETT, V62, P1852, DOI 10.1103/PhysRevLett.62.1852; Avgeropoulos A, 1998, CHEM MATER, V10, P2109, DOI 10.1021/cm970682y; Black CT, 2001, APPL PHYS LETT, V79, P409, DOI 10.1063/1.1383805; CHAUDHURY MK, 1992, SCIENCE, V256, P1539, DOI 10.1126/science.256.5063.1539; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; COULON G, 1989, MACROMOLECULES, V22, P2581, DOI 10.1021/ma00196a006; Genzer J, 2000, SCIENCE, V290, P2130, DOI 10.1126/science.290.5499.2130; Huang E, 1998, NATURE, V395, P757, DOI 10.1038/27358; Mansky P, 1997, SCIENCE, V275, P1458, DOI 10.1126/science.275.5305.1458; Mansky P, 1996, APPL PHYS LETT, V68, P2586, DOI 10.1063/1.116192; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; Russell TP, 2002, SCIENCE, V297, P964, DOI 10.1126/science.1075997; Shin K, 2002, NANO LETT, V2, P933, DOI 10.1021/nl0256560; Thurn-Albrecht T, 2000, SCIENCE, V290, P2126, DOI 10.1126/science.290.5499.2126; Thurn-Albrecht T, 2000, ADV MATER, V12, P787, DOI 10.1002/(SICI)1521-4095(200006)12:11<787::AID-ADMA787>3.0.CO;2-1; WILTZIUS P, 1991, PHYS REV LETT, V66, P3000, DOI 10.1103/PhysRevLett.66.3000	16	471	520	6	272	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					236	239		10.1126/science.1106604	http://dx.doi.org/10.1126/science.1106604			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821087				2022-12-28	WOS:000228273700048
J	Zollikofer, CPE; de Leon, MSP; Lieberman, DE; Guy, F; Pilbeam, D; Likius, A; Mackaye, HT; Vignaud, P; Brunet, M				Zollikofer, CPE; de Leon, MSP; Lieberman, DE; Guy, F; Pilbeam, D; Likius, A; Mackaye, HT; Vignaud, P; Brunet, M			Virtual cranial reconstruction of Sahelanthropus tchadensis	NATURE			English	Article							UPPER MIOCENE; PALEOANTHROPOLOGY; HOMINIDS; HEAD	Previous research in Chad at the Toros-Menalla 266 fossiliferous locality (about 7 million years old) uncovered a nearly complete cranium (TM 266-01-60-1), three mandibular fragments and several isolated teeth attributed to Sahelanthropus tchadensis(1-3). Of this material, the cranium is especially important for testing hypotheses about the systematics and behavioural characteristics of this species, but is partly distorted from fracturing, displacement and plastic deformation. Here we present a detailed virtual reconstruction of the TM 266 cranium that corrects these distortions. The reconstruction confirms that S. tchadensis is a hominid and is not more closely related to the African great apes(4,5). Analysis of the basicranium further indicates that S. tchadensis might have been an upright biped, suggesting that bipedalism was present in the earliest known hominids, and probably arose soon after the divergence of the chimpanzee and human lineages.	Univ Poitiers, Fac Sci, CNRS,UMR 6046, Lab Geobiol Biochronol & Paleontol Humaine, F-86022 Poitiers, France; Univ Zurich Irchel, MultiMedia Lab, Inst Anthropol, CH-8057 Zurich, Switzerland; Harvard Univ, Peabody Museum, Cambridge, MA 02138 USA; Univ Ndjamena, Ndjamena, Chad	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; University of Zurich; Harvard University	Brunet, M (corresponding author), Univ Poitiers, Fac Sci, CNRS,UMR 6046, Lab Geobiol Biochronol & Paleontol Humaine, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	michel.brunet@univ-poitiers.fr	Lund, Laura/H-7335-2012	GUY, Franck/0000-0001-7032-7963				Aiello L, 1990, INTRO HUMAN EVOLUTIO; Brunet M, 2002, NATURE, V419, P582, DOI 10.1038/419582a; Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; De Leon MSP, 1999, ANAT REC, V254, P474; Delattre A., 1960, HOMINISATION CRANE E; Enlow D. H., 1990, FACIAL GROWTH; Gonzalez R. C., 2006, DIGITAL IMAGE PROCES, V3rd; GRAF W, 1995, J ANAT, V186, P55; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; HOLLOWAY RL, 2004, HUMAN FOSSIL RECORD, V4; Kimbel W.H., 2004, HUMAN EVOLUTION SERI; KIMBEL WH, 1984, AM J PHYS ANTHROPOL, V64, P337, DOI 10.1002/ajpa.1330640403; Lieberman DE, 2000, YEARB PHYS ANTHROPOL, V43, P117; McCarthy RC, 2001, ANAT REC, V264, P247, DOI 10.1002/ar.1167; Penin X, 2002, AM J PHYS ANTHROPOL, V118, P50, DOI 10.1002/ajpa.10044; Pickford M, 2002, C R PALEVOL, V1, P191, DOI 10.1016/S1631-0683(02)00028-3; ROHLF FJ, 1990, SYST ZOOL, V39, P40, DOI 10.2307/2992207; Strait DS, 1999, AM J PHYS ANTHROPOL, V108, P205, DOI 10.1002/(SICI)1096-8644(199902)108:2<205::AID-AJPA6>3.0.CO;2-F; Vignaud P, 2002, NATURE, V418, P152, DOI 10.1038/nature00880; White T, 2003, SCIENCE, V299, P1994, DOI 10.1126/science.1078294; Wolpoff MH, 2002, NATURE, V419, P581, DOI 10.1038/419581a; Wood B, 2000, J ANAT, V197, P19, DOI 10.1046/j.1469-7580.2000.19710019.x; Zollikofer CPE, 2002, P ROY SOC B-BIOL SCI, V269, P801, DOI 10.1098/rspb.2002.1960; Zollikofer CPE, 1998, EVOL ANTHROPOL, V6, P41, DOI 10.1002/(SICI)1520-6505(1998)6:2<41::AID-EVAN2>3.0.CO;2-Z; ZOLLIKOFER CPE, 1995, NATURE, V375, P283, DOI 10.1038/375283b0	25	202	213	3	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					755	759		10.1038/nature03397	http://dx.doi.org/10.1038/nature03397			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815628	Green Published			2022-12-28	WOS:000228160700039
J	Snow, V; Barry, P; Fitterman, N; Qaseem, A; Weiss, K				Snow, V; Barry, P; Fitterman, N; Qaseem, A; Weiss, K		Amer College Physicians	Pharmacologic and surgical management of obesity in primary care: A clinical practice guideline from the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							ROUX-EN-Y; GASTRIC BYPASS-SURGERY; INTENTIONAL WEIGHT-LOSS; LOW-FAT DIET; LOW-CARBOHYDRATE; SUBJECTS SOS; LONG-TERM; BARIATRIC SURGERY; CONTROLLED-TRIAL; UNITED-STATES	This guideline is based on the evidence report and accompanying background papers developed by the Southern California Evidence-Based Practice Center. The American College of Physicians nominated this topic to the Agency for Healthcare Research and Quality Evidence-Based Practice Center program as part of a concerted effort to complement the guidelines of the U.S. Preventive Services Task Force. The College recommends that all clinicians refer to the Task Force recommendations as part of an overall strategy for managing overweight and obesity, which should always include appropriate diet and exercise for all patients who are overweight or obese. The intent of this guideline is to provide recommendations based on a review of the evidence on pharmacologic and surgical treatments of obesity. The target audience is all clinicians caring for obese patients, defined as a body mass index of 30 kg/m(2) or greater. This guideline is not intended to be used by commercial weight loss centers or for direct-to-consumer marketing by manufacturers and does not apply to patients with body mass indices below 30 kg/m(2).	Amer Coll Physicians, Philadelphia, PA 19106 USA; Merck Inst Aging & Hlth, Washington, DC USA; Hines VA Hosp, Chicago, IL USA; Northwestern Univ, Chicago, IL 60611 USA	American College of Physicians; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Northwestern University	Snow, V (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	vincenza@acponline.org	Casey, Donald/AFM-6658-2022	Casey, Donald/0000-0002-3820-598X				Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Arterburn DE, 2004, ARCH INTERN MED, V164, P994, DOI 10.1001/archinte.164.9.994; Berg AO, 2003, ANN INTERN MED, V139, P930, DOI 10.7326/0003-4819-139-11-200312020-00012; Blachar A, 2002, RADIOLOGY, V223, P625, DOI 10.1148/radiol.2233011323; Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837; Bray GA, 2003, OBES RES, V11, P722, DOI 10.1038/oby.2003.102; Colditz GA, 1999, MED SCI SPORT EXER, V31, pS663, DOI 10.1097/00005768-199911001-00026; Cooney RN, 2003, OBES SURG, V13, P29, DOI 10.1381/096089203321136557; Courcoulas A, 2003, SURGERY, V134, P613, DOI 10.1016/S0039-6060(03)00306-4; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; FLUM D, 2003, AM COLL SURG 89 ANN; Gadde KM, 2003, JAMA-J AM MED ASSOC, V289, P1820, DOI 10.1001/jama.289.14.1820; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; Haddock CK, 2002, INT J OBESITY, V26, P262, DOI 10.1038/sj.ijo.0801889; Higa KD, 2000, ARCH SURG-CHICAGO, V135, P1029, DOI 10.1001/archsurg.135.9.1029; Karason K, 2000, ARCH INTERN MED, V160, P1797, DOI 10.1001/archinte.160.12.1797; Karason K, 1999, AM J CARDIOL, V83, P1242, DOI 10.1016/S0002-9149(99)00066-1; Karason K, 1999, INT J OBESITY, V23, P948, DOI 10.1038/sj.ijo.0801024; Karlsson J, 1998, INT J OBESITY, V22, P113, DOI 10.1038/sj.ijo.0800553; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Li ZP, 2005, ANN INTERN MED, V142, P532, DOI 10.7326/0003-4819-142-7-200504050-00012; Liu JH, 2003, AM SURGEON, V69, P823; Maggard MA, 2005, ANN INTERN MED, V142, P547, DOI 10.7326/0003-4819-142-7-200504050-00013; McTigue KM, 2003, ANN INTERN MED, V139, P933, DOI 10.7326/0003-4819-139-11-200312020-00013; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Narbro K, 1999, INT J OBESITY, V23, P619, DOI 10.1038/sj.ijo.0800890; Nguyen NT, 2003, J GASTROINTEST SURG, V7, P997, DOI 10.1016/j.gassur.2003.09.016; PiSunyer FX, 1996, CLIN THER, V18, P1006, DOI 10.1016/S0149-2918(96)80057-9; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; SCHAUER P, 2003, LEARNING CURVE LAPAR, V17, P406; SHEKELLE P, AHRQ PUBLICATION; Sjostrom CD, 2000, HYPERTENSION, V36, P20, DOI 10.1161/01.HYP.36.1.20; Sjostrom CD, 1999, OBES RES, V7, P477; Sjostrom CD, 2001, OBES RES, V9, P188, DOI 10.1038/oby.2001.20; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Sturm R, 2003, ARCH INTERN MED, V163, P2146, DOI 10.1001/archinte.163.18.2146; Suter M, 2003, SURG ENDOSC, V17, P603, DOI 10.1007/s00464-002-8952-1; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Wadden T A, 1995, Obes Res, V3, P549; Wittgrove AC, 2000, OBES SURG, V10, P233, DOI 10.1381/096089200321643511; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	42	190	206	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 5	2005	142	7					525	531		10.7326/0003-4819-142-7-200504050-00011	http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913QL	15809464				2022-12-28	WOS:000228167800006
J	Banerjee, A; Yang, W; Karplus, M; Verdine, GL				Banerjee, A; Yang, W; Karplus, M; Verdine, GL			Structure of a repair enzyme interrogating undamaged DNA elucidates recognition of damaged DNA	NATURE			English	Article							FREE-ENERGY SIMULATIONS; CRYSTAL-STRUCTURE; SUBSTRATE RECOGNITION; REVERSE-TRANSCRIPTASE; PROTEIN; GLYCOSYLASE; 8-OXOGUANINE; CATALYSIS; COMPLEX; BASES	How DNA repair proteins distinguish between the rare sites of damage and the vast expanse of normal DNA is poorly understood. Recognizing the mutagenic lesion 8-oxoguanine (oxoG) represents an especially formidable challenge, because this oxidized nucleobase differs by only two atoms from its normal counterpart, guanine (G). Here we report the use of a covalent trapping strategy to capture a human oxoG repair protein, 8-oxogunanine DNA glycosylase I (hOGG1), in the act of interrogating normal DNA. The X-ray structure of the trapped complex features a target G nucleobase extruded from the DNA helix but denied insertion into the lesion recognition pocket of the enzyme. Free energy difference calculations show that both attractive and repulsive interactions have an important role in the preferential binding of oxoG compared with G to the active site. The structure reveals a remarkably effective gate-keeping strategy for lesion discrimination and suggests a mechanism for oxoG insertion into the hOGG1 active site.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Univ Strasbourg 1, ISIS, F-67000 Strasbourg, France	Harvard University; Harvard University; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Karplus, M (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	marci@tammy.harvard.edu; verdine@chemistry.harvard.edu	Yang, Wei/H-5428-2011; Banerjee, Anirban/AAC-4286-2020	Banerjee, Anirban/0000-0002-9314-2862; banerjee, anirban/0000-0003-1494-6801	NATIONAL CANCER INSTITUTE [R01CA100742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044853] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100742] Funding Source: Medline; NIGMS NIH HHS [R01 GM044853] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASH PA, 1991, BIOCHEMISTRY-US, V30, P5826, DOI 10.1021/bi00238a003; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; Bjoras M, 2002, J MOL BIOL, V317, P171, DOI 10.1006/jmbi.2002.5400; BROOKS CL, 1988, ADV CHEM PHYS, V71; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; Cappelli E, 2001, CARCINOGENESIS, V22, P387, DOI 10.1093/carcin/22.3.387; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P379; CERVI AR, 1993, NUCLEIC ACIDS RES, V21, P5623, DOI 10.1093/nar/21.24.5623; Cui Q, 2001, J PHYS CHEM B, V105, P569, DOI 10.1021/jp0029109; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Fromme JC, 2004, NATURE, V427, P652, DOI 10.1038/nature02306; Fromme JC, 2003, NAT STRUCT BIOL, V10, P204, DOI 10.1038/nsb902; Gao YG, 1998, NAT STRUCT BIOL, V5, P782, DOI 10.1038/1822; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang HF, 2000, CHEM BIOL, V7, P355, DOI 10.1016/S1074-5521(00)00113-7; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MACMILLAN AM, 1991, TETRAHEDRON, V47, P2603, DOI 10.1016/S0040-4020(01)81793-2; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Norman DPG, 2003, BIOCHEMISTRY-US, V42, P1564, DOI 10.1021/bi026823d; Norman DPG, 2001, J AM CHEM SOC, V123, P359, DOI 10.1021/ja003144m; O'Brien PJ, 2004, J BIOL CHEM, V279, P26876, DOI 10.1074/jbc.M403860200; Robinson H, 1998, NATURE, V392, P202, DOI 10.1038/32455; Schaefer M, 1997, J PHYS CHEM B, V101, P1663, DOI 10.1021/jp962972s; Simonson T, 2002, ACCOUNTS CHEM RES, V35, P430, DOI 10.1021/ar010030m; SIMONSON T, 1997, J PHYS CHEM-US, V41, P8347; Verdine GL, 2003, ANNU REV BIOCHEM, V72, P337, DOI 10.1146/annurev.biochem.72.121801.161447; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; Yang W, 2004, J CHEM PHYS, V120, P9450, DOI 10.1063/1.1738106	31	290	319	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					612	618		10.1038/nature03458	http://dx.doi.org/10.1038/nature03458			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800616				2022-12-28	WOS:000228011000037
J	Sobolev, AV; Hofmann, AW; Sobolev, SV; Nikogosian, IK				Sobolev, AV; Hofmann, AW; Sobolev, SV; Nikogosian, IK			An olivine-free mantle source of Hawaiian shield basalts	NATURE			English	Article							GEOCHEMICAL EVIDENCE; MELTING EXPERIMENTS; GHOST PLAGIOCLASE; UPWELLING MANTLE; MIDOCEAN RIDGE; OCEANIC-CRUST; VOLCANO; PLUME; PERIDOTITE; MAGMAS	More than 50 per cent of the Earth's upper mantle consists of olivine and it is generally thought that mantle-derived melts are generated in equilibrium with this mineral. Here, however, we show that the unusually high nickel and silicon contents of most parental Hawaiian magmas are inconsistent with a deep olivine-bearing source, because this mineral together with pyroxene buffers both nickel and silicon at lower levels. This can be resolved if the olivine of the mantle peridotite is consumed by reaction with melts derived from recycled oceanic crust, to form a secondary pyroxenitic source. Our modelling shows that more than half of Hawaiian magmas formed during the past 1 Myr came from this source. In addition, we estimate that the proportion of recycled ( oceanic) crust varies from 30 per cent near the plume centre to insignificant levels at the plume edge. These results are also consistent with volcano volumes, magma volume flux and seismological observations.	Max Planck Inst Chem, D-55020 Mainz, Germany; Russian Acad Sci, Vernadskii Inst Geochem, Moscow 117975, Russia; Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; Russian Acad Sci, Inst Phys Earth, Moscow 123995, Russia; Univ Utrecht, Dept Petrol, Fac Geosci, NL-3584 CD Utrecht, Netherlands; Free Univ Amsterdam, Dept Petrol, Fac Earth & Life Sci, NL-1081 HV Amsterdam, Netherlands	Max Planck Society; Russian Academy of Sciences; Vernadsky Institute of Geochemistry & Analytical Chemistry; Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; Russian Academy of Sciences; Schmidt Institute of Physics of the Earth of the Russian Academy of Sciences; Utrecht University; Vrije Universiteit Amsterdam	Sobolev, AV (corresponding author), Max Planck Inst Chem, Postfach 3060, D-55020 Mainz, Germany.	asobolev@mpch-mainz.mpg.de	Sobolev, Stephan V/G-3813-2011; Sobolev, Alexander/E-6367-2010; Sobolev, Alexander/AAQ-6001-2021; Sobolev, Alexander/AAB-4269-2021	Sobolev, Stephan V/0000-0002-3382-4028; Sobolev, Alexander/0000-0002-1997-2032; Nikogosian, I.K./0000-0002-1270-5134				BEATTIE P, 1991, CONTRIB MINERAL PETR, V109, P212, DOI 10.1007/BF00306480; Bennett VC, 1996, NATURE, V381, P221, DOI 10.1038/381221a0; Blichert-Toft J, 1999, SCIENCE, V285, P879, DOI 10.1126/science.285.5429.879; Brandon AD, 1999, EARTH PLANET SC LETT, V174, P25, DOI 10.1016/S0012-821X(99)00251-4; Danyushevsky LV, 2001, J VOLCANOL GEOTH RES, V110, P265, DOI 10.1016/S0377-0273(01)00213-X; EGGINS SM, 1992, CONTRIB MINERAL PETR, V110, P387, DOI 10.1007/BF00310752; Garcia MO, 2002, GEOPH MONOG SERIES, V128, P391; Garcia MO, 1995, J PETROL, V36, P1647; Gibson SA, 2000, EARTH PLANET SC LETT, V174, P355, DOI 10.1016/S0012-821X(99)00274-5; Haskins EH, 2004, CONTRIB MINERAL PETR, V147, P162, DOI 10.1007/s00410-003-0546-y; Hauri E, 2002, CHEM GEOL, V183, P115, DOI 10.1016/S0009-2541(01)00374-6; Hauri EH, 1997, EARTH PLANET SC LETT, V153, P21, DOI 10.1016/S0012-821X(97)00158-1; Hauri EH, 1996, NATURE, V382, P415, DOI 10.1038/382415a0; Herzberg C, 2002, J PETROL, V43, P1857, DOI 10.1093/petrology/43.10.1857; Herzberg C, 1996, J GEOPHYS RES-SOL EA, V101, P8271, DOI 10.1029/96JB00170; Hirschmann MM, 2003, GEOLOGY, V31, P481, DOI 10.1130/0091-7613(2003)031<0481:AMGBPM>2.0.CO;2; HOFMANN AW, 1982, EARTH PLANET SC LETT, V57, P421, DOI 10.1016/0012-821X(82)90161-3; Humayun M, 2004, SCIENCE, V306, P91, DOI 10.1126/science.1101050; KELEMEN PB, 1995, NATURE, V375, P747, DOI 10.1038/375747a0; Kogiso T, 2004, GEOCHIM COSMOCHIM AC, V68, P345, DOI 10.1016/S0016-7037(03)00419-8; Kogiso T, 2003, EARTH PLANET SC LETT, V216, P603, DOI 10.1016/S0012-821X(03)00538-7; Korzhinskii D. S., 1970, THEORY METASOMATIC Z; Kurz MD, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2002GC000439; Lassiter JC, 1998, EARTH PLANET SC LETT, V164, P483, DOI 10.1016/S0012-821X(98)00240-4; LEHNERT KA, 1998, EOS S, V79, pF44; Li C, 2003, CHEM GEOL, V201, P295, DOI 10.1016/j.chemgeo.2003.08.008; Li X, 2000, NATURE, V405, P938, DOI 10.1038/35016054; Li XQ, 2004, NATURE, V427, P827, DOI 10.1038/nature02349; Manglik A, 1997, J GEOPHYS RES-SOL EA, V102, P5019, DOI 10.1029/96JB03623; Mavrogenes JA, 1999, GEOCHIM COSMOCHIM AC, V63, P1173, DOI 10.1016/S0016-7037(98)00289-0; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; MOORE JG, 1992, GEOL SOC AM BULL, V104, P1471, DOI 10.1130/0016-7606(1992)104<1471:VGAEOT>2.3.CO;2; MORGAN JP, 1995, J GEOPHYS RES-SOL EA, V100, P8045, DOI 10.1029/94JB02887; Ono S, 2001, EARTH PLANET SC LETT, V190, P57, DOI 10.1016/S0012-821X(01)00375-2; Pertermann M, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2000JB000118; Ribe NM, 1999, EARTH PLANET SC LETT, V171, P517, DOI 10.1016/S0012-821X(99)00179-X; Ryabchikov ID, 2003, DOKL EARTH SCI, V389, P437; Sobolev AV, 2000, NATURE, V404, P986, DOI 10.1038/35010098; Sobolev AV., 1994, PETROLOGY+, V2, P111; Stolper EM, 1996, J GEOPHYS RES-SOL EA, V101, P11593, DOI 10.1029/96JB00332; Takahashi E, 2002, GEOPH MONOG SERIES, V128, P403; Van Ark E, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002949; Vidal V, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002559; Wagner TP, 1998, CONTRIB MINERAL PETR, V131, P1, DOI 10.1007/s004100050374; Walter MJ, 1998, J PETROL, V39, P29, DOI 10.1093/petrology/39.1.29; YAROSEWICH EJ, 1980, GEOSTANDARD NEWSLETT, V4, P43; YASUDA A, 1994, J GEOPHYS RES-SOL EA, V99, P9401, DOI 10.1029/93JB03205; Yaxley GM, 2000, CONTRIB MINERAL PETR, V139, P326, DOI 10.1007/s004100000134; Yaxley GM, 2004, GEOCHIM COSMOCHIM AC, V68, pA578; Yaxley GM, 1998, SCHWEIZ MINER PETROG, V78, P243	50	819	889	16	195	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					590	597		10.1038/nature03411	http://dx.doi.org/10.1038/nature03411			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800614				2022-12-28	WOS:000228011000034
J	Stallone, G; Schena, A; Infante, B; Di Paolo, S; Loverre, A; Maggio, G; Ranieri, E; Gesualdo, L; Schena, FP; Grandaliano, G				Stallone, G; Schena, A; Infante, B; Di Paolo, S; Loverre, A; Maggio, G; Ranieri, E; Gesualdo, L; Schena, FP; Grandaliano, G			Sirolimus for Kaposi's sarcoma in renal-transplant recipients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TUMOR-FORMATION; RAPAMYCIN; CYCLOSPORINE; PROGRESSION; AKT; SURVIVAL; INSIGHTS	Background: Recipients of organ transplants are susceptible to Kaposi's sarcoma as a result of treatment with immunosuppressive drugs. Sirolimus (rapamycin), an immunosuppressive drug, may also have antitumor effects. Methods: We stopped cyclosporine therapy in 15 kidney-transplant recipients who had biopsy-proven Kaposi's sarcoma and began sirolimus therapy. All patients underwent an excisional biopsy of the lesion and one biopsy of normal skin at the time of diagnosis. A second biopsy was performed at the site of a previous Kaposi's sarcoma lesion six months after sirolimus therapy was begun. We examined biopsy specimens for vascular endothelial growth factor (VEGF), Flk-1/KDR protein, and phosphorylated Akt and p70S6 kinase, two enzymes in the signaling pathway targeted by sirolimus. Results: Three months after sirolimus therapy was begun, all cutaneous Kaposi's sarcoma lesions had disappeared in all patients. Remission was confirmed histologically in all patients six months after sirolimus therapy was begun. There were no acute episodes of rejection or changes in kidney-graft function. Levels of Flk-1/KDR and phosphorylated Akt and p70S6 kinase were increased in Kaposi's sarcoma cells. The expression of VEGF was increased in Kaposi's sarcoma cells and even more so in normal skin cells around the Kaposi's sarcoma lesions. Conclusions: Sirolimus inhibits the progression of dermal Kaposi's sarcoma in kidney-transplant recipients while providing effective immunosuppression.	Univ Bari, Dept Emergency & Transplantat, Div Nephrol, I-70124 Bari, Italy; Univ Bari, Div Plast Surg, I-70124 Bari, Italy; Univ Foggia, Dept Biomed Sci, Div Nephrol, Foggia, Italy; Univ Foggia, Dept Clin Pathol, Foggia, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Foggia; University of Foggia	Grandaliano, G (corresponding author), Univ Bari, Dept Emergency & Transplantat, Div Nephrol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	g.grandaliano@nephro.uniba.it	Gesualdo, Loreto/K-7751-2016; Ranieri, Elena/AAD-8449-2019; Di+Paolo, Salvatore/AAX-5463-2021; Schena, Francesco P/K-6982-2016; Grandaliano, Giuseppe/J-7822-2016; Grandaliano, Giuseppe/G-2963-2012	Gesualdo, Loreto/0000-0002-4861-0911; Schena, Francesco P/0000-0001-7927-5207; Grandaliano, Giuseppe/0000-0003-1213-2177; Stallone, Giovanni/0000-0002-2862-9017				Campistol JM, 2004, TRANSPLANTATION, V77, P760, DOI 10.1097/01.TP.0000115344.18025.0B; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Doutrelepont JM, 1996, TRANSPLANTATION, V62, P463, DOI 10.1097/00007890-199608270-00007; Freise CE, 1999, TRANSPLANTATION, V67, P510, DOI 10.1097/00007890-199902270-00003; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hayward GS, 2003, CANCER CELL, V3, P1, DOI 10.1016/S1535-6108(03)00002-3; Herman M, 2001, J LAB CLIN MED, V137, P14, DOI 10.1067/mlc.2001.111469; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; Koehl GE, 2004, TRANSPLANTATION, V77, P1319, DOI 10.1097/00007890-200405150-00002; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; Luan FL, 2002, TRANSPLANTATION, V73, P1565, DOI 10.1097/00007890-200205270-00008; Marchio S, 1999, J BIOL CHEM, V274, P27617, DOI 10.1074/jbc.274.39.27617; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Morath C, 2004, J AM SOC NEPHROL, V15, P1582, DOI 10.1097/01.ASN.0000126194.77004.9B; Panwalkar A, 2004, CANCER-AM CANCER SOC, V100, P657, DOI 10.1002/cncr.20026; Penn I, 1995, TRANSPLANTATION, V60, P1485, DOI 10.1097/00007890-199560120-00020; Penn I, 1996, TRANSPLANT P, V28, P876; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Shihab FS, 2001, TRANSPLANTATION, V72, P164, DOI 10.1097/00007890-200107150-00032; Sodhi A, 2004, P NATL ACAD SCI USA, V101, P4821, DOI 10.1073/pnas.0400835101; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wiederrecht G J, 1995, Prog Cell Cycle Res, V1, P53	24	702	736	2	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1317	1323		10.1056/NEJMoa042831	http://dx.doi.org/10.1056/NEJMoa042831			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800227				2022-12-28	WOS:000227998300008
J	Rott, S; Mrowietz, U				Rott, S; Mrowietz, U			Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies	BMJ-BRITISH MEDICAL JOURNAL			English	Review							NECROSIS-FACTOR-ALPHA; RECEIVING CONCOMITANT METHOTREXATE; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; CROHNS-DISEASE; INFUSION REACTIONS; FACTOR INHIBITORS; DOUBLE-BLIND; TNF THERAPY; PHASE-III		Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany	University of Kiel	Mrowietz, U (corresponding author), Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany.	umrowietz@dermatology.uni-kiel.de	Mrowietz, U/B-1645-2010	Mrowietz, U/0000-0002-9539-0712				Antoni C, 2002, CLIN EXP RHEUMATOL, V20, pS152; Augustsson JM, 2004, ANN RHEUM DIS, V63, P180; Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888; Bobbio-Pallavicini F, 2004, ARTHRITIS RES THER, V6, pR264, DOI 10.1186/ar1173; Breedveld FC, 2000, LANCET, V355, P735, DOI 10.1016/S0140-6736(00)01034-5; Brown SL, 2002, ARTHRITIS RHEUM-US, V46, P3151, DOI 10.1002/art.10679; Cassano N, 2004, INT J IMMUNOPATH PH, V17, P373, DOI 10.1177/039463200401700317; Charles PJ, 2000, ARTHRITIS RHEUM, V43, P2383, DOI 10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.3.CO;2-4; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Chew AL, 2004, BRIT J DERMATOL, V151, P492, DOI 10.1111/j.1365-2133.2004.06105.x; De Bandt MJ, 2004, ANN RHEUM DIS, V63, P213; De Rycke L, 2003, ARTHRITIS RHEUM, V48, P1015, DOI 10.1002/art.10876; Debandt M, 2003, CLIN RHEUMATOL, V22, P56, DOI 10.1007/s10067-002-0654-5; Ellis CN, 2001, NEW ENGL J MED, V345, P248, DOI 10.1056/NEJM200107263450403; Farrell RJ, 2003, GASTROENTEROLOGY, V124, P917, DOI 10.1053/gast.2003.50145; Ferraro-Peyret C, 2004, ARTHRITIS RES THER, V6, pR535, DOI 10.1186/ar1440; Furst DE, 2003, J RHEUMATOL, V30, P2563; Furst DE, 2004, ANN RHEUM DIS, V63, P2, DOI 10.1136/ard.2004.029272; Gelfand JM, 2003, ARCH DERMATOL, V139, P1425, DOI 10.1001/archderm.139.11.1425; Gomez-Reino JJ, 2003, ARTHRITIS RHEUM-US, V48, P2122, DOI 10.1002/art.11137; Gottlieb AB, 2004, J AM ACAD DERMATOL, V51, P534, DOI 10.1016/j.jaad.2004.02.021; Gottlieb AB, 2003, ARCH DERMATOL, V139, P1627, DOI 10.1001/archderm.139.12.1627; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; Hall CH, 2003, J CLIN GASTROENTEROL, V36, P332, DOI 10.1097/00004836-200304000-00011; Hamilton CD, 2003, ARTHRITIS RHEUM-US, V48, P2085, DOI 10.1002/art.11134; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Imperato AK, 2004, CURR OPIN RHEUMATOL, V16, P199, DOI 10.1097/00002281-200405000-00006; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Keystone EC, 2004, ARTHRITIS RHEUM, V50, P1400, DOI 10.1002/art.20217; Khanna D, 2004, DRUG SAFETY, V27, P307, DOI 10.2165/00002018-200427050-00003; KINLEN L, 1992, CANCER RES, V52, pS5474; Klapman JB, 2003, INFLAMM BOWEL DIS, V9, P176, DOI 10.1097/00054725-200305000-00005; Krueger GG, 2002, J AM ACAD DERMATOL, V47, P821, DOI 10.1067/mjd.2002.127247; Kwon HJ, 2003, ANN INTERN MED, V138, P807, DOI 10.7326/0003-4819-138-10-200305200-00008; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; Louis M, 2003, J RHEUMATOL, V30, P2557; Mahe E, 2003, BRIT J DERMATOL, V149, P170, DOI 10.1046/j.1365-2133.2003.05384.x; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Mellemkjaer L, 1996, EUR J CANCER, V32A, P1753, DOI 10.1016/0959-8049(96)00210-9; Miele E, 2004, J PEDIATR GASTR NUTR, V38, P502, DOI 10.1097/00005176-200405000-00008; Patel Toral, 2004, Dermatol Ther, V17, P427, DOI 10.1111/j.1396-0296.2004.04045.x; Pendley C, 2003, CURR OPIN MOL THER, V5, P172; Rozin AP, 2004, ANN RHEUM DIS, V63, P751; Sarzi-Puttini P, 2003, DIGEST LIVER DIS, V35, P814, DOI 10.1016/S1590-8658(03)00448-1; Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149-2918(02)80075-3; Shakoor N, 2002, LANCET, V359, P579, DOI 10.1016/S0140-6736(02)07714-0; Sicotte NL, 2001, NEUROLOGY, V57, P1885, DOI 10.1212/WNL.57.10.1885; Stockwin LH, 2003, EXPERT OPIN BIOL TH, V3, P1133, DOI 10.1517/14712598.3.7.1133; Stratigos AJ, 2004, CLIN EXP DERMATOL, V29, P150, DOI 10.1111/j.1365-2230.2004.01471.x; Theofilopoulos AN, 1999, ANN RHEUM DIS, V58, P49, DOI 10.1136/ard.58.2008.i49; Thomas CW, 2004, INFLAMM BOWEL DIS, V10, P28, DOI 10.1097/00054725-200401000-00004; van de Putte BA, 2004, ANN RHEUM DIS, V63, P508, DOI 10.1136/ard.2003.013052; Vermeire S, 2003, GASTROENTEROLOGY, V125, P32, DOI 10.1016/S0016-5085(03)00701-7; VIDAL F, 2003, ANN INTERN MED, V139, pE238; Wagner C L, 2003, Dev Biol (Basel), V112, P37; Weinberg JM, 2003, CUTIS, V71, P25; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weinblatt ME, 2003, ARTHRITIS RHEUM-US, V48, P35, DOI 10.1002/art.10697; Weisman MH, 2002, J RHEUMATOL, V29, P33; Wolbink GJ, 2004, ANN RHEUM DIS, V63, P284; Wood KL, 2003, AM J RESP CRIT CARE, V167, P1279, DOI 10.1164/rccm.200206-563OC; Zeltser R, 2001, ARCH DERMATOL, V137, P893; Ziakas Panayiotis D, 2003, Haematologica, V88, pECR25	64	15	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	2005	330	7493					716	720E		10.1136/bmj.330.7493.716	http://dx.doi.org/10.1136/bmj.330.7493.716			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912IT	15790644	Green Published			2022-12-28	WOS:000228071900021
J	Murphy, DM				Murphy, DM			Something in the air	SCIENCE			English	Editorial Material							AEROSOLS; COMPONENTS		NOAA, Aeron Lab, Boulder, CO 80305 USA	National Oceanic Atmospheric Admin (NOAA) - USA	Murphy, DM (corresponding author), NOAA, Aeron Lab, Boulder, CO 80305 USA.	daniel.m.murphy@noaa.gov	Murphy, Daniel/J-4357-2012	Murphy, Daniel/0000-0002-8091-7235				Dobson CM, 2000, P NATL ACAD SCI USA, V97, P11864, DOI 10.1073/pnas.200366897; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Hamilton JF, 2004, ATMOS CHEM PHYS, V4, P1279, DOI 10.5194/acp-4-1279-2004; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Jayne JT, 2000, AEROSOL SCI TECH, V33, P49, DOI 10.1080/027868200410840; Kalberer M, 2004, SCIENCE, V303, P1659, DOI 10.1126/science.1092185; Liu DY, 1997, ANAL CHEM, V69, P1808, DOI 10.1021/ac9612988; LIU P, 1995, AEROSOL SCI TECH, V22, P314, DOI 10.1080/02786829408959749; Marcolli C, 2004, J PHYS CHEM A, V108, P2216, DOI [10.1021/jp036080l, 10.1021/jp0360801]; McMurry PH, 2000, ATMOS ENVIRON, V34, P1959, DOI 10.1016/S1352-2310(99)00455-0; Murphy DM, 1998, SCIENCE, V282, P1664, DOI 10.1126/science.282.5394.1664; Noble CA, 2000, MASS SPECTROM REV, V19, P248, DOI 10.1002/1098-2787(200007)19:4<248::AID-MAS3>3.0.CO;2-I; Novakov T, 1997, J GEOPHYS RES-ATMOS, V102, P30023, DOI 10.1029/97JD02793; Tolocka MP, 2004, ENVIRON SCI TECHNOL, V38, P1428, DOI 10.1021/es035030r; Weber R, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2001JD001220	15	43	43	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1888	1890		10.1126/science.1108160	http://dx.doi.org/10.1126/science.1108160			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790835				2022-12-28	WOS:000227957300037
J	Penkner, AM; Prinz, S; Ferscha, S; Klein, F				Penkner, AM; Prinz, S; Ferscha, S; Klein, F			Mnd2, an essential antagonist of the anaphase-promoting complex during meiotic prophase	CELL			English	Article							MEIOSIS-I DEPENDS; CHROMOSOME SEGREGATION; MITOTIC EXIT; SACCHAROMYCES-CEREVISIAE; SPORE FORMATION; PROTEIN; SEPARASE; SUBUNITS; CDC20; DEGRADATION	Melotic cohesin serves in sister chromatid linkage and DNA repair until its subunit Rec8 is cleaved by separase. Separase is activated when its inhibitor, securin, is polyubiquitinated by the Cdc20 regulated anaphase-promoting complex (ApC(Cdc20)) and consequently degraded. Differently regulated APCs (ApC(Cdh1), ApC(Ama1)) have not been implicated in securin degradation at meiosis 1. We show that Mnd2, a factor known to associate with APC components, prevents premature securin degradation in meiosis by ApC(Ama1). mnd2 Delta cells lack linear chromosome axes and exhibit precocious sister chromatid separation, but deletion of AMA1 suppresses these defects. Besides securin, Sgo1, a protein essential for protection of centromeric cohesion during anaphase 1, is also destabilized in mnd2 Delta cells. Mnd2 ' s disappearance prior to anaphase 11 may activate ApC(Ama1). Human oocytes may spend many years in meiotic prophase before maturation. Inhibitors of meiotic APC variants could prevent loss of chiasmata also in these cells, thereby guarding against aberrant chromosome segregation.	Vienna Bioctr 2, Max Perutz Labs, Dept Chromosome Biol, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL)	Klein, F (corresponding author), Vienna Bioctr 2, Max Perutz Labs, Dept Chromosome Biol, Dr Bohr Gasse 1, A-1030 Vienna, Austria.	franz.klein@univie.ac.at		Klein, Franz/0000-0001-7204-1432				Asakawa H, 2001, MOL GENET GENOMICS, V265, P424, DOI 10.1007/s004380000429; Blanco MA, 2001, J CELL SCI, V114, P2135; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Buonomo SBC, 2003, DEV CELL, V4, P727, DOI 10.1016/S1534-5807(03)00129-1; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; Davis ES, 2002, GENETICS, V160, P805; Dong XZ, 1997, GENE DEV, V11, P94, DOI 10.1101/gad.11.1.94; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Golden A, 2000, J CELL BIOL, V151, P1469, DOI 10.1083/jcb.151.7.1469; GOLDWAY M, 1993, GENETICS, V133, P159; Grosskortenhaus R, 2002, DEV CELL, V2, P29, DOI 10.1016/S1534-5807(01)00104-6; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hall MC, 2003, J BIOL CHEM, V278, P16698, DOI 10.1074/jbc.M213109200; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kamieniecki RJ, 2000, CURR BIOL, V10, P1182, DOI 10.1016/S0960-9822(00)00723-5; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; Katis VL, 2004, CURR BIOL, V14, P560, DOI 10.1016/j.cub.2004.03.001; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Loidl J, 1998, METHOD CELL BIOL, V53, P257; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Marston AL, 2004, SCIENCE, V303, P1367, DOI 10.1126/science.1094220; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Passmore LA, 2003, EMBO J, V22, P786, DOI 10.1093/emboj/cdg084; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Peters JM, 1999, EXP CELL RES, V248, P339, DOI 10.1006/excr.1999.4443; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; PRIELER S, 2005, GENE DEV, V19, P1516; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; Rabitsch KP, 2004, CURR BIOL, V14, P287, DOI 10.1016/j.cub.2004.01.051; Rabitsch KP, 2001, CURR BIOL, V11, P1001, DOI 10.1016/S0960-9822(01)00274-3; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Salic A, 2004, CELL, V118, P567, DOI 10.1016/j.cell.2004.08.016; Schwickart M, 2004, MOL CELL BIOL, V24, P3562, DOI 10.1128/MCB.24.8.3562-3576.2004; Siomos MF, 2001, CURR BIOL, V11, P1825, DOI 10.1016/S0960-9822(01)00588-7; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Sullivan M, 2001, NAT CELL BIOL, V3, P771, DOI 10.1038/ncb0901-771; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Tinker-Kulberg RL, 1999, GENE DEV, V13, P1936, DOI 10.1101/gad.13.15.1936; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zeng XM, 1999, J CELL BIOL, V146, P415, DOI 10.1083/jcb.146.2.415	55	51	56	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					789	801		10.1016/j.cell.2005.01.017	http://dx.doi.org/10.1016/j.cell.2005.01.017			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797380	Bronze			2022-12-28	WOS:000228067500009
J	Snow, ES; Perkins, FK; Houser, EJ; Badescu, SC; Reinecke, TL				Snow, ES; Perkins, FK; Houser, EJ; Badescu, SC; Reinecke, TL			Chemical detection with a single-walled carbon nanotube capacitor	SCIENCE			English	Article							THIN-FILMS; SENSORS; GASES; MICROSENSORS; TRANSISTORS; NETWORKS; ARRAYS	We show that the capacitance of single-walled carbon nanotubes (SWNTs) is highly sensitive to a broad class of chemical vapors and that this transduction mechanism can form the basis for a fast, low-power sorption-based chemical sensor. In the presence of a dilute chemical vapor, molecular adsorbates are polarized by the fringing electric fields radiating from the surface of a SWNT electrode, which causes an increase in its capacitance. We use this effect to construct a high-performance chemical sensor by thinly coating the SWNTs with chemoselective materials that provide a large, class-specific gain to the capacitance response. Such SWNT chemicapacitors are fast, highly sensitive, and completely reversible.	USN, Res Lab, Washington, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	Snow, ES (corresponding author), USN, Res Lab, Washington, DC 20375 USA.	snow@bloch.nrl.navy.mil	Perkins, Keith/GSN-3514-2022	Badescu, Stefan C./0000-0002-7838-2673				Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023; DELAPIERRE G, 1983, SENSOR ACTUATOR, V4, P97, DOI 10.1016/0250-6874(83)85013-6; Eastman MP, 1999, J ELECTROCHEM SOC, V146, P3907, DOI 10.1149/1.1392571; Frisch M. J., 2019, GAUSSIAN 16 REVISION; Goldoni A, 2003, J AM CHEM SOC, V125, P11329, DOI 10.1021/ja034898e; Grate JW, 1999, ANAL CHEM, V71, P4544, DOI 10.1021/ac990336v; Hierlemann A, 2000, SENSOR ACTUAT B-CHEM, V70, P2, DOI 10.1016/S0925-4005(00)00546-3; Jackson J.D., 1975, CLASSICAL ELECTRODYN, P155; Kim BM, 2004, APPL PHYS LETT, V84, P1946, DOI 10.1063/1.1682691; Kong J, 2000, SCIENCE, V287, P622, DOI 10.1126/science.287.5453.622; KOSOLAPOFF GM, 1954, J CHEM SOC, P3222, DOI 10.1039/jr9540003222; Li J, 2003, NANO LETT, V3, P929, DOI 10.1021/nl034220x; Li JR, 2003, CARBON, V41, P2353, DOI 10.1016/S0008-6223(03)00273-2; Lide D. R., 1995, CRC HDB CHEM PHYS; Lonergan MC, 1996, CHEM MATER, V8, P2298, DOI 10.1021/cm960036j; McGill RA, 2000, SENSOR ACTUAT B-CHEM, V65, P10, DOI 10.1016/S0925-4005(99)00352-4; Nagle HT, 1998, IEEE SPECTRUM, V35, P22, DOI 10.1109/6.715180; Novak JP, 2003, APPL PHYS LETT, V83, P4026, DOI 10.1063/1.1626265; Patel SV, 2003, SENSOR ACTUAT B-CHEM, V96, P541, DOI 10.1016/S0925-4005(03)00637-3; QI P, 2003, NANO LETT, V3, P347, DOI DOI 10.1021/NL034010K; Snow ES, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1854721; Snow ES, 2003, APPL PHYS LETT, V82, P2145, DOI 10.1063/1.1564291; Someya T, 2003, NANO LETT, V3, P877, DOI 10.1021/nl034061h; Valentini L, 2004, DIAM RELAT MATER, V13, P1301, DOI 10.1016/j.diamond.2003.11.011; Valentini L, 2003, APPL PHYS LETT, V82, P961, DOI 10.1063/1.1545166; Walther JH, 2001, J PHYS CHEM B, V105, P9980, DOI 10.1021/jp011344u	26	811	883	6	315	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 25	2005	307	5717					1942	1945		10.1126/science.1109128	http://dx.doi.org/10.1126/science.1109128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790850				2022-12-28	WOS:000227957300051
J	Lolle, SJ; Victor, JL; Young, JM; Pruitt, RE				Lolle, SJ; Victor, JL; Young, JM; Pruitt, RE			Genome-wide non-mendelian inheritance of extra-genomic information in Arabidopsis	NATURE			English	Article							CHIMERIC RNA/DNA OLIGONUCLEOTIDES; DEPENDENT RNA-POLYMERASE; DOUBLE-STRANDED-RNA; ORGAN FUSION; GENE; METHYLATION; MUTATION; TRANSGENE; NEUROSPORA; EVOLUTION	A fundamental tenet of classical mendelian genetics is that allelic information is stably inherited from one generation to the next, resulting in predictable segregation patterns of differing alleles(1). Although several exceptions to this principle are known, all represent specialized cases that are mechanistically restricted to either a limited set of specific genes ( for example mating type conversion in yeast(2)) or specific types of alleles ( for example alleles containing transposons(3) or repeated sequences(4)). Here we show that Arabidopsis plants homozygous for recessive mutant alleles of the organ fusion gene HOTHEAD(5) (HTH) can inherit allele-specific DNA sequence information that was not present in the chromosomal genome of their parents but was present in previous generations. This previously undescribed process is shown to occur at all DNA sequence polymorphisms examined and therefore seems to be a general mechanism for extragenomic inheritance of DNA sequence information. We postulate that these genetic restoration events are the result of a template-directed process that makes use of an ancestral RNA-sequence cache.	Purdue Univ, Dept Bot & Plant Pathol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Pruitt, RE (corresponding author), Purdue Univ, Dept Bot & Plant Pathol, 915 W State St, W Lafayette, IN 47907 USA.	pruittr@purdue.edu		Pruitt, Robert E/0000-0003-4817-5806				AUERBACH C, 1971, ANNU REV GENET, V5, P163, DOI 10.1146/annurev.ge.05.120171.001115; Bao N, 2004, DEV CELL, V7, P653, DOI 10.1016/j.devcel.2004.10.003; Beetham PR, 1999, P NATL ACAD SCI USA, V96, P8774, DOI 10.1073/pnas.96.15.8774; Bjedov I, 2003, SCIENCE, V300, P1404, DOI 10.1126/science.1082240; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; ColeStrauss A, 1996, SCIENCE, V273, P1386, DOI 10.1126/science.273.5280.1386; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FOSTER PL, 1992, GENETICS, V131, P783; Galitski T, 1996, GENETICS, V143, P645; GONDO Y, 1993, P NATL ACAD SCI USA, V90, P297, DOI 10.1073/pnas.90.1.297; HALL BG, 1990, GENETICS, V126, P5; KLAR AJS, 1979, GENETICS, V92, P777; Kovalchuk I, 2003, NATURE, V423, P760, DOI 10.1038/nature01683; Krolikowski KA, 2003, PLANT J, V35, P501, DOI 10.1046/j.1365-313X.2003.01824.x; Lolle SJ, 1998, GENETICS, V149, P607; MCCLINTOCK B, 1950, P NATL ACAD SCI USA, V36, P344, DOI 10.1073/pnas.36.6.344; Mendel G., 1866, VERHAND NATURF VER B, V4, P3, DOI DOI 10.5962/BHL.TITLE.61004; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Pruitt RE, 2000, P NATL ACAD SCI USA, V97, P1311, DOI 10.1073/pnas.97.3.1311; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; Ries G, 2000, NATURE, V406, P98, DOI 10.1038/35017595; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; SONG KM, 1995, P NATL ACAD SCI USA, V92, P7719, DOI 10.1073/pnas.92.17.7719; Taller J, 1998, THEOR APPL GENET, V97, P705, DOI 10.1007/s001220050946; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Zhu T, 1999, P NATL ACAD SCI USA, V96, P8768, DOI 10.1073/pnas.96.15.8768	30	142	152	0	124	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					505	509		10.1038/nature03380	http://dx.doi.org/10.1038/nature03380			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15785770				2022-12-28	WOS:000227836000042
J	Sonnichsen, B; Koski, LB; Walsh, A; Marschall, P; Neumann, B; Brehm, M; Alleaume, AM; Artelt, J; Bettencourt, P; Cassin, E; Hewitson, M; Holz, C; Khan, M; Lazik, S; Martin, C; Nitzsche, B; Ruer, M; Stamford, J; Winzi, M; Heinkel, R; Roder, M; Finell, J; Hantsch, H; Jones, SJM; Jones, M; Piano, F; Gunsalus, KC; Oegema, K; Gonczy, P; Coulson, A; Hyman, AA; Echeverri, CJ				Sonnichsen, B; Koski, LB; Walsh, A; Marschall, P; Neumann, B; Brehm, M; Alleaume, AM; Artelt, J; Bettencourt, P; Cassin, E; Hewitson, M; Holz, C; Khan, M; Lazik, S; Martin, C; Nitzsche, B; Ruer, M; Stamford, J; Winzi, M; Heinkel, R; Roder, M; Finell, J; Hantsch, H; Jones, SJM; Jones, M; Piano, F; Gunsalus, KC; Oegema, K; Gonczy, P; Coulson, A; Hyman, AA; Echeverri, CJ			Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans	NATURE			English	Article							DOUBLE-STRANDED-RNA; C-ELEGANS; CELL-DIVISION; INTERFERENCE; GENES; GENERATION; EMBRYOS	A key challenge of functional genomics today is to generate well-annotated data sets that can be interpreted across different platforms and technologies. Large-scale functional genomics data often fail to connect to standard experimental approaches of gene characterization in individual laboratories. Furthermore, a lack of universal annotation standards for phenotypic data sets makes it difficult to compare different screening approaches. Here we address this problem in a screen designed to identify all genes required for the first two rounds of cell division in the Caenorhabditis elegans embryo. We used RNA-mediated interference to target 98% of all genes predicted in the C. elegans genome in combination with differential interference contrast time-lapse microscopy. Through systematic annotation of the resulting movies, we developed a phenotypic profiling system, which shows high correlation with cellular processes and biochemical pathways, thus enabling us to predict new functions for previously uncharacterized genes.	Cenix Biosci GmbH, D-01307 Dresden, Germany; Max Planck Inst Cell Biol & Genet, D-01307 Dresden, Germany; British Columbia Canc Res Ctr, Genome Sci Ctr, Vancouver, BC V5Z 4E6, Canada; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; NYU, Dept Biol, Ctr Comparat Funct Genom, New York, NY 10003 USA	Max Planck Society; British Columbia Cancer Agency; Wellcome Trust Sanger Institute; New York University	Sonnichsen, B (corresponding author), Cenix Biosci GmbH, Tatzberg 47-51, D-01307 Dresden, Germany.	soennichsen@cenix.bioscience.com	Hyman, Tony/F-1923-2011; Jones, Steven J/C-3621-2009; Bettencourt, Paulo/V-5793-2017; Hyman, Anthony A/B-3917-2017	Jones, Steven J/0000-0003-3394-2208; Bettencourt, Paulo/0000-0002-4884-5470; Hyman, Anthony A/0000-0003-3664-154X; Alleaume, Anne-Marie/0000-0001-7881-1880; Gonczy, Pierre/0000-0002-6305-6883; Neumann, Beate/0000-0002-6899-502X; Nitzsche, Bjorn/0000-0002-4759-0760				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Askjaer P, 2002, MOL BIOL CELL, V13, P4355, DOI 10.1091/mbc.E02-06-0346; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gonczy P, 1999, J CELL BIOL, V147, P135, DOI 10.1083/jcb.147.1.135; Gonczy P, 1999, J CELL BIOL, V144, P927, DOI 10.1083/jcb.144.5.927; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KIGER A, 2003, J BIOL, V2; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Piano F, 2002, CURR BIOL, V12, P1959, DOI 10.1016/S0960-9822(02)01301-5; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; Walhout AJM, 2002, CURR BIOL, V12, P1952, DOI 10.1016/S0960-9822(02)01279-4; Zipperlen P, 2001, EMBO J, V20, P3984, DOI 10.1093/emboj/20.15.3984	21	682	704	2	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					462	469		10.1038/nature03353	http://dx.doi.org/10.1038/nature03353			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791247				2022-12-28	WOS:000227836000032
J	Nkhoma, E; van Hensbroek, BP; van Lieshout, L; van Hensbroek, MB				Nkhoma, E; van Hensbroek, BP; van Lieshout, L; van Hensbroek, MB			Severe anaemia in an 11-month-old girl	LANCET			English	Editorial Material							MALARIA		Liverpool Sch Trop Med UK, Child & Reprod Hlth Grp, Liverpool, Merseyside, England; Univ Amsterdam, Emma Childrens Hosp AMC, NL-1012 WX Amsterdam, Netherlands; Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Zomba, Malawi; Leiden Univ, LUMC, Dept Parasitol, NL-2300 RA Leiden, Netherlands	Liverpool School of Tropical Medicine; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Malawi; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Hensbroek, MB (corresponding author), Liverpool Sch Trop Med UK, Child & Reprod Hlth Grp, Liverpool, Merseyside, England.	mbvh@mlw.medcol.mw		Boele van Hensbroek, Michael/0000-0003-1907-5427				Albonico M, 1998, INT J EPIDEMIOL, V27, P530, DOI 10.1093/ije/27.3.530; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; Moore RD, 1999, CLIN INFECT DIS, V29, P44, DOI 10.1086/520178; Verweij JJ, 2001, TROP MED INT HEALTH, V6, P726, DOI 10.1046/j.1365-3156.2001.00770.x; Zucker JR, 1996, AM J TROP MED HYG, V55, P655, DOI 10.4269/ajtmh.1996.55.655	5	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1202	1202		10.1016/S0140-6736(05)71885-7	http://dx.doi.org/10.1016/S0140-6736(05)71885-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794977				2022-12-28	WOS:000227909500035
J	Sailas, ES; Feodoroff, B; Virkkunen, M; Wahlbeck, K				Sailas, ES; Feodoroff, B; Virkkunen, M; Wahlbeck, K			Mental disorders in prison populations aged 15-21: national register study of two cohorts in Finland	BRITISH MEDICAL JOURNAL			English	Article							PSYCHIATRIC-DISORDERS; REPRESENTATIVE SAMPLE; JUVENILE DETENTION; COMORBIDITY; ADOLESCENTS; PREVALENCE; YOUTH	Juvenile delinquency is linked to psychiatric morbidity.(1 w1-w9) We were interested in temporal changes in psychiatric morbidity in offenders. Criminal policy in many Western countries emphasises the need for alternative methods of punishment for adolescent prisoners.(2) In Finland, successful policy to diminish the number of adolescents in prisons has been internationally recognise.(3) We studied the changes in psychiatric hospitalisations in Finnish prisoners aged 15 to 21 to see whether a selection process occurs as the number of young prisoners decreases.	Natl Res & Dev Ctr Welf & Hlth, STAKES, Helsinki 00531, Finland; Vaasa Cent Hosp, Psychiat Unit, Vaasa, Finland; Univ Helsinki, Cent Hosp, Helsinki 00029, Finland	Vaasa Central Hospital; University of Helsinki; Helsinki University Central Hospital	Sailas, ES (corresponding author), Natl Res & Dev Ctr Welf & Hlth, STAKES, POB 220, Helsinki 00531, Finland.	eila.sailas@stakes.fi	Wahlbeck, Kristian/F-8394-2011	Wahlbeck, Kristian/0000-0003-3754-3933				Abram KM, 2003, ARCH GEN PSYCHIAT, V60, P1097, DOI 10.1001/archpsyc.60.11.1097; Arseneault L, 2000, ARCH GEN PSYCHIAT, V57, P979, DOI 10.1001/archpsyc.57.10.979; Duclos CW, 1998, J AM ACAD CHILD PSY, V37, P866, DOI 10.1097/00004583-199808000-00017; Gosden NP, 2003, ACTA PSYCHIAT SCAND, V107, P102, DOI 10.1034/j.1600-0447.2003.01298.x; LAPPISEPPALA T, 1998, 381998 NAT RES I LEG; Moeller AA, 2003, ACTA PSYCHIAT SCAND, V107, P203, DOI 10.1034/j.1600-0447.2003.02377.x; Pliszka SR, 2000, AM J PSYCHIAT, V157, P130, DOI 10.1176/ajp.157.1.130; Suvisaari JM, 1999, ARCH GEN PSYCHIAT, V56, P733, DOI 10.1001/archpsyc.56.8.733; Teplin LA, 2002, ARCH GEN PSYCHIAT, V59, P1133, DOI 10.1001/archpsyc.59.12.1133; Tonry M., 2001, PENAL REFORM OVERCRO; Ulzen TPM, 1998, CAN J PSYCHIAT, V43, P57, DOI 10.1177/070674379804300106; Vreugdenhil C, 2004, J AM ACAD CHILD PSY, V43, P97, DOI 10.1097/00004583-200401000-00019; Vreugdenhil C, 2003, J NERV MENT DIS, V191, P372	13	10	10	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 11	2005	330	7504					1364	1365		10.1136/bmj.38415.633762.F7	http://dx.doi.org/10.1136/bmj.38415.633762.F7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	936FE	15829486	Green Published			2022-12-28	WOS:000229840100020
J	Weiner, SJ; Barnet, B; Cheng, TL; Daaleman, TP				Weiner, SJ; Barnet, B; Cheng, TL; Daaleman, TP			Processes for effective communication in primary care	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN-PATIENT COMMUNICATION; INTERVIEWING SKILLS; QUALITY; INTERVENTION; DEPARTMENTS; SPECIALISTS; MEDICINE; OUTCOMES; MODEL	Communication in the delivery of health care services occurs along 2 axes: between providers and patients and among several providers. In primary care, a principle objective in the provider-patient relationship is facilitating whole-person care, which is care provided in the context of family and community. In addition, primary care emphasizes communication between the primary care physician and other providers with the goal of integrated care, or care provided in the context of a patient's overall health care needs. However, considering both the U.S. health care delivery system and medical education programs, several obstacles interfere with the necessary processes of communication. This paper addresses those obstacles with a conceptual framework for effective communication in primary care. Recommendations propose formalizing requirements for the exchange of information among providers, enhancing communication training, disseminating information technology, and mitigating external factors that disrupt communication in primary care.	Univ Illinois, Chicago, IL 60612 USA; Vet Affairs Mid W Ctr Hlth Serv & Policy Res, Chicago, IL USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Johns Hopkins Univ, Baltimore, MD USA; Univ N Carolina, Chapel Hill, NC USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; University of North Carolina; University of North Carolina Chapel Hill	Weiner, SJ (corresponding author), Univ Illinois, 840 S Wood St,M-C 718, Chicago, IL 60612 USA.	sweiner@uic.edu		Daaleman, Timothy/0000-0002-1649-4266				*ASS AM MED COLL, 1998, EM TRENDS US STAND P; *ASS AM MED COLL, 1999, CONT ISS MED COMM ME; Beck Rainer S, 2002, J Am Board Fam Pract, V15, P25; Bowman M A, 1995, Arch Fam Med, V4, P401, DOI 10.1001/archfami.4.5.401; Brunett PH, 2001, ACAD MED, V76, P390, DOI 10.1097/00001888-200104000-00021; Cegala DJ, 2002, MED EDUC, V36, P1004, DOI 10.1046/j.1365-2923.2002.01331.x; Charon R, 2001, JAMA-J AM MED ASSOC, V286, P1897, DOI 10.1001/jama.286.15.1897; COHEN D, 2004, MED ENCOUNTER, V18, P12; Coiera E, 2000, J AM MED INFORM ASSN, V7, P277, DOI 10.1136/jamia.2000.0070277; COIERA E, 1997, GUIDE MED INFORMATIC; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; Cunningham PJ, 1995, MED CARE RES REV, V52, P453, DOI 10.1177/107755879505200402; Dick RS, 1997, COMPUTER BASED PATIE; Flocke SA, 1997, J FAM PRACTICE, V45, P129; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Hafferty FW, 1998, ACAD MED, V73, P403, DOI 10.1097/00001888-199804000-00013; Haynes R Brian, 2002, ACP J Club, V136, pA11; HERBERS JE, 1989, J GEN INTERN MED, V4, P202, DOI 10.1007/BF02599524; HESZENKLEMENS I, 1984, SOC SCI MED, V19, P9, DOI 10.1016/0277-9536(84)90132-1; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; Hulsman RL, 1999, MED EDUC, V33, P655, DOI 10.1046/j.1365-2923.1999.00519.x; Institute of Medicine Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM NEW; JENKINS RM, 1993, BRIT J GEN PRACT, V43, P111; Joos SK, 1996, J GEN INTERN MED, V11, P147, DOI 10.1007/BF02600266; *KAIS FAM FDN, NAT SURV CONS EXP AT; KALET A, 1992, J GEN INTERN MED, V7, P499, DOI 10.1007/BF02599452; KELLER VF, 1994, PATIENT EDUC COUNS, V23, P131, DOI 10.1016/0738-3991(94)90051-5; Kurtz S., 1998, TEACHING LEARNING CO; Langewitz WA, 1998, PSYCHOSOM MED, V60, P268, DOI 10.1097/00006842-199805000-00009; Makoul G, 1999, PATIENT EDUC COUNS, V37, P191, DOI 10.1016/S0738-3991(99)00023-3; Makoul G, 2001, PATIENT EDUC COUNS, V45, P1, DOI 10.1016/S0738-3991(01)00145-8; Markakis KM, 2000, ACAD MED, V75, P141, DOI 10.1097/00001888-200002000-00009; Morrison I, 2000, BRIT MED J, V321, P1541, DOI 10.1136/bmj.321.7276.1541; *NAT AC SCI, 1996, PRIM CAR AM HLTH NEW; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; NOVACK DH, 1992, ARCH INTERN MED, V152, P1814, DOI 10.1001/archinte.152.9.1814; ORTH JE, 1987, HEALTH PSYCHOL, V6, P29, DOI 10.1037/0278-6133.6.1.29; Parley Louis, 1995, ETHICAL FAMILY LAWYE; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Safran C, 1999, METHOD INFORM MED, V38, P308; Safran DG, 1998, MED CARE, V36, P728, DOI 10.1097/00005650-199805000-00012; Safran DG, 2003, ANN INTERN MED, V138, P248, DOI 10.7326/0003-4819-138-3-200302040-00033; STEWART M, 1995, PATIENT CENTERED MED; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; Stille CJ, 2005, ANN INTERN MED, V142, P700, DOI 10.7326/0003-4819-142-8-200504190-00038; Tang P C, 1996, Proc AMIA Annu Fall Symp, P12; Tang P. C., 2003, KEY CAPABILITIES ELE; Weiner Saul J, 2004, ACP J Club, V141, pA11; Weiner SJ, 2004, J GEN INTERN MED, V19, P281, DOI 10.1111/j.1525-1497.2004.30261.x; WESTERMAN RF, 1990, BRIT J GEN PRACT, V40, P445	50	52	53	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					709	714		10.7326/0003-4819-142-8-200504190-00039	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00039			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916TZ	15838090				2022-12-28	WOS:000228410400029
J	Indovina, I; Maffei, V; Bosco, G; Zago, M; Macaluso, E; Lacquaniti, F				Indovina, I; Maffei, V; Bosco, G; Zago, M; Macaluso, E; Lacquaniti, F			Representation of visual gravitational motion in the human vestibular cortex	SCIENCE			English	Article							INTERNAL-MODELS; EYE-MOVEMENTS; PERCEPTION; GRAVITY; ACCELERATION; INTERCEPTION; RESPONSES; BRAIN; LAWS; STIMULATION	How do we perceive the visual motion of objects that. are accelerated by gravity? We propose that, because vision is poorly sensitive to accelerations, an internal model that calculates the effects of gravity is derived from graviceptive information, is stored in the vestibular cortex, and is activated by visual motion that appears to be coherent with natural gravity. The acceleration of visual targets was manipulated while brain activity was measured using functional magnetic resonance imaging. In agreement with the internal model hypothesis, we found that the vestibular network was selectively engaged when acceleration was consistent with natural gravity. These findings demonstrate that predictive mechanisms of physical laws of motion are represented in the human brain.	Sci Inst Fdn Santa Lucia, Dept Neuromotor Physiol, I-00179 Rome, Italy; Sci Inst Fdn Santa Lucia, Dept Neuroimaging, I-00179 Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, I-00133 Rome, Italy; Univ Roma Tor Vergata, Ctr Space Biomed, I-00173 Rome, Italy	IRCCS Santa Lucia; IRCCS Santa Lucia; University of Rome Tor Vergata; University of Rome Tor Vergata	Lacquaniti, F (corresponding author), Sci Inst Fdn Santa Lucia, Dept Neuromotor Physiol, Via Ardeatina 306, I-00179 Rome, Italy.	lacquaniti@caspur.it	Indovina, Iole/Z-2978-2019; Macaluso, Emiliano/H-3139-2017; Macaluso, Emiliano/AAE-9185-2019; Zago, Myrka/B-3669-2012; Lacquaniti, Francesco/J-9842-2016; Bosco, Gianfranco/AAA-1548-2019	Indovina, Iole/0000-0002-1183-0013; Macaluso, Emiliano/0000-0002-1919-5288; Macaluso, Emiliano/0000-0002-1919-5288; Zago, Myrka/0000-0001-7100-7582; Lacquaniti, Francesco/0000-0003-0896-7315; Bosco, Gianfranco/0000-0002-7080-0674; maffei, vincenzo/0000-0003-0957-6615				Angelaki DE, 2004, NATURE, V430, P560, DOI 10.1038/nature02754; Bense S, 2001, J NEUROPHYSIOL, V85, P886, DOI 10.1152/jn.2001.85.2.886; Blanke O, 2002, NATURE, V419, P269, DOI 10.1038/419269a; BOTTINI G, 1994, EXP BRAIN RES, V99, P164; BRANDT T, 1994, ANN NEUROL, V35, P403, DOI 10.1002/ana.410350406; Brouwer AM, 2002, PERCEPT PSYCHOPHYS, V64, P1160, DOI 10.3758/BF03194764; GRUSSER OJ, 1990, J PHYSIOL-LONDON, V430, P537; Guldin WO, 1998, TRENDS NEUROSCI, V21, P254, DOI 10.1016/S0166-2236(97)01211-3; Imamizu H, 2000, NATURE, V403, P192, DOI 10.1038/35003194; Jokisch D, 2003, J VISION, V3, P252, DOI 10.1167/3.4.1; KIM IK, 1992, J EXP PSYCHOL HUMAN, V18, P385, DOI 10.1037/0096-1523.18.2.385; LACQUANITI F, 1989, J NEUROSCI, V9, P134, DOI 10.1523/JNEUROSCI.09-01-00134.1989; Lacquaniti F., 1993, MULTISENSORY CONTROL, P379, DOI [10.1093/acprof:oso/9780198547853.003.0190, DOI 10.1093/ACPROF:OSO/9780198547853.003.0190]; LEE DN, 1981, NATURE, V293, P293, DOI 10.1038/293293a0; Lisberger SG, 1999, J NEUROSCI, V19, P2224; MCBEATH MK, 1995, SCIENCE, V268, P569, DOI 10.1126/science.7725104; McIntyre J, 2001, NAT NEUROSCI, V4, P693, DOI 10.1038/89477; Merchant H, 2004, CEREB CORTEX, V14, P314, DOI 10.1093/cercor/bhg130; Merfeld DM, 1999, NATURE, V398, P615, DOI 10.1038/19303; Orban GA, 2003, NEUROPSYCHOLOGIA, V41, P1757, DOI 10.1016/S0028-3932(03)00177-5; Peterka RJ, 2004, J NEUROPHYSIOL, V92, P2333, DOI 10.1152/jn.00174.2004; Port NL, 1997, EXP BRAIN RES, V116, P406, DOI 10.1007/PL00005769; Rees G, 2000, NAT NEUROSCI, V3, P716, DOI 10.1038/76673; SHEPARD RN, 1984, PSYCHOL REV, V91, P417, DOI 10.1037/0033-295X.91.4.417; Smetacek V, 2002, NATURE, V415, P481, DOI 10.1038/415481a; Todd J T, 1981, J Exp Psychol Hum Percept Perform, V7, P975; Twardy CR, 2002, PERCEPT PSYCHOPHYS, V64, P956, DOI 10.3758/BF03196799; WATSON JS, 1992, PERCEPTION, V21, P69, DOI 10.1068/p210069; WERKHOVEN P, 1992, VISION RES, V32, P2313, DOI 10.1016/0042-6989(92)90095-Z; Zago M, 2004, J NEUROPHYSIOL, V91, P1620, DOI 10.1152/jn.00862.2003; Zupan LH, 2002, BIOL CYBERN, V86, P209, DOI 10.1007/s00422-001-0290-1	31	234	236	3	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					416	419		10.1126/science.1107961	http://dx.doi.org/10.1126/science.1107961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831760	Green Published			2022-12-28	WOS:000228492000054
J	Wootton, SK; Halbert, CL; Miller, AD				Wootton, SK; Halbert, CL; Miller, AD			Sheep retrovirus structural protein induces lung tumours	NATURE			English	Article							RODENT FIBROBLASTS; JAAGSIEKTE; TRANSFORMATION; RECEPTOR; VECTORS; TRANSDUCTION; CELLS; HYAL2; GENE; BRONCHIOLOALVEOLAR	Jaagsiekte sheep retrovirus ( JSRV) causes a contagious lung cancer in sheep and goats, with significant animal health and economic consequences(1). The host range of JSRV is in part limited by species-specific differences in the virus entry receptor, hyaluronidase 2 (Hyal2), which is not functional as a receptor in mice but is functional in humans(2). Sheep are immunotolerant of JSRV because of the expression of closely related endogenous retroviruses(3,4), which are not present in humans and most other species, and this may facilitate oncogenesis. Here we show that expression of the JSRV envelope (Env) protein alone in lungs of mice, by using a replication-incompetent adeno-associated virus vector, results in tumours with a bronchiolo-alveolar localization like those seen in sheep. Whereas lethal disease was observed in immunodeficient mice, tumour development was almost entirely blocked in immunocompetent mice. Our results provide a rare example of an oncogenic viral structural protein, show that interaction of the viral Env protein with the virus entry receptor Hyal2 is not required for tumorigenesis, and indicate that immune recognition of Env can protect against JSRV tumorigenesis.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Miller, AD (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	dmiller@fhcrc.org		Miller, Dusty/0000-0002-3736-3660	NIDDK NIH HHS [P30 DK047754] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047754] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen JM, 2000, MOL THER, V1, P88, DOI 10.1006/mthe.1999.0010; Allen TE, 2002, J GEN VIROL, V83, P2733, DOI 10.1099/0022-1317-83-11-2733; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; De las Heras M, 2000, EUR RESPIR J, V16, P330, DOI 10.1034/j.1399-3003.2000.16b23.x; FAN H, 2003, JAAGSIEKTE SHEEP RET; Fisher GH, 1999, ONCOGENE, V18, P5253, DOI 10.1038/sj.onc.1203087; Halbert CL, 2002, NAT BIOTECHNOL, V20, P697, DOI 10.1038/nbt0702-697; Halbert CL, 1997, J VIROL, V71, P5932, DOI 10.1128/JVI.71.8.5932-5941.1997; Halbert CL, 2001, J VIROL, V75, P6615, DOI 10.1128/JVI.75.14.6615-6624.2001; Hiatt KM, 2002, HUM PATHOL, V33, P680, DOI 10.1053/hupa.2002.125776; Liu SL, 2005, J VIROL, V79, P927, DOI 10.1128/JVI.79.2.927-933.2005; Liu SL, 2003, J VIROL, V77, P7924, DOI 10.1128/JVI.77.14.7924-7935.2003; Liu SL, 2003, J VIROL, V77, P2850, DOI 10.1128/JVI.77.5.2850-2858.2003; Maeda N, 2001, P NATL ACAD SCI USA, V98, P4449, DOI 10.1073/pnas.071547598; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Miller AD, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-64; Palmarini M, 2001, J VIROL, V75, P11002, DOI 10.1128/JVI.75.22.11002-11009.2001; Platt JA, 2002, VET PATHOL, V39, P341, DOI 10.1354/vp.39-3-341; Rai SK, 2000, J VIROL, V74, P4698, DOI 10.1128/JVI.74.10.4698-4704.2000; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; SHARP JM, 1983, ARCH VIROL, V78, P89, DOI 10.1007/BF01310861; Spencer TE, 2003, J VIROL, V77, P749, DOI 10.1128/JVI.77.1.749-753.2003; Summers C, 2002, J GEN VIROL, V83, P1753, DOI 10.1099/0022-1317-83-7-1753; Yousem SA, 2001, HUM PATHOL, V32, P1039, DOI 10.1053/hupa.2001.28249	24	115	126	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					904	907		10.1038/nature03492	http://dx.doi.org/10.1038/nature03492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829964	Green Accepted			2022-12-28	WOS:000228327600042
J	Michaud, PA; Fombonne, E				Michaud, PA; Fombonne, E			ABC of adolescence - Common mental health problems	BRITISH MEDICAL JOURNAL			English	Review							CHILD		CHU Vaudois, Multidisciplinary Adolescent Unit, Lausanne, Switzerland; McGill Univ, Montreal, PQ, Canada	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); McGill University	Michaud, PA (corresponding author), CHU Vaudois, Multidisciplinary Adolescent Unit, Lausanne, Switzerland.		Fombonne, Eric/M-4893-2018; Michaud, Pierre-André/C-6355-2009	Fombonne, Eric/0000-0002-8605-3538; 				[Anonymous], 1995, PSYCHOSOCIAL DISORDE; Bower P, 2001, FAM PRACT, V18, P373, DOI 10.1093/fampra/18.4.373; HACK S, 1996, ADOLESCENT MED STATE, P335; Kondo Douglas G, 2003, Psychopharmacol Bull, V37, P7; Meltzer H., 2000, MENTAL HLTH CHILDREN; Michael KD, 2002, CLIN PSYCHOL REV, V22, P247, DOI 10.1016/S0272-7358(01)00089-7; World Health Organization, 2003, INV MENT HLTH	7	32	33	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	APR 9	2005	330	7495					835	838		10.1136/bmj.330.7495.835	http://dx.doi.org/10.1136/bmj.330.7495.835			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915BZ	15817553	Green Published			2022-12-28	WOS:000228273900022
J	Bunz, UHF				Bunz, UHF			How are alkynes scrambled?	SCIENCE			English	Editorial Material							METATHESIS CATALYSTS; MOLYBDENUM; COMPLEXES; POLY(P-PHENYLENEETHYNYLENE)S; CLEAVAGE; BONDS		Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Bunz, UHF (corresponding author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA.	uwe.bunz@chem-istry.gatech.edu	Bunz, Uwe H. F./L-9232-2013					ARDON M, 1981, INORG CHEM, V20, P4083, DOI 10.1021/ic50226a010; Bino A, 2005, SCIENCE, V308, P234, DOI 10.1126/science.1109965; Bunz UHF, 2001, ACCOUNTS CHEM RES, V34, P998, DOI 10.1021/ar010092c; Cummins CC, 1998, CHEM COMMUN, P1777, DOI 10.1039/a802402b; FRITCH JR, 1979, ANGEW CHEM INT EDIT, V18, P409, DOI 10.1002/anie.197904091; FRITCH JR, 1980, ANGEW CHEM INT EDIT, V19, P559, DOI 10.1002/anie.198005591; FURSTNER A, 1997, J AM CHEM SOC, V119, P11108; KANETA N, 1995, CHEM LETT, P1055, DOI 10.1246/cl.1995.1055; Kloppenburg L, 1998, J AM CHEM SOC, V120, P7973, DOI 10.1021/ja9813865; Mortreux A., 1974, CHEM COMMUN, P786; Sashuk V, 2004, J ORG CHEM, V69, P7748, DOI 10.1021/jo049158i; SCHROCK RR, 1986, ACCOUNTS CHEM RES, V19, P342, DOI 10.1021/ar00131a003; SCHROCK RR, 1982, ORGANOMETALLICS, V1, P1645, DOI 10.1021/om00072a018; SCHWAB P, 1995, ANGEW CHEM INT EDIT, V34, P2039, DOI 10.1002/anie.199520391; Trnka TM, 2001, ACCOUNTS CHEM RES, V34, P18, DOI 10.1021/ar000114f; Zhang W, 2004, J AM CHEM SOC, V126, P329, DOI 10.1021/ja0379868; Zhang W, 2004, MACROMOLECULES, V37, P3973, DOI 10.1021/ma049371g	17	25	25	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					216	217		10.1126/science.1111098	http://dx.doi.org/10.1126/science.1111098			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821080				2022-12-28	WOS:000228273700040
J	Iglehart, JK				Iglehart, JK			The uncertain future of specialty hospitals	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*DEP HHS OFF INSP, 0505 OIG DEP HLTH HU; Iglehart JK, 2005, NEW ENGL J MED, V352, P78, DOI 10.1056/NEJMhpr043631; Iglehart JK, 2005, NEW ENGL J MED, V352, P638; *MED PAYM ADV COMM, 2005, REP C PHYS OWN SPEC	4	11	11	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1405	1407		10.1056/NEJMp058037	http://dx.doi.org/10.1056/NEJMp058037			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814875				2022-12-28	WOS:000228145200002
J	Offit, PA				Offit, PA			The Cutter incident, 50 years later	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Offit, PA (corresponding author), Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA.							[Anonymous], 1955, YALE LAW J, V65, P262; *I MED, 2004, VACC AUT; LANGMUIR A, 1955, WYETH PROBLEM EPIDEM; NATHANSON N, 1963, AM J HYG, V78, P29, DOI 10.1093/oxfordjournals.aje.a120328	4	68	72	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1411	1412		10.1056/NEJMp048180	http://dx.doi.org/10.1056/NEJMp048180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814877				2022-12-28	WOS:000228145200004
J	Mackenzie, GM				Mackenzie, GM			Old docs and new tricks - Efficiency is important	BRITISH MEDICAL JOURNAL			English	Letter												graeme.mackenzie@gp-a82041.nhs.uk						SPURGEON D, 2005, BRIT MED J, V330, pA384	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 2	2005	330	7494					792	792		10.1136/bmj.330.7494.792-c	http://dx.doi.org/10.1136/bmj.330.7494.792-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15802734	Green Published			2022-12-28	WOS:000228222900045
J	Pyzalla, A; Camin, B; Buslaps, T; Di Michiel, M; Kaminski, H; Kottar, A; Pernack, A; Reimers, W				Pyzalla, A; Camin, B; Buslaps, T; Di Michiel, M; Kaminski, H; Kottar, A; Pernack, A; Reimers, W			Simultaneous tomography and diffraction analysis of creep damage	SCIENCE			English	Article								Creep damage by void nucleation and growth limits the lifetime of components subjected to loading at high temperatures. We report a combined tomography and diffraction experiment using high-energy synchrotron radiation that permitted us to follow in situ void growth and microstructure development in bulk samples. The results reveal that void growth versus time follows an exponential growth law. The formation of large void volumes coincides with texture evolution and dislocation density, reaching a steady state. Creep damage during a large proportion of sample creep life is homogeneous before damage localization occurs, which leads to rapid failure. The in situ determination of void evolution in bulk samples should allow for the assessment of creep damage in metallic materials and subsequently for lifetime predictions about samples and components that are subject to high-temperature loading.	Vienna Univ Technol, Inst Mat Sci & Technol, A-1040 Vienna, Austria; TU Berlin, Inst Mat Sci & Technol, Sekr BH18, D-10587 Berlin, Germany; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Technische Universitat Wien; Technical University of Berlin; European Synchrotron Radiation Facility (ESRF)	Pyzalla, A (corresponding author), Vienna Univ Technol, Inst Mat Sci & Technol, Karlspl 13-308, A-1040 Vienna, Austria.	anke.pyzalla@tuwien.ac.ot	Camin, Bettina/AAW-5276-2020	Camin, Bettina/0000-0002-0482-3931				Buffiere JY, 1999, ACTA MATER, V47, P1613, DOI 10.1016/S1359-6454(99)00024-5; DIMICHIEL M, IN PRESS REV SCI I; EGGELER G, 1991, ACTA METALL MATER, V39, P221, DOI 10.1016/0956-7151(91)90270-B; EGGELER G, 1989, ACTA METALL MATER, V37, P49, DOI 10.1016/0001-6160(89)90265-4; GREWEN J, 1954, Z METALLKD, V45, P498; KACHANOV LM, 1958, IZV AKAD NAUK USS TN, V8, P27; KAK AC, 1988, PRINCIPLES COMPUTERI, P186; Lame O, 2003, NUCL INSTRUM METH B, V200, P287, DOI 10.1016/S0168-583X(02)01690-7; MADER K, 1974, SCRIPTA METALL MATER, V8, P979, DOI 10.1016/0036-9748(74)90396-2; Rabotnov IN, 1969, CREEP PROBLEMS STRUC, V7; Reimers W, 1999, J MATER SCI LETT, V18, P581, DOI 10.1023/A:1006651217517; *RES SYST INC, 2000, IDL REF GUID VERS 5; Riedel H., 1987, FRACTURE HIGH TEMPER; Sinclair R, 2004, ACTA MATER, V52, P1423, DOI 10.1016/j.actamat.2003.11.024; Willis MR, 2001, SCRIPTA MATER, V44, P31, DOI 10.1016/S1359-6462(00)00554-6	15	86	90	5	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					92	95		10.1126/science.1106778	http://dx.doi.org/10.1126/science.1106778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802600				2022-12-28	WOS:000228221500039
J	Hughes, AL; Todd, BL; Espenshade, PJ				Hughes, AL; Todd, BL; Espenshade, PJ			SREBP pathway responds to sterols and functions as an oxygen sensor in fission yeast	CELL			English	Article							CLEAVAGE-ACTIVATING PROTEIN; ELEMENT-BINDING PROTEINS; SACCHAROMYCES-CEREVISIAE; REGULATORY ELEMENT; SCHIZOSACCHAROMYCES-POMBE; CHOLESTEROL HOMEOSTASIS; SITE-1 PROTEASE; LIPID-SYNTHESIS; SCAP; GENES	Cholesterol and fatty acid synthesis in mammals are controlled by SREBPs, a family of membrane bound transcription factors. Our studies identified homologs of SREBP, its binding partner SCAP, and the ER retention protein Insig in Schizosaccharomyces pombe, named sre1(+), scp1(+), and ins1(+). Like SREBP, Sre1 is cleaved and activated in response to sterol depletion in a Scp1-dependent manner. Microarray analysis revealed that Sre1 activates sterol biosynthetic enzymes as in mammals, and, surprisingly, Sre1 also stimulates transcription of genes required for adaptation to hypoxia. Furthermore, Sre1 rapidly activates these target genes in response to low oxygen and is itself required for anaerobic growth. Based on these findings, we propose and test a model in which Sre1 and Scp1 monitor oxygen-dependent sterol synthesis as an indirect measure of oxygen supply and mediate a hypoxic response in fission yeast.	Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA	Johns Hopkins University	Espenshade, PJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA.	peter.espenshade@jhmi.edu		Hughes, Adam/0000-0002-7095-3793	NHLBI NIH HHS [HL-077588, R01 HL077588-01, R01 HL077588] Funding Source: Medline; NIGMS NIH HHS [GM007445] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077588] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alfa C, 1993, EXPT FISSION YEAST L; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BURKE JD, 1994, MOL GEN GENET, V242, P169, DOI 10.1007/BF00391010; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; Feramisco JD, 2004, J BIOL CHEM, V279, P8487, DOI 10.1074/jbc.M312623200; Gardner RG, 2001, J BIOL CHEM, V276, P8681, DOI 10.1074/jbc.M007888200; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Kwast KE, 2002, J BACTERIOL, V184, P250, DOI 10.1128/JB.184.1.250-265.2002; Kwast KE, 1998, J EXP BIOL, V201, P1177; Loewen CJR, 2002, CURR BIOL, V12, pR779, DOI 10.1016/S0960-9822(02)01292-7; LORENZ RT, 1991, LIPIDS, V26, P598, DOI 10.1007/BF02536423; Matsuda M, 2001, GENE DEV, V15, P1206, DOI 10.1101/gad.891301; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Parraga A, 1998, STRUCT FOLD DES, V6, P661, DOI 10.1016/S0969-2126(98)00067-7; Rawson RB, 1999, J BIOL CHEM, V274, P28549, DOI 10.1074/jbc.274.40.28549; Rawson RB, 2003, NAT REV MOL CELL BIO, V4, P631, DOI 10.1038/nrm1174; Rosenfeld E, 2003, YEAST, V20, P1115, DOI 10.1002/yea.1026; Sambrook J., 2001, MOL CLONING LAB MANU; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Vik A, 2001, MOL CELL BIOL, V21, P6395, DOI 10.1128/MCB.21.19.6395-6405.2001; Wang H, 2001, J NEUROCHEM, V77, P53; Wilcox LJ, 2002, J BIOL CHEM, V277, P32466, DOI 10.1074/jbc.M204707200; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Ye J, 2000, P NATL ACAD SCI USA, V97, P5123, DOI 10.1073/pnas.97.10.5123	36	254	256	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					831	842		10.1016/j.cell.2005.01.012	http://dx.doi.org/10.1016/j.cell.2005.01.012			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797383	Bronze			2022-12-28	WOS:000228067500012
J	Rosenfeld, N; Young, JW; Alon, U; Swain, PS; Elowitz, MB				Rosenfeld, N; Young, JW; Alon, U; Swain, PS; Elowitz, MB			Gene regulation at the single-cell level	SCIENCE			English	Article							BACTERIOPHAGE-LAMBDA; ESCHERICHIA-COLI; EXPRESSION; NETWORKS; STOCHASTICITY; REPRESSOR; NOISE; TRANSCRIPTION; FEEDBACK; OPERATOR	The quantitative relation between transcription factor concentrations and the rate of protein production from downstream genes is central to the function of genetic networks. Here we show that this relation, which we call the gene regulation function (GRF), fluctuates dynamically in individual living cells, thereby limiting the accuracy with which transcriptional genetic circuits can transfer signals. Using fluorescent reporter genes and fusion proteins, we characterized the bacteriophage lambda promoter P-R in Escherichia coli. A novel technique based on binomial errors in protein partitioning enabled calibration of in vivo biochemical parameters in molecular units. We found that protein production rates fluctuate over a time scale of about one cell cycle, while intrinsic noise decays rapidly. Thus, biochemical parameters, noise, and slowly varying cellular states together determine the effective single-cell GRF. These results can form a basis for quantitative modeling of natural gene circuits and for design of synthetic ones.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Dept Appl Phys, Pasadena, CA 91125 USA; Weizmann Inst Sci, Dept Mol Cell Biol & Phys Complex Syst, IL-76100 Rehovot, Israel; McGill Univ, Dept Physiol, Ctr Nonlinear Dynam, Montreal, PQ H3G 1Y6, Canada	California Institute of Technology; California Institute of Technology; Weizmann Institute of Science; McGill University	Elowitz, MB (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	melowitz@caltech.edu	Swain, Peter S/AAW-3265-2020	Swain, Peter/0000-0001-7489-8587				Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Cluzel P, 2000, SCIENCE, V287, P1652, DOI 10.1126/science.287.5458.1652; Darling PJ, 2000, J MOL BIOL, V302, P625, DOI 10.1006/jmbi.2000.4050; Davidson EH, 2002, SCIENCE, V295, P1669, DOI 10.1126/science.1069883; Dodd IB, 2004, GENE DEV, V18, P344, DOI 10.1101/gad.1167904; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; KOBLAN KS, 1992, BIOCHEMISTRY-US, V31, P57, DOI 10.1021/bi00116a010; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; MEYER BJ, 1980, J MOL BIOL, V139, P163, DOI 10.1016/0022-2836(80)90303-4; Mirasoli M, 2002, ANAL CHEM, V74, P5948, DOI 10.1021/ac0259008; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257; Ptashne M, 1992, GENETIC SWITCH PHAGE; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; SAVAGEAU MA, 1976, BIOCH SYSTEMS ANAL; Shapiro JA, 1998, ANNU REV MICROBIOL, V52, P81, DOI 10.1146/annurev.micro.52.1.81; Shen-Orr SS, 2002, NAT GENET, V31, P64, DOI 10.1038/ng881; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Swain PS, 2002, P NATL ACAD SCI USA, V99, P12795, DOI 10.1073/pnas.162041399; Swain PS, 2004, J MOL BIOL, V344, P965, DOI 10.1016/j.jmb.2004.09.073	29	788	809	3	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1962	1965		10.1126/science.1106914	http://dx.doi.org/10.1126/science.1106914			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790856				2022-12-28	WOS:000227957300057
J	Voulgarelis, M; Ziakas, PD				Voulgarelis, M; Ziakas, PD			Renal papillary necrosis unmasking sickle cell disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Natl Univ Athens, Sch Med, Athens 11527, Greece	Athens Medical School; National & Kapodistrian University of Athens	Voulgarelis, M (corresponding author), Natl Univ Athens, Sch Med, Athens 11527, Greece.			Ziakas, Panayiotis/0000-0002-5943-8635					0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1237	1237		10.1056/NEJMicm030682	http://dx.doi.org/10.1056/NEJMicm030682			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788500				2022-12-28	WOS:000227832300010
J	Wright, JG; Wang, EEL; Owen, JL; Stephens, D; Graham, HK; Hanlon, M; Nattrass, GR; Reynolds, RAK; Coyte, P				Wright, JG; Wang, EEL; Owen, JL; Stephens, D; Graham, HK; Hanlon, M; Nattrass, GR; Reynolds, RAK; Coyte, P			Treatments for paediatric femoral fractures: a randomised trial	LANCET			English	Article							TITANIUM ELASTIC NAILS; SHAFT FRACTURES; EXTERNAL FIXATION; FEMUR FRACTURES; SPICA CAST; CHILDREN; COMPLICATIONS; MULTICENTER; MANAGEMENT; CHILDHOOD	Background Treatments for femoral fractures in children vary widely and have been investigated only in case series. We did a multicentre randomised trial to compare malunion rates after external fixation and after early application of a hip Spica cast for paediatric femoral shaft fractures. Methods All children aged 4-10 years with femoral fractures, admitted to four paediatric hospitals, were randomly assigned early application of hip Spica or external fixation. The primary outcome was malunion at 2 years after the fracture. Secondary outcomes were scores on the RAND physical function child health questionnaire and the post-hospitalisation behavioural questionnaire, and parents' and children's ratings of overall satisfaction with treatment. Analysis was by intention to treat based on children who reached the 2-year evaluation. Findings Of 60 children assigned to the hip-spica group, 56 reached the 2-year assessment; of them, six (11%) required other forms of treatment because of unacceptable loss of reduction. Of 48 children assigned external fixation, 45 reached the 2-year assessment; two (4%) had refractures and five (11%) required operative adjustment of the fixator. The rate of malunion was significantly higher in the hip-spica group than in the external-fixator group (25/56 [45%] vs 7/45 [16%]; 95% C1 for difference 12-46%; p=O center dot 002). The two groups had similar mean scores for the RAND physical function health questionnaire (0 center dot 34 vs 0 center dot 45; 95% Cl for difference, -0 center dot 57 to 0 center dot 34; p=O center dot 61), for the post-hospitalisation questionnaire (106 center dot 8 vs 106 center dot 3; -4 center dot 9 to 5 center dot 9; p=O center dot 86), and for parents' satisfaction (4 center dot 3 vs 4 center dot 2; -0 center dot 3 to 0 center dot 6; p=O center dot 5) and children's ratings of happiness with treatment (6 center dot 9 vs 7 center dot 7; -2 center dot 2 to 0 center dot 5; p=O center dot 21). Interpretation Early application of hip spica has a small role in the treatment of paediatric femoral fractures. Future trials need to compare external fixation with flexible intramedullary nails.	Hosp Sick Children, Dept Surg, Div Orthopaed Surg, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Populat Hlth Sci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Aventis Pasteur, Toronto, ON, Canada; Univ Melbourne, Royal Childrens Hosp, Dept Orthopaed Surg, Parkville, Vic 3052, Australia; Starship Childrens Hosp, Dept Paediat Orthopaed Surg, Auckland, New Zealand; Royal Childrens Hosp, Dept Paediat Orthopaed Surg, Melbourne, Vic, Australia; USC Sch Med, Childrens Hosp Los Angeles, Dept Orthopaed, Los Angeles, CA USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; Sanofi-Aventis; Royal Children's Hospital Melbourne; University of Melbourne; Starship Children's Hospital; Royal Children's Hospital Melbourne; Children's Hospital Los Angeles; University of Southern California	Wright, JG (corresponding author), Hosp Sick Children, Dept Surg, Div Orthopaed Surg, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	james.wright@sickkids.ca	Graham, Kerr/AAK-4383-2020		Canadian Institutes of Health Research [12788-1] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		ARONSON J, 1992, J PEDIATR ORTHOPED, V12, P157, DOI 10.1097/01241398-199203000-00003; BarOn E, 1997, J BONE JOINT SURG BR, V79B, P975, DOI 10.1302/0301-620X.79B6.7740; Blasier RD, 1997, J PEDIATR ORTHOPED, V17, P342, DOI 10.1097/00004694-199705000-00014; Buechsenschuetz KE, 2002, J TRAUMA, V53, P914, DOI 10.1097/00005373-200211000-00017; CAMPBELL L, 1986, AM J ORTHOPSYCHIAT, V56, P234, DOI 10.1111/j.1939-0025.1986.tb02723.x; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; Coyte PC, 1997, CLIN ORTHOP RELAT R, P205; DEBASTIANI G, 1984, J BONE JOINT SURG BR, V66, P538, DOI 10.1302/0301-620X.66B4.6746689; ECKHOFF DG, 1994, J PEDIATR ORTHOPED, V14, P608, DOI 10.1097/01241398-199409000-00010; EISEN M, 1979, MED CARE, V17, P902, DOI 10.1097/00005650-197909000-00003; EISEN M, 1980, R2313HEW RAND HLTH; EVANOFF M, 1993, J PEDIATR ORTHOPED, V13, P98, DOI 10.1097/01241398-199301000-00020; Flynn JM, 2002, J BONE JOINT SURG AM, V84A, P2288, DOI 10.2106/00004623-200212000-00025; Flynn JM, 2001, J PEDIATR ORTHOPED, V21, P4, DOI 10.1097/01241398-200101000-00003; Griffin P P, 1972, Orthop Clin North Am, V3, P213; Hedin H, 2003, ACTA ORTHOP SCAND, V74, P305; HENNRIKUS WL, 1993, J BONE JOINT SURG AM, V75A, P508, DOI 10.2106/00004623-199304000-00005; Hinton RY, 1999, J BONE JOINT SURG AM, V81A, P500, DOI 10.2106/00004623-199904000-00007; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; HUGHES BF, 1995, J PEDIATR ORTHOPED, V15, P457, DOI 10.1097/01241398-199507000-00009; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V286, P821, DOI 10.1001/jama.286.7.821; IRANI RN, 1976, J BONE JOINT SURG AM, V58, P945, DOI 10.2106/00004623-197658070-00009; Kain ZN, 1999, ANESTHESIOLOGY, V90, P758, DOI 10.1097/00000542-199903000-00018; Kain ZN, 2001, ANESTH ANALG, V92, P897; KIRSCHENBAUM D, 1990, J PEDIATR ORTHOPED, V10, P588, DOI 10.1097/01241398-199009000-00003; LIGIER JN, 1988, J BONE JOINT SURG BR, V70, P74, DOI 10.1302/0301-620X.70B1.3339064; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; LODER RT, 1995, J PEDIATR ORTHOPED, V15, P41, DOI 10.1097/01241398-199501000-00010; Luhmann SJ, 2003, J PEDIATR ORTHOPED, V23, P443; Macnicol MF, 1997, J BONE JOINT SURG BR, V79B, P891, DOI 10.1302/0301-620X.79B6.8376; NAFEI A, 1992, J PEDIATR ORTHOPED, V12, P499, DOI 10.1097/01241398-199207000-00016; NEWTON PO, 1994, J PEDIATR ORTHOPED, V14, P508, DOI 10.1097/01241398-199407000-00017; PROBE R, 1993, J PEDIATR ORTHOPED, V13, P102, DOI 10.1097/01241398-199301000-00021; Rennick JE, 2002, J DEV BEHAV PEDIATR, V23, DOI 10.1097/00004703-200206000-00002; REYNOLDS DA, 1981, J BONE JOINT SURG BR, V63, P83, DOI 10.1302/0301-620X.63B1.7204480; Rohde RS, 2003, J PEDIATR ORTHOPED, V23, P635, DOI 10.1097/01241398-200309000-00011; Sanders JO, 2001, J PEDIATR ORTHOPED, V21, P436, DOI 10.1097/00004694-200107000-00004; Skaggs DL, 1999, J PEDIATR ORTHOPED, V19, P582, DOI 10.1097/00004694-199909000-00005; SUGI M, 1987, J BONE JOINT SURG BR, V69, P743, DOI 10.1302/0301-620X.69B5.2824519; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Thompson JD, 1997, CLIN ORTHOP RELAT R, P74; VERBEEK HOF, 1976, INJURY, V8, P43, DOI 10.1016/0020-1383(76)90009-7; VERNON DTA, 1966, AM J DIS CHILD, V111, P581, DOI 10.1001/archpedi.1966.02090090053003; WEBER B G, 1969, Injury, V1, P65, DOI 10.1016/S0020-1383(69)80034-3; Wong J, 2004, J PEDIATR ORTHOPED, V24, P463, DOI 10.1097/01241398-200409000-00003; Wright JG, 2000, CAN J SURG, V43, P180; 1998, SKELETAL TRAUMA CHIL; 1990, SKELETAL INJURY CHIL; 1991, FRACTURES CHILDREN	49	59	62	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR-APR	2005	365	9465					1153	1158		10.1016/S0140-6736(05)71878-X	http://dx.doi.org/10.1016/S0140-6736(05)71878-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794970				2022-12-28	WOS:000227909500028
J	Fowler, RA; Sanders, GD; Bravata, DM; Nouri, B; Gastwirth, JM; Peterson, D; Broker, AG; Garber, AM; Owens, DK				Fowler, RA; Sanders, GD; Bravata, DM; Nouri, B; Gastwirth, JM; Peterson, D; Broker, AG; Garber, AM; Owens, DK			Cost-effectiveness of defending against bioterrorism: A comparison of vaccination and antibiotic prophylaxis against anthrax	ANNALS OF INTERNAL MEDICINE			English	Article							INHALATIONAL ANTHRAX; HEALTH-ASSESSMENT; UNITED-STATES; SEPSIS; EPIDEMIOLOGY; EFFICACY; OUTCOMES; PROGRAM; RISK	Background: Weaponized Bacillus anthracis is one of the few biological agents that can cause death and disease in sufficient numbers to devastate an urban setting. Objective: To evaluate the cost-effectiveness of strategies for prophylaxis and treatment of an aerosolized B. anthracis bioterror attack. Design: Decision analytic model. Data Sources: we derived probabilities of anthrax exposure, vaccine and treatment characteristics, and their costs and associated clinical outcomes from the medical literature and bioterrorism -preparedness experts. Target Population: Persons living and working in a large metropolitan U.S. city. Time Horizon: Patient lifetime. Perspective: Societal. Intervention: we evaluated 4 postattack strategies: no prophylaxis, vaccination alone, antibiotic prophylaxis alone, or vaccination and antibiotic prophylaxis, as well as preattack vaccination versus no vaccination. Outcome Measures: Costs, quality-adjusted life-years, lifeyears, and incremental cost-effectiveness. Results of Base-Case Analysis: if an aerosolized B. anthracis bioweapon attack occurs, postexposure prophylactic vaccination and antibiotic therapy for those potentially exposed is the most effective (0.33 life-year gained per person) and least costly ($355 saved per person) strategy, as compared with vaccination alone. At low baseline probabilities of attack and exposure, mass previous vaccination of a metropolitan population is more costly ($815 million for a city of 5 million people) and not more effective than no vaccination. Results of Sensitivity Analysis: if prophylactic antibiotics cannot be promptly distributed after exposure, previous vaccination may become cost-effective. Limitations: The probability of exposure and disease critically depends on the probability and mechanism of bioweapon release. Conclusions: In the event of an aerosolized B. anthracis bioweapon attack over an unvaccinated metropolitan U.S. population, postattack prophylactic vaccination and antibiotic therapy is the most effective and least expensive strategy.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Duke Univ, Duke Clin Res Inst, Durham, NC 27706 USA; Stanford Univ, Ctr Primary Care & Outcomes Res, Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA 94305 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Duke University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Fowler, RA (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, 2075 Bayview Ave,Room D478, Toronto, ON M4N 3M5, Canada.	rob.fowler@sw.ca	Garber, Alan M/F-1476-2010					*AG HLTHC RES QU, 1996, HLTH C COST UT PROJ; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; *BIOP CORP, 1978, ANTH VACC ADS BIO TH; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P973; Christopher GW, 1997, JAMA-J AM MED ASSOC, V278, P412, DOI 10.1001/jama.278.5.412; COHEN HE, 2002, DRUG TOPICS RED BOOK; *CTR MED MED SERV, MED PRESCR REIMB IF; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Edbrooke DL, 1999, CRIT CARE MED, V27, P1760, DOI 10.1097/00003246-199909000-00010; Friedlander AM, 1999, JAMA-J AM MED ASSOC, V282, P2104, DOI 10.1001/jama.282.22.2104; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GOLD MR, 1996, COS EFFECTIVENESS HL; Gould MK, 1999, ANN INTERN MED, V130, P789, DOI 10.7326/0003-4819-130-10-199905180-00002; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; IVINS BE, 1994, VACCINE, V12, P872, DOI 10.1016/0264-410X(94)90027-2; JEFFERSON T, 2000, COCHRANE DB SYST REV; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; Lieu TA, 2000, JAMA-J AM MED ASSOC, V283, P1460, DOI 10.1001/jama.283.11.1460; LIEU TA, 1994, JAMA-J AM MED ASSOC, V271, P375, DOI 10.1001/jama.271.5.375; Mazzuchi JF, 2000, AVIAT SPACE ENVIR MD, V71, P260; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; Miller MA, 1996, JAMA-J AM MED ASSOC, V276, P967, DOI 10.1001/jama.276.12.967; *NAT AER SPACE ADM, GROSS DOM PROD DEFL; *NEW STAT DEP HLTH, 2000, OFF MED MANA DOH MED, V15; *NEW YORK STAT DEP, COUNT HLHT IND PROF; *NEW YORK STAT DEP, NEW YORK STAT LIF TA; PERKINS WA, 1961, BACTERIOL REV, V25, P347, DOI 10.1128/MMBR.25.3.347-355.1961; PERL TM, 1995, JAMA-J AM MED ASSOC, V274, P338, DOI 10.1001/jama.274.4.338; Postema A S, 2000, MMWR Recomm Rep, V49, P1; Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058; Reissman DB, 2004, JAMA-J AM MED ASSOC, V291, P1994, DOI 10.1001/jama.291.16.1994; Rotz LD, 2002, EMERG INFECT DIS, V8, P225, DOI 10.3201/eid0802.010164; Salpeter SR, 1997, ANN INTERN MED, V127, P1051, DOI 10.7326/0003-4819-127-12-199712150-00001; Sande MA, 2004, SANFORD GUIDE ANTIMI; Shafazand S, 1999, CHEST, V116, P1369, DOI 10.1378/chest.116.5.1369; Shepard CW, 2002, EMERG INFECT DIS, V8, P1124, DOI 10.3201/eid0810.020349; SHLYAKHOV EN, 1994, VACCINE, V12, P727, DOI 10.1016/0264-410X(94)90223-2; STOLBERG SG, 2002, PROMED DIGEST, V52, P1; Swartz MN, 2001, NEW ENGL J MED, V345, P1621, DOI 10.1056/NEJMra012892; Tengs TO, 2000, MED CARE, V38, P583, DOI 10.1097/00005650-200006000-00004; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Tucker AW, 1998, JAMA-J AM MED ASSOC, V279, P1371, DOI 10.1001/jama.279.17.1371; *US BUR LAB STAT, CONS EXP SURV; *US C OFF TECHN AS, 1993, OTAISC599; *US CEN BUR, 1999, STAT ABSTR US; *US CEN BUR, 1990, 1990 CENS POP GEN PO; *US CEN BUR, CENS 2000; *US DEP DEF, ANTHR VACC PROGR QUE; *US DHHS, US LIFE TABL; *US FOOD DRUG ADM, 1985, 51002 US FOOD DRUG A; WATSON A, 1994, EPIDEMIOL INFECT, V113, P479, DOI 10.1017/S0950268800068497; Wein LM, 2003, P NATL ACAD SCI USA, V100, P4346, DOI 10.1073/pnas.0636861100; Wiesen AR, 2002, JAMA-J AM MED ASSOC, V287, P1556, DOI 10.1001/jama.287.12.1556; World Health Organization, 1970, HLTH ASP CHEM BIOL W; WUDUNN S, 1998, NY TIMES        0526, P1; ZOON KC, STATEMENT ANTHRAX VA; 2002, MMWR MORB MORTAL WKL, V51, P1024; 2001, MMWR MORB MORTAL WKL, V50, P1051; 1998, MED LETT DRUGS THER, V40, P52; 2002, MMWR MORB MORTAL WKL, V51, P59; 1965, BR MED J, V5464, P717	64	53	53	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					601	610		10.7326/0003-4819-142-8-200504190-00008	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916TZ	15838066				2022-12-28	WOS:000228410400002
J	Siotia, AK; Chaudhuri, A; Muzulu, SI; Harling, D; Muthusamy, R				Siotia, AK; Chaudhuri, A; Muzulu, SI; Harling, D; Muthusamy, R			Interactive case report - Postoperative hypoxia in a woman with Down's syndrome: case progression	BRITISH MEDICAL JOURNAL			English	Article									No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England; Ninewells Hosp, Dundee DD1 95Y, Scotland; Rotherham Dist Gen Hosp, Rotherham S60 2UD, S Yorkshire, England	Northern General Hospital	Siotia, AK (corresponding author), No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England.	Anjan.Siotia@sth.nhs.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 16	2005	330	7496					888	888		10.1136/bmj.330.7496.888	http://dx.doi.org/10.1136/bmj.330.7496.888			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	917UA	15831875	Green Published			2022-12-28	WOS:000228493500021
J	Sato, T; Cheng, YN; Wu, XC; Zelenitsky, DK; Hsiao, YF				Sato, T; Cheng, YN; Wu, XC; Zelenitsky, DK; Hsiao, YF			A pair of shelled eggs inside a female dinosaur	SCIENCE			English	Article							CHINA; NEST		Canadian Museum Nat, Ottawa, ON K1P 6P4, Canada; Natl Museum Nat Hist, Taichung, Taiwan; Univ Calgary, Dept Geol & Geophys, Calgary, AB T2N 1N4, Canada; Paleowonders Fossil & Mineral Museum, Taipei, Taiwan	University of Calgary	Sato, T (corresponding author), Canadian Museum Nat, POB 3443,Stn D, Ottawa, ON K1P 6P4, Canada.	tsato@mus-nature.ca; xcwu@mus-nature.ca						Chen PJ, 1998, NATURE, V391, P147, DOI 10.1038/34356; Clark James M., 1999, American Museum Novitates, V3265, P1; Dong ZM, 1996, CAN J EARTH SCI, V33, P631, DOI 10.1139/e96-046; NORELL MA, 1995, NATURE, V378, P774, DOI 10.1038/378774a0; Varricchio DJ, 1997, NATURE, V385, P247, DOI 10.1038/385247a0; Varricchio DJ, 2004, LIFE O PAST, P215	6	95	102	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					375	375		10.1126/science.1110578	http://dx.doi.org/10.1126/science.1110578			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831749	Green Submitted			2022-12-28	WOS:000228492000041
J	Bartkova, J; Horejsi, Z; Koed, K; Kramer, A; Tort, F; Zieger, K; Guldberg, P; Sehested, M; Nesland, JM; Lukas, C; Orntoft, T; Lukas, J; Bartek, J				Bartkova, J; Horejsi, Z; Koed, K; Kramer, A; Tort, F; Zieger, K; Guldberg, P; Sehested, M; Nesland, JM; Lukas, C; Orntoft, T; Lukas, J; Bartek, J			DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis	NATURE			English	Article							CELL-CYCLE CONTROL; CHROMOSOME INSTABILITY; GENOMIC INSTABILITY; BREAST-CANCER; HISTONE H2AX; PHOSPHORYLATION; REPLICATION; PROTEIN; ATM; P53	During the evolution of cancer, the incipient tumour experiences 'oncogenic stress', which evokes a counter- response to eliminate such hazardous cells. However, the nature of this stress remains elusive, as does the inducible anti-cancer barrier that elicits growth arrest or cell death. Here we show that in clinical specimens from different stages of human tumours of the urinary bladder, breast, lung and colon, the early precursor lesions ( but not normal tissues) commonly express markers of an activated DNA damage response. These include phosphorylated kinases ATM and Chk2, and phosphorylated histone H2AX and p53. Similar checkpoint responses were induced in cultured cells upon expression of different oncogenes that deregulate DNA replication. Together with genetic analyses, including a genome-wide assessment of allelic imbalances, our data indicate that early in tumorigenesis ( before genomic instability and malignant conversion), human cells activate an ATR/ATM- regulated DNA damage response network that delays or prevents cancer. Mutations compromising this checkpoint, including defects in the ATM - Chk2 p53 pathway, might allow cell proliferation, survival, increased genomic instability and tumour progression.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Danish Canc Soc, Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Clin Biochem, DK-8200 Aarhus, Denmark; Univ Copenhagen Hosp, Dept Pathol, DK-2100 Copenhagen, Denmark; Univ Oslo, Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway; Acad Sci Czech Republ, Inst Genet Mol, CZ-16637 Prague, Czech Republic	Danish Cancer Society; Danish Cancer Society; Aarhus University; University of Copenhagen; University of Oslo; Czech Academy of Sciences	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.	jb@cancer.dk	Bartek, Jiri/G-5870-2014	Lukas, Claudia/0000-0001-7169-6883; Tort, Frederic/0000-0003-2733-1603; Lukas, Jiri/0000-0001-9087-506X; Licenikova Horejsi, Zuzana/0000-0002-9943-1649				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Binz SK, 2004, DNA REPAIR, V3, P1015, DOI 10.1016/j.dnarep.2004.03.028; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Lindstrom MS, 2003, ONCOGENE, V22, P4993, DOI 10.1038/sj.onc.1206659; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Meeker AK, 2004, CLIN CANCER RES, V10, P3317, DOI 10.1158/1078-0432.CCR-0984-03; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	49	2123	2201	7	210	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					864	870		10.1038/nature03482	http://dx.doi.org/10.1038/nature03482			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829956				2022-12-28	WOS:000228327600032
J	Caballero, B				Caballero, B			A nutrition paradox - Uderweight and obesity in developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRANSITION; BURDEN		Johns Hopkins Univ, Ctr Human Nutr, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Caballero, B (corresponding author), Johns Hopkins Univ, Ctr Human Nutr, Baltimore, MD 21218 USA.							Doak CM, 2005, INT J OBESITY, V29, P129, DOI 10.1038/sj.ijo.0802824; Monteiro C, 2004, INT J OBESITY, V28, P1181, DOI 10.1038/sj.ijo.0802716; Monteiro CA, 2004, AM J PUBLIC HEALTH, V94, P433, DOI 10.2105/AJPH.94.3.433; Ruel M. T., 2001, Nutrition and health in developing countries, P465; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20	5	234	248	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1514	1516		10.1056/NEJMp048310	http://dx.doi.org/10.1056/NEJMp048310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	915SH	15829531				2022-12-28	WOS:000228324200002
J	Burton, MJ; Holland, MJ; Makalo, P; Aryee, EAN; Alexander, NDE; Sillah, A; Faal, H; West, SK; Foster, A; Johnson, GJ; Mabey, DCW; Bailey, RL				Burton, MJ; Holland, MJ; Makalo, P; Aryee, EAN; Alexander, NDE; Sillah, A; Faal, H; West, SK; Foster, A; Johnson, GJ; Mabey, DCW; Bailey, RL			Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIAL; AZITHROMYCIN; DIAGNOSIS; CHILDREN; AREA	Background Community-wide mass antibiotic treatment is a central component of trachoma control. The optimum frequency and duration of treatment are unknown. We measured the effect of mass treatment on the conjunctival burden of Chlamydia trachomatis in a Gambian community with low to medium trachoma prevalence and investigated the rate, route, and determinants of re-emergent infection. Methods 14 trachoma-endemic villages in rural Gambia were examined and conjunctival swabs obtained at baseline, 2, 6, 12, and 17 months. Mass antibiotic treatment with azithromycin was given to the community at baseline. C trachomatis was detected by qualitative PCR and individual infection load then estimated by real-time quantitative PCR. Findings C trachomatis was detected in 95 (7%) of 1319 individuals at baseline. Treatment coverage was 83% of the population (1328 of 1595 people). The effect of mass treatment was heterogeneous. In 12 villages all baseline infections (34 [3%] of 1062 individuals) resolved, and prevalence (three [0.3%]) and infection load remained low throughout the study. Two villages (baseline infection: 61 [24%] of 257 individuals) had increased infection 2 months after treatment (74 [30%]), after extensive contact with other untreated communities. Subsequently, this value reduced to less than half of that before treatment (25 [11%]). Interpretation Mass antibiotic treatment generally results in effective, longlasting control of C trachomatis in this environment. For low prevalence regions, one treatment episode might be sufficient. Infection can be reintroduced through contact with untreated populations. Communities need to be monitored for treatment failure and control measures implemented over wide geographical areas.	Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England; MRC Labs, Fajara, Gambia; Natl Eye Care Programme, Banjul, Gambia; Johns Hopkins Univ, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA; Inst Ophthalmol, Div Epidemiol & Int Eye Hlth, London, England	University of London; London School of Hygiene & Tropical Medicine; MRC Laboratory Molecular Biology; Johns Hopkins University; University of London; University College London	Burton, MJ (corresponding author), Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Keppel St, London WC1E 7HT, England.	matthew.burton@lshtm.ac.uk	Holland, Martin J/K-6502-2012	Holland, Martin J/0000-0002-5828-6318; Mabey, David/0000-0002-0031-8276; Foster, Allen/0000-0003-2368-4436; Burton, Matthew/0000-0003-1872-9169	MRC [MC_U190081961] Funding Source: UKRI; Medical Research Council [MC_U190081961] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bailey R, 1999, EPIDEMIOL INFECT, V123, P479, DOI 10.1017/S0950268899003076; BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; Baral K, 1999, B WORLD HEALTH ORGAN, V77, P461; Bird M, 2003, J INFECT DIS, V187, P1669, DOI 10.1086/374743; Burton MJ, 2003, INVEST OPHTH VIS SCI, V44, P4215, DOI 10.1167/iovs.03-0107; Dawson CR, 1981, GUIDE TRACHOMA CONTR; Dolin PJ, 1998, BRIT J OPHTHALMOL, V82, P930, DOI 10.1136/bjo.82.8.930; Emerson PM, 2004, LANCET, V363, P1093, DOI 10.1016/S0140-6736(04)15891-1; Emerson PM, 2000, TROP MED INT HEALTH, V5, P515, DOI 10.1046/j.1365-3156.2000.00603.x; Emerson PM, 1999, LANCET, V353, P1401, DOI 10.1016/S0140-6736(98)09158-2; Fraser-Hurt N, 2001, B WORLD HEALTH ORGAN, V79, P632; Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451; Moalic E, 2000, PEDIATR INFECT DIS J, V19, P979, DOI 10.1097/00006454-200010000-00008; Munoz B, 2003, INVEST OPHTH VIS SCI, V44, P1464, DOI 10.1167/iovs.02-0234; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; Smith A, 2001, Ophthalmic Epidemiol, V8, P127, DOI 10.1076/opep.8.2.127.4164; Solomon AW, 2003, LANCET, V362, P198, DOI 10.1016/S0140-6736(03)13909-8; Sterne J., 1988, ESSENTIAL MED STAT; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; WARD M, 1990, SCAND J INFECT DIS, P137; WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; *WHO, 1997, WHOPBL9656; *WHO, 2001, 6 M WHO ALL GLOB EL	25	110	110	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2005	365	9467					1321	1328		10.1016/S0140-6736(05)61029-X	http://dx.doi.org/10.1016/S0140-6736(05)61029-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823382				2022-12-28	WOS:000228219600027
J	Dupont, S; Zacchigna, L; Cordenonsi, M; Soligo, S; Adorno, M; Rugge, M; Piccolo, S				Dupont, S; Zacchigna, L; Cordenonsi, M; Soligo, S; Adorno, M; Rugge, M; Piccolo, S			Germ-layer specification and control of cell growth by ectodermin, a Smad4 ubiquitin ligase	CELL			English	Article							TGF-BETA; COLORECTAL-CANCER; SPEMANNS ORGANIZER; TUMOR SUPPRESSORS; XENOPUS; MUTATIONS; INDUCTION; PATHWAY; GENE; BMP	TGF-beta signaling is essential for development and proliferative homeostasis. During embryogenesis, maternal determinants act in concert with TGF-beta signals to form mesoderm and endoderm. In contrast, ectoderm specification requires the TGF-beta response to be attenuated, although the mechanisms by which this is achieved remain unknown. In a functional screen for ectoderm determinants, we have identified Ecto-dermin (Ecto). In Xenopus embryos, Ecto is essential for the specification of the ectoderm and acts by restricting the mesoderm-inducing activity of TGF-beta signals to the mesoderm and favoring neural induction. Ecto is a RING-type ubiquitin ligase for Smad4, a TGF-beta signal transducer. Depletion of Ecto in human cells enforces TGF-beta-induced cytostasis and, moreover, plays a causal role in limiting the antimitogenic effects of Smad4 in tumor cells. We propose that Ectodermin is a key switch in the control of TGF-beta gene responses during early embryonic development and cell proliferation.	Univ Padua, Dept Histol Microbiol & Med Biotechnol, Sect Histol & Embryol, I-35121 Padua, Italy; Univ Padua, Dept Oncol & Surg Sci, Pathol Sect, I-35121 Padua, Italy	University of Padua; IRCCS Istituto Oncologico Veneto (IOV); University of Padua	Piccolo, S (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Sect Histol & Embryol, I-35121 Padua, Italy.	piccolo@civ.bio.unipd.it	Dupont, Sirio/AAP-8133-2021; Cordenonsi, Michelangelo/K-7692-2016; Rugge, Massimo/K-7525-2016	Cordenonsi, Michelangelo/0000-0002-8253-5724; Dupont, Sirio/0000-0002-6869-1966; PICCOLO, STEFANO/0000-0002-2037-0004	Telethon [GGP04030] Funding Source: Medline	Telethon(Fondazione Telethon)		Bell E, 2003, DEVELOPMENT, V130, P1381, DOI 10.1242/dev.00344; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howell M, 1999, DEV BIOL, V214, P354, DOI 10.1006/dbio.1999.9430; LeSueur JA, 2002, DEV CELL, V2, P771, DOI 10.1016/S1534-5807(02)00172-7; Lin X, 2003, J BIOL CHEM, V278, P18714, DOI 10.1074/jbc.M302243200; Mizuseki K, 1998, DEVELOPMENT, V125, P579; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Nicolas FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Schmidt JE, 1996, DEVELOPMENT, V122, P1711; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; SNAPE A, 1987, DEV BIOL, V119, P503, DOI 10.1016/0012-1606(87)90053-4; Takaku K, 1999, CANCER RES, V59, P6113; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Wessely O, 2000, DEVELOPMENT, V127, P2053; Whitman M, 2001, DEV CELL, V1, P605, DOI 10.1016/S1534-5807(01)00076-4; WILSON PA, 1995, NATURE, V376, P331, DOI 10.1038/376331a0; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Xu J, 2000, P NATL ACAD SCI USA, V97, P4820, DOI 10.1073/pnas.97.9.4820; Zhang J, 1998, CELL, V94, P515, DOI 10.1016/S0092-8674(00)81592-5; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	32	257	277	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					87	99		10.1016/j.cell.2005.01.033	http://dx.doi.org/10.1016/j.cell.2005.01.033			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820681	Bronze			2022-12-28	WOS:000228348500012
J	Walt, DR				Walt, DR			Miniature analytical methods for medical diagnostics	SCIENCE			English	Editorial Material							TOTAL ANALYSIS SYSTEMS; GENOMIC MICROARRAYS; LUNG-CANCER; ARRAYS; BREATH; CHIPS		Tufts Univ, Dept Chem, Medford, MA 02155 USA; Illumina Inc, San Diego, CA 92121 USA	Tufts University; Illumina	Walt, DR (corresponding author), Tufts Univ, Dept Chem, Medford, MA 02155 USA.	david.walt@tufts.edu						Albert KJ, 2000, CHEM REV, V100, P2595, DOI 10.1021/cr980102w; Albertson DG, 2003, HUM MOL GENET, V12, pR145, DOI 10.1093/hmg/ddg261; Beebe DJ, 2002, ANNU REV BIOMED ENG, V4, P261, DOI 10.1146/annurev.bioeng.4.112601.125916; Bodrossy L, 2004, CURR OPIN MICROBIOL, V7, P245, DOI 10.1016/j.mib.2004.04.005; Bryant PA, 2004, LANCET INFECT DIS, V4, P100, DOI 10.1016/S1473-3099(04)00930-2; Campbell CJ, 2004, J APPL MICROBIOL, V96, P18, DOI 10.1046/j.1365-2672.2003.02112.x; Di Natale C, 2003, BIOSENS BIOELECTRON, V18, P1209, DOI 10.1016/S0956-5663(03)00086-1; Duffy DC, 1999, ANAL CHEM, V71, P4669, DOI 10.1021/ac990682c; Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994; Kricka LJ, 2001, CLIN CHIM ACTA, V307, P219, DOI 10.1016/S0009-8981(01)00451-X; Lee SW, 2003, ADV MATER, V15, P689, DOI 10.1002/adma.200304818; Mantripragada KK, 2004, TRENDS GENET, V20, P87, DOI 10.1016/j.tig.2003.12.008; Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755; Phillips M, 1999, LANCET, V353, P1930, DOI 10.1016/S0140-6736(98)07552-7; Schulte TH, 2002, CLIN CHIM ACTA, V321, P1, DOI 10.1016/S0009-8981(02)00093-1; Stitzel SE, 2001, ANAL CHEM, V73, P5266, DOI 10.1021/ac010111w; Tudos AJ, 2001, LAB CHIP, V1, P83, DOI 10.1039/b106958f; Verpoorte E, 2003, LAB CHIP, V3, p60N, DOI 10.1039/b313217j; Vilkner T, 2004, ANAL CHEM, V76, P3373, DOI 10.1021/ac040063q; Yonzon CR, 2004, ANAL CHEM, V76, P78, DOI 10.1021/ac035134k; Zhong ZH, 2003, SCIENCE, V302, P1377, DOI 10.1126/science.1090899	21	107	108	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					217	219		10.1126/science.1108161	http://dx.doi.org/10.1126/science.1108161			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821081				2022-12-28	WOS:000228273700041
J	Bradley, CP				Bradley, CP			Commentary: Can we avoid bias?	BRITISH MEDICAL JOURNAL			English	Editorial Material							DECISION-MAKING; STRATEGIES; DIAGNOSIS		Natl Univ Ireland Univ Coll Cork, Cork, Ireland	University College Cork	Bradley, CP (corresponding author), Natl Univ Ireland Univ Coll Cork, Cork, Ireland.	c.bradley@ucc.ie		Bradley, Colin/0000-0002-3595-9567				Croskerry P, 2003, ACAD MED, V78, P775, DOI 10.1097/00001888-200308000-00003; Croskerry P, 2003, ANN EMERG MED, V41, P110, DOI 10.1067/mem.2003.22; Elstein AS, 2002, BRIT MED J, V324, P729, DOI 10.1136/bmj.324.7339.729; ELSTEIN AS, 2003, ACAD MED, V78, P775; Klein JG, 2005, BMJ-BRIT MED J, V330, P781, DOI 10.1136/bmj.330.7494.781	5	7	7	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 2	2005	330	7494					784	784		10.1136/bmj.330.7494.784	http://dx.doi.org/10.1136/bmj.330.7494.784			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15802724	Green Published			2022-12-28	WOS:000228222900029
J	Feachem, RGA; Sekhri, NK				Feachem, RGA; Sekhri, NK			US and UK health care: a special relationship? Moving towards true integration	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NHS		WHO, CH-1211 Geneva, Switzerland; Global Fund Fight AIDS TB & Malaria, CH-1216 Geneva, Switzerland	World Health Organization	Sekhri, NK (corresponding author), WHO, CH-1211 Geneva, Switzerland.	nsekhri@hcredesign.com						Berwick DM, 2002, BRIT MED J, V324, P142; BERWICK DM, 2002, BMJ-BRIT MED J, V324, P135; Burns LR, 2002, HEALTH AFFAIR, V21, P128, DOI 10.1377/hlthaff.21.4.128; Dixon J, 1998, BRIT MED J, V317, P125, DOI 10.1136/bmj.317.7151.125; ENTHOVEN A, 2002, BRIT MED J, V324, P135; Enthoven AC, 2002, BRIT MED J, V324, P143; Feachem RGA, 2002, BMJ-BRIT MED J, V324, P135, DOI 10.1136/bmj.324.7330.135; Ham C, 2003, BRIT MED J, V327, P1257, DOI 10.1136/bmj.327.7426.1257; HARDING ML, 2005, HLTH SERV J, V115, P5; JACOB JA, 2000, AM MED NEWS     1218; Light D, 2004, BRIT MED J, V328, P763, DOI 10.1136/bmj.328.7442.763; LOHR S, 2004, NY TIMES        1031; Walshe K, 2004, BRIT MED J, V329, P871, DOI 10.1136/bmj.329.7471.871	13	5	6	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					787	788		10.1136/bmj.330.7494.787	http://dx.doi.org/10.1136/bmj.330.7494.787			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15802726	Green Published, Green Accepted			2022-12-28	WOS:000228222900031
J	Jorde, LB				Jorde, LB			Where we're hot, they're not	SCIENCE			English	Editorial Material							MEIOTIC RECOMBINATION HOTSPOTS; LINKAGE DISEQUILIBRIUM; SACCHAROMYCES-CEREVISIAE; HUMAN GENOME; ASSOCIATION; DISEASE; SUSCEPTIBILITY; CROSSOVERS; PATTERNS; TRAITS		Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Jorde, LB (corresponding author), Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84112 USA.	lbj@genetics.utah.edu						Bamshad MJ, 2003, AM J HUM GENET, V72, P578, DOI 10.1086/368061; Ben-Aroya S, 2004, MOL CELL, V15, P221, DOI 10.1016/j.molcel.2004.06.002; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Crawford DC, 2004, NAT GENET, V36, P700, DOI 10.1038/ng1376; de Massy B, 2003, TRENDS GENET, V19, P514, DOI 10.1016/S0168-9525(03)00201-4; Evans DM, 2005, AM J HUM GENET, V76, P681, DOI 10.1086/429274; Fischer A, 2004, MOL BIOL EVOL, V21, P799, DOI 10.1093/molbev/msh083; Gerton JL, 2000, P NATL ACAD SCI USA, V97, P11383, DOI 10.1073/pnas.97.21.11383; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Hedges DJ, 2004, GENOME RES, V14, P1068, DOI 10.1101/gr.2530404; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Jorde LB, 2000, GENOME RES, V10, P1435, DOI 10.1101/gr.144500; Kauppi L, 2004, NAT REV GENET, V5, P413, DOI 10.1038/nrg1346; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Petes TD, 2001, NAT REV GENET, V2, P360, DOI 10.1038/35072078; Prieler S, 2005, GENE DEV, V19, P255, DOI 10.1101/gad.321105; PTAK SE, 2005, NAT GENET       0218; Terwilliger JD, 2002, CURR OPIN GENET DEV, V12, P726, DOI 10.1016/S0959-437X(02)00357-X; WICKLER W, 2005, SCIENCE, V308, P107, DOI DOI 10.1126/SCIENCE.1105322; Zhang K, 2003, HUM GENET, V113, P51, DOI 10.1007/s00439-003-0941-5; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270	23	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					60	62		10.1126/science.1110903	http://dx.doi.org/10.1126/science.1110903			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802591				2022-12-28	WOS:000228221500029
J	King-Casas, B; Tomlin, D; Anen, C; Camerer, CF; Quartz, SR; Montague, PR				King-Casas, B; Tomlin, D; Anen, C; Camerer, CF; Quartz, SR; Montague, PR			Getting to know you: Reputation and trust in a two-person economic exchange	SCIENCE			English	Article							TEMPORAL DIFFERENCE MODELS; NEURAL BASIS; FMRI; COOPERATION; PREDICTION; EVOLUTION; STRIATUM; ERRORS; ROLES; BRAIN	Using a multiround version of an economic exchange (trust game), we report that reciprocity expressed by one player strongly predicts future trust expressed by their partner - a behavioral finding mirrored by neural responses in the dorsal striatum. Here, analyses within and between brains revealed two signals - one encoded by response magnitude, and the other by response timing. Response magnitude correlated with the "intention to trust" on the next play of the game, and the peak of these "intention to trust" responses shifted its time of occurrence by 14 seconds as player reputations developed. This temporal transfer resembles a similar shift of reward prediction errors common to reinforcement learning models, but in the context of a social exchange. These data extend previous model-based functional magnetic resonance imaging, studies into the social domain and broaden our view of the spectrum of functions implemented by the dorsal striatum.	Baylor Coll Med, Dept Neurosci, Human Neuroimaging Lab, Houston, TX 77030 USA; Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; CALTECH, Div Humanities & Social Sci 228 77, Social Cognit Neurosci Lab, Pasadena, CA 91125 USA	Baylor College of Medicine; Baylor College of Medicine; California Institute of Technology	Montague, PR (corresponding author), Baylor Coll Med, Dept Neurosci, Human Neuroimaging Lab, 1 Baylor Plaza, Houston, TX 77030 USA.	read@bcm.tmc.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045790] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011723, R21DA014883] Funding Source: NIH RePORTER; NIDA NIH HHS [DA11723, DA14883] Funding Source: Medline; NIMH NIH HHS [MH52797] Funding Source: Medline; NINDS NIH HHS [NS045790] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adolphs R, 2003, NAT REV NEUROSCI, V4, P165, DOI 10.1038/nrn1056; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; BERG J, 1995, GAME ECON BEHAV, V10, P122, DOI 10.1006/game.1995.1027; Berridge KC, 2001, PSYCHOL LEARN MOTIV, V40, P223, DOI 10.1016/s0079-7421(00)80022-5; CAMERER C, 1988, ECONOMETRICA, V56, P1, DOI 10.2307/1911840; CAMERER CF, 2003, BEHAV GAME THEORY EX, P60; Coleman James S., 1990, FDN SOCIAL THEORY, P177; Dayan P, 2001, COMPUTATIONAL NEUROS; de Quervain DJF, 2004, SCIENCE, V305, P1254, DOI 10.1126/science.1100735; Decety J, 2004, NEUROIMAGE, V23, P744, DOI 10.1016/j.neuroimage.2004.05.025; DICKINSON A, 2002, STEVENS HDB EXPT PSY, V3, P26; Eisenberger NI, 2003, SCIENCE, V302, P290, DOI 10.1126/science.1089134; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; FEHR E, 1993, Q J ECON, V108, P437, DOI 10.2307/2118338; Glimcher PW, 2004, SCIENCE, V306, P447, DOI 10.1126/science.1102566; Hill EL, 2003, PHILOS T R SOC B, V358, P281, DOI 10.1098/rstb.2002.1209; Johnson PA, 2003, J NEUROPSYCH CLIN N, V15, P397, DOI 10.1176/appi.neuropsych.15.4.397; Lee KH, 2004, PSYCHOL MED, V34, P391, DOI 10.1017/S0033291703001284; McCabe K, 2001, P NATL ACAD SCI USA, V98, P11832, DOI 10.1073/pnas.211415698; McClure SM, 2003, NEURON, V38, P339, DOI 10.1016/S0896-6273(03)00154-5; Montague PR, 2004, NATURE, V431, P760, DOI 10.1038/nature03015; Montague PR, 2002, NEUROIMAGE, V16, P1159, DOI 10.1006/nimg.2002.1150; O'Doherty J, 2004, SCIENCE, V304, P452, DOI 10.1126/science.1094285; O'Doherty JP, 2003, NEURON, V38, P329, DOI 10.1016/S0896-6273(03)00169-7; OREILLY RC, 1999, WMODELS WORKING MEMO, P375; Pagnoni G, 2002, NAT NEUROSCI, V5, P97, DOI 10.1038/nn802; Rachlin H, 2002, BEHAV BRAIN SCI, V25, P239, DOI 10.1017/S0140525X02000055; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Seymour B, 2004, NATURE, V429, P664, DOI 10.1038/nature02581; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755	32	799	829	16	239	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					78	83		10.1126/science.1108062	http://dx.doi.org/10.1126/science.1108062			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	914IQ	15802598	Green Published			2022-12-28	WOS:000228221500036
J	Singer, BS; Hoffman, KA; Coe, RS; Brown, LL; Jicha, BR; Pringle, MS; Chauvin, A				Singer, BS; Hoffman, KA; Coe, RS; Brown, LL; Jicha, BR; Pringle, MS; Chauvin, A			Structural and temporal requirements for geomagnetic field reversal deduced from lava flows	NATURE			English	Article							MATUYAMA-BRUNHES BOUNDARY; ASTRONOMICAL CALIBRATION; POLARITY REVERSALS; RECORDS; AGES; TIMESCALE; DURATION; MANTLE; CORE	Reversals of the Earth's magnetic field reflect changes in the geodynamo-flow within the outer core-that generates the field. Constraining core processes or mantle properties that induce or modulate reversals requires knowing the timing and morphology of field changes that precede and accompany these reversals(1-4). But the short duration of transitional field states and fragmentary nature of even the best palaeomagnetic records make it difficult to provide a timeline for the reversal process(1,5). Ar-40/Ar-39 dating of lavas on Tahiti, long thought to record the primary part of the most recent 'Matuyama-Brunhes' reversal, gives an age of 795 +/- 7 kyr, indistinguishable from that of lavas in Chile and La Palma that record a transition in the Earth's magnetic field, but older than the accepted age for the reversal. Only the 'transitional' lavas on Maui and one from La Palma (dated at 776 +/- 2 kyr), agree with the astronomical age for the reversal. Here we propose that the older lavas record the onset of a geodynamo process, which only on occasion would result in polarity change. This initial instability, associated with the first of two decreases in field intensity, began similar to 18 kyr before the actual polarity switch. These data support the claim(6) that complete reversals require a significant period for magnetic flux to escape from the solid inner core and sufficiently weaken its stabilizing effect(7).	Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA; Calif Polytech State Univ San Luis Obispo, Dept Phys, San Luis Obispo, CA 93407 USA; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Univ Massachusetts, Dept Geosci, Amherst, MA 01003 USA; MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA; Geosci Rennes UMR CNRS, F-35042 Rennes, France	University of Wisconsin System; University of Wisconsin Madison; California State University System; California Polytechnic State University San Luis Obispo; University of California System; University of California Santa Cruz; University of Massachusetts System; University of Massachusetts Amherst; Massachusetts Institute of Technology (MIT); Centre National de la Recherche Scientifique (CNRS)	Singer, BS (corresponding author), Univ Wisconsin, Dept Geol & Geophys, 1215 W Dayton St, Madison, WI 53706 USA.	bsinger@geology.wisc.edu	Singer, Bradley/F-4991-2012; Pringle, Malcolm/ABD-5663-2020	Singer, Bradley/0000-0003-3595-5168; 				BROWN L, 1994, GEOLOGY, V22, P299, DOI 10.1130/0091-7613(1994)022<0299:MBTRIL>2.3.CO;2; Brown LL, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2004JB003007; Channell JET, 1997, NATURE, V389, P712, DOI 10.1038/39570; Channell JET, 2000, PHILOS T ROY SOC A, V358, P1027, DOI 10.1098/rsta.2000.0572; CHAUVIN A, 1990, J GEOPHYS RES-SOLID, V95, P2727, DOI 10.1029/JB095iB03p02727; CLEMENT BM, 1987, INITIAL REP DEEP SEA, V94, P831; Clement BM, 2004, NATURE, V428, P637, DOI 10.1038/nature02459; Coe RS, 2004, EARTH PLANET SC LETT, V222, P667, DOI 10.1016/j.epsl.2004.03.003; COE RS, 2004, AM GEOPHYS UN GEOPHY, V145, P221; Glatzmaier GA, 1999, NATURE, V401, P885, DOI 10.1038/44776; Gubbins D, 1999, GEOPHYS J INT, V137, pF1, DOI 10.1046/j.1365-246x.1999.00810.x; Hartl P, 1996, EARTH PLANET SC LETT, V138, P121, DOI 10.1016/0012-821X(95)00231-Z; Hoffman K. A., 2004, AM GEOPHYS UN GEOPHY, V145, P223; HOFFMAN KA, 1986, NATURE, V320, P228, DOI 10.1038/320228a0; HOFFMAN KA, 1992, NATURE, V359, P789, DOI 10.1038/359789a0; HOLLERBACH R, 1993, NATURE, V365, P541, DOI 10.1038/365541a0; KENT DV, 1995, EARTH PLANET SC LETT, V129, P135, DOI 10.1016/0012-821X(94)00236-R; LAJ C, 1987, NATURE, V330, P145, DOI 10.1038/330145a0; LAJ C, 1991, NATURE, V351, P447, DOI 10.1038/351447a0; Love JJ, 1997, PHYS EARTH PLANET IN, V103, P207, DOI 10.1016/S0031-9201(97)00034-4; Merrill RT, 1999, REV GEOPHYS, V37, P201, DOI 10.1029/1998RG900004; PREVOT M, 1985, NATURE, V316, P230, DOI 10.1038/316230a0; Renne PR, 1998, CHEM GEOL, V145, P117, DOI 10.1016/S0009-2541(97)00159-9; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; Singer BS, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB001613; Singer BS, 1999, J GEOPHYS RES-SOL EA, V104, P679, DOI 10.1029/1998JB900016; Singer BS, 1996, EARTH PLANET SC LETT, V139, P47, DOI 10.1016/0012-821X(96)00003-9; Tauxe L, 1996, EARTH PLANET SC LETT, V140, P133, DOI 10.1016/0012-821X(96)00030-1	28	94	99	0	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					633	636		10.1038/nature03431	http://dx.doi.org/10.1038/nature03431			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800621				2022-12-28	WOS:000228011000042
J	Patterson, F; Ferguson, E; Norfolk, T; Lane, P				Patterson, F; Ferguson, E; Norfolk, T; Lane, P			A new selection system to recruit general practice registrars: preliminary findings from a validation study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							STATEMENTS; VALIDITY; FUTURE; MODEL	Objective To design and validate a new competency based selection system to recruit general practice registrars, comprising a competency based. application form, referees' reports, and an assessment centre. Design Longitudinal predictive validity study and a matched case comparison. Setting South Yorkshire and East Midlands region, United Kingdom, comprising three deaneries. Participants 46 of 167 doctors were followed up in training after three months in practice, and 20 general practice trainers were selected by using traditional recruitment methods. Main outcome measures Trainer ratings of trainee performance in practice on targeted competencies. Results Performance ratings of targeted competencies at the assessment centre predicted trainer ratings of performance in the job.. Furthermore, those trainees recruited through the new competency based process performed significantly better in the job than those recruited through traditional recruitment processes. Conclusion A new competency based selection process using assessment centres improves the validity of selection of general practice registrars compared with traditional selection techniques.	City Univ London, Dept Psychol, London EC1V 0HB, England; Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England	City University London; University of Nottingham	Patterson, F (corresponding author), City Univ London, Dept Psychol, London EC1V 0HB, England.	f.patterson@city.ac.uk		Ferguson, Eamonn/0000-0002-7678-1451	Economic and Social Research Council [M551285002] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Arnold J, 2004, WORK PSYCHOL UNDERST; Bright JEH, 2000, INT J SELECT ASSESS, V8, P41, DOI 10.1111/1468-2389.00132; Ferguson E, 2002, BMJ-BRIT MED J, V324, P952, DOI 10.1136/bmj.324.7343.952; Ferguson E, 2000, J OCCUP ORGAN PSYCH, V73, P321, DOI 10.1348/096317900167056; Harvey-Cook JE, 2000, J OCCUP ORGAN PSYCH, V73, P103, DOI 10.1348/096317900166903; Hough LM, 2000, ANNU REV PSYCHOL, V51, P631, DOI 10.1146/annurev.psych.51.1.631; HUNTER JE, 1984, PSYCHOL BULL, V96, P72, DOI 10.1037/0033-2909.96.1.72; KEENAN T, 1995, J ORGAN BEHAV, V16, P303, DOI 10.1002/job.4030160403; MCMANUS IC, 1986, BRIT MED J, V293, P124, DOI 10.1136/bmj.293.6539.124; Patterson F, 2000, BRIT J GEN PRACT, V50, P188; Patterson F, 2001, J OCCUP ORGAN PSYCH, V74, P381, DOI 10.1348/096317901167442; PATTERSON F, 2001, BMJ-BRIT MED J, V323, P2; Robertson IT, 2001, J OCCUP ORGAN PSYCH, V74, P441, DOI 10.1348/096317901167479; Salgado J.F., 2001, HDB IND WORK ORG PSY, V1, P165, DOI DOI 10.4135/9781848608320.N10; Schmidt FL, 1998, PSYCHOL BULL, V124, P262, DOI 10.1037/0033-2909.124.2.262; Schmitt N., 1998, PERSONNEL SELECTION; Tabachnick BG, 2001, MULTIVARIATE STAT; Wood R., 1998, COMPETENCY BASED REC; WOODRUFFE C, 2000, DEV ASSESSMENT CTR	19	63	66	2	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	2005	330	7493					711	714		10.1136/bmj.330.7493.711	http://dx.doi.org/10.1136/bmj.330.7493.711			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912IT	15790641	Green Published, Bronze			2022-12-28	WOS:000228071900019
J	Poole, JH; Tyack, PL; Stoeger-Horwath, AS; Watwood, S				Poole, JH; Tyack, PL; Stoeger-Horwath, AS; Watwood, S			Elephants are capable of vocal learning	NATURE			English	Editorial Material							AFRICAN ELEPHANTS		Amboseli Trust Elephants, ElephantVoices, Nairobi, Kenya; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA; Univ Vienna, Inst Zool, A-1090 Vienna, Austria	Woods Hole Oceanographic Institution; University of Vienna	Poole, JH (corresponding author), Amboseli Trust Elephants, ElephantVoices, POB 15135,Langata 00509, Nairobi, Kenya.	ptyack@whoi.edu	Watwood, Stephanie/AAE-7191-2019; Tyack, Peter/AAC-4513-2019; Tyack, Peter L/D-6209-2013	Tyack, Peter/0000-0002-8409-4790; Tyack, Peter L/0000-0002-8409-4790; Stoeger, Angela S/0000-0002-6714-8291				GARSTANG M, 1995, J EXP BIOL, V198, P939; Janik VM, 1997, ADV STUD BEHAV, V26, P59, DOI 10.1016/S0065-3454(08)60377-0; McComb K, 2000, ANIM BEHAV, V59, P1103, DOI 10.1006/anbe.2000.1406; McKay G.M., 1973, Smithsonian Contributions to Zoology, VNo. 125, P1; Moss CJ, 1983, PRIMATE SOCIAL RELAT, P315; POOLE JH, 1988, BEHAV ECOL SOCIOBIOL, V22, P385, DOI 10.1007/BF00294975; Tyack PL, 2003, ANIMAL SOCIAL COMPLEXITY, P342	7	171	175	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					455	456		10.1038/434455a	http://dx.doi.org/10.1038/434455a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791244				2022-12-28	WOS:000227836000029
J	Duan, NH				Duan, NH			Listening to consumers and HIV vaccine preparedness	LANCET			English	Editorial Material							DEVELOPING-COUNTRIES; TRIAL; AIDS; SWITZERLAND; RISK; IF		Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles	Duan, NH (corresponding author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.	naihua@mednet.ucla.edu		Duan, Naihua/0000-0001-9411-2924				Andreasen AlanR., 1995, MARKETING SOCIAL CHA; Buchbinder SP, 2004, JAIDS-J ACQ IMM DEF, V36, P604, DOI 10.1097/00126334-200405010-00009; CELENTANO DD, 1995, AIDS, V9, P1079, DOI 10.1097/00002030-199509000-00015; Chang ML, 2003, AIDS, V17, pW1, DOI [10.1097/01.aids.0000076356.20434.a0, 10.1097/00002030-200310170-00025]; Dubois-Arber F, 1999, AIDS, V13, P2571, DOI 10.1097/00002030-199912240-00011; DUBOIS-ARBER F, 1988, World Health Forum, V9, P376; DuboisArber F, 1997, AM J PUBLIC HEALTH, V87, P558, DOI 10.2105/AJPH.87.4.558; Esparza J, 2002, VACCINE, V20, P1897, DOI 10.1016/S0264-410X(02)00062-2; Francis DP, 2003, AIDS, V17, P147, DOI 10.1097/00002030-200301240-00003; Mills E, 2004, AIDS, V18, P2235, DOI 10.1097/00002030-200411190-00003; Newman PA, 2004, AIDS PATIENT CARE ST, V18, P691, DOI 10.1089/apc.2004.18.691; Newman PA, 2004, JAIDS-J ACQ IMM DEF, V37, P1393, DOI 10.1097/01.qai.0000127064.84325.ad; Streefland PH, 2003, VACCINE, V21, P1304, DOI 10.1016/S0264-410X(02)00685-0; Tucker T, 2003, LANCET, V362, P995, DOI 10.1016/S0140-6736(03)14374-7; Urban GL, 1993, DESIGN MARKETING NEW; WOODS DR, 1991, PUBLIC HEALTH REP, V106, P616; Zimet GD, 1999, J PEDIATR PSYCHOL, V24, P67, DOI 10.1093/jpepsy/24.1.67; [No title captured]	18	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1119	1121		10.1016/S0140-6736(05)71857-2	http://dx.doi.org/10.1016/S0140-6736(05)71857-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	910DD	15794955				2022-12-28	WOS:000227909500008
J	Law, M; Morris, JK; Wald, N; Luczynska, C; Burney, P				Law, M; Morris, JK; Wald, N; Luczynska, C; Burney, P			Changes in atopy over a quarter of a century, based on cross sectional data at three time periods	BRITISH MEDICAL JOURNAL			English	Article							POPULATION		Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, Ctr Environm & Prevent Med, London EC1M 6BQ, England; Guys Hosp, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, Div Primary Care & Publ Hlth Sci, London SE1 3QD, England	University of London; Queen Mary University London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Law, M (corresponding author), Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, Ctr Environm & Prevent Med, London EC1M 6BQ, England.	m.r.law@qmul.ac.uk	Wald, Nicholas/AAY-8924-2021; Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X; Burney, Peter/0000-0001-8635-5678				Kosunen TU, 2002, CLIN EXP ALLERGY, V32, P373, DOI 10.1046/j.1365-2222.2002.01330.x; Krause TG, 2002, LANCET, V360, P691, DOI 10.1016/S0140-6736(02)09841-0; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; POTTS J, 2002, EUR RESP J S38, V20, pS120	5	79	82	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 21	2005	330	7501					1187	1188		10.1136/bmj.38435.582975.AE	http://dx.doi.org/10.1136/bmj.38435.582975.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	929CU	15833748	Bronze, Green Published			2022-12-28	WOS:000229320500020
J	Cheng, J; Kapranov, P; Drenkow, J; Dike, S; Brubaker, S; Patel, S; Long, J; Stern, D; Tammana, H; Helt, G; Sementchenko, V; Piccolboni, A; Bekiranov, S; Bailey, DK; Ganesh, M; Ghosh, S; Bell, I; Gerhard, DS; Gingeras, TR				Cheng, J; Kapranov, P; Drenkow, J; Dike, S; Brubaker, S; Patel, S; Long, J; Stern, D; Tammana, H; Helt, G; Sementchenko, V; Piccolboni, A; Bekiranov, S; Bailey, DK; Ganesh, M; Ghosh, S; Bell, I; Gerhard, DS; Gingeras, TR			Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution	SCIENCE			English	Article							TRANS-ACTING SIRNAS; HUMAN GENOME; BINDING SITES; CDNA; ANNOTATION; HUMAN-CHROMOSOME-21; BROWSER; GENES; RNAS	Sites of transcription of polyadenylated and nonpolyadenylated RNAs for 10 human chromosomes were mapped at 5-base pair resolution in eight cell lines. Unannotated, nonpotyadenylated transcripts comprise the major proportion of the transcriptional output of the human genome. Of all transcribed sequences, 19.4, 43.7, and 36.9% were observed to be polyadenytated, nonpolyadenylated, and bimorphic, respectively. Half of all transcribed sequences are found only in the nucleus and for the most part are unannotated. Overall, the transcribed portions of the human genome are predominantly composed of interlaced networks of both poly A+ and poly A- annotated transcripts and unannotated transcripts of unknown function. This organization has important implications for interpreting genotype-phenotype associations, regulation of gene expression, and the definition of a gene.	Affymetrix Inc, Santa Clara, CA 95051 USA; NCI, Off Canc Genom, Bethesda, MD 20892 USA	Affymetrix; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Center for Cancer Genomics (CCG)	Gingeras, TR (corresponding author), Affymetrix Inc, Santa Clara, CA 95051 USA.	tom_gingeras@affymetrix.com		Gingeras, Thomas/0000-0001-9106-3573; Kapranov, Philipp/0000-0003-2647-4856				Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; Bono H, 2003, GENOME RES, V13, P1318, DOI 10.1101/gr.1075103; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen JJ, 2002, P NATL ACAD SCI USA, V99, P12257, DOI 10.1073/pnas.192436499; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; EDMONDS M, 1969, J BIOL CHEM, V244, P1314; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; GEOGHEGAN TE, 1978, BIOCHEMISTRY-US, V17, P4200, DOI 10.1021/bi00613a014; Gerhard DS, 2004, GENOME RES, V14, P2121, DOI 10.1101/gr.2596504; Imanishi T, 2004, PLOS BIOL, V2, P856, DOI 10.1371/journal.pbio.0020162; INHORN RC, 1986, BIOCHEM BIOPH RES CO, V137, P431, DOI 10.1016/0006-291X(86)91228-3; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; KATINAKIS PK, 1980, FEBS LETT, V116, P1, DOI 10.1016/0014-5793(80)80515-1; Kawabe Y, 2001, J BIOL CHEM, V276, P20364, DOI 10.1074/jbc.C100035200; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; MILCAREK C, 1974, CELL, V3, P1, DOI 10.1016/0092-8674(74)90030-0; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Peragine A, 2004, GENE DEV, V18, P2368, DOI 10.1101/gad.1231804; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; SALDITTGEORGIEFF M, 1981, MOL CELL BIOL, V1, P179, DOI 10.1128/MCB.1.2.179; Seki M, 2004, J EXP BOT, V55, P213, DOI 10.1093/jxb/erh007; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; SNIDER BJ, 1992, BRAIN RES REV, V17, P263, DOI 10.1016/0165-0173(92)90019-I; Stolc V, 2004, SCIENCE, V306, P655, DOI 10.1126/science.1101312; Vazquez F, 2004, MOL CELL, V16, P69, DOI 10.1016/j.molcel.2004.09.028; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808	35	878	988	3	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	2005	308	5725					1149	1154		10.1126/science.1108625	http://dx.doi.org/10.1126/science.1108625			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	928TA	15790807				2022-12-28	WOS:000229293400038
J	Rosvold, EA; Tyssen, R				Rosvold, EA; Tyssen, R			Should physicians' self-prescribing be restricted by law?	LANCET			English	Editorial Material							MENTAL-HEALTH PROBLEMS; DOCTORS; CARE		Univ Oslo, Fac Med, Inst Gen Practice & Community Med, N-0318 Oslo, Norway; Univ Oslo, Fac Med, Dept Behav Sci Med, Inst Basic Med Sci, N-0318 Oslo, Norway	University of Oslo; University of Oslo	Rosvold, EA (corresponding author), Univ Oslo, Fac Med, Inst Gen Practice & Community Med, N-0318 Oslo, Norway.	e.o.rosvold@medisin.uio.no						Forsythe M, 1999, BRIT MED J, V319, P605, DOI 10.1136/bmj.319.7210.605; Fromme E, 2003, JAMA-J AM MED ASSOC, V290, P2048, DOI 10.1001/jama.290.15.2048; Garfinkel PE, 1997, CAN J PSYCHIAT, V42, P764, DOI 10.1177/070674379704200710; HUGHES PH, 1992, JAMA-J AM MED ASSOC, V267, P2333, DOI 10.1001/jama.267.17.2333; Ingstad B., 2001, ANTHROPOL MED, V8, P201, DOI [DOI 10.HTTP://DX.D0I.0RG/10.1080/13648470120101372, 10.1080/13648470120101372, DOI 10.1080/13648470120101372]; Kay Margaret, 2005, Aust Fam Physician, V34, P94; LOTT DA, 2001, PSYCHIAT TIMES, V18; ROSVOLD EO, 2002, THESIS U OSLO OSLO N; Schneck SA, 1998, JAMA-J AM MED ASSOC, V280, P2039, DOI 10.1001/jama.280.23.2039; STOUDEMIRE A, 1983, ANN INTERN MED, V98, P654, DOI 10.7326/0003-4819-98-5-654; Toyry S, 2000, ARCH FAM MED, V9, P1079, DOI 10.1001/archfami.9.10.1079; Tyssen R, 2004, SOC PSYCH PSYCH EPID, V39, P989, DOI 10.1007/s00127-004-0831-8; Tyssen R, 2002, HARVARD REV PSYCHIAT, V10, P154, DOI 10.1080/10673220216218	13	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 16	2005	365	9468					1372	1374		10.1016/S0140-6736(05)66353-2	http://dx.doi.org/10.1016/S0140-6736(05)66353-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916QY	15836873				2022-12-28	WOS:000228401900009
J	Rosenberg, GA				Rosenberg, GA			Matrix metalloproteinases biomarkers in multiple sclerosis	LANCET			English	Editorial Material							MATRIX-METALLOPROTEINASE-9; GELATINASE; TIMP-1; INTERFERON-BETA-1A; MMP-9; BETA; MRI		Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Physiol, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center	Rosenberg, GA (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Neurol, Albuquerque, NM 87131 USA.	grosenberg@salud.unm.edu						Dubois B, 2003, J NEUROL, V250, P1037, DOI 10.1007/s00415-003-0110-8; GIJBELS K, 1992, J NEUROIMMUNOL, V41, P29, DOI 10.1016/0165-5728(92)90192-N; Karabudak R, 2004, J NEUROL, V251, P279, DOI 10.1007/s00415-004-0285-7; Lee MA, 1999, BRAIN, V122, P191, DOI 10.1093/brain/122.2.191; LEPPERT D, 1995, J IMMUNOL, V154, P4379; Liuzzi GM, 2002, MULT SCLER, V8, P222, DOI 10.1191/1352458502ms800oa; Rosenberg GA, 1996, NEUROLOGY, V46, P1626, DOI 10.1212/WNL.46.6.1626; Rosenberg GA, 2002, NEUROSCIENTIST, V8, P586, DOI 10.1177/1073858402238517; Waubant E, 1999, NEUROLOGY, V53, P1397, DOI 10.1212/WNL.53.7.1397; Waubant E, 2003, NEUROLOGY, V60, P52, DOI 10.1212/WNL.60.1.52; Yong VW, 1998, NEUROLOGY, V51, P682; Yushchenko M, 2003, J NEUROL, V250, P1224, DOI 10.1007/s00415-003-0191-4	12	29	32	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1291	1293		10.1016/S0140-6736(05)61008-2	http://dx.doi.org/10.1016/S0140-6736(05)61008-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823367				2022-12-28	WOS:000228219600009
J	Klein, R				Klein, R			Axon guidance: Opposing EPHects in the growth cone	CELL			English	Editorial Material							MOTOR-NEURONS; EPHRINS; ROLES		Max Planck Inst Neurobiol, Dept Mol Neurobiol, Munich, Germany	Max Planck Society	Klein, R (corresponding author), Max Planck Inst Neurobiol, Dept Mol Neurobiol, Munich, Germany.		Klein, Ruediger/C-6147-2008	Klein, Ruediger/0000-0002-3109-0163				Eberhart J, 2002, DEV BIOL, V247, P89, DOI 10.1006/dbio.2002.0695; Feng GP, 2000, NEURON, V25, P295, DOI 10.1016/S0896-6273(00)80895-8; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gauthier LR, 2003, LIFE SCI, V74, P207, DOI 10.1016/j.lfs.2003.09.029; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; Marquardt T, 2005, CELL, V121, P127, DOI 10.1016/j.cell.2005.01.020; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	9	2	2	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 8	2005	121	1					4	6		10.1016/j.cell.2005.03.018	http://dx.doi.org/10.1016/j.cell.2005.03.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820672	Bronze			2022-12-28	WOS:000228348500003
J	Deming, D; Seager, S; Richardson, LJ; Harrington, J				Deming, D; Seager, S; Richardson, LJ; Harrington, J			Infrared radiation from an extrasolar planet	NATURE			English	Article							TRANSITING PLANET; MODEL	A class of extrasolar giant planets-the so-called 'hot Jupiters' (ref. 1)-orbit within 0.05 AU of their primary stars ( 1 AU is the Sun-Earth distance). These planets should be hot and so emit detectable infrared radiation(2). The planet HD 209458b (refs 3, 4) is an ideal candidate for the detection and characterization of this infrared light because it is eclipsed by the star. This planet has an anomalously large radius (1.35 times that of Jupiter(5)), which may be the result of ongoing tidal dissipation(6), but this explanation requires a non-zero orbital eccentricity (similar to 0.03; refs 6, 7), maintained by interaction with a hypothetical second planet. Here we report detection of infrared (24-mu m) radiation from HD 209458b, by observing the decrement in flux during secondary eclipse, when the planet passes behind the star. The planet's 24-mu m flux is 55 +/- 10 mu Jy (1 sigma), with a brightness temperature of 1,130 +/- 150 K, confirming the predicted heating by stellar irradiation(2,8). The secondary eclipse occurs at the midpoint between transits of the planet in front of the star (to within +/- 7 min, 1 sigma), which means that a dynamically significant orbital eccentricity is unlikely.	NASA, Goddard Space Flight Ctr, Planetary Syst Lab, Greenbelt, MD 20771 USA; NASA, Goddard Ctr Astrobiol, Greenbelt, MD 20771 USA; NASA, Goddard Space Flight Ctr, Exoplanet & Stellar Astrophys Lab, Greenbelt, MD 20771 USA; Carnegie Inst Sci, Dept Terr Magnetism, Washington, DC 20015 USA; Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Aeronautics & Space Administration (NASA); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Carnegie Institution for Science; Cornell University	Deming, D (corresponding author), NASA, Goddard Space Flight Ctr, Planetary Syst Lab, Code 693, Greenbelt, MD 20771 USA.	Leo.D.Deming@nasa.gov	Harrington, Joseph/E-6250-2011	Harrington, Joseph/0000-0002-8955-8531				Alonso R, 2004, ASTROPHYS J, V613, pL153, DOI 10.1086/425256; Barman TAS, 2001, ASTROPHYS J, V556, P885, DOI 10.1086/321610; BEICHMAN CA, IN PRESS ASTROPHYS J; Bodenheimer P, 2001, ASTROPHYS J, V548, P466, DOI 10.1086/318667; Brown TM, 2001, ASTROPHYS J, V552, P699, DOI 10.1086/320580; Burrows A, 2004, AIP CONF PROC, V713, P143, DOI 10.1063/1.1774514; Charbonneau D, 2003, ASTR SOC P, V294, P449; Charbonneau D, 2000, ASTROPHYS J, V529, pL45, DOI 10.1086/312457; CHARBONNEAU D, IN PRESS ASTROPHYS J; COLLIERCAMERON A, 2002, GEOPHYSICS, V43, P421; GORDON KD, IN PRESS PUBL ASTRON; Goukenleuque C, 2000, ICARUS, V143, P308, DOI 10.1006/icar.1999.6256; HENRY GW, 2000, APJ, V529, P41; HORNE K, 1986, PUBL ASTRON SOC PAC, V98, P609, DOI 10.1086/131801; Kelsall T, 1998, ASTROPHYS J, V508, P44, DOI 10.1086/306380; Krist J, 1995, ASTR SOC P, V77, P349; Kurucz R, 1994, SOLAR ABUNDANCE MODE; LAUGHLIN G, IN PRESS ASTROPHYS J; Perryman M. A. C., 1997, ESA; PRESS WH, 1992, NUMERICAL RECIPES; Ribas I, 2003, ASTRON ASTROPHYS, V411, pL501, DOI 10.1051/0004-6361:20031626; Rieke GH, 2004, ASTROPHYS J SUPPL S, V154, P25, DOI 10.1086/422717; Rieke GH, 2004, PROC SPIE, V5487, P50, DOI 10.1117/12.551965; Seager S, 2000, ASTROPHYS J, V540, P504, DOI 10.1086/309292; Sudarsky D, 2003, ASTROPHYS J, V588, P1121, DOI 10.1086/374331; WITTENMYER RA, 2003, THESIS SAN DIEGO STA; [No title captured]	28	463	468	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					740	743		10.1038/nature03507	http://dx.doi.org/10.1038/nature03507			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15785769				2022-12-28	WOS:000228160700034
J	Aronson, JK				Aronson, JK			Commentary: Open access publishing: too much oxygen?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Aronson, JK (corresponding author), Univ Oxford, Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England.	Jeffrey.aronson@clinpharm.ox.ac.uk						Delamothe T, 2004, BMJ-BRIT MED J, V328, P1, DOI 10.1136/bmj.328.7430.1; Katikireddi SV, 2004, BRIT MED J, V328, P1190, DOI 10.1136/bmj.328.7449.1190; Merton RK, 1936, AM SOCIOL REV, V1, P894, DOI 10.2307/2084615; Schroter S, 2005, BMJ-BRIT MED J, V330, P756, DOI 10.1136/bmj.38359.695220.82; SMITH R, 2004, BMJ, V329	5	9	9	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					759	759		10.1136/bmj.330.7494.759	http://dx.doi.org/10.1136/bmj.330.7494.759			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15802718	Bronze, Green Published			2022-12-28	WOS:000228222900017
J	Furse, RM; Mee, AS				Furse, RM; Mee, AS			Lesson of the week - Atypical presentation of coeliac disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							OBESITY		Royal Berkshire Hosp, Dept Gastroenterol, Reading RG1 5AN, Berks, England	Royal Berkshire Hospital	Mee, AS (corresponding author), Royal Berkshire Hosp, Dept Gastroenterol, Reading RG1 5AN, Berks, England.	anthony.mee@rbbh-tr.nhs.uk						Bottaro G, 1999, AM J GASTROENTEROL, V94, P691, DOI 10.1111/j.1572-0241.1999.00938.x; Czaja-Bulsa G, 2001, J PEDIATR GASTR NUTR, V32, P226, DOI 10.1097/00005176-200102000-00031; Department of Health, 2004, CHOOS HLTH CONS IMPR; Loftus CG, 2002, GASTROENTEROLOGY, V123, P1726, DOI 10.1053/gast.2002.36850; NIBALI SC, 1987, HELV PAEDIATR ACTA, V42, P45; OWEN DA, 1980, ARCH INTERN MED, V140, P1380, DOI 10.1001/archinte.140.10.1380; SEMERARO LA, 1986, J CLIN GASTROENTEROL, V8, P177, DOI 10.1097/00004836-198604000-00015	7	22	22	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					773	774		10.1136/bmj.330.7494.773	http://dx.doi.org/10.1136/bmj.330.7494.773			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15802720	Green Published			2022-12-28	WOS:000228222900025
J	Chimowitz, MI; Lynn, MJ; Howlett-Smith, H; Stern, BJ; Hertzberg, VS; Frankel, MR; Levine, SR; Chaturvedi, S; Kasner, SE; Benesch, CG; Sila, CA; Jovin, TG; Romano, JG				Chimowitz, MI; Lynn, MJ; Howlett-Smith, H; Stern, BJ; Hertzberg, VS; Frankel, MR; Levine, SR; Chaturvedi, S; Kasner, SE; Benesch, CG; Sila, CA; Jovin, TG; Romano, JG		Warfarin-Aspirin Symptomatic	Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STROKE PREVENTION; RECURRENT STROKE; ISCHEMIC-STROKE; INFLAMMATION; ANGIOPLASTY; INFARCTION; DRUGS; RACE	Background: Atherosclerotic intracranial arterial stenosis is an important cause of stroke. Warfarin is commonly used in preference to aspirin for this disorder, but these therapies have not been compared in a randomized trial. Methods: We randomly assigned patients with transient ischemic attack or stroke caused by angiographically verified 50 to 99 percent stenosis of a major intracranial artery to receive warfarin (target international normalized ratio, 2.0 to 3.0) or aspirin (1300 mg per day) in a double-blind, multicenter clinical trial. The primary end point was ischemic stroke, brain hemorrhage, or death from vascular causes other than stroke. Results: After 569 patients had undergone randomization, enrollment was stopped because of concerns about the safety of the patients who had been assigned to receive warfarin. During a mean follow-up period of 1.8 years, adverse events in the two groups included death (4.3 percent in the aspirin group vs. 9.7 percent in the warfarin group; hazard ratio for aspirin relative to warfarin, 0.46; 95 percent confidence interval, 0.23 to 0.90; P=0.02), major hemorrhage (3.2 percent vs. 8.3 percent, respectively; hazard ratio, 0.39; 95 percent confidence interval, 0.18 to 0.84; P=0.01), and myocardial infarction or sudden death (2.9 percent vs. 7.3 percent, respectively; hazard ratio, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.02). The rate of death from vascular causes was 3.2 percent in the aspirin group and 5.9 percent in the warfarin group (P=0.16); the rate of death from nonvascular causes was 1.1 percent and 3.8 percent, respectively (P=0.05). The primary end point occurred in 22.1 percent of the patients in the aspirin group and 21.8 percent of those in the warfarin group (hazard ratio, 1.04; 95 percent confidence interval, 0.73 to 1.48; P=0.83). Conclusions: Warfarin was associated with significantly higher rates of adverse events and provided no benefit over aspirin in this trial. Aspirin should be used in preference to warfarin for patients with intracranial arterial stenosis.	Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA; CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; Wayne State Univ, Dept Neurol, Detroit, MI USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; Univ Rochester, Sch Med, Dept Neurol, Rochester, NY USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Miami, Sch Med, Dept Neurol, Miami, FL USA	Emory University; Emory University; Rollins School Public Health; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Wayne State University; University of Pennsylvania; University of Rochester; Cleveland Clinic Foundation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Miami	Chimowitz, MI (corresponding author), Emory Clin, Dept Neurol, 4th Fl,Clin A Bldg,1365 Clifton Rd, Atlanta, GA 30322 USA.	mchimow@emory.edu	Kasner, Scott/C-6109-2011		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083, M01RR000425, M01RR000750, M01RR000039, M01RR000080, M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036643] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00039, 5M01 RR00080, 5M01 RR000750-32, M01 RR000052, M01 RR00083-42, M01 RR165001, M01 RR00425] Funding Source: Medline; NINDS NIH HHS [R01 NS36643] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberts MJ, 2004, STROKE, V35, P175, DOI 10.1161/01.STR.0000106763.46123.F6; Ansell J, 2004, CHEST, V126, p204S, DOI 10.1378/chest.126.3_suppl.204S; Barnett HJM, 1998, NEW ENGL J MED, V339, P1415, DOI 10.1056/NEJM199811123392002; Benesch CG, 2000, NEUROLOGY, V55, P465, DOI 10.1212/WNL.55.4.465; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Chan AT, 2003, CANCER CAUSE CONTROL, V14, P413, DOI 10.1023/A:1024986220526; Chimowitz M, 2003, NEUROEPIDEMIOLOGY, V22, P106, DOI 10.1159/000068744; Chimowitz MI, 2004, NEUROLOGY, V62, pA266; Chimowitz MI, 1998, STROKE, V29, P1389, DOI 10.1161/01.str.29.7.1389; CHIMOWITZ MI, 1995, NEUROLOGY, V45, P1488, DOI 10.1212/WNL.45.8.1488; Chimowitz MI, 2001, ARCH NEUROL-CHICAGO, V58, P1690, DOI 10.1001/archneur.58.10.1690; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; FELDMANN E, 1990, NEUROLOGY, V40, P1541, DOI 10.1212/wnl.40.10.1540; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; Gomez CR, 2001, ARCH NEUROL-CHICAGO, V58, P1687, DOI 10.1001/archneur.58.10.1687; Gorelick PB, 2003, JAMA-J AM MED ASSOC, V289, P2947, DOI 10.1001/jama.289.22.2947; HART RG, 1995, STROKE, V26, P1471, DOI 10.1161/01.STR.26.8.1471; HELGASON CM, 1994, STROKE, V25, P2331, DOI 10.1161/01.STR.25.12.2331; Hurlen M, 2002, NEW ENGL J MED, V347, P969, DOI 10.1056/NEJMoa020496; Johnston SC, 2002, NEW ENGL J MED, V347, P1687, DOI 10.1056/NEJMcp020891; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI, P163; Kharbanda RK, 2002, CIRCULATION, V105, P2600, DOI 10.1161/01.CIR.0000017863.52347.6C; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAN KKG, 1988, BIOMETRICS, V44, P579, DOI 10.2307/2531870; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; Levine SR, 2004, JAMA-J AM MED ASSOC, V291, P576, DOI 10.1001/jama.291.5.576; MCBRIDE R, 1994, LANCET, V343, P687; MILLIKAN CH, 1955, P STAFF M MAYO CLIN, V30, P116; Mohr JP, 2001, NEW ENGL J MED, V345, P1444, DOI 10.1056/NEJMoa011258; RATNATUNGA CP, 1992, CIRCULATION, V85, P1077, DOI 10.1161/01.CIR.85.3.1077; Ridker PM, 1997, NEW ENGL J MED, V337, P356; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; SACCO RL, 1995, STROKE, V26, P14, DOI 10.1161/01.STR.26.1.14; Samuels OB, 2000, AM J NEURORADIOL, V21, P643; Thijs VN, 2000, NEUROLOGY, V55, P490, DOI 10.1212/WNL.55.4.490; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; Urbano LA, 2004, CEREBROVASC DIS, V17, P74, DOI 10.1159/000074800; van Es RF, 2002, LANCET, V360, P109, DOI 10.1016/S0140-6736(02)09409-6; WALKER MD, 1995, JAMA-J AM MED ASSOC, V273, P1421, DOI 10.1001/jama.1995.03520420037035; Wityk RJ, 1996, STROKE, V27, P1974, DOI 10.1161/01.STR.27.11.1974	41	1110	1227	0	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1305	1316		10.1056/NEJMoa043033	http://dx.doi.org/10.1056/NEJMoa043033			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800226				2022-12-28	WOS:000227998300007
J	Heller, HM; Telford, SR; Branda, JA; Harris, NL; Goodson, JD; Ryan, ET; Bloom, D				Heller, HM; Telford, SR; Branda, JA; Harris, NL; Goodson, JD; Ryan, ET; Bloom, D			A Man with weakness and pain in the legs - Human granulocytic ehrlichiosis (A-phagocytophilum infection)	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ANAPLASMATACEAE; RHABDOMYOLYSIS; AGENT; EQUI		Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Tufts Univ, Sch Vet Med, Div Infect Dis, North Grafton, MA 01536 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Lab Publ Hlth Entomol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Tufts University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Heller, HM (corresponding author), Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA.		Branda, John/ABD-5620-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039002] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 39002] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AgueroRosenfeld ME, 1996, ANN INTERN MED, V125, P904, DOI 10.7326/0003-4819-125-11-199612010-00006; Bakken JS, 2000, CLIN INFECT DIS, V31, P554, DOI 10.1086/313948; Bakken JS, 2001, CLIN INFECT DIS, V32, P862, DOI 10.1086/319350; Bakken JS, 1996, JAMA-J AM MED ASSOC, V275, P199, DOI 10.1001/jama.275.3.199; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; Dumler JS, 2001, INT J SYST EVOL MICR, V51, P2145, DOI 10.1099/00207713-51-6-2145; Dumler JS, 1998, ANNU REV MED, V49, P201, DOI 10.1146/annurev.med.49.1.201; DUMLER JS, 1997, PATHOLOGY INFECT DIS, P441; Jayed MZ, 2001, MAYO CLIN PROC, V76, P563, DOI 10.4065/76.5.563; Rikihisa Y, 2003, ANN NY ACAD SCI, V990, P548, DOI 10.1111/j.1749-6632.2003.tb07425.x; SHEA KW, 1995, CLIN INFECT DIS, V21, P1056, DOI 10.1093/clinids/21.4.1056; Shea KW, 1996, CLIN INFECT DIS, V22, P605, DOI 10.1093/clinids/22.3.605-a; Telford SR, 1996, P NATL ACAD SCI USA, V93, P6209, DOI 10.1073/pnas.93.12.6209; Walker DH, 1997, ARCH PATHOL LAB MED, V121, P785; 1995, MMWR MORB MORTAL WKL, V44, P593; 1995, MMWR MORB MORTAL WKL, V44, P653	16	8	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1358	1364		10.1056/NEJMcpc059004	http://dx.doi.org/10.1056/NEJMcpc059004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800232				2022-12-28	WOS:000227998300014
J	Folling, S; Gerbier, F; Widera, A; Mandel, O; Gericke, T; Bloch, I				Folling, S; Gerbier, F; Widera, A; Mandel, O; Gericke, T; Bloch, I			Spatial quantum noise interferometry in expanding ultracold atom clouds	NATURE			English	Article							HANBURY-BROWN; SUPERFLUID; COHERENCE	In a pioneering experiment(1), Hanbury Brown and Twiss (HBT) demonstrated that noise correlations could be used to probe the properties of a (bosonic) particle source through quantum statistics; the effect relies on quantum interference between possible detection paths for two indistinguishable particles. HBT correlations - together with their fermionic counterparts(2-4) - find numerous applications, ranging from quantum optics(5) to nuclear and elementary particle physics(6). Spatial HBT interferometry has been suggested(7) as a means to probe hidden order in strongly correlated phases of ultracold atoms. Here we report such a measurement on the Mott insulator(8-10) phase of a rubidium Bose gas as it is released from an optical lattice trap. We show that strong periodic quantum correlations exist between density fluctuations in the expanding atom cloud. These spatial correlations reflect the underlying ordering in the lattice, and find a natural interpretation in terms of a multiplewave HBT interference effect. The method should provide a useful tool for identifying complex quantum phases of ultracold bosonic and fermionic atoms(11-15).	Johannes Gutenberg Univ Mainz, Inst Phys, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Bloch, I (corresponding author), Johannes Gutenberg Univ Mainz, Inst Phys, Staudinger Weg 7, D-55099 Mainz, Germany.	bloch@uni-mainz.de	Gerbier, Fabrice/A-9813-2008; Widera, Artur/D-1032-2017	Folling, Simon/0000-0002-6951-3651; Widera, Artur/0000-0002-0338-9969; Gerbier, Fabrice/0000-0003-1746-5149				Altman E, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.013603; Bach R, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.063622; Bachor H.A., 2004, GUIDE EXPT QUANTUM O; Batrouni GG, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.117203; Baym G, 1998, ACTA PHYS POL B, V29, P1839; BROWN RH, 1956, NATURE, V177, P27, DOI 10.1038/177027a0; Burt EA, 1997, PHYS REV LETT, V79, P337, DOI 10.1103/PhysRevLett.79.337; Duan LM, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.090402; Greiner M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.160405; GREINER M, 2005, CONDMAT0502411; Grondalski J, 1999, OPT EXPRESS, V5, P249, DOI 10.1364/OE.5.000249; Hadzibabic Z, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.180403; Henny M, 1999, SCIENCE, V284, P296, DOI 10.1126/science.284.5412.296; Hofstetter W, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.220407; Jurczak C, 1996, PHYS REV LETT, V77, P1727, DOI 10.1103/PhysRevLett.77.1727; KAGAN Y, 1985, JETP LETT+, V42, P209; Ketterle W, 1999, P INT SCH PHYS, V140, P67; Kiesel H, 2002, NATURE, V418, P392, DOI 10.1038/nature00911; Kolovsky AR, 2004, EUROPHYS LETT, V68, P330, DOI 10.1209/epl/i2004-10212-8; Kuklov AB, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.100401; Laburthe-Tolra B., 2004, PHYS REV LETT, V92; Lewenstein M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.050401; Naraschewski M, 1999, PHYS REV A, V59, P4595, DOI 10.1103/PhysRevA.59.4595; Oliver WD, 1999, SCIENCE, V284, P299, DOI 10.1126/science.284.5412.299; Roth R, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.021601; SHESHADRI K, 1993, EUROPHYS LETT, V22, P257, DOI 10.1209/0295-5075/22/4/004; Stoferle T, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.130403; Yasuda M, 1996, PHYS REV LETT, V77, P3090, DOI 10.1103/PhysRevLett.77.3090	30	443	446	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					481	484		10.1038/nature03500	http://dx.doi.org/10.1038/nature03500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791249	Green Submitted			2022-12-28	WOS:000227836000035
J	Mayhew, SH; Tibenderana, J; Haines, A				Mayhew, SH; Tibenderana, J; Haines, A			Commission for Africa: can it make a difference to health?	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Mayhew, SH (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	Susannah.Mayhew@lshtm.ac.uk	Tibenderana, James Kananura/M-2272-2018	Tibenderana, James Kananura/0000-0002-0755-4597; Haines, Andy/0000-0002-8053-4605; Mayhew, Susannah/0000-0002-2433-3809				Acharya T, 2003, NAT BIOTECHNOL, V21, P1434, DOI 10.1038/nbt1203-1434; [Anonymous], 2001, MACR HLTH INV HLTH E; Commission for Africa, 2005, OUR COMMON INTEREST; Haines A, 2004, BMJ-BRIT MED J, V329, P394, DOI 10.1136/bmj.329.7462.394; *HM TREAS, 2004, INT FIN FAC; Hongoro C, 2004, LANCET, V364, P1451, DOI 10.1016/S0140-6736(04)17229-2; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; LABONTE R, 2004, FATAL INDIFFERENCE G; Mayhew SH, 2004, HEALTH POLICY PLANN, V19, pI50, DOI 10.1093/heapol/czh045; Stilwell Barbara, 2003, Hum Resour Health, V1, P8, DOI 10.1186/1478-4491-1-8; *UNAIDS, 2004, AIDS EP UPD; UNDP, 2004, HUMAN DEV REPORT 200; *UNFPA, 2003, ACH MILL DEV GOALS P; Victora CG, 2004, LANCET, V364, P1541, DOI 10.1016/S0140-6736(04)17279-6; Wagstaff A., 2004, MILLENNIUM DEVELOPME; WHO, 2004, MAT MORT 2000 EST DE; World Bank, 2004, RIS CHALL MILL DEV G; World Health Organization, 2002, WORLD REPORT VIOLENC; 2004, LANCET, V364, P1741	19	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1122	1124		10.1016/S0140-6736(05)71858-4	http://dx.doi.org/10.1016/S0140-6736(05)71858-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794956				2022-12-28	WOS:000227909500009
J	Berger, JT				Berger, JT			The ethics of deactivating implanted cardioverter defibrillators	ANNALS OF INTERNAL MEDICINE			English	Article							LIFE-SUSTAINING TREATMENT; PHYSICIANS OWN PREFERENCES; ASSOCIATION TASK-FORCE; NOT-RESUSCITATE ORDERS; OF-LIFE; ANTIARRHYTHMIA DEVICES; PRACTICE GUIDELINES; CARDIAC-PACEMAKERS; THERAPY; CARE	Implantable cardioverter defibrillators are life-saving devices for many patients with cardiac disease. Recipients of these devices, nevertheless, often suffer from progressive comorbid and cardiac conditions. Therefore, physicians should anticipate situations in which the defibrillator is no longer desired by the patient or no longer medically appropriate. Near the end of life, many of these patients may decline cardiopulmonary resuscitation. The comanagement of do-not-resuscitate orders and implanted defibrillators can be confusing to patients and physicians alike since the former proscribe the use of electrical cardioversion while the latter provide this precise treatment. Although the use of implanted defibrillators has important ethical implications, few studies have examined these issues, and guidelines have not yet been developed to assist physicians in caring for patients who have received defibrillators. This paper discusses bioethical considerations in disabling implantable cardioverter defibrillators.	Winthrop Univ Hosp, Dept Med, Mineola, NY 11501 USA; SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Berger, JT (corresponding author), Winthrop Univ Hosp, Dept Med, 222 Stn Plaza N,Suite 518, Mineola, NY 11501 USA.	jberger@winthrop.org						Alexander RW, 2000, CIRCULATION, V102, P112; BAUME P, 1995, J MED ETHICS, V21, P49, DOI 10.1136/jme.21.1.49; BEAUCHAMP JR, 1994, NONMALEFICENCE PRINC, P189; Berger J T, 1998, HEC Forum, V10, P102, DOI 10.1023/A:1008827206192; Berger JT, 2003, ARCH INTERN MED, V163, P2270, DOI 10.1001/archinte.163.19.2270; BRETT AS, 1991, JAMA-J AM MED ASSOC, V266, P825, DOI 10.1001/jama.266.6.825; Brock DW, 1996, MILBANK Q, V74, P599, DOI 10.2307/3350394; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P17; Coats AJS, 2002, INT J CARDIOL, V82, P1; Council of Europe, 1997, CONV PROT HUM RIGHTS; DEMARCHENA E, 1991, AM J CARDIOL, V67, P812, DOI 10.1016/0002-9149(91)90612-O; DESAI AS, 2004, JAMA-J AM MED ASSOC, V22, P2874; FABERLANGENDOEN K, 1994, CHEST, V106, P880, DOI 10.1378/chest.106.3.880; Gillick MR, 2004, NEW ENGL J MED, V350, P7, DOI 10.1056/NEJMp038202; Goldstein NE, 2004, ANN INTERN MED, V141, P835, DOI 10.7326/0003-4819-141-11-200412070-00006; Gregoratos G, 1998, CIRCULATION, V97, P1325, DOI 10.1161/01.CIR.97.13.1325; Gregoratos G, 2002, J AM COLL CARDIOL, V40, P1703, DOI 10.1016/S0735-1097(02)02528-7; Hlatky Mark A, 2003, Card Electrophysiol Rev, V7, P479, DOI 10.1023/B:CEPR.0000023153.81976.3a; Jayatilleke I, 2004, AM J CARDIOL, V93, P1192, DOI 10.1016/j.amjcard.2004.01.057; Kadish A, 2004, NEW ENGL J MED, V350, P2151, DOI 10.1056/NEJMoa033088; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; LANKEN PN, 1991, ANN INTERN MED, V115, P478; LEE MA, 1992, J AM GERIATR SOC, V40, P983, DOI 10.1111/j.1532-5415.1992.tb04473.x; Miller FG, 2000, ANN INTERN MED, V132, P470, DOI 10.7326/0003-4819-132-6-200003210-00008; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Mueller PS, 2003, MAYO CLIN PROC, V78, P959; Nambisan V, 2004, PALLIATIVE MED, V18, P482, DOI 10.1191/0269216304pm907cr; Nichol G, 2004, ANN INTERN MED, V141, P343, DOI 10.7326/0003-4819-141-5-200409070-00102; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V265, P1868; Puchalski CM, 2000, J AM GERIATR SOC, V48, pS84, DOI 10.1111/j.1532-5415.2000.tb03146.x; SACHS GA, 1994, CLIN RES, V42, P403; Schneiderman LJ, 2000, CAMB Q HEALTHC ETHIC, V9, P524, DOI 10.1017/S0963180100904110; SCHNEIDERMAN LJ, 1993, J CLIN ETHIC, V4, P28; Schneiderman LJ, 1997, CAMB Q HEALTHC ETHIC, V6, P131, DOI 10.1017/S0963180100007751; Silveira Maria J, 2003, Am J Geriatr Cardiol, V12, P275; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; UHLMANN RF, 1991, ARCH INTERN MED, V151, P495, DOI 10.1001/archinte.151.3.495; Weissman DE, 1998, J PAIN SYMPTOM MANAG, V15, P82, DOI 10.1016/S0885-3924(97)00253-4; Wilbur S L, 1999, Cardiol Rev, V7, P176, DOI 10.1097/00045415-199907000-00009; 2002, FED REG, V67, P79109	40	61	61	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					631	634		10.7326/0003-4819-142-8-200504190-00012	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916TZ	15838070				2022-12-28	WOS:000228410400006
J	Langgartner, M; Langgartner, I; Drlicek, M				Langgartner, M; Langgartner, I; Drlicek, M			The patient's journey: multiple sclerosis	BRITISH MEDICAL JOURNAL			English	Review									Med Univ Vienna, Allgemeines Krankenhaus Wien, Dept Pediat, A-1090 Vienna, Austria; Med Univ Vienna, Allgemeines Krankenhaus Wien, Clin Inst Neurol, A-1090 Vienna, Austria; Landeskrankenhaus Kirchdorf, Dept Anesthesiol, Lab Blood Grp, A-4560 Kirchdorf, Austria	Medical University of Vienna; Medical University of Vienna	Langgartner, M (corresponding author), Med Univ Vienna, Allgemeines Krankenhaus Wien, Dept Pediat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Michaela.langgartner@meduniwien.ac.at						Frankl Viktor E., 2000, MANS SEARCH MEANING; Hawkins SA, 1999, J NEUROL NEUROSUR PS, V67, P148, DOI 10.1136/jnnp.67.2.148; Ramsey NF, 2000, LASER SCI TECHNOL, V1, P5	3	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 16	2005	330	7496					885	888		10.1136/bmj.330.7496.885	http://dx.doi.org/10.1136/bmj.330.7496.885			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	917UA	15831874	Green Published			2022-12-28	WOS:000228493500020
J	Williams, S; Bottle, A; Rogers, R; Aylin, P				Williams, S; Bottle, A; Rogers, R; Aylin, P			Dr Foster's case notes - "Frequent flier" patients	BRITISH MEDICAL JOURNAL			English	Article									Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England	Imperial College London	Williams, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London SW7 2AZ, England.		Aylin, Paul/A-1073-2014	Aylin, Paul/0000-0003-4589-1743; Bottle, Alex/0000-0001-9978-2011					0	5	5	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 16	2005	330	7496					869	+		10.1136/bmj.330.7496.869	http://dx.doi.org/10.1136/bmj.330.7496.869			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	917UA	15831873	Green Published			2022-12-28	WOS:000228493500014
J	Yach, D; McKee, M; Lopez, AD; Novotny, T				Yach, D; McKee, M; Lopez, AD; Novotny, T		Oxford Vision 2020	Improving diet and physical activity: 12 lessons from controlling tobacco smoking	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Yale Univ, New Haven, CT USA; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Univ Queensland, Brisbane, Qld, Australia; Univ Calif San Francisco, Sch Med, San Francisco, CA USA	Yale University; University of London; London School of Hygiene & Tropical Medicine; University of Queensland; University of California System; University of California San Francisco	Yach, D (corresponding author), Chandler Chicco Agcy, London W1M 1JD, England.	C.griffin@cca-uk.com	Lopez, Alan/AAA-2734-2022; McKee, Marc D/E-2187-2011; Lopez, Alan D/F-1487-2010; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Lopez, Alan D/0000-0001-5818-6512; Mckee, Martin/0000-0002-0121-9683				BOYLE P, 2004, TOBACCO PUBLIC HLTH; Chopra M, 2004, BMJ-BRIT MED J, V328, P1558, DOI 10.1136/bmj.328.7455.1558; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Feldman E, 2004, UNFILTERED CONFLICTS; Glantz S.A., 1996, CIGARETTE PAPERS; *IARC WORK GROUP E, 2004, IARC MON, V83; *TOB WORK GROUP, 2004, 2020 TOB WORK GROUP; World Health Organization, 1986, OTT CHART GES; Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616; Yach D, 2003, J PUBLIC HEALTH POL, V24, P274, DOI 10.2307/3343374	10	70	71	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	2005	330	7496					898	900		10.1136/bmj.330.7496.898	http://dx.doi.org/10.1136/bmj.330.7496.898			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	917UA	15831879	Green Published, Green Accepted			2022-12-28	WOS:000228493500027
J	Krosnar, K				Krosnar, K			Cross-border trade in medicines causes concern in the EU	LANCET			English	Editorial Material																			0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1297	1298		10.1016/S0140-6736(05)61011-2	http://dx.doi.org/10.1016/S0140-6736(05)61011-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15828082				2022-12-28	WOS:000228219600012
J	Sarnak, MJ; Katz, R; Stehman-Breen, CO; Fried, LF; Jenny, NS; Psaty, BM; Newman, AB; Siscovick, D; Shlipak, MG				Sarnak, MJ; Katz, R; Stehman-Breen, CO; Fried, LF; Jenny, NS; Psaty, BM; Newman, AB; Siscovick, D; Shlipak, MG		Cardio Hlth Study	Cystatin C concentration as a risk factor for heart failure in older adults	ANNALS OF INTERNAL MEDICINE			English	Article							GLOMERULAR-FILTRATION-RATE; RENAL-INSUFFICIENCY; CARDIOVASCULAR OUTCOMES; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; MARKER; DYSFUNCTION; CREATININE; KIDNEY; EPIDEMIOLOGY	Background: Previous studies that evaluated the association of kidney function with incident heart failure may be limited by the insensitivity of serum creatinine concentration for detecting abnormal kidney function. Objective: To compare serum concentrations of cystatin C (a novel marker of kidney function) and creatinine as predictors of incident heart failure. Design: Observational study based on measurement of serum cystatin C from frozen sera obtained at the 1992-1993 visit of the Cardiovascular Health Study. Follow-up occurred every 6 months. Setting: Adults 65 years of age or older from 4 communities in the United States. Participants: 4384 persons without previous heart failure who had measurements of serum cystatin C and serum creatinine. Measurements: incident heart failure. Results: The mean ( +/- SD) serum concentrations of cystatin C and creatinine were 82 +/- 25 nmol/L (1.10 +/- 0.33 mg/L) and 89 +/- 34 mu mol/L (1.01 +/- 0.39 mg/dL, respectively. During a median follow-up of 8.3 years (maximum, 9.1 years), 763 (17%) participants developed heart failure. After adjustment for demographic factors, traditional and novel cardiovascular risk factors, cardiovascular disease status, and medication use, sequential quintiles of cystatin C concentration were associated with a stepwise increased risk for heart failure in Cox proportional hazards models (hazard ratios, 1.0 [reference], 1.30 [95% Cl, 0.96 to 1.75], 1.44 [CI, 1.07 to 1.94], 1.58 [CI, 1.18 to 2.12], and 2.16 [CI, 1.61 to 2.91]). In contrast, quintiles of serum creatinine concentration were not associated with risk for heart failure in adjusted analysis (hazard ratios, 1.0 [reference], 0.77 [Cl, 0.59 to 1.01), 0.85 [CI, 0.64 to 1.131, 0.97 [Cl, 0.72 to 1.29], and 1.14 [CI, 0.87 to 1.491). Limitations: The mechanism by which cystatin C concentration predicts risk for heart failure remains unclear. Conclusions: The cystatin C concentration is an independent risk factor for heart failure in older adults and appears to provide a better measure of risk assessment than the serum creatinine concentration.	Tufts Univ New England Med Ctr, Boston, MA USA; Collaborat Hlth Studies Coordinating Ctr, Seattle, WA USA; Univ Washington, Seattle, WA 98195 USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Vet Affairs Med Ctr, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA; Univ Vermont, Burlington, VT USA	Tufts Medical Center; University of Washington; University of Washington Seattle; Amgen; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Vermont	Shlipak, MG (corresponding author), Vet Affairs Med Ctr 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	shlip@itsa.ucsf.edu	Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150	NHLBI NIH HHS [N01-HC-85085, R01 HL073208-01, N01-HC-85086, N01-HC-35129, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01 HC-15103] Funding Source: Medline; NIDDK NIH HHS [K23 DK67303] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085085, N01HC085079, N01HC015103, N01HC085082, N01HC085083, N01HC085081, N01HC085084, N01HC035129, N01HC085080, N01HC085086] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK067303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beddhu S, 2002, KIDNEY INT, V62, P1776, DOI 10.1046/j.1523-1755.2002.00629.x; Bibbins-Domingo K, 2004, CIRCULATION, V110, P1424, DOI 10.1161/01.CIR.0000141726.01302.83; Bokenkamp A, 1998, PEDIATRICS, V101, P875, DOI 10.1542/peds.101.5.875; Burkhardt H, 2002, GERONTOLOGY, V48, P140, DOI 10.1159/000052832; Chae CU, 2003, AM J CARDIOL, V92, P682, DOI 10.1016/S0002-9149(03)00822-1; Coll E, 2000, AM J KIDNEY DIS, V36, P29, DOI 10.1053/ajkd.2000.8237; De Leeuw PW, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000027871.86296.92; Dries DL, 2000, J AM COLL CARDIOL, V35, P681, DOI 10.1016/S0735-1097(99)00608-7; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Eriksson P, 2004, ARTERIOSCL THROM VAS, V24, P551, DOI 10.1161/01.ATV.0000117180.57731.36; Erlandsen EJ, 1999, SCAND J CLIN LAB INV, V59, P1, DOI 10.1080/00365519950185940; Fliser D, 2001, AM J KIDNEY DIS, V37, P79, DOI 10.1053/ajkd.2001.20591; Fried LF, 2003, J AM COLL CARDIOL, V41, P1364, DOI 10.1016/S0735-1097(03)00163-3; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gottdiener JS, 2000, J AM COLL CARDIOL, V35, P1628, DOI 10.1016/S0735-1097(00)00582-9; Hsu CY, 2002, J AM SOC NEPHROL, V13, P504, DOI 10.1681/ASN.V132504; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Keevil BG, 1998, CLIN CHEM, V44, P1535; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; LEVEY AS, 1990, KIDNEY INT, V38, P167, DOI 10.1038/ki.1990.182; Manjunath G, 2003, J AM COLL CARDIOL, V41, P47, DOI 10.1016/S0735-1097(02)02663-3; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; NEWMAN DJ, 1995, KIDNEY INT, V47, P312, DOI 10.1038/ki.1995.40; O'Riordan SE, 2003, ANN CLIN BIOCHEM, V40, P648, DOI 10.1258/000456303770367243; Oddoze C, 2001, AM J KIDNEY DIS, V38, P310, DOI 10.1053/ajkd.2001.26096; Price T R, 1993, Ann Epidemiol, V3, P504; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; Randers E, 1998, SCAND J CLIN LAB INV, V58, P585, DOI 10.1080/00365519850186210; Randers E, 1999, CLIN CHEM LAB MED, V37, P389, DOI 10.1515/CCLM.1999.064; Ruilope LM, 2001, J AM SOC NEPHROL, V12, P218, DOI 10.1681/ASN.V122218; Sarnak MJ, 2003, HYPERTENSION, V42, P1050, DOI 10.1161/01.HYP.0000102971.85504.7c; Shlipak MG, 2002, ANN INTERN MED, V137, P555, DOI 10.7326/0003-4819-137-7-200210010-00006; Shlipak MG, 2003, CIRCULATION, V107, P87, DOI 10.1161/01.CIR.0000042700.48769.59; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; Vasan RS, 2003, JAMA-J AM MED ASSOC, V289, P1251, DOI 10.1001/jama.289.10.1251; Wasen E, 2002, CLIN CHEM, V48, P1138; Wright RS, 2002, ANN INTERN MED, V137, P563, DOI 10.7326/0003-4819-137-7-200210010-00007; Zoccali C, 2003, J INTERN MED, V254, P132, DOI 10.1046/j.1365-2796.2003.01180.x	40	247	267	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 5	2005	142	7					497	505		10.7326/0003-4819-142-7-200504050-00008	http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913QL	15809461				2022-12-28	WOS:000228167800003
J	Starfield, B				Starfield, B			US and UK health care: a special relationship? Why is the grass greener?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							UNITED-KINGDOM; QUALITY; STATES; RATES	As well as learning from each other's existing systems, US and UK researchers have potential for collaborative research into improving health care.	Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University	Starfield, B (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, 624 N Broadway, Baltimore, MD 21205 USA.	bstarfie@jhsph.edu						Acheson D., 1998, INDEPENDENT INQUIRY; BAICKER K, 2004, HLTH AFF MILWOO 0407; Black D, 1980, INEQUALITIES HLTH RE; Bunker J., 2001, MED MATTERS ALL MEAS; Fireman B, 2004, HEALTH AFFAIR, V23, P63, DOI 10.1377/hlthaff.23.6.63; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Forrest CB, 2002, BRIT MED J, V325, P370, DOI 10.1136/bmj.325.7360.370; Forrest CB, 2003, ARCH PEDIAT ADOL MED, V157, P279, DOI 10.1001/archpedi.157.3.279; Ham C, 2003, BRIT MED J, V327, P1257, DOI 10.1136/bmj.327.7426.1257; Majeed A, 1997, BRIT MED J, V315, P1515, DOI 10.1136/bmj.315.7121.1515; Mushlin A I, 1980, Med Care, V18, P1; *NAT COMM VIT HLTH, 2001, INF HLTH STRAT BUILD; Nolte E, 2003, BRIT MED J, V327, P1129, DOI 10.1136/bmj.327.7424.1129; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; Senn S, 2004, BMJ-BRIT MED J, V329, P966, DOI 10.1136/bmj.329.7472.966; Starfield B, 2001, BRIT J GEN PRACT, V51, P303; STARFIELD B, 2005, HLTH AFF MILWOOD MAR; Starfield Barbara, 2002, J Am Board Fam Pract, V15, P473; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; van den Akker M, 2001, J CLIN EPIDEMIOL, V54, P675, DOI 10.1016/S0895-4356(00)00358-9; Wennberg JE, 2004, HLTH AFF S	21	1	1	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	2005	330	7493					727	729		10.1136/bmj.330.7493.727	http://dx.doi.org/10.1136/bmj.330.7493.727			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912IT	15790647	Green Published			2022-12-28	WOS:000228071900024
J	MacDonald, TT; Monteleone, G				MacDonald, TT; Monteleone, G			Immunity, inflammation, and allergy in the gut	SCIENCE			English	Review							INTESTINAL EPITHELIAL-CELLS; NF-KAPPA-B; TOLL-LIKE RECEPTORS; REGULATORY T-CELLS; CROHNS-DISEASE; CELIAC-DISEASE; BOWEL-DISEASE; LAMINA PROPRIA; INTRAEPITHELIAL LYMPHOCYTES; FILAMENTOUS BACTERIA	The gut immune system has the challenge of responding to pathogens while remaining relatively unresponsive to food antigens and the commensal microflora. In the developed world, this ability appears to be breaking down, with chronic inflammatory diseases of the gut commonplace in the apparent absence of overt infections. In both mouse and man, mutations in genes that control innate immune recognition, adaptive immunity, and epithelial permeability are all associated with gut inflammation. This suggests that perturbing homeostasis between gut antigens and host immunity represents a critical determinant in the development of gut inflammation and allergy.	Univ Southampton, Sch Med, Southampton Gen Hosp, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; Univ Roma Tor Vergata, Dipartimento Med Interna, Rome, Italy; Univ Roma Tor Vergata, Ctr Eccellenza Studio Malattie Complesse & Multif, Rome, Italy	University of Southampton; University of Rome Tor Vergata; University of Rome Tor Vergata	MacDonald, TT (corresponding author), Barts & London Sch Med & Dent, Turner St, London E1 2AD, England.	t.t.macdonald@qmul.ac.uk	Monteleone, Giovanni/AAE-1418-2021; Eckhardt, Erik/G-1567-2010					Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Berg Rodney D., 1995, Trends in Microbiology, V3, P149, DOI 10.1016/S0966-842X(00)88906-4; Boirivant M, 1999, GASTROENTEROLOGY, V116, P557, DOI 10.1016/S0016-5085(99)70177-0; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; Campbell DJ, 2003, IMMUNOL REV, V195, P58, DOI 10.1034/j.1600-065X.2003.00067.x; Cario E, 2004, GASTROENTEROLOGY, V127, P224, DOI 10.1053/j.gastro.2004.04.015; Cheroutre H, 2004, ANNU REV IMMUNOL, V22, P217, DOI 10.1146/annurev.immunol.22.012703.104522; Cong YZ, 2002, J IMMUNOL, V169, P6112, DOI 10.4049/jimmunol.169.11.6112; Cong YZ, 1998, J EXP MED, V187, P855, DOI 10.1084/jem.187.6.855; Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448; ELSON CO, COMMUNICATION; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; GJERTSEN HA, 1994, HUM IMMUNOL, V39, P243, DOI 10.1016/0198-8859(94)90267-4; Haller D, 2003, J BIOL CHEM, V278, P23851, DOI 10.1074/jbc.M300075200; Hayday A, 2001, NAT IMMUNOL, V2, P997, DOI 10.1038/ni1101-997; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Hilsden RJ, 1996, GASTROENTEROLOGY, V110, P1395, DOI 10.1053/gast.1996.v110.pm8613043; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; HOMEF MW, 2003, J EXP MED, V198, P1225; Hue S, 2004, IMMUNITY, V21, P367, DOI 10.1016/j.immuni.2004.06.018; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; HUSBY S, 1985, SCAND J IMMUNOL, V22, P83, DOI 10.1111/j.1365-3083.1985.tb01862.x; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Inoue N, 2002, GASTROENTEROLOGY, V123, P86, DOI 10.1053/gast.2002.34155; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Kim CY, 2004, P NATL ACAD SCI USA, V101, P4175, DOI 10.1073/pnas.0306885101; KLAASEN HLBM, 1993, INFECT IMMUN, V61, P303, DOI 10.1128/IAI.61.1.303-306.1993; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Kojima K, 2003, GASTROENTEROLOGY, V124, P1395, DOI 10.1016/S0016-5085(03)00215-4; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Lodes MJ, 2004, J CLIN INVEST, V113, P1296, DOI 10.1172/JCI200420295; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; MacDonald TT, 2005, MUCOSAL IMMUNOLOGY, 3RD EDITION, P407, DOI 10.1016/B978-012491543-5/50026-7; MacDonald TT, 1999, IMMUNOL TODAY, V20, P505, DOI 10.1016/S0167-5699(99)01536-4; Macdonald TT, 2003, PARASITE IMMUNOL, V25, P235, DOI 10.1046/j.1365-3024.2003.00632.x; MacDonald TT, 2001, TRENDS IMMUNOL, V22, P244, DOI 10.1016/S1471-4906(01)01892-0; MacDonald TT, 2004, KIRSNERS INFLAMMATOR, P163; Madsen K, 2001, GASTROENTEROLOGY, V121, P580, DOI 10.1053/gast.2001.27224; Maeda S, 2005, SCIENCE, V307, P734, DOI 10.1126/science.1103685; Maiuri L, 2003, LANCET, V362, P30, DOI 10.1016/S0140-6736(03)13803-2; Makita S, 2004, J IMMUNOL, V173, P3119, DOI 10.4049/jimmunol.173.5.3119; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Melis D, 2003, ACTA PAEDIATR, V92, P1415, DOI 10.1080/08035250310007033; Meresse B, 2004, IMMUNITY, V21, P357, DOI 10.1016/j.immuni.2004.06.020; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Molberg O, 2003, GASTROENTEROLOGY, V125, P337, DOI 10.1016/S0016-5085(03)00890-4; Monteleone G, 2004, TRENDS IMMUNOL, V25, P513, DOI 10.1016/j.it.2004.07.008; Monteleone G, 1999, J IMMUNOL, V163, P143; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Neurath MF, 2002, J EXP MED, V195, P1129, DOI 10.1084/jem.20011956; Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Otte JM, 2004, GASTROENTEROLOGY, V126, P1054, DOI 10.1053/j.gastro.2004.01.007; Ouellette AJ, 2004, BEST PRACT RES CL GA, V18, P405, DOI 10.1016/j.bpg.2003.10.010; Pauleau AL, 2003, MOL CELL BIOL, V23, P7531, DOI 10.1128/MCB.23.21.7531-7539.2003; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Piccirillo CA, 2004, SEMIN IMMUNOL, V16, P81, DOI 10.1016/j.smim.2003.12.003; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; RUTGEERTS P, 1995, GASTROENTEROLOGY, V108, P1617, DOI 10.1016/0016-5085(95)90121-3; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sartor R., 2004, KIRSNERS INFLAMMATOR, P138; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Smythies LE, 2005, J CLIN INVEST, V115, P66, DOI 10.1172/JCI200519229; Stoll M, 2004, NAT GENET, V36, P476, DOI 10.1038/ng1345; STURGESS R, 1994, LANCET, V343, P758, DOI 10.1016/S0140-6736(94)91837-6; Sturm A, 2004, GUT, V53, P1624, DOI 10.1136/gut.2003.033613; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432; UMESAKI Y, 1995, MICROBIOL IMMUNOL, V39, P555, DOI 10.1111/j.1348-0421.1995.tb02242.x; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; Van Den Brande JMH, 2003, GASTROENTEROLOGY, V124, P1774, DOI 10.1016/S0016-5085(03)00382-2; vandeWal Y, 1996, IMMUNOGENETICS, V44, P246, DOI 10.1007/s002510050120; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805; Wild GE, 2004, BEST PRACT RES CL GA, V18, P541, DOI 10.1016/j.bpg.2003.12.007; Winkelstein JA, 2000, MEDICINE, V79, P155, DOI 10.1097/00005792-200005000-00003	88	749	796	8	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 25	2005	307	5717					1920	1925		10.1126/science.1106442	http://dx.doi.org/10.1126/science.1106442			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790845				2022-12-28	WOS:000227957300046
J	Ehrmann, DA				Ehrmann, DA			Medical progress: Polycystic ovary syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							IMPAIRED GLUCOSE-TOLERANCE; HORMONE-BINDING GLOBULIN; TYPE-2 DIABETES-MELLITUS; INSULIN GENE VNTR; OBSTRUCTIVE SLEEP-APNEA; LIFE-STYLE MODIFICATION; BETA-CELL FUNCTION; ANDROGEN EXCESS; CAUCASIAN WOMEN; THECA CELLS		Univ Chicago, Dept Med, Endocrinol Sect, Chicago, IL 60637 USA	University of Chicago	Ehrmann, DA (corresponding author), 5841 S Maryland Ave,Mail Code 1027, Chicago, IL 60637 USA.	dehrmann@uchicago.edu			NCRR NIH HHS [M01-RR00055] Funding Source: Medline; NHLBI NIH HHS [R01-HL075079] Funding Source: Medline; NIDDK NIH HHS [P60-DK20595, K08-DK002315] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595, K08DK002315] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DH, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740001; ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; Alcoser SY, 2004, J CLIN ENDOCR METAB, V89, P2973, DOI 10.1210/jc.2003-031189; *AM DIAB ASS, 2004, DIABETES CARE S1, V27, pS11, DOI DOI 10.2337/DIACARE.27.2007.S11; Asuncion M, 2000, J CLIN ENDOCR METAB, V85, P2434, DOI 10.1210/jc.85.7.2434; Atiomo WU, 1998, FERTIL STERIL, V69, P236, DOI 10.1016/S0015-0282(97)00486-X; Attia GR, 2001, FERTIL STERIL, V76, P517, DOI 10.1016/S0015-0282(01)01975-6; Azziz R, 1998, J CLIN ENDOCR METAB, V83, P2317, DOI 10.1210/jc.83.7.2317; Azziz R, 2001, J CLIN ENDOCR METAB, V86, P1626, DOI 10.1210/jc.86.4.1626; Azziz R, 2000, J PEDIATR ENDOCR MET, V13, P1303; Azziz R, 1999, J CLIN ENDOCR METAB, V84, P946, DOI 10.1210/jc.84.3.946; Balen A, 2001, HUM REPROD UPDATE, V7, P522, DOI 10.1093/humupd/7.6.522; Barbieri R L, 2004, Minerva Ginecol, V56, P63; Belli SH, 2004, FERTIL STERIL, V81, P624, DOI 10.1016/j.fertnstert.2003.08.024; CAREY AH, 1994, HUM MOL GENET, V3, P1873, DOI 10.1093/hmg/3.10.1873; Carmina E, 2003, HUM REPROD, V18, P2289, DOI 10.1093/humrep/deg440; Carmina E, 2003, J ENDOCRINOL INVEST, V26, P1151, DOI 10.1007/BF03345266; Christian RC, 2003, J CLIN ENDOCR METAB, V88, P2562, DOI 10.1210/jc.2003-030334; CONWAY GS, 1989, CLIN ENDOCRINOL, V30, P459, DOI 10.1111/j.1365-2265.1989.tb00446.x; Cousin P, 2004, J CLIN ENDOCR METAB, V89, P917, DOI 10.1210/jc.2002-021553; CRAVE JC, 1995, J CLIN ENDOCR METAB, V80, P2057, DOI 10.1210/jc.80.7.2057; DAHLGREN E, 1994, FERTIL STERIL, V61, P455; DAHLGREN E, 1992, ACTA OBSTET GYN SCAN, V71, P599, DOI 10.3109/00016349209006227; DAHLGREN E, 1992, FERTIL STERIL, V57, P505; Diamanti-Kandarakis E, 2003, J CLIN ENDOCR METAB, V88, P1927, DOI 10.1210/jc.2002-021528; Diamanti-Kandarakis E, 2000, FERTIL STERIL, V73, P735, DOI 10.1016/S0015-0282(99)00628-7; Diamanti-Kandarakis E, 2004, J CLIN ENDOCR METAB, V89, P1273, DOI 10.1210/jc.2003-031205; Diamanti-Kandarakis E, 1999, FERTIL STERIL, V71, P431, DOI 10.1016/S0015-0282(98)00512-3; Diamanti-Kandarakis E, 1999, J CLIN ENDOCR METAB, V84, P4006, DOI 10.1210/jc.84.11.4006; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P942, DOI 10.1210/jc.81.3.942; Dunaif A, 1997, ENDOCR REV, V18, P774, DOI 10.1210/er.18.6.774; Dunaif A, 1996, J CLIN ENDOCR METAB, V81, P3299, DOI 10.1210/jc.81.9.3299; Dunaif A, 2001, AM J PHYSIOL-ENDOC M, V281, pE392, DOI 10.1152/ajpendo.2001.281.2.E392; DUNAIF A, 1993, DIABETES, V42, P1462, DOI 10.2337/diabetes.42.10.1462; Eagleson CA, 2000, J CLIN ENDOCR METAB, V85, P4047, DOI 10.1210/jc.85.11.4047; Ehrmann DA, 2002, J CLIN ENDOCR METAB, V87, P4297, DOI 10.1210/jc.2002-020216; Ehrmann DA, 2004, AM J PHYSIOL-ENDOC M, V287, pE241, DOI 10.1152/ajpendo.00475.2003; EHRMANN DA, 1992, NEW ENGL J MED, V327, P157, DOI 10.1056/NEJM199207163270304; Ehrmann DA, 2002, DIABETOLOGIA, V45, P509, DOI 10.1007/s00125-002-0776-y; Ehrmann DA, 2002, J CLIN ENDOCR METAB, V87, P1669, DOI 10.1210/jc.87.4.1669; Ehrmann DA, 1999, DIABETES CARE, V22, P141, DOI 10.2337/diacare.22.1.141; Ehrmann DA, 1997, J CLIN ENDOCR METAB, V82, P2108, DOI 10.1210/jc.82.7.2108; EHRMANN DA, 1995, J CLIN INVEST, V96, P520, DOI 10.1172/JCI118064; Eisner JR, 2003, OBES RES, V11, P279, DOI 10.1038/oby.2003.42; Eisner JR, 2002, FERTIL STERIL, V77, P167, DOI 10.1016/S0015-0282(01)02947-8; Eisner JR, 2000, J CLIN ENDOCR METAB, V85, P1206, DOI 10.1210/jc.85.3.1206; El Mkadem SA, 2001, DIABETES, V50, P2164, DOI 10.2337/diabetes.50.9.2164; Falsetti L, 1999, EUR J ENDOCRINOL, V141, P361, DOI 10.1530/eje.0.1410361; Fauser BCJM, 2004, HUM REPROD, V19, P41, DOI 10.1093/humrep/deh098; Fogel RB, 2001, J CLIN ENDOCR METAB, V86, P1175, DOI 10.1210/jc.86.3.1175; Franks S, 2003, ENDOCRIN METAB CLIN, V32, P639, DOI 10.1016/S0889-8529(03)00044-6; Franks S, 2002, BEST PRACT RES CL EN, V16, P263, DOI 10.1053/beem.2002.0203; Franks S, 1996, BAILLIERE CLIN ENDOC, V10, P193, DOI 10.1016/S0950-351X(96)80057-7; FRANKS S, 1995, NEW ENGL J MED, V333, P853, DOI 10.1056/NEJM199509283331307; FRANKS S, 1989, CLIN ENDOCRINOL, V31, P87, DOI 10.1111/j.1365-2265.1989.tb00457.x; FRANKS S, 1995, NEW ENGL J MED, V333, P1435; Gaasenbeek M, 2004, J CLIN ENDOCR METAB, V89, P2408, DOI 10.1210/jc.2003-031640; Gambineri A, 2004, CLIN ENDOCRINOL, V60, P241, DOI 10.1111/j.1365-2265.2004.01973.x; Gharani N, 1997, HUM MOL GENET, V6, P397, DOI 10.1093/hmg/6.3.397; Ghazeeri G, 2003, FERTIL STERIL, V79, P562, DOI 10.1016/S0015-0282(02)04843-4; Glueck CJ, 2002, FERTIL STERIL, V77, P520, DOI 10.1016/S0015-0282(01)03202-2; Glueck CJ, 2004, HUM REPROD, V19, P1323, DOI 10.1093/humrep/deh263; Glueck CJ, 2002, HUM REPROD, V17, P2858, DOI 10.1093/humrep/17.11.2858; Glueck CJ, 2001, FERTIL STERIL, V75, P46, DOI 10.1016/S0015-0282(00)01666-6; Glueck CJ, 2003, METABOLISM, V52, P908, DOI 10.1016/S0026-0495(03)00104-5; GOLLAND IM, 1993, ANN NY ACAD SCI, V687, P263; Gonzalez A, 2003, J CLIN ENDOCR METAB, V88, P5529, DOI 10.1210/jc.2003-030322; Gopal Mira, 2002, Sleep Med, V3, P401, DOI 10.1016/S1389-9457(02)00033-3; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Guido M, 2004, J CLIN ENDOCR METAB, V89, P2817, DOI 10.1210/jc.2003-031158; HAISENLEDER DJ, 1991, ENDOCRINOLOGY, V128, P509, DOI 10.1210/endo-128-1-509; Hardiman P, 2003, LANCET, V362, P1082; Hickey T, 2002, J CLIN ENDOCR METAB, V87, P161, DOI 10.1210/jc.87.1.161; Hoeger KM, 2004, FERTIL STERIL, V82, P421, DOI 10.1016/j.fertnstert.2004.02.104; Huber-Buchholz MM, 1999, J CLIN ENDOCR METAB, V84, P1470, DOI 10.1210/jc.84.4.1470; Ibanez L, 2001, CLIN ENDOCRINOL, V55, P667, DOI 10.1046/j.1365-2265.2001.01399.x; KAHN SE, 1993, DIABETES, V42, P1663, DOI 10.2337/diabetes.42.11.1663; Kahsar-Miller MD, 2001, FERTIL STERIL, V75, P53, DOI 10.1016/S0015-0282(00)01662-9; Kauffman RP, 2002, AM J OBSTET GYNECOL, V187, P1362, DOI 10.1067/mob.2002.126650; Kelly CJG, 2002, J CLIN ENDOCR METAB, V87, P742, DOI 10.1210/jc.87.2.742; Knochenhauer ES, 1998, J CLIN ENDOCR METAB, V83, P3078, DOI 10.1210/jc.83.9.3078; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Korhonen S, 2003, HUM REPROD, V18, P540, DOI 10.1093/humrep/deg128; Kousta E, 2000, CLIN ENDOCRINOL, V53, P501, DOI 10.1046/j.1365-2265.2000.01123.x; Krattenmacher R, 2000, CONTRACEPTION, V62, P29, DOI 10.1016/S0010-7824(00)00133-5; Krosnick A, 2000, N J Med, V97, P31; Kuhl H, 1996, DRUGS, V51, P188, DOI 10.2165/00003495-199651020-00002; Legro RS, 1998, P NATL ACAD SCI USA, V95, P14956, DOI 10.1073/pnas.95.25.14956; Legro RS, 1999, J CLIN ENDOCR METAB, V84, P165, DOI 10.1210/jc.84.1.165; Legro RS, 2004, OBSTET GYNECOL SURV, V59, P141, DOI 10.1097/01.OGX.0000109523.25076.E2; Legro RS, 2003, ENDOCR REV, V24, P302, DOI 10.1210/er.2003-0004; Legro RS, 1998, J CLIN ENDOCR METAB, V83, P2694, DOI 10.1210/jc.83.8.2694; LIANG T, 1983, ENDOCRINOLOGY, V112, P1460, DOI 10.1210/endo-112-4-1460; Liovic M, 1997, J ENDOCRINOL INVEST, V20, P189, DOI 10.1007/BF03346901; Lord J.M., 2003, COCHRANE DATABASE SY, DOI [10.1002/14651858.Cd003053, DOI 10.1002/14651858.CD003053]; Mansfield R, 2003, FERTIL STERIL, V79, P956, DOI 10.1016/S0015-0282(02)04925-7; Mather KJ, 2000, J CLIN ENDOCR METAB, V85, P1851, DOI 10.1210/jc.85.5.1851; Michelmore K, 2001, CLIN ENDOCRINOL, V55, P439, DOI 10.1046/j.1365-2265.2001.01375.x; Michelmore KF, 1999, CLIN ENDOCRINOL, V51, P779, DOI 10.1046/j.1365-2265.1999.00886.x; Mitwally MFM, 2002, J SOC GYNECOL INVEST, V9, P163, DOI 10.1016/S1071-5576(02)00149-1; Moghetti P, 2000, J CLIN ENDOCR METAB, V85, P89, DOI 10.1210/jc.85.1.89; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Moran LJ, 2003, J CLIN ENDOCR METAB, V88, P812, DOI 10.1210/jc.2002-020815; Muderris II, 2000, GYNECOL ENDOCRINOL, V14, P38; Nelson VL, 1999, MOL ENDOCRINOL, V13, P946, DOI 10.1210/me.13.6.946; Nelson VL, 2001, J CLIN ENDOCR METAB, V86, P5925, DOI 10.1210/jc.86.12.5925; Nestler JE, 1998, NEW ENGL J MED, V338, P1876, DOI 10.1056/NEJM199806253382603; Nestler JE, 2002, FERTIL STERIL, V77, P209, DOI 10.1016/S0015-0282(01)02963-6; Norman RJ, 2001, HUM REPROD, V16, P1995, DOI 10.1093/humrep/16.9.1995; OMEARA NM, 1993, J CLIN ENDOCR METAB, V76, P1241, DOI 10.1210/jc.76.5.1241; Orio F, 2004, J CLIN ENDOCR METAB, V89, P4588, DOI 10.1210/jc.2003-031867; Orio F, 2003, J CLIN ENDOCR METAB, V88, P5887, DOI 10.1210/jc.2002-021816; Orio F, 2004, J CLIN ENDOCR METAB, V89, P3696, DOI 10.1210/jc.2003-032049; Paradisi G, 2001, CIRCULATION, V103, P1410, DOI 10.1161/01.CIR.103.10.1410; Paradisi G, 2003, J CLIN ENDOCR METAB, V88, P576, DOI 10.1210/jc.2002-020386; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; POLSON DW, 1988, LANCET, V1, P870; Roldan Belen, 2004, Am J Pharmacogenomics, V4, P93, DOI 10.2165/00129785-200404020-00004; Romualdi D, 2003, HUM REPROD, V18, P1210, DOI 10.1093/humrep/deg264; Sam S, 2003, TRENDS ENDOCRIN MET, V14, P365, DOI 10.1016/j.tem.2003.08.002; San Millan JL, 2004, J CLIN ENDOCR METAB, V89, P2640, DOI 10.1210/jc.2003-031252; Spritzer PM, 2000, CLIN ENDOCRINOL, V52, P587, DOI 10.1046/j.1365-2265.2000.00982.x; Stamets K, 2004, FERTIL STERIL, V81, P630, DOI 10.1016/j.fertnstert.2003.08.023; Stein IF, 1935, AM J OBSTET GYNECOL, V29, P181, DOI 10.1016/S0002-9378(15)30642-6; TALBOTT E, 1995, ARTERIOSCL THROM VAS, V15, P821, DOI 10.1161/01.ATV.15.7.821; Talbott E O, 2004, Minerva Ginecol, V56, P27; Techatraisak K, 1997, CLIN ENDOCRINOL, V46, P131, DOI 10.1046/j.1365-2265.1997.8700880.x; Tucci S, 2001, J CLIN ENDOCR METAB, V86, P446, DOI 10.1210/jc.86.1.446; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Urbanek M, 1999, P NATL ACAD SCI USA, V96, P8573, DOI 10.1073/pnas.96.15.8573; Urbanek M, 2000, J CLIN ENDOCR METAB, V85, P4455, DOI 10.1210/jc.85.12.4455; URBANEK M, 2002, CURR OPIN ENDOCRINOL, V9, P492; Vankova M, 2002, ANN NY ACAD SCI, V967, P558, DOI 10.1111/j.1749-6632.2002.tb04317.x; Vgontzas AN, 2001, J CLIN ENDOCR METAB, V86, P517, DOI 10.1210/jc.86.2.517; WALDSTREICHER J, 1988, J CLIN ENDOCR METAB, V66, P165, DOI 10.1210/jcem-66-1-165; Waterworth DM, 1997, LANCET, V349, P986, DOI 10.1016/S0140-6736(96)08368-7; Wild Sarah, 2000, Hum Fertil (Camb), V3, P101, DOI 10.1080/1464727002000198781; Williamson K, 2001, AUST NZ J OBSTET GYN, V41, P202, DOI 10.1111/j.1479-828X.2001.tb01210.x; Wood JR, 2003, J BIOL CHEM, V278, P26380, DOI 10.1074/jbc.M300688200; Xita N, 2003, J CLIN ENDOCR METAB, V88, P5976, DOI 10.1210/jc.2003-030197; Yildiz B O, 2003, Minerva Ginecol, V55, P425; Yildiz BO, 2002, J CLIN ENDOCR METAB, V87, P3871, DOI 10.1210/jc.87.8.3871; ZIMMERMANN S, 1992, J CLIN ENDOCR METAB, V75, P508, DOI 10.1210/jc.75.2.508	145	1340	1445	2	102	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1223	1236		10.1056/NEJMra041536	http://dx.doi.org/10.1056/NEJMra041536			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788499				2022-12-28	WOS:000227832300009
J	Loubieres, Y; Chereau, O				Loubieres, Y; Chereau, O			Severe fecal impaction	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Hosp Poissy Saint Germain En Laye, F-78105 St Germain En Laye, France		Loubieres, Y (corresponding author), Ctr Hosp Poissy Saint Germain En Laye, F-78105 St Germain En Laye, France.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					E12	E12		10.1056/NEJMicm040185	http://dx.doi.org/10.1056/NEJMicm040185			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788491				2022-12-28	WOS:000227832300011
J	Perlo, J; Demas, V; Casanova, F; Meriles, CA; Reimer, J; Pines, A; Blumich, B				Perlo, J; Demas, V; Casanova, F; Meriles, CA; Reimer, J; Pines, A; Blumich, B			High-resolution NMR spectroscopy with a portable single-sided sensor	SCIENCE			English	Article							SPECTRA; FIELDS		Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Rhein Westfal TH Aachen, Inst Tech Chem & Makromol Chem, D-52056 Aachen, Germany; Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; CUNY City Coll, Dept Phys, New York, NY 10031 USA	University of California System; University of California Berkeley; RWTH Aachen University; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; City University of New York (CUNY) System; City College of New York (CUNY)	Demas, V (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	vdemas@berkeley.edu; bluemich@mc.rwth-aachen.de	Bluemich, Bernhard P/B-4378-2016	Bluemich, Bernhard P/0000-0002-1152-4438				Balbach JJ, 1997, CHEM PHYS LETT, V277, P367, DOI 10.1016/S0009-2614(97)00858-0; Blumich B, 2000, NMR IMAGING MAT; Ernst R.R., 1994, PRINCIPLES NUCL MAGN; HALL LD, 1987, J AM CHEM SOC, V109, P7579, DOI 10.1021/ja00258a080; Meriles CA, 2001, SCIENCE, V293, P82, DOI 10.1126/science.1061498; RICHTER W, 1995, SCIENCE, V267, P654, DOI 10.1126/science.7839140; WEITEKAMP DP, 1981, J AM CHEM SOC, V103, P3578, DOI 10.1021/ja00402a057	7	134	138	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 27	2005	308	5726					1279	1279		10.1126/science.1108944	http://dx.doi.org/10.1126/science.1108944			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931JT	15817815				2022-12-28	WOS:000229482300037
J	Almond, CSD; Shin, AY; Fortescue, EB; Mannix, RC; Wypij, D; Binstadt, BA; Duncan, CN; Olson, DP; Salerno, AE; Newburger, JW; Greenes, DS				Almond, CSD; Shin, AY; Fortescue, EB; Mannix, RC; Wypij, D; Binstadt, BA; Duncan, CN; Olson, DP; Salerno, AE; Newburger, JW; Greenes, DS			Hyponatremia among runners in the Boston Marathon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY-EDEMA; EXERCISE; ILLNESS	Background Hyponatremia has emerged as an important cause of race-related death and life-threatening illness among marathon runners. We studied a cohort of marathon runners to estimate the incidence of hyponatremia and to identify the principal risk factors. Methods Participants in the 2002 Boston Marathon were recruited one or two days before the race. Subjects completed a survey describing demographic information and training history. After the race, runners provided a blood sample and completed a questionnaire detailing their fluid consumption and urine output during the race. Prerace and postrace weights were recorded. Multivariate regression analyses were performed to identify risk factors associated with hyponatremia. Results Of 766 runners enrolled, 488 runners (64 percent) provided a usable blood sample at the finish line. Thirteen percent had hyponatremia (a serum sodium concentration of 135 mmol per liter or less); 0.6 percent had critical hyponatremia (120 mmol per liter or less). On univariate analyses, hyponatremia was associated with substantial weight gain, consumption of more than 3 liters of fluids during the race, consumption of fluids every mile, a racing time of >4:00 hours, female sex, and low body-mass index. On multivariate analysis, hyponatremia was associated with weight gain (odds ratio, 4.2; 95 percent confidence interval, 2.2 to 8.2), a racing time of >4:00 hours (odds ratio for the comparison with a time of <3:30 hours, 7.4; 95 percent confidence interval, 2.9 to 23.1), and body-mass-index extremes. Conclusions Hyponatremia occurs in a substantial fraction of nonelite marathon runners and can be severe. Considerable weight gain while running, a long racing time, and body-mass-index extremes were associated with hyponatremia, whereas female sex, composition of fluids ingested, and use of nonsteroidal antiinflammatory drugs were not.	Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Clin Res Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Almond, CSD (corresponding author), Childrens Hosp, Dept Cardiol, Bader 2,300 Longwood Ave, Boston, MA 02115 USA.	christopher.almond@childrens.harvard.edu	Binstadt, Bryce/N-1305-2013; Hug, Balthasar L./G-1568-2010; Mannix, Rebekah/AAD-8702-2020	Binstadt, Bryce/0000-0003-3127-3856; Mannix, Rebekah/0000-0003-3608-2792; Wypij, David/0000-0001-8367-8711	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-02172] Funding Source: Medline; NHLBI NIH HHS [T32 HL007572] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayus JC, 2000, ANN INTERN MED, V132, P711, DOI 10.7326/0003-4819-132-9-200005020-00005; Backer HD, 1999, AM J EMERG MED, V17, P532, DOI 10.1016/S0735-6757(99)90191-2; CASA DJ, 2003, PROPER HYDRATION DIS; Davis DP, 2001, J EMERG MED, V21, P47, DOI 10.1016/S0736-4679(01)00320-1; FRIZZELL RT, 1986, JAMA-J AM MED ASSOC, V255, P772, DOI 10.1001/jama.255.6.772; Garigan TP, 1999, MIL MED, V164, P234, DOI 10.1093/milmed/164.3.234; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; Hew TD, 2003, CLIN J SPORT MED, V13, P41, DOI 10.1097/00042752-200301000-00008; HILLMAN M, CLOSE CALL HYPONATRE; Hsieh M, 2002, MED SCI SPORT EXER, V34, P185, DOI 10.1097/00005768-200202000-00001; IRVING RA, 1991, J APPL PHYSIOL, V70, P342, DOI 10.1152/jappl.1991.70.1.342; NEARMAN S, 2002, WASHINGTON TIME 1030; Noakes T, 2003, CLIN J SPORT MED, V13, P309, DOI 10.1097/00042752-200309000-00007; NOAKES TD, 1990, MED SCI SPORT EXER, V22, P165; Noakes TD, 2003, BRIT MED J, V327, P113, DOI 10.1136/bmj.327.7407.113; NOALES TD, 2004, BRIT J SPORT MED, V38, pE16; O'Brien KK, 2001, MIL MED, V166, P405, DOI 10.1093/milmed/166.5.405; Roberts WO, 2000, MED SCI SPORT EXER, V32, P1549; SMITH S, 2002, NY TIMES        0813; Speedy D B, 2001, Emerg Med (Fremantle), V13, P17, DOI 10.1046/j.1442-2026.2001.00173.x; Speedy DB, 1999, MED SCI SPORT EXER, V31, P809, DOI 10.1097/00005768-199906000-00008; Steinberg D., 2003, WASH POST, pA1; *TRACK FIELD RUNN, RUNN US; YOUNG M, 1987, AM REV RESPIR DIS, V136, P737, DOI 10.1164/ajrccm/136.3.737	24	350	358	0	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1550	1556		10.1056/NEJMoa043901	http://dx.doi.org/10.1056/NEJMoa043901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829535				2022-12-28	WOS:000228324200007
J	Levine, BD; Thompson, PD				Levine, BD; Thompson, PD			Marathon maladies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, SW Med Ctr, Presbyterian Hosp Dallas, Inst Exercise & Environm Med, Dallas, TX 75235 USA; Hartford Hosp, Div Prevent Cardiol, Prevent Cardiol Program, Hartford, CT 06115 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Hartford Hospital	Levine, BD (corresponding author), Univ Texas, SW Med Ctr, Presbyterian Hosp Dallas, Inst Exercise & Environm Med, Dallas, TX 75235 USA.							CASA DJ, 2003, PROPER HYDRATION DIS; CURRENS JH, 1961, NEW ENGL J MED, V265, P988, DOI 10.1056/NEJM196111162652006; DERDERIAN T, 1996, BOSTON MARATHON 1 CE; MAUHAN RJ, 2004, FOOD NUTR SPORTS PER, V2; Williams H, 1899, PHILA MED J, P1233	5	15	15	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1516	1518		10.1056/NEJMp058043	http://dx.doi.org/10.1056/NEJMp058043			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829532				2022-12-28	WOS:000228324200003
J	Tamura, G; Suda, Y				Tamura, G; Suda, Y			Airway dilatation after inhalation of a beta-agonist	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tohoku Univ Hosp, Sendai, Miyagi 9808574, Japan; Sendai City Med Ctr, Sendai, Miyagi 9830824, Japan	Tohoku University	Tamura, G (corresponding author), Tohoku Univ Hosp, Sendai, Miyagi 9808574, Japan.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					E14	E14		10.1056/NEJMicm050052	http://dx.doi.org/10.1056/NEJMicm050052			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829529				2022-12-28	WOS:000228324200011
J	Feudtner, C				Feudtner, C			Control of suffering on the slippery slope of care	LANCET			English	Editorial Material							PHYSICIANS; ATTITUDES; EUTHANASIA		Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia	Feudtner, C (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	feudtner@email.chop.edu	Feudtner, Chris/AAI-1126-2019	Feudtner, Chris/0000-0002-5879-0434				CARTER B, 2004, PALLIATIVE CARE INFA; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; De Vries R, 2003, B HIST MED, V77, P752, DOI 10.1353/bhm.2003.0146; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; Gardner H., 2006, CHANGING MINDS ART S; Milstein Jay M, 2003, J Perinatol, V23, P333, DOI 10.1038/sj.jp.7210903; Pernick M., 1996, BLACK STORK EUGENICS; Ryynanen OP, 2002, PUBLIC HEALTH, V116, P322, DOI 10.1038/sj.ph.1900875; Saigal S, 1999, JAMA-J AM MED ASSOC, V281, P1991, DOI 10.1001/jama.281.21.1991; THOMASMA DC, 1998, ASKING DIE INSIDE DU; Wolfe J, 1999, J CLIN ONCOL, V17, P1274, DOI 10.1200/JCO.1999.17.4.1274	11	7	7	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1284	1286		10.1016/S0140-6736(05)61004-5	http://dx.doi.org/10.1016/S0140-6736(05)61004-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823363				2022-12-28	WOS:000228219600005
J	Wilson, B; Dewers, T; Reches, Z; Brune, J				Wilson, B; Dewers, T; Reches, Z; Brune, J			Particle size and energetics of gouge from earthquake rupture zones	NATURE			English	Article							SAN-ANDREAS FAULT; MICROSTRUCTURES; FRAGMENTATION; MECHANISMS; STRESS; SYSTEM	Grain size reduction and gouge formation are found to be ubiquitous in brittle faults at all scales(1-4), and most slip along mature faults is observed to have been localized within gouge zones(5,6). This fine-grain gouge is thought to control earthquake instability(3,6-8), and thus understanding its properties is central to an understanding of the earthquake process(7,9). Here we show that gouge from the San Andreas fault, California, with similar to 160 km slip, and the rupture zone of a recent earthquake in a South African mine with only similar to 0.4 m slip, display similar characteristics, in that ultrafine grains approach the nanometre scale, gouge surface areas approach 80 m(2) g(-1), and grain size distribution is nonfractal. These observations challenge the common perception that gouge texture is fractal(10,11) and that gouge surface energy is a negligible contributor to the earthquake energy budget(3,9,12). We propose that the observed fine-grain gouge is not related to quasistatic cumulative slip, but is instead formed by dynamic rock pulverization during the propagation of a single earthquake.	Univ Oklahoma, Sch Geol & Geophys, Norman, OK 73019 USA; Univ Nevada, Dept Geol Sci, Reno, NV 89557 USA	University of Oklahoma System; University of Oklahoma - Norman; Nevada System of Higher Education (NSHE); University of Nevada Reno	Reches, Z (corresponding author), Univ Oklahoma, Sch Geol & Geophys, Norman, OK 73019 USA.	reches@.ou.edu						AN LJ, 1994, PURE APPL GEOPHYS, V143, P203, DOI 10.1007/BF00874329; Atkinson B. K., 1987, FRACTURE MECH ROCK P, P351, DOI DOI 10.1016/B978-0-12-066266-1.50014-4; Ben-Zion Y, 2003, PURE APPL GEOPHYS, V160, P677, DOI 10.1007/PL00012554; BRUNE JN, 2001, EOS, V8, P47; CHESTER FM, 1993, J GEOPHYS RES-SOL EA, V98, P771, DOI 10.1029/92JB01866; DEWERS TA, 2003, EOS, V84; DOR O, 2001, ROCKBURST SEISMICITY, V5, P109; EVANS JP, 1995, J GEOPHYS RES-SOL EA, V100, P13007, DOI 10.1029/94JB02625; Franco F, 2004, J COLLOID INTERF SCI, V274, P107, DOI 10.1016/j.jcis.2003.12.003; GRADY DE, 1985, J APPL PHYS, V58, P1210, DOI 10.1063/1.336139; GREGG SJ, 1982, ADSORPTION SURFACE P; HOCHELLA MF, 1995, CHEM WEATHERING RATE, V31, P353; KANAMORI H, 1994, ANNU REV EARTH PL SC, V22, P207, DOI 10.1146/annurev.ea.22.050194.001231; MARONE C, 1989, J STRUCT GEOL, V11, P799, DOI 10.1016/0191-8141(89)90099-0; MCGARR A, 1979, J GEOPHYS RES, V84, P2251, DOI 10.1029/JB084iB05p02251; Ogasawara H., 2002, SEISMOGENIC PROCESS; OLGAARD DL, 1983, INT J ROCK MECH MIN, V20, P11, DOI 10.1016/0148-9062(83)91610-8; ORTLEPP WD, 1997, S AFRICA I MINING M, V9; Poliakov ANB, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000572; Reches Z, 1999, EARTH PLANET SC LETT, V170, P475, DOI 10.1016/S0012-821X(99)00122-3; RECHES Z, UNPUB EARTH PLANET S; SAMMIS CG, 1986, PURE APPL GEOPHYS, V124, P53, DOI 10.1007/BF00875719; Scholz C.H., 2002, MECH EARTHQUAKES FAU, DOI 10.1017/CBO9780511818516; SLEEP NH, 1992, NATURE, V359, P687, DOI 10.1038/359687a0; Smith B, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002136; STEACY SJ, 1991, NATURE, V353, P250, DOI 10.1038/353250a0; WILSON B, 2004, MESO MICROSTRUCTURAL; Xu R, 2000, PARTICLE CHARACTERIZ; YUNG RA, 1990, J GEOPHYS RES-SOLID, V95, P15589, DOI 10.1029/JB095iB10p15589; ZOBZCK MD, 2002, SAN ANDREAS FAULT OB	30	201	218	7	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					749	752		10.1038/nature03433	http://dx.doi.org/10.1038/nature03433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815626				2022-12-28	WOS:000228160700037
J	Freeman, R				Freeman, R			Autonomic peripheral neuropathy	LANCET			English	Review							FAMILIAL AMYLOID POLYNEUROPATHY; NERVOUS-SYSTEM DYSFUNCTION; GUILLAIN-BARRE-SYNDROME; ACUTE PANAUTONOMIC NEUROPATHY; EATON-MYASTHENIC-SYNDROME; PRIMARY SJOGRENS-SYNDROME; DIABETES-MELLITUS; CHAGAS-DISEASE; SENSORY NEUROPATHY; LIVER-TRANSPLANTATION	The autonomic neuropathies are a group of disorders in which the small, lightly myelinated and unmyelinated autonomic nerve fibres are selectively targeted. Autonomic features, which involve the cardiovascular, gastrointestinal I urogenital, sudomotor, and pupillomotor systems, occur in varying combination in these disorders. Diabetes is the most common cause of autonomic neuropathy in more developed countries. Autonomic neuropathies can also occur as a result of amyloid deposition, after acute infection, as part of a paraneoplastic syndrome, and after exposure to neurotoxins including therapeutic drugs. Certain antibodies (eg, anti-Hu and those directed against neuronal nicotinic acetylcholine receptor) are associated with autonomic signs and symptoms. There are several familial autonomic neuropathies with autosomal dominant, autosomal recessive,, or X-linked patterns of inheritance. Autonomic dysfunction can occur in association with specific infections. The availability of sensitive and reproducible measures of autonomic function has improved physicians' ability to diagnose these disorders.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Auton & Peripheral Nerve Disorders,Dept Neuro, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Freeman, R (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Auton & Peripheral Nerve Disorders,Dept Neuro, Boston, MA 02215 USA.	rfreeman@bidmc.harvard.edu						Adams D, 2001, J NEUROL, V248, P647, DOI 10.1007/s004150170109; Adams D, 2000, BRAIN, V123, P1495, DOI 10.1093/brain/123.7.1495; APPENZELLER O, 1976, ARCH NEUROL-CHICAGO, V33, P733, DOI 10.1001/archneur.1976.00500110001001; ARRUDA WO, 1989, J NEUROL NEUROSUR PS, V52, P539, DOI 10.1136/jnnp.52.4.539-a; AULD RB, 1967, CAN MED ASSOC J, V96, P652; Axelrod FB, 2004, MUSCLE NERVE, V29, P352, DOI 10.1002/mus.10499; AXELROD FB, 2002, CLIN AUTON RES S1, V12, P12; Bacon CG, 2002, DIABETES CARE, V25, P1458, DOI 10.2337/diacare.25.8.1458; Bergethon PR, 1996, NEUROLOGY, V47, P944, DOI 10.1212/WNL.47.4.944; Berghoff M, 2002, J APPL PHYSIOL, V92, P780, DOI 10.1152/japplphysiol.01167.2000; Bertinotti L, 2004, CLIN RHEUMATOL, V23, P1, DOI 10.1007/s10067-003-0812-4; BOOGERD W, 1990, J NEURO-ONCOL, V9, P255, DOI 10.1007/BF02341156; BRADY RO, 1993, PERIPHERAL NEUROPATH, P1169; BURGOS LG, 1989, ANESTHESIOLOGY, V70, P591, DOI 10.1097/00000542-198904000-00006; CABLE WJL, 1982, NEUROLOGY, V32, P498, DOI 10.1212/WNL.32.5.498; Camdessanche JP, 2002, BRAIN, V125, P166, DOI 10.1093/brain/awf006; CORTELLI P, 1990, ITAL J NEUROL SCI, V11, P159; DALMAU J, 1992, MEDICINE, V71, P59, DOI 10.1097/00005792-199203000-00001; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; DETEJADA IS, 1989, NEW ENGL J MED, V320, P1025, DOI 10.1056/NEJM198904203201601; DYCK PJ, 1979, ANN NEUROL, V6, P302; Enzlin P, 2002, DIABETES CARE, V25, P672, DOI 10.2337/diacare.25.4.672; EWING DJ, 1981, LANCET, V1, P183; Facer P, 1998, BRAIN, V121, P2239, DOI 10.1093/brain/121.12.2239; FAGIUS J, 1983, J NEUROL NEUROSUR PS, V46, P725, DOI 10.1136/jnnp.46.8.725; Falk RH, 1997, NEW ENGL J MED, V337, P898, DOI 10.1056/NEJM199709253371306; FEALEY RD, 1989, MAYO CLIN PROC, V64, P617, DOI 10.1016/S0025-6196(12)65338-5; FELDMAN EL, 1991, NEUROLOGY, V41, P746, DOI 10.1212/WNL.41.5.746; FRASER DM, 1977, BRIT MED J, V2, P675, DOI 10.1136/bmj.2.6088.675-a; FREEMAN R, 1990, NEUROLOGY, V40, P575, DOI 10.1212/WNL.40.4.575; Freeman R, 2003, SEMIN NEUROL, V23, P435; Freeman R, 2004, JOSLINS DIABETES MEL, P951; FREEMAN R, 1997, CLIN AUTONOMIC DISOR, P297; FRIMODTMOLLER C, 1980, ANN INTERN MED, V92, P327, DOI 10.7326/0003-4819-92-2-327; Gertz MA, 2002, AM J MED, V113, P549, DOI 10.1016/S0002-9343(02)01208-1; GOEBEL HH, 1986, ITAL J NEUROL SCI, V7, P325, DOI 10.1007/BF02340870; Goldstein DS, 2002, CLIN AUTON RES, V12, P281, DOI 10.1007/s10286-002-0020-3; Goto H, 2000, J NEUROL NEUROSUR PS, V69, P135, DOI 10.1136/jnnp.69.1.135; Graus F, 2001, BRAIN, V124, P1138, DOI 10.1093/brain/124.6.1138; GUZZETTI S, 1991, AM HEART J, V121, P1727, DOI 10.1016/0002-8703(91)90019-E; HALTIA M, 1992, AM J MED GENET, V42, P357, DOI 10.1002/ajmg.1320420321; HART RG, 1990, ARCH INTERN MED, V150, P2373, DOI 10.1001/archinte.150.11.2373; Heafield MTE, 1996, LANCET, V347, P28, DOI 10.1016/S0140-6736(96)91559-7; Houlden H, 2002, BRAIN, V125, P2681, DOI 10.1093/brain/awf270; Houlden H, 2001, ANN NEUROL, V49, P521; HOYLE C, 1985, ANN RHEUM DIS, V44, P420, DOI 10.1136/ard.44.6.420; HUGHES JM, 1981, ANN INTERN MED, V95, P442, DOI 10.7326/0003-4819-95-4-442; Hund E, 2001, NEUROLOGY, V56, P431, DOI 10.1212/WNL.56.4.431; IDIAQUEZ J, 1992, J NEUROL NEUROSUR PS, V55, P159, DOI 10.1136/jnnp.55.2.159; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; Indo Y, 2002, CLIN AUTON RES S1, V12, pI20; IOSA D, 1990, J AUTONOM NERV SYST, V30, pS83, DOI 10.1016/0165-1838(90)90107-T; JERIAN SM, 1993, GYNECOL ONCOL, V51, P277, DOI 10.1006/gyno.1993.1287; JOHNSEN SD, 1993, NEUROLOGY, V43, P1120, DOI 10.1212/WNL.43.6.1120; Jones KL, 2001, DIABETES CARE, V24, P1264, DOI 10.2337/diacare.24.7.1264; KANG W H, 1987, Journal of the American Academy of Dermatology, V17, P883, DOI 10.1016/S0190-9622(87)70274-6; Kaplan S A, 1988, J Diabet Complications, V2, P133, DOI 10.1016/S0891-6632(88)80024-2; KAPLAN SA, 1995, J UROLOGY, V153, P342, DOI 10.1097/00005392-199502000-00013; KIURU S, 1994, J NEUROL SCI, V126, P40, DOI 10.1016/0022-510X(94)90092-2; Klein CM, 2003, ANN NEUROL, V53, P752, DOI 10.1002/ana.10556; Kong MF, 1999, DIABETES CARE, V22, P503, DOI 10.2337/diacare.22.3.503; Kovacs L, 2004, RHEUMATOLOGY, V43, P95, DOI 10.1093/rheumatology/keg468; Kyle RA, 1997, NEW ENGL J MED, V336, P1202, DOI 10.1056/NEJM199704243361702; KYLE RA, 1990, CRIT REV ONCOL HEMAT, V10, P49, DOI 10.1016/1040-8428(90)90021-J; KYLE RA, 1993, PERIPHERAL NEUROPATH, P1294; Lafreniere RG, 2004, AM J HUM GENET, V74, P1064, DOI 10.1086/420795; LANGER A, 1991, AM J CARDIOL, V67, P1073, DOI 10.1016/0002-9149(91)90868-L; LEGHA SS, 1986, MED TOXICOL ADV DRUG, V1, P421, DOI 10.1007/BF03259853; LENNON VA, 1991, GASTROENTEROLOGY, V100, P137, DOI 10.1016/0016-5085(91)90593-A; LEQUESNE PM, 1977, J NEUROL SCI, V32, P437, DOI 10.1016/0022-510X(77)90025-9; LEWITT PA, 1980, NEW ENGL J MED, V302, P73, DOI 10.1056/NEJM198001103020202; LOW PA, 1975, BRAIN, V98, P341, DOI 10.1093/brain/98.3.341; LOW PA, 1981, NEUROLOGY, V31, P461; Low PA, 2003, SEMIN NEUROL, V23, P407; LOW PA, 1983, ANN NEUROL, V13, P412, DOI 10.1002/ana.410130407; LOW PA, 1978, ANN NEUROL, V3, P179, DOI 10.1002/ana.410030215; Lucchinetti CF, 1998, NEUROLOGY, V50, P652, DOI 10.1212/WNL.50.3.652; Lysy J, 1999, AM J GASTROENTEROL, V94, P2165; MAHLOUDJI M, 1969, MEDICINE, V48, P1; Maleki D, 2000, ARCH INTERN MED, V160, P2808, DOI 10.1001/archinte.160.18.2808; MANOLIS AS, 1987, ARCH INTERN MED, V147, P1805, DOI 10.1001/archinte.147.10.1805; Maser RE, 2003, DIABETES CARE, V26, P1895, DOI 10.2337/diacare.26.6.1895; MATIKAINEN E, 1985, J NEUROL NEUROSUR PS, V48, P1021, DOI 10.1136/jnnp.48.10.1021; MCEVOY KM, 1989, NEW ENGL J MED, V321, P1567, DOI 10.1056/NEJM198912073212303; Merz B, 2003, CLIN AUTON RES, V13, P337, DOI 10.1007/s10286-003-0118-2; Misu K, 1999, BRAIN, V122, P1951, DOI 10.1093/brain/122.10.1951; MURATA K, 1991, AM J IND MED, V20, P663, DOI 10.1002/ajim.4700200509; NEVILLE BGR, 1984, J NEUROL NEUROSUR PS, V47, P648, DOI 10.1136/jnnp.47.6.648; NICHOLS WC, 1990, GENOMICS, V8, P318, DOI 10.1016/0888-7543(90)90288-6; Nolano M, 2000, CLIN NEUROPHYSIOL, V111, P1596, DOI 10.1016/S1388-2457(00)00351-5; Nordentoft T, 1998, NEUROTOXICOLOGY, V19, P421; O'Suilleabhain P, 1998, NEUROLOGY, V50, P88, DOI 10.1212/WNL.50.1.88; OHNISHI A, 1974, ARCH NEUROL-CHICAGO, V31, P120, DOI 10.1001/archneur.1974.00490380068009; PAVESI G, 1992, J NEUROL NEUROSUR PS, V55, P613, DOI 10.1136/jnnp.55.7.613; Pearn J, 2001, J NEUROL NEUROSUR PS, V70, P4, DOI 10.1136/jnnp.70.1.4; Piradov MA, 2001, ARCH NEUROL-CHICAGO, V58, P1438, DOI 10.1001/archneur.58.9.1438; Pomfret EA, 1998, TRANSPLANTATION, V65, P918, DOI 10.1097/00007890-199804150-00010; Rajkumar SV, 1998, AM J MED, V104, P232, DOI 10.1016/S0002-9343(98)00037-0; Rayner CK, 2001, DIABETES CARE, V24, P371, DOI 10.2337/diacare.24.2.371; Ribeiro ALP, 2001, AM HEART J, V141, P260, DOI 10.1067/mhj.2001.111406; Ropper AH., 1991, CONT NEUROLOGY SERIE, P73; Santos SL, 2000, BRAZ J MED BIOL RES, V33, P43, DOI 10.1590/S0100-879X2000000100006; Satake M, 1998, J NEUROL NEUROSUR PS, V64, P561, DOI 10.1136/jnnp.64.4.561; SCHILLER LR, 1982, NEW ENGL J MED, V307, P1666, DOI 10.1056/NEJM198212303072702; SCHMUNIS GA, 1991, TRANSFUSION, V31, P547, DOI 10.1046/j.1537-2995.1991.31691306255.x; Scott LJC, 1999, NEUROLOGY, V52, P1249, DOI 10.1212/WNL.52.6.1249; Shah P K, 1990, Indian J Lepr, V62, P91; Shaw JE, 1996, DIABETIC MED, V13, P1033, DOI 10.1002/(SICI)1096-9136(199612)13:12<1033::AID-DIA280>3.0.CO;2-B; SIDDIQUI MA, 1995, SOUTHERN MED J, V88, P1087, DOI 10.1097/00007611-199510000-00022; SIMMONS Z, 1993, J NEUROL SCI, V120, P60, DOI 10.1016/0022-510X(93)90025-T; Skinner M, 1996, AM J MED, V100, P290, DOI 10.1016/S0002-9343(97)89487-9; Slaugenhaupt SA, 2001, AM J HUM GENET, V68, P598, DOI 10.1086/318810; Smit AAJ, 1997, MAYO CLIN PROC, V72, P333, DOI 10.4065/72.4.333; Sorajja P, 1999, MAYO CLIN PROC, V74, P695, DOI 10.4065/74.7.695; Stevens MJ, 1998, CIRCULATION, V98, P961, DOI 10.1161/01.CIR.98.10.961; STOLL G, 1991, NEUROLOGY, V41, P723, DOI 10.1212/WNL.41.5.723; SUAREZ GA, 1994, NEUROLOGY, V44, P1675, DOI 10.1212/WNL.44.9.1675; SUMMERS Q, 1987, MED J AUSTRALIA, V147, P353, DOI 10.5694/j.1326-5377.1987.tb133521.x; TAUBNER RW, 1984, ARCH NEUROL-CHICAGO, V41, P1100, DOI 10.1001/archneur.1984.04050210102025; THOMASHEFSKY AJ, 1972, NEUROLOGY, V22, P251, DOI 10.1212/WNL.22.3.251; TOHGI H, 1989, ACTA NEUROPATHOL, V77, P659, DOI 10.1007/BF00687895; VANALLEN MW, 1969, NEUROLOGY, V19, P10, DOI 10.1212/WNL.19.1.10; VANLIESHOUT JJ, 1986, J NEUROL NEUROSUR PS, V49, P830, DOI 10.1136/jnnp.49.7.830; VANLIESHOUT JJ, 1986, J NEUROL NEUROSUR PS, V49, P1461; Veglio M, 2000, DIABETES CARE, V23, P1381, DOI 10.2337/diacare.23.9.1381; Vernino S, 2000, ANN NEUROL, V47, P297, DOI 10.1002/1531-8249(200003)47:3<297::AID-ANA4>3.3.CO;2-W; Vernino S, 2000, NEW ENGL J MED, V343, P847, DOI 10.1056/NEJM200009213431204; Vernino S, 2001, AUTON NEUROSCI-BASIC, V88, P187, DOI 10.1016/S1566-0702(01)00239-9; VILLA A, 1992, AIDS, V6, P85, DOI 10.1097/00002030-199201000-00011; Villar JC, 2004, INT J CARDIOL, V93, P189, DOI 10.1016/j.ijcard.2003.03.002; Vinik AI, 2003, DIABETES CARE, V26, P1553, DOI 10.2337/diacare.26.5.1553; VITA G, 1987, ARCH NEUROL-CHICAGO, V44, P202, DOI 10.1001/archneur.1987.00520140064019; Waterman SA, 2001, CLIN AUTON RES, V11, P145, DOI 10.1007/BF02329922; WEGENER M, 1990, DIGEST DIS, V8, P23, DOI 10.1159/000171237; Wilder-Smith EPV, 2000, MUSCLE NERVE, V23, P1105, DOI 10.1002/1097-4598(200007)23:7<1105::AID-MUS14>3.0.CO;2-A; WINER JB, 1988, Q J MED, V68, P735; Wright RA, 1999, J AUTONOM NERV SYST, V75, P70, DOI 10.1016/S0165-1838(98)00164-7; YAHR MD, 1975, ARCH NEUROL-CHICAGO, V32, P132, DOI 10.1001/archneur.1975.00490440082014; YOUNG RR, 1975, BRAIN, V98, P613, DOI 10.1093/brain/98.4.613; Yu ZY, 2001, ANN NEUROL, V49, P146; ZOCHODNE DW, 1994, MUSCLE NERVE, V17, P1145, DOI 10.1002/mus.880171004	141	144	158	2	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1259	1270		10.1016/S0140-6736(05)74815-7	http://dx.doi.org/10.1016/S0140-6736(05)74815-7			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811460				2022-12-28	WOS:000228107600030
J	Robinson, DA; Kearns, AM; Holmes, A; Morrison, D; Grundmann, H; Edwards, G; O'Brien, FG; Tenover, FC; McDougal, LK; Monk, AB; Enright, MC				Robinson, DA; Kearns, AM; Holmes, A; Morrison, D; Grundmann, H; Edwards, G; O'Brien, FG; Tenover, FC; McDougal, LK; Monk, AB; Enright, MC			Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone	LANCET			English	Article							PANTON-VALENTINE LEUKOCIDIN; EMERGENCE; STRAINS	During the 1950s, the notorious penicillin-resistant clone of Staphylococcus aureus known as phage type 80/81 emerged and caused serious hospital-acquired and community-acquired infections worldwide. This clone was largely eliminated in the 1960s, concurrent with the widespread use of penicillinase-resistant beta lactams. We investigated whether early 80/81 isolates had the genes for Panton-Valentine leucocidin, a toxin associated with virulence in healthy young people. Multilocus sequence analysis suggested that descendants of 80/81 have acquired meticillin resistance, are re-emerging as a community-acquired meticillin-resistant S aureus (MRSA) clone, and represent a sister lineage to pandemic hospital-acquired MRSA.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Hlth Protect Agcy, Lab Healthcare Associated Infect, Specialist & Reference Microbiol Div, London, England; Stobhill Hosp, Dept Microbiol, Scottish MRSA Reference Lab, Glasgow, Lanark, Scotland; Natl Inst Publ Hlth & Environm, RIVM, Dept Infect Dis Epidemiol, NL-3720 BA Bilthoven, Netherlands; Curtin Univ Technol, Sch Biomed Sci, Perth, WA 6001, Australia; Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA	University of Bath; Health Protection Agency; Netherlands National Institute for Public Health & the Environment; Curtin University; Centers for Disease Control & Prevention - USA	Enright, MC (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	m.c.enright@bath.ac.uk		Enright, Mark/0000-0001-5273-8750				DONAHUE JA, 1966, J INFECT DIS, V116, P324, DOI 10.1093/infdis/116.3.324; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Robinson DA, 2003, ANTIMICROB AGENTS CH, V47, P3926, DOI 10.1128/AAC.47.12.3926-3934.2003; ROUNTREE Phyllis M., 1958, Medical Journal of Australia, V2, P789; Vandenesch F, 2003, EMERG INFECT DIS, V9, P978	5	199	206	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2005	365	9466					1256	1258		10.1016/S0140-6736(05)74814-5	http://dx.doi.org/10.1016/S0140-6736(05)74814-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811459				2022-12-28	WOS:000228107600029
J	Skinner, H; Abdeen, Z; Abdeen, H; Aber, P; Al-Masri, M; Attias, J; Avraham, KB; Carmi, R; Chalin, C; El Nasser, Z; Hijazi, M; Jebara, RO; Kanaan, M; Pratt, H; Raad, F; Roth, Y; Williams, AP; Noyek, A				Skinner, H; Abdeen, Z; Abdeen, H; Aber, P; Al-Masri, M; Attias, J; Avraham, KB; Carmi, R; Chalin, C; El Nasser, Z; Hijazi, M; Jebara, RO; Kanaan, M; Pratt, H; Raad, F; Roth, Y; Williams, AP; Noyek, A			Promoting Arab and Israeli cooperation: peacebuilding through health initiatives	LANCET			English	Article							POPULATION; CONFLICT	This article describes a positive experience in building Arab and Israeli cooperation through health initiatives. Over the past 10 years Israeli, Jordanian, and Palestinian health professionals have worked together through the Canada International Scientific Exchange Program (CISEPO). In the initial project, nearly 17 000 Arab and Israeli newborn babies were tested for early detection of hearing loss, an important health issue for the region. The network has grown to address additional needs, including mother-child health, nutrition, infectious diseases, and youth health. Our guiding model emphasises two goals: project-specific outcomes in health improvement, and broader effects on cross-border cooperation Lessons learned from this experience and the model provide direction for ways that health professionals can contribute to peacebuilding.	Univ Toronto, Toronto, ON, Canada; Al Quds Univ, Abu Dis, West Bank, Israel; Jordan Univ Sci & Technol, Irbid, Jordan; Univ Haifa, IL-31999 Haifa, Israel; Tel Aviv Univ, IL-69978 Tel Aviv, Israel; Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Royal Med Serv Jordan, Amman, Jordan; Bethlehem Univ, Bethlehem, West Bank, Palestine; Technion Israel Inst Technol, Haifa, Israel; Harvard Univ, Boston, MA 02115 USA; Amman Univ, Amman, Jordan	University of Toronto; Jordan University of Science & Technology; University of Haifa; Tel Aviv University; Ben Gurion University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Technion Israel Institute of Technology; Harvard University; Al-Ahliyya Amman University	Skinner, H (corresponding author), Univ Toronto, Toronto, ON, Canada.	harvey.skinner@utoronto.ca	Abdeen, Ziad/AAC-7889-2019	Avraham, Karen B/0000-0002-4913-251X				Adam D, 2003, NATURE, V421, P777, DOI 10.1038/421777b; [Anonymous], 2002, LANCET, V359, P1261; Barnea T, 2000, ISRAELI PALESTINIAN; BENSIMHON K, 2004, HAARETZ TEL AVI 0602; Dajani KK, 2002, CROAT MED J, V43, P138; Garber R., 2002, Journal of Peacebuilding & Development, V1, P69; Grundfast Kenneth M., 1992, Ear Nose and Throat Journal, V71, P479; Hershman T, 2003, SCIENCE, V301, P303, DOI 10.1126/science.301.5631.303; Horton R, 2003, LANCET, V362, P928, DOI 10.1016/S0140-6736(03)14394-2; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; Santa Barbara J, 2004, LANCET, V364, P384; SCHAM P, 2000, MIDDLE E REV INT AFF, V4, P1; Shahin H, 2002, HUM GENET, V110, P284, DOI 10.1007/s00439-001-0674-2; Skinner H.A., 2002, PROMOTING HLTH ORG C; SKINNER HA, 2003, BUILDING ARAB ISRAEL; Sobe T, 2000, HUM GENET, V106, P50, DOI 10.1007/s004390051009; Stein JG, 2001, NETWORKS KNOWLEDGE; *UN DEV PROGR, 2003, BUILD KNOWL SOC AR H; Vardi-Saliternik R, 2002, ANN HUM BIOL, V29, P422, DOI 10.1080/03014460110100928	19	27	27	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2005	365	9466					1274	1277		10.1016/S0140-6736(05)74817-0	http://dx.doi.org/10.1016/S0140-6736(05)74817-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811462				2022-12-28	WOS:000228107600032
J	Aharonian, F; Akhperjanian, AG; Aye, KM; Bazer-Bachi, AR; Beilicke, M; Benbow, W; Berge, D; Berghaus, P; Bernlohr, K; Boisson, C; Bolz, O; Borgmeier, C; Braun, I; Breitling, F; Brown, AM; Gordo, JB; Chadwick, PM; Chounet, LM; Cornils, R; Costamante, L; Degrange, B; Djannati-Ata, A; Drury, LO; Dubus, G; Ergin, T; Espigat, P; Feinstein, F; Fteury, P; Fontaine, G; Funk, S; Gallant, YA; Giebels, B; Gillessen, S; Goret, P; Hadjichristidis, C; Hauser, M; Heinzelmann, G; Henri, G; Hermann, G; Hinton, JA; Hofmann, W; Holleran, M; Horns, D; de Jager, OC; Jung, I; Khelifi, B; Komin, N; Konopelko, A; Latham, IJ; Le Gallou, R; Lemiere, A; Lemoine, M; Leroy, N; Lohse, T; Marcowith, A; Masterson, C; McComb, TJL; de Naurois, M; Nolan, SJ; Noutsos, A; Orford, KJ; Osborne, JL; Ouchrif, M; Panter, M; Pelletier, G; Pita, S; Puhlhofer, G; Punch, M; Raubenheimer, BC; Raue, M; Raux, J; Rayner, SM; Redondo, I; Reimer, A; Reimer, O; Ripken, J; Rob, L; Rolland, L; Rowell, G; Sahakian, V; Sauge, L; Schlenker, S; Schlickeiser, R; Schuster, C; Schwanke, U; Siewert, M; Sol, H; Steenkamp, R; Stegmann, C; Tavernet, JP; Terrier, R; Theoret, CG; Tluczykont, M; van der Walt, DJ; Vasileiadis, G; Venter, C; Vincent, P; Visser, B; Volk, HJ; Wagner, SJ				Aharonian, F; Akhperjanian, AG; Aye, KM; Bazer-Bachi, AR; Beilicke, M; Benbow, W; Berge, D; Berghaus, P; Bernlohr, K; Boisson, C; Bolz, O; Borgmeier, C; Braun, I; Breitling, F; Brown, AM; Gordo, JB; Chadwick, PM; Chounet, LM; Cornils, R; Costamante, L; Degrange, B; Djannati-Ata, A; Drury, LO; Dubus, G; Ergin, T; Espigat, P; Feinstein, F; Fteury, P; Fontaine, G; Funk, S; Gallant, YA; Giebels, B; Gillessen, S; Goret, P; Hadjichristidis, C; Hauser, M; Heinzelmann, G; Henri, G; Hermann, G; Hinton, JA; Hofmann, W; Holleran, M; Horns, D; de Jager, OC; Jung, I; Khelifi, B; Komin, N; Konopelko, A; Latham, IJ; Le Gallou, R; Lemiere, A; Lemoine, M; Leroy, N; Lohse, T; Marcowith, A; Masterson, C; McComb, TJL; de Naurois, M; Nolan, SJ; Noutsos, A; Orford, KJ; Osborne, JL; Ouchrif, M; Panter, M; Pelletier, G; Pita, S; Puhlhofer, G; Punch, M; Raubenheimer, BC; Raue, M; Raux, J; Rayner, SM; Redondo, I; Reimer, A; Reimer, O; Ripken, J; Rob, L; Rolland, L; Rowell, G; Sahakian, V; Sauge, L; Schlenker, S; Schlickeiser, R; Schuster, C; Schwanke, U; Siewert, M; Sol, H; Steenkamp, R; Stegmann, C; Tavernet, JP; Terrier, R; Theoret, CG; Tluczykont, M; van der Walt, DJ; Vasileiadis, G; Venter, C; Vincent, P; Visser, B; Volk, HJ; Wagner, SJ			A new population of very high energy gamma-ray sources in the Milky Way	SCIENCE			English	Article							ATMOSPHERIC CHERENKOV TELESCOPES; SUPERNOVA REMNANT; GALACTIC PLANE; PULSAR; ARRAY; VICINITY; CATALOG; REGIONS; SYSTEM	Very high energy gamma-rays probe the long-standing mystery of the origin of cosmic rays. Produced in the interactions of accelerated particles in astrophysical objects, they can be used to image cosmic particle accelerators. A first-sensitive survey of the inner part of the Milky Way with the High Energy Stereoscopic System (HESS) reveals a population of eight previously unknown firmly detected sources of very high energy gamma-rays. At least two have no known radio or x-ray counterpart and may be representative of a new class of "dark" nucleonic cosmic ray sources.	Max Planck Inst Kernphys, D-69029 Heidelberg, Germany; Yerevan Phys Inst, Yerevan 375036, Armenia; Univ Durham, Dept Phys, Durham DH1 3LE, England; UPS, CNRS, Ctr Etud Spatiale Rayonnements, F-31029 Toulouse, France; Univ Hamburg, Inst Expt Phys, D-22761 Hamburg, Germany; Coll France, CNRS, IN2P3, F-75231 Paris, France; Humboldt Univ, Inst Phys, D-12489 Berlin, Germany; Observ Paris, Sect Meudon, CNRS,UMR 8102, LUTH, F-92195 Meudon, France; Univ Montpellier 2, CNRS, IN2P3, Grp Astroparticules Montpellier, F-34095 Montpellier, France; Ecole Polytech, CNRS, IN2P3, Lab Leprince Ringuet, F-91128 Palaiseau, France; Dublin Inst Adv Studies, Dublin 2, Ireland; Ctr Etud Saclay, CEA, DAPNIA,DSM, Serv Astrophys, F-91191 Gif Sur Yvette, France; Landessternwarte Konigstuhl, D-69117 Heidelberg, Germany; Univ Grenoble 1, CNRS, INSU, Lab Astrophys Grenoble, F-38041 Grenoble, France; NW Univ, Unit Space Phys, ZA-2520 Potchefstroom, South Africa; Univ Paris 06, CNRS, IN2P3, Lab Phys Nucl & Hautes Energies, F-75231 Paris, France; Univ Paris 07, CNRS, IN2P3, Lab Phys Nucl & Hautes Energies, F-75231 Paris, France; Ruhr Univ Bochum, Inst Theoret Phys, Lehrstuhl Weltraum & Astrophys 4, D-44780 Bochum, Germany; Charles Univ, Inst Nucl & Particle Phys, CR-18000 Prague, Czech Republic; Univ Namibia, Windhoek, Namibia	Max Planck Society; Yerevan Physics Institute; Durham University; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Hamburg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; PSL Research University Paris; College de France; Humboldt University of Berlin; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); Institut Polytechnique de Paris; Dublin Institute for Advanced Studies; CEA; UDICE-French Research Universities; Universite Paris Saclay; Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); North West University - South Africa; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Ruhr University Bochum; Charles University Prague; University of Namibia	Funk, S (corresponding author), Max Planck Inst Kernphys, POB 103980, D-69029 Heidelberg, Germany.	stefan.funk@mpi-hd.mpg.de	Marcowith, Alexandre/ABH-1254-2020; Reimer, Olaf/A-3117-2013; Funk, Stefan/B-7629-2015; Reimer, Anita/K-5822-2015; Ergin, Tulun/AAQ-1106-2021; White, Richard/AAF-4527-2019; Gordo, Javier Bussons/B-5572-2019; Venter, Christo/E-6884-2011; Berge, David/P-2179-2017; Horns, Dieter/ABE-9516-2020; Pühlhofer, Gerd/Q-2336-2018; Fontaine, Gerard/D-6420-2014; Aye, Klaus-Michael/D-2425-2009; Drury, Luke O'C/B-1916-2017; Braun, Isabel V/C-9373-2012; Hadjichristidis, Christos/G-7284-2012; Jung-Richardt, Ira/AAT-8884-2020; Horns, Dieter/C-9727-2011; Funk, Stefan/AAI-1568-2021; Komin, Nukri/J-6781-2015; Aye, Klaus-Michael/W-1271-2018; Redondo, Ignacio/K-8639-2014	Marcowith, Alexandre/0000-0002-3971-0910; Reimer, Olaf/0000-0001-6953-1385; Funk, Stefan/0000-0002-2012-0080; Reimer, Anita/0000-0001-8604-7077; Ergin, Tulun/0000-0003-2423-4656; White, Richard/0000-0002-3356-0763; Gordo, Javier Bussons/0000-0002-8275-592X; Venter, Christo/0000-0002-2666-4812; Berge, David/0000-0002-2918-1824; Horns, Dieter/0000-0003-1945-0119; Fontaine, Gerard/0000-0002-6443-5025; Drury, Luke O'C/0000-0002-9257-2270; Braun, Isabel V/0000-0002-9389-0502; Hadjichristidis, Christos/0000-0002-5933-0755; Funk, Stefan/0000-0002-2012-0080; Punch, Michael/0000-0002-4710-2165; Hinton, James/0000-0002-1031-7760; Komin, Nukri/0000-0003-3280-0582; Noutsos, Aristeidis/0000-0002-4151-3860; Rowell, Gavin/0000-0002-9516-1581; Benbow, Wystan/0000-0003-2098-170X; Aye, Klaus-Michael/0000-0002-4088-1928; Brown, Anthony/0000-0003-0259-3148; Khelifi, Bruno/0000-0001-6876-5577; Hermann, German/0000-0002-4595-1032; van der Walt, Johan/0000-0001-6666-6866; Chadwick, Paula/0000-0002-1468-2685; Redondo, Ignacio/0000-0003-3737-4121; Bernlohr, Konrad/0000-0001-8065-3252; Dubus, Guillaume/0000-0002-5130-2514				Aharonian F, 2005, ASTRON ASTROPHYS, V430, P865, DOI 10.1051/0004-6361:20041853; Aharonian F, 2004, ASTRON ASTROPHYS, V425, pL13, DOI 10.1051/0004-6361:200400055; Aharonian F, 2002, ASTRON ASTROPHYS, V393, pL37, DOI 10.1051/0004-6361:20021171; Aharonian FA, 1997, ASTROPART PHYS, V6, P369, DOI 10.1016/S0927-6505(96)00070-9; Aharonian FA, 2004, NATURE, V432, P75, DOI 10.1038/nature02960; Aharonian FA, 2002, ASTRON ASTROPHYS, V395, P803, DOI 10.1051/0004-6361:20021347; Amenomori M, 2002, ASTROPHYS J, V580, P887, DOI 10.1086/343857; Atkins R, 2004, ASTROPHYS J, V608, P680, DOI 10.1086/420880; Bamba A, 2003, ASTROPHYS J, V589, P253, DOI 10.1086/374354; Beilicke M, 2005, AIP CONF PROC, V745, P347, DOI 10.1063/1.1878428; Benbow W, 2005, AIP CONF PROC, V745, P611, DOI 10.1063/1.1878471; Bernlohr K, 2003, ASTROPART PHYS, V20, P111, DOI 10.1016/S0927-6505(03)00171-3; BLITZ L, 1982, ASTROPHYS J SUPPL S, V49, P183, DOI 10.1086/190795; CHURCHWELL E, 1990, ASTRON ASTROPHYS REV, V2, P79, DOI 10.1007/BF00872764; Daum A, 1997, ASTROPART PHYS, V8, P1, DOI 10.1016/S0927-6505(97)00031-5; DENAUROIS M, 2003, P 28 INT COSM RAY C, P2907; Funk S, 2004, ASTROPART PHYS, V22, P285, DOI 10.1016/j.astropartphys.2004.08.001; Gaensler BM, 2003, ASTROPHYS J, V588, P441, DOI 10.1086/368356; Gotthelf EV, 1997, ASTROPHYS J, V487, pL175, DOI 10.1086/310900; Green D.A., 2004, BASI, V32, P335; Hartman RC, 1999, ASTROPHYS J SUPPL S, V123, P79, DOI 10.1086/313231; HASCHICK AD, 1983, ASTROPHYS J, V267, P638, DOI 10.1086/160900; KASSIM NE, 1990, NATURE, V343, P146, DOI 10.1038/343146a0; KASSIM NE, 1992, ASTRON J, V103, P943, DOI 10.1086/116116; LI TP, 1983, ASTROPHYS J, V272, P317, DOI 10.1086/161295; MALIZIA A, 2004, P 5 INTEGRAL WORKSH; MANCHESTER RN, IN PRESS ASTRON J; Nolan PL, 2003, ASTROPHYS J, V597, P615, DOI 10.1086/378353; Torii K, 1998, ASTROPHYS J, V494, pL207, DOI 10.1086/311186; VINCENT P, 2003, P 28 ICRC TSUK, P2887; Vink J, 2004, ASTROPHYS J, V604, P693, DOI 10.1086/381930	31	287	288	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1938	1942		10.1126/science.1108643	http://dx.doi.org/10.1126/science.1108643			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790849	Green Submitted			2022-12-28	WOS:000227957300050
J	Butler, D				Butler, D			Hubert Curien (1924-2005) - Obituary	NATURE			English	Biographical-Item																		1990, NATURE, V346, P126	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 24	2005	434	7032					453	453		10.1038/434453a	http://dx.doi.org/10.1038/434453a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791242	Bronze			2022-12-28	WOS:000227836000028
J	Gami, AS; Howard, DE; Olson, EJ; Somers, VK				Gami, AS; Howard, DE; Olson, EJ; Somers, VK			Day-night pattern of sudden death in obstructive sleep apnea	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; CERTIFICATE DIAGNOSIS; CARDIAC DEATH; ATRIOVENTRICULAR-CONDUCTION; MYOCARDIAL-INFARCTION; BREATHING DISORDERS; QT INTERVAL; VALIDATION; POPULATION; DISTURBANCES	BACKGROUND: The risk of sudden death from cardiac causes in the general population peaks from 6 a.m. to noon and has a nadir from midnight to 6 a.m. Obstructive sleep apnea is highly prevalent and associated with neurohormonal and electrophysiological abnormalities that may increase the risk of sudden death from cardiac causes, especially during sleep. METHODS: We reviewed polysomnograms and the death certificates of 112 Minnesota residents who had undergone polysomnography and had died suddenly from cardiac causes between July 1987 and July 2003. For four intervals of the day, we compared the rates of sudden death from cardiac causes among people with obstructive sleep apnea and the following: the rates among people without obstructive sleep apnea, the rates in the general population, and the expectations according to chance. For each interval, we assessed the median apnea-hypopnea index and the relative risk of sudden death from cardiac causes. We similarly analyzed sudden death from cardiac causes during three time intervals that correlate with usual sleep-wake cycles. RESULTS: From midnight to 6 a.m., sudden death from cardiac causes occurred in 46 percent of people with obstructive sleep apnea, as compared with 21 percent of people without obstructive sleep apnea (P=0.01), 16 percent of the general population (P<0.001), and the 25 percent expected by chance (P<0.001). People with sudden death from cardiac causes from midnight to 6 a.m. had a significantly higher apnea-hypopnea index than those with sudden death from cardiac causes during other intervals, and the apnea-hypopnea index correlated directly with the relative risk of sudden death from cardiac causes from midnight to 6 a.m. For people with obstructive sleep apnea, the relative risk of sudden death from cardiac causes from midnight to 6 a.m. was 2.57 (95 percent confidence interval, 1.87 to 3.52). The analysis of usual sleep-wake cycles showed similar results. CONCLUSIONS: People with obstructive sleep apnea have a peak in sudden death from cardiac causes during the sleeping hours, which contrasts strikingly with the nadir of sudden death from cardiac causes during this period in people without obstructive sleep apnea and in the general population.	Mayo Clin & Mayo Fdn, Coll Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Pulm & Crit Care Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Div Hypertens, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Internal Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Somers, VK (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	somers.virend@mayo.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065176, R01HL061560, R01HL073211] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREOTTI F, 1988, AM J CARDIOL, V62, P635, DOI 10.1016/0002-9149(88)90669-8; BECKER H, 1995, AM J RESP CRIT CARE, V151, P215, DOI 10.1164/ajrccm.151.1.7812557; BEXTON RS, 1986, BRIT HEART J, V55, P253; CLARKE JM, 1976, LANCET, V2, P508, DOI 10.1016/S0140-6736(76)90801-1; Coady SA, 2001, J CLIN EPIDEMIOL, V54, P40, DOI 10.1016/S0895-4356(00)00272-9; Cohen MC, 1997, AM J CARDIOL, V79, P1512, DOI 10.1016/S0002-9149(97)00181-1; Fichter J, 2002, CHEST, V122, P558, DOI 10.1378/chest.122.2.558; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FOLSOM AR, 1987, AM J EPIDEMIOL, V125, P1012, DOI 10.1093/oxfordjournals.aje.a114617; Fox CS, 2004, CIRCULATION, V110, P522, DOI 10.1161/01.CIR.0000136993.34344.41; Fries R, 1999, PACE, V22, P223, DOI 10.1111/j.1540-8159.1999.tb00337.x; GILLIS AM, 1991, SLEEP, V14, P346, DOI 10.1093/sleep/14.4.346; GONZALEZROTHI RJ, 1988, CHEST, V94, P531, DOI 10.1378/chest.94.3.531; Goraya TY, 2000, MAYO CLIN PROC, V75, P681; Goraya TY, 2003, AM J EPIDEMIOL, V157, P763, DOI 10.1093/aje/kwg057; Grimm W, 1996, AM J CARDIOL, V77, P1310, DOI 10.1016/S0002-9149(96)00197-X; GUILLEMINAULT C, 1983, AM J CARDIOL, V52, P490, DOI 10.1016/0002-9149(83)90013-9; Harbison J, 2000, CHEST, V118, P591, DOI 10.1378/chest.118.3.591; HUIKURI HV, 1994, CIRCULATION, V90, P121, DOI 10.1161/01.CIR.90.1.121; HUIKURI HV, 1995, PACE, V18, P1362, DOI 10.1111/j.1540-8159.1995.tb02597.x; Iribarren C, 1998, AM J CARDIOL, V82, P50, DOI 10.1016/S0002-9149(98)00240-9; Koehler U, 1998, EUR RESPIR J, V11, P434, DOI 10.1183/09031936.98.11020434; Legramante JM, 2003, J HYPERTENS, V21, P1555, DOI 10.1097/00004872-200308000-00021; MOSER DK, 1994, J AM COLL CARDIOL, V24, P963, DOI 10.1016/0735-1097(94)90856-7; MULLER JE, 1987, CIRCULATION, V75, P131, DOI 10.1161/01.CIR.75.1.131; Narkiewicz K, 1999, CIRCULATION, V99, P1183, DOI 10.1161/01.CIR.99.9.1183; Narkiewicz K, 1998, CIRCULATION, V98, P1071, DOI 10.1161/01.CIR.98.11.1071; Priori SG, 2002, EUR HEART J, V23, P257; Sanner BM, 2000, EUR RESPIR J, V16, P648, DOI 10.1034/j.1399-3003.2000.16d14.x; Schafer H, 1997, CHEST, V111, P387, DOI 10.1378/chest.111.2.387; SEPPALA T, 1991, J INTERN MED, V229, P23, DOI 10.1111/j.1365-2796.1991.tb00301.x; Shamsuzzaman ASM, 2003, JAMA-J AM MED ASSOC, V290, P1906, DOI 10.1001/jama.290.14.1906; SHEPARD JW, 1985, CHEST, V88, P335, DOI 10.1378/chest.88.3.335; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; SOMERS VK, 1993, NEW ENGL J MED, V328, P303, DOI 10.1056/NEJM199302043280502; TILKIAN AG, 1977, AM J MED, V63, P348, DOI 10.1016/0002-9343(77)90272-8; VIROLAINEN J, 1995, J APPL PHYSIOL, V79, P455, DOI 10.1152/jappl.1995.79.2.455; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705; ZWILLICH C, 1982, J CLIN INVEST, V69, P1286, DOI 10.1172/JCI110568; [No title captured]	41	640	688	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1206	1214		10.1056/NEJMoa041832	http://dx.doi.org/10.1056/NEJMoa041832			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788497				2022-12-28	WOS:000227832300007
J	Garcia, CM; Ramirez, E				Garcia, CM; Ramirez, E			Evidence that sensory traps can evolve into honest signals	NATURE			English	Article							SEXUAL SELECTION; FEMALE CHOICE; MATING PREFERENCES; MATE CHOICE; CAROTENOIDS; EVOLUTION; BIASES; MALES	Conventional models(1-4) explaining extreme sexual ornaments propose that these reflect male genetic quality(2-4) or are arbitrary results of genetic linkage between female preference and the ornament(1). The chase-away model(5) emphasizes sexual conflict: male signals attract females because they exploit receiver biases(6-9). As males gain control of mating decisions, females may experience fitness costs through suboptimal mating rates or post-copulatory exploitation. Elaboration of male signals is expected if females increase their response threshold to resist such exploitation. If ornaments target otherwise adaptive biases such as feeding responses(8-10), selection on females might eventually separate sexual and non-sexual responses to the signal. Here we show that the terminal yellow band (TYB) of several Goodeinae species evokes both feeding and sexual responses; sexual responsiveness phylogenetically pre-dates the expression of the TYB in males and is comparable across taxa, yet feeding responsiveness decreases in species with more elaborated TYBs. Displaying a TYB is costly, and thus provides an example where a trait arose as a sensory trap but has evolved into an honest signal.	Univ Nacl Autonoma Mexico, Dept Ecol Evolut, Inst Ecol, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Garcia, CM (corresponding author), Univ Nacl Autonoma Mexico, Dept Ecol Evolut, Inst Ecol, AP 70-275, Mexico City 04510, DF, Mexico.	maciasg@servidor.unam.mx	Garcia, Constantino Macias/S-1948-2019; Garcia, Constantino Macías/A-9399-2010	Garcia, Constantino Macías/0000-0003-3242-4214; Ramirez-Carrillo, Elvia/0000-0001-8447-0971				ANDERSSON M, 1986, EVOLUTION, V40, P804, DOI 10.1111/j.1558-5646.1986.tb00540.x; Basolo AL, 2002, BEHAV ECOL, V13, P832, DOI 10.1093/beheco/13.6.832; Basolo AL, 1998, P ROY SOC B-BIOL SCI, V265, P2223, DOI 10.1098/rspb.1998.0563; Burton BG, 2003, J EXP BIOL, V206, P3963, DOI 10.1242/jeb.00600; Cordero C, 2003, J EVOLUTION BIOL, V16, P1, DOI 10.1046/j.1420-9101.2003.00506.x; Cordoba-Aguilar A, 2002, AM NAT, V160, P594, DOI 10.1086/342819; Dawkins MS, 1996, AM NAT, V148, P937, DOI 10.1086/285964; Endler JA, 1998, TRENDS ECOL EVOL, V13, P415, DOI 10.1016/S0169-5347(98)01471-2; FISHER RA, 1958, GENETICAL THEORY NAT, P146; Grether GF, 2002, SCIENCE, V296, P847; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; Holland B, 1998, EVOLUTION, V52, P1, DOI 10.1111/j.1558-5646.1998.tb05132.x; Holland B, 1999, P NATL ACAD SCI USA, V96, P5083, DOI 10.1073/pnas.96.9.5083; Jayasooriya AP, 2002, SCIENCE, V296, P847; KODRICBROWN A, 1989, BEHAV ECOL SOCIOBIOL, V25, P393, DOI 10.1007/BF00300185; Kokko H, 2002, P ROY SOC B-BIOL SCI, V269, P1331, DOI 10.1098/rspb.2002.2020; Kokko H, 2003, P ROY SOC B-BIOL SCI, V270, P653, DOI 10.1098/rspb.2002.2235; LeBas NR, 2003, P ROY SOC B-BIOL SCI, V270, P2159, DOI 10.1098/rspb.2003.2482; MILINSKI M, 1990, NATURE, V344, P330, DOI 10.1038/344330a0; Olson VA, 1998, TRENDS ECOL EVOL, V13, P510, DOI 10.1016/S0169-5347(98)01484-0; Partridge L, 1999, EVOLUTION OF BIOLOGICAL DIVERSITY, P130; Rodd FH, 2002, P ROY SOC B-BIOL SCI, V269, P475, DOI 10.1098/rspb.2001.1891; Ryan M.J., 1990, Oxford Surveys in Evolutionary Biology, V7, P157; RYAN MJ, 1987, SCIENCE, V236, P595, DOI 10.1126/science.236.4801.595; Webb SA, 2004, MOL PHYLOGENET EVOL, V30, P527, DOI 10.1016/S1055-7903(03)00257-4; [No title captured], DOI DOI 10.1086/285303)	26	111	114	0	138	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					501	505		10.1038/nature03363	http://dx.doi.org/10.1038/nature03363			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791255				2022-12-28	WOS:000227836000041
J	Jarillo-Herrero, P; Kong, J; van der Zant, HSJ; Dekker, C; Kouwenhoven, LP; De Franceschi, S				Jarillo-Herrero, P; Kong, J; van der Zant, HSJ; Dekker, C; Kouwenhoven, LP; De Franceschi, S			Orbital Kondo effect in carbon nanotubes	NATURE			English	Article							RESONANCE; TRANSPORT; FIELD	Progress in the fabrication of nanometre-scale electronic devices is opening new opportunities to uncover deeper aspects of the Kondo effect(1) - a characteristic phenomenon in the physics of strongly correlated electrons. Artificial single-impurity Kondo systems have been realized in various nanostructures, including semiconductor quantum dots(2-4), carbon nanotubes(5,6) and individual molecules(7,8). The Kondo effect is usually regarded as a spin-related phenomenon, namely the coherent exchange of the spin between a localized state and a Fermi sea of delocalized electrons. In principle, however, the role of the spin could be replaced by other degrees of freedom, such as an orbital quantum number(9,10). Here we show that the unique electronic structure of carbon nanotubes enables the observation of a purely orbital Kondo effect. We use a magnetic field to tune spin-polarized states into orbital degeneracy and conclude that the orbital quantum number is conserved during tunnelling. When orbital and spin degeneracies are present simultaneously, we observe a strongly enhanced Kondo effect, with a multiple splitting of the Kondo resonance at finite field and predicted to obey a so-called SU(4) symmetry.	Delft Univ Technol, Kavli Inst Nanosci, NL-2600 GA Delft, Netherlands	Delft University of Technology	Jarillo-Herrero, P (corresponding author), Delft Univ Technol, Kavli Inst Nanosci, POB 5046, NL-2600 GA Delft, Netherlands.	pablo@qt.tn.tudelft.nl	van der Zant, Herre S.J./J-9467-2016	van der Zant, Herre S.J./0000-0002-5385-0282; Dekker, Cees/0000-0001-6273-071X				AJIKI H, 1993, J PHYS SOC JPN, V62, P1255, DOI 10.1143/JPSJ.62.1255; Bonet E, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.045317; Borda L, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.026602; Buitelaar MR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.156801; CHOI MS, UNPUB PHYS REV LETT; Coskun UC, 2004, SCIENCE, V304, P1132, DOI 10.1126/science.1096647; Costi TA, 2000, PHYS REV LETT, V85, P1504, DOI 10.1103/PhysRevLett.85.1504; Cox DL, 1998, ADV PHYS, V47, P599, DOI 10.1080/000187398243500; Cronenwett SM, 1998, SCIENCE, V281, P540, DOI 10.1126/science.281.5376.540; De Franceschi S, 2001, PHYS REV LETT, V86, P878, DOI 10.1103/PhysRevLett.86.878; Dresselhaus M.S., 1996, SCI FULLERENES CARBO; Goldhaber-Gordon D, 1998, NATURE, V391, P156, DOI 10.1038/34373; Hewson A C, 1993, KONDO PROBLEM HEAVY; INOSHITA T, 1993, PHYS REV B, V48, P14725, DOI 10.1103/PhysRevB.48.14725; JARILLOHERRERO P, CONDMAT0411440; Kolesnychenko OY, 2002, NATURE, V415, P507, DOI 10.1038/415507a; Liang WJ, 2002, NATURE, V417, P725, DOI 10.1038/nature00790; Liang WJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.126801; LOPEZ R, CONDMAT0402361; Mann D, 2003, NANO LETT, V3, P1541, DOI 10.1021/nl034700o; Minot ED, 2004, NATURE, V428, P536, DOI 10.1038/nature02425; Nygard J, 2000, NATURE, V408, P342, DOI 10.1038/35042545; Paaske J, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.155330; Pasupathy AN, 2004, SCIENCE, V306, P86, DOI 10.1126/science.1102068; Sasaki S, 2000, NATURE, V405, P764, DOI 10.1038/35015509; Sasaki S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.017205; Schmid J, 1998, PHYSICA B, V256, P182, DOI 10.1016/S0921-4526(98)00533-X; Zarand G, 2003, SOLID STATE COMMUN, V126, P463, DOI 10.1016/S0038-1098(03)00180-7; Zaric S, 2004, SCIENCE, V304, P1129, DOI 10.1126/science.1096524	29	327	327	2	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					484	488		10.1038/nature03422	http://dx.doi.org/10.1038/nature03422			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791250	Green Submitted			2022-12-28	WOS:000227836000036
J	Flaherty, JD; Davidson, CJ				Flaherty, JD; Davidson, CJ			Diabetes and coronary revascularization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; SIROLIMUS-ELUTING STENTS; ANGIOGRAPHIC FOLLOW-UP; BYPASS GRAFT-SURGERY; ARTERY-DISEASE; CARDIOVASCULAR-DISEASE; THROMBOLYTIC THERAPY; CLINICAL-OUTCOMES; REDUCES MORTALITY; RANDOMIZED-TRIAL	Context Patients with diabetes mellitus account for approximately 25% of the nearly 1.5 million coronary revascularization procedures performed each year in the United States and experience worse outcomes compared with nondiabetic patients. Objectives To summarize the current state of evidence comparing the effectiveness and safety of coronary artery bypass graft (CABG) surgery and percutaneous coronary intervention (PCI) in diabetic patients and to examine developments that may affect future outcomes in this high-risk group. Evidence Acquisition Using the key terms diabetes mellitus, revascularization, coronary artery bypass, angioplasty, and coronary intervention, we searched MEDLINE from 1985 to 2004 for all randomized controlled trials (RCTs) comparing CABG surgery and PCI that reported outcomes in diabetic patients. Bibliographies and the Web sites of cardiology conferences were also reviewed. Studies comparing drug-eluting stents and bare-metal stents were identified in a similar fashion. The literature was reviewed to identify clinical measures that may impact revascularization outcomes in diabetic patients. Evidence Synthesis We identified 6 RCTs comparing CABG surgery and PCI in a total of 950 diabetic patients. A mortality benefit for CABG over balloon-only PCI has been demonstrated in diabetic patients with multivessel coronary artery disease but has not been clearly established against stent-assisted PCI or in high-risk CABG patients. Use of glycoprotein IIb/IIIa receptor inhibitors has improved survival in diabetic patients undergoing PCI. Restenosis after PCI in diabetic patients has led to substantia higher repeat revascularization rates than after CABG. The use of drug-eluting stents has led to dramatic reductions in restenosis in diabetic patients. Ongoing RCTs comparing CABG and PCI using drug-eluting stents in diabetic patients will clarify the impact of these advances on outcomes. Conclusions There is a relative lack of data from RCTs specifically comparing CABG surgery and PCI as currently practiced in diabetic patients. The mortality advantage and decreased rates of revascularization seen with CABG in subgroups from early trials may not be applicable in the era of drug-eluting stents, glycoprotein IIb/IIIa inhibitors, and the latest medical therapies.	Northwestern Univ, Feinberg Sch Med, NW Cardiovasc Inst, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Davidson, CJ (corresponding author), NW Mem Hosp, 251 E Huron St,Feinberg Pavil 8-526, Chicago, IL 60611 USA.	cdavidso@nmh.org	Fonarow, Gregg C/D-5988-2014	Fonarow, Gregg C/0000-0002-3192-8093				Abaci A, 1999, CIRCULATION, V99, P2239, DOI 10.1161/01.CIR.99.17.2239; Abizaid A, 2001, CIRCULATION, V104, P533, DOI 10.1161/hc3101.093700; Alderman E, 1997, CIRCULATION, V96, P1761, DOI 10.1161/01.CIR.96.6.1761; Alderman EL, 1996, NEW ENGL J MED, V335, P217; Alderman EL, 2000, J AM COLL CARDIOL, V35, P1122; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Barsness GW, 1997, CIRCULATION, V96, P2551, DOI 10.1161/01.CIR.96.8.2551; Bhatt DL, 2000, J AM COLL CARDIOL, V35, P922, DOI 10.1016/S0735-1097(99)00650-6; Bonow RO, 2004, AM J MED, V116, P2, DOI 10.1016/j.amjmed.2003.10.014; Bonow RO, 2002, CIRCULATION, V106, P1602, DOI 10.1161/01.CIR.0000035036.22612.2B; BURCHFIEL CM, 1993, AM J EPIDEMIOL, V137, P1328, DOI 10.1093/oxfordjournals.aje.a116642; Carson JL, 2002, J AM COLL CARDIOL, V40, P418, DOI 10.1016/S0735-1097(02)01969-1; Colhoun HM, 2004, LANCET, V364, P685, DOI 10.1016/S0140-6736(04)16895-5; Collins R, 2003, LANCET, V361, P2005; Corpus RA, 2004, J AM COLL CARDIOL, V43, P8, DOI 10.1016/j.jacc.2003.06.019; Creager MA, 2003, CIRCULATION, V108, P1527, DOI 10.1161/01.CIR.0000091257.27563.32; Detre KM, 1999, CIRCULATION, V99, P633, DOI 10.1161/01.CIR.99.5.633; Detre KM, 2000, NEW ENGL J MED, V342, P989, DOI 10.1056/NEJM200004063421401; Eagle KA, 2004, J AM COLL CARDIOL, V44, P1146, DOI 10.1016/j.jacc.2004.07.021; Endo M, 2003, CIRCULATION, V108, P1343, DOI 10.1161/01.CIR.0000085995.87982.6E; Furnary AP, 2003, J THORAC CARDIOV SUR, V125, P1007, DOI 10.1067/mtc.2003.181; Gerstein HC, 2000, LANCET, V355, P253; Goraya TY, 2002, J AM COLL CARDIOL, V40, P946, DOI 10.1016/S0735-1097(02)02065-X; Grines C, 2003, AM HEART J, V145, P47, DOI 10.1067/mhj.2003.40; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hammoud T, 2000, J AM COLL CARDIOL, V36, P355, DOI 10.1016/S0735-1097(00)00732-4; Henderson RA, 1998, LANCET, V352, P1419, DOI 10.1016/S0140-6736(98)03358-3; HERMILLER JB, 1993, AM J CARDIOL, V71, P665, DOI 10.1016/0002-9149(93)91007-5; Holmes DR, 2004, CIRCULATION, V109, P634, DOI 10.1161/01.CIR.0000112572.57794.22; Hsu LF, 2002, HEART, V88, P260, DOI 10.1136/heart.88.3.260; Jonas M, 1996, AM J CARDIOL, V77, P1273, DOI 10.1016/S0002-9149(96)00191-9; King SB, 2000, J AM COLL CARDIOL, V35, P1116, DOI 10.1016/S0735-1097(00)00546-5; Kip KE, 2002, CIRCULATION, V105, P1914, DOI 10.1161/01.CIR.0000014967.78190.BB; Kugelmass Aaron D, 2003, J Invasive Cardiol, V15, P568; Kurbaan AS, 2001, AM J CARDIOL, V87, P947, DOI 10.1016/S0002-9149(01)01426-6; Lazar HL, 2004, CIRCULATION, V109, P1497, DOI 10.1161/01.CIR.0000121747.71054.79; Ledru F, 2001, J AM COLL CARDIOL, V37, P1543, DOI 10.1016/S0735-1097(01)01183-4; Lee CD, 2004, CIRCULATION, V109, P855, DOI 10.1161/01.CIR.0000116389.61864.DE; Legrand VMG, 2004, CIRCULATION, V109, P1114, DOI 10.1161/01.CIR.0000118504.61212.4B; LEMP GF, 1987, AM J CARDIOL, V60, P1015, DOI 10.1016/0002-9149(87)90344-4; Magee MJ, 2001, ANN THORAC SURG, V72, P776, DOI 10.1016/S0003-4975(01)02840-5; Mak KH, 1997, J AM COLL CARDIOL, V30, P171, DOI 10.1016/S0735-1097(97)00118-6; Mak KH, 2003, EUR HEART J, V24, P1087, DOI 10.1016/S0195-668X(03)00111-8; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Mehilli J, 2004, CIRCULATION, V110, P3627, DOI 10.1161/01.CIR.0000148956.93631.4D; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P437; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Moreno PR, 2000, CIRCULATION, V102, P2180; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Moussa I, 2004, CIRCULATION, V109, P2273, DOI 10.1161/01.CIR.0000129767.45513.71; Nesto RW, 2004, AM J MED, V116, P11, DOI 10.1016/j.amjmed.2003.10.016; Reeder GS, 2002, AM J CARDIOL, V89, P760, DOI 10.1016/S0002-9149(01)02350-5; Roffi M, 2001, CIRCULATION, V104, P2767, DOI 10.1161/hc4801.100029; Rozenman Y, 1997, J AM COLL CARDIOL, V30, P1420, DOI 10.1016/S0735-1097(97)00342-2; SABATE M, 2004, DIABETES INVESTIGATO; Schwartz L, 2002, CIRCULATION, V106, P2652, DOI 10.1161/01.CIR.0000038885.94771.43; Sedlis SP, 2002, J AM COLL CARDIOL, V40, P1555, DOI 10.1016/S0735-1097(02)02346-X; SILVA JA, 1995, CIRCULATION, V92, P1731, DOI 10.1161/01.CIR.92.7.1731; Smith SC, 2001, CIRCULATION, V103, P3019, DOI 10.1161/01.CIR.103.24.3019; Sobel BE, 2003, CIRCULATION, V107, P636, DOI 10.1161/01.CIR.0000048897.03553.E4; SPRAFKA JM, 1991, DIABETES CARE, V14, P537, DOI 10.2337/diacare.14.7.537; Stone GW, 2004, CIRCULATION, V109, P1942, DOI 10.1161/01.CIR.0000127110.49192.72; Stone GW, 2004, NEW ENGL J MED, V350, P221, DOI 10.1056/NEJMoa032441; STONE GW, 2004, PIV PROSP TRIAL SLOW; Takagi T, 2003, AM HEART J, V146, DOI 10.1016/S0002-8703(03)00146-7; Van Belle E, 2001, CIRCULATION, V103, P1218; van den Brand MJBM, 2002, J AM COLL CARDIOL, V39, P559, DOI 10.1016/S0735-1097(01)01785-5; Vavuranakis M, 1997, EUR HEART J, V18, P1090; WALLER BF, 1980, AM J MED, V69, P498, DOI 10.1016/S0149-2918(05)80002-5; Woodfield SL, 1996, J AM COLL CARDIOL, V28, P1661, DOI 10.1016/S0735-1097(96)00397-X	71	198	219	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2005	293	12					1501	1508		10.1001/jama.293.12.1501	http://dx.doi.org/10.1001/jama.293.12.1501			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908KA	15784875				2022-12-28	WOS:000227784700031
J	van Wijngaarden, P; Coster, DJ; Williams, KA				van Wijngaarden, P; Coster, DJ; Williams, KA			Inhibitors of ocular neovascularization - Promises and potential problems	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; BLOOD-RETINAL BARRIER; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; FACTOR VEGF; MACULAR DEGENERATION; SAFETY; PHARMACOKINETICS; BREAKDOWN; PHOTOCOAGULATION		Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA 5042, Australia	Flinders Medical Centre; Flinders University South Australia	van Wijngaarden, P (corresponding author), Flinders Univ S Australia, Flinders Med Ctr, Dept Ophthalmol, Adelaide, SA 5042, Australia.	vanw0009@flinders.edu.au		van Wijngaarden, Peter/0000-0002-8800-7834				AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Azzouz M, 2004, NATURE, V429, P413, DOI 10.1038/nature02544; Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156; Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477; Csaky K, 2003, OPHTHALMOLOGY, V110, P879; CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649; Drolet DW, 2000, PHARMACEUT RES, V17, P1503, DOI 10.1023/A:1007657109012; Famiglietti EV, 2003, BRAIN RES, V969, P195, DOI 10.1016/S0006-8993(02)03766-6; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X; Fontanarosa PB, 2004, JAMA-J AM MED ASSOC, V292, P2647, DOI 10.1001/jama.292.21.2647; Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601; Gehlbach P, 2003, HUM GENE THER, V14, P129, DOI 10.1089/104303403321070829; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; HEIER JS, 2003, INVEST OPHTHALMOL VI, V44; KAUFMAN SC, 1989, INVEST OPHTH VIS SCI, V30, P23; Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552; Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115; Klein BEK, 2004, ARCH INTERN MED, V164, P1917, DOI 10.1001/archinte.164.17.1917; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; Larsson A., 2002, Angiogenesis, V5, P107, DOI 10.1023/A:1021588227705; Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143; Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507; Pahor D, 1998, INT OPHTHALMOL, V22, P313, DOI 10.1023/A:1006367029134; Presta LG, 1997, CANCER RES, V57, P4593; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; Ratner M, 2004, NAT BIOTECHNOL, V22, P1198, DOI 10.1038/nbt1004-1198; Robinson CJ, 2001, J CELL SCI, V114, P853; Ryan AM, 1999, TOXICOL PATHOL, V27, P78, DOI 10.1177/019262339902700115; Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Takeda A, 2003, GRAEF ARCH CLIN EXP, V241, P765, DOI 10.1007/s00417-003-0688-7; TAYLOR KP, 2005, OPHTHALMOLOGY T 0115; Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018; Vinores SA, 1999, DOC OPHTHALMOL, V97, P217, DOI 10.1023/A:1002136712070; Yourey PA, 2000, J NEUROSCI, V20, P6781, DOI 10.1523/JNEUROSCI.20-18-06781.2000	42	201	229	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2005	293	12					1509	1513		10.1001/jama.293.12.1509	http://dx.doi.org/10.1001/jama.293.12.1509			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908KA	15784876				2022-12-28	WOS:000227784700032
J	Thompson, WG; Goldstein, SL				Thompson, WG; Goldstein, SL			Open-system coral ages reveal persistent suborbital sea-level cycles	SCIENCE			English	Article							LAST INTERGLACIAL PERIOD; HUON PENINSULA; NORTH-ATLANTIC; REEF TERRACES; CLIMATE; TEMPERATURE; STALAGMITE; FLUCTUATIONS; OSCILLATIONS; CHRONOLOGY	Sea level is a sensitive index of global climate that has been linked to Earth's orbital variations, with a minimum periodicity of about 21,000 years. Although there is ample evidence for climate oscillations that are too frequent to be explained by orbital forcing, suborbital-frequency sea-level change has been difficult to resolve, primarily because of problems with uranium/thorium coral dating. Here we use a new approach that corrects coral ages for the frequently observed open-system behavior of uranium-series nuclides, substantially improving the resolution of sea-level reconstruction. This curve reveals persistent sea-level oscillations that are too frequent to be explained exclusively by orbital forcing.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Columbia Univ, Dept Earth & Environm Sci, Palisades, NY 10964 USA	Columbia University; Columbia University	Thompson, WG (corresponding author), Woods Hole Oceanog Inst, Dept Geol & Geophys, Clark Lab 118, Mail Stop 23, Woods Hole, MA 02543 USA.	wthompson@whoi.edu	Thompson, William/H-2407-2011					Abegg C, 2002, BIOL J LINN SOC, V75, P555, DOI 10.1046/j.1095-8312.2002.00045.x; [Anonymous], [No title captured]; Bard E, 2002, EARTH PLANET SC LETT, V196, P135, DOI 10.1016/S0012-821X(01)00600-8; BROECKER WS, 1963, J GEOPHYS RES, V68, P2817, DOI 10.1029/JZ068i009p02817; Chappell J, 2002, QUATERNARY SCI REV, V21, P1229, DOI 10.1016/S0277-3791(01)00141-X; CHEN JH, 1991, GEOL SOC AM BULL, V103, P82, DOI 10.1130/0016-7606(1991)103<0082:PCOTLI>2.3.CO;2; Cutler KB, 2003, EARTH PLANET SC LETT, V206, P253, DOI 10.1016/S0012-821X(02)01107-X; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Esat TM, 1999, SCIENCE, V283, P197, DOI 10.1126/science.283.5399.197; Fruijtier C, 2000, GEOL SOC AM BULL, V112, P267, DOI 10.1130/0016-7606(2000)112<0267:MSUTAF>2.3.CO;2; GALLUP CD, 1994, SCIENCE, V263, P796, DOI 10.1126/science.263.5148.796; Gallup CD, 2002, SCIENCE, V295, P310, DOI 10.1126/science.1065494; Genty D, 2003, NATURE, V421, P833, DOI 10.1038/nature01391; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; Henderson GM, 2000, NATURE, V404, P61, DOI 10.1038/35003541; Holgate SJ, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019626; Lea DW, 2002, QUATERNARY SCI REV, V21, P283, DOI 10.1016/S0277-3791(01)00081-6; LI WX, 1989, NATURE, V339, P534, DOI 10.1038/339534a0; LUNDBERG J, 1994, QUATERNARY SCI REV, V13, P1, DOI 10.1016/0277-3791(94)90121-X; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; MESOLELL.KJ, 1969, J GEOL, V77, P250, DOI 10.1086/627434; Oppo DW, 2001, PALEOCEANOGRAPHY, V16, P280, DOI 10.1029/2000PA000527; Oppo DW, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000260; PLANGES V, 2002, EARTH PLANET SC LETT, V201, P87; Potter EK, 2004, EARTH PLANET SC LETT, V225, P191, DOI 10.1016/j.epsl.2004.05.034; Potter EK, 2004, EARTH PLANET SC LETT, V217, P171, DOI 10.1016/S0012-821X(03)00587-9; Richards DA, 2003, REV MINERAL GEOCHEM, V52, P407, DOI 10.2113/0520407; RICHARDS DA, 1994, NATURE, V367, P357, DOI 10.1038/367357a0; Sasaki K, 2004, QUATERN INT, V120, P51, DOI 10.1016/j.quaint.2004.01.006; Schellmann G, 2004, EARTH-SCI REV, V64, P157, DOI 10.1016/S0012-8252(03)00043-6; Schmidt MW, 2004, NATURE, V428, P160, DOI 10.1038/nature02346; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; Siddall M, 2003, NATURE, V423, P853, DOI 10.1038/nature01690; Smart P. L., 1998, CAVE KARST SCI, V25, P67; Speed RC, 2004, GEOL SOC AM BULL, V116, P219, DOI 10.1130/B25167.1; Spotl C, 2002, GEOLOGY, V30, P815, DOI 10.1130/0091-7613(2002)030<0815:SOTLIP>2.0.CO;2; STEIN M, 1993, GEOCHIM COSMOCHIM AC, V57, P2541, DOI 10.1016/0016-7037(93)90416-T; STIRLING CH, 1995, EARTH PLANET SC LETT, V135, P115, DOI 10.1016/0012-821X(95)00152-3; Stirling CH, 2001, SCIENCE, V291, P290, DOI 10.1126/science.291.5502.290; STIRLING CH, 1998, EARTH PLANET SC LETT, V160, P115; Thompson WG, 2003, EARTH PLANET SC LETT, V210, P365, DOI 10.1016/S0012-821X(03)00121-3; Waelbroeck C, 2002, QUATERNARY SCI REV, V21, P295, DOI 10.1016/S0277-3791(01)00101-9; Wang XF, 2004, NATURE, V432, P740, DOI 10.1038/nature03067; Yokoyama Y, 2001, EARTH PLANET SC LETT, V193, P579, DOI 10.1016/S0012-821X(01)00515-5; Zhao JX, 2001, EARTH PLANET SC LETT, V184, P635, DOI 10.1016/S0012-821X(00)00353-8	45	199	205	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					401	404		10.1126/science.1104035	http://dx.doi.org/10.1126/science.1104035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831756				2022-12-28	WOS:000228492000049
J	Bryant, HE; Schultz, N; Thomas, HD; Parker, KM; Flower, D; Lopez, E; Kyle, S; Meuth, M; Curtin, NJ; Helleday, T				Bryant, HE; Schultz, N; Thomas, HD; Parker, KM; Flower, D; Lopez, E; Kyle, S; Meuth, M; Curtin, NJ; Helleday, T			Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase	NATURE			English	Article							DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; DNA-DAMAGE; REPLICATION FORKS; NUCLEAR FOCI; REPAIR; PARP-1; STABILITY; REQUIREMENT	Poly( ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage(1-3). Nevertheless, PARP1(-/-) mice are viable, fertile and do not develop early onset tumours(4). Here, we show that PARP inhibitors trigger gamma-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours ( which are BRCA2(-/-)) in BRCA2(+/-) patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.	Univ Sheffield, Sch Med, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England; Stockholm Univ, Arrhenius Lab, Dept Genet Microbiol & Toxicol, S-10691 Stockholm, Sweden; Newcastle Univ, Sch Med, No Inst Canc Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Sheffield; Stockholm University; Newcastle University - UK	Helleday, T (corresponding author), Univ Sheffield, Sch Med, Inst Canc Studies, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	t.helleday@sheffield.ac.uk	bryant, helen/AHB-1139-2022; Schultz, Niklas/AFQ-8244-2022; Helleday, Thomas/D-5224-2013	bryant, helen/0000-0003-2720-7020; Lopez Knowles, Elena/0000-0002-0893-3361; Helleday, Thomas/0000-0002-7384-092X; Curtin, Nicola/0000-0003-1369-1843	NCI NIH HHS [F31 CA260794] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Bowman KJ, 2001, BRIT J CANCER, V84, P106, DOI 10.1054/bjoc.2000.1555; Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005; CALDECOTT KW, 1992, NUCLEIC ACIDS RES, V20, P4575, DOI 10.1093/nar/20.17.4575; Conde C, 2001, EMBO J, V20, P3535, DOI 10.1093/emboj/20.13.3535; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; GRUBE K, 1991, ANAL BIOCHEM, V193, P236, DOI 10.1016/0003-2697(91)90015-L; HALLDORSSON H, 1978, FEBS LETT, V85, P349, DOI 10.1016/0014-5793(78)80489-X; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Lundin C, 2003, J MOL BIOL, V328, P521, DOI 10.1016/S0022-2836(03)00313-9; Mohindra A, 2002, HUM MOL GENET, V11, P2189, DOI 10.1093/hmg/11.18.2189; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Skalitzky DJ, 2003, J MED CHEM, V46, P210, DOI 10.1021/jm0255769; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491	25	3389	3512	16	309	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	2005	434	7035					913	917		10.1038/nature03443	http://dx.doi.org/10.1038/nature03443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829966				2022-12-28	WOS:000228327600044
J	Riedl, SJ; Li, WY; Chao, Y; Schwarzenbacher, R; Shi, YG				Riedl, SJ; Li, WY; Chao, Y; Schwarzenbacher, R; Shi, YG			Structure of the apoptotic protease-activating factor 1 bound to ADP	NATURE			English	Article							CYTOCHROME-C; CASPASE-9 ACTIVATION; PROCASPASE-9; APAF-1; OLIGOMERIZATION; ASSOCIATION; MECHANISMS; APOPTOSOME; BINDING; PROGRAM	Apoptosis is executed by caspases, which undergo proteolytic activation in response to cell death stimuli(1). The apoptotic protease-activating factor 1 (Apaf-1) controls caspase activation downstream of mitochondria(2). During apoptosis, Apaf-1 binds to cytochrome c and in the presence of ATP/dATP forms an apoptosome, leading to the recruitment and activation of the initiator caspase, caspase-9 ( ref. 2). The mechanisms underlying Apaf-1 function are largely unknown. Here we report the 2.2-angstrom crystal structure of an ADP-bound, WD40-deleted Apaf-1, which reveals the molecular mechanism by which Apaf-1 exists in an inactive state before ATP binding. The amino-terminal caspase recruitment domain packs against a three-layered alpha/beta fold, a short helical motif and a winged-helix domain, resulting in the burial of the caspase-9-binding interface. The deeply buried ADP molecule serves as an organizing centre to strengthen interactions between these four adjoining domains, thus locking Apaf-1 in an inactive conformation. Apaf-1 binds to and hydrolyses ATP/dATP and their analogues. The binding and hydrolysis of nucleotides seem to drive conformational changes that are essential for the formation of the apoptosome and the activation of caspase-9.	Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Calif San Diego, Joint Ctr Struct Genom, La Jolla, CA 92093 USA	Princeton University; University of California System; University of California San Diego	Shi, YG (corresponding author), Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Washington Rd, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu		Shi, Yigong/0000-0003-2030-168X				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Gai' DH, 2004, CELL, V119, P47, DOI 10.1016/j.cell.2004.09.017; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Inohara N, 2001, ONCOGENE, V20, P6473, DOI 10.1038/sj.onc.1204787; Jaroszewski L, 2000, PROTEINS, V39, P197, DOI 10.1002/(SICI)1097-0134(20000515)39:3<197::AID-PROT10>3.0.CO;2-V; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wang XD, 2001, GENE DEV, V15, P2922; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	30	261	274	5	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					926	933		10.1038/nature03465	http://dx.doi.org/10.1038/nature03465			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829969				2022-12-28	WOS:000228327600047
J	Hasham, S; Matteucci, P; Stanley, PRW; Hart, NB				Hasham, S; Matteucci, P; Stanley, PRW; Hart, NB			Necrotising fasciitis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SOFT-TISSUE INFECTIONS; MORTALITY	Necrotising fasciitis is a rare but life threatening condition that requires immediate action, but uncertainties still hamper prompt diagnosis and treatment.	Castle Hill Hosp, Dept Plast Reconstruct & Hand Surg, Cottingham HU16 5JQ, East Yorkshire, England	University of Hull	Hasham, S (corresponding author), Castle Hill Hosp, Dept Plast Reconstruct & Hand Surg, Cottingham HU16 5JQ, East Yorkshire, England.	saiidyhasham@hotmail.com		Matteucci, Paolo/0000-0002-0594-1577				DELLINGER EP, 1981, JAMA-J AM MED ASSOC, V246, P1717, DOI 10.1001/jama.246.15.1717; DESCAMPS V, 1994, LANCET, V344, P556, DOI 10.1016/S0140-6736(94)91956-9; Eke N, 2000, BRIT J SURG, V87, P718, DOI 10.1046/j.1365-2168.2000.01497.x; Elliott DC, 1996, ANN SURG, V224, P672, DOI 10.1097/00000658-199611000-00011; FILE TM, 1995, AM J SURG, V169, pS27; HACKETT SP, 1992, J INFECT DIS, V165, P879, DOI 10.1093/infdis/165.5.879; Hsieh WS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e53; Lille ST, 1996, J AM COLL SURGEONS, V182, P7; Majeski J, 1997, SOUTHERN MED J, V90, P1065, DOI 10.1097/00007611-199711000-00001; MCHENRY CR, 1995, ANN SURG, V221, P558, DOI 10.1097/00000658-199505000-00013; RAHMOUNI A, 1994, RADIOLOGY, V192, P493, DOI 10.1148/radiology.192.2.8029421; RISEMAN JA, 1990, SURGERY, V108, P847; Singh G, 2002, EUR J SURG, V168, P366, DOI 10.1080/11024150260284897; WILSON B, 1952, Am Surg, V18, P416; Wysoki MG, 1997, RADIOLOGY, V203, P859, DOI 10.1148/radiology.203.3.9169717	15	148	155	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 9	2005	330	7495					830	833		10.1136/bmj.330.7495.830	http://dx.doi.org/10.1136/bmj.330.7495.830			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915BZ	15817551	Green Published			2022-12-28	WOS:000228273900020
J	Lordkipanidze, D; Vekua, A; Ferring, R; Rightmire, GP; Agustill, J; Kiladze, G; Mouskhelishvili, A; Nioradze, M; de Leon, MSP; Tappen, M; Zollikofer, CPE				Lordkipanidze, D; Vekua, A; Ferring, R; Rightmire, GP; Agustill, J; Kiladze, G; Mouskhelishvili, A; Nioradze, M; de Leon, MSP; Tappen, M; Zollikofer, CPE			The earliest toothless hominin skull	NATURE			English	Article							REMAINS; DMANISI		Georgian State Museum, GE-0105 Tbilisi, Georgia; Inst Palaeobiol, GE-0104 Tbilisi, Georgia; N Texas State Univ, Dept Geog, Denton, TX 76203 USA; SUNY Binghamton, Binghamton, NY 13902 USA; Inst Paleontol M Crussafont, Sabadell 08201, Spain; Georgian Archaeol Ctr, GE-0102 Tbilisi, Georgia; Univ Zurich, Inst Anthropol, CH-8057 Zurich, Switzerland; Univ Minnesota, Dept Anthropol, Minneapolis, MN 55455 USA	University of North Texas System; University of North Texas Denton; State University of New York (SUNY) System; State University of New York (SUNY) Binghamton; University of Zurich; University of Minnesota System; University of Minnesota Twin Cities	Lordkipanidze, D (corresponding author), Georgian State Museum, GE-0105 Tbilisi, Georgia.	geonathist@ip.osgf.ge	Lordkipanidze, David/AAH-6472-2020					ATWOOD DA, 1971, J PROSTHET DENT, V26, P266, DOI 10.1016/0022-3913(71)90069-2; Dominguez-Rodrigo M, 2005, J HUM EVOL, V48, P109, DOI 10.1016/j.jhevol.2004.09.004; Foley Robert, 2001, P305; Gabunia L, 2000, SCIENCE, V288, P1019, DOI 10.1126/science.288.5468.1019; Gaudzinski S, 2004, J ARCHAEOL SCI, V31, P65, DOI 10.1016/S0305-4403(03)00100-6; Lebel S, 2001, P NATL ACAD SCI USA, V98, P11097, DOI 10.1073/pnas.181353998; Miles AEW, 1990, COLYERS VARIATIONS D; TAPPEN NC, 1985, AM J PHYS ANTHROPOL, V67, P43, DOI 10.1002/ajpa.1330670106; Vekua A, 2002, SCIENCE, V297, P85, DOI 10.1126/science.1072953	9	149	156	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					717	718		10.1038/434717b	http://dx.doi.org/10.1038/434717b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815618				2022-12-28	WOS:000228160700029
J	Kistorp, C; Raymond, I; Pedersen, F; Gustafsson, F; Faber, J; Hildebrandt, P				Kistorp, C; Raymond, I; Pedersen, F; Gustafsson, F; Faber, J; Hildebrandt, P			N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; VENTRICULAR SYSTOLIC FUNCTION; ACUTE MYOCARDIAL-INFARCTION; GENERAL-POPULATION; RISK PREDICTION; LARGE-SAMPLE; PLASMA; DYSFUNCTION; FAILURE; MARKERS	Context B-type natriuretic peptides have been shown to predict cardiovascular disease in apparently healthy individuals but their predictive ability for mortality and future cardiovascular events compared with C-reactive protein (CRP) and urinary albumin/creatinine ratio is unknown. Objective To assess the prognostic value of the N-amino terminal fragment of the prohormone brain natriuretic peptide (NT-proBNP) vs CRP and urinary albumin/creatinine ratio in an older adult population. Design, Setting, and Participants A population-based prospective study of 764 participants aged 50 to 89 years from a community in Copenhagen, Denmark, in which 658 participants provided blood and urinary samples and were examined between September 1, 1998, and January 24, 2000. Of these participants, 626 without heart or renal failure were enrolled. A subgroup of 537 had no history of cardiovascular disease at baseline. During 5 years of follow-up (to December 31, 2003), 94 participants died and 65 developed a first major cardiovascular event. Main Outcome Measures Risk of mortality and first major cardiovascular event by baseline levels of NT-proBNP, CRP, and urinary albumin/creatinine ratio levels. Results After adjustment for the cardiovascular risk factors of age, sex, smoking, diabetes mellitus, hypertension or ischemic heart disease, total cholesterol, and serum creatinine, the hazard ratio (HR) of mortality for values above the 80th percentile of NT-proBNP was 1.96 (95% confidence interval [CI], 1.21-3.19); for CRP, 1.46 (95% CI, 0.89-2.24); and for urinary albumin/creatinine ratio, 1.88 (95% CI, 1.18-2.98). Additional adjustment for left ventricular systolic dysfunction did not markedly attenuate the predictive value of NT-proBNP (HR, 1.82; 95% CI, 1.11-2.98). The absolute unadjusted increase in mortality risk for participants with values above the 80th percentile vs equal to or below the 80th percentile was 24.5% for NT-proBNP, 7.8% for CRP, and 19.5% for urinary albumin/creatinine ratio. The NT-proBNP levels were associated with first major cardiovascular events (nonfatal myocardial infarction, fatal coronary heart disease, unstable angina, heart failure, stroke, and transient ischemic attack) with an adjusted HR of 3.24 (95% CI, 1.80-5.79) vs 1.02 (95% CI, 0.56-1.85) for CRP and 2.32 (95% CI, 1.33-4.05) for urinary albumin/creatinine ratio when comparing participants with values above the 80th percentile with those with values equal to or below the 80th percentile. Conclusions Measurements of NT-proBNP provide prognostic information of mortality and first major cardiovascular events beyond traditional risk factors. NT-proBNP was a stronger risk biomarker for cardiovascular disease and death than CRP was in nonhospitalized individuals aged 50 to 89 years.	Frederiksberg Univ Hosp, Dept Cardiol & Endocrinol, DK-2000 Copenhagen, Denmark; Rigshosp, Dept Cardiol, DK-2100 Copenhagen, Denmark; Herlev Univ Hosp, Dept Endocrinol, DK-2730 Herlev, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital	Kistorp, C (corresponding author), Frederiksberg Univ Hosp, Dept Cardiol & Endocrinol, 57 Nordre Fasanvej, DK-2000 Copenhagen, Denmark.	cnkistorp@dadlnet.dk		Gustafsson, Finn/0000-0003-2144-341X; Kistorp, Caroline/0000-0002-3019-6775				Andersen TF, 1999, DAN MED BULL, V46, P263; Berger R, 2002, CIRCULATION, V105, P2392, DOI 10.1161/01.CIR.0000016642.15031.34; Blake GJ, 2002, J INTERN MED, V252, P283, DOI 10.1046/j.1365-2796.2002.01019.x; Borch-Johnsen K, 1999, ARTERIOSCL THROM VAS, V19, P1992, DOI 10.1161/01.ATV.19.8.1992; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; Danesh J, 2004, NEW ENGL J MED, V350, P1387, DOI 10.1056/NEJMoa032804; de Lemos JA, 2001, NEW ENGL J MED, V345, P1014, DOI 10.1056/NEJMoa011053; Eda S, 1998, J CLIN LAB ANAL, V12, P137, DOI 10.1002/(SICI)1098-2825(1998)12:3<137::AID-JCLA2>3.0.CO;2-6; Folsom AR, 2002, AM HEART J, V144, P233, DOI 10.1067/mhj.2002.124054; Goetze JP, 2004, EUR HEART J, V25, P759, DOI 10.1016/j.ehj.2004.02.009; Groenning BA, 2004, HEART, V90, P297, DOI 10.1136/hrt.2003.026021; Gustafsson Finn, 2003, HeartDrug, V3, P141, DOI 10.1159/000073839; HAMA N, 1995, CIRCULATION, V92, P1558, DOI 10.1161/01.CIR.92.6.1558; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; HUNT PJ, 1995, BIOCHEM BIOPH RES CO, V214, P1175, DOI 10.1006/bbrc.1995.2410; Karl J, 1999, SCAND J CLIN LAB INV, V59, P177; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; Lubien E, 2002, CIRCULATION, V105, P595, DOI 10.1161/hc0502.103010; McClure SJ, 1998, BRIT MED J, V317, P516; McDonagh TA, 2001, HEART, V86, P21, DOI 10.1136/heart.86.1.21; Mendall MA, 2000, EUR HEART J, V21, P1584, DOI 10.1053/euhj.1999.1982; Mizuno Y, 2000, AM J CARDIOL, V86, P1036, DOI 10.1016/S0002-9149(00)01147-4; Omland T, 2002, CIRCULATION, V106, P2913, DOI 10.1161/01.CIR.0000041661.63285.AE; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232; Pearson TA, 2003, CIRCULATION, V107, P645, DOI 10.1161/01.CIR.0000054482.38437.13; Pradhan AD, 2002, JAMA-J AM MED ASSOC, V288, P980, DOI 10.1001/jama.288.8.980; Raymond I, 2003, HEART, V89, P745, DOI 10.1136/heart.89.7.745; Raymond Ilan, 2002, HeartDrug, V2, P167, DOI 10.1159/000065944; Richards AM, 2003, CIRCULATION, V107, P2786, DOI 10.1161/01.CIR.0000070953.76250.B9; Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Rossing P, 1996, BRIT MED J, V313, P779; Rubattu S, 2004, STROKE, V35, P814, DOI 10.1161/01.STR.0000119381.52589.AB; Tateishi J, 2000, CLIN CARDIOL, V23, P776, DOI 10.1002/clc.4960231016; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; Troughton RW, 2004, J AM COLL CARDIOL, V43, P416, DOI 10.1016/j.jacc.2003.08.046; Tsutamoto T, 1997, CIRCULATION, V96, P509; van der Meer IM, 2003, ARCH INTERN MED, V163, P1323, DOI 10.1001/archinte.163.11.1323; Vasan RS, 2003, CIRCULATION, V107, P1486, DOI 10.1161/01.CIR.0000057810.48709.F6; Vasan RS, 2002, JAMA-J AM MED ASSOC, V288, P1252, DOI 10.1001/jama.288.10.1252; Wallen T, 1997, HEART, V77, P264, DOI 10.1136/hrt.77.3.264; Wang TJ, 2004, NEW ENGL J MED, V350, P655, DOI 10.1056/NEJMoa031994; Wiese S, 2000, CIRCULATION, V102, P3074	44	426	441	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2005	293	13					1609	1616		10.1001/jama.293.13.1609	http://dx.doi.org/10.1001/jama.293.13.1609			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913EV	15811980	Bronze			2022-12-28	WOS:000228135300023
J	Sanders, DS; Hurlstone, DP; McAlindon, ME; Hadjivassiliou, M; Cross, SS; Wild, G; Atkins, CJ				Sanders, DS; Hurlstone, DP; McAlindon, ME; Hadjivassiliou, M; Cross, SS; Wild, G; Atkins, CJ			Lesson of the week - Antibody negative coeliac disease presenting in elderly people - an easily missed diagnosis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PRIMARY-CARE; SENSITIVITY; RETICULIN		Royal Hallamshire Hosp, Gastroenterol & Liver Unit, Sheffield S10 2JF, S Yorkshire, England; Greystones Med Ctr, Sheffield G11 7BJ, S Yorkshire, England	University of Sheffield	Sanders, DS (corresponding author), Royal Hallamshire Hosp, Gastroenterol & Liver Unit, Room P39,P Floor, Sheffield S10 2JF, S Yorkshire, England.	d.s.sanders28@btopenworld.com		Cross, Simon/0000-0003-2044-1754				Bingley PJ, 2004, BRIT MED J, V328, P322, DOI 10.1136/bmj.328.7435.322; COLLIN P, 1993, SCAND J GASTROENTERO, V28, P595, DOI 10.3109/00365529309096094; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; Fasano A, 2001, GASTROENTEROLOGY, V120, P636, DOI 10.1053/gast.2001.22123; Gasbarrini G, 2001, GERONTOLOGY, V47, P306, DOI 10.1159/000052819; Green PHR, 2001, AM J GASTROENTEROL, V96, P126, DOI 10.1111/j.1572-0241.2001.03462.x; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; Hin H, 1999, BMJ-BRIT MED J, V318, P164, DOI 10.1136/bmj.318.7177.164; Horoldt BS, 2004, EUR J GASTROEN HEPAT, V16, P1143; Johnston SD, 1998, QJM-MON J ASSOC PHYS, V91, P853, DOI 10.1093/qjmed/91.12.853; Kaukinen K, 1998, SCAND J GASTROENTERO, V33, P944; Rostami K, 1999, AM J GASTROENTEROL, V94, P888; Sanders DS, 2003, EUR J GASTROEN HEPAT, V15, P407, DOI 10.1097/00042737-200304000-00012; Sanders DS, 2001, LANCET, V358, P1504, DOI 10.1016/S0140-6736(01)06581-3; Thomas PD, 2003, GUT, V52, P1; West J, 2003, GUT, V52, P960, DOI 10.1136/gut.52.7.960	16	21	22	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					775	776		10.1136/bmj.330.7494.775	http://dx.doi.org/10.1136/bmj.330.7494.775			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15802721	Green Published			2022-12-28	WOS:000228222900026
J	Xu, Y; Padiath, QS; Shapiro, RE; Jones, CR; Wu, SC; Saigoh, N; Saigoh, K; Ptacek, LJ; Fu, YH				Xu, Y; Padiath, QS; Shapiro, RE; Jones, CR; Wu, SC; Saigoh, N; Saigoh, K; Ptacek, LJ; Fu, YH			Functional consequences of a CKI delta mutation causing familial advanced sleep phase syndrome	NATURE			English	Article							CASEIN KINASE-I; DROSOPHILA CIRCADIAN CLOCK; PERIOD PROTEIN; DOUBLE-TIME; GENE; DOUBLETIME; EPSILON; PHOSPHORYLATION; EXPRESSION; RHYTHMS	Familial advanced sleep phase syndrome (FASPS) is a human behavioural phenotype characterized by early sleep times and early-morning awakening(1). It was the first human, mendelian circadian rhythm variant to be well-characterized, and was shown to result from a mutation in a phosphorylation site within the casein kinase I (CKI)-binding domain of the human PER2 gene. To gain a deeper understanding of the mechanisms of circadian rhythm regulation in humans, we set out to identify mutations in human subjects leading to FASPS. We report here the identification of a missense mutation (T44A) in the human CKI delta gene, which results in FASPS. This mutant kinase has decreased enzymatic activity in vitro. Transgenic Drosophila carrying the human CKI delta-T44A gene showed a phenotype with lengthened circadian period. In contrast, transgenic mice carrying the same mutation have a shorter circadian period, a phenotype mimicking human FASPS. These results show that CKI delta is a central component in the mammalian clock, and suggest that mammalian and fly clocks might have different regulatory mechanisms despite the highly conserved nature of their individual components.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA; Univ Utah, Dept Neurol, Salt Lake City, UT 84132 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of Vermont; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Fu, YH (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.	yinghui@itsa.ucsf.edu	saigoh, Kazumasa/AAG-4678-2022; saigoh, Kazumasa/AFK-6417-2022; Xu, Ying/AAF-3081-2019; Xu, Ying/A-3009-2013; Saigoh, Kazumasa/AAG-2956-2020	Xu, Ying/0000-0002-6689-7768; Xu, Ying/0000-0002-6689-7768; Saigoh, Kazumasa/0000-0002-0905-5935				Akten B, 2003, NAT NEUROSCI, V6, P251, DOI 10.1038/nn1007; Antoch MP, 1997, CELL, V89, P655, DOI 10.1016/S0092-8674(00)80246-9; Beck A.T, 1978, BECK DEPRESSION INVE; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; Dahl RE, 1996, BIOL PSYCHIAT, V39, P400, DOI 10.1016/0006-3223(95)00190-5; Denault DL, 2001, EMBO J, V20, P109, DOI 10.1093/emboj/20.1.109; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Eide EJ, 2002, J BIOL CHEM, V277, P17248, DOI 10.1074/jbc.M111466200; GILLIN JC, 1983, PROG NEURO-PSYCHOPH, V7, P351, DOI 10.1016/0278-5846(83)90123-9; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; Heintz N, 2001, NAT REV NEUROSCI, V2, P861, DOI 10.1038/35104049; Jones CR, 1999, NAT MED, V5, P1062, DOI 10.1038/12502; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee C, 2004, MOL CELL BIOL, V24, P584, DOI 10.1128/MCB.24.2.584-594.2004; Lin JM, 2002, NATURE, V420, P816, DOI 10.1038/nature01235; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Nawathean P, 2004, MOL CELL, V13, P213, DOI 10.1016/S1097-2765(03)00503-3; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Preuss F, 2004, MOL CELL BIOL, V24, P886, DOI 10.1128/MCB.24.2.886-898.2004; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; Sathyanarayanan S, 2004, CELL, V116, P603, DOI 10.1016/S0092-8674(04)00128-X; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Suri V, 2000, J NEUROSCI, V20, P7547; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Young MW, 2000, TRENDS BIOCHEM SCI, V25, P601, DOI 10.1016/S0968-0004(00)01695-9	30	563	581	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					640	644		10.1038/nature03453	http://dx.doi.org/10.1038/nature03453			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800623				2022-12-28	WOS:000228011000044
J	Crawford, ME				Crawford, ME			Commentary: Reassuring evidence on competency based selection	BRITISH MEDICAL JOURNAL			English	Editorial Material									No Ireland Med & Dent Training Agcy, Belfast BT8 7RS, Antrim, North Ireland		Crawford, ME (corresponding author), No Ireland Med & Dent Training Agcy, Belfast BT8 7RS, Antrim, North Ireland.	Maureen.crawford@nimdta.gov.uk						Patterson F, 2005, BMJ-BRIT MED J, V330, P711, DOI 10.1136/bmj.330.7493.711	1	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 26	2005	330	7493					714	714		10.1136/bmj.330.7493.714	http://dx.doi.org/10.1136/bmj.330.7493.714			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912IT	15790642	Green Published, Bronze			2022-12-28	WOS:000228071900020
J	Gardner, RG; Nelson, ZW; Gottschling, DE				Gardner, RG; Nelson, ZW; Gottschling, DE			Degradation-mediated protein quality control in the nucleus	CELL			English	Article							OCULOPHARYNGEAL MUSCULAR-DYSTROPHY; UBIQUITIN-CONJUGATING ENZYMES; ER-ASSOCIATED DEGRADATION; YEAST SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; INTRACELLULAR-LOCALIZATION; MOLECULAR CHAPERONES; PROTEASOME PATHWAY; BINDING-PROTEIN; BUDDING YEAST	Protein quality control degradation systems rid the cell of aberrant proteins, preventing detrimental effects on normal cellular function. Although such systems have been identified in most subcellular compartments, none have been found in the nucleus. Here, we report the discovery of such a system in Saccharomyces cerevisiae. It is defined by San1p, a ubiquitin-protein ligase that, in conjunction with the ubiquitin-conjugating enzymes Cdc34p and Ubc1p, targets four distinct mutant nuclear proteins for ubiquitination and destruction by the proteasome. San1p has exquisite specificity for aberrant proteins and does not target the wild-type versions of its mutant substrates. San1p is nuclear localized and requires nuclear localization for function. Loss of SAN1 results in a chronic stress response, underscoring its role of protein quality control in the cell. We propose that San1p-mediated degradation acts as the last line of proteolytic defense against the deleterious accumulation of aberrant proteins in the nucleus and that analogous systems exist in other eukaryotes.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Gottschling, DE (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98109 USA.	dgottsch@fhcrc.org		Gardner, Richard/0000-0003-2162-6275	NIGMS NIH HHS [R01 GM043893-14, GM43893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Baker A, 2003, HUM MOL GENET, V12, P2609, DOI 10.1093/hmg/ddg293; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; BANERJEE A, 1995, J BIOL CHEM, V270, P26209, DOI 10.1074/jbc.270.44.26209; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Betting J, 1996, J BIOL CHEM, V271, P25790, DOI 10.1074/jbc.271.42.25790; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Blondel M, 2000, EMBO J, V19, P6085, DOI 10.1093/emboj/19.22.6085; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Brais B, 2003, CYTOGENET GENOME RES, V100, P252, DOI 10.1159/000072861; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; Burchett SA, 2002, J BIOL CHEM, V277, P22156, DOI 10.1074/jbc.M202254200; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Cameroni E, 2004, CELL CYCLE, V3, P462; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Chernova TA, 2003, J BIOL CHEM, V278, P52102, DOI 10.1074/jbc.M310283200; Chughtai ZS, 2001, J BIOL CHEM, V276, P20261, DOI 10.1074/jbc.M100364200; Cullen PJ, 2004, GENE DEV, V18, P1695, DOI 10.1101/gad.1178604; Dasgupta A, 2004, J BIOL CHEM, V279, P26830, DOI 10.1074/jbc.M400894200; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Evans DRH, 1998, GENETICS, V150, P1393; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Gardner RG, 1999, EMBO J, V18, P5994, DOI 10.1093/emboj/18.21.5994; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grandin N, 2001, MOL GENET GENOMICS, V265, P126, DOI 10.1007/s004380000398; Grant CM, 2000, BBA-GENE STRUCT EXPR, V1490, P33, DOI 10.1016/S0167-4781(99)00234-1; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jana NR, 2003, J CHEM NEUROANAT, V26, P95, DOI 10.1016/S0891-0618(03)00029-2; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kahana A, 1999, MOL CELL BIOL, V19, P6608; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kawai R, 1999, CELL STRESS CHAPERON, V4, P46, DOI 10.1054/csac.1999.0076; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; LIU Y, 1995, MOL CELL BIOL, V15, P5635; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; MADURA K, 1993, J BIOL CHEM, V268, P12046; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Ptak C, 2001, MOL CELL BIOL, V21, P6537, DOI 10.1128/MCB.21.19.6537-6548.2001; Qi HY, 2000, GENE DEV, V14, P1777; RINE J, 1987, GENETICS, V116, P9; ROSSI JM, 1989, J CELL BIOL, V108, P425, DOI 10.1083/jcb.108.2.425; ROWLEY A, 1991, MOL CELL BIOL, V11, P5718, DOI 10.1128/MCB.11.11.5718; SCHNELL R, 1989, GENETICS, V122, P29; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Shastry BS, 2003, NEUROCHEM INT, V43, P1, DOI 10.1016/S0197-0186(02)00196-1; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Stirling PC, 2003, EMBO REP, V4, P565, DOI 10.1038/sj.embor.embor869; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wojcik C, 2003, INT J BIOCHEM CELL B, V35, P579, DOI 10.1016/S1357-2725(02)00380-1; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; XU QL, 1995, MOL CELL BIOL, V15, P6025; XU QL, 1993, MOL CELL BIOL, V13, P7553, DOI 10.1128/MCB.13.12.7553	72	207	209	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					803	815		10.1016/j.cell.2005.01.016	http://dx.doi.org/10.1016/j.cell.2005.01.016			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797381	Bronze			2022-12-28	WOS:000228067500010
J	Lurie, P; Greco, DB				Lurie, P; Greco, DB			US exceptionalism comes to research ethics	LANCET			English	Editorial Material							PLACEBO-CONTROLLED TRIALS; ACTIVE-CONTROL TRIALS		Publ Citizens Hlth Res Grp, Washington, DC 20009 USA; Univ Fed Minas Gerais, Infect Dis Serv, Belo Horizonte, MG, Brazil	Universidade Federal de Minas Gerais	Lurie, P (corresponding author), Publ Citizens Hlth Res Grp, Washington, DC 20009 USA.	plurie@citizen.org	Greco, Dirceu/AAR-4714-2020	Greco, Dirceu/0000-0002-4419-5634				*CTR DRUG EV RES, 2001, GUID IND ACC FOR CLI; Ellenberg SS, 2000, ANN INTERN MED, V133, P464, DOI 10.7326/0003-4819-133-6-200009190-00015; Greco DB, 2004, CAN MED ASSOC J, V170, P20; *INT C HARM, 1996, GUID IND E6 GOOD CLI; Koski G, 2001, NEW ENGL J MED, V345, P136, DOI 10.1056/NEJM200107123450211; Lie RK, 2004, J MED ETHICS, V30, P190, DOI 10.1136/jme.2003.006031; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Temple Robert, 1996, Account Res, V4, P267, DOI 10.1080/08989629608573887; *WHIT HOUS, 2005, BUSH SWORN 2 TERM; 2001, TEMPLE EXPLAINS ETHI; 2003, CMAJ, V10, P169; 2004, FED REG         0610, V69, P32467	12	22	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1117	1119		10.1016/S0140-6736(05)71856-0	http://dx.doi.org/10.1016/S0140-6736(05)71856-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794954				2022-12-28	WOS:000227909500007
J	Tian, F; Toon, OB; Pavlov, AA; De Sterck, H				Tian, F; Toon, OB; Pavlov, AA; De Sterck, H			A hydrogen-rich early Earth atmosphere	SCIENCE			English	Article							NONTHERMAL ESCAPE; PHOTOCHEMISTRY; FORMALDEHYDE; OXIDATION; ORIGIN; WATER; LIFE; SUN; HCN; CO2	We show that the escape of hydrogen from early Earth's atmosphere likely occurred at rates slower by two orders of magnitude than previously thought. The balance between slow hydrogen escape and volcanic outgassing could have maintained a hydrogen. mixing ratio of more than 30%. The production of prebiotic organic compounds in such an atmosphere would have been more efficient than either exogenous delivery or synthesis in hydrothermal systems. The organic soup in the oceans and ponds on early Earth would have been a more favorable place for the origin of life than previously thought.	Univ Colorado, Astrophys & Planetary Sci Dept, Boulder, CO 80309 USA; Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; Univ Colorado, Program Atmospher & Ocean Sci, Boulder, CO 80309 USA; Univ Waterloo, Dept Appl Math, Waterloo, ON N2L 3G1, Canada	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Waterloo	Tian, F (corresponding author), Univ Colorado, Astrophys & Planetary Sci Dept, Boulder, CO 80309 USA.	tian@colorado.edu	Tian, Feng/C-1344-2015; Pavlov, Alexander A./F-3779-2012	Tian, Feng/0000-0002-9607-560X; Pavlov, Alexander A./0000-0001-8771-1646; De Sterck, Hans/0000-0002-1641-932X				ABELSON PH, 1966, P NATL ACAD SCI USA, V55, P1365, DOI 10.1073/pnas.55.6.1365; Anbar AD, 2001, J GEOPHYS RES-PLANET, V106, P3219, DOI 10.1029/2000JE001272; CANUTO VM, 1983, NATURE, V305, P281, DOI 10.1038/305281a0; CHYBA C, 1991, ORIGINS LIFE EVOL B, V21, P3, DOI 10.1007/BF01809509; CHYBA CF, 1997, COMETS ORIGIN EVOLUT, P00147, DOI DOI 10.1002/2017JE005406; de Pater I, 2001, PLANETARY SCI, P66; Delano JW, 2001, ORIGINS LIFE EVOL B, V31, P311, DOI 10.1023/A:1011895600380; Dobson CM, 2000, P NATL ACAD SCI USA, V97, P11864, DOI 10.1073/pnas.200366897; DORREN JD, 1994, ASTROPHYS J, V428, P805, DOI 10.1086/174289; Ehrenfreund P, 2002, REP PROG PHYS, V65, P1427, DOI 10.1088/0034-4885/65/10/202; Holland HD, 2002, GEOCHIM COSMOCHIM AC, V66, P3811, DOI 10.1016/S0016-7037(02)00950-X; HUNTEN DM, 1982, PLANET SPACE SCI, V30, P773, DOI 10.1016/0032-0633(82)90110-6; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; KUMAR S, 1983, ICARUS, V55, P369, DOI 10.1016/0019-1035(83)90109-4; Lammer H, 2003, ICARUS, V165, P9, DOI 10.1016/S0019-1035(03)00170-2; LOVE SG, 1993, SCIENCE, V262, P550, DOI 10.1126/science.262.5133.550; McCollom TM, 2001, GEOCHIM COSMOCHIM AC, V65, P3769, DOI 10.1016/S0016-7037(01)00655-X; MILLER SL, 1953, SCIENCE, V117, P528, DOI 10.1126/science.117.3046.528; Pavlov AA, 2001, GEOLOGY, V29, P1003, DOI 10.1130/0091-7613(2001)029<1003:OHIESE>2.0.CO;2; Pierazzo E, 1999, METEORIT PLANET SCI, V34, P909, DOI 10.1111/j.1945-5100.1999.tb01409.x; PINTO JP, 1980, SCIENCE, V210, P183, DOI 10.1126/science.210.4466.183; Ryder G, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001583; SCHLESINGER G, 1983, J MOL EVOL, V19, P376, DOI 10.1007/BF02101642; STRIBLING R, 1987, ORIGINS LIFE EVOL B, V17, P261, DOI 10.1007/BF02386466; TURCOTTE DL, 1980, EARTH PLANET SC LETT, V48, P53, DOI 10.1016/0012-821X(80)90169-7; Walker, 1977, EVOLUTION ATMOSPHERE, V32, P71; WALKER JCG, 1985, ORIGINS LIFE EVOL B, V16, P117, DOI 10.1007/BF01809466; ZAHNLE KJ, 1986, J GEOPHYS RES-ATMOS, V91, P2819, DOI 10.1029/JD091iD02p02819; ZUILEN MA, 2002, NATURE, V418, P627	29	279	296	5	143	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 13	2005	308	5724					1014	1017		10.1126/science.1106983	http://dx.doi.org/10.1126/science.1106983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	927JR	15817816				2022-12-28	WOS:000229190700044
J	Pildal, J; Chan, AW; Hrobjartsson, A; Forfang, E; Altman, DG; Gotzsche, PC				Pildal, J; Chan, AW; Hrobjartsson, A; Forfang, E; Altman, DG; Gotzsche, PC			Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED-TRIALS; EMPIRICAL-EVIDENCE; QUALITY; BIAS	Objectives To compare how allocation concealment is described in publications of randomised clinical trials and corresponding protocols, and to estimate how often trial publications with unclear allocation concealment have adequate concealment according to the protocol. Design Cohort study of 102 sets of trial protocols and corresponding publications.. Setting Protocols of randomised trials approved by the scientific and ethical committees for Copenhagen and Frederiksberg, 1994 and 1995. Main outcome measures Frequency of adequate, unclear, and inadequate allocation concealment and sequence generation in trial publications compared with protocols, and the proportion of protocols where methods were reported to be adequate but descriptions were unclear in the trial publications. Results 96 of the 102 trials had unclear allocation concealment according to, the trial publication. According to the protocols, 15 of these 96 trials had adequate adequate allocation concealment (16%, 95% confidence interval 9% to 24%), 80 had unclear concealment (83%, 74% to 90%), and one had inadequate concealment. When retrospectively defined loose criteria for concealment were applied, 83 of the 102 trial publications had unclear concealment. According to their protocol, 33 of these 83 trials had adequate allocation concealment (40%, 29% to 51%), 49 had unclear concealment (59%, 48% to 70%), and one had inadequate concealment. Conclusions Most randomised clinical trials have unclear allocation concealment on the basis, of the trial publication alone. Most of these trials also have unclear allocation concealment according to their protocol.	Rigshosp, Nord Cochrane Ctr, DK-2100 Copenhagen, Denmark; Univ Toronto, Dept Med, Toronto, ON, Canada; Canc Res UK Med Stat Grp, Ctr Stat Med, Oxford OX3 7LF, England	Rigshospitalet; University of Copenhagen; University of Toronto; Cancer Research UK; University of Oxford	Pildal, J (corresponding author), Rigshosp, Nord Cochrane Ctr, DK-2100 Copenhagen, Denmark.	jpl@dadlnet.dk						Abraham J, 2002, LANCET, V360, P1498, DOI 10.1016/S0140-6736(02)11477-2; Alderson P, 2004, COCHRANE LIB; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Balk EM, 2002, JAMA-J AM MED ASSOC, V287, P2973, DOI 10.1001/jama.287.22.2973; Berger VW, 2003, VACCINE, V21, P468, DOI 10.1016/S0264-410X(02)00475-9; Chalmers I, 1999, LANCET, V353, P490, DOI 10.1016/S0140-6736(98)07618-1; Chan AW, 2004, CAN MED ASSOC J, V171, P735, DOI 10.1503/cmaj.1041086; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Devereaux PJ, 2004, J CLIN EPIDEMIOL, V57, P1232, DOI 10.1016/j.jclinepi.2004.03.017; Ghersi D, 2004, LANCET ONCOL, V5, P325, DOI 10.1016/S1470-2045(04)01473-1; Hill CL, 2002, J CLIN EPIDEMIOL, V55, P783, DOI 10.1016/S0895-4356(02)00440-7; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Juni P, 2002, JAMA-J AM MED ASSOC, V288, P2407; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; Meinert CL., 1986, CLIN TRIALS DESIGN C; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Schulz KF, 2002, JAMA-J AM MED ASSOC, V288, P2406, DOI 10.1001/jama.288.19.2406; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 2002, LANCET, V359, P614, DOI 10.1016/S0140-6736(02)07750-4; Soares HP, 2004, BRIT MED J, V328, P22, DOI 10.1136/bmj.328.7430.22	22	137	142	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 7	2005	330	7499					1049	1052A		10.1136/bmj.38414.422650.8F	http://dx.doi.org/10.1136/bmj.38414.422650.8F			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	925YY	15817527	Green Published, Bronze			2022-12-28	WOS:000229090900013
J	Zhan, ZL; Barnett, SA				Zhan, ZL; Barnett, SA			An octane-fueled olid oxide fuel cell	SCIENCE			English	Article							DIRECT ELECTROCHEMICAL OXIDATION; SOFC ANODES; METHANE	There are substantial barriers to the introduction of hydrogen fuel cells for transportation, including the high cost of fuel-cell systems, the current tack of a hydrogen infrastructure, and the relatively low fuel efficiency when using hydrogen produced from hydrocarbons. Here, we describe a solid oxide fuel cell that combines a catalyst layer with a conventional anode, allowing internal reforming of iso-octane without coking and yielding stable power densities of 0.3 to 0.6 watts per square centimeter. This approach is potentially the basis of a simple low-cost System that can provide substantially higher fuel efficiency by using excess fuel-cell heat for the endothermic reforming reaction.	Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA	Northwestern University	Barnett, SA (corresponding author), Northwestern Univ, Dept Mat Sci & Engn, 2220 Campus Dr, Evanston, IL 60208 USA.	s-barnett@northwestern.edu	Barnett, Scott A/B-7502-2009					Ahmed K, 2000, CATAL TODAY, V63, P479, DOI 10.1016/S0920-5861(00)00494-6; ASHCROFT AT, 1991, NATURE, V352, P225, DOI 10.1038/352225a0; Atkinson A, 2004, NAT MATER, V3, P17, DOI 10.1038/nmat1040; BOSSEL U, 2003, E08 EUR FUEL CELL FO; BOTTI J, 2003, P 8 INT S SOL OX FUE, P16; DEVITT J, 2003, P 8 INT S SOL OX FUE, P1276; GEORGE R, 2002, 2002 FUEL CELL SEM W, P977; Gorte RJ, 2003, J CATAL, V216, P477, DOI 10.1016/S0021-9517(02)00121-5; Gorte RJ, 2002, J POWER SOURCES, V106, P10, DOI 10.1016/S0378-7753(01)01021-7; LIN Y, UNPUB SOLID STATE IO; Liu J, 2002, J AM CERAM SOC, V85, P3096; MINH N, 2003, P 8 INT S SOL OX FUE, P43; MUKERJEE S, 2003, P 8 INT S SOL OX FUE, P88; RODRIGUEZ NM, 1993, J MATER RES, V8, P3233, DOI 10.1557/JMR.1993.3233; ROSTRUPNIELSEN JR, 1995, APPL CATAL A-GEN, V126, P381, DOI 10.1016/0926-860X(95)00028-3; Singhal SC, 2002, SOLID STATE IONICS, V152, P405, DOI 10.1016/S0167-2738(02)00349-1; STEVENSON JW, 2003, P 8 INT S SOL OX FUE, P31; Toebes ML, 2002, CATAL TODAY, V76, P33, DOI 10.1016/S0920-5861(02)00209-2; Xia CR, 2001, ELECTROCHEM SOLID ST, V4, pA52, DOI 10.1149/1.1361158; Yang RT, 2003, SCIENCE, V301, P79, DOI 10.1126/science.1085088; Zhan ZL, 2004, APPL CATAL A-GEN, V262, P255, DOI 10.1016/j.apcata.2003.11.033; Zhou ZF, 2004, J POWER SOURCES, V133, P181, DOI 10.1016/j.jpowsour.2003.12.044	22	468	487	5	238	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 6	2005	308	5723					844	847		10.1126/science.1109213	http://dx.doi.org/10.1126/science.1109213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	924NW	15802567				2022-12-28	WOS:000228986500045
J	James, C; Ugo, V; Le Couedic, JP; Staerk, J; Delhommeau, F; Lacout, C; Garcon, L; Raslova, H; Berger, R; Bennaceur-Griscelli, A; Villeval, JL; Constantinescu, SN; Casadevall, N; Vainchenker, W				James, C; Ugo, V; Le Couedic, JP; Staerk, J; Delhommeau, F; Lacout, C; Garcon, L; Raslova, H; Berger, R; Bennaceur-Griscelli, A; Villeval, JL; Constantinescu, SN; Casadevall, N; Vainchenker, W			A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera	NATURE			English	Article							ERYTHROID PROGENITORS; PSEUDOKINASE DOMAIN; TYROSINE KINASE; T-CELL; ERYTHROPOIETIN; EXPRESSION; LEUKEMIA; JANUS-KINASE-2; INTERFERON; RESPONSES	Myeloproliferative disorders are clonal haematopoietic stem cell malignancies characterized by independency or hypersensitivity of haematopoietic progenitors to numerous cytokines(1,2). The molecular basis of most myeloproliferative disorders is unknown. On the basis of the model of chronic myeloid leukaemia, it is expected that a constitutive tyrosine kinase activity could be at the origin of these diseases. Polycythaemia vera is an acquired myeloproliferative disorder, characterized by the presence of polycythaemia diversely associated with thrombocytosis, leukocytosis and splenomegaly(3). Polycythaemia vera progenitors are hypersensitive to erythropoietin and other cytokines(4,5). Here, we describe a clonal and recurrent mutation in the JH2 pseudo-kinase domain of the Janus kinase 2 (JAK2) gene in most (>80%) polycythaemia vera patients. The mutation, a valine-to-phenylalanine substitution at amino acid position 617, leads to constitutive tyrosine phosphorylation activity that promotes cytokine hypersensitivity and induces erythrocytosis in a mouse model. As this mutation is also found in other myeloproliferative disorders, this unique mutation will permit a new molecular classification of these disorders and novel therapeutical approaches.	Univ Paris 11, Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; CHU Brest, Hematol Lab, F-29609 Brest, France; Hop Hotel Dieu, Hematol Lab, F-75181 Paris, France; Catholic Univ Louvain, Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium; Catholic Univ Louvain, MEXP Unit, B-1200 Brussels, Belgium; Hop Necker Enfants Malad, INSERM, E0210, F-75743 Paris, France; Inst Gustave Roussy, Hematol Lab, F-94805 Villejuif, France; Hop St Louis, Polyclin Hematol, F-75475 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; CHU Brest; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Ludwig Institute for Cancer Research; Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Vainchenker, W (corresponding author), Univ Paris 11, Inst Gustave Roussy, INSERM, U362, PR1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	verpre@igr.fr	Constantinescu, Stefan N/E-5277-2012; Raslova, Hana/N-3562-2018; james, chloe/A-2015-2012	Raslova, Hana/0000-0001-8846-5299; James, Chloe/0000-0001-9553-2701; Ugo, Valerie/0000-0002-4678-2138; Vainchenker, William/0000-0003-4705-202X; Staerk, Judith/0000-0001-8698-6998; Delhommeau, Francois/0000-0002-4915-0734; bennaceur griscelli, annelise/0000-0002-3557-4499; Constantinescu, Stefan N./0000-0002-8599-2699; Villeval, Jean-Luc/0000-0002-0562-925X				Argetsinger LS, 2004, MOL CELL BIOL, V24, P4955, DOI 10.1128/MCB.24.11.4955-4967.2004; Bernabei P, 2001, J LEUKOCYTE BIOL, V70, P950; CASADEVALL N, 1982, BLOOD, V59, P447; Chagraoui C, 2003, BLOOD, V101, P2983, DOI 10.1182/blood-2002-09-2839; Cools J, 1999, CYTOGENET CELL GENET, V85, P260, DOI 10.1159/000015308; Dorsch M, 2002, BLOOD, V100, P2046, DOI 10.1182/blood.V100.6.2046.h81802002046_2046_2055; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Feener EP, 2004, MOL CELL BIOL, V24, P4968, DOI 10.1128/MCB.24.11.4968-4978.2004; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kralovics R, 2003, BLOOD, V102, P3793, DOI 10.1182/blood-2003-03-0885; Kralovics R, 2002, EXP HEMATOL, V30, P229, DOI 10.1016/S0301-472X(01)00789-5; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LECONIAT M, 1995, GENE CHROMOSOME CANC, V14, P204; Lindauer K, 2001, PROTEIN ENG, V14, P27, DOI 10.1093/protein/14.1.27; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Najfeld V, 2002, BRIT J HAEMATOL, V119, P558, DOI 10.1046/j.1365-2141.2002.03763.x; Pearson TC, 1996, LEUKEMIA LYMPHOMA, V22, P87; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; Prchal JT, 2005, CURR OPIN HEMATOL, V12, P112, DOI 10.1097/01.moh.0000154029.05396.d2; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; Spivak JL, 2004, SEMIN HEMATOL, V41, P1, DOI 10.1053/j.seminhematol.2004.02.011; Spivak JL, 2002, BLOOD, V100, P4272, DOI 10.1182/blood-2001-12-0349; Ugo V, 2004, EXP HEMATOL, V32, P179, DOI 10.1016/j.exphem.2003.11.003; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Zhao SM, 2002, EMBO J, V21, P2159, DOI 10.1093/emboj/21.9.2159	27	2627	2888	0	125	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 28	2005	434	7037					1144	1148		10.1038/nature03546	http://dx.doi.org/10.1038/nature03546			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	920MD	15793561				2022-12-28	WOS:000228693300046
J	Viner, RM; Barker, M				Viner, RM; Barker, M			Young people's health: the need for action	BRITISH MEDICAL JOURNAL			English	Article							ADOLESCENT HEALTH; GATEHOUSE PROJECT; PLANET-HEALTH; CARE; INTERVENTION; INEQUALITIES; SUICIDE; ENGLAND; SCHOOLS; SYSTEM		UCL, Royal Free & Univ Coll Med Sch, Dept Paediat, London NW3 2PF, England; Great Ormond St Hosp London NHS Trust, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Viner, RM (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Paediat, London NW3 2PF, England.	R.Viner@ich.ucl.ac.uk						Bond L, 2001, HEALTH EDUC BEHAV, V28, P368, DOI 10.1177/109019810102800310; BOREHAM R, 2002, DRUG USE SMOKING DRI; *DEP HLTH, 2004, 200506200708 DOH; Department of Health, 2003, HLTH SURV ENGL 2002; Gortmaker SL, 1999, ARCH PEDIAT ADOL MED, V153, P409, DOI 10.1001/archpedi.153.4.409; Gunnell D, 2003, SOC SCI MED, V57, P595, DOI 10.1016/S0277-9536(02)00408-2; Jacobson L, 2001, BRIT J GEN PRACT, V51, P811; JACOBSON LD, 1994, FAM PRACT, V11, P296, DOI 10.1093/fampra/11.3.296; *JOINT WORK PART A, 2003, BRIDG GAPS HEALTHC A; Koivusilta LK, 1999, HEALTH EDUC RES, V14, P339, DOI 10.1093/her/14.3.339; McClure GMG, 2001, BRIT J PSYCHIAT, V178, P469, DOI 10.1192/bjp.178.5.469; *NAT STAT, 2000, STAT B NAT STAT, V17, P1; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; *OFF NAT STAT, 2004, DEATHS AG SEX UND CA; Patton G, 1996, AUST NZ J PSYCHIAT, V30, P563, DOI 10.3109/00048679609062650; Patton GC, 2000, AUST NZ J PSYCHIAT, V34, P586, DOI 10.1046/j.1440-1614.2000.00718.x; Resnick MD, 1997, JAMA-J AM MED ASSOC, V278, P823, DOI 10.1001/jama.278.10.823; *ROYAL COLL PSYCH, 2001, NAT IN PAT CHILD AD; Sanci LA, 2000, BRIT MED J, V320, P224, DOI 10.1136/bmj.320.7229.224; Shrier LA, 1997, J ADOLESCENT HEALTH, V20, P377, DOI 10.1016/S1054-139X(96)00180-2; *SOC EXCL UN, 1999, TEEN PREGN; *UK DAT ARCH, 2004, NAT STUD HLTH GROWTH; *UK DAT ARCH, 1994, NAT STUD HLTH GROWTH; UK Government, 2021, GP IT FUTURES SYSTEM; Viner RM, 2001, BRIT MED J, V322, P957, DOI 10.1136/bmj.322.7292.957; Wanless, 2002, SECURING OUR FUTURE; West P, 1997, SOC SCI MED, V44, P833, DOI 10.1016/S0277-9536(96)00188-8; WEST P, 1991, SOC SCI MED, V32, P373, DOI 10.1016/0277-9536(91)90338-D; Wiecha JL, 2004, J PEDIATR PSYCHOL, V29, P467, DOI 10.1093/jpepsy/jsh050	29	93	95	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 16	2005	330	7496					901	903		10.1136/bmj.330.7496.901	http://dx.doi.org/10.1136/bmj.330.7496.901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	917UA	15831880	Green Published, Green Submitted			2022-12-28	WOS:000228493500028
J	Lindenberg, AM; Larsson, J; Sokolowski-Tinten, K; Gaffney, KJ; Blome, C; Synnergren, O; Sheppard, J; Caleman, C; MacPhee, AG; Weinstein, D; Lowney, DP; Allison, TK; Matthews, T; Falcone, RW; Cavalieri, AL; Fritz, DM; Lee, SH; Bucksbaum, PH; Reis, DA; Rudati, J; Fuoss, PH; Kao, CC; Siddons, DP; Pahl, R; Als-Nielsen, J; Duesterer, S; Ischebeck, R; Schlarb, H; Schulte-Schrepping, H; Tschentscher, T; Schneider, J; von der Linde, D; Hignette, O; Sette, F; Chapman, HN; Lee, RW; Hansen, TN; Techert, S; Wark, JS; Bergh, M; Huldt, G; van der Spoel, D; Timneanu, N; Hajdu, J; Akre, RA; Bong, E; Krejcik, P; Arthur, J; Brennan, S; Luening, K; Hastings, JB				Lindenberg, AM; Larsson, J; Sokolowski-Tinten, K; Gaffney, KJ; Blome, C; Synnergren, O; Sheppard, J; Caleman, C; MacPhee, AG; Weinstein, D; Lowney, DP; Allison, TK; Matthews, T; Falcone, RW; Cavalieri, AL; Fritz, DM; Lee, SH; Bucksbaum, PH; Reis, DA; Rudati, J; Fuoss, PH; Kao, CC; Siddons, DP; Pahl, R; Als-Nielsen, J; Duesterer, S; Ischebeck, R; Schlarb, H; Schulte-Schrepping, H; Tschentscher, T; Schneider, J; von der Linde, D; Hignette, O; Sette, F; Chapman, HN; Lee, RW; Hansen, TN; Techert, S; Wark, JS; Bergh, M; Huldt, G; van der Spoel, D; Timneanu, N; Hajdu, J; Akre, RA; Bong, E; Krejcik, P; Arthur, J; Brennan, S; Luening, K; Hastings, JB			Atomic-scale visualization of inertial dynamics	SCIENCE			English	Article							X-RAY-DIFFRACTION; FEMTOSECOND LASER-PULSES; STRUCTURAL DYNAMICS; SEMICONDUCTORS; INSB; TRANSITIONS; RESOLUTION; LIQUIDS; SILICON; SI	The motion of atoms on interatomic potential energy surfaces is fundamental to the dynamics of liquids and solids. An accelerator-based source of femtosecond x-ray pulses allowed us to follow directly atomic displacements on an optically modified energy landscape, leading eventually to the transition from crystalline solid to disordered liquid. We show that, to first order in time, the dynamics are inertial, and we place constraints on the shape and curvature of the transition-state potential energy surface. Our measurements point toward analogies between this nonequilibrium phase transition and the short-time dynamics intrinsic to equilibrium liquids.	Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA; Lund Inst Technol, Dept Phys, S-22100 Lund, Sweden; Univ Jena, Inst Opt & Quantenelektron, D-07743 Jena, Germany; DESY, D-22607 Hamburg, Germany; Univ Oxford, Dept Phys, Clarendon Lab, Oxford OX1 3PU, England; Uppsala Univ, Dept Cell & Mol Biol, Ctr Biomed, SE-75124 Uppsala, Sweden; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Michigan, FOCUS Ctr, Dept Phys, Ann Arbor, MI 48109 USA; Univ Michigan, Appl Phys Program, Ann Arbor, MI 48109 USA; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA; Brookhaven Natl Lab, Natl Synchrotron Light Source, Upton, NY 11973 USA; Univ Chicago, Consortium Adv Radiat Sources, Chicago, IL 60637 USA; Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark; Univ Duisburg Essen, Inst Expt Phys, D-45117 Essen, Germany; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Lawrence Livermore Natl Lab, Dept Phys, Livermore, CA 94550 USA; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; SLAC, Menlo Pk, CA 94025 USA	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Lund University; Friedrich Schiller University of Jena; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Oxford; Uppsala University; University of California System; University of California Berkeley; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; United States Department of Energy (DOE); Argonne National Laboratory; State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory; University of Chicago; University of Copenhagen; Niels Bohr Institute; University of Duisburg Essen; European Synchrotron Radiation Facility (ESRF); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Max Planck Society; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Lindenberg, AM (corresponding author), Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA.		van der Spoel, David/A-5471-2008; van der Spoel, David/AAD-9820-2019; Gaffney, Kelly/AAG-7136-2020; Timneanu, Nicusor/C-7691-2012; Sokolowski-Tinten, Klaus/A-5415-2015; Allison, Thomas/F-8060-2012; FRS, Henry N Chapman/G-2153-2010; Gaffney, Kelly J/N-1597-2017	van der Spoel, David/0000-0002-7659-8526; van der Spoel, David/0000-0002-7659-8526; Timneanu, Nicusor/0000-0001-7328-0400; FRS, Henry N Chapman/0000-0002-4655-1743; Gaffney, Kelly J/0000-0002-0525-6465; Dusterer, Stefan/0000-0003-4379-1327; Allison, Thomas/0000-0003-0289-8830; Bucksbaum, Philip/0000-0003-1258-5571; Techert, Simone/0000-0002-7549-7651				CAVALIERI A, IN PRESS PHYS RES LE; Chin AH, 1999, PHYS REV LETT, V83, P336, DOI 10.1103/PhysRevLett.83.336; Dasannacharya B. A., 1965, PHYS REV A, V137, pA417; Dumitrica T, 2004, PHYS STATUS SOLIDI B, V241, P2331, DOI 10.1002/pssb.200404934; Jeschke HO, 2002, APPL SURF SCI, V197, P839, DOI 10.1016/S0169-4332(02)00458-0; Krejcik P, 2003, PROCEEDINGS OF THE 2003 PARTICLE ACCELERATOR CONFERENCE, VOLS 1-5, P423, DOI 10.1109/PAC.2003.1288941; Lindemann FA, 1910, PHYS Z, V11, P609; Liu PC, 1999, PHYS REV B, V60, P800, DOI 10.1103/PhysRevB.60.800; LUI X, 1997, IEEE J QUANTUM ELECT, V33, P1706; Neutze R, 1997, P NATL ACAD SCI USA, V94, P5651, DOI 10.1073/pnas.94.11.5651; PASKIN A, 1966, PHYS REV LETT, V16, P300, DOI 10.1103/PhysRevLett.16.300; Rousse A, 2001, NATURE, V410, P65, DOI 10.1038/35065045; Service RF, 2002, SCIENCE, V298, P1356, DOI 10.1126/science.298.5597.1356; SHANK CV, 1983, PHYS REV LETT, V51, P900, DOI 10.1103/PhysRevLett.51.900; Shumay IL, 1996, PHYS REV B, V53, P15878, DOI 10.1103/PhysRevB.53.15878; Siders CW, 1999, SCIENCE, V286, P1340, DOI 10.1126/science.286.5443.1340; Siwick BJ, 2003, SCIENCE, V302, P1382, DOI 10.1126/science.1090052; Sokolowski-Tinten K, 2001, PHYS REV LETT, V87, part. no., DOI 10.1103/PhysRevLett.87.225701; SOKOLOWSKITINTEN K, 1995, PHYS REV B, V51, P14186, DOI 10.1103/PhysRevB.51.14186; STAMPFLI P, 1994, PHYS REV B, V49, P7299, DOI 10.1103/PhysRevB.49.7299; STILLINGER FH, 1982, PHYS REV A, V25, P978, DOI 10.1103/PhysRevA.25.978; STRATT RM, 1995, ACCOUNTS CHEM RES, V28, P201, DOI 10.1021/ar00053a001; Sundaram SK, 2002, NAT MATER, V1, P217, DOI 10.1038/nmat767; Synnergren O, 2002, APPL PHYS LETT, V80, P3727, DOI 10.1063/1.1476957; VETELINO JF, 1972, PHYS REV B, V5, P2360, DOI 10.1103/PhysRevB.5.2360; Zoppi M., 1994, DYNAMICS LIQUID STAT	27	280	281	2	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 15	2005	308	5720					392	395		10.1126/science.1107996	http://dx.doi.org/10.1126/science.1107996			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831753	Green Published			2022-12-28	WOS:000228492000046
J	Buttery, JP; Riddell, A; MeVernon, J; Chantler, T; Lane, L; Bowen-Morris, J; Diggle, L; Morris, R; Harnden, A; Lockhart, S; Pollard, AI; Cartwright, K; Moxon, ER				Buttery, JP; Riddell, A; MeVernon, J; Chantler, T; Lane, L; Bowen-Morris, J; Diggle, L; Morris, R; Harnden, A; Lockhart, S; Pollard, AI; Cartwright, K; Moxon, ER			Immunogenicity and safety of a combination pneumococcal-meningococcal in infants - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C CONJUGATE VACCINE; ANTIBODY-RESPONSE; CHILDREN; PROTEIN; POLYSACCHARIDE; PROTECTION; IMMUNITY; TOLERABILITY; INFECTION; EFFICACY	Context The success of conjugate vaccines in decreasing invasive disease due to Streptococcus pneumoniae and group C Neisseria meningitidis has placed pressure on crowded infant immunization schedules, making development of combination vaccines a priority. Objective To determine the safety and immunogenicity of a combination 9-valent pneumococcal-group C meningococcal conjugate candidate vaccine (Pnc9-MenC) administered as part of the routine UK infant immunization schedule at ages 2, 3, and 4 months. Design, Setting, and Participants Phase 2 randomized controlled trial conducted from August 2000 to January 2002 and enrolling 240 healthy infants aged 7 to 11 weeks from 2 UK centers, with home follow-up visits at ages 2, 3, 4, and 5 months. Intervention Pnc9-MenC (n=120) or monovalent group C meningococcal conjugate vaccine (MenC) (n=120) administered in addition to routine immunizations (diphtheria and tetanus toxoids and whole-cell pertussis [DTwP], Haemophilus influenzae type b [Hib] polyribosylribitol phosphate-tetanus toxoid protein conjugate, oral polio vaccine). Main Outcome Measures Group C meningococcal immunogenicity measured by serum bactericidal titer (SBT) 1 month following the third dose; rates of postimmunization reactions. Results MenC component immunogenicity was reduced in the Pnc9-MenC vs the MenC group (geometric mean SBT, 179 [95% confidence interval {Cl}, 133-243] vs 808 [95% Cl, 630-1037], respectively; P<.001). The proportion with group C meningococcal SBT greater than 1:8 was lower in the Pnc9-MenC vs the MenC group (95% vs 100%, P=.05). The geometric mean concentration of antibodies to concomitantly administered Hib vaccine was reduced in the Pnc9-MenC vs the MenC group (2.11 [95% Cl, 1.57-2.84] mu g/mL vs 3.36 [95% Cl, 2.57-4.39] mu g/mL; P=.02), as were antibodies against diphtheria (0.74 [95% Cl, 0.63-0.87] mu g/mL vs 1.47 [95% Cl, 1.28-1.69] mu g/mL; P<.001). Pnc9-MenC was immunogenic for each of 9 contained pneumococcal serotypes, with responses greater than 0.35 mu g/mL observed in more than 88% of infants. Increased irritability and decreased activity were observed after the third dose in the Pnc9-MenC group. Conclusions Pnc9-MenC combination vaccine administered to infants at ages 2, 3, and 4 months demonstrated reduced group C meningococcal immunogenicity compared with MenC vaccine. The immunogenicity of concomitantly administered Hib and DTwP vaccines was also diminished. The Pnc9-MenC vaccine was safe and immunogenic for all contained pneumococcal serotypes. The reduced MenC immunogenicity may limit the development of the Pnc9-MenC vaccine.	Oxford Vaccine Grp, Ctr Clin Vaccinol & Trop Med, Dept Paediat, Oxford, England; Univ Oxford, Churchill Hosp, Dept Primary Hlth Care, Oxford, England; Gloucestershire Royal Hosp, Publ Hlth Lab, Gloucester GL1 3NN, England; Wyeth Vaccines, Maidenhead, England	University of Oxford; University of Oxford; Gloucestershire Royal Hospital; Pfizer	Buttery, JP (corresponding author), Univ Melbourne, Dept Paediat, Dept Gen Med,Murdoch Childrens Res Inst, Paediat Infect Dis,Royal Childrens Hosp, Flemington Rd, Parkville, Vic 3052, Australia.	jim.buttery@rch.org.au		McVernon, Jodie/0000-0001-9774-1961; Chantler, Tracey/0000-0001-7776-7339; Lockhart, Stephen/0000-0002-0805-2193				Anderson P, 2003, VACCINE, V21, P1554, DOI 10.1016/S0264-410X(02)00675-8; Andrews N, 2003, CLIN DIAGN LAB IMMUN, V10, P780, DOI 10.1128/CDLI.10.5.780-786.2003; Balmer P, 2002, J MED MICROBIOL, V51, P717, DOI 10.1099/0022-1317-51-9-717; BARINGTON T, 1993, INFECT IMMUN, V61, P432, DOI 10.1128/IAI.61.2.432-438.1993; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; Burrage M, 2002, INFECT IMMUN, V70, P4946, DOI 10.1128/IAI.70.9.4946-4954.2002; CRONIN WA, 1990, INFECT CONT HOSP EP, V11, P301; Dagan R, 2004, PEDIATR INFECT DIS J, V23, P91, DOI 10.1097/01.inf.0000109221.50972.53; English M, 2000, VACCINE, V19, P1232, DOI 10.1016/S0264-410X(00)00241-3; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; Greenberg DP, 2000, PEDIATR INFECT DIS J, V19, P1135, DOI 10.1097/00006454-200012000-00003; Heath PT, 2000, JAMA-J AM MED ASSOC, V284, P2334, DOI 10.1001/jama.284.18.2334; Huebner RE, 2000, Int J Infect Dis, V4, P214, DOI 10.1016/S1201-9712(00)90112-7; Kayhty H, 1998, Dev Biol Stand, V95, P175; Klugman KP, 2003, NEW ENGL J MED, V349, P1341, DOI 10.1056/NEJMoa035060; Lee LH, 2003, VACCINE, V21, P2190, DOI 10.1016/S0264-410X(03)00025-2; McVernon J, 2003, VACCINE, V21, P2573, DOI 10.1016/S0264-410X(03)00058-6; Puumalainen T, 2002, PEDIATR INFECT DIS J, V21, P309, DOI 10.1097/00006454-200204000-00010; Quataert S, 2001, IMMUNOL INVEST, V30, P191, DOI 10.1081/IMM-100105064; Sleeman K, 2001, J INFECT DIS, V183, P239, DOI 10.1086/317924; Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; *WHO, 1997, VACC RES DEV REP TEC, P32	23	52	75	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1751	1758		10.1001/jama.293.14.1751	http://dx.doi.org/10.1001/jama.293.14.1751			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827314	Bronze, Green Accepted			2022-12-28	WOS:000228301100029
J	Duraisingh, MT; Voss, TS; Marty, AJ; Duffy, MF; Good, RT; Thompson, JK; Freitas-Junior, LH; Scherf, A; Crabb, BS; Cowman, AF				Duraisingh, MT; Voss, TS; Marty, AJ; Duffy, MF; Good, RT; Thompson, JK; Freitas-Junior, LH; Scherf, A; Crabb, BS; Cowman, AF			Heterochromatin silencing and locus repositioning linked to regulation of virulence genes in Plasmodium faiciparum	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ANTIGENIC VARIATION; HUMAN ERYTHROCYTES; FALCIPARUM; EXPRESSION; MALARIA; ORGANIZATION; PROTEINS; RECOMBINATION; TRANSCRIPTION	The malaria parasite Plasmodium falciparum undergoes antigenic variation to evade host immune responses through switching expression of variant surface proteins encoded by the var gene family. We demonstrate that both a subtelomeric transgene and var genes are subject to reversible gene silencing. Var gene silencing involves the SIR complex as gene disruption of PfSIR2 results in activation of this gene family. We also demonstrate that perinuclear gene activation involves chromatin alterations and repositioning into a location that may be permissive for transcription. Together, this implies that locus repositioning and heterochromatic silencing play important roles in the epigenetic regulation of virulence genes in P. falciparum.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Inst Pasteur, Paris, France; Univ Melbourne, Dept Med, Melbourne, Vic, Australia	Walter & Eliza Hall Institute; Monash University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Melbourne	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.	crabb@wehi.edu.au	Duffy, Michael/A-8618-2012; Scherf, Artur/A-9674-2014; Cowman, Alan F/C-7642-2013; Jackson, Allison/D-6528-2012; Crabb, Brendan/F-5287-2013; Freitas-Junior, Lucio H/C-8677-2011	Duffy, Michael/0000-0001-5635-4033; Cowman, Alan F/0000-0001-5145-9004; Jackson, Allison/0000-0002-9614-6471; Freitas-Junior, Lucio H/0000-0002-8904-7897; Scherf, Artur/0000-0003-2411-3328				Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; ASLUND L, 1985, J MOL BIOL, V185, P509, DOI 10.1016/0022-2836(85)90067-1; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Duffy MF, 2002, MOL MICROBIOL, V43, P1285, DOI 10.1046/j.1365-2958.2002.02822.x; DUFFY MF, 2005, IN PRESS MOL MICROB; Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096; Ersfeld K, 1998, CHROMOSOMA, V107, P237, DOI 10.1007/s004120050302; Feuerbach F, 2002, NAT CELL BIOL, V4, P214, DOI 10.1038/ncb756; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Figueiredo LM, 2000, MOL BIOCHEM PARASIT, V106, P169, DOI 10.1016/S0166-6851(99)00199-1; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gasser SM, 2001, CELL, V104, P639, DOI 10.1016/S0092-8674(01)00259-8; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Grewal SIS, 2000, J CELL PHYSIOL, V184, P311, DOI 10.1002/1097-4652(200009)184:3<311::AID-JCP4>3.0.CO;2-D; Henikoff S., 2000, BIOCHIM BIOPHYS ACTA, V1470, P01; Hsieh J, 2000, ANNU REV GENET, V34, P187, DOI 10.1146/annurev.genet.34.1.187; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Navarro M, 2001, NATURE, V414, P759, DOI 10.1038/414759a; O'Donnell RA, 2002, EMBO J, V21, P1231, DOI 10.1093/emboj/21.5.1231; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Skok JA, 2001, NAT IMMUNOL, V2, P848, DOI 10.1038/ni0901-848; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; TELFORD DJ, 1989, INT J BIOCHEM, V21, P127, DOI 10.1016/0020-711X(89)90100-6; Voss TS, 2003, MOL MICROBIOL, V48, P1593, DOI 10.1046/j.1365-2958.2003.03528.x	38	361	369	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					13	24		10.1016/j.cell.2005.01.036	http://dx.doi.org/10.1016/j.cell.2005.01.036			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820675	Bronze			2022-12-28	WOS:000228348500006
J	Marquardt, T; Shirasaki, R; Ghosh, S; Andrews, SE; Carter, N; Hunter, T; Pfaff, SL				Marquardt, T; Shirasaki, R; Ghosh, S; Andrews, SE; Carter, N; Hunter, T; Pfaff, SL			Coexpressed EphA receptors and ephrin-A ligands mediate opposing actions on growth cone navigation from distinct membrane domains	CELL			English	Article							MOTOR-NEURONS; AXON GUIDANCE; LIPID RAFTS; INTERMEDIATE TARGET; TYROSINE KINASES; FAMILY; MECHANISMS; MORPHOGENESIS; EXPRESSION; REQUIRES	Contact-dependent signaling between membrane-linked ligands and receptors such as the ephrins and Eph receptor tyrosine kinases controls a wide range of developmental and pathological processes. Paradoxically, many cell types coexpress both ligands and receptors, raising the question of how specific signaling readouts are achieved under these conditions. Here, we studied the signaling activities exerted by coexpressed EphA receptors and GPI-linked ephrin-A ligands in spinal motor neuron growth cones. We demonstrate that coexpressed Eph and ephrin proteins segregate laterally into distinct membrane domains from which they signal opposing effects on the growth cone: EphAs direct growth cone collapse/repulsion and ephrin-As signal motor axon growth/attraction. This subcellular arrangement of Eph-ephrin proteins enables axons to discriminate between cis- versus trans-configurations of ligand/receptor proteins, thereby allowing the utilization of both Ephs and ephrins as functional guidance receptors within the same neuronal growth cone.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	Salk Institute; Salk Institute	Pfaff, SL (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pfaff@salk.edu		Ghosh, Sourav/0000-0001-5990-8708	NATIONAL CANCER INSTITUTE [R01CA082683] Funding Source: NIH RePORTER; NCI NIH HHS [CA82683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RH, 2001, CELL, V104, P57, DOI 10.1016/S0092-8674(01)00191-X; Brittis PA, 2002, CELL, V110, P223, DOI 10.1016/S0092-8674(02)00813-9; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Carter N, 2002, NAT CELL BIOL, V4, P565, DOI 10.1038/ncb823; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Cutforth T, 2003, CELL, V114, P311, DOI 10.1016/S0092-8674(03)00568-3; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; Dravis C, 2004, DEV BIOL, V271, P272, DOI 10.1016/j.ydbio.2004.03.027; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Eberhart J, 2002, DEV BIOL, V247, P89, DOI 10.1006/dbio.2002.0695; Feng GP, 2000, NEURON, V25, P295, DOI 10.1016/S0896-6273(00)80895-8; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Gerety SS, 2002, DEVELOPMENT, V129, P1397; Godenschwege TA, 2002, NAT NEUROSCI, V5, P1294, DOI 10.1038/nn976; Guirland C, 2004, NEURON, V42, P51, DOI 10.1016/S0896-6273(04)00157-6; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Helmbacher F, 2000, DEVELOPMENT, V127, P3313; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Iwamasa H, 1999, DEV GROWTH DIFFER, V41, P685; Kamiguchi H, 2000, CURR OPIN CELL BIOL, V12, P598, DOI 10.1016/S0955-0674(00)00138-1; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; Knoll B, 2001, DEVELOPMENT, V128, P895; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Lemke G, 1997, MOL CELL NEUROSCI, V9, P331, DOI 10.1006/mcne.1997.0630; Manes S, 2003, TRENDS IMMUNOL, V24, P320, DOI 10.1016/S1471-4906(03)00137-6; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thaler J, 1999, NEURON, V23, P675, DOI 10.1016/S0896-6273(01)80027-1; Thaler JP, 2002, CELL, V110, P237, DOI 10.1016/S0092-8674(02)00823-1; VarelaEchavarria A, 1997, NEURON, V18, P193, DOI 10.1016/S0896-6273(00)80261-5; Wang XM, 1999, MOL CELL, V4, P903, DOI 10.1016/S1097-2765(00)80220-8; Yin Y, 2004, NEUROSCI RES, V48, P285, DOI 10.1016/j.neures.2003.11.009; Zimmer M, 2003, NAT CELL BIOL, V5, P869, DOI 10.1038/ncb1045	44	195	199	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					127	139		10.1016/j.cell.2005.01.020	http://dx.doi.org/10.1016/j.cell.2005.01.020			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820684	Bronze			2022-12-28	WOS:000228348500015
J	Ostermaier, R; Taut, M				Ostermaier, R; Taut, M			Medical mystery - 50 years of medical progress	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Asklepios Fachkliniken Munchen Gauting, D-82131 Gauting, Germany; Klin Tharandter Wald, D-09600 Niederschona, Germany		Ostermaier, R (corresponding author), Asklepios Fachkliniken Munchen Gauting, D-82131 Gauting, Germany.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1473	1473		10.1056/NEJMicm030528	http://dx.doi.org/10.1056/NEJMicm030528			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814883				2022-12-28	WOS:000228145200011
J	Goldenberg, NA; Jacobson, L; Manco-Johnson, MJ				Goldenberg, NA; Jacobson, L; Manco-Johnson, MJ			Brief communication: Duration of platelet dysfunction after a 1-day course of ibuprofen	ANNALS OF INTERNAL MEDICINE			English	Article							FUNCTION ANALYZER; BLEEDING-TIME; BLOOD-LOSS; ASPIRIN; PFA-100(TM); VOLUNTEERS; DRUGS	Background: Despite a paucity of evidence, clinicians routinely advise that patients discontinue using nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen, at least 1 week before most surgical procedures. Objective: To define the duration of ibuprofen-induced platelet dysfunction. Design: Prospective cohort study. Setting: Denver/Aurora, Colorado. Participants: 11 healthy adult volunteers. Measurements: individuals were tested at baseline and serially after completion of a 7-day course of ibuprofen (600 mg orally every 8 hours). The platelet function analyzer (PFA-100, Dade Behring, Newark, Delaware, a test that has replaced the bleeding time in many clinical settings, was used. Results: All participants exhibited normal platelet function before starting ibuprofen. Platelet dysfunction was apparent after completion of the ibuprofen course in 7 of the 11 participants and normalized by 24 hours after the last ibuprofen dose. Limitations: The sample size in this study was small, and no participants had a major illness. Correlation between PFA-100 results and clinical bleeding has not been established. Conclusions: Platelet function seems to normalize within 24 hours after cessation of regular ibuprofen use in healthy individuals. Further studies are warranted to provide a rational basis for timing of NSAID withdrawal in a range of patients undergoing surgery.	Univ Colorado, Hlth Sci Ctr, Mt States Hemophilia & Thrombosis Ctr, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Goldenberg, NA (corresponding author), Univ Colorado, Hlth Sci Ctr, Mt States Hemophilia & Thrombosis Ctr, POB 6507,Mail Stop F416, Aurora, CO 80045 USA.	neil.goidenberg@uchsc.edu						FERRARIS VA, 1983, SURG GYNECOL OBSTET, V156, P439; FERRARIS VA, 1988, ANN THORAC SURG, V45, P71, DOI 10.1016/S0003-4975(10)62401-0; Fressinaud E, 1998, BLOOD, V91, P1325, DOI 10.1182/blood.V91.4.1325; *I CLIN SYST IMPR, 2003, HLTH CAR GUID PREOP; Kadakia SC, 1996, GASTROINTEST ENDOSC, V44, P309, DOI 10.1016/S0016-5107(96)70170-0; Knijff-Dutmer EAJ, 2003, QJM-INT J MED, V96, P513, DOI 10.1093/qjmed/hcg090; KUNDU SK, 1995, SEMIN THROMB HEMOST, V21, P106; Leese PT, 2000, J CLIN PHARMACOL, V40, P124, DOI 10.1177/00912700022008766; Leese PT, 2002, AM J EMERG MED, V20, P275, DOI 10.1053/ajem.2002.32635; Mammen EF, 1998, SEMIN THROMB HEMOST, V24, P195, DOI 10.1055/s-2007-995840; Munsterhjelm E, 2003, BRIT J ANAESTH, V91, P357, DOI 10.1093/bja/aeg195; NADELL J, 1974, J CLIN PHARMACOL, V14, P176, DOI 10.1002/j.1552-4604.1974.tb01395.x; Peterson P, 1998, ARCH SURG-CHICAGO, V133, P134, DOI 10.1001/archsurg.133.2.134; Schafer AI, 2003, CIRCULATION, V108, P910, DOI 10.1161/01.CIR.0000088843.52678.8A; Sonksen JR, 1999, BRIT J ANAESTH, V82, P360, DOI 10.1093/bja/82.3.360; Spell NO, 2001, MED CLIN N AM, V85, P1117, DOI 10.1016/S0025-7125(05)70367-9; TOROSIAN M, 1978, ANN INTERN MED, V89, P325, DOI 10.7326/0003-4819-89-3-325; Wuillemin WA, 2002, SWISS MED WKLY, V132, P443	18	56	59	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 5	2005	142	7					506	509		10.7326/0003-4819-142-7-200504050-00009	http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913QL	15809462				2022-12-28	WOS:000228167800004
J	Fenton, KA; Mercer, CH; McManus, S; Erens, B; Wellings, K; Macdowall, W; Byron, CL; Copas, AJ; Nanchahal, K; Field, J; Johnson, AM				Fenton, KA; Mercer, CH; McManus, S; Erens, B; Wellings, K; Macdowall, W; Byron, CL; Copas, AJ; Nanchahal, K; Field, J; Johnson, AM			Ethnic variations in sexual behaviour in Great Britain and risk of sexually transmitted infections: a probability survey	LANCET			English	Article							HIV TRANSMISSION; GONORRHEA; LONDON; RACE; EPIDEMIOLOGY; PARTNERSHIPS; CHLAMYDIA; EDUCATION; PATTERNS; HEALTH	Background Ethnic variations in the rate of diagnosed sexually transmitted infections (STIs) have been reported in many developed countries. We used data from the second British National Survey of Sexual Attitudes and Lifestyles (Natsal 2000) to investigate the frequency of high-risk sexual behaviours and, adverse sexual health outcomes in five ethnic groups in Great Britain. Methods We did a stratified probability sample survey of 11161 men and women aged 16-44 years, resident in Great Britain, using computer-assisted interviews. Additional sampling enabled us to do more detailed analyses for 949 black Caribbean, black African, Indian, and Pakistani respondents. We used logistic regression to assess reporting of STI diagnoses in the past 5 years, after controlling for demographic and behavioural variables. Findings We rioted striking variations in number of sexual partnerships by ethnic group and between men and women. Reported numbers of sexual partnerships in a lifetime were highest in black Caribbean (median 9 [IQR 4-20]) and black African (9 [3-20]) men, and in white (5 [2-9]) and black Caribbean (4 [2-7]) women. Indian and Pakistani men and women reported fewer sexual partnerships, later first intercourse, and substantially lower prevalence of diagnosed STIs than did other groups. We recorded a significant association between ethnic origin and reported STIs in the past 5 years with increased risk in sexually active black Caribbean (OR 2.74 [95% CI 1.22-6.15]) and black African (2.95 [1.45-5.99]) men compared with white men, and black Caribbean (2.41 [1.35-4.28]) women compared with white women. odds ratios changed little after controlling for age, number of sexual partnerships, homosexual and overseas partnerships, and condom use at last sexual intercourse. Interpretation Individual sexual behaviour is a key determinant of STI transmission risk, but alone does not explain the varying risk across ethnic groups. Our findings suggest a need for targeted and culturally competent prevention interventions.	UCL, Ctr Sexual Hlth & HIV Res, Dept Primary Care & Populat Sci, London, England; Hlth Protect Agcy, Ctr Communicable Dis Surveillance, HIV & STI Dept, London, England; Natl Ctr Social Res, London, England; London Sch Hyg & Trop Med, Ctr Sexual & Reprod Hlth Res, London WC1, England	University of London; University College London; Health Protection Agency; University of London; London School of Hygiene & Tropical Medicine	Fenton, KA (corresponding author), Hlth Protect Agcy, Ctr Communicable Dis Surveillance, HIV & Sexually Transmitted Infect Dept, London NW9 5EQ, England.	Kevin.fenton@hpa.org.uk	McManus, Sally/S-4697-2019; McManus, Sally/HGD-4860-2022	McManus, Sally/0000-0003-2711-0819; Macdowall, Wendy/0000-0001-5868-8336; Copas, Andrew/0000-0001-8968-5963; Mercer, Catherine/0000-0002-4220-5034; Nanchahal, Kiran/0000-0001-8812-7628; Erens, Robert/0000-0002-3054-504X; Johnson, Anne/0000-0003-1330-7100; Erens, Bob/0000-0002-4430-954X				Aral SO, 2000, SEX TRANSM INFECT, V76, P415, DOI 10.1136/sti.76.6.415; Buzi RS, 1998, ADOLESCENCE, V33, P313; CHINOUYA M, 2000, SEXUAL ATTITUDES LIF; Choi KH, 2003, AIDS EDUC PREV, V15, P53, DOI 10.1521/aeap.15.1.5.53.23609; Cliffe S, 1999, Ethn Health, V4, P5; Copas AJ, 1997, AIDS, V11, P783, DOI 10.1097/00002030-199706000-00011; Department of Health, 2001, NAT STRAT SEX HLTH H, P1; Dodds JP, 2004, SEX TRANSM INFECT, V80, P236, DOI 10.1136/sti.2003.007286; Elam G., 1999, EXPLORING ETHNICITY, P1; Erens B, 2001, NATL SURVEY SEXUAL A; Fenton K, 1997, BRIT MED J, V314, P1703, DOI 10.1136/bmj.314.7096.1703; Fenton KA, 2001, SEX TRANSM INFECT, V77, P84, DOI 10.1136/sti.77.2.84; Fenton KA, 2001, AIDS, V15, P1442, DOI 10.1097/00002030-200107270-00017; Fenton KA, 2001, LANCET, V358, P1851, DOI 10.1016/S0140-6736(01)06886-6; Ghani AC, 1997, SEX TRANSM DIS, V24, P45, DOI 10.1097/00007435-199701000-00009; HOLMES KK, 1984, UROL CLIN N AM, V11, P3; HOOYKAAS C, 1991, GENITOURIN MED, V67, P378; Hughes G, 2001, SEX TRANSM DIS, V28, P379, DOI 10.1097/00007435-200107000-00004; *ISD SCIEH HLTH PR, 2003, REN FOC HIV OTH SEX; JAMES NJ, 1991, AIDS, V5, P333, DOI 10.1097/00002030-199103000-00016; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0; Johnson AM, 1994, SEXUAL ATTITUDES LIF; Jonsson M, 1997, INT J STD AIDS, V8, P501, DOI 10.1258/0956462971920659; Lacey CJN, 1997, BRIT MED J, V314, P1715, DOI 10.1136/bmj.314.7096.1715; LAUMANN EO, 2000, SEX TRANSM DIS, V26, P264; Low N, 2001, SEX TRANSM INFECT, V77, P15, DOI 10.1136/sti.77.1.15; Low N, 1997, BRIT MED J, V314, P1719, DOI 10.1136/bmj.314.7096.1719; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; McFarlane M, 1999, J ADOLESCENT HEALTH, V25, P199, DOI 10.1016/S1054-139X(98)00156-6; *OFF NAT STAT, 2000, POP EST 1999; Rogstad KE, 2004, BRIT MED J, V329, P214, DOI 10.1136/bmj.329.7459.214; Ross MW, 1998, SEX TRANSM INFECT, V74, P2; Santelli JS, 2000, AM J PUBLIC HEALTH, V90, P1582, DOI 10.2105/AJPH.90.10.1582; Sinka K, 2003, AIDS, V17, P1683, DOI 10.1097/00002030-200307250-00013; STATA, 2001, STAT STAT SOFTW REL; Stephenson JM, 2003, CONTROL CLIN TRIALS, V24, P643, DOI 10.1016/S0197-2456(03)00070-9; THOMAS JC, 2000, SOC SCI MED, V49, P1084; Wellings F, 2001, LANCET, V358, P1843, DOI 10.1016/S0140-6736(01)06885-4; Wight D, 2002, BMJ-BRIT MED J, V324, P1430, DOI 10.1136/bmj.324.7351.1430; Williams DR, 2002, AM J PUBLIC HEALTH, V92, P588, DOI 10.2105/AJPH.92.4.588	40	122	122	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2005	365	9466					1246	1255		10.1016/S0140-6736(05)74813-3	http://dx.doi.org/10.1016/S0140-6736(05)74813-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	912VI	15811458				2022-12-28	WOS:000228107600028
J	Baines, CP; Kaiser, RA; Purcell, NH; Blair, NS; Osinska, H; Hambleton, MA; Brunskill, EW; Sayen, MR; Gottlieb, RA; Dorn, GW; Robbins, J; Molkentin, JD				Baines, CP; Kaiser, RA; Purcell, NH; Blair, NS; Osinska, H; Hambleton, MA; Brunskill, EW; Sayen, MR; Gottlieb, RA; Dorn, GW; Robbins, J; Molkentin, JD			Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death	NATURE			English	Article							CYTOCHROME-C RELEASE; CYCLOSPORINE-A; LETHAL INJURY; PORE COMPLEX; BAX; APOPTOSIS; ISCHEMIA; TRANSLOCATOR; HEPATOCYTES; ACTIVATION	Mitochondria play a critical role in mediating both apoptotic and necrotic cell death. The mitochondrial permeability transition (mPT) leads to mitochondrial swelling, outer membrane rupture and the release of apoptotic mediators. The mPT pore is thought to consist of the adenine nucleotide translocator, a voltage-dependent anion channel, and cyclophilin D (the Ppif gene product), a prolyl isomerase located within the mitochondrial matrix(1,2). Here we generated mice lacking Ppif and mice overexpressing cyclophilin D in the heart. Ppif null mice are protected from ischaemia/reperfusion-induced cell death in vivo, whereas cyclophilin D-overexpressing mice show mitochondrial swelling and spontaneous cell death. Mitochondria isolated from the livers, hearts and brains of Ppif null mice are resistant to mitochondrial swelling and permeability transition in vitro. Moreover, primary hepatocytes and fibroblasts isolated from Ppif null mice are largely protected from Ca2+-overload and oxidative stress-induced cell death. However, Bcl-2 family member-induced cell death does not depend on cyclophilin D, and Ppif null fibroblasts are not protected from staurosporine or tumour-necrosis factor-alpha-induced death. Thus, cyclophilin D and the mitochondrial permeability transition are required for mediating Ca2+-and oxidative damage-induced cell death, but not Bcl-2 family member-regulated death.	Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Mol Genet, Cincinnati, OH 45229 USA; Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Med, Cincinnati, OH 45229 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Scripps Research Institute	Molkentin, JD (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA.	jeff.molkentin@cchmc.org		Baines, Christopher/0000-0002-4473-3869; Molkentin, Jeffery/0000-0002-3558-6529; Gottlieb, Roberta/0000-0002-1432-006X				Adams JW, 2000, CIRC RES, V87, P1180, DOI 10.1161/01.RES.87.12.1180; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Crompton M, 2003, CURR MED CHEM, V10, P1473, DOI 10.2174/0929867033457197; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; Halestrap A, 2005, NATURE, V434, P578, DOI 10.1038/434578a; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; IMBERTI R, 1993, J PHARMACOL EXP THER, V265, P392; Kagawa S, 2000, GENE THER, V7, P75, DOI 10.1038/sj.gt.3301048; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Li YM, 2004, BIOCHEM J, V383, P101, DOI 10.1042/BJ20040669; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petronilli V, 2001, J BIOL CHEM, V276, P12030, DOI 10.1074/jbc.M010604200; Qian T, 1997, AM J PHYSIOL-CELL PH, V273, pC1783, DOI 10.1152/ajpcell.1997.273.6.C1783; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030	27	1736	1797	8	172	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					658	662		10.1038/nature03434	http://dx.doi.org/10.1038/nature03434			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800627				2022-12-28	WOS:000228011000048
J	Oelschlaegel, T; Schwickart, M; Matos, J; Bogdanova, A; Camasses, A; Havlis, J; Shevchenko, A; Zachariae, W				Oelschlaegel, T; Schwickart, M; Matos, J; Bogdanova, A; Camasses, A; Havlis, J; Shevchenko, A; Zachariae, W			The yeast APC/C subunit Mnd2 prevents premature sister chromatid separation triggered by the meiosis-specific APC/C-Ama1	CELL			English	Article							ANAPHASE-PROMOTING COMPLEX; CHROMOSOME SEGREGATION; FISSION YEAST; CENTROMERIC COHESION; SPORE FORMATION; PROTEIN FAMILY; KINASE CDC5; CLEAVAGE; MITOSIS; PROTEOLYSIS	Cohesion established between sister chromatids during pre-meiotic DNA replication mediates two rounds of chromosome segregation. The first division is preceded by an extended prophase wherein homologous chromosomes undergo recombination. The persistence of cohesion during prophase is essential for recombination and both meiotic divisions. Here we show that Mnd2, a subunit of the anaphase-promoting complex (APC/C) from budding yeast, is essential to prevent premature destruction of cohesion in meiosis. During S- and prophase, Mnd2 prevents activation of the APC/C by a melosis-specific activator called Ama1. In cells lacking Mnd2 the APC/C-Ama1 enzyme triggers degradation of Pds1, which causes premature sister chromatid separation due to unrestrained separase activity. In vitro, Mnd2 inhibits ubiquitination of Pds1 by APC/C-Ama1 but not by other APC/C holo-enzymes. We conclude that chromosome segregation in meiosis depends on the selective inhibition of a meiosis-specific form of the APC/C.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Max Planck Society	Zachariae, W (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	Zachariae@mpi-cbg.de; Zachariae@mpi-cbg.de	Matos, Joao/C-1488-2014; Havlis, Jan/AAC-9525-2019; Havliš, Jan/D-9508-2012	Matos, Joao/0000-0002-3754-3709; Havlis, Jan/0000-0001-7822-2023; Havliš, Jan/0000-0001-7822-2023				Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Asakawa H, 2001, MOL GENET GENOMICS, V265, P424, DOI 10.1007/s004380000429; Benjamin KR, 2003, GENE DEV, V17, P1524, DOI 10.1101/gad.1101503; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Blanco MA, 2001, J CELL SCI, V114, P2135; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Camasses A, 2003, MOL CELL, V12, P87, DOI 10.1016/S1097-2765(03)00244-2; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; Chu T, 2001, GENESIS, V29, P141, DOI 10.1002/gene.1017; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Cooper KF, 2000, P NATL ACAD SCI USA, V97, P14548, DOI 10.1073/pnas.250351297; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Grosskortenhaus R, 2002, DEV CELL, V2, P29, DOI 10.1016/S1534-5807(01)00104-6; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Indjeian VB, 2005, SCIENCE, V307, P130, DOI 10.1126/science.1101366; Jacobs HW, 2002, CURR BIOL, V12, P1435, DOI 10.1016/S0960-9822(02)01074-6; Katis VL, 2004, CURR BIOL, V14, P560, DOI 10.1016/j.cub.2004.03.001; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; Kitajima TS, 2003, EMBO J, V22, P5643, DOI 10.1093/emboj/cdg527; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; KLAPHOLZ S, 1985, GENETICS, V110, P187; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Loidl J, 1998, METHOD CELL BIOL, V53, P257; Marston AL, 2004, SCIENCE, V303, P1367, DOI 10.1126/science.1094220; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Pfleger CM, 2001, GENE DEV, V15, P1759, DOI 10.1101/gad.897901; Rabitsch KP, 2001, CURR BIOL, V11, P1001, DOI 10.1016/S0960-9822(01)00274-3; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Reimann JDR, 2001, GENE DEV, V15, P3278, DOI 10.1101/gad.945701; Roeder GS, 2000, TRENDS GENET, V16, P395, DOI 10.1016/S0168-9525(00)02080-1; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Schwickart M, 2004, MOL CELL BIOL, V24, P3562, DOI 10.1128/MCB.24.8.3562-3576.2004; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; Toth A, 2000, CELL, V103, P1155, DOI 10.1016/S0092-8674(00)00217-8; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Watanabe Y, 2004, J CELL SCI, V117, P4017, DOI 10.1242/jcs.01352; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774; Yoon HJ, 2002, CURR BIOL, V12, P2048, DOI 10.1016/S0960-9822(02)01331-3; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	51	69	73	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					773	788		10.1016/j.cell.2005.01.032	http://dx.doi.org/10.1016/j.cell.2005.01.032			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797379	Bronze			2022-12-28	WOS:000228067500008
J	McGuire, JJ; Boettcher, MS; Jordan, TH				McGuire, JJ; Boettcher, MS; Jordan, TH			Foreshock sequences and short-term earthquake predictability on East Pacific Rise transform faults	NATURE			English	Article							AFTERSHOCK SEQUENCES; SLIP EVENT; SEISMICITY; PREDICTION	East Pacific Rise transform faults are characterized by high slip rates ( more than ten centimetres a year), predominately aseismic slip and maximum earthquake magnitudes of about 6.5. Using recordings from a hydroacoustic array deployed by the National Oceanic and Atmospheric Administration, we show here that East Pacific Rise transform faults also have a low number of aftershocks and high foreshock rates compared to continental strike-slip faults. The high ratio of foreshocks to aftershocks implies that such transform-fault seismicity cannot be explained by seismic triggering models in which there is no fundamental distinction between foreshocks, mainshocks and aftershocks. The foreshock sequences on East Pacific Rise transform faults can be used to predict ( retrospectively) earthquakes of magnitude 5.4 or greater, in narrow spatial and temporal windows and with a high probability gain. The predictability of such transform earthquakes is consistent with a model in which slow slip transients trigger earthquakes, enrich their low-frequency radiation and accommodate much of the aseismic plate motion.	Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA; MIT Woods Hole Oceanog Inst Joint Program, Woods Hole, MA 02543 USA; Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA	Woods Hole Oceanographic Institution; Massachusetts Institute of Technology (MIT); University of Southern California	McGuire, JJ (corresponding author), Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA.	jmcguire@whoi.edu	Jordan, Thomas/W-5579-2019	Jordan, Thomas/0000-0001-6511-148X; Boettcher, Margaret/0000-0002-5031-7116				Abercrombie RE, 2001, NATURE, V410, P74, DOI 10.1038/35065064; Abercrombie RE, 1996, NATURE, V381, P303, DOI 10.1038/381303a0; Aki K., 1981, EARTHQUAKE PRED RES, P556; Bird P, 2004, B SEISMOL SOC AM, V94, P2380, DOI 10.1785/0120030107; BIRD P, 2002, GEODYNAMICS, V30, P203; Boettcher MS, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2004JB003110; Bohnenstiehl DR, 2002, TECTONOPHYSICS, V354, P49, DOI 10.1016/S0040-1951(02)00289-5; BRUNE JN, 1968, J GEOPHYS RES, V73, P777, DOI 10.1029/JB073i002p00777; Dodge DA, 1996, J GEOPHYS RES-SOL EA, V101, P22371, DOI 10.1029/96JB02269; Dragert H, 2001, SCIENCE, V292, P1525, DOI 10.1126/science.1060152; Ekstrom G, 2003, PHYS EARTH PLANET IN, V136, P165, DOI 10.1016/S0031-9201(03)00030-X; Felzer KR, 2004, B SEISMOL SOC AM, V94, P88, DOI 10.1785/0120030069; Forsyth DW, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016454; FOX CG, 1995, GEOPHYS RES LETT, V22, P131, DOI 10.1029/94GL02059; Fox CG, 2001, J GEOPHYS RES-SOL EA, V106, P4183, DOI 10.1029/2000JB900404; Geller RJ, 1997, SCIENCE, V275, P1616, DOI 10.1126/science.275.5306.1616; Hanson JA, 1998, GEOPHYS RES LETT, V25, P365, DOI 10.1029/97GL53697; Helmstetter A, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018186; Helmstetter A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.058501; Helmstetter A, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB001991; Helmstetter A, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB001580; HELMSTETTER A, IN PRESS J GEOPHYS R; Helmstetter AS, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017670; Hirose H, 1999, GEOPHYS RES LETT, V26, P3237, DOI 10.1029/1999GL010999; IHMLE PF, 1994, SCIENCE, V266, P1547, DOI 10.1126/science.266.5190.1547; JONES LM, 1979, J GEOPHYS RES, V84, P3596, DOI 10.1029/JB084iB07p03596; KANAMORI H, 1976, PHYS EARTH PLANET IN, V11, P312, DOI 10.1016/0031-9201(76)90018-2; Kanamori H., 1974, Physics of the Earth and Planetary Interiors, V9, P128, DOI 10.1016/0031-9201(74)90029-6; Keilis-Borok V, 2004, PHYS EARTH PLANET IN, V145, P75, DOI 10.1016/j.pepi.2004.02.010; KISSLINGER C, 1991, J GEOPHYS RES-SOLID, V96, P11947, DOI 10.1029/91JB01200; McGuire JJ, 1996, SCIENCE, V274, P82, DOI 10.1126/science.274.5284.82; McGuire JJ, 2000, J GEOPHYS RES-SOL EA, V105, P7819, DOI 10.1029/1999JB900439; McGuire JJ, 2003, B SEISMOL SOC AM, V93, P948, DOI 10.1785/0120020151; Molchan GM, 1997, PURE APPL GEOPHYS, V149, P233, DOI 10.1007/BF00945169; OGATA Y, 1988, J AM STAT ASSOC, V83, P9, DOI 10.1080/01621459.1988.10478560; Ozawa S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016665; Ozawa S, 2002, SCIENCE, V298, P1009, DOI 10.1126/science.1076780; Perez-Campos X, 2003, J GEOPHYS RES-SOL EA, V108, P1, DOI 10.1029/2002JB002312; REASENBERG PA, 1994, SCIENCE, V265, P1251, DOI 10.1126/science.265.5176.1251; Reasenberg PA, 1999, J GEOPHYS RES-SOL EA, V104, P4755, DOI 10.1029/1998JB900089; REASENBERG PA, 1989, SCIENCE, V243, P1173, DOI 10.1126/science.243.4895.1173; Sandwell DT, 1997, J GEOPHYS RES-SOL EA, V102, P10039, DOI 10.1029/96JB03223; Smith DK, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL013912; YAMANAKA Y, 1990, J PHYS EARTH, V38, P305, DOI 10.4294/jpe1952.38.305	44	143	146	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					457	461		10.1038/nature03377	http://dx.doi.org/10.1038/nature03377			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791246				2022-12-28	WOS:000227836000031
J	Petersen, RC; Thomas, RG; Grundman, M; Bennett, D; Doody, R; Ferris, S; Galasko, D; Jin, S; Kaye, J; Levey, A; Pfeiffer, E; Sano, M; van Dyck, CH; Thal, LJ				Petersen, RC; Thomas, RG; Grundman, M; Bennett, D; Doody, R; Ferris, S; Galasko, D; Jin, S; Kaye, J; Levey, A; Pfeiffer, E; Sano, M; van Dyck, CH; Thal, LJ		Alzheimer's Dis Cooperative Study	Vitamin E and donepezil for the treatment of mild cognitive impairment	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY STANDARDS SUBCOMMITTEE; ALZHEIMER-DISEASE; PRACTICE PARAMETER; CONTROLLED-TRIAL; DEMENTIA; PLACEBO; HEALTH; RISK	BACKGROUND: Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease. METHODS: In a double-blind study, we evaluated subjects with the amnestic subtype of mild cognitive impairment. Subjects were randomly assigned to receive 2000 IU of vitamin E daily, 10 mg of donepezil daily, or placebo for three years. The primary outcome was clinically possible or probable Alzheimer's disease; secondary outcomes were cognition and function. RESULTS: A total of 769 subjects were enrolled, and possible or probable Alzheimer's disease developed in 212. The overall rate of progression from mild cognitive impairment to Alzheimer's disease was 16 percent per year. As compared with the placebo group, there were no significant differences in the probability of progression to Alzheimer's disease in the vitamin E group (hazard ratio, 1.02; 95 percent confidence interval, 0.74 to 1.41; P=0.91) or the donepezil group (hazard ratio, 0.80; 95 percent confidence interval, 0.57 to 1.13; P=0.42) during the three years of treatment. Prespecified analyses of the treatment effects at 6-month intervals showed that as compared with the placebo group, the donepezil group had a reduced likelihood of progression to Alzheimer's disease during the first 12 months of the study (P=0.04), a finding supported by the secondary outcome measures. Among carriers of one or more apolipoprotein E (epsilon)4 alleles, the benefit of donepezil was evident throughout the three-year follow-up. There were no significant differences in the rate of progression to Alzheimer's disease between the vitamin E and placebo groups at any point, either among all patients or among apolipoprotein E (epsilon)4 carriers. CONCLUSIONS: Vitamin E had no benefit in patients with mild cognitive impairment. Although donepezil therapy was associated with a lower rate of progression to Alzheimer's disease during the first 12 months of treatment, the rate of progression to Alzheimer's disease after three years was not lower among patients treated with donepezil than among those given placebo.	Mayo Clin & Mayo Fdn, Coll Med, Alzheimers Dis Res Ctr, Rochester, MN 55905 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Elan Pharmaceut, San Diego, CA USA; Rush Univ, Sch Med, Chicago, IL 60612 USA; Baylor Coll Med, Houston, TX 77030 USA; NYU, New York, NY USA; Oregon Hlth & Sci Univ, Portland, OR USA; Emory Univ, Atlanta, GA 30322 USA; Univ S Florida, Tampa, FL USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Yale Univ, New Haven, CT USA	Mayo Clinic; University of California System; University of California San Diego; Rush University; Baylor College of Medicine; New York University; Oregon Health & Science University; Emory University; State University System of Florida; University of South Florida; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Yale University	Petersen, RC (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Alzheimers Dis Res Ctr, 200 1st St SW, Rochester, MN 55905 USA.	peter8@mayo.edu	Hogan, David Bryan/I-4360-2013; Darvesh/AAG-2052-2019	Hogan, David Bryan/0000-0002-9462-5460; Darvesh/0000-0001-9881-7761; Kaye, Jeffrey/0000-0002-9971-3478; Ferris, Steven/0000-0001-8641-6223	NATIONAL INSTITUTE ON AGING [U01AG010483, U19AG010483] Funding Source: NIH RePORTER; NIA NIH HHS [UO1 AG10483, U19 AG010483] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Bennett DA, 2002, NEUROLOGY, V59, P198, DOI 10.1212/WNL.59.2.198; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; Ganguli M, 2004, NEUROLOGY, V63, P115, DOI 10.1212/01.WNL.0000132523.27540.81; Grundman M, 2004, ARCH NEUROL-CHICAGO, V61, P59, DOI 10.1001/archneur.61.1.59; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Lopez OL, 2003, ARCH NEUROL-CHICAGO, V60, P1385, DOI 10.1001/archneur.60.10.1385; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Morris MC, 2002, JAMA-J AM MED ASSOC, V287, P3230, DOI 10.1001/jama.287.24.3230; Morris MC, 2002, ARCH NEUROL-CHICAGO, V59, P1125, DOI 10.1001/archneur.59.7.1125; Petersen, 1999, ARCH NEUROL-CHICAGO, V56, P760; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V274, P538; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petersen RC, 2003, MILD COGNITIVE IMPAIRMENT: AGING TO ALZHEIMER'S DISEASE, P1; PETERSEN RC, 1995, JAMA-J AM MED ASSOC, V273, P1274, DOI 10.1001/jama.273.16.1274; Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; RIDOUT MS, 1991, BIOMETRICS, V47, P1617, DOI 10.2307/2532413; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Tierney MC, 1996, NEUROLOGY, V46, P149, DOI 10.1212/WNL.46.1.149; Zandi PP, 2004, ARCH NEUROL-CHICAGO, V61, P82, DOI 10.1001/archneur.61.1.82	24	1286	1385	1	118	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2005	352	23					2379	2388		10.1056/NEJMoa050151	http://dx.doi.org/10.1056/NEJMoa050151			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	933NL	15829527	Bronze			2022-12-28	WOS:000229638900004
J	Chiu, YL; Soros, VB; Kreisberg, JF; Stopak, K; Yonemoto, W; Greene, WC				Chiu, YL; Soros, VB; Kreisberg, JF; Stopak, K; Yonemoto, W; Greene, WC			RETRACTED: Cellular APOBEC3G restricts HIV-1 infection in resting CD4(+) T cells (Retracted Article. See vol 466, pg 276, 2010)	NATURE			English	Article; Retracted Publication							VIRUS TYPE-1 INFECTION; RNA EDITING ENZYME; VIF PROTEIN; DNA; HYPERMUTATION; REPLICATION; ACTIVATION; DEGRADATION; LYMPHOCYTES; BLOCKS	In contrast to activated CD4(+) T cells, resting human CD4(+) T cells circulating in blood are highly resistant to infection with human immunodeficiency virus (HIV)(1-4). Whether the inability of HIV to infect these resting CD4(+) T cells is due to the lack of a key factor, or alternatively reflects the presence of an efficient mechanism for defence against HIV, is not clear. Here we show that the anti-retroviral deoxycytidine deaminase APOBEC3G(5) strongly protects unstimulated peripheral blood CD4(+) T cells against HIV-1 infection. In activated CD4(+) T cells, cytoplasmic APOBEC3G resides in an enzymatically inactive, high-molecular-mass (HMM) ribonucleoprotein complex that converts to an enzymatically active low-molecular-mass (LMM) form after treatment with RNase. In contrast, LMM APOBEC3G predominates in unstimulated CD4(+) T cells, where HIV-1 replication is blocked and reverse transcription is impaired(1-3). Mitogen activation induces the recruitment of LMM APOBEC3G into the HMM complex, and this correlates with a sharp increase in permissivity for HIV infection in these stimulated cells. Notably, when APOBEC3G-specific small interfering RNAs are introduced into unstimulated CD4(+) T cells, the early replication block encountered by HIV-1 is greatly relieved. Thus, LMM APOBEC3G functions as a potent post-entry restriction factor for HIV-1 in unstimulated CD4(+) T cells. Surprisingly, sequencing of the reverse transcripts slowly formed in unstimulated CD4(+) T cells reveals only low levels of dG --> dA hypermutation, raising the possibility that the APOBEC3G-restricting activity may not be strictly dependent on deoxycytidine deamination.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Greene, WC (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94143 USA.	wgreene@gladstone.ucsf.edu						Anant S, 2001, CURR OPIN LIPIDOL, V12, P159, DOI 10.1097/00041433-200104000-00009; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Camaur D, 1996, J VIROL, V70, P6106, DOI 10.1128/JVI.70.9.6106-6111.1996; Eckstein DA, 2001, IMMUNITY, V15, P671, DOI 10.1016/S1074-7613(01)00217-5; Ganesh L, 2003, NATURE, V426, P853, DOI 10.1038/nature02171; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Pierson TC, 2002, J VIROL, V76, P8518, DOI 10.1128/JVI.76.17.8518-8513.2002; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Triques K, 2004, J VIROL, V78, P5523, DOI 10.1128/JVI.78.10.5523-5527.2004; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	30	370	386	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 5	2005	435	7038					108	114		10.1038/nature03493	http://dx.doi.org/10.1038/nature03493			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	922UL	15829920				2022-12-28	WOS:000228864600048
J	Gu, DF; Reynolds, K; Wu, XG; Chen, F; Duan, XF; Reynolds, RF; Whelton, PK; He, J				Gu, DF; Reynolds, K; Wu, XG; Chen, F; Duan, XF; Reynolds, RF; Whelton, PK; He, J		InterASIA Collaborative Grp	Prevalence of the metabolic syndrome and overweight among adults in China	LANCET			English	Article							REPUBLIC-OF-CHINA; CARDIOVASCULAR-DISEASES; BLOOD-PRESSURE; GLOBAL BURDEN; RISK-FACTORS; LIPOPROTEIN CHOLESTEROL; GEOGRAPHIC VARIATIONS; DIABETES-MELLITUS; NATIONAL-HEALTH; PART I	Background The metabolic syndrome and obesity are major risk factors for cardiovascular disease. Little information exists on the prevalence of the metabolic syndrome in China. We aimed to provide up-to-date estimates of the prevalence of the metabolic syndrome and overweight in the general adult population in China. Methods We did a cross-sectional survey in a nationally representative sample of 15 540 Chinese adults aged 35-74 years in 2000-01. Metabolic syndrome was defined according to guidelines from the US National Cholesterol Education Program. Overweight was defined as body-mass index of 25.0 kg/m(2) or greater. Findings The age-standardised prevalence of metabolic syndrome was 9.8% (95% CI 9.0-10.6) in men and 17.8% (16.6-19.0) in women. The age-standardised prevalence of overweight was 26.9% (25.7-28.1) in men and 31.1% (29.7-32.5) in women. The prevalence of the metabolic syndrome and overweight was higher in northern than in southern China, and higher in urban than rural residents. Interpretation Our results indicate that a large proportion of Chinese adults have the metabolic syndrome and that overweight has become an important public health problem in China. These findings emphasise the urgent need to develop national strategies for the prevention, detection, and treatment of overweight and the metabolic syndrome, to reduce the societal burden of cardiovascular disease in China.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA; Chinese Acad Med Sci, Cardiovasc Inst, Beijing 100037, Peoples R China; Chinese Acad Med Sci, Fuwai Hosp, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Pfizer Inc, New York, NY USA	Tulane University; Tulane University; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Pfizer	He, J (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave SL18, New Orleans, LA 70112 USA.	jhe@tulane.edu	He, Jiang/AAF-5303-2020; Reynolds, Kristi/AAN-1434-2021	He, Jiang/0000-0002-8286-9652; Reynolds, Kristi/0000-0001-7619-1649				*3 NAT HLTH NUTR E, 1994, VITAL HLTH STAT, V32, P1; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; ALLAIN CC, 1974, CLIN CHEM, V20, P470; Chen J, 2004, ANN INTERN MED, V140, P167, DOI 10.7326/0003-4819-140-3-200402030-00007; Chuang SY, 2002, ACTA CARDIOL SIN, V18, P16; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Ford ES, 2003, DIABETES CARE, V26, P575, DOI 10.2337/diacare.26.3.575; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Further Study Of Risk Factors For Stroke And Coronary Heart Disease group, 2002, Zhonghua Yu Fang Yi Xue Za Zhi, V36, P298; Gu D, 2003, DIABETOLOGIA, V46, P1190, DOI 10.1007/s00125-003-1167-8; Gu DF, 2002, HYPERTENSION, V40, P920, DOI 10.1161/01.HYP.0000040263.94619.D5; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; He J, 2004, CIRCULATION, V110, P405, DOI 10.1161/01.CIR.0000136583.52681.0D; HE J, 1995, STROKE, V26, P2222, DOI 10.1161/01.STR.26.12.2222; HUANG ZD, 1994, J HYPERTENS, V12, P1103; Ismail M N, 2002, Obes Rev, V3, P203, DOI 10.1046/j.1467-789X.2002.00074.x; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Krauss R M, 1998, Circulation, V98, P1472; Laaksonen DE, 2002, AM J EPIDEMIOL, V156, P1070, DOI 10.1093/aje/kwf145; Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709; Liese AD, 1998, EPIDEMIOL REV, V20, P157, DOI 10.1093/oxfordjournals.epirev.a017978; Lopez Alan D., 1993, World Health Statistics Quarterly, V46, P91; Meigs JB, 2002, AM J MANAG CARE, V8, pS283; MOON OR, 2002, OBES REV, V3, P191, DOI DOI 10.1046/J.1467-789X.2002.00073.X; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; MYERS GL, 1989, CLIN LAB MED, V9, P105, DOI 10.1016/S0272-2712(18)30645-0; *NIH, 1997, OBES RES S2, V6, pS51; Organization WH, 2000, WHO TECHN REP SER, DOI DOI 10.1016/J.BBI.2016.02.019; Pan XR, 1997, DIABETES CARE, V20, P1664, DOI 10.2337/diacare.20.11.1664; PERLOFF D, 1993, CIRCULATION, V88, P2460, DOI 10.1161/01.CIR.88.5.2460; Popkin BM, 2001, NUTR REV, V59, P379, DOI 10.1111/j.1753-4887.2001.tb06967.x; Popkin BM, 1998, NUTR REV, V56, P106; POPKIN BM, 1993, EUR J CLIN NUTR, V47, P333; POPKIN BM, 1995, AM J PUBLIC HEALTH, V85, P690, DOI 10.2105/AJPH.85.5.690; Reynolds K, 2003, J HYPERTENS, V21, P1273, DOI 10.1097/00004872-200307000-00014; Saw S. M., 1997, Annals Academy of Medicine Singapore, V26, P489; Tan CE, 1999, DIABETES CARE, V22, P241, DOI 10.2337/diacare.22.2.241; TAO SQ, 1995, CHINESE MED J-PEKING, V108, P483; Trevisan M, 1998, AM J EPIDEMIOL, V148, P958; *WHO W PAC REG INT, 2000, AS PAC PERSP RED OB; World Health Organization, DEF DIAGN CLASS DI 1; Wu XG, 1996, J HYPERTENS, V14, P1267, DOI 10.1097/00004872-199611000-00003; Wu ZS, 2001, CIRCULATION, V103, P462; Yao C, 1993, World Health Stat Q, V46, P113; Yoshiike N, 2002, Obes Rev, V3, P183, DOI 10.1046/j.1467-789X.2002.00070.x; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; ZHOU BF, 1995, INT J EPIDEMIOL, V24, P528, DOI 10.1093/ije/24.3.528; Zhou BF, 2002, BIOMED ENVIRON SCI, V15, P245; 2000, ARCH INTERN MED, V160, P898	52	735	889	1	95	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2005	365	9468					1398	1405		10.1016/S0140-6736(05)66375-1	http://dx.doi.org/10.1016/S0140-6736(05)66375-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836888				2022-12-28	WOS:000228401900028
J	Ronnow, HM; Parthasarathy, R; Jensen, J; Aeppli, G; Rosenbaum, TF; McMorrow, DF				Ronnow, HM; Parthasarathy, R; Jensen, J; Aeppli, G; Rosenbaum, TF; McMorrow, DF			Quantum phase transition of a magnet in a spin bath	SCIENCE			English	Article							SINGLET SYSTEM HOF3; DISORDERED MAGNET; TRANSVERSE FIELD; ISING-MODEL; STATE; BEHAVIOR; LIHOF4; HEAT	The excitation spectrum of a model magnetic system, LiHoF4, was studied with the use of neutron spectroscopy as the system was tuned to its quantum critical point by an applied magnetic field. The electronic mode softening expected for a quantum phase transition was forestalled by hyperfine coupling to the nuclear spins. We found that interactions with the nuclear spin bath controlled the length scale over which the excitations could be entangled. This generic result places a limit on our ability to observe intrinsic electronic quantum criticality.	ETH, Neutron Scattering Lab, CH-5232 Villigen, Switzerland; Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Phys, Chicago, IL 60637 USA; Riso Natl Lab, DK-4000 Roskilde, Denmark; Niels Bohr Inst fAPG, Orsted Lab, DK-2100 Copenhagen, Denmark; UCL, London Ctr Nanotechnol, London WC1E 6BT, England; UCL, Dept Phys & Astron, London WC1E 6BT, England; Rutherford Appleton Lab, ISIS, Didcot OX11 0QX, Oxon, England	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; University of Chicago; University of Chicago; Technical University of Denmark; University of Copenhagen; Niels Bohr Institute; University of London; University College London; University of London; University College London; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory	Ronnow, HM (corresponding author), ETH, Neutron Scattering Lab, CH-5232 Villigen, Switzerland.	henrik.ronnow@psi.ch	McMorrow, Desmond/C-2655-2008; Parthasarathy, Raghuveer/A-5958-2008; Jensen, Jens/C-7484-2015; McMorrow, Desmond Francis/M-9036-2019; Ronnow, Henrik M/A-4953-2009	McMorrow, Desmond/0000-0002-4947-7788; Parthasarathy, Raghuveer/0000-0002-6006-4749; Jensen, Jens/0000-0002-7954-8073; McMorrow, Desmond Francis/0000-0002-4947-7788; Ronnow, Henrik M/0000-0002-8832-8865				ANDRES K, 1973, PHYS REV B, V7, P4295, DOI 10.1103/PhysRevB.7.4295; Bitko D, 1996, PHYS REV LETT, V77, P940, DOI 10.1103/PhysRevLett.77.940; BITKO D, 1997, THESIS U CHICAGO; Brooke J, 1999, SCIENCE, V284, P779, DOI 10.1126/science.284.5415.779; Chakraborty PB, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.144411; DEGENNES PG, 1963, SOLID STATE COMMUN, V1, P132, DOI 10.1016/0038-1098(63)90212-6; ELLIOTT RJ, 1970, PHYS REV LETT, V25, P443, DOI 10.1103/PhysRevLett.25.443; FEYNMAN RP, 1963, ANN PHYS-NEW YORK, V24, P118, DOI 10.1016/0003-4916(63)90068-X; Gegenwart P, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.056402; Ghosh S, 2003, NATURE, V425, P48, DOI 10.1038/nature01888; Ghosh S, 2002, SCIENCE, V296, P2195, DOI 10.1126/science.1070731; Giraud R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.057203; JENSEN J, 1994, PHYS REV B, V49, P11833, DOI 10.1103/PhysRevB.49.11833; LEASK MJM, 1994, J PHYS-CONDENS MAT, V6, P505, DOI 10.1088/0953-8984/6/2/021; MAGARINO J, 1980, PHYS REV B, V21, P18, DOI 10.1103/PhysRevB.21.18; MENNENGA G, 1984, J MAGN MAGN MATER, V44, P59, DOI 10.1016/0304-8853(84)90047-7; Osterloh A, 2002, NATURE, V416, P608, DOI 10.1038/416608a; Prokof'ev NV, 2000, REP PROG PHYS, V63, P669, DOI 10.1088/0034-4885/63/4/204; RAMIREZ AP, 1994, J PHYS-CONDENS MAT, V6, pL215, DOI 10.1088/0953-8984/6/15/002; RONNOW HM, 2000, THESIS DENMARK; RONNOW HM, UNPUB; ROSENBAUM TF, 1991, J APPL PHYS, V70, P5946, DOI 10.1063/1.350087; Sachdev S, 1999, PHYS WORLD, V12, P33; Sachdev S., 1999, QUANTUM PHASE TRANSI; Stamp PCE, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.014401; STINCHCOMBE RB, 1973, J PHYS C SOLID STATE, V6, P2459, DOI 10.1088/0022-3719/6/15/009; Wernsdorfer W, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.197201; YOUNGBLOOD RW, 1982, PHYS REV LETT, V49, P1724, DOI 10.1103/PhysRevLett.49.1724	29	109	111	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 15	2005	308	5720					389	392		10.1126/science.1108317	http://dx.doi.org/10.1126/science.1108317			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831752	Green Accepted, Green Submitted			2022-12-28	WOS:000228492000045
J	Wiesel, E				Wiesel, E			Without conscience	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Boston, MA 02215 USA	Boston University	Wiesel, E (corresponding author), Boston Univ, Boston, MA 02215 USA.								0	35	35	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1511	1513		10.1056/NEJMp058069	http://dx.doi.org/10.1056/NEJMp058069			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829530				2022-12-28	WOS:000228324200001
J	Radcliffe, M; Scadding, G; Brown, HM				Radcliffe, M; Scadding, G; Brown, HM			Lupin flour anaphylaxis	LANCET			English	Editorial Material							ALLERGY; PEANUT; RISK		Royal Free Hosp, Royal Natl TNE Div, Allergy Clin, London WC1X 8DA, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Radcliffe, M (corresponding author), Royal Free Hosp, Royal Natl TNE Div, Allergy Clin, Grays Inn Rd, London WC1X 8DA, England.	mradcliffe@nhs.net						Gutierrez D, 1997, CONTACT DERMATITIS, V36, P311, DOI 10.1111/j.1600-0536.1997.tb00012.x; HEFLE SL, 1994, J ALLERGY CLIN IMMUN, V33, P256; Kanny G, 2000, REV MED INTERNE, V21, P191, DOI 10.1016/S0248-8663(00)88250-8; Matheu V, 1999, ANN ALLERG ASTHMA IM, V83, P406, DOI 10.1016/S1081-1206(10)62838-4; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883, DOI 10.1016/S0091-6749(99)70303-9	5	46	48	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1360	1360		10.1016/S0140-6736(05)61036-7	http://dx.doi.org/10.1016/S0140-6736(05)61036-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823389				2022-12-28	WOS:000228219600034
J	Harris, I; Mulford, J; Solomon, M; van Gelder, JM; Young, J				Harris, I; Mulford, J; Solomon, M; van Gelder, JM; Young, J			Association between compensation status and outcome after surgery - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BACK-PAIN; CARPAL-TUNNEL RELEASE; WORKERS-COMPENSATION; LUMBAR-DISK; NONCOMPENSATION PATIENTS; DISABILITY SYNDROMES; SURGICAL-MANAGEMENT; INTERBODY FUSION; SPINAL SURGERY; SECONDARY GAIN	Context Compensation, whether through workers' compensation or through litigation, has been associated with poor outcome after surgery; however, this association has not been examined by meta-analysis. Objective To investigate the association between compensation status and outcome after surgery. Data Sources We searched MEDLINE (1966-2003), EM BASE (1980-2003), CINAHL, the Cochrane Controlled Trials Register, and reference lists of retrieved articles and textbooks, and we contacted experts in the field. Study Selection The review included any trial of surgical intervention in which compensation status was reported and results were compared according to that status. No restrictions were placed on study design, language, or publication date. Studies were selected by 2 unblinded independent reviewers. Data Extraction Two reviewers independently extracted data on study type, study quality, surgical procedure, outcome, country of origin, length and completeness of follow-up, and compensation type. Data Synthesis Two hundred eleven studies satisfied the inclusion criteria. Of these, 175 stated that the presence of compensation (workers' compensation with or without litigation) was associated with a worse outcome, 35 found no difference or did not describe a difference, and 1 described a benefit associated with compensation. A meta-analysis of 129 studies with available data (n = 20 498 patients) revealed the summary odds ratio for an unsatisfactory outcome in compensated patients to be 3.79 (95% confidence interval, 3.28-4.37 by random-effects model). Grouping studies by country, procedure, length of follow-up, completeness of follow-up study type, and type of compensation showed the association to be consistent for all subgroups. Conclusions Compensation status is associated with poor outcome after surgery. This effect is significant, clinically important, and consistent. Because data were obtained from observational studies and were not homogeneous, the summary effect should be interpreted with caution. Compensation status should be considered a potential confounder in all studies of surgical intervention. Determination of the mechanism for this association requires further study.	Liverpool Hosp, Dept Orthopaed, Liverpool, NSW 2170, Australia; Curg Outcome Res Ctr, Camperdown, NSW, Australia; Univ New S Wales, Kensington, NSW 2033, Australia	Liverpool Hospital; University of New South Wales Sydney	Harris, I (corresponding author), Liverpool Hosp, Dept Orthopaed, Liverpool, NSW 2170, Australia.	iaharris@optushome.com.au		Solomon, Michael/0000-0002-5602-6045				Agazzi S, 1999, J NEUROSURG, V91, P186, DOI 10.3171/spi.1999.91.2.0186; ALQATTAN MM, 1994, J HAND SURG-BRIT EUR, V19B, P622, DOI 10.1016/0266-7681(94)90130-9; [Anonymous], COCHRANE REV MANAGER; [Anonymous], 1861, LANCET          0914, P255; Arcand MA, 2000, INT ORTHOP, V24, P61, DOI 10.1007/s002640000124; Asch HL, 2002, J NEUROSURG, V96, P34, DOI 10.3171/spi.2002.96.1.0034; Atlas SJ, 2000, J BONE JOINT SURG AM, V82A, P4, DOI 10.2106/00004623-200001000-00002; Baldwin ML, 1996, AM J IND MED, V29, P632; BEALS RK, 1984, WESTERN J MED, V140, P233; Bednar JM, 1998, CLIN ORTHOP RELAT R, P74; BIGOS SJ, 1994, J MUSCULOSKELETAL ME, V11, P17; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BREWIN CR, 1983, INJURY, V14, P451, DOI 10.1016/0020-1383(83)90097-9; Bryant B, 1997, MED SCI LAW, V37, P326, DOI 10.1177/002580249703700408; Buckley R, 2002, J BONE JOINT SURG AM, V84A, P1733, DOI 10.2106/00004623-200210000-00001; BUTLER RJ, 1983, SAFETY WORK FORCE, P61; Callaham ML, 1998, JAMA-J AM MED ASSOC, V280, P254, DOI 10.1001/jama.280.3.254; CARRON H, 1985, PAIN, V21, P77, DOI 10.1016/0304-3959(85)90079-X; Cassidy JD, 2000, NEW ENGL J MED, V342, P1179, DOI 10.1056/NEJM200004203421606; Cassidy JD, 2003, SPINE, V28, P1002, DOI 10.1097/00007632-200305150-00008; CASSISI JE, 1993, NEUROSURGERY, V33, P379; CHERINGTON M, 1992, NEUROLOGY, V42, P943, DOI 10.1212/WNL.42.5.943; DANSAK DA, 1973, COMPR PSYCHIAT, V14, P523, DOI 10.1016/0010-440X(73)90038-2; Dichraff R M, 1993, AAOHN J, V41, P491; DZIOBA RB, 1984, SPINE, V9, P614, DOI 10.1097/00007632-198409000-00013; Egger M, 2003, Health Technol Assess, V7, P1; ENTERLINE PE, 1966, ARCH ENVIRON HEALTH, V12, P467, DOI 10.1080/00039896.1966.10664408; Ferrari R, 2001, MED HYPOTHESES, V56, P77, DOI 10.1054/mehy.2000.1115; Fishbain DA, 1999, CLIN J PAIN, V15, P244, DOI 10.1097/00002508-199912000-00002; Greenough CG, 1998, SPINE, V23, P479, DOI 10.1097/00007632-199802150-00015; GREENOUGH CG, 1992, SPINE, V17, P36, DOI 10.1097/00007632-199201000-00006; GREENOUGH CG, 1994, CLIN ORTHOP RELAT R, P30; HADLER NM, 1995, SPINE, V20, P640, DOI 10.1097/00007632-199503150-00002; HALLOCK GG, 1995, PLAST RECONSTR SURG, V96, P941, DOI 10.1097/00006534-199509001-00027; HANLEY EN, 1989, J BONE JOINT SURG AM, V71A, P719, DOI 10.2106/00004623-198971050-00013; HANLEY EN, 1989, SPINE, V14, P48, DOI 10.1097/00007632-198901000-00009; HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012; Hattrup SJ, 2001, J SHOULDER ELB SURG, V10, P508, DOI 10.1067/mse.2001.118417; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hulsizer DL, 1998, J HAND SURG-AM, V23A, P865, DOI 10.1016/S0363-5023(98)80164-0; ISELIN F, 1984, B HOSP JOINT DIS ORT, V44, P233; JAVID MJ, 1988, SPINE, V13, P1428, DOI 10.1097/00007632-198812000-00017; JAVID MJ, 1992, J NEUROSURG, V76, P184, DOI 10.3171/jns.1992.76.2.0184; JEROSCH J, 1993, Z ORTHOP GRENZGEB, V131, P241, DOI 10.1055/s-2008-1040235; Katz JN, 1998, J HAND SURG-AM, V23A, P697, DOI 10.1016/S0363-5023(98)80058-0; Katz JN, 2001, ARTHRITIS RHEUM-US, V44, P1184, DOI 10.1002/1529-0131(200105)44:5<1184::AID-ANR202>3.3.CO;2-1; Klassen TP, 2002, ARCH PEDIAT ADOL MED, V156, P474, DOI 10.1001/archpedi.156.5.474; Klekamp J, 1998, J SPINAL DISORD, V11, P277; Kwan O, 2001, MED HYPOTHESES, V57, P459, DOI 10.1054/mehy.2001.1360; LeesHaley PR, 1997, ASSESSMENT, V4, P321, DOI 10.1177/107319119700400402; LEIGH JP, 1985, IND RELAT, V24, P247, DOI 10.1111/j.1468-232X.1985.tb00993.x; LITTLE DG, 1994, SPINE, V19, P2139, DOI 10.1097/00007632-199410000-00001; MacDermid JC, 2002, J CLIN EPIDEMIOL, V55, P849, DOI 10.1016/S0895-4356(02)00445-6; MACKAY MA, 1995, SPINE, V20, P1793, DOI 10.1097/00007632-199508150-00008; MARTIN LF, 1991, AM J SURG, V161, P625, DOI 10.1016/0002-9610(91)91244-D; MARTIN RD, 1974, J OCCUP ENVIRON MED, V16, P800, DOI 10.1097/00043764-197412000-00008; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0; MELZACK R, 1985, PAIN, V23, P101, DOI 10.1016/0304-3959(85)90052-1; Mendelson G, 1986, J Pain Symptom Manage, V1, P135, DOI 10.1016/S0885-3924(86)80062-8; Micheli LJ, 2001, CLIN J SPORT MED, V11, P223, DOI 10.1097/00042752-200110000-00003; MONT MA, 1994, CLIN ORTHOP RELAT R, P125; MRC Biostatistics Unit, WINBUGS; NOVAK CB, 1995, J HAND SURG-AM, V20A, P221, DOI 10.1016/S0363-5023(05)80011-5; Olney J R, 1999, Iowa Orthop J, V19, P111; PARKER N, 1977, MED J AUSTRALIA, V2, P318, DOI 10.5694/j.1326-5377.1977.tb99164.x; Pfeiffer M, 1996, Eur Spine J, V5, P299, DOI 10.1007/BF00304344; Quigley MR, 1998, SURG NEUROL, V49, P263, DOI 10.1016/S0090-3019(97)00448-5; RISH BL, 1984, SPINE, V9, P500, DOI 10.1097/00007632-198407000-00016; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; RUSER JW, 1985, RAND J ECON, V16, P487, DOI 10.2307/2555508; SALCEDOWASICEK MC, 1995, ARCH SURG-CHICAGO, V130, P29; Sanderson PL, 1999, EUR SPINE J, V8, P495, DOI 10.1007/s005860050212; Scholten-Peeters GGM, 2003, PAIN, V104, P303, DOI 10.1016/S0304-3959(03)00050-2; Schrader H, 1996, LANCET, V347, P1207, DOI 10.1016/S0140-6736(96)90733-3; SHAFFER JW, 1972, AM J PSYCHIAT, V129, P403, DOI 10.1176/ajp.129.4.403; Shinners TJ, 2002, ARTHROSCOPY, V18, P21, DOI 10.1053/jars.2002.26480; Spangehl MJ, 2002, J SHOULDER ELB SURG, V11, P101, DOI 10.1067/mse.2002.120915; Spiegelhalter D, 2004, BAYESIAN APPROACHES, P267; STRASBERG SR, 1994, ANN PLAS SURG, V32, P485, DOI 10.1097/00000637-199405000-00008; Taylor VM, 2000, SPINE, V25, P2445, DOI 10.1097/00007632-200010010-00005; TREGONNING GD, 1991, J BONE JOINT SURG BR, V73, P481, DOI 10.1302/0301-620X.73B3.1670454; Trimble M. R., 1981, POSTTRAUMATIC NEUROS; Vaccaro AR, 1997, SPINE, V22, P2030, DOI 10.1097/00007632-199709010-00018; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEIGHILL VE, 1983, J PSYCHOSOM RES, V27, P97, DOI 10.1016/0022-3999(83)90085-5; WETZEL FT, 1993, YALE J BIOL MED, V66, P263; WILLIAMS CW, 1993, PSYCHOL REP, V72, P483, DOI 10.2466/pr0.1993.72.2.483; Winspur I, 2001, J HAND SURG-BRIT EUR, V26, P409, DOI 10.1054/jhsb.2000.0517; WORRALL J, 1985, WORKERS COMPENSATION, P57; WORRALL JD, 1982, J RISK INSUR, V49, P361, DOI 10.2307/252492; WORRALL JD, 1987, CLIN CONCEPTS REGION, P281; Young JN, 1997, SURG NEUROL, V48, P552, DOI 10.1016/S0090-3019(97)00393-5	93	260	262	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2005	293	13					1644	1652		10.1001/jama.293.13.1644	http://dx.doi.org/10.1001/jama.293.13.1644			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	913EV	15811984				2022-12-28	WOS:000228135300027
J	Rother, RP; Bell, L; Hillmen, P; Gladwin, MT				Rother, RP; Bell, L; Hillmen, P; Gladwin, MT			The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin - A novel mechanism of human disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; SICKLE-CELL-DISEASE; CROSS-LINKED HEMOGLOBIN; PRIMARY PULMONARY-HYPERTENSION; NITRIC-OXIDE BIOAVAILABILITY; RECOMBINANT HUMAN HEMOGLOBIN; LOWER ESOPHAGEAL SPHINCTER; BETA-THALASSEMIA MAJOR; REGIONAL BLOOD-FLOW; PIG-A GENE	Context The efficient sequestration of hemoglobin by the red blood cell membrane and the presence of multiple hemoglobin clearance mechanisms suggest a critical need to prevent the buildup of this molecule in the plasma. A growing list of clinical manifestations attributed to hemoglobin release in a variety of acquired and iatrogenic hemolytic disorders suggests that hemolysis and hemoglobinemia should be considered as a novel mechanism of human disease. Evidence Acquisition Pertinent scientific literature databases and references were searched through October 2004 using terms that encompassed various aspects of hemolysis, hemoglobin preparations, clinical symptoms associated with plasma hemoglobin, nitric oxide in hemolysis, anemia, pulmonary hypertension, paroxysmal nocturnal hemoglobinuria, and sickle-cell disease. Evidence Synthesis Hemoglobin is released into the plasma from the erythrocyte during intravascular hemolysis in hereditary, acquired, and iatrogenic hemolytic conditions. When the capacity of protective hemoglobin-scavenging mechanisms has been saturated, levels of cell-free hemoglobin increase in the plasma, resulting in the consumption of nitric oxide and clinical sequelae. Nitric oxide plays a major role in vascular homeostasis and has been shown to be a critical regulator of basal and stress-mediated smooth muscle relaxation and vasomotor tone, endothelial adhesion molecule expression, and platelet activation and aggregation. Thus, clinical consequences of excessive cell-free plasma hemoglobin levels during intravascular hemolysis or the administration of hemoglobin preparations include dystonias involving the gastrointestinal, cardiovascular, pulmonary, and urogenital systems, as well as clotting disorders. Many of the clinical sequelae of intravascular hemolysis in a prototypic hemolytic disease, paroxysmal nocturnal hemoglobinuria, are readily explained by hemoglobin-mediated nitric oxide scavenging. Conclusion A growing body of evidence supports the existence of a novel mechanism of human disease, namely, hemolysis-associated smooth muscle dystonia, vasculopathy, and endothelial dysfunction.	Alexion Pharmaceut, Res, Cheshire, CT 06410 USA; Leeds Teaching Hosp NHS Trust, Dept Haematol, Leeds, W Yorkshire, England; NHLBI, Vasc Therapeut Sect, Cardiovasc Branch, Bethesda, MD 20892 USA; NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA	University of Leeds; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Rother, RP (corresponding author), Alexion Pharmaceut, Res, 352 Knotter Dr, Cheshire, CT 06410 USA.	rotherr@alxn.com; mgladwin@nih.gov			CLINICAL CENTER [Z01CL001174, Z01CL008070] Funding Source: NIH RePORTER	CLINICAL CENTER		Adedeji MO, 2001, ARCH PATHOL LAB MED, V125, P1436; Aessopos A, 2001, BLOOD, V97, P3411, DOI 10.1182/blood.V97.11.3411; Atichartakarn V, 2003, INT J HEMATOL, V78, P139, DOI 10.1007/BF02983382; AZIZI E, 1970, CLIN CHIM ACTA, V28, P391, DOI 10.1016/0009-8981(70)90063-X; Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; BIGNOLD LP, 1980, PATHOLOGY, V12, P169, DOI 10.3109/00313028009060070; Bortolotti M, 2002, EUR J CLIN INVEST, V32, P682, DOI 10.1046/j.1365-2362.2002.01059.x; BROEKMAN MJ, 1991, BLOOD, V78, P1033, DOI 10.1182/blood.V78.4.1033.bloodjournal7841033; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; Carmichael FJL, 2000, CRIT CARE MED, V28, P2283, DOI 10.1097/00003246-200007000-00017; Castro O, 2003, BLOOD, V101, P1257, DOI 10.1182/blood-2002-03-0948; Catani MV, 1998, BIOCHEM BIOPH RES CO, V249, P275, DOI 10.1006/bbrc.1998.9130; Chou R, 2001, AM J HEMATOL, V67, P197, DOI 10.1002/ajh.1107; CLARK DA, 1981, BLOOD, V57, P83; COIN JT, 1979, J BIOL CHEM, V254, P1178; Corbin JD, 2002, UROLOGY, V60, P4, DOI 10.1016/S0090-4295(02)01686-2; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DE CR, 1995, J CLIN INVEST, V96, P60; Deem S, 2002, CIRC RES, V91, P626, DOI 10.1161/01.RES.0000036268.47509.02; deFigueiredo LFP, 1997, J TRAUMA, V42, P847; Du ZD, 1997, AM HEART J, V134, P532, DOI 10.1016/S0002-8703(97)70091-7; Eberhardt RT, 2003, AM J HEMATOL, V74, P104, DOI 10.1002/ajh.10387; Eherer AJ, 2002, GUT, V50, P758, DOI 10.1136/gut.50.6.758; Erhart SM, 2000, ARTIF CELL BLOOD SUB, V28, P385, DOI 10.3109/10731190009118583; Fischer EG, 2000, ARCH PATHOL LAB MED, V124, P1813; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; GAULT MH, 1992, NEPHRON, V62, P267, DOI 10.1159/000187057; GEISSLER RG, 1995, INTERNIST, V36, P385; Gladwin MT, 2003, NAT MED, V9, P496, DOI 10.1038/nm0503-496; Gladwin MT, 2004, NEW ENGL J MED, V350, P886, DOI 10.1056/NEJMoa035477; Gladwin MT, 2003, CIRCULATION, V107, P271, DOI 10.1161/01.CIR.0000044943.12533.A8; Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160; GRISARU D, 1990, CHEST, V98, P1138, DOI 10.1378/chest.98.5.1138; Hahalis G, 2002, EUR HEART J, V23, P147, DOI 10.1053/euhj.2001.2709; Hall C, 2003, BLOOD, V102, P3587, DOI 10.1182/blood-2003-01-0009; HARTMANN RC, 1966, MEDICINE, V45, P331, DOI 10.1097/00005792-196609000-00001; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hayag-Barin JE, 1998, AM J HEMATOL, V57, P82, DOI 10.1002/(SICI)1096-8652(199801)57:1<82::AID-AJH15>3.0.CO;2-B; HEBBEL RP, 1985, CLIN HAEMATOL, V14, P129; HELLER PG, 1992, CHEST, V102, P642, DOI 10.1378/chest.102.2.642; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; Hill A, 2004, BLOOD, V104, p772A; Hillmen P, 2004, NEW ENGL J MED, V350, P552, DOI 10.1056/NEJMoa031688; HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904; Hirsch DP, 1998, GASTROENTEROLOGY, V115, P1374, DOI 10.1016/S0016-5085(98)70015-0; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; Jais X, 2003, HEMOGLOBIN, V27, P139, DOI 10.1081/HEM-120023377; Jardine DL, 2004, INTERN MED J, V34, P214, DOI 10.1111/j.1444-0903.2004.00580.x; Jison ML, 2004, BLOOD, V104, P270, DOI 10.1182/blood-2003-08-2760; Jison ML, 2003, AM J RESP CRIT CARE, V168, P3, DOI 10.1164/rccm.2304002; JUBELIRER SJ, 1991, ARCH INTERN MED, V151, P1221, DOI 10.1001/archinte.151.6.1221; Kannan M S, 1998, Indian J Pediatr, V65, P333; Kaul DK, 2004, J CLIN INVEST, V114, P1136, DOI 10.1172/JCI200421633; Kaul DK, 2000, AM J PHYSIOL-HEART C, V278, pH1799, DOI 10.1152/ajpheart.2000.278.6.H1799; Kayanoki Y, 1999, METABOLISM, V48, P1136, DOI 10.1016/S0026-0495(99)90127-0; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; Labrune P, 1999, EUR J PEDIATR, V158, P734, DOI 10.1007/s004310051190; LaMuraglia GM, 2000, J VASC SURG, V31, P299, DOI 10.1016/S0741-5214(00)90161-7; Lamy ML, 2000, ANESTHESIOLOGY, V92, P646, DOI 10.1097/00000542-200003000-00007; Langlois MR, 1996, CLIN CHEM, V42, P1589; LEE R, 1995, J APPL PHYSIOL, V79, P236, DOI 10.1152/jappl.1995.79.1.236; Liao JC, 1999, P NATL ACAD SCI USA, V96, P8757, DOI 10.1073/pnas.96.15.8757; Littera R, 2002, BLOOD, V100, P1516, DOI 10.1182/blood-2002-04-1171; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Manci EA, 2003, BRIT J HAEMATOL, V123, P359, DOI 10.1046/j.1365-2141.2003.04594.x; MCCARTHY JT, 1986, CHEST, V89, P608, DOI 10.1378/chest.89.4.608; Megson IL, 2000, BRIT J PHARMACOL, V131, P1391, DOI 10.1038/sj.bjp.0703731; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; Morris CR, 2003, AM J RESP CRIT CARE, V168, P63, DOI 10.1164/rccm.200208-967OC; Moyo VM, 2004, BRIT J HAEMATOL, V126, P133, DOI 10.1111/j.1365-2141.2004.04992.x; Murali B, 2003, BRIT J ANAESTH, V91, P739, DOI 10.1093/bja/aeg237; MURRAY JA, 1995, GASTROENTEROLOGY, V109, P1241, DOI 10.1016/0016-5085(95)90584-7; NAGEL RL, 1971, J BIOL CHEM, V246, P69; Nakai K, 1996, J CARDIOVASC PHARM, V28, P115, DOI 10.1097/00005344-199607000-00018; Nath KA, 2000, AM J PHYSIOL-REG I, V279, pR1949, DOI 10.1152/ajpregu.2000.279.6.R1949; NAUMANN HN, 1971, AM J CLIN PATHOL, V56, P137; Norris S L, 1992, J Assoc Acad Minor Phys, V3, P20; Olsen SB, 1996, CIRCULATION, V93, P327, DOI 10.1161/01.CIR.93.2.327; Olson JS, 2004, FREE RADICAL BIO MED, V36, P685, DOI 10.1016/j.freeradbiomed.2003.11.030; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Paquette RL, 1997, BRIT J HAEMATOL, V96, P92, DOI 10.1046/j.1365-2141.1997.d01-1984.x; Philippidis P, 2004, CIRC RES, V94, P119, DOI 10.1161/01.RES.0000109414.78907.F9; POHL U, 1991, BASIC RES CARDIOL, V86, P97; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Przybelski RJ, 1996, CRIT CARE MED, V24, P1993, DOI 10.1097/00003246-199612000-00011; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RAVEL R, 1995, CLIN LAB MED CLIN AP, P29; RAVEL R, 1995, CLIN LAB MED CLIN AP, P54; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; ROSSE WF, 2000, HEMATOLOGY BASIC PRI, P331; RUBIN H, 1971, J AMER MED ASSOC, V215, P433, DOI 10.1001/jama.215.3.433; Ryter SW, 2002, MOL CELL BIOCHEM, V234, P249, DOI 10.1023/A:1015957026924; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SAVITSKY JP, 1978, CLIN PHARMACOL THER, V23, P73; Saxena R, 1999, STROKE, V30, P993, DOI 10.1161/01.STR.30.5.993; Schafer A, 2004, CIRCULATION, V109, P1819, DOI 10.1161/01.CIR.0000126837.88743.DD; Schechter AN, 2003, NEW ENGL J MED, V348, P1483, DOI 10.1056/NEJMcibr023045; Schnog JJB, 2004, ANN HEMATOL, V83, P371, DOI 10.1007/s00277-004-0856-9; SEARS DA, 1970, J CLIN INVEST, V49, P5, DOI 10.1172/JCI106222; Sedlak TW, 2004, PEDIATRICS, V113, P1776, DOI 10.1542/peds.113.6.1776; Shao J, 2001, J AM SOC NEPHROL, V12, P2088, DOI 10.1681/ASN.V12102088; SIMIONATTO CS, 1988, AM J MED, V85, P538; SIMS PJ, 1989, J BIOL CHEM, V264, P19228; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Stewart GW, 1996, BRIT J HAEMATOL, V93, P303, DOI 10.1046/j.1365-2141.1996.4881033.x; STUARD ID, 1972, NEW ENGL J MED, V287, P869, DOI 10.1056/NEJM197210262871710; Studt JD, 2005, BLOOD, V105, P542, DOI 10.1182/blood-2004-06-2096; SUTTON LL, 1994, AM J CARDIOL, V74, P626, DOI 10.1016/0002-9149(94)90760-9; Suzuki H, 1997, TOHOKU J EXP MED, V181, P379, DOI 10.1620/tjem.181.379; TABBARA IA, 1992, MED CLIN N AM, V76, P649, DOI 10.1016/S0025-7125(16)30345-5; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Uchida T, 1998, Rinsho Ketsueki, V39, P150; Ulatowski JA, 1996, CRIT CARE MED, V24, P558, DOI 10.1097/00003246-199604000-00003; VALLA D, 1987, GASTROENTEROLOGY, V93, P569, DOI 10.1016/0016-5085(87)90920-6; VANLENTE F, 1981, CLIN CHEM, V27, P1453; VERRESEN D, 1991, EUR RESPIR J, V4, P629; Vichinsky EP, 2004, NEW ENGL J MED, V350, P857, DOI 10.1056/NEJMp038250; Viele MK, 1997, ANESTHESIOLOGY, V86, P848, DOI 10.1097/00000542-199704000-00015; VOGEL WM, 1986, AM J PHYSIOL, V251, pH413, DOI 10.1152/ajpheart.1986.251.2.H413; Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456; Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802; WIEDMER T, 1993, BLOOD, V82, P1192, DOI 10.1182/blood.V82.4.1192.bloodjournal8241192; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Zakynthinos E, 2001, THORAX, V56, P737, DOI 10.1136/thorax.56.9.737	127	1060	1096	4	64	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2005	293	13					1653	1662		10.1001/jama.293.13.1653	http://dx.doi.org/10.1001/jama.293.13.1653			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913EV	15811985	Bronze			2022-12-28	WOS:000228135300028
J	Kaufman, AJ				Kaufman, AJ			The calibration of Ediacaran time	SCIENCE			English	Editorial Material							SNOWBALL EARTH; CONSTRAINTS; AUSTRALIA; EVOLUTION; FOSSILS; OMAN; AGES		Univ Maryland, Dept Geol, College Pk, MD 20742 USA; Univ Maryland, Earth Sci Interdisciplinary Ctr, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Kaufman, AJ (corresponding author), Univ Maryland, Dept Geol, College Pk, MD 20742 USA.	kauf-man@geol.umd.edu						Amthor JE, 2003, GEOLOGY, V31, P431, DOI 10.1130/0091-7613(2003)031<0431:EOCANA>2.0.CO;2; BURNS SJ, 1993, ECLOGAE GEOL HELV, V86, P595; Calver CR, 2000, PRECAMBRIAN RES, V100, P121, DOI 10.1016/S0301-9268(99)00072-8; Chen JY, 2004, SCIENCE, V305, P218, DOI 10.1126/science.1099213; CHRISTIEBLICK N, 1990, AM J SCI, V290A, P295; Condon D, 2005, SCIENCE, V308, P95, DOI 10.1126/science.1107765; Corsetti FA, 2003, GEOL SOC AM BULL, V115, P916, DOI 10.1130/B25066.1; GROTZINGER JP, 1995, SCIENCE, V270, P598, DOI 10.1126/science.270.5236.598; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hoffman PF, 2002, TERRA NOVA, V14, P129, DOI 10.1046/j.1365-3121.2002.00408.x; Hoffmann KH, 2004, GEOLOGY, V32, P817, DOI 10.1130/G20519.1; KAUFMAN AJ, 2004, EOS T AGU S, V85; Knoll AH, 2004, SCIENCE, V305, P621, DOI 10.1126/science.1098803; Martin MW, 2000, SCIENCE, V288, P841, DOI 10.1126/science.288.5467.841; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318; Zhou CM, 2004, GEOLOGY, V32, P437, DOI 10.1130/G20286.1	16	7	8	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					59	60		10.1126/science.1111101	http://dx.doi.org/10.1126/science.1111101			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802590	Green Submitted			2022-12-28	WOS:000228221500028
J	Ma, JB; Yuan, YR; Meister, G; Pei, Y; Tuschl, T; Patel, DJ				Ma, JB; Yuan, YR; Meister, G; Pei, Y; Tuschl, T; Patel, DJ			Structural basis for 5 '-end-specific recognition of guide RNA by the A-fulgidus Piwi protein	NATURE			English	Article							CRYSTAL-STRUCTURE; ARGONAUTE2; MICRORNA; BINDING; INTERFERENCE; MECHANISMS; CLEAVAGE	RNA interference (RNAi) is a conserved sequence-specific gene regulatory mechanism(1-3) mediated by the RNA-induced silencing complex ( RISC), which is composed of a single-stranded guide RNA and an Argonaute protein. The PIWI domain, a highly conserved motif within Argonaute, has been shown to adopt an RNase H fold(4,5) critical for the endonuclease cleavage activity of RISC4-6. Here we report the crystal structure of Archaeoglobus fulgidus Piwi protein bound to double-stranded RNA, thereby identifying the binding pocket for guide-strand 5 '-end recognition and providing insight into guide-strand-mediated messenger RNA target recognition. The phosphorylated 5 ' end of the guide RNA is anchored within a highly conserved basic pocket, supplemented by the carboxy-terminal carboxylate and a bound divalent cation. The first nucleotide from the 5 ' end of the guide RNA is unpaired and stacks over a conserved tyrosine residue, whereas successive nucleotides form a four-base-pair RNA duplex. Mutation of the corresponding amino acids that contact the 5 ' phosphate in human Ago2 resulted in attenuated mRNA cleavage activity. Our structure of the Piwi-RNA complex, and that determined elsewhere(7), provide direct support for the 5 ' region of the guide RNA serving as a nucleation site for pairing with target mRNA and for a fixed distance separating the RISC-mediated mRNA cleavage site from the anchored 5 ' end of the guide RNA.	Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA; Rockefeller Univ, Lab RNA Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Rockefeller University	Patel, DJ (corresponding author), Mem Sloan Kettering Canc Ctr, Struct Biol Program, 1275 York Ave, New York, NY 10021 USA.	pateld@mskcc.org	Pei, Yi/D-8998-2011	Pei, Yi/0000-0002-3466-760X	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068776] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline; NIAID NIH HHS [R01 AI068776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lingel A, 2004, NAT STRUCT MOL BIOL, V11, P576, DOI 10.1038/nsmb777; Lingel A, 2003, NATURE, V426, P465, DOI 10.1038/nature02123; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Mallory AC, 2004, EMBO J, V23, P3356, DOI 10.1038/sj.emboj.7600340; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488; Rand TA, 2004, P NATL ACAD SCI USA, V101, P14385, DOI 10.1073/pnas.0405913101; Sagar MB, 2004, RNA, V10, P772, DOI 10.1261/rna.5266504; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Yan KS, 2003, NATURE, V426, P469, DOI 10.1038/nature02129; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3	29	468	511	4	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					666	670		10.1038/nature03514	http://dx.doi.org/10.1038/nature03514			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800629	Green Accepted			2022-12-28	WOS:000228011000050
J	Harrison, CJ; Corley, SB; Moylan, EC; Alexander, DL; Scotland, RW; Langdale, JA				Harrison, CJ; Corley, SB; Moylan, EC; Alexander, DL; Scotland, RW; Langdale, JA			Independent recruitment of a conserved developmental mechanism during leaf evolution	NATURE			English	Article							KNOTTED1-LIKE HOMEOBOX GENE; COMPOUND LEAF; ROUGH-SHEATH2 GENE; KNOX GENES; EXPRESSION; LEAVES; TOMATO; ARABIDOPSIS; PLANTS; PRIMORDIA	Vascular plants evolved in the Middle to Late Silurian period, about 420 million years ago(1). The fossil record indicates that these primitive plants had branched stems with sporangia but no leaves. Leaf-like lateral outgrowths subsequently evolved on at least two independent occasions(2-4). In extant plants, these events are represented by microphyllous leaves in lycophytes (clubmosses, spikemosses and quillworts) and megaphyllous leaves in euphyllophytes ( ferns, gymnosperms and angiosperms). Our current understanding of how leaves develop is restricted to processes that operate during megaphyll formation. Because microphylls and megaphylls evolved independently, different mechanisms might be required for leaf formation. Here we show that this is not so. Gene expression data from a microphyllous lycophyte, phylogenetic analyses, and a cross-species complementation experiment all show that a common developmental mechanism can underpin both microphyll and megaphyll formation. We propose that this mechanism might have operated originally in the context of primitive plant apices to facilitate bifurcation. Recruitment of this pathway to formleaves occurred independently and in parallel in different plant lineages.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England	University of Oxford	Langdale, JA (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	jane.langdale@plants.ox.ac.uk	Moylan, Elizabeth C/J-5611-2019; Langdale, Jane A./AAE-8343-2019	Langdale, Jane/0000-0001-7648-3924; Harrison, Jill/0000-0002-5228-600X	Biotechnology and Biological Sciences Research Council [G19201] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bharathan G, 2002, SCIENCE, V296, P1858, DOI 10.1126/science.1070343; BIERHORST DW, 1977, AM J BOT, V64, P125, DOI 10.2307/2442101; Boyce CK, 2002, PALEOBIOLOGY, V28, P70, DOI 10.1666/0094-8373(2002)028&lt;0070:EODPAT&gt;2.0.CO;2; Byrne ME, 2000, NATURE, V408, P967, DOI 10.1038/35050091; EDWARDS D, 1983, BOT J LINN SOC, V86, P19, DOI 10.1111/j.1095-8339.1983.tb00715.x; Gifford EM, 1989, MORPHOLOGY EVOLUTION; Golz JF, 2002, CURR BIOL, V12, P515, DOI 10.1016/S0960-9822(02)00721-2; Hareven D, 1996, CELL, V84, P735, DOI 10.1016/S0092-8674(00)81051-X; Hofer J, 2001, PLANT MOL BIOL, V45, P387, DOI 10.1023/A:1010739812836; JACKSON D, 1994, DEVELOPMENT, V120, P405; Janssen BJ, 1998, PLANT PHYSIOL, V117, P771, DOI 10.1104/pp.117.3.771; Kenrick P., 1997, ORIGIN EARLY DIVERSI; Kim M, 2003, DEVELOPMENT, V130, P4405, DOI 10.1242/dev.00655; Kim M, 2003, NATURE, V424, P438, DOI 10.1038/nature01820; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; McHale NA, 2004, PLANT CELL, V16, P1251, DOI 10.1105/tpc.019307; Muller J, 2001, PLANT J, V27, P13, DOI 10.1046/j.1365-313x.2001.01064.x; Nishimura A, 1999, PLANT J, V18, P337, DOI 10.1046/j.1365-313X.1999.00457.x; Parnis A, 1997, PLANT CELL, V9, P2143, DOI 10.1105/tpc.9.12.2143; Pautot W, 2001, PLANT CELL, V13, P1719, DOI 10.1105/tpc.13.8.1719; Schneeberger R, 1998, DEVELOPMENT, V125, P2857; Sentoku N, 1999, PLANT CELL, V11, P1651, DOI 10.1105/tpc.11.9.1651; SMITH LG, 1992, DEVELOPMENT, V116, P21; STEEVES TA, 1957, AM J BOT, V44, P665, DOI 10.2307/2438631; Theodoris G, 2003, P NATL ACAD SCI USA, V100, P6837, DOI 10.1073/pnas.1132113100; Timmermans MCP, 1999, SCIENCE, V284, P151, DOI 10.1126/science.284.5411.151; Tsiantis M, 2003, NAT REV GENET, V4, P169, DOI 10.1038/nrg1002; Tsiantis M, 1999, SCIENCE, V284, P154, DOI 10.1126/science.284.5411.154; Wikstrom N, 2001, P ROY SOC B-BIOL SCI, V268, P2211, DOI 10.1098/rspb.2001.1782	30	153	160	2	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					509	514		10.1038/nature03410	http://dx.doi.org/10.1038/nature03410			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791256				2022-12-28	WOS:000227836000043
J	Pincock, S				Pincock, S			Paul E Lacy - Obituary	LANCET			English	Biographical-Item												stephenpincock@blueyonder.co.uk		Pincock, Stephen/0000-0003-1655-2902					0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 19	2005	365	9464					1024	1024						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	907QB	15816074				2022-12-28	WOS:000227731800014
J	Oransky, I				Oransky, I			Sonja Buckley - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 12	2005	365	9463					932	932		10.1016/S0140-6736(05)71068-0	http://dx.doi.org/10.1016/S0140-6736(05)71068-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	905HS	15786567	Bronze			2022-12-28	WOS:000227559800013
J	Cummings, R				Cummings, R			Paediatric femoral fracture	LANCET			English	Editorial Material							EXTERNAL FIXATION; FEMUR FRACTURES; SHAFT FRACTURES; CHILDREN		Nemours Childrens Clin, Dept Surg, Div Orthopaed, Jacksonville, FL 32207 USA		Cummings, R (corresponding author), Nemours Childrens Clin, Dept Surg, Div Orthopaed, Jacksonville, FL 32207 USA.	jcumming@nemours.org						ARONSON J, 1992, J PEDIATR ORTHOPED, V12, P157, DOI 10.1097/01241398-199203000-00003; BarOn E, 1997, J BONE JOINT SURG BR, V79B, P975, DOI 10.1302/0301-620X.79B6.7740; ECKHOFF DG, 1994, J PEDIATR ORTHOPED, V14, P608, DOI 10.1097/01241398-199409000-00010; Flynn JM, 2001, J PEDIATR ORTHOPED, V21, P4, DOI 10.1097/01241398-200101000-00003; IRANI RN, 1976, J BONE JOINT SURG AM, V58, P945, DOI 10.2106/00004623-197658070-00009; Kanlic EM, 2004, CLIN ORTHOP RELAT R, P244, DOI 10.1097/01.blo.0000138961.34810.af; Sanders JO, 2001, J PEDIATR ORTHOPED, V21, P436, DOI 10.1097/00004694-200107000-00004; Stanitski D F, 1999, J Am Acad Orthop Surg, V7, P143; VERBEEK HOF, 1976, INJURY, V8, P43, DOI 10.1016/0020-1383(76)90009-7; WEBER B G, 1969, Injury, V1, P65, DOI 10.1016/S0020-1383(69)80034-3; Wong J, 2004, J PEDIATR ORTHOPED, V24, P463, DOI 10.1097/01241398-200409000-00003	11	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR-APR	2005	365	9465					1116	1117		10.1016/S0140-6736(05)71855-9	http://dx.doi.org/10.1016/S0140-6736(05)71855-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	910DD	15794953				2022-12-28	WOS:000227909500006
J	Li, QS; Duan, LJ; Estes, JD; Ma, ZM; Rourke, T; Wang, YC; Reilly, C; Carlis, J; Miller, CJ; Haase, AT				Li, QS; Duan, LJ; Estes, JD; Ma, ZM; Rourke, T; Wang, YC; Reilly, C; Carlis, J; Miller, CJ; Haase, AT			Peak SIV replication in resting memory CD4(+) T cells depletes gut lamina propria CD4(+) T cells	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GASTROINTESTINAL-TRACT; HIV-1 INFECTION; RHESUS MACAQUES; LYMPHOCYTES; TRANSMISSION; FAS; EXPRESSION; APOPTOSIS; LEU-23	In early simian immunodeficiency virus (SIV) and human immunodeficiency virus-1 (HIV-1) infections, gut-associated lymphatic tissue (GALT), the largest component of the lymphoid organ system(1), is a principal site of both virus production and depletion of primarily lamina propria memory CD4(+) T cells; that is, CD4-expressing T cells that previously encountered antigens and microbes and homed to the lamina propria of GALT(2-9). Here, we show that peak virus production in gut tissues of SIV-infected rhesus macaques coincides with peak numbers of infected memory CD4(+) T cells. Surprisingly, most of the initially infected memory cells were not, as expected(10,11), activated but were instead immunophenotypically 'resting' cells that, unlike truly resting cells, but like the first cells mainly infected at other mucosal sites and peripheral lymph nodes(12,13), are capable of supporting virus production. In addition to inducing immune activation and thereby providing activated CD4(+) T-cell targets to sustain infection, virus production also triggered(14) an immunopathologically limiting Fas-Fas-ligand-mediated apoptotic pathway(15,16) in lamina propria CD4(+) T cells, resulting in their preferential ablation. Thus, SIV exploits a large, resident population of resting memory CD4(+) T cells in GALT to produce peak levels of virus that directly (through lytic infection) and indirectly ( through apoptosis of infected and uninfected cells) deplete CD4(+) T cells in the effector arm of GALT. The scale of this CD4(+) T-cell depletion has adverse effects on the immune system of the host, underscoring the importance of developing countermeasures to SIV that are effective before infection of GALT.	Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Technol, Dept Comp Sci & Engn, Minneapolis, MN 55455 USA; Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Div Infect Dis, Davis, CA 95616 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Haase, AT (corresponding author), Univ Minnesota, Sch Med, Dept Microbiol, MMC 196,420 Delaware St SE, Minneapolis, MN 55455 USA.	haase001@umn.edu						Boirivant M, 1996, J CLIN INVEST, V98, P2616, DOI 10.1172/JCI119082; Boirivant M, 1998, J CLIN IMMUNOL, V18, P39, DOI 10.1023/A:1023235803948; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Clayton F, 1997, CLIN EXP IMMUNOL, V107, P288, DOI 10.1111/j.1365-2249.1997.236-ce1111.x; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Kewenig S, 1999, GASTROENTEROLOGY, V116, P1115, DOI 10.1016/S0016-5085(99)70014-4; LIM SG, 1993, CLIN EXP IMMUNOL, V92, P448, DOI 10.1111/j.1365-2249.1993.tb03419.x; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; MILLER CJ, 1994, J VIROL, V68, P6391, DOI 10.1128/JVI.68.10.6391-6400.1994; MILLER CJ, UNPUB J VIROL; Mothe BR, 2002, J VIROL, V76, P875, DOI 10.1128/JVI.76.2.875-884.2002; Mowat AM, 1997, IMMUNOL REV, V156, P145, DOI 10.1111/j.1600-065X.1997.tb00966.x; Phillips AN, 1996, SCIENCE, V271, P497, DOI 10.1126/science.271.5248.497; Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847; POPPEMA S, 1991, AM J PATHOL, V139, P725; Reilly C, 2002, J AM STAT ASSOC, V97, P943, DOI 10.1198/016214502388618735; REYNOLDS MR, IN PRESS J VIROL; SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524; TESTI R, 1989, J IMMUNOL, V142, P1854; TESTI R, 1988, J IMMUNOL, V141, P2557; Veazey Ronald, 2003, AIDS Rev, V5, P245; Veazey RS, 2000, J VIROL, V74, P57, DOI 10.1128/JVI.74.1.57-64.2000; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zhang ZQ, 2004, P NATL ACAD SCI USA, V101, P5640, DOI 10.1073/pnas.0308425101	26	755	788	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 28	2005	434	7037					1148	1152		10.1038/nature03513	http://dx.doi.org/10.1038/nature03513			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	920MD	15793562				2022-12-28	WOS:000228693300047
J	Honda, K; Ohba, Y; Yanai, H; Negishi, H; Mizutani, T; Takaoka, A; Taya, C; Taniguchi, T				Honda, K; Ohba, Y; Yanai, H; Negishi, H; Mizutani, T; Takaoka, A; Taya, C; Taniguchi, T			Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction	NATURE			English	Article							CPG-DNA; BACTERIAL-DNA; CELLS; ACTIVATION; RECOGNITION; ENDOCYTOSIS; ALPHA/BETA; EXPRESSION; MOTIFS; MYD88	Robust type-I interferon (IFN-alpha/beta) induction in plasmacytoid dendritic cells, through the activation of Toll-like receptor 9 (TLR9), constitutes a critical aspect of immunity(1-6). It is absolutely dependent on the transcription factor IRF-7, which interacts with and is activated by the adaptor MyD88 (ref. 7). How plasmacytoid dendritic cells, but not other cell types (such as conventional dendritic cells), are able to activate the MyD88 IRF-7-dependent IFN induction pathway remains unknown. Here we show that the spatiotemporal regulation of MyD88 IRF-7 signalling is critical for a high-level IFN induction in response to TLR9 activation. The IFN-inducing TLR9 ligand, A/D-type CpG oligodeoxynucleotide (CpG-A)(3,4,8-11), is retained for long periods in the endosomal vesicles of plasmacytoid dendritic cells, together with the MyD88-IRF-7 complex. However, in conventional dendritic cells, CpG-A is rapidly transferred to lysosomal vesicles. We further show that conventional dendritic cells can also mount a robust IFN induction if CpG-A is manipulated for endosomal retention using a cationic lipid. This strategy also allows us to demonstrate endosomal activation of the IFN pathway by the otherwise inactive TLR9 ligand B/K-type oligodeoxynucleotide (CpG-B)(3,4,8-12). Thus, our study offers insights into the regulation of TLR9 signalling in space, potentially suggesting a new avenue for therapeutic intervention.	Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; JST, PRESTO, Informat & Cell Funct, Kawaguchi, Saitama 3320012, Japan; Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Bunkyo Ku, Tokyo 1138613, Japan	University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science	Taniguchi, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	tada@m.u-tokyo.ac.jp	Mizutani, Tatsuaki/AAA-5044-2021; Ohba, Yusuke/E-7944-2011; Honda, Kenya/N-5297-2015; Serei, Virian D/B-4616-2015; Yanai, Hideyuki/AGK-5933-2022	Mizutani, Tatsuaki/0000-0002-4323-4347; Yanai, Hideyuki/0000-0002-0115-9000; Honda, Kenya/0000-0001-8937-9835				Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466; Brunetti CR, 1998, J VIROL, V72, P3330, DOI 10.1128/JVI.72.4.3330-3339.1998; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2003, J IMMUNOL, V170, P3059, DOI 10.4049/jimmunol.170.6.3059; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; HONDA K, 2005, NATURE          0330, DOI DOI 10.1038/NATURE03464; Izaguirre A, 2003, J LEUKOCYTE BIOL, V74, P1125, DOI 10.1189/jlb.0603255; Kerkmann M, 2003, J IMMUNOL, V170, P4465, DOI 10.4049/jimmunol.170.9.4465; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Ronnblom L, 2003, ARTHRITIS RES THER, V5, P68, DOI 10.1186/ar625; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Verthelyi D, 2001, J IMMUNOL, V166, P2372, DOI 10.4049/jimmunol.166.4.2372; Wagner H, 2004, TRENDS IMMUNOL, V25, P381, DOI 10.1016/j.it.2004.04.011; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997	30	695	731	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	2005	434	7036					1035	1040		10.1038/nature03547	http://dx.doi.org/10.1038/nature03547			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	918EH	15815647				2022-12-28	WOS:000228524600042
J	Merkel, PA; Lo, GH; Holbrook, JT; Tibbs, AK; Allen, NB; Davis, JC; Hoffman, GS; McCune, J; St Clair, EW; Specks, U; Spiera, R; Petri, M; Stone, JH				Merkel, PA; Lo, GH; Holbrook, JT; Tibbs, AK; Allen, NB; Davis, JC; Hoffman, GS; McCune, J; St Clair, EW; Specks, U; Spiera, R; Petri, M; Stone, JH		Wegner's Granul Etane Tria Res Grp	Brief communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis: The Wegener's clinical occurrence of thrombosis (WeCLOT) study	ANNALS OF INTERNAL MEDICINE			English	Article							VEIN-THROMBOSIS; LONG-TERM; COHORT; INDEX	Background: venous thrombotic events (VTEs) have been observed in Wegener granulomatosis, but the incidence rate is not known. Objective: To measure the incidence of VTEs in patients with Wegener granulomatosis. Design: Prospective, observational cohort study. Setting: A multicenter, randomized, double-blind, placebo-controlled treatment trial for Wegener granulomatosis. Patients: 180 patients with Wegener granulomatosis enrolled during periods of active disease. Measurements: venous thrombotic events (deep venous thromboses or pulmonary emboli) were documented and confirmed prospectively. Incidence rates were calculated on the basis of time to first VTE. Results: Thirteen patients had VTEs before enrollment. During 228 person-years of prospective follow-up, 16 VTEs occurred in 167 patients with no history of VTE. Median time from enrollment to VTE for patients with an event was 2.1 months. The incidence of VTE among patients with Wegener granulomatosis was 7.0 per 100 person-years (95% Cl, 4.0 to 11.4). Limitations: Although prospectively recorded, screening for VTEs did not occur. Conclusions: The incidence rate of VTEs in Wegener granulomatosis is high when compared with available rates in the general population, patients with lupus, and patients with rheumatoid arthritis. These results have important implications for clinical care of patients with Wegener granulomatosis.	Boston Univ, Sch Med, Vasculitis Ctr, Boston, MA 02118 USA; Johns Hopkins Univ, Baltimore, MD 21218 USA; Duke Univ, Durham, NC 27706 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Beth Israel Deaconess Med Ctr, New York, NY 10003 USA	Boston University; Johns Hopkins University; Duke University; University of California System; University of California San Francisco; Cleveland Clinic Foundation; University of Michigan System; University of Michigan; Mayo Clinic; Harvard University; Beth Israel Deaconess Medical Center	Merkel, PA (corresponding author), Boston Univ, Sch Med, Vasculitis Ctr, E-5,715 Albany St, Boston, MA 02118 USA.	pmerkel@bu.edu	Hug, Balthasar L./G-1568-2010; Spiera, Robert/W-7479-2019		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042, M01RR002719, M01RR000533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR002224, N01AR092240, K24AR049185, P60AR047785] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RRO-0042, M01-RRO-2719, M01-RRO-00533, M01-RR-30] Funding Source: Medline; NIAMS NIH HHS [AR2224, AR47785, K24 AR2224-01A1, K24 AR049185-01, N01-AR-9-2240] Funding Source: Medline; FDA HHS [FD-R-001652-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FDA HHS		Exley AR, 1997, ARTHRITIS RHEUM, V40, P371, DOI 10.1002/art.1780400222; Hansen KE, 1999, ARTHRITIS RHEUM, V42, P2250, DOI 10.1002/1529-0131(199910)42:10<2250::AID-ANR32>3.0.CO;2-7; Hansson PO, 1997, ARCH INTERN MED, V157, P1665, DOI 10.1001/archinte.157.15.1665; Hoff G, 2001, ICSD '01: PROCEEDINGS OF THE 2001 IEEE 7TH INTERNATIONAL CONFERENCE ON SOLID DIELECTRICS, P381, DOI 10.1109/ICSD.2001.955664; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hopkins J, 2003, ARTHRITIS RHEUM-US, V48, P2299, DOI 10.1002/art.11075; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; MICKLE JP, 1977, J NEUROSURG, V46, P248, DOI 10.3171/jns.1977.46.2.0248; PETRI M, 1991, ARTHRITIS RHEUM, V34, P937, DOI 10.1002/art.1780340802; PETRI M, 1992, J RHEUMATOL, V19, P53; Petri M, 2000, RHEUM DIS CLIN N AM, V26, P199, DOI 10.1016/S0889-857X(05)70135-6; Reinhold-Keller E, 2000, ARTHRITIS RHEUM, V43, P1021, DOI 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; Stone JH, 2005, NEW ENGL J MED, V352, P351; Stone JH, 2002, CONTROL CLIN TRIALS, V23, P450; Stone JH, 2001, ARTHRITIS RHEUM, V44, P912, DOI 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5; Von Scheven E, 2003, ARTHRIT RHEUM-ARTHR, V49, P862, DOI 10.1002/art.11454	17	224	236	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					620	626		10.7326/0003-4819-142-8-200505030-00011	http://dx.doi.org/10.7326/0003-4819-142-8-200505030-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916TZ	15838068				2022-12-28	WOS:000228410400004
J	Chen, EH; Olson, EN				Chen, EH; Olson, EN			Unveiling the mechanisms of cell-cell fusion	SCIENCE			English	Review							MYOBLAST FUSION; IMMUNOGLOBULIN SUPERFAMILY; MEMBRANE-FUSION; MYELOMONOCYTIC CELLS; PLASMA-MEMBRANE; STEM-CELLS; BLOWN-FUSE; PROTEIN; SPERM; EGG	Cell-cell fusion is fundamental to the development and physiology of multicellular organisms, but little is known of its mechanistic underpinnings. Recent studies have revealed that many proteins involved in cell-cell fusion are also required for seemingly unrelated cellular processes such as phagocytosis, cell migration, axon growth, and synaptogenesis. We review advances in understanding cell-cell fusion by contrasting it with virus-cell and intracellular vesicle fusion. We also consider how proteins involved in general aspects of membrane dynamics have been co-opted to control fusion of diverse cell types by coupling with specialized proteins involved in cell-cell recognition, adhesion, and signaling.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chen, EH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	echen@jhmi.edu; eric.olson@utsouthwestern.edu						Abmayr SM, 2003, INT REV CYTOL, V225, P33, DOI 10.1016/S0074-7696(05)25002-7; Anderson JM, 2000, CURR OPIN HEMATOL, V7, P40, DOI 10.1097/00062752-200001000-00008; Artero RD, 2001, DEVELOPMENT, V128, P4251; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bell DR, 2004, ONCOGENE, V23, P7290, DOI 10.1038/sj.onc.1207949; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Blau HM, 1999, SEMIN CELL DEV BIOL, V10, P267, DOI 10.1006/scdb.1999.0311; Blond JL, 2000, J VIROL, V74, P3321, DOI 10.1128/JVI.74.7.3321-3329.2000; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Bour BA, 2000, GENE DEV, V14, P1498; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Camargo FD, 2004, J CLIN INVEST, V113, P1266, DOI 10.1172/JCI200421301; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Camargo FD, 2004, CELL PROLIFERAT, V37, P55, DOI 10.1111/j.1365-2184.2004.00300.x; Chen EH, 2004, TRENDS CELL BIOL, V14, P452, DOI 10.1016/j.tcb.2004.07.008; Chen EH, 2001, DEV CELL, V1, P705, DOI 10.1016/S1534-5807(01)00084-3; Chen EH, 2003, CELL, V114, P751, DOI 10.1016/S0092-8674(03)00720-7; Cho CH, 2000, DEV BIOL, V222, P289, DOI 10.1006/dbio.2000.9703; Daley GQ, 2004, NAT MED, V10, P671, DOI 10.1038/nm0704-671; del Campo JJ, 2005, CURR BIOL, V15, P413, DOI 10.1016/j.cub.2005.01.054; Doberstein SK, 1997, J CELL BIOL, V136, P1249, DOI 10.1083/jcb.136.6.1249; Duelli D, 2003, CANCER CELL, V3, P445, DOI 10.1016/S1535-6108(03)00114-4; Duelli DM, 2000, NAT CELL BIOL, V2, P859, DOI 10.1038/35041112; Dworak HA, 2001, DEVELOPMENT, V128, P4265; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Erickson MRS, 1997, J CELL BIOL, V138, P589, DOI 10.1083/jcb.138.3.589; FARKASBARGETON E, 1988, J NEUROL SCI, V83, P145, DOI 10.1016/0022-510X(88)90064-0; Galletta BJ, 2004, MECH DEVELOP, V121, P1455, DOI 10.1016/j.mod.2004.08.001; Hakeda-Suzuki S, 2002, NATURE, V416, P438, DOI 10.1038/416438a; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; He ZY, 2003, DEV BIOL, V254, P226, DOI 10.1016/S0012-1606(02)00043-X; Heiman MG, 2000, J CELL BIOL, V151, P719, DOI 10.1083/jcb.151.3.719; Heinz FX, 2001, CURR OPIN MICROBIOL, V4, P450, DOI 10.1016/S1369-5274(00)00234-4; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Hummel T, 2000, GENE DEV, V14, P863; Inoue N, 2005, NATURE, V434, P234, DOI 10.1038/nature03362; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kaji K, 2004, REPRODUCTION, V127, P423, DOI 10.1530/rep.1.00163; Kaji K, 2002, DEV BIOL, V247, P327, DOI 10.1006/dbio.2002.0694; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LARIZZA L, 1984, CANCER METAST REV, V3, P193, DOI 10.1007/BF00048385; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Menon SD, 2001, DEV CELL, V1, P691, DOI 10.1016/S1534-5807(01)00075-2; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; MILLER FR, 1989, CANCER RES, V49, P4316; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; Miyamoto Takeshi, 2003, Keio J Med, V52, P1; Mohler WA, 2002, DEV CELL, V2, P355, DOI 10.1016/S1534-5807(02)00129-6; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; O'Malley K, 2004, EXP HEMATOL, V32, P131, DOI 10.1016/j.exphem.2003.11.009; OKADA Y, 1962, EXP CELL RES, V26, P98, DOI 10.1016/0014-4827(62)90205-7; Partridge T, 2002, NEUROMUSCULAR DISORD, V12, pS3, DOI 10.1016/S0960-8966(02)00076-7; Pawelek JM, 2000, MELANOMA RES, V10, P507, DOI 10.1097/00008390-200012000-00001; PIJNENBORG R, 1981, PLACENTA, V2, P71, DOI 10.1016/S0143-4004(81)80042-2; Pomerantz J, 2004, NAT CELL BIOL, V6, P810, DOI 10.1038/ncb0904-810; Pontow SE, 2004, J VIROL, V78, P7138, DOI 10.1128/JVI.78.13.7138-7147.2004; Potgens AJG, 2002, PLACENTA, V23, pS107, DOI 10.1053/plac.2002.0772; Primakoff P, 2002, SCIENCE, V296, P2183, DOI 10.1126/science.1072029; Rau A, 2001, DEVELOPMENT, V128, P5061; REDDIEN PW, 2004, ANN REV CELL DEV BIO; Redman CWG, 2000, PLACENTA, V21, P597, DOI 10.1053/plac.2000.0560; Ruiz-Gomez M, 2000, CELL, V102, P189, DOI 10.1016/S0092-8674(00)00024-6; Schroter RH, 2004, DEVELOPMENT, V131, P4501, DOI 10.1242/dev.01309; Shemer G, 2000, DEV DYNAM, V218, P30, DOI 10.1002/(SICI)1097-0177(200005)218:1<30::AID-DVDY4>3.0.CO;2-W; Shemer G, 2004, CURR BIOL, V14, P1587, DOI 10.1016/j.cub.2004.07.059; Shemer G, 2003, BIOESSAYS, V25, P672, DOI 10.1002/bies.10301; Shen K, 2003, CELL, V112, P619, DOI 10.1016/S0092-8674(03)00113-2; Shen K, 2004, CELL, V116, P869, DOI 10.1016/S0092-8674(04)00251-X; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Strunkelnberg M, 2001, DEVELOPMENT, V128, P4229; Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011; Trefzer U, 2004, INT J CANCER, V110, P730, DOI 10.1002/ijc.20191; Trefzer U, 2003, MOL BIOTECHNOL, V25, P63, DOI 10.1385/MB:25:1:63; Vignery A, 2000, INT J EXP PATHOL, V81, P291, DOI 10.1046/j.1365-2613.2000.00164.x; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; White JM, 2001, CURR BIOL, V11, pR16, DOI 10.1016/S0960-9822(00)00036-1; Willenbring H, 2004, NAT MED, V10, P744, DOI 10.1038/nm1062; Wockel L, 1998, ACTA NEUROPATHOL, V95, P547, DOI 10.1007/s004010050836	81	265	283	1	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					369	373		10.1126/science.1104799	http://dx.doi.org/10.1126/science.1104799			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831748				2022-12-28	WOS:000228492000040
J	Ford, EB; Lystad, V; Rasio, FA				Ford, EB; Lystad, V; Rasio, FA			Planet-planet scattering in the upsilon Andromedae system	NATURE			English	Article							DYNAMICAL INSTABILITIES; GIANT PLANETS; APSIDAL RESONANCE; V-ANDROMEDAE; ECCENTRICITY; STABILITY; MODELS	Doppler spectroscopy has detected 152 planets around nearby stars(1). A major puzzle is why many of their orbits are highly eccentric; all planets in our Solar System are on nearly circular orbits, as is expected if they formed by accretion processes in a protostellar disk. Several mechanisms have been proposed to generate large eccentricities after planet formation, but so far there has been little observational evidence to support any particular model. Here we report that the current orbital configuration of the three giant planets around upsilon Andromedae(2,3) (v And) probably results from a close dynamical interaction with another planet(4), now lost from the system. The planets started on nearly circular orbits, but chaotic evolution caused the outer planet (v And d) to be perturbed suddenly into a higher-eccentricity orbit. The coupled evolution of the system then causes slow periodic variations in the eccentricity of the middle planet (v And c). Indeed, we show that v And c periodically returns to a very nearly circular state every 6,700 years.	Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA	Northwestern University; University of California System; University of California Berkeley	Rasio, FA (corresponding author), Northwestern Univ, Dept Phys & Astron, Evanston, IL 60208 USA.	rasio@northwestern.edu		/0000-0001-6545-639X; Rasio, Frederic/0000-0002-7132-418X				Bodenheimer P, 2000, ICARUS, V143, P2, DOI 10.1006/icar.1999.6246; Butler RP, 1999, ASTROPHYS J, V526, P916, DOI 10.1086/308035; Chambers JE, 1999, MON NOT R ASTRON SOC, V304, P793, DOI 10.1046/j.1365-8711.1999.02379.x; Chiang EI, 2001, ASTRON J, V122, P1607, DOI 10.1086/322115; Chiang EI, 2002, ASTROPHYS J, V576, P473, DOI 10.1086/341617; Fischer DA, 2003, ASTROPHYS J, V586, P1394, DOI 10.1086/367889; Ford EB, 2003, ASTR SOC P, V294, P181; FORD EB, UNPUB ASTRON J; GLADMAN B, 1993, ICARUS, V106, P247, DOI 10.1006/icar.1993.1169; Goldreich P, 2003, ASTROPHYS J, V585, P1024, DOI 10.1086/346202; Holman M, 1997, NATURE, V386, P254, DOI 10.1038/386254a0; Lin D. N. C., 2000, Protostars and planets 4, P1111; Lissauer JJ, 2001, ASTROPHYS J, V554, P1141, DOI 10.1086/321426; Lystad V, 2004, AIP CONF PROC, V713, P273, DOI 10.1063/1.1774537; Malhotra R, 2002, ASTROPHYS J, V575, pL33, DOI 10.1086/342637; Marzari F, 2002, ICARUS, V156, P570, DOI 10.1006/icar.2001.6786; Murray C. D., 1999, SOLAR SYSTEM DYNAMIC; Rasio FA, 1996, SCIENCE, V274, P954, DOI 10.1126/science.274.5289.954; Rasio FA, 1996, ASTROPHYS J, V470, P1187, DOI 10.1086/177941; SCHNEIDER J, 2005, EXTRA SOLAR PLANETS; Stepinski TF, 2000, ASTROPHYS J, V545, P1044, DOI 10.1086/317829; Weidenschilling SJ, 1996, NATURE, V384, P619, DOI 10.1038/384619a0	23	89	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					873	876		10.1038/nature03427	http://dx.doi.org/10.1038/nature03427			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829958	Green Submitted			2022-12-28	WOS:000228327600034
J	Frevert, U; Nardin, E				Frevert, U; Nardin, E			Arrest in the liver - A genetically defined malaria vaccine?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10003 USA	New York University	Frevert, U (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10003 USA.			Frevert, Ute/0000-0001-9556-7330				CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; Frevert U, 2004, TRENDS PARASITOL, V20, P417, DOI 10.1016/j.pt.2004.07.007; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; Matuschewski K, 2002, J BIOL CHEM, V277, P41948, DOI 10.1074/jbc.M207315200; Mueller AK, 2005, NATURE, V433, P164, DOI 10.1038/nature03188	5	7	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1600	1602		10.1056/NEJMcibr050521	http://dx.doi.org/10.1056/NEJMcibr050521			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829544				2022-12-28	WOS:000228324200017
J	Leliveld, J; Lechtenbolumer, S; Assonov, SS; Brenninkmeijer, CAM; Dienst, C; Fischedick, M; Hanke, T				Leliveld, J; Lechtenbolumer, S; Assonov, SS; Brenninkmeijer, CAM; Dienst, C; Fischedick, M; Hanke, T			Greenhouse gases: Low methane leakage from gas pipelines	NATURE			English	Editorial Material									Max Planck Inst Chem, D-55128 Mainz, Germany; Wuppertal Inst Climate Environm & Energy, D-42103 Wuppertal, Germany	Max Planck Society	Leliveld, J (corresponding author), Max Planck Inst Chem, D-55128 Mainz, Germany.	leliveld@mpch-mainz.mpg.de	Lelieveld, Jos/A-1986-2013; Brenninkmeijer, Carl/B-6860-2013; Lechtenböhmer, Stefan/H-4940-2019	Lelieveld, Jos/0000-0001-6307-3846; Lechtenböhmer, Stefan/0000-0001-5987-5416; Assonov, Sergey/0000-0001-9096-4150; Fischedick, Manfred/0000-0003-2893-5003				*BRIT PETR, 2004, STAT REV WORLD EN 20; Dedikov JV, 1999, ATMOS ENVIRON, V33, P3291, DOI 10.1016/S1352-2310(98)00388-4; Dlugokencky EJ, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018126; Fiore AM, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015601; International Energy Agency, 2004, NAT GAS INF 2004; LELIEVELD J, 1992, NATURE, V355, P339, DOI 10.1038/355339a0; Ramaswamy V., CLIMATE CHANGE 2001, P349; Reshetnikov AI, 2000, J GEOPHYS RES-ATMOS, V105, P3517, DOI 10.1029/1999JD900761; *US EPA, 2004, INV US GREENH GAS SO; *US EPA, 1996, EPA600R96080 US; Wang JS, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002180	11	71	72	3	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 14	2005	434	7035					841	842		10.1038/434841a	http://dx.doi.org/10.1038/434841a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829951				2022-12-28	WOS:000228327600027
J	Mason, E				Mason, E			Child survival: time to match commitments with action	LANCET			English	Editorial Material									WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland	University of Geneva; World Health Organization	Mason, E (corresponding author), WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland.	masone@who.int						ARIFEEN ES, 2004, LANCET, V364, P1595; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Gwatkin DR, 2004, LANCET, V364, P1557, DOI 10.1016/S0140-6736(04)17324-8; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lee JW, 2003, LANCET, V362, P262, DOI 10.1016/S0140-6736(03)14006-8; Schellenberg JRMA, 2004, LANCET, V364, P1583, DOI 10.1016/S0140-6736(04)17311-X	8	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2005	365	9467					1286	1288		10.1016/S0140-6736(05)61005-7	http://dx.doi.org/10.1016/S0140-6736(05)61005-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823364				2022-12-28	WOS:000228219600006
J	Schulz, KF; Grimes, DA				Schulz, KF; Grimes, DA			Epidemiology 1 - Sample size calculations in randomised trials: mandatory and mystical	LANCET			English	Article							CLINICAL-TRIALS; EMPIRICAL-EVIDENCE; PUBLICATION BIAS; POWER	Investigators should properly calculate sample sizes before the start of their randomised trials and adequately describe the details in their published report. In these a-priori calculations, determining the effect size to detect - eg, event rates in treatment and control groups-reflects inherently subjective clinical judgments. Furthermore, these judgments greatly affect sample size calculations. We question the branding of trials as unethical on the basis of an imprecise sample size calculation process. So-called underpowered trials might be acceptable if investigators use methodological rigor to eliminate bias, properly report to avoid misinterpretation, and always publish results to avert publication bias. Some shift of emphasis from a fixation on sample size to a focus on methodological quality would yield more trials with less bias. Unbiased trials with imprecise results trump no results at all. Clinicians and patients deserve guidance now.	Family Hlth Int, Res Triangle Pk, NC 27709 USA		Schulz, KF (corresponding author), Family Hlth Int, POB 13950, Res Triangle Pk, NC 27709 USA.	KSchulz@fhi.org						ALTMAN DG, 1995, BRIT MED J, V311, P485, DOI 10.1136/bmj.311.7003.485; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 1988, LANCET, V2, P349; Antes G, 2003, LANCET, V361, P978, DOI 10.1016/S0140-6736(03)12838-3; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; Chalmers I, 2002, BRIT MED J, V324, P483; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Clarke M, 2002, JAMA-J AM MED ASSOC, V287, P2799, DOI 10.1001/jama.287.21.2799; Cui L, 1999, BIOMETRICS, V55, P853, DOI 10.1111/j.0006-341X.1999.00853.x; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; Edwards SJL, 1997, LANCET, V350, P804, DOI 10.1016/S0140-6736(97)02290-3; Ellenberg SS., 2002, DATA MONITORING COMM; FAYERS PM, 1995, BRIT J CANCER, V72, P1, DOI 10.1038/bjc.1995.268; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GOODMAN SN, 1994, ANN INTERN MED, V121, P200, DOI 10.7326/0003-4819-121-3-199408010-00008; Halpern SD, 2002, JAMA-J AM MED ASSOC, V288, P358, DOI 10.1001/jama.288.3.358; Lehmacher W, 1999, BIOMETRICS, V55, P1286, DOI 10.1111/j.0006-341X.1999.01286.x; Lilford RJ, 1995, BMJ-BRIT MED J, V311, P1621, DOI 10.1136/bmj.311.7020.1621; Lilford RJ, 2002, JAMA-J AM MED ASSOC, V288, P2118; MATTHEWS JNS, 1995, STAT MED, V14, P115, DOI 10.1002/sim.4780140204; Meinert CL., 1986, CLIN TRIALS DESIGN C; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; PEIPERT JF, 1995, OBSTET GYNECOL, V86, P302, DOI 10.1016/0029-7844(95)00104-Y; Peto R, 1999, LANCET, V354, P73, DOI 10.1016/S0140-6736(05)75340-X; PIANTADOSI S, 1997, CLIN TRIALS METHODOL; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SACKETT DL, 1993, ANN NY ACAD SCI, V703, P25, DOI 10.1111/j.1749-6632.1993.tb26331.x; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; Schulz KF, 2002, LANCET, V359, P966, DOI 10.1016/S0140-6736(02)08029-7; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 2002, LANCET, V359, P614, DOI 10.1016/S0140-6736(02)07750-4; Schulz KF, 2002, LANCET, V359, P781, DOI 10.1016/S0140-6736(02)07882-0; Schulz KF, 2002, LANCET, V359, P515, DOI 10.1016/S0140-6736(02)07683-3; Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9; SCHULZ KF, IN PRESS LANCET; SINEI SKA, 1990, BRIT J OBSTET GYNAEC, V97, P412, DOI 10.1111/j.1471-0528.1990.tb01828.x; WALKER MD, 1989, LANCET, V1, P325; Wang SJ, 2001, STAT MED, V20, P1903, DOI 10.1002/sim.820.abs; WITTES J, 1990, STAT MED, V9, P65, DOI 10.1002/sim.4780090113	43	364	372	2	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2005	365	9467					1348	1353		10.1016/S0140-6736(05)61034-3	http://dx.doi.org/10.1016/S0140-6736(05)61034-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823387				2022-12-28	WOS:000228219600032
J	Malausa, T; Bethenod, MT; Bontemps, A; Bourguet, D; Cornuet, JM; Ponsard, S				Malausa, T; Bethenod, MT; Bontemps, A; Bourguet, D; Cornuet, JM; Ponsard, S			Assortative mating in sympatric host races of the European corn borer	SCIENCE			English	Article							OSTRINIA-NUBILALIS HUBNER; REPRODUCTIVE ISOLATION; GENETIC ISOLATION; LARCH BUDMOTH; PLANT RACES; SPECIATION; POPULATIONS; SPECIALIZATION; LEPIDOPTERA; PYRALIDAE	Although a growing body of work supports the plausibility of sympatric speciation in animals, the practical difficulties of directly quantifying reproductive isolation between diverging taxa remain an obstacle to analyzing this process. We used a combination of genetic and biogeochemical markers to produce a direct field estimate of assortative mating in phytophagous insect populations. We show that individuals of the same insect species, the European corn borer Ostrinia nubilalis, that develop on different host plants can display almost absolute reproductive isolation-the proportion of assortative mating was >95%-even in the absence of temporal or spatial isolation.	Univ Toulouse 3, Lab Dynam Biodivers, CNRS, UMR 5172, F-31062 Toulouse, France; Inst Natl Rech Agron, CBGP, F-34988 Montferrier Sur Lez, France; Inst Natl Rech Agron, Unite Genet Microbienne & Environm, F-78285 Guyancourt, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; INRAE; Institut de Recherche pour le Developpement (IRD); INRAE	Malausa, T (corresponding author), Univ Toulouse 3, Lab Dynam Biodivers, CNRS, UMR 5172, F-31062 Toulouse, France.	malausa@cict.fr	Malausa, Thibaut/X-1614-2018	Malausa, Thibaut/0000-0003-1681-7958; Bourguet, Denis/0000-0002-2109-5323				Berlocher SH, 2002, ANNU REV ENTOMOL, V47, P773, DOI 10.1146/annurev.ento.47.091201.145312; Bethenod MT, 2005, HEREDITY, V94, P264, DOI 10.1038/sj.hdy.6800611; Bontemps A, 2004, P ROY SOC B-BIOL SCI, V271, P2179, DOI 10.1098/rspb.2004.2851; Craig TP, 1997, EVOLUTION, V51, P1552, DOI 10.1111/j.1558-5646.1997.tb01478.x; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; Dres M, 2002, PHILOS T R SOC B, V357, P471, DOI 10.1098/rstb.2002.1059; Emelianov I, 2003, J EVOLUTION BIOL, V16, P208, DOI 10.1046/j.1420-9101.2003.00524.x; Emelianov I, 2001, EVOLUTION, V55, P2002, DOI 10.1111/j.0014-3820.2001.tb01317.x; FEDER JL, 1994, P NATL ACAD SCI USA, V91, P7990, DOI 10.1073/pnas.91.17.7990; FEDER JL, 1993, ENTOMOL EXP APPL, V69, P117, DOI 10.1007/BF02380639; KLUN JA, 1975, ENVIRON ENTOMOL, V4, P891, DOI 10.1093/ee/4.6.891; Kondrashov AS, 1998, P ROY SOC B-BIOL SCI, V265, P2273, DOI 10.1098/rspb.1998.0570; Martel C, 2003, HEREDITY, V90, P141, DOI 10.1038/sj.hdy.6800186; Noor MAF, 1999, HEREDITY, V83, P503, DOI 10.1038/sj.hdy.6886320; Parker PG, 1998, ECOLOGY, V79, P361, DOI 10.1890/0012-9658(1998)079[0361:WMCTUA]2.0.CO;2; Pelozuelo L, 2004, J CHEM ECOL, V30, P335, DOI 10.1023/B:JOEC.0000017981.03762.ed; Rice WR, 1987, EVOL ECOL, V1, P301, DOI 10.1007/BF02071555; Rubenstein DR, 2004, TRENDS ECOL EVOL, V19, P256, DOI 10.1016/j.tree.2004.03.017; SHOWERS WB, 1976, ENVIRON ENTOMOL, V5, P1099, DOI 10.1093/ee/5.6.1099; Thomas Y, 2003, EVOLUTION, V57, P261; Via S, 2001, TRENDS ECOL EVOL, V16, P381, DOI 10.1016/S0169-5347(01)02188-7; Via S, 1999, EVOLUTION, V53, P1446, DOI 10.1111/j.1558-5646.1999.tb05409.x	22	124	131	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					258	260		10.1126/science.1107577	http://dx.doi.org/10.1126/science.1107577			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821092				2022-12-28	WOS:000228273700055
J	Dudai, Y; Carruthers, M				Dudai, Y; Carruthers, M			The Janus face of mnemosyne	NATURE			English	Editorial Material									Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; NYU, Fac English, New York, NY 10003 USA; NYU, Fac Hist, New York, NY 10003 USA; NYU, Fac Religious Studies, New York, NY 10003 USA	Weizmann Institute of Science; New York University; New York University; New York University	Dudai, Y (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.							Bolzoni Lina, 2001, GALLERY MEMORY; CARRUTHERS M, 1990, BOOK MEMORY; Dudai Y., 2002, MEMORY A Z; Tulving E., 2005, MISSING LINK COGNITI, P3, DOI [10.1093/acprof:oso/9780195161564.003.0001, DOI 10.1093/ACPROF:OSO/9780195161564.003.0001]	4	76	78	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					567	567		10.1038/434567a	http://dx.doi.org/10.1038/434567a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800602	Bronze			2022-12-28	WOS:000228011000023
J	Mooney, H; Cropper, A; Reid, W				Mooney, H; Cropper, A; Reid, W			Confronting the human dilemma	NATURE			English	Editorial Material									Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Millennium Ecosyst Assessment, Oakland, CA 94611 USA; Cropper Fdn, Port Of Spain, Trinidad Tobago	Stanford University	Mooney, H (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.							2002, NATURE, V417, P112	1	93	102	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					561	562		10.1038/434561a	http://dx.doi.org/10.1038/434561a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800597				2022-12-28	WOS:000228011000019
J	Coulibaly, F; Chevalier, C; Gutsche, I; Pous, J; Navaza, J; Bressanelli, S; Delmas, B; Rey, FA				Coulibaly, F; Chevalier, C; Gutsche, I; Pous, J; Navaza, J; Bressanelli, S; Delmas, B; Rey, FA			The birnavirus crystal structure reveals structural relationships among icosahedral viruses	CELL			English	Article							INFECTIOUS BURSAL DISEASE; DOUBLE-STRANDED-RNA; PANCREATIC NECROSIS VIRUS; MAJOR CAPSID PROTEIN; L-A VIRUS; ATOMIC-STRUCTURE; ANGSTROM RESOLUTION; POLYMERASE-ACTIVITY; MATURATION PROCESS; AMINO-ACIDS	Double-stranded RNA virions are transcriptionally competent icosahedral particles that must translocate across a lipid bilayer to function within the cytoplasm of the target cell. Birnaviruses are unique among dsRNA viruses as they have a single T = 13 icosahedral shell, lacking the characteristic inner capsid observed in the others. We determined the crystal structures of the T = 1 subviral particle (260 A in diameter) and of the T = 13 intact virus particle (700 A in diameter) of an avian birnavirus to 3 A and 7 A resolution, respectively. Our results show that VP2, the only component of the virus icosahedral capsid, is homologous both to the capsid protein of positive-strand RNA viruses, like the T = 3 nodaviruses, and to the T = 13 capsid protein of members of the Reoviridae family of dsRNA viruses. Together, these results provide important insights into the multiple functions of the birnavirus capsid and reveal unexpected structural relationships among icosahedral viruses.	INRA, Unite Virol & Immunol Mol, Domaine Vilvert, F-78350 Jouy En Josas, France; CNRS, INRA, UMR 2472 1157, Lab Virol Mol & Struct, F-91198 Gif Sur Yvette, France; IFR 115, F-91198 Gif Sur Yvette, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); INRAE; Universite Paris Saclay	Delmas, B (corresponding author), INRA, Unite Virol & Immunol Mol, Domaine Vilvert, F-78350 Jouy En Josas, France.	delmas@jouy.inra.fr	Chevalier, Christophe/AAK-4461-2020; Chevalier, Christophe/AAW-5560-2020; Rey, Felix/B-6497-2012; Chevalier, Christophe/C-2575-2009	Chevalier, Christophe/0000-0003-3231-9027; Coulibaly, Fasseli/0000-0003-3380-2117; Rey, Felix/0000-0002-9953-7988; Bressanelli, Stephane/0000-0002-0921-6727				Bamford DH, 2002, THEOR POPUL BIOL, V61, P461, DOI 10.1006/tpbi.2002.1591; Birghan C, 2000, EMBO J, V19, P114, DOI 10.1093/emboj/19.1.114; Bottcher B, 1997, J VIROL, V71, P325; Bourgeois D, 1999, ACTA CRYSTALLOGR D, V55, P1733, DOI 10.1107/S0907444999008355; Brandt M, 2001, J VIROL, V75, P11974, DOI 10.1128/JVI.75.24.11974-11982.2001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Caston JR, 1997, J CELL BIOL, V138, P975, DOI 10.1083/jcb.138.5.975; Caston JR, 2001, J VIROL, V75, P10815, DOI 10.1128/JVI.75.22.10815-10828.2001; Chevalier C, 2004, J VIROL, V78, P3296, DOI 10.1128/JVI.78.7.3296-3303.2004; Chevalier C, 2002, J VIROL, V76, P2384, DOI 10.1128/JVI.76.5.2384-2392.2002; COHEN J, 1975, BIOCHEM BIOPH RES CO, V62, P689, DOI 10.1016/0006-291X(75)90454-4; Da Costa B, 2002, J VIROL, V76, P2393, DOI 10.1128/JVI.76.5.2393-2402.2002; DeFilippis VR, 2001, FIELDS VIROLOGY, P353; Delmas B, 2004, VIRUS TAXONOMY, P561; Diprose JM, 2001, EMBO J, V20, P7229, DOI 10.1093/emboj/20.24.7229; DOBOS P, 1979, J VIROL, V32, P593, DOI 10.1128/JVI.32.2.593-605.1979; Dryden KA, 1998, VIROLOGY, V245, P33, DOI 10.1006/viro.1998.9146; Estes M.K., 2001, FIELDS VIROLOGY, V2., P1747; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; Gorbalenya AE, 2002, J MOL BIOL, V324, P47, DOI 10.1016/S0022-2836(02)01033-1; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Gouet P, 1999, CELL, V97, P481, DOI 10.1016/S0092-8674(00)80758-8; GRIMES J, 1995, NATURE, V373, P167, DOI 10.1038/373167a0; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Hanzlik TN, 1997, ADV VIRUS RES, V48, P101, DOI 10.1016/S0065-3527(08)60287-0; Harrison SC, 2001, CURR OPIN STRUC BIOL, V11, P195, DOI 10.1016/S0959-440X(00)00189-5; Helgstrand C, 2004, VIROLOGY, V318, P192, DOI 10.1016/j.virol.2003.08.045; Hjalmarsson A, 1999, J VIROL, V73, P3484, DOI 10.1128/JVI.73.4.3484-3490.1999; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Johnson JE, 1997, J MOL BIOL, V269, P665, DOI 10.1006/jmbi.1997.1068; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; JONES TA, 1992, MOL REPLACEMENT, P91; Lawton JA, 1997, NAT STRUCT BIOL, V4, P118, DOI 10.1038/nsb0297-118; Liemann S, 2002, CELL, V108, P283, DOI 10.1016/S0092-8674(02)00612-8; Lim BL, 1999, J VIROL, V73, P2854, DOI 10.1128/JVI.73.4.2854-2862.1999; Mertens PPC, 1996, VIROLOGY, V217, P582, DOI 10.1006/viro.1996.0153; Muller H, 2003, VET MICROBIOL, V97, P153, DOI 10.1016/j.vetmic.2003.08.005; Mundt E, 1999, J GEN VIROL, V80, P2067, DOI 10.1099/0022-1317-80-8-2067; Munshi S, 1996, J MOL BIOL, V261, P1, DOI 10.1006/jmbi.1996.0437; Naitow H, 2002, NAT STRUCT BIOL, V9, P725, DOI 10.1038/nsb844; Nakagawa A, 2003, STRUCTURE, V11, P1227, DOI 10.1016/j.str.2003.08.012; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Navaza J, 2002, ACTA CRYSTALLOGR D, V58, P1820, DOI 10.1107/S0907444902013707; Nibert ML., 2001, FIELDS VIROLOGY, P1679; Ona A, 2004, VIROLOGY, V322, P135, DOI 10.1016/j.virol.2004.01.025; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OZEL M, 1985, ARCH VIROL, V84, P149, DOI 10.1007/BF01378968; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Reinisch KM, 2000, NATURE, V404, P960, DOI 10.1038/35010041; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; Schneemann A, 1998, ADV VIRUS RES, V50, P381, DOI 10.1016/S0065-3527(08)60812-X; SCHNITZLER D, 1993, J GEN VIROL, V74, P1563, DOI 10.1099/0022-1317-74-8-1563; SPIES U, 1987, VIRUS RES, V8, P127, DOI 10.1016/0168-1702(87)90024-4; Tan BH, 2001, J VIROL, V75, P3937, DOI 10.1128/JVI.75.8.3937-3947.2001; Tang L, 2002, J VIROL, V76, P6370, DOI 10.1128/JVI.76.12.6370-6375.2002; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; van Loon AAWM, 2002, J GEN VIROL, V83, P121, DOI 10.1099/0022-1317-83-1-121; [No title captured]	64	243	262	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					761	772		10.1016/j.cell.2005.01.009	http://dx.doi.org/10.1016/j.cell.2005.01.009			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797378	Bronze			2022-12-28	WOS:000228067500007
J	Ihrie, RA; Marques, MR; Nguyen, BT; Horner, JS; Papazoglu, C; Bronson, RT; Mills, AA; Attardi, LD				Ihrie, RA; Marques, MR; Nguyen, BT; Horner, JS; Papazoglu, C; Bronson, RT; Mills, AA; Attardi, LD			Perp is a p63-regulated gene essential for epithelial integrity	CELL			English	Article							P53-DEPENDENT APOPTOSIS; EPIDERMAL MORPHOGENESIS; P53 HOMOLOG; P63; CELL; PLAKOPHILIN-1; TARGET; DESMOPLAKIN; DESMOSOMES; COMPLEX	p63 is a master regulator of stratified epithelial development that is both necessary and sufficient for specitying this multifaceted program. We show here that Perp, a tetraspan membrane protein originally identified as an apoptosis-associated target of the p53 tumor suppressor, is the first direct target of p63 clearly involved in mediating this developmental program in vivo. During embryogenesis, Perp is expressed in an epithelial pattern, and its expression depends on p63. Perp(-/-) mice die postnatally, with dramatic blistering in stratified epithelia symptomatic of compromised adhesion. Perp localizes specifically to desmosomes, adhesion junctions important for tissue integrity, and numerous structural defects in desmosomes are observed in Perp-deficient skin, suggesting a role for Perp in promoting the stable assembly of desmosomal adhesive complexes. These findings demonstrate that Perp is a key effector in the p63 developmental program, playing an essential role in an adhesion subprogram central to epithelial integrity and homeostasis.	Stanford Univ, Sch Med, Div Radiat & Canc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Stanford University; Stanford University; Stanford University; Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Harvard Medical School	Attardi, LD (corresponding author), Stanford Univ, Sch Med, Div Radiat & Canc Biol, Stanford, CA 94305 USA.	attardi@stanford.edu		Ihrie, Rebecca/0000-0003-0439-0141	NCI NIH HHS [CA09302, CA93665-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093665] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 2000, GENE DEV, V14, P704; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Bornslaeger EA, 2001, J CELL SCI, V114, P727; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; FRANTZ GD, 1994, J NEUROSCI, V14, P5725; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Ihrie RA, 2003, CURR BIOL, V13, P1985, DOI 10.1016/j.cub.2003.10.055; Jetten AM, 2000, PROG NUCLEIC ACID RE, V64, P97, DOI 10.1016/S0079-6603(00)64003-5; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Kurata S, 2004, J BIOL CHEM, V279, P50069, DOI 10.1074/jbc.M406322200; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; McMillan JR, 2003, J INVEST DERMATOL, V121, P96, DOI 10.1046/j.1523-1747.2003.12324.x; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Reczek EE, 2003, MOL CANCER RES, V1, P1048; South AP, 2003, J CELL SCI, V116, P3303, DOI 10.1242/jcs.00636; Tsukita S, 2002, CURR OPIN CELL BIOL, V14, P531, DOI 10.1016/S0955-0674(02)00362-9; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wong P, 2000, J CELL BIOL, V150, P921, DOI 10.1083/jcb.150.4.921; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yeaman C, 2004, J CELL SCI, V117, P559, DOI 10.1242/jcs.00893	31	247	255	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					843	856		10.1016/j.cell.2005.01.008	http://dx.doi.org/10.1016/j.cell.2005.01.008			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797384	Bronze			2022-12-28	WOS:000228067500013
J	Tao, QH; Yokota, C; Puck, H; Kofron, M; Birsoy, B; Yan, D; Asashima, M; Wylie, CC; Lin, XH; Heasman, J				Tao, QH; Yokota, C; Puck, H; Kofron, M; Birsoy, B; Yan, D; Asashima, M; Wylie, CC; Lin, XH; Heasman, J			Maternal Wnt11 activates the canonical wnt signaling pathway required for axis formation in Xenopus embryos	CELL			English	Article							CONVERGENT EXTENSION MOVEMENTS; HEPARAN-SULFATE PROTEOGLYCANS; DORSAL-VENTRAL AXIS; BETA-CATENIN; CORTICAL ROTATION; ZEBRAFISH GASTRULATION; MIDBLASTULA TRANSITION; VERTEBRATE DEVELOPMENT; MESODERM INDUCTION; KIDNEY DEVELOPMENT	Wnt signaling pathways play essential roles in patterning and proliferation of embryonic and adult tissues. In many organisms, this signaling pathway directs axis formation. Although the importance of intracellular components of the pathway, including P-catenin and Tcf3, has been established, the mechanism of their activation is uncertain. In Xenopus, the initiating signal that localizes p-catenin to dorsal nuclei has been suggested to be intracellular and Wnt independent. Here, we provide three lines of evidence that the pathway specifying the dorsal axis is activated extracellularly in Xenopus embryos. First, we identify Wnt11 as the initiating signal. Second, we show that activation requires the glycosyl transferase X.EXT1. Third, we find that the EGF-CFC protein, FRL1, is also essential and interacts with Wnt11 to activate canonical Wnt signaling.	Cincinnati Childrens Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; Univ Tokyo, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Tokyo	Heasman, J (corresponding author), Cincinnati Childrens Res Fdn, Div Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	heabq9@chmcc.org		Kofron, Matthew/0000-0001-6427-4148; Birsoy, Bilge/0000-0003-4337-4582	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063891] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33002] Funding Source: Medline; NIGMS NIH HHS [GM-63891] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adamson ED, 2002, J CELL PHYSIOL, V190, P267, DOI 10.1002/jcp.10072; AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Branford WW, 2002, CURR BIOL, V12, P2136, DOI 10.1016/S0960-9822(02)01360-X; Chang CB, 2000, MECH DEVELOP, V90, P227, DOI 10.1016/S0925-4773(99)00257-9; Chen CH, 2004, CURR BIOL, V14, P618, DOI 10.1016/j.cub.2004.02.042; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Chi LJ, 2004, DEVELOPMENT, V131, P3345, DOI 10.1242/dev.01200; Christiansen JH, 1996, ONCOGENE, V12, P2705; CUI YZ, 1995, DEVELOPMENT, V121, P2177; Desbordes SC, 2003, DEVELOPMENT, V130, P6245, DOI 10.1242/dev.00874; Ding XY, 1998, MECH DEVELOP, V70, P15, DOI 10.1016/S0925-4773(97)00163-9; Djiane A, 2000, DEVELOPMENT, V127, P3091; Dominguez I, 2000, DEVELOPMENT, V127, P861; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Eisenberg CA, 1999, DEV DYNAM, V216, P45, DOI 10.1002/(SICI)1097-0177(199909)216:1<45::AID-DVDY7>3.0.CO;2-L; ELINSON RP, 1988, DEV BIOL, V128, P185, DOI 10.1016/0012-1606(88)90281-3; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Hacker U, 1997, DEVELOPMENT, V124, P3565; Han C, 2004, DEVELOPMENT, V131, P1563, DOI 10.1242/dev.01051; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Heasman J, 2000, DEV BIOL, V222, P124, DOI 10.1006/dbio.2000.9720; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; HOULISTON E, 1991, J CELL BIOL, V114, P1017, DOI 10.1083/jcb.114.5.1017; Houston DW, 2002, DEVELOPMENT, V129, P4015; Katada T, 2002, DEV GENES EVOL, V212, P248, DOI 10.1007/s00427-002-0237-0; Kelly C, 2000, DEVELOPMENT, V127, P3899; Kilian B, 2003, MECH DEVELOP, V120, P467, DOI 10.1016/S0925-4773(03)00004-2; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Kirikoshi H, 2001, INT J MOL MED, V8, P651; Kofron M, 2004, DEVELOPMENT, V131, P5065, DOI 10.1242/dev.01396; Kofron M, 2001, DEV BIOL, V237, P183, DOI 10.1006/dbio.2001.0371; KU M, 1993, DEVELOPMENT, V119, P1161; Kuhl M, 2002, SEMIN CELL DEV BIOL, V13, P243, DOI 10.1016/S1084-9521(02)00050-2; Lako M, 1998, GENE, V219, P101, DOI 10.1016/S0378-1119(98)00393-X; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Larabell CA, 1996, DEVELOPMENT, V122, P1281; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lopez SL, 2003, DEVELOPMENT, V130, P2225, DOI 10.1242/dev.00443; Majumdar A, 2003, DEVELOPMENT, V130, P3175, DOI 10.1242/dev.00520; Marlow F, 2002, CURR BIOL, V12, P876, DOI 10.1016/S0960-9822(02)00864-3; Merrill BJ, 2004, DEVELOPMENT, V131, P263, DOI 10.1242/dev.00935; Miller JR, 1999, J CELL BIOL, V146, P427, DOI 10.1083/jcb.146.2.427; MOON RT, 1993, DEVELOPMENT, V119, P97; Morkel M, 2003, DEVELOPMENT, V130, P6283, DOI 10.1242/dev.00859; Nasevicius A, 1998, DEVELOPMENT, V125, P4283; Nojima H, 2004, MECH DEVELOP, V121, P371, DOI 10.1016/j.mod.2004.02.003; Ohkawara B, 2003, DEVELOPMENT, V130, P2129, DOI 10.1242/dev.00435; Ouko L, 2004, J BIOL CHEM, V279, P26707, DOI 10.1074/jbc.M402877200; Perrimon N, 2004, DEVELOPMENT, V131, P2509, DOI 10.1242/dev.01225; Quaas J, 2002, DEV BIOL, V243, P272, DOI 10.1006/dbio.2001.0564; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Rowning BA, 1997, P NATL ACAD SCI USA, V94, P1224, DOI 10.1073/pnas.94.4.1224; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; Schohl A, 2002, DEVELOPMENT, V129, P37; Schroeder KE, 1999, DEV BIOL, V214, P288, DOI 10.1006/dbio.1999.9426; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; Sumanas S, 2000, DEVELOPMENT, V127, P1981; Sun BI, 1999, DEVELOPMENT, V126, P1467; Tanegashima K, 2004, INT J DEV BIOL, V48, P275, DOI 10.1387/ijdb.041805kt; Teel AL, 1996, MECH DEVELOP, V59, P115, DOI 10.1016/0925-4773(96)00584-9; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Ulrich F, 2003, DEVELOPMENT, V130, P5375, DOI 10.1242/dev.00758; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044; Westfall TA, 2003, J CELL BIOL, V162, P889, DOI 10.1083/jcb.200303107; Wikramanayake AH, 2003, NATURE, V426, P446, DOI 10.1038/nature02113; Xanthos JB, 2002, DEVELOPMENT, V129, P4027; Xanthos JB, 2001, DEVELOPMENT, V128, P167; Yabe SI, 2003, DEVELOPMENT, V130, P2071, DOI 10.1242/dev.00430; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yang J, 2002, DEVELOPMENT, V129, P5743, DOI 10.1242/dev.00150; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Yokota C, 2003, DEVELOPMENT, V130, P2199, DOI 10.1242/dev.00434; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang J, 1998, CELL, V94, P515, DOI 10.1016/S0092-8674(00)81592-5; Zuck M. V., 1998, COMP METHODS APPROAC, P341	85	384	404	0	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					857	871		10.1016/j.cell.2005.01.013	http://dx.doi.org/10.1016/j.cell.2005.01.013			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797385	Bronze			2022-12-28	WOS:000228067500014
J	Systrom, DM; Wittram, C; Harris, NL; Thorner, AR; Mark, EJ				Systrom, DM; Wittram, C; Harris, NL; Thorner, AR; Mark, EJ			A 67-year-old man with acute respiratory failure - Hypersensitivity pneumonitis due to M-avium complex infection (hot-tub lung).	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RESOLUTION COMPUTED-TOMOGRAPHY; COMMUNITY-ACQUIRED PNEUMONIA; THIN-SECTION CT; INTERSTITIAL PNEUMONIA; MYCOPLASMA-PNEUMONIAE; EXPOSURE; DISEASE		Massachusetts Gen Hosp, Dept Pulm & Crit Care, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University	Systrom, DM (corresponding author), Massachusetts Gen Hosp, Dept Pulm & Crit Care, Boston, MA 02114 USA.			Systrom, David/0000-0002-9610-6330				Agusti C, 2002, AM J RESP CRIT CARE, V166, P426; Aksamit Timothy R, 2003, Semin Respir Infect, V18, P33, DOI 10.1053/srin.2003.50003; American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [DOI 10.1164/AJRCCM.165.2.ATS01, 10.1164/ajrccm.165.2.ats01]; BLACKMORE TK, 1995, PATHOLOGY, V27, P177, DOI 10.1080/00313029500169832; Burns MJ, 1997, CHEST, V111, P816, DOI 10.1378/chest.111.3.816; Cappelluti E, 2003, ARCH INTERN MED, V163, P845, DOI 10.1001/archinte.163.7.845; Choi YH, 2000, CHEST, V117, P117, DOI 10.1378/chest.117.1.117; Embil J, 1997, CHEST, V111, P813, DOI 10.1378/chest.111.3.813; Gruden JF, 1999, RADIOLOGY, V210, P711, DOI 10.1148/radiology.210.3.r99mr21711; Hunninghake GW, 2003, CHEST, V124, P1215, DOI 10.1378/chest.124.4.1215; Johkoh T, 1999, RADIOLOGY, V212, P567, DOI 10.1148/radiology.212.2.r99au05567; Kahana LM, 1997, CHEST, V111, P242, DOI 10.1378/chest.111.1.242; Khoor A, 2001, AM J CLIN PATHOL, V115, P755, DOI 10.1309/JRDC-0MJV-ACA3-2U9L; Marchiori E, 2001, J THORAC IMAG, V16, P127, DOI 10.1097/00005382-200104000-00012; Marrie TJ, 1996, AM J MED, V101, P508, DOI 10.1016/S0002-9343(96)00255-0; Miyashita N, 2004, RESP MED, V98, P542, DOI 10.1016/j.rmed.2003.11.012; Nobauer-Huhmann IM, 2001, EUR RADIOL, V11, P2436, DOI 10.1007/s003300101103; Pham RV, 2003, J THORAC IMAG, V18, P48, DOI 10.1097/00005382-200301000-00008; Philit F, 2002, AM J RESP CRIT CARE, V166, P1235, DOI 10.1164/rccm.2112056; Rickman OB, 2002, MAYO CLIN PROC, V77, P1233, DOI 10.4065/77.11.1233; Schwartzstein RM, 2000, NEW ENGL J MED, V343, P642, DOI 10.1056/NEJM200008313430908; VERWEIJ PE, 1995, CLIN INFECT DIS, V20, P440, DOI 10.1093/clinids/20.2.440; 2003, MMWR MORB MORTAL WKL, V52, P269	23	9	10	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1238	1246		10.1056/NEJMcpc059003	http://dx.doi.org/10.1056/NEJMcpc059003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788501				2022-12-28	WOS:000227832300012
J	Grandesso, F; Sanderson, F; Kruijt, J; Koene, T; Brown, V				Grandesso, F; Sanderson, F; Kruijt, J; Koene, T; Brown, V			Mortality and malnutrition among populations living in South Darfur, Sudan - Results of 3 surveys, September 2004	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Mass violence against civilians in the west of Sudan has resulted in the displacement of more than 1.5 million people (25% of the population of the Darfur region). Most of these people are camped in 142 settlements. There has been increasing international concern about the health status of the displaced population. Objective To perform rapid epidemiological assessments of mortality and nutritional status at 3 sites in South Darfur for relief efforts. Design, Setting, and Participants In August and September 2004, mortality surveys were conducted among 137000 internally displaced persons (IDPs) in 3 sites in South Darfur (Kass [n = 900 households], Kalma [n = 893 households], and Muhajiria [n = 900 households]). A nutritional survey was performed concomitantly among children aged 6 to 59 months using weight for height as an index of acute malnutrition (Kass [n = 894], Kalma [n = 8881, and Muhajiria [n = 8961). A questionnaire detailing access to food and basic services was administered to a subset of households (n = 210 in each site). Main Outcome Measures Crude and under 5-year mortality rates and nutritional status of IDPs in Kass, Kalma, and Muhajiria, South Darfur. Results Crude mortality rates, expressed as deaths per 10000 per day, were 3.2 (95% confidence interval [CI], 2.2-4.1) in Kass, 2.0 (95% Cl, 1.3-2.7) in Kalma, and 2.3 (95% Cl, 1.2-3.4) in Muhajiria. Under 5-year mortality rates were 5.9 (95% Cl, 3.8-8.0) in Kass, 3.5 (95% Cl, 1.5-5.7) in Kalma, and 1.0 (95% Cl, 0.03-1.9) in Muhajiria. During the period of displacement covered by our survey in Muhajiria, violence was reported to be responsible for 72% of deaths, mainly among young men. Diarrheal disease was reported to cause between 25% and 47% of deaths in camp residents and mainly affected the youngest and oldest age groups. Acute malnutrition was common, affecting 14.1% of the target population in Kass, 23.6% in Kalma, and 10.7% in Muhajiria. Conclusion This study provides epidemiological evidence of the high rates of mortality and malnutrition among the displaced population in South Darfur and reinforces the need to mount appropriate and timely humanitarian responses.	Charing Cross Hosp, Dept Infect, London W6 8RF, England; Epictr, Paris, France; Med Sans Frontieres, Amsterdam, Netherlands	Imperial College London; Doctors Without Borders	Sanderson, F (corresponding author), Charing Cross Hosp, Dept Infect, London W6 8RF, England.	frances.sanderson@imperial.ac.uk						*CEDAT BRIEF DARF, 2004, AN MORT NUTR SURV N; Depoortere E, 2004, LANCET, V364, P1315, DOI 10.1016/S0140-6736(04)17187-0; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; *MED FRONT, 1995, NUTR GUID; Spiegel PB, 2004, JAMA-J AM MED ASSOC, V292, P613, DOI 10.1001/jama.292.5.613; The Sphere Project, 1998, HUM CHART MIN STAND; UN. High Commission for Refugees, 1999, HDB EM; WOODRUFF BA, 2002, FIELD EXCHANGE, V17, P16; *WORLD MED ASS, DECL HELS 2004	9	33	33	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2005	293	12					1490	1494		10.1001/jama.293.12.1490	http://dx.doi.org/10.1001/jama.293.12.1490			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908KA	15784873				2022-12-28	WOS:000227784700029
J	Zaidi, AKM; Huskins, WC; Thaver, D; Bhutta, ZA; Abbas, Z; Goldmann, DA				Zaidi, AKM; Huskins, WC; Thaver, D; Bhutta, ZA; Abbas, Z; Goldmann, DA			Hospital-acquired neonatal infections in developing countries	LANCET			English	Review							INTENSIVE-CARE-UNIT; SPECTRUM BETA-LACTAMASE; LOW-BIRTH-WEIGHT; LATE-ONSET INFECTION; KLEBSIELLA-PNEUMONIAE; NOSOCOMIAL INFECTIONS; MOLECULAR EPIDEMIOLOGY; BACTERIAL-MENINGITIS; PEDIATRIC CARE; RISK-FACTORS	Hospital-born babies in developing countries are at increased risk of neonatal infections because of poor intraparturn and postnatal infection-control practices. We reviewed data from developing countries on rates of neonatal infections among hospital-born babies, range of pathogens, antimicrobial resistance, and infection-control interventions. Reported rates of neonatal infections were 3-20 times higher than those reported for hospital-born babies in industrialised countries. Klebsiella pneumoniae, other gram-negative rods (Escherichia coli, Pseudomonas spp, Acinetobacter spp), and Staphylococcus aureus were the major pathogens among 11471 bloodstream isolates reported. These infections can often present soon after birth. About 70% would not be covered by an empiric regimen of ampicillin and gentamicin, and many might be untreatable in resource-constrained environments. The associated morbidity, mortality, costs, and adverse effect on future health-seeking behaviour by communities pose barriers to improvement of neonatal outcomes in developing countries. Low-cost, "bundled" interventions using systems quality improvement approaches for improved infection control are possible, but should be supported by evidence in developing country settings.	Aga Khan Univ, Dept Paediat & Child Hlth, Karachi 74800, Pakistan; Mayo Clin, Dept Pediat & Adolescent Med, Div Pediat Infect Dis, Rochester, MN USA; Mayo Clin, Coll Med, Rochester, MN USA; Harvard Univ, Childrens Hosp Boston, Sch Med, Boston, MA 02115 USA; Inst Healthcare Improvement, Cambridge, MA USA	Aga Khan University; Mayo Clinic; Mayo Clinic; Harvard University; Boston Children's Hospital; Harvard Medical School; Institute for Healthcare Improvement	Zaidi, AKM (corresponding author), Aga Khan Univ, Dept Paediat & Child Hlth, Stadium Rd,POB 3500, Karachi 74800, Pakistan.	anita.zaidi@aku.edu		Huskins, W. Charles/0000-0002-9989-175X				Adejuyigbe E A, 2001, East Afr Med J, V78, P540; ADHIKARI M, 1995, J TROP PEDIATRICS, V41, P81, DOI 10.1093/tropej/41.2.81; ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Ahmed A S M Nawshad Uddin, 2002, Indian Pediatr, V39, P1034; AIREDE AI, 1993, DEV MED CHILD NEUROL, V35, P424; AIREDE AI, 1992, J TROP PEDIATRICS, V38, P189, DOI 10.1093/tropej/38.4.189; Aktas E, 2002, J INT MED RES, V30, P445, DOI 10.1177/147323000203000414; Al-Harthi AA, 2000, SAUDI MED J, V21, P550; Ali Z, 2004, ANN TROP PAEDIATR, V24, P41, DOI 10.1179/027249304225013367; [Anonymous], HAZ AN CRIT CONTR PO; [Anonymous], 1980, EXPLORATIONS QUALITY; ANTIAOBONG OE, 1992, CENT AFR J MED, V38, P161; Anwer S K, 2000, J Pak Med Assoc, V50, P91; Anyebuno M, 1995, E AFR MED J, V72, P805; Arif MA, 1999, J TROP PEDIATRICS, V45, P278, DOI 10.1093/tropej/45.5.278; Aurangzeb Brekhna, 2003, J Coll Physicians Surg Pak, V13, P629; Ayan M, 2003, INFECT CONT HOSP EP, V24, P495, DOI 10.1086/502245; AYENGAR V, 1991, Indian Journal of Pediatrics, V58, P661, DOI 10.1007/BF02820186; Bakr AF, 2003, J TROP PEDIATRICS, V49, P295, DOI 10.1093/tropej/49.5.295; Baltimore Robert S, 2003, Paediatr Drugs, V5, P723, DOI 10.2165/00148581-200305110-00002; Baltimore RS, 1998, SEMIN PERINATOL, V22, P25, DOI 10.1016/S0146-0005(98)80005-0; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Barroso-Aguirre J, 1992, Bol Med Hosp Infant Mex, V49, P666; Becerra-Posada F, 2004, LANCET, V364, P997, DOI 10.1016/S0140-6736(04)17026-8; Ben-Hamouda T, 2003, J MED MICROBIOL, V52, P427, DOI 10.1099/jmm.0.04981-0; BERG DE, 1995, CLIN INFECT DIS, V21, P588, DOI 10.1093/clinids/21.3.588; Bhutta ZA, 2004, BRIT MED J, V329, P1151, DOI 10.1136/bmj.329.7475.1151; Bhutta ZA, 1997, AM J PERINAT, V14, P577, DOI 10.1055/s-2007-994338; Bhutta ZA, 2000, IMPROVING NEWBORN INFANT HEALTH IN DEVELOPING COUNTRIES, P289, DOI 10.1142/9781848160705_0016; BHUTTA ZA, 1991, ACTA PAEDIATR SCAND, V80, P596, DOI 10.1111/j.1651-2227.1991.tb11916.x; BOO NY, 1994, J PAEDIATR CHILD H, V30, P23, DOI 10.1111/j.1440-1754.1994.tb00560.x; Boukadida J, 2002, ARCH PEDIATRIE, V9, P463, DOI 10.1016/S0929-693X(01)00827-2; Brown SM, 2003, INFECT CONT HOSP EP, V24, P172, DOI 10.1086/502186; BUETOW KC, 1965, AM J DIS CHILD, V110, P29, DOI 10.1001/archpedi.1965.02090030035005; Chandrashekar M R, 1997, J Indian Med Assoc, V95, P72; Cisse C T, 2001, Gynecol Obstet Fertil, V29, P433, DOI 10.1016/S1297-9589(01)00157-6; CISSE MF, 1992, PRESSE MED, V21, P413; Clark Reese, 2004, J Perinatol, V24, P382, DOI 10.1038/sj.jp.7211120; CONDEAGUDELO A, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002771.PUB2]; CONNER JM, 2003, COCHRANE DB SYST REV, V4; Cotton MF, 2000, J HOSP INFECT, V44, P13, DOI 10.1053/jhin.1999.0650; CRAIG WS, 1962, CARE NEWLY BORN INFA; Daoud AS, 1996, J TROP PEDIATRICS, V42, P267, DOI 10.1093/tropej/42.5.267; DAOUD AS, 1995, ANN TROP PAEDIATR, V15, P93, DOI 10.1080/02724936.1995.11747755; Darmstadt GL, 2004, PEDIATR INFECT DIS J, V23, P719, DOI 10.1097/01.inf.0000133047.50836.6f; Darmstadt GL, 2003, B WORLD HEALTH ORGAN, V81, P224; Dawodu A, 1997, J TROP PEDIATRICS, V43, P84, DOI 10.1093/tropej/43.2.84; DEALMEIDA SH, 2003, BRAZ J INFECT DIS, V7, P381; Desinor OY, 2004, J TROP PEDIATRICS, V50, P48, DOI 10.1093/tropej/50.1.48; DREWS MB, 1995, J HOSP INFECT, V30, P65, DOI 10.1016/0195-6701(95)90250-3; Edwards MS., 2015, INFECT DIS FETUS NEW, V8th ed., P1091; EICKHOFF TC, 1964, NEW ENGL J MED, V271, P1221, DOI 10.1056/NEJM196412102712401; English M, 2004, LANCET, V364, P1622, DOI 10.1016/S0140-6736(04)17318-2; English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8; Ferguson JK, 1996, J PAEDIATR CHILD H, V32, P525, DOI 10.1111/j.1440-1754.1996.tb00967.x; Fernandez A, 1993, J Postgrad Med, V39, P57; Fernandez Armida, 2003, Indian Pediatr, V40, P1161; FIKREE FF, 2001, STATE WORLDS NEWBORN; Gebremariam A, 1998, ANN TROP PAEDIATR, V18, P279, DOI 10.1080/02724936.1998.11747960; Ghiorghis B, 1997, ETHIOPIAN MED J, V35, P169; GHIORGIS B, 1991, ETHIOPIAN MED J, V29, P167; GLUCK L, 1966, PEDIATR CLIN N AM, V13, P1131; Goldmann DA, 1997, CLIN INFECT DIS, V24, pS139, DOI 10.1093/clinids/24.Supplement_1.S139; Gonzalez-Vertiz A, 2001, INFECT CONT HOSP EP, V22, P723, DOI 10.1086/501854; GUPTA AK, 1993, J TROP PEDIATRICS, V39, P32, DOI 10.1093/tropej/39.1.32; Gupta P, 1997, Indian Pediatr, V34, P144; Gupta Piyush, 1993, Indian Journal of Pediatrics, V60, P565, DOI 10.1007/BF02751435; Halder D, 1999, Med J Malaysia, V54, P52; HALEY RW, 1995, J INFECT DIS, V171, P614, DOI 10.1093/infdis/171.3.614; HAQUE KN, 1990, J TROP PEDIATRICS, V36, P20, DOI 10.1093/tropej/36.1.20; Harris JS, 2001, INFECT DIS FETUS NEW, P1371; Ho JJ, 2001, PEDIATR INFECT DIS J, V20, P557, DOI 10.1097/00006454-200106000-00002; Hyder AA, 2003, BJOG-INT J OBSTET GY, V110, P894, DOI 10.1111/j.1471-0528.2003.02446.x; Isturiz RE, 2000, INFECT CONT HOSP EP, V21, P394, DOI 10.1086/501780; Jain A, 2003, J MED MICROBIOL, V52, P421, DOI 10.1099/jmm.0.04966-0; Jain S, 2004, J TROP PEDIATRICS, V50, P170, DOI 10.1093/tropej/50.3.170; Joshi S. G., 2000, Indian Journal of Pediatrics, V67, P27; KARPUCH J, 1983, ISRAEL J MED SCI, V19, P963; Karthikeyan G., 2001, Indian Journal of Pediatrics, V68, P715, DOI 10.1007/BF02752407; Karunasekera K. A. W., 1999, Ceylon Medical Journal, V44, P81; Kaushik Shayam L., 1998, Journal of Communicable Diseases, V30, P147; Kilani R A, 2000, J Med Liban, V48, P77; Klein O.J., 2001, INFECT DIS FETUS NEW, P943; Klingenberg C, 2003, ANN TROP PAEDIATR, V23, P293, DOI 10.1179/027249303225007806; Koksal Nilgun, 2001, Indian Journal of Pediatrics, V68, P15, DOI 10.1007/BF02728850; KONAI AK, 1999, J TROP PEDIATRICS, V45, P146; Kumar M, 2002, J TROP PEDIATRICS, V48, P43, DOI 10.1093/tropej/48.1.43; Kumhar GD, 2002, J HEALTH POPUL NUTR, V20, P343; Kurlat I, 1998, J HOSP INFECT, V40, P149, DOI 10.1016/S0195-6701(98)90094-9; Kuruvilla K A, 1998, Indian Pediatr, V35, P851; Langley Gj., 1996, IMPROVEMENT GUIDE PR; Lawn JE, 2004, LANCET, V364, P399, DOI 10.1016/S0140-6736(04)16783-4; Lim N L, 1995, Med J Malaysia, V50, P59; Luby SP, 2004, JAMA-J AM MED ASSOC, V291, P2547, DOI 10.1001/jama.291.21.2547; LUMBIGANON P, 2004, COCHRANE DB SYST REV, V4; Mahmood A, 2002, J Pak Med Assoc, V52, P348; Malik A S, 1994, Med J Malaysia, V49, P17; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; MANTARING JB, 2004, REDUCTION NEONATAL B, P80; Martinez-Aguilar G, 2001, INFECT CONT HOSP EP, V22, P725, DOI 10.1086/501855; Mas-Munoz R L, 1992, Bol Med Hosp Infant Mex, V49, P839; MASSOUD R, MODERN PARADIGM IMPR; MATHUR N B, 1991, Indian Pediatrics, V28, P1259; MCCRACKEN GH, 1966, AM J DIS CHILD, V112, P33, DOI 10.1001/archpedi.1966.02090100069006; Misallati A, 2000, East Mediterr Health J, V6, P483; Mishra A, 1998, Indian Pediatr, V35, P27; MOFFET HL, 1967, AM J DIS CHILD, V114, P13, DOI 10.1001/archpedi.1967.02090220019003; Mokuolu A O, 2002, Afr J Med Med Sci, V31, P127; MONDAL G P, 1991, Indian Journal of Pediatrics, V58, P529, DOI 10.1007/BF02750936; MORENO MT, 1994, PEDIATR INFECT DIS J, V13, P516, DOI 10.1097/00006454-199406000-00010; Moss William, 2002, J Perinatol, V22, P484; Mullany LC, 2003, PEDIATR INFECT DIS J, V22, P996, DOI 10.1097/01.inf.0000095429.97172.48; Musoke RN, 2000, J TROP PEDIATRICS, V46, P86, DOI 10.1093/tropej/46.2.86; Mussi-Pinhata MM, 2004, J TROP PEDIATRICS, V50, P6, DOI 10.1093/tropej/50.1.6; Nagata E, 2002, AM J INFECT CONTROL, V30, P26, DOI 10.1067/mic.2002.119823; *NAT NEON FOR, 2000, NAT NEON PER DAT REP; NATHOO KJ, 1990, CENT AFR J MED, V36, P150; NATHOO KJ, 1993, PEDIATR INFECT DIS J, V12, P840, DOI 10.1097/00006454-199310000-00009; NATHOO KJ, 1991, ANN TROP PAEDIATR, V11, P11, DOI 10.1080/02724936.1991.11747472; Nejjari Noureddine, 2003, Tunis Med, V81, P121; Nel E, 2000, J TROP PEDIATRICS, V46, P237, DOI 10.1093/tropej/46.4.237; Newman Mercy J, 2002, West Afr J Med, V21, P310; Ng PC, 2004, ARCH DIS CHILD-FETAL, V89, pF336, DOI 10.1136/adc.2003.031104; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; NTIAOBONG OE, 1991, TROP DOCT, V21, P169; Nuland SB, 2003, DOCTORS PLAGUE GERMS; Orrett FA, 1998, INFECT CONT HOSP EP, V19, P136; Orrett FA, 2001, ANN TROP PAEDIATR, V21, P20, DOI 10.1080/02724930020028867; Palmer A, 1999, J TROP PEDIATRICS, V45, P51, DOI 10.1093/tropej/45.1.51; PANNUTI CS, 1995, INFECT CONT HOSP EP, V16, P170; Pearse J, 1997, Afr Health, V19, P10; PEGUES DA, 1994, AM J INFECT CONTROL, V22, P163, DOI 10.1016/0196-6553(94)90005-1; Pengsaa Krisana, 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P102; Pessoa-Silva CL, 2004, INFECT CONT HOSP EP, V25, P772, DOI 10.1086/502475; Pessoa-Silva CL, 2003, J HOSP INFECT, V53, P198, DOI 10.1053/jhin.2002.1373; Petdachai Witaya, 2000, Journal of the Medical Association of Thailand, V83, P392; Peterson S, 2004, LANCET, V363, P1955, DOI 10.1016/S0140-6736(04)16411-8; Pillay T, 1998, AM J PERINAT, V15, P47, DOI 10.1055/s-2007-993898; Pittet D, 2004, J HOSP INFECT, V58, P1, DOI 10.1016/j.jhin.2004.06.002; PONCEDELEON S, 1991, J HOSP INFECT, V18, P376, DOI 10.1016/0195-6701(91)90044-9; PRASERTSOM W, 1990, Journal of the Medical Association of Thailand, V73, P106; RAGHAVAN M, 1992, Indian Journal of Pediatrics, V59, P335, DOI 10.1007/BF02821801; Rahman S, 2002, ARCH DIS CHILD-FETAL, V87, pF52, DOI 10.1136/fn.87.1.F52; RAJAB A, 1990, ANN TROP PAEDIATR, V10, P39, DOI 10.1080/02724936.1990.11747407; RAO PS, 1993, J TROP PEDIATRICS, V39, P230, DOI 10.1093/tropej/39.4.230; Raza MW, 2004, J HOSP INFECT, V57, P294, DOI 10.1016/j.jhin.2004.03.019; RHINEHART E, 1991, AM J MED, V91, pS213, DOI 10.1016/0002-9343(91)90371-4; Richards C, 2004, INFECT CONT HOSP EP, V25, P221, DOI 10.1086/502382; Saez-Llorens X, 2000, PEDIATR INFECT DIS J, V19, P200, DOI 10.1097/00006454-200003000-00005; Sanghvi KP, 1996, J PAEDIATR CHILD H, V32, P333, DOI 10.1111/j.1440-1754.1996.tb02565.x; SENSES D A, 1991, Mikrobiyoloji Bulteni, V25, P238; SHINEFIELD HR, 2001, INFECT DIS FETUS NEW, P1217; Silva J, 2001, J CLIN MICROBIOL, V39, P3193, DOI 10.1128/JCM.39.9.3193-3196.2001; Singh D, 2000, IMPROVING NEWBORN INFANT HEALTH IN DEVELOPING COUNTRIES, P503, DOI 10.1142/9781848160705_0030; Sjahrodji A M, 1990, Paediatr Indones, V30, P191; SOBAYO EI, 1991, J HOSP INFECT, V18, P388, DOI 10.1016/0195-6701(91)90046-B; Stoll BJ, 2002, NEW ENGL J MED, V347, P240, DOI 10.1056/NEJMoa012657; Stoll BJ, 2001, J PEDIATR-US, V139, P729, DOI 10.1067/mpd.2001.118881; Stoll BJ, 2001, INFECT DIS FETUS NEW, P139; Szabo D, 1999, J CLIN MICROBIOL, V37, P4167; Tallur Shashikala S., 2000, Indian Journal of Pediatrics, V67, P169, DOI 10.1007/BF02723654; Taskin E, 2004, J TROP PEDIATRICS, V50, P124, DOI 10.1093/tropej/50.2.124; Tietjen L, 2003, INFECT PREVENTION GU; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; Ursprung R, 2004, PEDIATR RES, V55, p435A; VAIDYA U, 1991, Indian Pediatrics, V28, P1265; Vargas P E, 1990, Rev Med Panama, V15, P127; Velazco E, 2002, ENFERM INFEC MICR CL, V20, P321, DOI 10.1016/S0213-005X(02)72808-5; Waheed Maryam, 2003, J Coll Physicians Surg Pak, V13, P449; Webster J, 2003, Cochrane Database Syst Rev, pCD003670; Weinberg M, 2001, ARCH INTERN MED, V161, P2357, DOI 10.1001/archinte.161.19.2357; WHEELER WE, 1967, AM J DIS CHILD, V101, P273; *WHO, 1993, MOTH BAB PACK ROAD M; *WHO, APPR RAP SCAL UP US; *WHO DEP REPR HLTH, 2001, INT MAN PREGN CHILD; *WHO UNICEF, 2000, WHOFCHCAH0012000; Yalcin Ata Nevzat, 2003, Indian J Med Sci, V57, P450; Yu J. L., 2001, SMJ Singapore Medical Journal, V42, P107; ZAIDI AK, 2002, EXPLORE SIMPLIFIED A; ZAIDI M, 1995, J HOSP INFECT, V31, P25, DOI 10.1016/0195-6701(95)90080-2; ZAIDI-JACOBSON M, 1991, Boletin Medico del Hospital Infantil de Mexico, V48, P538; Zupan J, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/1465-1858.CD001057; 1999, MARTINDALE COMPLETE, P1108; 2001, SAVING NEWBORN LIVES	184	433	448	1	35	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2005	365	9465					1175	1188		10.1016/S0140-6736(05)71881-X	http://dx.doi.org/10.1016/S0140-6736(05)71881-X			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	910DD	15794973				2022-12-28	WOS:000227909500031
J	Murata, T; Yamato, I; Kakinuma, Y; Leslie, AGW; Walker, JE				Murata, T; Yamato, I; Kakinuma, Y; Leslie, AGW; Walker, JE			Structure of the rotor of the V-type Na+-ATPase from Enterococcus hirae	SCIENCE			English	Article							SUBUNIT-C; MOLECULAR ARCHITECTURE; ROTARY MOTOR; F1F0; SYNTHASE; BINDING; RING; SYMMETRY; SINGLE	The membrane rotor ring from the vacuolar-type (V-type) sodium ion-pumping adenosine triphosphatase (Na+-ATPase) from Enterococcus hirae consists of 10 NtpK subunits, which are homologs of the 16-kilodalton and 8-kilodalton proteotipids found in other V-ATPases and in F1F0- or F-ATPases, respectively. Each NtpK subunit has four transmembrane a helices, with a sodium ion bound between helices 2 and 4 at a site buried deeply in the membrane that includes the essential residue glutamate-139. This site is probably connected to the membrane surface by two half-channels in subunit Ntpl, against which the ring rotates. Symmetry mismatch between the rotor and catalytic domains appears to be an intrinsic feature of both V- and F-ATPases.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Tokyo Univ Sci, Dept Biol Sci & Technol, Chiba 2788510, Japan; Ehime Univ, Fac Agr, Matsuyama, Ehime 7908566, Japan	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Tokyo University of Science; Ehime University	Leslie, AGW (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	andrew@mrc-tmb.cam.ac.uk; watker@mrc-dunn.cam.ac.uk	Murata, Takeshi/J-6181-2017; Murata, Takeshi/F-6114-2011	Murata, Takeshi/0000-0002-5748-4670; Walker, John/0000-0001-7929-2162				ARAI H, 1988, J BIOL CHEM, V263, P8796; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Harding MM, 2002, ACTA CRYSTALLOGR D, V58, P872, DOI 10.1107/S0907444902003712; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; HERMOLIN J, 1989, J BIOL CHEM, V264, P3896; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; IBBOTT FA, 1964, BIOCHEMISTRY-US, V3, P2008, DOI 10.1021/bi00900a039; Iwata M, 2004, P NATL ACAD SCI USA, V101, P59, DOI 10.1073/pnas.0305165101; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaim G, 1998, EMBO J, V17, P5887, DOI 10.1093/emboj/17.20.5887; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Kaim G, 1997, BIOCHEMISTRY-US, V36, P9185, DOI 10.1021/bi970831q; Kawano M, 2002, J BIOL CHEM, V277, P24405, DOI 10.1074/jbc.M200973200; Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7; Mitome N, 2004, P NATL ACAD SCI USA, V101, P12159, DOI 10.1073/pnas.0403545101; Murata T, 2000, J BIOL CHEM, V275, P13415, DOI 10.1074/jbc.275.18.13415; Murata T, 2003, J BIOL CHEM, V278, P21162, DOI 10.1074/jbc.M301620200; Murata T, 2001, BBA-BIOENERGETICS, V1505, P75, DOI 10.1016/S0005-2728(00)00278-4; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; Palsdottir H, 2004, BBA-BIOMEMBRANES, V1666, P2, DOI 10.1016/j.bbamem.2004.06.012; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Thomas DR, 1999, P NATL ACAD SCI USA, V96, P10134, DOI 10.1073/pnas.96.18.10134; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; von Ballmoos C, 2002, EUR J BIOCHEM, V269, P5581, DOI 10.1046/j.1432-1033.2002.03264.x; von Ballmoos C, 2002, J BIOL CHEM, V277, P3504, DOI 10.1074/jbc.M110301200; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W	31	308	316	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 29	2005	308	5722					654	659		10.1126/science.1110064	http://dx.doi.org/10.1126/science.1110064			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	922BO	15802565				2022-12-28	WOS:000228810900038
J	Henderson, GM				Henderson, GM			Coral clues to rapid sea-level change	SCIENCE			English	Editorial Material							AGE		Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	University of Oxford	Henderson, GM (corresponding author), Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England.	gideon.henderson@earth.ox.ac.uk		Henderson, Gideon/0000-0002-6279-7137				MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; Siddall M, 2003, NATURE, V423, P853, DOI 10.1038/nature01690; Thompson WG, 2005, SCIENCE, V308, P401, DOI 10.1126/science.1104035; White B, 1998, CARBONATE EVAPORITE, V13, P10, DOI 10.1007/BF03175430; Yokoyama Y, 2001, EARTH PLANET SC LETT, V193, P579, DOI 10.1016/S0012-821X(01)00515-5	5	6	6	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 15	2005	308	5720					361	362		10.1126/science.1110550	http://dx.doi.org/10.1126/science.1110550			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831744				2022-12-28	WOS:000228492000035
J	Strewler, GJ				Strewler, GJ			A 64-year-old woman with primary hyperparathyroidism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASYMPTOMATIC PRIMARY HYPERPARATHYROIDISM; MILD PRIMARY HYPERPARATHYROIDISM; BONE-MINERAL DENSITY; PARATHYROID-HORMONE ASSAY; STAGE RENAL-DISEASE; POSTMENOPAUSAL WOMEN; SECONDARY HYPERPARATHYROIDISM; EXTRACELLULAR CALCIUM; CONTROLLED-TRIAL; FOLLOW-UP		Harvard Univ, Sch Med, Tosteson Med Educ Ctr, Walter Bradford Cannon Soc, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Strewler, GJ (corresponding author), Harvard Univ, Sch Med, Tosteson Med Educ Ctr, Walter Bradford Cannon Soc, 260 Longwood Ave,Room 232A, Boston, MA 02115 USA.	gordon_strewler@hms.harvard.edu						Antoniucci DM, 2002, J BONE MINER RES, V17, pN141; Awad SS, 2003, WORLD J SURG, V27, P486, DOI 10.1007/s00268-002-6824-4; Bendz H, 1996, J INTERN MED, V240, P357, DOI 10.1046/j.1365-2796.1996.28864000.x; Bilezikian JP, 2002, J CLIN ENDOCR METAB, V87, P5353, DOI 10.1210/jc.2002-021370; Bilezikian JP, 2002, J BONE MINER RES, V17, pN2; Bilezikian JP, 2004, NEW ENGL J MED, V350, P1746, DOI 10.1056/NEJMcp032200; BOONSTRA CE, 1971, AM J CLIN PATHOL, V55, P523; Bostrom K, 2000, CRIT REV EUKAR GENE, V10, P151; BRADLEY EL, 1983, AM SURGEON, V49, P569; Brown EM, 2000, ENDOCRIN METAB CLIN, V29, P503, DOI 10.1016/S0889-8529(05)70148-1; BROWN EM, 1983, J CLIN ENDOCR METAB, V56, P572, DOI 10.1210/jcem-56-3-572; Brown EM, 2002, J BONE MINER RES, V17, pN24; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Carling T, 1998, J CLIN ENDOCR METAB, V83, P2960, DOI 10.1210/jc.83.8.2960; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; CHAN AK, 1995, ANN SURG, V222, P402, DOI 10.1097/00000658-199509000-00017; Chin J, 2000, J AM SOC NEPHROL, V11, P903, DOI 10.1681/ASN.V115903; Chow CC, 2003, J CLIN ENDOCR METAB, V88, P581, DOI 10.1210/jc.2002-020890; Civelek AC, 2002, SURGERY, V131, P149, DOI 10.1067/msy.2002.119817; Curhan GC, 1997, ANN INTERN MED, V126, P497, DOI 10.7326/0003-4819-126-7-199704010-00001; Davies MR, 2001, KIDNEY INT, V60, P472, DOI 10.1046/j.1523-1755.2001.060002472.x; DEACONSON TF, 1987, SURGERY, V102, P910; Dempster DW, 1999, J CLIN ENDOCR METAB, V84, P1562, DOI 10.1210/jc.84.5.1562; Denham DW, 1998, J AM COLL SURGEONS, V186, P293, DOI 10.1016/S1072-7515(98)00016-7; ERIKSEN EF, 1985, BONE, V6, P421, DOI 10.1016/8756-3282(85)90218-2; Farnebo F, 1998, J CLIN ENDOCR METAB, V83, P2627, DOI 10.1210/jc.83.8.2627; Garner SC, 1999, SURGERY, V126, P1132, DOI 10.1067/msy.2099.101429; Goodman WG, 2003, PEDIATR NEPHROL, V18, P1206, DOI 10.1007/s00467-003-1290-2; GREY A, 2005, J CLIN ENDOCRINOL ME; Grey AB, 1996, ANN INTERN MED, V125, P360, DOI 10.7326/0003-4819-125-5-199609010-00002; Haciyanli M, 2003, J AM COLL SURGEONS, V197, P739, DOI 10.1016/S1072-7515(03)00676-8; Haden ST, 1997, J CLIN ENDOCR METAB, V82, P2844, DOI 10.1210/jc.82.9.2844; HEATH H, 1980, NEW ENGL J MED, V302, P189, DOI 10.1056/NEJM198001243020402; Hedback G, 1998, EUR J CLIN INVEST, V28, P271; Hemmer S, 2001, AM J PATHOL, V158, P1355, DOI 10.1016/S0002-9440(10)64086-2; Heppner C, 1997, NAT GENET, V16, P375, DOI 10.1038/ng0897-375; Hsi ED, 1996, J CLIN ENDOCR METAB, V81, P1736, DOI 10.1210/jc.81.5.1736; Imanishi Y, 2001, J CLIN INVEST, V107, P1093, DOI 10.1172/JCI10523; IRVIN GL, 1993, SURGERY, V114, P1019; KAO PC, 1992, MAYO CLIN PROC, V67, P637, DOI 10.1016/S0025-6196(12)60717-4; Khan AA, 2004, J CLIN ENDOCR METAB, V89, P3319, DOI 10.1210/jc.2003-030908; Khosla S, 1999, J BONE MINER RES, V14, P1700, DOI 10.1359/jbmr.1999.14.10.1700; Lundgren E, 2001, SURGERY, V130, P978, DOI 10.1067/msy.2001.118377; MARCUS R, 1984, ANN INTERN MED, V100, P633, DOI 10.7326/0003-4819-100-5-633; Marx SJ, 2002, J BONE MINER RES, V17, pN37; Miller L, 2002, J GEN INTERN MED, V17, P98; Mollerup CL, 2002, BMJ-BRIT MED J, V325, P807, DOI 10.1136/bmj.325.7368.807; NAINBYLUXMOORE JC, 1982, J CLIN ENDOCR METAB, V55, P303, DOI 10.1210/jcem-55-2-303; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; *NIDDK WORKSH PROG, 2003, J BONE MINER RES S2, V17, pN1; Nilsson IL, 2002, J BONE MINER RES, V17, pN68; Parfitt AM, 2003, BONE, V33, P259, DOI 10.1016/j.bone.2003.05.002; Parfitt AM, 1998, J CLIN ENDOCR METAB, V83, P863, DOI 10.1210/jc.83.3.863; PARFITT AM, 2001, PARATHYROIDS BASIC C, P293; PARISIEN M, 1992, J BONE MINER RES, V7, P913; Parker CR, 2002, J CLIN ENDOCR METAB, V87, P4482, DOI 10.1210/jc.2001-010385; Pasieka JL, 1998, WORLD J SURG, V22, P513, DOI 10.1007/s002689900428; Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004-0842; Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD; REASNER CA, 1993, J CLIN ENDOCR METAB, V77, P1067, DOI 10.1210/jc.77.4.1067; Rossini M, 2001, J BONE MINER RES, V16, P113, DOI 10.1359/jbmr.2001.16.1.113; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; SCHOLZ DA, 1981, MAYO CLIN PROC, V56, P473; SELBY PL, 1986, NEW ENGL J MED, V314, P1481, DOI 10.1056/NEJM198606053142304; SILVERBERG SJ, 1995, J CLIN ENDOCR METAB, V80, P723, DOI 10.1210/jc.80.3.723; Silverberg SJ, 2003, J CLIN ENDOCR METAB, V88, P4725, DOI 10.1210/jc.2002-021266; Silverberg SJ, 2002, J BONE MINER RES, V17, pN117; Silverberg SJ, 1999, NEW ENGL J MED, V341, P1249, DOI 10.1056/NEJM199910213411701; Sosa JA, 1998, J CLIN ENDOCR METAB, V83, P2658, DOI 10.1210/jc.83.8.2658; Sosa JA, 2003, SURG ONCOL, V12, P125, DOI 10.1016/S0960-7404(03)00041-0; STEFENELLI T, 1993, AM J MED, V95, P197, DOI 10.1016/0002-9343(93)90260-V; Stefenelli T, 1997, J CLIN ENDOCR METAB, V82, P106, DOI 10.1210/jc.82.1.106; Strewler GJ, 2000, ENDOCRIN METAB CLIN, V29, P523, DOI 10.1016/S0889-8529(05)70149-3; Talpos GB, 2000, SURGERY, V128, P1013, DOI 10.1067/msy.2000.110844; Udelsman R, 2002, ANN SURG, V235, P665, DOI 10.1097/00000658-200205000-00008; Udelsman R, 2002, J BONE MINER RES, V17, pN126; Vestergaard P, 2000, BRIT MED J, V321, P598, DOI 10.1136/bmj.321.7261.598; Wada M, 2000, KIDNEY INT, V57, P50, DOI 10.1046/j.1523-1755.2000.00837.x; Wada M, 2003, NEPHROL DIAL TRANSPL, V18, P13, DOI 10.1093/ndt/gfg1004; Walgenbach S, 2000, WORLD J SURG, V24, P564, DOI 10.1007/s002689910092; Wermers RA, 1998, AM J MED, V104, P115, DOI 10.1016/S0002-9343(97)00270-2; WILSON RJ, 1988, ANN INTERN MED, V109, P959, DOI 10.7326/0003-4819-109-12-959; 1991, J BONE MINER RES S2, V6, pS1	84	6	6	1	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1772	1779		10.1001/jama.293.14.1772	http://dx.doi.org/10.1001/jama.293.14.1772			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827317				2022-12-28	WOS:000228301100032
J	Bower, P; Gilbody, S				Bower, P; Gilbody, S			Managing common mental health disorders in primary care: conceptual models and evidence base	BRITISH MEDICAL JOURNAL			English	Article							CHRONIC ILLNESS; DEPRESSION; GUIDELINES	The use of conceptual models can help to bridge the gap between research findings and policy development, illustrated here by the complex area of primary care mental health services.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Bower, P (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	peter.bower@manchester.ac.uk	Gilbody, Simon/E-6543-2010; Bower, Peter/A-1508-2011; Gilbody, Simon/AAY-3720-2021	Bower, Peter/0000-0001-9558-3349; Gilbody, Simon/0000-0002-8236-6983				Black N, 2001, BRIT MED J, V323, P275, DOI 10.1136/bmj.323.7307.275; *CTR REV DISS, 2001, SCOP REV EFF MENT HL; *DEP HLTH, 2001, TREATM CHOIC PSYCH T; Gask L, 1997, BRIT J PSYCHIAT, V170, P6, DOI 10.1192/bjp.170.1.6; Goldberg D, 1997, GEN PRACTITIONER PSY; Goldberg D., 1983, INT J REHABIL RES, V6, P127, DOI [10.1097/00004356-198303000-00021, DOI 10.1097/00004356-198303000-00021]; Katon W, 2001, GEN HOSP PSYCHIAT, V23, P138, DOI 10.1016/S0163-8343(01)00136-0; Kendrick T, 2000, BMJ-BRIT MED J, V320, P200, DOI 10.1136/bmj.320.7229.200; Lovell K., 2000, BEHAV COGN PSYCHOTH, V28, P379, DOI [DOI 10.1017/S1352465800004070, 10.1017/S1352465800004070]; OXMAN AD, 1988, CAN MED ASSOC J, V138, P697; PINCUS HA, 1987, GEN HOSP PSYCHIAT, V9, P95, DOI 10.1016/0163-8343(87)90020-X; Shekelle P, 2003, BRIT MED J, V326, P457, DOI 10.1136/bmj.326.7387.457; Shepherd M, 1966, PSYCHIAT ILLNESS GEN; Siegler M, 1974, MODELS MADNESS MODEL; Valenstein M, 2001, ANN INTERN MED, V134, P345, DOI 10.7326/0003-4819-134-5-200103060-00007; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WHO, 2001, WORLD HLTH REPORT 20; World Health Organization, 2001, ATLAS MENT HLTH RES	18	153	158	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	APR 9	2005	330	7495					839	842		10.1136/bmj.330.7495.839	http://dx.doi.org/10.1136/bmj.330.7495.839			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	915BZ	15817554	Green Published			2022-12-28	WOS:000228273900023
J	Rajan, S; Plant, LD; Rabin, ML; Butler, MH; Goldstein, SAN				Rajan, S; Plant, LD; Rabin, ML; Butler, MH; Goldstein, SAN			Sumoylation silences the plasma membrane leak K+ channel K2P1	CELL			English	Article							CEREBELLAR GRANULE NEURONS; DOMAIN POTASSIUM CHANNELS; CONJUGATING ENZYME MUBC9; 2 PORE DOMAINS; SUMO CONJUGATION; UBIQUITIN; EXPRESSION; TASK-1; LOCALIZATION; PROTEINS	Reversible, covalent modification with small ubiquitin-related modifier proteins (SUMOs) is known to mediate nuclear import/export and activity of transcription factors. Here, the SUMO pathway is shown to operate at the plasma membrane to control ion channel function. SUMO-conjugating enzyme is seen to be resident in plasma membrane, to assemble with K2P1, and to modify K2P1 lysine 274. K2P1 had not previously shown function despite mRNA expression in heart, brain, and kidney and sequence features like other two-P loop K+ leak (K2P) pores that control activity of excitable cells. Removal of the peptide adduct by SUMO protease reveals K2P1 to be a K+-selective, pH-sensitive, openly rectifying channel regulated by reversible peptide linkage.	Univ Chicago, Pritzker Sch Med, Dept Pediat, Chicago, IL 60637 USA	University of Chicago	Goldstein, SAN (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Pediat, 5721 S Maryland Ave, Chicago, IL 60637 USA.	sangoldstein@uchicago.edu	Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Bockenhauer D, 2000, GENE, V261, P365, DOI 10.1016/S0378-1119(00)00492-3; Colquhoun David, 1995, P483; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, P NATL ACAD SCI USA, V93, P13256, DOI 10.1073/pnas.93.23.13256; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; GOLDSTEIN SAN, 2002, IUPHAR COMPENDIUM VO, P173; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Han J, 2002, J PHYSIOL-LONDON, V542, P431, DOI 10.1113/jphysiol.2002.017590; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; Ilan N, 2001, BIOPHYS J, V80, P241, DOI 10.1016/S0006-3495(01)76010-9; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kim LA, 2004, NEURON, V41, P513, DOI 10.1016/S0896-6273(04)00050-9; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Levy DI, 2004, KIDNEY INT, V65, P918, DOI 10.1111/j.1523-1755.2004.00458.x; Li SJ, 2003, J CELL BIOL, V160, P1069, DOI 10.1083/jcb.200212052; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; Machon O, 2000, MECH DEVELOP, V97, P3, DOI 10.1016/S0925-4773(00)00402-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Malbert-Colas L, 2003, CR BIOL, V326, P615, DOI 10.1016/S1631-0691(03)00154-9; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Orias M, 1997, AM J PHYSIOL-RENAL, V273, pF663, DOI 10.1152/ajprenal.1997.273.4.F663; Plant LD, 2002, STROKE, V33, P2324, DOI 10.1161/01.STR.0000027440.68031.B0; Rajan S, 2001, J BIOL CHEM, V276, P7302, DOI 10.1074/jbc.M008985200; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; Talley EM, 2001, J NEUROSCI, V21, P7491, DOI 10.1523/JNEUROSCI.21-19-07491.2001; Ubbels GA, 1997, CELL MOL LIFE SCI, V53, P382, DOI 10.1007/PL00000613; Wang ZG, 1998, CIRCULATION, V98, P2422, DOI 10.1161/01.CIR.98.22.2422; Washburn CP, 2002, J NEUROSCI, V22, P1256, DOI 10.1523/JNEUROSCI.22-04-01256.2002; Zilberberg N, 2000, J GEN PHYSIOL, V116, P721, DOI 10.1085/jgp.116.5.721; Zilberberg N, 2001, NEURON, V32, P635, DOI 10.1016/S0896-6273(01)00503-7	51	206	212	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					37	47		10.1016/j.cell.2005.01.019	http://dx.doi.org/10.1016/j.cell.2005.01.019			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820677	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000228348500008
J	Shin, S; El-Diwany, R; Schaffert, S; Adams, EJ; Garcia, KC; Pereira, P; Chien, YH				Shin, S; El-Diwany, R; Schaffert, S; Adams, EJ; Garcia, KC; Pereira, P; Chien, YH			Antigen recognition determinants of gamma delta T cell receptors	SCIENCE			English	Article							REPERTOIRE; SELECTION; SPECIFICITY; LYMPHOCYTES; POPULATION; REGION; MICE	The molecular basis of gamma delta T cell receptor (TCR) recognition is poorly understood. Here, we analyze the TCR sequences of a natural gamma delta T cell population specific for the major histocompatibility complex class Ib molecule T22. We find that T22 recognition correlates strongly with a somatically recombined TCR delta complementarity-determining region 3 (CDR3) motif derived from germ line-encoded residues. Sequence diversity around these residues modulates TCR ligand-binding affinities, whereas V gene usage correlates mainly with tissue origin. These results show how an antigen-specific gamma delta TCR repertoire can be generated at a high frequency and suggest that gamma delta T cells recognize a limited number of antigens.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Immunol, Stanford, CA 94305 USA; Inst Pasteur, Unite Dev Lymphocytes, CNRS, URA 1961, F-75724 Paris, France	Stanford University; Stanford University; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Chien, YH (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	chien@stanford.edu	Pereira, Pablo/M-7224-2014	El-Diwany, Ramy/0000-0002-3224-6414; Pereira, Pablo/0000-0003-1784-2776; Schaffert, Steven/0000-0001-8842-0218	NIAID NIH HHS [AI33431] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033431] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams EJ, 2005, SCIENCE, V308, P227, DOI 10.1126/science.1106885; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; Azuara V, 1998, EUR J IMMUNOL, V28, P3456, DOI 10.1002/(SICI)1521-4141(199811)28:11&lt;3456::AID-IMMU3456&gt;3.0.CO;2-F; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BONNEVILLE M, 1989, P NATL ACAD SCI USA, V86, P5928, DOI 10.1073/pnas.86.15.5928; Bousso P, 1998, IMMUNITY, V9, P169, DOI 10.1016/S1074-7613(00)80599-3; CANDEIAS S, 1991, J EXP MED, V174, P989, DOI 10.1084/jem.174.5.989; Chien YH, 1996, ANNU REV IMMUNOL, V14, P511, DOI 10.1146/annurev.immunol.14.1.511; Crowley MP, 2000, SCIENCE, V287, P314, DOI 10.1126/science.287.5451.314; DAVIS MM, 2003, FUNDAMENTAL IMMUNOLO; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; MCHEYZERWILLIAMS MG, 1995, SCIENCE, V268, P106, DOI 10.1126/science.7535476; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; PEREIRA P, 1995, J EXP MED, V182, P1921, DOI 10.1084/jem.182.6.1921; Pereira P, 2004, J IMMUNOL, V173, P3261, DOI 10.4049/jimmunol.173.5.3261; Pereira P, 2000, EUR J IMMUNOL, V30, P1988, DOI 10.1002/1521-4141(200007)30:7<1988::AID-IMMU1988>3.0.CO;2-W; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; Savage PA, 1999, IMMUNITY, V10, P485, DOI 10.1016/S1074-7613(00)80048-5; Scotet E, 2005, IMMUNITY, V22, P71, DOI 10.1016/j.immuni.2004.11.012; SHIN S, UNPUB; Spada FM, 2000, J EXP MED, V191, P937, DOI 10.1084/jem.191.6.937; SPERLING AI, 1992, J IMMUNOL, V149, P3200; Wu J, 2002, J IMMUNOL, V169, P1236, DOI 10.4049/jimmunol.169.3.1236; Xu JL, 2000, IMMUNITY, V13, P37, DOI 10.1016/S1074-7613(00)00006-6	25	138	141	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					252	255		10.1126/science.1106480	http://dx.doi.org/10.1126/science.1106480			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821090				2022-12-28	WOS:000228273700053
J	Simpson, SD; Meekan, M; Montgomery, J; McCauley, R; Jeffs, A				Simpson, SD; Meekan, M; Montgomery, J; McCauley, R; Jeffs, A			Homeward sound	SCIENCE			English	Article							CORAL-REEF FISHES; RECRUITMENT; POPULATION		Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland; Australian Inst Marine Sci, Darwin, NT, Australia; Univ Auckland, Leigh Marine Lab, Auckland 1, New Zealand; Curtin Univ, Ctr Marine Sci & Technol, Perth, WA 6845, Australia; Natl Inst Water & Atmospher Res Ltd, Auckland, New Zealand	University of Edinburgh; Australian Institute of Marine Science; University of Auckland; Curtin University; National Institute of Water & Atmospheric Research (NIWA) - New Zealand	Simpson, SD (corresponding author), Univ Edinburgh, Sch Biol Sci, Edinburgh EH9 3JT, Midlothian, Scotland.	s.simpson@ed.ac.uk	Jeffs, Andrew G/D-9474-2012; Montgomery, John C/D-4310-2009	Montgomery, John C/0000-0002-7451-3541; Simpson, Stephen/0000-0002-4856-6164; Meekan, Mark/0000-0002-3067-9427; Jeffs, Andrew/0000-0002-8504-1949	Natural Environment Research Council [NE/B501720/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Ackerman JL, 2000, MAR ECOL PROG SER, V206, P227, DOI 10.3354/meps206227; Jones GP, 1999, NATURE, V402, P802, DOI 10.1038/45538; McCauley RD, 2000, PHILOS T ROY SOC B, V355, P1289, DOI 10.1098/rstb.2000.0686; Simpson SD, 2004, MAR ECOL PROG SER, V276, P263, DOI 10.3354/meps276263; Stobutzki IC, 1997, MAR ECOL PROG SER, V149, P35, DOI 10.3354/meps149035; Swearer SE, 1999, NATURE, V402, P799, DOI 10.1038/45533	6	245	249	0	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					221	221		10.1126/science.1107406	http://dx.doi.org/10.1126/science.1107406			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821083				2022-12-28	WOS:000228273700043
J	Wang, MC; Bohmann, D; Jasper, H				Wang, MC; Bohmann, D; Jasper, H			JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling	CELL			English	Article							TRANSCRIPTION FACTOR FOXO3A; N-TERMINAL KINASE; OXIDATIVE STRESS; CAENORHABDITIS-ELEGANS; GENE-EXPRESSION; FAT-BODY; DROSOPHILA; RECEPTOR; DAF-16; PATHWAY	Aging of a eukaryotic organism is affected by its nutrition state and by its ability to prevent or repair oxidative damage. Consequently, signal transduction systems that control metabolism and oxidative stress responses influence life span. When nutrients are abundant, the insulin/IGF signaling (IIS) pathway promotes growth and energy storage but shortens life span. The transcription factor Foxo, which is inhibited by IIS, extends life span in conditions of low IIS activity. Life span can also be increased by activating the stress-responsive Jun-N-terminal kinase (JNK) pathway. Here we show that JNK requires Foxo to extend life span in Drosophila. JNK antagonizes IIS, causing nuclear localization of Foxo and inducing its targets, including growth control and stress defense genes. JNK and Foxo also restrict IIS activity systemically by repressing IIS ligand expression in neuroendocrine cells. The convergence of JNK signaling and IIS on Foxo provides a model to explain the effects of stress and nutrition on longevity.	Univ Rochester, Med Ctr, Dept Biomed Genet, Aab Inst Biomed Sci, Rochester, NY 14642 USA	University of Rochester	Bohmann, D (corresponding author), Univ Rochester, Med Ctr, Dept Biomed Genet, Aab Inst Biomed Sci, 601 Elmwood Ave,Box 633, Rochester, NY 14642 USA.	dirk_bohmann@urmc.rochester.edu; henri_jasper@urmc.rochester.edu	Gimenez, Luis E Diaz/D-9291-2011; Wang, Meng/F-2951-2019	Wang, Meng/0000-0002-5898-6007				Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Arrigo AP, 1998, BIOL CHEM, V379, P19; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Garofalo RS, 2002, TRENDS ENDOCRIN MET, V13, P156, DOI 10.1016/S1043-2760(01)00548-3; Giannakou ME, 2004, SCIENCE, V305, P361, DOI 10.1126/science.1098219; Goberdhan DCI, 2003, DIFFERENTIATION, V71, P375, DOI 10.1046/j.1432-0436.2003.7107001.x; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; Jasper H, 2001, DEV CELL, V1, P579, DOI 10.1016/S1534-5807(01)00045-4; Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Kockel L, 2001, ONCOGENE, V20, P2347, DOI 10.1038/sj.onc.1204300; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Landis GN, 2004, P NATL ACAD SCI USA, V101, P7663, DOI 10.1073/pnas.0307605101; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Li WQ, 2003, GENE DEV, V17, P844, DOI 10.1101/gad.1066503; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Oldham S, 2002, DEVELOPMENT, V129, P4103; Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Tatar M, 2001, EXP GERONTOL, V36, P723, DOI 10.1016/S0531-5565(00)00238-2; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Tu MP, 2002, AGING CELL, V1, P75, DOI 10.1046/j.1474-9728.2002.00010.x; Wang MC, 2003, DEV CELL, V5, P811, DOI 10.1016/S1534-5807(03)00323-X; Weber U, 2000, DEVELOPMENT, V127, P3619; Welsh MJ, 1998, ANN NY ACAD SCI, V851, P28, DOI 10.1111/j.1749-6632.1998.tb08973.x; WESSELL RJ, 2004, GENET, V36, P1275; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Zeitlinger J, 1999, DEVELOPMENT, V126, P3947; Zhang B, 2003, DIABETES, V52, P2720, DOI 10.2337/diabetes.52.11.2720	59	420	439	0	39	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					115	125		10.1016/j.cell.2005.02.030	http://dx.doi.org/10.1016/j.cell.2005.02.030			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820683	Bronze			2022-12-28	WOS:000228348500014
J	Yamashita, M; Ying, SX; Zhang, GM; Li, CL; Cheng, SY; Deng, CX; Zhang, YE				Yamashita, M; Ying, SX; Zhang, GM; Li, CL; Cheng, SY; Deng, CX; Zhang, YE			Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation	CELL			English	Article							ACTIVATED PROTEIN-KINASE; TGF-BETA RECEPTOR; C-JUN; TRANSCRIPTIONAL ACTIVATION; I RECEPTOR; SMAD; DIFFERENTIATION; EXPRESSION; PROMOTER; ELEMENTS	Bone is constantly resorbed and formed throughout life by coordinated actions of osteoclasts and osteoblasts. Here we show that Smurf1, a HECT domain ubiquitin ligase, has a specific physiological role in suppressing the osteogenic activity of osteoblasts. Smurf1-deficient mice are born normal but exhibit an age-dependent increase of bone mass. The cause of this increase can be traced to enhanced activities of osteoblasts, which become sensitized to bone morphogenesis protein (BMP) in the absence of Smurf1. However, loss of Smurf1 does not affect the canonical Smad-mediated intracellular TGF beta or BMP signaling; instead, it leads to accumulation of phosphorylated MEKK2 and activation of the downstream JNK signaling cascade. We demonstrate that Smurf1 physically interacts with MEKK2 and promotes the ubiquitination and turnover of MEKK2. These results indicate that Smurf1 negatively regulates osteoblast activity and response to BMP through controlling MEKK2 degradation.	NCI, Cellular & Mol Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA; NCI, Lab Anim Sci Program, Frederick, MD 21702 USA; NIDDKD, Mammalian Genet Sect, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Zhang, YE (corresponding author), NCI, Cellular & Mol Biol Lab, Ctr Canc Res, Bldg 37, Bethesda, MD 20892 USA.	yingz@helix.nih.gov	Zhang, Ying E/G-3657-2015; deng, chuxia/N-6713-2016	Zhang, Ying E/0000-0003-2753-7601; 	Intramural NIH HHS [ZIA BC011168-01, Z01 BC010419-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056001] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Bakin AV, 2002, J CELL SCI, V115, P3193; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; BHARGAVA U, 1988, BONE, V9, P155, DOI 10.1016/8756-3282(88)90005-1; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; FRACESCHI RT, 2003, J CELL BIOCHEM, V88, P446; Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060; Hess J, 2001, J BIOL CHEM, V276, P20029, DOI 10.1074/jbc.M010601200; HOGAN B, 1994, MANUPULATING MOUSE E; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Itoh S, 2003, J BIOL CHEM, V278, P3751, DOI 10.1074/jbc.M208258200; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Maeda S, 2004, EMBO J, V23, P552, DOI 10.1038/sj.emboj.7600067; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wong C, 1999, MOL CELL BIOL, V19, P1821; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhao M, 2002, J CELL BIOL, V157, P1049, DOI 10.1083/jcb.200109012; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	51	270	287	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					101	113		10.1016/j.cell.2005.01.035	http://dx.doi.org/10.1016/j.cell.2005.01.035			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820682	Green Accepted, Bronze			2022-12-28	WOS:000228348500013
J	Lee, H; Lee, JW; Kim, DY; Park, J; Seo, YT; Zeng, H; Moudrakovski, IL; Ratcliffe, CI; Ripmeester, JA				Lee, H; Lee, JW; Kim, DY; Park, J; Seo, YT; Zeng, H; Moudrakovski, IL; Ratcliffe, CI; Ripmeester, JA			Tuning clathrate hydrates for hydrogen storage	NATURE			English	Article							CLUSTERS	The storage of large quantities of hydrogen at safe pressures(1) is a key factor in establishing a hydrogen-based economy. Previous strategies-where hydrogen has been bound chemically(2), adsorbed in materials with permanent void space(3) or stored in hybrid materials that combine these elements(3)-have problems arising from either technical considerations or materials cost(2-5). A recently reported(6-8) clathrate hydrate of hydrogen exhibiting two different-sized cages does seem to meet the necessary storage requirements; however, the extreme pressures (similar to 2 kbar) required to produce the material make it impractical. The synthesis pressure can be decreased by filling the larger cavity with tetrahydrofuran (THF) to stabilize the material(9), but the potential storage capacity of the material is compromised with this approach. Here we report that hydrogen storage capacities in THF-containing binary-clathrate hydrates can be increased to similar to 4wt% at modest pressures by tuning their composition to allow the hydrogen guests to enter both the larger and the smaller cages, while retaining low-pressure stability. The tuning mechanism is quite general and convenient, using water-soluble hydrate promoters and various small gaseous guests.	Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Taejon 305701, South Korea; Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada	Korea Advanced Institute of Science & Technology (KAIST); National Research Council Canada	Lee, H (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem & Biomol Engn, Taejon 305701, South Korea.	h_lee@kaist.ac.kr; John.Ripmeester@nrc-cnrc.gc.ca	Seo, Yutaek/B-3384-2012; Ripmeester, John A/G-1950-2011; Zeng, Huang/A-2192-2010; Lee, Huen/C-1922-2011	Seo, Yutaek/0000-0001-8537-579X; Zeng, Huang/0000-0003-0293-7692; Park, Jeasung/0000-0001-8016-001X				Berry GD, 1998, ENERG FUEL, V12, P49, DOI 10.1021/ef9700947; Florusse LJ, 2004, SCIENCE, V306, P469, DOI 10.1126/science.1102076; Jeffrey GA., 1996, COMPREHENSIVE SUPRAM, P757; Lokshin KA, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.125503; Mao WL, 2004, P NATL ACAD SCI USA, V101, P708, DOI 10.1073/pnas.0307449100; Mao WL, 2002, SCIENCE, V297, P2247, DOI 10.1126/science.1075394; NAKAHARA J, 1988, PHILOS MAG B, V57, P421, DOI 10.1080/13642818808208514; Nakamoto K., 2009, INFRARED RAMAN SPECT; Patchkovskii S, 2003, P NATL ACAD SCI USA, V100, P14645, DOI 10.1073/pnas.2430913100; Rosi NL, 2003, SCIENCE, V300, P1127, DOI 10.1126/science.1083440; Schimmel HG, 2003, CHEM-EUR J, V9, P4764, DOI 10.1002/chem.200304845; Schlapbach L, 2001, NATURE, V414, P353, DOI 10.1038/35104634; WEITKAMP J, 1995, INT J HYDROGEN ENERG, V20, P967, DOI 10.1016/0360-3199(95)00058-L	13	650	663	7	227	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					743	746		10.1038/nature03457	http://dx.doi.org/10.1038/nature03457			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815624				2022-12-28	WOS:000228160700035
J	Wright, JT; Dunn, JK; Cutler, JA; Davis, BR; Cushman, WC; Ford, CE; Haywood, LJ; Leenen, FHH; Margolis, KL; Papademetriou, V; Probstfield, JL; Whelton, PK; Habib, GB				Wright, JT; Dunn, JK; Cutler, JA; Davis, BR; Cushman, WC; Ford, CE; Haywood, LJ; Leenen, FHH; Margolis, KL; Papademetriou, V; Probstfield, JL; Whelton, PK; Habib, GB		ALLHAT Collaborative Res Grp	Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONVERTING-ENZYME-INHIBITOR; LIPID-LOWERING TREATMENT; CALCIUM-CHANNEL BLOCKER; HEART-FAILURE EVENTS; ATTACK TRIAL ALLHAT; BLOOD-PRESSURE; COMBINATION THERAPY; CARDIOVASCULAR MORBIDITY; RANDOMIZED-TRIAL; MORTALITY	Context Few cardiovascular outcome data are available for blacks with hypertension treated with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs). Objective To determine whether an ACE inhibitor or CCB is superior to a thiazide-type diuretic in reducing cardiovascular disease (CVD) incidence in racial subgroups. Design, Setting, and Participants Prespecified subgroup analysis of ALLHAT, a randomized, double-blind, active-controlled, clinical outcome trial conducted between February 1994 and March 2002 in 33 357 hypertensive US and Canadian patients aged 55 years or older (35% black) with at least 1 other cardiovascular risk factor. Interventions Anti hypertensive regimens initiated with a CCB (amlodipine) or an ACE inhibitor (lisinopril) vs a thiazide-type diuretic (chlorthalidone). Other medications were added to achieve goal blood pressures (BPs) less than 140/90 mm Hg. Main Outcome Measures The primary outcome was combined fatal coronary heart disease (CHD) or nonfatal myocardial infarction (MI), analyzed by intention-to-treat. Secondary outcomes included all-cause mortality, stroke, combined CVD (CND death, nonfatal MI, stroke, angina, coronary revascularization, heart failure [HF], or peripheral vascular disease), and end-stage renal disease. Results No significant difference was found between treatment groups for the primary CHD outcome in either racial subgroup. For amlodipine vs chlorthalidone only, HF was the only prespecified clinical outcome that differed significantly (overall: relative risk [RR], 1.37; 95% confidence interval [Cl], 1.24-1.51; blacks: RR, 1.46; 95% CI, 1.24-1.73; nonblacks: RR, 1.32; 95% CI, 1.17-1.49; P<.001 for each comparison) with no difference in treatment effects by race (P=.38 for interaction). For lisinopril vs chlorthalidone, results differed by race for systolic BP (greater decrease in blacks with chlorthalidone), stroke, and combined CVD outcomes (P<.001, P=.01, and P=.04, respectively, for interactions). In blacks and nonblacks, respectively, the RRs for stroke were 1.40 (95% CI, 1.17-1.68) and 1.00 (95% CI, 0.85-1.17) and for combined CVD were 1.19 (95% CI, 1.09-1.30) and 1.06(95% CI, 1.00-1.13). For HF, the RRs were 1.30 (95% CI, 1.10-1.54) and 1.13 (95% CI, 1.00-1.28), with no significant interaction by race. Time-dependent BP adjustment did not significantly alter differences in outcome for lisinopril vs chlorthalidone in blacks. Conclusions In blacks and nonblack subgroups, rates were not lower in the amlodipine or lisinopril groups than in the chlorthalidone group for either the primary CHD or any other prespecified clinical outcome, and diuretic-based treatment resulted in the lowest risk of heart failure. While the improved outcomes with chlorthalidone were more pronounced for some outcomes in blacks than in nonblacks, thiazide-type diuretics remain the drugs of choice for initial therapy of hypertension in both black and nonblack hypertensive patients.	Case Western Reserve Univ, Gen Clin Res Ctr, Cleveland, OH 44106 USA; Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Memphis Vet Affairs Med Ctr, Memphis, TN USA; Univ So Calif, Los Angeles Cty Med Ctr, Los Angeles, CA 90033 USA; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; Berman Ctr Outcomes & Clin Res, Minneapolis, MN USA; Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA; Vet Affairs Med Ctr, Washington, DC 20422 USA; Univ Washington, Seattle, WA 98195 USA; Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA; Houston Vet Affairs Med Ctr, Houston, TX USA	Case Western Reserve University; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Southern California; University of Ottawa; University of Ottawa Heart Institute; Hennepin County Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; Tulane University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center	Wright, JT (corresponding author), Case Western Reserve Univ, Gen Clin Res Ctr, 11000 Euclid Ave,Bowell Bldg,5th Floor, Cleveland, OH 44106 USA.	jackson.wright@case.edu		Margolis, Karen/0000-0003-1862-7402; Papademetriou, Vasilios/0000-0002-2882-2757	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC035130] Funding Source: NIH RePORTER	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alderman MH, 2003, HYPERTENSION, V42, P239, DOI 10.1161/01.HYP.0000086521.95630.5A; Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; BOLZANO K, 1987, J CARDIOVASC PHARM, V9, pS43, DOI 10.1097/00005344-198700003-00011; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Cushman WC, 2000, ARCH INTERN MED, V160, P825, DOI 10.1001/archinte.160.6.825; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Davis BR, 2002, ANN INTERN MED, V137, P313, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00006; Douglas JG, 2003, ARCH INTERN MED, V163, P525, DOI 10.1001/archinte.163.5.525; Dries DL, 2002, J AM COLL CARDIOL, V40, P311, DOI 10.1016/S0735-1097(02)01943-5; Einhorn P, 2003, CIRCULATION, V108, P399; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; Grimm RH, 2001, HYPERTENSION, V37, P19, DOI 10.1161/01.HYP.37.1.19; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; JOHNSON E, 2005, HYPERTENSION, P587; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; Khan NA, 2004, CAN J CARDIOL, V20, P41; Klein JP., 2003, SURVIVAL ANAL TECHNI; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; LUTHER RR, 1986, AM J MED, V80, P73, DOI 10.1016/0002-9343(86)90856-9; MACGREGOR GA, 1985, J CARDIOVASC PHARM, V7, pS82, DOI 10.1097/00005344-198507001-00016; MANDER A, 2000, HOTDECK IMPUTATION, P196; Materson BJ, 1996, AM J HYPERTENS, V9, pS187, DOI 10.1016/S0895-7061(96)90100-4; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; Messerli FH, 2000, AM J CARDIOL, V86, P1182, DOI 10.1016/S0002-9149(00)01199-1; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Piller LB, 2002, CURR CONTR TRIALS C, V3, DOI 10.1186/1468-6708-3-10; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Rahman M, 1997, ENDOCRIN METAB CLIN, V26, P125, DOI 10.1016/S0889-8529(05)70237-1; RAHMAN M, IN PRESS ARCH INTERN; Roca-Cusachs A, 2001, J CARDIOVASC PHARM, V38, P840, DOI 10.1097/00005344-200112000-00005; SAUNDERS E, 1990, ARCH INTERN MED, V150, P1707, DOI 10.1001/archinte.150.8.1707; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; The AO, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981; Turnbull F, 2003, LANCET, V362, P1527; WHO, 2002, RED RISKS PROM HLTH; Williams B, 2004, BMJ-BRIT MED J, V328, P634, DOI 10.1136/bmj.328.7440.634; WILLIAMS GH, 1988, NEW ENGL J MED, V319, P1517; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Yusuf S, 2000, NEW ENGL J MED, V342, P145	51	304	311	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2005	293	13					1595	1607		10.1001/jama.293.13.1595	http://dx.doi.org/10.1001/jama.293.13.1595			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913EV	15811979				2022-12-28	WOS:000228135300022
J	Koller, H; Kieseier, BC; Jander, S; Hartung, H				Koller, H; Kieseier, BC; Jander, S; Hartung, H			Medical progress: Chronic inflammatory demyelinating polyneuropathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							GUILLAIN-BARRE-SYNDROME; MULTIFOCAL MOTOR NEUROPATHY; PERIPHERAL NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE NEURITIS; RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS IMMUNOGLOBULIN TREATMENT; CHRONIC RELAPSING POLYNEUROPATHY; INTERFERON-ALPHA; DOUBLE-BLIND; T-CELLS		Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Hartung, H (corresponding author), Univ Dusseldorf, Dept Neurol, Moorenstr 5, D-40225 Dusseldorf, Germany.	hartung@uni-duesseldorf.de						Alaedini A, 2003, ARCH NEUROL-CHICAGO, V60, P42, DOI 10.1001/archneur.60.1.42; Andorfer B, 2001, J NEUROIMMUNOL, V116, P226, DOI 10.1016/S0165-5728(01)00306-X; Anthoney DA, 2000, ANN ONCOL, V11, P1197, DOI 10.1023/A:1008362714023; AUSTIN JH, 1958, BRAIN, V81, P157, DOI 10.1093/brain/81.2.157; Barnett MH, 1998, MUSCLE NERVE, V21, P454, DOI 10.1002/(SICI)1097-4598(199804)21:4<454::AID-MUS3>3.0.CO;2-8; BAROHN RJ, 1989, ARCH NEUROL-CHICAGO, V46, P878, DOI 10.1001/archneur.1989.00520440064022; Benedetti L, 2004, MUSCLE NERVE, V29, P748, DOI 10.1002/mus.20024; Berger AR, 2003, J PERIPHER NERV SYST, V8, P282; Bosboom WMJ, 2001, BRAIN, V124, P2427, DOI 10.1093/brain/124.12.2427; Bosboom WMJ, 2001, NEUROLOGY, V56, P74, DOI 10.1212/WNL.56.1.74; Bouchard C, 1999, NEUROLOGY, V52, P498, DOI 10.1212/WNL.52.3.498; Brannagan TH, 2002, NEUROLOGY, V58, P1856, DOI 10.1212/WNL.58.12.1856; Chaudhry V, 2001, NEUROLOGY, V56, P94, DOI 10.1212/WNL.56.1.94; Chin RL, 2003, J NEUROL SCI, V210, P19, DOI 10.1016/S0022-510X(03)00010-8; Connolly AM, 2001, PEDIATR NEUROL, V24, P177, DOI 10.1016/S0887-8994(00)00237-X; CORNBLATH DR, 1991, NEUROLOGY, V41, P617; Dalakas MC, 2002, NEUROLOGY, V59, pS13, DOI 10.1212/WNL.59.12_suppl_6.S13; DALAKAS MC, 1981, ANN NEUROL, V9, P134, DOI 10.1002/ana.410090719; DALAKAS MC, 1980, NEUROLOGY, V30, P864, DOI 10.1212/WNL.30.8.864; DALAKAS MC, 1980, ARCH NEUROL-CHICAGO, V37, P637, DOI 10.1001/archneur.1980.00500590061010; Dalakas MC, 1999, CURR OPIN NEUROL, V12, P403, DOI 10.1097/00019052-199908000-00006; Duggins AJ, 1999, BRAIN, V122, P1383, DOI 10.1093/brain/122.7.1383; DYCK PJ, 1975, MAYO CLIN PROC, V50, P621; DYCK PJ, 1994, ANN NEUROL, V36, P838, DOI 10.1002/ana.410360607; DYCK PJ, 1985, NEUROLOGY, V35, P1173, DOI 10.1212/WNL.35.8.1173; Eurelings M, 2001, MUSCLE NERVE, V24, P1312, DOI 10.1002/mus.1149; Federico P, 2000, NEUROLOGY, V55, P1256, DOI 10.1212/WNL.55.9.1256; Fee DB, 2003, J PERIPHER NERV SYST, V8, P155, DOI 10.1046/j.1529-8027.2003.03022.x; Gabriel CM, 2000, J NEUROL NEUROSUR PS, V69, P442, DOI 10.1136/jnnp.69.4.442; Ginsberg L, 2004, BRAIN, V127, P193, DOI 10.1093/brain/awh017; Gold R, 1999, BRAIN PATHOL, V9, P343; Gold R, 1997, TRENDS NEUROSCI, V20, P399, DOI 10.1016/S0166-2236(97)01079-5; Good JL, 1998, NEUROLOGY, V51, P1735, DOI 10.1212/WNL.51.6.1735; Gorson KC, 1997, NEUROLOGY, V48, P321, DOI 10.1212/WNL.48.2.321; Gorson KC, 2004, NEUROLOGY, V63, P715, DOI 10.1212/01.WNL.0000134676.05850.C0; Gorson KC, 1998, NEUROLOGY, V50, P84, DOI 10.1212/WNL.50.1.84; Gorson KC, 2001, MUSCLE NERVE, V24, P778, DOI 10.1002/mus.1069; Gorson KC, 2000, MUSCLE NERVE, V23, P37, DOI 10.1002/(SICI)1097-4598(200001)23:1<37::AID-MUS5>3.0.CO;2-9; Hadden RDM, 1999, NEUROLOGY, V53, P57, DOI 10.1212/WNL.53.1.57; Hahn AF, 1996, BRAIN, V119, P1055, DOI 10.1093/brain/119.4.1055; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; Hao RU, 2003, MUSCLE NERVE, V27, P465, DOI 10.1002/mus.1250; Haq RU, 2000, ARCH NEUROL-CHICAGO, V57, P1745, DOI 10.1001/archneur.57.12.1745; Harada H, 2000, MUSCLE NERVE, V23, P295, DOI 10.1002/(SICI)1097-4598(200002)23:2<295::AID-MUS26>3.0.CO;2-C; HARTUNG HP, 1991, ANN NEUROL, V30, P48, DOI 10.1002/ana.410300110; Hu W, 2003, NEUROLOGY, V61, P1774, DOI 10.1212/01.WNL.0000098884.75756.4D; Hughes R, 2001, ANN NEUROL, V50, P195, DOI 10.1002/ana.1088; HUGHES RA, 2003, COCHRANE DB SYST REV, V1; Hughes RAC, 2004, BRAIN, V127, P1723, DOI 10.1093/brain/awh192; Illes Z, 2000, J IMMUNOL, V164, P4375, DOI 10.4049/jimmunol.164.8.4375; Illes Z, 2004, INT IMMUNOL, V16, P223, DOI 10.1093/intimm/dxh018; Kanda T, 2004, J NEUROL NEUROSUR PS, V75, P765, DOI 10.1136/jnnp.2003.025692; Kastenbauer S, 2003, J NEUROIMMUNOL, V137, P210, DOI 10.1016/S0165-5728(03)00085-7; Katz JS, 2000, NEUROLOGY, V54, P615, DOI 10.1212/WNL.54.3.615; Katz JS, 2002, NEUROLOGY, V58, P615, DOI 10.1212/WNL.58.4.615; Kiefer R, 2001, PROG NEUROBIOL, V64, P109, DOI 10.1016/S0301-0082(00)00060-5; Kieseier BC, 1998, ANN NEUROL, V43, P427, DOI 10.1002/ana.410430404; Kieseier BC, 2002, BRAIN, V125, P823, DOI 10.1093/brain/awf070; Kuntzer T, 1999, NEUROLOGY, V53, P1364, DOI 10.1212/WNL.53.6.1364; Kwa MSG, 2003, BRAIN, V126, P361, DOI 10.1093/brain/awg030; Latov N, 2002, NEUROLOGY, V59, pS2, DOI 10.1212/WNL.59.12_suppl_6.S2; Leppert D, 1999, NEUROLOGY, V53, P62, DOI 10.1212/WNL.53.1.62; LEWIS RA, 1982, NEUROLOGY, V32, P958, DOI 10.1212/WNL.32.9.958; Lisak RP, 2000, MUSCLE NERVE, V23, P307, DOI 10.1002/(SICI)1097-4598(200003)23:3<307::AID-MUS1>3.0.CO;2-U; Lunn MPT, 1999, J NEUROL NEUROSUR PS, V66, P677, DOI 10.1136/jnnp.66.5.677; Magda P, 2003, ARCH NEUROL-CHICAGO, V60, P1755, DOI 10.1001/archneur.60.12.1755; Mahattanakul W, 1996, J NEUROL NEUROSUR PS, V60, P185, DOI 10.1136/jnnp.60.2.185; Mariette X, 2000, J NEUROL NEUROSUR PS, V69, P279, DOI 10.1136/jnnp.69.2.279; Marzo ME, 1998, J NEUROL NEUROSUR PS, V65, P604, DOI 10.1136/jnnp.65.4.604; Mathey EK, 1999, J NEUROL SCI, V163, P47, DOI 10.1016/S0022-510X(99)00009-X; Matsuda M, 2004, J NEUROL SCI, V224, P29, DOI 10.1016/j.jns.2004.05.014; McCrone P, 2003, EUR J NEUROL, V10, P687, DOI 10.1046/j.1351-5101.2003.00701.x; McLeod JG, 1999, ANN NEUROL, V46, P910, DOI 10.1002/1531-8249(199912)46:6<910::AID-ANA14>3.3.CO;2-U; Mehndiratta MM, 2002, COCHRANE DB SYST REV, V1; MelendezVasquez C, 1997, J NEUROIMMUNOL, V73, P124, DOI 10.1016/S0165-5728(96)00189-0; Mendell JR, 2001, NEUROLOGY, V56, P445, DOI 10.1212/WNL.56.4.445; Meriggioli MN, 2000, MUSCLE NERVE, V23, P433, DOI 10.1002/(SICI)1097-4598(200003)23:3<433::AID-MUS17>3.0.CO;2-O; Midroni G, 1999, J NEUROL SCI, V170, P36, DOI 10.1016/S0022-510X(99)00195-1; Molenaar DSM, 1998, J NEUROL NEUROSUR PS, V64, P84, DOI 10.1136/jnnp.64.1.84; Mygland A, 2003, ARCH NEUROL-CHICAGO, V60, P260, DOI 10.1001/archneur.60.2.260; Nobile-Orazio E, 2000, BRAIN, V123, P710, DOI 10.1093/brain/123.4.710; Oh S J, 1997, J Peripher Nerv Syst, V2, P362; Pestronk A, 1998, NEUROLOGY, V51, pS22, DOI 10.1212/WNL.51.6_Suppl_5.S22; Pestronk A, 2003, J NEUROL NEUROSUR PS, V74, P485, DOI 10.1136/jnnp.74.4.485; Pirko I, 2003, NEUROLOGY, V60, P1697, DOI 10.1212/01.WNL.0000064163.94122.EB; Previtali SC, 1998, ANN NEUROL, V44, P611, DOI 10.1002/ana.410440406; Previtali SC, 2001, PROG NEUROBIOL, V64, P35, DOI 10.1016/S0301-0082(00)00045-9; Pritchard J, 2003, NEUROLOGY, V61, P1282, DOI 10.1212/01.WNL.0000092019.53628.88; Quattrini Angelo, 2003, Critical Reviews in Neurobiology, V15, P1, DOI 10.1615/CritRevNeurobiol.v15.i1.10; Renaud S, 2003, MUSCLE NERVE, V27, P611, DOI 10.1002/mus.10359; Rotta FT, 2000, J NEUROL SCI, V173, P129, DOI 10.1016/S0022-510X(99)00317-2; SABATELLI M, 1995, J NEUROL NEUROSUR PS, V58, P638, DOI 10.1136/jnnp.58.5.638; Salomon B, 2001, J EXP MED, V194, P1393; Sander HW, 2003, NEUROLOGY, V60, pS8, DOI 10.1212/WNL.60.8_suppl_3.S8; Saperstein DS, 2001, MUSCLE NERVE, V24, P311, DOI 10.1002/1097-4598(200103)24:3<311::AID-MUS1001>3.3.CO;2-1; Schmidt B, 1996, MUSCLE NERVE, V19, P474, DOI 10.1002/(SICI)1097-4598(199604)19:4<474::AID-MUS8>3.0.CO;2-9; Sghirlanzoni A, 2000, NEUROL SCI, V21, P31, DOI 10.1007/s100720070116; Stojkovic T, 2000, CLIN NEUROPHYSIOL, V111, P2285, DOI 10.1016/S1388-2457(00)00478-8; Takigawa T, 2000, INTERNAL MED, V39, P123, DOI 10.2169/internalmedicine.39.123; Thaisetthawatkul P, 2002, NEUROLOGY, V59, P1526, DOI 10.1212/01.WNL.0000034172.47882.20; THOMAS PK, 1969, BRAIN, V92, P589, DOI 10.1093/brain/92.3.589; TSUCHIDA T, 1989, CANCER, V63, P1166, DOI 10.1002/1097-0142(19890315)63:6<1166::AID-CNCR2820630621>3.0.CO;2-5; Umapathi T, 2002, EUR J NEUROL, V9, P683, DOI 10.1046/j.1468-1331.2002.00478.x; Vallat JM, 2003, NEUROLOGY, V60, pS23, DOI 10.1212/WNL.60.8_suppl_3.S23; Vallat JM, 2003, MUSCLE NERVE, V27, P478, DOI 10.1002/mus.10348; Van Rhijn I, 2000, BRAIN, V123, P2020, DOI 10.1093/brain/123.10.2020; VANDENBERG LH, 1995, J NEUROIMMUNOL, V58, P37, DOI 10.1016/0165-5728(94)00185-Q; VanEs HW, 1997, NEUROLOGY, V48, P1218, DOI 10.1212/WNL.48.5.1218; VANSCHAIK IN, 2002, COCHRANE DB SYST REV, V2; Vermeulen M, 2002, J NEUROL NEUROSUR PS, V72, P127, DOI 10.1136/jnnp.72.1.127; VERMEULEN M, 1993, J NEUROL NEUROSUR PS, V56, P36, DOI 10.1136/jnnp.56.1.36; Viala K, 2004, BRAIN, V127, P2010, DOI 10.1093/brain/awh222; Walk D, 2004, NEUROLOGY, V62, P155, DOI 10.1212/WNL.62.1.155; Weiss MD, 1998, NEUROLOGY, V51, P1738, DOI 10.1212/WNL.51.6.1738; Winer J, 2002, J NEUROL, V249, P616, DOI 10.1007/s004150200072; Yan WX, 2001, ANN NEUROL, V50, P286, DOI 10.1002/ana.1129; Yan WX, 2000, ANN NEUROL, V47, P765; ZETTL UK, 1995, J NEUROPATH EXP NEUR, V54, P540, DOI 10.1097/00005072-199507000-00008	118	298	305	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1343	1356		10.1056/nejmra041347	http://dx.doi.org/10.1056/nejmra041347			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800230				2022-12-28	WOS:000227998300011
J	Yeo, M; Saayer, S				Yeo, M; Saayer, S			ABC of adolescence - Chronic illness and disability	BRITISH MEDICAL JOURNAL			English	Review									Royal Childrens Hosp, Ctr Adolescent Hlth, Melbourne, Vic, Australia	Royal Children's Hospital Melbourne	Yeo, M (corresponding author), Royal Childrens Hosp, Ctr Adolescent Hlth, Melbourne, Vic, Australia.							Neinstein LS, 2002, ADOLESCENT HLTH CARE; Suris JC, 2004, ARCH DIS CHILD, V89, P938, DOI 10.1136/adc.2003.045369	2	102	108	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	MAR 26	2005	330	7493					721	723		10.1136/bmj.330.7493.721	http://dx.doi.org/10.1136/bmj.330.7493.721			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912IT	15790645	Green Published			2022-12-28	WOS:000228071900022
J	Badman, MK; Flier, JS				Badman, MK; Flier, JS			The gut and energy balance: Visceral allies in the obesity wars	SCIENCE			English	Review							GLUCAGON-LIKE PEPTIDE-1; REDUCES FOOD-INTAKE; PYLORIC ELECTRICAL-STIMULATION; GASTRIC BYPASS-SURGERY; PLASMA GHRELIN LEVELS; BODY-WEIGHT; PANCREATIC-POLYPEPTIDE; IN-VIVO; RECEPTOR; LEPTIN	In addition to digesting and assimilating nutrients, the intestine and associated visceral organs play a key sensing and signaling role in the physiology of energy homeostasis. The gut, the pancreatic islets of Langerhans, elements in the portal vasculature, and even visceral adipose tissue communicate with the controllers of energy balance in the brain by means of neural and endocrine pathways. Signals reflecting energy stores, recent nutritional state, and other parameters are integrated in the central nervous system, particularly in the hypothalamus, to coordinate energy intake and expenditure. Our understanding of regulatory neural circuits and the signaling molecules that influence them has progressed rapidly, particularly after the discovery of the adipocyte hormone leptin. These discoveries have led to exploration of novel routes for obesity control, some of which involve gut-derived pathways.	Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Flier, JS (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Finard 202,330 Brookline Ave, Boston, MA 02215 USA.	jFlier@bidmc.harvard.edu	Flier, jeffrey/AAG-6223-2019					ADRIAN TE, 1986, GASTROENTEROLOGY, V90, P379, DOI 10.1016/0016-5085(86)90936-4; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Baggio LL, 2004, GASTROENTEROLOGY, V127, P546, DOI 10.1053/j.gastro.2004.04.063; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Batterham RL, 2003, NEW ENGL J MED, V349, P941, DOI 10.1056/NEJMoa030204; Batterham RL, 2003, J CLIN ENDOCR METAB, V88, P3989, DOI 10.1210/jc.2003-030630; Bays HE, 2004, OBES RES, V12, P1197, DOI 10.1038/oby.2004.151; Beglinger C, 2001, AM J PHYSIOL-REG I, V280, pR1149, DOI 10.1152/ajpregu.2001.280.4.R1149; Benoit SC, 2004, RECENT PROG HORM RES, V59, P267, DOI 10.1210/rp.59.1.267; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Cigaina V, 2003, OBES RES, V11, P1456, DOI 10.1038/oby.2003.195; Clark A, 2004, DIABETOLOGIA, V47, P157, DOI 10.1007/s00125-003-1304-4; Cohen MA, 2003, J CLIN ENDOCR METAB, V88, P4696, DOI 10.1210/jc.2003-030421; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714; Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908; Dakin CL, 2004, ENDOCRINOLOGY, V145, P2687, DOI 10.1210/en.2003-1338; Dakin CL, 2001, ENDOCRINOLOGY, V142, P4244, DOI 10.1210/en.142.10.4244; Date Y, 2002, GASTROENTEROLOGY, V123, P1120, DOI 10.1053/gast.2002.35954; Edwards CMB, 2001, AM J PHYSIOL-ENDOC M, V281, pE155, DOI 10.1152/ajpendo.2001.281.1.E155; Ettinger MP, 2003, JAMA-J AM MED ASSOC, V289, P1826, DOI 10.1001/jama.289.14.1826; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Faulconbridge LF, 2003, DIABETES, V52, P2260, DOI 10.2337/diabetes.52.9.2260; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Fu J, 2003, NATURE, V425, P90, DOI 10.1038/nature01921; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Gribble FM, 2003, DIABETES, V52, P1147, DOI 10.2337/diabetes.52.5.1147; GRILL HJ, 1988, AM J PHYSIOL, V254, pR853, DOI 10.1152/ajpregu.1988.254.6.R853; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Katsuura G, 2002, PEPTIDES, V23, P323, DOI 10.1016/S0196-9781(01)00604-0; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Korner J, 2005, J CLIN ENDOCR METAB, V90, P359, DOI 10.1210/jc.2004-1076; Kovacs EMR, 2003, BRIT J NUTR, V90, P207, DOI 10.1079/BJN2003871; KREYMANN B, 1987, LANCET, V2, P1300; Larsen PJ, 2001, DIABETES, V50, P2530, DOI 10.2337/diabetes.50.11.2530; Lehrke M, 2004, PLOS MED, V1, P161, DOI 10.1371/journal.pmed.0010045; LIEVERSE RJ, 1993, J CLIN ENDOCR METAB, V76, P1495, DOI 10.1210/jc.76.6.1495; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; MCLAUGHLIN CL, 1981, PHYSIOL BEHAV, V26, P433, DOI 10.1016/0031-9384(81)90171-2; Meeran K, 1999, ENDOCRINOLOGY, V140, P244, DOI 10.1210/en.140.1.244; Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727; Moran TH, 2005, AM J PHYSIOL-REG I, V288, pR384, DOI 10.1152/ajpregu.00535.2004; MUURAHAINEN N, 1988, PHYSIOL BEHAV, V44, P645, DOI 10.1016/0031-9384(88)90330-7; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Neary NM, 2004, J CLIN ENDOCR METAB, V89, P2832, DOI 10.1210/jc.2003-031768; Reidelberger RD, 2002, AM J PHYSIOL-REG I, V282, pR1395, DOI 10.1152/ajpregu.00597.2001; Reimann F, 2002, DIABETES, V51, P2757, DOI 10.2337/diabetes.51.9.2757; Roslin M, 2001, EPILEPSY BEHAV, V2, pS11, DOI 10.1006/ebeh.2001.0213; Schmidt PT, 2003, REGUL PEPTIDES, V116, P21, DOI 10.1016/S0167-0115(03)00175-7; Schmitz O, 2004, DIABETES, V53, pS233, DOI 10.2337/diabetes.53.suppl_3.S233; Schwartz GJ, 2000, NUTRITION, V16, P866, DOI 10.1016/S0899-9007(00)00464-0; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Shi H, 2004, J BIOL CHEM, V279, P34733, DOI 10.1074/jbc.M403886200; Shikora SA, 2004, OBES SURG, V14, pS40, DOI 10.1007/BF03342137; SMITH GP, 1981, SCIENCE, V213, P1036, DOI 10.1126/science.7268408; Steinbrook R, 2004, NEW ENGL J MED, V350, P1075, DOI 10.1056/NEJMp048029; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Sun YX, 2003, MOL CELL BIOL, V23, P7973, DOI 10.1128/MCB.23.22.7973-7981.2003; Sun YX, 2004, P NATL ACAD SCI USA, V101, P4679, DOI 10.1073/pnas.0305930101; Tang-Christensen M, 2001, INT J OBESITY, V25, pS42, DOI 10.1038/sj.ijo.0801912; Thorne A, 2002, INT J OBESITY, V26, P193, DOI 10.1038/sj.ijo.0801871; Tourrel C, 2001, DIABETES, V50, P1562, DOI 10.2337/diabetes.50.7.1562; Verdich C, 2001, J CLIN ENDOCR METAB, V86, P4382, DOI 10.1210/jc.86.9.4382; Vrang N, 2003, AM J PHYSIOL-REG I, V285, pR470, DOI 10.1152/ajpregu.00732.2002; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Wolfe BM, 2005, GASTROENTEROLOGY, V128, P225, DOI 10.1053/j.gastro.2004.11.055; WOODS SC, 1981, DIABETOLOGIA, V20, P305, DOI 10.1007/BF00254497; Wu SV, 2002, P NATL ACAD SCI USA, V99, P2392, DOI 10.1073/pnas.042617699; Xu XH, 2005, GASTROENTEROLOGY, V128, P43, DOI 10.1053/j.gastro.2004.09.079; Yamamoto H, 2003, J NEUROSCI, V23, P2939; Yamamoto H, 2002, J CLIN INVEST, V110, P43, DOI 10.1172/JCI200215595; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	78	359	375	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 25	2005	307	5717					1909	1914		10.1126/science.1109951	http://dx.doi.org/10.1126/science.1109951			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790843				2022-12-28	WOS:000227957300044
J	Nasmyth, K				Nasmyth, K			How do so few control so many?	CELL			English	Review							SPINDLE CHECKPOINT PROTEIN; ANAPHASE-PROMOTING COMPLEX; ASSEMBLY CHECKPOINT; BUDDING YEAST; MAD2; CDC20; KINETOCHORES; TENSION; BINDING; MITOSIS	The separation of sister chromatids at the metaphase-to-anaphase transition is triggered by a protease called separase that is activated by the destruction of an inhibitory chaperone (securin). This process is mediated by a ubiquitin protein ligase called the anaphase-promoting complex or cyclosome (APC/C), along with a protein called Cdc20. It is vital that separase not be activated before every single chromosome has been aligned on the mitotic spindle. Kinetochores that have not yet attached to microtubules; catalyze the sequestration of Cdc20 by an inhibitor called Mad2. Recent experiments shed important insight into how Mad2 molecules bound to centromeres through their association with a protein called Mad1 might be transferred to Cdc20 and thereby inhibit securin ' s destruction.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	knasmyth@imp.univie.ac.at		Nasmyth, Kim/0000-0001-7030-4403				Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P284, DOI 10.1016/S0968-0004(98)01257-2; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Luo XL, 2004, NAT STRUCT MOL BIOL, V11, P338, DOI 10.1038/nsmb748; Luo XL, 2000, NAT STRUCT BIOL, V7, P224; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Sironi L, 2002, EMBO J, V21, P2496, DOI 10.1093/emboj/21.10.2496; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Stern BM, 2001, CURR BIOL, V11, P1462, DOI 10.1016/S0960-9822(01)00451-1; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	25	130	135	1	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 25	2005	120	6					739	746		10.1016/j.cell.2005.03.006	http://dx.doi.org/10.1016/j.cell.2005.03.006			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797376	Bronze			2022-12-28	WOS:000228067500005
J	Pedraza, JM; van Oudenaarden, A				Pedraza, JM; van Oudenaarden, A			Noise propagation in gene networks	SCIENCE			English	Article							STOCHASTICITY; EXPRESSION	Accurately predicting noise propagation in gene networks is crucial for understanding signal fidelity in natural networks and designing noise-tolerant gene circuits. To quantify how noise propagates through gene networks, we measured expression correlations between genes in single cells. We found that noise in a gene was determined by its intrinsic fluctuations, transmitted noise from upstream genes, and global noise affecting all genes. A model was developed that explains the complex behavior exhibited by the correlations and reveals the dominant noise sources. The model successfully predicts the correlations as the network is systematically perturbed. This approach provides a step toward understanding and manipulating noise propagation in more complex gene networks.	MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	van Oudenaarden, A (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.	avano@mit.edu	van Oudenaarden, Alexander/AAA-1705-2019	Pedraza, Juan/0000-0002-1802-3337	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068957] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM068957] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; CHOCK PB, 1977, P NATL ACAD SCI USA, V74, P2766, DOI 10.1073/pnas.74.7.2766; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; Hasty J, 2000, P NATL ACAD SCI USA, V97, P2075, DOI 10.1073/pnas.040411297; Kepler TB, 2001, BIOPHYS J, V81, P3116, DOI 10.1016/S0006-3495(01)75949-8; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Paulsson J, 2001, Q REV BIOPHYS, V34, P1, DOI 10.1017/S0033583501003663; Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; SAVAGEAU MA, 1976, BIOCH SYSTEMS ANAL; Thattai M, 2002, BIOPHYS J, V82, P2943, DOI 10.1016/S0006-3495(02)75635-X; van Kampen N. G., 1981, STOCHASTIC PROCESSES	18	588	601	1	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1965	1969		10.1126/science.1109090	http://dx.doi.org/10.1126/science.1109090			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790857				2022-12-28	WOS:000227957300058
J	Huybers, P; Wunsch, C				Huybers, P; Wunsch, C			Obliquity pacing of the late Pleistocene glacial terminations	NATURE			English	Article							CLIMATE-CHANGE; SEA-ICE; INSOLATION; GREENLAND; FLUCTUATIONS	The 100,000-year timescale in the glacial/interglacial cycles of the late Pleistocene epoch ( the past similar to 700,000 years) is commonly attributed to control by variations in the Earth's orbit(1). This hypothesis has inspired models that depend on the Earth's obliquity (similar to 40,000 yr; similar to 40 kyr), orbital eccentricity (similar to 100 kyr) and precessional (similar to 20 kyr) fluctuations(2-5), with the emphasis usually on eccentricity and precessional forcing. According to a contrasting hypothesis, the glacial cycles arise primarily because of random internal climate variability(6-8). Taking these two perspectives together, there are currently more than thirty different models of the seven late-Pleistocene glacial cycles(9). Here we present a statistical test of the orbital forcing hypothesis, focusing on the rapid deglaciation events known as terminations(10,11). According to our analysis, the null hypothesis that glacial terminations are independent of obliquity can be rejected at the 5% significance level, whereas the corresponding null hypotheses for eccentricity and precession cannot be rejected. The simplest inference consistent with the test results is that the ice sheets terminated every second or third obliquity cycle at times of high obliquity, similar to the original proposal by Milankovitch(12). We also present simple stochastic and deterministic models that describe the timing of the late-Pleistocene glacial terminations purely in terms of obliquity forcing.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; MIT, Cambridge, MA 02139 USA	Woods Hole Oceanographic Institution; Massachusetts Institute of Technology (MIT)	Huybers, P (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	phuybers@whoi.edu		Huybers, Peter/0000-0002-3734-8145				BERGER A, 1992, EARTH PLANET SC LETT, V111, P369, DOI 10.1016/0012-821X(92)90190-7; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Broecker W. S, 1984, MILANKOVITCH CLIMA 2, V126, P687; Gildor H, 2000, PALEOCEANOGRAPHY, V15, P605, DOI 10.1029/1999PA000461; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; Huybers P, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2002PA000857; Huybers P, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017875; HUYBERS P, 2004, THESIS MIT; IMBRIE J, 1980, SCIENCE, V207, P943, DOI 10.1126/science.207.4434.943; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; Liu HS, 1999, J GEOPHYS RES-SOL EA, V104, P25197, DOI 10.1029/1999JB900246; Marshall SJ, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015192; Milankovitch M., 1941, KANON ERDBESTRAHLUNG; Paillard D, 1998, NATURE, V391, P378, DOI 10.1038/34891; Pelletier JD, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003120; Raymo ME, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000791; Raymo ME, 1997, PALEOCEANOGRAPHY, V12, P577, DOI 10.1029/97PA01169; Roe GH, 1999, GEOPHYS RES LETT, V26, P2259, DOI 10.1029/1999GL900509; Rosenblum M, 2003, CONTEMP PHYS, V44, P401, DOI 10.1080/00107510310001603129; RUBINCAM DP, 1994, THEOR APPL CLIMATOL, V48, P195, DOI 10.1007/BF00867049; Ruddiman WF, 2003, QUATERNARY SCI REV, V22, P1597, DOI 10.1016/S0277-3791(03)00087-8; SALTZMAN B, 1982, TELLUS, V34, P97, DOI 10.1111/j.2153-3490.1982.tb01797.x; Saltzman B., 2002, DYNAMICAL PALEOCLIMA; Schreiber T, 2000, PHYSICA D, V142, P346, DOI 10.1016/S0167-2789(00)00043-9; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; Upton G. J. G., 1989, SPATIAL DATA ANAL EX, V2; Wunsch C, 2004, QUATERNARY SCI REV, V23, P1001, DOI 10.1016/j.quascirev.2004.02.014; Wunsch C, 2003, QUATERNARY SCI REV, V22, P1631, DOI 10.1016/S0277-3791(03)00152-5; Wunsch C, 2003, CLIM DYNAM, V20, P353, DOI 10.1007/s00382-002-0279-z; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	30	206	218	1	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					491	494		10.1038/nature03401	http://dx.doi.org/10.1038/nature03401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791252	Green Submitted, Green Published			2022-12-28	WOS:000227836000038
J	Mattner, J; DeBord, KL; Ismail, N; Goff, RD; Cantu, C; Zhou, DP; Saint-Mezard, P; Wang, V; Gao, Y; Yin, N; Hoebe, K; Schneewind, O; Walker, D; Beutler, B; Teyton, L; Savage, PB; Bendelac, A				Mattner, J; DeBord, KL; Ismail, N; Goff, RD; Cantu, C; Zhou, DP; Saint-Mezard, P; Wang, V; Gao, Y; Yin, N; Hoebe, K; Schneewind, O; Walker, D; Beutler, B; Teyton, L; Savage, PB; Bendelac, A			Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections	NATURE			English	Article							KILLER T-CELLS; ANAPLASMA-PHAGOCYTOPHILUM; GLYCOSPHINGOLIPIDS; IDENTIFICATION; BACTERIUM; SYNTHASE; INNATE	CD1d-restricted natural killer T ( NKT) cells are innate-like lymphocytes that express a conserved T-cell receptor and contribute to host defence against various microbial pathogens(1,2). However, their target lipid antigens have remained elusive. Here we report evidence for microbial, antigen-specific activation of NKT cells against Gram-negative, lipopolysaccharide (LPS)negative alpha-Proteobacteria such as Ehrlichia muris and Sphingomonas capsulata. We have identified glycosylceramides from the cell wall of Sphingomonas that serve as direct targets for mouse and human NKT cells, controlling both septic shock reaction and bacterial clearance in infected mice. In contrast, Gram-negative, LPS-positive Salmonella typhimurium activates NKT cells through the recognition of an endogenous lysosomal glycosphingolipid, iGb3, presented by LPS-activated dendritic cells. These findings identify two novel antigenic targets of NKT cells in antimicrobial defence, and show that glycosylceramides are an alternative to LPS for innate recognition of the Gram-negative, LPS-negative bacterial cell wall.	Univ Chicago, Comm Immunol, Chicago, IL 60637 USA; Univ Chicago, Comm Microbiol, Chicago, IL 60637 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Chicago; University of Chicago; University of Texas System; University of Texas Medical Branch Galveston; Brigham Young University; Scripps Research Institute	Savage, PB (corresponding author), Univ Chicago, Comm Immunol, Chicago, IL 60637 USA.	paul_savage@byu.edu; abendela@bsd.uchicago.edu	Zhou, Dapeng/A-6446-2019; zhou, dapeng/GXG-9715-2022; Savage, Paul B/HGB-3414-2022; Mattner, Jochen/AAT-7866-2021; Savage, Paul B/E-1448-2011; Yin, NIng/C-8991-2011	Zhou, Dapeng/0000-0003-1347-3811; Savage, Paul B/0000-0002-4642-6109; Savage, Paul B/0000-0002-4642-6109; Hoebe, Kasper/0000-0002-3626-8098				AMANO K, 1987, INFECT IMMUN, V55, P2290, DOI 10.1128/IAI.55.9.2290-2292.1987; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; Fischer K, 2004, P NATL ACAD SCI USA, V101, P10685, DOI 10.1073/pnas.0403787101; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hsueh PR, 1998, CLIN INFECT DIS, V26, P676, DOI 10.1086/514595; Ismail N, 2004, J IMMUNOL, V172, P1786, DOI 10.4049/jimmunol.172.3.1786; Kawahara K, 2000, EUR J BIOCHEM, V267, P1837, DOI 10.1046/j.1432-1327.2000.01189.x; Kawakami K, 2003, EUR J IMMUNOL, V33, P3322, DOI 10.1002/eji.200324254; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; Kita H, 2002, GASTROENTEROLOGY, V123, P1031, DOI 10.1053/gast.2002.36020; Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908; Lin MQ, 2003, INFECT IMMUN, V71, P5324, DOI 10.1128/IAI.71.9.5324-5331.2003; Nieuwenhuis EES, 2002, NAT MED, V8, P588, DOI 10.1038/nm0602-588; Olano JP, 2002, MED CLIN N AM, V86, P375, DOI 10.1016/S0025-7125(03)00093-2; Park SH, 2000, NATURE, V406, P788, DOI 10.1038/35021233; Proia RL, 2003, PHILOS T R SOC B, V358, P879, DOI 10.1098/rstb.2003.1268; Selmi C, 2003, HEPATOLOGY, V38, P1250, DOI 10.1053/jhep.2003.50446; Stetson DB, 2003, J EXP MED, V198, P1069, DOI 10.1084/jem.20030630; von Loewenich FD, 2004, EUR J IMMUNOL, V34, P1789, DOI 10.1002/eji.200425250; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science.1103440	24	890	933	3	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 24	2005	434	7032					525	529		10.1038/nature03408	http://dx.doi.org/10.1038/nature03408			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791258				2022-12-28	WOS:000227836000046
J	Reyes, F; Lepage, E; Ganem, G; Molina, TJ; Brice, P; Coiffier, B; Morel, P; Ferme, C; Bosly, A; Lederlin, P; Laurent, G; Tilly, H; Aoudjane, M; Assouline, D; Audhuy, B; Azagury, M; Bauduer, F; Baumelou, E; Bichoffe, MA; Biron, P; Blanc, M; Bordessoulle, D; Bosly, A; Bouabdallah, R; Bourquard, P; Brice, P; Mounier, N; Simon, D; Gisselbrecht, C; Dombret, H; Briere, J; Caillot, D; Casanovas, O; Flesch, M; Chauffert, B; Cassuto, GP; Castaigne, S; Christian, B; Coiffier, B; Colin, P; Pinon-Netter, G; Conroy, T; Cure, H; Delmer, A; Delwail, V; Devidas, A; Dreyfus, F; Dupont, G; Eisenmann, JC; Fabbro, M; Ferme, C; Fillet, G; Furchart, C; Gabarre, J; Gabez, M; Gautier, M; Haioun, C; Divine, M; Belhadj, K; Reyes, F; Herbrecht, R; Hermine, O; Varet, B; Janvier, M; Jourdan, E; Kamioner, D; Kerneis, Y; Morvan, F; Lederlin, P; Lefort, S; Lepeu, G; Lotz, JP; Machover, D; Marechal, F; Marit, G; Martin, C; Meyer, S; Morel, P; Dupriez, B; Munck, JN; Ferme, C; Carde, P; Offner, F; Pavlovitch, JM; Plantier, I; Orfeuvre, H; Peaud, PY; Peny, AM; Platini, C; Pullik, M; Quesnel, B; Morschausher, F; Reman, O; Leporrier, M; Rose, C; Rodon, P; Rossi, JF; Salles, B; Schlaifer, D; Huguet, F; Huyn, A; Sebban, C; Simon, M; Solal-Celigny, P; Sotto, JJ; Soussain, C; Allard, C; Tertian, G; Tilly, H; Thyss, A; Traulle, C; Travade, P; Van Hoof, A; Zini, JM; Briere, J; Diebold, J; Fabiani, B; Gaulard, P; Guettier, C; Molina, T; Petrella, T				Reyes, F; Lepage, E; Ganem, G; Molina, TJ; Brice, P; Coiffier, B; Morel, P; Ferme, C; Bosly, A; Lederlin, P; Laurent, G; Tilly, H; Aoudjane, M; Assouline, D; Audhuy, B; Azagury, M; Bauduer, F; Baumelou, E; Bichoffe, MA; Biron, P; Blanc, M; Bordessoulle, D; Bosly, A; Bouabdallah, R; Bourquard, P; Brice, P; Mounier, N; Simon, D; Gisselbrecht, C; Dombret, H; Briere, J; Caillot, D; Casanovas, O; Flesch, M; Chauffert, B; Cassuto, GP; Castaigne, S; Christian, B; Coiffier, B; Colin, P; Pinon-Netter, G; Conroy, T; Cure, H; Delmer, A; Delwail, V; Devidas, A; Dreyfus, F; Dupont, G; Eisenmann, JC; Fabbro, M; Ferme, C; Fillet, G; Furchart, C; Gabarre, J; Gabez, M; Gautier, M; Haioun, C; Divine, M; Belhadj, K; Reyes, F; Herbrecht, R; Hermine, O; Varet, B; Janvier, M; Jourdan, E; Kamioner, D; Kerneis, Y; Morvan, F; Lederlin, P; Lefort, S; Lepeu, G; Lotz, JP; Machover, D; Marechal, F; Marit, G; Martin, C; Meyer, S; Morel, P; Dupriez, B; Munck, JN; Ferme, C; Carde, P; Offner, F; Pavlovitch, JM; Plantier, I; Orfeuvre, H; Peaud, PY; Peny, AM; Platini, C; Pullik, M; Quesnel, B; Morschausher, F; Reman, O; Leporrier, M; Rose, C; Rodon, P; Rossi, JF; Salles, B; Schlaifer, D; Huguet, F; Huyn, A; Sebban, C; Simon, M; Solal-Celigny, P; Sotto, JJ; Soussain, C; Allard, C; Tertian, G; Tilly, H; Thyss, A; Traulle, C; Travade, P; Van Hoof, A; Zini, JM; Briere, J; Diebold, J; Fabiani, B; Gaulard, P; Guettier, C; Molina, T; Petrella, T		GELA	ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; LARGE-CELL LYMPHOMA; LIMITED-STAGE; BRIEF CHEMOTHERAPY; REGIMEN; MANAGEMENT; GRADE	BACKGROUND: Chemoradiotherapy is standard treatment for localized aggressive lymphoma. To determine the optimal therapy for nonelderly persons with low-risk localized lymphoma, we conducted a randomized trial comparing chemoradiotherapy with chemotherapy alone. METHODS: Previously untreated patients less than 61 years old with localized stage I or II aggressive lymphoma and no adverse prognostic factors according to the International Prognostic Index were randomly assigned to three cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus involved-field radiotherapy (329 patients) or chemotherapy alone with dose-intensified doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus sequential consolidation (318 patients). RESULTS: With a median follow-up of 7.7 years, event-free and overall survival rates were significantly higher in the group given chemotherapy alone than in the group given CHOP plus radiotherapy (P<0.001 and P=0.001, respectively). The five-year estimates of event-free survival were 82 percent (95 percent confidence interval, 78 to 87 percent) for patients receiving chemotherapy alone and 74 percent (95 percent confidence interval, 69 to 78 percent) for those receiving chemoradiotherapy. The respective five-year estimates of overall survival were 90 percent (95 percent confidence interval, 87 to 93 percent) and 81 percent (95 percent confidence interval, 77 to 86 percent). In a multivariate analysis, event-free and overall survival rates were affected by treatment group, independently of tumor stage and the presence or absence of bulky disease. CONCLUSIONS: In patients under 61 years of age, chemotherapy with three cycles of ACVBP followed by sequential consolidation is superior to three cycles of CHOP plus radiotherapy for the treatment of low-risk localized lymphoma.	Hop Henri Mondor, Assistance Publ Hop Paris, F-94010 Creteil, France; Clin Victor Hugo, Le Mans, France; Hop Hotel Dieu, Assistance Publ Hop Paris, F-75181 Paris, France; Hop St Louis, Assistance Publ Hop Paris, Paris, France; Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France; Inst Gustave Roussy, Villejuif, France; Ctr Hosp Brabois, Nancy, France; Hop Purpan, Toulouse, France; Ctr Henri Becquerel, F-76038 Rouen, France; Clin Univ Mt Godinne, Yvoir, Belgium	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; CHU Lyon; UNICANCER; Gustave Roussy; CHU de Nancy; CHU de Toulouse; UNICANCER; Centre Henri Becquerel; Universite Catholique Louvain; Universite Catholique Louvain Hospital	Reyes, F (corresponding author), Hop Henri Mondor, Serv Hematol Clin, F-94010 Creteil, France.	felix.reyes@hmn.ap-hop-paris.fr	Conroy, Thierry/X-8127-2019; Herbrecht, Raoul/D-3471-2013; Herbrecht, Raoul/GVU-1333-2022; Hermine, Olivier/Q-7072-2018; Herbrecht, Raoul/AAT-1763-2021; Molina, Thierry/ABA-5214-2020; de Salles, Belmiro Freitas/C-6281-2018	Herbrecht, Raoul/0000-0002-9381-4876; Molina, Thierry/0000-0002-3929-9754; 				Aleman BMP, 2003, NEW ENGL J MED, V348, P2396, DOI 10.1056/NEJMoa022628; Andre M, 2004, BLOOD, V103, P1222, DOI 10.1182/blood-2003-04-1124; Armitage JO, 2003, J CLIN ONCOL, V21, P897, DOI 10.1200/JCO.2003.07.113; Blayney DW, 2003, J CLIN ONCOL, V21, P2466, DOI 10.1200/JCO.2003.06.137; CABANILLAS F, 1980, CANCER, V46, P2356, DOI 10.1002/1097-0142(19801201)46:11<2356::AID-CNCR2820461107>3.0.CO;2-X; CHEN MG, 1979, CANCER, V43, P1245, DOI 10.1002/1097-0142(197904)43:4<1245::AID-CNCR2820430412>3.0.CO;2-Z; Cheson, 2000, J CLIN ONCOL, V18, P2351; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; CONNORS J, 2004, NONHODGKINS LYMPHOMA, P201; CONNORS JM, 1987, ANN INTERN MED, V107, P25, DOI 10.7326/0003-4819-107-1-25; COX DR, 1972, J R STAT SOC B, V34, P187; Dumontet C, 2002, BRIT J HAEMATOL, V118, P210, DOI 10.1046/j.1365-2141.2002.03565.x; Jaffe ES, 2001, PATHOLOGY GENETICS T, V3; JONES SE, 1989, J CLIN ONCOL, V7, P1186, DOI 10.1200/JCO.1989.7.9.1186; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Miller TP, 2001, BLOOD, V98, p724A; Miller TP, 1998, NEW ENGL J MED, V339, P21, DOI 10.1056/NEJM199807023390104; Pfreundschuh M, 2004, BLOOD, V104, P626, DOI 10.1182/blood-2003-06-2094; ROSENBERG SA, 1982, CANCER, V49, P2112; SAVAGE KJ, 2004, NON HODGKINS LYMPHOM, P97; Shenkier TN, 2002, J CLIN ONCOL, V20, P197, DOI 10.1200/JCO.20.1.197; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; STANSFELD AG, 1988, LANCET, V1, P372; Tilly H, 2003, BLOOD, V102, P4284, DOI 10.1182/blood-2003-02-0542; Tilly H, 2000, J CLIN ONCOL, V18, P1309, DOI 10.1200/JCO.2000.18.6.1309; Zinzani PL, 1999, BLOOD, V94, P3289, DOI 10.1182/blood.V94.10.3289.422k32_3289_3293	28	248	261	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1197	1205		10.1056/NEJMoa042040	http://dx.doi.org/10.1056/NEJMoa042040			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788496				2022-12-28	WOS:000227832300006
J	Moses, H; Thier, SO; Matheson, DHM				Moses, H; Thier, SO; Matheson, DHM			Why have academic medical centers survived?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Over the past decade, many observers predicted the demise of the academic medical center (AMC) due to competition from community hospitals and physicians, fragile finances, inefficiency, and organizational complexity. In 2004, we interviewed 23 AMC and community hospital administrators to determine why those predictions have proven unfounded, learn the leaders' current concerns and priorities, and to identify desirable changes. Chief concerns were reimbursement uncertainty, federal research policy, ineffective internal decision-making, and clinical quality (mentioned in more than 75% of interviews). Priorities included ensuring sufficient investment capital, revising undergraduate and graduate curricula, strengthening ties with physicians and community hospitals, attracting faculty, and meeting regulatory requirements. We advocate that the AMC: (1) modify the re-search model to allow greater collaboration with institutions and researchers; (2) enhance free and open export of new and proven clinical techniques and knowledge; (3) devote greater attention to meeting patients' increasing needs for counsel and guidance, not just intervention, given the plethora of complex new technologies and their promotion in the popular media; and (4) simplify their organizations. To accomplish this, it is desirable for future leaders to gain experience outside the AMC, and for faculty and institutions to be less inwardly focused and more attentive to preserving the public's trust.	Aler Inst, N Garden, VA 22959 USA; Boston Consulting Grp Inc, Bethesda, MD USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Boston Consulting Group (BCG); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Moses, H (corresponding author), Aler Inst, POB 150, N Garden, VA 22959 USA.	hm@alerion.us						ABELSON R, 2002, NY TIMES        0621, pD12; ABELSON R, 2002, NY TIMES        0621, pD1; Berns KI, 1996, ACAD MED, V71, P117, DOI 10.1097/00001888-199602000-00011; BRENNAN N, 2001, ARE SAFETY NET HOSP; Carey RM, 1996, ACAD MED, V71, P839, DOI 10.1097/00001888-199608000-00011; Casalino LP, 2003, HEALTH AFFAIR, V22, P56, DOI 10.1377/hlthaff.22.6.56; Collins FS, 2003, SCIENCE, V300, P286, DOI 10.1126/science.1084564; DRUCKER PF, 1989, NEW REALITIES GOVT P, P211; FISHER ES, VARIATIONS LONGITUDI; HANDY C, 1993, UNDERSTANDING ORG, P170; HERZLINGER R, 1999, MARKET DRIVEN HLTH C, P270; *I MED, 2004, CROSS QUAL CHASM SUM; Jones RF, 1996, ACAD MED, V71, P300, DOI 10.1097/00001888-199603000-00027; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; Koenig L, 2003, HEALTH AFFAIR, V22, P112, DOI 10.1377/hlthaff.22.6.112; Krauss K, 1997, ACAD MED, V72, P571, DOI 10.1097/00001888-199707000-00008; *LEAPFR GROUP PAT, LEAPFR FACT SHEET; *MED GROUP MAN ASS, 2004, COST SURV 2004; Ofman JJ, 2004, AM J MED, V117, P182, DOI 10.1016/j.amjmed.2004.03.018; STARR P, 1982, SOCIAL TRANSFORMATIO, P372; *US FDA, 2004, INN STAGN CHALL OPP; Weissman JS, 1999, JAMA-J AM MED ASSOC, V281, P1093, DOI 10.1001/jama.281.12.1093; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867	23	25	25	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	2005	293	12					1495	1500		10.1001/jama.293.12.1495	http://dx.doi.org/10.1001/jama.293.12.1495			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	908KA	15784874				2022-12-28	WOS:000227784700030
J	Messerlin, PA				Messerlin, PA			Trade, drugs, and health-care services	LANCET			English	Editorial Material									Inst Etud Polit Paris, F-75007 Paris, France		Messerlin, PA (corresponding author), Inst Etud Polit Paris, 27 Rue St Guillaume, F-75007 Paris, France.	patrick.messerlin@sciences-po.ft						BROWN D, 2003, OPTIONS REVISING TRI; Brown D K, 2003, OPTIMAL INTELLECTUAL; Fink C., 2003, 5 WORLD BANK; Fink Carsten, 2005, 20 WORLD BANK; LEHMAN B, 2002, PATENTS HLTH; LUTHRIA M, 2003, TRADE POVERTY REGION; NIELSON J, 2004, HDB TRADE HLTH SERVI; Nielson J., 2003, MOVING PEOPLE DELIVE; *OECD, IN PRESS TRAD STRUCT; *OXF, UND ACC MED COMP 5 U; *OXF, ROBB POOR PAY RICH U; PANAGARIYA A, TRIPS WTO UNEASY MAR; *UNCTAD ICTSD, 2003, INT PROP RIGHTS IMPL; *US DEP STAT, 2002, DOH DECL TRIPS AGR P	14	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR-APR	2005	365	9465					1198	1200		10.1016/S0140-6736(05)71883-3	http://dx.doi.org/10.1016/S0140-6736(05)71883-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	910DD	15794975				2022-12-28	WOS:000227909500033
J	Kural, C; Kim, H; Syed, S; Goshima, G; Gelfand, VI; Selvin, PR				Kural, C; Kim, H; Syed, S; Goshima, G; Gelfand, VI; Selvin, PR			Kinesin and dynein move a peroxisome in vivo: A tug-of-war or coordinated movement?	SCIENCE			English	Article							HAND-OVER-HAND; CYTOPLASMIC DYNEIN; ORGANELLE TRANSPORT; MOLECULAR MOTORS; PROTEINS; NEURONS; LOAD	We used fluorescence imaging with one nanometer accuracy (FIONA) to analyze organelle movement by conventional kinesin and cytoplasmic dynein in a cell. We located a green fluorescence protein (GFP)-tagged peroxisome in cultured Drosophila S2 cells to within 1.5 nanometers in 1.1 milliseconds, a 400-fold improvement in temporal resolution, sufficient to, determine the average step size to be similar to 8 nanometers for both dynein and kinesin. Furthermore, we found that dynein and kinesin do not work against each other in vivo during peroxisome transport. Rather, multiple kinesins or multiple dyneins work together, producing up to 10 times the in vitro speed.	Univ Illinois, Loomis Lab Phys, Ctr Biophys, Urbana, IL 61801 USA; Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94107 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of California System; University of California San Francisco	Selvin, PR (corresponding author), Univ Illinois, Loomis Lab Phys, Ctr Biophys, 1110 W Green St, Urbana, IL 61801 USA.	selvin@uiuc.edu	Gelfand, Vladimir I/D-2545-2013; Gelfand, Vladimir/M-1974-2019	Gelfand, Vladimir I/0000-0002-6361-2798; Gelfand, Vladimir/0000-0002-6361-2798; Kural, Comert/0000-0002-9065-6542	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044420, R01AR044420] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM052111, R01GM052111, R01GM068625] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44420] Funding Source: Medline; NIGMS NIH HHS [GM52111, GM 068625] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; BRADY ST, 1982, SCIENCE, V218, P1129, DOI 10.1126/science.6183745; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; Gross SP, 2000, J CELL BIOL, V148, P945, DOI 10.1083/jcb.148.5.945; Gross SP, 2002, J CELL BIOL, V156, P855, DOI 10.1083/jcb.200105055; Hill DB, 2004, EUR BIOPHYS J BIOPHY, V33, P623, DOI 10.1007/s00249-004-0403-6; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Kaether C, 2000, MOL BIOL CELL, V11, P1213, DOI 10.1091/mbc.11.4.1213; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Kon T, 2004, BIOCHEMISTRY-US, V43, P11266, DOI 10.1021/bi048985a; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; Ma YT, 2004, CURR BIOL, V14, P725, DOI 10.1016/j.cub.2004.03.061; Mallik R, 2004, CURR BIOL, V14, pR971, DOI 10.1016/j.cub.2004.10.046; Mallik R, 2004, NATURE, V427, P649, DOI 10.1038/nature02293; Nishiura M, 2004, J BIOL CHEM, V279, P22799, DOI 10.1074/jbc.M313362200; Rogers SL, 2000, CURR OPIN CELL BIOL, V12, P57, DOI 10.1016/S0955-0674(99)00057-5; Rogers SL, 2002, J CELL BIOL, V158, P873, DOI 10.1083/jcb.200202032; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398	23	465	481	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 3	2005	308	5727					1469	1472		10.1126/science.1108408	http://dx.doi.org/10.1126/science.1108408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	933HK	15817813				2022-12-28	WOS:000229619300054
J	Urnov, FD; Miller, JC; Lee, YL; Beausejour, CM; Rock, JM; Augustus, S; Jamieson, AC; Porteus, MH; Gregory, PD; Holmes, MC				Urnov, FD; Miller, JC; Lee, YL; Beausejour, CM; Rock, JM; Augustus, S; Jamieson, AC; Porteus, MH; Gregory, PD; Holmes, MC			Highly efficient endogenous human gene correction using designed zinc-finger nucleases	NATURE			English	Article							DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; DNA RECOGNITION; SITE; CLEAVAGE; SPECIFICITY; ACTIVATION; PROTEINS; THERAPY; REPAIR	Permanent modification of the human genome in vivo is impractical owing to the low frequency of homologous recombination in human cells, a fact that hampers biomedical research and progress towards safe and effective gene therapy. Here we report a general solution using two fundamental biological processes: DNA recognition by C2H2 zinc-finger proteins and homology-directed repair of DNA double-strand breaks. Zinc-finger proteins engineered to recognize a unique chromosomal site can be fused to a nuclease domain, and a double-strand break induced by the resulting zinc-finger nuclease can create specific sequence alterations by stimulating homologous recombination between the chromosome and an extrachromosomal DNA donor. We show that zinc-finger nucleases designed against an X-linked severe combined immune deficiency ( SCID) mutation in the IL2R gamma gene yielded more than 18% gene-modified human cells without selection. Remarkably, about 7% of the cells acquired the desired genetic modification on both X chromosomes, with cell genotype accurately reflected at the messenger RNA and protein levels. We observe comparably high frequencies in human T cells, raising the possibility of strategies based on zinc-finger nucleases for the treatment of disease.	Sangamo BioSci Inc, Richmond, CA 94804 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Sangamo Therapeutics, Inc.; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Holmes, MC (corresponding author), Sangamo BioSci Inc, Pt Richmond Tech Ctr 501,Canal Blvd,Suite A100, Richmond, CA 94804 USA.	matthew.porteus@UTSouthwestern.edu; mholmes@sangamo.com	Wilson, Matthew H/K-3193-2013	Rock, Jeremy/0000-0002-9310-951X; Gregory, Philip/0000-0001-9249-2468; Urnov, Fyodor/0000-0001-7542-4084				Bibikova M, 2001, MOL CELL BIOL, V21, P289, DOI 10.1128/MCB.21.1.289-297.2001; Bibikova M, 2003, SCIENCE, V300, P764, DOI 10.1126/science.1079512; Bibikova M, 2002, GENETICS, V161, P1169; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Buckley RH, 2000, NEW ENGL J MED, V343, P1313, DOI 10.1056/NEJM200011023431806; Bunz F, 2002, CANCER RES, V62, P1129; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; Choo Y, 2000, CURR OPIN STRUC BIOL, V10, P411, DOI 10.1016/S0959-440X(00)00107-X; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; Elliott B, 1998, MOL CELL BIOL, V18, P93, DOI 10.1128/MCB.18.1.93; Isalan M, 2001, METHOD ENZYMOL, V340, P593; Isalan M, 2001, NAT BIOTECHNOL, V19, P656, DOI 10.1038/90264; Jamieson AC, 2003, NAT REV DRUG DISCOV, V2, P361, DOI 10.1038/nrd1087; Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156; KLUG A, 1993, GENE, V135, P83, DOI 10.1016/0378-1119(93)90052-5; Kohn DB, 2003, NAT REV CANCER, V3, P477, DOI 10.1038/nrc1122; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Moore M, 2001, P NATL ACAD SCI USA, V98, P1437, DOI 10.1073/pnas.98.4.1437; Pabo CO, 2001, ANNU REV BIOCHEM, V70, P313, DOI 10.1146/annurev.biochem.70.1.313; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Persons Derek A, 2003, Curr Hematol Rep, V2, P348; Porteus MH, 2003, SCIENCE, V300, P763, DOI 10.1126/science.1078395; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schell T, 2002, GENOME BIOL, V3; SEDIVY JM, 1992, GENE TARGETING; Smith J, 1999, NUCLEIC ACIDS RES, V27, P674, DOI 10.1093/nar/27.2.674; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Wilson JH, 2003, NAT BIOTECHNOL, V21, P759, DOI 10.1038/nbt0703-759; Yanez RJ, 1998, GENE THER, V5, P149, DOI 10.1038/sj.gt.3300601; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200	39	1177	1517	5	203	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 2	2005	435	7042					646	651		10.1038/nature03556	http://dx.doi.org/10.1038/nature03556			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	931HK	15806097				2022-12-28	WOS:000229476200043
J	Rosati, P; Boldrini, R; Devito, R; Menditto, A; Barbuti, D; Nibbi, F; Mancini, S; Reale, A; Vignati, E; Romanini, M; Iannelli, M; Marchili, MR; Fierimonte, V; Castelli, M; Vitale, L; Villani, A				Rosati, P; Boldrini, R; Devito, R; Menditto, A; Barbuti, D; Nibbi, F; Mancini, S; Reale, A; Vignati, E; Romanini, M; Iannelli, M; Marchili, MR; Fierimonte, V; Castelli, M; Vitale, L; Villani, A			A child with painful legs	LANCET			English	Editorial Material							SCURVY		Bambino Gesu Childrens Hosp Natl Inst Hlth, Dept Paediat Med, Rome, Italy; Bambino Gesu Childrens Hosp Natl Inst Hlth, Anat Pathol Unit, Rome, Italy; Bambino Gesu Childrens Hosp Natl Inst Hlth, Radiol Unit, Rome, Italy; Bambino Gesu Childrens Hosp Natl Inst Hlth, Unit Dent, Rome, Italy	IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS Bambino Gesu	Rosati, P (corresponding author), Osped Pediat, Dipartimento Med Pediat, Piazza S Onofrio 4, I-00161 Rome, Italy.	prosati@opbg.net	Rosaria, Marchili Maria/AAA-5315-2020; barbuti, domenico/AAB-5060-2020; Rosati, Paola/AAA-5229-2020	Rosaria, Marchili Maria/0000-0002-6787-8198; De Vito, rita/0000-0002-7450-8398; Rosati, Paola/0000-0002-1713-4879; reale, antonino/0000-0001-8058-7742				HALLEL T, 1980, CLIN ORTHOP RELAT R, P166; HURLIMANN R, 1994, SCHWEIZ MED WSCHR, V124, P1373; ORDIROS J, 1994, HAEMOSTASIS, V24, P165; Pimentel L, 2003, AM J EMERG MED, V21, P328, DOI 10.1016/S0735-6757(03)00083-4; Schubarth P, 1994, Ther Umsch, V51, P510	5	9	9	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 16	2005	365	9468					1438	1438		10.1016/S0140-6736(05)66381-7	http://dx.doi.org/10.1016/S0140-6736(05)66381-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836894				2022-12-28	WOS:000228401900034
J	Mistry, AR; Felix, CA; Whitmarsh, RJ; Mason, A; Reiter, A; Cassinat, B; Parry, A; Walz, C; Wiemels, JL; Segal, MR; Ades, L; Blair, IA; Osheroff, N; Peniket, AJ; Lafage-Pochitaloff, M; Cross, NCP; Chomienne, C; Solomon, E; Fenaux, P; Grimwade, D				Mistry, AR; Felix, CA; Whitmarsh, RJ; Mason, A; Reiter, A; Cassinat, B; Parry, A; Walz, C; Wiemels, JL; Segal, MR; Ades, L; Blair, IA; Osheroff, N; Peniket, AJ; Lafage-Pochitaloff, M; Cross, NCP; Chomienne, C; Solomon, E; Fenaux, P; Grimwade, D			DNA topoisomerase II in therapy-related acute promyelocytic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BREAKPOINT CLUSTER REGION; BALANCED CHROMOSOME-ABERRATIONS; ACUTE MYELOID-LEUKEMIA; MYELODYSPLASTIC SYNDROMES; INTERNATIONAL WORKSHOP; TRANSLOCATION BREAKPOINTS; SECONDARY LEUKEMIA; CLEAVAGE; MLL; INHIBITORS	Background Chromosomal translocations leading to chimeric oncoproteins are important in leukemogenesis, but how they form is unclear. We studied acute promyelocytic leukemia (APL) with the t(15;17) translocation that developed after treatment of breast or laryngeal cancer with chemotherapeutic agents that poison topoisomerase II. Methods We used long-range polymerase chain reaction and sequence analysis to characterize t(15;17) genomic breakpoints in therapy-related APL. To determine whether topoisomerase II was directly involved in mediating breaks of double-stranded DNA at the observed translocation breakpoints, we used a functional in vitro assay to examine topoisomerase II-mediated cleavage in the normal homologues of the PML and RARA breakpoints. Results Translocation breakpoints in APL that developed after exposure to mitoxantrone, a topoisomerase II poison, were tightly clustered in an 8-bp region within PML intron 6. In functional assays, this ``hot spot'' and the corresponding RARA breakpoints were common sites of mitoxantrone-induced cleavage by topoisomerase II. Etoposide and doxorubicin also induced cleavage by topoisomerase II at the translocation breakpoints in APL arising after exposure to these agents. Short, homologous sequences in PML and RARA suggested the occurrence of DNA repair by means of the nonhomologous end-joining pathway. Conclusions Drug-induced cleavage of DNA by topoisomerase II mediates the formation of chromosomal translocation breakpoints in mitoxantrone-related APL and in APL that occurs after therapy with other topoisomerase II poisons.	Guys Kings & St Thomas Sch Med, Dept Med & Mol Genet, London, England; Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Heidelberg, Fak Klin Med Mannheim, D-6800 Mannheim, Germany; Hop St Louis, Nucl Med Serv, Unite Biol Cellulaire, Paris, France; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Paris 13, Hop Avicenne, Bobigny, France; Univ Penn, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; John Radcliffe Hosp, Dept Haematol, Oxford OX3 9DU, England; Inst J Paoli I Calmettes, INSERM, UMR 599, F-13009 Marseille, France; Univ Aix Marseille 2, Marseille, France; Wessex Reg Genet Lab, Salisbury, Wilts, England; UCL Hosp, Dept Haematol, London, England	University of London; King's College London; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Ruprecht Karls University Heidelberg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; University of Pennsylvania; Pennsylvania Medicine; Vanderbilt University; Vanderbilt University; University of Oxford; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; University College London Hospitals NHS Foundation Trust; University of London; University College London	Mistry, AR (corresponding author), Guys Hosp, Dept Med & Mol Genet, Canc Genet Lab, 8th Fl,Guys Tower, London SE1 9RT, England.	david.grimwade@genetics.kcl.ac.uk	CASSINAT, BRUNO/N-2752-2017; Cross, Nicholas/B-4817-2009; Ades, lionel/T-6882-2019; Blair, Ian A/B-3320-2010	CASSINAT, BRUNO/0000-0002-6514-3905; Cross, Nicholas/0000-0001-5481-2555; CHOMIENNE, Christine/0000-0001-5513-5752	NATIONAL CANCER INSTITUTE [R01CA089032, R01CA080175, R01CA077683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80175, R01 CA77683, CA89032] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline; PHS HHS [R0185469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ahuja HG, 2000, GENE CHROMOSOME CANC, V29, P96, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1013>3.0.CO;2-T; Andersen MK, 2002, GENE CHROMOSOME CANC, V33, P395, DOI 10.1002/gcc.10043; Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; Beaumont M, 2003, J CLIN ONCOL, V21, P2123, DOI 10.1200/JCO.2003.09.072; Betti CJ, 2003, CANCER RES, V63, P1377; Betti CJ, 2001, CANCER RES, V61, P4550; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Carli PM, 2000, LEUKEMIA, V14, P1014, DOI 10.1038/sj.leu.2401787; DOMER PH, 1995, LEUKEMIA, V9, P1305; DONG S, 1993, GENE CHROMOSOME CANC, V6, P133, DOI 10.1002/gcc.2870060302; Eguchi-Ishimae M, 2001, BLOOD, V97, P737, DOI 10.1182/blood.V97.3.737; Felix CA, 2001, MED PEDIATR ONCOL, V36, P525, DOI 10.1002/mpo.1125; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; GLAZ J, 1991, ADV APPL PROBAB, V23, P751; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grimwade D, 2001, BEST PRACT RES CL HA, V14, P497, DOI 10.1053/beha.2001.0152; Grimwade D, 1996, BRIT J HAEMATOL, V94, P557; Kudo K, 1998, LEUKEMIA, V12, P1171, DOI 10.1038/sj.leu.2401089; Lovett BD, 2001, BIOCHEMISTRY-US, V40, P1159, DOI 10.1021/bi002361x; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; Mistry AR, 2003, BLOOD REV, V17, P71, DOI 10.1016/S0268-960X(02)00075-9; NEGRINI M, 1993, CANCER RES, V53, P4489; PEDERSENBJERGAARD, 2002, BLOOD, V99, P1909; PEDERSENBJERGAARD, 1994, BLOOD, V83, P2780; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Pulsoni A, 2002, BLOOD, V100, P1972, DOI 10.1182/blood-2001-12-0312; Reiter A, 2003, GENE CHROMOSOME CANC, V36, P175, DOI 10.1002/gcc.10154; Rowley JD, 2001, NAT REV CANCER, V1, P245, DOI 10.1038/35106108; Rowley JD, 2002, GENE CHROMOSOME CANC, V33, P331, DOI 10.1002/gcc.10040; Segal MR, 2002, J AM STAT ASSOC, V97, P66, DOI 10.1198/016214502753479239; Smith MA, 1999, J CLIN ONCOL, V17, P569, DOI 10.1200/JCO.1999.17.2.569; Smith SM, 2003, BLOOD, V102, P43, DOI 10.1182/blood-2002-11-3343; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Whitmarsh RJ, 2003, ONCOGENE, V22, P8448, DOI 10.1038/sj.onc.1207052; Zhang YM, 2002, P NATL ACAD SCI USA, V99, P3070, DOI 10.1073/pnas.042702899	38	215	220	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1529	1538		10.1056/NEJMoa042715	http://dx.doi.org/10.1056/NEJMoa042715			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829534				2022-12-28	WOS:000228324200005
J	Pirisi, A				Pirisi, A			Philip Landrigan: children's health crusader	LANCET			English	Biographical-Item												apirisi@interlynx.net						LANDRIGAN P, PUBLICATION LIST	1	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1301	1301		10.1016/S0140-6736(05)61015-X	http://dx.doi.org/10.1016/S0140-6736(05)61015-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823369				2022-12-28	WOS:000228219600013
J	Lima, SQ; Miesenbock, G				Lima, SQ; Miesenbock, G			Remote control of behavior through genetically targeted photostimulation of neurons	CELL			English	Article							DROSOPHILA NERVOUS-SYSTEM; ION CHANNELS; GIANT-FIBER; CAPSAICIN RECEPTOR; IDENTIFIED NEURONS; MAMMALIAN NEURONS; EXPRESSION; MELANOGASTER; DOPAMINE; MUTATIONS	Optically gated ion channels were expressed in circumscribed groups of neurons in the Drosophila CNS so that broad illumination of flies evoked action potentials only in genetically designated target cells. Flies harboring the "phototriggers" in different sets of neurons responded to laser light with behaviors specific to the sites of phototrigger expression. Photostimulation of neurons in the giant fiber system elicited the characteristic escape behaviors of jumping, wing beating, and flight; photostimulation of dopaminergic neurons caused changes in locomotor activity and locomotor patterns. These responses reflected the direct optical activation of central neuronal targets rather than confounding visual input, as they persisted unabated in carriers of a mutation that eliminates phototransduction. Encodable phototriggers provide noninvasive control interfaces for studying the connectivity and dynamics of neural circuits, for assigning behavioral content to neurons and their activity patterns, and, potentially, for restoring information corrupted by injury or disease.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University	Miesenbock, G (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.	gero.miesenboeck@yale.edu		Lima, Susana/0000-0003-2446-9869; Miesenboeck, Gero/0000-0003-2940-3228				Allen MJ, 1999, J NEUROSCI, V19, P9374; ARBUTHNOTT GW, 1975, EXP NEUROL, V47, P162, DOI 10.1016/0014-4886(75)90244-7; Bainton RJ, 2000, CURR BIOL, V10, P187, DOI 10.1016/S0960-9822(00)00336-5; Banghart M, 2004, NAT NEUROSCI, V7, P1381, DOI 10.1038/nn1356; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BROADIE KS, 2000, DROSOPHILA PROTOCOLS, P273; Broughton SJ, 2004, CURR BIOL, V14, pR290, DOI 10.1016/j.cub.2004.03.037; BUCHNER E, 1991, J NEUROGENET, V7, P153, DOI 10.3109/01677069109167432; BUDNIK V, 1988, J COMP NEUROL, V268, P400, DOI 10.1002/cne.902680309; Burrows M., 1996, NEUROBIOLOGY INSECT; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; Carlson SD, 2000, ANNU REV ENTOMOL, V45, P151, DOI 10.1146/annurev.ento.45.1.151; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen S, 2002, P NATL ACAD SCI USA, V99, P5664, DOI 10.1073/pnas.082102599; FARBER IC, 1983, SCIENCE, V222, P1025, DOI 10.1126/science.6648515; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; FORK RL, 1971, SCIENCE, V171, P907, DOI 10.1126/science.171.3974.907; Friggi-Grelin F, 2003, J NEUROBIOL, V54, P618, DOI 10.1002/neu.10185; GALVANI L, 1791, DEVIRIBUS ELECT MOTU; Hendricks JC, 2000, NEURON, V25, P129, DOI 10.1016/S0896-6273(00)80877-6; Hoang B, 2001, DEV BIOL, V229, P55, DOI 10.1006/dbio.2000.9983; HOTTA Y, 1970, P NATL ACAD SCI USA, V67, P1156, DOI 10.1073/pnas.67.3.1156; Jacobs K, 2000, DEVELOPMENT, V127, P5203; Johns DC, 1999, J NEUROSCI, V19, P1691; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018; KOTO M, 1981, BRAIN RES, V221, P213, DOI 10.1016/0006-8993(81)90772-1; KUPFERMANN I, 1978, BEHAV BRAIN SCI, V1, P3, DOI 10.1017/S0140525X00059057; Kupfermann I, 2001, CURR OPIN NEUROBIOL, V11, P673, DOI 10.1016/S0959-4388(01)00267-7; Lechner HAE, 2002, J NEUROSCI, V22, P5287; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Liu L, 1999, NATURE, V400, P753, DOI 10.1038/23456; Manseau L, 1997, DEV DYNAM, V209, P310, DOI 10.1002/(SICI)1097-0177(199707)209:3<310::AID-AJA6>3.0.CO;2-L; McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7; MCCRAY JA, 1989, ANNU REV BIOPHYS BIO, V18, P239, DOI 10.1146/annurev.biophys.18.1.239; MCKENNA M, 1989, P NATL ACAD SCI USA, V86, P8118, DOI 10.1073/pnas.86.20.8118; Miesenbock G, 2004, CURR OPIN NEUROBIOL, V14, P395, DOI 10.1016/j.conb.2004.05.004; Nakayama S, 1997, MOL GEN GENET, V254, P449, DOI 10.1007/s004380050438; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; PAK WL, 1970, NATURE, V227, P518, DOI 10.1038/227518b0; QUINN WG, 1984, ANNU REV NEUROSCI, V7, P67, DOI 10.1146/annurev.ne.07.030184.000435; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; SELVERSTON AI, 1985, ANNU REV PHYSIOL, V47, P29; Shaw PJ, 2000, SCIENCE, V287, P1834, DOI 10.1126/science.287.5459.1834; Slimko EM, 2002, J NEUROSCI, V22, P7373; Sun BH, 1999, P NATL ACAD SCI USA, V96, P10438, DOI 10.1073/pnas.96.18.10438; SWEENEY ST, 1995, NEURON, V14, P341, DOI 10.1016/0896-6273(95)90290-2; TANOUYE MA, 1980, J NEUROPHYSIOL, V44, P405, DOI 10.1152/jn.1980.44.2.405; TEMPEL BL, 1984, P NATL ACAD SCI-BIOL, V81, P3577, DOI 10.1073/pnas.81.11.3577; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS JB, 1982, NATURE, V298, P650, DOI 10.1038/298650a0; THOMAS JB, 1984, J NEUROSCI, V4, P530; Tobin DM, 2002, NEURON, V35, P307, DOI 10.1016/S0896-6273(02)00757-2; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Trimarchi JR, 1999, INT REV NEUROBIOL, V43, P241, DOI 10.1016/S0074-7742(08)60548-6; TRIMARCHI JR, 1995, J COMP PHYSIOL A, V176, P355, DOI 10.1007/BF00219061; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WIERSMA CAG, 1964, COMP BIOCHEM PHYSIOL, V12, P509, DOI 10.1016/0010-406X(64)90153-7; Wyman R.J., 1984, P133; Yasuyama K, 1999, MICROSC RES TECHNIQ, V45, P65, DOI 10.1002/(SICI)1097-0029(19990415)45:2<65::AID-JEMT2>3.0.CO;2-0; Yellman C, 1997, P NATL ACAD SCI USA, V94, P4131, DOI 10.1073/pnas.94.8.4131; Zemelman BV, 2003, P NATL ACAD SCI USA, V100, P1352, DOI 10.1073/pnas.242738899; Zemelman BV, 2002, NEURON, V33, P15, DOI 10.1016/S0896-6273(01)00574-8; Zemelman BV, 2001, CURR OPIN NEUROBIOL, V11, P409, DOI 10.1016/S0959-4388(00)00227-0	69	385	428	1	82	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					141	152		10.1016/j.cell.2005.02.004	http://dx.doi.org/10.1016/j.cell.2005.02.004			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820685	Bronze			2022-12-28	WOS:000228348500016
J	Huang, XG; Xu, YS; Karato, SI				Huang, XG; Xu, YS; Karato, SI			Water content in the transition zone from electrical conductivity of wadsleyite and ringwoodite	NATURE			English	Article							UPPER-MANTLE; HIGH-PRESSURES; EARTHS MANTLE; OLIVINE; TEMPERATURE; DIFFUSION; RHEOLOGY; BENEATH; REGION; QUARTZ	The distribution of water in the Earth's interior reflects the way in which the Earth has evolved, and has an important influence on its material properties. Minerals in the transition zone of the Earth's mantle (from similar to 410 to similar to 660 km depth) have large water solubility(1-3), and hence it is thought that the transition zone might act as a water reservoir. When the water content of the transition zone exceeds a critical value, upwelling flow might result in partial melting at similar to 410 km, which would affect the distribution of certain elements in the Earth(4). However, the amount of water in the transition zone has remained unknown. Here we determined the effects of water and temperature on the electrical conductivity of the minerals wadsleyite and ringwoodite to infer the water content of the transition zone. We find that the electrical conductivity of these minerals depends strongly on water content but only weakly on temperature. By comparing these results with geophysically inferred conductivity(5-7), we infer that the water content in the mantle transition zone varies regionally, but that its value in the Pacific is estimated to be similar to 0.1-0.2wt%. These values significantly exceed the estimated critical water content in the upper mantle(3,8,9), suggesting that partial melting may indeed occur at similar to 410 km depth, at least in this region.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06511 USA; Chinese Acad Sci, Inst Geol & Geophys, Beijing 100029, Peoples R China	Yale University; Chinese Academy of Sciences; Institute of Geology & Geophysics, CAS	Karato, SI (corresponding author), Yale Univ, Dept Geol & Geophys, POB 6666, New Haven, CT 06511 USA.	shun-ichiro.karato@yale.edu						BELL DR, 1992, SCIENCE, V255, P1391, DOI 10.1126/science.255.5050.1391; Bercovici D, 2003, NATURE, V425, P39, DOI 10.1038/nature01918; FARVER JR, 1991, CHEM GEOL, V90, P55, DOI 10.1016/0009-2541(91)90033-N; Grove TL, 2003, CONTRIB MINERAL PETR, V145, P515, DOI 10.1007/s00410-003-0448-z; HIROSE K, 1993, EARTH PLANET SC LETT, V114, P477, DOI 10.1016/0012-821X(93)90077-M; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; Ichiki M, 2001, GEOPHYS RES LETT, V28, P3773, DOI 10.1029/2001GL012983; KARATO S, 1990, NATURE, V347, P272, DOI 10.1038/347272a0; KARATO S, 2003, INSIDE SUBDUCTION FA, P138; Karato SI, 2003, PHILOS MAG, V83, P401, DOI 10.1080/0141861021000025829; KARATO SI, 1986, J GEOPHYS RES-SOLID, V91, P8151, DOI 10.1029/JB091iB08p08151; Kawamoto T, 1996, EARTH PLANET SC LETT, V142, P587, DOI 10.1016/0012-821X(96)00113-6; Kohlstedt DL, 1996, CONTRIB MINERAL PETR, V123, P345, DOI 10.1007/s004100050161; KUSHIRO I, 1968, J GEOPHYS RES, V73, P6023, DOI 10.1029/JB073i018p06023; Mei S, 2000, J GEOPHYS RES-SOL EA, V105, P21457, DOI 10.1029/2000JB900179; PATERSON MS, 1982, B MINERAL, V105, P20; SMYTH JR, 1987, AM MINERAL, V72, P1051; Tarits P, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019277; Utada H, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016092; WOOD BJ, 1990, SCIENCE, V248, P337, DOI 10.1126/science.248.4953.337; Xu YS, 1998, SCIENCE, V280, P1415, DOI 10.1126/science.280.5368.1415; Xu YS, 2000, PHYS EARTH PLANET IN, V118, P149, DOI 10.1016/S0031-9201(99)00135-1	22	316	360	2	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					746	749		10.1038/nature03426	http://dx.doi.org/10.1038/nature03426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815625				2022-12-28	WOS:000228160700036
J	Pan, H; Yan, BS; Rojas, M; Shebzukhov, YV; Zhou, HW; Kobzik, L; Higgins, DE; Daly, MJ; Bloom, BR; Kramnik, I				Pan, H; Yan, BS; Rojas, M; Shebzukhov, YV; Zhou, HW; Kobzik, L; Higgins, DE; Daly, MJ; Bloom, BR; Kramnik, I			Ipr1 gene mediates innate immunity to tuberculosis	NATURE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; RECEPTOR; MICE; INFECTION; PROTEIN; SUSCEPTIBILITY; SUBSTRAINS; EXPRESSION; RESISTANCE; EVOLUTION	An estimated eight million people are infected each year with the pathogen Mycobacterium tuberculosis, and more than two million die annually(1). Yet only about 10% of those infected develop tuberculosis. Genetic variation within host populations is known to be significant in humans and animals(2,3), but the nature of genetic control of host resistance to tuberculosis remains poorly understood. Previously we mapped a new genetic locus on mouse chromosome 1, designated sst1 (for supersusceptibility to tuberculosis 1)(4). Here we show that this locus mediates innate immunity in sst1 congenic mouse strains and identify a candidate gene, Intracellular pathogen resistance 1 (Ipr1), within the sst1 locus. The Ipr1 gene is upregulated in the sst1 resistant macrophages after activation and infection, but it is not expressed in the sst1 susceptible macrophages. Expression of the Ipr1 transgene in the sst1 susceptible macrophages limits the multiplication not only of M. tuberculosis but also of Listeria monocytogenes and switches a cell death pathway of the infected macrophages from necrosis to apoptosis. Our data indicate that the Ipr1 gene product might have a previously undocumented function in integrating signals generated by intracellular pathogens with mechanisms controlling innate immunity, cell death and pathogenesis.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Physiol Program, Boston, MA 02115 USA; Univ Antioquia, Fac Med, Grp Inmunol Celular & Inmunogenet, Medellin, Colombia; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Universidad de Antioquia; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute	Kramnik, I (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 667 Huntington Ave, Boston, MA 02115 USA.	ikramnik@hsph.harvard.edu	Daly, Mark J/B-2453-2017; Rojas Lopez, Mauricio/P-4924-2018	Daly, Mark J/0000-0002-0949-8752; Rojas Lopez, Mauricio/0000-0002-7791-9328; Yan, Bo-Shiun/0000-0002-9613-4788; Kramnik, Igor/0000-0001-6511-9246	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049421] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI049421] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGULNIK S, 1993, MAMM GENOME, V4, P704, DOI 10.1007/BF00357793; Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897; Bleed D, 2000, Curr Opin Pulm Med, V6, P174, DOI 10.1097/00063198-200005000-00002; Bloch DB, 2000, MOL CELL BIOL, V20, P6138, DOI 10.1128/MCB.20.16.6138-6146.2000; Bloom BR, 2002, NEW ENGL J MED, V346, P1434, DOI 10.1056/NEJM200205093461902; Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675; Boyartchuk V, 2004, J IMMUNOL, V173, P5112, DOI 10.4049/jimmunol.173.8.5112; Casanova JL, 2002, ANNU REV IMMUNOL, V20, P581, DOI 10.1146/annurev.immunol.20.081501.125851; Castrillo A, 2004, ANNU REV CELL DEV BI, V20, P455, DOI 10.1146/annurev.cellbio.20.012103.134432; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Cosma CL, 2003, ANNU REV MICROBIOL, V57, P641, DOI 10.1146/annurev.micro.57.030502.091033; Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; HORVAI A, 1995, P NATL ACAD SCI USA, V92, P5391, DOI 10.1073/pnas.92.12.5391; Hsu T, 2003, P NATL ACAD SCI USA, V100, P12420, DOI 10.1073/pnas.1635213100; KADEREIT S, 1993, J BIOL CHEM, V268, P24432; Kamath AB, 2003, INFECT IMMUN, V71, P4112, DOI 10.1128/IAI.71.7.4112-4118.2003; Kramnik I, 1998, NOVART FDN SYMP, V217, P120, DOI 10.1002/0470846526.ch9; Kramnik I, 2000, P NATL ACAD SCI USA, V97, P8560, DOI 10.1073/pnas.150227197; KROG HH, 1978, J HERED, V69, P66, DOI 10.1093/oxfordjournals.jhered.a108905; Lo Surdo P, 2003, MOL ENDOCRINOL, V17, P1283, DOI 10.1210/me.2002-0409; Nicewonger J, 2004, J VIROL, V78, P9412, DOI 10.1128/JVI.78.17.9412-9422.2004; Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9; Saito T, 2004, BIOCHEM BIOPH RES CO, V317, P335, DOI 10.1016/j.bbrc.2004.03.056; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Taylor JL, 2003, INFECT IMMUN, V71, P2192, DOI 10.1128/IAI.71.4.2192-2198.2003; Traut W, 2001, CHROMOSOMA, V110, P247, DOI 10.1007/s004120100152; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Watashi K, 2003, MOL CELL BIOL, V23, P7498, DOI 10.1128/MCB.23.21.7498-7509.2003; Weichenhan D, 2001, MAMM GENOME, V12, P590, DOI 10.1007/s00335-001-3015-9	30	324	351	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					767	772		10.1038/nature03419	http://dx.doi.org/10.1038/nature03419			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815631	Green Accepted			2022-12-28	WOS:000228160700042
J	Klein, JG				Klein, JG			Five pitfalls in decisions about diagnosis and prescribing	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHRONIC NONMALIGNANT PAIN; PRIMARY-CARE PHYSICIANS; COGNITIVE BIAS; ATTITUDES; HEURISTICS; NURSES		INSEAD, Mkt, Singapore 138676, Singapore	INSEAD Business School	Klein, JG (corresponding author), INSEAD, Mkt, 1 Ayer Rajah Ave, Singapore 138676, Singapore.	jill.klein@insead.edu						Andersen S, 1996, BRIT J CLIN PRACT, V50, P324; BAUMANN AO, 1991, SOC SCI MED, V32, P167, DOI 10.1016/0277-9536(91)90057-J; Bennett Daniel S, 2002, J Pain Palliat Care Pharmacother, V16, P105; BORAK J, 1982, SOC SCI MED, V16, P1939, DOI 10.1016/0277-9536(82)90393-8; Bornstein BH, 2001, J EVAL CLIN PRACT, V7, P97, DOI 10.1046/j.1365-2753.2001.00284.x; Brannon LA, 2003, APPL NURS RES, V16, P201, DOI 10.1016/S0897-1897(03)00043-0; BROOKOFF D, 1993, J GEN INTERN MED, V8, P688, DOI 10.1007/BF02598290; DAWSON NV, 1993, CLIN CHEM, V39, P1468; Denig P, 2002, QUAL SAF HEALTH CARE, V11, P137, DOI 10.1136/qhc.11.2.137; DETMER DE, 1978, J MED EDUC, V53, P682; Devulder J, 1999, ACTA CLIN BELG, V54, P346, DOI 10.1080/17843286.1999.11754258; Ernst E, 2002, BRIT J CLIN PHARMACO, V54, P577, DOI 10.1046/j.1365-2125.2002.01699.x; Hershberger PJ, 1996, ADV HEALTH SCI EDUC, V1, P221, DOI 10.1007/BF00162919; HERSHBERGER PJ, 1994, ACAD MED, V69, P839, DOI 10.1097/00001888-199410000-00014; Jonas WB, 2003, ANN INTERN MED, V138, P393, DOI 10.7326/0003-4819-138-5-200303040-00009; KAHNEMAN D, 1973, PSYCHOL REV, V80, P237, DOI 10.1037/h0034747; Kahneman D., 1982, JUDGEMENT UNCERTAINT; KORIAT A, 1980, J EXP PSYCHOL-HUM L, V6, P107, DOI 10.1037/0278-7393.6.2.107; LARUE F, 1995, CANCER, V76, P2375, DOI 10.1002/1097-0142(19951201)76:11<2375::AID-CNCR2820761129>3.0.CO;2-C; Mahoney M.J., 1977, COGNITIVE THER RES, V1, P161, DOI [10.1007/BF01173636, DOI 10.1007/BF01173636]; McCarberg B H, 2001, Am J Ther, V8, P181, DOI 10.1097/00045391-200105000-00006; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; MORGAN J P, 1985, Advances in Alcohol and Substance Abuse, V5, P163; Nott MR, 2001, ANAESTHESIA, V56, P917; Passik SD, 2000, ADV THER, V17, P70, DOI 10.1007/BF02854840; POSES RM, 1991, MED DECIS MAKING, V11, P159, DOI 10.1177/0272989X9101100303; Potter M, 2001, J FAM PRACTICE, V50, P145; Russo JE, 2002, WINNING DECISIONS MA; Schwartz JA, 1999, MED DECIS MAKING, V19, P315, DOI 10.1177/0272989X9901900310; Wallsten T S, 1981, Med Decis Making, V1, P145, DOI 10.1177/0272989X8100100205; Weinstein SM, 2000, SOUTHERN MED J, V93, P479	31	143	144	2	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					781	783		10.1136/bmj.330.7494.781	http://dx.doi.org/10.1136/bmj.330.7494.781			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	914JE	15802723	Green Published			2022-12-28	WOS:000228222900028
J	Luo, ZX; Wible, JR				Luo, ZX; Wible, JR			A Late Jurassic digging mammal and early mammalian diversification	SCIENCE			English	Article							EVOLUTION; CHINA	A fossil mammal from the Late Jurassic Morrison Formation, Colorado, has highly specialized teeth similar to those of xenarthran and tubulidentate placental mammals and different from the generalized insectivorous or omnivorous dentitions of other Jurassic mammals. It has many forelimb features specialized for digging, and its lumbar vertebrae show xenarthrous articulations. Parsimony analysis suggests that this fossil represents a separate basal mammalian lineage with some dental and vertebral convergences to those of modern xenarthran placentals, and reveals a previously unknown ecomorph of early mammals.	Carnegie Museum Nat Hist, Pittsburgh, PA 15213 USA		Luo, ZX (corresponding author), Carnegie Museum Nat Hist, Pittsburgh, PA 15213 USA.	luoz@carnegiemnh.org	Luo, Zhe-XI/AAU-2263-2021					Gaudin Timothy J., 1999, Fieldiana Geology, V41, P1; GAUDIN TJ, 1992, J MORPHOL, V214, P63, DOI 10.1002/jmor.1052140105; Gow C. E., 2001, Palaeontologia Africana, V37, P93; Hildebrand M., 1985, P89; Hu Yaoming, 1998, Vertebrata Palasiatica, V36, P102; Hu YM, 1997, NATURE, V390, P137, DOI 10.1038/36505; JENKINS FA, 1976, PHILOS T ROY SOC B, V273, P387, DOI 10.1098/rstb.1976.0022; Ji Q, 2002, NATURE, V416, P816, DOI 10.1038/416816a; Ji Q, 1999, NATURE, V398, P326; KIELAN-JAWOROWSKA Z, 2004, MAMMALS AGE DINOSAUR; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; KRAUSE D W, 1983, Bulletin of the Museum of Comparative Zoology, V150, P199; Krebs B., 1991, Berliner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V133, P1; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Luo ZX, 2003, SCIENCE, V302, P1934, DOI 10.1126/science.1090718; Luo ZX, 2002, ACTA PALAEONTOL POL, V47, P1; Luo ZX, 2001, SCIENCE, V292, P1535, DOI 10.1126/science.1058476; LUO ZX, IN PRESS J MAMM EVOL; Martin T, 2000, GUIMAROTA JURASSIC E; McKenna MC, 1997, CLASSIFICATION MAMMA; MCLEOD N, 1993, AM J SCI, V293, P300; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Novacek MJ, 1997, NATURE, V389, P483, DOI 10.1038/39020; Nowak RM, 1983, WALKERS MAMMALS WORL; Prothero DR, 1981, B AM MUS NAT HIST, V167, P277; ROSE KD, 1993, MAMMAL PHYLOGENY : PLACENTALS, P81; ROSE KD, 1999, ENCY PALEONTOLOGY, V1, P220; Rougier GW, 2003, ACTA GEOL SIN-ENGL, V77, P7; Rougier GW, 1998, NATURE, V396, P459, DOI 10.1038/24856; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; SIMPSON GEORGE GAYLORD, 1929, MEM PEABODY MUS YALE UNIV, V3, P1; SUES HD, 1983, THESIS HARVARD U; Swofford D. L., 2011, PAUP PHYLOGENETIC AN; Szalay F. S., 1994, EVOLUTIONARY HIST MA; Weil A, 2002, NATURE, V416, P798, DOI 10.1038/416798a	35	146	161	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					103	107		10.1126/science.1108875	http://dx.doi.org/10.1126/science.1108875			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802602				2022-12-28	WOS:000228221500042
J	Zatz, M				Zatz, M			When science is not enough: Fighting genetic disease in Brazil	SCIENCE			English	Editorial Material									Univ Sao Paulo, Biosci Inst, BR-05508090 Sao Paulo, Brazil	Universidade de Sao Paulo	Zatz, M (corresponding author), Univ Sao Paulo, Biosci Inst, Rua Matao 277,Sala 211, BR-05508090 Sao Paulo, Brazil.		Zatz, Mayana/M-5338-2015	Zatz, Mayana/0000-0003-3970-8025					0	5	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 1	2005	308	5718					55	57		10.1126/science.1111730	http://dx.doi.org/10.1126/science.1111730			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802588				2022-12-28	WOS:000228221500026
J	Curro, NJ; Caldwell, T; Bauer, ED; Morales, LA; Graf, MJ; Bang, Y; Balatsky, AV; Thompson, JD; Sarrao, JL				Curro, NJ; Caldwell, T; Bauer, ED; Morales, LA; Graf, MJ; Bang, Y; Balatsky, AV; Thompson, JD; Sarrao, JL			Unconventional superconductivity in PuCoGa5	NATURE			English	Article							NUCLEAR-RELAXATION; SPIN FLUCTUATION; KNIGHT-SHIFT; TEMPERATURE; CONSEQUENCES	In the Bardeen-Cooper-Schrieffer theory of superconductivity, electrons form ( Cooper) pairs through an interaction mediated by vibrations in the underlying crystal structure. Like lattice vibrations, antiferromagnetic fluctuations can also produce an attractive interaction creating Cooper pairs, though with spin and angular momentum properties different from those of conventional superconductors. Such interactions have been implicated for two disparate classes of materials-the copper oxides(1,2) and a set of Ce- and U-based compounds(3). But because their transition temperatures differ by nearly two orders of magnitude, this raises the question of whether a common pairing mechanism applies. PuCoGa5 has a transition temperature intermediate between those classes and therefore may bridge these extremes(4). Here we report measurements of the nuclear spin-lattice relaxation rate and Knight shift in PuCoGa5, which demonstrate that it is an unconventional superconductor with properties as expected for antiferromagnetically mediated superconductivity. Scaling of the relaxation rates among all of these materials ( a feature not exhibited by their Knight shifts) establishes antiferromagnetic fluctuations as a likely mechanism for their unconventional superconductivity and suggests that related classes of exotic superconductors may yet be discovered.	Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Chonnam Natl Univ, Dept Phys, Kwangju 500757, South Korea	United States Department of Energy (DOE); Los Alamos National Laboratory; Chonnam National University	Curro, NJ (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	curro@lanl.gov	Bauer, Eric D/D-7212-2011; Curro, Nicholas/D-3413-2009	Curro, Nicholas/0000-0001-7829-0237				ABRIKOSOV AA, 1975, METHODS QUANTUM FIEL, pCH7; ANDERSON PW, 1985, PHYS REV B, V32, P499, DOI 10.1103/PhysRevB.32.499; Bang Y, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.014505; Bang Y, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.104512; Bauer ED, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.147005; Colineau E, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.184411; Griveau JC, 2004, J MAGN MAGN MATER, V272, P154, DOI 10.1016/j.jmmm.2003.11.056; HIRSCHFELD PJ, 1988, PHYS REV B, V37, P83, DOI 10.1103/PhysRevB.37.83; Ishida K, 1998, NATURE, V396, P658, DOI 10.1038/25315; Ishigaki A, 1996, J PHYS SOC JPN, V65, P3402, DOI 10.1143/JPSJ.65.3402; Kawasaki Y, 2003, J PHYS SOC JPN, V72, P2308, DOI [10.1143/JPSJ.72.2308, 10.1143/JPSJ.72.72.2308]; KITAOKA Y, 1988, J PHYS SOC JPN, V57, P30, DOI 10.1143/JPSJ.57.30; Kohori Y, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.134526; Kotegawa H, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.127001; MASUDA Y, 1962, PHYS REV, V125, P159, DOI 10.1103/PhysRev.125.159; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; MONTHOUX P, 1991, PHYS REV LETT, V67, P3448, DOI 10.1103/PhysRevLett.67.3448; Moriya T, 2003, REP PROG PHYS, V66, P1299, DOI 10.1088/0034-4885/66/8/202; MORIYA T, 1994, J PHYS SOC JPN, V63, P1871, DOI 10.1143/JPSJ.63.1871; OHSUGI S, 1992, J PHYS SOC JPN, V61, P3054, DOI 10.1143/JPSJ.61.3054; Opahle I, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.157001; Petrovic C, 2001, J PHYS-CONDENS MAT, V13, pL337, DOI 10.1088/0953-8984/13/17/103; Sarrao JL, 2002, NATURE, V420, P297, DOI 10.1038/nature01212; Savrasov SY, 2000, PHYS REV LETT, V84, P3670, DOI 10.1103/PhysRevLett.84.3670; STENGER VA, 1995, PHYS REV LETT, V74, P1649, DOI 10.1103/PhysRevLett.74.1649; UEDA K, 1987, J PHYS SOC JPN, V56, P867, DOI 10.1143/JPSJ.56.867; Wolfer W.G., 2000, LOS ALAMOS SCI, V26, P274	27	261	263	6	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					622	625		10.1038/nature03428	http://dx.doi.org/10.1038/nature03428			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800618	Bronze			2022-12-28	WOS:000228011000039
J	Friedman, MJ				Friedman, MJ			Veterans' mental health in the wake of war	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							POSTTRAUMATIC-STRESS-DISORDER; AFGHANISTAN; CARE; IRAQ		Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, White River Jct, VT USA		Friedman, MJ (corresponding author), Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, White River Jct, VT USA.							Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303	5	49	49	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1287	+		10.1056/NEJMp058028	http://dx.doi.org/10.1056/NEJMp058028			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	911JL	15800223				2022-12-28	WOS:000227998300003
J	Parker, JS; Roe, SM; Barford, D				Parker, JS; Roe, SM; Barford, D			Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex	NATURE			English	Article							CRYSTAL-STRUCTURE; MICRORNA; ARGONAUTE2; INTERFERENCE; MECHANISMS; CLEAVAGE	RNA interference and related RNA silencing phenomena use short antisense guide RNA molecules to repress the expression of target genes(1,2). Argonaute proteins(3), containing amino-terminal PAZ (for PIWI/Argonaute/Zwille) domains and carboxy-terminal PIWI domains, are core components of these mechanisms. Here we show the crystal structure of a Piwi protein from Archaeoglobus fulgidus (AfPiwi) in complex with a small interfering RNA (siRNA)-like duplex, which mimics the 5 ' end of a guide RNA strand bound to an overhanging target messenger RNA. The structure contains a highly conserved metal-binding site that anchors the 5 ' nucleotide of the guide RNA. The first base pair of the duplex is unwound, separating the 5 ' nucleotide of the guide from the complementary nucleotide on the target strand, which exits with the 3 ' overhang through a short channel. The remaining base-paired nucleotides assume an A-form helix, accommodated within a channel in the PIWI domain, which can be extended to place the scissile phosphate of the target strand adjacent to the putative slicer catalytic site. This study provides insights into mechanisms of target mRNA recognition and cleavage by an Argonaute-siRNA guide complex.	Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Barford, D (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	david.barford@icr.ac.uk		Roe, Mark/0000-0002-7371-9855	Wellcome Trust [074543] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lingel A, 2004, NAT STRUCT MOL BIOL, V11, P576, DOI 10.1038/nsmb777; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Yan KS, 2003, NATURE, V426, P469, DOI 10.1038/nature02129	30	371	408	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					663	666		10.1038/nature03462	http://dx.doi.org/10.1038/nature03462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800628	Green Accepted			2022-12-28	WOS:000228011000049
J	Beuvink, I; Boulay, A; Fumagalli, S; Zilbermann, F; Ruetz, S; O'Reilly, T; Natt, F; Hall, J; Lane, HA; Thomas, G				Beuvink, I; Boulay, A; Fumagalli, S; Zilbermann, F; Ruetz, S; O'Reilly, T; Natt, F; Hall, J; Lane, HA; Thomas, G			The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation	CELL			English	Article							INDUCED G(1) ARREST; P53 GENE-MUTATIONS; CDK INHIBITOR; GROWTH ARREST; CANCER; ACTIVATION; CISPLATIN; KINASE; TARGET; MYC	Although DNA damaging agents have revolutionized chemotherapy against solid tumors, a narrow therapeutic window combined with severe side effects has limited their broader use. Here we show that RAD001 (everolimus), a rapamycin derivative, dramatically enhances cisplatin-induced apoptosis in wild-type p53, but not mutant p53 tumor cells. The use of isogenic tumor cell lines expressing either wild-type mTOR cDNA or a mutant that does not bind RAD001 demonstrates that the effects of RAD001 are through inhibition of mTOR function. We further show that RAD001 sensitizes cells to cisplatin by inhibiting p53-induced p21 expression. Unexpectedly, this effect is attributed to a small but significant inhibition of p2l translation combined with its short half-life. These findings provide the molecular rationale for combining DNA damaging agents with RAD001, showing that a general effect on a major anabolic process may dramatically enhance the efficacy of an established drug protocol in the treatment of cancer patients with solid tumors.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland; Novartis Pharma AG, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research; Novartis	Lane, HA (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66,POB 2543, CH-4058 Basel, Switzerland.	heidi.lane@pharma.novartis.com; gthomas@fmi.ch	FUMAGALLI, Stefano/C-2914-2019; Thomas, George/K-9235-2014	Thomas, George/0000-0003-3518-8149; Hall, Jonathan/0000-0003-4160-7135; Fumagalli, Stefano/0000-0001-5832-8680				Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Boulay A, 2004, CANCER RES, V64, P252, DOI 10.1158/0008-5472.CAN-3554-2; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dutcher Janice P, 2004, Curr Oncol Rep, V6, P111, DOI 10.1007/s11912-004-0022-5; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FAN SJ, 1994, CANCER RES, V54, P5824; Fumagalli S, 2000, COLD SPRING HARBOR M, V39, P695; Gaben AM, 2004, INT J CANCER, V108, P200, DOI 10.1002/ijc.11521; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Huang SL, 2001, CANCER RES, V61, P3373; Jaeschke A, 2003, CURR TOP MICROBIOL, V279, P283; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kralj M, 2003, CANCER GENE THER, V10, P457, DOI 10.1038/sj.cgt.7700588; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173; Luan FL, 2002, TRANSPLANTATION, V73, P1565, DOI 10.1097/00007890-200205270-00008; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; McCormick F, 2004, NATURE, V428, P267, DOI 10.1038/428267a; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Panwalkar A, 2004, CANCER-AM CANCER SOC, V100, P657, DOI 10.1002/cncr.20026; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Prendergast GC, 2003, CANCER CELL, V4, P244, DOI 10.1016/S1535-6108(03)00247-2; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Segal-Bendirdjian E, 1998, CELL DEATH DIFFER, V5, P390, DOI 10.1038/sj.cdd.4400357; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHI YF, 1995, CANCER RES, V55, P1982; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tian H, 2000, CANCER RES, V60, P679; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, CANCER CELL, V2, P351, DOI 10.1016/S1535-6108(02)00186-1; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Weiss RH, 2003, CANCER LETT, V189, P39, DOI 10.1016/S0304-3835(02)00495-0; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	57	423	437	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					747	759		10.1016/j.cell.2004.12.040	http://dx.doi.org/10.1016/j.cell.2004.12.040			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797377	Bronze			2022-12-28	WOS:000228067500006
J	Hewlett, EL; Edwards, KM				Hewlett, EL; Edwards, KM			Pertussis - Not just for kids	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; BORDETELLA-PERTUSSIS; LABORATORY DIAGNOSIS; UNITED-STATES; ERYTHROMYCIN; ADULTS; INFANTS; PCR; RECOMMENDATIONS; ADOLESCENTS	Six weeks ago, a 45-year-old woman noticed a scratchy feeling in her throat that has now progressed to more than 20 episodes of severe, spasmodic coughing per day. Her coughing spells are worse at night and are sometimes associated with gagging and vomiting. Her adolescent son and several of his friends, who received all of their childhood immunizations on schedule, had similar illnesses involving cough several weeks before the onset of her symptoms, and they continue to cough. How should the patient be assessed for possible pertussis? Should she be treated and, if so, how? Could this illness have been prevented?	Univ Virginia, Sch Med, Div Infect Dis & Int Hlth, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Div Infect Dis & Int Hlth, Dept Pharmacol, Charlottesville, VA 22908 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Div Pediat Infect Dis, Nashville, TN 37212 USA	University of Virginia; University of Virginia; Vanderbilt University	Hewlett, EL (corresponding author), Univ Virginia, Sch Med, Div Infect Dis & Int Hlth, Dept Med, POB 800419, Charlottesville, VA 22908 USA.	eh2v@virginia.edu						Aoyama T, 1996, J PEDIATR-US, V129, P761, DOI 10.1016/S0022-3476(96)70163-4; BERGQUIST, 1987, PEDIATR INFECT DIS J, V6, P1035; BERGQUIST SO, 1987, PEDIATR INFECT DIS J, V6, P458, DOI 10.1097/00006454-198705000-00009; Birkebaek NH, 1999, CLIN INFECT DIS, V29, P1239, DOI 10.1086/313448; Casano P, 2002, ARCH DIS CHILD, V86, P453, DOI 10.1136/adc.86.6.453-a; Cattaneo LA, 1996, J INFECT DIS, V173, P1256, DOI 10.1093/infdis/173.5.1256; CHERRY J D, 1988, Pediatrics, V81, P939; Cherry JD, 2003, PEDIATRICS, V112, P405, DOI 10.1542/peds.112.2.405; Cloud JL, 2003, DIAGN MICR INFEC DIS, V46, P189, DOI 10.1016/S0732-8893(03)00045-2; Crowcroft NS, 2003, LANCET INFECT DIS, V3, P413, DOI 10.1016/S1473-3099(03)00669-8; De Serres G, 2000, J INFECT DIS, V182, P174, DOI 10.1086/315648; Deeks S, 1999, CLIN INFECT DIS, V28, P840, DOI 10.1086/515203; Edelman K, 1996, PEDIATR INFECT DIS J, V15, P54, DOI 10.1097/00006454-199601000-00012; Edwards KM, 2003, VACCINE, V21, P3483, DOI 10.1016/S0264-410X(03)00356-6; Edwards KM, 2001, INFECT DIS CLIN N AM, V15, P209, DOI 10.1016/S0891-5520(05)70276-2; EWANOWICH CA, 1993, J CLIN MICROBIOL, V31, P1715, DOI 10.1128/JCM.31.7.1715-1725.1993; Farrell DJ, 2000, J CLIN MICROBIOL, V38, P4499, DOI 10.1128/JCM.38.12.4499-4502.2000; Fry NK, 2004, J MED MICROBIOL, V53, P519, DOI 10.1099/jmm.0.45624-0; GOULIN GD, 1993, CRIT CARE MED, V21, P1791, DOI 10.1097/00003246-199311000-00033; Hallander HO, 1999, CLIN INFECT DIS, V28, pS99, DOI 10.1086/515056; HALPERIN SA, 1991, REV INFECT DIS, V13, P1043; Halperin SA, 1997, PEDIATRICS, V100, P65, DOI 10.1542/peds.100.1.65; Healy CM, 2004, J INFECT DIS, V190, P335, DOI 10.1086/421033; Heininger U, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.3.e31; Hoppe JE, 1998, ANTIMICROB AGENTS CH, V42, P965, DOI 10.1128/AAC.42.4.965; Kosters K, 2000, CLIN DIAGN LAB IMMUN, V7, P422, DOI 10.1128/CDLI.7.3.422-426.2000; KURT TL, 1972, J AMER MED ASSOC, V221, P264, DOI 10.1001/jama.221.3.264; Langley JM, 2004, PEDIATRICS, V114, pE96, DOI 10.1542/peds.114.1.e96; Lievano FA, 2002, J CLIN MICROBIOL, V40, P2801, DOI 10.1128/JCM.40.8.2801-2805.2002; Mahon BE, 2001, J PEDIATR-US, V139, P380, DOI 10.1067/mpd.2001.117577; Mastrantonio P, 1999, MICROBIOL-UK, V145, P2069, DOI 10.1099/13500872-145-8-2069; McEniery JA, 2004, J PAEDIATR CHILD H, V40, P230, DOI 10.1111/j.1440-1754.2004.00344.x; MEADE BD, 1994, J MED MICROBIOL, V41, P51, DOI 10.1099/00222615-41-1-51; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; Muller FMC, 1997, J CLIN MICROBIOL, V35, P2435; *NAT IMM PROGR, 2000, GUID CONTR PERT OUTB; Nennig ME, 1996, JAMA-J AM MED ASSOC, V275, P1672, DOI 10.1001/jama.275.21.1672; PICKERING L, 2003, 2003 RED BOOK REPORT, P472; PILLAY V, 2003, COCHRANE DB SYST REV, V4; POSTELSMULTANI S, 1995, INFECTION, V23, P139, DOI 10.1007/BF01793853; Purdy KW, 2004, CLIN INFECT DIS, V39, P20, DOI 10.1086/421091; Ray WA, 2004, NEW ENGL J MED, V351, P1089, DOI 10.1056/NEJMoa040582; SCHMITTGROHE S, 1995, CLIN INFECT DIS, V21, P860, DOI 10.1093/clinids/21.4.860; Skowronski DM, 2003, CLIN INFECT DIS, V36, pE1, DOI 10.1086/344776; Skowronski DM, 2002, J INFECT DIS, V185, P1696; Skowronski DM, 2002, J INFECT DIS, V185, P1448, DOI 10.1086/340280; Smith C, 2000, EUR J PEDIATR, V159, P898, DOI 10.1007/PL00008365; STEKETEE RW, 1988, J INFECT DIS, V157, P434, DOI 10.1093/infdis/157.3.434; Strebel P, 2001, J INFECT DIS, V183, P1353, DOI 10.1086/319853; Tanaka M, 2003, JAMA-J AM MED ASSOC, V290, P2968, DOI 10.1001/jama.290.22.2968; Thomas PF, 2000, MED J AUSTRALIA, V173, P74, DOI 10.5694/j.1326-5377.2000.tb139246.x; TROLLFORS B, 1981, BRIT MED J, V283, P696, DOI 10.1136/bmj.283.6293.696; Vitek CR, 2003, PEDIATR INFECT DIS J, V22, P628, DOI 10.1097/00006454-200307000-00012; von Konig CHW, 2002, LANCET INFECT DIS, V2, P744, DOI 10.1016/S1473-3099(02)00452-8; WARD JI, 2001, 41 INT C ANT AG CHEM, P520; WRIGHT SW, 1995, JAMA-J AM MED ASSOC, V273, P1044, DOI 10.1001/jama.273.13.1044; 2002, MMWR MORB MORTAL WKL, V51, P73	57	182	200	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1215	1222		10.1056/NEJMcp041025	http://dx.doi.org/10.1056/NEJMcp041025			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788498				2022-12-28	WOS:000227832300008
J	Lange, S; Xiang, FQ; Yakovenko, A; Vihola, A; Hackman, P; Rostkova, E; Kristensen, J; Brandmeier, B; Franzen, G; Hedberg, B; Gunnarsson, LG; Hughes, SM; Marchand, S; Sejersen, T; Richard, I; Edstrom, L; Ehler, E; Udd, B; Gautel, M				Lange, S; Xiang, FQ; Yakovenko, A; Vihola, A; Hackman, P; Rostkova, E; Kristensen, J; Brandmeier, B; Franzen, G; Hedberg, B; Gunnarsson, LG; Hughes, SM; Marchand, S; Sejersen, T; Richard, I; Edstrom, L; Ehler, E; Udd, B; Gautel, M			The kinase domain of titin controls muscle gene expression and protein turnover	SCIENCE			English	Article							SERUM RESPONSE FACTOR; M-BAND; IDENTIFICATION; INACTIVATION; ACTIVATION; MYOMESIN; DYNAMICS; MYOPATHY; DELETION; FAMILY	The giant sarcomeric protein titin contains a protein kinase domain (TK) ideally positioned to sense mechanical load. We identified a signaling complex where TK interacts with the zinc-finger protein nbr1 through a mechanically inducible conformation. Nbr1 targets the ubiquitin-associated p62/SQSTM1 to sarcomeres, and p62 in turn interacts with MuRF2, a muscle-specific RING-B-box E3 ligase and ligand of the transactivation domain of the serum response transcription factor (SRF). Nuclear translocation of MuRF2 was induced by mechanical inactivity and caused reduction of nuclear SRF and repression of transcription. A human mutation in the titin,protein kinase domain causes hereditary muscle disease by disrupting this pathway.	Univ Helsinki, Folkhalsen Inst Genet, Biomedicum, FIN-00290 Helsinki, Finland; Univ Helsinki, Dept Med Genet, Biomedicum, FIN-00290 Helsinki, Finland; Kings Coll London, Randall Div, London SE1 1UL, England; Kings Coll London, Div Cardiovasc, London SE1 1UL, England; ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, S-17176 Stockholm, Sweden; Orebro Univ Hosp, Dept Environm Med, S-70185 Orebro, Sweden; Genethon, CNRS, UMR 8115, F-91000 Evry, France; Astrid Lindgren Childrens Hosp, Dept Woman & Child Hlth, Neuropediat Unit, S-17176 Stockholm, Sweden; Vasa Cent Hosp, Dept Neurol, Vaasa 65130, Finland; Tampere Univ Hosp, Dept Neurol, Tampere 33520, Finland	University of Helsinki; University of Helsinki; University of London; King's College London; University of London; King's College London; Swiss Federal Institutes of Technology Domain; ETH Zurich; Karolinska Institutet; Karolinska University Hospital; Orebro University; Centre National de la Recherche Scientifique (CNRS); Vaasa Central Hospital; Tampere University; Tampere University Hospital	Gautel, M (corresponding author), Univ Helsinki, Folkhalsen Inst Genet, Biomedicum, FIN-00290 Helsinki, Finland.	Bjarne.Udd@vshp.fi; mathias.gautel@kcl.ac.uk	Richard, isabelle/J-8298-2013; Lange, Stephan/A-1422-2010; Hughes, Simon M/S-1073-2016; Gautel, Mathias/AAB-9860-2019	Lange, Stephan/0000-0001-9361-6602; Hughes, Simon M/0000-0001-8227-9225; Gautel, Mathias/0000-0003-4027-9803; Xiang, Fengqing/0000-0003-0892-1536; Sejersen, Thomas/0000-0001-5961-7097; Ehler, Elisabeth/0000-0001-5646-5964	MRC [G0300213] Funding Source: UKRI; British Heart Foundation [PG/03/049/15364] Funding Source: Medline; Medical Research Council [G0300213, G0200496(63216)] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agarkova I, 2003, J MUSCLE RES CELL M, V24, P191, DOI 10.1023/A:1026094924677; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; Centner T, 2001, J MOL BIOL, V306, P717, DOI 10.1006/jmbi.2001.4448; Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200; Dai KS, 2001, J BIOL CHEM, V276, P23992, DOI 10.1074/jbc.M011208200; EDSTROM L, 1990, J NEUROL SCI, V96, P211, DOI 10.1016/0022-510X(90)90134-9; Fuller SJ, 1998, J BIOL CHEM, V273, P18146, DOI 10.1074/jbc.273.29.18146; Gautel M, 1999, REV PHYSIOL BIOCH P, V138, P97, DOI 10.1007/BF02346661; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; GOTTHARDT M, 2002, J BIOL CHEM, V2, P2; Grater F, 2005, BIOPHYS J, V88, P790, DOI 10.1529/biophysj.104.052423; Hackman P, 2002, AM J HUM GENET, V71, P492, DOI 10.1086/342380; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Liang PQ, 1997, J BIOL CHEM, V272, P28050, DOI 10.1074/jbc.272.44.28050; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; MCETHINNY MS, 2002, J CELL BIOL, V157, P125; Miano JM, 2004, P NATL ACAD SCI USA, V101, P17132, DOI 10.1073/pnas.0406041101; Miller G, 2003, J CELL SCI, V116, P4811, DOI 10.1242/jcs.00768; Nicolao P, 1999, AM J HUM GENET, V64, P788, DOI 10.1086/302281; Obermann WMJ, 1996, J CELL BIOL, V134, P1441, DOI 10.1083/jcb.134.6.1441; Parlakian A, 2004, MOL CELL BIOL, V24, P5281, DOI 10.1128/MCB.24.12.5281-5289.2004; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pizon V, 2002, J CELL SCI, V115, P4469, DOI 10.1242/jcs.00131; Pridgeon Julia W., 2003, Biol Proced Online, V5, P228, DOI 10.1251/bpo66; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; Spencer JA, 2000, J CELL BIOL, V150, P771, DOI 10.1083/jcb.150.4.771; Steiner F, 1999, GENOMICS, V56, P78, DOI 10.1006/geno.1998.5682; Tskhovrebova L, 2003, NAT REV MOL CELL BIO, V4, P679, DOI 10.1038/nrm1198; van der Ven PFM, 2000, J CELL SCI, V113, P1405	32	421	441	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 10	2005	308	5728					1599	1603		10.1126/science.1110463	http://dx.doi.org/10.1126/science.1110463			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	936BH	15802564				2022-12-28	WOS:000229827000048
J	Harley, M; Mohammed, MA; Hussain, S; Yates, J; Almasri, A				Harley, M; Mohammed, MA; Hussain, S; Yates, J; Almasri, A			Was Rodney Ledward a statistical outlier? Retrospective analysis using routine hospital data to identify gynaecologists' performance	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRISTOL	Objectives To investigate whether routinely collected data from hospital episode statistics could be used to identify the gynaecologist Rodney Ledward, who was suspended in 1996 and was the subject of die Ritchie inquiry into quality and practice within the NHS. Design A mixed scanning approach was used to identify seven variables from hospital episode statistics that were likely to be associated with potentially poor performance. A blinded multivariate analysis was undertaken to determine the distance (known as the Mahalanobis distance) in the seven indicator multidimensional space that each consultant was from the average consultant in each year. The change in Mahalanobis distance over time was also investigated by using a mixed effects model. Setting NHS hospital trusts in two English regions, in the five years from 1991-2 to 1995-6. Population Gynaecology consultants (n = 143) and their hospital episode statistics data. Main outcome measure Whether Ledward was a statistical outlier at the 95% level. Results The proportion of consultants who were outliers in any one year (at the 95% significance level) ranged from 9% to 20%. Ledward appeared as an outlier in three of the five years. Our mixed effects (multi-year) model identified nine high outlier consultants, including Ledward. Conclusion It was possible to identify Ledward as an outlier by using hospital episode statistics data. Although our method found other outlier consultants, we strongly caution that these outliers should not be overinterpreted as indicative of "poor" performance. Instead, a scientific search for a credible explanation should be undertaken, but this was outside the remit of our study. The set of indicators used means that cancer specialists, for example, are likely to have high values for several indicators, and the approach needs to be refined to deal with case mix variation. Even after allowing for that, the interpretation of outlier status is still as yet unclear. Further prospective evaluation of our method is warranted, but our overall approach may be potentially useful in other settings, especially where performance entails several indicator variables.	Univ Birmingham, Hlth Serv Management Ctr, Interauthor Comparisons & Consultancy, Birmingham B15 2RT, W Midlands, England; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham	Harley, M (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Interauthor Comparisons & Consultancy, Birmingham B15 2RT, W Midlands, England.	M.J.Harley@bham.ac.uk						Aylin P, 2001, LANCET, V358, P181, DOI 10.1016/S0140-6736(01)05404-6; *BBC, BBC NEWS ONL 2 SURG; *BBC, BBC NEWS ONL WISH CA; BIGNELL V, 1977, CATASTROPHIC FAILURE; Campbell SE, 2001, J PUBLIC HEALTH MED, V23, P205, DOI 10.1093/pubmed/23.3.205; *DEP HLTH, 2001, REP PUBL INQ CHILDR; *DEP HLTH, 2000, REP INQ QUAL PRACT N; Donaldson L., 2005, ORG MEMORY REPORT EX; Dunn PM, 1998, BRIT MED J, V317, P1144; ETZIONI A, PUBLIC ADM REV, V27, P385; Foster, 2004, BMJ-BRIT MED J, V329, P369, DOI 10.1136/bmj.329.7462.369; Insightful Corporation, 2002, S PLUS 6 ROB LIB US; Jarman B, 1999, BMJ-BRIT MED J, V318, P1515, DOI 10.1136/bmj.318.7197.1515; Lilford R, 2004, LANCET, V363, P1147, DOI 10.1016/S0140-6736(04)15901-1; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; MASON S, 2003, BRIT MED J, V324, P419; Mohammed MA, 2004, BMJ-BRIT MED J, V328, P1474, DOI 10.1136/bmj.328.7454.1474; Rousseeuw P. J., 1987, ROBUST REGRESSION OU; SPIEGELHALTER D, 2002, MONITORING CLIN PERF; TURNER BA, 1976, ADMIN SCI QUART, V21, P378, DOI 10.2307/2391850; YATES JM, 1986, USE ROUTINELY COLLEC	21	25	25	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 23	2005	330	7497					929	932		10.1136/bmj.38377.675440.8F	http://dx.doi.org/10.1136/bmj.38377.675440.8F			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	920UP	15833750	Green Published, Bronze			2022-12-28	WOS:000228715900017
J	Al-Khatib, SM; Anstrom, KJ; Eisenstein, EL; Peterson, ED; Jollis, JG; Mark, DB; Li, Y; O'Connor, CM; Shaw, LK; Califf, RM				Al-Khatib, SM; Anstrom, KJ; Eisenstein, EL; Peterson, ED; Jollis, JG; Mark, DB; Li, Y; O'Connor, CM; Shaw, LK; Califf, RM			Clinical and economic implications of the multicenter automatic defibrillator implantation trial-II	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	52nd Annual Scientific Session of the American-College-of-Cardiology	MAR 30-APR 02, 2003	CHICAGO, IL	Amer Coll Cardiol			CORONARY-ARTERY-DISEASE; SUDDEN CARDIAC DEATH; COST-EFFECTIVENESS; CARDIOVERTER-DEFIBRILLATOR; MYOCARDIAL-INFARCTION; DRUG-THERAPY; HIGH-RISK; AMIODARONE; SURVIVAL; RECOMMENDATIONS	Background: The Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II demonstrated that implantable cardioverter defibrillators (ICDs) save lives when used in patients with a history of myocardial infarction (MI) and an ejection fraction of 0.3 or less. Objective: To investigate the cost-effectiveness of implanting ICDs in patients who met MADIT-II eligibility criteria and were enrolled in the Duke Cardiovascular Database between 1 January 1986 and 31 December 2001. Design: Cost-effectiveness analysis. Data Sources: Published literature, databases owned by Duke University Medical Center, and Medicare data. Target Population: Adults with a history of MI and an ejection fraction of 0.3 or less. Time Horizon: Lifetime. Perspective: societal. Interventions: ICD therapy versus conventional medical therapy. Outcomes Measures: Cost per life-year gained and incremental cost-effectiveness. Results: compared with conventional medical therapy, ICDs are projected to result in an increase of 1.80 discounted years in life expectancy and an incremental cost-effectiveness ratio of $50 500 per life-year gained. Cost-effectiveness varied dramatically with changes in time horizon: The cost-effectiveness ratio increased to $67 800 per life-year gained, $79 900 per life-year gained, $100 000 per life-year gained, $167 900 per life-year gained, and $367 200 per life-year gained for 15-year, 12-year, 9-year, 6-year, and 3-year time horizons, respectively. Changing the frequency of follow-up visits, complication rates, and battery replacements had less of an effect on the cost-effectiveness ratios than reducing the cost of ICD placement and leads. Limitations: The study was limited by the completeness of the data, referral bias, difference in medical therapy between the Duke cohort and the MADIT-II cohort, and not addressing potential upgrades to biventricular devices. Conclusions: The economic expense of defibrillator implantation in all patients who meet MADIT-II eligibility criteria is substantial. However, in the range of survival benefit observed in MADIT-II, ICD therapy for these patients is economically attractive by conventional standards.	Duke Univ, Clin Res Inst, Durham, NC 27715 USA	Duke University	Al-Khatib, SM (corresponding author), Duke Univ, Clin Res Inst, 2400 Pratt St, Durham, NC 27715 USA.		Peterson, Eric David/ABF-5033-2021	Mark, Daniel/0000-0001-6340-8087				American Heart Association, 2002, HEART DIS STROKE STA; Anderson R N, 2000, Vital Health Stat 2, P1; Bang H, 2000, BIOMETRIKA, V87, P329, DOI 10.1093/biomet/87.2.329; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; COX DR, 1972, J R STAT SOC B, V34, P187; Eisenstein EL, 2001, MED CARE, V39, P824, DOI 10.1097/00005650-200108000-00008; EISENSTEIN EL, ACUTE CORONARY SYSND, P723; FORTIN DF, 1995, AM J CARDIOL, V76, P1177, DOI 10.1016/S0002-9149(99)80331-2; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; Kennergren C, 1996, AM J CARDIOL, V78, P15, DOI 10.1016/S0002-9149(96)00497-3; KUPPERMANN M, 1990, CIRCULATION, V81, P91, DOI 10.1161/01.CIR.81.1.91; Larsen G, 2002, CIRCULATION, V105, P2049, DOI 10.1161/01.CIR.0000015504.57641.D0; LARSEN GC, 1992, J AM COLL CARDIOL, V19, P1323, DOI 10.1016/0735-1097(92)90341-J; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MARK DB, 1996, CIRCULATION, V94, P168; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Mushlin AI, 1998, CIRCULATION, V97, P2129, DOI 10.1161/01.CIR.97.21.2129; O'Brien BJ, 2001, CIRCULATION, V103, P1416, DOI 10.1161/01.CIR.103.10.1416; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; Sanders GD, 2001, ANN INTERN MED, V135, P870, DOI 10.7326/0003-4819-135-10-200111200-00007; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Spath MA, 2002, PHARMACOECONOMICS, V20, P727, DOI 10.2165/00019053-200220110-00002; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Zipes DP, 1998, CIRCULATION, V98, P2334, DOI 10.1161/01.CIR.98.21.2334; 2003, MEDTRONIC PRODUCT PE, V13	31	90	89	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					593	600		10.7326/0003-4819-142-8-200504190-00007	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	916TZ	15838065				2022-12-28	WOS:000228410400001
J	Orchard, TJ; Temprosa, M; Goldberg, R; Haffner, S; Ratner, R; Marcovina, S; Fowler, S				Orchard, TJ; Temprosa, M; Goldberg, R; Haffner, S; Ratner, R; Marcovina, S; Fowler, S		Diabet Prevention Program Res Grp	The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The diabetes prevention program randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-HEART-DISEASE; PREVALENCE; MELLITUS; GLUCOSE; DIET; RISK	Background: The metabolic syndrome is a high-risk state for diabetes and cardiovascular disease. Little is known about its prevalence and prevention in those with impaired glucose tolerance. Objective: To determine the prevalence of the metabolic syndrome at baseline in the Diabetes Prevention Program and the effect of intensive lifestyle intervention and metformin therapy on the syndrome's incidence and resolution. Design: Randomized, controlled clinical trial. Setting: Research and community-based centers. Participants: Participants had impaired glucose tolerance (World Health Organization criteria plus fasting plasma glucose level >= 53 mmol/L [ >= 95 mg/dL]) and were followed for a mean of 3.2 years after random assignment to intensive lifestyle intervention, metformin therapy, or placebo. Interventions: Metformin, 850 ring twice daily, or intensive lifestyle intervention designed to achieve and maintain a 7% weight loss and 150 minutes of exercise per week. Measurements: The metabolic syndrome was defined as having 3 or more characteristics (waist circumference; blood pressure; and levels of high-density lipoprotein cholesterol, triglycerides, and fasting plasma glucose) that met criteria from the National Cholesterol Education Program Adult Treatment Panel III. Results: Fifty-three percent of participants (n = 1711) had the metabolic syndrome at baseline; incidence did not vary substantially by age. However, low levels of high-density lipoprotein cholesterol predominated in younger participants (age 25 to 44 years), and high blood pressure predominated in older participants (age 60 to 82 years). In life-table analyses (log-rank test), incidence of the metabolic syndrome was reduced by 41% in the lifestyle group (P < 0.001) and by 17% in the metformin group (P = 0.03) compared with placebo. Three-year cumulative incidences were 51%, 45%, and 34% in the placebo, metformin, and lifestyle groups, respectively. There was no significant heterogeneity by ethnic group. Limitations: The study involved a volunteer group with impaired glucose tolerance, which limits generalizability. Conclusions: The metabolic syndrome affected approximately half of the participants in the Diabetes Prevention Program at baseline. Both lifestyle intervention and metformin therapy reduced the development of the syndrome in the remaining participants.	George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, Rockville, MD 20852 USA	George Washington University	Orchard, TJ (corresponding author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA.			orchard, trevor/0000-0001-9552-3215	NIDDK NIH HHS [U01 DK048489, 5U01DK048489, U01 DK048489-06] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK048489] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Alexander CM, 2003, DIABETES, V52, P1210, DOI 10.2337/diabetes.52.5.1210; American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS11; Bonora E, 2003, DIABETES CARE, V26, P1251, DOI 10.2337/diacare.26.4.1251; Borch-Johnsen K, 1999, LANCET, V354, P617; Borch-Johnsen K, 2001, ARCH INTERN MED, V161, P397, DOI 10.1001/archinte.161.3.397; Bray GA, 1999, DIABETES CARE, V22, P623; Bureau of the Census, 1990, CENS POP 1990; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; CROUSE JR, 1989, LANCET, V1, P318, DOI 10.1016/S0140-6736(89)91320-2; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Han TS, 2002, DIABETES CARE, V25, P2016, DOI 10.2337/diacare.25.11.2016; HOKANSON JE, 1997, HDB LIPOPROTEIN TEST, P267; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lachin J. M., 2000, WILEY SER PROB STAT; Lindstrom J, 2003, DIABETES CARE, V26, P3230, DOI 10.2337/diacare.26.12.3230; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Ozata M, 2001, OBES RES, V9, P662, DOI 10.1038/oby.2001.90; Stern MP, 2002, ANN INTERN MED, V136, P575, DOI 10.7326/0003-4819-136-8-200204160-00006; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; Vrbikova J, 2001, EUR J ENDOCRINOL, V144, P619, DOI 10.1530/eje.0.1440619; Warnick G R, 1986, Methods Enzymol, V129, P101; WARNICK GR, 1982, CLIN CHEM, V28, P1379	24	653	672	2	53	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					611	619		10.7326/0003-4819-142-8-200504190-00009	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916TZ	15838067	Green Accepted			2022-12-28	WOS:000228410400003
J	Rochon, PA; Gurwitz, JH; Sykora, K; Mamdani, M; Streiner, DL; Garfinkel, S; Normand, SLT; Anderson, GM				Rochon, PA; Gurwitz, JH; Sykora, K; Mamdani, M; Streiner, DL; Garfinkel, S; Normand, SLT; Anderson, GM			Reader's guide to critical appraisal of cohort studies: 1. Role and design	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED-TRIALS		Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Meyers Primary Care Inst, Worcester, MA 01605 USA; Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Chair Hlth Management Strategies, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; University of Toronto; Harvard University; Harvard Medical School; University of Toronto	Anderson, GM (corresponding author), Inst Clin Evaluat Sci, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	geoff.anderson@utoronto.ca	Rochon, Paula A/J-2918-2016; Streiner, David/E-6563-2011	Rochon, Paula A/0000-0002-5973-4151; Streiner, David/0000-0003-0610-6271; Normand, Sharon-Lise/0000-0001-7027-4769				Altman DG, 1999, BRIT MED J, V318, P1209; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Black N, 1996, BRIT MED J, V312, P1215; Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3; Greenland S, 2001, ANNU REV PUBL HEALTH, V22, P189, DOI 10.1146/annurev.publhealth.22.1.189; Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; Mamdani M, 2002, BMJ-BRIT MED J, V325, P1, DOI [10.1136/bmj.325.7365.624, DOI 10.1136/BMJ.325.7365.624]; McKee M, 1999, BMJ-BRIT MED J, V319, P312, DOI 10.1136/bmj.319.7205.312; Murray MD, 2003, ANN INTERN MED, V139, P425, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00009; Psaty BM, 1999, J AM GERIATR SOC, V47, P749, DOI 10.1111/j.1532-5415.1999.tb01603.x	13	116	118	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	2005	330	7496					895	897		10.1136/bmj.330.7496.895	http://dx.doi.org/10.1136/bmj.330.7496.895			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	917UA	15831878	Green Published, Green Submitted			2022-12-28	WOS:000228493500026
J	Baird, JK				Baird, JK			Drug therapy: Effectiveness of antimalarial drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLASMODIUM-FALCIPARUM MALARIA; IN-VIVO RESISTANCE; NEUROPSYCHIATRIC ADVERSE EVENTS; PLUS SULFADOXINE-PYRIMETHAMINE; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; CHLOROQUINE RESISTANCE; MEFLOQUINE-ARTESUNATE; ATOVAQUONE-PROGUANIL; IRIAN-JAYA		USN, Med Res Unit 2, Jakarta, Indonesia	University of 19 November Kolaka	Baird, JK (corresponding author), Amer Embassy, FPO, AP 96520 USA.	baird@namru2.org						Ache A, 2002, TROP MED INT HEALTH, V7, P737, DOI 10.1046/j.1365-3156.2002.00936.x; Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Al-Maktari Mohamed T, 2003, J Egypt Soc Parasitol, V33, P829; Al-Yaman Fadwa, 1996, Papua New Guinea Medical Journal, V39, P16; [Anonymous], 2003, ASS MON ANT DRUG EFF; ARNOLD J., 1961, TRANS ROY SOC TROP MED AND HYG, V55, P345, DOI 10.1016/0035-9203(61)90103-1; ARROW KJ, 2004, SAVING LIVES BUYING, P12; Attaran A, 2004, LANCET, V363, P237, DOI 10.1016/S0140-6736(03)15330-5; Avila JC, 2004, TROP MED INT HEALTH, V9, P217, DOI 10.1046/j.1365-3156.2003.01184.x; Awad MI, 2003, AM J TROP MED HYG, V68, P153, DOI 10.4269/ajtmh.2003.68.153; Baird JK, 2004, ANTIMICROB AGENTS CH, V48, P4075, DOI 10.1128/AAC.48.11.4075-4083.2004; Baird JK, 2004, CLIN INFECT DIS, V39, P1336, DOI 10.1086/424663; Baird JK, 2000, DRUGS, V59, P719, DOI 10.2165/00003495-200059040-00001; Baird JK, 2003, CLIN INFECT DIS, V37, P1659, DOI 10.1086/379714; Baird JK, 2002, AM J TROP MED HYG, V66, P659, DOI 10.4269/ajtmh.2002.66.659; Baird JK, 2002, ANN TROP MED PARASIT, V96, P339, DOI 10.1179/000349802125001023; Barnes KI, 2004, LANCET, V363, P1598, DOI 10.1016/S0140-6736(04)16203-X; Basco LK, 2004, AM J TROP MED HYG, V70, P245, DOI 10.4269/ajtmh.2004.70.245; Blair S, 2001, Rev Panam Salud Publica, V9, P23, DOI 10.1590/S1020-49892001000100006; Blair Silvia, 2003, Biomedica, V23, P318; Blair-Trujillo S, 2002, MEM I OSWALDO CRUZ, V97, P401, DOI 10.1590/S0074-02762002000300022; Bolaji OO, 2002, EUR J CLIN PHARMACOL, V58, P543, DOI 10.1007/s00228-002-0509-7; Bunnag Danai, 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P15; Bustos DG, 1999, J INFECT DIS, V179, P1587, DOI 10.1086/314770; Caraballo A, 1999, AM J TROP MED HYG, V61, P120, DOI 10.4269/ajtmh.1999.61.120; *CDCP, 2003, HLTH INF INT TRAV 20, P99; COATNEY GR, 1963, AM J TROP MED HYG, V12, P121, DOI 10.4269/ajtmh.1963.12.121; Collins WE, 2002, AM J TROP MED HYG, V67, P406, DOI 10.4269/ajtmh.2002.67.406; Collins WE, 1996, AM J TROP MED HYG, V55, P243, DOI 10.4269/ajtmh.1996.55.243; Curtis Chris F, 2002, Biomedica, V22, P455; Day NPJ, 1996, BLOOD, V88, P4694, DOI 10.1182/blood.V88.12.4694.bloodjournal88124694; Demar M, 2004, AM J TROP MED HYG, V70, P125, DOI 10.4269/ajtmh.2004.70.125; Denis M B, 1998, Bull World Health Organ, V76 Suppl 1, P43; Deressa W, 2003, B WORLD HEALTH ORGAN, V81, P261; Dev V, 2003, ANN TROP MED PARASIT, V97, P783, DOI 10.1179/000349803225002660; Djimde AA, 2003, AM J TROP MED HYG, V69, P558, DOI 10.4269/ajtmh.2003.69.558; Duarte EC, 2003, TROP MED INT HEALTH, V8, P518, DOI 10.1046/j.1365-3156.2003.01042.x; Ejov MN, 1999, B WORLD HEALTH ORGAN, V77, P244; Ezard N, 2004, ANN TROP MED PARASIT, V98, P85, DOI 10.1179/000349804225003019; Fryauff DJ, 2002, ANN TROP MED PARASIT, V96, P447, DOI 10.1179/000349802125001249; Fryauff DJ, 1997, AM J TROP MED HYG, V56, P241, DOI 10.4269/ajtmh.1997.56.241; Fryauff DJ, 1999, AM J TROP MED HYG, V60, P542, DOI 10.4269/ajtmh.1999.60.542; Fungladda W, 1998, Bull World Health Organ, V76 Suppl 1, P59; Ghalib HW, 2001, ANN TROP MED PARASIT, V95, P773, DOI 10.1080/0003498012011127; GONZALEZ U, 2003, BIOMEDICA, V23, P38; Goodman C, 2004, TROP MED INT HEALTH, V9, P655, DOI 10.1111/j.1365-3156.2004.01245.x; Guerin PJ, 2002, LANCET INFECT DIS, V2, P564, DOI 10.1016/S1473-3099(02)00372-9; Hakim SL, 1996, T ROY SOC TROP MED H, V90, P294, DOI 10.1016/S0035-9203(96)90258-8; HOPPERUS BAP, 1996, J INFECT DIS, V173, P1506; Ittarat W, 2003, AM J TROP MED HYG, V68, P147, DOI 10.4269/ajtmh.2003.68.147; Kebede F, 1999, ETHIOPIAN MED J, V37, P97; Kremsner PG, 2004, LANCET, V364, P285, DOI 10.1016/S0140-6736(04)16680-4; LIM P, 2002, MEKONG MALAR FORUM, V10, P49; Llanos-Cuentas A, 2001, Braz J Infect Dis, V5, P67; Lobel HO, 1998, AM J TROP MED HYG, V59, P129, DOI 10.4269/ajtmh.1998.59.129; Looareesuwan S, 1999, ANN TROP MED PARASIT, V93, P225, DOI 10.1080/00034989958474; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P533, DOI 10.4269/ajtmh.1999.60.533; Looareesuwan S, 1999, AM J TROP MED HYG, V60, P526, DOI 10.4269/ajtmh.1999.60.526; Lwin Myint, 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P247; Maguire JD, 2002, ANN TROP MED PARASIT, V96, P655, DOI 10.1179/000349802125002310; Maguire JD, 2002, LANCET, V360, P58, DOI 10.1016/S0140-6736(02)09336-4; Marquino W, 2003, AM J TROP MED HYG, V68, P608, DOI 10.4269/ajtmh.2003.68.608; Marquino W, 2003, AM J TROP MED HYG, V68, P120, DOI 10.4269/ajtmh.2003.68.120; Mayxay M, 2003, CLIN INFECT DIS, V37, P1021, DOI 10.1086/377734; McGready R, 2003, EUR J CLIN PHARMACOL, V59, P553, DOI 10.1007/s00228-003-0651-x; McGready R, 2000, T ROY SOC TROP MED H, V94, P689, DOI 10.1016/S0035-9203(00)90235-9; Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97; Minzi OMS, 2003, J CLIN PHARM THER, V28, P117, DOI 10.1046/j.1365-2710.2003.00470.x; Mohapatra PK, 2003, INDIAN J MED RES, V118, P71; Muller O, 2003, TROP MED INT HEALTH, V8, P290, DOI 10.1046/j.1365-3156.2003.01030.x; Newton P, 2001, LANCET, V357, P1948, DOI 10.1016/S0140-6736(00)05085-6; Newton PN, 2002, BRIT MED J, V324, P800, DOI 10.1136/bmj.324.7341.800; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; Ohrt C, 1997, ANN INTERN MED, V126, P963, DOI 10.7326/0003-4819-126-12-199706150-00006; Okonkwo PO, 2001, T ROY SOC TROP MED H, V95, P320, DOI 10.1016/S0035-9203(01)90252-4; Overbosch D, 2001, CLIN INFECT DIS, V33, P1015, DOI 10.1086/322694; PETERS W, 1969, T ROY SOC TROP MED H, V63, P25, DOI 10.1016/0035-9203(69)90063-7; PhillipsHoward PA, 1996, DRUG SAFETY, V14, P131, DOI 10.2165/00002018-199614030-00001; Pickard AL, 2003, ANTIMICROB AGENTS CH, V47, P2418, DOI 10.1128/AAC.47.8.2418-2423.2003; Plowe CV, 1997, J INFECT DIS, V176, P1590, DOI 10.1086/514159; Pukrittayakamee S, 2003, ANTIMICROB AGENTS CH, V47, P3458, DOI 10.1128/AAC.47.11.3458-3463.2003; PUKRITTAYAKAMEE S, 1994, J INFECT DIS, V169, P932, DOI 10.1093/infdis/169.4.932; Rab MA, 2001, ANN TROP MED PARASIT, V95, P41, DOI 10.1080/00034980020035906; Rahman MR, 2001, T ROY SOC TROP MED H, V95, P661, DOI 10.1016/S0035-9203(01)90108-7; Roberts DR, 1997, EMERG INFECT DIS, V3, P295, DOI 10.3201/eid0303.970305; Roche J, 2003, AM J TROP MED HYG, V68, P598, DOI 10.4269/ajtmh.2003.68.598; Rowland M, 1997, TROP MED INT HEALTH, V2, P1049, DOI 10.1046/j.1365-3156.1997.d01-185.x; Schlagenhauf P, 2003, BMJ-BRIT MED J, V327, P1078, DOI 10.1136/bmj.327.7423.1078; Schwobel B, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-5; Schwobel B, 2003, TROP MED INT HEALTH, V8, P19, DOI 10.1046/j.1365-3156.2003.00977.x; Shah I, 1997, ANN TROP MED PARASIT, V91, P591, DOI 10.1080/00034989760680; Singh N, 2003, AM J TROP MED HYG, V68, P602, DOI 10.4269/ajtmh.2003.68.602; Smithuis FM, 1997, T ROY SOC TROP MED H, V91, P468, DOI 10.1016/S0035-9203(97)90288-1; Sumawinata IW, 2003, AM J TROP MED HYG, V68, P416, DOI 10.4269/ajtmh.2003.68.416; Taylor WRJ, 1999, CLIN INFECT DIS, V28, P74, DOI 10.1086/515071; Taylor WRJ, 2004, DRUG SAFETY, V27, P25, DOI 10.2165/00002018-200427010-00003; Tjitra E, 2002, T ROY SOC TROP MED H, V96, P434, DOI 10.1016/S0035-9203(02)90385-8; Tjitra E, 2001, AM J TROP MED HYG, V65, P309, DOI 10.4269/ajtmh.2001.65.309; Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7; Trigg PI, 1998, B WORLD HEALTH ORGAN, V76, P11; van den Broek IVF, 2003, T ROY SOC TROP MED H, V97, P229, DOI 10.1016/S0035-9203(03)90128-3; van Riemsdijk MM, 2004, BRIT J CLIN PHARMACO, V57, P506, DOI 10.1046/j.1365-2125.2003.02035.x; van Riemsdijk MM, 2002, EUR J CLIN PHARMACOL, V58, P441, DOI 10.1007/s00228-002-0492-z; van Riemsdijk MM, 2002, CLIN PHARMACOL THER, V72, P294, DOI 10.1067/mcp.2002.127113; Warsame M, 2002, B WORLD HEALTH ORGAN, V80, P704; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; Wernsdorfer Walther H, 2004, Expert Rev Anti Infect Ther, V2, P181, DOI 10.1586/14787210.2.2.181; Wernsdorfer WH, 2003, CURR OPIN INFECT DIS, V16, P553, DOI 10.1097/00001432-200312000-00007; WEZAM A, 1993, ETHIOPIAN MED J, V31, P271; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; White NJ, 2004, J CLIN INVEST, V113, P1084, DOI [10.1172/JCI21682, 10.1172/JCI200421682]; WHITE NJ, 1989, T ROY SOC TROP MED H, V83, P767, DOI 10.1016/0035-9203(89)90322-2; White NJ, 1998, ANN TROP MED PARASIT, V92, P449, DOI 10.1080/00034989859429; Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6; Wongsrichanalai Chansuda, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P300; Wongsrichanalai Chansuda, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P41; Zalis MG, 1998, AM J TROP MED HYG, V58, P630, DOI 10.4269/ajtmh.1998.58.630; Zhang Zai-xing, 2002, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V20, P94; Zucker JR, 2003, AM J TROP MED HYG, V68, P386, DOI 10.4269/ajtmh.2003.68.386	119	230	250	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 14	2005	352	15					1565	1577		10.1056/NEJMra043207	http://dx.doi.org/10.1056/NEJMra043207			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915SH	15829537	Green Published			2022-12-28	WOS:000228324200009
J	Gorgoulis, VG; Vassiliou, LVF; Karakaidos, P; Zacharatos, P; Kotsinas, A; Liloglou, T; Venere, M; DiTullio, RA; Kastrinakis, NG; Levy, B; Kletsas, D; Yoneta, A; Herlyn, M; Kittas, C; Halazonetis, TD				Gorgoulis, VG; Vassiliou, LVF; Karakaidos, P; Zacharatos, P; Kotsinas, A; Liloglou, T; Venere, M; DiTullio, RA; Kastrinakis, NG; Levy, B; Kletsas, D; Yoneta, A; Herlyn, M; Kittas, C; Halazonetis, TD			Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions	NATURE			English	Article							CELL LUNG CARCINOMAS; DOUBLE-STRAND BREAKS; P53 MUTATIONS; HISTONE H2AX; HUMAN CANCER; ALLELE LOSS; CYCLIN-E; 53BP1; EXPRESSION; PATHWAY	DNA damage checkpoint genes, such as p53, are frequently mutated in human cancer, but the selective pressure for their inactivation remains elusive(1-3). We analysed a panel of human lung hyperplasias, all of which retained wild-type p53 genes and had no signs of gross chromosomal instability, and found signs of a DNA damage response, including histone H2AX and Chk2 phosphorylation, p53 accumulation, focal staining of p53 binding protein 1 (53BP1) and apoptosis. Progression to carcinoma was associated with p53 or 53BP1 inactivation and decreased apoptosis. A DNA damage response was also observed in dysplastic nevi and in human skin xenografts, in which hyperplasia was induced by overexpression of growth factors. Both lung and experimentally-induced skin hyperplasias showed allelic imbalance at loci that are prone to DNA double-strand break formation when DNA replication is compromised ( common fragile sites). We propose that, from its earliest stages, cancer development is associated with DNA replication stress, which leads to DNA double-strand breaks, genomic instability and selective pressure for p53 mutations.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Athens, Sch Med, Dept Histol & Embryol, GR-11527 Athens, Greece; Univ Liverpool, Ctr Canc Res, Roy Castle Lung Canc Res Programme, Liverpool, Merseyside, England; Univ Penn, Grad Grp Biomed Sci, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Demokritos Natl Ctr Sci Res, Inst Biol, GR-15310 Athens, Greece	The Wistar Institute; Athens Medical School; National & Kapodistrian University of Athens; University of Liverpool; University of Pennsylvania; University of Pennsylvania; Icahn School of Medicine at Mount Sinai; National Centre of Scientific Research "Demokritos"	Halazonetis, TD (corresponding author), Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA.	halazonetis@wistar.upenn.edu	Kletsas, Dimitris/F-6953-2010; ZACHARATOS, PANAGIOTIS V/G-9954-2014; Karakaidos, Panagiotis/AAR-5858-2020; Halazonetis, Thanos/D-7923-2011; Gorgoulis, Vassilis/AAD-3630-2019	ZACHARATOS, PANAGIOTIS V/0000-0001-8324-5481; Karakaidos, Panagiotis/0000-0002-1156-4755; Gorgoulis, Vassilis/0000-0001-9001-4112; Kletsas, Dimitris/0000-0002-9828-3963				Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; DADDA DF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Gorgoulis VG, 1998, AM J PATHOL, V153, P1749, DOI 10.1016/S0002-9440(10)65690-8; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Halazonetis TD, 2004, DNA REPAIR, V3, P1057, DOI 10.1016/j.dnarep.2004.03.036; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; MacPhail SH, 2003, RADIAT RES, V159, P759, DOI 10.1667/RR3003; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; Mochan TA, 2003, CANCER RES, V63, P8586; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wistuba II, 2000, CANCER RES, V60, P1949	29	1617	1672	0	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					907	913		10.1038/nature03485	http://dx.doi.org/10.1038/nature03485			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829965				2022-12-28	WOS:000228327600043
J	Lo, B; Dornbrand, L; Dubler, NN				Lo, B; Dornbrand, L; Dubler, NN			HIPAA and patient care - The role for professional judgment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Federal health privacy regulations, commonly known as the Health Insurance Portability and Accountability Act (HIPAA) regulations, came into effect in April 2003. Many clinicians and institutions have relied on consultants and risk managers to tell them how to implement these regulations. Much of the controversy and confusion over the HIPAA regulations concern so-called incidental disclosures. Some interpretations of the privacy regulations would limit essential communication and compromise good patient care. This article analyzes misconceptions regarding what the regulations say about incidental disclosures and discusses the reasons for such misunderstandings. Many misconceptions arise from gaps in the regulations. These gaps are appropriately filled by professional judgment informed by ethical guidelines. The communication should be necessary and effective for good patient care, and the risks of a breach of confidentiality should be proportional to the likely benefit for the patient's care. The alternative for communication should be impractical. We offer specific recommendations to help physicians think through what incidental disclosures in patient care are ethically permissible and what safeguards ought to be taken. Physicians should work with risk managers and practice administrators to develop policies that promote good communication in patient care, while taking appropriate steps to protect patient privacy.	Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA; Montefiore Med Ctr, Dept Epidemiol & Social Med, New York, NY USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Montefiore Medical Center	Lo, B (corresponding author), Univ Calif San Francisco, Program Med Eth, Room C 126,521 Parnassus Ave, San Francisco, CA 94143 USA.	bernie@medicine.ucsf.edu						Annas GJ, 2003, NEW ENGL J MED, V348, P1486, DOI 10.1056/NEJMlim035027; BEAUCHAMP TL, 1989, PRINCIPLES BIOMEDICA, P329; BEAUCHAMP TL, 2001, PRINCIPLES BIOMEDICA, P303; Beauchamp Tom L, 2001, PRINCIPLES BIOMEDICA, P165; Beauchamp Tom L., 2001, PRINCIPLES BIOMEDICA, P63; CALFEE JE, 1984, VA LAW REV, V70, P965, DOI 10.2307/1072946; Childress JF, 2002, J LAW MED ETHICS, V30, P170, DOI 10.1111/j.1748-720X.2002.tb00384.x; CLARK C, 2003, SAN DIEGO UNION 0609, pA1; *CTR MED MED SERV, 2003, IS MAND ENCR HIPAA S; *DEP HLTH HUM SERV, 2003, MAY DOCT FAX EMAIL D; *DEP HLTH HUM SERV, 2004, US OCR RES FIGHT MYT; *DEP HLTH HUM SERV, 2003, CAN HLTH CAR PROV CO; *DEP HLTH HUM SERV, 2001, HHS ISS 1 GUID NEW P; *DEP HLTH HUM SERV, 2003, CAN PAT HAV FRIEND F; *DEP HLTH HUM SERV, 2003, MUST FAC PRIV SOUNDP; *DEP HLTH HUM SERV, 2003, HLTH CAR PROV CONF C; *DEP HLTH HUM SERV, 2003, WHAT SAF NEED CONT C; *DEP HLTH HUM SERV, 2003, GEN WHAT DOES HIPAA; GOSTIN LO, 2000, PUBLIC HLTH LAW, P85; *HLTH PRIV PROJ, 2003, MYTHS FACTS HLPAA PR; *HLTH PRIV WORK GR, 1999, BEST PRINC HLTH PRIV; JONSEN AR, 1978, ANN INTERN MED, V88, P827, DOI 10.7326/0003-4819-88-6-827; KISSINGER M, 2003, MILWAUKEE J SEN 1109, pA1; Lo B, 2000, JAMA-J AM MED ASSOC, V283, P801, DOI 10.1001/jama.283.6.801; LO B, 2000, RESOLVING ETHICAL DI, P43; *LTH PRIV PROJ, 2003, MED PRIV STOR; *MARKL FDN, 2004, CONN HLTH PRIV SEC W; *OFF CIV RIGHTS HI, 2002, STAND PRIV IND ID HL; *OFF CIV RIGHTS HI, 2003, MED PRIV NAT STAND P; OSTROM CM, 2004, SEATTLE TIMES   0330, pA1; SORKIN MD, 2003, ST LOUIS POST D 0629, pA12; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; STEIN R, 2003, WASH POST       0330, pA1; SUNNSTEIN CR, 1996, LEGAL REASONING POLI; TARKAN L, 2003, NY TIMES        0603, pA1; UBEL PA, 1995, AM J MED, V99, P190, DOI 10.1016/S0002-9343(99)80139-9; *US ATT OFF W DIST, 2004, SEATTL AR MAN GETS P; WEISS BD, 1982, JAMA-J AM MED ASSOC, V247, P2695, DOI 10.1001/jama.247.19.2695; 2002, FED REG, V67, P14793; 2002, FED REG, V67, P55918	40	20	20	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1766	1771		10.1001/jama.293.14.1766	http://dx.doi.org/10.1001/jama.293.14.1766			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827316				2022-12-28	WOS:000228301100031
J	Vrakking, AM; van der Heide, A; Onwuteaka-Philipsen, BD; Keij-Deerenberg, IM; van der Maas, PJ; van der Wal, G				Vrakking, AM; van der Heide, A; Onwuteaka-Philipsen, BD; Keij-Deerenberg, IM; van der Maas, PJ; van der Wal, G			Medical end-of-life decisions made for neonates and infants in the Netherlands, 1995-2001	LANCET			English	Article							INTENSIVE-CARE	End-of-life decision-making for severely affected infants might be influenced by technical advances and societal debates. In 2001, we assessed the proportion of deaths of infants younger than 1 year that were preceded by end-of-life decisions, by replicating a questionnaire study from 1995. This proportion increased from 62% to 68% (weighted percentages), but the difference was not significant. Most of these decisions were to forgo life-sustaining treatment. Decisions to actively end the lives of infants not dependent on life-sustaining treatment remained stable at 1%. The practice of end-of-life decision-making in neonatology of 2001 has changed little since 1995.	Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, NL-3000 DR Rotterdam, Netherlands; VU Univ Med Ctr Amsterdam, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; VU Univ Med Ctr Amsterdam, Inst Res Extramural Med, Amsterdam, Netherlands; Stat Netherlands, Div Social & Spatial Stat, Voorburg, Netherlands	Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Vrakking, AM (corresponding author), Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, POB 1738, NL-3000 DR Rotterdam, Netherlands.	a.vrakking@erasmusmc.nl						Buitendijk S, 2003, EUR J OBSTET GYN R B, V111, pS66, DOI 10.1016/j.ejogrb.2003.09.007; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; Lemons JA, 2000, PEDIATRICS, V105, P454; vanderHeide A, 1997, LANCET, V350, P251, DOI 10.1016/S0140-6736(97)02315-5; Wall SN, 1997, PEDIATRICS, V99, P64, DOI 10.1542/peds.99.1.64	5	43	43	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1329	1331		10.1016/S0140-6736(05)61030-6	http://dx.doi.org/10.1016/S0140-6736(05)61030-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823383	Green Submitted			2022-12-28	WOS:000228219600028
J	Adams, EJ; Chien, YH; Garcia, KC				Adams, EJ; Chien, YH; Garcia, KC			Structure of a gamma delta T cell receptor in complex with the nonclassical MHC T22	SCIENCE			English	Article							CRYSTAL-STRUCTURE; ANTIGEN-RECOGNITION; LIGAND; PEPTIDE; LYMPHOCYTES; SPECIFICITY	gamma delta T cell receptors (TCRs), alpha beta TCRs, and antibodies are the three lineages of somatically recombined antigen receptors. The structural basis for ligand recognition is well. defined for alpha beta TCR and antibodies but is lacking for gamma delta TCRs. We present the 3.4 angstrom structure of the murine gamma delta TCR G8 bound to its major histocompatibillity complex (MHC) class Ib ligand, T22. G8 predominantly uses germ line-en coded residues of its 8 chain complementarity-determining region 3 (CDR3) loop to bind T22 in an orientation substantially different from that seen in alpha beta TCR/peptide-MHC. That junctionaily encoded G8 residues play an ancillary role in binding suggests a fusion of innate and adaptive recognition strategies.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94035 USA; Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94035 USA; Stanford Univ, Sch Med, Program Immunol, Stanford, CA 94035 USA	Stanford University; Stanford University; Stanford University	Garcia, KC (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Fairchild D319,299 Campus Dr, Stanford, CA 94035 USA.	kcgarcia@stanford.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048540, R56AI048540] Funding Source: NIH RePORTER; NIAID NIH HHS [AI048540] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allison TJ, 2001, NATURE, V411, P820, DOI 10.1038/35081115; CARDING SR, 1990, J EXP MED, V172, P1225, DOI 10.1084/jem.172.4.1225; Chien YH, 2000, SPRINGER SEMIN IMMUN, V22, P239, DOI 10.1007/PL00006752; Chien YH, 1996, ANNU REV IMMUNOL, V14, P511, DOI 10.1146/annurev.immunol.14.1.511; Crowley MP, 2000, SCIENCE, V287, P314, DOI 10.1126/science.287.5451.314; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; Hayes SM, 2002, IMMUNITY, V16, P827, DOI 10.1016/S1074-7613(02)00320-5; Kabelitz D, 2003, CRIT REV IMMUNOL, V23, P339, DOI 10.1615/CritRevImmunol.v23.i56.10; Li PW, 1999, IMMUNITY, V10, P577, DOI 10.1016/S1074-7613(00)80057-6; Li PW, 2001, NAT IMMUNOL, V2, P443, DOI 10.1038/87757; Li YL, 2003, NAT STRUCT BIOL, V10, P482, DOI 10.1038/nsb930; Matis L A, 1991, Semin Immunol, V3, P75; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; Morita CT, 2000, SPRINGER SEMIN IMMUN, V22, P191, DOI 10.1007/s002810000042; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; Rudolph MG, 2004, ACTA CRYSTALLOGR D, V60, P656, DOI 10.1107/S0907444904002239; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; Shin S, 2005, SCIENCE, V308, P252, DOI 10.1126/science.1106480; Stanfield RL, 2004, SCIENCE, V305, P1770, DOI 10.1126/science.1101148; Sundberg EJ, 2002, CURR OPIN IMMUNOL, V14, P36, DOI 10.1016/S0952-7915(01)00296-5; Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X; Wingren C, 2000, SCIENCE, V287, P310, DOI 10.1126/science.287.5451.310	31	192	196	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					227	231		10.1126/science.1106885	http://dx.doi.org/10.1126/science.1106885			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821084				2022-12-28	WOS:000228273700045
J	Steingrimsson, E; Copeland, NG; Jenkins, NA				Steingrimsson, E; Copeland, NG; Jenkins, NA			Melanocyte stem cell maintenance and hair graying	CELL			English	Review							C-KIT ANTIBODY; NICHE; CYCLE; DIFFERENTIATION; ACTIVATION; EXPRESSION; FATE; PAX3; MICE		NCI, Ctr Canc Res, Mouse Canc Genet Program, Frederick, MD 21702 USA; Univ Iceland, Fac Med, Dept Biochem & Mol Biol, IS-101 Reykjavik, Iceland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Iceland	Jenkins, NA (corresponding author), NCI, Ctr Canc Res, Mouse Canc Genet Program, Frederick, MD 21702 USA.	jenkins@ncifcrf.gov		Steingrimsson, Eirikur/0000-0001-5826-7486	DIVISION OF BASIC SCIENCES - NCI [Z01BC010556] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Botchkareva NV, 2003, J INVEST DERM SYMP P, V8, P76, DOI 10.1046/j.1523-1747.2003.12176.x; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Commo S, 2000, PIGM CELL RES, V13, P253, DOI 10.1034/j.1600-0749.2000.130407.x; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Galibert MD, 1999, J BIOL CHEM, V274, P26894, DOI 10.1074/jbc.274.38.26894; JOHNSON R, 1992, NAT GENET, V1, P226, DOI 10.1038/ng0692-226; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; Lang D, 2005, NATURE, V433, P884, DOI 10.1038/nature03292; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; Nishimura EK, 2005, SCIENCE, V307, P720, DOI 10.1126/science.1099593; Nishimura EK, 2002, NATURE, V416, P854, DOI 10.1038/416854a; OKURA M, 1995, J INVEST DERMATOL, V105, P322, DOI 10.1111/1523-1747.ep12319939; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Whetton AD, 1999, TRENDS CELL BIOL, V9, P233, DOI 10.1016/S0962-8924(99)01559-7	20	70	78	4	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					9	12		10.1016/j.cell.2005.03.021	http://dx.doi.org/10.1016/j.cell.2005.03.021			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820674	Bronze			2022-12-28	WOS:000228348500005
J	Geffeney, SL; Fujimoto, E; Brodie, ED; Brodie, ED; Ruben, PC				Geffeney, SL; Fujimoto, E; Brodie, ED; Brodie, ED; Ruben, PC			Evolutionary diversification of TTX-resistant sodium channels in a predator-prey interaction	NATURE			English	Article							NA+ CHANNEL; SKELETAL-MUSCLE; OUTER VESTIBULE; GARTER SNAKES; GENES; TETRODOTOXIN; EXPRESSION; SAXITOXIN; PATTERNS; PORE	Understanding the molecular genetic basis of adaptations provides incomparable insight into the genetic mechanisms by which evolutionary diversification takes place. Whether the evolution of common traits in different lineages proceeds by similar or unique mutations, and the degree to which phenotypic evolution is controlled by changes in gene regulation as opposed to gene function, are fundamental questions in evolutionary biology that require such an understanding of genetic mechanisms(1-3). Here we identify novel changes in the molecular structure of a sodium channel expressed in snake skeletal muscle, tsNa(V)1.4, that are responsible for differences in tetrodotoxin (TTX) resistance among garter snake populations coevolving with toxic newts(4). By the functional expression of tsNa(V)1.4, we show how differences in the amino-acid sequence of the channel affect TTX binding and impart different levels of resistance in four snake populations. These results indicate that the evolution of a physiological trait has occurred through a series of unique functional changes in a gene that is otherwise highly conserved among vertebrates.	Utah State Univ, Dept Biol, Logan, UT 84322 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Utah System of Higher Education; Utah State University; Indiana University System; Indiana University Bloomington	Geffeney, SL (corresponding author), Utah State Univ, Dept Biol, Logan, UT 84322 USA.	geffeney@biology.usu.edu	Brodie, Edmund D/B-2335-2013	Geffeney, Shana/0000-0003-0504-2077				Abzhanov A, 2004, SCIENCE, V305, P1462, DOI 10.1126/science.1098095; Beldade P, 2002, NATURE, V415, P315, DOI 10.1038/415315a; Brodie ED, 2002, EVOLUTION, V56, P2067; Brodie ED, 1999, BIOSCIENCE, V49, P557, DOI 10.2307/1313476; Choudhary G, 2003, BIOPHYS J, V84, P287, DOI 10.1016/S0006-3495(03)74849-8; ffrench-Constant RH, 2004, TRENDS GENET, V20, P163, DOI 10.1016/j.tig.2004.01.003; Geffeney S, 2002, SCIENCE, V297, P1336, DOI 10.1126/science.1074310; Goldin AL, 2001, ANNU REV PHYSIOL, V63, P871, DOI 10.1146/annurev.physiol.63.1.871; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hoekstra HE, 2003, MOL ECOL, V12, P1185, DOI 10.1046/j.1365-294X.2003.01788.x; Huey RB, 2002, SCIENCE, V297, P1289, DOI 10.1126/science.1075987; Janzen FJ, 2002, MOL ECOL, V11, P1739, DOI 10.1046/j.1365-294X.2002.01571.x; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; Kaneko Y, 1997, BIOCHEM BIOPH RES CO, V240, P651, DOI 10.1006/bbrc.1997.7696; Lipkind GM, 2000, BIOCHEMISTRY-US, V39, P8161, DOI 10.1021/bi000486w; Penzotti JL, 1998, BIOPHYS J, V75, P2647, DOI 10.1016/S0006-3495(98)77710-0; Plummer NW, 1999, GENOMICS, V57, P323, DOI 10.1006/geno.1998.5735; Rausher MD, 1999, MOL BIOL EVOL, V16, P266, DOI 10.1093/oxfordjournals.molbev.a026108; Raymond CK, 2004, J BIOL CHEM, V279, P46234, DOI 10.1074/jbc.M406387200; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; Schluter D, 2004, AM NAT, V163, P809, DOI 10.1086/383621; Shapiro MD, 2004, NATURE, V428, P717, DOI 10.1038/nature02415; Stefani E, 1998, METHOD ENZYMOL, V293, P300; Stern DL, 2000, EVOLUTION, V54, P1079, DOI 10.1554/0014-3820(2000)054[1079:PEDBAT]2.0.CO;2; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; TRIMMER JS, 1990, DEV BIOL, V142, P360, DOI 10.1016/0012-1606(90)90356-N; Yamagishi T, 2001, J GEN PHYSIOL, V118, P171, DOI 10.1085/jgp.118.2.171; Yamamoto Y, 2004, NATURE, V431, P844, DOI 10.1038/nature02864; Yotsu-Yamashita M, 2000, BIOCHEM BIOPH RES CO, V267, P403, DOI 10.1006/bbrc.1999.1974; Zakon HH, 2002, BRAIN BEHAV EVOLUT, V59, P250, DOI 10.1159/000063562	30	164	174	0	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 7	2005	434	7034					759	763		10.1038/nature03444	http://dx.doi.org/10.1038/nature03444			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815629				2022-12-28	WOS:000228160700040
J	Steffens, S; Veillard, NR; Arnaud, C; Pelli, G; Burger, F; Staub, C; Zimmer, A; Frossard, JL; Mach, F				Steffens, S; Veillard, NR; Arnaud, C; Pelli, G; Burger, F; Staub, C; Zimmer, A; Frossard, JL; Mach, F			Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice	NATURE			English	Article							E-DEFICIENT MICE; LESION FORMATION; RECEPTOR-DEFICIENT; CB2 RECEPTOR; LYMPHOCYTES; DELTA-9-TETRAHYDROCANNABINOL; INFLAMMATION; EXPRESSION; CELLS; DELTA(9)-TETRAHYDROCANNABINOL	Atherosclerosis is a chronic inflammatory disease, and is the primary cause of heart disease and stroke in Western countries(1). Derivatives of cannabinoids such as delta-9-tetrahydrocannabinol (THC) modulate immune functions(2) and therefore have potential for the treatment of inflammatory diseases. We investigated the effects of THC in a murine model of established atherosclerosis. Oral administration of THC (1 mg kg(-1) per day) resulted in significant inhibition of disease progression. This effective dose is lower than the dose usually associated with psychotropic effects of THC. Furthermore, we detected the CB2 receptor ( the main cannabinoid receptor expressed on immune cells(2,3)) in both human and mouse atherosclerotic plaques. Lymphoid cells isolated from THC-treated mice showed diminished proliferation capacity and decreased interferon-gamma secretion. Macrophage chemotaxis, which is a crucial step for the development of atherosclerosis(1), was also inhibited in vitro by THC. All these effects were completely blocked by a specific CB2 receptor antagonist(4). Our data demonstrate that oral treatment with a low dose of THC inhibits atherosclerosis progression in the apolipoprotein E knockout mouse model, through pleiotropic immunomodulatory effects on lymphoid and myeloid cells. Thus, THC or cannabinoids with activity at the CB2 receptor may be valuable targets for treating atherosclerosis.	Fdn Med Res, Dept Med, Div Cardiol, CH-1211 Geneva, Switzerland; Univ Hosp, Fac Med, Div Gastroenterol, CH-1211 Geneva, Switzerland; Univ Hosp, Fac Med, Inst Legal Med, CH-1211 Geneva, Switzerland; Univ Bonn, Dept Psychiat, Mol Neurobiol Lab, D-53105 Bonn, Germany	University of Geneva; University of Geneva; University of Geneva; University of Bonn	Mach, F (corresponding author), Fdn Med Res, Dept Med, Div Cardiol, CH-1211 Geneva, Switzerland.	Francois.Mach@medecine.unige.ch	Arnaud, Claire/D-4698-2014; Steffens, Sabine/AAV-4551-2020	Arnaud, Claire/0000-0003-0964-9423; Steffens, Sabine/0000-0002-6892-9751; Karsak, Meliha/0000-0001-6612-6317				Benagiano M, 2003, P NATL ACAD SCI USA, V100, P6658, DOI 10.1073/pnas.1135726100; Brenneisen R, 1996, INT J CLIN PHARM TH, V34, P446; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; CHESHER GB, 1990, PHARMACOL BIOCHEM BE, V35, P861, DOI 10.1016/0091-3057(90)90371-N; Daugherty A, 2002, CIRC RES, V90, P1039, DOI 10.1161/01.RES.0000021397.28936.F9; Giroud C, 2001, FORENSIC SCI INT, V123, P159, DOI 10.1016/S0379-0738(01)00538-2; Hickey MJ, 2002, J IMMUNOL, V168, P4728, DOI 10.4049/jimmunol.168.9.4728; Johnson Z, 2004, J IMMUNOL, V173, P5776, DOI 10.4049/jimmunol.173.9.5776; Klein TW, 2003, J LEUKOCYTE BIOL, V74, P486, DOI 10.1189/jlb.0303101; Kwak BR, 2003, CIRCULATION, V107, P1033, DOI 10.1161/01.CIR.0000051364.70064.D1; Laurat E, 2001, CIRCULATION, V104, P197, DOI 10.1161/01.CIR.104.2.197; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lichtman AH, 2001, DRUG ALCOHOL DEPEN, V63, P107, DOI 10.1016/S0376-8716(00)00205-2; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; Mach F, 2004, CIRCULATION, V109, P15, DOI 10.1161/01.CIR.0000129502.10459.fe; Malfait AM, 2000, P NATL ACAD SCI USA, V97, P9561, DOI 10.1073/pnas.160105897; Moeller F, 2003, ATHEROSCLEROSIS, V168, P49, DOI 10.1016/S0021-9150(03)00026-1; Mulhaupt F, 2003, CARDIOVASC RES, V59, P755, DOI 10.1016/S0008-6363(03)00515-7; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; Song L, 2001, J CLIN INVEST, V108, P251, DOI 10.1172/JCI11380; Srivastava MD, 1998, IMMUNOPHARMACOLOGY, V40, P179, DOI 10.1016/S0162-3109(98)00041-1; Sulcova E, 1998, PHARMACOL BIOCHEM BE, V59, P347, DOI 10.1016/S0091-3057(97)00422-X; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Varvel SA, 2001, PSYCHOPHARMACOLOGY, V157, P142; Veillard NR, 2004, ARTERIOSCL THROM VAS, V24, P2339, DOI 10.1161/01.ATV.0000146532.98235.e6; Yuan M, 2002, J NEUROIMMUNOL, V133, P124, DOI 10.1016/S0165-5728(02)00370-3; Zhu LX, 2000, J IMMUNOL, V165, P373, DOI 10.4049/jimmunol.165.1.373	30	348	391	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					782	786		10.1038/nature03389	http://dx.doi.org/10.1038/nature03389			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815632				2022-12-28	WOS:000228160700045
J	Yamaguchi, H; Calado, RT; Ly, H; Kajigaya, S; Baerlocher, GM; Chanock, SJ; Lansdorp, PM; Young, NS				Yamaguchi, H; Calado, RT; Ly, H; Kajigaya, S; Baerlocher, GM; Chanock, SJ; Lansdorp, PM; Young, NS			Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKED DYSKERATOSIS-CONGENITA; CATALYTIC SUBUNIT; IN-VIVO; FUNCTIONAL MULTIMERIZATION; MYELODYSPLASTIC SYNDROME; ENZYME-ACTIVITY; RNA INTERACTION; DISEASE; HAPLOINSUFFICIENCY; DEFICIENT	BACKGROUND: Mutations in TERC, the gene for the RNA component of telomerase, cause short telomeres in congenital aplastic anemia and in some cases of apparently acquired hematopoietic failure. We investigated whether mutations in genes for other components of telomerase also occur in aplastic anemia. METHODS: We screened blood or marrow cells from 124 patients with apparently acquired aplastic anemia and 282 control subjects for sequence variations in the TERT, DKC1, NHP2, and NOP10 genes; an additional 81 patients and 246 controls were examined for genetic variations in TERT. Telomere lengths and the telomerase activity of peripheral-blood leukocytes were evaluated in patients carrying genetic variants. Identified mutations were transfected into telomerase-deficient cell lines to examine their effects and their mechanism of action on telomerase function. RESULTS: Five heterozygous, nonsynonymous mutations (which cause an amino acid change in the corresponding protein) were identified in TERT, the gene for the telomerase reverse transcriptase catalytic enzyme, among seven unrelated patients. Leukocytes from these patients had short telomeres and low telomerase enzymatic activity. In three of these patients, the mutation was also detected in buccal mucosa cells. Family members carrying the mutations also had short telomeres and reduced telomerase activity but no evident hematologic abnormality. The results of coexpression of wild-type TERT and TERT with aplastic anemia-associated mutations in a telomerase-deficient cell line suggested that haploinsufficiency was the mechanism of telomere shortening due to TERT mutations. CONCLUSIONS: Heterozygous mutations in the TERT gene impair telomerase activity by haploinsufficiency and may be risk factors for marrow failure.	NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA; NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; Emory Univ, Dept Pathol & Lab Med, Div Expt Pathol, Atlanta, GA 30322 USA; Univ British Columbia, Terry Fox Lab, BC Canc Res Ctr, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Emory University; British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Young, NS (corresponding author), NHLBI, Hematol Branch, NIH, 10 Ctr Dr,Bldg 10,CRC,Rm 3E-5140, Bethesda, MD 20892 USA.	youngns@mail.nih.gov	Calado, Rodrigo T./G-2619-2011	Calado, Rodrigo T./0000-0002-7966-6029; Lansdorp, Peter/0000-0001-7435-1071	NATIONAL CANCER INSTITUTE [Z01SC010083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002315, Z01HL002315] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alter B.P., 1994, APLASTIC ANEMIA ACQU, P271; Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Baerlocher GM, 2003, CYTOM PART A, V55A, P1, DOI 10.1002/cyto.a.10064; Ball SE, 1998, BLOOD, V91, P3582; Banik SSR, 2002, MOL CELL BIOL, V22, P6234, DOI 10.1128/MCB.22.17.6234-6246.2002; Beattie TL, 2001, MOL CELL BIOL, V21, P6151, DOI 10.1128/MCB.21.18.6151-6160.2001; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Brummendorf TH, 2001, BLOOD, V97, P895, DOI 10.1182/blood.V97.4.895; Bryan TM, 2000, MOL CELL, V6, P493, DOI 10.1016/S1097-2765(00)00048-4; Calado RT, 2002, LANCET, V360, P1608, DOI 10.1016/S0140-6736(02)11551-0; Collins K, 2002, ONCOGENE, V21, P564, DOI 10.1038/sj.onc.1205083; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; Dufour C, 2004, BRIT J HAEMATOL, V126, P682, DOI 10.1111/j.1365-2141.2004.05102.x; Fogarty PF, 2003, LANCET, V362, P1628, DOI 10.1016/S0140-6736(03)14797-6; Harrington L, 2003, CANCER LETT, V194, P139, DOI 10.1016/S0304-3835(02)00701-2; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Kaufman DW, 1991, DRUG ETIOLOGY AGRANU; Kiss AM, 2004, MOL CELL BIOL, V24, P5797, DOI 10.1128/MCB.24.13.5797-5807.2004; Knight SW, 1999, AM J HUM GENET, V65, P50, DOI 10.1086/302446; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Liu Y, 2001, CURR BIOL, V11, P907; Liu Y, 2000, CURR BIOL, V10, P1459, DOI 10.1016/S0960-9822(00)00805-8; Ly H, 2005, BLOOD, V105, P2332, DOI 10.1182/blood-2004-09-3659; Ly H, 2003, MOL CELL BIOL, V23, P6849, DOI 10.1128/MCB.23.19.6849-6856.2003; Ly H, 2003, GENE DEV, V17, P1078, DOI 10.1101/gad.1060803; Maciejewski JP, 2001, BLOOD, V98, P3513, DOI 10.1182/blood.V98.13.3513; Marrone A, 2004, BLOOD, V104, P3936, DOI 10.1182/blood-2004-05-1829; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Moriarty TJ, 2004, MOL CELL BIOL, V24, P3720, DOI 10.1128/MCB.24.9.3720-3733.2004; Moriarty TJ, 2002, MOL CELL BIOL, V22, P1253, DOI 10.1128/MCB.22.4.1253-1265.2002; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Packer BR, 2004, NUCLEIC ACIDS RES, V32, pD528, DOI 10.1093/nar/gkh005; Peng J, 2003, HUM IMMUNOL, V64, P896, DOI 10.1016/S0198-8859(03)00141-1; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Risitano AM, 2004, LANCET, V364, P355, DOI 10.1016/S0140-6736(04)16724-X; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Saunthararajah Y, 2002, BLOOD, V100, P1570, DOI 10.1182/blood.V100.5.1570.h81702001570_1570_1574; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Theimer CA, 2003, P NATL ACAD SCI USA, V100, P449, DOI 10.1073/pnas.242720799; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346; Vulliamy T, 2002, LANCET, V359, P2168, DOI 10.1016/S0140-6736(02)09087-6; Wenz C, 2001, EMBO J, V20, P3526, DOI 10.1093/emboj/20.13.3526; Yamaguchi H, 2003, BLOOD, V102, P916, DOI 10.1182/blood-2003-01-0335; Young NS, 1997, NEW ENGL J MED, V336, P1365, DOI 10.1056/NEJM199705083361906; Young NS, 2002, ANN INTERN MED, V136, P534, DOI 10.7326/0003-4819-136-7-200204020-00011; Zeng WH, 2001, J CLIN INVEST, V108, P765, DOI 10.1172/JCI12687; Zhang AJ, 2003, AM J HUM GENET, V72, P940, DOI 10.1086/374565	53	514	556	2	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1413	1424		10.1056/NEJMoa042980	http://dx.doi.org/10.1056/NEJMoa042980			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814878				2022-12-28	WOS:000228145200005
J	Eisenberg, RS				Eisenberg, RS			Learning the value of drugs - Is rofecoxib a regulatory success story?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Michigan, Sch Law, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Eisenberg, RS (corresponding author), Univ Michigan, Sch Law, Ann Arbor, MI 48109 USA.							DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Eisenberg RS, 2001, HEALTH AFFAIR, V20, P119, DOI 10.1377/hlthaff.20.5.119; Mathews Anna Wilde, 2004, Wall St J (East Ed), pA7; Merrill RA, 1996, VA LAW REV, V82, P1753, DOI 10.2307/1073689; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286	5	14	14	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1285	1287		10.1056/NEJMp048358	http://dx.doi.org/10.1056/NEJMp048358			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800222	Green Submitted			2022-12-28	WOS:000227998300002
J	Sassen, K				Sassen, K			Dusty ice clouds over Alaska	NATURE			English	Editorial Material							STORMS		Univ Alaska Fairbanks, Inst Geophys, Fairbanks, AK 99775 USA	University of Alaska System; University of Alaska Fairbanks	Sassen, K (corresponding author), Univ Alaska Fairbanks, Inst Geophys, Fairbanks, AK 99775 USA.	ksassen@gi.alaska.edu						Bailey M, 2002, Q J ROY METEOR SOC, V128, P1461, DOI 10.1002/qj.200212858304; Comstock JM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019705; Isono K., 1959, J METEOR SOC JAPAN, V37, P211, DOI DOI 10.2151/JMSJ1923.37.6_211; Kaufman YJ, 2002, NATURE, V419, P215, DOI 10.1038/nature01091; Murayama T, 2001, J GEOPHYS RES-ATMOS, V106, P18345, DOI 10.1029/2000JD900554; Sakai T, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019332; Sassen K, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017371; Sassen K, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014051; Sassen K, 2001, J ATMOS SCI, V58, P481, DOI 10.1175/1520-0469(2001)058<0481:AMCCCF>2.0.CO;2; Sassen K, 2005, LIDAR RANGE RESOLVED, P19, DOI DOI 10.1007/0-387-25101-4_2	10	37	38	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 24	2005	434	7032					456	456		10.1038/434456a	http://dx.doi.org/10.1038/434456a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	909CH	15791245				2022-12-28	WOS:000227836000030
J	Spear, SJ; Schmidhofer, M				Spear, SJ; Schmidhofer, M			Ambiguity and workarounds as contributors to medical error	ANNALS OF INTERNAL MEDICINE			English	Article							TOYOTA PRODUCTION SYSTEM; INFECTION-CONTROL; PATIENT SAFETY; CARE; IMPROVEMENT; DECISIONS; OUTCOMES; PLANTS; TIME	Why are some organizations error-prone-regularly subject to interruptions and inconveniences, some of which periodically coalesce catastrophically-whereas other organizations, although similar in the products and services they generate and the process technologies they use, are reliable, adaptable, and continuously self-improving, relentlessly learning from experience to get ever better? Analyzing medical error reports and studies of high-performing, non-health care organizations reveals 2 differences. High performers know how to prevent problems from producing further consequences once they occur and how to prevent their recurrence. They do this by specifying how work is expected to proceed-who will do what for whom, with what purpose, when, where, and how-before work is actually done. Then, when anything contrary to expectations occurs, it is immediately identified as a problem. Through this approach, the effects of problems are contained, the causes are quickly investigated, process knowledge is deepened, and recurrence is prevented. In contrast, error-prone organizations tolerate ambiguity, a prevailing lack of clarity over what is supposed to happen at any given time. Problems are thus hard to identify, and, even when recognized, they are worked around. People "get the job done," but don't initiate efforts to learn from the problem or improve the process. We believe that coupling high degrees of specification with rapid responses to individual problems can improve health care. Superlative manufacturing, service, and military organizations apply this approach to myriad processes and situations, and initial health care trials of this approach have been promising. We discuss how such an approach could be initiated in health care more broadly.	Harvard Univ, Sch Business, Boston, MA 02163 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA	Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Spear, SJ (corresponding author), Harvard Univ, Sch Business, Morgan Hall T13, Boston, MA 02163 USA.	sspear@hbs.edu						Adler PS, 1999, ORGAN SCI, V10, P43, DOI 10.1287/orsc.10.1.43; ADLER PS, 1993, SLOAN MANAGE REV, V34, P85; ADLER PS, 1993, HARVARD BUS REV, V71, P97; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; Bates DW, 2002, ANN INTERN MED, V137, P110, DOI 10.7326/0003-4819-137-2-200207160-00009; Burke JP, 2003, NEW ENGL J MED, V348, P651, DOI 10.1056/NEJMhpr020557; Chassin MR, 2002, ANN INTERN MED, V136, P826, DOI 10.7326/0003-4819-136-11-200206040-00012; Clark K.B., 1991, PRODUCT DEV PERFORMA; Clemmer TP, 1999, CRIT CARE MED, V27, P1768, DOI 10.1097/00003246-199909000-00011; Gittell J.H., 2003, SW AIRLINES WAY USIN, P25; Hofer TP, 2002, ANN INTERN MED, V137, P327, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00008; JAIKUMAR R, 1992, INT J PROD ECON, V27, P265, DOI 10.1016/0925-5273(92)90101-C; Jarvis WR, 2001, EMERG INFECT DIS, V7, P170, DOI 10.3201/eid0702.010202; KOHN LT, 2000, ERR HUMAN BUILING SA; MacDuffie JP, 1997, MANAGE SCI, V43, P479, DOI 10.1287/mnsc.43.4.479; REITMAN V, 1997, WALL STREET J   0508, pA1; Spear S, 1999, HARVARD BUS REV, V77, P96; Spear SJ, 2004, HARVARD BUS REV, V82, P78; Spear SJ, 2002, PROD PLAN CONTROL, V13, P754, DOI 10.1080/0953728031000057307; Thompson DN, 2003, J NURS ADMIN, V33, P585, DOI 10.1097/00005110-200311000-00008; VANDERSCHAAF TW, 2002, QUAL SAF HEALTH CARE, V11, P206; Wachter RM, 2002, ANN INTERN MED, V136, P850, DOI 10.7326/0003-4819-136-11-200206040-00015; WARD A, 1995, SLOAN MANAGE REV, V36, P43; WEICK KE, 1993, ADMIN SCI QUART, V38, P357, DOI 10.2307/2393372; Weinstein RA, 1998, EMERG INFECT DIS, V4, P416, DOI 10.3201/eid0403.980320	25	82	82	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2005	142	8					627	630		10.7326/0003-4819-142-8-200504190-00011	http://dx.doi.org/10.7326/0003-4819-142-8-200504190-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	916TZ	15838069				2022-12-28	WOS:000228410400005
J	Burns, TM				Burns, TM			A step forward for stiff-person syndrome	LANCET			English	Editorial Material							GLUTAMIC-ACID DECARBOXYLASE; PARANEOPLASTIC NEUROLOGICAL SYNDROMES; DIABETES-MELLITUS; AUTOANTIBODIES; ANTIBODIES; AMPHIPHYSIN; CANCER		Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA	University of Virginia	Burns, TM (corresponding author), Univ Virginia, Dept Neurol, Charlottesville, VA 22908 USA.	tmb8r@virginia.edu						Antoine JC, 1999, ARCH NEUROL-CHICAGO, V56, P172, DOI 10.1001/archneur.56.2.172; Atkinson MA, 2000, LANCET, V356, P4, DOI 10.1016/S0140-6736(00)02421-1; BRASHEAR HR, 1991, NEUROLOGY, V41, P1588, DOI 10.1212/WNL.41.10.1588; Burns TM, 2005, NEUROLOGY, V64, P399, DOI 10.1212/WNL.64.2.399-a; Burns TM, 2003, NEUROLOGY, V61, P1291, DOI 10.1212/01.WNL.0000092016.98256.21; Dalakas MC, 2001, NEUROLOGY, V57, P780, DOI 10.1212/WNL.57.5.780; Dinkel K, 1998, ANN NEUROL, V44, P194, DOI 10.1002/ana.410440209; FOLLI F, 1993, NEW ENGL J MED, V328, P546, DOI 10.1056/NEJM199302253280805; Graus F, 2004, J NEUROL NEUROSUR PS, V75, P1135, DOI 10.1136/jnnp.2003.034447; Koerner C, 2004, NEUROLOGY, V62, P1357, DOI 10.1212/01.WNL.0000120543.65812.33; Lohmann T, 2000, LANCET, V356, P31, DOI 10.1016/S0140-6736(00)02431-4; MOERSCH FP, 1956, P STAFF M MAYO CLIN, V31, P421; Pittock SJ, 2004, ANN NEUROL, V56, P715, DOI 10.1002/ana.20269; Saiz A, 1999, J NEUROL NEUROSUR PS, V66, P214, DOI 10.1136/jnnp.66.2.214; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; Wessig C, 2003, NEUROLOGY, V61, P195, DOI 10.1212/01.WNL.0000073143.53337.DD; Yoshida Y, 2004, EMBO J, V23, P3483, DOI 10.1038/sj.emboj.7600355	17	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2005	365	9468					1365	1367		10.1016/S0140-6736(05)66349-0	http://dx.doi.org/10.1016/S0140-6736(05)66349-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836869				2022-12-28	WOS:000228401900005
J	Nakajima, M; Imai, K; Ito, H; Nishiwaki, T; Murayama, Y; Iwasaki, H; Oyarna, T; Kondo, T				Nakajima, M; Imai, K; Ito, H; Nishiwaki, T; Murayama, Y; Iwasaki, H; Oyarna, T; Kondo, T			Reconstitution of circadian oscillation of cyanobacterial KaiC phosphorylation in vitro	SCIENCE			English	Article							CLOCK SYSTEM; EXPRESSION; FEEDBACK; GENETICS; TIME	Kai proteins globally regulate circadian gene expression of cyanobacteria. The KaiC phosphorylation cycle, which persists even without transcription or translation, is assumed to be a basic timing process of the circadian clock. We have reconstituted the self-sustainable oscillation of KaiC phosphorylation in vitro by incubating KaiC with KaiA, KaiB, and adenosine triphosphate. The period of the in vitro oscillation was stable despite temperature change (temperature compensation), and the circadian periods observed in vivo in KaiC mutant strains were consistent with those measured in vitro. The enigma of the circadian clock can now be studied in vitro by examining the interactions between three Kai proteins.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; JST, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Japan Science & Technology Agency (JST)	Kondo, T (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan.	kondo@bio.nagoya-u.ac.jp	Ito, Hiroshi/A-7782-2010; Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Iwasaki, Hideo/0000-0002-3754-4955				Allada R, 2001, ANNU REV NEUROSCI, V24, P1091, DOI 10.1146/annurev.neuro.24.1.1091; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Dunlap JC, 2004, J BIOL RHYTHM, V19, P414, DOI 10.1177/0748730404269116; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; Mori T, 2002, P NATL ACAD SCI USA, V99, P17203, DOI 10.1073/pnas.262578499; Nakahira Y, 2004, P NATL ACAD SCI USA, V101, P881, DOI 10.1073/pnas.0307411100; Nishiwaki T, 2004, P NATL ACAD SCI USA, V101, P13927, DOI 10.1073/pnas.0403906101; Tomita J, 2005, SCIENCE, V307, P251, DOI 10.1126/science.1102540; Xu Y, 2004, P NATL ACAD SCI USA, V101, P13933, DOI 10.1073/pnas.0404768101; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	15	739	775	5	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					414	415		10.1126/science.1108451	http://dx.doi.org/10.1126/science.1108451			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831759				2022-12-28	WOS:000228492000053
J	Miller, LG; Perdreau-Remington, F; Rieg, G; Mehdi, S; Perlroth, J; Bayer, AS; Tang, AW; Phung, TO; Spellberg, B				Miller, LG; Perdreau-Remington, F; Rieg, G; Mehdi, S; Perlroth, J; Bayer, AS; Tang, AW; Phung, TO; Spellberg, B			Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PANTON-VALENTINE LEUKOCIDIN; FIELD GEL-ELECTROPHORESIS; SOFT-TISSUE INFECTIONS; STREPTOCOCCAL INFECTIONS; ACQUIRED PNEUMONIA; VIRULENCE FACTORS; UNITED-STATES; RISK-FACTORS; SKIN; IDENTIFICATION	BACKGROUND: Necrotizing fasciitis is a life-threatening infection requiring urgent surgical and medical therapy. Staphylococcus aureus has been a very uncommon cause of necrotizing fasciitis, but we have recently noted an alarming number of these infections caused by community-associated methicillin-resistant S. aureus (MRSA). METHODS: We reviewed the records of 843 patients whose wound cultures grew MRSA at our center from January 15, 2003, to April 15, 2004. Among this cohort, 14 were identified as patients presenting from the community with clinical and intraoperative findings of necrotizing fasciitis, necrotizing myositis, or both. Results: The median age of the patients was 46 years (range, 28 to 68), and 71 percent were men. Coexisting conditions or risk factors included current or past injection-drug use (43 percent); previous MRSA infection, diabetes, and chronic hepatitis C (21 percent each); and cancer and human immunodeficiency virus infection or the acquired immunodeficiency syndrome (7 percent each). Four patients (29 percent) had no serious coexisting conditions or risk factors. All patients received combined medical and surgical therapy, and none died, but they had serious complications, including the need for reconstructive surgery and prolonged stay in the intensive care unit. Wound cultures were monomicrobial for MRSA in 86 percent, and 40 percent of patients (4 of 10) for whom blood cultures were obtained had positive results. All MRSA isolates were susceptible in vitro to clindamycin, trimethoprim-sulfamethoxazole, and rifampin. All recovered isolates belonged to the same genotype (multilocus sequence type ST8, pulsed-field type USA300, and staphylococcal cassette chromosome mec type IV [SCCmecIV]) and carried the Panton-Valentine leukocidin (pvl), lukD, and lukE genes, but no other toxin genes were detected. CONCLUSIONS: Necrotizing fasciitis caused by community-associated MRSA is an emerging clinical entity. In areas in which community-associated MRSA infection is endemic, empirical treatment of suspected necrotizing fasciitis should include antibiotics predictably active against this pathogen.	Harbor UCLA Med Ctr, Div Infect Dis, Torrance, CA 90509 USA; Harbor UCLA Med Ctr, Div HIV Med, Torrance, CA 90509 USA; Harbor UCLA Med Ctr, Dept Internal Med, Torrance, CA 90509 USA; Harbor UCLA Med Ctr, Los Angeles Biomed Inst, Torrance, CA 90509 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; St Mary Hosp, Long Beach, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; University of California System; University of California San Francisco	Miller, LG (corresponding author), Harbor UCLA Med Ctr, Div Infect Dis, Torrance, CA 90509 USA.		a, a/M-9467-2013		ODCDC CDC HHS [R01/CCR923417-01] Funding Source: Medline	ODCDC CDC HHS		Baggett HC, 2004, J INFECT DIS, V189, P1565, DOI 10.1086/383247; Bancroft E, 2003, 41 ANN M INF DIS SOC; Bisno AL, 1996, NEW ENGL J MED, V334, P240, DOI 10.1056/NEJM199601253340407; Blevins JS, 2002, INFECT IMMUN, V70, P470, DOI 10.1128/IAI.70.2.470-480.2002; Boussaud V, 2003, INTENS CARE MED, V29, P1840, DOI 10.1007/s00134-003-1918-5; BROOK I, 1995, ARCH SURG-CHICAGO, V130, P786; BROOK I, 1995, J CLIN MICROBIOL, V33, P2382, DOI 10.1128/JCM.33.9.2382-2387.1995; Carleton HA, 2004, J INFECT DIS, V190, P1730, DOI 10.1086/425019; Carratala J, 2003, EUR J CLIN MICROBIOL, V22, P151, DOI 10.1007/s10096-003-0902-x; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P88; Chambers HF, 2001, EMERG INFECT DIS, V7, P178, DOI 10.3201/eid0702.010204; Charlebois ED, 2002, CLIN INFECT DIS, V34, P425, DOI 10.1086/338069; CRIBIER B, 1992, DERMATOLOGY, V185, P175, DOI 10.1159/000247443; Davies HD, 1996, NEW ENGL J MED, V335, P547, DOI 10.1056/NEJM199608223350803; Diekema DJ, 2001, CLIN INFECT DIS, V32, pS114, DOI 10.1086/320184; Diep BA, 2004, J CLIN MICROBIOL, V42, P2080, DOI 10.1128/JCM.42.5.2080-2084.2004; Diep BA, 2003, J CLIN MICROBIOL, V41, P4559, DOI 10.1128/JCM.41.10.4559-4564.2003; Eady EA, 2003, CURR OPIN INFECT DIS, V16, P103, DOI 10.1097/00001432-200304000-00007; Eguia Jose M., 2003, Curr Infect Dis Rep, V5, P459, DOI 10.1007/s11908-003-0087-6; Elliott D, 2000, AM J SURG, V179, P361, DOI 10.1016/S0002-9610(00)00360-3; Enright MC, 2000, J CLIN MICROBIOL, V38, P1008, DOI 10.1128/JCM.38.3.1008-1015.2000; File Thomas M. Jr., 2000, Comprehensive Therapy, V26, P73, DOI 10.1007/s12019-000-0015-8; Fontes R A Jr, 2000, J Am Acad Orthop Surg, V8, P151; Foster TJ, 1998, TRENDS MICROBIOL, V6, P484, DOI 10.1016/S0966-842X(98)01400-0; FRAZEE B, IN PRESS ANN EMERG M; Gillet Y, 2002, LANCET, V359, P753, DOI 10.1016/S0140-6736(02)07877-7; Headley AJ, 2003, AM FAM PHYSICIAN, V68, P323; Imamura Yuzo, 1995, Journal of Dermatology (Tokyo), V22, P960; Ito T, 2001, ANTIMICROB AGENTS CH, V45, P3677; Ito T, 2001, ANTIMICROB AGENTS CH, V45, P1323, DOI 10.1128/AAC.45.5.1323-1336.2001; Jarraud S, 2002, INFECT IMMUN, V70, P631, DOI 10.1128/IAI.70.2.631-641.2002; Klein JL, 2003, INTENS CARE MED, V29, P1399, DOI 10.1007/s00134-003-1844-6; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; Ma XX, 2002, ANTIMICROB AGENTS CH, V46, P1147, DOI 10.1128/AAC.46.4.1147-1152.2002; McDougal LK, 2003, J CLIN MICROBIOL, V41, P5113, DOI 10.1128/JCM.41.11.5113-5120.2003; MCHENRY CR, 1995, ANN SURG, V221, P558, DOI 10.1097/00000658-199505000-00013; MILLER LG, 2004, 42 ANN M INF DIS SOC; Mongkolrattanothai K, 2003, CLIN INFECT DIS, V37, P1050, DOI 10.1086/378277; Moore PCL, 2001, J CLIN MICROBIOL, V39, P2760, DOI 10.1128/JCM.39.8.2760-2767.2001; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; Munckhof Wendy J., 2003, International Journal of Infectious Diseases, V7, P259, DOI 10.1016/S1201-9712(03)90104-4; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; Okuma K, 2002, J CLIN MICROBIOL, V40, P4289, DOI 10.1128/JCM.40.11.4289-4294.2002; Oliveira DC, 2002, ANTIMICROB AGENTS CH, V46, P2155, DOI 10.1128/AAC.46.7.2155-2161.2002; Osterlund A, 2002, SCAND J INFECT DIS, V34, P763, DOI 10.1080/0036554021000026927; Pan ES, 2003, CLIN INFECT DIS, V37, P1384, DOI 10.1086/379019; PERDREAUREMINGT.F, 2003, 43 INT C ANT AG CHEM; PREVOST G, 1995, J MED MICROBIOL, V42, P237, DOI 10.1099/00222615-42-4-237; Purcell K, 2002, PEDIATR INFECT DIS J, V21, P988, DOI 10.1097/00006454-200210000-00028; Rezende NA, 2002, AM J MED SCI, V323, P117, DOI 10.1097/00000441-200203000-00001; Roth A, 2003, ARCH ORTHOP TRAUM SU, V123, P429, DOI 10.1007/s00402-003-0535-7; Sande MA, 2004, SANFORD GUIDE ANTIMI; Sattler CA, 2002, PEDIATR INFECT DIS J, V21, P910, DOI 10.1097/00006454-200210000-00005; Seal DV, 2001, CURR OPIN INFECT DIS, V14, P127, DOI 10.1097/00001432-200104000-00003; Siberry GK, 2003, CLIN INFECT DIS, V37, P1257, DOI 10.1086/377501; SIGURDSSON AF, 1989, SCAND J INFECT DIS, V21, P537, DOI 10.3109/00365548909037882; SWARTZ MN, 2000, MANDELL DOUGLAS BENN, P1037; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Vandenesch F, 2003, EMERG INFECT DIS, V9, P978; WARD PD, 1980, INFECT IMMUN, V28, P393; Witte W., 2004, EUROSURVEILLANCE, V9, P1; Wong CH, 2003, J BONE JOINT SURG AM, V85A, P1454, DOI 10.2106/00004623-200308000-00005; Wu Kun-Chan, 2002, Journal of Microbiology Immunology and Infection, V35, P53; 2003, MMWR MORB MORTAL WKL, V52, P793; 2003, MMWR MORB MORTAL WKL, V52, P992; 2003, JAMA, V289, P1377	67	733	759	1	57	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 7	2005	352	14					1445	1453		10.1056/NEJMoa042683	http://dx.doi.org/10.1056/NEJMoa042683			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913IP	15814880				2022-12-28	WOS:000228145200008
J	Maggard, MA; Shugarman, LR; Suttorp, M; Maglione, M; Sugarman, HJ; Livingston, EH; Nguyen, NT; Li, ZP; Mojica, WA; Hilton, L; Rhodes, S; Morton, SC; Shekelle, PG				Maggard, MA; Shugarman, LR; Suttorp, M; Maglione, M; Sugarman, HJ; Livingston, EH; Nguyen, NT; Li, ZP; Mojica, WA; Hilton, L; Rhodes, S; Morton, SC; Shekelle, PG			Meta-analysis: Surgical treatment of obesity	ANNALS OF INTERNAL MEDICINE			English	Article							VERTICAL BANDED GASTROPLASTY; ROUX-EN-Y; QUALITY-OF-LIFE; GASTRIC BYPASS-SURGERY; INDUCED WEIGHT-LOSS; LONG-TERM; MORBID-OBESITY; BARIATRIC SURGERY; BLOOD-PRESSURE; SUBJECTS SOS	Background: controversy exists regarding the effectiveness of surgery for weight loss and the resulting improvement in healthrelated outcomes. Purpose: To perform a meta-analysis of effectiveness and adverse events associated with surgical treatment of obesity. Data Sources: MEDLINE, EMBASE, Cochrane Controlled Trials Register, and systematic reviews. Study Selection: Randomized, controlled trials; observational studies; and case series reporting on surgical treatment of obesity. Data Extraction: Information about study design, procedure, population, comorbid conditions, and adverse events. Data Synthesis: The authors assessed 147 studies. Of these, 89 contributed to the weight loss analysis, 134 contributed to the mortality analysis, and 128 contributed to the complications analysis. The authors identified 1 large, matched cohort analysis that reported greater weight loss with surgery than with medical treatment in individuals with an average body mass index (BMI) of 40 kg/m(2) or greater. Surgery resulted in a weight loss of 20 to 30 kg, which was maintained for up to 10 years and was accompanied by improvements in some comorbid conditions. For BMIs of 35 to 39 kg/m(2), data from case series strongly support superiority of surgery but cannot be considered conclusive. Gastric bypass procedures result in more weight loss than gastroplasty. Bariatric procedures in current use (gastric bypass, laparoscopic adjustable gastric band, vertical banded gastroplasty, and biliopancreatic diversion and switch) have been performed with an overall mortality rate of less than 1%. Adverse events occur in about 20% of cases. A laparoscopic approach results in fewer wound complications than an open approach. Limitations: only a few controlled trials were available for analysis. Heterogeneity was seen among studies, and publication bias is possible. Conclusions: Surgery is more effective than nonsurgical treatment for weight loss and control of some comorbid conditions in patients with a BMI of 40 kg/m(2) or greater. More data are needed to determine the efficacy of surgery relative to nonsurgical therapy for less severely obese people. Procedures differ in efficacy and incidence of complications.	Univ Calif Los Angeles, Med Ctr, Dept Surg, Los Angeles, CA 90095 USA; So Calif Evidence Based Practice Ctr, RAND Hlth Div, Santa Monica, CA USA; Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Maggard, MA (corresponding author), Univ Calif Los Angeles, Med Ctr, Dept Surg, CHS Room 72-215,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	mmaggard@mednet.ucla.edu	Kohn, Geoffrey P/A-9056-2009					AGREN G, 1989, INT J OBESITY, V13, P595; ANDERSEN B, 1979, LANCET, V2, P1255; ANDERSEN T, 1984, NEW ENGL J MED, V310, P352, DOI 10.1056/NEJM198402093100604; ANDERSEN T, 1988, INT J OBESITY, V12, P277; Arcila D, 2002, OBES SURG, V12, P661, DOI 10.1381/096089202321019648; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Ballantyne GH, 2003, OBES SURG, V13, P954, DOI 10.1381/096089203322618867; Blachar A, 2002, RADIOLOGY, V223, P625, DOI 10.1148/radiol.2233011323; Buchwald H, 2004, JAMA-J AM MED ASSOC, V292, P1724, DOI 10.1001/jama.292.14.1724; Buchwald H, 2004, OBES SURG, V14, P1157, DOI 10.1381/0960892042387057; BUMP RC, 1992, AM J OBSTET GYNECOL, V167, P392, DOI 10.1016/S0002-9378(11)91418-5; Choban PS, 1999, J AM COLL SURGEONS, V188, P491, DOI 10.1016/S1072-7515(99)00030-7; Christou NV, 2004, ANN SURG, V240, P416, DOI 10.1097/01.sla.0000137343.63376.19; Clegg A J, 2002, Health Technol Assess, V6, P1; COLQUITT J, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003641; Cooney RN, 2003, OBES SURG, V13, P29, DOI 10.1381/096089203321136557; Courcoulas A, 2003, SURGERY, V134, P613, DOI 10.1016/S0039-6060(03)00306-4; DATTILO AM, 1992, AM J CLIN NUTR, V56, P320, DOI 10.1093/ajcn/56.2.320; DEITEL M, 1988, AM J SURG, V155, P512, DOI 10.1016/S0002-9610(88)80125-9; DEITEL M, 1987, GASTROENTEROL CLIN N, V16, P511; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Dixon JB, 2002, AM J SURG, V184, p51S, DOI 10.1016/S0002-9610(02)01181-9; Dixon JB, 2001, OBES SURG, V11, P59, DOI 10.1381/096089201321454123; Dymek MP, 2002, OBES RES, V10, P1135, DOI 10.1038/oby.2002.154; Eckel RH, 1998, CIRCULATION, V97, P2099, DOI 10.1161/01.CIR.97.21.2099; Ferrannini E, 1997, HYPERTENSION, V30, P1144, DOI 10.1161/01.HYP.30.5.1144; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Flum DR, 2004, J AM COLL SURGEONS, V199, P543, DOI 10.1016/j.jamcollsurg.2004.06.014; FRIEDMAN D, 1995, OBES SURG, V5, P308, DOI 10.1381/096089295765557692; Gami AS, 2003, ENDOCRIN METAB CLIN, V32, P869, DOI 10.1016/S0889-8529(03)00069-0; Gomez C A, 1981, World J Surg, V5, P823; Guisado JA, 2002, OBES SURG, V12, P835, DOI 10.1381/096089202320995664; HALL JC, 1990, ANN SURG, V211, P419, DOI 10.1097/00000658-199004000-00007; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Hell E, 2000, OBES SURG, V10, P214, DOI 10.1381/096089200321643485; Herpertz S, 2003, INT J OBESITY, V27, P1300, DOI 10.1038/sj.ijo.0802410; Higa KD, 2000, ARCH SURG-CHICAGO, V135, P1029, DOI 10.1001/archsurg.135.9.1029; HOWARD L, 1995, OBES SURG, V5, P55, DOI 10.1381/096089295765558169; Joehl RJ, 2003, SURGERY, V134, P621; Kanoupakis E, 2001, OBES SURG, V11, P552, DOI 10.1381/09608920160556715; Karason K, 1997, BRIT MED J, V315, P912, DOI 10.1136/bmj.315.7113.912; Karason K, 1998, OBES RES, V6, P422, DOI 10.1002/j.1550-8528.1998.tb00374.x; Karason K, 2000, ARCH INTERN MED, V160, P1797, DOI 10.1001/archinte.160.12.1797; Karason K, 1999, AM J CARDIOL, V83, P1242, DOI 10.1016/S0002-9149(99)00066-1; Karason K, 1999, INT J OBESITY, V23, P948, DOI 10.1038/sj.ijo.0801024; Karlsson J, 1998, INT J OBESITY, V22, P113, DOI 10.1038/sj.ijo.0800553; KIM CH, 1992, MAYO CLIN PROC, V67, P33, DOI 10.1016/S0025-6196(12)60274-2; Klein S, 2004, DIABETES CARE, V27, P2067, DOI 10.2337/diacare.27.8.2067; KRAL JG, 1992, AM J CLIN NUTR, V55, P611, DOI 10.1093/ajcn/55.2.611s; Kral JG, 2004, SURGERY, V135, P48, DOI 10.1016/j.surg.2003.10.003; LAWS HL, 1981, ANN SURG, V193, P334, DOI 10.1097/00000658-198103000-00014; Liu JH, 2003, AM SURGEON, V69, P823; Luyckx FH, 1998, INT J OBESITY, V22, P222, DOI 10.1038/sj.ijo.0800571; MACGREGOR AMC, 1993, OBES SURG, V3, P15, DOI 10.1381/096089293765559700; MASON EE, 1967, SURG CLIN N AM, V47, P1345; MASON EE, 1982, ARCH SURG-CHICAGO, V117, P701; Melissas J, 2003, OBES SURG, V13, P389, DOI 10.1381/096089203765887714; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Murr M, 2003, J GASTROINTEST SURG, V7, P1002; Narbro K, 1999, INT J OBESITY, V23, P619, DOI 10.1038/sj.ijo.0800890; Naslund E, 1996, EUR J SURG, V162, P303; Naslund I, 1999, PROG OBES R, P815; Nguyen NT, 2003, J GASTROINTEST SURG, V7, P997, DOI 10.1016/j.gassur.2003.09.016; OBRIEN P, 2004, 21 ANN M AM SOC BAR; Peltonen M, 2003, PAIN, V104, P549, DOI 10.1016/S0304-3959(03)00091-5; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; PiSunyer FX, 1996, CLIN THER, V18, P1006, DOI 10.1016/S0149-2918(96)80057-9; RAND CSW, 1986, SOUTHERN MED J, V79, P1511, DOI 10.1097/00007611-198612000-00010; Schauer P, 2003, SURG ENDOSC, V17, P212, DOI 10.1007/s00464-002-8857-z; SILVERMAN EM, 1995, AM J CLIN PATHOL, V104, P23, DOI 10.1093/ajcp/104.1.23; Sjostrom CD, 2000, HYPERTENSION, V36, P20, DOI 10.1161/01.HYP.36.1.20; Sjostrom CD, 1999, OBES RES, V7, P477; Sjostrom CD, 2001, OBES RES, V9, P188, DOI 10.1038/oby.2001.20; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; SUGERMAN HJ, 1988, ANN SURG, V207, P604, DOI 10.1097/00000658-198805000-00015; SUGERMAN HJ, 1987, ANN SURG, V205, P613, DOI 10.1097/00000658-198706000-00002; SUGERMAN HJ, 1995, NEUROLOGY, V45, P1655, DOI 10.1212/WNL.45.9.1655; Sugerman HJ, 1996, AM J SURG, V171, P263, DOI 10.1016/S0002-9610(97)89565-7; Sugerman HJ, 2001, ANN SURG, V234, P41, DOI 10.1097/00000658-200107000-00007; SUGERMAN HJ, 1999, ANN SURG, V21, P682; Suter M, 2003, SURG ENDOSC, V17, P603, DOI 10.1007/s00464-002-8952-1; Torgerson JS, 2001, INT J OBESITY, V25, pS2, DOI 10.1038/sj.ijo.0801687; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; VANRIJ AM, 1984, NZ SOC GASTROENTEROL, V14, P340; VANWOERT J, 1992, CLIN RES, V40, pA642; Weiner R, 1999, OBES SURG, V9, P539, DOI 10.1381/096089299765552639; Westling A, 2001, OBES SURG, V11, P284, DOI 10.1381/096089201321336610; Wing RR, 2004, OBES RES, V12, P1426; Wittgrove AC, 1998, OBES SURG, V8, P461, DOI 10.1381/096089298765554368; Wittgrove AC, 2000, OBES SURG, V10, P233, DOI 10.1381/096089200321643511	91	1047	1077	0	84	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 5	2005	142	7					547	559		10.7326/0003-4819-142-7-200504050-00013	http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00013			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913QL	15809466				2022-12-28	WOS:000228167800008
J	Kimmins, S; Sassone-Corsi, P				Kimmins, S; Sassone-Corsi, P			Chromatin remodelling and epigenetic features of germ cells	NATURE			English	Review							HISTONE H2A VARIANTS; MICE LACKING; TARGETED DISRUPTION; NUCLEAR PROTEINS; DNA-METHYLATION; GENE-EXPRESSION; MESSENGER-RNA; MOUSE; H1; KINASE	Germ cells have the unique capacity to start a new life upon fertilization. They are generated during a sex-specific differentiation programme called gametogenesis. Maturation of germ cells is characterized by an impressive degree of cellular restructuring and gene regulation that involves remarkable genomic reorganization. These events are finely tuned, but are also susceptible to the introduction of various types of error. Because stable genetic transmission to future generations is essential for life, understanding the control of these processes has far-reaching implications for human health and reproduction.	Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Sassone-Corsi, P (corresponding author), Inst Genet & Biol Mol & Cellulaire, BP 10142, F-67404 Strasbourg, France.	paolosc@igbmc.u-strasbg.fr	Sassone-Corsi, Paolo/H-6182-2011	Kimmins, Sarah/0000-0002-0168-7233				Abraham RT, 2003, BIOESSAYS, V25, P627, DOI 10.1002/bies.10310; ALBIG W, 1993, GENOMICS, V16, P649, DOI 10.1006/geno.1993.1243; Baarends WM, 1999, MOL CELL ENDOCRINOL, V151, P5, DOI 10.1016/S0303-7207(99)00060-X; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Barlow C, 1998, DEVELOPMENT, V125, P4007; Bramlage B, 1997, DIFFERENTIATION, V62, P13, DOI 10.1046/j.1432-0436.1997.6210013.x; Brinster RL, 2002, SCIENCE, V296, P2174, DOI 10.1126/science.1071607; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chadwick BP, 2001, HUM MOL GENET, V10, P1101, DOI 10.1093/hmg/10.10.1101; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cho C, 2001, NAT GENET, V28, P82, DOI 10.1038/ng0501-82; Clarke HJ, 1997, J CELL SCI, V110, P477; Contreras A, 2003, MOL CELL BIOL, V23, P8626, DOI 10.1128/MCB.23.23.8626-8636.2003; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; De La Fuente R, 2004, DEV BIOL, V272, P1, DOI 10.1016/j.ydbio.2003.12.012; DeBaun MR, 2003, AM J HUM GENET, V72, P156, DOI 10.1086/346031; DEBEY P, 1993, MOL REPROD DEV, V36, P59, DOI 10.1002/mrd.1080360110; Doenecke D, 1997, ADV EXP MED BIOL, V424, P37; Fantz DA, 2001, BIOL REPROD, V64, P425, DOI 10.1095/biolreprod64.2.425; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; GRIMES S, 1987, EXP CELL RES, V173, P534, DOI 10.1016/0014-4827(87)90293-X; HAY B, 1988, DEVELOPMENT, V103, P625; Hazzouri M, 2000, EUR J CELL BIOL, V79, P950, DOI 10.1078/0171-9335-00123; Hendzel MJ, 2004, J BIOL CHEM, V279, P20028, DOI 10.1074/jbc.M400070200; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; HOLLIDAY R, 1989, CELL BIOPHYS, V15, P15, DOI 10.1007/BF02991575; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jedrusik MA, 2001, DEVELOPMENT, V128, P1069; Kim JM, 2003, J CELL BIOL, V162, P37, DOI 10.1083/jcb.200303047; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lahn BT, 2002, P NATL ACAD SCI USA, V99, P8707, DOI 10.1073/pnas.082248899; Lee K, 1995, P NATL ACAD SCI USA, V92, P12451, DOI 10.1073/pnas.92.26.12451; Lewis JD, 2004, P NATL ACAD SCI USA, V101, P4148, DOI 10.1073/pnas.0308721101; Marston AL, 2004, NAT REV MOL CELL BIO, V5, P983, DOI 10.1038/nrm1526; Martianov I, 2005, P NATL ACAD SCI USA, V102, P2808, DOI 10.1073/pnas.0406060102; MCKEE BD, 1993, CHROMOSOMA, V102, P71, DOI 10.1007/BF00356023; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Meetei AR, 2002, BIOCHEMISTRY-US, V41, P185, DOI 10.1021/bi0117652; Meistrich ML, 2003, CHROMOSOMA, V111, P483, DOI 10.1007/s00412-002-0227-z; MOSS SB, 1993, BIOL REPROD, V48, P1047, DOI 10.1095/biolreprod48.5.1047; MOSS SB, 1989, DEV BIOL, V133, P83, DOI 10.1016/0012-1606(89)90299-6; Nayernia K, 2003, BIOL REPROD, V69, P1973, DOI 10.1095/biolreprod.103.018564; Niino YS, 2001, J BIOL CHEM, V276, P36711, DOI 10.1074/jbc.M104348200; OLIVA R, 1991, PROG NUCLEIC ACID RE, V40, P25; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; Park EJ, 2003, NUCLEIC ACIDS RES, V31, P6819, DOI 10.1093/nar/gkg921; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pivot-Pajot C, 2003, MOL CELL BIOL, V23, P5354, DOI 10.1128/MCB.23.15.5354-5365.2003; POGANY GC, 1981, EXP CELL RES, V136, P127, DOI 10.1016/0014-4827(81)90044-6; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rhind SM, 2003, NAT REV GENET, V4, P855, DOI 10.1038/nrg1205; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; SARMA K, 2005, NATURE REV MOL CELL, V6, P1; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; Sedgwick B, 2004, NAT REV MOL CELL BIO, V5, P148, DOI 10.1038/nrm1312; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; SUNG MT, 1970, P NATL ACAD SCI USA, V67, P1616, DOI 10.1073/pnas.67.3.1616; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Teranishi T, 2004, DEV BIOL, V266, P76, DOI 10.1016/j.ydbio.2003.10.004; Toyooka Y, 2000, MECH DEVELOP, V93, P139, DOI 10.1016/S0925-4773(00)00283-5; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Yan W, 2003, P NATL ACAD SCI USA, V100, P10546, DOI 10.1073/pnas.1837812100; Yu YE, 2000, P NATL ACAD SCI USA, V97, P4683, DOI 10.1073/pnas.97.9.4683; Zalensky AO, 2002, J BIOL CHEM, V277, P43474, DOI 10.1074/jbc.M206065200; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125; Zhao M, 2001, MOL CELL BIOL, V21, P7243, DOI 10.1128/MCB.21.21.7243-7255.2001	77	326	362	1	30	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					583	589		10.1038/nature03368	http://dx.doi.org/10.1038/nature03368			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800613				2022-12-28	WOS:000228011000033
J	Walsh, SR; Parada, NA				Walsh, SR; Parada, NA			Uremic frost	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA	Harvard University; Massachusetts General Hospital; Tulane University	Walsh, SR (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.								0	6	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					E13	E13		10.1056/NEJMicm030792	http://dx.doi.org/10.1056/NEJMicm030792			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800220				2022-12-28	WOS:000227998300013
J	Chacinska, A; Lind, M; Frazier, AE; Dudek, J; Meisinger, C; Geissler, A; Sickmann, A; Meyer, HE; Truscott, KN; Guiard, B; Pfanner, N; Rehling, P				Chacinska, A; Lind, M; Frazier, AE; Dudek, J; Meisinger, C; Geissler, A; Sickmann, A; Meyer, HE; Truscott, KN; Guiard, B; Pfanner, N; Rehling, P			Mitochondrial presequence translocase: Switching between TOM tethering and motor recruitment involves Tim21 and Tim17	CELL			English	Article							PROTEIN IMPORT MOTOR; PREPROTEIN TRANSLOCASE; INTERMEMBRANE SPACE; CONTACT SITES; MEMBRANES; MATRIX; TIM50; INNER; COCHAPERONE; COMPONENT	The presequence translocase of the inner mitochondrial membrane (TIM23 complex) operates at a central junction of protein import. It accepts preproteins from the outer membrane TOM complex and directs them to inner membrane insertion or, in cooperation with the presequence translocase-associated motor (PAM), to the matrix. Little is known of how the TIM23 complex coordinates these tasks. We have identified Tim21 (YGR033c) that interacts with the TOM complex. Tim21 is specific for a TIM23 form that cooperates with TOM and promotes inner membrane insertion. Protein translocation into the matrix requires a switch to a Tim21-free, PAM bound presequence translocase. Tim17 is crucial for the switch by performing two separable functions: promotion of inner membrane insertion and binding of Pam18 to form the functional TIM-PAM complex. Thus, the presequence translocase is not a static complex but switches between TOM tethering and PAM binding in a reaction cycle involving Tim21 and Tim17.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Uppsala Univ, Evolut Biol Ctr, Dept Comparat Physiol, SE-75236 Uppsala, Sweden; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Germany; Ruhr Univ Bochum, Med Proteom Ctr, D-44780 Bochum, Germany; La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia; Univ Paris 06, CNRS, Lab Propre, F-91190 Gif Sur Yvette, France	University of Freiburg; Uppsala University; University of Freiburg; University of Wurzburg; Ruhr University Bochum; La Trobe University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	nikolaus.pfanner@biochemie.uni-freiburg.de; peter.rehling@biochemie.uni-freiburg.de	Truscott, Kaye/D-3362-2012; Sickmann, Albert/A-1010-2011; Pfanner, Nikolaus/AAV-7878-2021; Meisinger, Chris/J-1110-2014	Sickmann, Albert/0000-0002-2388-5265; Meisinger, Chris/0000-0002-8326-3548; Frazier, Ann/0000-0002-6491-3437; Truscott, Kaye/0000-0002-5352-9835; Chacinska, Agnieszka/0000-0002-2832-2568				Bauer MF, 2000, TRENDS CELL BIOL, V10, P25, DOI 10.1016/S0962-8924(99)01684-0; Chacinska A, 2003, EMBO J, V22, P5370, DOI 10.1093/emboj/cdg532; D'Silva PD, 2003, P NATL ACAD SCI USA, V100, P13839, DOI 10.1073/pnas.1936150100; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Donzeau M, 2000, CELL, V101, P401, DOI 10.1016/S0092-8674(00)80850-8; Frazier AE, 2004, NAT STRUCT MOL BIOL, V11, P226, DOI 10.1038/nsmb735; Frazier AE, 2003, MOL CELL BIOL, V23, P7818, DOI 10.1128/MCB.23.21.7818-7828.2003; Geissler A, 2002, CELL, V111, P507, DOI 10.1016/S0092-8674(02)01073-5; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Jensen RE, 2001, NAT STRUCT BIOL, V8, P1008, DOI 10.1038/nsb1201-1008; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Kozany C, 2004, NAT STRUCT MOL BIOL, V11, P234, DOI 10.1038/nsmb734; Li YF, 2004, J BIOL CHEM, V279, P38047, DOI 10.1074/jbc.M404319200; Mokranjac D, 2003, EMBO J, V22, P4945, DOI 10.1093/emboj/cdg485; Mokranjac D, 2003, EMBO J, V22, P816, DOI 10.1093/emboj/cdg090; Rehling P, 2004, NAT REV MOL CELL BIO, V5, P519, DOI 10.1038/nrm1426; Ryan MT, 2001, METHOD CELL BIOL, V65, P189, DOI 10.1016/S0091-679X(01)65012-X; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; Truscott KN, 2003, J CELL BIOL, V163, P707, DOI 10.1083/jcb.200308004; Truscott KN, 2001, NAT STRUCT BIOL, V8, P1074, DOI 10.1038/nsb726; VOOS W, 1993, J CELL BIOL, V123, P119, DOI 10.1083/jcb.123.1.119; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	22	263	271	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					817	829		10.1016/j.cell.2005.01.011	http://dx.doi.org/10.1016/j.cell.2005.01.011			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797382	hybrid			2022-12-28	WOS:000228067500011
J	Fields, S; Johnston, M				Fields, S; Johnston, M			Whither model organism research?	SCIENCE			English	Editorial Material									Univ Washington, Howard Hughes Med Inst, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Dept Med, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Washington University (WUSTL)	Fields, S (corresponding author), Univ Washington, Howard Hughes Med Inst, Dept Genome Sci, Seattle, WA 98195 USA.	fields@u.washington.edu; mj@genetics.wustl.edu	Johnston, Mark/R-6156-2019; Johnston, Mark/K-3543-2019	Johnston, Mark/0000-0002-4932-7229					0	79	85	1	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 25	2005	307	5717					1885	1886		10.1126/science.1108872	http://dx.doi.org/10.1126/science.1108872			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790833				2022-12-28	WOS:000227957300035
J	Mongan, JJ; Lee, TH				Mongan, JJ; Lee, TH			Do we really want broad access to health care?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Partners HealthCare Syst, Boston, MA 02199 USA; Harvard Univ, Sch Med, Boston, MA USA	Partners Healthcare System; Harvard University; Harvard Medical School	Mongan, JJ (corresponding author), Partners HealthCare Syst, Prudential Tower,11th Fl,800 Boylston St, Boston, MA 02199 USA.	jmongan@partners.org						Budetti PP, 2004, JAMA-J AM MED ASSOC, V292, P2000, DOI 10.1001/jama.292.16.2000; Bush GW, 2004, NEW ENGL J MED, V351, P1815, DOI 10.1056/NEJMp048272; Institute of Medicine (US) Committee on the Consequences of Uninsurance, 2003, HIDD COSTS VAL LOST; *KAIS COMM MED UN, 2003, HLTH INS COV AM 2002; *OFF MAN BUDG, FISC YEAR 2005 BUDG	5	10	10	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1260	1263		10.1056/NEJMsb043863	http://dx.doi.org/10.1056/NEJMsb043863			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	909AW	15788505				2022-12-28	WOS:000227832300017
J	Okie, S				Okie, S			Safety in numbers - Monitoring risk in approved drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Dai CL, 2005, ARCH INTERN MED, V165, P171, DOI 10.1001/archinte.165.2.171; *GEN ACC OFF, 1990, GAOPEMD9015; HARRIS G, 2005, NY TIMES        0220, pA28; Psaty BM, 2004, JAMA-J AM MED ASSOC, V292, P2622, DOI 10.1001/jama.292.21.2622	4	46	48	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1173	1176		10.1056/NEJMp058029	http://dx.doi.org/10.1056/NEJMp058029			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788493				2022-12-28	WOS:000227832300002
J	Pagotto, U; Pasquali, R				Pagotto, U; Pasquali, R			Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors	LANCET			English	Editorial Material							SR141716		Univ Alma Mater Studiorum, S Orsola Malpighi Gen Hosp, Dept Internal Med & Gastroenterol, Endocrine Unit, I-40138 Bologna, Italy; Univ Alma Mater Studiorum, S Orsola Malpighi Gen Hosp, Ctr Appl Biomed Res, I-40138 Bologna, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Pagotto, U (corresponding author), Univ Alma Mater Studiorum, S Orsola Malpighi Gen Hosp, Dept Internal Med & Gastroenterol, Endocrine Unit, I-40138 Bologna, Italy.	pagube@med.unibo.it						Bensaid M, 2003, MOL PHARMACOL, V63, P908, DOI 10.1124/mol.63.4.908; Bray GA, 1999, ENDOCR REV, V20, P805, DOI 10.1210/er.20.6.805; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Cota D, 2003, J ENDOCRINOL INVEST, V26, P1041, DOI 10.1007/BF03348205; Despres JP, 2001, ANN MED, V33, P534, DOI 10.3109/07853890108995963; Gomez R, 2002, J NEUROSCI, V22, P9612; James WPT, 2000, LANCET, V356, P2119, DOI 10.1016/S0140-6736(00)03491-7; Kirkham TC, 2001, NUTR RES REV, V14, P65, DOI 10.1079/NRR200118; Liu YL, 2005, INT J OBESITY, V29, P183, DOI 10.1038/sj.ijo.0802847; *NIH, 2005, 3 NIH NAT HEART LUNG; Olshansky SJ, 2005, NEW ENGL J MED, V352, P1138, DOI 10.1056/NEJMsr043743; PASQUALI R, 2003, HDB OBESITY, P671; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Wolf AM, 1998, OBES RES, V6, P97, DOI 10.1002/j.1550-8528.1998.tb00322.x; World Health Organization, 1997, OB PREV MAN GLOB EP	15	51	60	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 16	2005	365	9468					1363	1364		10.1016/S0140-6736(05)66348-9	http://dx.doi.org/10.1016/S0140-6736(05)66348-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916QY	15836868				2022-12-28	WOS:000228401900004
J	Nilsson, C; Reidy, CA; Dynesius, M; Revenga, C				Nilsson, C; Reidy, CA; Dynesius, M; Revenga, C			Fragmentation and flow regulation of the world's large river systems	SCIENCE			English	Article							CONSERVATION; DAM; RESERVOIR; ZONE; FISH	A global overview of dam-based impacts on large river systems shows that over half (172 out of 292) are affected by dams, including the eight most biogeographicalty diverse. Dam-impacted catchments experience higher irrigation pressure and about 25 times more economic activity per unit of water than do unaffected catchments. In view of projected changes in climate and water resource use, these findings can be used to identify ecological risks associated with further impacts on large river systems.	Umea Univ, Dept Ecol & Environm Sci, Landscape Ecol Grp, SE-90187 Umea, Sweden; Nature Conservancy, Global Prior Grp, Arlington, VA 22203 USA	Umea University; Nature Conservancy	Nilsson, C (corresponding author), Umea Univ, Dept Ecol & Environm Sci, Landscape Ecol Grp, SE-90187 Umea, Sweden.	christer.nilsson@emg.umu.se	Nilsson, Christer/AAI-1354-2019; Dynesius, Mats/A-6219-2009	Dynesius, Mats/0000-0003-0628-4203				ARTHINGTON AH, 1995, CONDITION WORLDS AQU; Avakyan A. B., 1998, Lakes Reservoirs Research and Management, V3, P45, DOI 10.1111/j.1440-1770.1998.tb00031.x; Bubb DH, 2004, FRESHWATER BIOL, V49, P357, DOI 10.1111/j.1365-2426.2003.01178.x; Chang SP, 1998, WATER SCI TECHNOL, V37, P325, DOI 10.1016/S0273-1223(98)00040-7; DYNESIUS M, 1994, SCIENCE, V266, P753, DOI 10.1126/science.266.5186.753; FEKETE B, 1999, 22 WORLD MET ORG GLO; Gehrke PC, 2002, RIVER RES APPL, V18, P265, DOI 10.1002/rra.669; Gillett RM, 2002, AM J HUM BIOL, V14, P50, DOI 10.1002/ajhb.10019; GORMITZ V, 2000, SEA LEVEL RISE HIST, P97; Humborg C, 1997, NATURE, V386, P385, DOI 10.1038/386385a0; Indrabudi H, 1998, LAND DEGRAD DEV, V9, P311, DOI 10.1002/(SICI)1099-145X(199807/08)9:4<311::AID-LDR294>3.0.CO;2-X; *INT COMM LARG DAM, 2003, WORLD REG DAMS 2003; Jansson R, 2000, ECOLOGY, V81, P899, DOI 10.1890/0012-9658(2000)081[0899:FORFIR]2.0.CO;2; Lemly AD, 2000, ENVIRON MANAGE, V25, P485, DOI 10.1007/s002679910039; Levine JM, 2003, ECOLOGY, V84, P1215, DOI 10.1890/0012-9658(2003)084[1215:APMATT]2.0.CO;2; McCully P., 1996, SILENCED RIVERS; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; Nilsson C, 2000, BIOSCIENCE, V50, P783, DOI 10.1641/0006-3568(2000)050[0783:AORECB]2.0.CO;2; Olson DM, 2001, BIOSCIENCE, V51, P933, DOI 10.1641/0006-3568(2001)051[0933:TEOTWA]2.0.CO;2; Penczak T, 2000, ECOL FRESHW FISH, V9, P109, DOI 10.1034/j.1600-0633.2000.90113.x; Poff NL, 1997, BIOSCIENCE, V47, P769, DOI 10.2307/1313099; Prowse TD, 2002, WATER INT, V27, P58, DOI 10.1080/02508060208686978; Pusey BJ, 2003, MAR FRESHWATER RES, V54, P1, DOI 10.1071/MF02041; QING D, 1998, RIVER DRAGON COM 3 G; Rosa LP, 2004, CLIMATIC CHANGE, V66, P9, DOI 10.1023/B:CLIM.0000043158.52222.ee; SHIKLOMANOV A, 1997, COMPREHENSIVE ASSESS; SIEBERT S, 2001, GLOBAL MAP IRRIGATED; St Louis VL, 2000, BIOSCIENCE, V50, P766, DOI 10.1641/0006-3568(2000)050[0766:RSASOG]2.0.CO;2; STGEORGES M, 1995, CAN J ZOOL, V73, P755, DOI 10.1139/z95-089; Tockner K, 2002, ENVIRON CONSERV, V29, P308, DOI 10.1017/S037689290200022X; World Commission on Dams, 2000, REP WORLD COMM DAMS	31	2237	2380	43	1122	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					405	408		10.1126/science.1107887	http://dx.doi.org/10.1126/science.1107887			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831757				2022-12-28	WOS:000228492000050
J	Westall, F				Westall, F			Life on the early earth: A sedimentary view	SCIENCE			English	Editorial Material							GREENSTONE-BELT; SOUTH-AFRICA; MICROFOSSILS; FOSSILS; ROCKS		CNRS, Ctr Biophys Mol, F-45071 Orleans, France	Centre National de la Recherche Scientifique (CNRS)	Westall, F (corresponding author), CNRS, Ctr Biophys Mol, Rue Charles Sadron, F-45071 Orleans, France.	westall@cnrs-orleans.fr						Brasier MD, 2002, NATURE, V416, P76, DOI 10.1038/416076a; Furnes H, 2004, SCIENCE, V304, P578, DOI 10.1126/science.1095858; Garcia-Ruiz JM, 2003, SCIENCE, V302, P1194, DOI 10.1126/science.1090163; Rasmussen B, 2000, NATURE, V405, P676, DOI 10.1038/35015063; Schopf JW, 2002, NATURE, V416, P73, DOI 10.1038/416073a; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; Tice MM, 2004, NATURE, V431, P549, DOI 10.1038/nature02888; TYLER SA, 1954, SCIENCE, V119, P606, DOI 10.1126/science.119.3096.606; Ueno Y, 2001, INT GEOL REV, V43, P196, DOI 10.1080/00206810109465008; van Zuilen MA, 2002, NATURE, V418, P627, DOI 10.1038/nature00934; WALSH MM, 1992, PRECAMBRIAN RES, V54, P271, DOI 10.1016/0301-9268(92)90074-X; Walsh MM, 2004, ASTROBIOLOGY, V4, P429, DOI 10.1089/ast.2004.4.429; Westall F, 2003, CR PALEVOL, V2, P485, DOI 10.1016/j.crpv.2003.09.009; Westall F, 2003, PRECAMBRIAN RES, V126, P313, DOI 10.1016/S0301-9268(03)00102-5; Westall F, 2001, PRECAMBRIAN RES, V106, P93, DOI 10.1016/S0301-9268(00)00127-3; WESTALL F, ASTROBIOLOGY FUTURE, P287	16	54	56	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 15	2005	308	5720					366	367		10.1126/science.1107227	http://dx.doi.org/10.1126/science.1107227			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831746				2022-12-28	WOS:000228492000038
J	Armstrong, K; Micco, E; Carney, A; Stopfer, J; Putt, M				Armstrong, K; Micco, E; Carney, A; Stopfer, J; Putt, M			Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFRICAN-AMERICAN FAMILIES; GENERAL-POPULATION; ETHNIC-DIFFERENCES; HEREDITARY BREAST; INCREASED RISK; HEALTH-CARE; MUTATIONS; DECISIONS; ATTITUDES; RACE	Context Given the current context of racial disparities in health and health care and the historical context of eugenics, racial disparities in the use of genetic susceptibility testing have been widely anticipated. However, to our knowledge there are no published studies examining the magnitude and determinants of racial differences in the use of genetic susceptibility testing. Objectives To investigate the relationship between race and the use of BRCA1/2 counseling among women with a family history of breast or ovarian cancer and to determine the contribution of socioeconomic characteristics, cancer risk perception and worry, attitudes about genetic testing, and interactions with primary care physicians to racial differences in utilization. Design, Setting, and Participants Case-control study (December 1999-August 2003) of 408 women with a family history of breast or ovarian cancer, of whom 217 underwent genetic counseling for BRCA1/2 testing (cases) and 191 women did not (controls). Participants received primary care within a large health system in greater Philadelphia, Pa. Main Outcome Measures Probability of carrying a BRCA1/2 mutation, socioeconomic characteristics, perception of breast and ovarian cancer risk, worry about breast and ovarian cancer, attitudes about BRCA1/2 testing, and primary care physician discussion of BRCA1/2 testing were measured prior to undergoing BRCA1/2 counseling for cases and at the time of enrollment for controls. Results African American women with a family history of breast or ovarian cancer were significantly less likely to undergo genetic counseling for BRCA1/2 testing than were white women with a family history of breast or ovarian cancer (odds ratio, 0.22; 95% confidence interval, 0.12-0.40). This association persisted after adjustment for probability of BRCA1/2 mutation, socioeconomic characteristics, breast and ovarian cancer risk perception and worry, attitudes about the risks and benefits of BRCA1/2 testing, and primary care physician discussion of BRCA1/2 testing (adjusted odds ratio for African American vs white, 0.28; 95% confidence interval, 0.09-0.89). Conclusions Racial disparities in the use of BRCA1/2 counseling are large and do not appear to be explained by differences in risk factors for carrying a BRCA1/2 mutation, socioeconomic factors, risk perception, attitudes, or primary care physician recommendations. The benefit of predictive genetic testing will not be fully realized unless these disparities can be addressed.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Pennsylvania Medicine; Philadelphia Veterans Affairs Medical Center	Armstrong, K (corresponding author), 1204 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	karmstro@mail.med.upenn.edu						American Cancer Society, 2002, CANC FACTS FIG 2002; Andrykowski MA, 1997, J CLIN ONCOL, V15, P2139, DOI 10.1200/JCO.1997.15.5.2139; Armstrong K, 2002, PREV MED, V34, P590, DOI 10.1006/pmed.2002.1022; Armstrong K, 2000, MED DECIS MAKING, V20, P308, DOI 10.1177/0272989X0002000307; Armstrong K, 2003, AM J MED GENET A, V117A, P154, DOI 10.1002/ajmg.a.10928; Armstrong K, 2000, CANCER EPIDEM BIOMAR, V9, P1251; Ashton CM, 2003, J GEN INTERN MED, V18, P146, DOI 10.1046/j.1525-1497.2003.20532.x; Bach PB, 2004, NEW ENGL J MED, V351, P575, DOI 10.1056/NEJMsa040609; Berry DA, 2002, J CLIN ONCOL, V20, P2701, DOI 10.1200/JCO.2002.05.121; Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Bluman LG, 1999, J CLIN ONCOL, V17, P1040, DOI 10.1200/JCO.1999.17.3.1040; Bosompra K, 2000, PREV MED, V30, P155, DOI 10.1006/pmed.1999.0610; Centers for Disease Control and Prevention, BEH RISK FACT SURV S; Chen WY, 2002, J CLIN ONCOL, V20, P4485, DOI 10.1200/JCO.2002.08.147; Corbie-Smith G, 2002, ARCH INTERN MED, V162, P2458, DOI 10.1001/archinte.162.21.2458; Domchek SM, 2003, J CLIN ONCOL, V21, P593, DOI 10.1200/JCO.2003.07.007; Frank TS, 2002, J CLIN ONCOL, V20, P1480, DOI 10.1200/JCO.20.6.1480; Gao Q, 2000, HUM GENET, V107, P186, DOI 10.1007/s004390000290; Gao Q, 1997, AM J HUM GENET, V60, P1233; Gao Q, 2001, HUM GENET, V109, P239, DOI 10.1007/s004390100533; Grann VR, 2002, J CLIN ONCOL, V20, P2520, DOI 10.1200/JCO.2002.10.101; Grieco EM, 2001, OVERVIEW RACE HISPAN; HOLTZMAN NA, 1992, AM J HUM GENET, V50, P457; Hughes C, 1997, PATIENT EDUC COUNS, V32, P51, DOI 10.1016/S0738-3991(97)00064-5; Hughes C, 1996, BREAST CANCER RES TR, V40, P25, DOI 10.1007/BF01806000; *I MED, 2002, UN TREATM CONFR RAC; Lee SC, 2002, CANCER-AM CANCER SOC, V94, P1876, DOI 10.1002/cncr.10420; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; Lerman C, 1999, CANCER EPIDEM BIOMAR, V8, P361; Lerman C, 2000, PREV MED, V31, P75, DOI 10.1006/pmed.2000.0684; Mefford HC, 1999, AM J HUM GENET, V65, P575, DOI 10.1086/302511; Meijers-Heijboer H, 2003, J CLIN ONCOL, V21, P1675, DOI 10.1200/JCO.2003.09.052; Olopade Olufunmilayo I., 2003, Cancer, V97, P236, DOI 10.1002/cncr.11019; Panguluri RCK, 1999, HUM GENET, V105, P28, DOI 10.1007/s004390051059; Peters N, 2004, CANCER EPIDEM BIOMAR, V13, P361; Rose A, 2004, J GEN INTERN MED, V19, P57, DOI 10.1111/j.1525-1497.2004.21146.x; STRUEWING JP, 1995, CANCER EPIDEM BIOMAR, V4, P169; Tambor ES, 1997, AM J MED GENET, V68, P43, DOI 10.1002/(SICI)1096-8628(19970110)68:1<43::AID-AJMG8>3.0.CO;2-Z; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Thompson HS, 2002, CANCER EPIDEM BIOMAR, V11, P1579; MUTATION PREVALENCE	42	325	324	1	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2005	293	14					1729	1736		10.1001/jama.293.14.1729	http://dx.doi.org/10.1001/jama.293.14.1729			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	915JS	15827311	Bronze			2022-12-28	WOS:000228301100026
J	Foster, GR				Foster, GR			Apoptotic cell death: the caspase-cleavage "gold rush"	LANCET			English	Editorial Material									Barts & London NHS Trust, Queen Marys Sch Med & Dent, London E1 2AT, England	Barts Health NHS Trust; University of London; Queen Mary University London	Foster, GR (corresponding author), Barts & London NHS Trust, Queen Marys Sch Med & Dent, London E1 2AT, England.	g.r.foster@qmul.ac.uk		Foster, Graham/0000-0002-3704-386X				Bantel H, 2004, HEPATOLOGY, V40, P1078, DOI 10.1002/hep.20411; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Matteucci C, 1999, CYTOMETRY, V35, P145, DOI 10.1002/(SICI)1097-0320(19990201)35:2<145::AID-CYTO6>3.0.CO;2-2; Que FG, 1996, GASTROENTEROLOGY, V110, P1238, DOI 10.1053/gast.1996.v110.pm8613014; Zeuzem S, 2004, GASTROENTEROLOGY, V127, P1724, DOI 10.1053/j.gastro.2004.09.050	5	3	3	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 9	2005	365	9467					1293	1294		10.1016/S0140-6736(05)61009-4	http://dx.doi.org/10.1016/S0140-6736(05)61009-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914HY	15823368				2022-12-28	WOS:000228219600010
J	Jones, EM; Surewicz, WK				Jones, EM; Surewicz, WK			Fibril conformation as the basis of species- and strain-dependent seeding specificity of mammalian prion amyloids	CELL			English	Article							MOLECULAR-BASIS; HAMSTER PRP; PROTEIN; CONVERSION; SCRAPIE; TRANSMISSION; VARIANT; YEAST; PROPAGATION; OXIDATION	Spongiform encephalopathies are believed to be transmitted by self-perpetuating conformational conversion of the prion protein. It was shown recently that fundamental aspects of mammalian prion propagation can be reproduced in vitro in a seeded fibrillization of the recombinant prion protein variant Y145Stop (PrP23-144). Here we demonstrate that PrP23-144 amyloids from different species adopt distinct secondary structures and morphologies, and that these structural differences are controlled by one or two residues in a critical region. These sequence-specific structural characteristics correlate strictly with the seeding specificity of amyloid fibrils. However, cross-seeding of PrP23-144 from one species with preformed fibrils from another species may overcome natural sequence-based structural preferences, resulting in a new amyloid strain that inherits the secondary structure and morphology of the template. These data provide direct biophysical evidence that protein conformations are transmitted in PrP amyloid strains, establishing a foundation for a structural basis of mammalian prion transmission barriers.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	witold.surewicz@case.edu			NHLBI NIH HHS [HL007653] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguzzi A, 2004, CELL, V116, P313, DOI 10.1016/S0092-8674(03)01031-6; ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; Baskakov IV, 2004, J BIOL CHEM, V279, P7671, DOI 10.1074/jbc.M310594200; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Bruce M E, 1991, Curr Top Microbiol Immunol, V172, P125; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Chien P, 2003, NATURE, V424, P948, DOI 10.1038/nature01894; Chien P, 2001, NATURE, V410, P223, DOI 10.1038/35065632; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Derkatch IL, 1996, GENETICS, V144, P1375; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Kad NM, 2003, J MOL BIOL, V330, P785, DOI 10.1016/S0022-2836(03)00583-7; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KIMBERLIN RH, 1977, J GEN VIROL, V34, P295, DOI 10.1099/0022-1317-34-2-295; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; Kundu B, 2003, P NATL ACAD SCI USA, V100, P12069, DOI 10.1073/pnas.2033281100; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Miller MW, 2004, CURR TOP MICROBIOL, V284, P193; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; PRIOLA SA, 1995, J VIROL, V69, P7754, DOI 10.1128/JVI.69.12.7754-7758.1995; Priola SA, 2001, J VIROL, V75, P4673, DOI 10.1128/JVI.75.10.4673-4680.2001; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Scott Michael, 2004, VVolume 41, P435; Scott MR, 1999, P NATL ACAD SCI USA, V96, P15137, DOI 10.1073/pnas.96.26.15137; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Supattapone S, 2004, J MOL MED, V82, P348, DOI 10.1007/s00109-004-0534-3; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Uptain SM, 2002, ANNU REV MICROBIOL, V56, P703, DOI 10.1146/annurev.micro.56.013002.100603; Vanik DL, 2004, MOL CELL, V14, P139, DOI 10.1016/S1097-2765(04)00155-8; Weissmann C, 2004, NAT REV MICROBIOL, V2, P861, DOI 10.1038/nrmicro1025; Wickner RB, 2000, J STRUCT BIOL, V130, P310, DOI 10.1006/jsbi.2000.4250; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zandomeneghi G, 2004, PROTEIN SCI, V13, P3314, DOI 10.1110/ps.041024904	50	214	219	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	2005	121	1					63	72		10.1016/j.cell.2005.01.034	http://dx.doi.org/10.1016/j.cell.2005.01.034			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820679	Bronze			2022-12-28	WOS:000228348500010
J	Levesque, LE; Brophy, JM; Zhang, B				Levesque, LE; Brophy, JM; Zhang, B			The risk for myocardial infarction with cyclooxygenase-2 inhibitors: A population study of elderly adults	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARDIOVASCULAR THROMBOTIC EVENTS; RANDOMIZED CONTROLLED-TRIAL; CORONARY HEART-DISEASE; GASTROINTESTINAL TOXICITY; RHEUMATOID-ARTHRITIS; NAPROXEN; COX-2; ROFECOXIB; HYPERTENSION	Background: Cyclooxygenase-2 (COX-2) selective inhibitors have been marketed since 1999 as safer alternatives to nonsterok dal anti-inflammatory drugs (NSAIDs). Debate about their cardiac safety has culminated in the recent withdrawal of rofecoxib. Additional studies are needed to better understand this risk and to determine whether this safety concern represents a class effect. Objective: To assess the influence of various NSAIDs on the risk for a first myocardial infarction (MI). Design: Population-based, retrospective cohort study analyzed using a time-matched, nested case-control approach. Setting: Quebec, Canada. Participants: 113 927 elderly persons without previous MI and newly treated with an NSAID between 1 January 1999 and 30 June 2002. Measurements: NSAID exposure and occurrence of MI assessed by using Quebec's administrative health databases. Results: Compared with no use of NSAIDs in the year preceding the event, current use of rofecoxib was associated with an increased risk for an acute MI (rate ratio [11111, 1.24 [95% Cl, 1.05 to 1.46]) that was more pronounced at higher doses (RR, 1.73 [Cl, 1.09 to 2.76]). The concomitant use of aspirin appears to decrease the risk associated with low-dose rofecoxib (1111, 1.00 [CI, 0.77 to 1.28]) but not with high-dose rofecoxib (1111, 2.36 [Cl, 1.27 to 4.391). No increased risks were observed with celecoxib (1111, 0.99 [Cl, 0.85 to 1.161) or the other NSAIDs. Limitations: The study could not completely account for all potential confounders, including over-the-counter use of aspirin and ibuprofen. Conclusions: These results provide evidence of an increased risk for acute MI in current users of rofecoxib among elderly persons with no history of MI. This risk appears greater at higher doses. Aspirin use mitigates the risk associated with low-dose but not high-dose rofecoxib. There was no evidence of an increased risk with the other NSAIDs.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Cardiol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital	Brophy, JM (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Cardiol, Room M4-76,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	james.brophy@mcgill.ca	brophy, james/H-6673-2019	brophy, james/0000-0001-8049-6875				ABRAHAM C, 2004, GLOBE MAIL      0901, pA1; [Anonymous], 2000, PHARMACOEPIDEM DR S; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Beaulieu MD, 2004, QJM-INT J MED, V97, P21, DOI 10.1093/qjmed/hch006; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Brassard P, 2003, AM HEART J, V145, DOI 10.1016/S0002-8703(03)00087-5; Brassard P, 2003, STROKE, V34, DOI 10.1161/01.STR.0000085831.91042.BF; Breslow NL, 1987, STAT METHODS CANC RE, VII, P178; Brophy JM, 2003, CAN MED ASSOC J, V169, P1153; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Collet D, 1999, MODELLING BINARY DAT, P223; Cryer B, 1998, AM J MED, V104, P413, DOI 10.1016/S0002-9343(98)00091-6; *FDA ADV COMM, 2001, CARD SAF REV ROF; FitzGerald GA, 2001, CLIN EXP RHEUMATOL, V19, pS31; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; HOSMER DW, 1989, APPL LOGISTIC REGRES; Jick SS, 2000, PHARMACOTHERAPY, V20, P741, DOI 10.1592/phco.20.9.741.35209; Juni P, 2004, LANCET, V364, P2021, DOI 10.1016/S0140-6736(04)17514-4; Kimmel SE, 2005, ANN INTERN MED, V142, P157, DOI 10.7326/0003-4819-142-3-200502010-00005; Konstam MA, 2001, CIRCULATION, V104, P2280, DOI 10.1161/hc4401.100078; LEVESQUE L, 2004, PHARMACOEPIDEMIOL S1, V13, pS49; Levy AR, 1999, CAN J CARDIOL, V15, P1277; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; MORROW JD, 2001, GOODMAN GILMANS PHAR; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; NEILAN T, 2004, NY TIMES        0930; Patrono Carlo, 2001, American Journal of Medicine, V110, p62S, DOI 10.1016/S0002-9343(00)00645-8; Rahme E, 2002, ARCH INTERN MED, V162, P1111, DOI 10.1001/archinte.162.10.1111; Rahme E, 2000, ARTHRITIS RHEUM-US, V43, P917, DOI 10.1002/1529-0131(200004)43:4<917::AID-ANR25>3.0.CO;2-F; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Ray WA, 2002, LANCET, V359, P118, DOI 10.1016/S0140-6736(02)07370-1; Reicin AS, 2002, AM J CARDIOL, V89, P204, DOI 10.1016/S0002-9149(01)02201-9; Roberts LJMJ, 2001, GOODMAN GILMANS PHAR; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Singh G, 1998, AM J MED, V105, p31S, DOI DOI 10.1016/S0002-9343(98)00072-2; Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E; Solomon DH, 2002, ARCH INTERN MED, V162, P1099, DOI 10.1001/archinte.162.10.1099; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; *US FOOD DRUG ADM, FDA PUBL HLTH ADV SA; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; VELENTGAS P, 2001, PHARMACOEPIDEM DR S, V10, pS103; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Watson DJ, 2002, ARCH INTERN MED, V162, P1105, DOI 10.1001/archinte.162.10.1105; White WB, 2003, AM J CARDIOL, V92, P411, DOI 10.1016/S0002-9149(03)00659-3; Wright JM, 2002, CAN MED ASSOC J, V167, P1131	50	178	184	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 5	2005	142	7					481	489		10.7326/0003-4819-142-7-200504050-00113	http://dx.doi.org/10.7326/0003-4819-142-7-200504050-00113			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913QL	15809459				2022-12-28	WOS:000228167800001
J	Venter, L				Venter, L			Firms fill antiretroviral gap in South Africa	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Venter, L (corresponding author), The Lancet, London NW1 7BY, England.	lester.venter@btopenworld.com						*AS BUS COAL AIDS, 2002, WELC THAIL BUS COAL; *AV, 2005, HIV THAIL; BLOOM D, 2005, BUSINESS HIV AIDS CO; UNAIDS, UNAIDS S AFR; *WHO UNAIDS, 2004, UNAIDS S AFR; 2004, WORLD EC FOR GLOB HL; 2004, WORLD EC FOR US DIR; 2004, WORLD EC FOR RAP ASS; 2004, WORLD EC FOR PROV CO; 2004, WORLD EC FOR CHANG B	10	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 2	2005	365	9466					1215	1216		10.1016/S0140-6736(05)74793-0	http://dx.doi.org/10.1016/S0140-6736(05)74793-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811443				2022-12-28	WOS:000228107600010
J	Wilkinson, L				Wilkinson, L			Historical keywords - epidemiology	LANCET			English	Editorial Material									UCL, Wellcome Trust Ctr Hist Med, London, England	University of London; University College London	Wilkinson, L (corresponding author), UCL, Wellcome Trust Ctr Hist Med, London, England.	ucgalwi@ucl.ac.uk							0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2005	365	9466					1223	1223		10.1016/S0140-6736(05)74798-X	http://dx.doi.org/10.1016/S0140-6736(05)74798-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	912VI	15811445				2022-12-28	WOS:000228107600013
J	Hashizume, K; Chaussidon, M				Hashizume, K; Chaussidon, M			A non-terrestrial O-16-rich isotopic composition for the protosolar nebula	NATURE			English	Article							EARLY SOLAR-SYSTEM; OXYGEN ISOTOPES; METEORITES; HETEROGENEITY; INCLUSIONS; RESERVOIR; NITROGEN; SAMPLES; GRAINS; ORIGIN	The discovery in primitive components of meteorites(1,2) of large oxygen isotopic variations that could not be attributed to mass-dependent fractionation effects has raised a fundamental question: what is the composition of the protosolar gas from which the host grains formed? This composition is probably preserved in the outer layers of the Sun, but the resolution of astronomical spectroscopic measurements is still too poor to be useful for comparison with planetary material(3,4). Here we report a precise determination of the oxygen isotopic composition of the solar wind from particles implanted in the outer hundreds of nanometres of metallic grains in the lunar regolith. These layers of the grains are enriched in O-16 by >20 +/- 4 parts per thousand relative to the Earth, Mars and bulk meteorites, which implies the existence in the solar accretion disk of reactions-as yet unknown-that were able to change the O-17/O-16 and O-18/O-16 ratios in a way that was not dependent strictly on the mass of the isotope. Photochemical self-shielding of the CO gas irradiated by ultraviolet light(5-7) may be one of these key processes, because it depends on the abundance of the isotopes, rather than their masses.	Osaka Univ, Grad Sch Sci, Dept Earth & Space Sci, Osaka 5600043, Japan; CNRS, CRPG, F-54501 Vandoeuvre Les Nancy, France	Osaka University; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Hashizume, K (corresponding author), Osaka Univ, Grad Sch Sci, Dept Earth & Space Sci, Osaka 5600043, Japan.	kohash@ess.sci.osaka-u.ac.jp	Chaussidon, Marc/E-7067-2017					Chaussidon M, 1999, NATURE, V402, P270, DOI 10.1038/46235; CLAYTON, 1974, P LUNAR PLANET SCI C, V2, P1801; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; Clayton RN, 2002, NATURE, V415, P860, DOI 10.1038/415860b; CLAYTON RN, 1973, SCIENCE, V182, P485, DOI 10.1126/science.182.4111.485; EPSTEIN S, 1973, P LUNAR PLANET SCI C, P1559; Hashizume K, 2000, SCIENCE, V290, P1142, DOI 10.1126/science.290.5494.1142; Hashizume K, 2004, ASTROPHYS J, V600, P480, DOI 10.1086/379637; Hashizume K, 2002, EARTH PLANET SC LETT, V202, P201, DOI 10.1016/S0012-821X(02)00781-1; IRELAND TR, 1992, GEOCHIM COSMOCHIM AC, V56, P2503, DOI 10.1016/0016-7037(92)90205-W; IRELAND TR, 2004, LUNAR PLANET SCI, V35, P1448; Kobayashi S, 2003, GEOCHEM J, V37, P663, DOI 10.2343/geochemj.37.663; Krot AN, 2002, SCIENCE, V295, P1051, DOI 10.1126/science.1068200; LYONS JR, 2004, LUNAR PLANET SCI, V35, P1970; McKeegan KD, 1998, SCIENCE, V280, P414, DOI 10.1126/science.280.5362.414; Messenger S, 2003, SCIENCE, V300, P105, DOI 10.1126/science.1080576; Morris R.V., 1980, P 11 LUN PLAN SCI C, P1697; Nagashima K, 2004, NATURE, V428, P921, DOI 10.1038/nature02510; ROBERT F, 1992, EARTH PLANET SC LETT, V108, P1, DOI 10.1016/0012-821X(92)90055-Z; Taylor Jr. H. P., 1973, P 4 LUN SCI C, P1657; THIEMENS MH, 1983, SCIENCE, V219, P1073, DOI 10.1126/science.219.4588.1073; Thiemens MH, 1999, SCIENCE, V283, P341, DOI 10.1126/science.283.5400.341; Wiechert U, 2001, SCIENCE, V294, P345, DOI 10.1126/science.1063037; Wieler R, 1998, SPACE SCI REV, V85, P303, DOI 10.1023/A:1005166904225; Wiens RC, 1999, METEORIT PLANET SCI, V34, P99, DOI 10.1111/j.1945-5100.1999.tb01735.x; Wiens RC, 2004, EARTH PLANET SC LETT, V222, P697, DOI 10.1016/j.epsl.2004.03.025; Wimmer-Schweingruber RF, 2003, AIP CONF PROC, V679, P577, DOI 10.1063/1.1618662; Young ED, 1998, SCIENCE, V282, P452, DOI 10.1126/science.282.5388.452; Yurimoto H, 2004, SCIENCE, V305, P1763, DOI 10.1126/science.1100989; Ziegler J.F, 1985, STOPPING RANGE IONS	30	84	86	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					619	622		10.1038/nature03432	http://dx.doi.org/10.1038/nature03432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800617				2022-12-28	WOS:000228011000038
J	Ni, S; Kanamori, H; Helmberger, D				Ni, S; Kanamori, H; Helmberger, D			Seismology - Energy radiation from the Sumatra earthquake	NATURE			English	Editorial Material									Univ Sci & Technol China, Sch Earth & Space Sci, Hefei 230026, Anhui, Peoples R China; CALTECH, Tecton Observ, Pasadena, CA 91125 USA	Chinese Academy of Sciences; University of Science & Technology of China, CAS; California Institute of Technology	Ni, S (corresponding author), Univ Sci & Technol China, Sch Earth & Space Sci, Hefei 230026, Anhui, Peoples R China.	sdni@ustc.edu.cn		Ni, Sidao/0000-0003-2988-4850				HOUSTON H, 1986, B SEISMOL SOC AM, V76, P19; MADARIAGA R, 1983, ANN GEOPHYS, V1, P17; Shearer PM, 2004, GEOPHYS J INT, V158, P1103, DOI 10.1111/j.1365-246X.2004.02378.x	3	136	154	4	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					582	582		10.1038/434582a	http://dx.doi.org/10.1038/434582a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800612	Bronze			2022-12-28	WOS:000228011000032
J	Winshall, JS; Weissman, BN				Winshall, JS; Weissman, BN			Benign subcutaneous emphysema of the upper extremity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Winshall, JS (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.								0	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2005	352	13					1357	1357		10.1056/NEJMicm040914	http://dx.doi.org/10.1056/NEJMicm040914			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	911JL	15800231				2022-12-28	WOS:000227998300012
J	Arndt, K; Winston, F				Arndt, K; Winston, F			An unexpected role for ubiquitylation of a transcriptional activator	CELL			English	Editorial Material							RNA-POLYMERASE-II; GAL4; UBIQUITIN	The yeast transcriptional activator Gal4 has served as a paradigm for understanding how eukaryotic cells mount rapid transcriptional responses to environmental changes. In this issue of Cell, Muratani et al. (2005) provide evidence that Gal4 ubiquitylation and destruction are required for activation by Gal4. Surprisingly, this modification is required at a postinitiation step in transcription for the production of mRNAs that are correctly processed and fully functional for translation.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School	Arndt, K (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA.							Fritz S, 2003, MOL BIOL CELL, V14, P2303, DOI 10.1091/mbc.E02-12-0831; Hirst M, 1999, MOL CELL, V3, P673, DOI 10.1016/S1097-2765(00)80360-3; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; SADOWSKI I, 1991, P NATL ACAD SCI USA, V88, P10510, DOI 10.1073/pnas.88.23.10510; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Xiao TJ, 2005, MOL CELL BIOL, V25, P637, DOI 10.1128/MCB.25.2.637-651.2005	8	3	3	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 25	2005	120	6					733	734		10.1016/j.cell.2005.03.004	http://dx.doi.org/10.1016/j.cell.2005.03.004			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	912HF	15797373	Bronze			2022-12-28	WOS:000228067500002
J	Gibson, G				Gibson, G			The synthesis and evolution of a supermodel	SCIENCE			English	Editorial Material							ECTODYSPLASIN-A; STICKLEBACKS; SELECTION; ENCODES; MOUSE		N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Gibson, G (corresponding author), N Carolina State Univ, Dept Genet, Box 7614, Raleigh, NC 27695 USA.	ggibson@ncsu.edu						Bell M.A., 1994, EVOLUTIONARY BIOL TH; Colosimo PF, 2005, SCIENCE, V307, P1928, DOI 10.1126/science.1107239; Colosimo PF, 2004, PLOS BIOL, V2, P635, DOI 10.1371/journal.pbio.0020109; DUN RB, 1958, NATURE, V181, P1018, DOI 10.1038/1811018a0; Gibson G, 2004, NAT REV GENET, V5, P681, DOI 10.1038/nrg1426; HERRMISSON J, IN PRESS GENETICS; Innan H, 2004, P NATL ACAD SCI USA, V101, P10667, DOI 10.1073/pnas.0401720101; Kangas AT, 2004, NATURE, V432, P211, DOI 10.1038/nature02927; KAPLAN NL, 1989, GENETICS, V123, P887; Kondo S, 2001, CURR BIOL, V11, P1202, DOI 10.1016/S0960-9822(01)00324-4; LINDSEY CC, 1962, CAN J ZOOLOG, V40, P271, DOI 10.1139/z62-028; ORTI G, 1994, EVOLUTION, V48, P608, DOI 10.1111/j.1558-5646.1994.tb01348.x; Paakkonen K, 2001, Hum Mutat, V17, P349, DOI 10.1002/humu.33; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069	14	70	73	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 25	2005	307	5717					1890	1891		10.1126/science.1109835	http://dx.doi.org/10.1126/science.1109835			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	910UI	15790836				2022-12-28	WOS:000227957300038
J	De Smet, PAGM				De Smet, PAGM			Herbal medicine in Europe - Relaxing regulatory standards	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Sci Inst Dutch Pharmacists, The Hague, Netherlands; Univ Med Ctr St Radboud, Dept Clin Pharm, Nijmegen, Netherlands	Radboud University Nijmegen	De Smet, PAGM (corresponding author), Sci Inst Dutch Pharmacists, The Hague, Netherlands.		Smet, P.A.G.M./L-4654-2015						0	74	74	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 24	2005	352	12					1176	1178		10.1056/NEJMp048083	http://dx.doi.org/10.1056/NEJMp048083			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	909AW	15788494				2022-12-28	WOS:000227832300003
J	Seagroatt, V				Seagroatt, V			MMR vaccine and Crohn's disease: ecological study of hospital admissions in England, 1991 to 2002	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFLAMMATORY-BOWEL-DISEASE; MEASLES VACCINATION; RISK		Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Seagroatt, V (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.	valerie.seagroatt@dphpc.ox.ac.uk						Davis RL, 2001, ARCH PEDIAT ADOL MED, V155, P354, DOI 10.1001/archpedi.155.3.354; Department of Health, HOSP EP STAT; *HLTH PROT AG, COMPL PRIM COURS VAC; Montgomery SM, 1999, GASTROENTEROLOGY, V116, P796, DOI 10.1016/S0016-5085(99)70062-4; Pebody RG, 1998, BRIT MED J, V316, P1745; Seagroatt V, 2003, J EPIDEMIOL COMMUN H, V57, P883, DOI 10.1136/jech.57.11.883; Smeeth L, 2004, LANCET, V364, P963, DOI 10.1016/S0140-6736(04)17020-7; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; WHEELER JG, 2001, JOINT C SOC SOC MED	9	14	14	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 14	2005	330	7500					1120	1121		10.1136/bmj.38449.476759.AE	http://dx.doi.org/10.1136/bmj.38449.476759.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	927BH	15837703	Bronze, Green Published			2022-12-28	WOS:000229166900019
J	Mace, KA; Pearson, JC; McGinnis, W				Mace, KA; Pearson, JC; McGinnis, W			An epidermal barrier wound repair pathway in Drosophila is mediated by grainy head	SCIENCE			English	Article							DEVELOPMENTAL TRANSCRIPTION FACTORS; DOPA DECARBOXYLASE GENE; HOMEOTIC GENES; MELANOGASTER; CUTICLE; FAMILY; IDENTIFICATION; EXPRESSION; INDUCTION; IMMUNITY	We used wounded Drosophila embryos to define an evolutionarily conserved pathway for repairing the epidermal surface barrier. This pathway includes a wound response enhancer from the Ddc gene that requires grainy head (grh) function and binding sites for the Grh transcription factor. At the signaling level, tyrosine kinase and extracellular signal-regulated kinase (ERK) activities are induced in epidermal cells near wounds, and activated ERK is required for a robust wound response. The conservation of this Grh-dependent pathway suggests that the repair of insect cuticle and mammal skin is controlled by an ancient, shared control system for constructing and heating the animal body surface barrier.	Univ Calif San Diego, Div Biol, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	McGinnis, W (corresponding author), Univ Calif San Diego, Div Biol, Sect Cell & Dev Biol, La Jolla, CA 92093 USA.	wmcginnis@ucsd.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007240] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD28315] Funding Source: Medline; NIGMS NIH HHS [T32GM07240] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; Barolo S, 2004, BIOTECHNIQUES, V36, P436, DOI 10.2144/04363ST03; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BRAY SJ, 1991, GENE DEV, V5, P1672, DOI 10.1101/gad.5.9.1672; Chen L, 2002, MECH DEVELOP, V114, P95, DOI 10.1016/S0925-4773(02)00064-3; Dieckgraefe BK, 1999, AM J PHYSIOL-GASTR L, V276, pG322, DOI 10.1152/ajpgi.1999.276.2.G322; Galko MJ, 2004, PLOS BIOL, V2, P1114, DOI 10.1371/journal.pbio.0020239; Hemphala J, 2003, DEVELOPMENT, V130, P249, DOI 10.1242/dev.00218; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Jacinto A, 2001, NAT CELL BIOL, V3, pE117, DOI 10.1038/35074643; Kockel L, 2001, ONCOGENE, V20, P2347, DOI 10.1038/sj.onc.1204300; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; Lee HY, 2004, MECH DEVELOP, V121, P37, DOI 10.1016/j.mod.2003.11.002; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Li GC, 2003, DEV CELL, V4, P865, DOI 10.1016/S1534-5807(03)00159-X; Liaw GJ, 1995, GENE DEV, V9, P3163, DOI 10.1101/gad.9.24.3163; Macias A, 1996, EMBO J, V15, P334, DOI 10.1002/j.1460-2075.1996.tb00363.x; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Nappi AJ, 2000, BIOESSAYS, V22, P469, DOI 10.1002/(SICI)1521-1878(200005)22:5<469::AID-BIES9>3.3.CO;2-W; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Ostrowski S, 2002, GENETICS, V161, P171; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; SCHAEFER J, 1987, SCIENCE, V235, P1200, DOI 10.1126/science.3823880; SCHOLNICK SB, 1986, SCIENCE, V234, P998, DOI 10.1126/science.3095924; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; STRUHL G, 1983, J EMBRYOL EXP MORPH, V76, P297; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Ting SB, 2003, NAT MED, V9, P1513, DOI 10.1038/nm961; Ting SB, 2003, BIOCHEM J, V370, P953, DOI 10.1042/BJ20021476; Uv AE, 1997, MOL CELL BIOL, V17, P6727, DOI 10.1128/MCB.17.11.6727; Venkatesan K, 2003, NUCLEIC ACIDS RES, V31, P4304, DOI 10.1093/nar/gkg644; Walsh PN, 2002, ESSAYS BIOCHEM, V38, P95, DOI 10.1042/bse0380095; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; Wiellette EL, 1999, DEVELOPMENT, V126, P5373; Wilanowski T, 2002, MECH DEVELOP, V114, P37, DOI 10.1016/S0925-4773(02)00046-1; Wood W, 2002, NAT CELL BIOL, V4, P907, DOI 10.1038/ncb875; Wright TRF, 1996, J HERED, V87, P175, DOI 10.1093/oxfordjournals.jhered.a022983	38	178	180	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 15	2005	308	5720					381	385		10.1126/science.1107573	http://dx.doi.org/10.1126/science.1107573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	917TL	15831751				2022-12-28	WOS:000228492000043
J	Emison, ES; McCallion, AS; Kashuk, CS; Bush, RT; Grice, E; Lin, S; Portnoy, ME; Cutler, DJ; Green, ED; Chakravarti, A				Emison, ES; McCallion, AS; Kashuk, CS; Bush, RT; Grice, E; Lin, S; Portnoy, ME; Cutler, DJ; Green, ED; Chakravarti, A			A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk	NATURE			English	Article							GENOME-WIDE ASSOCIATION; DIABETES-MELLITUS; HIV-1 INFECTION; MOUSE MODEL; EXPRESSION; HAPLOTYPE; GENE; TRANSMISSION; DISEQUILIBRIUM; IDENTIFICATION	The identification of common variants that contribute to the genesis of human inherited disorders remains a significant challenge. Hirschsprung disease (HSCR) is a multifactorial, non-mendelian disorder in which rare high-penetrance coding sequence mutations in the receptor tyrosine kinase RET contribute to risk in combination with mutations at other genes. We have used family-based association studies to identify a disease interval, and integrated this with comparative and functional genomic analysis to prioritize conserved and functional elements within which mutations can be sought. We now show that a common non-coding RET variant within a conserved enhancer-like sequence in intron 1 is significantly associated with HSCR susceptibility and makes a 20-fold greater contribution to risk than rare alleles do. This mutation reduces in vitro enhancer activity markedly, has low penetrance, has different genetic effects in males and females, and explains several features of the complex inheritance pattern of HSCR. Thus, common low-penetrance variants, identified by association studies, can underlie both common and rare diseases.	Johns Hopkins Univ, Sch Med, KcKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; NHGRI, NIH Intramural Sequencing Ctr, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Chakravarti, A (corresponding author), Johns Hopkins Univ, Sch Med, KcKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.	aravinda@jhmi.edu		Grice, Elizabeth/0000-0003-3939-2200; Lin, Shin/0000-0003-0118-0413	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIBHG000196, ZIAHG000060, Z01HG000196, Z01HG000060] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALLISON AC, 1960, NATURE, V186, P531, DOI 10.1038/186531a0; ALLISON AC, 1961, BRIT MED J, V5236, P1346; Batourina E, 2001, NAT GENET, V27, P74, DOI 10.1038/83792; Bolk S, 2000, P NATL ACAD SCI USA, V97, P268, DOI 10.1073/pnas.97.1.268; Borrego S, 2000, J MED GENET, V37, P572, DOI 10.1136/jmg.37.8.572; Bray N, 2003, GENOME RES, V13, P97, DOI 10.1101/gr.789803; Cann HM, 2002, SCIENCE, V296, P261; Carrasquillo MM, 2002, NAT GENET, V32, P237, DOI 10.1038/ng998; CHAKRAVARTI A, 2001, METABOLIC MOL BASES, P251; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Cutler DJ, 2001, GENOME RES, V11, P1913, DOI 10.1101/gr.197201; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; FALCONER DS, 1967, ANN HUM GENET, V31, P1; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Gabriel SB, 2002, NAT GENET, V31, P89, DOI 10.1038/ng868; Garcia-Barcelo MM, 2003, J MED GENET, V40; Haldane J.B.S., 1949, HEREDITAS, V35, P267; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lin S, 2004, NAT GENET, V36, P1181, DOI 10.1038/ng1457; Lin S, 2004, GENOME RES, V14, P1624, DOI 10.1101/gr.2204604; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Margulies EH, 2003, GENOME RES, V13, P2507, DOI 10.1101/gr.1602203; McCallion AS, 2003, COLD SPRING HARB SYM, V68, P373, DOI 10.1101/sqb.2003.68.373; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MOTULSKY ARNO G., 1960, HUMAN BIOL, V32, P28; Nobrega MA, 2004, J PHYSIOL-LONDON, V554, P31, DOI 10.1113/jphysiol.2003.050948; Pitera JE, 2001, AM J PATHOL, V159, P2321, DOI 10.1016/S0002-9440(10)63082-9; Rivas E, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-8; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Sancandi M, 2003, J MED GENET, V40, P714, DOI 10.1136/jmg.40.9.714; Sato Takeshi, 2000, Research Communications in Biochemistry and Cell and Molecular Biology, V4, P3; Shepherd IT, 2004, DEVELOPMENT, V131, P241, DOI 10.1242/dev.00912; Shepherd IT, 2001, DEV BIOL, V231, P420, DOI 10.1006/dbio.2000.0145; Shoba T, 2002, NEUROSCI LETT, V318, P129, DOI 10.1016/S0304-3940(01)02491-0; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Thomas JW, 2003, NATURE, V424, P788, DOI 10.1038/nature01858; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262	42	338	350	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 14	2005	434	7035					857	863		10.1038/nature03467	http://dx.doi.org/10.1038/nature03467			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915SV	15829955				2022-12-28	WOS:000228327600031
J	Datto, M; Wang, XF				Datto, M; Wang, XF			Ubiquitin-mediated degradation: A mechanism for fine-tuning TGF-beta signaling	CELL			English	Editorial Material							LIGASE; SMURF2; TARGETS		Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Duke University	Datto, M (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.							Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Whitman M, 2001, DEV CELL, V1, P605, DOI 10.1016/S1534-5807(01)00076-4; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	9	33	42	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 8	2005	121	1					2	4		10.1016/j.cell.2005.03.017	http://dx.doi.org/10.1016/j.cell.2005.03.017			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	915YU	15820671	Bronze			2022-12-28	WOS:000228348500002
J	Hunt, JH; Amdam, GV				Hunt, JH; Amdam, GV			Bivoltinism as an antecedent to eusociality in the paper wasp genus Polistes	SCIENCE			English	Article							SOCIAL WASP; HYMENOPTERA; DIAPAUSE; BEHAVIOR; MOTH; PROTEINS; CASTE; FOOD	To learn the evolutionary trajectories of caste differentiation in eusocial species is a major goal of sociobiology. We present an explanatory framework for caste evolution in the eusocial wasp genus Polistes (Vespidae), which is a model system for insect eusocial evolution. We hypothesize that Polistes worker and gyne castes stem from two developmental pathways that characterized the bivoltine life cycle of a solitary ancestor. Through individual-based simulations, we show that our mechanistic framework can reproduce colony-level characteristics of Polistes and, thereby, that social castes can emerge from solitary regulatory pathways. Our explanatory framework illustrates, by specific example, a changed perspective for understanding insect social evolution.	Univ Missouri, Dept Biol, St Louis, MO 63121 USA; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Norwegian Univ Life Sci, Dept Anim & Aquacultural Sci, N-1432 As, Norway	University of Missouri System; University of Missouri Saint Louis; University of California System; University of California Davis; Norwegian University of Life Sciences	Hunt, JH (corresponding author), Univ Missouri, Dept Biol, 1 Univ Blvd, St Louis, MO 63121 USA.	jimhunt@umst.edu; gvamdam@ucdavis.edu	Hunt, James/D-1740-2009		NATIONAL INSTITUTE ON AGING [P01AG022500] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG 22500, P01 AG022500, P01 AG022500-03] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Amdam GV, 2004, P NATL ACAD SCI USA, V101, P11350, DOI 10.1073/pnas.0403073101; BOHM MK, 1972, J INSECT PHYSIOL, V18, P1875, DOI 10.1016/0022-1910(72)90158-8; BOYNE JV, 1986, J ENTOMOL SCI, V21, P301, DOI 10.18474/0749-8004-21.4.301; Cervo Rita, 1996, P98; Cowan D.P., 1991, P33; DAPPORTO L, IN PRESS ANN ZOOL FE; Eickwort G.C., 1981, P199; Field J, 1999, BEHAV ECOL SOCIOBIOL, V45, P378, DOI 10.1007/s002650050574; Gadagkar R, 2001, SOCIAL BIOL ROPALIDI; Godlewski J, 2001, J INSECT PHYSIOL, V47, P759, DOI 10.1016/S0022-1910(01)00050-6; Hunt J.H., 1991, P426; Hunt JH, 2003, J INSECT PHYSIOL, V49, P785, DOI 10.1016/S0022-1910(03)00115-X; Hunt JH, 2002, ECOL ENTOMOL, V27, P467, DOI 10.1046/j.1365-2311.2002.00369.x; HUNT JH, 1982, EVOLUTION, V36, P1318, DOI 10.1111/j.1558-5646.1982.tb05501.x; ISHAY J, 1968, ANIM BEHAV, V16, P298, DOI 10.1016/0003-3472(68)90013-4; Karsai I, 2002, ENVIRON ENTOMOL, V31, P99, DOI 10.1603/0046-225X-31.1.99; Marchal P., 1897, Compte Rendu des Seances de la Societe de Biologie, P557; MEAD F, 1995, INSECT SOC, V42, P385, DOI 10.1007/BF01242167; Michener C.D., 1990, P77; Munyiri FN, 2004, J INSECT PHYSIOL, V50, P295, DOI 10.1016/j.jinsphys.2004.01.005; O'Donnell S, 1998, ANNU REV ENTOMOL, V43, P323, DOI 10.1146/annurev.ento.43.1.323; O'Neill K., 2001, CORNELL S ARTHR BIOL, pXIV + 406; PAGE RE, 1989, AM NAT, V134, P731, DOI 10.1086/285008; Reeve HK, 1998, P NATL ACAD SCI USA, V95, P13737, DOI 10.1073/pnas.95.23.13737; Roubaud E, 1916, ANN SCI NATUR Z, V1, P1; SEGER J, 1983, NATURE, V301, P59, DOI 10.1038/301059a0; STEINBERG S, 1992, ENTOMOL EXP APPL, V62, P269, DOI 10.1007/BF00353446; STRASSMANN JE, 1983, ANIM BEHAV, V31, P431, DOI 10.1016/S0003-3472(83)80063-3; STRASSMANN JE, 1989, J KANSAS ENTOMOL SOC, V62, P353; STRASSMANN JE, 1981, BEHAV ECOL SOCIOBIOL, V8, P55, DOI 10.1007/BF00302844; Suzuki T, 1998, ETHOL ECOL EVOL, V10, P347, DOI 10.1080/08927014.1998.9522848; West Eberhard M. J., 1969, Miscellaneous Publications Museum of Zoology University of Michigan, VNo. 140, P1; WEST-EBERHARD M J, 1978, Journal of the Kansas Entomological Society, V51, P832; WHEELER DE, 1986, AM NAT, V128, P13, DOI 10.1086/284536	34	123	124	3	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 8	2005	308	5719					264	267		10.1126/science.1109724	http://dx.doi.org/10.1126/science.1109724			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821094	Green Accepted			2022-12-28	WOS:000228273700057
J	Maizel, A; Busch, MA; Tanahashi, T; Perkovic, J; Kato, M; Hasebe, M; Weigel, D				Maizel, A; Busch, MA; Tanahashi, T; Perkovic, J; Kato, M; Hasebe, M; Weigel, D			The floral regulator LEAFY evolves by substitutions in the DNA binding domain	SCIENCE			English	Article							HOMEOTIC GENE; HOX PROTEIN; EVOLUTION; ARABIDOPSIS; EXPRESSION; DIVERSIFICATION; REPRESSION; INDUCTION; PRIMORDIA; HOMOLOGS	The plant-specific transcription factor LEAFY controls general aspects of the life cycle in a basal plant, the moss Physcomitrella patens. In contrast, LEAFY has more specialized functions in angiosperms, where it specifically induces floral fate during the reproductive phase. This raises the question of a concomitant change in the biochemical function of LEAFY during the evolution of land plants. We report that the DNA binding domain of LEAFY, although largely conserved, has diverged in activity. On the contrary, other, more rapidly evolving portions of the protein have few effects on LEAFY activity.	Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 1130033, Japan; Natl Inst Basic Biol, Okazaki, Aichi 4448585, Japan	Max Planck Society; Salk Institute; University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Weigel, D (corresponding author), Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany.	weiget@weigelworld.org	Maizel, Alexis/D-3560-2012; Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008	Maizel, Alexis/0000-0001-6843-1059; Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Hasebe, Mitsuyasu/0000-0001-7425-8758				Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Bomblies K, 2003, DEVELOPMENT, V130, P2385, DOI 10.1242/dev.00457; Busch MA, 1999, SCIENCE, V285, P585, DOI 10.1126/science.285.5427.585; Carroll SB, 2000, CELL, V101, P577, DOI 10.1016/S0092-8674(00)80868-5; Frohlich MW, 2000, SYST BOT, V25, P155, DOI 10.2307/2666635; Frohlich MW, 2000, MOL BIOL EVOL, V17, P1914, DOI 10.1093/oxfordjournals.molbev.a026293; Galant R, 2002, NATURE, V415, P910, DOI 10.1038/nature717; Gebelein B, 2002, DEV CELL, V3, P487, DOI 10.1016/S1534-5807(02)00257-5; Himi S, 2001, J MOL EVOL, V53, P387, DOI 10.1007/s002390010228; Kozmik Z, 2003, DEV CELL, V5, P773, DOI 10.1016/S1534-5807(03)00325-3; Lamb RS, 2002, DEVELOPMENT, V129, P2079; Litt A, 2003, GENETICS, V165, P821; Lohmann JU, 2001, CELL, V105, P793, DOI 10.1016/S0092-8674(01)00384-1; Lynch M, 2000, GENETICS, V154, P459; Mellerowicz EJ, 1998, PLANTA, V206, P619, DOI 10.1007/s004250050440; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Ronshaugen M, 2002, NATURE, V415, P914, DOI 10.1038/nature716; Schmid M, 2003, DEVELOPMENT, V130, P6001, DOI 10.1242/dev.00842; Tanahashi T, 2005, DEVELOPMENT, V132, P1727, DOI 10.1242/dev.01709; Wada M, 2002, PLANT MOL BIOL, V49, P567, DOI 10.1023/A:1015544207121; William DA, 2004, P NATL ACAD SCI USA, V101, P1775, DOI 10.1073/pnas.0307842100	21	146	163	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 8	2005	308	5719					260	263		10.1126/science.1108229	http://dx.doi.org/10.1126/science.1108229			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	915BX	15821093				2022-12-28	WOS:000228273700056
J	Hillier, LW; Graves, TA; Fulton, RS; Fulton, LA; Pepin, KH; Minx, P; Wagner-McPherson, C; Layman, D; Wylie, K; Sekhon, M; Becker, MC; Fewell, GA; Delehaunty, KD; Miner, TL; Nash, WE; Kremitzki, C; Oddy, L; Du, H; Sun, H; Bradshaw-Cordum, H; Ali, J; Carter, J; Cordes, M; Harris, A; Isak, A; van Brunt, A; Nguyen, C; Du, FY; Courtney, L; Kalicki, J; Ozersky, P; Abbott, S; Armstrong, J; Belter, EA; Caruso, L; Cedroni, M; Cotton, M; Davidson, T; Desai, A; Elliott, G; Erb, T; Fronick, C; Gaige, T; Haakenson, W; Haglund, K; Holmes, A; Harkins, R; Kim, K; Kruchowski, SS; Strong, CM; Grewal, N; Goyea, E; Hou, S; Levy, A; Martinka, S; Mead, K; McLellan, MD; Meyer, R; Maher, JR; Tomlinson, C; Kohlberg, SD; Kozlowicz-Reilly, A; Shah, N; Swearengen-Shahid, S; Snider, J; Strong, JT; Thompson, J; Yoakum, M; Leonard, S; Pearman, C; Trani, L; Radionenko, M; Waligorski, JE; Wang, CY; Rock, SM; Tin-Wollam, AM; Maupin, R; Latreille, P; Wendl, MC; Yang, SP; Pohl, C; Wallis, JW; Spieth, J; Bieri, TA; Berkowicz, N; Nelson, JO; Osborne, J; Ding, L; Meyer, R; Sabo, A; Shotland, Y; Sinha, P; Wohldmann, PE; Cook, LL; Hickenbotham, MT; Eldred, J; Williams, D; Jones, TA; She, XW; Ciccarelli, FD; Izaurralde, E; Taylor, J; Schmutz, J; Myers, RM; Cox, DR; Huang, XQ; McPherson, JD; Mardis, ER; Clifton, SW; Warren, WC; Chinwalla, AT; Eddy, SR; Marra, MA; Ovcharenko, I; Furey, TS; Miller, W; Eichler, EE; Bork, P; Suyama, M; Torrents, D; Waterston, RH; Wilson, RK				Hillier, LW; Graves, TA; Fulton, RS; Fulton, LA; Pepin, KH; Minx, P; Wagner-McPherson, C; Layman, D; Wylie, K; Sekhon, M; Becker, MC; Fewell, GA; Delehaunty, KD; Miner, TL; Nash, WE; Kremitzki, C; Oddy, L; Du, H; Sun, H; Bradshaw-Cordum, H; Ali, J; Carter, J; Cordes, M; Harris, A; Isak, A; van Brunt, A; Nguyen, C; Du, FY; Courtney, L; Kalicki, J; Ozersky, P; Abbott, S; Armstrong, J; Belter, EA; Caruso, L; Cedroni, M; Cotton, M; Davidson, T; Desai, A; Elliott, G; Erb, T; Fronick, C; Gaige, T; Haakenson, W; Haglund, K; Holmes, A; Harkins, R; Kim, K; Kruchowski, SS; Strong, CM; Grewal, N; Goyea, E; Hou, S; Levy, A; Martinka, S; Mead, K; McLellan, MD; Meyer, R; Maher, JR; Tomlinson, C; Kohlberg, SD; Kozlowicz-Reilly, A; Shah, N; Swearengen-Shahid, S; Snider, J; Strong, JT; Thompson, J; Yoakum, M; Leonard, S; Pearman, C; Trani, L; Radionenko, M; Waligorski, JE; Wang, CY; Rock, SM; Tin-Wollam, AM; Maupin, R; Latreille, P; Wendl, MC; Yang, SP; Pohl, C; Wallis, JW; Spieth, J; Bieri, TA; Berkowicz, N; Nelson, JO; Osborne, J; Ding, L; Meyer, R; Sabo, A; Shotland, Y; Sinha, P; Wohldmann, PE; Cook, LL; Hickenbotham, MT; Eldred, J; Williams, D; Jones, TA; She, XW; Ciccarelli, FD; Izaurralde, E; Taylor, J; Schmutz, J; Myers, RM; Cox, DR; Huang, XQ; McPherson, JD; Mardis, ER; Clifton, SW; Warren, WC; Chinwalla, AT; Eddy, SR; Marra, MA; Ovcharenko, I; Furey, TS; Miller, W; Eichler, EE; Bork, P; Suyama, M; Torrents, D; Waterston, RH; Wilson, RK			Generation and annotation of the DNA sequences of human chromosomes 2 and 4	NATURE			English	Article							HUMAN-GENOME; CPG ISLANDS; GENE; MAP; MOUSE; INTEGRATION; ALIGNMENTS; EVOLUTION; INSIGHTS; QUALITY	Human chromosome 2 is unique to the human lineage in being the product of a head-to-head fusion of two intermediate-sized ancestral chromosomes. Chromosome 4 has received attention primarily related to the search for the Huntington's disease gene, but also for genes associated with Wolf-Hirschhorn syndrome, polycystic kidney disease and a form of muscular dystrophy. Here we present approximately 237 million base pairs of sequence for chromosome 2, and 186 million base pairs for chromosome 4, representing more than 99.6% of their euchromatic sequences. Our initial analyses have identified 1,346 protein-coding genes and 1,239 pseudogenes on chromosome 2, and 796 protein-coding genes and 778 pseudogenes on chromosome 4. Extensive analyses confirm the underlying construction of the sequence, and expand our understanding of the structure and evolution of mammalian chromosomes, including gene deserts, segmental duplications and highly variant regions.	Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany; Penn State Univ, Dept Biol, Ctr Comparat Genom & Bioinformat, University Pk, PA 16802 USA; Penn State Univ, Dept Comp Sci, University Pk, PA 16802 USA; Stanford Univ, Sch Med, Dept Genet, Stanford Human Genome Ctr, Stanford, CA 94305 USA; Iowa State Univ, Dept Comp Sci, Ames, IA 50011 USA; Lawrence Livermore Natl Lab, EEBI Div, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Genome Biol Div, Livermore, CA 94550 USA; Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); University of Washington; University of Washington Seattle; European Molecular Biology Laboratory (EMBL); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Stanford University; Iowa State University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Santa Cruz	Wilson, RK (corresponding author), Washington Univ, Sch Med, Genome Sequencing Ctr, Campus Box 8501,4444 Forest Pk Ave, St Louis, MO 63108 USA.	rwilson@watson.wustl.edu	Taylor, James/F-1026-2011; Marra, Marco A/B-5987-2008; Sekhon, Mandeep/L-4665-2018; Wendl, Michael C/A-2741-2008; McPherson, John D/D-2633-2017; Mardis, Elaine/W-2202-2019; Izaurralde, Elisa/G-3239-2012; Bork, Peer/F-1813-2013; Schmutz, Jeremy/N-3173-2013; Wilson, Richard K./AAF-4139-2019; Ciccarelli, Francesca/D-5380-2014; Torrents, David/G-5785-2015	Taylor, James/0000-0001-5079-840X; Marra, Marco A/0000-0001-7146-7175; Sekhon, Mandeep/0000-0002-9993-6938; McPherson, John D/0000-0001-8049-9347; Bork, Peer/0000-0002-2627-833X; Schmutz, Jeremy/0000-0001-8062-9172; Wilson, Richard K./0000-0002-1992-1358; Izaurralde, Elisa/0000-0001-7365-2649; Waligorski, Jason/0000-0001-8422-6004; Kremitzki, Colin/0000-0001-9175-3136; Chinwalla, Asif/0000-0001-7831-3996; Suyama, Mikita/0000-0001-9526-3193; Ciccarelli, Francesca/0000-0002-9325-0900; Eddy, Sean/0000-0001-6676-4706; Shiina, Takashi/0000-0002-2067-6708; Furey, Terry/0000-0001-5546-9672; MCLELLAN, MICHAEL/0000-0002-2703-8784; Torrents, David/0000-0002-6086-9037				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Ashburner M, 2001, GENOME RES, V11, P1425; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bailey JA, 2002, AM J HUM GENET, V70, P83, DOI 10.1086/338458; Birney E, 2000, GENOME RES, V10, P547, DOI 10.1101/gr.10.4.547; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Ciccarelli FD, 2005, GENOME RES, V15, P343, DOI 10.1101/gr.3266405; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eddy SR, 2002, CELL, V109, P137, DOI 10.1016/S0092-8674(02)00727-4; Fan Y, 2002, GENOME RES, V12, P1651, DOI 10.1101/gr.337602; Felsenfeld A, 1999, GENOME RES, V9, P1; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; Hillier LW, 2003, NATURE, V424, P157, DOI 10.1038/nature01782; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kolbe D, 2004, GENOME RES, V14, P700, DOI 10.1101/gr.1976004; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Korf I, 2001, Bioinformatics, V17 Suppl 1, pS140; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liu CX, 2000, GENOMICS, V69, P271, DOI 10.1006/geno.2000.6331; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Mishmar D, 2004, HUM MUTAT, V23, P125, DOI 10.1002/humu.10304; Mulder Nicola J, 2002, Brief Bioinform, V3, P225; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Olivier M, 2001, SCIENCE, V291, P1298, DOI 10.1126/science.1057437; Ovcharenko I, 2005, GENOME RES, V15, P137, DOI 10.1101/gr.3015505; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Riethman HC, 2001, NATURE, V409, P948, DOI 10.1038/35057180; Roest Crollius H, 2000, NAT GENET, V25, P235, DOI 10.1038/76118; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Schmutz J, 2003, COLD SPRING HARB SYM, V68, P31, DOI 10.1101/sqb.2003.68.31; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Suyama M, 2004, BIOINFORMATICS, V20, P1968, DOI 10.1093/bioinformatics/bth172; Torrents D, 2003, GENOME RES, V13, P2559, DOI 10.1101/gr.1455503; Wang Y, 2004, BIOINFORMATICS, V20, P1170, DOI 10.1093/bioinformatics/bth059; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; YUNIS JJ, 1982, SCIENCE, V215, P1525, DOI 10.1126/science.7063861; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847; Zhang ZL, 2004, TRENDS GENET, V20, P62, DOI 10.1016/j.tig.2003.12.005	50	59	1622	3	49	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					724	731		10.1038/nature03466	http://dx.doi.org/10.1038/nature03466			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15815621	Bronze			2022-12-28	WOS:000228160700031
J	Honda, K; Yanai, H; Negishi, H; Asagiri, M; Sato, M; Mizutani, T; Shimada, N; Ohba, Y; Takaoka, A; Yoshida, N; Taniguchi, T				Honda, K; Yanai, H; Negishi, H; Asagiri, M; Sato, M; Mizutani, T; Shimada, N; Ohba, Y; Takaoka, A; Yoshida, N; Taniguchi, T			IRF-7 is the master regulator of type-I interferon-dependent immune responses	NATURE			English	Article							PLASMACYTOID DENDRITIC CELLS; SINGLE-STRANDED RNA; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTORS; POSITIVE FEEDBACK; ALPHA PRODUCTION; DISTINCT; RECOGNITION; INDUCTION; MYD88	The type-I interferon (IFN-alpha/beta) response is critical to immunity against viruses and can be triggered in many cell types by cytosolic detection of viral infection, or in differentiated plasmacytoid dendritic cells by the Toll-like receptor 9 (TLR9) subfamily, which generates signals via the adaptor MyD88 to elicit robust IFN induction(1-4). Using mice deficient in the Irf7 gene (Irf7(-/-) mice), we show that the transcription factor IRF-7 is essential for the induction of IFN-alpha/beta genes via the virus-activated, MyD88-independent pathway and the TLR-activated, MyD88-dependent pathway. Viral induction of MyD88-independent IFN-alpha/beta genes is severely impaired in Irf7(-/-) fibroblasts. Consistently, Irf7(-/-) mice are more vulnerable than Myd88(-/-) mice to viral infection, and this correlates with a marked decrease in serum IFN levels, indicating the importance of the IRF-7-dependent induction of systemic IFN responses for innate antiviral immunity. Furthermore, robust induction of IFN production by activation of the TLR9 subfamily in plasmacytoid dendritic cells is entirely dependent on IRF-7, and this MyD88-IRF-7 pathway governs the induction of CD8(+) T-cell responses. Thus, all elements of IFN responses, whether the systemic production of IFN in innate immunity or the local action of IFN from plasmacytoid dendritic cells in adaptive immunity, are under the control of IRF-7.	Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Tokyo 1130033, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; JST, PRESTO, Informat & Cell Funct, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST)	Taniguchi, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	tada@m.u-tokyo.ac.jp	Yang, Chen/G-1379-2010; Honda, Kenya/N-5297-2015; Yanai, Hideyuki/AGK-5933-2022; Mizutani, Tatsuaki/AAA-5044-2021; Ohba, Yusuke/E-7944-2011	Yanai, Hideyuki/0000-0002-0115-9000; Mizutani, Tatsuaki/0000-0002-4323-4347; Honda, Kenya/0000-0001-8937-9835				Ahonen CL, 2004, J EXP MED, V199, P775, DOI 10.1084/jem.20031591; Asselin-Paturel C, 2003, J IMMUNOL, V171, P6466, DOI 10.4049/jimmunol.171.12.6466; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Barchet W, 2002, J EXP MED, V195, P507, DOI 10.1084/jem.20011666; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2003, J IMMUNOL, V170, P3059, DOI 10.4049/jimmunol.170.6.3059; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Le Bon A, 2003, NAT IMMUNOL, V4, P1009, DOI 10.1038/ni978; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Qing J, 2004, MOL CELL BIOL, V24, P1411, DOI 10.1128/MCB.24.3.1411-1425.2004; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Verthelyi D, 2001, J IMMUNOL, V166, P2372, DOI 10.4049/jimmunol.166.4.2372; Wagner H, 2004, CURR OPIN BIOTECH, V15, P538, DOI 10.1016/j.copbio.2004.09.006; Wagner H, 2004, TRENDS IMMUNOL, V25, P381, DOI 10.1016/j.it.2004.04.011; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	30	1660	1734	3	139	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 7	2005	434	7034					772	777		10.1038/nature03464	http://dx.doi.org/10.1038/nature03464			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	913NU	15800576				2022-12-28	WOS:000228160700043
J	Blumenthal, JA; Sherwood, A; Babyak, MA; Watkins, LL; Waugh, R; Georgiades, A; Bacon, SL; Hayano, J; Coleman, RE; Hinderliter, A				Blumenthal, JA; Sherwood, A; Babyak, MA; Watkins, LL; Waugh, R; Georgiades, A; Bacon, SL; Hayano, J; Coleman, RE; Hinderliter, A			Effects of exercise and stress management training on markers of cardiovascular risk in patients with ischemic heart disease - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; IMPROVE CLINICAL OUTCOMES; ENDOTHELIAL DYSFUNCTION; RATE-VARIABILITY; PSYCHOSOCIAL INTERVENTIONS; BAROREFLEX SENSITIVITY; CARDIAC MORTALITY; PROGNOSTIC VALUE; PART I	Context Observational studies have shown that psychosocial factors are associated with increased risk for cardiovascular morbidity and mortality, but the effects of behavioral interventions on psychosocial and medical end points remain uncertain. Objective To determine the effect of 2 behavioral programs, aerobic exercise training and stress management training, with routine medical care on psychosocial functioning and markers of cardiovascular risk. Design, Setting, and Patients Randomized controlled trial of 134 patients (92 male and 42 female; aged 40-84 years) with stable ischemic heart disease (IHD) and exercise-induced myocardial ischemia. Conducted from January 1999 to February 2003. Interventions Routine medical care (usual care); usual care plus supervised aerobic exercise training for 35 minutes 3 times per week for 16 weeks; usual care plus weekly 1.5-hour stress management training for 16 weeks. Main Outcome Measures Self-reported measures of general distress (General Health Questionnaire [GHQ]) and depression (Beck Depression Inventory [BDI]); left ventricular ejection fraction (LVEF) and wall motion abnormalities (WMA); flow-mediated dilation; and cardiac autonomic control (heart rate variability during deep breathing and baroreflex sensitivity). Results Patients in the exercise and stress management groups had lower mean (SE) BDI scores (exercise: 8.2 [0.6]; stress management: 8.2 [0.6]) vs usual care (10.1 [0.6]; P = .02); reduced distress by GHQ scores (exercise: 56.3 [0.9]; stress management: 56.8 [0.9]) vs usual care (53.6 [0.9]; P = .02); and smaller reductions in LVEF during mental stress testing (exercise: -0.54% [0.44%]; stress management: -0.34% [0.45%]) vs usual care (-1.69% [0.46%]; P = .03). Exercise and stress management were associated with lower mean (SE) WMA rating scores (exercise: 0.20 [0.07]; stress management: 0.10 [0.07]) in a subset of patients with significant stress-induced WMA at baseline vs usual care (0.36 [0.07]; P = .02). Patients in the exercise and stress management groups had greater mean (SE) improvements in flow-mediated dilation (exercise: mean [SD], 5.6% [0.45%]; stress management: 5.2% [0.47%]) vs usual care patients (4.1% [0.48%]; P = .03). In a subgroup, those receiving stress management showed improved mean (SE) baroreflex sensitivity (8.2 [0.8] ms/mm Hg) vs usual care (5.1 [0.9] ms/mm Hg; P = .02) and significant increases in heart rate variability (193.7 [19.6] ms) vs usual care (132.1 [21.5] ms; P = .04). Conclusion For patients with stable IHD, exercise and stress management training reduced emotional distress and improved markers of cardiovascular risk more than usual medical care alone.	Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; Nagoya City Univ Hosp, Ctr Mental Hlth & Care, Nagoya, Aichi, Japan; Univ N Carolina Hosp, Dept Med, Chapel Hill, NC USA	Duke University; Duke University; Duke University; Nagoya City University; University North Carolina Hospital	Blumenthal, JA (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Box 3119, Durham, NC 27710 USA.	blume003@mc.duke.edu	Bacon, Simon/B-2637-2012; Coleman, Ralph E/A-7865-2009	Bacon, Simon/0000-0001-7075-0358; Hayano, Junichiro/0000-0002-5340-6325	NCRR NIH HHS [M01-RR-30] Funding Source: Medline; NHLBI NIH HHS [HL59672] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059672] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Heart Association, 2002, HEART STROK STAT UPD; Beck A.T., 1978, COGNITIVE THERAPY DE; BENNETT T, 1978, DIABETES, V27, P1167, DOI 10.2337/diabetes.27.12.1167; Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106; BILLMAN GE, 1982, CIRCULATION, V66, P874, DOI 10.1161/01.CIR.66.4.874; Blumenthal JA, 1997, ARCH INTERN MED, V157, P2213, DOI 10.1001/archinte.157.19.2213; BLUMENTHAL JA, 1995, CIRCULATION, V92, P2102, DOI 10.1161/01.CIR.92.8.2102; Blumenthal JA, 2002, AM J CARDIOL, V89, P164, DOI 10.1016/S0002-9149(01)02194-4; BLUMENTHAL JA, 1988, AM J CARDIOL, V61, P26, DOI 10.1016/0002-9149(88)91298-2; Carney RM, 2003, AM J CARDIOL, V92, P1277, DOI 10.1016/j.amjcard.2003.08.007; Cook WW, 1954, J APPL PSYCHOL, V38, P414, DOI 10.1037/h0060667; Davidson KW, 2004, PSYCHOSOM MED, V66, P165, DOI 10.1097/01.psy.0000116716.19848.65; DEFERRARI GM, 1995, AM HEART J, V130, P473, DOI 10.1016/0002-8703(95)90354-2; DeMets DL, 2002, CIRCULATION, V106, P746, DOI 10.1161/01.CIR.0000023219.51483.66; Edwards DG, 2004, AM J CARDIOL, V93, P617, DOI 10.1016/j.amjcard.2003.11.032; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; FRASURESMITH N, 1991, AM J CARDIOL, V67, P121, DOI 10.1016/0002-9149(91)90432-K; FRIEDMAN LM, 1996, FUNDAMENTALS CLIN TR; Ghiadoni L, 2000, CIRCULATION, V102, P2473, DOI 10.1161/01.CIR.102.20.2473; Gokce N, 2003, J AM COLL CARDIOL, V41, P1769, DOI 10.1016/S0735-1097(03)00333-4; Gokce N, 2002, AM J CARDIOL, V90, P124, DOI 10.1016/S0002-9149(02)02433-5; Goldberg D.P, 1972, DETECTION PSYCHIAT I; Hambrecht R, 2003, CIRCULATION, V107, P3152, DOI 10.1161/01.CIR.0000074229.93804.5C; Heitzer T, 2001, CIRCULATION, V104, P2673, DOI 10.1161/hc4601.099485; HOHNLOSER SH, 1994, CIRCULATION, V89, P1068, DOI 10.1161/01.CIR.89.3.1068; JAIN D, 1995, AM J CARDIOL, V76, P31, DOI 10.1016/S0002-9149(99)80796-6; Jiang W, 1996, JAMA-J AM MED ASSOC, V275, P1651, DOI 10.1001/jama.275.21.1651; Jones DA, 1996, BRIT MED J, V313, P1517, DOI 10.1136/bmj.313.7071.1517; Katz A, 1999, AM HEART J, V138, P32, DOI 10.1016/S0002-8703(99)70242-5; Krantz DS, 1999, AM J CARDIOL, V84, P1292, DOI 10.1016/S0002-9149(99)00560-3; La Rovere MT, 1998, LANCET, V351, P478; Lesperance F, 2002, CIRCULATION, V105, P1049, DOI 10.1161/hc0902.104707; METLER FA, 1986, ESSENTIALS NUCL MED, P151; Modena MG, 2002, J AM COLL CARDIOL, V40, P505, DOI 10.1016/S0735-1097(02)01976-9; Neunteufl T, 2000, AM J CARDIOL, V86, P207, DOI 10.1016/S0002-9149(00)00857-2; Perticone F, 2001, CIRCULATION, V104, P191, DOI 10.1161/01.CIR.104.2.191; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151, DOI 10.1152/ajpheart.1985.248.1.H151; Relman AS, 2002, PSYCHOSOM MED, V64, P558, DOI 10.1097/01.PSY.0000023411.02546.14; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rozanski A, 2005, J AM COLL CARDIOL, V45, P637, DOI 10.1016/j.jacc.2004.12.005; Rozanski A, 1999, CIRCULATION, V99, P2192, DOI 10.1161/01.CIR.99.16.2192; Sheps DS, 2002, CIRCULATION, V105, P1780, DOI 10.1161/01.CIR.0000014491.90666.06; SMITH NF, 1997, LANCET, V350, P473; Spieker LE, 2002, CIRCULATION, V105, P2817, DOI 10.1161/01.CIR.0000021598.15895.34; Spielberger CD, 1970, MANUAL STATE TRAIT A; Walsh JH, 2003, J APPL PHYSIOL, V95, P20, DOI 10.1152/japplphysiol.00012.2003; Watkins LL, 1999, AM HEART J, V137, P453, DOI 10.1016/S0002-8703(99)70491-6; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Wheeler SG, 2002, DIABETES RES CLIN PR, V58, P131, DOI 10.1016/S0168-8227(02)00128-6; Williams RB, 2002, PSYCHOSOM MED, V64, P552, DOI 10.1097/01.PSY.0000023410.02546.5D; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487	51	267	279	1	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2005	293	13					1626	1634		10.1001/jama.293.13.1626	http://dx.doi.org/10.1001/jama.293.13.1626			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	913EV	15811982	Bronze			2022-12-28	WOS:000228135300025
J	Taggart, DP				Taggart, DP			Current controversies - Surgery is the best intervention for severe coronary artery disease	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; REVASCULARIZATION; RESTENOSIS; STENTS		John Radcliffe Hosp, Oxford OX3 9DU, England; Univ Oxford, Oxford OX1 2JD, England	University of Oxford; University of Oxford	Taggart, DP (corresponding author), John Radcliffe Hosp, Oxford OX3 9DU, England.	david.taggart@orh.nhs.uk						Brener SJ, 2004, CIRCULATION, V109, P2290, DOI 10.1161/01.CIR.0000126826.58526.14; HILL R, 2004, HLTH TECHNOLOGY ASSE, V8; Keogh B, 2003, 5 NATL ADULT CARDIAC; Lansky AJ, 2004, CIRCULATION, V109, P1948, DOI 10.1161/01.CIR.0000127129.94129.6F; Lemos PA, 2004, CIRCULATION, V109, P1366, DOI 10.1161/01.CIR.0000121358.26097.06; McFadden EP, 2004, LANCET, V364, P1519, DOI 10.1016/S0140-6736(04)17275-9; Niles NW, 2001, J AM COLL CARDIOL, V37, P1008, DOI 10.1016/S0735-1097(00)01205-5; Scott R, 2000, J THORAC CARDIOV SUR, V120, P173, DOI 10.1067/mtc.2000.107280; Taggart DP, 1996, LANCET, V347, P271; Tanabe K, 2004, AM J CARDIOL, V94, P115, DOI 10.1016/j.amjcard.2004.03.040; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	11	36	38	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 2	2005	330	7494					785	786		10.1136/bmj.330.7494.785	http://dx.doi.org/10.1136/bmj.330.7494.785			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	914JE	15802725	Green Published			2022-12-28	WOS:000228222900030
J	Jickells, TD; An, ZS; Andersen, KK; Baker, AR; Bergametti, G; Brooks, N; Cao, JJ; Boyd, PW; Duce, RA; Hunter, KA; Kawahata, H; Kubilay, N; laRoche, J; Liss, PS; Mahowald, N; Prospero, JM; Ridgwell, AJ; Tegen, I; Torres, R				Jickells, TD; An, ZS; Andersen, KK; Baker, AR; Bergametti, G; Brooks, N; Cao, JJ; Boyd, PW; Duce, RA; Hunter, KA; Kawahata, H; Kubilay, N; laRoche, J; Liss, PS; Mahowald, N; Prospero, JM; Ridgwell, AJ; Tegen, I; Torres, R			Global iron connections between desert dust, ocean biogeochemistry, and climate	SCIENCE			English	Review							NITROGEN-FIXATION; ATMOSPHERIC CO2; ATLANTIC-OCEAN; SARGASSO SEA; ART.; DEPOSITION; AEROSOLS; GENOME; POPULATIONS; TRANSPORT	The environmental conditions of Earth, including the climate, are determined by physical, chemical, biological, and human interactions that transform and transport materials and energy. This is the "Earth system": a highly complex entity characterized by multiple nonlinear responses and thresholds, with linkages between disparate components. One important part of this system is the iron cycle, in which iron-containing soil dust is transported from land through the atmosphere to the oceans, affecting ocean biogeochemistry and hence having feedback effects on climate and dust production. Here we review the key components of this cycle, identifying critical uncertainties and priorities for future research.	Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England; Chinese Acad Sci, Inst Earth Environm, State Key Lab Loess & Quaternary Geol, Beijing 100864, Peoples R China; Univ Copenhagen, Niels Bohr Inst, DK-2100 Copenhagen, Denmark; Univ Paris 07, Lab Interuniv Syst Atmospher, Paris, France; Univ Paris 12, CNRS, UMR 7583, Paris, France; Natl Inst Water & Atmospher Res, Ctr Chem & Phys Oceanog, Dept Chem, Dunedin, New Zealand; Univ Otago, Dept Chem, Dunedin, New Zealand; Texas A&M Univ, Dept Oceanog, College Stn, TX 77843 USA; Texas A&M Univ, Dept Atmospher Sci, College Stn, TX 77843 USA; Geol Survey Japan, Natl Inst Adv Ind Sci & Technol, Ibaraki 3058567, Japan; Middle E Tech Univ, Inst Marine Sci, TR-33731 Erdemli Mersin, Turkey; Leibniz Inst Meereswissensch, IFM GEOMAR, D-24105 Kiel, Germany; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada; Max Planck Inst Biogeochem, D-07701 Jena, Germany; Univ Concepcion, Dept Oceanog, Concepcion, Chile	University of East Anglia; Chinese Academy of Sciences; University of Copenhagen; Niels Bohr Institute; UDICE-French Research Universities; Universite Paris Cite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite Paris Cite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); National Institute of Water & Atmospheric Research (NIWA) - New Zealand; University of Otago; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; National Institute of Advanced Industrial Science & Technology (AIST); Middle East Technical University; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; National Center Atmospheric Research (NCAR) - USA; University of Miami; University of British Columbia; Max Planck Society; Universidad de Concepcion	Jickells, TD (corresponding author), Univ E Anglia, Sch Environm Sci, Norwich NR4 7TJ, Norfolk, England.		Andersen, Katrine/B-4082-2016; Prospero, Joseph/AAT-6996-2020; Duce, Robert A/A-9917-2010; Tegen, Ina/W-4299-2018; Junji, Cao/D-3259-2014; LISS, Peter S./A-8219-2013; Ridgwell, Andy/AAD-9487-2021; Mahowald, Natalie M/D-8388-2013; KAWAHATA, HODAKA/F-9065-2016; LaRoche, Julie/A-1109-2010; Baker, Alex R/D-1233-2011; AN, Zhisheng/F-8834-2012; Boyd, Philip W/J-7624-2014	Andersen, Katrine/0000-0003-4178-2195; Tegen, Ina/0000-0003-3700-3232; Junji, Cao/0000-0003-1000-7241; Ridgwell, Andy/0000-0003-2333-0128; Mahowald, Natalie M/0000-0002-2873-997X; KAWAHATA, HODAKA/0000-0003-4236-7356; Baker, Alex R/0000-0002-8365-8953; Boyd, Philip W/0000-0001-7850-1911; Bergametti, Gilles/0000-0002-0839-1048; Torres, Rodrigo/0000-0003-0416-4291; Prospero, Joseph/0000-0003-3608-6160; an, zhi sheng/0000-0002-9538-9826; LaRoche, Julie/0000-0003-4809-6411; Brooks, Nick/0000-0002-5073-9386				Altabet MA, 2002, NATURE, V415, P159, DOI 10.1038/415159a; AN Z, UNPUB; AN ZS, 1991, CATENA, V18, P125, DOI 10.1016/0341-8162(91)90012-M; [Anonymous], 2001, SCOR IUPAC SERIES; Baker AR, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018518; Bopp L, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000810; Boyd PW, 2003, GLOB CHANGE IGBP SER, P157; Boyd PW, 2004, NATURE, V428, P549, DOI 10.1038/nature02437; Brooks N, 2000, ADV GLOB CHANGE RES, V6, P1; Chisholm SW, 2002, SCIENCE, V296, P467; Claussen M, 2003, CLIMATIC CHANGE, V57, P99, DOI 10.1023/A:1022115604225; de Baar H.J.W., 2001, BIOGEO CHEM IRON SEA, P123; Duce RA, 1991, GLOBAL BIOGEOCHEM CY, V5, P193, DOI 10.1029/91GB01778; Duce RA, 1995, DAHL WS ENV, V17, P43; Elrod VA, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020216; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Francois R, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001722; Ginoux P, 2001, J GEOPHYS RES-ATMOS, V106, P20255, DOI 10.1029/2000JD000053; Gledhill M, 2004, MAR CHEM, V88, P75, DOI 10.1016/j.marchem.2004.03.003; Griffin Dale W., 2003, Aerobiologia, V19, P143, DOI 10.1023/B:AERO.0000006530.32845.8d; Hand JL, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004574; Huebert BJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003550; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Jickells TD, 1999, MAR CHEM, V68, P5, DOI 10.1016/S0304-4203(99)00061-4; Johnson KS, 2001, GLOBAL BIOGEOCHEM CY, V15, P61, DOI 10.1029/2000GB001295; KAUFMAN YJ, 2005, J GEOPHYS RES, V110, DOI DOI 10.1029/2003JD004436; Kraemer SM, 2004, AQUAT SCI, V66, P3, DOI 10.1007/s00027-003-0690-5; Kustka AB, 2003, LIMNOL OCEANOGR, V48, P1869, DOI 10.4319/lo.2003.48.5.1869; LISS PS, IN PRESS TELLUS; Mahowald NM, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017880; Martin JH, 1990, PALEOCEANOGRAPHY, V5, P1, DOI 10.1029/PA005i001p00001; Mills MM, 2004, NATURE, V429, P292, DOI 10.1038/nature02550; Morel FMM, 2003, SCIENCE, V300, P944, DOI 10.1126/science.1083545; Moulin C, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018931; Oba T, 1999, PALEOCEANOGRAPHY, V14, P34, DOI 10.1029/98PA02507; Palenik B, 2003, NATURE, V424, P1037, DOI 10.1038/nature01943; Parekh P, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002061; Poulton SW, 2002, AM J SCI, V302, P774, DOI 10.2475/ajs.302.9.774; Prospero JM, 2003, SCIENCE, V302, P1024, DOI 10.1126/science.1089915; PROSPERO JM, 1986, NATURE, V320, P735, DOI 10.1038/320735a0; Prospero JM, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000095; REA DK, 1994, REV GEOPHYS, V32, P159, DOI 10.1029/93RG03257; Ridgwell AJ, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014304; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Rosenfeld D, 2001, P NATL ACAD SCI USA, V98, P5975, DOI 10.1073/pnas.101122798; Rothlisberger R, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020338; Sarthou G, 2003, DEEP-SEA RES PT I, V50, P1339, DOI 10.1016/S0967-0637(03)00126-2; Schubert SD, 2004, SCIENCE, V303, P1855, DOI 10.1126/science.1095048; Schulz KG, 2004, NATURE, V430, P673, DOI 10.1038/nature02631; Tegen I, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019216; Turner SM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020296; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Watson A.J., 2001, BIOGEOCHEMISTRY IRON; Wingenter OW, 2004, P NATL ACAD SCI USA, V101, P8537, DOI 10.1073/pnas.0402744101; Zender CS, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003039; Zhang XY, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018206; Zhao CS, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018351; ZHUANG GS, 1992, NATURE, V355, P537, DOI 10.1038/355537a0	59	1933	2027	36	911	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	2005	308	5718					67	71		10.1126/science.1105959	http://dx.doi.org/10.1126/science.1105959			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	914IQ	15802595				2022-12-28	WOS:000228221500033
J	Glasson, SS; Askew, R; Sheppard, B; Carito, B; Blanchet, T; Ma, HL; Flannery, CR; Peluso, D; Kanki, K; Yang, ZY; Majumdar, MK; Morris, EA				Glasson, SS; Askew, R; Sheppard, B; Carito, B; Blanchet, T; Ma, HL; Flannery, CR; Peluso, D; Kanki, K; Yang, ZY; Majumdar, MK; Morris, EA			Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis	NATURE			English	Article							HUMAN SYNOVIAL-FLUID; AGGRECAN FRAGMENTS; EXPLANTS; CLONING; CLEAVES	Human osteoarthritis is a progressive disease of the joints characterized by degradation of articular cartilage. Although disease initiation may be multifactorial, the cartilage destruction appears to be a result of uncontrolled proteolytic extracellular matrix destruction. A major component of the cartilage extracellular matrix is aggrecan, a proteoglycan that imparts compressive resistance to the tissue. Aggrecan is cleaved at a specific 'aggrecanase' site in human osteoarthritic cartilage(1-2); this cleavage can be performed by several members of ADAMTS family of metalloproteases(3-9). The relative contribution of individual ADAMTS proteases to cartilage destruction during osteoarthritis has not been resolved. Here we describe experiments with a genetically modified mouse in which the catalytic domain of ADAMTS5 (aggrecanase-2) was deleted. After surgically induced joint instability, there was significant reduction in the severity of cartilage destruction in the ADAMTS5 knockout mice compared with wild-type mice. This is the first report of a single gene deletion capable of abrogating the course of cartilage destruction in an animal model of osteoarthritis. These results demonstrate that ADAMTS5 is the primary 'aggrecanase' responsible for aggrecan degradation in a murine model of osteoarthritis, and suggest rational strategies for therapeutic intervention in osteoarthritis.	Wyeth Res, Dept Womens Hlth & Bone, Cambridge, MA 02140 USA; Wyeth Res, Genom, Cambridge, MA 02140 USA; Wyeth Res, Drug Safety & Metab, Cambridge, MA 02140 USA	Pfizer; Pfizer; Pfizer	Morris, EA (corresponding author), Wyeth Res, Dept Womens Hlth & Bone, 200 CambridgePk Dr, Cambridge, MA 02140 USA.	Emorris@Wyeth.com						Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Chambers MG, 2001, ARTHRITIS RHEUM-US, V44, P1455, DOI 10.1002/1529-0131(200106)44:6<1455::AID-ART241>3.0.CO;2-J; Clements KM, 2003, ARTHRITIS RHEUM-US, V48, P3452, DOI 10.1002/art.11355; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; Glasson SS, 2004, ARTHRITIS RHEUM-US, V50, P2547, DOI 10.1002/art.20558; Hughes Clare E, 2003, Methods Mol Biol, V225, P89; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Little CB, 2003, T ORTHOP RES SOC, V28, P699; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8683; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; YAMAJI N, 2004, Patent No. 6716613	16	932	995	3	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					644	648		10.1038/nature03369	http://dx.doi.org/10.1038/nature03369			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800624				2022-12-28	WOS:000228011000045
J	Nakagawa, T; Shimizu, S; Watanabe, T; Yamaguchi, O; Otsu, K; Yamagata, H; Inohara, H; Kubo, T; Tsujimoto, Y				Nakagawa, T; Shimizu, S; Watanabe, T; Yamaguchi, O; Otsu, K; Yamagata, H; Inohara, H; Kubo, T; Tsujimoto, Y			Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death	NATURE			English	Article							CYTOCHROME-C RELEASE; CYCLOSPORINE-A; PORE; RAT; BAX; DYSFUNCTION; ACTIVATION; CA2+	Mitochondria play an important role in energy production, Ca2+ homeostasis and cell death. In recent years, the role of the mitochondria in apoptotic and necrotic cell death has attracted much attention(1,2). In apoptosis and necrosis, the mitochondrial permeability transition (mPT), which leads to disruption of the mitochondrial membranes and mitochondrial dysfunction, is considered to be one of the key events, although its exact role in cell death remains elusive. We therefore created mice lacking cyclophilin D (CypD), a protein considered to be involved in the mPT, to analyse its role in cell death. CypD-deficient mice were developmentally normal and showed no apparent anomalies, but CypD-deficient mitochondria did not undergo the cyclosporin A-sensitive mPT. CypD-deficient cells died normally in response to various apoptotic stimuli, but showed resistance to necrotic cell death induced by reactive oxygen species and Ca2+ overload. In addition, CypD-deficient mice showed a high level of resistance to ischaemia/reperfusion-induced cardiac injury. Our results indicate that the CypD-dependent mPT regulates some forms of necrotic death, but not apoptotic death.	Osaka Univ, Sch Med, Dept Postgenom & Dis, Mol Genet Lab, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Otolaryngol & Sensory Organ Surg, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, SORST, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Dept Postgenom & Dis, Mol Genet Lab, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsujimot@gene.med.osaka-u.ac.jp	Nakagawa, Takashi/F-3015-2010	Nakagawa, Takashi/0000-0001-5539-7605; Yamaguchi, Osamu/0000-0002-7461-369X				BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Byrne AM, 1999, HEPATOLOGY, V29, P1523, DOI 10.1002/hep.510290521; Crompton M, 2003, CURR MED CHEM, V10, P1473, DOI 10.2174/0929867033457197; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 2004, NATURE, V430, DOI 10.1038/nature02816; Hatano E, 2000, J BIOL CHEM, V275, P11814, DOI 10.1074/jbc.275.16.11814; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Javadov SA, 2003, J PHYSIOL-LONDON, V549, P513, DOI 10.1113/jphysiol.2003.034231; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Li YM, 2004, BIOCHEM J, V383, P101, DOI 10.1042/BJ20040669; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; SHIMIZU S, 1994, TRANSPLANTATION, V57, P1562; Shimizu S, 1996, ONCOGENE, V12, P2251; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shinzawa K, 2003, J CELL BIOL, V163, P1219, DOI 10.1083/jcb.200306159; Trollinger DR, 1997, BIOCHEM BIOPH RES CO, V236, P738, DOI 10.1006/bbrc.1997.7042; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weiss JN, 2003, CIRC RES, V93, P292, DOI 10.1161/01.RES.0000087542.26971.D4; Yamashita N, 1999, J EXP MED, V189, P1699, DOI 10.1084/jem.189.11.1699; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	30	1269	1327	3	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	2005	434	7033					652	658		10.1038/nature03317	http://dx.doi.org/10.1038/nature03317			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	911NN	15800626				2022-12-28	WOS:000228011000047
